DrugBank ID,Name,CAS Number,Drug Groups,InChIKey,InChI,SMILES,Formula,KEGG Compound ID,KEGG Drug ID,PubChem Compound ID,PubChem Substance ID,ChEBI ID,ChEMBL ID,HET ID,ChemSpider ID,BindingDB ID,AverageMass,Predicted_logp,KnownUse
DB00006,Bivalirudin,128270-60-0,approved; investigational,OIRCOABEOLEUMC-GEJPAHFPSA-N,"InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1",CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C4CCCN4C(=O)C(CCCNC(=N)N)NC(=O)C5CCCN5C(=O)C(CC6=CC=CC=C6)N,C98H138N24O33,,D03136,16129704,46507415,59173,CHEMBL2103749,,10482069,50248103,2180.2853,-14.34551278,"Amino Acids, Peptides, and Proteins; Anticoagulants; Antithrombin Proteins; Antithrombins; Blood and Blood Forming Organs; Enzyme Inhibitors; Hematologic Agents; Peptides; Protease Inhibitors; Proteins; Serine Protease Inhibitors; Serpins; Thrombin Inhibitors"
DB00007,Leuprolide,53714-56-0,approved; investigational,GFIJNRVAKGFPGQ-LIJARHBVSA-N,"InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1",CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c(c34)cccc4)NC(=O)[C@H](Cc5c[nH]cn5)NC(=O)[C@@H]6CCC(=O)N6,C59H84N16O12,C07612,D08113,,46507635,6427,CHEMBL1201199,,571356,50369395,1209.3983,-2.40151467,"Adrenal Cortex Hormones; Agents Causing Muscle Toxicity; Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Endocrine Therapy; Fertility Agents; Fertility Agents, Female; Gonadotropin Releasing Hormone Receptor Agonist; Gonadotropin Releasing Hormone Receptor Agonists; Gonadotropin-releasing hormone agonist; Gonadotropins; Hormones; Hormones and Related Agents; Hyperglycemia-Associated Agents; Hypothalamic Hormones; Moderate Risk QTc-Prolonging Agents; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Photosensitizing Agents; Pituitary Hormone-Releasing Hormones; Proteins; QTc Prolonging Agents; Reproductive Control Agents"
DB00014,Goserelin,65807-02-5,approved,BLCLNMBMMGCOAS-URPVMXJPSA-N,"InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1",NC(=O)NNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c(c34)cccc4)NC(=O)[C@H](Cc5cnc[nH]5)NC(=O)[C@@H]6CCC(=O)N6,C59H84N18O14,,D00573,5311128,46507336,5523,CHEMBL1201247,,4470656,,1269.4105,-5.175573318,"Adrenal Cortex Hormones; Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Drugs that are Mainly Renally Excreted; Endocrine Therapy; Gonadotropin Releasing Hormone Receptor Agonist; Gonadotropin Releasing Hormone Receptor Agonists; Gonadotropin-releasing hormone agonist; Gonadotropins and Antigonadotropins; Hormones; Hormones and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Hypothalamic Hormones; Miscellaneous Therapeutic Agents; Moderate Risk QTc-Prolonging Agents; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary Hormone-Releasing Hormones; Proteins; QTc Prolonging Agents"
DB00027,Gramicidin D,1405-97-6,approved,NDAYQJDHGXTBJL-MWWSRJDJSA-N,"InChI=1S/C96H135N19O16/c1-50(2)36-71(105-79(118)48-102-93(128)80(54(9)10)103-49-117)86(121)104-58(17)84(119)113-82(56(13)14)95(130)115-83(57(15)16)96(131)114-81(55(11)12)94(129)112-78(43-62-47-101-70-33-25-21-29-66(62)70)92(127)108-74(39-53(7)8)89(124)111-77(42-61-46-100-69-32-24-20-28-65(61)69)91(126)107-73(38-52(5)6)88(123)110-76(41-60-45-99-68-31-23-19-27-64(60)68)90(125)106-72(37-51(3)4)87(122)109-75(85(120)97-34-35-116)40-59-44-98-67-30-22-18-26-63(59)67/h18-33,44-47,49-58,71-78,80-83,98-101,116H,34-43,48H2,1-17H3,(H,97,120)(H,102,128)(H,103,117)(H,104,121)(H,105,118)(H,106,125)(H,107,126)(H,108,127)(H,109,122)(H,110,123)(H,111,124)(H,112,129)(H,113,119)(H,114,131)(H,115,130)/t58-,71+,72+,73+,74+,75-,76-,77-,78-,80-,81+,82+,83-/m0/s1",CC(C)CC(C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CC5=CNC6=CC=CC=C65)C(=O)NC(CC(C)C)C(=O)NC(CC7=CNC8=CC=CC=C87)C(=O)NCCO)NC(=O)CNC(=O)C(C(C)C)NC=O,C96H135N19O16,,D04369,45267103,46507412,,CHEMBL557217,,24623445,,1811.253,5.961331766,"Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Macrocyclic Compounds; Membrane Proteins; P-glycoprotein inhibitors; P-glycoprotein substrates; Peptides; Peptides, Cyclic; Polycyclic Compounds; Pore Forming Cytotoxic Proteins; Proteins; Respiratory System; Throat Preparations"
DB00035,Desmopressin,16679-58-6,approved,NFLWUMRGJYTJIN-PNIOQBSNSA-N,"InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1",NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)CCSSC[C@H](NC(=O)[C@@H](NC1=O)CC(=O)N)C(=O)N4CCC[C@H]4C(=O)N[C@@H](C(=O)NCC(=O)N)CCCNC(N)=N,C46H64N14O12S2,C06944,D00291,,,4450,CHEMBL1429,,4470602,50205308,1069.22,-6.128255122,"Agents that produce hypertension; Amino Acids, Peptides, and Proteins; Antidiuretic Agents; Arginine Vasopressin; Cardiovascular Agents; Coagulants; Drugs that are Mainly Renally Excreted; Factor VIII Activator; Hematologic Agents; Hemostatics; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Increased Coagulation Factor VIII Activity; Increased Coagulation Factor VIII Concentration; Natriuretic Agents; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormones; Pituitary Hormones, Posterior; Posterior Pituitary Lobe Hormones; Proteins; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Vasopressin Analog; Vasopressin and Analogues; Vasopressins"
DB00050,Cetrorelix,120287-85-6,approved; investigational,SBNPWPIBESPSIF-MHWMIDJBSA-N,"InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1",CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C,C70H92ClN17O14,,D07665,25074887,46505494,59224,CHEMBL1200490,,10482082,50369965,1431.038,-1.698626314,"Amino Acids, Peptides, and Proteins; Anti-Gonadotropin-Releasing Hormones; Decreased GnRH Secretion; Fertility Agents; Fertility Agents, Female; Gonadotropin Releasing Hormone Receptor Antagonists; Gonadotropin-releasing Hormone Antagonists; Hormone Antagonists; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormone-Releasing Hormones; Proteins; Reproductive Control Agents; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB00067,Vasopressin,11000-17-2,approved,JLTCWSBVQSZVLT-UHFFFAOYSA-N,"InChI=1S/C46H65N15O12S2.C46H65N13O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25;47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53);1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)", ,C92H130N28O24S4,C00840,D00101,,46505933,,CHEMBL373742,,10152658,,2140.46,-7.249321714,"Amino Acids, Peptides, and Proteins; Antidiuretic Agents; Arginine Vasopressin; Arginine Vasopressin, agonists; Arginine Vasopressin, analogs & derivatives; Arginine Vasopressin, antagonists & inhibitors; Cardiovascular Agents; Coagulants; Hematologic Agents; Hemostatics; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Natriuretic Agents; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary; Pituitary Hormones; Pituitary Hormones, Posterior; Proteins; Vasoconstrictor Agents; Vasopressin and Analogues; Vasopressins; Vasopressins, antagonists & inhibitors"
DB00080,Daptomycin,103060-53-3,approved; investigational,DOAKLVKFURWEDJ-QCMAZARJSA-N,"InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45-,46+,47+,48+,49+,50-,60+,61+/m1/s1",CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,C72H101N17O26,C12013,D01080,16134395,46504551,600103,CHEMBL387675,,10200644,,1620.693,-9.365402671,"Agents Causing Muscle Toxicity; Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cyclic Lipopeptides; Drugs that are Mainly Renally Excreted; Lipids; Lipopeptide Antibacterial; Lipopeptides; Macrocyclic Compounds; Peptides; Peptides, Cyclic; Polycyclic Compounds"
DB00091,Cyclosporine,59865-13-3,approved; investigational; vet_approved,PMATZTZNYRCHOR-CGLBZJNRSA-N,"InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1",C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,C62H111N11O12,C05086,D00184,5284373,46508198,4031,CHEMBL160,,4447449,50022815,1202.635,3.638157327,"Agents causing hyperkalemia; Agents Causing Muscle Toxicity; Agents that produce hypertension; Agents that produce neuromuscular block (indirect); Agents that reduce seizure threshold; Amino Acids, Peptides, and Proteins; Anti-Inflammatory Agents; Antirheumatic Agents; BCRP/ABCG2 Inhibitors; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Calcineurin Inhibitor Immunosuppressant; Calcineurin Inhibitors; Cyclosporins; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Enzyme Inhibitors; Immunologic Factors; Immunosuppressive Agents; Macrocyclic Compounds; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Neurotoxic agents; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; Ophthalmologicals; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Peptides; Peptides, Cyclic"
DB00104,Octreotide,83150-76-9,approved; investigational,DEQANNDTNATYII-OULOTJBUSA-N,"InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1",NCCCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)N[C@H](CO)[C@@H](C)O)CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](C(=O)N1)Cc4c[nH]c(c45)cccc5,C49H66N10O10S2,C07306,D00442,448601,46504600,,CHEMBL1680,,395352,50272772,1019.25,-1.411264911,"Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bradycardia-Causing Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Gastrointestinal Agents; Hyperglycemia-Associated Agents; Hypoglycemia-Associated Agents; Hypothalamic Hormones; Macrocyclic Compounds; Miscellaneous Therapeutic Agents; P-glycoprotein substrates; Peptides; Peptides, Cyclic; Pituitary and Hypothalamic Hormones and Analogues; Polycyclic Compounds; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Somatostatin and Analogues; Somatostatin Receptor Agonists; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB00106,Abarelix,183552-38-7,approved; investigational; withdrawn,AIWRTTMUVOZGPW-HSPKUQOVSA-N,"InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1",CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)N(C)C(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C,C72H95ClN14O14,,D02738,16131215,46508237,337298,CHEMBL1252,,10482301,50102442,1416.09,-0.462875906,"Amino Acids, Peptides, and Proteins; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides"
DB00114,Pyridoxal phosphate,54-47-7,approved; investigational; nutraceutical,NGVDGCNFYWLIFO-UHFFFAOYSA-N,"InChI=1S/C8H10NO6P/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14/h2-3,11H,4H2,1H3,(H2,12,13,14)",Cc1ncc(c(C=O)c1O)COP(=O)(O)O,C8H10NO6P,C00018,D00006,1051,46506428,18405,CHEMBL82202,PLP,1022,50118216,247.1419,-2.085608704,"Alimentary Tract and Metabolism; Coenzymes; Diet, Food, and Nutrition; Dietary Supplements; Enzymes and Coenzymes; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Micronutrients; Physiological Phenomena; Picolines; Pyridines; Supplements; Vitamin B Complex; Vitamins"
DB00115,Cyanocobalamin,68-19-9,approved; nutraceutical,RMRCNWBMXRMIRW-WZHZPDAFSA-L,"InChI=1S/C62H90N13O14P.CN.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-2;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;/q;;+2/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1",Cc(c1)c(C)cc(c12)ncn2[C@@H]3[C@H](O)[C@@H]([C@H](O3)CO)OP([O-])(=O)O[C@H](C)CNC(=O)CC[C@](C)([C@@H](CC(=O)N)[C@@H]4[C@]56C)C(=N4)/C(C)=C7\N=C(C(C)(C)[C@@H]7CCC(=O)N)/C=C8\N=C([C@@](C)(CC(=O)N)[C@@H]8CCC(=O)N)/C(C)=C(\N5[Co+]C#N)[C@@H](CCC(=O)N)[C@]6(C)CC(=O)N,C63H88CoN14O14P,C02823,D00166,70678590,46509031,17439,CHEMBL2110563,CNC,21864832,,1355.3652,-3.237631305,"Antianemic Preparations; Blood and Blood Forming Organs; Corrinoids; Diet, Food, and Nutrition; Drugs that are Mainly Renally Excreted; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Iron Preparations; Macrocyclic Compounds; Micronutrients; Polycyclic Compounds; Pyrroles; Tetrapyrroles; Vitamin B 12, biosynthesis; Vitamin B Complex; VITAMIN B12 AND FOLIC ACID; Vitamins"
DB00118,Ademetionine,29908-03-0,approved; investigational; nutraceutical,MEFKEPWMEQBLKI-AIRLBKTGSA-N,"InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1",[O-]C(=O)[C@@H](N)CC[S+](C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(N)ncn3,C15H22N6O5S,C00019,,34755,46505280,67040,CHEMBL1088977,SAM,31982,28422,398.44,-5.31867776,"Alimentary Tract and Metabolism; Amino Acids; Amino Acids and Derivatives; Amino Acids, Essential; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Carbohydrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Dietary Supplements; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Purine Nucleosides; Purines; Ribonucleosides; Sulfur Compounds; Supplements"
DB00119,Pyruvic acid,127-17-3,approved; investigational; nutraceutical,LCTONWCANYUPML-UHFFFAOYSA-N,"InChI=1S/C3H4O3/c1-2(4)3(5)6/h1H3,(H,5,6)",CC(=O)C(=O)O,C3H4O3,C00022,,1060,46505692,32816,CHEMBL1162144,PYR,1031,19473,88.0621,0.065873953,Carboxylic Acids; Dietary Supplements; Keto Acids; Pyruvates; Supplements
DB00120,Phenylalanine,63-91-2,approved; investigational; nutraceutical,COLNVLDHVKWLRT-QMMMGPOBSA-N,"InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1",OC(=O)[C@@H](N)Cc1ccccc1,C9H11NO2,C00079,D00021,6140,46505708,17295,CHEMBL301523,PHE,5910,18073,165.1891,-1.184438469,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Dietary Supplements; Immunosuppressive Agents; Myelosuppressive Agents; Supplements"
DB00121,Biotin,58-85-5,approved; investigational; nutraceutical,YBJHBAHKTGYVGT-ZKWXMUAHSA-N,"InChI=1S/C10H16N2O3S/c13-8(14)4-2-1-3-7-9-6(5-16-7)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)/t6-,7-,9-/m0/s1",O=C(N1)N[C@H]([C@H]12)CS[C@H]2CCCCC(=O)O,C10H16N2O3S,C00120,D00029,171548,46508694,15956,CHEMBL857,BTN,149962,12,244.311,0.319423648,"Alimentary Tract and Metabolism; Azoles; Coenzymes; Diet, Food, and Nutrition; Dietary Supplements; Enzymes and Coenzymes; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Micronutrients; Physiological Phenomena; Supplements; Vitamin B Complex; Vitamins"
DB00122,Choline,62-49-7,approved; nutraceutical,OEYIOHPDSNJKLS-UHFFFAOYSA-N,"InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1",C[N+](C)(C)CCO,C5H14NO,C00114,D07690,305,46508132,15354,CHEMBL920,CHT,299,50026220,104.1708,-4.662269163,Alcohols; Amines; Amino Alcohols; Ammonium Compounds; Analgesics; Antimetabolites; Central Nervous System Agents; Dietary Supplements; Ethanolamines; Gastrointestinal Agents; Hypolipidemic Agents; Lipid Regulating Agents; Lipotropic Agents; Nervous System; Nitrogen Compounds; Nootropic Agents; Noxae; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; Onium Compounds; Other Nutritional Agents; Quaternary Ammonium Compounds; Salicylic Acid and Derivatives; Supplements; Toxic Actions; Trimethyl Ammonium Compounds; Vitamin B Complex; Vitamins
DB00123,L-Lysine,56-87-1,approved; nutraceutical,KDXKERNSBIXSRK-YFKPBYRVSA-N,"InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1",NCCCC[C@H](N)C(=O)O,C6H14N2O2,C00047,D02304,5962,46504770,18019,CHEMBL8085,LYS,5747,217367,146.1876,-3.214534721,"Amino Acids; Amino Acids, Basic; Amino Acids, Diamino; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Detoxifying Agents for Antineoplastic Treatment; Dietary Supplements; I.V. Solution Additives; Lysine; Supplements"
DB00126,Ascorbic acid,50-81-7,approved; nutraceutical,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,"InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1",OC[C@H](O)[C@H]1OC(=O)C(O)=C1O,C6H8O6,C00072,D00018,54670067,46505070,29073,CHEMBL196,ASC,10189562,50090256,176.1241,-1.913558876,"Acids, Acyclic; Alimentary Tract and Metabolism; Antioxidants; Carbohydrates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Food; Food and Beverages; Gastrointestinal Acidifying Agents; Genito Urinary System and Sex Hormones; Growth Substances; Gynecological Antiinfectives and Antiseptics; Hydroxy Acids; Micronutrients; Ophthalmologicals; Organic Acids; Physiological Phenomena; Protective Agents; Sensory Organs; Sugar Acids; Urinary Acidifying Agents; Vitamin C and analogues; Vitamins"
DB00128,Aspartic acid,56-84-8,approved; nutraceutical,CKLJMWTZIZZHCS-REOHCLBHSA-N,"InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1",OC(=O)[C@@H](N)CC(=O)O,C4H7NO4,C00049,D00013,5960,46507997,17053,CHEMBL274323,IAS,5745,18125,133.1027,-3.503752755,"Amino Acids; Amino Acids, Acidic; Amino Acids, Dicarboxylic; Amino Acids, Peptides, and Proteins; Dietary Supplements; Excitatory Amino Acids; Supplements"
DB00129,Ornithine,70-26-8,approved; nutraceutical,AHLPHDHHMVZTML-BYPYZUCNSA-N,"InChI=1S/C5H12N2O2/c6-3-1-2-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1",NCCC[C@H](N)C(=O)O,C5H12N2O2,C00077,,6262,46505239,15729,CHEMBL446143,ORN,6026,,132.161,-3.658287608,"Alimentary Tract and Metabolism; Amino Acids; Amino Acids, Basic; Amino Acids, Diamino; Amino Acids, Peptides, and Proteins; Bile and Liver Therapy; Dietary Supplements; Liver Therapy; Liver Therapy, Lipotropics; Oligopeptides; Peptides; Supplements"
DB00130,L-Glutamine,56-85-9,approved; investigational; nutraceutical,ZDXPYRJPNDTMRX-VKHMYHEASA-N,"InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1",OC(=O)[C@@H](N)CCC(=O)N,C5H10N2O3,C00064,D00015,5961,46505866,58359,CHEMBL930,GLN,5746,18121,146.1445,-4.001133427,"Alimentary Tract and Metabolism; Amino Acids; Amino Acids and Derivatives; Amino Acids, Basic; Amino Acids, Diamino; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Dietary Supplements; Glutamine; Supplements"
DB00131,Adenosine phosphate,61-19-8,approved; investigational; nutraceutical,UDMBCSSLTHHNCD-KQYNXXCUSA-N,"InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1",n1cnc(N)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)O,C10H14N5O7P,C00020,D02769,6083,46507628,16027,CHEMBL752,AMP,5858,18137,347.2212,-4.788289392,"Adenine Nucleotides; Carbohydrates; Dietary Supplements; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Purine Nucleotides; Purines; Ribonucleotides; Supplements"
DB00132,alpha-Linolenic acid,463-40-1,approved; investigational; nutraceutical,DTOSIQBPPRVQHS-PDBXOOCHSA-N,"InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-",CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,C18H30O2,C06427,,5280934,46507620,27432,CHEMBL8739,LNL,4444437,50240347,278.4296,6.059955138,"Diet, Food, and Nutrition; Dietary Fats; Dietary Fats, Unsaturated; Dietary Supplements; Fats; Fatty Acids; Fatty Acids, Essential; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fish Oils; Food; Food and Beverages; Linolenic Acids; Lipids; Oils; Physiological Phenomena; Supplements"
DB00134,Methionine,63-68-3,approved; nutraceutical,FFEARJCKVFRZRR-BYPYZUCNSA-N,"InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1",CSCC[C@H](N)C(=O)O,C5H11NO2S,C00073,D00019,6137,46505750,16643,CHEMBL42336,MET,5907,50142500,149.211,-2.189326617,"Amino Acids; Amino Acids, Essential; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Antidotes; Dietary Supplements; Sulfur Compounds; Supplements"
DB00135,Tyrosine,60-18-4,approved; investigational; nutraceutical,OUYCCCASQSFEME-QMMMGPOBSA-N,"InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1",OC(=O)[C@@H](N)Cc1ccc(O)cc1,C9H11NO3,C00082,D00022,6057,46507885,58315,CHEMBL925,TYR,5833,18129,181.1885,-1.488594037,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Dietary Supplements; Supplements"
DB00136,Calcitriol,32222-06-3,approved; nutraceutical,GMRQFYUYWCNGIN-NKMMMXOESA-N,"InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1",CC(C)(O)CCC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)/C(CCC2)=C/C=C3/C[C@@H](O)C[C@H](O)C3=C,C27H44O3,C01673,D00129,5280453,46508162,17823,CHEMBL846,VDX,4444108,50200182,416.6365,4.350740997,"Alimentary Tract and Metabolism; Antipsoriatics; Antipsoriatics for Topical Use; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Cholestanes; Cholestenes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Diet, Food, and Nutrition; Food; Food and Beverages; Fused-Ring Compounds; Growth Substances; Lipids; Membrane Lipids; Membrane Transport Modulators; Micronutrients; Misc. Skin and Mucous Membrane Agents; Physiological Phenomena; Polycyclic Compounds; Secosteroids; Steroids; Sterols; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)"
DB00137,Lutein,127-40-2,approved; investigational; nutraceutical,KBPHJBAIARWVSC-RGZFRNHPSA-N,"InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-25,35-37,41-42H,26-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36+,37-/m0/s1",CC1(C)C[C@@H](O)C=C(C)[C@@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C(C2(C)C)=C(C)C[C@@H](O)C2,C40H56O2,C08601,,5281243,46508835,28838,CHEMBL173929,LUT,4444655,,568.886,8.550209331,"Alkenes; Biological Factors; Carotenoids; Cyclohexanes; Cyclohexenes; Cycloparaffins; Dietary Supplements; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Pigments, Biological; Polycyclic Compounds; Polyenes; Supplements; Terpenes; Xanthophylls"
DB00138,Cystine,56-89-3,approved; nutraceutical,LEVWYRKDKASIDU-IMJSIDKUSA-N,"InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)/t3-,4-/m0/s1",OC(=O)[C@@H](N)CSSC[C@H](N)C(=O)O,C6H12N2O4S2,C00491,D03636,67678,46506670,16283,CHEMBL590540,,60997,,240.3,-5.89768796,"Acids; Acids, Noncarboxylic; Amino Acids; Amino Acids, Diamino; Amino Acids, Dicarboxylic; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Anions; Cysteine; Dietary Supplements; Disulfides; Electrolytes; Gases; Hydrogen Sulfide; Ions; Sulfhydryl Compounds; Sulfides; Sulfur Compounds; Supplements"
DB00139,Succinic acid,110-15-6,approved; nutraceutical,KDYFGRWQOYBRFD-UHFFFAOYSA-N,"InChI=1S/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)",OC(=O)CCC(=O)O,C4H6O4,C00042,,1110,46505859,15741,CHEMBL576,SIN,1078,26121,118.088,-0.398482967,"Acids, Acyclic; Carboxylic Acids; Dicarboxylic Acids; Dietary Supplements; OAT3/SLC22A8 Substrates; Succinates; Supplements"
DB00140,Riboflavin,83-88-5,approved; investigational; nutraceutical; vet_approved,AUNGANRZJHBGPY-SCRDCRAPSA-N,"InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1",OC[C@@H](O)[C@@H](O)[C@@H](O)Cn(c(c12)cc(C)c(C)c1)c3c(n2)c(=O)[nH]c(n3)=O,C17H20N4O6,C00255,D00050,493570,46507342,17015,CHEMBL1534,RBF,431981,50362895,376.3639,-0.91654026,"Alimentary Tract and Metabolism; Biological Factors; Coenzymes; Dermatologicals; Diet, Food, and Nutrition; Enzymes and Coenzymes; Flavins; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Micronutrients; OAT1/SLC22A6 inhibitors; Ophthalmologicals; Photosensitizing Agents; Physiological Phenomena; Pigments, Biological; Pteridines; Radiation-Sensitizing Agents; Sensory Organs; Vitamin B Complex; Vitamins"
DB00141,N-Acetylglucosamine,7512-17-6,approved; investigational; nutraceutical,MBLBDJOUHNCFQT-LXGUWJNJSA-N,"InChI=1S/C8H15NO6/c1-4(12)9-5(2-10)7(14)8(15)6(13)3-11/h2,5-8,11,13-15H,3H2,1H3,(H,9,12)/t5-,6+,7+,8+/m0/s1",CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO,C8H15NO6,C00140,,1738118,46509139,17411,CHEMBL447878,NAG,1376695,50223349,221.2078,-3.856395757,Dietary Supplements; Supplements
DB00142,Glutamic acid,56-86-0,approved; nutraceutical,WHUUTDBJXJRKMK-VKHMYHEASA-N,"InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1",OC(=O)[C@@H](N)CCC(=O)O,C5H9NO4,C00025,D00007,33032,46505816,16015,CHEMBL575060,GGL,30572,17657,147.1293,-3.241447076,"Acid Preparations; Alimentary Tract and Metabolism; Amino Acids; Amino Acids, Acidic; Amino Acids, Dicarboxylic; Amino Acids, Peptides, and Proteins; Dietary Supplements; Digestives, Incl. Enzymes; Excitatory Amino Acids; Gastrointestinal Acidifying Agents; Gastrointestinal Agents; Glutamates; Supplements"
DB00143,Glutathione,70-18-8,approved; investigational; nutraceutical,RWSXRVCMGQZWBV-WDSKDSINSA-N,"InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1",OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O,C10H17N3O6S,C02471,D00014,124886,46504598,16856,CHEMBL1543,GSH,111188,50422268,307.323,-3.341817516,"Amino Acids, Peptides, and Proteins; Antidotes; Dietary Supplements; Glutathione, antagonists & inhibitors; Oligopeptides; Peptides; Supplements"
DB00144,Phosphatidyl serine,1446756-47-3,approved; investigational; nutraceutical,UNJJBGNPUUVVFQ-ZJUUUORDSA-N,"InChI=1S/C13H24NO10P/c1-3-5-12(16)24-9(6-21-11(15)4-2)7-22-25(19,20)23-8-10(14)13(17)18/h9-10H,3-8,14H2,1-2H3,(H,17,18)(H,19,20)/t9-,10+/m1/s1",CCCC(=O)O[C@H](COC(=O)CC)COP(=O)(O)OC[C@H](N)C(=O)O,C13H24NO10P,,,6323481,46505650,18303,,PSF,13628254,,792.089,11.27178143,Alcohols; Carbohydrates; Dietary Supplements; Glycerophosphates; Glycerophospholipids; Lipids; Membrane Lipids; Phosphatidic Acids; Phosphatidylserines; Phospholipids; Sugar Alcohols; Sugar Phosphates; Supplements; Triose Sugar Alcohols
DB00145,Glycine,56-40-6,approved; nutraceutical; vet_approved,DHMQDGOQFOQNFH-UHFFFAOYSA-N,"InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)",NCC(=O)O,C2H5NO2,C00037,D00011,750,46508219,15428,CHEMBL773,GLY,730,18133,75.0666,-3.409459573,"Amino Acids; Amino Acids, Peptides, and Proteins; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Dietary Supplements; Glycine Agents; Irrigating Solutions; Neurotransmitter Agents; Supplements"
DB00146,Calcifediol,19356-17-3,approved; nutraceutical,JWUBBDSIWDLEOM-DTOXIADCSA-N,"InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1",CC(C)(O)CCC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)/C(CCC2)=C/C=C3/C[C@@H](O)CCC3=C,C27H44O2,C01561,,5283731,46505690,17933,CHEMBL1040,VDY,4446820,,400.6371,5.65434607,"Alimentary Tract and Metabolism; Bone Density Conservation Agents; Cholestanes; Cholestenes; Diet, Food, and Nutrition; Food; Food and Beverages; Fused-Ring Compounds; Growth Substances; Lipids; Membrane Lipids; Micronutrients; Physiological Phenomena; Polycyclic Compounds; Secosteroids; Steroids; Sterols; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)"
DB00148,Creatine,57-00-1,approved; investigational; nutraceutical,CVSVTCORWBXHQV-UHFFFAOYSA-N,"InChI=1S/C4H9N3O2/c1-7(4(5)6)2-3(8)9/h2H2,1H3,(H3,5,6)(H,8,9)",NC(=N)N(C)CC(=O)O,C4H9N3O2,C00300,,586,46504868,16919,CHEMBL283800,CRN,566,50357229,131.1332,-2.864223884,"Amidines; Amino Acids; Amino Acids, Peptides, and Proteins; Dietary Supplements; Guanidines; Supplements"
DB00150,Tryptophan,73-22-3,approved; nutraceutical; withdrawn,QIVBCDIJIAJPQS-VIFPVBQESA-N,"InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1",OC(=O)[C@@H](N)Cc1c[nH]c(c12)cccc2,C11H12N2O2,C00078,D00020,6305,46508329,16828,CHEMBL54976,TRP,6066,21974,204.2252,-1.085456914,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Antidepressive Agents; Antidepressive Agents, Second-Generation; Central Nervous System Agents; Central Nervous System Depressants; Dietary Supplements; Miscellaneous Antidepressants; Nervous System; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Supplements; Tryptophan"
DB00151,Cysteine,52-90-4,approved; nutraceutical,XUJNEKJLAYXESH-REOHCLBHSA-N,"InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1",OC(=O)[C@@H](N)CS,C3H7NO2S,C00097,D00026,5862,46506553,17561,CHEMBL863,CYS,5653,50109609,121.158,-2.792133298,"Amino Acids; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Caloric Agents; Cysteine; Dietary Supplements; Nutritional Support; Sulfhydryl Compounds; Sulfur Compounds; Supplements"
DB00152,Thiamine,70-16-6,approved; investigational; nutraceutical; vet_approved,JZRWCGZRTZMZEH-UHFFFAOYSA-N,"InChI=1S/C12H17N4OS/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15)/q+1",OCCc1c(C)[n+](cs1)Cc2cnc(C)nc2N,C12H17N4OS,C00378,D08580,1130,46507321,18385,CHEMBL1547,VIB,1098,50373877,265.355,-3.097412649,"Alimentary Tract and Metabolism; Azoles; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Micronutrients; OCT1 substrates; OCT2 Inhibitors; Physiological Phenomena; Pyrimidines; Sulfur Compounds; Thiazoles; Vitamin B Complex; Vitamins"
DB00153,Ergocalciferol,50-14-6,approved; nutraceutical,MECHNRXZTMCUDQ-RKHKHRCZSA-N,"InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1",CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]([C@@]12C)/C(CCC2)=C/C=C3/C[C@@H](O)CCC3=C,C28H44O,C05441,D00187,5280793,46505053,28934,CHEMBL1536,D2V,4444351,,396.6484,7.050558194,"Alimentary Tract and Metabolism; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Diet, Food, and Nutrition; Food; Food and Beverages; Fused-Ring Compounds; Growth Substances; Lipids; Micronutrients; Physiological Phenomena; Polycyclic Compounds; Secosteroids; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)"
DB00155,Citrulline,372-75-8,approved; investigational; nutraceutical,RHGKLRLOHDJJDR-BYPYZUCNSA-N,"InChI=1S/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1",OC(=O)[C@@H](N)CCCNC(=O)N,C6H13N3O3,C00327,D07706,9750,46506583,16349,CHEMBL444814,CIR,9367,92903,175.1857,-3.931957838,"Acids, Acyclic; Amino Acids; Amino Acids, Diamino; Amino Acids, Peptides, and Proteins; Carboxylic Acids; Dicarboxylic Acids; Dietary Supplements; Hydroxy Acids; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; Proteins; Supplements"
DB00156,Threonine,72-19-5,approved; nutraceutical,AYFVYJQAPQTCCC-GBXIJSLDSA-N,"InChI=1S/C4H9NO3/c1-2(6)3(5)4(7)8/h2-3,6H,5H2,1H3,(H,7,8)/t2-,3+/m1/s1",C[C@@H](O)[C@H](N)C(=O)O,C4H9NO3,C00188,D00041,6288,46506798,16857,CHEMBL291747,THR,6051,,119.1192,-3.470963524,"Amino Acids; Amino Acids, Essential; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Dietary Supplements; Supplements; Threonine, antagonists & inhibitors"
DB00157,NADH,58-68-4,approved; nutraceutical,BOPGDPNILDQYTO-NNYOXOHSSA-N,"InChI=1S/C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1",NC(=O)C1=CN(C=CC1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO[P@@](=O)(O)O[P@@](=O)(O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n4cnc(c45)c(N)ncn5,C21H29N7O14P2,C00004,,439153,46504879,16908,,NAI,388299,,665.441,-6.47175584,"Adenine Nucleotides; Carbohydrates; Coenzymes; Dietary Supplements; Enzymes and Coenzymes; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Purine Nucleotides; Purines; Ribonucleotides; Supplements"
DB00158,Folic acid,59-30-3,approved; nutraceutical; vet_approved,OVBPIULPVIDEAO-LBPRGKRZSA-N,"InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1",Nc([nH]1)nc(=O)c(c12)nc(cn2)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O,C19H19N7O6,C00504,D00070,6037,46508092,27470,CHEMBL1622,FOL,5815,50237629,441.3975,-0.682249252,"Antianemic Preparations; Autacoids; BCRP/ABCG2 Substrates; Biological Factors; Diagnostic Agents; Diet, Food, and Nutrition; Dietary Supplements; Drugs that are Mainly Renally Excreted; Folic Acid and Derivatives; Food; Food and Beverages; Growth Substances; Hematinics; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Micronutrients; OAT1/SLC22A6 inhibitors; Pteridines; Pterins; Supplements; Vitamin B Complex; VITAMIN B12 AND FOLIC ACID; Vitamins"
DB00159,Icosapent,10417-94-4,approved; nutraceutical,JAZBEHYOTPTENJ-JLNKQSITSA-N,"InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-",CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,C20H30O2,C06428,D08061,446284,46506267,28364,CHEMBL460026,EPA,393682,50242349,302.451,6.225249154,"Agents causing hyperkalemia; Agents that produce hypertension; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Autacoids; Biological Factors; Diet, Food, and Nutrition; Dietary Fats; Dietary Fats, Unsaturated; Dietary Supplements; Eicosanoids; Fats; Fatty Acids; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fish Oils; Food; Food and Beverages; Hypolipidemic Agents; Inflammation Mediators; Lipids; Nephrotoxic agents; Non COX-2 selective NSAIDS; Oils; Physiological Phenomena; Supplements"
DB00161,Valine,72-18-4,approved; nutraceutical,KZSNJWFQEVHDMF-BYPYZUCNSA-N,"InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1",CC(C)[C@H](N)C(=O)O,C5H11NO2,C00183,D00039,6287,46504886,16414,CHEMBL43068,VAL,6050,,117.1463,-1.953136464,"Amino Acids; Amino Acids, Branched-Chain; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Dietary Supplements; Valine"
DB00162,Vitamin A,68-26-8,approved; nutraceutical; vet_approved,FPIPGXGPPPQFEQ-OVSJKPMPSA-N,"InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+",OC/C=C(\C)/C=C/C=C(\C)/C=C/C(C1(C)C)=C(C)CCC1,C20H30O,C17276,D00069,445354,46508191,17336,CHEMBL986,RTL,393012,50092056,286.4516,4.694093173,"Adjuvants, Immunologic; Alimentary Tract and Metabolism; Alkenes; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anticarcinogenic Agents; Antioxidants; Biological Factors; Carotenoids; Compounds used in a research, industrial, or household setting; Cyclohexanes; Cyclohexenes; Cycloparaffins; Dermatologicals; Diagnostic Agents; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Immunologic Factors; Macrocyclic Compounds; Micronutrients; Nasal Preparations; Ophthalmologicals; Physiological Phenomena; Pigments, Biological; Polycyclic Compounds; Polyenes; Protective Agents; Respiratory System; Retinoids; Retinoids for Topical Use in Acne; Sensory Organs; Terpenes; Tests for Fat Absorption; Vitamin A; Vitamins; Vitamins (Fat Soluble)"
DB00163,Vitamin E,59-02-9,approved; nutraceutical; vet_approved,GVJHHUAWPYXKBD-IEOSBIPESA-N,"InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1",CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(O)c(C)c2C,C29H50O2,C02477,,14985,46506524,18145,CHEMBL47,VIV,14265,,430.7061,10.50771726,"Antioxidants; Basic Ointments and Protectants; Benzopyrans; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Diet, Food, and Nutrition; Dietary Supplements; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Micronutrients; Physiological Phenomena; Protective Agents; Pyrans; Supplements; Vitamin E; Vitamin E, analogs & derivatives; Vitamins; Vitamins (Fat Soluble)"
DB00165,Pyridoxine,65-23-6,approved; investigational; nutraceutical; vet_approved,LXNHXLLTXMVWPM-UHFFFAOYSA-N,"InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3",Cc1c(O)c(CO)c(cn1)CO,C8H11NO3,C00314,,1054,46508560,16709,CHEMBL1364,UEG,1025,50103505,169.1778,-0.951321298,"Alimentary Tract and Metabolism; Analogs/Derivatives; Antiinfectives for Systemic Use; Antimycobacterials; Diet, Food, and Nutrition; Drugs for Treatment of Tuberculosis; Drugs that are Mainly Renally Excreted; Food; Food and Beverages; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Micronutrients; Picolines; Pyridines; Vitamin B Complex; Vitamins"
DB00166,Lipoic acid,1200-22-2,approved; investigational; nutraceutical,AGBQKNBQESQNJD-SSDOTTSWSA-N,"InChI=1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)/t7-/m1/s1",OC(=O)CCCC[C@@H]1CCSS1,C8H14O2S2,C16241,D00086,6112,46504826,30314,CHEMBL134342,LPA,5886,50106731,206.326,2.113779408,"Alimentary Tract and Metabolism; Antioxidants; Carboxylic Acids; Coenzymes; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Dietary Supplements; Enzymes and Coenzymes; Fatty Acids; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypoglycemia-Associated Agents; Lipids; Micronutrients; Physiological Phenomena; Protective Agents; Sulfur Compounds; Supplements; Thiophenes; Various Alimentary Tract and Metabolism Products; Vitamin B Complex; Vitamins"
DB00169,Cholecalciferol,67-97-0,approved; nutraceutical,QYSXJUFSXHHAJI-YRZJJWOYSA-N,"InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1",CC(C)CCC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)/C(CCC2)=C/C=C3/C[C@@H](O)CCC3=C,C27H44O,C05443,D00188,5280795,46506365,28940,CHEMBL1042,VD3,4444353,50030475,384.6377,7.125460755,"Alimentary Tract and Metabolism; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Cholecalciferol, antagonists & inhibitors; Cholestanes; Cholestenes; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diet, Food, and Nutrition; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Food; Food and Beverages; Fused-Ring Compounds; Growth Substances; Lipids; Membrane Lipids; Micronutrients; Musculo-Skeletal System; Physiological Phenomena; Polycyclic Compounds; Secosteroids; Steroids; Sterols; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)"
DB00170,Menadione,58-27-5,approved; nutraceutical,MJVAVZPDRWSRRC-UHFFFAOYSA-N,"InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3",O=C1C(C)=CC(=O)c(c12)cccc2,C11H8O2,C05377,D02335,4055,46505447,28869,CHEMBL590,VK3,3915,24778,172.18,1.88986844,"Antifibrinolytic Agents; Blood and Blood Forming Organs; Coagulants; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Diet, Food, and Nutrition; Dietary Supplements; Diterpenes; Fibrin Modulating Agents; Food; Food and Beverages; Growth Substances; Hematologic Agents; Hemostatics; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Micronutrients; Naphthalenes; Naphthoquinones; Physiological Phenomena; Phytol; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quinones; Supplements; Terpenes; Vitamin K; Vitamins; Vitamins (Fat Soluble)"
DB00173,Adenine,73-24-5,approved; nutraceutical,GFFGJBXGBJISGV-UHFFFAOYSA-N,"InChI=1S/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10)",n1cnc(N)c(c12)[nH]cn2,C5H5N5,C00147,D00034,190,46507319,16708,CHEMBL226345,ADE,185,181146,135.1267,-0.573470231,"Dietary Supplements; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Purines; Supplements; UGT1A1 Inhibitors"
DB00174,Asparagine,70-47-3,approved; investigational; nutraceutical,DCXYFEDJOCDNAF-REOHCLBHSA-N,"InChI=1S/C4H8N2O3/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H2,6,7)(H,8,9)/t2-/m0/s1",OC(=O)[C@@H](N)CC(=O)N,C4H8N2O3,C00152,,6267,46507804,58048,CHEMBL58832,41Q,6031,181137,132.1179,-4.287830841,"Amino Acids; Amino Acids, Basic; Amino Acids, Diamino; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Dietary Supplements; Supplements"
DB00175,Pravastatin,81093-37-0,approved,TUZYXOIXSAXUGO-PZAWKZKUSA-N,"InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1",CC[C@H](C)C(=O)O[C@@H](C[C@H](O)C=1)[C@@H](C12)[C@H]([C@@H](C)C=C2)CC[C@@H](O)C[C@@H](O)CC(=O)O,C23H36O7,C01844,D08410,54687,46504851,63618,CHEMBL1144,,49398,20688,424.5277,1.64709162,"Agents Causing Muscle Toxicity; Anticholesteremic Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; BSEP/ABCB11 Substrates; Cardiovascular System; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Noxae; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Toxic Actions"
DB00176,Fluvoxamine,54739-18-3,approved; investigational,CJOFXWAVKWHTFT-XSFVSMFZSA-N,"InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+",COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,C15H21F3N2O2,C07571,,3404,46507588,5138,CHEMBL814,FVX,4481878,50028091,318.34,2.79531958,"Amines; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Second-Generation; BSEP/ABCB11 Substrates; Central Nervous System Agents; Central Nervous System Depressants; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strong); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydroxylamines; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Metabolic Side Effects of Drugs and Substances; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Oximes; P-glycoprotein inhibitors; Psychoanaleptics; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Tranquilizing Agents"
DB00177,Valsartan,137862-53-4,approved; investigational,ACWBQPMHZXGDFX-QFIPXVFZSA-N,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",CCCCC(=O)N([C@@H](C(C)C)C(=O)O)Cc1ccc(cc1)-c2ccccc2-c3n[nH]nn3,C24H29N5O3,,D00400,60846,46509000,9927,CHEMBL1069,,54833,50049186,435.5188,5.269378978,"Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin 2 Receptor Blocker; Angiotensin II Antagonists and Calcium Channel Blockers; Angiotensin II Antagonists and Diuretics; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Angiotensin II receptor blockers (ARBs) and diuretics; Angiotensin II receptor blockers (ARBs), plain; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Hypotensive Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates"
DB00178,Ramipril,87333-19-5,approved,HDACQVRGBOVJII-JBDAPHQKSA-N,"InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1",C1CC[C@H]([C@H]12)C[C@@H](C(=O)O)N2C(=O)[C@H](C)N[C@H](C(=O)OCC)CCc3ccccc3,C23H32N2O5,,D00421,5362129,46506390,8774,CHEMBL1168,,4514937,50084681,416.5106,1.473811438,"ACE Inhibitors and Calcium Channel Blockers; ACE Inhibitors and Diuretics; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Cholinesterase Inhibitors; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Lipid Modifying Agents; Photosensitizing Agents; Protease Inhibitors"
DB00179,Masoprocol,27686-84-6,approved; investigational,HCZKYJDFEPMADG-TXEJJXNPSA-N,"InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+",Oc1ccc(cc1O)C[C@H](C)[C@H](C)Cc2cc(O)c(O)cc2,C18H22O4,C10719,D04862,71398,46508042,73468,CHEMBL313972,,64490,22372,302.3649,4.758522744,"Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Antioxidants; Benzene Derivatives; Benzyl Compounds; Catechols; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lignans; Lipoxygenase Inhibitors; Peripheral Nervous System Agents; Phenols; Protective Agents; Sensory System Agents"
DB00180,Flunisolide,03-03-3385,approved; investigational,XSFJVAJPIHIPKU-XWCQMRHXSA-N,"InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1",OCC(=O)[C@]12[C@H](OC(O1)(C)C)C[C@@H]3[C@]2(C)C[C@H](O)[C@H]4[C@H]3C[C@H](F)C=5[C@]4(C)C=CC(=O)C5,C24H31FO6,C07005,,82153,46507894,5106,CHEMBL1512,,74144,,434.4977,1.56079164,"Adrenal Cortex Hormones; Adrenals; Agents to Treat Airway Disease; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids for Systemic Use; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Fused-Ring Compounds; Immunosuppressive Agents; Medications that reduce magnesium levels; Nasal Preparations; Polycyclic Compounds; Pregnadienes; Pregnanes; Respiratory System; Respiratory System Agents; Steroids; Steroids, Fluorinated"
DB00181,Baclofen,1134-47-0,approved,KPYSYYIEGFHWSV-UHFFFAOYSA-N,"InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)",OC(=O)CC(CN)c1ccc(Cl)cc1,C10H12ClNO2,,D00241,2284,46508181,2972,CHEMBL701,,2197,24182,213.661,-0.78240026,"Agents Causing Muscle Toxicity; Amino Acids; Amino Acids, Peptides, and Proteins; Aminobutyrates; Butyrates; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Agonists; GABA-B Receptor Agonists; Gaba-derivative Skeletal Muscle Relaxants; gamma-Aminobutyric Acid-ergic Agonist; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neurotransmitter Agents"
DB00182,Amphetamine,300-62-9,approved; illicit; investigational,KWTSXDURSIMDCE-UHFFFAOYSA-N,"InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3",CC(N)Cc1ccccc1,C9H13N,C07514,D07445,3007,46506414,132233,CHEMBL405,,13852819,50005246,135.2062,1.804250482,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Amines; Amphetamines; Antidepressive Agents; Autonomic Agents; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Catechols; Central Nervous System Agents; Central Nervous System Depressants; Central Nervous System Stimulants; Central Nervous System Stimulation; Centrally Acting Sympathomimetics; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Uptake Inhibitors; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Membrane Transport Modulators; Monoamine Oxidase Inhibitors; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Peripheral Nervous System Agents; Phenethylamines; Phenols; Photosensitizing Agents; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetics"
DB00183,Pentagastrin,5534-95-2,approved,NEYNJQRKHLUJRU-DZUOILHNSA-N,"InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1",CC(C)(C)OC(=O)NCCC(=O)N[C@@H](Cc1c[nH]c(c12)cccc2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N)Cc3ccccc3,C37H49N7O9S,,D01631,9853654,46507747,31974,CHEMBL1328,,8029364,50024321,767.9,1.04964716,"Amino Acids, Peptides, and Proteins; Diagnostic Agents; Gastrins; Gastrointestinal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Pentagastrin, antagonists & inhibitors; Peptide Hormones; Peptides; Proteins; Tests for Gastric Secretion"
DB00184,Nicotine,54-11-5,approved,SNICXCGAKADSCV-JTQLQIEISA-N,"InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1",CN1CCC[C@H]1c2cnccc2,C10H14N2,C00745,D03365,89594,46506924,17688,CHEMBL3,NCT,80863,82070,162.2316,1.162534693,"Agents producing tachycardia; Alkaloids; Autonomic Agents; Cholinergic Agents; Cholinergic Agonists; Cholinergic Nicotinic Agonist; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs Used in Addictive Disorders; Drugs Used in Nicotine Dependence; Ganglion Blockers; Ganglionic Stimulants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Miscellaneous Autonomic Drugs; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Nervous System; Neurotransmitter Agents; Nicotine, antagonists & inhibitors; Nicotine, metabolism; Nicotinic Agonists; OCT1 inhibitors; OCT2 Inhibitors; Peripheral Nervous System Agents; Pyridines; Smoking Cessation Agents; Solanaceous Alkaloids"
DB00185,Cevimeline,107233-08-9,approved,WUTYZMFRCNBCHQ-LHIURRSHSA-N,"InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8?,10-/m1/s1",CC(O1)SC[C@]12C3CCN(C2)CC3,C10H17NOS,,D00661,25137844,46507202,3568,,,21864737,,199.313,0.996406312,"Autonomic Agents; Cholinergic Agents; Cholinergic Agonists; Cholinergic Receptor Agonist; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Bridged-Ring; Muscarinic Agonists; Nervous System; Neurotransmitter Agents; Parasympathomimetics; Peripheral Nervous System Agents; Sulfur Compounds"
DB00186,Lorazepam,846-49-1,approved,DIWRORZWFLOCLC-UHFFFAOYSA-N,"InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)",c1cc(Cl)cc(c12)C(=NC(O)C(=O)N2)c3ccccc3Cl,C15H10Cl2N2O2,,D00365,3958,46508468,6539,CHEMBL580,,3821,50292627,321.158,3.527325488,"Anti-Anxiety Agents; Anticonvulsants; Antiemetics; Autonomic Agents; Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; Neurotransmitter Agents; Peripheral Nervous System Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB00187,Esmolol,81147-92-4,approved,AQNDDEOPVVGCPG-UHFFFAOYSA-N,"InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3",COC(=O)CCc1ccc(cc1)OCC(O)CNC(C)C,C16H25NO4,C06980,D07916,59768,46506146,88206,CHEMBL768,,53916,50404796,295.374,1.822430183,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Beta Blocking Agents, Selective; Beta-Blockers (Beta1 Selective); Bradycardia-Causing Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Hypotensive Agents; Neurotransmitter Agents; Potential QTc-Prolonging Agents; Propanols; QTc Prolonging Agents"
DB00188,Bortezomib,179324-69-7,approved; investigational,GXJABQQUPOEUTA-RDJZCZTQSA-N,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",c1ccccc1C[C@@H](C(=O)N[C@H](B(O)O)CC(C)C)NC(=O)c2cnccn2,C19H25BN4O4,,D03150,387447,46508736,52717,CHEMBL325041,BO2,343402,50069989,384.237,1.5303,"Acids; Acids, Noncarboxylic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Boron Compounds; Boronic Acids; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B3 inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Potential QTc-Prolonging Agents; Proteasome Inhibitors; Pyrazines; QTc Prolonging Agents"
DB00189,Ethchlorvynol,113-18-8,approved; illicit; withdrawn,ZEHYJZXQEQOSON-AATRIKPKSA-N,"InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+",CCC(O)(/C=C/Cl)C#C,C7H9ClO,C07833,D00704,5281077,46505006,4882,CHEMBL591,,4444534,,144.6,1.620819461,Alcohols; Central Nervous System Agents; Central Nervous System Depressants; Chlorohydrins; Hypnotics and Sedatives; Nervous System; Psycholeptics
DB00190,Carbidopa,28860-95-9,approved,TZFNLOMSOLWIDK-JTQLQIEISA-N,"InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1",NN[C@](C)(C(=O)O)Cc1cc(O)c(O)cc1,C10H14N2O4,,D00558,34359,46508775,39585,CHEMBL1201236,142,31640,50418773,226.2292,-1.207836201,"Amines; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic L-amino Acid Decarboxylase Inhibitors; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Catecholamines; Catechols; Central Nervous System Agents; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydrazines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols"
DB00191,Phentermine,122-09-8,approved; illicit,DHHVAGZRUROJKS-UHFFFAOYSA-N,"InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3",CC(C)(N)Cc1ccccc1,C10H15N,C07438,D05458,4771,46508515,8080,CHEMBL1574,,4607,50246598,149.2328,2.08482715,"Adrenergic Agents; Agents producing tachycardia; Agents that produce hypertension; Alimentary Tract and Metabolism; Amines; Amphetamines; Anti-Obesity Agents; Antiobesity Preparations, Excl. Diet Products; Appetite Depressants; Appetite Suppression; Autonomic Agents; Central Nervous System Agents; Centrally Acting Antiobesity Products; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Increased Sympathetic Activity; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenethylamines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetic Amine Anorectic; Sympathomimetics"
DB00192,Indecainide,74517-78-5,approved,UCEWGESNIULAGX-UHFFFAOYSA-N,"InChI=1S/C20H24N2O/c1-14(2)22-13-7-12-20(19(21)23)17-10-5-3-8-15(17)16-9-4-6-11-18(16)20/h3-6,8-11,14,22H,7,12-13H2,1-2H3,(H2,21,23)",CC(C)NCCCC1(C(=O)N)c(cccc2)c2c(c13)cccc3,C20H24N2O,,,52195,46506714,135314,CHEMBL1201242,,47194,,308.4174,3.26237588,"Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic"
DB00193,Tramadol,27203-92-5,approved; investigational,TVYLLZQTGLZFBW-ZBFHGGJFSA-N,"InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1",COc1cccc(c1)[C@@]2(O)CCCC[C@@H]2CN(C)C,C16H25NO2,C07153,D08623,33741,46506256,75725,CHEMBL1066,,31105,50176259,263.3752,2.449861499,"Agents producing tachycardia; Agents that reduce seizure threshold; Alcohols; Amines; Analgesics; Anticholinergic Agents; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cyclohexanes; Cyclohexanols; Cycloparaffins; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dimethylamines; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Cyclic; Muscarinic Antagonists; Narcotics; Nervous System; NMDA Receptor Antagonists; Opiate Agonists; Opioid Agonist; Opioids; Peripheral Nervous System Agents; Phenylpropylamine opioids; Polycyclic Compounds; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; UGT1A1 Substrates"
DB00194,Vidarabine,24356-66-9,approved; investigational,OIRDTQYFTABQOQ-UHTZMRCNSA-N,"InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1",Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O,C10H13N5O4,C07195,D00406,21704,46506630,45327,CHEMBL1090,RAB,20400,50144936,267.2413,-2.090963872,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antimetabolites; Antiviral Agents; Antivirals for Systemic Use; Arabinonucleosides; Carbohydrates; Direct Acting Antivirals; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Noxae; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; Ophthalmologicals; Purine Nucleosides; Purines; Ribonucleosides; Sensory Organs; Toxic Actions"
DB00195,Betaxolol,63659-18-7,approved; investigational,NWIUTZDMDHAVTP-UHFFFAOYSA-N,"InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3",CC(C)NCC(O)COc1ccc(cc1)CCOCC2CC2,C18H29NO3,C06849,,2369,46506041,3082,CHEMBL423,,2279,50405521,307.4278,2.539234387,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Autonomic Agents; Beta Blocking Agents, Selective; Beta-adrenergic Agents; Beta-Blockers (Beta1 Selective); Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Hypotensive Agents; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Ophthalmologicals; Peripheral Nervous System Agents; Phenoxypropanolamines; Propanolamines; Propanols; QTc Prolonging Agents; Sensory Organs; Sympatholytics"
DB00196,Fluconazole,86386-73-4,approved; investigational,RFHAOTPXVQNOHP-UHFFFAOYSA-N,"InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2",c1ncnn1CC(O)(Cn2cncn2)c3c(F)cc(F)cc3,C13H12F2N6O,,D00322,3365,46505735,46081,CHEMBL106,TPF,3248,25817,306.2708,0.560958282,"14-alpha Demethylase Inhibitors; Agents causing hyperkalemia; Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; Azole Antifungals; Azoles; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Imidazole and Triazole Derivatives; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Steroid Synthesis Inhibitors; Triazole Derivatives; Triazoles"
DB00197,Troglitazone,97322-87-7,approved; investigational; withdrawn,GXPHKUHSUJUWKP-UHFFFAOYSA-N,"InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)",Cc1c(O)c(C)c(C)c(c12)OC(C)(CC2)COc3ccc(cc3)CC4SC(=O)NC4=O,C24H27NO5S,,D00395,5591,46504655,9753,CHEMBL408,,5389,50088494,441.54,5.495204458,"Alimentary Tract and Metabolism; Azoles; Benzopyrans; Blood Glucose Lowering Agents; BSEP/ABCB11 Inhibitors; Chromans; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; OATP1B1/SLCO1B1 Inhibitors; Pyrans; Sulfur Compounds; Thiazoles; Thiazolidinediones; UGT1A1 Substrates; UGT1A3 substrates; UGT1A4 substrates; UGT1A6 Inhibitors; UGT1A6 substrate; UGT1A9 Substrates; UGT2B7 substrates"
DB00198,Oseltamivir,196618-13-0,approved,VSZGPKBBMSAYNT-RRFJBIMHSA-N,"InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1",CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@@H]([C@@H](N)C1)NC(=O)C,C16H28N2O4,C08092,D00900,65028,46507602,7798,CHEMBL1229,,58540,5025,312.4045,1.16259855,Acetamides; Acetates; Amides; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Neuraminidase Inhibitors; OAT3/SLC22A8 Substrates
DB00199,Erythromycin,114-07-8,approved; investigational; vet_approved,ULGZDMOVFRHVEP-RWJQBGPGSA-N,"InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1",C[C@]1(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@@H]([C@@H](C)[C@@H]([C@@H](C)C(=O)O[C@@H]1CC)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C,C37H67NO13,C01912,D00140,12560,46508487,42355,CHEMBL532,ERY,12041,50344942,733.9268,2.596388847,"Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antiinfectives for Treatment of Acne; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Enzyme Inhibitors; Erythromycin and similars; Erythromycins; Gastrointestinal Agents; Lactones; Macrocyclic Compounds; Macrolide Antimicrobial; Macrolides; Macrolides, Lincosamides and Streptogramins; Moderate Risk QTc-Prolonging Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; OATP1B3 substrates; Ophthalmologicals; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Protein Synthesis Inhibitors; QTc Prolonging Agents"
DB00200,Hydroxocobalamin,13422-51-0,approved,YOZNUFWCRFCGIH-WZHZPDAFSA-K,"InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+3;/p-3/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1",c1c(C)c(C)cc(c1[n+]2[Co-3]3456O)n(c2)[C@H]7O[C@H](CO)[C@H]([C@H]7O)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@@]8(C)C=9N3[C@H]([C@@H]8CC(=O)N)[C@]1(C)[N+]4=C([C@H]([C@]1(C)CC(=O)N)CCC(=O)N)C(C)=C1[N+]5=C([C@H]([C@]1(C)CC(=O)N)CCC(=O)N)C=C1[N+]6=C(C9C)[C@H](C1(C)C)CCC(=O)N,C62H89CoN13O15P,C08230,D01027,70678542,46505751,27786,CHEMBL2103737,,21403074,,1346.3551,-14.43269677,"Antianemic Preparations; Antidotes; Azoles; Blood and Blood Forming Organs; Corrinoids; Diet, Food, and Nutrition; Drugs that are Mainly Renally Excreted; Food; Food and Beverages; Growth Substances; Hematinics; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Macrocyclic Compounds; Micronutrients; Nutritional Support; Physiological Phenomena; Polycyclic Compounds; Pyrroles; Tetrapyrroles; Vitamin B Complex; VITAMIN B12 AND FOLIC ACID; Vitamins"
DB00201,Caffeine,58-08-2,approved,RYYVLZVUVIJVGH-UHFFFAOYSA-N,"InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3",Cn1cnc(c12)n(C)c(=O)n(c2=O)C,C8H10N4O2,C07481,D00528,2519,46506408,27732,CHEMBL113,CFF,2424,10849,194.1906,-0.545645592,"Alkaloids; Anorexigenic Agents & Respiratory and CNS Stimulants; BCRP/ABCG2 Inhibitors; Caffeine and Caffeine Containing Products; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Stimulants; Central Nervous System Stimulation; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diagnostic Agents; Drugs for Obstructive Airway Diseases; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotransmitter Agents; Phosphodiesterase Inhibitors; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Purinergic Agents; Purinergic Antagonists; Purines; Purinones; Respiratory and CNS Stimulants; Respiratory System; Tests for Gastric Secretion; Tricarboxylic Acids; Xanthine derivatives"
DB00202,Succinylcholine,306-40-1,approved,AXOIZCJOOAYSMI-UHFFFAOYSA-N,"InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2",C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,C14H30N2O4,C07546,,5314,46506023,45652,CHEMBL703,SCK,5123,50061568,290.399,-8.394079044,"Acids, Acyclic; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Ammonium Compounds; Carboxylic Acids; Central Nervous System Depressants; Choline Derivatives; Cholinesterase substrates; Dicarboxylic Acids; Ethanolamines; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular Depolarizing Agents; Neuromuscular Depolarizing Blockade; Neurotoxic agents; Nitrogen Compounds; Onium Compounds; Peripheral Nervous System Agents; Quaternary Ammonium Compounds; Succinates; Trimethyl Ammonium Compounds"
DB00203,Sildenafil,139755-83-2,approved; investigational,BNRNXUUZRGQAQC-UHFFFAOYSA-N,"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",CCCc1nn(C)c(c12)c(=O)[nH]c(n2)-c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4,C22H30N6O4S,C07259,D08514,5212,46508371,9139,CHEMBL192,VIA,5023,14390,474.576,1.869200772,"Agents Causing Muscle Toxicity; Amides; Cardiovascular Agents; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs Used in Erectile Dysfunction; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sulfonamides; Sulfones; Sulfur Compounds; Urological Agents; Urologicals; Vasodilating Agents"
DB00204,Dofetilide,115256-11-6,approved; investigational,IXTMWRCNAAVVAI-UHFFFAOYSA-N,"InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3",CS(=O)(=O)Nc1ccc(cc1)CCN(C)CCOc2ccc(cc2)NS(=O)(=O)C,C19H27N3O5S2,C07751,D00647,71329,46509127,4681,CHEMBL473,,64435,50031720,441.565,0.237915753,"Amides; Amines; Antiarrhythmic agents; Antiarrhythmics, Class III; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Ethylamines; Highest Risk QTc-Prolonging Agents; Membrane Transport Modulators; Narrow Therapeutic Index Drugs; OCT2 Substrates; OCT2 substrates with narrow therapeutic index; Potassium Channel Blockers; QTc Prolonging Agents; Sulfones; Sulfur Compounds"
DB00205,Pyrimethamine,58-14-0,approved; investigational; vet_approved,WKSAUQYGYAYLPV-UHFFFAOYSA-N,"InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)",Nc1nc(CC)c(c(n1)N)-c2ccc(Cl)cc2,C12H13ClN4,C07391,D00488,4993,46505987,8673,CHEMBL36,CP6,4819,18512,248.711,2.748303154,"Anti-Infective Agents; Antibiotics for Pneumocystis Pneumonia; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Diaminopyrimidines; Enzyme Inhibitors; Folic Acid Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; Pyrimidines"
DB00206,Reserpine,50-55-5,approved; investigational,QEVHRUUCFGRFIF-MDEJGZGSSA-N,"InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1",COc1c(OC)cc(cc1OC)C(=O)O[C@@H]([C@H](OC)[C@H]2C(=O)OC)C[C@@H]([C@@H]23)CN4[C@H](C3)c5c(CC4)c6c([nH]5)cc(cc6)OC,C33H40N2O9,C06539,D00197,5770,46505863,28487,CHEMBL772,,5566,50017712,608.6787,3.531495943,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Alkaloids; Antiadrenergic Agents, Centrally Acting; Antidepressive Agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Antipsychotic Agents; BSEP/ABCB11 Inhibitors; Cardiovascular Agents; Cardiovascular System; Catecholamine-depleting Sympatholytic; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Decreased Sympathetic Activity; Drugs that are Mainly Renally Excreted; Gastrointestinal Acidifying Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Indole Alkaloids; Indoles; Membrane Transport Modulators; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT2 Substrates; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Psychotropic Drugs; Secologanin Tryptamine Alkaloids; Tranquilizing Agents"
DB00207,Azithromycin,83905-01-5,approved,MQTOSJVFKKJCRP-BICOPXKESA-N,"InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1",C[C@]1(O)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@@H]([C@@H](C)[C@@H]([C@@H](C)C(=O)O[C@@H]1CC)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C,C38H72N2O12,C06838,,447043,46507743,2955,CHEMBL529,ZIT,10482163,50373918,748.9845,2.444781599,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Experimental Unapproved Treatments for COVID-19; Lactones; Macrocyclic Compounds; Macrolide Antimicrobial; Macrolides; Macrolides, Lincosamides and Streptogramins; Medications that reduce magnesium levels; Moderate Risk QTc-Prolonging Agents; Ophthalmologicals; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Polycyclic Compounds; Polyketides; QTc Prolonging Agents"
DB00208,Ticlopidine,55142-85-3,approved,PHWBOXQYWZNQIN-UHFFFAOYSA-N,"InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2",Clc1ccccc1CN(C2)CCc(c23)scc3,C14H14ClNS,C07140,D08594,5472,46504438,9588,CHEMBL833,TIC,5273,85509,263.786,4.195930256,"Antiplatelet agents; Blood and Blood Forming Organs; Cardiovascular Agents; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Inhibitors (strong); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (moderate); Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Platelet Aggregation; Drug-Related Side Effects and Adverse Reactions; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Fibrin Modulating Agents; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Metabolic Side Effects of Drugs and Substances; Neurotransmitter Agents; Platelet Aggregation Inhibitors Excl. Heparin; Purinergic Agents; Purinergic Antagonists; Purinergic P2 Receptor Antagonists; Purinergic P2Y Receptor Antagonists; Pyridines; Sulfur Compounds; Thienopyridines; Thiophenes"
DB00209,Trospium,47608-32-2,approved,OYYDSUSKLWTMMQ-JKHIJQBDSA-N,"InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23+",C1CCC[N+]12[C@H]3CC[C@@H]2C[C@@H](C3)OC(=O)C(O)(c4ccccc4)c5ccccc5,C25H30NO3,,D01103,5284632,46506398,145791,CHEMBL1888176,,10482307,,392.518,-0.500960272,"Acids, Carbocyclic; Agents producing tachycardia; Alimentary Tract and Metabolism; Alkaloids; Anticholinergic Agents; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Bicyclo Compounds, Heterocyclic; Carboxylic Acids; Cholinergic Agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Diphenylacetic Acids; Drugs for Functional Gastrointestinal Disorders; Drugs for Urinary Frequency and Incontinence; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Hydroxy Acids; Muscarinic Antagonists; Neurotransmitter Agents; Parasympatholytics; Peripheral Nervous System Agents; Phenylacetates; Tropanes; Urological Agents; Urologicals"
DB00210,Adapalene,106685-40-9,approved,LZCDAPDGXCYOEH-UHFFFAOYSA-N,"InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)",C1C(C2)CC(C3)CC1CC23c4c(OC)ccc(c4)-c(cc5)cc(c56)ccc(c6)C(=O)O,C28H28O3,,D01112,60164,46505019,31174,CHEMBL1265,,54244,50048280,412.5201,6.458501424,"Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Inflammatory Agents; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Misc. Skin and Mucous Membrane Agents; Naphthalenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Retinoids; Retinoids for Topical Use in Acne"
DB00211,Midodrine,42794-76-3,approved,PTKSEFOSCHHMPD-UHFFFAOYSA-N,"InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)",COc1cc(c(OC)cc1)C(O)CNC(=O)CN,C12H18N2O4,C07890,D08220,4195,46507373,6933,CHEMBL1201212,,4050,,254.2823,-0.951946461,Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Autonomic Agents; Bradycardia-Causing Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Ethanolamines; Neurotransmitter Agents; Peripheral Nervous System Agents; Sympathomimetics; Vasoconstrictor Agents
DB00213,Pantoprazole,102625-70-7,approved,IQPSEEYGBUAQFF-UHFFFAOYSA-N,"InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)",COc1c(OC)c(ncc1)CS(=O)c([nH]2)nc(c23)ccc(c3)OC(F)F,C16H15F2N3O4S,C11806,D05353,4679,46504622,7915,CHEMBL1502,,4517,50241342,383.37,2.175753323,"2-Pyridinylmethylsulfinylbenzimidazoles; Acid Reducers; Alimentary Tract and Metabolism; Anti-Ulcer Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Benzimidazoles; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Gastric Acid Lowering Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Medications that reduce magnesium levels; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Proton Pump Inhibitors; Proton-pump Inhibitors; Pyridines; Sulfoxides; Sulfur Compounds"
DB00214,Torasemide,56211-40-6,approved,NGBFQHCMQULJNZ-UHFFFAOYSA-N,"InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)",CC(C)NC(=O)NS(=O)(=O)c1c(ccnc1)Nc2cccc(C)c2,C16H20N4O3S,,D00382,41781,46504760,9637,CHEMBL1148,,38123,64107,348.42,1.863903595,"Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diuretics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; High-Ceiling Diuretics; Hyperglycemia-Associated Agents; Hypotensive Agents; Increased Diuresis at Loop of Henle; Membrane Transport Modulators; Natriuretic Agents; Non Potassium Sparing Diuretics; OATP1B1/SLCO1B1 Substrates; Ototoxic agents; Pyridines; Sodium Potassium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds"
DB00215,Citalopram,59729-33-8,approved,WSEQXVZVJXJVFP-UHFFFAOYSA-N,"InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3",Fc1ccc(cc1)C2(CCCN(C)C)OCc(c23)cc(C#N)cc3,C20H21FN2O,C07572,D07704,2771,46508746,77397,CHEMBL549,,2669,25870,324.3919,3.764304206,"Amines; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Second-Generation; Benzofurans; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Hypoglycemia-Associated Agents; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Nitriles; P-glycoprotein inhibitors; P-glycoprotein substrates; Propylamines; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Vasodilating Agents"
DB00216,Eletriptan,143322-58-1,approved; investigational,PWVXXGRKLHYWKM-LJQANCHMSA-N,"InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1",CN1CCC[C@@H]1Cc2c[nH]c(c23)ccc(c3)CCS(=O)(=O)c4ccccc4,C22H26N2O2S,,D07887,77993,46506380,50922,CHEMBL1510,,70379,50103594,382.519,3.7732624,"Agents that produce hypertension; Amines; Analgesics; Antidepressive Agents; Antimigraine Preparations; Biogenic Amines; Biogenic Monoamines; Central Nervous System Depressants; Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Nervous System; Neurotransmitter Agents; P-glycoprotein substrates; Selective Serotonin 5-HT1 Receptor Agonists; Selective Serotonin Agonists; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 1b Receptor Agonists; Serotonin 1d Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Serotonin-1b and Serotonin-1d Receptor Agonist; Triptans"
DB00217,Bethanidine,55-73-2,approved,NIVZHWNOUVJHKV-UHFFFAOYSA-N,"InChI=1S/C10H15N3/c1-11-10(12-2)13-8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3,(H2,11,12,13)",CN/C(=N\C)NCc1ccccc1,C10H15N3,,D01603,2368,46507605,37937,CHEMBL1201260,,2278,,177.2462,1.266528966,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Amidines; Antiadrenergic Agents, Peripherally Acting; Antihypertensive Agents; Autonomic Agents; Cardiovascular Agents; Cardiovascular System; Guanidine Derivatives; Guanidines; Neurotransmitter Agents; Peripheral Nervous System Agents; Sympatholytics"
DB00218,Moxifloxacin,151096-09-2,approved; investigational,FABPRXSRWADJSP-MEDUHNTESA-N,"InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1",N1CCC[C@H]([C@H]12)CN(C2)c(c3OC)c(F)cc(c34)c(=O)c(C(=O)O)cn4C5CC5,C21H24FN3O4,C07663,D08237,152946,46508509,63611,CHEMBL32,MFX,134802,50366824,401.4314,-0.498974939,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; Ophthalmologicals; QTc Prolonging Agents; Quinolines; Quinolone Antimicrobial; Quinolones; Sensory Organs; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00219,Oxyphenonium,14214-84-7,approved,GFRUPHOKLBPHTQ-UHFFFAOYSA-N,"InChI=1S/C21H34NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3/q+1",CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c2ccccc2,C21H34NO3,,,5749,46508840,94329,CHEMBL1201286,,5547,,348.4996,-0.198105284,"Agents producing tachycardia; Alimentary Tract and Metabolism; Amines; Ammonium Compounds; Anticholinergic Agents; Autonomic Agents; Cholinergic Agents; Drugs for Functional Gastrointestinal Disorders; Muscarinic Antagonists; Mydriatics; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Parasympatholytics; Peripheral Nervous System Agents; Quaternary Ammonium Compounds; Synthetic Anticholinergics, Quaternary Ammonium Compounds"
DB00220,Nelfinavir,159989-64-7,approved,QAGYKUNXZHXKMR-HKWSIXNMSA-N,"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1",C1CCC[C@H]([C@H]12)C[C@@H](C(=O)NC(C)(C)C)N(C2)C[C@@H](O)[C@H](CSc3ccccc3)NC(=O)c4c(C)c(O)ccc4,C32H45N3O4S,C07257,D08259,64143,46507719,7496,CHEMBL584,1UN,57718,518,567.782,4.718828143,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BCRP/ABCG2 Inhibitors; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strong); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strong); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; HIV Protease Inhibitors; Hyperglycemia-Associated Agents; Isoquinolines; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; OCT1 inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Potential QTc-Prolonging Agents; Protease Inhibitors; QTc Prolonging Agents; UGT1A1 Inducers"
DB00221,Isoetharine,79490-84-9,approved,HUYWAWARQUIQLE-UHFFFAOYSA-N,"InChI=1S/C13H21NO3/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9/h5-8,10,13-17H,4H2,1-3H3",CC(C)NC(CC)C(O)c1cc(O)c(O)cc1,C13H21NO3,C07053,D04625,3762,46505384,6005,CHEMBL1201213,,3630,52083,239.3107,1.047480061,Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Respiratory System Agents
DB00222,Glimepiride,93479-97-1,approved,WIGIZIANZCJQQY-RUCARUNLSA-N,"InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-",CCC1=C(C)CN(C1=O)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3,C24H34N4O5S,C07669,D00593,3476,46508842,5383,CHEMBL1481,,16740595,50237590,490.62,3.120534473,Alimentary Tract and Metabolism; Antiarrhythmic agents; Blood Glucose Lowering Agents; BSEP/ABCB11 Substrates; Cardiovascular Agents; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Hypoglycemia-Associated Agents; Immunosuppressive Agents; Sulfones; Sulfonylureas; Sulfur Compounds
DB00223,Diflorasone,2557-49-5,approved,WXURHACBFYSXBI-XHIJKXOTSA-N,"InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1",OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4,C22H28F2O5,,D07827,71415,46504519,59750,CHEMBL1201380,,64505,,410.4515,1.341850387,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated"
DB00224,Indinavir,150378-17-9,approved,CBVCZFGXHXORBI-PXQQMZJSSA-N,"InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1",c1ncccc1CN2C[C@@H](C(=O)NC(C)(C)C)N(CC2)C[C@@H](O)C[C@@H](Cc3ccccc3)C(=O)N[C@@H]4[C@H](O)Cc(c45)cccc5,C36H47N5O4,C07051,,5362440,46506442,44032,CHEMBL115,MK1,4515036,517,613.7895,2.809930858,"Agents Causing Muscle Toxicity; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (weak); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV Protease Inhibitors; Hyperglycemia-Associated Agents; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Protease Inhibitors; Pyridines; UGT1A1 Inhibitors"
DB00225,Gadodiamide,131410-48-5,approved; investigational,HZHFFEYYPYZMNU-UHFFFAOYSA-K,"InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3",CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3],C16H26GdN5O8,,,24847884,46504789,37333,,,135661,,573.66,-8.73963908,"Acetates; Acids, Acyclic; Amines; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Fatty Acids; Fatty Acids, Volatile; Injections, Intravenous; Lipids; Magnetic Resonance Contrast Activity; Magnetic Resonance Imaging Contrast Media; Miscellaneous Therapeutic Agents; Organometallic Compounds; Paramagnetic Contrast Agent; Paramagnetic Contrast Media; Polyamines"
DB00226,Guanadrel,40580-59-4,approved,HPBNRIOWIXYZFK-UHFFFAOYSA-N,"InChI=1S/C10H19N3O2/c11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10/h8H,1-7H2,(H4,11,12,13)",NC(N)=NCC(CO1)OC12CCCCC2,C10H19N3O2,C07035,D08029,38521,46506457,5555,CHEMBL1037,,35305,,213.2768,0.623413731,Adrenergic Antagonists; Amidines; Antihypertensive Agents; Cardiovascular Agents
DB00227,Lovastatin,75330-75-5,approved; investigational,PCZOHLXUXFIOCF-BXMDZJJMSA-N,"InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1",CC[C@H](C)C(=O)O[C@@H](C[C@@H](C)C=1)[C@@H](C12)[C@H]([C@@H](C)C=C2)CC[C@@H]3C[C@@H](O)CC(=O)O3,C24H36O5,C07074,D00359,53232,46508223,40303,CHEMBL503,803,48085,34168,404.5396,3.902186914,"Agents Causing Muscle Toxicity; Agents that modify thyroid function; Anticholesteremic Agents; BSEP/ABCB11 Substrates; Cardiovascular System; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Regulating Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; P-glycoprotein inhibitors; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; UGT1A1 Substrates; UGT1A3 substrates; UGT2B7 substrates"
DB00228,Enflurane,13838-16-9,approved; investigational; vet_approved,JPGQOUSTVILISH-UHFFFAOYSA-N,"InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H",FC(F)OC(F)(F)C(F)Cl,C3H2ClF5O,C07516,D00543,3226,46505314,4792,CHEMBL1257,,3113,,184.492,2.799209302,"Agents that reduce seizure threshold; Anesthetics; Anesthetics, General; Anesthetics, Inhalation; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Ethers; Methyl Ethers; Nervous System"
DB00229,Cefotiam,61622-34-2,approved; investigational,QYQDKDWGWDOFFU-IUODEOHRSA-N,"InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1",Nc1nc(cs1)CC(=O)N[C@H](C2=O)[C@H](N23)SCC(=C3C(=O)O)CSc4nnnn4CCN(C)C,C18H23N9O4S3,,D07648,43708,46506679,355510,CHEMBL1296,,39831,,525.628,-3.085743597,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephacetrile; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Second-Generation Cephalosporins; Sulfur Compounds; Thiazines"
DB00230,Pregabalin,148553-50-8,approved; investigational,AYXYPKUFHZROOJ-ZETCQYMHSA-N,"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",CC(C)C[C@H](CN)CC(=O)O,C8H17NO2,,D02716,5486971,46504934,64356,CHEMBL1059,,4589156,50164279,159.2261,-1.345584678,"Acids, Acyclic; Agents causing angioedema; Amino Acids; Amino Acids, Peptides, and Proteins; Aminobutyrates; Analgesics; Anti-Anxiety Agents; Antiarrhythmic agents; Anticonvulsants; Bradycardia-Causing Agents; Butyrates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Miscellaneous Anticonvulsants; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; Psychotropic Drugs; QTc Prolonging Agents; Sensory System Agents; Tranquilizing Agents; Vasodilating Agents"
DB00231,Temazepam,846-50-4,approved; investigational,SEQDDYPDSLOBDC-UHFFFAOYSA-N,"InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3",c1c(Cl)ccc(c12)N(C)C(=O)C(O)N=C2c3ccccc3,C16H13ClN2O2,C07125,D00370,5391,46506604,9435,CHEMBL967,,5198,50408032,300.74,2.78734688,"Anti-Anxiety Agents; Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Psychotropic Drugs; Tranquilizing Agents"
DB00233,Aminosalicylic acid,65-49-6,approved,WUBBRNOQWQTFEX-UHFFFAOYSA-N,"InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)",Nc1cc(O)c(cc1)C(=O)O,C7H7NO3,C02518,D00162,4649,46505572,27565,CHEMBL1169,BHA,4488,48319,153.1354,0.825075116,"Acids, Carbocyclic; Agents that modify thyroid function; Aminobenzoates; Aminosalicylic Acid and Derivatives; Aminosalicylic Acids; Anti-Bacterial Agents; Anti-Infective Agents; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Drugs for Treatment of Tuberculosis; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; para-Aminobenzoates; Phenols; Salicylates"
DB00234,Reboxetine,71620-89-8,approved; experimental,CBQGYUDMJHNJBX-RTBURBONSA-N,"InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1",c1ccccc1[C@H]([C@H]2CNCCO2)Oc3ccccc3OCC,C19H23NO3,,,127151,46504845,135342,CHEMBL383921,41X,112870,,313.397,3.27581463,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Morpholines; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Oxazines; P-glycoprotein inhibitors; Psychoanaleptics; Psychotropic Drugs"
DB00235,Milrinone,78415-72-2,approved,PZRHRDRVRGEVNW-UHFFFAOYSA-N,"InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)",N#Cc1c(=O)[nH]c(C)c(c1)-c2ccncc2,C12H9N3O,C07224,D00417,4197,46507838,50693,CHEMBL189,MIL,4052,15296,211.2194,0.329019384,"Amines; Aminopyridines; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Protective Agents; Pyridines; Vasodilating Agents"
DB00236,Pipobroman,54-91-1,approved,NJBFOOCLYDNZJN-UHFFFAOYSA-N,InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2,BrCCC(=O)N1CCN(CC1)C(=O)CCBr,C10H16Br2N2O2,C07362,D00467,4842,46506548,8242,CHEMBL1585,,4676,,356.054,0.410781338,"Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Noxae; Piperazines; Toxic Actions"
DB00237,Butabarbital,125-40-6,approved; illicit,ZRIHAIZYIMGOAB-UHFFFAOYSA-N,"InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)",CCC(C)C1(CC)C(=O)NC(=O)NC1=O,C10H16N2O3,C07827,D03180,2479,46505051,3228,CHEMBL449,,2385,,212.2456,1.448682582,"Anticholinergic Agents; Anticonvulsants; Barbiturates; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Nicotinic Antagonists; Psycholeptics; Pyrimidines; Pyrimidinones"
DB00238,Nevirapine,129618-40-2,approved,NQDJXKOVJZTUJA-UHFFFAOYSA-N,"InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)",n1ccc(C)c(c12)NC(=O)c3c(N2C4CC4)nccc3,C15H14N4O,C07263,D00435,4463,46506789,63613,CHEMBL57,NVP,4308,1434,266.2979,2.488042779,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strong); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Inducers of Drug Clearance; Metabolic Side Effects of Drugs and Substances; Non-Nucleoside Reverse Transcriptase Inhibitors; Nonnucleoside Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; OCT1 inhibitors; Pyridines; Reverse Transcriptase Inhibitors"
DB00239,Oxiconazole,64211-45-6,approved,QRJJEGAJXVEBNE-HKOYGPOVSA-N,"InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18+",Clc1cc(Cl)c(cc1)CO/N=C(\Cn2ccnc2)c3ccc(Cl)cc3Cl,C18H13Cl4N3O,C08074,D08313,5353853,46504752,7825,CHEMBL1262,,4510239,50051844,429.12,5.838766547,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Azole Antifungals; Azoles; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole and Triazole Derivatives; Imidazole Derivatives"
DB00240,Alclometasone,67452-97-5,approved,FJXOGVLKCZQRDN-PHCHRAKRSA-N,"InChI=1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1",OCC(=O)[C@@]1(O)[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C(C[C@H]3Cl)=CC(=O)C=C4,C22H29ClO5,,D07116,5311000,46508296,53776,CHEMBL1201361,,4470541,,408.916,1.68378981,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Moderately Potent (Group II); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Ophthalmologicals; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Sensory Organs; Steroids"
DB00241,Butalbital,77-26-9,approved; illicit,UZVHFVZFNXBMQJ-UHFFFAOYSA-N,"InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)",CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,C11H16N2O3,,D03182,2481,46505876,102524,CHEMBL454,,2387,,224.2563,1.58926326,"Anticholinergic Agents; Anticonvulsants; Barbiturates; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Methemoglobinemia Associated Agents; Nervous System; Nicotinic Antagonists; Psycholeptics; Pyrimidines; Pyrimidinones"
DB00242,Cladribine,4291-63-8,approved; investigational,PTOAARAWEBMLNO-KVQBGUIXSA-N,"InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1",Clc(n1)nc(N)c(c12)ncn2[C@H]3C[C@H](O)[C@H](O3)CO,C10H12ClN5O3,,D01370,20279,46504588,567361,CHEMBL1619,CL9,19105,38920,285.687,-0.281775463,"2-Chloroadenosine; Agents Causing Muscle Toxicity; Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Carbohydrates; Cardiotoxic antineoplastic agents; Deoxyadenosines; Deoxyribonucleosides; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunologic Factors; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Purine Analogues; Purine Antimetabolite; Purine Nucleosides; Purines; Ribonucleosides; Selective Immunosuppressants"
DB00243,Ranolazine,95635-55-5,approved; investigational,XKLMZUWKNUAPSZ-UHFFFAOYSA-N,"InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)",COc1ccccc1OCC(O)CN2CCN(CC2)CC(=O)Nc3c(C)cccc3C,C24H33N3O4,,,56959,46505145,87690,CHEMBL1404,,51354,50173335,427.5365,2.832460429,"Acetamides; Antianginal Agents; BSEP/ABCB11 Substrates; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Piperazines; QTc Prolonging Agents; Sodium Channel Blockers; Vasodilating Agents"
DB00244,Mesalazine,89-57-6,approved,KBOPZPXVLCULAV-UHFFFAOYSA-N,"InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)",Nc1cc(C(=O)O)c(O)cc1,C7H7NO3,,D00377,4075,46509142,6775,CHEMBL704,,3933,60918,153.1354,-0.289782406,"Agents causing hyperkalemia; Agents that produce hypertension; Aminosalicylate; Aminosalicylic Acids; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Benzene Derivatives; Hydroxybenzoates; Intestinal Antiinflammatory Agents; Nephrotoxic agents; Non COX-2 selective NSAIDS; Phenols; Salicylates"
DB00245,Benzatropine,86-13-5,approved,GIJXKZJWITVLHI-PMOLBWCYSA-N,"InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20+",[C@@H]12CC[C@@H](N1C)C[C@@H](C2)OC(c3ccccc3)c4ccccc4,C21H25NO,C06846,D07511,1201549,46505349,3048,CHEMBL1201203,CXQ,16736541,50366775,307.4293,4.185400473,"Agents producing tachycardia; Alkaloids; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Anticholinergic Agents; Aza Compounds; Bicyclo Compounds; Bridged Compounds; Central Nervous System Agents; Cholinergic Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Uptake Inhibitors; Drugs that are Mainly Renally Excreted; Ethers of Tropine or Tropine Derivatives; Histamine Antagonists; Histamine H1 Antagonists; Histamine Receptor Antagonists; Hydrocarbons; Hydrocarbons, Cyclic; Membrane Transport Modulators; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Peripheral Nervous System Agents; Polycyclic Compounds; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Tropanes"
DB00246,Ziprasidone,146939-27-7,approved,MVWVFYHBGMAFLY-UHFFFAOYSA-N,"InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)",O=C(N1)Cc(c12)cc(c(Cl)c2)CCN3CCN(CC3)c4nsc(c45)cccc5,C21H21ClN4OS,C07568,D08687,60854,46507627,10119,CHEMBL708,,54841,50048803,412.936,4.304046459,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Anticholinergic Agents; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Azoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Histamine Antagonists; Histamine H1 Antagonists; Hyperglycemia-Associated Agents; Indole Derivatives; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1D Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Serotonin Receptor Antagonists; Sulfur Compounds; Tranquilizing Agents"
DB00247,Methysergide,361-37-5,approved,KPJZHOPZRAFDTN-NQUBZZJWSA-N,"InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15?,19-/m1/s1",CCC(CO)NC(=O)[C@H](C=1)CN(C)[C@@H](C12)Cc3c4c2cccc4n(c3)C,C21H27N3O2,C07199,D02357,6540428,46506117,584020,CHEMBL485253,,5022813,50031942,353.458,1.816894446,"Agents that produce hypertension; Alkaloids; Analgesics; Antidepressive Agents; Antimigraine Preparations; Cardiovascular Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Ergolines; Ergot Alkaloids and Derivatives; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Lysergic Acid; Nervous System; Neurotransmitter Agents; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Vasoconstrictor Agents"
DB00248,Cabergoline,81409-90-7,approved,KORNTPPJEAJQIU-KJXAQDMKSA-N,"InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1",CN(C)CCCN(C(=O)NCC)C(=O)[C@H](C1)CN(CC=C)[C@@H]([C@H]12)Cc3c4c2cccc4[nH]c3,C26H37N5O2,C08187,D00987,54746,46508571,3286,CHEMBL1201087,,49452,50426497,451.6043,2.578516268,"Agents that produce hypertension; Alkaloids; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Antidepressive Agents; Antineoplastic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Ergolines; Ergot Alkaloids and Derivatives; Ergot-derivative Dopamine Receptor Agonists; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Nervous System; Neurotransmitter Agents; P-glycoprotein substrates; Prolactine Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists"
DB00249,Idoxuridine,54-42-2,approved; investigational,XQFRJNBWHJMXHO-RRKCRQDMSA-N,"InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1",OC[C@H]1O[C@H](C[C@@H]1O)n2cc(I)c(=O)[nH]c2=O,C9H11IN2O5,,D00342,5905,46507573,147675,CHEMBL788,ID2,5694,50370388,354.0985,-0.528918627,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Carbohydrates; Deoxyribonucleosides; Deoxyuridine; Dermatologicals; Direct Acting Antivirals; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Analog Antiviral; Nucleosides; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; Ophthalmologicals; Pyrimidine Nucleosides; Pyrimidines; Ribonucleosides; Sensory Organs"
DB00250,Dapsone,80-08-0,approved; investigational,MQJKPEGWNLWLTK-UHFFFAOYSA-N,"InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2",Nc1ccc(cc1)S(=O)(=O)c2ccc(N)cc2,C12H12N2O2S,C07666,D00592,2955,46505300,4325,CHEMBL1043,,2849,50029764,248.301,1.270228552,Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics for Pneumocystis Pneumonia; Antiinfectives for Systemic Use; Antimalarials; Antimycobacterials; Antiparasitic Agents; Antiprotozoals; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Drugs causing inadvertant photosensitivity; Drugs for Treatment of Lepra; Enzyme Inhibitors; Folic Acid Antagonists; Leprostatic Agents; Methemoglobinemia Associated Agents; Miscellaneous Antimycobacterials; Miscellaneous Local Anti-infectives; Photosensitizing Agents; Sulfones; Sulfur Compounds
DB00251,Terconazole,67915-31-5,approved,BLSQLHNBWJLIBQ-OZXSUGGESA-N,"InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1",CC(C)N1CCN(CC1)c2ccc(cc2)OC[C@@H](CO3)O[C@@]3(Cn4cncn4)c5c(Cl)cc(Cl)cc5,C26H31Cl2N5O3,C08080,D00888,441383,46505257,82980,CHEMBL1306,,390122,50375318,532.462,5.374220876,"Anti-Infective Agents; Antifungal Agents; Antifungal Agents (Vaginal); Azole Antifungals; Azoles; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Triazole Derivatives"
DB00252,Phenytoin,57-41-0,approved; vet_approved,CXOFVDLJLONNDW-UHFFFAOYSA-N,"InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)",c1ccccc1C2(C(=O)NC(=O)N2)c3ccccc3,C15H12N2O2,C07443,D00512,1775,46508847,8107,CHEMBL16,,1710,50003655,252.268,2.147920381,"Agents Causing Muscle Toxicity; Anti-epileptic Agent; Anticonvulsants; Azoles; Central Nervous System Agents; Central Nervous System Depressants; COMT Substrates; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers (strong); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (moderate); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strong); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP3A7 Inducers (weak); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Drug-Related Side Effects and Adverse Reactions; Enzyme Inducing Antiepileptic Drugs; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydantoins; Imidazoles; Imidazolidines; Inducers of Drug Clearance; Medications that reduce magnesium levels; Membrane Transport Modulators; Metabolic Side Effects of Drugs and Substances; Methemoglobinemia Associated Agents; Narrow Therapeutic Index Drugs; Nervous System; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Phenytoin and Prodrugs; Sodium Channel Blockers; Thyroxine-binding globulin substrates; UGT1A1 Inducers; UGT1A1 Substrates; UGT1A4 substrates; UGT1A6 Inhibitors; UGT1A6 substrate; UGT1A9 Inhibitors; UGT1A9 Substrates; Voltage-Gated Sodium Channel Blockers"
DB00253,Medrysone,2668-66-8,approved,GZENKSODFLBBHQ-ILSZZQPISA-N,"InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1",CC(=O)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C([C@H](C3)C)=CC(=O)CC4,C22H32O3,C14643,D02289,247839,46506584,34829,CHEMBL1201173,,216968,,344.4877,3.1268587,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; OAT3/SLC22A8 Substrates; Ophthalmologicals; P-glycoprotein substrates; Polycyclic Compounds; Pregnanes; Pregnenes; Sensory Organs; Steroids; Thyroxine-binding globulin inhibitors"
DB00254,Doxycycline,564-25-0,approved; investigational; vet_approved,JBIWCJUYHHGXTC-AKNGSSGZSA-N,"InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)[C@@H](O)[C@H]3C(=C2O)C(=O)c4c([C@@H]3C)cccc4O,C22H24N2O8,C06973,D07876,54671203,46506491,50845,CHEMBL1433,DXT,10469369,50041429,444.4346,-3.337123925,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives and Antiseptics for Local Oral Treatment; Antiinfectives for Systemic Use; Antiparasitic Agents; Antiprotozoals; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; Naphthacenes; OAT1/SLC22A6 inhibitors; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Stomatological Preparations; Tetracyclines"
DB00255,Diethylstilbestrol,56-53-1,approved; investigational,RGLYKWWBQGJZGM-ISLYRVAYSA-N,"InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+",Oc1ccc(cc1)/C(CC)=C(\CC)c2ccc(O)cc2,C18H20O2,C07620,D00577,3054,46507453,41922,CHEMBL411,DES,395306,20625,268.356,5.193882748,"Adrenal Cortex Hormones; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Benzene Derivatives; Benzylidene Compounds; BSEP/ABCB11 Substrates; Carcinogens; COMT Substrates; Contraceptive Agents, Female; Contraceptive Agents, Male; Contraceptives, Postcoital; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Endocrine Therapy; Estrogen Contraceptives; Estrogens; Estrogens, Non-Steroidal; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; Noxae; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein substrates; Sex Hormones and Modulators of the Genital System; Stilbenes; Synthetic Estrogens, Plain; Thyroxine-binding globulin inducers; Toxic Actions"
DB00256,Lymecycline,992-21-2,approved; investigational,AHEVKYYGXVEWNO-UEPZRUIBSA-N,"InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34,36-37,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14-,15-,16-,21-,28+,29-/m0/s1",Oc1cccc([C@@]2(C)O)c1C(=O)C(=C3O)[C@@H]2C[C@H]([C@]34O)[C@H](N(C)C)C(O)=C(C4=O)C(=O)NCNCCCC[C@H](N)C(=O)O,C29H38N4O10,,D06884,54707177,46505518,59040,CHEMBL2103929,,20121315,,602.6328,-7.065616825,"Agents that produce neuromuscular block (indirect); Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Tetracyclines"
DB00257,Clotrimazole,23593-75-1,approved; vet_approved,VNFPBHJOKIVQEB-UHFFFAOYSA-N,"InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H",Clc1ccccc1C(n2ccnc2)(c3ccccc3)c4ccccc4,C22H17ClN2,C06922,D00282,2812,46507927,3764,CHEMBL104,CL6,2710,31774,344.837,5.839451671,"Anti-Infective Agents; Anti-Infective Agents, Local; Antifungal Agents; Antifungal Agents (Vaginal); Antifungals for Dermatological Use; Antifungals for Topical Use; Antiinfectives and Antiseptics for Local Oral Treatment; Azole Antifungals; Azoles; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strong); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strong); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (moderate); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP3A7 Inducers (strong); Cytochrome P-450 CYP3A7 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Enzyme Inhibitors; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Imidazole and Triazole Derivatives; Imidazole Derivatives; Imidazoles; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inducers; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Steroid Synthesis Inhibitors; Stomatological Preparations"
DB00258,Calcium acetate,62-54-4,approved; investigational,VSGNNIFQASZAOI-UHFFFAOYSA-L,"InChI=1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2",[Ca+2].CC([O-])=O.CC([O-])=O,C4H6CaO4,,D00931,6116,46507985,3310,CHEMBL1200800,,5890,,158.166,-0.223345714,"Acids; Acids, Acyclic; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Arylsulfonates; Arylsulfonic Acids; Benzene Derivatives; Blood Coagulation Factors; Calcium Salts; Carboxylic Acids; Chelating Agents; Compounds used in a research, industrial, or household setting; Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Fatty Acids; Fatty Acids, Volatile; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lipids; Minerals; Phosphate Binder; Phosphate-removing Agents; Sequestering Agents; Sulfonic Acids; Sulfur Acids; Sulfur Compounds"
DB00259,Sulfanilamide,63-74-1,approved,FDDDEECHVMSUSB-UHFFFAOYSA-N,"InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)",Nc1ccc(cc1)S(=O)(=O)N,C6H8N2O2S,C07458,D08543,5333,46508306,45373,CHEMBL21,SAN,5142,10857,172.205,-0.249649368,Amides; Amines; Aniline Compounds; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Methemoglobinemia Associated Agents; Short-Acting Sulfonamides; Sulfanilamides; Sulfonamide Antibacterial; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds
DB00260,Cycloserine,68-41-7,approved,DYDCUQKUCUHJBH-UWTATZPHSA-N,"InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1",N[C@@H]1CONC1=O,C3H6N2O2,C08057,,6234,46506865,40009,CHEMBL771,4AX,5998,50038178,102.0919,-2.421332342,"Amino Acids; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibiotics, Antitubercular; Antiinfectives for Systemic Use; Antimetabolites; Antimycobacterials; Antituberculosis Agents; Azoles; Drugs for Treatment of Tuberculosis; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isoxazoles; Neurotoxic agents; Noxae; Oxazoles; Oxazolidinones; Renal Agents; Toxic Actions"
DB00261,Anagrelide,68475-42-3,approved,OTBXOEAOVRKTNQ-UHFFFAOYSA-N,"InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)",Clc1c(Cl)ccc(c12)N=C3N(C2)CC(=O)N3,C10H7Cl2N3O,,D07455,2182,46508863,142290,CHEMBL760,,2097,50000334,256.088,1.94393082,"Agents producing tachycardia; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Antiplatelet agents; Cardiovascular Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Platelet Production; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Narrow Therapeutic Index Drugs; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Platelet-reducing Agents; QTc Prolonging Agents; Thrombocytosis; Vasodilating Agents"
DB00262,Carmustine,154-93-8,approved; investigational,DLGOEMSEDOSKAD-UHFFFAOYSA-N,"InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)",ClCCNC(=O)N(N=O)CCCl,C5H9Cl2N3O2,C06873,D00254,2578,46506980,3423,CHEMBL513,,2480,50015950,214.05,1.022656282,"Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nitroso Compounds; Nitrosourea Compounds; Nitrosoureas; Noxae; Toxic Actions"
DB00263,Sulfisoxazole,127-69-5,approved; vet_approved,NHUHCSRWZMLRLA-UHFFFAOYSA-N,"InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3",Cc1noc(c1C)NS(=O)(=O)c2ccc(N)cc2,C11H13N3O3S,C07318,D00450,5344,46505342,102484,CHEMBL453,,5151,50034452,267.304,0.730613113,Amides; Amines; Aniline Compounds; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drugs causing inadvertant photosensitivity; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Hypoglycemia-Associated Agents; Moderate Risk QTc-Prolonging Agents; Ophthalmologicals; Photosensitizing Agents; QTc Prolonging Agents; Sensory Organs; Short-Acting Sulfonamides; Sulfanilamides; Sulfonamide Antibacterial; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds
DB00264,Metoprolol,51384-51-1,approved; investigational,IUBSYMUCCVWXPE-UHFFFAOYSA-N,"InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3",COCCc1ccc(cc1)OCC(O)CNC(C)C,C15H25NO3,C07202,D02358,4171,46506211,6904,CHEMBL13,,4027,25756,267.3639,1.758657114,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Beta blocking agents and calcium channel blockers; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Selective; Beta Blocking Agents, Selective, and Thiazides; Beta-Blockers (Beta1 Selective); Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Hypotensive Agents; OCT2 Inhibitors; Photosensitizing Agents; Propanolamines"
DB00265,Crotamiton,483-63-6,approved,DNTGGZPQPQTDQF-XBXARRHUSA-N,"InChI=1S/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3/b8-4+",C/C=C/C(=O)N(CC)c1ccccc1C,C13H17NO,,D01381,2883,46508599,,CHEMBL1200709,,599515,50240091,203.2802,3.088179598,"Agrochemicals; Amines; Aniline Compounds; Benzene Derivatives; Compounds used in a research, industrial, or household setting; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Pesticides; Scabicides and Pediculicides; Toxic Actions"
DB00266,Dicoumarol,66-76-2,approved,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,"InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2",c1cccc(c12)oc(=O)c(c2O)Cc(c(=O)o3)c(O)c(c34)cccc4,C19H12O6,C00796,D03798,54676038,46505536,4513,CHEMBL1466,,10183330,35525,336.295,-1.592789372,"4-Hydroxycoumarins; Anticoagulants; Benzopyrans; Blood and Blood Forming Organs; Coumarins; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Enzyme Inhibitors; Fibrinolytic Agents; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Pyrans; Uncoupling Agents; Vitamin K Antagonists"
DB00267,Cefmenoxime,65085-01-0,approved,HJJDBAOLQAWBMH-YCRCPZNHSA-N,"InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1",Nc1nc(cs1)/C(=N/OC)C(=O)N[C@H](C2=O)[C@H](N23)SCC(=C3C(=O)O)CSc4nnnn4C,C16H17N9O5S3,,D01739,9570757,46506246,55490,CHEMBL1201224,,7845223,,511.558,-0.830595677,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephacetrile; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB00268,Ropinirole,91374-21-9,approved; investigational,UHSKFQJFRQCDBE-UHFFFAOYSA-N,"InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)",CCCN(CCC)CCc(ccc1)c(c12)CC(=O)N2,C16H24N2O,C07564,D08489,5095,46507918,8888,CHEMBL589,,4916,50020680,260.3746,3.060768858,"Anti-Dyskinesia Agents; Anti-Parkinson Agents (Dopamine Agonist); Anti-Parkinson Drugs; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Nervous System; Neurotransmitter Agents; Nonergot-derivative Dopamine Receptor Agonists"
DB00270,Isradipine,75695-93-1,approved; investigational,HMJIYCCIJYRONP-UHFFFAOYSA-N,"InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3",COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c2cccc(c23)non3,C19H21N3O5,,D00349,3784,46505034,6073,CHEMBL1648,,3652,50436176,371.3871,1.998915759,"Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Bradycardia-Causing Agents; BSEP/ABCB11 Substrates; Calcium Channel Blockers; Calcium Channel Blockers (Dihydropyridine); Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Dihydropyridines; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB00271,Diatrizoate,117-96-4,approved; vet_approved,YVPYQUNUQOZFHG-UHFFFAOYSA-N,"InChI=1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20)",CC(=O)Nc1c(I)c(C(=O)O)c(I)c(c1I)NC(=O)C,C11H9I3N2O4,,D01013,2140,46504704,53691,CHEMBL1201220,,2055,62875,613.9136,2.893082894,"Acids, Carbocyclic; Alcohols; Amino Sugars; Benzene Derivatives; Benzoates; Carbohydrates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Hexosamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodinated Contrast Agents; Iodobenzoates; Radiographic Contrast Agent; Roentgenography; Sugar Alcohols; Triiodobenzoic Acids; Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB00272,Betazole,105-20-4,approved,JXDFEQONERDKSS-UHFFFAOYSA-N,"InChI=1S/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8)",NCCc1ccn[nH]1,C5H9N3,,,7741,46506808,59170,CHEMBL1201323,,7455,,111.1451,-0.616840893,"Azoles; Diagnostic Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Agonists; Neurotransmitter Agents; Pyrazoles; Tests for Gastric Secretion"
DB00273,Topiramate,97240-79-4,approved,KJADKKWYZYXHBB-XBWDGYHZSA-N,"InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1",O1C(C)(C)O[C@H](CO2)[C@@H]1[C@H](OC(O3)(C)C)[C@@]23COS(=O)(=O)N,C12H21NO8S,C07502,D00537,5284627,46508334,63631,CHEMBL220492,TOR,4447672,10887,339.362,0.126959734,Anti-Obesity Agents; Anticonvulsants; Carbohydrates; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Drugs that are Mainly Renally Excreted; Enzyme Inducing Antiepileptic Drugs; Fructose; Hexoses; Ketoses; Miscellaneous Anticonvulsants; Monosaccharides; Nervous System; Neuroprotective Agents; P-glycoprotein substrates
DB00274,Cefmetazole,56796-20-4,approved; investigational,SNBUBQHDYVFSQF-HIFRSBDPSA-N,"InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1",N#CCSCC(=O)N[C@@](C1=O)(OC)[C@H](N12)SCC(=C2C(=O)O)CSc3nnnn3C,C15H17N7O5S3,C08103,D00910,42008,46504461,3489,CHEMBL1201195,4KO,38311,50350471,471.534,-0.64829115,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Cephamycins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Second-Generation Cephalosporins; Sulfur Compounds; Thiazines"
DB00275,Olmesartan,144689-24-7,approved; investigational,VTRAEEWXHOVJFV-UHFFFAOYSA-N,"InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)",CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc2ccc(cc2)-c3c(cccc3)-c4nnn[nH]4,C24H26N6O3,,D01204,158781,46508275,48416,CHEMBL1516,OLM,139674,50241364,446.5016,2.142183678,"Agents Acting on the Renin-Angiotensin System; Agents causing hyperkalemia; Angiotensin 2 Receptor Blocker; Angiotensin II Antagonists and Calcium Channel Blockers; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Angiotensin II receptor blockers (ARBs) and diuretics; Angiotensin II receptor blockers (ARBs), plain; Angiotensin Receptor Antagonists; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Azoles; BSEP/ABCB11 Inhibitors; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Hypotensive Agents; Imidazoles; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Tetrazoles"
DB00276,Amsacrine,51264-14-3,approved; investigational,XCPGHVQEEXUHNC-UHFFFAOYSA-N,"InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)",CS(=O)(=O)Nc1cc(OC)c(cc1)Nc2c(cccc3)c3nc(c24)cccc4,C21H19N3O3S,C01553,D02321,2179,46507539,2687,CHEMBL43,ASW,2094,87351,393.459,3.161621246,"Acridines; Aminoacridines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cardiotoxic antineoplastic agents; Compounds used in a research, industrial, or household setting; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Indicators and Reagents; Intercalating Agents; Laboratory Chemicals; Medications that reduce magnesium levels; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors"
DB00277,Theophylline,58-55-9,approved,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,"InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)",[nH]1cnc(c12)n(C)c(=O)n(C)c2=O,C7H8N4O2,C07130,D00371,2153,46505949,28177,CHEMBL190,TEP,2068,10847,180.164,-0.769321657,"Agents that reduce seizure threshold; Alkaloids; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cardiovascular Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; Neurotransmitter Agents; Peripheral Nervous System Agents; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Purinergic Agents; Purinergic Antagonists; Purinergic P1 Receptor Antagonists; Purines; Purinones; Respiratory Smooth Muscle Relaxants; Respiratory System; Respiratory System Agents; Vasodilating Agents; Xanthine derivatives; Xanthines and Adrenergics"
DB00278,Argatroban,74863-84-6,approved; investigational,KXNPVXPOPUZYGB-IOVMHBDKSA-N,"InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1",C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c2cccc(c23)CC(C)CN3,C23H36N6O5S,C04931,,152951,46507650,94385,CHEMBL1166,,83702,50038001,508.64,-0.915700927,"Acids, Heterocyclic; Anticoagulants; Antithrombins; Blood and Blood Forming Organs; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Enzyme Inhibitors; Fibrinolytic Agents; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Narrow Therapeutic Index Drugs; Piperidines; Protease Inhibitors; Serine Protease Inhibitors; Thrombin Inhibitors"
DB00279,Liothyronine,03-02-6893,approved; vet_approved,AUYYCJSJGJYCDS-LBPRGKRZSA-N,"InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1",OC(=O)[C@@H](N)Cc1cc(I)c(c(I)c1)Oc2cc(I)c(O)cc2,C15H12I3NO4,C02465,,5920,46506352,18258,CHEMBL1544,T3,5707,18860,650.9735,2.798504975,"Agents used to treat hypothyroidism; Drugs that are Mainly Renally Excreted; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; l-Triiodothyronine; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein inducers; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroid Products; Thyronines; Thyroxine-binding globulin substrates; Triiodothyronine; UGT1A1 Substrates"
DB00280,Disopyramide,05-09-3737,approved,UVTNFZQICZKOEM-UHFFFAOYSA-N,"InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)",n1ccccc1C(C(=O)N)(CCN(C(C)C)C(C)C)c2ccccc2,C21H29N3O,C06965,D00303,3114,46508226,4657,CHEMBL517,,3002,50028893,339.4745,3.468436485,"Agents producing tachycardia; Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ia; Anticholinergic Agents; Blood Glucose Lowering Agents; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Muscarinic Antagonists; OCT1 inhibitors; OCT2 Inhibitors; Pyridines; QTc Prolonging Agents; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB00281,Lidocaine,137-58-6,approved; vet_approved,NNJVILVZKWQKPM-UHFFFAOYSA-N,"InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)",CCN(CC)CC(=O)Nc1c(C)cccc1C,C14H22N2O,C07073,D00358,3676,46505060,6456,CHEMBL79,LQZ,3548,50017662,234.3373,2.84291336,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Agents that reduce seizure threshold; Amides; Amines; Analgesics and Anesthetics; Anesthetics; Anesthetics for Topical Use; Anesthetics, Local; Anilides; Aniline Compounds; Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ib; Antipruritics and Local Anesthetics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Local Anesthesia; Local Anesthetics (Amide); Membrane Transport Modulators; Methemoglobinemia Associated Agents; Nervous System; Neuraxial Anesthetics; Ophthalmologicals; Otologicals; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Respiratory System; Sensory System Agents; Sodium Channel Blockers; Throat Preparations; Vasoprotectives; Voltage-Gated Sodium Channel Blockers"
DB00282,Pamidronic acid,40391-99-9,approved,WRUUGTRCQOWXEG-UHFFFAOYSA-N,"InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)",NCCC(O)(P(=O)(O)O)P(=O)(O)O,C3H11NO7P2,C07395,D07281,4674,46504823,7903,CHEMBL834,210,4512,12581,235.0695,-4.536482727,Agents Causing Muscle Toxicity; Antineoplastic Agents; Bisphosphonates; Bone Density Conservation Agents; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Medications that reduce magnesium levels; Musculo-Skeletal System; Nephrotoxic agents; Organophosphonates; Organophosphorus Compounds
DB00283,Clemastine,15686-51-8,approved; investigational,YNNUSGIPVFPVBX-NHCUHLMSSA-N,"InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1",CN1CCC[C@@H]1CCO[C@](C)(c2ccccc2)c3ccc(Cl)cc3,C21H26ClNO,C06913,D03535,26987,46506492,3738,CHEMBL1626,,25129,94606,343.89,4.923333277,"Aminoalkyl Ethers; Anti-Allergic Agents; Antihistamines for Systemic Use; Antihistamines for Topical Use; Antipruritics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Neurotransmitter Agents; Photosensitizing Agents; Pyrrolidines; QTc Prolonging Agents; Respiratory System"
DB00284,Acarbose,56180-94-0,approved; investigational,CEMXHAPUFJOOSV-XGWNLRGSSA-N,"InChI=1S/C25H43NO18/c1-7-13(26-9-2-8(3-27)14(33)18(37)15(9)34)17(36)20(39)24(41-7)44-23-12(6-30)42-25(21(40)19(23)38)43-22(11(32)5-29)16(35)10(31)4-28/h2,4,7,9-27,29-40H,3,5-6H2,1H3/t7-,9+,10+,11-,12-,13-,14-,15+,16-,17+,18+,19-,20-,21-,22-,23-,24-,25-/m1/s1",O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@H]([C@H](O)[C@H]1O)O[C@H]2O[C@H](C)[C@H]([C@H](O)[C@H]2O)N[C@H]3C=C(CO)[C@@H](O)[C@H](O)[C@H]3O,C25H43NO18,C06802,D00216,9811704,46508248,2376,CHEMBL1566,QPS,23264314,,645.608,-8.250380202,Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hypoglycemia-Associated Agents; Oligosaccharides; Polysaccharides; Trisaccharides
DB00285,Venlafaxine,93413-69-5,approved,PNVNVHUZROJLTJ-UHFFFAOYSA-N,"InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3",COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2,C17H27NO2,C07187,D08670,5656,46504593,9943,CHEMBL637,,5454,82071,277.4018,2.738522704,"Agents producing tachycardia; Agents that reduce seizure threshold; Alcohols; Amines; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Second-Generation; BCRP/ABCG2 Inducers; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cyclohexanes; Cyclohexanols; Cycloparaffins; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Ethylamines; Fatty Alcohols; Hexanols; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hypoglycemia-Associated Agents; Lipids; Macrocyclic Compounds; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Norepinephrine Uptake Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Phenethylamines; Polycyclic Compounds; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Serotonin Modulators"
DB00286,Conjugated estrogens,12126-59-9,approved,,, ,,,D04070,,46505680,8389,CHEMBL2106240,,9532,,NA,NA,"Agents causing angioedema; BCRP/ABCG2 Substrates; COMT Substrates; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estradiol Congeners; Estrogens; Estrogens, Conjugated (USP); Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Natural and Semisynthetic Estrogens, Plain; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; Sex Hormones and Modulators of the Genital System; Thyroxine-binding globulin inducers"
DB00287,Travoprost,157283-68-6,approved,MKPLKVHSHYCHOC-AHTXBMBWSA-N,"InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1",CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc2cccc(c2)C(F)(F)F,C26H35F3O6,,D01964,5282226,46507637,746859,CHEMBL1200799,,4445407,,500.5477,3.839193197,"Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Inflammation Mediators; Lipids; Ophthalmics; Ophthalmologicals; Prostaglandin analogs reducing intraocular pressure (IOP); Prostaglandins; Prostaglandins F, Synthetic; Prostaglandins, Synthetic"
DB00288,Amcinonide,51022-69-6,approved,ILKJAFIWWBXGDU-MOGDOJJUSA-N,"InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1",C1=CC(=O)C=C(CC2)[C@@]1(C)[C@@](F)([C@H](C3)O)[C@@H]2[C@H](C[C@H]4O5)[C@@]3(C)[C@]4(C(=O)COC(=O)C)OC56CCCC6,C28H35FO7,,D01387,443958,46506705,31199,CHEMBL1200732,,392009,,502.5717,3.195263626,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienes; Pregnanes; Steroids; Steroids, Fluorinated; Thyroxine-binding globulin inhibitors"
DB00289,Atomoxetine,83015-26-3,approved,VHGCDTVCOLNTBX-QGZVFWFLSA-N,"InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1",c1ccccc1[C@@H](CCNC)Oc2ccccc2C,C17H21NO,,D07473,54841,46506160,127342,CHEMBL641,,49516,50366567,255.3547,3.808792451,"Adrenergic Agents; Agents producing tachycardia; Agents that produce hypertension; Amines; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Membrane Transport Modulators; Miscellaneous Central Nervous System Agents; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Norepinephrine Reuptake Inhibitor; Norepinephrine Uptake Inhibitors; Potential QTc-Prolonging Agents; Propylamines; Psychostimulants, Agents Used for Adhd and Nootropics; QTc Prolonging Agents"
DB00290,Bleomycin,11056-06-7,approved; investigational,OYVAGSVQBOHSSS-WXFSZRTFSA-O,"InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1",NC(=O)OC1C(O)C(OC(C1O)CO)OC2C(O)C(O)C(CO)OC2O[C@@H](c3c[nH]cn3)[C@H](NC(=O)c4nc(nc(N)c4C)[C@H](CC(=O)N)NC[C@H](N)C(=O)N)C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCc5nc(cs5)-c6nc(cs6)C(=O)NCCC[S+](C)C,C55H84N17O21S3,C06854,,5360373,46509116,22907,CHEMBL403664,BLM,4514492,50122169,1415.552,-9.312738522,"ABVD chemotherapy regimen; Amino Acids, Peptides, and Proteins; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BEACOPP chemotherapy regimen; Carbohydrates; Cardiotoxic antineoplastic agents; Cytoprotective Agent; Cytotoxic Antibiotics and Related Substances; Drugs that are Mainly Renally Excreted; Glycoconjugates; Glycopeptides; Immunosuppressive Agents; Narrow Therapeutic Index Drugs; Peptides"
DB00291,Chlorambucil,305-03-3,approved,JCKYGMPEJWAADB-UHFFFAOYSA-N,"InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,C14H19Cl2NO2,C06900,D00266,2708,46506842,28830,CHEMBL515,CBL,2607,50003677,304.212,3.937154982,"Agents that reduce seizure threshold; Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Hydrocarbons; Hydrocarbons, Halogenated; Immunosuppressive Agents; Mustard Compounds; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nitrogen Mustard Analogues; Nitrogen Mustard Compounds; Noxae; Toxic Actions"
DB00292,Etomidate,33125-97-2,approved,NPUKDXXFDDZOKR-LLVKDONJSA-N,"InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1",CCOC(=O)c1cncn1[C@H](C)c2ccccc2,C14H16N2O2,C07522,D00548,667484,46507012,4910,CHEMBL681,,580864,50125935,244.289,2.499786043,"Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Azoles; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Imidazoles; Nervous System"
DB00293,Raltitrexed,112887-68-0,approved; investigational,IVTVGDXNLFLDRM-HNNXBMFYSA-N,"InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1",Cc([nH]1)nc(=O)c(c12)cc(cc2)CN(C)c3ccc(s3)C(=O)N[C@H](C(=O)O)CCC(=O)O,C21H22N4O6S,C11372,D01064,104758,46504880,5847,CHEMBL225071,D16,94568,18795,458.488,1.970358828,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Enzyme Inhibitors; Folic Acid Analogues; Folic Acid Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Sulfur Compounds; Thymidylate Synthase, antagonists & inhibitors; Toxic Actions"
DB00294,Etonogestrel,54048-10-1,approved; investigational,GCKFUYQCUCGESZ-BPIQYHPVSA-N,"InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1",C#C[C@]1(O)CC[C@H]([C@@]12CC)[C@H]3[C@H](C(C2)=C)[C@@H]4C(CC3)=CC(=O)CC4,C22H28O2,,,6917715,46505321,50777,CHEMBL1531,,5292944,50423516,324.4565,3.601169888,"Adrenal Cortex Hormones; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hyperglycemia-Associated Agents; Intravaginal Contraceptives; Norpregnanes; Norpregnenes; Norsteroids; Polycyclic Compounds; Progesterone Congeners; Progestins; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB00295,Morphine,57-27-2,approved; investigational,BQJCRHHNABKAKU-KBQPJGBKSA-N,"InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1",[C@]123[C@H]4Oc5c1c(ccc5O)C[C@@H](N(C)CC2)[C@@H]3C=C[C@@H]4O,C17H19NO3,C01516,D08233,5288826,46505161,17303,CHEMBL70,MOI,4450907,50000092,285.3377,0.89521082,"Alkaloids; Analgesics; Anesthetics; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; High-risk opioids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Narcotics; Natural Opium Alkaloids; Nervous System; Neuraxial Anesthetics; Opiate Agonists; Opiate Alkaloids; Opioid Agonist; Opioids; P-glycoprotein substrates; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; UGT1A1 Substrates; UGT1A3 substrates; UGT2B7 substrates"
DB00296,Ropivacaine,84057-95-4,approved,ZKMNUMMKYBVTFN-HNNXBMFYSA-N,"InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1",CCCN1CCCC[C@H]1C(=O)Nc2c(C)cccc2C,C17H26N2O,C07532,,175805,46504712,8890,CHEMBL1077896,,153165,50239375,274.4011,4.070950219,"Amides; Amines; Anesthetics; Anesthetics, Local; Anilides; Aniline Compounds; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hypotensive Agents; Local Anesthesia; Local Anesthetics (Amide); Nervous System; Neuraxial Anesthetics; Peripheral Nervous System Agents; Sensory System Agents"
DB00297,Bupivacaine,38396-39-3,approved; investigational,LEBVLXFERQHONN-UHFFFAOYSA-N,"InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)",CCCCN1CCCCC1C(=O)Nc2c(C)cccc2C,C18H28N2O,C07529,,2474,46506768,77431,CHEMBL1098,,2380,50350790,288.4277,4.515518884,"Agents that reduce seizure threshold; Amides; Amines; Anesthetics; Anesthetics, Local; Anilides; Aniline Compounds; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Hypotensive Agents; Local Anesthesia; Local Anesthetics (Amide); Nervous System; Neuraxial Anesthetics; Peripheral Nervous System Agents; Sensory System Agents"
DB00298,Dapiprazole,72822-12-9,approved,RFWZESUMWJKKRN-UHFFFAOYSA-N,"InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3",Cc1ccccc1N2CCN(CC2)CCc3nnc(n34)CCCC4,C19H27N5,,D07775,3033538,46508859,51066,CHEMBL1201216,,2298190,,325.4512,2.415873691,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antiglaucoma Preparations and Miotics; Antipsychotic Agents; Azoles; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Neurotoxic agents; Neurotransmitter Agents; Ophthalmics; Ophthalmologicals; Sensory Organs; Tranquilizing Agents"
DB00299,Penciclovir,39809-25-1,approved,JNTOCHDNEULJHD-UHFFFAOYSA-N,"InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)",Nc([nH]1)nc(=O)c(c12)ncn2CCC(CO)CO,C10H15N5O3,C07417,D05407,4725,46506498,7956,CHEMBL1540,PE2,4563,50210804,253.2578,-1.547908853,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Direct Acting Antivirals; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acid Synthesis Inhibitors; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; Purines; Purinones; Reverse Transcriptase Inhibitors"
DB00300,Tenofovir disoproxil,201341-05-1,approved; investigational,JFVZFKDSXNQEJW-CQSZACIVSA-N,"InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1",n1cnc(N)c(c12)ncn2C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C,C19H30N5O10P,,,5481350,46508131,63717,CHEMBL1538,,4587262,77145,519.448,2.653050922,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Nephrotoxic agents; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; Organophosphorus Compounds; P-glycoprotein inhibitors; P-glycoprotein substrates; Purines; Reverse Transcriptase Inhibitors; Tenofovir and prodrugs"
DB00301,Flucloxacillin,5250-39-5,approved; investigational,UIOFUWFRIANQPC-JKIFEVAISA-N,"InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)c3c(C)onc3-c4c(Cl)cccc4F,C19H17ClFN3O5S,C11748,D04196,21319,46508276,5098,CHEMBL222645,,20037,50370590,453.872,2.444441595,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; Beta-Lactamase Resistant Penicillins; beta-Lactams; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillins; Sulfur Compounds"
DB00302,Tranexamic acid,1197-18-8,approved,GYDJEQRTZSCIOI-LJGSYFOKSA-N,"InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-",NC[C@H]1CC[C@@H](CC1)C(=O)O,C8H15NO2,,D01136,5526,46508089,48669,CHEMBL877,AMH,10482000,50428067,157.2102,-1.552391565,"Acids, Carbocyclic; Amino Acids; Antifibrinolytic Agents; Blood and Blood Forming Organs; Carboxylic Acids; Coagulants; Cyclohexanecarboxylic Acids; Cyclohexanes; Cycloparaffins; Decreased Fibrinolysis; Fibrin Modulating Agents; Hematologic Agents; Hemostatics; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Polycyclic Compounds"
DB00303,Ertapenem,153832-46-3,approved; investigational,JUZNIMUFDBIJCM-ANEDZVCMSA-N,"InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1",C[C@@H](O)[C@@H](C1=O)[C@H](N12)[C@@H](C)C(=C2C(=O)O)S[C@@H]3CN[C@@H](C3)C(=O)Nc4cccc(c4)C(=O)O,C22H25N3O7S,,D07908,150610,46506508,404903,CHEMBL1359,,132758,,475.515,-3.225356194,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Carbapenems; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penem Antibacterial; Sulfur Compounds"
DB00304,Desogestrel,54024-22-5,approved,RPLCPCMSCLEKRS-BPIQYHPVSA-N,"InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1",C#C[C@]1(O)CC[C@H]([C@@]12CC)[C@H]3[C@H](C(C2)=C)[C@@H]4C(CC3)=CCCC4,C22H30O,C07629,D02367,40973,46505739,4453,CHEMBL1533,,37400,50423510,310.473,4.420642467,"Adrenal Cortex Hormones; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Norpregnanes; Norpregnenes; Norsteroids; Polycyclic Compounds; Progestin Contraceptives; Progestins; Progestogens and Estrogens, Sequential Preparations; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids; UGT1A1 Inducers"
DB00305,Mitomycin,50-07-7,approved,NWIBSHFKIJFRCO-WUDYKRTCSA-N,"InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1",CO[C@]12[C@@H]3[C@@H](N3)CN1C4=C(C(=O)C(N)=C(C)C4=O)[C@H]2COC(=O)N,C15H18N4O5,C06681,D00208,5746,46508353,27504,CHEMBL105,,5544,50428658,334.3272,-1.046474072,"Alkylating Activity; Alkylating Drugs; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azirines; Cardiotoxic antineoplastic agents; Compounds used in a research, industrial, or household setting; Cross-Linking Reagents; Cytotoxic Antibiotics and Related Substances; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Indicators and Reagents; Indolequinones; Indoles; Mitomycins; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Toxic Actions"
DB00306,Talbutal,115-44-6,approved; illicit,BJVVMKUXKQHWJK-UHFFFAOYSA-N,"InChI=1S/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)",CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,C11H16N2O3,,D06887,8275,46507821,134923,CHEMBL1200802,,7976,,224.2563,1.58926326,"Anticholinergic Agents; Barbiturates, Plain; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Nicotinic Antagonists; Psycholeptics; Pyrimidines; Pyrimidinones"
DB00307,Bexarotene,153559-49-0,approved; investigational,NAVMQTYZDKMPEU-UHFFFAOYSA-N,"InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)",CC1(C)CCC(C)(C)c(c12)cc(C)c(c2)C(=C)c3ccc(cc3)C(=O)O,C24H28O2,,D03106,82146,46509119,50859,CHEMBL1023,9RA,74139,50032675,348.4779,6.940537398,"Alkenes; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Biological Factors; Carotenoids; Compounds used in a research, industrial, or household setting; Cyclohexanes; Cyclohexenes; Cycloparaffins; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Macrocyclic Compounds; Myelosuppressive Agents; Naphthalenes; Pigments, Biological; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Polyenes; Retinoids; Terpenes; Tetrahydronaphthalenes"
DB00308,Ibutilide,122647-31-8,approved,ALOBUEHUHMBRLE-UHFFFAOYSA-N,"InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3",CCCCCCCN(CC)CCCC(O)c1ccc(cc1)NS(=O)(=O)C,C20H36N2O3S,C07753,D00648,60753,46507904,5856,CHEMBL533,,54755,50131432,384.576,2.542652195,"Amides; Antiarrhythmic agents; Antiarrhythmics, Class III; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Drugs that are Mainly Renally Excreted; Highest Risk QTc-Prolonging Agents; QTc Prolonging Agents; Sulfones; Sulfur Compounds"
DB00309,Vindesine,53643-48-4,approved; investigational,HHJUWIANJFBDHT-ZVTSDNJWSA-N,"InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34-,35+,36+,39-,40+,41+,42-,43-/m0/s1",C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](O)[C@](O)(C(=O)N)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(c9c([nH]8)cccc9)CCN(C6)C[C@@](O)(C7)CC,C43H55N5O7,,D01769,40839,46504548,36373,CHEMBL238071,,9818189,,753.941,2.789183208,"Alkaloids; Antimitotic Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic and Immunomodulating Agents; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Indole Alkaloids; Indoles; Mitosis Modulators; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Secologanin Tryptamine Alkaloids; Tubulin Modulators; Vinca Alkaloids"
DB00310,Chlorthalidone,77-36-1,approved,JIVPVXMEBJLZRO-UHFFFAOYSA-N,"InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)",NS(=O)(=O)c1c(Cl)ccc(c1)C2(O)NC(=O)c(c23)cccc3,C14H11ClN2O4S,,D00272,2732,46505541,3654,CHEMBL1055,,2631,25900,338.766,1.603421069,"Acids, Carbocyclic; Amides; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Benzene Derivatives; Benzophenones; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Diuretics; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hyperglycemia-Associated Agents; Hypotensive Agents; Imides; Increased Diuresis; Isoindoles; Ketones; Low-Ceiling Diuretics and Potassium-Sparing Agents; Low-Ceiling Diuretics, Excl. Thiazides; Medications that reduce magnesium levels; Membrane Transport Modulators; Natriuretic Agents; Non Potassium Sparing Diuretics; Photosensitizing Agents; Phthalic Acids; Phthalimides; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazide-like Diuretic"
DB00312,Pentobarbital,76-74-4,approved; investigational; vet_approved,WEXRUCMBJFQVBZ-UHFFFAOYSA-N,"InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)",CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,C11H18N2O3,C07422,D00499,4737,46508399,7983,CHEMBL448,,4575,50055935,226.2722,1.893251247,"Adjuvants, Anesthesia; Anticholinergic Agents; Anticonvulsants; Barbiturates; Barbiturates, Plain; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strong); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; Psycholeptics; Pyrimidines; Pyrimidinones"
DB00313,Valproic acid,99-66-1,approved; investigational,NIJJYAXOARWZEE-UHFFFAOYSA-N,"InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)",CCCC(C(=O)O)CCC,C8H16O2,C07185,D00399,3121,46505925,39867,CHEMBL109,2PP,3009,50003616,144.2114,2.798451071,"Acids, Acyclic; Anti-epileptic Agent; Anticonvulsants; Antimanic Agents; Antineoplastic Agents; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Fatty Acid Derivatives; Fatty Acids; Fatty Acids, Volatile; GABA Agents; Hepatotoxic Agents; Highest Risk QTc-Prolonging Agents; Histone Deacetylase Inhibitors; Lipids; Methemoglobinemia Associated Agents; Miscellaneous Anticonvulsants; Mood Stabilizer; Narrow Therapeutic Index Drugs; Nervous System; Neurotransmitter Agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OAT3/SLC22A8 Substrates with Narrow Therapeutic Index; Pentanoic Acids; Photosensitizing Agents; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Tranquilizing Agents; UGT1A1 Inhibitors; UGT1A1 Substrates; UGT1A1 substrates with narrow therapeutic index; UGT1A3 substrates; UGT1A3 substrates with narrow therapeutic index; UGT1A4 substrates; UGT1A6 substrate; UGT1A6 substrate with narrow therapeutic index; UGT1A9 Substrates; UGT1A9 substrates with narrow therapeutic index; UGT2B7 substrates; UGT2B7 substrates with narrow therapeutic index; Valerates"
DB00314,Capreomycin,11003-38-6,approved,VCOPTHOUUNAYKQ-WBTCAYNUSA-N,"InChI=1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1",NC1=NCC[C@@H](N1)[C@@H]2NC(=O)/C(=C\NC(=O)N)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC2=O,C50H88N28O15,C01790,D00135,3000502,46508514,3371,CHEMBL2303634,,2272094,,1321.4123,-11.19173328,"Agents that produce neuromuscular block (indirect); Amino Acids, Peptides, and Proteins; Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Drugs for Treatment of Tuberculosis; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inhibitors; Macrocyclic Compounds; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Peptides; Peptides, Cyclic; Polycyclic Compounds; Protein Synthesis Inhibitors"
DB00315,Zolmitriptan,139264-17-8,approved; investigational,ULSDMUVEXKOYBU-ZDUSSCGKSA-N,"InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1",CN(C)CCc1c[nH]c(c12)ccc(c2)C[C@H]3COC(=O)N3,C16H21N3O2,C07218,D00415,60857,46506452,10124,CHEMBL1185,,54844,50033383,287.3568,2.042875288,"Agents that produce hypertension; Amines; Analgesics; Antidepressive Agents; Antimigraine Preparations; Azoles; Biogenic Amines; Biogenic Monoamines; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Monoamine Oxidase A Substrates; Nervous System; Neurotransmitter Agents; Oxazoles; Selective Serotonin 5-HT1 Receptor Agonists; Selective Serotonin Agonists; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 1b Receptor Agonists; Serotonin 1d Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Serotonin-1b and Serotonin-1d Receptor Agonist; Triptans"
DB00316,Acetaminophen,103-90-2,approved,RZVAJINKPMORJF-UHFFFAOYSA-N,"InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)",CC(=O)Nc1ccc(O)cc1,C8H9NO2,C06804,D00217,1983,46506142,46195,CHEMBL112,TYL,1906,26197,151.1626,0.907390862,"Acetaminophen and Prodrugs; Amides; Amines; Analgesics; Analgesics, Non-Narcotic; Anilides; Aniline Compounds; Antipyretics; Central Nervous System Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Methemoglobinemia Associated Agents; Miscellaneous Analgesics and Antipyretics; Nervous System; P-glycoprotein inhibitors; P-glycoprotein substrates; Sensory System Agents; UGT1A1 Substrates; UGT1A6 substrate; UGT1A9 Substrates"
DB00317,Gefitinib,184475-35-2,approved; investigational,XGALLCVXEZPNRQ-UHFFFAOYSA-N,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",C1COCCN1CCCOc(c(c2)OC)cc(c23)c(ncn3)Nc4cc(Cl)c(F)cc4,C22H24ClFN4O3,,D01977,123631,46508649,49668,CHEMBL939,IRE,110217,5447,446.902,3.750953735,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Quinazolines; Tyrosine Kinase Inhibitors"
DB00318,Codeine,76-57-3,approved; illicit,OROGSEYTTFOCAN-DNJOTXNNSA-N,"InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1",C1CN(C)[C@@H]([C@H]2[C@@]134)Cc5c3c(c(cc5)OC)O[C@H]4[C@@H](O)C=C2,C18H21NO3,C06174,D03580,5284371,46507764,16714,CHEMBL485,,4447447,50105098,299.3642,1.342951283,"Alkaloids; Analgesics; Antitussive Agents; Central Nervous System Agents; Central Nervous System Depressants; Cough and Cold Preparations; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Morphine Derivatives; Narcotics; Natural Opium Alkaloids; Nervous System; OAT1/SLC22A6 inhibitors; OCT1 inhibitors; OCT1 substrates; Opiate Agonists; Opiate Alkaloids; Opioid Agonist; Opioids; Opium Alkaloids and Derivatives; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Respiratory System; Respiratory System Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; UGT2B7 substrates"
DB00319,Piperacillin,66258-76-2,approved,IVBHGBMCVLDMKU-GXNBUGAJSA-N,"InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)[C@@H](c3ccccc3)NC(=O)N4CCN(CC)C(=O)C4=O,C23H27N5O7S,C14034,D00466,43672,46504757,8232,CHEMBL702,WPP,39798,50240426,517.555,-0.25849019,"Agents that produce neuromuscular block (indirect); Amides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Pseudomonal Beta-Lactams; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Drugs that are Mainly Renally Excreted; Extended-spectrum Penicillins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Substrates; Penicillin G; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB00320,Dihydroergotamine,511-12-6,approved; investigational,LUZRJRNZXALNLM-JGRZULCMSA-N,"InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1",c1ccccc1C[C@@H](C(=O)N([C@@H]2[C@@]34O)CCC2)N3C(=O)[C@](O4)(C)NC(=O)[C@H](C5)CN(C)[C@@H]([C@H]56)Cc7c8c6cccc8[nH]c7,C33H37N5O5,C07798,,10531,46507711,4562,CHEMBL1732,2GM,10091,50295557,583.6774,2.711622291,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Alkaloids; Analgesics; Analgesics, Non-Narcotic; Antidepressive Agents; Antimigraine Preparations; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Ergot Alkaloids and Derivatives; Ergot-derivative Dopamine Receptor Agonists; Ergotamine Derivative; Ergotamines; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Nervous System; Neurotransmitter Agents; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Sympatholytic (Adrenergic Blocking) Agents; Vasoconstrictor Agents"
DB00321,Amitriptyline,50-48-6,approved,KRMDCWKBEZIMAB-UHFFFAOYSA-N,"InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3",CN(C)CCC=C1c(cccc2)c2CCc(c13)cccc3,C20H23N,C06824,D07448,2160,46508798,2666,CHEMBL629,TP0,2075,50020712,277.4033,4.809534915,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Analgesics; Analgesics, Non-Narcotic; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tricyclic; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that increase serum magnesium; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; Muscarinic Antagonists; Narrow Therapeutic Index Drugs; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Psychotropic Drugs; QTc Prolonging Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Tertiary amine tricyclic antidepressants; Tricyclics and Other Norepinephrine-reuptake Inhibitors; UGT1A1 Inhibitors; UGT1A1 Substrates; UGT1A4 substrates"
DB00322,Floxuridine,50-91-9,approved,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,"InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1",OC[C@H]1O[C@H](C[C@@H]1O)n2cc(F)c(=O)[nH]c2=O,C9H11FN2O5,C11736,D04197,5790,46508645,60761,CHEMBL917,,5586,50340678,246.1924,-1.315161169,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carbohydrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Deoxyribonucleosides; Deoxyuridine; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Noxae; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Pyrimidine Analogues; Pyrimidine Nucleosides; Pyrimidines; Ribonucleosides; Thyroxine-binding globulin inducers; Toxic Actions"
DB00323,Tolcapone,134308-13-7,approved; withdrawn,MIQPIUSUKVNLNT-UHFFFAOYSA-N,"InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3",Cc1ccc(cc1)C(=O)c2cc([N+]([O-])=O)c(O)c(O)c2,C14H11NO5,C07949,D00786,4659569,46504932,63630,CHEMBL1324,TCW,3848682,50108877,273.2408,3.278873789,"Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Benzene Derivatives; Benzophenones; Central Nervous System Agents; Central Nervous System Depressants; COMT Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dopamine Agents; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Ketones; Nervous System; Nitro Compounds; Nitrophenols; Phenols"
DB00324,Fluorometholone,426-13-1,approved; investigational,FAOZLTXFLGPHNG-KNAQIMQKSA-N,"InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1",CC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C([C@H](C3)C)=CC(=O)C=C4,C22H29FO4,,D01367,9878,46505984,31625,CHEMBL1200600,,9494,50103631,376.4617,2.420863996,"Adrenal Cortex Hormones; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Allergic Agents; Anti-Inflammatory Agents; Cardiovascular System; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Moderately Potent (Group II); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Ophthalmologicals; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnanes; Sensory Organs; Steroids; Steroids, Fluorinated; Thyroxine-binding globulin inhibitors; Vasoprotectives"
DB00325,Nitroprusside,15078-28-1,approved; investigational,ASPOIVQEUUCDQT-UHFFFAOYSA-N,InChI=1S/5CN.Fe.NO/c5*1-2;;1-2/q;;;;;2*-1,O=N[Fe-2](C#N)(C#N)(C#N)(C#N)C#N,C5FeN6O,C07269,,11963622,46508965,7596,CHEMBL2097081,,21607452,50377921,215.938,0.0712,"Acids; Acids, Noncarboxylic; Anions; Antihypertensive Agents; Arteriolar Smooth Muscle, Agents Acting On; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Cyanides; Direct Vasodilators; Drugs that are Mainly Renally Excreted; Electrolytes; Ferric Compounds; Ferricyanides; Hydrogen Cyanide; Hypotensive Agents; Indicators and Reagents; Ions; Iron Compounds; Laboratory Chemicals; Methemoglobinemia Associated Agents; Nitric Oxide Donors; Nitroferricyanide Derivatives; Nitrogen Compounds; Organometallic Compounds; Vasodilating Agents; Vasodilation"
DB00326,Calcium glucoheptonate,29039-00-7,approved,FATUQANACHZLRT-KMRXSBRUSA-L,"InChI=1S/2C7H14O8.Ca/c2*8-1-2(9)3(10)4(11)5(12)6(13)7(14)15;/h2*2-6,8-13H,1H2,(H,14,15);/q;;+2/p-2/t2*2-,3-,4+,5-,6?;/m11./s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O,C14H26CaO16,,D00934,62859,46507233,3314,CHEMBL1237066,,56591,,490.425,-4.040079253,"Acids, Acyclic; Alimentary Tract and Metabolism; Calcium Salts; Carbohydrates; Carboxylic Acids; Hydroxy Acids; Mineral Supplements; Supplements"
DB00327,Hydromorphone,466-99-9,approved; illicit,WVLOADHCBXTIJK-YNHQPCIGSA-N,"InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1",[C@]123[C@H]4Oc5c1c(ccc5O)C[C@@H](N(C)CC2)[C@@H]3CCC4=O,C17H19NO3,C07042,,5284570,46508700,5790,CHEMBL398707,,4447624,50241341,285.3377,1.622749676,"Alkaloids; Analgesics; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; High-risk opioids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Morphine Derivatives; Narcotics; Natural Opium Alkaloids; Nervous System; Opiate Agonists; Opiate Alkaloids; Opioid Agonist; Opioids; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Semi-synthetic Opioids; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; UGT1A3 substrates; UGT2B7 substrates"
DB00328,Indomethacin,53-86-1,approved; investigational,CGIGDMFJXJATDK-UHFFFAOYSA-N,"InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)",COc(cc1)cc(c12)c(CC(=O)O)c(C)n2C(=O)c3ccc(Cl)cc3,C19H16ClNO4,C01926,D00141,3715,46508291,49662,CHEMBL6,IMN,3584,17638,357.788,3.52967438,"Acetic Acid Derivatives and Related Substances; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antigout Preparations; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; BSEP/ABCB11 Substrates; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypoglycemia-Associated Agents; Immunosuppressive Agents; Indoles; Musculo-Skeletal System; Myelosuppressive Agents; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inhibitors; Ophthalmologicals; Other Nonsteroidal Anti-inflammatory Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Sensory Organs; Sensory System Agents; Tocolytic Agents; Topical Products for Joint and Muscular Pain; UGT1A1 Inhibitors; UGT1A1 Substrates; UGT1A9 Substrates; UGT2B7 Inhibitors; UGT2B7 substrates"
DB00330,Ethambutol,74-55-5,approved,AEUTYOVWOVBAKS-UWVGGRQHSA-N,"InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1",CC[C@@H](CO)NCCN[C@@H](CC)CO,C10H24N2O2,C06984,D07925,14052,46504788,4877,CHEMBL44884,95E,13433,50448407,204.3098,-0.059291071,Amines; Anti-Bacterial Agents; Anti-Infective Agents; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Diamines; Drugs for Treatment of Tuberculosis; Drugs that are Mainly Renally Excreted; Ethylenediamines; Polyamines
DB00331,Metformin,657-24-9,approved,XZWYZXLIPXDOLR-UHFFFAOYSA-N,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",CN(C)C(=N)NC(N)=N,C4H11N5,C07151,D04966,4091,46507752,6801,CHEMBL1431,MF8,3949,50229665,129.1636,-0.918429265,Alimentary Tract and Metabolism; Amidines; Biguanides; Blood Glucose Lowering Agents; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Guanidines; MATE 1 Substrates; MATE 2 Substrates; MATE substrates; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates
DB00332,Ipratropium,60205-81-4,approved; experimental,OEXHQOGQTVQTAT-BHIXFJMTSA-N,"InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18+,19?,21?",[C@@H]12CC[C@@H]([N+]1(C)C(C)C)C[C@@H](C2)OC(=O)C(CO)c3ccccc3,C20H30NO3,C07052,,657308,46506138,46659,CHEMBL1621597,,19962157,,332.463,-1.81771262,"Adrenergics, Inhalants; Agents producing tachycardia; Agents to Treat Airway Disease; Alkaloids; Anti-Asthmatic Agents; Anticholinergic Agents; Antimuscarinics Antispasmodics; Atropine Derivatives; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Belladonna Alkaloids; Bicyclo Compounds; Bicyclo Compounds, Heterocyclic; Bridged Compounds; Bronchodilator Agents; Cholinergic Agents; Drugs for Obstructive Airway Diseases; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Muscarinic Antagonists; Nasal Preparations; Neurotransmitter Agents; Peripheral Nervous System Agents; Polycyclic Compounds; Respiratory System; Respiratory System Agents; Solanaceous Alkaloids; Tropanes"
DB00333,Methadone,76-99-3,approved,USSIQXCVUWKGNF-UHFFFAOYSA-N,"InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3",c1ccccc1C(C(=O)CC)(CC(C)N(C)C)c2ccccc2,C21H27NO,C07163,D08195,4095,46505722,6807,CHEMBL651,,3953,82507,309.4452,5.007171635,Analgesics; Anticholinergic Agents; Antidepressive Agents; Antitussive Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diphenylheptane opioids; Diphenylpropylamine Derivatives; Drugs that are Mainly Renally Excreted; Drugs Used in Addictive Disorders; Drugs Used in Opioid Dependence; High-risk opioids; Ketones; Moderate Risk QTc-Prolonging Agents; Narcotics; Nervous System; Nicotinic Antagonists; NMDA Receptor Antagonists; Opiate Agonists; Opioid Agonist; Opioids; P-glycoprotein inhibitors; Peripheral Nervous System Agents; QTc Prolonging Agents; Respiratory System Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Thyroxine-binding globulin inducers
DB00334,Olanzapine,132539-06-1,approved; investigational,KVWDHTXUZHCGIO-UHFFFAOYSA-N,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",CN1CCN(CC1)C2=Nc(cccc3)c3Nc(c24)sc(c4)C,C17H20N4S,C07322,D00454,4585,46507666,7735,CHEMBL715,,10442212,35254,312.432,3.388495082,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Anticholinergic Agents; Antidepressive Agents; Antiemetics; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Autonomic Agents; Benzazepines; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diazepines, Oxazepines, Thiazepines and Oxepines; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Histamine H2 Antagonists; Hyperglycemia-Associated Agents; Hypotensive Agents; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; P-glycoprotein substrates; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents; UGT1A4 substrates"
DB00335,Atenolol,29122-68-7,approved,METKIMKYRPQLGS-UHFFFAOYSA-N,"InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)",CC(C)NCC(O)COc1ccc(cc1)CC(=O)N,C14H22N2O3,,D00235,2249,46506915,2904,CHEMBL24,,2162,25753,266.3361,0.425024848,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Autonomic Agents; Beta blocking agents and calcium channel blockers; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Selective; Beta Blocking Agents, Selective, and Thiazides; Beta-Blockers (Beta1 Selective); Bradycardia-Causing Agents; BSEP/ABCB11 Substrates; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Hypotensive Agents; Peripheral Nervous System Agents; QTc shortening agents; Sympatholytics"
DB00336,Nitrofural,59-87-0,approved; investigational; vet_approved,IAIWVQXQOWNYOU-FPYGCLRLSA-N,"InChI=1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+",NC(=O)N/N=C/c1ccc(o1)[N+]([O-])=O,C6H6N4O4,C08042,D00862,5447130,46506509,,CHEMBL869,NFZ,4566720,50420350,198.1362,-0.135063386,"Agents Against Leishmaniasis and Trypanosomiasis; Anti-Infective Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Antiseptics and Disinfectants; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Dermatologicals; Furans; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Irrigating Solutions; Medicated Dressings; Medicated Dressings With Antiinfectives; Nitro Compounds; Nitrofuran Derivatives; Nitrofurans; Ophthalmologicals; Otologicals; Sensory Organs"
DB00337,Pimecrolimus,137071-32-0,approved; investigational,KASDHRXLYQOAKZ-XDSKOBMDSA-N,"InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1",O[C@@]12C(=O)C(=O)N3[C@@H](CCCC3)C(=O)O[C@H](C(\C)=C\[C@H](CC[C@@H]4Cl)C[C@H]4OC)[C@H](C)[C@@H](O)CC(=O)[C@H](CC)/C=C(\C)C[C@H](C)C[C@H](OC)[C@@H](O1)[C@@H](OC)C[C@H]2C,C43H68ClNO11,,,6509979,46505748,135888,CHEMBL1200686,,21111755,,810.46,6.808131371,"Agents for Dermatitis, Excluding Corticosteroids; Analgesics; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-Inflammatory Agents; Calcineurin Inhibitor Immunosuppressant; Calcineurin Inhibitors; Central Nervous System Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Enzyme Inhibitors; Immunologic Factors; Immunosuppressive Agents; Lactones; Macrocyclic Compounds; Misc. Skin and Mucous Membrane Agents; Peptidylprolyl Isomerase, antagonists & inhibitors; Peripheral Nervous System Agents; Polycyclic Compounds; Polyketides; Sensory System Agents"
DB00338,Omeprazole,73590-58-6,approved; investigational; vet_approved,SUBDBMMJDZJVOS-UHFFFAOYSA-N,"InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)",COc(cc1)cc(c12)[nH]c(n2)S(=O)Cc3ncc(C)c(OC)c3C,C17H19N3O3S,C07324,D00455,4594,46509065,77260,CHEMBL1503,,4433,50241343,345.416,2.433509123,"2-Pyridinylmethylsulfinylbenzimidazoles; Acid Reducers; Alimentary Tract and Metabolism; Anti-Ulcer Agents; BCRP/ABCG2 Inhibitors; Benzimidazoles; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Enzyme Inhibitors; Gastric Acid Lowering Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Medications that reduce magnesium levels; Omeprazole and enantiomer; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Proton Pump Inhibitors; Proton-pump Inhibitors; Pyridines; Sulfoxides; Sulfur Compounds"
DB00339,Pyrazinamide,98-96-4,approved; investigational,IPEHBUMCGVEMRF-UHFFFAOYSA-N,"InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)",NC(=O)c1nccnc1,C5H5N3O,C01956,D00144,1046,46507478,45285,CHEMBL614,PZA,1017,228814,123.1127,-1.225608418,"Anti-Bacterial Agents; Anti-Infective Agents; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs for Treatment of Tuberculosis; Drugs that are Mainly Renally Excreted; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Photosensitizing Agents; Pyrazines"
DB00340,Metixene,02-02-4969,approved,MJFJKKXQDNNUJF-UHFFFAOYSA-N,"InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3",CN1CCCC(C1)CC2c(cccc3)c3Sc(c24)cccc4,C20H23NS,,D01871,4167,46508970,51024,CHEMBL1201342,,4023,79211,309.468,5.064776443,"Agents producing tachycardia; Anti-Parkinson Drugs; Anticholinergic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Muscarinic Antagonists; Nervous System; Sulfur Compounds; Tertiary Amines; Xanthenes"
DB00341,Cetirizine,83881-51-0,approved,ZKLPARSLTMPFCP-UHFFFAOYSA-N,"InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)",OC(=O)COCCN1CCN(CC1)C(c2ccccc2)c3ccc(Cl)cc3,C21H25ClN2O3,C07778,,2678,46508368,3561,CHEMBL1000,,2577,22890,388.888,0.859809303,"Anti-Allergic Agents; Antihistamines for Systemic Use; Central Nervous System Depressants; Cetirizine and isomer; Drugs that are Mainly Renally Excreted; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; P-glycoprotein inhibitors; P-glycoprotein substrates; Piperazine Derivatives; Piperazines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB00342,Terfenadine,50679-08-8,approved; withdrawn,GUGOEEXESWIERI-UHFFFAOYSA-N,"InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3",CC(C)(C)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4,C32H41NO2,C07463,D00521,5405,46507007,9453,CHEMBL17157,,5212,50017376,471.6734,6.479109076,"Anticholinergic Agents; Antihistamines for Systemic Use; Benzene Derivatives; Benzhydryl Compounds; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; Muscarinic Antagonists; Neurotransmitter Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Piperidines; QTc Prolonging Agents; Respiratory System"
DB00343,Diltiazem,42399-41-7,approved; investigational,HSUGRBWQSSZJOP-RTWAWAEBSA-N,"InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1",COc1ccc(cc1)[C@H](Sc(c23)cccc3)[C@@H](OC(=O)C)C(=O)N2CCN(C)C,C22H26N2O4S,C06958,D07845,39186,46505667,101278,CHEMBL23,C9F,35850,50004704,414.518,2.727251884,"Agents causing hyperkalemia; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Benzazepines; Benzothiazepine Derivatives; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium Channel Blockers (Nondihydropyridine); Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (moderate); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (moderate); Cytochrome P-450 CYP3A7 Inhibitors (strong); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Membrane Transport Modulators; Miscellaneous Calcium-channel Blocking Agents; Moderate Risk QTc-Prolonging Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; QTc Prolonging Agents; Selective Calcium Channel Blockers With Direct Cardiac Effects; Vasodilating Agents; Vasoprotectives"
DB00344,Protriptyline,438-60-8,approved,BWPIARFWQZKAIA-UHFFFAOYSA-N,"InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3",CNCCCC1c(cccc2)c2C=Cc(c13)cccc3,C19H21N,C07408,D08447,4976,46505128,8597,CHEMBL668,,4805,50176062,263.3767,4.496811469,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tricyclic; Benzocycloheptenes; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Dibenzocycloheptenes; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Membrane Transport Modulators; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; P-glycoprotein inhibitors; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB00345,Aminohippuric acid,61-78-9,approved; investigational,HSMNQINEKMPTIC-UHFFFAOYSA-N,"InChI=1S/C9H10N2O3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5,10H2,(H,11,14)(H,12,13)",Nc1ccc(cc1)C(=O)NCC(=O)O,C9H10N2O3,,D06890,2148,46507106,104011,CHEMBL463,,2063,50240008,194.1873,-1.01178876,"Acids, Carbocyclic; Amides; Aminobenzoates; Aminohippuric Acids; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Diagnostic Agents; Hippurates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indicators and Reagents; Keto Acids; Laboratory Chemicals; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inhibitors; OCT2 Inhibitors; para-Aminobenzoates; Tests for Renal Function and Ureteral Injuries"
DB00346,Alfuzosin,81403-80-7,approved; investigational,WNMJYKCGWZFFKR-UHFFFAOYSA-N,"InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)",COc(c1)c(OC)cc(c12)nc(nc2N)N(C)CCCNC(=O)C3CCCO3,C19H27N5O4,,D07124,2092,46508512,51141,CHEMBL709,,2008,50033110,389.4488,1.187536209,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs Used in Benign Prostatic Hypertrophy; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; Peripheral alpha-1 blockers; Potential QTc-Prolonging Agents; Prostatic Hyperplasia; QTc Prolonging Agents; Selective Alfa-1-adrenergic Blocking Agents; Urological Agents; Urologicals"
DB00347,Trimethadione,127-48-0,approved,IRYJRGCIQBGHIV-UHFFFAOYSA-N,InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3,CC1(C)C(=O)N(C)C(=O)O1,C6H9NO3,,D00392,5576,46504478,9727,CHEMBL695,,5374,50227239,143.1406,0.50414633,"Agents causing hyperkalemia; Anti-epileptic Agent; Antiarrhythmic agents; Anticonvulsants; Azoles; Bradycardia-Causing Agents; Calcium Channel Blockers; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Oxazoles; Oxazolidine Derivatives; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB00348,Nitisinone,104206-65-7,approved; investigational,OUBCNLGXQFSTLU-UHFFFAOYSA-N,"InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2",FC(F)(F)c1cc([N+]([O-])=O)c(cc1)C(=O)C2C(=O)CCCC2=O,C14H10F3NO5,,,115355,46507380,50378,CHEMBL1337,,103195,50088804,329.2281,3.127661501,"4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor; 4-Hydroxyphenylpyruvate Dioxygenase, antagonists & inhibitors; Acids, Carbocyclic; Alimentary Tract and Metabolism; Benzene Derivatives; Benzoates; Carboxylic Acids; Cyclohexanes; Cycloparaffins; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxyphenylpyruvate Dioxygenase Inhibitors; Ketones; Macrocyclic Compounds; Other Miscellaneous Therapeutic Agents; Polycyclic Compounds; Various Alimentary Tract and Metabolism Products"
DB00349,Clobazam,22316-47-8,approved; illicit,CXOXHMZGEKVPMT-UHFFFAOYSA-N,"InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3",c1c(Cl)ccc(c12)N(C)C(=O)CC(=O)N2c3ccccc3,C16H13ClN2O2,,D01253,2789,46506115,31413,CHEMBL70418,,2687,50247888,300.74,2.554375973,"Anti-Anxiety Agents; Anticonvulsants; Benzazepines; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Agonists; GABA-A Receptor Agonists; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotransmitter Agents; P-glycoprotein substrates; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB00350,Minoxidil,38304-91-5,approved; investigational,ZFMITUMMTDLWHR-UHFFFAOYSA-N,"InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6H,1-5,10H2,(H2,11,12)",[O-][n+]1c(N)nc(cc1N)N2CCCCC2,C9H15N5O,,D00418,4201,46508344,6942,CHEMBL802,MXD,10438564,50237593,209.2483,0.00079288,"Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Arteriolar Smooth Muscle, Agents Acting On; Arteriolar Vasodilation; Arteriolar Vasodilator; Cardiovascular Agents; Cardiovascular System; Dermatologicals; Direct Vasodilators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Misc. Skin and Mucous Membrane Agents; Piperidines; Pyrimidine Derivatives; Pyrimidines; UGT1A1 Substrates; Vasodilating Agents"
DB00351,Megestrol acetate,595-33-5,approved; investigational; vet_approved,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,"InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1",CC(=O)O[C@]1(C(=O)C)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(C(=C3)C)=CC(=O)CC4,C24H32O4,C08151,D00952,11683,46505827,6723,CHEMBL1201139,,11192,50238674,384.516,3.723744303,"Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Appetite Stimulants; Central Nervous System Agents; Central Nervous System Stimulants; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Endocrine Therapy; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hormones and Related Agents; Hyperglycemia-Associated Agents; Megestrol; P-glycoprotein inhibitors; Polycyclic Compounds; Pregnadien Derivatives; Pregnadienes; Pregnanes; Progestin Contraceptives; Progestins; Progestogens and Estrogens, Sequential Preparations; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB00352,Tioguanine,154-42-7,approved,WYWHKKSPHMUBEB-UHFFFAOYSA-N,"InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)",Nc([nH]1)nc(=S)c(c12)[nH]cn2,C5H5N5S,C07648,D08603,2723601,46508170,9555,CHEMBL727,DX4,2005804,50200099,167.192,-0.34946935,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Purine Analogues; Purines; Thiopurine Analogs; Toxic Actions"
DB00353,Methylergometrine,113-42-8,approved,UNBRKDKAWYKMIV-QWQRMKEZSA-N,"InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1",CC[C@@H](CO)NC(=O)[C@H](C=1)CN(C)[C@@H](C12)Cc3c4c2cccc4[nH]c3,C20H25N3O2,,D00680,8226,46507746,92607,CHEMBL1201356,H8D,7933,50330860,339.4314,1.593218381,"Agents that produce hypertension; Alkaloids; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Antagonists; Ergolines; Ergonovine; Ergot Alkaloids and Derivatives; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Reproductive Control Agents; Uterotonic agents"
DB00354,Buclizine,82-95-1,approved,MOYGZHXDRJNJEP-UHFFFAOYSA-N,"InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3",CC(C)(C)c1ccc(cc1)CN2CCN(CC2)C(c3ccccc3)c4ccc(Cl)cc4,C28H33ClN2,C07777,D07547,6729,46507608,3205,CHEMBL1201271,,6473,,433.028,7.419576414,"Agents producing tachycardia; Anticholinergic Agents; Antihistamines for Systemic Use; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Muscarinic Antagonists; Neurotransmitter Agents; Piperazine Derivatives; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB00355,Aztreonam,78110-38-0,approved,WZPBZJONDBGPKJ-VEHQQRBSSA-N,"InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1",[O-]S(=O)(=O)N1C(=O)[C@H]([C@@H]1C)NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(n2)[NH3+],C13H17N5O8S2,C06840,D00240,9568617,46505419,161680,CHEMBL158,AZR,4674940,50240480,435.433,-3.079000158,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Monobactam Antibacterial; Monobactams; Sulfur Compounds"
DB00356,Chlorzoxazone,95-25-0,approved,TZFWDZFKRBELIQ-UHFFFAOYSA-N,"InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)",c1cc(Cl)cc(c12)[nH]c(o2)=O,C7H4ClNO2,C07931,D00771,2733,46507755,3655,CHEMBL1371,CLW,2632,50290811,169.565,1.935671295,"Benzoxazoles; Central Nervous System Agents; Central Nervous System Depressants; Centrally-mediated Muscle Relaxation; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System; Oxazol, Thiazine, and Triazine Derivatives; Peripheral Nervous System Agents"
DB00357,Aminoglutethimide,125-84-8,approved; investigational,ROBVIMPUHSLWNV-UHFFFAOYSA-N,"InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)",Nc1ccc(cc1)C2(CC)CCC(=O)NC2=O,C13H16N2O2,C07617,D00574,2145,46506066,2654,CHEMBL488,,2060,9460,232.2783,1.299544368,"Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Aromatase Inhibitors; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Endocrine Therapy; Enzyme Inhibitors; Estrogen Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Piperidines; Piperidones; Steroid Synthesis Inhibitors"
DB00358,Mefloquine,53230-10-7,approved; investigational,XEEQGYMUWCZPDN-UHFFFAOYSA-N,"InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2",C1CCCNC1C(O)c2cc(C(F)(F)F)nc(c23)c(C(F)(F)F)ccc3,C17H16F6N2O,C07633,D04895,4046,46505610,63681,CHEMBL416956,,3906,50022889,378.3122,4.11059485,"Agents Causing Muscle Toxicity; Agents that reduce seizure threshold; Aminoquinolines; Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Cholinesterase Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Methanolquinolines; P-glycoprotein inhibitors; P-glycoprotein substrates; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines"
DB00359,Sulfadiazine,68-35-9,approved; investigational; vet_approved,SEEPANYCNGTZFQ-UHFFFAOYSA-N,"InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)",Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2,C10H10N4O2S,C07658,D00587,5215,46506164,9328,CHEMBL439,,5026,50166571,250.277,0.387260808,Amides; Amines; Aniline Compounds; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antiparasitic Agents; Antiprotozoals; Blood Glucose Lowering Agents; Coccidiostats; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Hypoglycemia-Associated Agents; Intermediate-Acting Sulfonamides; Methemoglobinemia Associated Agents; Sulfanilamides; Sulfonamide Antibacterial; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds
DB00360,Sapropterin,62989-33-7,approved; investigational,FNKQXYHWGSIFBK-RPDRRWSUSA-N,"InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4+,6-/m0/s1",C[C@H](O)[C@H](O)[C@H](N1)CNc(c12)nc(N)[nH]c2=O,C9H15N5O3,C00272,D08505,44257,46508597,59560,CHEMBL1201774,H4B,40270,50373697,241.2471,-2.321126438,"Alimentary Tract and Metabolism; Amines; Biological Factors; Breast Cancer Resistance Protein Inhibitors; Coenzymes; Dietary Supplements; Enzymes and Coenzymes; Ethylamines; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nitric Oxide Synthase; Other Miscellaneous Therapeutic Agents; P-glycoprotein inhibitors; Phenethylamines; Phenylalanine Hydroxylase Activator; Phenylalanine Hydroxylase Activators; Pigments, Biological; Pteridines; Pterins; Supplements; Various Alimentary Tract and Metabolism Products"
DB00361,Vinorelbine,71486-22-1,approved; investigational,GBABOYUKABKIAF-IELIFDKJSA-N,"InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1",C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(CN(C6)CC(=C7)CC)c9c([nH]8)cccc9,C45H54N4O8,,D08680,44424639,46507772,480999,CHEMBL553025,,4470974,,778.947,4.648204367,"Alkaloids; Antimitotic Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic and Immunomodulating Agents; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Indole Alkaloids; Indoles; Mitosis Modulators; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Neurotoxic agents; Secologanin Tryptamine Alkaloids; Tubulin Modulators; Vinca Alkaloids"
DB00362,Anidulafungin,166663-25-8,approved; investigational,JHVAMHSQVVQIOT-MFAJLEFUSA-N,"InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1",Oc1ccc(cc1)[C@H](O)[C@@H](O)[C@@H](C(=O)N[C@H](C2=O)[C@@H](C)O)NC(=O)[C@H](C[C@H](C3)O)N3C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@@H](N24)[C@@H](O)[C@H](C4)C)NC(=O)c5ccc(cc5)-c6ccc(cc6)-c7ccc(cc7)OCCCCC,C58H73N7O17,,D03211,166548,46505616,55346,CHEMBL264241,,145752,50417554,1140.2369,-1.457217151,"Amino Acids, Peptides, and Proteins; Anti-Infective Agents; Antifungal Agents; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; Echinocandin Antifungal; Echinocandins; Macrocyclic Compounds; Peptides; Peptides, Cyclic; Polycyclic Compounds"
DB00363,Clozapine,5786-21-0,approved,QZUDBNBUXVUHMW-UHFFFAOYSA-N,"InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3",CN1CCN(CC1)C2=Nc(cc(Cl)cc3)c3Nc(c24)cccc4,C18H19ClN4,C06924,D00283,2818,46506474,3766,CHEMBL42,,10442628,50001884,326.823,3.400241024,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Anticholinergic Agents; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diazepines, Oxazepines, Thiazepines and Oxepines; Dibenzazepines; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Hyperglycemia-Associated Agents; Hypotensive Agents; Moderate Risk QTc-Prolonging Agents; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein substrates; Photosensitizing Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT1D Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents; UGT1A4 substrates"
DB00364,Sucralfate,54182-58-0,approved,IPLJAZDIICJQEL-JTJNLBSYSA-A,"InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;9*+3;;;;;;;;;;;;;;;;;;;;/p-27/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1",O[Al](O)OS(=O)(=O)OC[C@@H](O1)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@]1(COS(=O)(=O)O[Al](O)O)O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O,C12H35Al9O55S8,C07314,,70789197,46508862,,CHEMBL2029132,,32701653,,1558.67,-5.8719,Alimentary Tract and Metabolism; Aluminium Compounds; Aluminum Complex; Anti-Ulcer Agents; Carbohydrates; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Glycosides; Metal cations; Metal divalent cations; Organometallic Compounds; Protectants; Sulfur Compounds; Thioglycosides
DB00365,Grepafloxacin,119914-60-2,approved; investigational; withdrawn,AIJTTZAVMXIJGM-UHFFFAOYSA-N,"InChI=1S/C19H22FN3O3/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26)",CC1CN(CCN1)c(c2)c(F)c(C)c(c23)c(=O)c(C(=O)O)cn3C4CC4,C19H22FN3O3,C11368,,72474,46507253,5543,CHEMBL583,,65391,50117924,359.3947,0.118112007,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; OAT1/SLC22A6 Substrates; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; QTc Prolonging Agents; Quinolines; Quinolones; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00366,Doxylamine,469-21-6,approved; vet_approved,HCFDWZZGGLSKEP-UHFFFAOYSA-N,"InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3",c1cccnc1C(C)(OCCN(C)C)c2ccccc2,C17H22N2O,,D02327,3162,46506354,51380,CHEMBL1004,,3050,50239996,270.3694,2.961942224,"Agents producing tachycardia; Aminoalkyl Ethers; Anticholinergic Agents; Antiemetics; Antihistamines for Systemic Use; Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Ethanolamine Derivatives; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine Receptor Antagonists; Muscarinic Antagonists; Neurotransmitter Agents; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Respiratory System"
DB00367,Levonorgestrel,797-63-7,approved; investigational,WWYNJERNGUHSAO-XUDSTZEESA-N,"InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1",C#C[C@]1(O)CC[C@H]([C@@]12CC)[C@H]3[C@H](CC2)[C@@H]4C(CC3)=CC(=O)CC4,C21H28O2,C08153,D00950,13109,46508082,6443,CHEMBL1389,NOG,12560,50410522,312.4458,3.661796602,"Adrenal Cortex Hormones; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hyperglycemia-Associated Agents; Inhibit Ovum Fertilization; Norpregnanes; Norpregnenes; Norsteroids; Polycyclic Compounds; Progestin Contraceptives; Progestin-containing Intrauterine Device; Progestins; Progestogens and Estrogens, Sequential Preparations; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB00368,Norepinephrine,51-41-2,approved,SFLSHLFXELFNJZ-QMMMGPOBSA-N,"InChI=1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-/m0/s1",NC[C@H](O)c1cc(O)c(O)cc1,C8H11NO3,C00547,D00076,439260,46506201,18357,CHEMBL1437,LNR,388394,50029051,169.1778,-0.683513395,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Alpha-and Beta-adrenergic Agonists; Amines; Amino Alcohols; Autonomic Agents; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Catecholamines; Catechols; COMT Substrates; Epinephrine and similars; Ethanolamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; Norepinephrine, antagonists & inhibitors; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; Peripheral Nervous System Agents; Phenols; Sympathomimetics; Vasoconstrictor Agents"
DB00369,Cidofovir,113852-37-2,approved,VWFCHDSQECPREK-LURJTMIESA-N,"InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1",Nc1nc(=O)n(cc1)C[C@@H](CO)OCP(=O)(O)O,C8H14N3O6P,C06909,,60613,46506054,3696,CHEMBL152,L8P,54636,31915,279.187,-3.41335189,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Cytosine; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nephrotoxic agents; Nucleic Acid Synthesis Inhibitors; Nucleosides and Nucleotides; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; Organophosphonates; Organophosphorus Compounds; Pyrimidines; Pyrimidinones"
DB00370,Mirtazapine,85650-52-8,approved,RONZAEMNMFQXRA-UHFFFAOYSA-N,"InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3",CN(C1)CCN(C12)c3c(cccn3)Cc4c2cccc4,C17H19N3,C07570,D00563,4205,46506965,6950,CHEMBL654,,4060,50115644,265.3529,3.207982755,"Adrenergic Agents; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tetracyclic; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Miscellaneous Antidepressants; Nervous System; Neurotransmitter Agents; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB00371,Meprobamate,57-53-4,approved; illicit,NPPQSCRMBWNHMW-UHFFFAOYSA-N,"InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)",NC(=O)OCC(C)(CCC)COC(=O)N,C9H18N2O4,,D00376,4064,46508142,6761,CHEMBL979,,3924,,218.2502,0.927252884,"Acids, Acyclic; Anti-Anxiety Agents; Carbamates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Hypnotics and Sedatives; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; Peripheral Nervous System Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB00372,Thiethylperazine,1420-55-9,approved; withdrawn,XCTYLCDETUVOIP-UHFFFAOYSA-N,"InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3",CCSc(cc1)cc(c12)N(c3c(S2)cccc3)CCCN4CCN(C)CC4,C22H29N3S2,C07132,D02354,5440,46506502,9544,CHEMBL1378,,5245,78436,399.616,4.659322274,"Antiemetics; Antihistamines for Systemic Use; Antipsychotic Agents; Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Neurotoxic agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenothiazine Derivatives; Phenothiazines; Piperazines; Respiratory System; Sulfur Compounds"
DB00373,Timolol,26839-75-8,approved,BLJRIMJGRPQVNF-JTQLQIEISA-N,"InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1",CC(C)(C)NC[C@H](O)COc1nsnc1N2CCOCC2,C13H24N4O3S,C07141,,33624,46507733,9599,CHEMBL499,TIM,31013,50292219,316.42,1.335705946,"Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Non-Selective; Beta Blocking Agents, Non-Selective, and Thiazides; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; EENT Drugs, Miscellaneous; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Morpholines; Ophthalmologicals; Oxazines; P-glycoprotein substrates; Potential QTc-Prolonging Agents; Propanolamines; Propanols; QTc Prolonging Agents; Sulfur Compounds; Thiadiazoles; Thiazoles"
DB00374,Treprostinil,81846-19-7,approved; investigational,PAJMKGZZBBTTOY-ZFORQUDYSA-N,"InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1",OC(=O)COc1cccc(c12)C[C@H]3[C@@H](C2)C[C@@H](O)[C@@H]3CC[C@@H](O)CCCCC,C23H34O5,,,6918140,46504572,50861,CHEMBL1237119,,5293353,,390.5131,4.004209447,"Antihypertensive Agents; Autacoids; Biological Factors; Blood and Blood Forming Organs; Cardiovascular Agents; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Inflammation Mediators; Lipids; Platelet Aggregation Inhibitors Excl. Heparin; Potential QTc-Prolonging Agents; Prostacyclin Analogues; Prostacycline Vasodilator; Prostaglandins; Prostaglandins I; QTc Prolonging Agents; Vasodilating Agents; Vasodilation"
DB00375,Colestipol,26658-42-4,approved,,, ,,C06925,,62816,46505777,,CHEMBL1909303,,56550,,NA,NA,"Amines; Anion Exchange Resins; Bile Acid Sequestrants; Bile-acid Binding Activity; Compounds used in a research, industrial, or household setting; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Macromolecular Substances; Medications that reduce magnesium levels; Polyamines; Polymers; Sequestering Agents"
DB00376,Trihexyphenidyl,144-11-6,approved,HWHLPVGTWGOCJO-UHFFFAOYSA-N,"InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2",C1CCCCC1C(O)(c2ccccc2)CCN3CCCCC3,C20H31NO,C07171,D08638,5572,46507717,9720,CHEMBL1490,,5371,81462,301.4662,4.232685494,"Agents producing tachycardia; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Anticholinergic Agents; Central Nervous System Agents; Cholinergic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; Piperidines; Tertiary Amines"
DB00377,Palonosetron,135729-56-5,approved; investigational,CPZBLNMUGSZIPR-NVXWUHKLSA-N,"InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1",C1CC[C@@H]2CN([C@H](CN34)C(CC3)CC4)C(=O)c(c2c15)ccc5,C19H24N2O,,D07175,6337614,46508530,85161,CHEMBL1189679,O7B,4892289,50417287,296.414,2.546012728,"Alimentary Tract and Metabolism; Antidepressive Agents; Antiemetics; Antiemetics and Antinauseants; Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Neurotransmitter Agents; Peripheral Nervous System Agents; Quinuclidines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 3 Receptor Antagonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB00378,Dydrogesterone,152-62-5,approved; investigational; withdrawn,JGMOKGBVKVMRFX-HQZYFCCVSA-N,"InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1",CC(=O)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@@H](CC2)[C@@]4(C)C(C=C3)=CC(=O)CC4,C21H28O2,,D01217,9051,46506195,31527,CHEMBL1200853,,8699,,312.4458,3.786682744,"Adrenal Cortex Hormones; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Pregnadien Derivatives; Pregnadienes; Pregnanes; Progestins; Progestogens and Estrogens, Sequential Preparations; Sex Hormones and Modulators of the Genital System; Steroids"
DB00379,Mexiletine,31828-71-4,approved; investigational,VLPIATFUUWWMKC-UHFFFAOYSA-N,"InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3",CC(N)COc1c(C)cccc1C,C11H17NO,C07220,,4178,46505491,6916,CHEMBL558,,4034,50117271,179.2588,2.462008545,"Amines; Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ib; Benzene Derivatives; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Membrane Transport Modulators; Phenols; Phenyl Ethers; Propylamines; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB00380,Dexrazoxane,24584-09-6,approved; withdrawn,BMKDZUISNHGIBY-ZETCQYMHSA-N,"InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1",O=C1CN(CC(=O)N1)[C@@H](C)CN2CC(=O)NC(=O)C2,C11H16N4O4,,D03730,71384,46505982,50223,CHEMBL1738,CDX,64479,,268.2691,-2.652654941,"Cardiotonic Agents; Cardiovascular Agents; Compounds used in a research, industrial, or household setting; Cytoprotective Agent; Detoxifying Agents for Antineoplastic Treatment; Diketopiperazines; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Miscellaneous Therapeutic Agents; Myelosuppressive Agents; Piperazines; Protective Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00381,Amlodipine,88150-42-9,approved,HTIQEAQVCYTUBX-UHFFFAOYSA-N,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3",CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c2ccccc2Cl,C20H25ClN2O5,C06825,D07450,2162,46507214,2668,CHEMBL1491,,2077,50088383,408.876,1.635595452,"ACE Inhibitors and Calcium Channel Blockers; Agents causing hyperkalemia; Angiotensin II Antagonists and Calcium Channel Blockers; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Antianginal Agents; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium Channel Blockers (Dihydropyridine); Calcium Channel Blockers and Diuretics; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (weak); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Dihydropyridines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; P-glycoprotein inhibitors; P-glycoprotein substrates; Pyridines; QTc Prolonging Agents; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB00382,Tacrine,321-64-2,approved; investigational; withdrawn,YLJREFDVOIBQDA-UHFFFAOYSA-N,"InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)",c1cccc(c12)nc3c(c2N)CCCC3,C13H14N2,C01453,D08555,1935,46505487,45980,CHEMBL95,THA,1859,8961,198.2637,2.628144685,"Acridines; Agents Causing Muscle Toxicity; Aminoacridines; Anti-Dementia Drugs; Autonomic Agents; Central Nervous System Agents; Cholinergic Agents; Cholinesterase Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotransmitter Agents; Nootropic Agents; P-glycoprotein substrates; Parasympathomimetics; Peripheral Nervous System Agents; Psychoanaleptics"
DB00383,Oxyphencyclimine,125-53-1,approved,DUDKAZCAISNGQN-UHFFFAOYSA-N,"InChI=1S/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3",CN1CCCN=C1COC(=O)C(O)(C2CCCCC2)c3ccccc3,C20H28N2O3,C07851,D08325,4642,46507487,7868,CHEMBL1495,,4481,,344.4479,2.624536101,"Agents producing tachycardia; Alimentary Tract and Metabolism; Anticholinergic Agents; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists; Synthetic Anticholinergics, Esters With Tertiary Amino Group"
DB00384,Triamterene,396-01-0,approved,FNYLWPVRPXGIIP-UHFFFAOYSA-N,"InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)",Nc(n1)nc(N)c(c12)nc(c(n2)N)-c3ccccc3,C12H11N7,,D00386,5546,46507623,9671,CHEMBL585,DX2,5345,6644,253.2626,1.114571472,"Agents causing hyperkalemia; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Decreased Renal K+ Excretion; Diuretics; Drugs causing inadvertant photosensitivity; Epithelial Sodium Channel Blockers; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Increased Diuresis; Membrane Transport Modulators; Natriuretic Agents; Nephrotoxic agents; Photosensitizing Agents; Potassium-Sparing Diuretics; Pteridines; Sodium Channel Blockers"
DB00385,Valrubicin,56124-62-0,approved,ZOCKGBMQLCSHFP-KQRAQHLDSA-N,"InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1",FC(F)(F)C(=O)N[C@H]([C@H](O)[C@@H](O1)C)C[C@@H]1O[C@H]2C[C@](O)(C(=O)COC(=O)CCCC)Cc(c23)c(O)c4c(c3O)C(=O)c5c(C4=O)cccc5OC,C34H36F3NO13,,,454216,46506642,135876,CHEMBL1096885,,399974,,723.651,4.486147122,"Anthracyclines; Anthracyclines and Related Substances; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carbohydrates; Cytotoxic Antibiotics and Related Substances; Enzyme Inhibitors; Glycosides; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00387,Procyclidine,77-37-2,approved,WYDUSKDSKCASEF-UHFFFAOYSA-N,"InChI=1S/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2",C1CCCCC1C(O)(c2ccccc2)CCN3CCCC3,C19H29NO,C07378,D08425,4919,46505553,8448,CHEMBL86715,,4750,50062598,287.4397,3.788116829,"Agents producing tachycardia; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Anticholinergic Agents; Central Nervous System Agents; Cholinergic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; Pyrrolidines; Tertiary Amines"
DB00388,Phenylephrine,59-42-7,approved,SONNWYBIRXJNDC-VIFPVBQESA-N,"InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",CNC[C@H](O)c1cc(O)ccc1,C9H13NO2,C07441,D08365,6041,46506961,8093,CHEMBL1215,,5818,50067212,167.205,-0.070160723,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Autonomic Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Decongestants and Antiallergics; Ethanolamines; Monoamine Oxidase A Substrates; Mydriatics; Mydriatics and Cycloplegics; Nasal Decongestants; Nasal Decongestants for Systemic Use; Nasal Preparations; Neurotransmitter Agents; Ophthalmologicals; Peripheral Nervous System Agents; Protective Agents; Respiratory System; Respiratory System Agents; Sensory Organs; Sympathomimetic (Adrenergic) Agents; Sympathomimetics; Sympathomimetics Excl. Antiglaucoma Preparations; Sympathomimetics Used as Decongestants; Sympathomimetics, Plain; Vasoconstrictor Agents"
DB00389,Carbimazole,22232-54-8,approved; investigational,CFOYWRHIYXMDOT-UHFFFAOYSA-N,"InChI=1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3",CCOC(=O)n1ccn(C)c1=S,C7H10N2O2S,C07615,D07616,31072,46506359,617099,CHEMBL508102,,28829,50275889,186.232,1.348511199,"Agents Causing Muscle Toxicity; Antithyroid agents; Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Imidazoles; Sulfur-Containing Imidazole Derivatives; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroid Products"
DB00390,Digoxin,20830-75-5,approved,LTMHDMANZUZIPE-PUGKRICDSA-N,"InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1",O=C1OCC(=C1)[C@@H](CC2)[C@](C)([C@]23O)[C@H](O)C[C@H]4[C@H]3CC[C@H]5[C@]4(C)CC[C@@H](C5)O[C@H]6C[C@H](O)[C@@H]([C@H](O6)C)O[C@H]7C[C@H](O)[C@@H]([C@H](O7)C)O[C@H]8C[C@H](O)[C@H](O)[C@H](O8)C,C41H64O14,C06956,D00298,2724385,46508524,4551,CHEMBL1751,DGX,2006532,46355,780.9385,2.366680672,"Agents causing hyperkalemia; Antiarrhythmic agents; Bradycardia-Causing Agents; BSEP/ABCB11 Substrates; BSEP/ABCB11 Substrates with Narrow Therapeutic Index; Carbohydrates; Cardanolides; Cardenolides; Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Digitalis Glycosides; Digoxin and derivatives; Digoxin, antagonists & inhibitors; Digoxin, immunology; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Fused-Ring Compounds; Glycosides; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Potential QTc-Prolonging Agents; Protective Agents; QTc Prolonging Agents"
DB00391,Sulpiride,15676-16-1,approved; investigational,BGRJTUBHPOOWDU-UHFFFAOYSA-N,"InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)",CCN1CCCC1CNC(=O)c2c(OC)ccc(c2)S(=O)(=O)N,C15H23N3O4S,,D01226,5355,46504855,32168,CHEMBL26,,5162,11638,341.426,0.21877045,"Acids, Carbocyclic; Amides; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase Inhibitors; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Moderate Risk QTc-Prolonging Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Tranquilizing Agents"
DB00392,Profenamine,522-00-9,approved,CDOZDBSBBXSXLB-UHFFFAOYSA-N,"InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3",CCN(CC)C(C)CN1c(cccc2)c2Sc(c13)cccc3,C19H24N2S,,D01118,3290,46507375,313639,CHEMBL1206,,3174,8958,312.472,5.001186761,"Adrenergic Agents; Adrenergic Antagonists; Agents producing tachycardia; Anti-Parkinson Drugs; Anticholinergic Agents; Cholinergic Agents; Cholinesterase Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; NMDA Receptor Antagonists; Sulfur Compounds; Tertiary Amines"
DB00393,Nimodipine,66085-59-4,approved; investigational,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,"InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3",COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c2cc([N+]([O-])=O)ccc2,C21H26N2O7,C07267,D00438,4497,46508497,7575,CHEMBL1428,,4341,50101971,418.4403,2.541901753,"Acids, Heterocyclic; Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium Channel Blockers (Dihydropyridine); Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Dihydropyridines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; Nicotinic Acids; P-glycoprotein inhibitors; Pyridines; QTc Prolonging Agents; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB00394,Beclomethasone dipropionate,08-09-5534,approved; investigational,KUVIULQEHSCUHY-XYWKZLDCSA-N,"InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@]2(Cl)[C@@H](O)C[C@@]4(C)[C@H]3C[C@H](C)[C@]4(OC(=O)CC)C(=O)COC(=O)CC,C28H37ClO7,C07813,D07495,21700,46509195,3002,CHEMBL1200500,,20396,,521.042,4.428392276,"Adrenal Cortex Hormones; Adrenals; Agents to Treat Airway Disease; Alimentary Tract and Metabolism; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; BCRP/ABCG2 Inhibitors; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids Acting Locally; Corticosteroids for inhalation use; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Drugs for Obstructive Airway Diseases; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Intestinal Antiinflammatory Agents; Nasal Preparations; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inducers; P-glycoprotein substrates; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Respiratory System; Respiratory System Agents; Steroids; Steroids, Chlorinated; Thyroxine-binding globulin inhibitors"
DB00395,Carisoprodol,78-44-4,approved,OFZCIYFFPZCNJE-UHFFFAOYSA-N,"InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)",NC(=O)OCC(C)(CCC)COC(=O)NC(C)C,C12H24N2O4,C07927,D00768,2576,46506377,3419,CHEMBL1233,,2478,,260.33,1.924311929,"Carbamates; Carbamic Acid Esters; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Centrally-mediated Muscle Relaxation; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 Substrates; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System"
DB00396,Progesterone,57-83-0,approved; vet_approved,RJKFOVLPORLFTN-LEKSSAKUSA-N,"InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1",CC(=O)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=CC(=O)CC4,C21H30O2,C00410,D00066,5994,46508968,17026,CHEMBL103,STR,5773,8903,314.4617,4.148604401,"Adrenal Cortex Hormones; BCRP/ABCG2 Inducers; BCRP/ABCG2 Inhibitors; BSEP/ABCB11 Inhibitors; Corpus Luteum Hormones; Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inducers; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Progesterone and Derivatives; Progesterone, antagonists & inhibitors; Progestin-containing Intrauterine Device; Progestins; Sex Hormones and Modulators of the Genital System; Steroids"
DB00397,Phenylpropanolamine,14838-15-4,approved; vet_approved; withdrawn,DLNKOYKMWOXYQA-CBAPKCEASA-N,"InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m0/s1",C[C@H](N)[C@H](O)c1ccccc1,C9H13NO,C16719,,26934,46508087,80680,CHEMBL136560,,9875,50405613,151.209,0.885254335,Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Alcohols; Amines; Amino Alcohols; Anti-Obesity Agents; Appetite Depressants; Autonomic Agents; Cardiovascular Agents; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Nasal Decongestants; Nasal Decongestants for Systemic Use; Nasal Preparations; Neurotransmitter Agents; Peripheral Nervous System Agents; Propanolamines; Propanols; Respiratory System; Respiratory System Agents; Sympathomimetics; Vasoconstrictor Agents
DB00398,Sorafenib,284461-73-0,approved; investigational,MLDQJTXFUGDVEO-UHFFFAOYSA-N,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",CNC(=O)c1nccc(c1)Oc2ccc(cc2)NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3,C21H16ClF3N4O3,,D08524,216239,46505329,50924,CHEMBL1336,BAX,187440,16673,464.825,4.343329761,"Acids, Heterocyclic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Benzene Derivatives; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (moderate); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nicotinic Acids; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Phenylurea Compounds; Potential QTc-Prolonging Agents; Protein Kinase Inhibitors; Pyridines; QTc Prolonging Agents; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors; UGT1A9 Inhibitors; UGT1A9 Substrates; UGT1A9 substrates with narrow therapeutic index; Vitamin B Complex; Vitamins"
DB00399,Zoledronic acid,118072-93-8,approved,XRASPMIURGNCCH-UHFFFAOYSA-N,"InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)",OP(=O)(O)C(O)(P(=O)(O)O)Cn1ccnc1,C5H10N2O7P2,,D01968,68740,46507310,46557,CHEMBL924,ZOL,61986,12578,272.0896,-3.851108564,"Azoles; Bisphosphonates; Bone Density Conservation Agents; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Musculo-Skeletal System; Organophosphonates; Organophosphorus Compounds"
DB00400,Griseofulvin,126-07-8,approved; investigational; vet_approved,DDUHZTYCFQRHIY-RBHXEPJQSA-N,"InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1",COc(c1Cl)cc(OC)c(C2=O)c1O[C@]23[C@H](C)CC(=O)C=C3OC,C17H17ClO6,C06686,D00209,441140,46508437,27779,CHEMBL562,,389934,31775,352.766,2.172137458,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Systemic Use; Antifungals for Topical Use; Benzofurans; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Decreased Mitosis; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Macrocyclic Compounds; Microtubule Inhibition; Tubulin Inhibiting Agent"
DB00401,Nisoldipine,63675-72-9,approved,VKQFCGNPDRICFG-UHFFFAOYSA-N,"InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3",COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c2ccccc2[N+]([O-])=O,C20H24N2O6,C07699,D00618,4499,46504546,76917,CHEMBL1726,,4343,50101963,388.4144,3.059797458,"Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium Channel Blockers (Dihydropyridine); Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Decreased Blood Pressure; Dihydropyridine Derivatives; Dihydropyridines; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; P-glycoprotein inhibitors; Photosensitizing Agents; Pyridines; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB00402,Eszopiclone,138729-47-2,approved; investigational,GBBSUAFBMRNDJC-INIZCTEOSA-N,"InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1",CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)c(c23)nccn3)c4ncc(Cl)cc4,C17H17ClN6O3,,,969472,46505809,53760,CHEMBL1522,,839530,26265,388.808,0.806543033,"Benzodiazepine hypnotics and sedatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics (Nonbenzodiazepine); Hypnotics and Sedatives; Miscellaneous Anxiolytics Sedatives and Hypnotics; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; Photosensitizing Agents; Piperazines; Psycholeptics; Pyrazines; Pyridines; Zopiclone and prodrugs"
DB00403,Ceruletide,17650-98-5,approved,YRALAIOMGQZKOW-HYAOXDFASA-N,"InChI=1S/C58H73N13O21S2/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91)/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+/m1/s1",O=C1N[C@@H](CC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2ccc(cc2)OS(=O)(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3c[nH]c(c34)cccc4)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N)Cc5ccccc5,C58H73N13O21S2,,D03442,16129675,46505766,59219,CHEMBL1201355,,10481982,,1352.405,-5.227808809,"Amino Acids, Peptides, and Proteins; Diagnostic Agents; Oligopeptides; Peptides; Tests for Bile Duct Patency"
DB00404,Alprazolam,28981-97-7,approved; illicit; investigational,VREFGVBLTWBCJP-UHFFFAOYSA-N,"InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3",Cc1nnc(n12)CN=C(c3c2ccc(Cl)c3)c4ccccc4,C17H13ClN4,C06817,D00225,2118,46507078,2611,CHEMBL661,08H,2034,50001728,308.765,2.3741,"Alcohols; Amines; Amino Alcohols; Anti-Anxiety Agents; Benzazepines; Benzene Derivatives; Benzodiazepines and benzodiazepine derivatives; Biogenic Amines; Biogenic Monoamines; Catechols; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Ethanolamines; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Phenols; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents; Triazolobenzodiazepines"
DB00405,Dexbrompheniramine,132-21-8,approved,ZDIGNSYAACHWNL-HNNXBMFYSA-N,"InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1",c1cccnc1[C@@H](CCN(C)C)c2ccc(Br)cc2,C16H19BrN2,,,16960,46505186,59269,CHEMBL1201287,,16068,,319.239,3.749658864,"Antihistamines for Systemic Use; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Neurotransmitter Agents; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Respiratory System; Substituted Alkylamines"
DB00406,Gentian violet cation,7438-46-2,approved,LGLFFNDHMLKUMI-UHFFFAOYSA-N,"InChI=1S/C25H30N3/c1-26(2)22-13-7-19(8-14-22)25(20-9-15-23(16-10-20)27(3)4)21-11-17-24(18-12-21)28(5)6/h7-18H,1-6H3/q+1",CN(C)c1ccc(cc1)C(c2ccc(cc2)N(C)C)=C3C=CC(C=C3)=[N+](C)C,C25H30N3,,D01046,3468,46505353,77181,CHEMBL459265,CVI,3349,50052802,372.5258,1.395511129,"Amines; Aniline Compounds; Anti-Infective Agents; Anti-Infective Agents, Local; Antifungals for Dermatological Use; Antifungals for Topical Use; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Miscellaneous Antifungals"
DB00407,Ardeparin,9005-49-6,approved; investigational; withdrawn,,, ,,,D02980,,46505194,,,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Carbohydrates; Cardiovascular Agents; Fibrin Modulating Agents; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Polysaccharides
DB00408,Loxapine,02-10-1977,approved,XJGVXQDUIWGIRW-UHFFFAOYSA-N,"InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3",CN1CCN(CC1)C2=Nc(cccc3)c3Oc(c24)ccc(Cl)c4,C18H18ClN3O,C07104,D02340,3964,46505047,50841,CHEMBL831,,3827,22871,327.808,3.460602432,"Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Diazepines, Oxazepines, Thiazepines and Oxepines; Dibenzoxazepines; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Miscellaneous Antipsychotics; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; Photosensitizing Agents; Psycholeptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB00409,Remoxipride,80125-14-0,approved; withdrawn,GUJRSXAPGDDABA-NSHDSACASA-N,"InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1",CCN1CCC[C@H]1CNC(=O)c2c(OC)ccc(Br)c2OC,C16H23BrN2O3,,,54477,46508689,92948,CHEMBL22242,,49195,50026045,371.269,2.341989284,"Acids, Carbocyclic; Amides; Antipsychotic Agents; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Bromobenzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB00410,Mupirocin,12650-69-0,approved; investigational; vet_approved,MINDHVHHQZYEEK-HBBNESRFSA-N,"InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1",C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]2CO[C@H]([C@H](O)[C@@H]2O)C/C(C)=C/C(=O)OCCCCCCCCC(=O)O,C26H44O9,C11758,D01076,446596,46505594,7025,CHEMBL719,MRC,393914,50290686,500.6222,2.451325676,"Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics for Topical Use; Dermatologicals; Enzyme Inhibitors; Epoxy Compounds; Ethers; Ethers, Cyclic; Fatty Acids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lipids; Macrocyclic Compounds; Nasal Preparations; Polycyclic Compounds; Protein Synthesis Inhibitors; Pyrans; Respiratory System; RNA Synthetase Inhibitor Antibacterial; RNA Synthetase Inhibitors"
DB00411,Carbamoylcholine,462-58-8,approved,VPJXQGSRWJZDOB-UHFFFAOYSA-O,"InChI=1S/C6H14N2O2/c1-8(2,3)4-5-10-6(7)9/h4-5H2,1-3H3,(H-,7,9)/p+1",C[N+](C)(C)CCOC(=O)N,C6H15N2O2,,D00524,5831,46509115,3385,CHEMBL965,CCE,2454,50004656,147.1955,-4.554689286,"Alcohols; Amines; Amino Alcohols; Ammonium Compounds; Analgesics; Analgesics, Non-Narcotic; Antiglaucoma Preparations and Miotics; Autonomic Agents; Cardiotonic Agents; Cardiovascular Agents; Central Nervous System Agents; Choline Esters; Cholinergic Agents; Cholinergic Agonists; Cholinergic Receptor Agonist; Compounds used in a research, industrial, or household setting; Ethanolamines; Miotics; Nervous System; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Ophthalmologicals; Parasympathomemetic (Cholinergic) Agents; Parasympathomimetics; Peripheral Nervous System Agents; Protective Agents; Quaternary Ammonium Compounds; Sensory Organs; Sensory System Agents; Trimethyl Ammonium Compounds"
DB00412,Rosiglitazone,122320-73-4,approved; investigational,YASAKCUCGLMORW-UHFFFAOYSA-N,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)",c1cccnc1N(C)CCOc2ccc(cc2)CC3SC(=O)NC3=O,C18H19N3O3S,,D00596,77999,46504556,50122,CHEMBL121,BRL,70383,50030474,357.427,2.446347899,"Alimentary Tract and Metabolism; Azoles; Blood Glucose Lowering Agents; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypoglycemia-Associated Agents; OATP1B1/SLCO1B1 Inhibitors; Peroxisome Proliferator Receptor gamma Agonist; Peroxisome Proliferator-activated Receptor Activity; Sulfur Compounds; Thiazoles; Thiazolidinediones; Vasodilating Agents"
DB00413,Pramipexole,104632-26-0,approved; investigational,FASDKYOPVNHBLU-ZETCQYMHSA-N,"InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1",CCCN[C@H](C1)CCc(c12)nc(s2)N,C10H17N3S,,D00559,119570,46505897,8356,CHEMBL301265,,106770,50116766,211.327,1.764282655,"Anti-Dyskinesia Agents; Anti-Parkinson Agents (Dopamine Agonist); Anti-Parkinson Drugs; Antioxidants; Azoles; Benzothiazoles; Central Nervous System Agents; Dopamine Agents; Dopamine Agonists; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Nervous System; Neurotransmitter Agents; Nonergot-derivative Dopamine Receptor Agonists; OCT1 substrates; OCT2 Substrates; Restless Legs Syndrome; Sulfur Compounds; Thiazoles"
DB00414,Acetohexamide,968-81-0,approved; investigational; withdrawn,VGZSUPCWNCWDAN-UHFFFAOYSA-N,"InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)",CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC2CCCCC2,C15H20N2O4S,C06806,D00219,1989,46505821,28052,CHEMBL1589,,1912,,324.395,1.814933474,Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Sulfones; Sulfonylureas; Sulfur Compounds
DB00415,Ampicillin,69-53-4,approved; vet_approved,AVKUERGKIZMTKX-NJBDSQKTSA-N,"InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccccc3,C16H19N3O4S,C06574,D00204,6249,46505346,28971,CHEMBL174,AIC,6013,50350465,349.405,-2.006650169,"Amides; Aminopenicillins; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Ophthalmologicals; Penicillin G; Penicillins; Penicillins With Extended Spectrum; Sensory Organs; Sulfur Compounds"
DB00416,Metocurine iodide,7601-55-0,approved; withdrawn,DIGFQJFCDPKEPF-OIUSMDOTSA-L,"InChI=1S/C40H48N2O6.2HI/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1",C1C[N+](C)(C)[C@H](c2c13)Cc4ccc(cc4)Oc5c6c(cc(OC)c5OC)CC[N+](C)(C)[C@@H]6Cc7cc(c(cc7)OC)Oc(c2)c(c3)OC,C40H48I2N2O6,,D00761,24244,46507773,6901,CHEMBL1739,,22666,,906.6279,-1.846410598,"Alkaloids; Amines; Ammonium Compounds; Anticholinergic Agents; Benzylisoquinolines; Central Nervous System Depressants; Drugs, Chinese Herbal; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular-Blocking Agents (Nondepolarizing); Nicotinic Antagonists; Nitrogen Compounds; Onium Compounds; Peripheral Nervous System Agents; Quaternary Ammonium Compounds; Tetrahydroisoquinolines"
DB00417,Phenoxymethylpenicillin,87-08-1,approved; vet_approved,BPLBGHOLXOTWMN-MBNYWOFBSA-N,"InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)COc3ccccc3,C16H18N2O5S,C08126,D05411,6869,46507164,27446,CHEMBL615,PNV,6607,50370584,350.39,0.763241706,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Aza Compounds; Azabicyclo Compounds; Beta-Lactam Antibacterials; Beta-Lactamase Sensitive Penicillins; beta-Lactams; Bicyclo Compounds; Bicyclo Compounds, Heterocyclic; Bridged Compounds; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Lactams; Natural Penicillins; Penicillin G; Penicillins; Polycyclic Compounds; Sulfur Compounds"
DB00418,Secobarbital,76-73-3,approved; vet_approved,KQPKPCNLIDLUMF-UHFFFAOYSA-N,"InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)",CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,C12H18N2O3,,D00430,5193,46508708,9073,CHEMBL447,,5005,,238.2829,2.033831925,"Adjuvants; Adjuvants, Anesthesia; Anticholinergic Agents; Anticonvulsants; Barbiturates; Barbiturates, Plain; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strong); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; Psycholeptics; Pyrimidines; Pyrimidinones"
DB00419,Miglustat,72599-27-0,approved,UQRORFVVSGFNRO-UTINFBMNSA-N,"InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1",CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,C10H21NO4,,D05032,51634,46506350,50381,CHEMBL1029,NBV,46764,18355,219.278,-1.178796231,"Alimentary Tract and Metabolism; Alkaloids; Anti-HIV Agents; Anti-Infective Agents; Carbohydrates; Enzyme Inhibitors; Gaucher Disease; Glucosylceramide Synthase Inhibitor; Glucosylceramide Synthase Inhibitors; Glycoside Hydrolase Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imines; Imino Pyranoses; Imino Sugars; Other Miscellaneous Therapeutic Agents; Piperidines; Various Alimentary Tract and Metabolism Products"
DB00420,Promazine,58-40-2,approved; vet_approved,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,"InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3",CN(C)CCCN1c(cccc2)c2Sc(c13)cccc3,C17H20N2S,C07379,D08430,4926,46504504,8459,CHEMBL564,P2Z,4757,67545,284.419,3.930955566,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Amino Acids; Amino Acids, Branched-Chain; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Anticholinergic Agents; Antidepressive Agents; Antiemetics; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Moderate Risk QTc-Prolonging Agents; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenothiazines; Phenothiazines With Aliphatic Side-Chain; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Tranquilizing Agents"
DB00421,Spironolactone,52-01-7,approved,LXMSZDCAJNLERA-ZHYRCANASA-N,"InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1",C1CC(=O)O[C@@]12[C@]3(C)[C@@H](CC2)[C@H]4[C@H](CC3)[C@]5(C)C(=CC(=O)CC5)C[C@H]4SC(=O)C,C24H32O4S,C07310,D00443,5833,46508525,9241,CHEMBL1393,SNL,5628,50228080,416.573,3.636754577,"Agents causing hyperkalemia; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; BSEP/ABCB11 Substrates; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Diuretics; Fused-Ring Compounds; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypotensive Agents; Lactones; Mineralocorticoid (Aldosterone) Receptor Antagonists; Mineralocorticoid Receptor Antagonists; Natriuretic Agents; P-glycoprotein inducers; Polycyclic Compounds; Potassium-Sparing Diuretics; Pregnanes; Pregnenes; Steroids"
DB00422,Methylphenidate,113-45-1,approved; investigational,DUGOZIWVEXMGBE-UHFFFAOYSA-N,"InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3",c1ccccc1C(C(=O)OC)C2CCCCN2,C14H19NO2,C07196,D04999,4158,46505929,84276,CHEMBL796,,4015,50062912,233.3062,2.254935082,"Acids, Carbocyclic; Agents that produce hypertension; Agents that reduce seizure threshold; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Stimulants; Central Nervous System Stimulation; Centrally Acting Sympathomimetics; Dopamine Agents; Dopamine Uptake Inhibitors; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Medications that reduce magnesium levels; Membrane Transport Modulators; Methylphenidate and isomer; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Phenylacetates; Piperidines; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Respiratory and CNS Stimulants"
DB00423,Methocarbamol,532-03-6,approved; vet_approved,GNXFOGHNGIVQEH-UHFFFAOYSA-N,"InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)",COc1ccccc1OCC(O)COC(=O)N,C11H15NO5,,D00402,4107,46507761,77498,CHEMBL1201117,,3964,50239995,241.2405,0.445046207,"Acids, Acyclic; Benzene Derivatives; Carbamates; Carbamic Acid Esters; Carboxylic Acids; Catechols; Central Nervous System Agents; Central Nervous System Depressants; Centrally-mediated Muscle Relaxation; Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Methyl Ethers; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System; Peripheral Nervous System Agents; Phenols; Phenyl Ethers; Phenylcarbamates"
DB00424,Hyoscyamine,101-31-5,approved,RKUNBYITZUJHSG-FXUDXRNXSA-N,"InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16-/m1/s1",CN([C@@H]12)[C@H](CC1)C[C@@H](C2)OC(=O)[C@H](CO)c3ccccc3,C17H23NO3,C02046,D00147,154417,46507345,17486,CHEMBL1331216,HYO,10246417,50239982,289.3694,1.571241017,"Adjuvants, Anesthesia; Agents producing tachycardia; Alimentary Tract and Metabolism; Alkaloids; Anti-Asthmatic Agents; Antiarrhythmic agents; Anticholinergic Agents; Atropine Derivatives; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Belladonna Alkaloids; Belladonna Alkaloids, Tertiary Amines; Belladonna and Derivatives, Plain; Bicyclo Compounds, Heterocyclic; Bronchodilator Agents; Cardiovascular Agents; Central Nervous System Agents; Cholinergic Agents; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Muscarinic Antagonists; Mydriatics; Neurotransmitter Agents; Parasympatholytics; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System Agents; Solanaceous Alkaloids; Tropanes"
DB00425,Zolpidem,82626-48-0,approved,ZAFYATHCZYHLPB-UHFFFAOYSA-N,"InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3",Cc(c1)ccc(n12)nc(c2CC(=O)N(C)C)-c3ccc(C)cc3,C19H21N3O,C07219,,5732,46507949,10125,CHEMBL911,,5530,26266,307.3895,3.017626821,"Benzodiazepine hypnotics and sedatives; Central Nervous System Agents; Central Nervous System Depressants; Central Nervous System Depression; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; GABA Agents; GABA Agonists; GABA-A Receptor Agonists; gamma-Aminobutyric Acid-ergic Agonist; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics (Nonbenzodiazepine); Hypnotics and Sedatives; Miscellaneous Anxiolytics Sedatives and Hypnotics; Nervous System; Neurotransmitter Agents; Psycholeptics; Pyridines; Sleep Aids, Pharmaceutical"
DB00426,Famciclovir,104227-87-4,approved; investigational,GGXKWVWZWMLJEH-UHFFFAOYSA-N,"InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)",CC(=O)OCC(COC(=O)C)CCn1cnc(c12)cnc(n2)N,C14H19N5O4,,D00317,3324,46507561,4974,CHEMBL880,,3207,50248001,321.3318,-0.483686017,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acid Synthesis Inhibitors; Nucleosides and Nucleotides; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; Ophthalmologicals; Purines; Sensory Organs"
DB00427,Triprolidine,486-12-4,approved,CBEQULMOCCWAQT-WOJGMQOQSA-N,"InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+",c1cccnc1/C(c2ccc(C)cc2)=C/CN3CCCC3,C19H22N2,,D01782,5282443,46505403,84116,CHEMBL855,,4445597,50292411,278.3914,4.045153589,"Anti-Allergic Agents; Antihistamines for Systemic Use; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Neurotransmitter Agents; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Respiratory System"
DB00428,Streptozocin,18883-66-4,approved; investigational,ZSJLQEPLLKMAKR-GKHCUFPYSA-N,"InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1",O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,C8H15N3O7,C07313,D05932,29327,46508872,9288,CHEMBL1603,,27273,,265.2206,-2.720285555,"Alkylating Activity; Alkylating Drugs; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Carbohydrates; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Glycosides; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nitroso Compounds; Nitrosourea Compounds; Nitrosoureas; P-glycoprotein inducers"
DB00429,Carboprost tromethamine,58551-69-2,approved,UMMADZJLZAPZAW-OVXHCKHTSA-N,"InChI=1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5-,14-12+;/t16-,17-,18+,19+,21+;/m1./s1",CCCCC[C@@](O)(C)/C=C/[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)[O-],C25H47NO8,,D00682,45266502,46508118,3404,CHEMBL1237105,,26333214,,489.65,2.891631086,"Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Alcohols; Autacoids; Biological Factors; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Genito Urinary System and Sex Hormones; Glycols; Inflammation Mediators; Lipids; Pharmaceutical Preparations; Propylene Glycols; Prostaglandins; Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Reproductive Control Agents; Uterotonic agents"
DB00430,Cefpiramide,70797-11-4,approved,PWAUCHMQEXVFJR-PMAPCBKXSA-N,"InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1",Cn1nnnc1SCC(=C2C(=O)O)CS[C@@H](N23)[C@@H](C3=O)NC(=O)[C@@H](c4ccc(O)cc4)NC(=O)c5c(O)cc(C)nc5,C25H24N8O7S2,C13376,D01904,636405,46505548,59213,CHEMBL1201204,,552192,,612.637,0.151598081,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB00431,Lindane,58-89-9,approved; withdrawn,JLYXXMFPNIAWKQ-GNIYUCBRSA-N,"InChI=1S/C6H6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H/t1-,2-,3-,4+,5+,6+",Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,C6H6Cl6,C07075,D00360,727,46508542,32888,CHEMBL15891,,10481896,50410525,290.83,4.345541484,"Agents that reduce seizure threshold; Agrochemicals; Antiparasitic Products, Insecticides and Repellents; Chlorine Containing Products; Compounds used in a research, industrial, or household setting; Ectoparasiticides, Incl. Scabicides; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents; Hydrocarbons; Hydrocarbons, Chlorinated; Hydrocarbons, Halogenated; Insecticides; Pesticides; Toxic Actions"
DB00432,Trifluridine,70-00-8,approved; investigational,VSQQQLOSPVPRAZ-RRKCRQDMSA-N,"InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1",OC[C@H]1O[C@H](C[C@@H]1O)n2cc(C(F)(F)F)c(=O)[nH]c2=O,C10H11F3N2O5,,D00391,6256,46506192,75179,CHEMBL1129,,6020,50132298,296.1999,-0.754626497,"Anti-Infective Agents; Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Antiviral Agents; Carbohydrates; Deoxyribonucleosides; Drugs that are Mainly Renally Excreted; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Analog Antiviral; Nucleoside Metabolic Inhibitor; Nucleosides; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; Ophthalmologicals; Pyrimidine Analogues; Pyrimidine Nucleosides; Pyrimidines; Sensory Organs; Toxic Actions"
DB00433,Prochlorperazine,58-38-8,approved; vet_approved,WIKYUJGCLQQFNW-UHFFFAOYSA-N,"InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3",CN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(Cl)c4,C20H24ClN3S,C07403,D00493,4917,46509018,8435,CHEMBL728,P77,4748,78434,373.943,4.382119821,"Antiemetics; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenothiazines; Phenothiazines With Piperazine Structure; Photosensitizing Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Schizophrenia; Sulfur Compounds; Tranquilizing Agents"
DB00434,Cyproheptadine,129-03-3,approved,JJCFRYNCJDLXIK-UHFFFAOYSA-N,"InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3",CN1CCC(CC1)=C2c(cccc3)c3C=Cc(c24)cccc4,C21H21N,C06935,,2913,46508613,4046,CHEMBL516,C7H,2810,50017721,287.3981,4.382841647,"Agents producing tachycardia; Agents that reduce seizure threshold; Anti-Allergic Agents; Anticholinergic Agents; Antidepressive Agents; Antihistamines for Systemic Use; Antipruritics; Benzocycloheptenes; Central Nervous System Depressants; Dermatologicals; Dibenzocycloheptenes; Drugs causing inadvertant photosensitivity; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Miscellaneous Derivatives; Muscarinic Antagonists; Neurotransmitter Agents; Photosensitizing Agents; Piperidines; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; UGT1A3 substrates"
DB00435,Nitric Oxide,10102-43-9,approved,MWUXSHHQAYIFBG-UHFFFAOYSA-N,InChI=1S/NO/c1-2,N=O,NO,C00533,D00074,145068,46506897,16480,CHEMBL1200689,,127983,,30.0061,-0.3514,"Anions; Anti-Asthmatic Agents; Antioxidants; Autonomic Agents; Bronchodilator Agents; Cardiovascular Agents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Electrolytes; Endothelium-Dependent Relaxing Factors; Free Radical Scavengers; Free Radicals; Gases; Gasotransmitters; Hypotensive Agents; Ions; Methemoglobinemia Associated Agents; Neurotransmitter Agents; Nitrates and Nitrites; Nitric Oxide, antagonists & inhibitors; Nitrogen Compounds; Nitrogen Oxides; Nitroso Compounds; Oxides; Oxygen Compounds; Peripheral Nervous System Agents; Protective Agents; Reactive Nitrogen Species; Respiratory System; Respiratory System Agents; Vasodilating Agents; Vasodilation"
DB00436,Bendroflumethiazide,73-48-3,approved,HDWIHXWEUNVBIY-UHFFFAOYSA-N,"InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)",FC(F)(F)c(c1)c(S(=O)(=O)N)cc(c12)S(=O)(=O)NC(N2)Cc3ccccc3,C15H14F3N3O4S2,C07758,D00650,2315,46508672,3013,CHEMBL1684,,2225,50238678,421.415,1.698396013,"Amides; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Benzothiadiazines; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Diuretics; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Hypotensive Agents; Increased Diuresis; Low-Ceiling Diuretics and Potassium-Sparing Agents; Membrane Transport Modulators; Natriuretic Agents; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazides"
DB00437,Allopurinol,315-30-0,approved,OFCNXPDARWKPPY-UHFFFAOYSA-N,"InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)",c1n[nH]c(c12)ncnc2O,C5H4N4O,,D00224,2094,46508516,40279,CHEMBL1467,7HP,2010,181133,136.1115,0.031151592,"Antigout Preparations; Antimetabolites; Antioxidants; BCRP/ABCG2 Substrates; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Free Radical Scavengers; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Musculo-Skeletal System; OAT3/SLC22A8 Substrates; Preparations Inhibiting Uric Acid Production; Protective Agents; Purines; Uricosuric Agents; Xanthine Oxidase Inhibitors"
DB00438,Ceftazidime,72558-82-8,approved,ORFOPKXBNMVMKC-DWVKKRMSSA-N,"InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1",c1cccc[n+]1CC(=C2C([O-])=O)CS[C@@H](N23)[C@@H](C3=O)NC(=O)/C(=N\OC(C)(C)C(=O)O)c4csc(n4)N,C22H22N6O7S2,C06889,D07654,5481173,46506143,3508,CHEMBL44354,,4587145,50420259,546.576,-4.121715653,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephaloridine; Cephalosporins; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB00439,Cerivastatin,145599-86-6,approved; withdrawn,SEERZIQQUAZTOL-ANMDKAQQSA-N,"InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1",Fc1ccc(cc1)-c2c(COC)c(C(C)C)nc(C(C)C)c2/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,C26H34FNO5,C07966,,446156,46505877,3558,CHEMBL1477,116,393588,18376,459.5503,2.668154238,"Agents Causing Muscle Toxicity; Anticholesteremic Agents; BCRP/ABCG2 Substrates; BSEP/ABCB11 Substrates; Cardiovascular System; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Noxae; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; P-glycoprotein substrates; Toxic Actions; UGT1A1 Substrates"
DB00440,Trimethoprim,738-70-5,approved; vet_approved,IEDVJHCEMCRBQM-UHFFFAOYSA-N,"InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)",COc1c(OC)cc(cc1OC)Cc2cnc(N)nc2N,C14H18N4O3,C01965,D00145,5578,46507125,45924,CHEMBL22,TOP,5376,18069,290.3177,1.28390733,"Agents causing hyperkalemia; Agents Causing Muscle Toxicity; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antibiotics for Pneumocystis Pneumonia; Antiinfectives for Systemic Use; Antimycobacterials; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Folic Acid Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Inhibitors; MATE 1 Substrates; MATE 2 Inhibitors; MATE 2 Substrates; MATE inhibitors; MATE substrates; Medications that reduce magnesium levels; Metabolic Side Effects of Drugs and Substances; OCT2 Inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Pyrimidines; Renal Agents; SULFONAMIDES AND TRIMETHOPRIM; Trimethoprim and Derivatives"
DB00441,Gemcitabine,95058-81-4,approved,SDUQYLNIPVEERB-QPPQHZFASA-N,"InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1",Nc1nc(=O)n(cc1)[C@@H](C2(F)F)O[C@H](CO)[C@H]2O,C9H11F2N3O4,C07650,D02368,60750,46506425,175901,CHEMBL888,GEO,54753,,263.1981,-1.466539628,"Anti-Infective Agents; Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carbohydrates; Cytidine Deaminase Substrates; Deoxyribonucleosides; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunologic Factors; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Metabolic Inhibitor; Nucleosides; P-glycoprotein substrates; Pyrimidine Analogues; Pyrimidine Nucleosides; Pyrimidines; Radiation-Sensitizing Agents; Ribonucleosides; Ribonucleotide Reductases, antagonists & inhibitors; Toxic Actions"
DB00442,Entecavir,142217-69-4,approved; investigational,QDGZDCVAUDNJFG-FXQIFTODSA-N,"InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1",Nc([nH]1)nc(=O)c(c12)ncn2[C@H]3C[C@H](O)[C@@H](CO)C3=C,C12H15N5O3,,D04008,153941,46504864,473990,CHEMBL713,,135679,,277.2792,-1.444659172,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides and Nucleotides; Purines; Purinones"
DB00443,Betamethasone,378-44-9,approved; vet_approved,UREBDLICKHMUKA-DVTGEIKXSA-N,"InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1",OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)C=C4,C22H29FO5,,D00244,9782,46505155,3077,CHEMBL632,,9399,73823,392.4611,1.68156968,"Adrenal Cortex Hormones; Adrenals; Agents Causing Muscle Toxicity; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Alimentary Tract and Metabolism; Anti-Inflammatory Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Cardiovascular System; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids Acting Locally; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Drugs for Obstructive Airway Diseases; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Intestinal Antiinflammatory Agents; Medications that reduce magnesium levels; Nasal Preparations; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; P-glycoprotein substrates; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Respiratory System; Respiratory System Agents; Steroids; Steroids, Fluorinated; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroxine-binding globulin inhibitors; Vasoprotectives"
DB00444,Teniposide,29767-20-2,approved,NRUKOCRGYNPUPR-QBPJDGROSA-N,"InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1",COc1cc(cc(c1O)OC)[C@@H]2c(cc3c(c4)OCO3)c4[C@H]([C@H]([C@@H]25)COC5=O)O[C@@H]([C@H](O)[C@H]6O)O[C@@H]([C@H]67)CO[C@H](O7)c8cccs8,C32H32O13S,C11153,D02698,452548,46507536,,CHEMBL452231,9TP,398606,50248198,656.654,2.784029192,Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Carbohydrates; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Glucosides; Glycosides; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Neurotoxic agents; Podophyllotoxin Derivatives; Topoisomerase II Inhibitors; Topoisomerase Inhibitors
DB00445,Epirubicin,56420-45-2,approved,AOJJSUZBOXZQNB-VTZDEGQISA-N,"InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1",COc1cccc(c12)C(=O)c3c(C2=O)c(O)c4c(c3O)C[C@@](O)(C(=O)CO)C[C@@H]4O[C@H]5C[C@H](N)[C@@H](O)[C@@H](O5)C,C27H29NO11,C11230,,41867,46507282,47898,CHEMBL417,,38201,43839,543.5193,0.916421642,"Anthracycline Topoisomerase Inhibitor; Anthracyclines; Anthracyclines and Related Substances; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carbohydrates; Cardiotoxic antineoplastic agents; Cytotoxic Antibiotics and Related Substances; Enzyme Inhibitors; Glycosides; Hepatotoxic Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Myelosuppressive Agents; Naphthacenes; Narrow Therapeutic Index Drugs; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; UGT2B7 substrates; UGT2B7 substrates with narrow therapeutic index"
DB00446,Chloramphenicol,56-75-7,approved; vet_approved,WIIZWVCIJKGZOK-RKDXNWHRSA-N,"InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1",ClC(Cl)C(=O)N[C@H](CO)[C@H](O)c1ccc([N+]([O-])=O)cc1,C11H12Cl2N2O5,C00918,D00104,5959,46505318,17698,CHEMBL130,CLM,5744,23447,323.129,0.878703488,"Alcohols; Amphenicols; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Topical Use; Antiinfectives for Systemic Use; Antiinfectives for Treatment of Acne; Benzene Derivatives; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Glycols; Gynecological Antiinfectives and Antiseptics; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Myelosuppressive Agents; Nitro Compounds; Nitrobenzenes; OAT1/SLC22A6 inhibitors; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; Propylene Glycols; Protein Synthesis Inhibitors; Sensory Organs"
DB00447,Loracarbef,76470-66-1,approved; investigational; withdrawn,JAPHQRWPEGVNBT-UTUOFQBUSA-N,"InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12+/m1/s1",c1ccccc1[C@@H](N)C(=O)N[C@H](C2=O)[C@H](N23)CCC(Cl)=C3C(=O)O,C16H16ClN3O4,C08109,D00916,5284585,46506369,47544,CHEMBL1013,,4447635,,349.769,-2.399644435,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Second-Generation Cephalosporins; Sulfur Compounds; Thiazines"
DB00448,Lansoprazole,103577-45-3,approved; investigational,MJIHNNLFOKEZEW-UHFFFAOYSA-N,"InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)",FC(F)(F)COc1c(C)c(ncc1)CS(=O)c([nH]2)nc(c23)cccc3,C16H14F3N3O2S,,D00355,3883,46508975,6375,CHEMBL480,,3746,47032,369.361,3.032855237,"Acid Reducers; Alimentary Tract and Metabolism; Anti-Ulcer Agents; BCRP/ABCG2 Inhibitors; Benzimidazoles; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Gastric Acid Lowering Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Inhibition Gastric Acid Secretion; OAT3/SLC22A8 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Proton Pump Inhibitors; Proton-pump Inhibitors; Pyridines; Sulfoxides; Sulfur Compounds"
DB00449,Dipivefrin,52365-63-6,approved,OCUJLLGVOUDECM-UHFFFAOYSA-N,"InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3",CNCC(O)c1cc(OC(=O)C(C)(C)C)c(cc1)OC(=O)C(C)(C)C,C19H29NO5,C06963,D02349,3105,46504716,4646,CHEMBL1201262,,2994,,351.4373,3.714854507,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Alcohols; Amines; Amino Alcohols; Antiglaucoma Preparations and Miotics; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Catecholamines; Catechols; Cholinesterase substrates; Ethanolamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Mydriatics; Neurotransmitter Agents; Ophthalmics; Ophthalmologicals; Phenols; Sensory Organs; Sympathomimetics in Glaucoma Therapy"
DB00450,Droperidol,548-73-2,approved; vet_approved,RMEDXOLNCUSCGS-UHFFFAOYSA-N,"InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)",Fc1ccc(cc1)C(=O)CCCN2CCC(=CC2)n3c(=O)[nH]c(c34)cccc4,C22H22FN3O2,,D00308,3168,46505291,4717,CHEMBL1108,,3056,50017705,379.4274,3.014257972,"Adjuvants, Anesthesia; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antiemetics; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Autonomic Agents; Benzimidazoles; Butyrophenone Derivatives; Butyrophenones; Central Nervous System Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Ketones; Miscellaneous Anxiolytics Sedatives and Hypnotics; Moderate Risk QTc-Prolonging Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Tranquilizing Agents"
DB00451,Levothyroxine,51-48-9,approved,XUIIKFGFIJCVMT-LBPRGKRZSA-N,"InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1",OC(=O)[C@@H](N)Cc1cc(I)c(c(I)c1)Oc2cc(I)c(O)c(I)c2,C15H11I4NO4,C01829,D08125,5819,46507672,18332,CHEMBL1624,T44,5614,50301375,776.87,3.727307065,"Agents used to treat hypothyroidism; Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; P-glycoprotein inducers; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroid Products; Thyroxine-binding globulin substrates; UGT1A1 Substrates; UGT1A1 substrates with narrow therapeutic index"
DB00452,Framycetin,119-04-0,approved,PGBHMTALBVVCIT-VCIWKGPPSA-N,"InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1",NC[C@@H]1O[C@@H]([C@H](N)[C@@H](O)[C@@H]1O)O[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]4O[C@H](CN)[C@@H](O)[C@H](O)[C@H]4N,C23H46N6O13,C01737,D05140,8378,46508892,7508,CHEMBL184618,NMY,8075,19,614.6437,-8.415177746,Agents that produce neuromuscular block (indirect); Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Carbohydrates; Dermatologicals; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycosides; Medicated Dressings; Medicated Dressings With Antiinfectives; Nasal Preparations; Nephrotoxic agents; Ophthalmologicals; Respiratory System; Sensory Organs
DB00454,Meperidine,57-42-1,approved,XADCESSVHJOZHK-UHFFFAOYSA-N,"InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3",C1CN(C)CCC1(C(=O)OCC)c2ccccc2,C15H21NO2,C07128,D08343,4058,46506899,6754,CHEMBL607,,3918,50026752,247.3327,2.455800396,"Acids, Heterocyclic; Adjuvants; Adjuvants, Anesthesia; Agents that reduce seizure threshold; Analgesics; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; High-risk opioids; Isonipecotic Acids; Narcotics; Nervous System; NMDA Receptor Antagonists; Opiate Agonists; Opioid Agonist; Opioids; P-glycoprotein substrates; Peripheral Nervous System Agents; Phenylpiperidine opioids; Piperidines; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB00455,Loratadine,79794-75-5,approved; investigational,JCCNYMKQOSZNPW-UHFFFAOYSA-N,"InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3",CCOC(=O)N1CCC(CC1)=C2c(ccc(Cl)c3)c3CCc(c24)cccn4,C22H23ClN2O2,,D00364,3957,46507853,6538,CHEMBL998,,3820,22876,382.883,4.554579307,"Anti-Allergic Agents; Antihistamines for Systemic Use; Antipruritics; Benzocycloheptenes; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Dibenzocycloheptenes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Loratadine and prodrug; Neurotransmitter Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Piperidines; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; QTc Prolonging Agents; Respiratory System"
DB00456,Cefalotin,153-61-7,approved; investigational; vet_approved,XIURVHNZVLADCM-IUODEOHRSA-N,"InChI=1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1",CC(=O)OCC(CS1)=C(C(=O)O)N([C@H]12)C(=O)[C@H]2NC(=O)Cc3cccs3,C16H16N2O6S2,C07761,D07635,6024,46509079,124991,CHEMBL617,CLS,5802,82898,396.438,0.016272907,"Agents that reduce seizure threshold; Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephacetrile; Cephalosporins; First-Generation Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Sulfur Compounds; Thiazines"
DB00457,Prazosin,19216-56-9,approved,IENZQIKPVFGBNW-UHFFFAOYSA-N,"InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)",COc(c1)c(OC)cc(c12)c(N)nc(n2)N3CCN(CC3)C(=O)c4ccco4,C19H21N5O4,C07368,D08411,4893,46508594,8364,CHEMBL2,XRA,4724,29568,383.4011,1.650516463,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Alpha-Adrenoreceptor Antagonists and Diuretics; Antiadrenergic Agents, Peripherally Acting; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; BCRP/ABCG2 Substrates; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; OCT1 inhibitors; OCT1 substrates; OCT2 Substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral alpha-1 blockers; Quinazolines; Vasodilating Agents"
DB00458,Imipramine,50-49-7,approved,BCGWQEUPMDMJNV-UHFFFAOYSA-N,"InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3",CN(C)CCCN1c(cccc2)c2CCc(c13)cccc3,C19H24N2,C07049,D08070,3696,46507351,47499,CHEMBL11,IXX,3568,50010859,280.4073,4.278568794,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tricyclic; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dibenzazepines; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Hypotensive Agents; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; Muscarinic Antagonists; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Tertiary amine tricyclic antidepressants; Tricyclics and Other Norepinephrine-reuptake Inhibitors"
DB00459,Acitretin,55079-83-9,approved,IHUNBGSDBOWDMA-AQFIFDHZSA-N,"InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+",COc1c(C)c(C)c(c(C)c1)/C=C/C(C)=C/C=C/C(C)=C/C(=O)O,C21H26O3,,D02754,5284513,46509178,50173,CHEMBL1131,,4447573,50088429,326.4293,5.587048726,"Alkenes; Antipsoriatics; Antipsoriatics for Systemic Use; Biological Factors; Carotenoids; Cyclohexanes; Cyclohexenes; Cycloparaffins; Dermatologicals; Drugs causing inadvertant photosensitivity; Hepatotoxic Agents; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Keratolytic Agents; Macrocyclic Compounds; Misc. Skin and Mucous Membrane Agents; Photosensitizing Agents; Pigments, Biological; Polycyclic Compounds; Polyenes; Retinoids; Retinoids for Treatment of Psoriasis; Terpenes"
DB00460,Verteporfin,129497-78-5,approved; investigational,YTZALCGQUPRCGW-MXVXOLGGSA-N,"InChI=1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/b28-16-,29-17-,30-19-,31-16-,32-18-,33-18-,34-17-,35-19-/t38-,41+/m0/s1",C[C@]12c3cc4c(C)c(CCC(=O)OC)c([nH]4)cc5nc(c(C)c5CCC(=O)O)cc6[nH]c(c(C)c6C=C)cc(n3)C1=CC=C(C(=O)OC)[C@H]2C(=O)OC,C41H42N4O8,,D01162,5362420,46506236,,CHEMBL2052016,,4515032,,718.7942,6.339655556,"Antineovascularisation Agents; Azoles; Biological Factors; Dermatologicals; EENT Drugs, Miscellaneous; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Macrocyclic Compounds; Ocular Vascular Disorder Agents; Ophthalmologicals; Photoabsorption; Photoenhancer; Photosensitizing Activity; Photosensitizing Agents; Pigments, Biological; Polycyclic Compounds; Porphyrins; Pyrroles; Radiation-Sensitizing Agents; Sensory Organs; Tetrapyrroles"
DB00461,Nabumetone,42924-53-8,approved,BLXXJMDCKKHMKV-UHFFFAOYSA-N,"InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3",COc(cc1)cc(c12)ccc(c2)CCC(=O)C,C15H16O2,,D00425,4409,46507729,7443,CHEMBL1070,NBO,4256,40128,228.2863,3.216993784,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Butanones; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Ketones; Musculo-Skeletal System; Nephrotoxic agents; Other Nonsteroidal Anti-inflammatory Agents; Photosensitizing Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs)"
DB00462,Methscopolamine bromide,155-41-9,approved,CXYRUNPLKGGUJF-JIRGPDKYSA-M,"InChI=1S/C18H24NO4.BrH/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11;/h3-7,12-17,20H,8-10H2,1-2H3;1H/q+1;/p-1/t12?,13-,14+,15+,16?,17?;/m1./s1",[C@H]12C3C(O3)[C@@H]([N+]1(C)C)C[C@H](C2)OC(=O)[C@H](CO)c4ccccc4,C18H24BrNO4,,D00715,23724781,46506260,6845,,,26329507,,398.297,-3.267384321,Agents producing tachycardia; Anticholinergic Agents; Muscarinic Antagonists
DB00464,Sodium tetradecyl sulfate,139-88-8,approved; investigational,FVEFRICMTUKAML-UHFFFAOYSA-M,"InChI=1S/C14H30O4S.Na/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17;/h12-14H,5-11H2,1-4H3,(H,15,16,17);/q;+1/p-1",CCCCC(CC)CCC(OS([O-])(=O)=O)CC(C)C,C14H29NaO4S,,D06882,23665772,46505919,75273,CHEMBL1200354,,8440,,316.43,5.040855316,"Acids; Acids, Noncarboxylic; Alcohols; Alkanes; Alkanesulfonates; Alkanesulfonic Acids; Antivaricose Therapy; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Fatty Alcohols; Hydrocarbons; Hydrocarbons, Acyclic; Lipids; Pharmaceutical Preparations; Pharmaceutical Solutions; Sclerosing Agents for Local Injection; Sclerosing Solutions; Solutions; Sulfonic Acids; Sulfur Acids; Sulfur Compounds; Surface-Active Agents; Vasoprotectives"
DB00465,Ketorolac,74103-06-3,approved,OZWKMVRBQXNZKK-UHFFFAOYSA-N,"InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)",OC(=O)C1CCn(c12)c(cc2)C(=O)c3ccccc3,C15H13NO3,C07062,,3826,46507019,76223,CHEMBL469,,3694,85511,255.2686,2.283362964,"Acetic Acid Derivatives and Related Substances; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heteroaryl acetic acid NSAIDS; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Musculo-Skeletal System; Mydriatics; Mydriatics and Cycloplegics; Nephrotoxic agents; Non COX-2 selective NSAIDS; Ophthalmologicals; Other Nonsteroidal Anti-inflammatory Agents; Photosensitizing Agents; Sensory Organs; Sympathomimetics Excl. Antiglaucoma Preparations; UGT2B7 substrates"
DB00467,Enoxacin,74011-58-8,approved; investigational,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,"InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)",CCn1cc(C(=O)O)c(=O)c(c12)cc(F)c(n2)N3CCNCC3,C15H17FN4O3,C06979,D00310,3229,46507505,157175,CHEMBL826,,3116,50296358,320.3189,-0.983051937,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Metabolic Side Effects of Drugs and Substances; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines; Quinolones; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00468,Quinine,130-95-0,approved,LOUPRKONTZGTKE-WZBLMQSHSA-N,"InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1",C=C[C@@H](CN12)[C@@H](CC1)C[C@H]2[C@H](O)c3ccnc(c34)ccc(c4)OC,C20H24N2O2,C06526,,3034034,46507493,15854,CHEMBL170,QI9,84989,50367247,324.4168,2.513463951,"Agents that produce neuromuscular block (indirect); Agents that reduce seizure threshold; Alkaloids; Analgesics; Analgesics, Non-Narcotic; Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Blood Glucose Lowering Agents; Central Nervous System Agents; Central Nervous System Depressants; Cinchona Alkaloids; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Herbs (Hypotensive Properties); Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Hypoglycemia-Associated Agents; Methanolquinolines; Methemoglobinemia Associated Agents; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; QTc Prolonging Agents; Quinine and stereoisomer; Quinolines; Quinuclidines; Sensory System Agents"
DB00469,Tenoxicam,59804-37-4,approved,LZNWYQJJBLGYLT-UHFFFAOYSA-N,"InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)",c1csc(c12)C(O)=C(N(S2(=O)=O)C)C(=O)Nc3ccccn3,C13H11N3O4S2,,D01767,54677971,46507303,32192,CHEMBL302795,,10442339,92332,337.37,-0.115899463,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT3/SLC22A8 Inhibitors; Other Nonsteroidal Anti-inflammatory Agents; Oxicams; Peripheral Nervous System Agents; Sensory System Agents; Sulfur Compounds; Thiazines"
DB00470,Dronabinol,03-08-1972,approved; illicit,CYQFCXCEBYINGO-IAGOWNOFSA-N,"InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1",C1CC(C)=C[C@H]([C@@H]12)c3c(OC2(C)C)cc(cc3O)CCCCC,C21H30O2,C06972,D00306,16078,46508472,66964,CHEMBL465,TCI,15266,60994,314.4617,5.944157107,"Agents producing tachycardia; Alimentary Tract and Metabolism; Analgesics; Analgesics, Non-Narcotic; Antiemetics and Antinauseants; BCRP/ABCG2 Inhibitors; Cannabinoid Receptor Agonists; Cannabinoids and similars; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Hallucinogens; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Miscellaneous Antiemetics; Neurotransmitter Agents; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Psychotropic Drugs; Sensory System Agents; Terpenes"
DB00471,Montelukast,158966-92-8,approved,UCHDWCPVSPXUMX-TZIWLTJVSA-N,"InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1",OC(C)(C)c1ccccc1CC[C@@H](SCC2(CC2)CC(=O)O)c3cccc(c3)/C=C/c(cc4)nc(c45)cc(Cl)cc5,C35H36ClNO3S,C07482,D08229,5281040,46505585,50730,CHEMBL787,MTK,4444507,50052024,586.183,8.493533065,"Acids, Acyclic; Agents Causing Muscle Toxicity; Agents to Treat Airway Disease; Anti-Asthmatic Agents; Carboxylic Acids; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Leukotriene Antagonists; Leukotriene Modifiers; Lipids; Respiratory System; Respiratory System Agents"
DB00472,Fluoxetine,54910-89-3,approved; vet_approved,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,"InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3",c1ccccc1C(CCNC)Oc2ccc(C(F)(F)F)cc2,C17H18F3NO,,D00823,3386,46507902,86990,CHEMBL41,,3269,30130,309.3261,4.173219543,"Agents that reduce seizure threshold; Amines; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Second-Generation; Central Nervous System Agents; Central Nervous System Depressants; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Highest Risk QTc-Prolonging Agents; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Metabolic Side Effects of Drugs and Substances; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Nicotinic Antagonists; P-glycoprotein inhibitors; Propylamines; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Vasodilating Agents"
DB00473,Hexylcaine,532-77-4,approved; withdrawn,DKLKMKYDWHYZTD-UHFFFAOYSA-N,"InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3",c1ccccc1C(=O)OC(C)CNC2CCCCC2,C16H23NO2,C14172,,10770,46506241,34791,CHEMBL1197,,10315,50225698,261.3593,3.828164921,"Amines; Cyclohexanes; Cycloparaffins; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Polycyclic Compounds"
DB00474,Methohexital,151-83-7,approved,NZXKDOXHBHYTKP-UHFFFAOYSA-N,"InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)",CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O,C14H18N2O3,C07844,D04985,9034,46507954,102216,CHEMBL7413,,8683,,262.3043,2.286783321,"Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Anticonvulsants; Barbiturates; Barbiturates, Plain; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Psycholeptics; Pyrimidines; Pyrimidinones"
DB00475,Chlordiazepoxide,58-25-3,approved; illicit; investigational,ANTSCNMPPGJYLG-UHFFFAOYSA-N,"InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9H,10H2,1H3,(H,18,19)",c1c(Cl)ccc(c12)N=C(NC)C[N+]([O-])=C2c3ccccc3,C16H14ClN3O,,D00267,2712,46505044,3611,CHEMBL451,,10248513,50007664,299.755,0.189566091,"Adjuvants, Anesthesia; Anti-Anxiety Agents; Benzazepines; Benzodiazepines and benzodiazepine derivatives; Carbohydrates; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Cytosine Nucleotides; GABA Agents; GABA Modulators; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Psycholeptics; Psychotropic Drugs; Pyrimidine Nucleotides; Pyrimidines; Ribonucleotides; Tranquilizing Agents"
DB00476,Duloxetine,116539-59-4,approved,ZEUITGRIYCTCEM-KRWDZBQOSA-N,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",c1ccsc1[C@H](CCNC)Oc2cccc(c23)cccc3,C18H19NOS,,,60835,46507937,36795,CHEMBL1175,29E,54822,84745,297.415,4.197729191,"Agents producing tachycardia; Analgesics; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Nervous System; Neurotransmitter Uptake Inhibitors; Norepinephrine Uptake Inhibitors; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Psychoanaleptics; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Serotonin Modulators; Sulfur Compounds; Thiophenes"
DB00477,Chlorpromazine,50-53-3,approved; investigational; vet_approved,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,"InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3",CN(C)CCCN1c(cccc2)c2Sc(c13)ccc(Cl)c3,C17H19ClN2S,C06906,D00270,2726,46508395,3647,CHEMBL71,Z80,2625,50001888,318.864,4.535000242,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Anticholinergic Agents; Antidepressive Agents; Antiemetics; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Autonomic Agents; BSEP/ABCB11 Inhibitors; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Hyperglycemia-Associated Agents; Hypotensive Agents; Moderate Risk QTc-Prolonging Agents; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Phenothiazines; Phenothiazines With Aliphatic Side-Chain; Photosensitizing Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Tranquilizing Agents"
DB00478,Rimantadine,13392-28-4,approved; investigational,UBCHPRBFMUDMNC-UHFFFAOYSA-N,"InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3",CC(N)C12CC3CC(C1)CC(C3)C2,C12H21N,C07236,D08483,5071,46505973,94440,CHEMBL959,,4893,50216627,179.3018,2.217005761,"Adamantanes; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Bridged Compounds; Cyclic Amines; Cycloparaffins; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Influenza A M2 Protein Inhibitor; M2 Protein Inhibitors; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Polycyclic Compounds"
DB00479,Amikacin,37517-28-5,approved; investigational; vet_approved,LKCWBDHBTVXHDL-RMDFUYIESA-N,"InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1",NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O,C22H43N5O13,C06820,D02543,37768,46506386,2637,CHEMBL177,AKN,34635,50237603,585.6025,-8.584382674,Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycosides; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; Nephrotoxic agents
DB00480,Lenalidomide,191732-72-6,approved,GOTYRUGSSMKFNF-UHFFFAOYSA-N,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",Nc1cccc(c12)C(=O)N(C2)C3CCC(=O)NC3=O,C13H13N3O3,,D04687,216326,46505725,63791,CHEMBL848,,187515,65454,259.2606,-0.707852159,"Acids, Carbocyclic; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Drugs that are Mainly Renally Excreted; Growth Inhibitors; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Imides; Immunologic Factors; Immunosuppressive Agents; Isoindoles; Myelosuppressive Agents; P-glycoprotein substrates; Phthalic Acids; Phthalimides; Piperidines; Piperidones; Thalidomide Analog"
DB00481,Raloxifene,84449-90-1,approved; investigational,GZUITABIAKMVPG-UHFFFAOYSA-N,"InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2",c1cc(O)ccc1-c(s2)c(c(c23)ccc(O)c3)C(=O)c4ccc(cc4)OCCN5CCCCC5,C28H27NO4S,C07228,,5035,46506514,8772,CHEMBL81,RAL,4859,19441,473.583,5.692629507,"BCRP/ABCG2 Substrates; Benzene Derivatives; Benzylidene Compounds; Bone Density Conservation Agents; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strong); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Estrogen Agonist-antagonists; Estrogen Agonist/Antagonist; Estrogen Antagonists; Estrogen Receptor Modulators; Genito Urinary System and Sex Hormones; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; Selective Estrogen Receptor Modulators; Sex Hormones and Modulators of the Genital System; Stilbenes; UGT1A1 Substrates"
DB00482,Celecoxib,169590-42-5,approved; investigational,RZEKVGVHFLEQIL-UHFFFAOYSA-N,"InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)",Cc1ccc(cc1)-c2cc(C(F)(F)F)nn2-c3ccc(cc3)S(=O)(=O)N,C17H14F3N3O2S,C07589,D00567,2662,46505596,41423,CHEMBL118,CEL,2562,11639,381.372,4.009441774,"Agents causing hyperkalemia; Agents that produce hypertension; Amides; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiarrhythmic agents; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; BCRP/ABCG2 Substrates; BSEP/ABCB11 Inhibitors; Calcium Channel Blockers; Cardiovascular System; Central Nervous System Agents; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cyclooxygenase-2 (COX-2) Inhibitors; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Methemoglobinemia Associated Agents; Musculo-Skeletal System; Nephrotoxic agents; P-glycoprotein substrates; Peripheral Nervous System Agents; Photosensitizing Agents; Pyrazoles; Selective Calcium Channel Blockers With Mainly Vascular Effects; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents; Sulfonamides; Sulfones; Sulfur Compounds"
DB00483,Gallamine triethiodide,65-29-2,approved,REEUVFCVXKWOFE-UHFFFAOYSA-K,"InChI=1S/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3",CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC,C30H60I3N3O3,,,6172,46508651,,CHEMBL1200993,,5937,,891.5291,-7.719572671,Agents producing tachycardia; Amines; Ammonium Compounds; Anticholinergic Agents; Central Nervous System Depressants; Cholinergic Agents; Cholinesterase Inhibitors; Muscarinic Antagonists; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular-Blocking Agents (Nondepolarizing); Neurotransmitter Agents; Nicotinic Antagonists; Nitrogen Compounds; Onium Compounds; Peripheral Nervous System Agents; Quaternary Ammonium Compounds
DB00484,Brimonidine,59803-98-4,approved,XYLJNLCSTIOKRM-UHFFFAOYSA-N,"InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)",n1ccnc(c12)ccc(c2Br)NC3=NCCN3,C11H10BrN5,C07886,D07540,2435,46507305,3175,CHEMBL844,,2341,34572,292.135,1.37158453,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Antiglaucoma Preparations and Miotics; Cardiovascular Agents; Central Nervous System Depressants; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Misc. Skin and Mucous Membrane Agents; Ophthalmologicals; Quinoxalines; Sensory Organs; Sympathomimetics in Glaucoma Therapy"
DB00485,Dicloxacillin,3116-76-5,approved; investigational; vet_approved,YFAGHNZHGGCZAX-JKIFEVAISA-N,"InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)c3c(C)onc3-c4c(Cl)cccc4Cl,C19H17Cl2N3O5S,C06950,D02348,18381,46508182,4511,CHEMBL893,,17358,50350476,470.326,2.905784335,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; Beta-Lactamase Resistant Penicillins; beta-Lactams; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillins; Sulfur Compounds"
DB00486,Nabilone,51022-71-0,approved; investigational,GECBBEABIDMGGL-RTBURBONSA-N,"InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1",C1CC(=O)C[C@H]([C@@H]12)c3c(OC2(C)C)cc(cc3O)C(C)(C)CCCCCC,C24H36O3,,D05099,5284592,46505171,,CHEMBL947,,4447641,50287941,372.5408,6.359703313,Agents producing tachycardia; Alimentary Tract and Metabolism; Antiemetics; Antiemetics and Antinauseants; Autonomic Agents; Cannabinoids and similars; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Drugs causing inadvertant photosensitivity; Gastrointestinal Agents; Hydrocarbons; Hypotensive Agents; Miscellaneous Antiemetics; Peripheral Nervous System Agents; Photosensitizing Agents; Psychotropic Drugs; Terpenes; Tranquilizing Agents
DB00487,Pefloxacin,70458-92-3,approved,FHFYDNQZQSQIAI-UHFFFAOYSA-N,"InChI=1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24)",CCn1cc(C(=O)O)c(=O)c(c12)cc(F)c(c2)N3CCN(C)CC3,C17H20FN3O3,,D02306,51081,46507338,50199,CHEMBL267648,,46291,57936,333.3574,0.876812568,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Metabolic Side Effects of Drugs and Substances; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines; Quinolones; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00488,Altretamine,645-05-6,approved,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3,CN(C)c1nc(N(C)C)nc(n1)N(C)C,C9H18N6,,,2123,46505760,24564,CHEMBL1455,,2038,37631,210.2794,2.216221659,"Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Toxic Actions; Triazines"
DB00489,Sotalol,3930-20-9,approved,ZBMZVLHSJCTVON-UHFFFAOYSA-N,"InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3",CC(C)NCC(O)c1ccc(cc1)NS(=O)(=O)C,C12H20N2O3S,C07309,,5253,46505012,63622,CHEMBL471,,5063,25762,272.364,-0.395064003,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Autonomic Agents; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Non-Selective; Beta Blocking Agents, Non-Selective, and Thiazides; Bradycardia-Causing Agents; Cardiac Rhythm Alteration; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Ethanolamines; Highest Risk QTc-Prolonging Agents; Hypotensive Agents; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; Neurotransmitter Agents; Peripheral Nervous System Agents; QTc Prolonging Agents; Sympatholytics"
DB00490,Buspirone,36505-84-7,approved; investigational,QWCRAEMEVRGPNT-UHFFFAOYSA-N,"InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2",C1CCCC12CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)c4ncccn4,C21H31N5O2,C06861,D07593,2477,46508113,3223,CHEMBL49,,2383,50001859,385.5031,1.776733196,"Agents that produce hypertension; Antidepressive Agents; Azaspirodecanedione Derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Miscellaneous Anxiolytics Sedatives and Hypnotics; Nervous System; Neurotransmitter Agents; P-glycoprotein inhibitors; Piperazines; Polycyclic Compounds; Psycholeptics; Pyrimidines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Spiro Compounds; Tranquilizing Agents"
DB00491,Miglitol,72432-03-2,approved,IBAQFPQHRJAVAV-ULAWRXDQSA-N,"InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1",OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,C8H17NO5,C07708,D00625,441314,46504492,6935,CHEMBL1561,MIG,390074,50242271,207.2243,-3.192797258,"Alimentary Tract and Metabolism; Alkaloids; Blood Glucose Lowering Agents; Carbohydrates; Drugs Used in Diabetes; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypoglycemia-Associated Agents; Imines; Imino Pyranoses; Imino Sugars; Piperidines"
DB00492,Fosinopril,98048-97-6,approved,BIDNLKIUORFRQP-XYGFDPSESA-N,"InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30+,39-/m1/s1",c1ccccc1CCCC[P@@](=O)(O[C@@H](C(C)C)OC(=O)CC)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3,C30H46NO7P,C07016,D00622,55891,46506495,5163,CHEMBL3039598,,7875352,,563.672,5.624851468,"ACE Inhibitors and Diuretics; Acids; Acids, Acyclic; Acids, Noncarboxylic; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Amino Acids; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hypotensive Agents; Imines; Imino Acids; Organophosphorus Compounds; Phosphinic Acids; Phosphorus Acids; Phosphorus Compounds; Photosensitizing Agents; Protease Inhibitors"
DB00493,Cefotaxime,63527-52-6,approved,GPRBEKHLDVQUJE-QSWIMTSFSA-N,"InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1",CC(=O)OCC(=C1C(=O)O)CS[C@@H](N12)[C@@H](C2=O)NC(=O)/C(=N\OC)c3csc(n3)N,C16H17N5O7S2,C06885,D07647,5742673,46506911,204928,CHEMBL1730,CE3,4674877,,455.465,-1.406114881,"Agents that reduce seizure threshold; Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephacetrile; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB00494,Entacapone,130929-57-6,approved; investigational,JRURYQJSLYLRLN-BJMVGYQFSA-N,"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",CCN(CC)C(=O)/C(C#N)=C/c1cc([N+]([O-])=O)c(O)c(O)c1,C14H15N3O5,C07943,D00781,5281081,46508734,4798,CHEMBL953,PD9,4444537,50108879,305.286,1.634823855,"Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Benzene Derivatives; Central Nervous System Agents; Central Nervous System Depressants; COMT Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Dopamine Agents; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Nervous System; Phenols; UGT1A9 Substrates"
DB00495,Zidovudine,30516-87-1,approved,HBOMLICNUCNMMY-XLPZGREQSA-N,"InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1",O=c1[nH]c(=O)n(cc1C)[C@H]2C[C@H](N=[N+]=[N-])[C@H](O2)CO,C10H13N5O4,C07210,D00413,35370,46508240,10110,CHEMBL129,AZZ,32555,50002692,267.2413,-0.298709158,"Agents Causing Muscle Toxicity; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antimetabolites; Antiviral Agents; Antivirals for Systemic Use; BCRP/ABCG2 Substrates; Carbohydrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Deoxyribonucleosides; Dideoxynucleosides; Direct Acting Antivirals; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Immunosuppressive Agents; Medications that reduce magnesium levels; Myelosuppressive Agents; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; P-glycoprotein substrates; Pyrimidine Nucleosides; Pyrimidines; Reverse Transcriptase Inhibitors; Toxic Actions; UGT1A1 Inducers; UGT1A1 Substrates; UGT2B7 substrates"
DB00496,Darifenacin,133099-04-4,approved; investigational,HXGBXQDTNZMWGS-RUZDIDTESA-N,"InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1",c1ccccc1C(C(=O)N)(c2ccccc2)[C@@H]3CCN(C3)CCc(cc4)cc(c45)CCO5,C28H30N2O2,,D01699,444031,46508104,391960,CHEMBL1346,,392054,50109647,426.55,4.540284134,"Agents producing tachycardia; Anticholinergic Agents; Cholinergic Agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Urinary Frequency and Incontinence; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Muscarinic Antagonists; Neurotransmitter Agents; Urological Agents; Urologicals"
DB00497,Oxycodone,76-42-6,approved; illicit; investigational,BRUQQQPBMZOVGD-XFKAJCMBSA-N,"InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1",[C@@]123c4c5ccc(OC)c4O[C@H]1C(=O)CC[C@@]3(O)[C@@H](C5)N(C)CC2,C18H21NO4,C08018,D05312,5284603,46508908,7852,CHEMBL656,,4447649,50370595,315.3636,1.034865393,"Alkaloids; Analgesics; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Morphine Derivatives; Narcotics; Natural Opium Alkaloids; Nervous System; Opiate Agonists; Opiate Alkaloids; Opioid Agonist; Opioids; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Semi-synthetic Opioids; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00498,Phenindione,83-12-5,approved; investigational,NFBAXHOPROOJAW-UHFFFAOYSA-N,"InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H",c1cccc(c12)C(=O)C(C2=O)c3ccccc3,C15H10O2,C07584,D08354,4760,46505018,8066,CHEMBL711,,4596,50280157,222.2387,2.880905265,"Anticoagulants; Blood and Blood Forming Organs; Hematologic Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indans; Indenes; Narrow Therapeutic Index Drugs; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Vitamin K Antagonists"
DB00499,Flutamide,13311-84-7,approved; investigational,MKXKFYHWDHIYRV-UHFFFAOYSA-N,"InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)",CC(C)C(=O)Nc1cc(C(F)(F)F)c([N+]([O-])=O)cc1,C11H11F3N2O3,C07653,D00586,3397,46508874,5132,CHEMBL806,HFT,3280,50131270,276.2118,3.27231098,"Amides; Amines; Androgen Receptor Antagonists; Androgen Receptor Inhibitor; Anilides; Aniline Compounds; Antiandrogens; Antiandrogens, non-steroidal; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Endocrine Therapy; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Methemoglobinemia Associated Agents"
DB00500,Tolmetin,26171-23-3,approved,UPSPUYADGBWSHF-UHFFFAOYSA-N,"InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)",OC(=O)Cc1n(C)c(cc1)C(=O)c2ccc(C)cc2,C15H15NO3,C07149,,5509,46507060,71941,CHEMBL1020,TLT,5308,50295287,257.2845,2.727330958,"Acetic Acid Derivatives and Related Substances; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Azoles; Central Nervous System Agents; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Heteroaryl acetic acid NSAIDS; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; Peripheral Nervous System Agents; Pyrroles; Sensory System Agents; Topical Products for Joint and Muscular Pain"
DB00501,Cimetidine,51481-61-9,approved; investigational,AQIXAKUUQRKLND-UHFFFAOYSA-N,"InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)",N#C/N=C(/NC)NCCSCc1c(C)[nH]cn1,C10H16N6S,C06952,D00295,2756,46505360,3699,CHEMBL30,,2654,22889,252.339,-0.109356107,"Acid Reducers; Adjuvants; Agents Causing Muscle Toxicity; Alimentary Tract and Metabolism; Amidines; Anti-Ulcer Agents; Azoles; BSEP/ABCB11 Inhibitors; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (moderate); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Gastric Acid Lowering Agents; Gastrointestinal Agents; Guanidines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H2 Antagonists; Imidazoles; MATE 1 Inhibitors; MATE 1 Substrates; MATE 2 Inhibitors; MATE 2 Substrates; MATE inhibitors; MATE substrates; Medications that reduce magnesium levels; Metabolic Side Effects of Drugs and Substances; Neurotransmitter Agents; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; P-glycoprotein inducers; P-glycoprotein substrates"
DB00502,Haloperidol,52-86-8,approved,LNEPOXFFQSENCJ-UHFFFAOYSA-N,"InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2",Clc1ccc(cc1)C2(O)CCN(CC2)CCCC(=O)c3ccc(F)cc3,C21H23ClFNO2,C01814,D00136,3559,46508794,5613,CHEMBL54,GMJ,3438,21398,375.864,3.661113801,Agents that reduce seizure threshold; Anti-Dyskinesia Agents; Antiemetics; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Autonomic Agents; Butyrophenone Derivatives; Butyrophenones; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Hyperglycemia-Associated Agents; Ketones; Moderate Risk QTc-Prolonging Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; NMDA Receptor Antagonists; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Photosensitizing Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Tranquilizing Agents; UGT1A9 Substrates
DB00503,Ritonavir,155213-67-5,approved; investigational,NCDNCNXCDXHOMX-XGKFQTDJSA-N,"InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1",CC(C)c1nc(cs1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc3ccccc3)NC(=O)OCc4cncs4,C37H48N6O5S2,C07240,D00427,392622,46505050,45409,CHEMBL163,RIT,347980,520,720.944,5.221782033,"Acids, Acyclic; Agents Causing Muscle Toxicity; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Breast Cancer Resistance Protein Inhibitors; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Carboxylic Acids; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (weak); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (weak); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strong); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strong); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Experimental Unapproved Treatments for COVID-19; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV Protease Inhibitors; Hyperglycemia-Associated Agents; Metabolic Side Effects of Drugs and Substances; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Potential QTc-Prolonging Agents; Protease Inhibitors; QTc Prolonging Agents; Sulfur Compounds; Thiazoles; UDP Glucuronosyltransferases Inducers; UGT1A1 Inducers"
DB00504,Levallorphan,152-02-3,approved,OZYUPQUCAUTOBP-QXAKKESOSA-N,"InChI=1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1",C1CCC[C@H]([C@@]123)[C@H](N(CC2)CC=C)Cc4c3cc(O)cc4,C19H25NO,C07069,,5359371,46505682,6431,CHEMBL1254682,,10481920,50326673,283.4079,3.755367302,"Alkaloids; Central Nervous System Agents; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Opiate Alkaloids; Opioid Antagonists; Peripheral Nervous System Agents; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents"
DB00507,Nitazoxanide,55981-09-4,approved; investigational; vet_approved,YQNQNVDNTFHQSW-UHFFFAOYSA-N,"InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)",CC(=O)Oc1ccccc1C(=O)Nc2ncc(s2)[N+]([O-])=O,C12H9N3O5S,,D02486,41684,46507813,94807,CHEMBL1401,NTI,38037,50075050,307.282,2.121414542,"Anti-Infective Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Sulfur Compounds"
DB00508,Triflupromazine,146-54-3,approved; vet_approved,XSCGXQMFQXDFCW-UHFFFAOYSA-N,"InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3",CN(C)CCCN1c(cccc2)c2Sc(c13)ccc(c3)C(F)(F)F,C18H19F3N2S,,D00390,5568,46507344,9711,CHEMBL570,,5367,67544,352.417,4.808804048,"Agents producing tachycardia; Anticholinergic Agents; Antidepressive Agents; Antiemetics; Antipsychotic Agents; Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase Inhibitors; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Phenothiazines; Phenothiazines With Aliphatic Side-Chain; Psycholeptics; Psychotropic Drugs; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Tranquilizing Agents"
DB00509,Dextrothyroxine,51-49-0,approved; investigational,XUIIKFGFIJCVMT-GFCCVEGCSA-N,"InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1",OC(=O)[C@H](N)Cc1cc(I)c(c(I)c1)Oc2cc(I)c(O)c(I)c2,C15H11I4NO4,,,8730,46508471,30659,CHEMBL559,,8402,50225220,776.87,3.727307065,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Cardiovascular System; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Lipid Modifying Agents; Lipid Modifying Agents, Plain"
DB00511,Acetyldigitoxin,1111-39-3,approved,HPMZBILYSWLILX-UMDUKNJSSA-N,"InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1",O=C1OCC(=C1)[C@H]2CC[C@@](O)([C@@]23C)[C@H]4[C@H](CC3)[C@]5(C)[C@H](CC4)C[C@H](CC5)O[C@H]6C[C@H](O)[C@@H]([C@H](O6)C)O[C@H]7C[C@H](O)[C@@H]([C@H](O7)C)O[C@H]8C[C@H](OC(=O)C)[C@H](O)[C@H](O8)C,C43H66O14,C16749,D06881,5284512,46507229,53773,CHEMBL3545057,,4447572,,806.9757,4.038617149,"Antiarrhythmic agents; Carbohydrates; Cardanolides; Cardenolides; Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Digitalis Glycosides; Enzyme Inhibitors; Fused-Ring Compounds; Glycosides; Polycyclic Compounds; Protective Agents; Steroids"
DB00512,Vancomycin,1404-90-6,approved,MYPYJXKWCTUITO-LYRMYLQWSA-N,"InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1",C[C@@]1(N)[C@H](O)[C@H](C)O[C@H](C1)O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc(c34)c5cc(c4)[C@@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c6ccc(O3)c(Cl)c6)C(=O)N[C@@H]7c8cc(c(O)cc8)c9c(cc(O)cc9O)[C@@H](C(=O)O)NC(=O)[C@@H](NC7=O)[C@H](O)c1cc(Cl)c(O5)cc1,C66H75Cl2N9O24,C06689,D00212,14969,46505261,28001,CHEMBL262777,,14253,50335519,1449.254,-4.406617998,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antiinfectives for Systemic Use; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycoconjugates; Glycopeptide Antibacterials; Glycopeptides; Intestinal Antiinfectives; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Ophthalmologicals; Peptides; Sensory Organs"
DB00513,Aminocaproic acid,60-32-2,approved; investigational,SLXKOJJOQWFEFD-UHFFFAOYSA-N,"InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)",NCCCCCC(=O)O,C6H13NO2,C02378,D00160,564,46506934,57826,CHEMBL1046,ACA,548,50357211,131.1729,-1.997155234,"Acids, Acyclic; Amino Acids; Amino Acids, Peptides, and Proteins; Aminocaproates; Antifibrinolytic Agents; Blood and Blood Forming Organs; Caproates; Carboxylic Acids; Coagulants; Decreased Fibrinolysis; Fatty Acids; Fatty Acids, Volatile; Fibrin Modulating Agents; Hematologic Agents; Hemostatics; Lipids"
DB00514,Dextromethorphan,125-71-3,approved,MKXZASYAUGDDCJ-NJAFHUGGSA-N,"InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1",C1CCC[C@@H]([C@]123)[C@@H](N(C)CC2)Cc4c3cc(OC)cc4,C18H25NO,C06947,D03742,5360696,46506530,4470,CHEMBL52440,,13109865,50366613,271.404,3.493774351,"Alkaloids; Anticholinergic Agents; Antidepressive Agents; Antitussive Agents; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cough and Cold Preparations; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Excitatory Amino Acid Agents; Excitatory Amino Acid Antagonists; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Narcotics; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; NMDA Receptor Antagonists; Opiate Alkaloids; Opioids; Opium Alkaloids and Derivatives; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Respiratory System; Respiratory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Sigma-1 Agonist; Sigma-1 Receptor Agonists; UGT2B7 substrates; Uncompetitive N-methyl-D-aspartate Receptor Antagonist; Uncompetitive NMDA Receptor Antagonists"
DB00515,Cisplatin,15663-27-1,approved,LXZZYRPGZAFOLE-UHFFFAOYSA-L,InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2,[NH3+][Pt](Cl)(Cl)[NH3+],Cl2H6N2Pt,C06911,D00275,2767,46504561,27899,CHEMBL2068237,CPT,76401,50028111,300.05,NA,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Cardiotoxic antineoplastic agents; Chlorine Compounds; Cholinesterase Inhibitors; Compounds used in a research, industrial, or household setting; Cross-Linking Reagents; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Immunosuppressive Agents; Indicators and Reagents; Laboratory Chemicals; Medications that reduce magnesium levels; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Nitrogen Compounds; OCT2 Inhibitors; OCT2 Substrates; OCT2 substrates with narrow therapeutic index; P-glycoprotein substrates; Platinum Compounds; Radiation-Sensitizing Agents"
DB00516,Bentoquatam,1340-69-8,approved,,, ,,,,,46508055,,CHEMBL1201446,,,,NA,NA,"Acids; Acids, Noncarboxylic; Aluminium Compounds; Aluminum Silicates; Anions; Dermatologicals; Electrolytes; Ions; Metal cations; Metal divalent cations; Minerals; Oxides; Oxygen Compounds; Silicates; Silicon Compounds"
DB00517,Anisotropine methylbromide,80-50-2,approved,QSFKGMJOKUZAJM-UHFFFAOYSA-M,"InChI=1S/C17H32NO2.BrH/c1-5-7-13(8-6-2)17(19)20-16-11-14-9-10-15(12-16)18(14,3)4;/h13-16H,5-12H2,1-4H3;1H/q+1;/p-1",CCCC(CCC)C(=O)O[C@@H](CC12)CC(CC1)[N+]2(C)C,C17H32BrNO2,C06830,D00232,21867154,46504810,2739,CHEMBL1578,,10611962,,362.345,-0.665853756,"Agents producing tachycardia; Alkaloids; Anticholinergic Agents; Aza Compounds; Azabicyclo Compounds; Bicyclo Compounds, Heterocyclic; Cholinergic Agents; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Muscarinic Antagonists; Neurotransmitter Agents"
DB00518,Albendazole,54965-21-8,approved; vet_approved,HXHWSAZORRCQMX-UHFFFAOYSA-N,"InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)",CCCSc(cc1)cc(c12)[nH]c(n2)NC(=O)OC,C12H15N3O2S,C01779,D00134,2082,46506472,16664,CHEMBL1483,ALW,1998,50241293,265.331,3.204525031,"Acids, Acyclic; Anthelmintics; Anti-Infective Agents; Anticestodal Agents; Antihelminthic; Antimitotic Agents; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiplatyhelmintic Agents; Benzimidazole Derivatives; Benzimidazoles; Carbamates; Carboxylic Acids; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strong); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Mitosis Modulators; P-glycoprotein substrates; Tubulin Modulators"
DB00519,Trandolapril,87679-37-6,approved,VXFJYXUZANRPDJ-WTNASJBWSA-N,"InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1",C1CCC[C@@H]([C@H]12)C[C@@H](C(=O)O)N2C(=O)[C@H](C)N[C@H](C(=O)OCC)CCc3ccccc3,C24H34N2O5,,D00383,5484727,46508300,9649,CHEMBL1519,,4588590,50369775,430.5372,1.947358794,"ACE Inhibitors and Calcium Channel Blockers; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Protease Inhibitors"
DB00520,Caspofungin,162808-62-0,approved,JYIKNQVWKBUSNH-OGZDCFRISA-N,"InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1",CCC(C)CC(C)CCCCCCCCC(=O)N[C@H](C(=O)N[C@H](C1=O)[C@@H](C)O)C[C@@H](O)[C@@H](NCCN)NC(=O)[C@H]([C@@H](O)CC2)N2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@@H](NC(=O)[C@@H](N13)C[C@H](C3)O)[C@H](O)[C@@H](O)c4ccc(O)cc4,C52H88N10O15,,D07626,3035406,46508288,474180,CHEMBL499808,,411774,,1093.331,-4.824428611,"Amino Acids, Peptides, and Proteins; Anti-Infective Agents; Antifungal Agents; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Echinocandin Antifungal; Echinocandins; Enzyme Inhibitors; Lipids; Lipopeptides; Macrocyclic Compounds; OAT1/SLC22A6 inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein inhibitors; Peptides; Peptides, Cyclic; Polycyclic Compounds"
DB00521,Carteolol,51781-06-7,approved,LWAFSWPYPHEXKX-UHFFFAOYSA-N,"InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)",CC(C)(C)NCC(O)COc1cccc(c12)NC(=O)CC2,C16H24N2O3,C06874,D07624,2583,46507513,3437,CHEMBL839,,2485,50040065,292.3734,1.418168877,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Autonomic Agents; Beta Blocking Agents, Non-Selective; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Neurotransmitter Agents; Ophthalmologicals; Peripheral Nervous System Agents; Phenoxypropanolamines; Potential QTc-Prolonging Agents; Propanolamines; Propanols; QTc Prolonging Agents; Quinolines; Quinolones; Sensory Organs; Sympatholytics"
DB00523,Alitretinoin,08-03-5300,approved; investigational,SHGAZHPCJJPHSC-ZVCIMWCZSA-N,"InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+",OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C(C1(C)C)=C(C)CCC1,C20H28O2,C15493,D02815,449171,46507356,50648,CHEMBL705,9CR,395778,31892,300.4351,5.014367711,"Agents for Dermatitis, Excluding Corticosteroids; Alkenes; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Biological Factors; Carotenoids; Cyclohexanes; Cyclohexenes; Cycloparaffins; Dermatologicals; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Misc. Skin and Mucous Membrane Agents; P-glycoprotein substrates; Pigments, Biological; Polycyclic Compounds; Polyenes; Retinoids; Terpenes; Tretinoin; Vitamin A; Vitamins; Vitamins (Fat Soluble)"
DB00524,Metolazone,17560-51-9,approved,AQCHWTWZEMGIFD-UHFFFAOYSA-N,"InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)",O=S(=O)(N)c(c1)c(Cl)cc(c12)NC(C)N(C2=O)c3ccccc3C,C16H16ClN3O3S,,D00431,4170,46509058,64354,CHEMBL878,,4026,25899,365.835,2.943580536,"Amides; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Diuretics; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Hypotensive Agents; Increased Diuresis; Low-Ceiling Diuretics and Potassium-Sparing Agents; Low-Ceiling Diuretics, Excl. Thiazides; Medications that reduce magnesium levels; Membrane Transport Modulators; Natriuretic Agents; Non Potassium Sparing Diuretics; Quinazolines; Quinazolinones; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazide-like Diuretic"
DB00525,Tolnaftate,2398-96-1,approved; investigational; vet_approved,FUSNMLFNXJSCDI-UHFFFAOYSA-N,"InChI=1S/C19H17NOS/c1-14-6-5-9-17(12-14)20(2)19(22)21-18-11-10-15-7-3-4-8-16(15)13-18/h3-13H,1-2H3",Cc1cc(ccc1)N(C)C(=S)Oc(cc2)cc(c23)cccc3,C19H17NOS,,D00381,5510,46505456,9620,CHEMBL83668,,5309,39349,307.409,5.745039567,"Acids, Acyclic; Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Carbamates; Carboxylic Acids; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthalenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sulfur Compounds; Thiocarbamates"
DB00526,Oxaliplatin,61825-94-3,approved; investigational,ZROHGHOFXNOHSO-BNTLRKBRSA-L,"InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1",O=C(O1)C(=O)O[Pt]12[NH2+][C@H]3[C@H]([NH2+]2)CCCC3,C8H14N2O4Pt,,D01790,6857599,46509083,31941,CHEMBL414804,,8062727,,397.294,NA,Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Coordination Complexes; FOLFOX chemotherapy regimen; Immunosuppressive Agents; Moderate Risk QTc-Prolonging Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OCT2 Substrates; OCT2 substrates with narrow therapeutic index; Organometallic Compounds; Platinum Compounds; QTc Prolonging Agents
DB00527,Cinchocaine,85-79-0,approved; vet_approved,PUFQVTATUTYEAL-UHFFFAOYSA-N,"InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)",c1cccc(c12)nc(OCCCC)cc2C(=O)NCCN(CC)CC,C20H29N3O2,C07879,D00733,3025,46506734,247956,CHEMBL1086,,2917,48532,343.4632,3.698162542,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Amides; Analgesics and Anesthetics; Anesthetics; Anesthetics for Topical Use; Anesthetics, Local; Antipruritics and Local Anesthetics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Cardiovascular System; Cell-mediated Immunity; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase Inhibitors; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Increased Histamine Release; Local Anesthetics (Amide); Nervous System; Ophthalmologicals; Otologicals; Peripheral Nervous System Agents; Quinolines; Sensory Organs; Sensory System Agents; Standardized Chemical Allergen; Vasoprotectives"
DB00528,Lercanidipine,100427-26-7,approved; investigational,ZDXUKAKRHYTAKV-UHFFFAOYSA-N,"InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3",COC(=O)C1=C(C)NC(C)=C(C1c2cc([N+]([O-])=O)ccc2)C(=O)OC(C)(C)CN(C)CCC(c3ccccc3)c4ccccc4,C36H41N3O6,,,65866,46508865,135930,CHEMBL250270,,59276,,611.7272,6.409816553,"ACE Inhibitors and Calcium Channel Blockers; Agents causing hyperkalemia; Agents Causing Muscle Toxicity; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Antiarrhythmic agents; Antihypertensive Agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; Pyridines; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB00529,Foscarnet,4428-95-9,approved,ZJAOAACCNHFJAH-UHFFFAOYSA-N,"InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)",OC(=O)P(=O)(O)O,CH3O5P,C06456,D00579,3415,46507873,127780,CHEMBL666,PPF,3297,50011181,126.0053,-0.830384105,"Acetates; Acids, Acyclic; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Carboxylic Acids; Chelating Activity; Direct Acting Antivirals; Enzyme Inhibitors; Fatty Acids; Fatty Acids, Volatile; Lipids; Medications that reduce magnesium levels; Nephrotoxic agents; Nucleic Acid Synthesis Inhibitors; OAT1/SLC22A6 inhibitors; Organophosphonates; Organophosphorus Compounds; Phosphonic Acid Derivatives; Potential QTc-Prolonging Agents; Pyrophosphate Analog DNA Polymerase Inhibitor; QTc Prolonging Agents; Reverse Transcriptase Inhibitors"
DB00530,Erlotinib,183321-74-6,approved; investigational,AAKJLRGGTJKAMG-UHFFFAOYSA-N,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",COCCOc(c1)c(OCCOC)cc(c12)ncnc2Nc3cc(C#C)ccc3,C22H23N3O4,,D07907,176870,46508021,114785,CHEMBL553,AQ4,154044,5446,393.4357,3.200987586,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Kinase Inhibitor; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Protein Kinase Inhibitors; QTc Prolonging Agents; Quinazolines; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors"
DB00531,Cyclophosphamide,50-18-0,approved; investigational,CMSMOCZEIVJLDB-UHFFFAOYSA-N,"InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)",ClCCN(CCCl)P1(=O)NCCCO1,C7H15Cl2N2O2P,C07888,D07760,2907,46505441,4027,CHEMBL88,,2804,50237604,261.086,0.096547687,"Acids; Acids, Noncarboxylic; Alkylating Activity; Alkylating Drugs; Anions; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; BEACOPP chemotherapy regimen; Cardiotoxic antineoplastic agents; CHOP chemotherapy regimen; CHOP-R chemotherapy regimen; CMF chemotherapy regimen; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Electrolytes; Hydrocarbons; Hydrocarbons, Halogenated; Immunologic Factors; Immunosuppressive Agents; Ions; Methemoglobinemia Associated Agents; Mustard Compounds; Mutagens; Myeloablative Agonists; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Neurotoxic agents; Nitrogen Mustard Analogues; Nitrogen Mustard Compounds; Noxae; Organophosphorus Compounds; Phosphoramide Mustards; Phosphoramides; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Toxic Actions"
DB00532,Mephenytoin,50-12-4,approved; investigational; withdrawn,GMHKMTDVRCWUDX-UHFFFAOYSA-N,"InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)",O=C(N1)N(C)C(=O)C1(CC)c2ccccc2,C12H14N2O2,,D00375,4060,46508677,6757,CHEMBL861,,3920,50103593,218.2518,1.665173284,"Anti-epileptic Agent; Anticonvulsants; Azoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydantoins; Imidazoles; Imidazolidines; Nervous System; Thyroxine-binding globulin substrates"
DB00533,Rofecoxib,162011-90-7,approved; investigational; withdrawn,RZJQGNCSTQAWON-UHFFFAOYSA-N,"InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3",CS(=O)(=O)c1ccc(cc1)C2=C(C(=O)OC2)c3ccccc3,C17H14O4S,C07590,D00568,5090,46504787,8887,CHEMBL122,RCX,4911,22369,314.356,2.560910504,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Azoles; Central Nervous System Agents; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strong); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Peripheral Nervous System Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents; Sulfur Compounds"
DB00534,Chlormerodrin,62-37-3,approved; withdrawn,BJFGVYCULWBXKF-UHFFFAOYSA-M,"InChI=1S/C5H11N2O2.ClH.Hg/c1-4(9-2)3-7-5(6)8;;/h4H,1,3H2,2H3,(H3,6,7,8);1H;/q;;+1/p-1",Cl[Hg]CC(OC)CNC(=O)N,C5H11ClHgN2O2,,,25210,46504793,59445,,,2615,,367.2,-0.8584,Alkylmercury Compounds; Organomercury Compounds; Organometallic Compounds
DB00535,Cefdinir,91832-40-5,approved,RTXOFQZKPXMALH-GHXIOONMSA-N,"InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1",O=C(O)C1=C(C=C)CS[C@@H](N12)[C@@H](C2=O)NC(=O)/C(=N\O)c3csc(n3)N,C14H13N5O5S2,C08110,D00917,6915944,46505573,3485,CHEMBL927,,5291705,,395.414,-1.668988099,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Aza Compounds; Azabicyclo Compounds; beta-Lactams; Bicyclo Compounds; Bicyclo Compounds, Heterocyclic; Bridged Compounds; Cephalosporins; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; Polycyclic Compounds; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB00536,Guanidine,113-00-8,approved,ZRALSGWEFCBTJO-UHFFFAOYSA-N,"InChI=1S/CH5N3/c2-1(3)4/h(H5,2,3,4)",NC(N)=N,CH5N3,,,3520,46507543,42820,CHEMBL821,GAI,3400,50420178,59.0705,-1.236839015,Acetylcholine Releasing Agent; Amidines; Guanidines; Increased Acetylcholine Activity; MATE 1 Substrates; MATE 2 Substrates; MATE substrates; OAT3/SLC22A8 Inhibitors; OCT1 inhibitors; OCT2 Inhibitors
DB00537,Ciprofloxacin,85721-33-1,approved; investigational,MYSWGUAQZAJSOK-UHFFFAOYSA-N,"InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)",O=C(O)c(c1=O)cn(C2CC2)c(c13)cc(c(F)c3)N4CCNCC4,C17H18FN3O3,C05349,D00186,2764,46504733,100241,CHEMBL8,CPF,2662,21690,331.3415,-0.814596043,"Agents Causing Muscle Toxicity; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (moderate); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; MATE 1 Inhibitors; MATE 1 Substrates; MATE 2 Inhibitors; MATE inhibitors; MATE substrates; Medications that reduce magnesium levels; Metabolic Side Effects of Drugs and Substances; Moderate Risk QTc-Prolonging Agents; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; P-glycoprotein substrates; Photosensitizing Agents; QTc Prolonging Agents; Quinolines; Quinolone Antimicrobial; Quinolones; Sensory Organs; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00538,Gadoversetamide,131069-91-5,approved; investigational,HBEAOBRDTOXWRZ-UHFFFAOYSA-K,"InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3",COCCNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NCCOC,C20H34GdN5O10,,D01646,444013,46504481,31644,CHEMBL1200457,,392041,,661.76,-7.042779602,"Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Gadolinium-based Contrast Agent; Magnetic Resonance Contrast Activity; Magnetic Resonance Imaging Contrast Media; Other Diagnostics; Paramagnetic Contrast Agent; Paramagnetic Contrast Media"
DB00539,Toremifene,89778-26-7,approved; investigational,XFCLJVABOIYOMF-QPLCGJKRSA-N,"InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-",CN(C)CCOc1ccc(cc1)/C(c2ccccc2)=C(/CCCl)c3ccccc3,C26H28ClNO,C08166,,3005573,46506087,9635,CHEMBL1655,T0R,2275722,58492,405.96,6.269135195,"Anti-Estrogens; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Benzene Derivatives; Benzylidene Compounds; Bone Density Conservation Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Endocrine Therapy; Estrogen Agonist/Antagonist; Estrogen Receptor Modulators; Highest Risk QTc-Prolonging Agents; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; P-glycoprotein inhibitors; P-glycoprotein substrates; QTc Prolonging Agents; Selective Estrogen Receptor Modulators; Stilbenes"
DB00540,Nortriptyline,72-69-5,approved,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,"InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3",CNCCC=C1c(cccc2)c2CCc(c13)cccc3,C19H21N,C07274,D08288,4543,46507783,7640,CHEMBL445,21B,4384,112777,263.3767,4.426486978,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tricyclic; Benzocycloheptenes; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dibenzocycloheptenes; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Membrane Transport Modulators; Muscarinic Antagonists; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Tricyclics and Other Norepinephrine-reuptake Inhibitors"
DB00541,Vincristine,57-22-7,approved; investigational,OGWKCGZFUXNPDA-CFWMRBGOSA-N,"InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1",C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C=O)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(c9c([nH]8)cccc9)CCN(C6)C[C@@](O)(C7)CC,C46H56N4O10,C07204,D08679,5978,46507033,28445,CHEMBL499458,,4535015,38872,824.972,3.128179157,"Agents Causing Muscle Toxicity; Alkaloids; Antimitotic Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; BEACOPP chemotherapy regimen; BSEP/ABCB11 Substrates; BSEP/ABCB11 Substrates with Narrow Therapeutic Index; Cardiotoxic antineoplastic agents; CHOP chemotherapy regimen; CHOP-R chemotherapy regimen; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Indole Alkaloids; Indoles; Mitosis Modulators; Narrow Therapeutic Index Drugs; Neurotoxic agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Secologanin Tryptamine Alkaloids; Tubulin Modulators; Vinca Alkaloids"
DB00542,Benazepril,86541-75-5,approved; investigational,XPCFTKFZXHTYIP-PMACEKPBSA-N,"InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1",c1cccc(c12)CC[C@@H](C(=O)N2CC(=O)O)N[C@H](C(=O)OCC)CCc3ccccc3,C24H28N2O5,C06843,D07499,5362124,46507884,3011,CHEMBL838,,4514935,50021153,424.4895,1.537439146,"ACE Inhibitors and Diuretics; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Decreased Blood Pressure; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Photosensitizing Agents; Protease Inhibitors"
DB00543,Amoxapine,14028-44-5,approved,QWGDMFLQWFTERH-UHFFFAOYSA-N,"InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2",C1CNCCN1C(c(c23)cc(Cl)cc2)=Nc4c(O3)cccc4,C17H16ClN3O,,D00228,2170,46509117,2675,CHEMBL1113,,2085,22870,313.781,3.077554495,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tetracyclic; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dibenzoxazepines; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Membrane Transport Modulators; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists"
DB00544,Fluorouracil,51-21-8,approved,GHASVSINZRGABV-UHFFFAOYSA-N,"InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)",Fc1c[nH]c(=O)[nH]c1=O,C4H3FN2O2,C07649,D00584,3385,46508557,46345,CHEMBL185,URF,3268,50340677,130.0772,-0.65584809,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Cardiotoxic antineoplastic agents; CMF chemotherapy regimen; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Fluoropyrimidines; Fluorouracil and prodrugs; FOLFIRI chemotherapy regimen; FOLFOX chemotherapy regimen; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunologic Factors; Immunosuppressive Agents; Misc. Skin and Mucous Membrane Agents; Moderate Risk QTc-Prolonging Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleoside Metabolic Inhibitor; Photosensitizing Agents; Pyrimidine Analogues; Pyrimidines; Pyrimidinones; QTc Prolonging Agents; Thyroxine-binding globulin inducers; Toxic Actions"
DB00545,Pyridostigmine,155-97-5,approved; investigational,RVOLLAQWKVFTGE-UHFFFAOYSA-N,"InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1",CN(C)C(=O)Oc1c[n+](C)ccc1,C9H13N2O2,C07410,D00487,4991,46506129,8665,CHEMBL1115,,4817,50313079,181.2117,-3.466727399,"Cholinergic Agents; Cholinesterase Inhibitors; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 Enzyme Inducers; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Neurotransmitter Agents; Parasympathomemetic (Cholinergic) Agents; Parasympathomimetics; Pyridines; Pyridinium Compounds"
DB00547,Desoximetasone,382-67-2,approved,VWVSBHGCDBMOOT-IIEHVVJPSA-N,"InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1",OCC(=O)[C@H]1[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)C=C4,C22H29FO4,,,5311067,46506793,691037,CHEMBL1766,,4470604,50103622,376.4617,2.351041073,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated"
DB00548,Azelaic acid,123-99-9,approved,BDJRBEYXGGNYIS-UHFFFAOYSA-N,"InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)",OC(=O)CCCCCCCC(=O)O,C9H16O4,C08261,D03034,2266,46506284,48131,CHEMBL1238,AZ1,2179,,188.2209,1.824360358,"Acids, Acyclic; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Carboxylic Acids; Decreased Protein Synthesis; Decreased Sebaceous Gland Activity; Dermatologicals; Drugs that are Mainly Renally Excreted; Misc. Skin and Mucous Membrane Agents"
DB00549,Zafirlukast,107753-78-6,approved; investigational,YEEZWCHGZNKEEK-UHFFFAOYSA-N,"InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)",Cc1ccccc1S(=O)(=O)NC(=O)c2cc(OC)c(cc2)Cc3cn(C)c(c34)ccc(c4)NC(=O)OC5CCCC5,C31H33N3O6S,C07206,D00411,5717,46506874,10100,CHEMBL603,ZLK,5515,50009073,575.675,6.403744909,"Agents to Treat Airway Disease; Anti-Asthmatic Agents; Benzene Derivatives; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Inhibitors (strong); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Leukotriene Antagonists; Leukotriene Modifiers; Respiratory System; Respiratory System Agents; Sulfones; Sulfur Compounds"
DB00550,Propylthiouracil,51-52-5,approved; investigational,KNAHARQHSZJURB-UHFFFAOYSA-N,"InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)",CCCc1cc(=O)[nH]c(=S)[nH]1,C7H10N2OS,C07569,D00562,657298,46505181,8502,CHEMBL1518,3CJ,571424,50133597,170.232,1.203742354,"Agents Causing Muscle Toxicity; Antimetabolites; Antithyroid agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Myelosuppressive Agents; Noxae; Pyrimidines; Pyrimidinones; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thiouracil; Thiouracils; Thyroid Hormone Synthesis Inhibitor; Thyroid Hormone Synthesis Inhibitors; Thyroid Products; Toxic Actions"
DB00551,Acetohydroxamic acid,546-88-3,approved,RRUDCFGSUDOHDG-UHFFFAOYSA-N,"InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)",CC(=O)NO,C2H5NO2,C06808,D00220,1990,46508546,49029,CHEMBL734,HAE,1913,50099857,75.0666,-1.033470055,Amines; Carboxylic Acids; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Hydroxy Acids; Hydroxylamines; Urease Inhibitor; Urease Inhibitors; Urologicals
DB00552,Pentostatin,53910-25-1,approved; investigational,FPVKHBSQESCIEP-JQCXWYLXSA-N,"InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1",OC[C@H]1O[C@H](C[C@@H]1O)n2cnc(c23)[C@H](O)CNC=N3,C11H16N4O4,C02267,D00155,439693,46507116,,CHEMBL1580,DCF,388759,22925,268.2691,-2.016391028,"Adenosine Deaminase Inhibitors; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carbohydrates; Cardiotoxic antineoplastic agents; Coformycin; Deoxyribonucleosides; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inhibitors; Formycins; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Metabolic Inhibitor; Nucleosides; Pyrimidine Nucleosides; Pyrimidines; Ribonucleosides"
DB00553,Methoxsalen,298-81-7,approved,QXKHYNVANLEOEG-UHFFFAOYSA-N,"InChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3",c1cc(=O)oc(c2OC)c1cc(c23)cco3,C12H8O4,C01864,D00139,4114,46506275,18358,CHEMBL416,8MO,3971,50041234,216.192,1.78481175,"Antipsoriatics; Antipsoriatics for Systemic Use; Antipsoriatics for Topical Use; Benzopyrans; Coloring Agents; Compounds used in a research, industrial, or household setting; Cross-Linking Reagents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Drugs that are Mainly Renally Excreted; Furocoumarins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indicators and Reagents; Laboratory Chemicals; Photoabsorption; Photoactivated Radical Generator; Photosensitizing Activity; Photosensitizing Agents; Photosensitizing agents used for phototherapy; Psoralens for Systemic Use; Psoralens for Topical Use; Pyrans; Radiation-Sensitizing Agents"
DB00554,Piroxicam,36322-90-4,approved; investigational,QYSPLQLAKJAUJT-UHFFFAOYSA-N,"InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)",c1cccc(c12)C(O)=C(N(S2(=O)=O)C)C(=O)Nc3ncccc3,C15H13N3O4S,C01608,D00127,54676228,46505225,8249,CHEMBL527,,10442653,85245,331.346,0.599883832,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Ophthalmologicals; Other Nonsteroidal Anti-inflammatory Agents; Oxicams; Peripheral Nervous System Agents; Photosensitizing Agents; Sensory Organs; Sensory System Agents; Sulfur Compounds; Thiazines; Topical Products for Joint and Muscular Pain"
DB00555,Lamotrigine,84057-84-1,approved; investigational,PYZRQGJRPPTADH-UHFFFAOYSA-N,"InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)",Nc1nc(N)c(nn1)-c2c(Cl)c(Cl)ccc2,C9H7Cl2N5,,D00354,3878,46505408,6367,CHEMBL741,,3741,50031299,256.091,1.926522189,"Agents causing hyperkalemia; Agents producing tachycardia; Anti-epileptic Agent; Antiarrhythmic agents; Anticholinergic Agents; Anticonvulsants; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Miscellaneous Anticonvulsants; Mood Stabilizer; Muscarinic Antagonists; Nervous System; OCT1 substrates; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Potential QTc-Prolonging Agents; Psychotropic Drugs; QTc Prolonging Agents; Sodium Channel Blockers; Tranquilizing Agents; Triazines; UGT1A1 Inducers; UGT1A1 Substrates; UGT1A3 substrates; UGT1A4 substrates"
DB00556,Perflutren,76-19-7,approved,QYSGYZVSCZSLHT-UHFFFAOYSA-N,"InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11",FC(F)(F)C(F)(F)C(F)(F)F,C3F8,,D01738,6432,46506030,31980,CHEMBL1663,,6192,,188.0193,2.782360132,"Amino Acids, Peptides, and Proteins; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Microspheres; Moderate Risk QTc-Prolonging Agents; Other Diagnostics; Proteins; QTc Prolonging Agents; Ultrasound Contrast Activity; Ultrasound Contrast Media"
DB00557,Hydroxyzine,68-88-2,approved,ZQDWXGKKHFNSQK-UHFFFAOYSA-N,"InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2",OCCOCCN1CCN(CC1)C(c2ccccc2)c3ccc(Cl)cc3,C21H27ClN2O2,C07045,D08054,3658,46508556,5818,CHEMBL896,,3531,22875,374.904,3.412969505,"Anti-Anxiety Agents; Antipruritics; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Diphenylmethane Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine Receptor Antagonists; Miscellaneous Anxiolytics Sedatives and Hypnotics; Nervous System; Neurotransmitter Agents; P-glycoprotein substrates; Piperazines; Potential QTc-Prolonging Agents; Psycholeptics; QTc Prolonging Agents"
DB00558,Zanamivir,139110-80-8,approved; investigational,ARAIBEBZBOPLMB-UFGQHTETSA-N,"InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1",OC[C@@H](O)[C@@H](O)[C@@H]1OC(C(=O)O)=C[C@H](N=C(N)N)[C@H]1NC(=O)C,C12H20N4O7,C08095,D00902,60855,46508581,50663,CHEMBL222813,ZMR,54842,50330326,332.3098,-5.827718904,"Acids, Acyclic; Amidines; Amino Sugars; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Carbohydrates; Carboxylic Acids; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Guanidines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydroxy Acids; Neuraminic Acids; Neuraminidase Inhibitors; Pyrans; Sialic Acids; Sugar Acids"
DB00559,Bosentan,147536-97-8,approved; investigational,GJPICJJJRGTNOD-UHFFFAOYSA-N,"InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)",COc1ccccc1Oc2c(NS(=O)(=O)c3ccc(cc3)C(C)(C)C)nc(-c4ncccn4)nc2OCCO,C27H29N5O6S,,D01227,104865,46507154,51450,CHEMBL957,K86,94651,50061101,551.614,4.941747168,"Amides; Antihypertensive Agents; Antihypertensives for Pulmonary Arterial Hypertension; BSEP/ABCB11 Inhibitors; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (moderate); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Endothelin Receptor Antagonists; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; OATP1B1/SLCO1B1 Substrates; Pyrimidines; Sulfonamides; Sulfones; Sulfur Compounds; Vasodilating Agents"
DB00560,Tigecycline,220620-09-7,approved,FPZLLRFZJZRHSY-HJYUBDRYSA-N,"InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36,38-39,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)cc(c4O)NC(=O)CNC(C)(C)C,C29H39N5O8,C12012,D01079,54686904,46509041,149836,CHEMBL376140,,10482314,50247905,585.6487,-3.871646971,"Agents that produce neuromuscular block (indirect); Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Enzyme Inhibitors; Glycylcyclines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Protein Synthesis Inhibitors; Tetracyclines"
DB00561,Doxapram,309-29-5,approved; vet_approved,XFDJYSQDBULQSI-UHFFFAOYSA-N,"InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3",c1ccccc1C2(c3ccccc3)C(CN(C2=O)CC)CCN4CCOCC4,C24H30N2O2,,D07873,3156,46506829,681848,CHEMBL1754,,3044,,378.5072,3.230592205,"Agents that produce hypertension; Central Nervous System Agents; Central Nervous System Stimulants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Increased Medullary Respiratory Drive; Pyrrolidines; Pyrrolidinones; Respiratory System; Respiratory System Agents"
DB00562,Benzthiazide,91-33-8,approved,NDTSRXAMMQDVSW-UHFFFAOYSA-N,"InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)",NS(=O)(=O)c(c(Cl)c1)cc(c12)S(=O)(=O)NC(=N2)CSCc3ccccc3,C15H14ClN3O4S3,C07759,D00651,2343,46506752,3047,CHEMBL1201039,,2253,50238676,431.937,1.840787008,"Amides; Diuretics; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Sodium Chloride Symporter Inhibitors; Stimulants; Sulfonamides; Sulfones; Sulfur Compounds; Thiazides"
DB00563,Methotrexate,59-05-2,approved,FBOZXECLQNJBKD-ZDUSSCGKSA-N,"InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1",Nc1nc(N)nc(c12)ncc(n2)CN(C)c3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O,C20H22N8O5,C01937,D00142,126941,46507678,44185,CHEMBL34259,MTX,112728,66082,454.4393,-2.346461342,"Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Agents Causing Muscle Toxicity; Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; BCRP/ABCG2 Substrates; Biological Factors; Cardiotoxic antineoplastic agents; CMF chemotherapy regimen; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Dermatologicals; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Folic Acid Analogues; Folic Acid Antagonists; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunologic Factors; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Noxae; Nucleic Acid Synthesis Inhibitors; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; Photosensitizing Agents; Pigments, Biological; Pteridines; Pterins; Reproductive Control Agents; Toxic Actions"
DB00564,Carbamazepine,298-46-4,approved; investigational,FFGPTBGBLSHEPO-UHFFFAOYSA-N,"InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)",c1cccc(c12)C=Cc3c(N2C(=O)N)cccc3,C15H12N2O,C06868,D00252,2554,46507583,3387,CHEMBL108,N6W,2457,50003659,236.2686,2.766030386,"Analgesics; Analgesics, Non-Narcotic; Anticonvulsants; Antimanic Agents; Carboxamide Derivatives; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strong); Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strong); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (moderate); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Inducers (strong); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Dibenzazepines; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inducing Antiepileptic Drugs; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Inducers of Drug Clearance; Membrane Transport Modulators; Miscellaneous Anticonvulsants; Mood Stabilizer; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inducers; P-glycoprotein substrates; Peripheral Nervous System Agents; Psychotropic Drugs; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sodium Channel Blockers; Thyroxine-binding globulin substrates; UGT1A1 Inducers; UGT1A6 inducer; UGT2B7 substrates"
DB00565,Cisatracurium,96946-41-7,approved,YXSLJKQTIDHPOT-LJCJQEJUSA-N,"InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1",COc1ccc(cc1OC)C[C@H]2[N@+](C)(CCc(c23)cc(OC)c(c3)OC)CCC(=O)OCCCCCOC(=O)CC[N@@+](C)(CCc(c45)cc(OC)c(c5)OC)[C@@H]4Cc6cc(OC)c(OC)cc6,C53H72N2O12,,,62886,46506666,140621,CHEMBL1201248,,56615,,929.16,-0.959032062,"Alkaloids; Anticholinergic Agents; Benzylisoquinolines; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular Nondepolarizing Blockade; Neuromuscular-Blocking Agents (Nondepolarizing); Nicotinic Antagonists; Peripheral Nervous System Agents"
DB00566,Succimer,304-55-2,approved,ACTRVOBWPAIOHC-XIXRPRMCSA-N,"InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)/t1-,2+",OC(=O)[C@@H](S)[C@@H](S)C(=O)O,C4H6O4S2,C07598,D00572,2724354,46504680,63623,CHEMBL1201073,,2006502,50232640,182.21,0.258827046,"Acids, Acyclic; Antidotes; Carboxylic Acids; Chelating Agents; Compounds used in a research, industrial, or household setting; Dicarboxylic Acids; Lead Chelating Activity; Lead Chelator; Protective Agents; Sequestering Agents; Succinates; Sulfhydryl Compounds; Sulfur Compounds"
DB00567,Cephalexin,15686-71-2,approved; investigational; vet_approved,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,"InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1",O=C(O)C1=C(C)CS[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccccc3,C16H17N3O4S,C06895,D00263,27447,46506749,3534,CHEMBL1727,,25541,50139896,347.389,-2.142065141,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Aza Compounds; Azabicyclo Compounds; beta-Lactams; Bicyclo Compounds; Bicyclo Compounds, Heterocyclic; Bridged Compounds; Cephalosporins; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; First-Generation Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Lactams; MATE 1 Substrates; MATE substrates; Medications that reduce magnesium levels; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Polycyclic Compounds; Sulfur Compounds; Thiazines"
DB00568,Cinnarizine,298-57-7,approved; investigational,DERZBLKQOCDDDZ-JLHYYAGUSA-N,"InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+",c1ccccc1/C=C/CN2CCN(CC2)C(c3ccccc3)c4ccccc4,C26H28N2,,D01295,2761,46506769,31403,CHEMBL43064,,1264793,50017657,368.5139,5.88039114,"Agents causing hyperkalemia; Antiarrhythmic agents; Antivertigo Preparations; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; Nervous System; Neurotransmitter Agents; Piperazines; QTc Prolonging Agents; Vasodilating Agents"
DB00569,Fondaparinux,104993-28-4,approved; investigational,KANJSNBRCNMZMV-ABRZTLGGSA-N,"InChI=1S/C31H53N3O49S8/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-/m1/s1",CO[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@H](O)[C@H]1NS(=O)(=O)O)O[C@@H]2O[C@@H](C(=O)O)[C@H]([C@H](O)[C@H]2OS(=O)(=O)O)O[C@H]3O[C@H](COS(=O)(=O)O)[C@H]([C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)O[C@@H]4O[C@H](C(=O)O)[C@H]([C@H](O)[C@H]4O)O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O,C31H53N3O49S8,,,49852292,46505595,61033,CHEMBL1201202,NTO,4445600,,1508.263,-10.47980189,Anticoagulants; Antithrombins; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Factor Xa Inhibitors; Fibrin Modulating Agents; Fibrinolytic Agents; Hematologic Agents; Miscellaneous Anticoagulants; Oligosaccharides; Polysaccharides; Protease Inhibitors; Serine Protease Inhibitors
DB00570,Vinblastine,865-21-4,approved,JXLYSJRDGCGARV-CFWMRBGOSA-N,"InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1",C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(c9c([nH]8)cccc9)CCN(C6)C[C@@](O)(C7)CC,C46H58N4O9,,,13342,46504550,,CHEMBL159,VLB,12773,50012278,810.9741,4.183145288,"ABVD chemotherapy regimen; Alkaloids; Antimitotic Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic and Immunomodulating Agents; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; BSEP/ABCB11 Substrates with Narrow Therapeutic Index; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Indole Alkaloids; Indoles; Mitosis Modulators; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Secologanin Tryptamine Alkaloids; Tubulin Modulators; Vinca Alkaloids"
DB00571,Propranolol,525-66-6,approved; investigational,AQHHHDLHHXJYJD-UHFFFAOYSA-N,"InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3",CC(C)NCC(O)COc1cccc(c12)cccc2,C16H21NO2,C07407,D08443,4946,46505387,8499,CHEMBL27,,4777,25761,259.3434,2.583695929,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Non-Selective; Beta Blocking Agents, Non-Selective, and Thiazides; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Moderate Risk QTc-Prolonging Agents; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Naphthalenes; Neurotransmitter Agents; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Phenoxypropanolamines; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Propanolamines; Propanols; QTc Prolonging Agents; Vasodilating Agents"
DB00572,Atropine,51-55-8,approved; vet_approved,RKUNBYITZUJHSG-SPUOUPEWSA-N,"InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16?",CN([C@@H]12)[C@H](CC1)C[C@@H](C2)OC(=O)C(CO)c3ccccc3,C17H23NO3,C01479,D00113,174174,46507540,78734,CHEMBL517712,OIN,10194105,50403547,289.3694,1.571241017,"Adjuvants, Anesthesia; Agents producing tachycardia; Agents that produce hypertension; Alimentary Tract and Metabolism; Alkaloids; Anti-Asthmatic Agents; Antiarrhythmic agents; Anticholinergic Agents; Antimuscarinics Antispasmodics; Atropine Derivatives; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Belladonna Alkaloids; Belladonna Alkaloids, Tertiary Amines; Belladonna and Derivatives, Plain; Bicyclo Compounds, Heterocyclic; Bronchodilator Agents; BSEP/ABCB11 Substrates; Cardiovascular Agents; Central Nervous System Agents; Cholinergic Agents; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Moderate Risk QTc-Prolonging Agents; Muscarinic Antagonists; Mydriatics; Mydriatics and Cycloplegics; Neurotransmitter Agents; Ophthalmologicals; Parasympatholytics; Peripheral Nervous System Agents; QTc Prolonging Agents; Respiratory System Agents; Sensory Organs; Solanaceous Alkaloids; Tropanes"
DB00573,Fenoprofen,29679-58-1,approved,RDJGLLICXDHJDY-UHFFFAOYSA-N,"InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)",OC(=O)C(C)c1cc(ccc1)Oc2ccccc2,C15H14O3,C06997,D00968,3342,46504597,5004,CHEMBL1297,,3225,54705,242.2699,3.654267567,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Arylpropionic acid NSAIDS; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Phenylpropionates; Propionates; Sensory System Agents"
DB00574,Fenfluramine,458-24-2,approved; illicit; investigational; withdrawn,DBGIVFWFUFKIQN-UHFFFAOYSA-N,"InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3",CCNC(C)Cc1cccc(c1)C(F)(F)F,C12H16F3N,C06996,D07945,3337,46506096,5000,CHEMBL87493,,3220,84738,231.2573,3.471487312,"Alimentary Tract and Metabolism; Amines; Antidepressive Agents; Antiobesity Preparations, Excl. Diet Products; Central Nervous System Depressants; Centrally Acting Antiobesity Products; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ethylamines; Membrane Transport Modulators; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Phenethylamines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Agonists; Serotonin Agents; Serotonin Receptor Agonists; Stimulants"
DB00575,Clonidine,4205-90-7,approved,GJSURZIOUXUGAL-UHFFFAOYSA-N,"InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)",Clc1cccc(Cl)c1NC2=NCCN2,C9H9Cl2N3,,D00281,2803,46508119,46632,CHEMBL134,CLU,2701,14062,230.094,2.485088704,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Analgesics; Anesthetics; Anesthetics, General; Antiadrenergic Agents, Centrally Acting; Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Antimigraine Preparations; Autonomic Agents; Azoles; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Central alpha-2 Adrenergic Agonist; Central Alpha-agonists; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Imidazoles; Imidazoline Receptor Agonists; Imidazolines; Narrow Therapeutic Index Drugs; Nervous System; Neurotransmitter Agents; Ophthalmologicals; P-glycoprotein substrates; Peripheral Nervous System Agents; Sensory Organs; Sensory System Agents; Sympatholytics; Sympathomimetics in Glaucoma Therapy"
DB00576,Sulfamethizole,144-82-1,approved; investigational; vet_approved,VACCAVUAMIDAGB-UHFFFAOYSA-N,"InChI=1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)",Cc1nnc(s1)NS(=O)(=O)c2ccc(N)cc2,C9H10N4O2S2,C08050,D00870,5328,46508656,9331,CHEMBL1191,,5137,50295558,270.331,0.214345965,"Amides; Amines; Aniline Compounds; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Azoles; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Irrigating Solutions; Ophthalmologicals; Sensory Organs; Short-Acting Sulfonamides; Sulfanilamides; Sulfathiazoles; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds; Thiazoles"
DB00577,Valaciclovir,124832-26-4,approved; investigational,HDOVUKNUBWVHOX-QMMMGPOBSA-N,"InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1",CC(C)[C@H](N)C(=O)OCCOCn1cnc(c12)c(=O)nc([nH]2)N,C13H20N6O4,C07184,D00398,60773,46508197,35854,CHEMBL1349,TXC,54770,50162073,324.3357,-0.451521167,"Acyclovir and prodrug; Amino Acids; Amino Acids, Branched-Chain; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nephrotoxic agents; Nucleic Acid Synthesis Inhibitors; Nucleosides and Nucleotides; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; OAT3/SLC22A8 Substrates; Prodrugs; Purines; Purinones"
DB00578,Carbenicillin,4697-36-3,approved; investigational,FPPNZSSZRUTDAP-UWFZAAFLSA-N,"InChI=1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)C(C(=O)O)c3ccccc3,C17H18N2O6S,C06869,D07614,20824,46505653,3393,CHEMBL1214,,19599,,378.4,0.81535683,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; OAT1/SLC22A6 inhibitors; Penicillin G; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB00579,Mazindol,22232-71-9,approved; investigational,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,"InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2",Clc1ccc(cc1)C2(O)N(CCN3)C=3c(c24)cccc4,C16H13ClN2O,,D00367,4020,46509094,6702,CHEMBL781,,3880,50005536,284.74,3.435279001,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Alimentary Tract and Metabolism; Anorexigenic Agents & Respiratory and Cerebral Stimulants, Miscellaneous; Anorexigenic Agents & Respiratory and CNS Stimulants; Antidepressive Agents; Antiobesity Preparations, Excl. Diet Products; Central Nervous System Agents; Central Nervous System Depressants; Central Nervous System Stimulants; Centrally Acting Antiobesity Products; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Dopamine Agents; Dopamine Uptake Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoindoles; Membrane Transport Modulators; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB00580,Valdecoxib,181695-72-7,approved; investigational; withdrawn,LNPDTQAFDNKSHK-UHFFFAOYSA-N,"InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)",O=S(=O)(N)c1ccc(cc1)-c2c(C)onc2-c3ccccc3,C16H14N2O3S,,,119607,46506229,63634,CHEMBL865,COX,106796,13063,314.359,2.823684358,"Agents causing hyperkalemia; Agents that produce hypertension; Amides; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Azoles; Central Nervous System Agents; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Peripheral Nervous System Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents; Sulfones; Sulfur Compounds; UGT1A9 Substrates"
DB00581,Lactulose,4618-18-2,approved,JCQLYHFGKNRPGE-FCVZTGTOSA-N,"InChI=1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12-/m1/s1",OC[C@@]1(O)O[C@H](CO)[C@H]([C@@H]1O)O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O,C12H22O11,C07064,D00352,11333,46506757,6359,CHEMBL296306,W9T,10856,50377984,342.2965,-4.528834964,Acidifying Activity; Alimentary Tract and Metabolism; Ammonia Detoxicants; Carbohydrates; Disaccharides; Drugs for Constipation; Gastrointestinal Agents; Laxatives; Osmotic Activity; Osmotic Laxatives; Stimulation Large Intestine Fluid/Electrolyte Secretion
DB00582,Voriconazole,137234-62-9,approved,BCEHBSKCWLPMDN-MGPLVRAMSA-N,"InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1",c1ncnn1C[C@](O)(c2c(F)cc(F)cc2)[C@@H](C)c3ncncc3F,C16H14F3N5O,C07622,D00578,71616,46506421,10023,CHEMBL638,VOR,64684,50333117,349.3105,1.823032592,"14-alpha Demethylase Inhibitors; Anti-Infective Agents; Antifungal Agents; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; Azole Antifungals; Azoles; Chemically-Induced Disorders; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (moderate); Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (moderate); Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Metabolic Side Effects of Drugs and Substances; Photosensitizing Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Steroid Synthesis Inhibitors; Triazole Derivatives; Triazoles"
DB00583,Levocarnitine,541-15-1,approved; investigational,PHIQHXFUZVPYII-ZCFIWIBFSA-N,"InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1",C[N+](C)(C)C[C@H](O)CC([O-])=O,C7H15NO3,C00318,D02176,10917,46505864,16347,CHEMBL1149,,10455,50037268,161.1989,-4.887506048,Alimentary Tract and Metabolism; Amines; Amino Acids and Derivatives; Ammonium Compounds; Caloric Agents; Carnitine Analog; Dietary Supplements; Drugs that are Mainly Renally Excreted; Nitrogen Compounds; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inhibitors; Onium Compounds; Quaternary Ammonium Compounds; Trimethyl Ammonium Compounds; Vitamin B Complex; Vitamins
DB00584,Enalapril,75847-73-3,approved; vet_approved,GBXSMTUPTTWBMN-XIRDDKMYSA-N,"InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1",c1ccccc1CC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O,C20H28N2O5,C06977,D07892,5388962,46507920,4784,CHEMBL578,,4534998,50017129,376.4467,0.587776603,"ACE Inhibitors and Calcium Channel Blockers; ACE Inhibitors and Diuretics; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Agents Causing Muscle Toxicity; Amino Acids, Peptides, and Proteins; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Decreased Blood Pressure; Dipeptides; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Hypotensive Agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Substrates; Oligopeptides; P-glycoprotein inhibitors; Peptides; Photosensitizing Agents; Protease Inhibitors"
DB00585,Nizatidine,76963-41-2,approved,SGXXNSQHWDMGGP-UHFFFAOYSA-N,"InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3",[O-][N+](=O)/C=C(\NC)NCCSCc1csc(n1)CN(C)C,C12H21N5O2S2,C07270,D00440,3033637,46507554,7601,CHEMBL3183075,,4356,,331.45,0.772313353,"Acid Reducers; Agents Causing Muscle Toxicity; Alimentary Tract and Metabolism; Anti-Ulcer Agents; Azoles; Cholinesterase Inhibitors; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Gastric Acid Lowering Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H2 Antagonists; Medications that reduce magnesium levels; Neurotransmitter Agents; P-glycoprotein substrates; Sulfur Compounds; Thiazoles"
DB00586,Diclofenac,15307-86-5,approved; vet_approved,DCOPUUMXTXDBNB-UHFFFAOYSA-N,"InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)",OC(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl,C14H11Cl2NO2,C01690,D07816,3033,46504644,47381,CHEMBL139,DIF,2925,13066,296.149,4.259009233,"Acetic Acid Derivatives and Related Substances; Acids, Carbocyclic; Agents causing angioedema; Agents causing hyperkalemia; Agents that produce hypertension; Amines; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antimigraine Agents, Miscellaneous; Antirheumatic Agents; BSEP/ABCB11 Substrates; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cyclooxygenase-2 (COX-2) Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Prostaglandin Production; Dermatologicals; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Ethylamines; Heteroaryl acetic acid NSAIDS; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; Ophthalmologicals; Other Nonsteroidal Anti-inflammatory Agents; P-glycoprotein inducers; Peripheral Nervous System Agents; Phenylacetates; Photosensitizing Agents; Sensory Organs; Sensory System Agents; Topical Products for Joint and Muscular Pain; UGT1A1 Substrates; UGT1A3 substrates; UGT1A9 Substrates; UGT2B7 substrates"
DB00588,Fluticasone propionate,80474-14-2,approved,WMWTYOKRWGGJOA-CENSZEJFSA-N,"InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1",CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4,C25H31F3O5S,,D01708,444036,46506140,31441,CHEMBL1473,,392059,50354849,500.571,3.718004616,"Adrenal Cortex Hormones; Adrenals; Agents to Treat Airway Disease; Androstadienes; Androstanes; Androstenes; Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Autonomic Agents; Bronchodilator Agents; Central Nervous System Depressants; Corticosteroids; Corticosteroids for inhalation use; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Immunosuppressive Agents; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Polycyclic Compounds; Respiratory System Agents; Steroids; Thyroxine-binding globulin inhibitors"
DB00589,Lisuride,18016-80-3,approved; investigational,BKRGVLQUQGGVSM-KBXCAEBGSA-N,"InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1",CCN(CC)C(=O)N[C@@H](C=1)CN(C)[C@@H](C12)Cc3c4c2cccc4[nH]c3,C20H26N4O,,D08132,28864,46505557,51164,CHEMBL157138,H8G,26847,50056445,338.4466,2.169228714,"Agents that produce hypertension; Alkaloids; Analgesics; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Antidepressive Agents; Antimigraine Preparations; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Ergolines; Ergot Alkaloids and Derivatives; Ergot-derivative Dopamine Receptor Agonists; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotransmitter Agents; Prolactine Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Serotonin Receptor Antagonists"
DB00590,Doxazosin,74191-85-8,approved,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,"InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)",COc(c1)c(OC)cc(c12)c(N)nc(n2)N3CCN(CC3)C(=O)C(O4)COc(c45)cccc5,C23H25N5O5,C06970,D07874,3157,46506825,4708,CHEMBL707,,3045,86731,451.4751,2.135759032,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Antiadrenergic Agents, Peripherally Acting; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Neurotransmitter Agents; OCT1 inhibitors; P-glycoprotein inhibitors; Peripheral alpha-1 blockers; Quinazolines"
DB00591,Fluocinolone acetonide,67-73-2,approved; investigational; vet_approved,FEBLZLNTKCEFIT-VSXGLTOVSA-N,"InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1",OCC(=O)[C@]12[C@H](OC(O1)(C)C)C[C@@H]3[C@]2(C)C[C@H](O)[C@@]4(F)[C@H]3C[C@H](F)C=5[C@]4(C)C=CC(=O)C5,C24H30F2O6,,D01825,6215,46506244,31623,CHEMBL989,,5980,,452.4882,1.604398569,"Adrenal Cortex Hormones; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Ophthalmologicals; Otologicals; Polycyclic Compounds; Pregnadienes; Pregnanes; Steroids; Steroids, Fluorinated; Vasoprotectives"
DB00592,Piperazine,110-85-0,approved; vet_approved,GLUUGHFHXGJENI-UHFFFAOYSA-N,"InChI=1S/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2",C1CNCCN1,C4H10N2,C07973,D00807,4837,46507642,28568,CHEMBL1412,PZE,13835459,,86.1356,-0.72880683,"Anthelmintics; Anti-Infective Agents; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hyperglycemia-Associated Agents; Piperazine and Derivatives; Piperazines"
DB00593,Ethosuximide,77-67-8,approved,HAPOVYFOVVWLRS-UHFFFAOYSA-N,"InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)",CCC1(C)CC(=O)NC1=O,C7H11NO2,C07505,D00539,3291,46507617,4887,CHEMBL696,,3175,50240424,141.1677,0.550097684,"Agents causing hyperkalemia; Anti-epileptic Agent; Antiarrhythmic agents; Anticonvulsants; Bradycardia-Causing Agents; Calcium Channel Blockers; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imides; Nervous System; Potential QTc-Prolonging Agents; Pyrrolidines; Pyrrolidinones; QTc Prolonging Agents; Succinimide Derivatives; Succinimides"
DB00594,Amiloride,2609-46-3,approved,XSDQTOBWRPYKKA-UHFFFAOYSA-N,"InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)",NC(=N)NC(=O)c1nc(Cl)c(N)nc1N,C6H8ClN7O,C06821,D07447,16231,46508156,2639,CHEMBL945,AMR,15403,16173,229.627,-0.495432461,"Acid Sensing Ion Channel Blockers; Agents causing hyperkalemia; Cardiovascular Agents; Cardiovascular System; Decreased Renal K+ Excretion; Diuretics; Epithelial Sodium Channel Blockers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Increased Diuresis; Membrane Transport Modulators; Natriuretic Agents; OCT2 Inhibitors; Potassium-Sparing Diuretics; Pyrazines; Sodium Channel Blockers"
DB00595,Oxytetracycline,79-57-2,approved; investigational; vet_approved,IWVCMVBTMGNXQD-PXOLEDIWSA-N,"InChI=1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,12-14,17,25,27-29,32-33H,1-3H3,(H2,23,31)/t12-,13-,14+,17+,21-,22+/m1/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)[C@@H](O)[C@H]3C(=C2O)C(=O)c4c([C@@]3(C)O)cccc4O,C22H24N2O9,C06624,,54675779,46507025,27701,CHEMBL1517,OTC,10482174,,460.434,-4.501348973,"Agents that produce neuromuscular block (indirect); Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Topical Use; Antiinfectives for Systemic Use; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Ophthalmologicals; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory Organs; Tetracyclines"
DB00596,Ulobetasol,98651-66-2,approved,LEHFPXVYPMWYQD-XHIJKXOTSA-N,"InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1",ClCC(=O)[C@@]1(O)[C@@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4,C22H27ClF2O4,,,5311167,46506187,,CHEMBL1201360,,4470691,,428.9,2.696442243,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Cardiovascular Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Dermatologicals; Fused-Ring Compounds; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Psoriasis; Steroids; Steroids, Fluorinated; Vasoconstrictor Agents"
DB00597,Gadoteridol,120066-54-8,approved; investigational,DPNNNPAKRZOSMO-UHFFFAOYSA-K,"InChI=1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3",CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,C17H29GdN4O7,,D01137,60714,46505738,31643,CHEMBL1200593,,54719,,558.68,-7.548479817,"Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Elements; Lanthanoid Series Elements; Magnetic Resonance Contrast Activity; Magnetic Resonance Imaging Contrast Media; Metals; Metals, Rare Earth; Other Diagnostics; Paramagnetic Contrast Agent; Paramagnetic Contrast Media"
DB00598,Labetalol,36894-69-6,approved,SGUAFYQXFOLMHL-UHFFFAOYSA-N,"InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)",c1ccccc1CCC(C)NCC(O)c2cc(C(=O)N)c(O)cc2,C19H24N2O3,C07063,D08106,3869,46505511,6343,CHEMBL429,,3734,25758,328.4055,1.886505184,Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Agents producing tachycardia; Alcohols; Alpha and Beta Blocking Agents; Alpha and Beta Blocking Agents and Thiazides; Amides; Amines; Amino Alcohols; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Autonomic Agents; Beta Blocking Agents and Thiazides; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Ethanolamines; Hypotensive Agents; Neurotransmitter Agents; Peripheral alpha-1 blockers; Peripheral Nervous System Agents; Salicylamides; Sympathomimetics; UGT1A1 Substrates; UGT1A9 Substrates; UGT2B7 substrates; Vasodilating Agents
DB00599,Thiopental,76-75-5,approved; vet_approved,IUJDSEJGGMCXSG-UHFFFAOYSA-N,"InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)",CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,C11H18N2O2S,C07521,,3000715,46504621,102166,CHEMBL441,,2272258,50058058,242.338,2.783120831,"Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Anticholinergic Agents; Anticonvulsants; Barbiturates; Barbiturates, Plain; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Hypotensive Agents; Narrow Therapeutic Index Drugs; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; Psycholeptics; Pyrimidines; Pyrimidinones; Thiobarbiturates"
DB00600,Monobenzone,103-16-2,approved,VYQNWZOUAUKGHI-UHFFFAOYSA-N,"InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2",Oc1ccc(cc1)OCc2ccccc2,C13H12O2,C14244,D05072,7638,46507466,34380,CHEMBL1388,,7356,50410520,200.2332,3.236482346,"alpha-Galactosidase, antagonists & inhibitors; Benzene Derivatives; Depigmenting Activity; Depigmenting Agents; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Melanin Synthesis Inhibitors; Phenols"
DB00601,Linezolid,165800-03-3,approved; investigational,TYZROVQLWOKYKF-ZDUSSCGKSA-N,"InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1",CC(=O)NC[C@H]1CN(C(=O)O1)c2cc(F)c(cc2)N3CCOCC3,C16H20FN3O4,C08146,D00947,441401,46504452,63607,CHEMBL126,ZLD,390139,50116067,337.3461,0.636663652,"Acetamides; Acetates; Acids, Acyclic; Agents that produce hypertension; Agents that reduce seizure threshold; Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antidepressive Agents; Antiinfectives for Systemic Use; Azoles; Carboxylic Acids; Central Nervous System Depressants; Enzyme Inhibitors; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Lipids; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Monoamine Oxidase Inhibitors; Myelosuppressive Agents; Oxazoles; Oxazolidinone Antibacterial; Oxazolidinones; Protein Synthesis Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB00602,Ivermectin,70288-86-7,approved; investigational; vet_approved,SPBDXSGPUHCETR-CVSKBELMSA-N,"InChI=1S/C48H74O14.C47H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38;1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3;11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b13-12+,27-15+,32-14+;12-11+,26-14+,31-13+/t25-,26+,28+,30+,31+,33-,34+,35+,36+,37+,38+,39+,40-,41+,42+,43-,44+,45-,47-,48-;25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m10/s1",CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@@H]2[C@@H](OC)C[C@@H](O[C@H]2C)O[C@H](/C(C)=C/C[C@H]3O[C@@]45O[C@H]([C@H](C)CC)[C@@H](C)CC4)[C@@H](C)/C=C/C=C6/[C@]7(O)[C@H](OC6)[C@H](O)C(C)=C[C@H]7C(=O)O[C@@H](C3)C5,C95H146O28,C07970,D00804,46936176,46506810,,CHEMBL1200633,,30776735,,1736.1589,5.825745656,"Agents Causing Muscle Toxicity; Agrochemicals; Anthelmintics; Anti-Bacterial Agents; Anti-Infective Agents; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Avermectines; BCRP/ABCG2 Substrates; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Insecticides; Lactones; Macrocyclic Compounds; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Pediculicides; Pesticides; Polycyclic Compounds; Polyketides; Scabicides and Pediculicides; Toxic Actions"
DB00603,Medroxyprogesterone acetate,71-58-9,approved; investigational,PSGAAPLEWMOORI-PEINSRQWSA-N,"InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1",CC(=O)O[C@]1(C(=O)C)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C([C@H](C3)C)=CC(=O)CC4,C24H34O4,C08150,D00951,6279,46508895,6716,CHEMBL717,,6043,50067678,386.5244,4.129323784,"Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptive Agents, Male; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Corpus Luteum Hormones; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Endocrine Therapy; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydroxyprogesterones; Hyperglycemia-Associated Agents; P-glycoprotein inhibitors; Polycyclic Compounds; Pregnanes; Pregnen (4) Derivatives; Pregnenediones; Pregnenes; Progesterone and Derivatives; Progesterone Congeners; Progestin Contraceptives; Progestins; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB00604,Cisapride,81098-60-4,approved; investigational; withdrawn,DCSUBABJRXZOMT-IRLDBZIGSA-N,"InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1",Fc1ccc(cc1)OCCCN2C[C@H](OC)[C@@H](CC2)NC(=O)c3cc(Cl)c(N)cc3OC,C23H29ClFN3O4,C06910,D00274,6917698,46504980,3720,CHEMBL560739,,5292927,50005836,465.945,2.491358865,"Acids, Carbocyclic; Alimentary Tract and Metabolism; Amides; Aminobenzoates; Anti-Ulcer Agents; Antidepressive Agents; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Depressants; Chlorobenzoates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (moderate); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Functional Gastrointestinal Disorders; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; para-Aminobenzoates; Piperidines; Propulsives; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Receptor Agonists"
DB00605,Sulindac,38194-50-2,approved; investigational,MLKXDPUZXIRXEP-MFOYZWKCSA-N,"InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-",c1cc(F)cc(c12)C(CC(=O)O)=C(C)/C2=C/c3ccc(cc3)S(=O)C,C20H17FO3S,C01531,D00120,1548887,46506570,9352,CHEMBL15770,,1265915,50012899,356.411,2.926154638,"Acetic Acid Derivatives and Related Substances; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Central Nervous System Agents; Cyclooxygenase Inhibitors; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indenes; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; Other Nonsteroidal Anti-inflammatory Agents; Peripheral Nervous System Agents; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents"
DB00606,Cyclothiazide,2259-96-3,approved,BOCUKUHCLICSIY-UHFFFAOYSA-N,"InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)",NS(=O)(=O)c(c1)c(Cl)cc(c12)NC(NS2(=O)=O)C(CC34)C(C3)C=C4,C14H16ClN3O4S2,C12685,D01256,2910,46508269,31448,CHEMBL61593,CYZ,2807,50192229,389.878,0.943913855,"Amides; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular System; Diuretics; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Natriuretic Agents; OAT1/SLC22A6 inhibitors; Receptors, AMPA; Sulfonamides; Sulfones; Sulfur Compounds; Thiazides"
DB00607,Nafcillin,147-52-4,approved; investigational,GPXLMGHLHQJAGZ-JTDSTZFVSA-N,"InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)c3c(OCC)ccc(c34)cccc4,C21H22N2O5S,C07250,D08242,8982,46508100,7447,CHEMBL1443,NFN,8634,50103525,414.475,2.289126017,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; Beta-Lactamase Resistant Penicillins; beta-Lactams; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (moderate); Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; OAT1/SLC22A6 inhibitors; Penicillins; Sulfur Compounds"
DB00608,Chloroquine,54-05-7,approved; investigational; vet_approved,WHTVZRBIWZFKQO-UHFFFAOYSA-N,"InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)",CCN(CC)CCCC(C)Nc1ccnc(c12)cc(Cl)cc2,C18H26ClN3,C07625,D02366,2719,46506925,3638,CHEMBL76,CLQ,2618,22985,319.872,3.933881141,"Agents Causing Muscle Toxicity; Agents that produce neuromuscular block (indirect); Agents that reduce seizure threshold; alpha-Galactosidase, antagonists & inhibitors; Amebicides; Aminoquinolines; Analgesics; Analgesics, Non-Narcotic; Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Antirheumatic Agents; Central Nervous System Agents; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Experimental Unapproved Treatments for COVID-19; Filaricides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Methemoglobinemia Associated Agents; Moderate Risk QTc-Prolonging Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Photosensitizing Agents; QTc Prolonging Agents; Quinolines; Sensory System Agents"
DB00609,Ethionamide,536-33-4,approved,AEOCXXJPGCBFJA-UHFFFAOYSA-N,"InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)",CCc1nccc(c1)C(=S)N,C8H10N2S,C07665,D00591,2761171,46506077,4885,CHEMBL1441,,2041901,50239976,166.243,1.327989284,"Acids, Heterocyclic; Agents that modify thyroid function; Anti-Bacterial Agents; Anti-Infective Agents; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Drugs causing inadvertant photosensitivity; Drugs for Treatment of Tuberculosis; Fatty Acid Synthesis Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypolipidemic Agents; Isonicotinic Acids; Lipid Regulating Agents; Noxae; Photosensitizing Agents; Pyridines; Thiocarbamide Derivatives; Toxic Actions"
DB00610,Metaraminol,54-49-9,approved; investigational,WXFIGDLSSYIKKV-RCOVLWMOSA-N,"InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1",C[C@H](N)[C@H](O)c1cc(O)ccc1,C9H13NO2,C07146,,5906,46505593,6794,CHEMBL1201319,,5695,50239972,167.205,-0.045079757,Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Autonomic Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Neurotransmitter Agents; Peripheral Nervous System Agents; Propanolamines; Propanols; Sympathomimetics; Vasoconstrictor Agents
DB00611,Butorphanol,42408-82-2,approved; illicit; vet_approved,IFKLAQQSCNILHL-QHAWAJNXSA-N,"InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1",C1CCC1CN(CC2)[C@@H]([C@]([C@]234)(O)CCCC3)Cc5c4cc(O)cc5,C21H29NO2,C06863,D00837,6916249,46507553,3242,CHEMBL33986,,16735714,50240437,327.4605,2.890329292,"Alkaloids; Analgesics; Antitussive Agents; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Mixed Agonist / Antagonist Opioids; Morphinan Derivatives; Morphinans; Narcotics; Nervous System; Opiate Alkaloids; Opiate Partial Agonists; Opioid Agonist/Antagonist; Opioid Antagonists; Opioids; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Respiratory System Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00612,Bisoprolol,66722-44-9,approved,VHYCDWMUTMEGQY-UHFFFAOYSA-N,"InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3",CC(C)NCC(O)COc1ccc(cc1)COCCOC(C)C,C18H31NO4,C06852,D02342,2405,46508844,3127,CHEMBL645,,2312,25751,325.443,2.19640338,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Autonomic Agents; Beta blocking agents and calcium channel blockers; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Selective; Beta Blocking Agents, Selective, and Thiazides; Beta-Blockers (Beta1 Selective); Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hypotensive Agents; Neurotransmitter Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Phenoxypropanolamines; Propanolamines; Propanols; Sympatholytics"
DB00613,Amodiaquine,86-42-0,approved; investigational,OVCDSSHSILBFBN-UHFFFAOYSA-N,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)",CCN(CC)Cc1c(O)ccc(c1)Nc(ccn2)c(c23)ccc(Cl)c3,C20H22ClN3O,C07626,D02922,2165,46506940,2674,CHEMBL682,CQA,2080,50041457,355.861,3.763005737,"Aminoquinolines; Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines"
DB00615,Rifabutin,72559-06-9,approved; investigational,ATEBXHFBFRCZMA-VXTBVIBXSA-N,"InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1",CC(C)CN(CC1)CCC12N=C3c4c5c6c(C)c(O)c4C(=O)C(=C3N2)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)C)[C@H](C)[C@@H](OC)/C=C/O[C@](O6)(C)C5=O,C46H62N4O11,C07235,D00424,6323490,46506468,45367,CHEMBL444633,RBT,10482168,50237607,847.0047,4.186444051,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (weak); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (moderate); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (weak); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs for Treatment of Tuberculosis; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Lactams, Macrocyclic; Macrocyclic Compounds; P-glycoprotein inducers; Polycyclic Compounds; Rifamycin Antimycobacterial; Rifamycins"
DB00617,Paramethadione,115-67-3,approved,VQASKUSHBVDKGU-UHFFFAOYSA-N,"InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3",CCC1(C)OC(=O)N(C)C1=O,C7H11NO3,C07411,D00495,8280,46509173,7921,CHEMBL1100,,7979,,157.1671,1.026668725,"Anticonvulsants; Azoles; Central Nervous System Depressants; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Oxazolidine Derivatives"
DB00618,Demeclocycline,127-33-3,approved,FMTDIUIBLCQGJB-SEYHBJAFSA-N,"InChI=1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-26,28-29,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1",NC(=O)C(C1=O)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c([C@H]3O)c(Cl)ccc4O,C21H21ClN2O8,,D00290,54680690,46506314,4392,CHEMBL1591,,10482117,,464.853,-3.234198233,"Agents that produce neuromuscular block (indirect); Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Topical Use; Antiinfectives for Systemic Use; Dermatologicals; Drugs causing inadvertant photosensitivity; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Tetracyclines"
DB00619,Imatinib,152459-95-5,approved,KTUFNOKKBVMGRW-UHFFFAOYSA-N,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",CN1CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cc(c(C)cc3)Nc4nccc(n4)-c5cnccc5,C29H31N7O,,D01441,5291,46505055,45783,CHEMBL941,STI,5101,13530,493.6027,4.377673055,"Acids, Carbocyclic; Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; BSEP/ABCB11 Substrates; Carboxylic Acids; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; OCT1 substrates; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Piperazines; Protein Kinase Inhibitors; Pyrimidines; QTc Prolonging Agents; Tyrosine Kinase Inhibitors"
DB00620,Triamcinolone,124-94-7,approved; vet_approved,GFNANZIMVAIWHM-OBYCQNJPSA-N,"InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1",OCC(=O)[C@@]1(O)[C@H](O)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)C=C4,C21H27FO6,,D00385,31307,46507950,9667,CHEMBL1451,,29046,41132,394.4339,0.241693246,"Adrenal Cortex Hormones; Adrenals; Agents Causing Muscle Toxicity; Agents to Treat Airway Disease; Alimentary Tract and Metabolism; Anti-Inflammatory Agents; Cardiovascular System; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids for Local Oral Treatment; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Corticosteroids, Dermatological Preparations; Corticosteroids, Moderately Potent (Group II); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP3A7 Inducers (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Drugs for Obstructive Airway Diseases; Enzyme Inhibitors; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunologic Factors; Immunosuppressive Agents; Medications that reduce magnesium levels; Nasal Preparations; Ophthalmologicals; Polycyclic Compounds; Pregnadienes; Pregnanes; Protein-Lysine 6-Oxidase, antagonists & inhibitors; Respiratory System; Sensory Organs; Steroids; Steroids, Fluorinated; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroxine-binding globulin inhibitors; Vasoprotectives"
DB00621,Oxandrolone,53-39-4,approved; investigational,QSLJIVKCVHQPLV-PEMPUTJUSA-N,"InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1",C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)[C@@H](CC3)CC(=O)OC4,C19H30O3,C07346,D00462,5878,46509027,7820,CHEMBL1200436,,5667,,306.4397,2.953667467,"Alimentary Tract and Metabolism; Anabolic Agents; Anabolic Agents for Systemic Use; Anabolic Steroids; Androgens; Androstan Derivatives; Androstanes; Androstanols; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroids; Thyroxine-binding globulin inhibitors"
DB00622,Nicardipine,55985-32-5,approved; investigational,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,"InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3",COC(=O)C1=C(C)NC(C)=C(C1c2cc([N+]([O-])=O)ccc2)C(=O)OCCN(C)Cc3ccccc3,C26H29N3O6,C07264,,4474,46504482,7550,CHEMBL1484,,4319,50101815,479.525,3.558611921,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents causing hyperkalemia; Agents producing tachycardia; Antiarrhythmic agents; Anticholinergic Agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Bradycardia-Causing Agents; BSEP/ABCB11 Substrates; Calcium Channel Blockers; Calcium Channel Blockers (Dihydropyridine); Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Dihydropyridines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; Muscarinic Antagonists; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB00623,Fluphenazine,69-23-8,approved,PLDUPXSUYLZYBN-UHFFFAOYSA-N,"InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2",OCCN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(c4)C(F)(F)F,C22H26F3N3OS,C07010,D07977,3372,46506645,5123,CHEMBL726,,3255,78433,437.522,3.965821615,"Agents that reduce seizure threshold; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Delayed-Action Preparations; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; Phenothiazines; Phenothiazines With Piperazine Structure; Photosensitizing Agents; Prodrugs; Psycholeptics; Psychotropic Drugs; Sulfur Compounds; Tranquilizing Agents"
DB00624,Testosterone,58-22-0,approved; investigational,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,"InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1",O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=CC(=O)CC4,C19H28O2,C00535,D00075,6013,46505691,17347,CHEMBL386630,TES,5791,8885,288.4244,3.365423298,"3-Oxoandrosten (4) Derivatives; Androgens; Androgens and Estrogens; Androstanes; Androstenes; Androstenols; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OAT3/SLC22A8 Inducers; OATP1B3 substrates; P-glycoprotein inhibitors; Polycyclic Compounds; Sex Hormones and Modulators of the Genital System; Steroids; Testosterone and derivatives; Testosterone Congeners; Thyroxine-binding globulin inhibitors"
DB00625,Efavirenz,154598-52-4,approved; investigational,XPOQHMRABVBWPR-ZDUSSCGKSA-N,"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1",C1CC1C#C[C@]2(C(F)(F)F)OC(=O)Nc(c23)ccc(Cl)c3,C14H9ClF3NO2,C08088,D00896,64139,46506827,119486,CHEMBL223228,EFZ,57715,2483,315.675,4.456526316,"Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BSEP/ABCB11 Substrates; Central Nervous System Depressants; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (moderate); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (moderate); Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP3A7 Inducers (moderate); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Inducers of Drug Clearance; Metabolic Side Effects of Drugs and Substances; Moderate Risk QTc-Prolonging Agents; Non-Nucleoside Reverse Transcriptase Inhibitors; Nonnucleoside Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; OCT1 inhibitors; Oxazines; QTc Prolonging Agents; Reverse Transcriptase Inhibitors; UGT1A1 Inducers"
DB00626,Bacitracin,1405-87-4,approved; vet_approved,CLKOFPXJLQSYAH-ABRJDSQDSA-N,"InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1",CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](NC2=O)CCCN,C66H103N17O16S,C15482,D00128,10909430,46504727,35862,CHEMBL1200558,,9084687,,1422.693,-6.837519879,"Acids, Carbocyclic; Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Antibacterials for Systemic Use; Antibiotics for Topical Use; Antiinfectives for Systemic Use; Bacitracins; Benzene Derivatives; Benzoates; Carboxylic Acids; Decreased Cell Wall Synthesis & Repair; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Macrocyclic Compounds; Nephrotoxic agents; Peptides; Peptides, Cyclic; Phenols; Polycyclic Compounds; Respiratory System; Throat Preparations"
DB00627,Niacin,59-67-6,approved; investigational; nutraceutical,PVNIIMVLHYAWGP-UHFFFAOYSA-N,"InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)",OC(=O)c1cnccc1,C6H5NO2,C00253,D00049,938,46507508,15940,CHEMBL573,NIO,913,23515,123.1094,-0.166445648,"Acids, Heterocyclic; Agents Causing Muscle Toxicity; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hyperglycemia-Associated Agents; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Micronutrients; Miscellaneous Antilipemic Agents; Nicotinic Acid and Derivatives; Nicotinic Acids; Noxae; Peripheral Vasodilators; Physiological Phenomena; Pyridines; Thyroxine-binding globulin inhibitors; Toxic Actions; Vasodilating Agents; Vitamin B Complex; Vitamins"
DB00628,Clorazepic acid,23887-31-2,approved; illicit,XDDJGVMJFWAHJX-UHFFFAOYSA-N,"InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)",c1cc(Cl)cc(c12)C(=NC(C(=O)N2)C(=O)O)c3ccccc3,C16H11ClN2O3,C06921,D00694,2809,46506595,3761,CHEMBL1213252,,2707,,314.723,3.20633853,"Anti-Anxiety Agents; Anticonvulsants; Benzazepines; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; Psychotropic Drugs; Tranquilizing Agents"
DB00629,Guanabenz,5051-62-7,approved; investigational,WDZVGELJXXEGPV-YIXHJXPBSA-N,"InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+",NC(N)=N/N=C/c1c(Cl)cccc1Cl,C8H8Cl2N4,C07034,D04375,3517,46505200,5553,CHEMBL420,,4642445,50225293,231.082,1.713098971,Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Amidines; Antihypertensive Agents; Cardiovascular Agents; Central alpha-2 Adrenergic Agonist; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Guanidines; Neurotransmitter Agents
DB00630,Alendronic acid,66376-36-1,approved,OGSPWJRAVKPPFI-UHFFFAOYSA-N,"InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)",NCCCC(O)(P(=O)(O)O)P(=O)(O)O,C4H13NO7P2,C07752,,2088,46507199,2567,CHEMBL870,212,2004,25313,249.096,-4.190998027,Agents Causing Muscle Toxicity; Bisphosphonates; Bone Density Conservation Agents; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Musculo-Skeletal System; Organophosphonates; Organophosphorus Compounds
DB00631,Clofarabine,123318-82-1,approved; investigational,WDDPHFBMKLOVOX-AYQXTPAHSA-N,"InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1",F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1n2cnc(c23)c(N)nc(n3)Cl,C10H11ClFN5O3,,,119182,46504968,681569,CHEMBL1750,CFB,106472,,303.677,-0.291321752,"Adenine Nucleotides; Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Arabinonucleosides; BCRP/ABCG2 Substrates; Carbohydrates; Drugs that are Mainly Renally Excreted; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Metabolic Inhibitor; Nucleosides; Nucleotides; OAT3/SLC22A8 Substrates; OAT3/SLC22A8 Substrates with Narrow Therapeutic Index; OCT2 substrates with narrow therapeutic index; Purine Analogues; Purine Nucleotides; Purines; Ribonucleotides; Toxic Actions"
DB00632,Docosanol,661-19-8,approved; investigational,NOPFSRXAKWQILS-UHFFFAOYSA-N,"InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3",CCCCCCCCCCCCCCCCCCCCCCO,C22H46O,,,12620,46508049,31000,CHEMBL1200453,,12100,50239998,326.6,8.807557916,Alcohols; Anti-Infective Agents; Antiviral Agents; Dermatologicals; Lipids
DB00633,Dexmedetomidine,113775-47-6,approved; vet_approved,CUHVIMMYOGQXCV-NSHDSACASA-N,"InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1",c1[nH]cnc1[C@@H](C)c2c(C)c(C)ccc2,C13H16N2,C07450,D00514,5311068,46507406,4466,CHEMBL778,CZX,4470605,50085683,200.2795,3.390314839,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anesthetics; Anesthetics, General; Azoles; Bradycardia-Causing Agents; Central alpha-2 Adrenergic Agonist; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Hypotensive Agents; Imidazoles; Miscellaneous Anxiolytics Sedatives and Hypnotics; Nervous System; Neurotransmitter Agents; Peripheral Nervous System Agents; Psycholeptics; Sensory System Agents"
DB00634,Sulfacetamide,144-80-9,approved,SKIVFJLNDNKQPD-UHFFFAOYSA-N,"InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)",CC(=O)NS(=O)(=O)c1ccc(N)cc1,C8H10N2O3S,,D05947,5320,46504544,63845,CHEMBL455,,5129,50316126,214.242,-0.261041063,"Amides; Amines; Aniline Compounds; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Anti-Infective Agents, Urinary; Antiinfectives for Treatment of Acne; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Ophthalmologicals; Renal Agents; Sensory Organs; Sulfanilamides; Sulfonamide Antibacterial; Sulfonamides; Sulfones; Sulfur Compounds"
DB00635,Prednisone,53-03-2,approved; vet_approved,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,"InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1",OCC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](C(=O)C2)[C@]4(C)C(CC3)=CC(=O)C=C4,C21H26O5,C07370,D00473,5865,46508166,8382,CHEMBL635,PDN,5656,,358.4281,1.658504178,"Adrenal Cortex Hormones; Adrenals; Alimentary Tract and Metabolism; Anti-Inflammatory Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; BEACOPP chemotherapy regimen; CHOP chemotherapy regimen; CHOP-R chemotherapy regimen; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids Acting Locally; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Intestinal Antiinflammatory Agents; Medications that reduce magnesium levels; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Prednisolone and Prodrugs; Pregnadienediols; Pregnadienes; Pregnanes; Steroids; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroxine-binding globulin inhibitors"
DB00636,Clofibrate,637-07-0,approved; investigational,KNHUKKLJHYUCFP-UHFFFAOYSA-N,"InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3",CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,C12H15ClO3,C06916,D00279,2796,46504748,3750,CHEMBL565,,2694,50085047,242.699,3.401834674,"Acids, Acyclic; Agents Causing Muscle Toxicity; Anticholesteremic Agents; Benzene Derivatives; Butyrates; Carboxylic Acids; Cardiovascular System; Clofibric Acid; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ethers; Fatty Acids; Fatty Acids, Volatile; Fibric Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypolipidemic Agents; Isobutyrates; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Lipids; Noxae; Phenols; Phenyl Ethers; Thyroxine-binding globulin inducers; Toxic Actions"
DB00637,Astemizole,68844-77-9,approved; withdrawn,GXDALQBWZGODGZ-UHFFFAOYSA-N,"InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)",COc1ccc(cc1)CCN2CCC(CC2)Nc(nc(c34)cccc4)n3Cc5ccc(F)cc5,C28H31FN4O,C06832,D00234,2247,46508569,2896,CHEMBL296419,,2160,24226,458.5703,5.389652434,"Anti-Allergic Agents; Antihistamines for Systemic Use; Benzimidazoles; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; Neurotransmitter Agents; P-glycoprotein inhibitors; QTc Prolonging Agents; Respiratory System"
DB00638,Inulin,9005-80-5,approved; investigational; nutraceutical,JYJIGFIDKWBXDU-MNNPPOADSA-N,"InChI=1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1",OC[C@@H](O1)[C@@H](O)[C@H](O)[C@]1(CO)OC[C@]2(O[C@H](CO)[C@@H](O)[C@@H]2O)OC[C@]3(O[C@H](CO)[C@@H](O)[C@@H]3O)OC[C@]4(O[C@H](CO)[C@@H](O)[C@@H]4O)OC[C@]5(O[C@H](CO)[C@@H](O)[C@@H]5O)OC[C@]6(O[C@H](CO)[C@@H](O)[C@@H]6O)OC[C@]7(O[C@H](CO)[C@@H](O)[C@@H]7O)OC[C@]8(O[C@H](CO)[C@@H](O)[C@@H]8O)OC[C@]9(O[C@H](CO)[C@@H](O)[C@@H]9O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)OC[C@]1(O[C@H](CO)[C@@H](O)[C@@H]1O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,C228H382O191,C03323,D00171,24763,46508287,15443,CHEMBL1201646,,23149,,6179.3581,-61.99548181,"Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Diagnostic Agents; Diet, Food, and Nutrition; Dietary Carbohydrates; Food; Food and Beverages; Fructans; Glucans; Macromolecular Substances; Manufactured Materials; Physiological Phenomena; Polymers; Polysaccharides; Starch; Tests for Renal Function and Ureteral Injuries"
DB00639,Butoconazole,64872-76-0,approved,SWLMUYACZKCSHZ-UHFFFAOYSA-N,"InChI=1S/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2",Clc1ccc(cc1)CCC(Cn2ccnc2)Sc3c(Cl)cccc3Cl,C19H17Cl3N2S,C08065,D07598,47472,46508016,3240,CHEMBL1295,,43192,79206,411.776,6.552484297,"Anti-Infective Agents; Antifungal Agents; Antifungal Agents (Vaginal); Azole Antifungals; Azoles; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole Derivatives"
DB00640,Adenosine,58-61-7,approved; investigational,OIRDTQYFTABQOQ-KQYNXXCUSA-N,"InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1",n1cnc(N)c(c12)ncn2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O,C10H13N5O4,C00212,D00045,60961,46508728,16335,CHEMBL477,ADN,54923,14487,267.2413,-2.090963872,"Adenosine, antagonists & inhibitors; Agents producing tachycardia; Alkenes; Analgesics; Antiarrhythmic agents; Antiarrhythmics, Class V; Biological Factors; Carbohydrates; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Central Nervous System Agents; Class IV Antiarrythmics; Cyclohexanes; Cyclohexenes; Cycloparaffins; Enzymes; Enzymes and Coenzymes; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Miscellaneous Cardiac Drugs; Miscellaneous Therapeutic Agents; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Oxidoreductases; Peripheral Nervous System Agents; Pigments, Biological; Polycyclic Compounds; Polyenes; Purine Nucleosides; Purinergic Agents; Purinergic Agonists; Purinergic P1 Receptor Agonists; Purines; QTc Prolonging Agents; Ribonucleosides; Sensory System Agents; Terpenes; Vasodilating Agents"
DB00641,Simvastatin,79902-63-9,approved,RYMZZMVNJRMUDD-HGQWONQESA-N,"InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1",CCC(C)(C)C(=O)O[C@@H](C[C@@H](C)C=1)[C@@H](C12)[C@H]([C@@H](C)C=C2)CC[C@@H]3C[C@@H](O)CC(=O)O3,C25H38O5,,D00434,54454,46508654,9150,CHEMBL1064,,49179,50139181,418.5662,4.458201216,"Agents Causing Muscle Toxicity; Anticholesteremic Agents; BSEP/ABCB11 Substrates; Cardiovascular System; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Naphthalenes; Noxae; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; UGT1A1 Substrates; UGT1A3 substrates; UGT2B7 substrates"
DB00642,Pemetrexed,137281-23-3,approved; investigational,WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,"InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1",Nc([nH]1)nc(=O)c(c12)c(c[nH]2)CCc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O,C20H21N5O6,,D07472,446556,46505640,63616,CHEMBL225072,LYA,393879,50027656,427.4106,1.203979898,"Amino Acids; Amino Acids, Acidic; Amino Acids, Dicarboxylic; Amino Acids, Peptides, and Proteins; Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inhibitors; Folic Acid Analogues; Folic Acid Antagonists; Glutamates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nucleic Acid Synthesis Inhibitors; OAT3/SLC22A8 Substrates; Purines; Purinones"
DB00643,Mebendazole,31431-39-7,approved; vet_approved,OPXLLQIJSORQAM-UHFFFAOYSA-N,"InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)",COC(=O)Nc([nH]1)nc(c12)ccc(c2)C(=O)c3ccccc3,C16H13N3O3,,D00368,4030,46508807,6704,CHEMBL685,,3890,50180753,295.2927,3.260108545,"Acids, Acyclic; Anthelmintics; Anti-Infective Agents; Antihelminthic; Antimitotic Agents; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Benzimidazole Derivatives; Benzimidazoles; Carbamates; Carboxylic Acids; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Mitosis Modulators; Tubulin Modulators"
DB00644,Gonadorelin,33515-09-2,approved; investigational; vet_approved,XLXSAKCOAKORKW-UHFFFAOYSA-N,"InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)",NC(=O)CNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(Cc2ccc(O)cc2)NC(=O)C(CO)NC(=O)C(Cc3c[nH]c(c34)cccc4)NC(=O)C(Cc5cnc[nH]5)NC(=O)C6CCC(=O)N6,C55H75N17O13,C07607,,36523,46506144,,CHEMBL1981292,,33562,,1182.2901,-6.319288588,"Adrenal Cortex Hormones; Amino Acids, Peptides, and Proteins; Diagnostic Agents; Gonadotropin-releasing hormone agonist; Gonadotropin-Releasing Hormone, agonists; Gonadotropin-Releasing Hormone, antagonists & inhibitors; Gonadotropins and Antigonadotropins; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Function; Pituitary Hormone-Releasing Hormones; Proteins; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Tests for Fertility Disturbances"
DB00645,Dyclonine,586-60-7,approved,BZEWSEKUUPWQDQ-UHFFFAOYSA-N,"InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3",CCCCOc1ccc(cc1)C(=O)CCN2CCCCC2,C18H27NO2,C07881,,3180,46506697,4724,CHEMBL1201217,,3068,50240047,289.4125,3.67599844,"Anesthetics; Anesthetics, Local; Central Nervous System Agents; Central Nervous System Depressants; Ketones; Nervous System; Peripheral Nervous System Agents; Respiratory System; Sensory System Agents; Throat Preparations"
DB00646,Nystatin,1400-61-9,approved; vet_approved,VQOXZBDYSJBXMA-RKEBNKJGSA-N,"InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1",O[C@H]1[C@H](N)[C@H](O)[C@H](O[C@@H]1C)OC(CC(O[C@@]23O)C(C(C2)O)C(=O)O)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(C3)O,C47H75NO17,C06572,D00202,11953884,46504780,473992,CHEMBL229383,,10468627,,926.107,-1.938326276,"Alimentary Tract and Metabolism; Anti-Infective Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antifungal Agents; Antifungal Agents (Vaginal); Antifungals for Dermatological Use; Antifungals for Topical Use; Compounds used in a research, industrial, or household setting; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Intestinal Antiinfectives; Ionophores; Lactones; Macrocyclic Compounds; Membrane Transport Modulators; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Polycyclic Compounds; Polyene Antifungal; Polyenes; Polyketides"
DB00647,Dextropropoxyphene,469-62-5,approved; illicit; investigational; withdrawn,XLMALTXPSGQGBX-GCJKJVERSA-N,"InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1",c1ccccc1[C@@](OC(=O)CC)([C@H](C)CN(C)C)Cc2ccccc2,C22H29NO2,C07406,D07809,10100,46506690,51173,CHEMBL1213351,,9696,82269,339.4712,4.902155233,"Acids, Acyclic; Agents that reduce seizure threshold; Analgesics; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diphenylheptane opioids; Diphenylpropylamine Derivatives; Fatty Acids; Fatty Acids, Volatile; High-risk opioids; Lipids; Narcotics; Nervous System; Opioid Agonist; Opioids; Peripheral Nervous System Agents; Propionates; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00648,Mitotane,53-19-0,approved,JWBOIMRXGHLCPP-UHFFFAOYSA-N,"InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H",Clc1ccc(cc1)C(C(Cl)Cl)c2ccccc2Cl,C14H10Cl4,,D00420,4211,46508319,6954,CHEMBL1670,,4066,50239991,320.041,6.110364791,"Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 Enzyme Inducers; Hydrocarbons; Hydrocarbons, Chlorinated; Hydrocarbons, Halogenated; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; Thyroxine-binding globulin inducers"
DB00649,Stavudine,3056-17-5,approved; investigational,XNKLLVCARDGLGL-JGVFFNPUSA-N,"InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1",O=c1[nH]c(=O)n(cc1C)[C@@H]2O[C@H](CO)C=C2,C10H12N2O4,C07312,D00445,18283,46506943,63581,CHEMBL991,,17270,50013111,224.2133,-0.231806095,"Agents Causing Muscle Toxicity; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antimetabolites; Antiviral Agents; Antivirals for Systemic Use; Carbohydrates; Deoxyribonucleosides; Dideoxynucleosides; Direct Acting Antivirals; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Neurotoxic agents; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides; OAT1/SLC22A6 Substrates; Pyrimidine Nucleosides; Pyrimidines; Reverse Transcriptase Inhibitors; Toxic Actions"
DB00650,Leucovorin,58-05-9,approved,VVIAGPKUTFNRDU-ABLWVSNPSA-N,"InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1",O=c1[nH]c(N)nc(c12)NCC(N2C=O)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O,C20H23N7O7,C03479,D07986,6006,46505436,15640,CHEMBL1679,,5784,50239970,473.446,-2.33508676,"Antidotes; Biological Factors; Coenzymes; Compounds used in a research, industrial, or household setting; Detoxifying Agents for Antineoplastic Treatment; Diet, Food, and Nutrition; Enzymes and Coenzymes; Folate Analog; FOLFIRI chemotherapy regimen; FOLFOX chemotherapy regimen; Folic Acid and Derivatives; Food; Food and Beverages; Formyltetrahydrofolates; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Leucovorin Calcium-Levoleucovorin; Micronutrients; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Physiological Phenomena; Pigments, Biological; Protective Agents; Pteridines; Pterins; Tetrahydrofolates; Vitamin B Complex; Vitamins"
DB00651,Dyphylline,479-18-5,approved,KSCFJBIXMNOVSH-UHFFFAOYSA-N,"InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3",O=c1n(C)c(=O)n(C)c(c12)ncn2CC(O)CO,C10H14N4O4,C07819,D00691,3182,46504443,4728,CHEMBL1752,,3070,82016,254.2426,-1.866082546,"Alkaloids; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cardiovascular Agents; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Peripheral Nervous System Agents; Phosphodiesterase Inhibitors; Purines; Purinones; Respiratory System; Respiratory System Agents; Vasodilating Agents; Xanthine derivatives; Xanthines and Adrenergics"
DB00652,Pentazocine,359-83-1,approved; vet_approved,VOKSWYLNZZRQPF-GDIGMMSISA-N,"InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1",CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(O)c3,C19H27NO,C07421,D00498,441278,46506363,7982,CHEMBL560,,390041,50001028,285.4238,3.893620046,"Adjuvants, Anesthesia; Agents that reduce seizure threshold; Alkaloids; Analgesics; Benzomorphan Derivatives; Benzomorphans; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Mixed Agonist / Antagonist Opioids; Morphinans; Narcotics; Nervous System; Opiate Alkaloids; Opiate Partial Agonists; Opioid Antagonists; Opioids; P-glycoprotein substrates; Partial Opioid Agonist/Antagonist; Peripheral Nervous System Agents; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00653,Magnesium sulfate,7487-88-9,approved; investigational; vet_approved,CSNNHWWHGAXBCP-UHFFFAOYSA-L,"InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",[O-]S([O-])(=O)=O,MgO4S,,D01108,24083,46508411,32599,CHEMBL2021423,,22515,,120.368,-0.841552023,"Acids; Acids, Noncarboxylic; Agents causing hyperkalemia; Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Analgesics; Anesthetics; Anions; Antiarrhythmic agents; Anticonvulsants; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Calculi Dissolution Agent; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Dermatologicals; Diagnostic Agents; Drugs for Constipation; Electrolyte Solutions; Electrolytes; I.V. Solution Additives; Ions; Laxatives; Laxatives, magnesium containing; Magnesium Compounds; Magnesium Salts; Membrane Transport Modulators; Metal cations; Metal divalent cations; Mineral Supplements; Miscellaneous Anticonvulsants; Osmotic Laxatives; Paramagnetic Contrast Agent; Peripheral Nervous System Agents; Replacement Preparations; Reproductive Control Agents; Sensory System Agents; Sulfates; Sulfur Acids; Sulfur Compounds; Sulfuric Acids; Tests for Bile Duct Patency; Tocolytic Agents; Vasodilating Agents"
DB00654,Latanoprost,130209-82-4,approved; investigational,GGXICVAJURFBLW-CEYXHVGTSA-N,"InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1",CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc2ccccc2,C26H40O5,,D00356,5311221,46506279,6384,CHEMBL1051,,4470740,50240648,432.5928,3.981012292,"Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Autacoids; Biological Factors; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Lipids; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Ophthalmologicals; Prostaglandin analogs reducing intraocular pressure (IOP); Prostaglandins; Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Sensory Organs"
DB00655,Estrone,53-16-7,approved,DNXHEGUUPJUMQT-CBZIJGRNSA-N,"InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1",O=C1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(O)cc4,C18H22O2,C00468,D00067,5870,46505916,17263,CHEMBL1405,J3Z,5660,17289,270.3661,4.309029034,"17-Ketosteroids; Adrenal Cortex Hormones; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Estradiol Congeners; Estranes; Estrenes; Estrogens; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Ketosteroids; Natural and Semisynthetic Estrogens, Plain; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inducers; P-glycoprotein substrates; Polycyclic Compounds; Sex Hormones and Modulators of the Genital System; Steroids; Thyroxine-binding globulin inducers"
DB00656,Trazodone,19794-93-5,approved; investigational,PHLBKPHSAVXXEF-UHFFFAOYSA-N,"InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2",Clc1cccc(c1)N2CCN(CC2)CCCn(c3=O)nc(n34)cccc4,C19H22ClN5O,C07156,D08626,5533,46506648,9654,CHEMBL621,,5332,50073444,371.864,3.131856604,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Agents that reduce seizure threshold; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Second-Generation; Antidepressive Agents, Triazolopyridine; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H1 Antagonists; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; P-glycoprotein inducers; Peripheral alpha-1 blockers; Piperazines; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; Pyridines; Pyridones; QTc Prolonging Agents; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB00657,Mecamylamine,60-40-2,approved; investigational,IMYZQPCYWPFTAG-UHFFFAOYSA-N,"InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3",CNC(C)(C12)C(C)(C)C(C1)CC2,C11H21N,C07511,,4032,46508607,6706,CHEMBL267936,,3892,50061565,167.2911,2.37363976,"Agents that produce neuromuscular block (indirect); Antiadrenergic Agents, Ganglion-Blocking; Anticholinergic Agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Autonomic Agents; Autonomic Ganglionic Blocker; Cardiovascular Agents; Cardiovascular System; Cholinergic Agents; Decreased Autonomic Ganglionic Activity; Drugs that are Mainly Renally Excreted; Ganglion Blockers; Hydrocarbons; Hypotensive Agents; Monoterpenes; Neurotransmitter Agents; Nicotinic Antagonists; Norbornanes; Peripheral Nervous System Agents; Secondary and Tertiary Amines; Terpenes"
DB00658,Sevelamer,52757-95-6,approved,ZNSIZMQNQCNRBW-UHFFFAOYSA-N,"InChI=1S/C3H5ClO.C3H7N/c4-1-3-2-5-3;1-2-3-4/h3H,1-2H2;2H,1,3-4H2",ClCC1CO1,C6H12ClNO,,D01983,3085017,46505951,,CHEMBL1201798,,2341997,,149.619,0.677281406,"Amines; Bile Acid Sequestrants; Chelating Agents; Compounds used in a research, industrial, or household setting; Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Lipid Regulating Agents; Phosphate Binder; Phosphate Chelating Activity; Phosphate-removing Agents; Polyamines; Polystyrene Sulfonates; Sequestering Agents"
DB00659,Acamprosate,77337-76-9,approved; investigational,AFCGFAGUEYAMAO-UHFFFAOYSA-N,"InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10)",CC(=O)NCCCS(=O)(=O)O,C5H11NO4S,,D07058,71158,46506657,51041,CHEMBL1201293,,64300,,181.21,-2.829227371,"Acids; Acids, Noncarboxylic; Alcohol Deterrents; Alkanes; Alkanesulfonic Acids; Central Nervous System Agents; Drugs Used in Addictive Disorders; Drugs Used in Alcohol Dependence; Hydrocarbons; Hydrocarbons, Acyclic; Miscellaneous Central Nervous System Agents; Nervous System; Sulfonic Acids; Sulfur Acids; Sulfur Compounds"
DB00660,Metaxalone,1665-48-1,approved,IMWZZHHPURKASS-UHFFFAOYSA-N,"InChI=1S/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14)",Cc1cc(cc(C)c1)OCC2CNC(=O)O2,C12H15NO3,C07934,D00773,15459,46506253,6797,CHEMBL1079604,,14709,,221.2524,2.371813386,"Azoles; Central Nervous System Depressants; Centrally-mediated Muscle Relaxation; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Oxazoles; Peripheral Nervous System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00661,Verapamil,52-53-9,approved,SGTNSNPWRIOYBX-UHFFFAOYSA-N,"InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3",COc1c(OC)cc(cc1)CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)cc2,C27H38N2O4,C07188,D02356,2520,46508158,77733,CHEMBL6966,,2425,81939,454.6016,5.043185821,ACE Inhibitors and Calcium Channel Blockers; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Amines; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium Channel Blockers (Nondihydropyridine); Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (moderate); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hypotensive Agents; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; Membrane Transport Modulators; Miscellaneous Calcium-channel Blocking Agents; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT1 substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; Phenylalkylamine Derivatives; Selective Calcium Channel Blockers With Direct Cardiac Effects; Vasodilating Agents; Verapamil and analogues
DB00662,Trimethobenzamide,138-56-7,approved; investigational,FEZBIKUBAYAZIU-UHFFFAOYSA-N,"InChI=1S/C21H28N2O5/c1-23(2)10-11-28-17-8-6-15(7-9-17)14-22-21(24)16-12-18(25-3)20(27-5)19(13-16)26-4/h6-9,12-13H,10-11,14H2,1-5H3,(H,22,24)",COc1c(OC)cc(cc1OC)C(=O)NCc2ccc(cc2)OCCN(C)C,C21H28N2O5,C07178,D08643,5577,46507787,27796,CHEMBL1201256,,5375,,388.4574,2.159994753,"Acids, Carbocyclic; Amides; Aminoalkyl Ethers; Antiemetics; Antihistamines for Systemic Use; Autonomic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Emesis Suppression; Gastrointestinal Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Peripheral Nervous System Agents; Respiratory System"
DB00663,Flumethasone,2135-17-3,approved; vet_approved,WXURHACBFYSXBI-GQKYHHCASA-N,"InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1",OCC(=O)[C@@]1(O)[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4,C22H28F2O5,C14479,D04208,16490,46505121,34764,CHEMBL1201392,,15632,50240002,410.458,1.341850387,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Moderately Potent (Group II); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Otologicals; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Sensory Organs; Steroids; Steroids, Fluorinated"
DB00664,Sulfametopyrazine,152-47-6,approved; withdrawn,KXRZBTAEDBELFD-UHFFFAOYSA-N,"InChI=1S/C11H12N4O3S/c1-18-11-10(13-6-7-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,15)",COc1nccnc1NS(=O)(=O)c2ccc(N)cc2,C11H12N4O3S,C12616,D01216,9047,46505111,32162,CHEMBL1525826,,8695,,280.303,0.227884086,"Amides; Amines; Aniline Compounds; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antiparasitic Agents; Antiprotozoals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Long-Acting Sulfonamides; Renal Agents; Sulfanilamides; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds"
DB00665,Nilutamide,63612-50-0,approved; investigational,XWXYUMMDTVBTOU-UHFFFAOYSA-N,"InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)",CC1(C)NC(=O)N(C1=O)c2cc(C(F)(F)F)c([N+]([O-])=O)cc2,C12H10F3N3O4,C08164,D00965,4493,46505381,7573,CHEMBL1274,,4337,50135912,317.2207,2.250776846,"Androgen Receptor Antagonists; Androgen Receptor Inhibitor; Antiandrogens; Antiandrogens, non-steroidal; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Endocrine Therapy; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Imidazoles"
DB00666,Nafarelin,76932-56-4,approved,RWHUEXWOYVBUCI-ITQXDASVSA-N,"InChI=1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1",NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc(cc2)cc(c23)cccc3)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CO)NC(=O)[C@H](Cc5c[nH]c(c56)cccc6)NC(=O)[C@H](Cc7c[nH]cn7)NC(=O)[C@@H]8CCC(=O)N8,C66H83N17O13,C07613,,25077405,46506496,,CHEMBL1201309,,10482014,84707,1322.496,-2.69558412,"Adrenal Cortex Hormones; Agents Causing Muscle Toxicity; Amino Acids, Peptides, and Proteins; Fertility Agents; Fertility Agents, Female; Gonadotropin Releasing Hormone Receptor Agonist; Gonadotropin Releasing Hormone Receptor Agonists; Gonadotropin-releasing hormone agonist; Gonadotropins and Antigonadotropins; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormone-Releasing Hormones; Proteins; Reproductive Control Agents; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB00668,Epinephrine,51-43-4,approved; vet_approved,UCTWMZQNUQWSLP-VIFPVBQESA-N,"InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1",CNC[C@H](O)c1cc(O)c(O)cc1,C9H13NO3,C00788,D00095,5816,46509097,28918,CHEMBL679,ALE,5611,44818,183.2044,-0.429529285,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Alpha-and Beta-adrenergic Agonists; Amines; Anti-Asthmatic Agents; Antiglaucoma Preparations and Miotics; Autonomic Agents; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Bronchodilator Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Catecholamines; Catechols; COMT Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dental Agents; Drugs for Obstructive Airway Diseases; Epinephrine and similars; Hemostatics; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hyperglycemia-Associated Agents; Local Hemostatics; Mydriatics; Nasal Preparations; Neurotransmitter Agents; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; Ophthalmologicals; Peripheral Nervous System Agents; Phenols; Respiratory System; Respiratory System Agents; Stomatological Preparations; Sympathomimetic (Adrenergic) Agents; Sympathomimetics; Sympathomimetics in Glaucoma Therapy; Sympathomimetics, Plain; Vasoconstrictor Agents"
DB00669,Sumatriptan,103628-46-2,approved; investigational,KQKPFRSPSRPDEB-UHFFFAOYSA-N,"InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3",CNS(=O)(=O)Cc(c1)ccc(c12)[nH]cc2CCN(C)C,C14H21N3O2S,C07319,D00451,5358,46506520,10650,CHEMBL128,,5165,50005835,295.4,0.741928861,"Agents that produce hypertension; Amides; Amines; Analgesics; Antidepressive Agents; Antimigraine Preparations; BCRP/ABCG2 Substrates; Biogenic Amines; Biogenic Monoamines; Cardiovascular Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Monoamine Oxidase A Substrates; Nervous System; Neurotransmitter Agents; OATP1B1/SLCO1B1 Substrates; P-glycoprotein substrates; Selective Serotonin 5-HT1 Receptor Agonists; Selective Serotonin Agonists; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 1b Receptor Agonists; Serotonin 1d Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Serotonin-1b and Serotonin-1d Receptor Agonist; Sulfonamides; Sulfones; Sulfur Compounds; Triptans; Tryptamines; Vasoconstrictor Agents"
DB00670,Pirenzepine,28797-61-7,approved,RMHMFHUVIITRHF-UHFFFAOYSA-N,"InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)",CN1CCN(CC1)CC(=O)N2c(cccc3)c3C(=O)Nc(c24)cccn4,C19H21N5O2,C07508,D08389,4848,46509029,8247,CHEMBL9967,,4682,39341,351.4023,0.852451263,"Agents producing tachycardia; Alimentary Tract and Metabolism; Anti-Ulcer Agents; Anticholinergic Agents; Benzazepines; Benzodiazepinones; Cholinergic Agents; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Muscarinic Antagonists; Neurotransmitter Agents"
DB00671,Cefixime,79350-37-1,approved; investigational,OKBVVJOGVLARMR-QSWIMTSFSA-N,"InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1",O=C(O)C1=C(C=C)CS[C@@H](N12)[C@@H](C2=O)NC(=O)/C(=N\OCC(=O)O)c3csc(n3)N,C16H15N5O7S2,C06881,D00258,5362065,46508684,472657,CHEMBL1541,C04,4514923,84007,453.45,-1.175533308,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephacetrile; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB00672,Chlorpropamide,94-20-2,approved; investigational,RKWGIWYCVPQPMF-UHFFFAOYSA-N,"InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)",CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,C10H13ClN2O3S,,D00271,2727,46506402,3650,CHEMBL498,,2626,50344965,276.74,1.941390449,Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Hypoglycemia-Associated Agents; OAT1/SLC22A6 inhibitors; Sulfones; Sulfonylureas; Sulfur Compounds
DB00673,Aprepitant,170729-80-3,approved; investigational,ATALOFNDEOCMKK-OITMNORJSA-N,"InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1",FC(F)(F)c1cc(cc(c1)C(F)(F)F)[C@@H](C)O[C@H]2OCCN(Cc3n[nH]c(=O)[nH]3)[C@H]2c4ccc(F)cc4,C23H21F7N4O3,,D02968,6918365,46505211,499361,CHEMBL1471,GBQ,5293568,50220136,534.4267,5.215729411,"Alimentary Tract and Metabolism; Antiemetics; Antiemetics and Antinauseants; Aprepitant and Prodrugs; Autonomic Agents; Central Nervous System Agents; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Morpholines; Neurokinin 1 Antagonists; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; Oxazines; Peripheral Nervous System Agents; Substance P/Neurokinin-1 Receptor Antagonist"
DB00674,Galantamine,357-70-0,approved,ASUTZQLVASHGKV-JDFRZJQESA-N,"InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1",C1=C[C@H](O)C[C@@H]([C@@]123)Oc4c2c(CN(C)CC3)ccc4OC,C17H21NO3,C08526,D04292,9651,46505659,42944,CHEMBL659,GNT,9272,10404,287.3535,1.163042804,"Alkaloids; Amaryllidaceae Alkaloids; Anti-Dementia Drugs; Autonomic Agents; Benzazepines; Bradycardia-Causing Agents; Central Nervous System Agents; Cholinergic Agents; Cholinesterase Inhibitors; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotransmitter Agents; Nootropic Agents; P-glycoprotein inhibitors; Parasympathomemetic (Cholinergic) Agents; Parasympathomimetics; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; Psychoanaleptics; QTc Prolonging Agents"
DB00675,Tamoxifen,10540-29-1,approved,NKANXQFJJICGDU-QPLCGJKRSA-N,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C,C26H29NO,C07108,D08559,2733526,46505515,41774,CHEMBL83,CTX,2015313,20607,371.5146,6.351221956,"Anti-Estrogens; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Benzene Derivatives; Benzylidene Compounds; BSEP/ABCB11 Inhibitors; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Endocrine Therapy; Estrogen Agonist/Antagonist; Estrogen Antagonists; Estrogen Receptor Modulators; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Selective Estrogen Receptor Modulators; Stilbenes; Thyroxine-binding globulin inducers; UGT2B7 substrates; UGT2B7 substrates with narrow therapeutic index"
DB00676,Benzyl benzoate,120-51-4,approved,SESFRYSPDFLNCH-UHFFFAOYSA-N,"InChI=1S/C14H12O2/c15-14(13-9-5-2-6-10-13)16-11-12-7-3-1-4-8-12/h1-10H,11H2",c1ccccc1C(=O)OCc2ccccc2,C14H12O2,C12537,D01138,2345,46508023,41237,CHEMBL1239,BZM,13856959,50134035,212.2439,3.701195897,"Acaricides; Acids, Carbocyclic; Agrochemicals; Antiparasitic Products, Insecticides and Repellents; Benzene Derivatives; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Ectoparasiticides, Incl. Scabicides; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Insecticides; Pesticides; Toxic Actions"
DB00677,Isoflurophate,55-91-4,approved; investigational; withdrawn,MUCZHBLJLSDCSD-UHFFFAOYSA-N,"InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3",CC(C)OP(F)(=O)OC(C)C,C6H14FO3P,C00202,D00043,5936,46504499,17941,CHEMBL1025,,5723,50022772,184.1457,1.760390645,Cholinergic Agents; Cholinesterase Inhibitors; Enzyme Inhibitors; Neurotransmitter Agents; Ophthalmics; Organofluorophosphonates; Organophosphonates; Organophosphorus Compounds; Protease Inhibitors
DB00678,Losartan,114798-26-4,approved,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,"InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)",CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)-c3ccccc3-c4n[nH]nn4,C22H23ClN6O,C07072,D08146,3961,46506538,6541,CHEMBL191,LSN,3824,82258,422.911,5.084907282,"Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin 2 Receptor Blocker; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Angiotensin II receptor blockers (ARBs) and diuretics; Angiotensin II receptor blockers (ARBs), plain; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Azoles; Benzene Derivatives; Biphenyl Compounds; BSEP/ABCB11 Substrates; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Imidazoles; OAT1/SLC22A6 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Tetrazoles; UGT1A1 Substrates; UGT1A3 substrates; UGT2B7 substrates"
DB00679,Thioridazine,50-52-2,approved; withdrawn,KLBQZWRITKRQQV-UHFFFAOYSA-N,"InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3",c1cccc(S2)c1N(c(c23)cc(SC)cc3)CCC4CCCCN4C,C21H26N2S2,,D00373,5452,46509070,9566,CHEMBL479,,5253,50002338,370.575,5.469305906,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Hypotensive Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Phenothiazines; Phenothiazines With Piperidine Structure; Photosensitizing Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Tranquilizing Agents"
DB00680,Moricizine,31883-05-3,approved; investigational; withdrawn,FUBVWMNBEHXPSU-UHFFFAOYSA-N,"InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)",CCOC(=O)Nc(cc1)cc(c12)N(c3c(S2)cccc3)C(=O)CCN4CCOCC4,C22H25N3O4S,C07743,D05077,34633,46509072,6997,CHEMBL1075,,31872,,427.517,3.072304579,"Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ic; Antipsychotic Agents; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Membrane Transport Modulators; Morpholines; Neurotoxic agents; Oxazines; Phenothiazines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sodium Channel Blockers; Sulfur Compounds; Voltage-Gated Sodium Channel Blockers"
DB00681,Amphotericin B,1397-89-3,approved; investigational,APKFDSVGJQXUKY-INPOYWNPSA-N,"InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1",O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H](C[C@H](O[C@@]23O)[C@@H]([C@H](C2)O)C(=O)O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C3,C47H73NO17,C06573,D00203,5280965,46505473,2682,CHEMBL267345,,10237579,,924.079,-2.300161692,"Agents Causing Muscle Toxicity; Agents that reduce seizure threshold; Alimentary Tract and Metabolism; Amebicides; Anti-Bacterial Agents; Anti-Infective Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antifungal Agents; Antiinfectives and Antiseptics for Local Oral Treatment; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; Antiparasitic Agents; Antiprotozoals; Biomimetic Materials; Carbohydrates; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drug Carriers; Drug Delivery Systems; Drug Therapy; Genito Urinary System and Sex Hormones; Glycosides; Gynecological Antiinfectives and Antiseptics; Hypotensive Agents; Intestinal Antiinfectives; Investigative Techniques; Lactones; Lipid-based Polyene Antifungal; Liposomes; Macrocyclic Compounds; Manufactured Materials; Medications that reduce magnesium levels; Membranes, Artificial; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Pharmaceutical Preparations; Polycyclic Compounds; Polyene Antifungal; Polyenes; Polyketides; Stomatological Preparations; Technology; Technology, Pharmaceutical; Therapeutics"
DB00682,Warfarin,81-81-2,approved,PJVWKTKQMONHTI-UHFFFAOYSA-N,"InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3",c1ccccc1C(CC(=O)C)c(c(=O)o2)c(O)c(c23)cccc3,C19H16O4,C01541,,54678486,46504711,87732,CHEMBL1464,,10442445,50343352,308.3279,2.744707362,"4-Hydroxycoumarins; Agrochemicals; Anticoagulants; Blood and Blood Forming Organs; Compounds used in a research, industrial, or household setting; Coumarins; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (weak); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Pesticides; Pyrans; Rodenticides; Toxic Actions; Vitamin K Antagonists; Vitamin K Inhibitors; Warfarin and isomers"
DB00683,Midazolam,59467-70-8,approved; illicit,DDLIGBOFAVUZHB-UHFFFAOYSA-N,"InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3",Cc1ncc(n12)CN=C(c3c2ccc(Cl)c3)c4ccccc4F,C18H13ClFN3,C07524,D00550,4192,46507611,6931,CHEMBL655,08J,4047,21363,325.767,3.3348,"Adjuvants, Anesthesia; Anesthetics; Anti-Anxiety Agents; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents; Triazolobenzodiazepines; UGT1A4 substrates"
DB00684,Tobramycin,32986-56-4,approved; investigational,NLVFBUXFDBBNBW-PBSUHMDJSA-N,"InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1",NC[C@H]1O[C@@H]([C@H](N)C[C@@H]1O)O[C@@H]2[C@@H](N)C[C@@H](N)[C@@H]([C@H]2O)O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O,C18H37N5O9,C00397,D00063,36294,46507662,28864,CHEMBL1747,TOY,33377,50366778,467.5145,-6.477500565,Agents that produce neuromuscular block (indirect); Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycosides; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; Nebramycin; Nephrotoxic agents; Ophthalmologicals; Sensory Organs
DB00685,Trovafloxacin,147059-72-1,approved; investigational; withdrawn,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,"InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16+",N[C@H]1[C@@H]([C@@H]12)CN(C2)c(c(F)c3)nc(c34)n(cc(c4=O)C(=O)O)-c5c(F)cc(F)cc5,C20H15F3N4O3,C07664,,62959,46508751,9763,CHEMBL428,TR6,16736478,50146361,416.36,0.136454767,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Photosensitizing Agents; QTc Prolonging Agents; Quinolines; Quinolones; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00686,Pentosan polysulfate,37300-21-3,approved,FCCNSUIJIOOXEZ-SJYYZXOBSA-N,"InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1",OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O)[C@@H](OC[C@H]1O)O[C@@H]2CO[C@@H](O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O,C10H18O21S4,,,37720,46509187,,CHEMBL4073796,,34595,,602.497,-11.39932633,"Acids; Acids, Noncarboxylic; Anticoagulants; Antivaricose Therapy; Carbohydrates; Cardiovascular System; Drugs causing inadvertant photosensitivity; Genito Urinary System and Sex Hormones; Glycosaminoglycans; Hematologic Agents; Miscellaneous Therapeutic Agents; Photosensitizing Agents; Polysaccharides; Sulfur Acids; Sulfur Compounds; Sulfuric Acids; Urologicals; Vasoprotectives"
DB00687,Fludrocortisone,127-31-1,approved; investigational,AAXVEMMRQDVLJB-BULBTXNYSA-N,"InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1",OCC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)CC4,C21H29FO5,C07004,D07967,31378,46508616,50885,CHEMBL1201388,ZK5,29111,,380.4504,1.318773364,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Adrenals; Anti-Inflammatory Agents; Corticosteroids; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydroxycorticosteroids; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Mineralocorticoids; Polycyclic Compounds; Pregnenes; Steroids; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB00688,Mycophenolate mofetil,128794-94-5,approved; investigational,RTGDFNSFWBGLEC-SYZQJQIISA-N,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",C1OC(=O)c(c12)c(O)c(c(c2C)OC)C/C=C(\C)CCC(=O)OCCN3CCOCC3,C23H31NO7,C07908,D00752,5281078,46505626,8764,CHEMBL1456,,4444535,50248299,433.4947,3.473635574,"Agents Causing Muscle Toxicity; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antineoplastic; Antibiotics, Antitubercular; Antimetabolite Immunosuppressant; Antituberculosis Agents; BCRP/ABCG2 Substrates; Carboxylic Acids; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fatty Acids; Immunologic Factors; Immunosuppressive Agents; IMP Dehydrogenase, antagonists & inhibitors; Lipids; Mycophenolic Acid and Prodrugs; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; UGT1A1 Substrates; UGT1A6 substrate; UGT1A9 Substrates; UGT2B7 substrates"
DB00689,Cephaloglycin,03-01-3577,approved,FUBBGQLTSCSAON-PBFPGSCMSA-N,"InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1",CC(=O)OCC(=C1C(=O)O)CS[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccccc3,C18H19N3O6S,C13440,D01949,19150,46506850,34613,CHEMBL1200971,,18069,,405.425,-2.984246541,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Sulfur Compounds; Thiazines"
DB00690,Flurazepam,17617-23-1,approved; illicit; investigational,SAADBVWGJQAEFS-UHFFFAOYSA-N,"InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3",CCN(CC)CCN(c(c12)ccc(Cl)c2)C(=O)CN=C1c3ccccc3F,C21H23ClFN3O,,D00329,3393,46508451,5128,CHEMBL968,FL7,3276,,387.878,3.951048935,"Anti-Anxiety Agents; Benzazepines; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; OCT2 Inhibitors; P-glycoprotein inhibitors; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB00691,Moexipril,103775-10-6,approved,UWWDHYUMIORJTA-HSQYWUDLSA-N,"InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1",c1ccccc1CC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N([C@@H](C2)C(=O)O)Cc(c23)cc(OC)c(c3)OC,C27H34N2O7,C07704,,91270,46508441,6960,CHEMBL1165,,82418,50084673,498.5681,1.50212168,"ACE Inhibitors and Diuretics; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Isoquinolines; Photosensitizing Agents; Potential QTc-Prolonging Agents; Protease Inhibitors; QTc Prolonging Agents"
DB00692,Phentolamine,50-60-2,approved,MRBDMNSDAVCSSF-UHFFFAOYSA-N,"InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)",Oc1cccc(c1)N(c2ccc(C)cc2)CC3=NCCN3,C17H19N3O,,,5775,46506535,8081,CHEMBL597,,5571,31046,281.3523,2.515108176,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antidotes; Antihypertensive Agents; Azoles; Cardiovascular Agents; Cardiovascular System; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Imidazoles; Imidazoline Derivatives; Neurotransmitter Agents; Non-selective Alfa-adrenergic Blocking Agents; Peripheral alpha-1 blockers; Peripheral Vasodilators; Sympatholytic (Adrenergic Blocking) Agents; Vasodilating Agents"
DB00693,Fluorescein,05-07-2321,approved,GNBHRKFJIUUOQI-UHFFFAOYSA-N,"InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H",c1c(O)ccc2c1Oc(cc(O)cc3)c3C24c5c(C(O4)=O)cccc5,C20H12O5,,D01261,16850,46504703,31624,CHEMBL1057,FLU,15968,50237588,332.3063,3.880342823,"BSEP/ABCB11 Substrates; Coloring Agents; Colouring Agents; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Agents; Diagnostic Dye; Diagnostic Uses of Chemicals; Fluoresceins; Fluorescent Dyes; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Indicators and Reagents; Laboratory Chemicals; Luminescent Agents; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; Ocular Disorders; Ophthalmologicals; Other Diagnostics; Polycyclic Compounds; Sensory Organs; Spiro Compounds; Xanthenes"
DB00694,Daunorubicin,20830-81-3,approved,STQGQHZAVUOBTE-VGBVRHCVSA-N,"InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1",COc1cccc(c12)C(=O)c3c(C2=O)c(O)c4c(c3O)C[C@@](O)(C(=O)C)C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@@H](O5)C,C27H29NO10,C01907,D07776,30323,46508433,41977,CHEMBL178,DM1,28163,32017,527.5199,1.733693141,"Anthracycline Topoisomerase Inhibitor; Anthracyclines; Anthracyclines and Related Substances; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; BSEP/ABCB11 Substrates; Carbohydrates; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Cytotoxic Antibiotics and Related Substances; Enzyme Inhibitors; Glycosides; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Myelosuppressive Agents; Naphthacenes; Narrow Therapeutic Index Drugs; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00695,Furosemide,54-31-9,approved; vet_approved,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,"InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)",NS(=O)(=O)c1c(Cl)cc(c(c1)C(=O)O)NCc2ccco2,C12H11ClN2O5S,C07017,D00331,3440,46506779,47426,CHEMBL35,FUN,3322,25902,330.744,1.748402059,"Acids, Carbocyclic; Amides; Amines; Aminobenzoates; Aniline Compounds; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Benzene Derivatives; Benzoates; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Diuretics; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; High-Ceiling Diuretics; High-Ceiling Diuretics and Potassium-Sparing Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hyperglycemia-Associated Agents; Hypotensive Agents; Increased Diuresis at Loop of Henle; Medications that reduce magnesium levels; Membrane Transport Modulators; Natriuretic Agents; Nephrotoxic agents; Non Potassium Sparing Diuretics; OAT1/SLC22A6 Inducers; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Ototoxic agents; Photosensitizing Agents; Sodium Potassium Chloride Symporter Inhibitors; Sulfanilamides; Sulfonamides; Sulfones; Sulfur Compounds; Thyroxine-binding globulin substrates; UGT1A1 Substrates"
DB00696,Ergotamine,113-15-5,approved,XCGSFFUVFURLIX-VFGNJEKYSA-N,"InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1",c1ccccc1C[C@@H](C(=O)N([C@@H]2[C@@]34O)CCC2)N3C(=O)[C@](O4)(C)NC(=O)[C@H](C=5)CN(C)[C@@H](C56)Cc7c8c6cccc8[nH]c7,C33H35N5O5,C07544,D07906,8223,46507632,64318,CHEMBL442,ERM,7930,50027065,581.6615,2.59769731,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Alkaloids; Analgesics; Analgesics, Non-Narcotic; Antidepressive Agents; Antimigraine Preparations; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ergot Alkaloids and Derivatives; Ergotamine Derivative; Ergotamines; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Nervous System; Neurotransmitter Agents; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Reproductive Control Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Sympatholytic (Adrenergic Blocking) Agents; Uterotonic agents; Vasoconstrictor Agents"
DB00697,Tizanidine,51322-75-9,approved; investigational,XFYDIVBRZNQMJC-UHFFFAOYSA-N,"InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)",n1snc(c12)c(c(Cl)cc2)NC3=NCCN3,C9H8ClN5S,C07452,,5487,46505373,63629,CHEMBL1079,,5287,50240671,253.711,2.024673073,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Analgesics; Anticonvulsants; Autonomic Agents; Bradycardia-Causing Agents; Central alpha-2 Adrenergic Agonist; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Imidazoles; Imidazolines; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System; Narrow Therapeutic Index Drugs; Neuromuscular Agents; Neurotransmitter Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sensory System Agents"
DB00698,Nitrofurantoin,67-20-9,approved; vet_approved,NXFQHRVNIOXGAQ-YCRREMRBSA-N,"InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+",[O-][N+](=O)c1ccc(o1)/C=N/N2CC(=O)NC2=O,C8H6N4O5,C07268,D00439,6604200,46504447,71415,CHEMBL572,,5036498,57045,238.159,-0.221449992,"Agents causing hyperkalemia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; BCRP/ABCG2 Substrates; BSEP/ABCB11 Substrates; Drugs that are Mainly Renally Excreted; Furans; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Methemoglobinemia Associated Agents; Nitro Compounds; Nitrofuran Antibacterial; Nitrofuran Derivatives; Nitrofurans; P-glycoprotein substrates; Renal Agents; Thyroxine-binding globulin substrates"
DB00699,Nicergoline,27848-84-6,approved; investigational,YSEXMKHXIOCEJA-FVFQAYNVSA-N,"InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1",CO[C@@]12c3c4c(ccc3)n(C)cc4C[C@H]1N(C)C[C@@H](C2)COC(=O)c5cncc(Br)c5,C24H26BrN3O3,,D01290,34040,46508741,31902,CHEMBL1372950,,31373,,484.386,3.695324944,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Alkaloids; Cardiovascular Agents; Cardiovascular System; Central Nervous System Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Ergolines; Ergot Alkaloids and Derivatives; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; Nootropic Agents; Peripheral Vasodilators; Vasodilating Agents"
DB00700,Eplerenone,107724-20-9,approved,JUKPWJGBANNWMW-VWBFHTRKSA-N,"InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1",C1CC(=O)O[C@@]12[C@]3(C)[C@@H](CC2)[C@H]4[C@]5([C@H](O5)C3)[C@]6(C)C(=CC(=O)CC6)C[C@H]4C(=O)OC,C24H30O6,C12512,D01115,443872,46509053,31547,CHEMBL1095097,YNU,10203511,50318300,414.4914,2.331412885,"Agents causing hyperkalemia; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Diuretics; Fused-Ring Compounds; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypotensive Agents; Lactones; Mineralocorticoid (Aldosterone) Receptor Antagonists; Mineralocorticoid Receptor Antagonists; Natriuretic Agents; Polycyclic Compounds; Potassium-Sparing Diuretics; Pregnanes; Pregnenes; Steroids"
DB00701,Amprenavir,161814-49-9,approved; investigational,YMARZQAQMVYCKC-OEMFJLHTSA-N,"InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1",Nc1ccc(cc1)S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]3CCOC3,C25H35N3O6S,C08086,D00894,65016,46507537,40050,CHEMBL116,478,58532,577,505.627,2.426952677,"Acids, Acyclic; Amides; Amprenavir and Prodrugs; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antibiotics, Antitubercular; Antiinfectives for Systemic Use; Antituberculosis Agents; Antiviral Agents; Antivirals for Systemic Use; Carboxylic Acids; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (weak); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; HIV Protease Inhibitors; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inducers; P-glycoprotein substrates; Protease Inhibitors; Sulfones; Sulfur Compounds"
DB00702,Icodextrin,337376-15-5,approved; investigational,,, ,,,,,46508585,,CHEMBL1201472,,,,NA,NA,"Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Dialysis Solutions; Glucans; Macromolecular Substances; Manufactured Materials; Pharmaceutical Preparations; Pharmaceutical Solutions; Polymers; Polysaccharides; Solutions"
DB00703,Methazolamide,554-57-4,approved,FLOSMHQXBMRNHR-UHFFFAOYSA-N,"InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)",Cn1nc(S(=O)(=O)N)sc\1=N\C(=O)C,C5H8N4O3S2,C07764,D00655,4100,46506393,94513,CHEMBL1335656,,21122102,10881,236.26,-0.593433132,"Antiglaucoma Preparations and Miotics; Azoles; Carbonic Anhydrase Inhibitors; Cardiovascular Agents; Diuretics; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Natriuretic Agents; OAT1/SLC22A6 inhibitors; Ophthalmologicals; Photosensitizing Agents; Sensory Organs; Sulfonamides; Sulfur Compounds; Thiadiazoles; Thiazoles"
DB00704,Naltrexone,16590-41-3,approved; investigational; vet_approved,DQCKKXVULJGBQN-XFWGSAIBSA-N,"InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1",[C@@]123[C@H]4Oc5c1c(ccc5O)C[C@H]([C@]2(O)CCC4=O)N(CC3)CC6CC6,C20H23NO4,C07253,D05113,5360515,46505333,7465,CHEMBL19019,,4514524,60212,341.4009,1.362675232,"Agents Causing Muscle Toxicity; Alcohol Deterrents; Alimentary Tract and Metabolism; Alkaloids; Analgesics; Antiobesity Preparations, Excl. Diet Products; Central Nervous System Agents; Centrally Acting Antiobesity Products; Drugs Used in Addictive Disorders; Drugs Used in Alcohol Dependence; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Narcotics; Natural Opium Alkaloids; Nervous System; Opiate Alkaloids; Opiate Antagonists; Opioid Antagonists; Opioids; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; UGT1A1 Substrates"
DB00705,Delavirdine,136817-59-9,approved,WHBIGIKBNXZKFE-UHFFFAOYSA-N,"InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3",CC(C)Nc1c(nccc1)N2CCN(CC2)C(=O)c([nH]3)cc(c34)cc(cc4)NS(=O)(=O)C,C22H28N6O3S,C06941,,5625,46508878,119573,CHEMBL593,SPP,5423,1944,456.561,1.024326538,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Indoles; Medications that reduce magnesium levels; Non-Nucleoside Reverse Transcriptase Inhibitors; Nonnucleoside Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Piperazines; Reverse Transcriptase Inhibitors"
DB00706,Tamsulosin,106133-20-4,approved; investigational,DRHKJLXJIQTDTD-OAHLLOKOSA-N,"InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1",CCOc1ccccc1OCCN[C@H](C)Cc2cc(S(=O)(=O)N)c(OC)cc2,C20H28N2O5S,C07124,,129211,46507763,9398,CHEMBL836,,114457,50060964,408.512,2.038114116,Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Amides; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs Used in Benign Prostatic Hypertrophy; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Hypotensive Agents; Neurotransmitter Agents; Peripheral alpha-1 blockers; Selective Alfa-1-adrenergic Blocking Agents; Sulfonamides; Sulfones; Sulfur Compounds; Urological Agents; Urologicals
DB00707,Porfimer sodium,87806-31-3,approved; investigational,,, ,,,,,46508600,60652,,,10482043,,NA,NA,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; Biological Factors; Dermatologicals; Hematoporphyrin Derivative; Hematoporphyrins; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Macrocyclic Compounds; Photoabsorption; Photoactivated Radical Generator; Photosensitizing Activity; Photosensitizing Agents; Photosensitizing agents used for phototherapy; Pigments, Biological; Polycyclic Compounds; Porphyrins; Pyrroles; Radiation-Sensitizing Agents; Sensitizers Used in Photodynamic/radiation Therapy; Tetrapyrroles"
DB00708,Sufentanil,56030-54-7,approved; investigational,GGCSSNBKKAUURC-UHFFFAOYSA-N,"InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3",c1ccccc1N(C(=O)CC)C2(COC)CCN(CC2)CCc3cccs3,C22H30N2O2S,C08022,D05938,41693,46504737,9316,CHEMBL658,,38043,94503,386.551,3.605173127,"Adjuvants, Anesthesia; Agents that produce hypertension; Analgesics; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Bradycardia-Causing Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fentanyl and fentanyl analogues; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; High-risk opioids; Hypotensive Agents; Narcotics; Nervous System; Neuraxial Anesthetics; Opiate Agonists; Opioid Agonist; Opioid Anesthetics; Opioids; Opioids, Anilidopiperidine; Peripheral Nervous System Agents; Phenylpiperidine opioids; Piperidines; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00709,Lamivudine,134678-17-4,approved; investigational,JTEGQNOMFQHVDC-NKWVEPMBSA-N,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",Nc1nc(=O)n(cc1)[C@@H]2CS[C@@H](O2)CO,C8H11N3O3S,C07065,D00353,60825,46507855,63577,CHEMBL141,3TC,54812,50366817,229.256,-1.095107588,"Agents Causing Muscle Toxicity; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BCRP/ABCG2 Substrates; Carbohydrates; Deoxycytidine; Deoxyribonucleosides; Dideoxynucleosides; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Glycosides; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Medications that reduce magnesium levels; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides; OAT1/SLC22A6 Substrates; OCT1 substrates; OCT2 Substrates; P-glycoprotein substrates; Pyrimidine Nucleosides; Pyrimidines; Reverse Transcriptase Inhibitors; Ribonucleosides"
DB00710,Ibandronate,114084-78-5,approved; investigational,MPBVHIBUJCELCL-UHFFFAOYSA-N,"InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,C9H23NO7P2,,,60852,46508134,,CHEMBL997,BFQ,54839,12577,319.2289,-2.48143488,Agents Causing Muscle Toxicity; Bisphosphonates; Bone Density Conservation Agents; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Musculo-Skeletal System; Organophosphonates; Organophosphorus Compounds; Potential QTc-Prolonging Agents; QTc Prolonging Agents
DB00711,Diethylcarbamazine,90-89-1,approved; investigational; vet_approved,RCKMWOKWVGPNJF-UHFFFAOYSA-N,"InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3",CCN(CC)C(=O)N1CCN(C)CC1,C10H21N3O,C07968,D07825,3052,46506830,4527,CHEMBL684,,2944,50024883,199.2932,0.091605889,"Acids, Acyclic; Anthelmintics; Anti-Infective Agents; Antihelminthic; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Carbamates; Carboxylic Acids; Cholinesterase Inhibitors; Enzyme Inhibitors; Filaricides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lipoxygenase Inhibitors; Piperazine and Derivatives; Piperazines"
DB00712,Flurbiprofen,5104-49-4,approved; investigational,SYTBZMRGLBWNTM-UHFFFAOYSA-N,"InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)",OC(=O)C(C)c1cc(F)c(cc1)-c2ccccc2,C15H13FO2,,D00330,3394,46505550,5130,CHEMBL563,,3277,50074922,244.2609,3.943907682,"Acids, Acyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Arylpropionic acid NSAIDS; Benzene Derivatives; Biphenyl Compounds; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Fatty Acids; Fatty Acids, Volatile; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lipids; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; Ophthalmologicals; Other Nonsteroidal Anti-inflammatory Agents; Peripheral Nervous System Agents; Photosensitizing Agents; Propionates; Respiratory System; Sensory Organs; Sensory System Agents; Throat Preparations; Topical Products for Joint and Muscular Pain; UGT1A1 Inhibitors; UGT1A1 Substrates; UGT1A3 substrates; UGT1A9 Substrates; UGT2B7 substrates"
DB00713,Oxacillin,66-79-5,approved; investigational,UWYHMGVUTGAWSP-JKIFEVAISA-N,"InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)c3c(C)onc3-c4ccccc4,C19H19N3O5S,C07334,D08307,6196,46505710,7809,CHEMBL819,105,5961,50350483,401.436,1.697694982,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; Beta-Lactamase Resistant Penicillins; beta-Lactams; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillins; Sulfur Compounds"
DB00714,Apomorphine,58-00-4,approved; investigational,VMWNQDUVQKEIOC-CYBMUJFWSA-N,"InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1",c1cc(O)c(O)c(c12)c3c4c(ccc3)CCN(C)[C@@H]4C2,C17H17NO2,,D07460,6005,46508653,48538,CHEMBL53,,5783,29644,267.3224,2.86663523,"Alkaloids; Anti-Parkinson Agents (Dopamine Agonist); Anti-Parkinson Drugs; Antidepressive Agents; Aporphines; Autonomic Agents; Benzylisoquinolines; Central Nervous System Agents; Central Nervous System Depressants; COMT Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Drugs Used in Erectile Dysfunction; Emetics; Gastrointestinal Agents; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Isoquinolines; Nervous System; Neurotransmitter Agents; Nonergot-derivative Dopamine Receptor Agonists; Opiate Agonists; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Receptor Antagonists; Urologicals"
DB00715,Paroxetine,61869-08-7,approved; investigational,AHOUBRCZNHFOSL-YOEHRIQHSA-N,"InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1",Fc1ccc(cc1)[C@@H]2CCNC[C@H]2COc(cc3)cc(c34)OCO4,C19H20FNO3,C07415,D02362,43815,46504821,7936,CHEMBL490,8PR,39888,22416,329.3654,3.148248689,"Agents producing tachycardia; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Second-Generation; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; P-glycoprotein inhibitors; Photosensitizing Agents; Piperidines; Psychoanaleptics; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB00716,Nedocromil,69049-73-6,approved; investigational,RQTOOFIXOKYGAN-UHFFFAOYSA-N,"InChI=1S/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26)",O=C(O)c(o1)cc(=O)c(c12)cc3c(c2CCC)n(CC)c(cc3=O)C(=O)O,C19H17NO7,C07255,D05129,50294,46507587,7492,CHEMBL746,,45608,50239990,371.3408,2.496716766,"4-Quinolones; Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Antiallergic Agents, Excl. Corticosteroids; Decongestants and Antiallergics; Decreased Histamine Release; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Mast Cell Stabilizers; Nasal Preparations; Ophthalmologicals; Quinolines; Quinolones; Respiratory Agents, Miscellaneous; Respiratory System; Respiratory System Agents; Sensory Organs"
DB00717,Norethisterone,68-22-4,approved,VIKNJXKGJWUCNN-XGXHKTLJSA-N,"InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1",C#C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@@H]4C(CC3)=CC(=O)CC4,C20H26O2,C05028,D00182,6230,46504816,7627,CHEMBL1162,NDR,5994,50148732,298.4192,3.217227937,"Adrenal Cortex Hormones; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Estren Derivatives; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hyperglycemia-Associated Agents; Norpregnenes; Norsteroids; P-glycoprotein inhibitors; Polycyclic Compounds; Progestin Contraceptives; Progestins; Progestogens and Estrogens, Sequential Preparations; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB00718,Adefovir dipivoxil,142340-99-6,approved; investigational,WOZSCQDILHKSGG-UHFFFAOYSA-N,"InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)",CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)COCCn1cnc(c12)c(N)ncn2,C20H32N5O8P,C11277,D01655,60871,46507520,31175,CHEMBL922,,54855,50248359,501.4705,3.058480914,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Direct Acting Antivirals; Enzyme Inhibitors; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nephrotoxic agents; Nucleic Acid Synthesis Inhibitors; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleosides and Nucleotides; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; Organophosphorus Compounds; Purines; Reverse Transcriptase Inhibitors"
DB00719,Azatadine,3964-81-6,approved,SEBMTIQKRHYNIT-UHFFFAOYSA-N,"InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3",CN1CCC(CC1)=C2c(cccc3)c3CCc(c24)cccn4,C20H22N2,C07774,,19861,46507958,2946,CHEMBL946,,18709,22868,290.4021,3.747541202,"Agents that reduce seizure threshold; Antihistamines for Systemic Use; Benzocycloheptenes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Dibenzocycloheptenes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; Piperidines; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB00720,Clodronic acid,10596-23-3,approved; investigational; vet_approved,ACSIXWWBWUQEHA-UHFFFAOYSA-N,"InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)",OP(=O)(O)C(Cl)(Cl)P(=O)(O)O,CH4Cl2O6P2,,,25419,46508646,110423,CHEMBL12318,,23731,50216172,244.892,-0.066694555,Bisphosphonates; Bone Density Conservation Agents; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Musculo-Skeletal System; Organophosphonates; Organophosphorus Compounds
DB00721,Procaine,59-46-1,approved; investigational; vet_approved,MFDFERRIHVXMIY-UHFFFAOYSA-N,"InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3",CCN(CC)CCOC(=O)c1ccc(N)cc1,C13H20N2O2,C07375,D08422,4914,46507724,8430,CHEMBL569,,4745,64452,236.3101,1.880057258,"Acids, Carbocyclic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Agents that reduce seizure threshold; Aminobenzoates; Anesthetics; Anesthetics, Local; Anticholinergic Agents; Antidepressive Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Cardiovascular System; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase Inhibitors; Cholinesterase substrates; Esters of Aminobenzoic Acid; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Local Anesthetics (Ester); Monoamine Oxidase Inhibitors; Nervous System; Nicotinic Antagonists; NMDA Receptor Antagonists; Ophthalmologicals; para-Aminobenzoates; Peripheral Nervous System Agents; Sensory Organs; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Vasoprotectives"
DB00722,Lisinopril,76547-98-3,approved; investigational,RLAWWYSOJDYHDC-BZSNNMDCSA-N,"InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1",OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N[C@H](C(=O)O)CCc2ccccc2,C21H31N3O5,,D00362,5362119,46504893,43755,CHEMBL1237,LPR,4514933,66979,405.4879,-3.102603246,"ACE Inhibitors and Calcium Channel Blockers; ACE Inhibitors and Diuretics; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Amino Acids, Peptides, and Proteins; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Dipeptides; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hypotensive Agents; Lipid Modifying Agents; Oligopeptides; Peptides; Photosensitizing Agents; Protease Inhibitors; Protective Agents"
DB00723,Methoxamine,390-28-3,approved; investigational,WJAJPNHVVFWKKL-UHFFFAOYSA-N,"InChI=1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3",COc1cc(C(O)C(C)N)c(OC)cc1,C11H17NO3,C07513,D08201,6082,46506264,6839,CHEMBL524,,5857,50026777,211.2576,0.569911803,Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Autonomic Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Ethylamines; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenethylamines; Propanolamines; Propanols; Sympathomimetics; Vasoconstrictor Agents
DB00724,Imiquimod,99011-02-6,approved; investigational,DOUYETYNHWVLEO-UHFFFAOYSA-N,"InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)",CC(C)Cn1cnc(c12)c(N)nc3c2cccc3,C14H16N4,,D02500,57469,46505394,36704,CHEMBL1282,6T0,51809,50240849,240.3036,2.650669472,"Adjuvants, Immunologic; Aminoquinolines; Antineoplastic Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunologic Factors; Immunosuppressive Agents; Increased Cytokine Activity; Increased Cytokine Production; Interferon Inducers; Misc. Skin and Mucous Membrane Agents; Quinolines"
DB00725,Homatropine methylbromide,80-49-9,approved,FUFVKLQESJNNAN-UHFFFAOYSA-M,"InChI=1S/C17H24NO3.BrH/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12;/h3-7,13-16,19H,8-11H2,1-2H3;1H/q+1;/p-1",C[N+](C)(C12)C(CC1)CC(C2)OC(=O)C(O)c3ccccc3,C17H24BrNO3,,D02070,6646,46509020,50373,CHEMBL1200851,,6394,,370.281,-2.568469182,"Agents producing tachycardia; Alimentary Tract and Metabolism; Alkaloids; Anticholinergic Agents; Aza Compounds; Azabicyclo Compounds; Belladonna Alkaloids, Semisynthetic, Quaternary Ammonium Compounds; Belladonna and Derivatives, Plain; Bicyclo Compounds, Heterocyclic; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Muscarinic Agonists; Muscarinic Antagonists"
DB00726,Trimipramine,739-71-9,approved,ZSCDBOWYZJWBIY-UHFFFAOYSA-N,"InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3",CN(C)CC(C)CN1c(cccc2)c2CCc(c13)cccc3,C20H26N2,,D00394,5584,46507121,9738,CHEMBL644,,5382,50240410,294.4338,4.757892354,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic Uptake Inhibitors; Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tricyclic; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Dibenzazepines; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Membrane Transport Modulators; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; P-glycoprotein substrates; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Tertiary amine tricyclic antidepressants; Tricyclics and Other Norepinephrine-reuptake Inhibitors"
DB00727,Nitroglycerin,55-63-0,approved; investigational,SNIOPGDIGTZGOP-UHFFFAOYSA-N,"InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2",[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O,C3H5N3O9,C07455,D00515,4510,46509120,28787,CHEMBL730,TNG,4354,,227.0865,0.256529901,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Antianginal Agents; Antihypertensive Agents; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Explosive Agents; Hypotensive Agents; Methemoglobinemia Associated Agents; Nitrate Vasodilator; Nitrates and Nitrites; Nitro Compounds; Organic Nitrates; Vasodilating Agents; Vasodilation; Vasodilators Used in Cardiac Diseases; Vasoprotectives"
DB00728,Rocuronium,143558-00-3,approved,YXRDKMPIGHSVRX-OOJCLDBCSA-N,"InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1",C1CCC[N+]1(CC=C)[C@H]([C@@H]2OC(=O)C)C[C@H]([C@@]23C)[C@H]4[C@H](CC3)[C@]5(C)[C@@H](CC4)C[C@H](O)[C@H](C5)N6CCOCC6,C32H53N2O4,C07556,D00765,441290,46506855,8884,CHEMBL1201244,,390053,,529.7742,-0.331221682,"Agents producing tachycardia; Androstanes; Androstanols; Anticholinergic Agents; Central Nervous System Depressants; Fused-Ring Compounds; Muscarinic Antagonists; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular Nondepolarizing Blockade; Neuromuscular-Blocking Agents (Nondepolarizing); Nicotinic Antagonists; OCT1 inhibitors; OCT1 substrates; Peripheral Nervous System Agents; Polycyclic Compounds; Steroids"
DB00730,Thiabendazole,148-79-8,approved; vet_approved,WJCNZQLZVWNLKY-UHFFFAOYSA-N,"InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)",c1scnc1-c(n2)[nH]c(c23)cccc3,C10H7N3S,C07131,D00372,5430,46505131,45979,CHEMBL625,TMG,5237,50121347,201.248,2.328917354,"Anthelmintics; Anti-Infective Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Antihelminthic; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Azoles; Benzimidazole Derivatives; Benzimidazoles; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Imidazole and Triazole Derivatives; Sulfur Compounds; Thiazoles"
DB00731,Nateglinide,105816-04-4,approved; investigational,OELFLUMRDSZNSF-BRWVUGGUSA-N,"InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1",CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](C(=O)O)Cc2ccccc2,C19H27NO3,C12508,D01111,5311309,46504836,31897,CHEMBL783,,10482084,50344967,317.429,4.028570731,"Alimentary Tract and Metabolism; Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Blood Glucose Lowering Agents; Cyclohexanes; Cycloparaffins; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Glinide; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hypoglycemia-Associated Agents; Macrocyclic Compounds; OAT1/SLC22A6 inhibitors; Phenylalanine; Polycyclic Compounds; Potassium Channel Antagonists; UGT1A9 Substrates"
DB00732,Atracurium besylate,64228-81-5,approved,XXZSQOVSEBAPGS-UHFFFAOYSA-L,"InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2",COc1ccc(cc1OC)CC2[N+](C)(CCc(c23)cc(OC)c(c3)OC)CCC(=O)OCCCCCOC(=O)CC[N+](C)(CCc(c45)cc(OC)c(c5)OC)C4Cc6cc(OC)c(OC)cc6,C65H82N2O18S2,,D00758,47320,46504689,2915,CHEMBL1200527,,43068,50149881,1243.49,-0.959032062,"Alkaloids; Anticholinergic Agents; Benzylisoquinolines; Central Nervous System Depressants; Cholinergic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Miscellaneous Skeletal Muscle Relaxants; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular-Blocking Agents (Nondepolarizing); Neurotransmitter Agents; Nicotinic Antagonists; Peripheral Nervous System Agents"
DB00733,Pralidoxime,6735-59-7,approved; vet_approved,JBKPUQTUERUYQE-UHFFFAOYSA-O,"InChI=1S/C7H8N2O/c1-9-5-3-2-4-7(9)6-8-10/h2-6H,1H3/p+1",O/N=C/c1[n+](C)cccc1,C7H9N2O,C07400,,5353894,46509152,8354,CHEMBL1420,,5193737,234367,137.1592,-3.257118933,"Amines; Antidotes; Cholinergic Agents; Cholinesterase Reactivators; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Enzyme Reactivators; Hydroxylamines; Neurotransmitter Agents; Oximes; Protective Agents"
DB00734,Risperidone,106266-06-2,approved; investigational,RAPZEAPATHNIPO-UHFFFAOYSA-N,"InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3",C1CCCn(c12)c(=O)c(c(n2)C)CCN3CCC(CC3)c4noc(c45)cc(F)cc5,C23H27FN4O2,,D00426,5073,46505850,8871,CHEMBL85,,4895,50001885,410.4845,2.627621084,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H1 Antagonists; Hyperglycemia-Associated Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein substrates; Potential QTc-Prolonging Agents; Psycholeptics; Psychotropic Drugs; Pyrimidines; Pyrimidinones; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT1D Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB00735,Naftifine,65472-88-0,approved,OZGNYLLQHRPOBR-DHZHZOJOSA-N,"InChI=1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3/b11-8+",c1cccc(c12)cccc2CN(C)C/C=C/c3ccccc3,C21H21N,C08071,,73342,46504777,7451,CHEMBL626,,43344,50170647,287.3981,5.23850813,"Alkenes; Allyl Compounds; Allylamine Antifungal; Amines; Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Dermatologicals; Hydrocarbons; Hydrocarbons, Acyclic"
DB00736,Esomeprazole,119141-88-7,approved; investigational,SUBDBMMJDZJVOS-DEOSSOPVSA-N,"InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1",COc(cc1)cc(c12)nc([nH]2)[S@@](=O)Cc3ncc(C)c(OC)c3C,C17H19N3O3S,,D07917,9568614,46504894,50275,CHEMBL1201320,,7843323,,345.416,2.433509123,"2-Pyridinylmethylsulfinylbenzimidazoles; Acid Reducers; Alimentary Tract and Metabolism; Anti-Ulcer Agents; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Benzimidazoles; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Enzyme Inhibitors; Gastric Acid Lowering Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Medications that reduce magnesium levels; Musculo-Skeletal System; OAT3/SLC22A8 Inhibitors; Omeprazole and enantiomer; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Propionates; Proton Pump Inhibitors; Proton-pump Inhibitors; Pyridines; Sulfoxides; Sulfur Compounds"
DB00737,Meclizine,569-65-3,approved,OCJYIGYOJCODJL-UHFFFAOYSA-N,"InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3",Cc1cc(ccc1)CN2CCN(CC2)C(c3ccccc3)c4ccc(Cl)cc4,C25H27ClN2,C07116,D08163,4034,46507782,6709,CHEMBL1623,,3894,81467,390.948,6.387941532,"Anti-Allergic Agents; Antiemetics; Antihistamines for Systemic Use; Antivertigo Preparations; Autonomic Agents; Benzene Derivatives; Benzhydryl Compounds; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Emesis Suppression; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; Peripheral Nervous System Agents; Piperazine Derivatives; Piperazines; Respiratory System"
DB00738,Pentamidine,100-33-4,approved; investigational,XDRYMKDFEDOLFX-UHFFFAOYSA-N,"InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)",NC(=N)c1ccc(cc1)OCCCCCOc2ccc(cc2)C(N)=N,C19H24N4O2,C07420,,4735,46508562,45081,CHEMBL55,PNT,4573,45440,340.4195,2.322452181,"Agents Against Leishmaniasis and Trypanosomiasis; Agents causing hyperkalemia; Amidines; Anti-Infective Agents; Antibiotics for Pneumocystis Pneumonia; Antifungal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Benzamidines; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Hyperglycemia-Associated Agents; Hypoglycemia-Associated Agents; Medications that reduce magnesium levels; Miscellaneous Antiprotozoals; Moderate Risk QTc-Prolonging Agents; Nephrotoxic agents; QTc Prolonging Agents; Trypanocidal Agents"
DB00739,Hetacillin,3511-16-8,approved; vet_approved; withdrawn,DXVUYOAEDJXBPY-NFFDBFGFSA-N,"InChI=1S/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)/t11-,12-,13+,16-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)N(C3(C)C)C(=O)[C@H](N3)c4ccccc4,C19H23N3O4S,C11729,D01074,443387,46504545,5683,CHEMBL1201116,,391616,,389.469,-0.015010228,"Amides; Anti-Bacterial Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB00740,Riluzole,1744-22-5,approved; investigational,FTALBRSUTCGOEG-UHFFFAOYSA-N,"InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)",Nc(s1)nc(c12)ccc(c2)OC(F)(F)F,C8H5F3N2OS,C07937,D00775,5070,46508094,8863,CHEMBL744,657,4892,30705,234.198,3.399907403,"Anticonvulsants; Azoles; BCRP/ABCG2 Substrates; Benzothiazoles; Central Nervous System Agents; Central Nervous System Depressants; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Excitatory Amino Acid Agents; Excitatory Amino Acid Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Miscellaneous Central Nervous System Agents; Nervous System; Neuroprotective Agents; Neurotransmitter Agents; Protective Agents; Sulfur Compounds; Thiazoles"
DB00741,Hydrocortisone,50-23-7,approved; vet_approved,JYGXADMDTFJGBT-VWUMJDOOSA-N,"InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",OCC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)CC4,C21H30O5,C00735,D00088,5754,46505089,17650,CHEMBL389621,HCY,5551,13775,362.4599,1.275166435,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Adrenals; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Alimentary Tract and Metabolism; Anti-Inflammatory Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Cardiovascular System; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids Acting Locally; Corticosteroids for Local Oral Treatment; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Corticosteroids, Dermatological Preparations; Corticosteroids, Weak (Group I); Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocortisone and derivatives; Hydroxycorticosteroids; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Intestinal Antiinflammatory Agents; Medications that reduce magnesium levels; Nasal Preparations; OAT3/SLC22A8 Substrates; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; P-glycoprotein inducers; P-glycoprotein substrates; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Respiratory System; Sensory Organs; Steroids; Stomatological Preparations; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Vasoprotectives"
DB00742,Mannitol,69-65-8,approved; investigational,FBPFZTCFMRRESA-KVTDHHQDSA-N,"InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,C6H14O6,C00392,D00062,6251,46506446,16899,CHEMBL689,MTL,6015,50142798,182.1718,-3.730018849,"Agents causing hyperkalemia; Alcohols; Alimentary Tract and Metabolism; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Carbohydrates; Cardiovascular Agents; Compounds used in a research, industrial, or household setting; Cough and Cold Preparations; Diagnostic Agents; Diet, Food, and Nutrition; Diuretics; Diuretics, Osmotic; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Expectorants; Flavoring Agents; Food; Food Additives; Food and Beverages; Food Ingredients; Hypotensive Agents; i.v. Solutions; Increased Diuresis; Irrigating Solutions; Kidney Function; Laxatives; Natriuretic Agents; Nephrotoxic agents; Osmotic Activity; Osmotic Laxatives; P-glycoprotein substrates; Pharmaceutic Aids; Pharmaceutical Preparations; Physiological Phenomena; Respiratory System; Solutions Producing Osmotic Diuresis; Sugar Alcohols; Sweetening Agents"
DB00743,Gadobenic acid,113662-23-0,approved; investigational,MXZROTBGJUUXID-UHFFFAOYSA-K,"InChI=1S/C22H31N3O11.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);/q;+3/p-3",[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(=O)O)C(C(=O)O)COCc1ccccc1,C22H28GdN3O11,,D08018,131704172,46506805,,CHEMBL1200571,,94843,,667.73,-4.13838613,"Alcohols; Amino Sugars; Carbohydrates; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Gadolinium-based Contrast Agent; Hexosamines; Magnetic Resonance Contrast Activity; Magnetic Resonance Imaging Contrast Media; Moderate Risk QTc-Prolonging Agents; Other Diagnostics; Paramagnetic Contrast Agent; Paramagnetic Contrast Media; QTc Prolonging Agents; Sugar Alcohols"
DB00744,Zileuton,111406-87-2,approved; investigational; withdrawn,MWLSOWXNZPKENC-UHFFFAOYSA-N,"InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)",NC(=O)N(O)C(C)c(s1)cc(c12)cccc2,C11H12N2O2S,,D00414,60490,46506394,10112,CHEMBL93,,54531,50000541,236.29,2.006172835,"Agents to Treat Airway Disease; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Central Nervous System Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Leukotriene Production; Enzyme Inhibitors; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Leukotriene Antagonists; Lipoxygenase Inhibitors; Peripheral Nervous System Agents; Sensory System Agents; UGT1A9 Substrates"
DB00745,Modafinil,68693-11-8,approved; investigational,YFGHCGITMMYXAQ-UHFFFAOYSA-N,"InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)",c1ccccc1C(S(=O)CC(=O)N)c2ccccc2,C15H15NO2S,,D01832,4236,46504648,77585,CHEMBL1373,,4088,50156055,273.35,1.53283444,"Benzene Derivatives; Benzhydryl Compounds; Central Nervous System Agents; Central Nervous System Stimulants; Central Nervous System Stimulation; Centrally Acting Sympathomimetics; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (moderate); Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (moderate); Cytochrome P-450 CYP3A5 Inducers (weak); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Increased Sympathetic Activity; Metabolic Side Effects of Drugs and Substances; Modafinil and isomer; Nervous System; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Stimulants; Sympathomimetic-like Agent; Wakefulness-Promoting Agents"
DB00746,Deferoxamine,70-51-9,approved; investigational,UBQYURCVBFRUQT-UHFFFAOYSA-N,"InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)",CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,C25H48N6O8,C06940,D03670,2973,46506395,4356,CHEMBL556,,2867,47715,560.684,-3.365161825,"Amines; Carboxylic Acids; Chelating Agents; Compounds used in a research, industrial, or household setting; Heavy Metal Antagonists; Hydroxamic Acids; Hydroxy Acids; Hydroxylamines; Iron Chelating Activity; Iron Chelating Agents; Sequestering Agents; Siderophores"
DB00747,Scopolamine,51-34-3,approved; investigational,STECJAGHUSJQJN-FWXGHANASA-N,"InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1",[C@H]12[C@H]3[C@H](O3)[C@H](N1C)C[C@H](C2)OC(=O)[C@H](CO)c4ccccc4,C17H21NO4,C01851,D00138,3000322,46506966,16794,CHEMBL569713,,10194106,50240039,303.3529,0.894952295,"Adjuvants; Adjuvants, Anesthesia; Agents producing tachycardia; Alimentary Tract and Metabolism; Alkaloids; Anticholinergic Agents; Antiemetics; Antiemetics and Antinauseants; Antimuscarinics Antispasmodics; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Belladonna Alkaloids; Bicyclo Compounds, Heterocyclic; Central Nervous System Agents; Central Nervous System Depressants; Cholinergic Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Hypnotics and Sedatives; Muscarinic Antagonists; Mydriatics; Mydriatics and Cycloplegics; Nervous System; Neurotransmitter Agents; Ophthalmologicals; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Psycholeptics; Scopolamine Derivatives; Sensory Organs; Solanaceous Alkaloids; Tropanes"
DB00748,Carbinoxamine,486-16-8,approved,OJFSXZCBGQGRNV-UHFFFAOYSA-N,"InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3",c1cccnc1C(OCCN(C)C)c2ccc(Cl)cc2,C16H19ClN2O,C06871,,2564,46506787,3398,CHEMBL864,,2466,81464,290.788,3.271940619,"Aminoalkyl Ethers; Antihistamines for Systemic Use; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Photosensitizing Agents; QTc Prolonging Agents; Respiratory System"
DB00749,Etodolac,41340-25-4,approved; investigational; vet_approved,NNYBQONXHNTVIJ-UHFFFAOYSA-N,"InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)",c1ccc(CC)c(c12)[nH]c3c2CCOC3(CC)CC(=O)O,C17H21NO3,C06991,D00315,3308,46505184,4909,CHEMBL622,,3192,50016799,287.3535,3.443526408,"Acetic Acid Derivatives and Related Substances; Acids, Heterocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Central Nervous System Agents; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoleacetic Acids; Indoles; Musculo-Skeletal System; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; Other Nonsteroidal Anti-inflammatory Agents; Peripheral Nervous System Agents; Photosensitizing Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents; UGT1A3 substrates; UGT1A9 Substrates; UGT2B7 substrates"
DB00750,Prilocaine,721-50-6,approved,MVFGUOIZUNYYSO-UHFFFAOYSA-N,"InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)",CCCNC(C)C(=O)Nc1ccccc1C,C13H20N2O,C07531,D00553,4906,46505066,8404,CHEMBL1194,,4737,50225477,220.3107,2.680922716,"Amides; Amines; Anesthetics; Anesthetics, Local; Anilides; Aniline Compounds; Central Nervous System Agents; Central Nervous System Depressants; Local Anesthesia; Local Anesthetics (Amide); Methemoglobinemia Associated Agents; Nervous System; Peripheral Nervous System Agents; Sensory System Agents"
DB00751,Epinastine,80012-43-7,approved; investigational,WHWZLSFABNNENI-UHFFFAOYSA-N,"InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)",NC1=NCC(N12)c3c(cccc3)Cc4c2cccc4,C16H15N3,,D01713,3241,46509056,51032,CHEMBL1106,,3128,50131441,249.3104,3.073111086,"Acid Reducers; Antidepressive Agents; Azoles; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decongestants and Antiallergics; Decreased Histamine Release; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Inhibitors; Histamine H2 Antagonists; Neurotransmitter Agents; Ophthalmics; Ophthalmologicals; P-glycoprotein substrates; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System; Sensory Organs; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB00752,Tranylcypromine,155-09-9,approved; investigational,AELCINSCMGFISI-UHFFFAOYSA-N,"InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2",NC1CC1c2ccccc2,C9H11N,C07155,D08625,5530,46505832,131512,CHEMBL313833,GJZ,5329,50113851,133.194,1.33888247,"Agents that produce hypertension; Agents that reduce seizure threshold; Amines; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strong); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hypotensive Agents; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Monoamine Oxidase Inhibitors; Monoamine Oxidase Inhibitors, Non-Selective; Nervous System; Propylamines; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Tranquilizing Agents"
DB00753,Isoflurane,26675-46-7,approved; vet_approved,PIWKPBJCKXDKJR-UHFFFAOYSA-N,"InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H",FC(F)OC(Cl)C(F)(F)F,C3H2ClF5O,C07518,D00545,3763,46505880,6015,CHEMBL1256,ICF,3631,217353,184.492,2.835938004,"Agents that produce hypertension; Agents that reduce seizure threshold; Anesthetics; Anesthetics, General; Anesthetics, Inhalation; Anticholinergic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ethers; Hydrocarbons, Halogenated; Hypotensive Agents; Methyl Ethers; Nervous System; Nicotinic Antagonists; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB00754,Ethotoin,86-35-1,approved,SZQIFWWUIBRPBZ-UHFFFAOYSA-N,"InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)",CCN1C(=O)NC(C1=O)c2ccccc2,C11H12N2O2,C07839,D00708,3292,46504521,4888,CHEMBL1095,,3176,50239975,204.2252,1.066692958,"Anti-epileptic Agent; Anticonvulsants; Azoles; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Decreased Central Nervous System Disorganized Electrical Activity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydantoins; Imidazoles; Imidazolidines; Membrane Transport Modulators; Nervous System; Sodium Channel Blockers; Thyroxine-binding globulin substrates; Voltage-Gated Sodium Channel Blockers"
DB00755,Tretinoin,302-79-4,approved; investigational; nutraceutical,SHGAZHPCJJPHSC-YCNIQYBTSA-N,"InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+",OC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C(C1(C)C)=C(C)CCC1,C20H28O2,C00777,D00094,5538,46504843,15367,CHEMBL38,REA,392618,31883,300.442,5.014367711,"Alkenes; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Biological Factors; Cardiotoxic antineoplastic agents; Carotenoids; Cell Stimulants and Proliferants; Cyclohexanes; Cyclohexenes; Cycloparaffins; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hypotensive Agents; Immunosuppressive Agents; Keratolytic Agents; Macrocyclic Compounds; Pigments, Biological; Polycyclic Compounds; Polyenes; Retinoids; Retinoids for Topical Use in Acne; Terpenes; Tretinoin; Vitamin A; Vitamins; Vitamins (Fat Soluble)"
DB00756,Hexachlorophene,70-30-4,approved; withdrawn,ACGUYXCXAPNIKK-UHFFFAOYSA-N,"InChI=1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2",Clc1cc(Cl)c(Cl)c(c1O)Cc2c(O)c(Cl)cc(Cl)c2Cl,C13H6Cl6O2,C08039,D00859,3598,46505858,5693,CHEMBL496,H3P,3472,31712,406.904,7.082177258,"Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Benzene Derivatives; Chlorobenzenes; Chlorophenols; Dermatologicals; Drugs causing inadvertant photosensitivity; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Chlorinated; Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Phenol and Derivatives; Phenols; Photosensitizing Agents"
DB00757,Dolasetron,115956-12-2,approved; investigational,UKTAZPQNNNJVKR-KJGYPYNMSA-N,"InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11-,12-,13+,14+",O=C([C@H]12)CN3[C@@H](C2)C[C@H](C[C@H]3C1)OC(=O)c4c[nH]c(c45)cccc5,C19H20N2O3,C07866,,3033818,46505209,,CHEMBL2368925,,30845229,50451546,324.38,2.32589023,"Alimentary Tract and Metabolism; Antidepressive Agents; Antiemetics; Antiemetics and Antinauseants; Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Peripheral Nervous System Agents; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 3 Receptor Antagonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB00758,Clopidogrel,113665-84-2,approved,GKTWGGQPFAXNFI-HNNXBMFYSA-N,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",c1csc(c12)CCN(C2)[C@H](C(=O)OC)c3ccccc3Cl,C16H16ClNO2S,,D00769,60606,46507295,37941,CHEMBL1771,CGE,54632,50397662,321.822,4.031763908,"Antiplatelet agents; Blood and Blood Forming Organs; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Platelet Aggregation; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; P2Y12 Platelet Inhibitor; Platelet Aggregation Inhibitors Excl. Heparin; Purinergic Agents; Purinergic Antagonists; Purinergic P2 Receptor Antagonists; Purinergic P2Y Receptor Antagonists; Pyridines; Sulfur Compounds; Thienopyridines; Thiophenes"
DB00759,Tetracycline,60-54-8,approved; vet_approved,OFVLGDICTFRJMM-WESIUVDSSA-N,"InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25,27-28,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c([C@@]3(C)O)cccc4O,C22H24N2O8,C06570,D00201,54675776,46506693,27902,CHEMBL1440,TAC,10257122,50237605,444.4346,-3.547615393,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Topical Use; Antiinfectives and Antiseptics for Local Oral Treatment; Antiinfectives for Systemic Use; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Drugs causing inadvertant photosensitivity; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; Naphthacenes; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Protein Synthesis Inhibitors; Sensory Organs; Stomatological Preparations; Tetracycline, antagonists & inhibitors; Tetracyclines"
DB00760,Meropenem,96036-03-2,approved; investigational,DMJNNHOOLUXYBV-PQTSNVLCSA-N,"InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1",C[C@@H](O)[C@H]1C(=O)N([C@@H]12)C(C(=O)O)=C([C@@H]2C)S[C@@H]3CN[C@@H](C3)C(=O)N(C)C,C17H25N3O5S,,D02222,441130,46504928,43968,CHEMBL127,MEM,389924,50129062,383.463,-4.353987287,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Carbapenems; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penem Antibacterial; Sulfur Compounds; Thienamycins"
DB00761,Potassium chloride,7447-40-7,approved; withdrawn,WCUXLLCKKVVCTQ-UHFFFAOYSA-M,InChI=1S/ClH.K/h1H;/q;+1/p-1,[Cl-],ClK,,D02060,4873,46506038,32588,CHEMBL1200731,,4707,,74.551,0.2,"Acids; Acids, Noncarboxylic; Agents causing hyperkalemia; Alimentary Tract and Metabolism; Anions; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Chlorides; Chlorine Compounds; Drugs that are Mainly Renally Excreted; Electrolyte Solutions; Electrolytes; Hemodialysis Solution; I.V. Solution Additives; Ions; Mineral Supplements; Minerals; Potassium Compounds; Potassium Salt; Replacement Preparations"
DB00762,Irinotecan,97682-44-5,approved; investigational,UWKQSNNFCGGAFS-XIFFEERXSA-N,"InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1",CC[C@@]1(O)C(=O)OCc(c12)c(=O)n3c(c2)c4c(C3)c(CC)c5c(n4)ccc(c5)OC(=O)N6CCC(CC6)N7CCCCC7,C33H38N4O6,C16641,D08086,60838,46505871,80630,CHEMBL481,CP0,54825,50128267,586.678,2.776473123,Alkaloids; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Carbohydrates; Cholinesterase substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Disaccharides; Enzyme Inhibitors; FOLFIRI chemotherapy regimen; Heterocyclic Compounds; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; Oligosaccharides; P-glycoprotein substrates; Pharmaceutical Preparations; Polysaccharides; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; UGT1A1 Substrates; UGT1A9 Substrates
DB00763,Methimazole,60-56-0,approved,PMRYVIKBURPHAH-UHFFFAOYSA-N,"InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)",Cn1cc[nH]c1=S,C4H6N2S,C07190,D00401,1349907,46506536,50673,CHEMBL1515,MMZ,1131173,50241361,114.169,0.74567047,"Antithyroid agents; Azoles; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (weak); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strong); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Imidazoles; Immunosuppressive Agents; Myelosuppressive Agents; Sulfur Compounds; Sulfur-Containing Imidazole Derivatives; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroid Hormone Synthesis Inhibitor; Thyroid Hormone Synthesis Inhibitors; Thyroid Products"
DB00765,Metyrosine,672-87-7,approved,NHTGHBARYWONDQ-JTQLQIEISA-N,"InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1",OC(=O)[C@@](C)(N)Cc1ccc(O)cc1,C10H13NO3,C07921,D00762,441350,46506079,6912,CHEMBL1200862,,390103,,195.2151,-1.055864237,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Antihypertensive Agents; Cardiovascular System; Catecholamine Synthesis Inhibitor; Enzyme Inhibitors; Methyltyrosines; Tyrosine Hydroxylase Inhibitors"
DB00766,Clavulanic acid,58001-44-8,approved; vet_approved,HZZVJAQRINQKSD-PBFISZAISA-N,"InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1",O=C1C[C@H](N12)OC(\[C@@H]2C(=O)O)=C/CO,C8H9NO5,C06662,,5280980,46508845,48947,CHEMBL777,J01,4444466,50021959,199.1608,-1.521207563,"Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamase Inhibitors; beta-Lactams; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams"
DB00768,Olopatadine,113806-05-6,approved,JBIMVDZLSHOPLA-LSCVHKIXSA-N,"InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-",CN(C)CC/C=C\1c(cccc2)c2COc(c13)ccc(c3)CC(=O)O,C21H23NO3,C07789,,5281071,46506025,,CHEMBL1189432,,4444528,50002096,337.4122,0.746255519,"Anti-Allergic Agents; Anti-Inflammatory Agents; Antiallergic Agents, Excl. Corticosteroids; Antihistamine Drugs; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Decongestants and Antiallergics; Decreased Histamine Release; Dibenzoxepins; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Histamine H1 Inhibitors; Mast Cell Stabilizers; Nasal Preparations; Neurotransmitter Agents; Ophthalmologicals; P-glycoprotein substrates; Peripheral Nervous System Agents; QTc Prolonging Agents; Respiratory System; Sensory Organs; Sensory System Agents"
DB00769,Hydrocortamate,76-47-1,approved,FWFVLWGEFDIZMJ-FOMYWIRZSA-N,"InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COC(=O)CN(CC)CC,C27H41NO6,,,84088,46509076,50851,CHEMBL1201263,,75860,,475.6175,2.321406243,Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers
DB00770,Alprostadil,745-65-3,approved; investigational,GMVPRGQOIOIIMI-DWKJAMRDSA-N,"InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1",CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,C20H34O5,C04741,D00180,149351,46508029,15544,CHEMBL495,XPG,4444306,50101853,354.487,3.587191794,"Autacoids; Biological Factors; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Drugs Used in Erectile Dysfunction; Eicosanoids; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Genito Urinary System and Sex Hormones; Genitourinary Arterial Vasodilation; Hematologic Agents; Inflammation Mediators; Lipids; Miscellaneous Vasodilatating Agents; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; Prostaglandin E1 Agonist; Prostaglandin Receptor Agonists; Prostaglandins; Prostaglandins E; Prostaglandins, Synthetic; Urological Agents; Urologicals; Vasodilating Agents; Venous Vasodilation"
DB00771,Clidinium,7020-55-5,approved,HOOSGZJRQIVJSZ-NNBUQUNQSA-N,"InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1/t17-,20?,23+",C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(c3ccccc3)c4ccccc4,C22H26NO3,C07853,,2784,46507814,3743,,,26330531,50055977,352.4467,-1.08324647,"Acids, Carbocyclic; Agents producing tachycardia; Alimentary Tract and Metabolism; Anticholinergic Agents; Autonomic Agents; Benzilates; Carboxylic Acids; Central Nervous System Depressants; Decreased Parasympathetic Acetylcholine Activity; Digestive/GI System Activity Alteration; Diphenylacetic Acids; Drugs for Functional Gastrointestinal Disorders; GI Motility Alteration; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Hydroxy Acids; Muscarinic Antagonists; Parasympatholytics; Peripheral Nervous System Agents; Phenylacetates; Quinuclidines"
DB00772,Malathion,121-75-5,approved; investigational,JXSJBGJIGXNWCI-UHFFFAOYSA-N,"InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3",CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,C10H19O6PS2,C07497,D00534,4004,46505287,141474,CHEMBL1200468,,3864,85372,330.358,1.857283206,"Agrochemicals; Antiparasitic Products, Insecticides and Repellents; Cholinergic Agents; Cholinesterase Inhibitors; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 Substrates; Ectoparasiticides, Incl. Scabicides; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents; Enzyme Inhibitors; Insecticides; Neurotransmitter Agents; Organophosphates; Organophosphorus Compounds; Organothiophosphates; Organothiophosphorus Compounds; Pesticides; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sulfur Compounds; Toxic Actions"
DB00773,Etoposide,33419-42-0,approved,VJJPUSNTGOMMGY-MRVIYFEKSA-N,"InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1",COc1cc(cc(c1O)OC)[C@@H]2c(cc3c(c4)OCO3)c4[C@H]([C@H]([C@@H]25)COC5=O)O[C@@H]([C@H](O)[C@H]6O)O[C@@H]([C@H]67)CO[C@H](O7)C,C29H32O13,C01576,D00125,36462,46505434,4911,CHEMBL44657,EVP,33510,50127140,588.5566,1.160430458,"Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; BEACOPP chemotherapy regimen; Benzene Derivatives; Benzyl Compounds; Carbohydrates; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Glucosides; Glycosides; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Lignans; Myelosuppressive Agents; Naphthalenes; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Podophyllotoxin; Podophyllotoxin Derivatives; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Tetrahydronaphthalenes; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; UGT1A1 Substrates; UGT1A1 substrates with narrow therapeutic index"
DB00774,Hydroflumethiazide,135-09-1,approved; investigational; withdrawn,DMDGGSIALPNSEE-UHFFFAOYSA-N,"InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)",FC(F)(F)c(c1)c(S(=O)(=O)N)cc(c12)S(=O)(=O)NCN2,C8H8F3N3O4S2,C07763,D00654,3647,46505220,5784,CHEMBL1763,HFZ,3521,25897,331.292,-0.301813971,"Amides; Antihypertensive Agents; Benzothiadiazines; Cardiovascular Agents; Cardiovascular System; Diuretics; Drugs causing inadvertant photosensitivity; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Increased Diuresis; Membrane Transport Modulators; Natriuretic Agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Photosensitizing Agents; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazides"
DB00775,Tirofiban,144494-65-5,approved,COKMIXFXJJXBQG-NRFANRHFSA-N,"InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1",CCCCS(=O)(=O)N[C@H](C(=O)O)Cc1ccc(cc1)OCCCCC2CCNCC2,C22H36N2O5S,C07965,,60947,46504678,9605,CHEMBL916,AGG,54912,50004058,440.597,0.598296992,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Antiplatelet agents; Blood and Blood Forming Organs; Cardiovascular Agents; Decreased Platelet Aggregation; Drugs that are Mainly Renally Excreted; Fibrin Modulating Agents; Hematologic Agents; Platelet Aggregation Inhibitors Excl. Heparin"
DB00776,Oxcarbazepine,28721-07-5,approved,CTRLABGOLIVAIY-UHFFFAOYSA-N,"InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)",c1cccc(c12)C(=O)Cc3c(N2C(=O)N)cccc3,C15H12N2O2,C07492,D00533,34312,46507580,7824,CHEMBL1068,,31608,34179,252.268,1.818176689,"Anti-epileptic Agent; Anticonvulsants; Carboxamide Derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Decreased Central Nervous System Disorganized Electrical Activity; Dibenzazepines; Drugs causing inadvertant photosensitivity; Enzyme Inducing Antiepileptic Drugs; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Membrane Transport Modulators; Metabolic Side Effects of Drugs and Substances; Miscellaneous Anticonvulsants; Nervous System; P-glycoprotein inducers; P-glycoprotein substrates; Photosensitizing Agents; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB00777,Propiomazine,362-29-8,approved,UVOIBTBFPOZKGP-UHFFFAOYSA-N,"InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3",CCC(=O)c(cc1)cc(c12)N(CC(C)N(C)C)c3c(S2)cccc3,C20H24N2OS,C07405,D02361,4940,46506205,8491,CHEMBL1201210,,4771,,340.482,4.545754217,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Anticholinergic Agents; Antidepressive Agents; Central Nervous System Depressants; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Hypnotics and Sedatives; Muscarinic Antagonists; Nervous System; Psycholeptics; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds"
DB00778,Roxithromycin,80214-83-1,approved; investigational; withdrawn,RXZBMPWDPOLZGW-XMRMVWPWSA-N,"InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1",COCCOCO/N=C([C@H](C)[C@@H](O)[C@]1(C)O)/[C@H](C)C[C@@](C)(O)[C@@H]([C@@H](C)[C@@H]([C@@H](C)C(=O)O[C@@H]1CC)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C,C41H76N2O15,C13173,D01710,6915744,46507676,48935,CHEMBL1214185,ROX,5291557,,837.0465,2.999979282,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Erythromycin and similars; Lactones; Macrocyclic Compounds; Macrolides; Macrolides, Lincosamides and Streptogramins; Moderate Risk QTc-Prolonging Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Polycyclic Compounds; Polyketides; QTc Prolonging Agents"
DB00779,Nalidixic acid,389-08-2,approved; investigational,MHWLWQUZZRMNGJ-UHFFFAOYSA-N,"InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)",CCn1cc(C(=O)O)c(=O)c(c12)ccc(n2)C,C12H12N2O3,C05079,D00183,4421,46507401,100147,CHEMBL5,NIX,4268,21691,232.2353,1.008252571,"4-Quinolones; Agents that reduce seizure threshold; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; Naphthyridines; OAT1/SLC22A6 inhibitors; Photosensitizing Agents; QTc Prolonging Agents; Quinolines; Quinolones; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00780,Phenelzine,51-71-8,approved,RMUCZJUITONUFY-UHFFFAOYSA-N,"InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2",NNCCc1ccccc1,C8H12N2,C07430,D08349,3675,46507348,8060,CHEMBL1089,,3547,50105417,136.1943,1.203020043,"Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydrazines; Hypotensive Agents; Monoamine Oxidase A Substrates; Monoamine Oxidase Inhibitors; Monoamine Oxidase Inhibitors, Non-Selective; Nervous System; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB00782,Propantheline,298-50-0,approved,VVWYOYDLCMFIEM-UHFFFAOYSA-N,"InChI=1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1",CC(C)[N+](C)(C(C)C)CCOC(=O)C1c(cccc2)c2Oc(c13)cccc3,C23H30NO3,C07506,,4934,46507187,8481,CHEMBL1180725,,4765,,368.4892,0.363793644,"Agents producing tachycardia; Alimentary Tract and Metabolism; Amines; Ammonium Compounds; Anti-Ulcer Agents; Anticholinergic Agents; Cholinergic Agents; Drugs for Functional Gastrointestinal Disorders; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Muscarinic Antagonists; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Quaternary Ammonium Compounds; Synthetic Anticholinergics, Quaternary Ammonium Compounds; Xanthenes"
DB00783,Estradiol,50-28-2,approved; investigational; vet_approved,VOXZDWNPVJITMN-ZBRFXRBCSA-N,"InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1",O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(O)cc4,C18H24O2,C00951,D00105,5757,46508115,16469,CHEMBL135,EST,5554,17292,272.382,3.745501328,"Adrenal Cortex Hormones; Androgens and Estrogens; Antiandrogens and Estrogens; BCRP/ABCG2 Inhibitors; COMT Substrates; Contraceptive Agents, Female; Contraceptives, Oral; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estradiol Congeners; Estradiol, agonists; Estranes; Estrenes; Estrogen Contraceptives; Estrogens; Estrogens, agonists; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Intravaginal Contraceptives; Medications that reduce magnesium levels; Natural and Semisynthetic Estrogens, Plain; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Progestogens and Estrogens, Sequential Preparations; Sex Hormones and Modulators of the Genital System; Steroids; Thyroxine-binding globulin inducers; UGT1A1 Substrates"
DB00784,Mefenamic acid,61-68-7,approved,HYYBABOKPJLUIN-UHFFFAOYSA-N,"InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)",Cc1c(C)c(ccc1)Nc2ccccc2C(=O)O,C15H15NO2,C02168,D00151,4044,46505405,6717,CHEMBL686,ID8,3904,50134036,241.2851,5.397597278,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Amines; Aminobenzoates; Analgesics; Analgesics, Non-Narcotic; Aniline Compounds; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Fenamates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Musculo-Skeletal System; Nephrotoxic agents; ortho-Aminobenzoates; Other Nonsteroidal Anti-inflammatory Agents; Peripheral Nervous System Agents; Photosensitizing Agents; Sensory System Agents; UGT1A9 Inhibitors"
DB00785,Cryptenamine,1356-18-9,approved,,, ,,,,,46507822,,,,,,NA,NA,"Alkaloids; Antihypertensive Agents; Cardiovascular Agents; Cevanes; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Veratrum Alkaloids"
DB00787,Acyclovir,59277-89-3,approved,MKUXAQIIEYXACX-UHFFFAOYSA-N,"InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)",Nc([nH]1)nc(=O)c(c12)ncn2COCCO,C8H11N5O3,C06810,D00222,2022,46506002,2453,CHEMBL184,AC2,1945,50021776,225.2046,-1.031956766,"Acyclovir and prodrug; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; MATE 1 Substrates; MATE 2 Substrates; MATE substrates; Nephrotoxic agents; Nucleic Acid Synthesis Inhibitors; Nucleosides and Nucleotides; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OCT1 inhibitors; OCT1 substrates; Ophthalmologicals; Purines; Purinones; Sensory Organs"
DB00788,Naproxen,22204-53-1,approved; vet_approved,CMWTZPSULFXXJA-VIFPVBQESA-N,"InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1",COc(cc1)cc(c12)ccc(c2)[C@H](C)C(=O)O,C14H14O3,C01517,D00118,156391,46505508,7476,CHEMBL154,NPS,137720,50339185,230.2592,2.985785875,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antigout Preparations; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antiinflammatory Products for Vaginal Administration; Antirheumatic Agents; Arylpropionic acid NSAIDS; BSEP/ABCB11 Substrates; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Musculo-Skeletal System; Naphthaleneacetic Acids; Naphthalenes; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; Other Nonsteroidal Anti-inflammatory Agents; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Propionates; Sensory System Agents; Topical Products for Joint and Muscular Pain; UGT1A1 Substrates; UGT1A3 substrates; UGT1A6 substrate; UGT1A9 Substrates; UGT2B7 substrates"
DB00789,Gadopentetic acid,80529-93-7,approved,IZOOGPBRAOKZFK-UHFFFAOYSA-K,"InChI=1S/C14H23N3O10.Gd/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3",OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)O,C14H20GdN3O10,,,55466,46504878,35778,CHEMBL1200431,,138549,,547.58,-6.273562252,"Acetates; Acids, Acyclic; Amines; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Fatty Acids; Fatty Acids, Volatile; Lipids; Magnetic Resonance Contrast Activity; Magnetic Resonance Imaging Contrast Media; Miscellaneous Therapeutic Agents; Organometallic Compounds; Paramagnetic Contrast Agent; Paramagnetic Contrast Media; Polyamines"
DB00790,Perindopril,82834-16-0,approved,IPVQLZZIHOAWMC-QXKUPLGCSA-N,"InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1",C1CCC[C@H]([C@H]12)C[C@@H](C(=O)O)N2C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC,C19H32N2O5,C07706,D03753,107807,46508767,8024,CHEMBL1581,,96956,,368.4678,0.630743839,"ACE Inhibitors and Calcium Channel Blockers; ACE Inhibitors and Diuretics; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Cholinesterase Inhibitors; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Indoles; Lipid Modifying Agents; Protease Inhibitors"
DB00791,Uracil mustard,66-75-1,approved,IDPUKCWIGUEADI-UHFFFAOYSA-N,"InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)",ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O,C8H11Cl2N3O2,C11686,D06265,6194,46506168,9884,CHEMBL1488,,5959,,252.098,0.40531176,"Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Halogenated; Mustard Compounds; Narrow Therapeutic Index Drugs; Nitrogen Mustard Compounds; Nitrosoureas; Noxae; Pyrimidines; Pyrimidinones; Toxic Actions"
DB00792,Tripelennamine,91-81-6,approved; vet_approved,UFLGIAIHIAPJJC-UHFFFAOYSA-N,"InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3",c1cccnc1N(CCN(C)C)Cc2ccccc2,C16H21N3,C07180,,5587,46506125,9741,CHEMBL1241,,5385,81471,255.358,3.201192417,"Amines; Aminopyridines; Anti-Allergic Agents; Antihistamines for Systemic Use; Antihistamines for Topical Use; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Diamines; Ethylenediamine Derivatives; Ethylenediamines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Neurotransmitter Agents; Polyamines; Pyridines; Respiratory System; Substituted Ethylene Diamines"
DB00793,Haloprogin,777-11-7,approved; withdrawn,CTETYYAZBPJBHE-UHFFFAOYSA-N,"InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2",Clc1cc(Cl)c(Cl)cc1OCC#CI,C9H4Cl3IO,,D00339,3561,46504892,5614,CHEMBL1289,,3440,50194601,361.391,4.8453,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Benzene Derivatives; Dermatologicals; Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols"
DB00794,Primidone,125-33-7,approved; vet_approved,DQMZLTXERSFNPB-UHFFFAOYSA-N,"InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)",c1ccccc1C2(CC)C(=O)NCNC2=O,C12H14N2O2,C07371,D00474,4909,46507775,8412,CHEMBL856,,4740,50248152,218.2518,1.118298853,"Anti-epileptic Agent; Anticholinergic Agents; Anticonvulsants; Barbiturates; Barbiturates and Derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Inducers (strong); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Enzyme Inducing Antiepileptic Drugs; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; Phenobarbital and similars; Psycholeptics; Pyrimidines; Pyrimidinones; UGT1A1 Inducers"
DB00795,Sulfasalazine,599-79-1,approved,NCEXYHBECQHGNR-QZQOTICOSA-N,"InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+",OC(=O)c1cc(ccc1O)/N=N/c2ccc(cc2)S(=O)(=O)Nc3ncccc3,C18H14N4O5S,C07316,D00448,5359476,46505451,9334,CHEMBL421,SAS,10605946,50103596,398.393,4.247607463,"Agents causing hyperkalemia; Agents that produce hypertension; Alimentary Tract and Metabolism; Amides; Aminosalicylate; Analgesics; Analgesics, Non-Narcotic; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antirheumatic Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Central Nervous System Agents; Gastrointestinal Agents; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Immunosuppressive Agents; Intestinal Antiinflammatory Agents; Methemoglobinemia Associated Agents; Nephrotoxic agents; Non COX-2 selective NSAIDS; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Peripheral Nervous System Agents; Salicylates; Sensory System Agents; Sulfonamides; Sulfones; Sulfur Compounds"
DB00796,Candesartan cilexetil,145040-37-5,approved,GHOSNRCGJFBJIB-UHFFFAOYSA-N,"InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)",C1CCCCC1OC(=O)OC(C)OC(=O)c2cccc(c23)nc(OCC)n3Cc4ccc(cc4)-c5ccccc5-c6nnn[nH]6,C33H34N6O6,,D00626,2540,46508342,3348,CHEMBL1014,,2444,50318907,610.671,7.531521167,"Agents Acting on the Renin-Angiotensin System; Agents causing hyperkalemia; Angiotensin 2 Receptor Blocker; Angiotensin II Antagonists and Diuretics; Angiotensin Receptor Antagonists; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Azoles; Benzene Derivatives; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; P-glycoprotein inhibitors; UGT1A3 substrates"
DB00797,Tolazoline,59-98-3,approved; vet_approved,JIVZKJJQOZQXQB-UHFFFAOYSA-N,"InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)",N1CCN=C1Cc2ccccc2,C10H12N2,C07147,,5504,46505641,28502,CHEMBL770,,5303,55436,160.2157,1.203640193,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antihypertensive Agents; Azoles; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Imidazoles; Imidazoline Derivatives; Imidazolines; Musculo-Skeletal System; Neurotransmitter Agents; Peripheral alpha-1 blockers; Peripheral Vasodilators; Topical Products for Joint and Muscular Pain; Vasodilating Agents"
DB00798,Gentamicin,1403-66-3,approved; vet_approved,CEAZRRDELHUEMR-UHFFFAOYSA-N,"InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3",CNC(C)C1CCC(N)C(O1)OC2C(N)CC(N)C(C2O)OC(OCC3(C)O)C(O)C3NC,C21H43N5O7,C00505,,3467,46506523,17833,CHEMBL329592,,3348,,477.5954,-3.137155529,"Agents that produce neuromuscular block (indirect); alpha-Galactosidase, antagonists & inhibitors; Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Topical Use; Antiinfectives for Systemic Use; Carbohydrates; Dermatologicals; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inhibitors; Gentamicins; Glycosides; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; Protein Synthesis Inhibitors; Sensory Organs"
DB00799,Tazarotene,118292-40-3,approved; investigational,OGQICQVSFDPSEI-UHFFFAOYSA-N,"InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3",CCOC(=O)c1cnc(cc1)C#Cc(cc2)cc(c23)C(C)(C)CCS3,C21H21NO2S,C12531,D01132,5381,46508992,32184,CHEMBL1657,,5188,50265951,351.462,5.218740552,"Acids, Heterocyclic; Antipsoriatics; Antipsoriatics for Topical Use; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Gels; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Keratolytic Agents; Misc. Skin and Mucous Membrane Agents; Noxae; Prodrugs; Pyridines; Retinoids; Teratogens; Toxic Actions"
DB00800,Fenoldopam,67227-56-9,approved,TVURRHSHRRELCG-UHFFFAOYSA-N,"InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2",Oc1ccc(cc1)C2CNCCc(c23)c(Cl)c(O)c(c3)O,C16H16ClNO3,C07693,D00613,3341,46504963,5002,CHEMBL588,,3224,60917,305.756,1.920520197,"Adrenergic and Dopaminergic Agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Benzazepines; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Dopamine Agents; Dopamine Agonists; Dopamine D1 Receptor Agonists; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Neurotransmitter Agents; Vasodilating Agents"
DB00801,Halazepam,23092-17-3,approved; illicit; withdrawn,WYCLKVQLVUQKNZ-UHFFFAOYSA-N,"InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2",c1c(Cl)ccc(c12)N(CC(F)(F)F)C(=O)CN=C2c3ccccc3,C17H12ClF3N2O,,D00338,31640,46508415,5603,CHEMBL970,,29343,50408018,352.738,4.031182804,"Anti-Anxiety Agents; Benzazepines; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB00802,Alfentanil,71195-58-9,approved; illicit,IDBPHNDTYPBSNI-UHFFFAOYSA-N,"InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3",CCn1nnn(c1=O)CCN(CC2)CCC2(COC)N(C(=O)CC)c3ccccc3,C21H32N6O3,C08005,D07122,51263,46505618,2569,CHEMBL634,,46451,83450,416.5172,2.807373758,"Agents that produce hypertension; Analgesics; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Bradycardia-Causing Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Fentanyl and fentanyl analogues; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; High-risk opioids; Narcotics; Nervous System; Opiate Agonists; Opioid Agonist; Opioid Anesthetics; Opioids; Opioids, Anilidopiperidine; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Phenylpiperidine opioids; Piperidines; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00803,Colistin,1066-17-7,approved,YKQOSKADJPQZHB-BRLOSWAASA-N,"InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36-,37+,38-,39?,41?,42+/m1/s1",CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C([C@@H](C)O)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC1=O)CCN,C52H98N16O13,C13768,D02138,131704173,46505467,,CHEMBL407135,,,,1155.455,-8.095955484,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Amino Acids, Peptides, and Proteins; Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antiinfectives for Systemic Use; Antimicrobial Cationic Peptides; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Intestinal Antiinfectives; Lipids; Lipopeptides; Macrocyclic Compounds; Membrane Proteins; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Peptides; Peptides, Cyclic; Polycyclic Compounds; Polymyxins; Pore Forming Cytotoxic Proteins; Proteins"
DB00804,Dicyclomine,77-19-0,approved,CURUTKGFNZGFSE-UHFFFAOYSA-N,"InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3",CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,C19H35NO2,C06951,,3042,46505371,4514,CHEMBL1123,,2934,50010101,309.4867,4.925893147,"Acids, Carbocyclic; Agents producing tachycardia; Alimentary Tract and Metabolism; Anticholinergic Agents; Antimuscarinics Antispasmodics; Autonomic Agents; Carboxylic Acids; Cholinergic Agents; Cyclohexanecarboxylic Acids; Cyclohexanes; Cycloparaffins; Drugs for Functional Gastrointestinal Disorders; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Muscarinic Antagonists; Neurotransmitter Agents; Parasympatholytics; Peripheral Nervous System Agents; Polycyclic Compounds; Synthetic Anticholinergics, Esters With Tertiary Amino Group"
DB00805,Minaprine,25905-77-5,approved,LDMWSLGGVTVJPG-UHFFFAOYSA-N,"InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)",c1ccccc1-c2cc(C)c(nn2)NCCN3CCOCC3,C17H22N4O,,D05039,4199,46505380,51038,CHEMBL278819,,4054,50074289,298.3828,2.189680242,"Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Monoamine Oxidase Inhibitors; Nervous System; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB00806,Pentoxifylline,06-05-6493,approved; investigational,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,"InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3",Cn1cnc(c12)n(C)c(=O)n(c2=O)CCCCC(=O)C,C13H18N4O3,C07424,D00501,4740,46505940,7986,CHEMBL628,PNX,4578,10850,278.307,0.232205846,"Alkaloids; Antioxidants; Antiplatelet agents; Blood Viscosity Reducer; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Free Radical Scavengers; Hematologic Activity Alteration; Hematologic Agents; Hemorrheologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Peripheral Vasodilators; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Protective Agents; Purine Derivatives; Purines; Purinones; Radiation-Protective Agents; Respiratory System; Vasodilating Agents; Xanthine derivatives"
DB00807,Proparacaine,499-67-2,approved; vet_approved,KCLANYCVBBTKTO-UHFFFAOYSA-N,"InChI=1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3",CCCOc1c(N)cc(cc1)C(=O)OCCN(CC)CC,C16H26N2O3,C07383,D08448,4935,46507960,8485,CHEMBL1196,,4766,50225500,294.3892,2.601716342,"Acids, Carbocyclic; Aminobenzoates; Anesthetics; Anesthetics, Local; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoate Ethers; Hydroxybenzoates; Isomerism; Local Anesthesia; Ophthalmologicals; para-Aminobenzoates; Peripheral Nervous System Agents; Phenols; Phenyl Ethers; Sensory Organs; Sensory System Agents"
DB00808,Indapamide,26807-65-8,approved,NDDAHWYSQHTHNT-UHFFFAOYSA-N,"InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)",c1cccc(c12)CC(C)N2NC(=O)c3cc(S(=O)(=O)N)c(Cl)cc3,C16H16ClN3O3S,,D00345,3702,46508626,5893,CHEMBL406,,3574,25901,365.835,2.639544322,"Amides; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diuretics; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Hypotensive Agents; Increased Diuresis; Indoles; Lipid Modifying Agents; Low-Ceiling Diuretics, Excl. Thiazides; Medications that reduce magnesium levels; Membrane Transport Modulators; Natriuretic Agents; Non Potassium Sparing Diuretics; Photosensitizing Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazide-like Diuretic"
DB00809,Tropicamide,1508-75-4,approved; investigational,BGDKAVGWHJFAGW-UHFFFAOYSA-N,"InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3",c1cnccc1CN(CC)C(=O)C(CO)c2ccccc2,C17H20N2O2,,D00397,5593,46505924,9757,CHEMBL1200604,,5391,82371,284.3529,1.37722739,"Anticholinergic Agents; Autonomic Agents; Cholinergic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists; Mydriatics; Mydriatics and Cycloplegics; Neurotransmitter Agents; Ophthalmologicals; Peripheral Nervous System Agents; Pyridines; Sensory Organs"
DB00810,Biperiden,514-65-8,approved; investigational,YSXKPIUOCJLQIE-UHFFFAOYSA-N,"InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2",c1ccccc1C(O)(C(CC23)C(C2)C=C3)CCN4CCCCC4,C21H29NO,C07941,D00779,2381,46508325,3112,CHEMBL1101,,2289,50240680,311.4611,3.536507462,"Agents producing tachycardia; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Anticholinergic Agents; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Bicyclo Compounds; Bicyclo Compounds, Heterocyclic; Bridged Compounds; Central Nervous System Agents; Cholinergic Agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Bridged-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; Parasympatholytics; Peripheral Nervous System Agents; Piperidines; Polycyclic Compounds; Tertiary Amines"
DB00811,Ribavirin,36791-04-5,approved,IWUCXVSUMQZMFG-AFCXAGJDSA-N,"InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1",NC(=O)c1nn(cn1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,C8H12N4O5,,D00423,37542,46505883,63580,CHEMBL1643,RBV,34439,50154375,244.2047,-2.768297395,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antimetabolites; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; Carbohydrates; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Glycosides; Noxae; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Analog Antiviral; Nucleosides; Nucleosides and Nucleotides; Ribonucleosides; Toxic Actions"
DB00812,Phenylbutazone,50-33-9,approved; vet_approved,VYMDGNCVAMGZFE-UHFFFAOYSA-N,"InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3",CCCCC1C(=O)N(c2ccccc2)N(C1=O)c3ccccc3,C19H20N2O2,C07440,D00510,4781,46507038,48574,CHEMBL101,P1Z,4617,,308.3743,4.135797766,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Azoles; Butylpyrazolidines; Central Nervous System Agents; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Peripheral Nervous System Agents; Pyrazoles; Pyrazolones; Sensory System Agents; Topical Products for Joint and Muscular Pain"
DB00813,Fentanyl,437-38-7,approved; illicit; investigational; vet_approved,PJMPHNIQZUBGLI-UHFFFAOYSA-N,"InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3",c1ccccc1N(C(=O)CC)C2CCN(CC2)CCc3ccccc3,C22H28N2O,,D00320,3345,46506372,119915,CHEMBL596,7V7,3228,50008984,336.4705,3.815498548,"Adjuvants; Adjuvants, Anesthesia; Agents that produce hypertension; Agents that reduce seizure threshold; Analgesics; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Antidepressive Agents; Bradycardia-Causing Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fentanyl and fentanyl analogues; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; High-risk opioids; Narcotics; Nervous System; Neuraxial Anesthetics; Opiate Agonists; Opioid Agonist; Opioid Anesthetics; Opioids; Opioids, Anilidopiperidine; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Phenylpiperidine opioids; Piperidines; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB00814,Meloxicam,71125-38-7,approved; vet_approved,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,"InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)",c1cccc(c12)C(O)=C(N(S2(=O)=O)C)C(=O)Nc3ncc(s3)C,C14H13N3O4S2,C08169,D00969,54677470,46506624,6741,CHEMBL599,MXM,10442740,50056998,351.401,1.600581361,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Azoles; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Other Nonsteroidal Anti-inflammatory Agents; Oxicams; Peripheral Nervous System Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents; Sulfur Compounds; Thiazines; Thiazoles"
DB00816,Orciprenaline,586-06-1,approved,LMOINURANNBYCM-UHFFFAOYSA-N,"InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8/h3-5,7,11-15H,6H2,1-2H3",CC(C)NCC(O)c1cc(O)cc(O)c1,C11H17NO3,C07144,D00685,4086,46504464,83329,CHEMBL776,,3944,50295572,211.2576,0.214961943,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Benzene Derivatives; Bronchodilator Agents; Catecholamines; Catechols; Drugs for Obstructive Airway Diseases; Ethanolamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; Non-selective Beta-adrenergic Agonists; Peripheral Nervous System Agents; Phenols; Reproductive Control Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists; Sympathomimetics; Tocolytic Agents"
DB00817,Rosoxacin,40034-42-2,approved; investigational,XBPZXDSZHPDXQU-UHFFFAOYSA-N,"InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)",CCn1cc(C(=O)O)c(=O)c(c12)ccc(c2)-c3ccncc3,C17H14N2O3,,D02305,287180,46508469,131715,CHEMBL291157,,253208,,294.3047,1.899295012,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines"
DB00818,Propofol,2078-54-8,approved; investigational; vet_approved,OLBCVFGFOZPWHH-UHFFFAOYSA-N,"InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3",CC(C)c1cccc(C(C)C)c1O,C12H18O,C07523,D00549,4943,46504991,44915,CHEMBL526,PFL,4774,50058046,178.2707,4.159698796,"Agents Causing Muscle Toxicity; Agents that produce hypertension; Agents that reduce seizure threshold; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Benzene Derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypnotics and Sedatives; Hypotensive Agents; Miscellaneous General Anesthetics; Nervous System; P-glycoprotein inducers; Phenols; Potential QTc-Prolonging Agents; QTc Prolonging Agents; UGT1A1 Inhibitors; UGT1A1 Substrates; UGT1A6 substrate; UGT1A9 Substrates"
DB00819,Acetazolamide,59-66-5,approved; vet_approved,BZKPWHYZMXOIDC-UHFFFAOYSA-N,"InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)",CC(=O)Nc1nnc(s1)S(=O)(=O)N,C4H6N4O3S2,C06805,D00218,1986,46504493,27690,CHEMBL20,AZM,1909,10880,222.245,-1.039466954,"Anticonvulsants; Antiglaucoma Agents; Antiglaucoma Preparations and Miotics; Azoles; Carbonic Anhydrase Inhibitors; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Diuretics; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Natriuretic Agents; OAT1/SLC22A6 inhibitors; Ophthalmologicals; Photosensitizing Agents; Sensory Organs; Sulfonamides; Sulfur Compounds; Thiadiazoles; Thiazoles"
DB00820,Tadalafil,171596-29-5,approved; investigational,WOXKDUGGOYFFRN-IIBYNOLFSA-N,"InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1",O1COc(c12)cc(cc2)[C@@H]3c(c4C[C@@H](N35)C(=O)N(C)CC5=O)[nH]c6c4cccc6,C22H19N3O4,,D02008,110635,46507646,71940,CHEMBL779,CIA,99301,14777,389.404,1.639340335,"Adrenergic alpha-Antagonists; Adrenergic Antagonists; Antihypertensive Agents; Antihypertensives for Pulmonary Arterial Hypertension; Carbolines; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs Used in Benign Prostatic Hypertrophy; Drugs Used in Erectile Dysfunction; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Pyridines; Urological Agents; Urologicals; Vasodilating Agents"
DB00821,Carprofen,53716-49-7,approved; vet_approved; withdrawn,PUXBGTOOZJQSKH-UHFFFAOYSA-N,"InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)",OC(=O)C(C)c(cc1)cc(c12)[nH]c3c2cc(Cl)cc3,C15H12ClNO2,C18364,,2581,46505357,364453,CHEMBL1316,,2483,50097346,273.714,3.875664933,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antirheumatic Agents; Central Nervous System Agents; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; Peripheral Nervous System Agents; Photosensitizing Agents; Radiation-Sensitizing Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents"
DB00822,Disulfiram,97-77-8,approved,AUZONCFQVSMFAP-UHFFFAOYSA-N,"InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3",CCN(CC)C(=S)SSC(=S)N(CC)CC,C10H20N2S4,C01692,D00131,3117,46506008,4659,CHEMBL964,,3005,50058655,296.539,4.159758922,"Acetyl Aldehyde Dehydrogenase Inhibitors; Acids; Acids, Acyclic; Acids, Noncarboxylic; Agents that reduce seizure threshold; Alcohol Deterrents; Aldehyde Dehydrogenase Inhibitor; Anions; Antiparasitic Products, Insecticides and Repellents; BSEP/ABCB11 Substrates; Carbamates; Carboxylic Acids; Central Nervous System Agents; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Disulfides; Drugs Used in Addictive Disorders; Drugs Used in Alcohol Dependence; Ectoparasiticides, Incl. Scabicides; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents; Electrolytes; Enzyme Inhibitors; Gases; Hydrogen Sulfide; Ions; Nervous System; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sulfides; Sulfur Compounds; Sulfur Containing Products; Thiocarbamates"
DB00823,Ethynodiol diacetate,297-76-7,approved,ONKUMRGIYFNPJW-KIEAKMPYSA-N,"InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1",CC(=O)O[C@@]1(C#C)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@@H]4C(CC3)=C[C@H](CC4)OC(=O)C,C24H32O4,C12724,D01294,9270,46506993,31580,CHEMBL1200624,,8913,50237627,384.5085,3.68814027,"Adrenal Cortex Hormones; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hyperglycemia-Associated Agents; Norpregnanes; Norpregnenes; Norsteroids; Polycyclic Compounds; Progestin Contraceptives; Progestins; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB00824,Enprofylline,41078-02-8,approved; experimental,SIQPXVQCUCHWDI-UHFFFAOYSA-N,"InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)",[nH]1cnc(c12)n(CCC)c(=O)[nH]c2=O,C8H10N4O2,,D04006,1676,46505790,126237,CHEMBL279898,,1613,50001493,194.1906,-0.113667373,"Adenosine A2 Receptor Antagonists; Alkaloids; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; Peripheral Nervous System Agents; Purinergic Agents; Purinergic Antagonists; Purinergic P1 Receptor Antagonists; Purines; Purinones; Respiratory System Agents"
DB00825,Levomenthol,2216-51-5,approved,NOOLISFMXDJSKH-KXUCPTDWSA-N,"InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1",CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C10H20O,C00400,D00064,16666,46506513,15409,CHEMBL470670,,15803,50318482,156.2652,2.664273147,"Agents causing hyperkalemia; Alcohols; Antiarrhythmic agents; Antipruritics; Antipruritics and Local Anesthetics; Basic Lotions and Liniments; Bradycardia-Causing Agents; Calcium Channel Blockers; Cyclohexanes; Cyclohexanols; Cycloparaffins; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; EENT Drugs, Miscellaneous; Fatty Alcohols; Herbs and Natural Products; Hexanols; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Lipids; Macrocyclic Compounds; Monoterpenes; Other Analgesics; Other Cold and Cough Preparations; Polycyclic Compounds; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Terpenes; Vasodilating Agents"
DB00826,Natamycin,7681-93-8,approved,NCXMLFZGDNKEPB-FFPOYIOWSA-N,"InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32+,33-/m1/s1",O[C@]12C[C@@H](O)C[C@@H]3[C@H](O3)/C=C/C(=O)O[C@H](C)C/C=C/C=C/C=C/C=C/[C@@H](C[C@H](O1)[C@@H]([C@H](C2)O)C(=O)O)O[C@@H]4O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O,C33H47NO13,C08073,D00884,5284447,46509171,,CHEMBL1200656,,10468784,50370755,665.733,-1.694913094,"Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Antiinfectives and Antiseptics for Local Oral Treatment; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Intestinal Antiinfectives; Lactones; Macrocyclic Compounds; Ophthalmologicals; Polycyclic Compounds; Polyene Antifungal; Polyene Antimicrobial; Polyketides; Sensory Organs; Stomatological Preparations"
DB00827,Cinoxacin,28657-80-9,approved; investigational; withdrawn,VDUWPHTZYNWKRN-UHFFFAOYSA-N,"InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)",CCn1nc(C(=O)O)c(=O)c(c12)cc3c(c2)OCO3,C12H10N2O5,C08052,D00872,2762,46507547,3716,CHEMBL1208,,2660,39350,262.2182,1.716116835,"Acids, Heterocyclic; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; OAT1/SLC22A6 inhibitors; QTc Prolonging Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00828,Fosfomycin,23155-02-4,approved,YMDXZJFXQJVXBF-STHAYSLISA-N,"InChI=1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1",C[C@@H]1O[C@@H]1P(=O)(O)O,C3H7O4P,C06454,D04253,446987,46506665,28915,CHEMBL1757,FCN,394204,50024894,138.059,-0.73777488,"Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Drugs that are Mainly Renally Excreted; Organophosphonates; Organophosphorus Compounds"
DB00829,Diazepam,439-14-5,approved; illicit; investigational; vet_approved,AAOVKJBEBIDNHE-UHFFFAOYSA-N,"InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3",c1c(Cl)ccc(c12)N(C)C(=O)CN=C2c3ccccc3,C16H13ClN2O,C06948,D00293,3016,46505210,49575,CHEMBL12,DZP,2908,50000766,284.74,3.076086567,"Adjuvants, Anesthesia; Agents that modify thyroid function; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Anti-Anxiety Agents; Anticonvulsants; Autonomic Agents; Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; P-glycoprotein substrates; Peripheral Nervous System Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB00830,Phenmetrazine,134-49-6,approved; illicit,OOBHFESNSZDWIU-UHFFFAOYSA-N,"InChI=1S/C11H15NO/c1-9-11(13-8-7-12-9)10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3",CC1NCCOC1c2ccccc2,C11H15NO,C07432,,4762,46504524,8067,CHEMBL1201208,,4598,,177.2429,1.789436289,"Agents producing tachycardia; Agents that produce hypertension; Anti-Obesity Agents; Appetite Depressants; Autonomic Agents; Central Nervous System Agents; Central Nervous System Stimulants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Morpholines; Oxazines; Peripheral Nervous System Agents; Sympathomimetics"
DB00831,Trifluoperazine,117-89-5,approved; investigational,ZEWQUBUPAILYHI-UHFFFAOYSA-N,"InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3",CN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(c4)C(F)(F)F,C21H24F3N3S,C07168,D08636,5566,46507961,45951,CHEMBL422,TFP,5365,79181,407.496,4.655923627,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antiemetics; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Phenothiazines; Phenothiazines With Piperazine Structure; Photosensitizing Agents; Psycholeptics; Psychotropic Drugs; Sulfur Compounds; Tranquilizing Agents; UGT1A4 substrates"
DB00832,Phensuximide,86-34-0,approved,WLWFNJKHKGIJNW-UHFFFAOYSA-N,"InChI=1S/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3",CN1C(=O)CC(C1=O)c2ccccc2,C11H11NO2,C07437,D00508,6839,46505695,8079,CHEMBL797,,6578,50240063,189.2105,0.906994756,"Anticonvulsants; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imides; Nervous System; Pyrrolidines; Pyrrolidinones; Succinimide Derivatives"
DB00833,Cefaclor,53994-73-3,approved,QYIYFLOTGYLRGG-GPCCPHFNSA-N,"InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1",O=C(O)C1=C(Cl)CS[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccccc3,C15H14ClN3O4S,C06877,D00256,51039,46507693,3478,CHEMBL680,,46260,42131,367.807,-2.306335476,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; BSEP/ABCB11 Substrates; Cephalosporins; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Second-Generation Cephalosporins; Sulfur Compounds; Thiazines"
DB00834,Mifepristone,84371-65-3,approved; investigational,VKHAHZOOUSRJNA-GCNJZUOMSA-N,"InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1",CC#C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3C(=C4C(CC3)=CC(=O)CC4)[C@H](C2)c5ccc(cc5)N(C)C,C29H35NO2,C07652,D00585,55245,46505795,50692,CHEMBL1276308,486,49889,50072024,429.5937,5.133287652,"Abortifacient Agents; Abortifacient Agents, Steroidal; Adrenal Cortex Hormones; Blood Glucose Lowering Agents; BSEP/ABCB11 Substrates; Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Estranes; Estrenes; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Highest Risk QTc-Prolonging Agents; Hormonal Contraceptives for Systemic Use; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypoglycemia-Associated Agents; Luteolytic Agents; Menstruation-Inducing Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; Polycyclic Compounds; Progestational Hormone Receptor Antagonists; Progesterone Receptor Modulators; Progestin Antagonist; QTc Prolonging Agents; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB00835,Brompheniramine,86-22-6,approved,ZDIGNSYAACHWNL-UHFFFAOYSA-N,"InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3",c1cccnc1C(CCN(C)C)c2ccc(Br)cc2,C16H19BrN2,C06857,D07543,6834,46508137,3183,CHEMBL811,,6573,50017666,319.239,3.749658864,"Agents producing tachycardia; Anti-Allergic Agents; Anticholinergic Agents; Antihistamines for Systemic Use; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Muscarinic Antagonists; Neurotransmitter Agents; Photosensitizing Agents; Potential QTc-Prolonging Agents; Propylamine Derivatives; Pyridines; QTc Prolonging Agents; Respiratory System; Substituted Alkylamines"
DB00836,Loperamide,53179-11-6,approved,RDOIQAHITMMDAJ-UHFFFAOYSA-N,"InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3",c1ccccc1C(C(=O)N(C)C)(c2ccccc2)CCN(CC3)CCC3(O)c4ccc(Cl)cc4,C29H33ClN2O2,C07080,D08144,3955,46504591,6532,CHEMBL841,,3818,50017698,477.038,4.771190859,"Agents causing hyperkalemia; Alimentary Tract and Metabolism; Antiarrhythmic agents; Antidiarrheals; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antipropulsives; Bradycardia-Causing Agents; Calcium Channel Blockers; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Moderate Risk QTc-Prolonging Agents; Opioid Agonist; P-glycoprotein substrates; Piperidines; QTc Prolonging Agents"
DB00838,Clocortolone,4828-27-7,approved,YMTMADLUXIRMGX-RFPWEZLHSA-N,"InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1",OCC(=O)[C@H]1[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@](Cl)([C@H](C2)O)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4,C22H28ClFO4,,D07719,5311052,46505290,59582,,,4470589,,410.907,2.474821862,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Moderately Potent (Group II); Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnanes; Steroids; Steroids, Fluorinated"
DB00839,Tolazamide,1156-19-0,approved; investigational,OUDSBRTVNLOZBN-UHFFFAOYSA-N,"InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)",Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CCCCCC2,C14H21N3O3S,,D00379,5503,46505642,9613,CHEMBL817,,5302,50240099,311.4,1.911990001,Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Hypoglycemia-Associated Agents; Sulfones; Sulfonylureas; Sulfur Compounds
DB00840,Hydroxypropyl cellulose,9004-64-2,approved,,, ,,,D01536,,46508483,,CHEMBL1201471,,,,NA,NA,"Artificial Tears; Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Demulcent; Demulcent Activity; Glucans; Macromolecular Substances; Manufactured Materials; Ophthalmics; Polymers; Polysaccharides"
DB00841,Dobutamine,34368-04-2,approved,JRWZLRBJNMZMFE-UHFFFAOYSA-N,"InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3",Oc1ccc(cc1)CCC(C)NCCc2cc(O)c(O)cc2,C18H23NO3,C06967,D03879,36811,46505241,4670,CHEMBL926,,33786,50325274,301.3801,2.616255192,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Amines; Autonomic Agents; Benzene Derivatives; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Catecholamines; Catechols; Compounds used in a research, industrial, or household setting; COMT Substrates; Drugs that are Mainly Renally Excreted; Ethylamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenethylamines; Phenols; Protective Agents; Selective Beta 1-adrenergic Agonists; Sympathomimetic (Adrenergic) Agents; Sympathomimetics"
DB00842,Oxazepam,604-75-1,approved,ADIMAYPTOBDMTL-UHFFFAOYSA-N,"InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)",c1cc(Cl)cc(c12)C(=NC(O)C(=O)N2)c3ccccc3,C15H11ClN2O2,C07359,D00464,4616,46506031,7823,CHEMBL568,,4455,85031,286.713,2.923280812,"Anti-Anxiety Agents; Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents; UGT1A9 Substrates; UGT2B7 substrates"
DB00843,Donepezil,120014-06-4,approved,ADEBPBSSDYVVLD-UHFFFAOYSA-N,"InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3",COc(c1)c(OC)cc(c12)C(=O)C(C2)CC3CCN(CC3)Cc4ccccc4,C24H29NO3,,D00670,3152,46504803,53289,CHEMBL502,,3040,8960,379.492,4.207932994,"Anti-Dementia Drugs; BCRP/ABCG2 Substrates; Bradycardia-Causing Agents; Central Nervous System Agents; Central Nervous System Depressants; Cholinergic Agents; Cholinesterase Inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indans; Indenes; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; Neurotransmitter Agents; Nootropic Agents; Parasympathomemetic (Cholinergic) Agents; Piperidines; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Psychoanaleptics; QTc Prolonging Agents"
DB00844,Nalbuphine,20594-83-6,approved,NETZHAKZCGBWSS-CEDHKZHLSA-N,"InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1",[C@@]123[C@@H]4[C@@H](O)CC[C@@]2(O)[C@H](N(CC3)CC5CCC5)Cc6c1c(O4)c(O)cc6,C21H27NO4,C07251,D08246,5311304,46507383,7454,CHEMBL895,,4470813,50105085,357.4434,1.192924548,"Alkaloids; Analgesics; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Mixed Agonist / Antagonist Opioids; Morphinan Derivatives; Morphinans; Narcotics; Nervous System; Opiate Alkaloids; Opiate Partial Agonists; Opioid Agonist/Antagonist; Opioid Antagonists; Opioids; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Semi-synthetic Opioids; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00845,Clofazimine,2030-63-9,approved; investigational,WDQPAMHFFCXSNU-BGABXYSRSA-N,"InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3/b30-24+",Clc1ccc(cc1)Nc(c2)/c(=N/C(C)C)cc(c23)n(c4c(n3)cccc4)-c5ccc(Cl)cc5,C27H22Cl2N4,C06915,D00278,2794,46508174,3749,CHEMBL1292,,2692,50378783,473.396,7.304315287,"Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antiinfectives for Systemic Use; Antimycobacterials; BCRP/ABCG2 Inhibitors; BSEP/ABCB11 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs for Treatment of Lepra; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Leprostatic Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Phenazines; Photosensitizing Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB00846,Flurandrenolide,1524-88-5,approved,POPFMWWJOGLOIF-XWCQMRHXSA-N,"InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1",OCC(=O)[C@]12[C@H](OC(O1)(C)C)C[C@@H]3[C@]2(C)C[C@H](O)[C@H]4[C@H]3C[C@H](F)C=5[C@]4(C)CCC(=O)C5,C24H33FO6,,D00328,15209,46505159,5127,CHEMBL1201012,,14475,50240003,436.5136,1.56296815,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids; Steroids, Fluorinated"
DB00847,Cysteamine,60-23-1,approved; investigational,UFULAYFCSOUIOV-UHFFFAOYSA-N,"InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2",NCCS,C2H7NS,C01678,D03634,6058,46507730,17141,CHEMBL602,DHL,5834,7968,77.149,-0.416613164,"Alimentary Tract and Metabolism; Amines; Amino Acids and Derivatives; Cystine Depleting Agents; Cystine Disulfide Reduction; EENT Drugs, Miscellaneous; Ethylamines; Mercaptoethylamines; Ophthalmics; Ophthalmologicals; Other Miscellaneous Therapeutic Agents; Sensory Organs; Sulfhydryl Compounds; Sulfur Compounds"
DB00848,Levamisole,14769-73-4,approved; investigational; vet_approved; withdrawn,HLFSDGLLUJUHTE-SNVBAGLBSA-N,"InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1",S1CCN(C1=2)C[C@@H](N2)c3ccccc3,C11H12N2S,C07070,D08114,26879,46509052,6432,CHEMBL1454,,25037,50241179,204.291,2.358226902,"Adjuvants, Immunologic; Anthelmintics; Anti-Infective Agents; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antirheumatic Agents; Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Imidazothiazole Derivatives; Immunologic Factors; Levamisole, analogs & derivatives; Sulfur Compounds; Thiazoles"
DB00849,Methylphenobarbital,115-38-8,approved,ALARQZQTBTVLJV-UHFFFAOYSA-N,"InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)",c1ccccc1C2(CC)C(=O)NC(=O)N(C)C2=O,C13H14N2O3,C07829,D00700,8271,46505197,6758,CHEMBL45029,,7972,,246.2619,1.630006194,"Anticholinergic Agents; Anticonvulsants; Barbiturates; Barbiturates and Derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; Phenobarbital and similars; Psycholeptics; Pyrimidines; Pyrimidinones"
DB00850,Perphenazine,58-39-9,approved,RGCVKNLCSQQDEP-UHFFFAOYSA-N,"InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2",OCCN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(Cl)c4,C21H26ClN3OS,C07427,D00503,4748,46507058,8028,CHEMBL567,,4586,50130273,403.969,3.692017809,"Agents that modify thyroid function; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Phenothiazines; Phenothiazines With Piperazine Structure; Photosensitizing Agents; Psycholeptics; Psychotropic Drugs; Sulfur Compounds; Tranquilizing Agents"
DB00851,Dacarbazine,04-03-4342,approved; investigational,FDKXTQMXEQVLRF-ZHACJKMWSA-N,"InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+",CN(C)/N=N/c1c(C(=O)N)nc[nH]1,C6H10N6O,C06936,D00288,5351166,46507029,4305,CHEMBL476,,10481959,50238687,182.187,-0.425888962,"ABVD chemotherapy regimen; Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Azoles; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Toxic Actions; Triazenes"
DB00852,Pseudoephedrine,90-82-4,approved,KWGRBVOPPLSCSI-WCBMZHEXSA-N,"InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1",CN[C@@H](C)[C@@H](O)c1ccccc1,C10H15NO,C02765,D08449,7028,46508190,51209,CHEMBL1590,,6761,,165.2322,1.317834728,Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Alpha-and Beta-adrenergic Agonists; Amines; Amino Alcohols; Amphetamines; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cardiovascular Agents; Ethylamines; Hyperglycemia-Associated Agents; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Nasal Decongestants; Nasal Decongestants for Systemic Use; Nasal Preparations; Norepinephrine Releasing Agent; Peripheral Nervous System Agents; Phenethylamines; Propanolamines; Propanols; Respiratory System; Respiratory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetic (Adrenergic) Agents; Sympathomimetics; Vasoconstrictor Agents
DB00853,Temozolomide,85622-93-1,approved; investigational,BPEGJWRSRHCHSN-UHFFFAOYSA-N,"InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",c1nc(C(=O)N)c(n12)nnn(C)c2=O,C6H6N6O2,,D06067,5394,46507934,72564,CHEMBL810,,5201,50034562,194.1508,-0.282538152,"Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Azoles; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 Enzyme Inducers; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Toxic Actions; Triazenes"
DB00854,Levorphanol,77-07-6,approved,JAQUASYNZVUNQP-USXIJHARSA-N,"InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1",C1CCC[C@H]([C@@]123)[C@H](N(C)CC2)Cc4c3cc(O)cc4,C17H23NO,C08014,D08123,5359272,46506558,6444,CHEMBL592,,16736212,50369518,257.3706,2.903043791,"Alkaloids; Analgesics; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Narcotics; Opiate Alkaloids; Opioid Agonist; Opioids; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00855,Aminolevulinic acid,106-60-5,approved,ZGXJTSGNIOSYLO-UHFFFAOYSA-N,"InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)",NCC(=O)CCC(=O)O,C5H9NO3,C00430,,137,46506856,17549,CHEMBL601,FVT,134,50240386,131.1299,-3.252645453,"Amino Acids; Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Dermatologicals; Enkephalins; Keto Acids; Levulinic Acids; Misc. Skin and Mucous Membrane Agents; Nerve Tissue Proteins; Neuropeptides; Opioid Peptides; Peptides; Photosensitizing Agents; Photosensitizing agents used for phototherapy; Porphyrin Precursor; Proteins; Radiation-Sensitizing Agents; Sensitizers Used in Photodynamic/radiation Therapy"
DB00856,Chlorphenesin,104-29-0,approved; experimental,MXOAEAUPQDYUQM-UHFFFAOYSA-N,"InChI=1S/C9H11ClO3/c10-7-1-3-9(4-2-7)13-6-8(12)5-11/h1-4,8,11-12H,5-6H2",OCC(O)COc1ccc(Cl)cc1,C9H11ClO3,C07928,,7697,46504714,3642,CHEMBL388751,,7411,,202.635,1.099182273,"Alcohols; Antifungals for Dermatological Use; Antifungals for Topical Use; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Dermatologicals; Glycols; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Peripheral Nervous System Agents; Propylene Glycols"
DB00857,Terbinafine,91161-71-6,approved; investigational; vet_approved,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,"InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+",c1cccc(c12)cccc2CN(C)C/C=C/C#CC(C)(C)C,C21H25N,C08079,D02375,1549008,46508519,9448,CHEMBL822,,1266005,50018518,291.4299,5.527483034,"Agents Causing Muscle Toxicity; Allylamine Antifungal; Allylamines; Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Systemic Use; Antifungals for Topical Use; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthalenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic"
DB00859,Penicillamine,52-67-5,approved,VVNCNSJFMMFHPL-VKHMYHEASA-N,"InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1",CC(C)(S)[C@@H](N)C(=O)O,C5H11NO2S,C07418,D00496,5852,46508305,7959,CHEMBL1430,LEI,5643,39346,149.211,-2.146518266,"Agents Causing Muscle Toxicity; Amino Acids; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Antidotes; Antiinflammatory and Antirheumatic Products; Antirheumatic Agents; Chelating Agents; Compounds used in a research, industrial, or household setting; Heavy Metal Antagonists; Immunosuppressive Agents; Musculo-Skeletal System; Myelosuppressive Agents; OATP1B1/SLCO1B1 Substrates; Penicillamine and Similar Agents; Protective Agents; Sequestering Agents; Specific Antirheumatic Agents; Sulfur Compounds"
DB00860,Prednisolone,50-24-8,approved; vet_approved,OIGNJSKKLXVSLS-VWUMJDOOSA-N,"InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",OCC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)C=C4,C21H28O5,C07369,D00472,5755,46504847,8378,CHEMBL131,,5552,19190,360.444,1.272989924,"Adrenal Cortex Hormones; Adrenals; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Alimentary Tract and Metabolism; Anti-Inflammatory Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antidotes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cardiovascular System; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids Acting Locally; Corticosteroids for Local Oral Treatment; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Corticosteroids, Dermatological Preparations; Corticosteroids, Weak (Group I); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Intestinal Antiinflammatory Agents; Nasal Preparations; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; P-glycoprotein substrates; Polycyclic Compounds; Prednisolone and Prodrugs; Pregnadienes; Pregnadienetriols; Pregnanes; Respiratory System; Sensory Organs; Steroids; Stomatological Preparations; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Vasoprotectives"
DB00861,Diflunisal,22494-42-4,approved; investigational,HUPFGZXOMWLGNK-UHFFFAOYSA-N,"InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)",OC(=O)c1c(O)ccc(c1)-c2c(F)cc(F)cc2,C13H8F2O3,C01691,D00130,3059,46507807,39669,CHEMBL898,1FL,2951,50240510,250.1976,3.909892637,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antirheumatic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; Other Nonsteroidal Anti-inflammatory Agents; Peripheral Nervous System Agents; Phenols; Photosensitizing Agents; Salicylates; Salicylic Acid and Derivatives; Sensory System Agents; UGT1A9 Inhibitors"
DB00862,Vardenafil,224785-90-4,approved,SECKRCOLJRRGGV-UHFFFAOYSA-N,"InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)",CCCc1nc(C)c(n12)c(=O)nc([nH]2)-c3c(OCC)ccc(c3)S(=O)(=O)N4CCN(CC)CC4,C23H32N6O4S,,D08668,110634,46506777,46295,CHEMBL1520,VDN,99300,50088373,488.603,1.325120505,"Azoles; Cardiovascular Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs Used in Erectile Dysfunction; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; P-glycoprotein inhibitors; P-glycoprotein substrates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Urological Agents; Urologicals; Vasodilating Agents"
DB00863,Ranitidine,66357-35-5,approved; withdrawn,VMXUWOKSQNHOCA-UHFFFAOYSA-N,"InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3",[O-][N+](=O)/C=C(\NC)NCCSCc1ccc(o1)CN(C)C,C13H22N4O3S,,D00422,3001055,46505543,92246,CHEMBL1790041,,4863,50103506,314.4,0.990778466,"Acid Reducers; Agents Causing Muscle Toxicity; Alimentary Tract and Metabolism; Anti-Ulcer Agents; Cholinesterase Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs that are Mainly Renally Excreted; Furans; Gastric Acid Lowering Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H2 Antagonists; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; P-glycoprotein inhibitors; P-glycoprotein substrates"
DB00864,Tacrolimus,104987-11-3,approved; investigational,QJJXYPPXXYFBGM-LFZNUXCKSA-N,"InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1",O[C@@]12C(=O)C(=O)N3[C@@H](CCCC3)C(=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@H](O)CC4)[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(\C)C[C@H](C)C[C@H](OC)[C@@H](O1)[C@@H](OC)C[C@H]2C,C44H69NO12,C01375,D00107,445643,46506004,61049,CHEMBL269732,FK5,393220,50079777,804.0182,5.594120193,"Agents causing hyperkalemia; Agents Causing Muscle Toxicity; Agents for Dermatitis, Excluding Corticosteroids; Anti-Bacterial Agents; Antineoplastic and Immunomodulating Agents; Calcineurin Inhibitor Immunosuppressant; Calcineurin Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Hyperglycemia-Associated Agents; Immunologic Factors; Immunosuppressive Agents; Lactones; Macrocyclic Compounds; Medications that reduce magnesium levels; Misc. Skin and Mucous Membrane Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nephrotoxic agents; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Photosensitizing Agents; Polycyclic Compounds; Polyketides; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB00865,Benzphetamine,156-08-1,approved; illicit,YXKTVDFXDRQTKV-HNNXBMFYSA-N,"InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1",c1ccccc1C[C@H](C)N(C)Cc2ccccc2,C17H21N,C07538,,5311017,46506102,3044,CHEMBL3545985,,4470556,,239.3553,4.34435193,Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Amines; Amphetamines; Antidepressive Agents; Appetite Suppression; Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Central Nervous System Stimulants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Uptake Inhibitors; Ethylamines; Increased Sympathetic Activity; Membrane Transport Modulators; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Peripheral Nervous System Agents; Phenethylamines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetic Amine Anorectic; Sympathomimetics
DB00867,Ritodrine,26652-09-5,approved; investigational,IOVGROKTTNBUGK-SJCJKPOMSA-N,"InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1",Oc1ccc(cc1)[C@@H](O)[C@H](C)NCCc2ccc(O)cc2,C17H21NO3,C07239,D02359,33572,46505273,8872,CHEMBL785,,30971,97162,287.3535,1.815584914,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Autonomic Agents; Ethylamines; Genito Urinary System and Sex Hormones; Medications that reduce magnesium levels; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenethylamines; Propanolamines; Propanols; Reproductive Control Agents; Sympathomimetics; Sympathomimetics, Labour Repressants; Tocolytic Agents"
DB00868,Benzonatate,104-31-4,approved,MAFMQEKGGFWBAB-UHFFFAOYSA-N,"InChI=1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3",CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,C30H53NO11,,D00242,7699,46506376,3032,CHEMBL1374379,,7413,50240086,603.7419,2.350620347,"Alkanes; Amines; Antitussive Agents; Butanes; Central Nervous System Agents; Cholinesterase substrates; Cough and Cold Preparations; Decreased Tracheobronchial Stretch Receptor Activity; Hydrocarbons; Hydrocarbons, Acyclic; Non-narcotic Antitussive; Respiratory System; Respiratory System Agents"
DB00869,Dorzolamide,120279-96-1,approved,IAVUPMFITXYVAF-XPUUQOCRSA-N,"InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1",O=S(=O)(N)c(c1)sc(c12)S(=O)(=O)[C@@H](C)C[C@@H]2NCC,C10H16N2O4S3,C06969,D07871,5284549,46506754,4702,CHEMBL218490,ETS,4447604,10884,324.44,-0.151113513,"Amides; Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Carbonic Anhydrase Inhibitors; Cardiovascular Agents; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Diuretics; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Intraocular Pressure, drug effects; Ophthalmologicals; Sensory Organs; Sulfonamides; Sulfones; Sulfur Compounds"
DB00870,Suprofen,40828-46-4,approved; withdrawn,MDKGKXOCJGEUJW-UHFFFAOYSA-N,"InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)",OC(=O)C(C)c1ccc(cc1)C(=O)c2cccs2,C14H12O3S,C07320,D00452,5359,46508210,9362,CHEMBL956,,5166,50090676,260.308,3.526214794,"Acids, Carbocyclic; Agents causing hyperkalemia; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Carboxylic Acids; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Phenylpropionates; Propionates; Sensory System Agents; UGT1A1 Substrates; UGT2B7 substrates"
DB00871,Terbutaline,23031-25-6,approved,XWTYSIMOBUGWOL-UHFFFAOYSA-N,"InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3",CC(C)(C)NCC(O)c1cc(O)cc(O)c1,C12H19NO3,C07129,,5403,46506887,9449,CHEMBL1760,,5210,25770,225.2842,0.441037404,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cholinesterase Inhibitors; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Ethanolamines; Neurotransmitter Agents; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Reproductive Control Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists; Sympathomimetics; Tocolytic Agents"
DB00872,Conivaptan,210101-16-9,approved; investigational,IKENVDNFQMCRTR-UHFFFAOYSA-N,"InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)",Cc([nH]1)nc(c12)c3c(cccc3)N(CC2)C(=O)c4ccc(cc4)NC(=O)c5ccccc5-c6ccccc6,C32H26N4O2,,D07748,151171,46504533,681850,CHEMBL1755,,133239,85095,498.5744,5.437165417,"Antidiuretic Hormone Receptor Antagonists; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diuretics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Narrow Therapeutic Index Drugs; Natriuretic Agents; P-glycoprotein inhibitors"
DB14596,Loteprednol etabonate,82034-46-6,approved,DMKSVUSAATWOCU-HROMYWEYSA-N,"InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@@]4(C(=O)OCCl)OC(=O)OCC,C24H31ClO7,,D01689,9865442,46504713,31784,CHEMBL1200865,,392049,,466.96,3.937487965,Adrenal Cortex Hormones; Androstadienes; Androstanes; Androstenes; Anti-Allergic Agents; Corticosteroids; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Immunosuppressive Agents; Polycyclic Compounds; Steroids
DB00874,Guaifenesin,93-14-1,approved; investigational; vet_approved,HSRJKNPTNIJEKV-UHFFFAOYSA-N,"InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3",COc1ccccc1OCC(O)CO,C10H14O4,,D00337,3516,46508004,5551,CHEMBL980,,3396,50240098,198.2158,0.337466331,"Benzene Derivatives; Catechols; Cough and Cold Preparations; Ethers; Expectorants; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Methyl Ethers; Phenols; Phenyl Ethers; Respiratory System; Respiratory System Agents"
DB00875,Flupentixol,2709-56-0,approved; investigational; withdrawn,NJMYODHXAKYRHW-DVZOWYKESA-N,"InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-",FC(F)(F)c(c1)ccc(S2)c1C(\c(c23)cccc3)=C/CCN4CCN(CC4)CCO,C23H25F3N2OS,C11191,D01044,5281881,46507816,10454,CHEMBL54661,,4445173,79172,434.52,4.496787735,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Anticholinergic Agents; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Piperazines; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Thioxanthene Derivatives; Thioxanthenes; Tranquilizing Agents; Xanthenes"
DB00876,Eprosartan,133040-01-4,approved,OROAFUQRIXKEMV-LDADJPATSA-N,"InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+",O=C(O)c1ccc(cc1)Cn2c(cnc2CCCC)/C=C(/C(=O)O)Cc3cccs3,C23H24N2O4S,C07467,D04040,5281037,46506765,4814,CHEMBL813,,4444504,50011977,424.513,3.797230394,"Acids, Acyclic; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Agents Causing Muscle Toxicity; Angiotensin 2 Receptor Blocker; Angiotensin II receptor blockers (ARBs) and diuretics; Angiotensin II receptor blockers (ARBs), plain; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Azoles; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Sulfur Compounds"
DB00877,Sirolimus,53123-88-9,approved; investigational,QFJCIRLUMZQUOT-HPLJOQBZSA-N,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",O[C@@]12C(=O)C(=O)N3[C@@H](CCCC3)C(=O)O[C@H]([C@H](C)C[C@@H](C[C@H]4OC)CC[C@H]4O)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H](O1)CC[C@H]2C,C51H79NO13,C07909,D00753,5284616,46505675,9168,CHEMBL413,RAP,10482078,36609,914.187,7.450839823,"Agents causing angioedema; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Decreased Immunologic Activity; Hyperglycemia-Associated Agents; Immunologic Factors; Immunosuppressive Agents; Kinase Inhibitor; Lactones; Macrocyclic Compounds; Macrolides; mTOR Inhibitor Immunosuppressant; mTOR Inhibitors; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; Ophthalmologicals; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Polyketides; Protein Kinase Inhibitors; Selective Immunosuppressants; Sensory Organs; Sirolimus and Prodrugs"
DB00878,Chlorhexidine,55-56-1,approved; vet_approved,GHXZTYHSJHQHIJ-UHFFFAOYSA-N,"InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)",Clc1ccc(cc1)NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2,C22H30Cl2N10,C06902,D07668,9552079,46506388,3614,CHEMBL790,,2612,50170723,505.447,4.510369177,"Alimentary Tract and Metabolism; Amidines; Anti-Infective Agents; Anti-Infective Agents, Local; Antiinfectives and Antiseptics for Local Oral Treatment; Antiseptics and Disinfectants; Biguanides; Biguanides and Amidines; Compounds used in a research, industrial, or household setting; Decreased Cell Wall Integrity; Dental Agents; Dermatologicals; Disinfectants; Guanidines; Household Products; Irrigating Solutions; Manufactured Materials; Medicated Dressings; Medicated Dressings With Antiinfectives; Miscellaneous Anti-infectives; Miscellaneous Local Anti-infectives; Mouthwashes; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; Respiratory System; Sensory Organs; Stomatological Preparations; Throat Preparations"
DB00879,Emtricitabine,143491-57-0,approved; investigational,XQSPYNMVSIKCOC-NTSWFWBYSA-N,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",Nc1nc(=O)n(cc1F)[C@@H]2CS[C@@H](O2)CO,C8H10FN3O3S,C12599,D01199,60877,46507606,31536,CHEMBL885,ETV,54859,50107843,247.247,-0.895664678,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Carbohydrates; Deoxycytidine; Deoxyribonucleosides; Dideoxynucleosides; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; MATE 1 Substrates; MATE substrates; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides; Pyrimidine Nucleosides; Pyrimidines; Reverse Transcriptase Inhibitors; Ribonucleosides"
DB00880,Chlorothiazide,58-94-6,approved; vet_approved,JBMKAUGHUNFTOL-UHFFFAOYSA-N,"InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)",NS(=O)(=O)c(c1)c(Cl)cc(c12)NC=NS2(=O)=O,C7H6ClN3O4S2,C07461,D00519,2720,46507032,3640,CHEMBL842,,2619,39351,295.723,-0.442181485,"Amides; Antihypertensive Agents; Benzothiadiazines; Cardiovascular Agents; Cardiovascular System; Diuretics; Drugs causing inadvertant photosensitivity; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Hypotensive Agents; Increased Diuresis; Medications that reduce magnesium levels; Membrane Transport Modulators; Natriuretic Agents; OAT1/SLC22A6 inhibitors; Photosensitizing Agents; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazides"
DB00881,Quinapril,85441-61-8,approved; investigational,JSDRRTOADPPCHY-HSQYWUDLSA-N,"InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1",c1ccccc1CC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N([C@@H](C2)C(=O)O)Cc(c23)cccc3,C25H30N2O5,C07398,D03752,54892,46506309,8713,CHEMBL1592,,49565,50368166,438.5161,1.963935582,"ACE Inhibitors and Diuretics; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Isoquinolines; OAT3/SLC22A8 Substrates; Protease Inhibitors; Tetrahydroisoquinolines"
DB00882,Clomifene,911-45-5,approved; investigational,GKIRPKYJQBWNGO-UHFFFAOYSA-N,"InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3",CCN(CC)CCOc1ccc(cc1)/C(c2ccccc2)=C(\Cl)c3ccccc3,C26H28ClNO,C06917,D07726,2800,46504463,3752,CHEMBL2355051,,2698,,405.96,6.474937694,"Benzene Derivatives; Benzylidene Compounds; Clomiphene; Estrogen Agonist-antagonists; Estrogen Agonist/Antagonist; Estrogen Antagonists; Estrogen Receptor Modulators; Fertility Agents; Fertility Agents, Female; Genito Urinary System and Sex Hormones; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Ovulation Stimulants, Synthetic; P-glycoprotein substrates; Reproductive Control Agents; Selective Estrogen Receptor Modulators; Sex Hormones and Modulators of the Genital System; Stilbenes"
DB00883,Isosorbide dinitrate,87-33-2,approved; investigational,MOYKHGMNXAOIAT-JGWLITMVSA-N,"InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1",[O-][N+](=O)O[C@H]1CO[C@@H]([C@@H]12)[C@@H](CO2)O[N+]([O-])=O,C6H8N2O8,C07456,D00516,6883,46506412,6061,CHEMBL6622,,6619,,236.1363,-0.009582421,Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Alcohols; Antianginal Agents; Carbohydrates; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Hypotensive Agents; Methemoglobinemia Associated Agents; Nitrate Vasodilator; Nitrates and Nitrites; Nitric Oxide Donors; Organic Nitrates; Sugar Alcohols; Vasodilating Agents; Vasodilation; Vasodilators Used in Cardiac Diseases; Vasoprotectives
DB00884,Risedronic acid,105462-24-6,approved; investigational,IIDJRNMFWXDHID-UHFFFAOYSA-N,"InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)",OP(=O)(O)C(O)(P(=O)(O)O)Cc1cnccc1,C7H11NO7P2,C08233,D08484,5245,46507526,8869,CHEMBL923,RIS,5055,12576,283.1123,-3.323865664,"Agents Causing Muscle Toxicity; Bisphosphonates; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Musculo-Skeletal System; Organophosphonates; Organophosphorus Compounds; Pyridines"
DB00885,Pemirolast,69372-19-6,approved; investigational,HIANJWSAHKJQTH-UHFFFAOYSA-N,"InChI=1S/C10H8N6O/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8/h2-5H,1H3,(H,12,13,14,15)",Cc1cccn(c12)c(=O)c(cn2)-c3n[nH]nn3,C10H8N6O,,D01088,57697,46509034,134936,CHEMBL1201198,,51990,,228.2101,1.458706813,"Decreased Histamine Release; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Mast Cell Stabilizers; Neurotransmitter Agents; Ophthalmics; Pyrimidines"
DB00887,Bumetanide,28395-03-1,approved,MAEIEVLCKWDQJH-UHFFFAOYSA-N,"InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)",CCCCNc1c(c(S(=O)(=O)N)cc(c1)C(=O)O)Oc2ccccc2,C17H20N2O5S,,D00247,2471,46508147,3213,CHEMBL1072,,2377,25903,364.416,2.423461698,"Acids, Carbocyclic; Agents Causing Muscle Toxicity; Amides; Aminobenzoates; Benzene Derivatives; Benzoates; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Diuretics; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; High-Ceiling Diuretics; High-Ceiling Diuretics and Potassium-Sparing Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hyperglycemia-Associated Agents; Hypotensive Agents; Increased Diuresis at Loop of Henle; Membrane Transport Modulators; meta-Aminobenzoates; Natriuretic Agents; Nephrotoxic agents; Non Potassium Sparing Diuretics; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Photosensitizing Agents; Sodium Potassium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds"
DB00888,Mechlorethamine,51-75-2,approved; investigational,HAWPXGHAZFHHAD-UHFFFAOYSA-N,"InChI=1S/C5H11Cl2N/c1-8(4-2-6)5-3-7/h2-5H2,1H3",ClCCN(C)CCCl,C5H11Cl2N,C07115,D07671,4033,46505784,28925,CHEMBL427,,3893,200297,156.054,1.519149154,"Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Cardiotoxic antineoplastic agents; Chemical Warfare Agents; Cholinesterase Inhibitors; Compounds used in a research, industrial, or household setting; Hydrocarbons; Hydrocarbons, Halogenated; Immunosuppressive Agents; Irritants; Manufactured Materials; Mustard Compounds; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nitrogen Mustard Analogues; Nitrogen Mustard Compounds; Noxae; Poisons; Toxic Actions; Weapons; Weapons of Mass Destruction"
DB00889,Granisetron,109889-09-0,approved; investigational,MFWNKCLOYSRHCJ-BTTYYORXSA-N,"InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12-,13+,14-",c1cccc(c12)c(nn2C)C(=O)N[C@H](C[C@@H]34)C[C@H](N3C)CCC4,C18H24N4O,C07023,D04370,5284566,46505137,5537,CHEMBL1290003,CWB,10482033,50443668,312.417,1.876856838,"Alimentary Tract and Metabolism; Antidepressive Agents; Antiemetics; Antiemetics and Antinauseants; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Azoles; Bicyclo Compounds, Heterocyclic; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Indazoles; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Pyrazoles; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 3 Receptor Antagonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB00890,Dienestrol,13029-44-2,approved; investigational,NFDFQCUYFHCNBW-SCGPFSFSSA-N,"InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+",Oc1ccc(cc1)/C(=C\C)/C(=C/C)c2ccc(O)cc2,C18H18O2,C08090,D00898,667476,46504661,4518,CHEMBL1018,,580857,40491,266.34,4.831961091,"Benzene Derivatives; Estrogens; Estrogens, Non-Steroidal; Genito Urinary System and Sex Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols; Sex Hormones and Modulators of the Genital System; Synthetic Estrogens, Plain"
DB00891,Sulfapyridine,144-83-2,approved,GECHUMIMRBOMGK-UHFFFAOYSA-N,"InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)",Nc1ccc(cc1)S(=O)(=O)Nc2ccccn2,C11H11N3O2S,,D02434,5336,46506991,132842,CHEMBL700,SFY,5145,39340,249.289,1.008770249,Amides; Amines; Aniline Compounds; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Methemoglobinemia Associated Agents; Short-Acting Sulfonamides; Sulfanilamides; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds
DB00892,Oxybuprocaine,99-43-4,approved; investigational,CMHHMUWAYWTMGS-UHFFFAOYSA-N,"InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3",CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,C17H28N2O3,,D08319,4633,46505399,309594,CHEMBL1200,,4472,50225499,308.4158,3.046285007,"Acids, Carbocyclic; Aminobenzoates; Anesthetics; Anesthetics for Topical Use; Anesthetics, Local; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase substrates; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Ophthalmologicals; para-Aminobenzoates; Peripheral Nervous System Agents; Sensory Organs; Sensory System Agents"
DB00893,Iron Dextran,9004-66-4,approved; vet_approved,,, ,,,D02141,,46506136,,CHEMBL1201544,,,,NA,NA,"Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Dextrans; Ferric Compounds; Glucans; Hematinics; Hematologic Agents; Iron Compounds; Macromolecular Substances; Manufactured Materials; Organometallic Compounds; Parenteral Iron Replacement; Phosphate Binder; Polymers; Polysaccharides; Supplements"
DB00894,Testolactone,968-93-4,approved; investigational,BPEWUONYVDABNZ-DZBHQSCQSA-N,"InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CCC(O4)=O,C19H24O3,C02197,D00153,13769,46508076,9460,CHEMBL1571,,13172,50367848,300.3921,3.231327437,"Androstadienes; Androstanes; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Homosteroids; Polycyclic Compounds; Steroids"
DB00895,Benzylpenicilloyl polylysine,31855-75-1,approved,IMPVZRLKKKXMKQ-SGDOCVTFSA-N,"InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1", ,C28H46N6O8S,,,45266800,46505002,59297,CHEMBL1201779,,26331550,,626.765,-3.782154907,"Acetamides; Acetates; Acids, Acyclic; Amides; Anti-Bacterial Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Benzene Derivatives; beta-Lactams; Carboxylic Acids; Drug Hypersensitivity; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lactams; Lipids; Penicillins; Sulfur Compounds"
DB00896,Rimexolone,49697-38-3,approved,QTTRZHGPGKRAFB-OOKHYKNYSA-N,"InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1",CCC(=O)[C@@]1(C)[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)C=C4,C24H34O3,,D05729,5311412,46504820,135566,CHEMBL1200617,,4470902,50103606,370.533,4.381232339,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids for Systemic Use, Plain; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Ophthalmologicals; Polycyclic Compounds; Pregnanes; Sensory Organs; Steroids; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroxine-binding globulin inhibitors"
DB00897,Triazolam,28911-01-5,approved; investigational,JOFWLTCLBGQGBO-UHFFFAOYSA-N,"InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3",Cc1nnc(n12)CN=C(c3c2ccc(Cl)c3)c4ccccc4Cl,C17H12Cl2N4,,D00387,5556,46509147,9674,CHEMBL646,,5355,50001765,343.21,2.8921,"Adjuvants, Anesthesia; Agents Causing Muscle Toxicity; Anti-Anxiety Agents; Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents; Triazolobenzodiazepines"
DB00898,Ethanol,64-17-5,approved,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,"InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3",CCO,C2H6O,C00469,D00068,702,46506969,16236,CHEMBL545,EOH,682,,46.0684,-0.161769114,"Agents Causing Muscle Toxicity; Alcohols; Anti-Infective Agents; Anti-Infective Agents, Local; Antidotes; Antiseptics and Disinfectants; Central Nervous System Agents; Central Nervous System Depressants; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (moderate); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Miscellaneous Local Anti-infectives; Miscellaneous Therapeutic Agents; Nerve Depressants; Neurotoxic agents; NMDA Receptor Antagonists; Solvents"
DB00899,Remifentanil,132875-61-7,approved,ZTVQQQVZCWLTDF-UHFFFAOYSA-N,"InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3",c1ccccc1N(C(=O)CC)C2(C(=O)OC)CCN(CC2)CCC(=O)OC,C20H28N2O5,C08021,D08473,60815,46504538,8802,CHEMBL1005,,54803,50012491,376.4467,1.51527884,"Acids, Acyclic; Agents producing tachycardia; Agents that produce hypertension; Analgesics; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Bradycardia-Causing Agents; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Fatty Acids; Fatty Acids, Volatile; Fentanyl and fentanyl analogues; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; High-risk opioids; Hypnotics and Sedatives; Hypotensive Agents; Lipids; Narcotics; Nervous System; Opiate Agonists; Opioid Agonist; Opioid Anesthetics; Opioids; Opioids, Anilidopiperidine; Peripheral Nervous System Agents; Phenylpiperidine opioids; Piperidines; Propionates; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00900,Didanosine,69655-05-6,approved,BXZVVICBKDXVGW-NKWVEPMBSA-N,"InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1",OC[C@@H]1CC[C@@H](O1)n2cnc(c23)c(=O)nc[nH]3,C10H12N4O3,C06953,D00296,50599,46506255,490877,CHEMBL1460,2DI,45864,50404252,236.2273,-0.351636408,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antimetabolites; Antiviral Agents; Antivirals for Systemic Use; Carbohydrates; Deoxyribonucleosides; Dideoxynucleosides; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Neurotoxic agents; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides; OAT1/SLC22A6 Substrates; Purine Nucleosides; Purines; Reverse Transcriptase Inhibitors; Ribonucleosides; Toxic Actions"
DB00902,Methdilazine,1982-37-2,approved,HTMIBDQKFHUPSX-UHFFFAOYSA-N,"InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3",CN1CCC(C1)CN2c(cccc3)c3Sc(c24)cccc4,C18H20N2S,C07175,D04979,14677,46505472,6823,CHEMBL1200959,,14009,81470,296.43,3.936746242,"Agents that reduce seizure threshold; Antihistamines for Systemic Use; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Phenothiazine Derivatives; Respiratory System; Sulfur Compounds"
DB00903,Etacrynic acid,58-54-8,approved; investigational,AVOLMBLBETYQHX-UHFFFAOYSA-N,"InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)",CCC(=C)C(=O)c1c(Cl)c(Cl)c(cc1)OCC(=O)O,C13H12Cl2O4,,D00313,3278,46507562,4876,CHEMBL456,EAA,3163,50186231,303.138,3.655706891,"Acetates; Acids, Acyclic; Agents that produce neuromuscular block (indirect); Aryloxyacetic Acid Derivatives; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Diuretics; Enzyme Inhibitors; Fatty Acids; Fatty Acids, Volatile; Glycolates; High-Ceiling Diuretics; Hydroxy Acids; Hyperglycemia-Associated Agents; Hypotensive Agents; Increased Diuresis at Loop of Henle; Lipids; Medications that reduce magnesium levels; Natriuretic Agents; Nephrotoxic agents; Non Potassium Sparing Diuretics; OAT1/SLC22A6 inhibitors; Ototoxic agents; Phenoxyacetates; Sodium Potassium Chloride Symporter Inhibitors"
DB00904,Ondansetron,99614-02-5,approved,FELGMEQIXOGIFQ-UHFFFAOYSA-N,"InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3",c1cccc(c12)c3c(n2C)CCC(C3=O)Cn4ccnc4C,C18H19N3O,C07325,D00456,4595,46504819,7773,CHEMBL46,,4434,85330,293.363,2.34996517,"Anti-Anxiety Agents; Antidepressive Agents; Antiemetics; Antiemetics and Antinauseants; Azoles; Carbazoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Imidazoles; Indoles; Moderate Risk QTc-Prolonging Agents; Peripheral Nervous System Agents; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 3 Receptor Antagonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB00905,Bimatoprost,155206-00-1,approved; investigational,AQOKCDNYWBIDND-FTOWTWDKSA-N,"InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1",CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc2ccccc2,C25H37NO4,,D02724,5311027,46505334,51230,CHEMBL1200963,15M,4470565,220120,415.5656,2.629262467,"Amides; Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Autacoids; Biological Factors; Cardiovascular Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Inflammation Mediators; Lipids; Ophthalmologicals; Prostaglandin analogs reducing intraocular pressure (IOP); Prostaglandins; Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Sensory Organs"
DB00906,Tiagabine,115103-54-3,approved; investigational,PBJUNZJWGZTSKL-MRXNPFEDSA-N,"InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1",Cc1ccsc1C(c2c(C)ccs2)=CCCN3CCC[C@H](C3)C(=O)O,C20H25NO2S2,C07503,,60648,46505560,9586,CHEMBL1027,,54661,50368628,375.548,2.601448472,"Acids, Heterocyclic; Anti-epileptic Agent; Anticonvulsants; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Fatty Acid Derivatives; GABA Agents; GABA Uptake Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Nipecotic Acids; Piperidines; UGT1A1 Substrates"
DB00907,Cocaine,50-36-2,approved; illicit,ZPUCINDJVBIVPJ-LJISPDSOSA-N,"InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1",[C@@H]12CC[C@@H](N1C)[C@@H](C(=O)OC)[C@H](C2)OC(=O)c3ccccc3,C17H21NO4,C01416,D00110,446220,46506326,27958,CHEMBL370805,COC,10194104,22418,303.3529,2.282108009,"Agents producing tachycardia; Agents that reduce seizure threshold; Alkaloids; Analgesics and Anesthetics; Anesthetics; Anesthetics, Local; Anticholinergic Agents; Aza Compounds; Azabicyclo Compounds; Bicyclo Compounds, Heterocyclic; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase substrates; Cocaine, antagonists & inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Uptake Inhibitors; Esters of Benzoic Acid; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Highest Risk QTc-Prolonging Agents; Local Anesthetics (Ester); Membrane Transport Modulators; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; OCT2 Inhibitors; Ophthalmologicals; Otologicals; Peripheral Nervous System Agents; QTc Prolonging Agents; Respiratory System; Sensory Organs; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Throat Preparations; Tropanes; Vasoconstrictor Agents"
DB00908,Quinidine,56-54-2,approved; investigational,LOUPRKONTZGTKE-LHHVKLHASA-N,"InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1",C=C[C@@H](CN12)[C@@H](CC1)C[C@@H]2[C@@H](O)c(ccn3)c(c34)cc(cc4)OC,C20H24N2O2,C06527,D08458,441074,46505356,28593,CHEMBL1294,QDN,389880,50121975,324.4168,2.513463951,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Agents that produce neuromuscular block (indirect); Agents that reduce seizure threshold; Alkaloids; Anti-Infective Agents; Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ia; Anticholinergic Agents; Antimalarials; Antiparasitic Agents; Antiprotozoals; Biological Products; Biopolymers; BSEP/ABCB11 Inhibitors; Carbohydrates; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Chemically-Induced Disorders; Cholinergic Agents; Cinchona Alkaloids; Complex Mixtures; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strong); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Macromolecular Substances; Manufactured Materials; Medications that reduce magnesium levels; Membrane Transport Modulators; Metabolic Side Effects of Drugs and Substances; Muscarinic Antagonists; Narrow Therapeutic Index Drugs; Neurotransmitter Agents; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Pharmaceutical Preparations; Photosensitizing Agents; Plant Extracts; Plant Preparations; Polymers; Polysaccharides; QTc Prolonging Agents; Quinine and stereoisomer; Quinolines; Quinuclidines; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB00909,Zonisamide,68291-97-4,approved; investigational,UBQNRHZMVUUOMG-UHFFFAOYSA-N,"InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)",NS(=O)(=O)Cc1noc(c12)cccc2,C8H8N2O3S,C07504,D00538,5734,46505278,10127,CHEMBL750,ZON,5532,10888,212.226,0.110686425,"Agents causing hyperkalemia; Amides; Anti-epileptic Agent; Antiarrhythmic agents; Anticonvulsants; Azoles; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Carbonic Anhydrase Inhibitors; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Diuretics; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isoxazoles; Membrane Transport Modulators; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Nervous System; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sulfonamides; Sulfones; Sulfur Compounds; UGT1A1 Substrates"
DB00910,Paricalcitol,131918-61-1,approved; investigational,BPKAHTKRCLCHEA-UBFJEZKGSA-N,"InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1",CC(C)(O)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]([C@@]12C)/C(CCC2)=C/C=C3C[C@@H](O)C[C@H](O)C3,C27H44O3,C08127,D00930,5281104,46505780,7931,CHEMBL1200622,,4444552,233195,416.6365,4.258511421,"Anti-Parathyroid Agents; Bone Density Conservation Agents; Calcium Homeostasis; Cholestanes; Cholestenes; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Lipids; Membrane Lipids; Polycyclic Compounds; Secosteroids; Steroids; Sterols; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; UGT1A4 substrates; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)"
DB00911,Tinidazole,19387-91-8,approved; investigational,HJLSLZFTEKNLFI-UHFFFAOYSA-N,"InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3",CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O,C8H13N3O4S,,D01426,5479,46506396,63627,CHEMBL1220,,5279,50248360,247.272,-0.580518509,"Alimentary Tract and Metabolism; Alkylating Drugs; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Antitrichomonal Agents; Azoles; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole Derivatives; Imidazoles; Nitro Compounds; Nitroimidazole Antimicrobial; Nitroimidazole Derivatives; Nitroimidazoles; Noxae; Toxic Actions"
DB00912,Repaglinide,135062-02-1,approved; investigational,FAEKWTJYAYMJKF-QHCPKHFHSA-N,"InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1",CCOc1c(C(=O)O)ccc(c1)CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3,C27H36N2O4,C07670,D00594,65981,46508150,8805,CHEMBL1272,BJX,59377,50153520,452.5857,3.946804455,"Acids, Acyclic; Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; BSEP/ABCB11 Substrates; Carboxylic Acids; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Glinide; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypoglycemia-Associated Agents; Meglitinides; OATP1B1/SLCO1B1 Substrates; Potassium Channel Antagonists; Stereoisomerism"
DB00913,Anileridine,144-14-9,approved; illicit,LKYQLAWMNBFNJT-UHFFFAOYSA-N,"InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3",c1ccccc1C2(C(=O)OCC)CCN(CC2)CCc3ccc(N)cc3,C22H28N2O2,,D02941,8944,46505199,61203,CHEMBL1201347,,8600,,352.4699,3.640008764,"Acids, Heterocyclic; Anesthetics; Anesthetics, General; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Opioid Anesthetics; Piperidines"
DB00914,Phenformin,114-86-3,approved; investigational; withdrawn,ICFJFFQQTFMIBG-UHFFFAOYSA-N,"InChI=1S/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)",NC(=N)NC(=N)NCCc1ccccc1,C10H15N5,C07673,D08351,8249,46505230,8064,CHEMBL170988,8CV,7953,50240908,205.2596,0.832728992,Alimentary Tract and Metabolism; Amidines; Biguanides; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Guanidines; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors
DB00915,Amantadine,768-94-5,approved,DKNWSYNQZKUICI-UHFFFAOYSA-N,"InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2",NC12CC3CC(C1)CC(C3)C2,C10H17N,C06818,,2130,46507081,2618,CHEMBL660,,2045,50033369,151.2487,1.465947548,"Adamantane Derivatives; Adamantanes; Analgesics; Analgesics, Non-Narcotic; Anti-Dyskinesia Agents; Anti-Infective Agents; Anti-Parkinson Drugs; Anticholinergic Agents; Antiviral Agents; Bridged Compounds; Central Nervous System Agents; Cycloparaffins; Dopamine Agents; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Influenza A M2 Protein Inhibitor; M2 Protein Inhibitors; Macrocyclic Compounds; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; NMDA Receptor Antagonists; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; Peripheral Nervous System Agents; Polycyclic Compounds; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00916,Metronidazole,443-48-1,approved,VAOCPAMSLUNLGC-UHFFFAOYSA-N,"InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3",Cc1ncc([N+]([O-])=O)n1CCO,C6H9N3O3,C07203,D00409,4173,46508911,6909,CHEMBL137,2MN,4029,50375309,171.154,-0.459310225,"Agents that reduce seizure threshold; Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives and Antiseptics for Local Oral Treatment; Antiinfectives for Systemic Use; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Azoles; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole Derivatives; Imidazoles; Miscellaneous Antiprotozoals; Miscellaneous Local Anti-infectives; Nitro Compounds; Nitroimidazole Antimicrobial; Nitroimidazole Derivatives; Nitroimidazoles; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Stomatological Preparations; UGT1A1 Substrates"
DB00917,Dinoprostone,363-24-6,approved,XEYBRNLFEZDVAW-ARSRFYASSA-N,"InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1",CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,C20H32O5,C00584,D00079,5280360,46505549,15551,CHEMBL548,P2E,4444059,35847,352.4651,3.225270137,"Autacoids; Biological Factors; Dinoprostone, antagonists & inhibitors; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Genito Urinary System and Sex Hormones; Inflammation Mediators; Lipids; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Substrates; OCT1 inhibitors; OCT2 Inhibitors; Prostaglandins; Prostaglandins E; Prostaglandins, Synthetic; Reproductive Control Agents; Uterotonic agents"
DB00918,Almotriptan,154323-57-6,approved; investigational,WKEMJKQOLOHJLZ-UHFFFAOYSA-N,"InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3",CN(C)CCc1c[nH]c(c12)ccc(c2)CS(=O)(=O)N3CCCC3,C17H25N3O2S,,,123606,46505165,520985,CHEMBL1505,,110198,,335.464,1.523382382,"Agents that produce hypertension; Amines; Analgesics; Antidepressive Agents; Antimigraine Preparations; Biogenic Amines; Biogenic Monoamines; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Migraine Disorders; Monoamine Oxidase A Substrates; Nervous System; Neurotransmitter Agents; Selective Serotonin 5-HT1 Receptor Agonists; Selective Serotonin Agonists; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 1b Receptor Agonists; Serotonin 1d Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Serotonin-1b and Serotonin-1d Receptor Agonist; Triptans"
DB00919,Spectinomycin,1695-77-8,approved; investigational; vet_approved,UNFWWIHTNXNPBV-WXKVUWSESA-N,"InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1",O=C1C[C@@H](C)O[C@H]([C@]12O)O[C@H]3[C@H](O2)[C@@H](NC)[C@@H](O)[C@@H](NC)[C@@H]3O,C14H24N2O7,C02078,,15541,46505032,9215,CHEMBL1167,SCM,14785,,332.3496,-2.369337287,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Dioxanes; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring"
DB00920,Ketotifen,34580-13-7,approved,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,"InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3",CN1CCC(CC1)=C2c(ccs3)c3C(=O)Cc(c24)cccc4,C19H19NOS,,D01332,3827,46508921,92511,CHEMBL534,,3695,94597,309.425,3.347869323,"Anti-Allergic Agents; Antihistamine Drugs; Antihistamines for Systemic Use; Antipruritics; Decongestants and Antiallergics; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Inhibitors; Neurotransmitter Agents; Ophthalmologicals; Other Antihistamines; Piperidines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System; Sensory Organs; Sulfur Compounds; Thiophenes"
DB00921,Buprenorphine,52485-79-7,approved; illicit; investigational; vet_approved,RMRJXGBAOAMLHD-IHFGGWKQSA-N,"InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1",CC(C)(C)[C@@](C)(O)[C@@H](C1)[C@](OC)(CC2)[C@@H]3Oc(c(O)cc4)c5c4C[C@H]([C@]12[C@]356)N(CC6)CC7CC7,C29H41NO4,C08007,D07132,644073,46505782,3216,CHEMBL560511,,559124,50026603,467.6401,3.549880758,"Alkaloids; Analgesics; BCRP/ABCG2 Inhibitors; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs Used in Addictive Disorders; Drugs Used in Opioid Dependence; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Mixed Agonist / Antagonist Opioids; Morphinans; Narcotics; Nervous System; Opiate Agonists; Opiate Alkaloids; Opiate Partial Agonists; Opioid Antagonists; Opioids; Oripavine Derivatives; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; UGT1A1 Substrates; UGT1A9 Substrates"
DB00922,Levosimendan,141505-33-1,approved; investigational,WHXMKTBCFHIYNQ-SECBINFHSA-N,"InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1",C[C@@H]1CC(=O)NN=C1c2ccc(cc2)NN=C(C#N)C#N,C14H12N6O,,D04720,3033825,46507149,50567,CHEMBL2051955,,2298414,,280.2847,2.161618159,"Antiarrhythmic agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrazines; Hydrazones; Hypotensive Agents; Moderate Risk QTc-Prolonging Agents; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Protective Agents; Pyridazines; QTc Prolonging Agents; Vasodilating Agents"
DB00923,Ceforanide,60925-61-3,approved,SLAYUXIURFNXPG-CRAIPNDOSA-N,"InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1",OC(=O)Cn1nnnc1SCC(=C2C(=O)O)CS[C@@H](N23)[C@@H](C3=O)NC(=O)Cc4ccccc4CN,C20H21N7O6S2,C06884,D00259,43507,46504532,3495,CHEMBL1201046,,39656,,519.554,-3.171896407,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Second-Generation Cephalosporins; Sulfur Compounds; Thiazines"
DB00924,Cyclobenzaprine,303-53-7,approved,JURKNVYFZMSNLP-UHFFFAOYSA-N,"InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3",CN(C)CCC=C1c(cccc2)c2C=Cc(c13)cccc3,C20H21N,C06931,D07758,2895,46508313,3996,CHEMBL669,,2792,112774,275.3874,4.613013258,"Agents that reduce seizure threshold; Antidepressive Agents; Benzocycloheptenes; Central Nervous System Agents; Central Nervous System Depressants; Centrally-mediated Muscle Relaxation; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dibenzocycloheptenes; Drugs causing inadvertant photosensitivity; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System; Neurotoxic agents; Photosensitizing Agents; Polycyclic Compounds; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents; UGT1A4 substrates"
DB00925,Phenoxybenzamine,59-96-1,approved,QZVCTJOXCFMACW-UHFFFAOYSA-N,"InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3",c1ccccc1CN(CCCl)C(C)COc2ccccc2,C18H22ClNO,C07435,,4768,46507191,8077,CHEMBL753,,4604,50017679,303.826,4.639757059,Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Amines; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular System; Ethylamines; Hypotensive Agents; Neurotransmitter Agents; OCT1 inhibitors; OCT2 Inhibitors; Peripheral alpha-1 blockers; Peripheral Vasodilators; Vasodilating Agents
DB00927,Famotidine,76824-35-6,approved,XUFQPHANEAPEMJ-UHFFFAOYSA-N,"InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)",NC(N)=Nc1nc(cs1)CSCC/C(N)=N/S(=O)(=O)N,C8H15N7O2S3,,D00318,3325,46507397,4975,CHEMBL902,,3208,50036754,337.445,-1.950081878,"Acid Reducers; Alimentary Tract and Metabolism; Anti-Ulcer Agents; Azoles; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Gastric Acid Lowering Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H2 Antagonists; MATE 1 Inhibitors; MATE inhibitors; Neurotransmitter Agents; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OCT2 Inhibitors; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sulfur Compounds; Thiazoles"
DB00928,Azacitidine,320-67-2,approved; investigational,NMUSYJAQQFHJEW-KVTDHHQDSA-N,"InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1",Nc1nc(=O)n(cn1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,C8H12N4O5,C11262,D03021,9444,46509032,2038,CHEMBL1489,5AE,9072,50424715,244.2047,-3.065332952,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Aza Compounds; Carbohydrates; Cytidine Deaminase Substrates; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Metabolic Inhibitor; Nucleosides; Pyrimidine Analogues; Pyrimidine Nucleosides; Pyrimidines; Ribonucleosides; Toxic Actions"
DB00929,Misoprostol,59122-46-2,approved,OJLOPKGSLYJEMD-URPKTTJQSA-N,"InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1",CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,C22H38O5,,D00419,5282381,46505041,63610,CHEMBL606,,4445541,85606,382.5341,3.857755058,"Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Alimentary Tract and Metabolism; Anti-Ulcer Agents; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Autacoids; Biological Factors; Drugs causing inadvertant photosensitivity; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Gastrointestinal Agents; Genito Urinary System and Sex Hormones; Inflammation Mediators; Lipids; Musculo-Skeletal System; Photosensitizing Agents; Propionates; Prostaglandin E1 Analog; Prostaglandins; Prostaglandins E, Synthetic; Prostaglandins, Synthetic; Reproductive Control Agents; Uterotonic agents"
DB00930,Colesevelam,182815-43-6,approved,,, ,,,,,46505437,,,,,,NA,NA,"Alkenes; Allyl Compounds; Allylamine; Amines; Anticholesteremic Agents; Bile Acid Sequestrants; Bile-acid Binding Activity; Cardiovascular System; Hydrocarbons; Hydrocarbons, Acyclic; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Noxae; Toxic Actions"
DB00931,Metacycline,914-00-1,approved; investigational,MHIGBKBJSQVXNH-IWVLMIASSA-N,"InChI=1S/C22H22N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-6,10,14-15,17,25,27-29,32H,1H2,2-3H3,(H2,23,31)/t10-,14-,15+,17+,22+/m1/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)[C@@H](O)[C@H]3C(=C2O)C(=O)c4c(C3=C)cccc4O,C22H22N2O8,C07654,D04972,54675785,46506631,6805,CHEMBL249837,,10468596,50046500,442.424,-3.507732201,"Agents that produce neuromuscular block (indirect); Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Tetracyclines"
DB00932,Tipranavir,174484-41-4,approved; investigational,SUJUHGSWHZTSEU-FYBSXPHGSA-N,"InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1",FC(F)(F)c1ccc(nc1)S(=O)(=O)Nc2cccc(c2)[C@@H](CC)C(=C(O)C3)C(=O)O[C@]3(CCC)CCc4ccccc4,C31H33F3N2O5S,,,54682461,46506257,63628,CHEMBL222559,TPV,10482313,558,602.664,7.138675971,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Drugs causing inadvertant photosensitivity; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV Protease Inhibitors; Hyperglycemia-Associated Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Protease Inhibitors; Pyrans; UGT1A1 Inducers"
DB00933,Mesoridazine,5588-33-0,approved; investigational,SLVMESMUVMCQIY-UHFFFAOYSA-N,"InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3",CN1CCCCC1CCN2c(cccc3)c3Sc(c24)ccc(c4)S(=O)C,C21H26N2OS2,C07143,D02671,4078,46506724,6780,CHEMBL1088,,3936,50131440,386.574,3.574503406,"Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Phenothiazines; Phenothiazines With Piperidine Structure; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Tranquilizing Agents"
DB00934,Maprotiline,10262-69-8,approved; investigational,QSLMDECMDJKHMQ-UHFFFAOYSA-N,"InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3",CNCCCC12c3c(cccc3)C(CC1)c4c2cccc4,C20H23N,C07107,D02566,4011,46508358,6690,CHEMBL21731,,3871,35228,277.4033,4.372104774,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that reduce seizure threshold; Anthracenes; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tetracyclic; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Membrane Transport Modulators; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Tricyclics and Other Norepinephrine-reuptake Inhibitors"
DB00935,Oxymetazoline,1491-59-4,approved; investigational,WYWIFABBXFUGLM-UHFFFAOYSA-N,"InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)",Cc1cc(C(C)(C)C)c(O)c(C)c1CC2=NCCN2,C16H24N2O,C07363,,4636,46505622,7862,CHEMBL762,,4475,30712,260.3746,3.032315205,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Autonomic Agents; Azoles; Cardiovascular Agents; Decongestants and Antiallergics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Increased Sympathetic Activity; Nasal Decongestants; Nasal Preparations; Neurotransmitter Agents; Ophthalmologicals; Peripheral Nervous System Agents; Respiratory System; Respiratory System Agents; Sensory Organs; Sympathomimetics; Sympathomimetics Used as Decongestants; Sympathomimetics, Plain; Vasoconstriction; Vasoconstrictor Agents"
DB00936,Salicylic acid,69-72-7,approved; investigational; vet_approved,YGSDEFSMJLZEOE-UHFFFAOYSA-N,"InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)",OC(=O)c1ccccc1O,C7H6O3,C00805,D00097,338,46504942,16914,CHEMBL424,SAL,331,26193,138.1207,1.977263402,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Keratolytic Agents; Nephrotoxic agents; Nervous System; Nitrogen Binding Agent; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Ophthalmologicals; Peripheral Nervous System Agents; Phenols; Salicylates; Salicylic Acid and Derivatives; Sclerosing Solutions; Sensory Organs; Sensory System Agents"
DB00937,Diethylpropion,90-84-6,approved; illicit,XXEPPPIWZFICOJ-UHFFFAOYSA-N,"InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3",CCN(CC)C(C)C(=O)c1ccccc1,C13H19NO,C06954,D07444,7029,46506622,4530,CHEMBL1194666,,6762,,205.2961,2.704771975,"Agents producing tachycardia; Agents that produce hypertension; Alimentary Tract and Metabolism; Amines; Amphetamines; Anti-Obesity Agents; Antiobesity Preparations, Excl. Diet Products; Appetite Depressants; Appetite Suppression; Central Nervous System Depressants; Centrally Acting Antiobesity Products; Ethylamines; Increased Sympathetic Activity; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Stimulants; Sympathomimetic Amine Anorectic; Sympathomimetics"
DB00938,Salmeterol,89365-50-4,approved,GIIZNNXWQWCKIB-UHFFFAOYSA-N,"InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2",OCc1c(O)ccc(c1)C(O)CNCCCCCCOCCCCc2ccccc2,C25H37NO4,C07241,D05792,5152,46508024,64064,CHEMBL1263,,4968,25771,415.5656,3.614696207,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics, Inhalants; Agents Causing Muscle Toxicity; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Ethanolamines; Ethylamines; Long-acting beta-adrenoceptor agonists; Neurotransmitter Agents; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors; Peripheral Nervous System Agents; Phenethylamines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists; Sympathomimetic (Adrenergic) Agents"
DB00939,Meclofenamic acid,644-62-2,approved; vet_approved,SBDNJUWAMKYJOX-UHFFFAOYSA-N,"InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)",Cc1c(Cl)c(c(Cl)cc1)Nc2ccccc2C(=O)O,C14H11Cl2NO2,C07117,D02341,4037,46507887,6710,CHEMBL509,JMS,3897,22971,296.149,6.092265241,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Amines; Aminobenzoates; Analgesics; Analgesics, Non-Narcotic; Aniline Compounds; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Fenamates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; ortho-Aminobenzoates; Peripheral Nervous System Agents; Sensory System Agents; Thyroxine-binding globulin substrates; Topical Products for Joint and Muscular Pain"
DB00940,Methantheline,5818-17-7,approved; investigational,GZHFODJQISUKAY-UHFFFAOYSA-N,"InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1",CC[N+](C)(CC)CCOC(=O)C1c(cccc2)c2Oc(c13)cccc3,C21H26NO3,C07849,,4097,46505807,6817,CHEMBL1201264,,3955,,340.436,-0.469356405,"Acid Reducers; Agents producing tachycardia; Alimentary Tract and Metabolism; Amines; Ammonium Compounds; Anticholinergic Agents; Cholinergic Agents; Drugs for Functional Gastrointestinal Disorders; Gastric Acid Lowering Agents; Histamine Antagonists; Histamine H2 Antagonists; Muscarinic Antagonists; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Quaternary Ammonium Compounds; Synthetic Anticholinergics, Quaternary Ammonium Compounds"
DB00941,Hexafluronium,04-10-4844,approved,HDZAQYPYABGTCL-UHFFFAOYSA-N,"InChI=1S/C36H42N2/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3/q+2",c1cccc2c1C(c(c23)cccc3)[N+](C)(C)CCCCCC[N+](C)(C)C4c(cccc5)c5c(c46)cccc6,C36H42N2,,D04435,3601,46507171,135804,CHEMBL1201349,,3475,,502.745,-0.284013804,"Amines; Ammonium Compounds; Anticholinergic Agents; Bis-Trimethylammonium Compounds; Central Nervous System Depressants; Cholinergic Agents; Cholinesterase Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neurotransmitter Agents; Nicotinic Antagonists; Nitrogen Compounds; Onium Compounds; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quaternary Ammonium Compounds"
DB00942,Cycrimine,77-39-4,approved,SWRUZBWLEWHWRI-UHFFFAOYSA-N,"InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2",c1ccccc1C(O)(C2CCCC2)CCN3CCCCC3,C19H29NO,,,2911,46506736,59692,CHEMBL1201227,,2808,,287.4397,3.788116829,"Agents producing tachycardia; Anticholinergic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists"
DB00943,Zalcitabine,7481-89-2,approved; investigational,WREGKURFCTUGRC-POYBYMJQSA-N,"InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1",Nc1nc(=O)n(cc1)[C@H]2CC[C@H](O2)CO,C9H13N3O3,C07207,D00412,24066,46507879,10101,CHEMBL853,,22498,50145605,211.2178,-1.188226456,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antimetabolites; Antiviral Agents; Antivirals for Systemic Use; Carbohydrates; Deoxycytidine; Deoxyribonucleosides; Dideoxynucleosides; Direct Acting Antivirals; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides; OAT1/SLC22A6 Substrates; Pyrimidine Nucleosides; Pyrimidines; Reverse Transcriptase Inhibitors; Ribonucleosides; Toxic Actions"
DB00944,Demecarium,16505-84-3,approved,RWZVPVOZTJJMNU-UHFFFAOYSA-N,"InChI=1S/C32H52N4O4/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8/h17-22,25-26H,9-16,23-24H2,1-8H3/q+2",C[N+](C)(C)c1cc(ccc1)OC(=O)N(C)CCCCCCCCCCN(C)C(=O)Oc2cccc(c2)[N+](C)(C)C,C32H52N4O4,,D00667,5966,46507824,59719,CHEMBL1201229,,5751,,556.7797,-1.418755321,Amines; Ammonium Compounds; Antiglaucoma Preparations and Miotics; Cholinergic Agents; Cholinesterase Inhibitors; Enzyme Inhibitors; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Ophthalmologicals; Parasympathomimetics; Sensory Organs
DB00945,Acetylsalicylic acid,50-78-2,approved; vet_approved,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",CC(=O)Oc1ccccc1C(=O)O,C9H8O4,C01405,D00109,2244,46505803,15365,CHEMBL25,AIN,2157,22360,180.1574,1.238089698,"Acids, Carbocyclic; Agents causing angioedema; Agents causing hyperkalemia; Agents that produce hypertension; Alimentary Tract and Metabolism; Amino Acids; Amino Acids, Basic; Amino Acids, Diamino; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Anticoagulants; Antiinflammatory and Antirheumatic Products; Antiplatelet agents; Antipyretics; Benzene Derivatives; Blood and Blood Forming Organs; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Decreased Platelet Aggregation; Decreased Prostaglandin Production; Drugs that are Mainly Renally Excreted; Hematologic Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxybenzoates; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; P-glycoprotein inducers; P-glycoprotein substrates; Peripheral Nervous System Agents; Platelet Aggregation Inhibitors Excl. Heparin; Salicylates; Salicylic Acid and Derivatives; Sensory System Agents; Stomatological Preparations; UGT1A6 substrate"
DB00946,Phenprocoumon,435-97-2,approved; investigational,DQDAYGNAKTZFIW-UHFFFAOYSA-N,"InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3",c1ccccc1C(CC)c(c(=O)o2)c(O)c(c23)cccc3,C18H16O3,,D05457,54680692,46506423,50438,CHEMBL1465,,10441592,768,280.3178,3.735323605,"4-Hydroxycoumarins; Anticoagulants; Benzopyrans; Blood and Blood Forming Organs; Coumarins; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Pyrans; Vitamin K Antagonists; Vitamin K Inhibitors"
DB00947,Fulvestrant,129453-61-8,approved; investigational,VWUXBMIQPBEWFH-WCCTWKNTSA-N,"InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1",O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(cc(O)cc4)C[C@H]3CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F,C32H47F5O3S,,D01161,17756771,46508664,31638,CHEMBL1358,,94553,50238741,606.78,7.57184088,"Anti-Estrogens; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Endocrine Therapy; Estradiol Congeners; Estranes; Estrenes; Estrogen Antagonists; Estrogen Receptor Antagonists; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Selective Estrogen Receptor Modulators; Steroids; UGT1A1 Substrates"
DB00948,Mezlocillin,51481-65-3,approved; investigational,YPBATNHYBCGSSN-VWPFQQQWSA-N,"InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)[C@@H](c3ccccc3)NC(=O)N4CCN(C4=O)S(=O)(=O)C,C21H25N5O8S2,C07221,D05021,656511,46506692,6919,CHEMBL1731,,570894,,539.582,-0.841524157,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillin G; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB00949,Felbamate,25451-15-4,approved,WKGXYQFOCVYPAC-UHFFFAOYSA-N,"InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)",NC(=O)OCC(COC(=O)N)c1ccccc1,C11H14N2O4,C07501,D00536,3331,46506375,4995,CHEMBL1094,,3214,50088430,238.2399,0.679567944,"Acids, Acyclic; Alcohols; Anti-epileptic Agent; Anticonvulsants; Carbamates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Excitatory Amino Acid Agents; Excitatory Amino Acid Antagonists; Glycols; Nervous System; Neurotransmitter Agents; NMDA Receptor Antagonists; Phenylcarbamates; Potential QTc-Prolonging Agents; Propylene Glycols; QTc Prolonging Agents"
DB00950,Fexofenadine,83799-24-0,approved; investigational,RWTNPBWLLIMQHL-UHFFFAOYSA-N,"InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)",OC(=O)C(C)(C)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4,C32H39NO4,C06999,D07958,3348,46504676,5050,CHEMBL914,,3231,22874,501.6564,2.938500987,"Anti-Allergic Agents; Antihistamines for Systemic Use; Benzene Derivatives; Benzhydryl Compounds; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; Piperidines; Respiratory System"
DB00951,Isoniazid,54-85-3,approved; investigational,QRXWMOHMRWLFEY-UHFFFAOYSA-N,"InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)",NNC(=O)c1ccncc1,C6H7N3O,C07054,D00346,3767,46506039,6030,CHEMBL64,NIZ,3635,50336507,137.1393,-0.69026201,"Acids, Heterocyclic; Agents Causing Muscle Toxicity; Agents that reduce seizure threshold; Anti-Bacterial Agents; Anti-Infective Agents; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (moderate); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Treatment of Tuberculosis; Drugs that are Mainly Renally Excreted; Fatty Acid Synthesis Inhibitors; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrazides; Hydrazines; Hypolipidemic Agents; Isonicotinic Acids; Lipid Regulating Agents; Noxae; Pyridines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Toxic Actions"
DB00952,Naratriptan,121679-13-8,approved; investigational,AMKVXSZCKVJAGH-UHFFFAOYSA-N,"InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3",CNS(=O)(=O)CCc(cc1)cc(c12)c(c[nH]2)C3CCN(C)CC3,C17H25N3O2S,C07792,D08255,4440,46507243,7478,CHEMBL1278,,4287,50073682,335.464,1.440624933,"Agents that produce hypertension; Amines; Analgesics; Antidepressive Agents; Antimigraine Preparations; Biogenic Amines; Biogenic Monoamines; Cardiovascular Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Monoamine Oxidase A Substrates; Nervous System; Neurotransmitter Agents; Selective Serotonin 5-HT1 Receptor Agonists; Selective Serotonin Agonists; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 1b Receptor Agonists; Serotonin 1d Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Serotonin-1b and Serotonin-1d Receptor Agonist; Triptans; Vasoconstrictor Agents"
DB00953,Rizatriptan,144034-80-0,approved,ULFRLSNUDGIQQP-UHFFFAOYSA-N,"InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3",CN(C)CCc1c[nH]c(c12)ccc(c2)Cn3cncn3,C15H19N5,,D00675,5078,46506557,48273,CHEMBL905,,4900,50033437,269.3449,1.767879314,"Agents that produce hypertension; Amines; Analgesics; Antidepressive Agents; Antimigraine Preparations; Azoles; Biogenic Amines; Biogenic Monoamines; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Migraine Disorders; Monoamine Oxidase A Substrates; Nervous System; Neurotransmitter Agents; Selective Serotonin 5-HT1 Receptor Agonists; Selective Serotonin Agonists; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 1b Receptor Agonists; Serotonin 1d Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Serotonin-1b and Serotonin-1d Receptor Agonist; Triptans"
DB00955,Netilmicin,56391-56-1,approved; investigational,CIDUJQMULVCIBT-MQDUPKMGSA-N,"InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1",C[C@]1(O)CO[C@@H]([C@H](O)[C@H]1NC)O[C@@H]2[C@@H](O)[C@@H]([C@@H](N)C[C@H]2NCC)O[C@H]3OC(CN)=CC[C@H]3N,C21H41N5O7,C07657,D08268,441306,46507404,7528,CHEMBL1572,,20152952,,475.587,-3.529179202,Agents that produce neuromuscular block (indirect); Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inhibitors; Gentamicins; Glycosides; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Ophthalmologicals; Protein Synthesis Inhibitors; Sensory Organs
DB00956,Hydrocodone,125-29-1,approved; illicit; investigational,LLPOLZWFYMWNKH-CMKMFDCUSA-N,"InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1",[C@@]123c4c5ccc(OC)c4O[C@H]1C(=O)CC[C@H]3[C@@H](C5)N(C)CC2,C18H21NO3,C08024,D08045,5284569,46506225,5779,CHEMBL1457,,4447623,50386689,299.3642,1.960303968,"Alkaloids; Analgesics; Antitussive Agents; Central Nervous System Agents; Central Nervous System Depressants; Cough and Cold Preparations; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Morphine Derivatives; Narcotics; Opiate Alkaloids; Opioid Agonist; Opioids; Opium Alkaloids and Derivatives; Peripheral Nervous System Agents; Phenanthrene opioids; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Respiratory System; Respiratory System Agents; Semi-synthetic Opioids; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB00957,Norgestimate,35189-28-7,approved; investigational,KIQQMECNKUGGKA-NMYWJIRASA-N,"InChI=1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1",CC(=O)O[C@@]1(C#C)CC[C@H]([C@@]12CC)[C@H]3[C@H](CC2)[C@@H]4C(CC3)=C/C(CC4)=N/O,C23H31NO3,,D05209,6540478,46507381,50815,CHEMBL1200934,,5022837,,369.4971,4.112401799,"Adrenal Cortex Hormones; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hyperglycemia-Associated Agents; Norpregnanes; Norpregnenes; Norsteroids; P-glycoprotein inhibitors; Polycyclic Compounds; Progestin Contraceptives; Progestins; Progestogens and Estrogens, Sequential Preparations; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids; UGT1A1 Substrates"
DB00958,Carboplatin,41575-94-4,approved,OLESAACUTLOWQZ-UHFFFAOYSA-L,"InChI=1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2",C1CCC12C(=O)O[Pt]([NH3+])([NH3+])OC2=O,C6H12N2O4Pt,,D01363,38904,46507170,31355,CHEMBL1351,,8514637,,371.254,NA,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Compounds used in a research, industrial, or household setting; Cross-Linking Reagents; Drugs that are Mainly Renally Excreted; Immunosuppressive Agents; Indicators and Reagents; Laboratory Chemicals; Medications that reduce magnesium levels; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Organometallic Compounds; Platinum Compounds"
DB00959,Methylprednisolone,83-43-2,approved; vet_approved,VHRSUDSXCMQTMA-PJHHCJLFSA-N,"InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1",OCC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C([C@H](C3)C)=CC(=O)C=C4,C22H30O5,,D00407,6741,46504885,6888,CHEMBL650,,6485,50103616,374.4706,1.560009021,"Adrenal Cortex Hormones; Adrenals; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Autonomic Agents; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Corticosteroids, Dermatological Preparations; Corticosteroids, Weak (Group I); Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Experimental Unapproved Treatments for COVID-19; Fused-Ring Compounds; Gastrointestinal Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Neuroprotective Agents; Ophthalmologicals; P-glycoprotein inducers; P-glycoprotein substrates; Peripheral Nervous System Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Protective Agents; Sensory Organs; Steroids; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB00960,Pindolol,13523-86-9,approved; investigational,JZQKKSLKJUAGIC-UHFFFAOYSA-N,"InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3",CC(C)NCC(O)COc1cccc(c12)[nH]cc2,C14H20N2O2,C07445,D00513,4828,46508362,8214,CHEMBL500,,4662,50019443,248.3208,1.692981166,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antidepressive Agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Beta Blocking Agents, Non-Selective; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hypotensive Agents; Neurotransmitter Agents; Phenoxypropanolamines; Propanolamines; Propanols; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Vasodilating Agents"
DB00961,Mepivacaine,96-88-8,approved; vet_approved,INWLQCZOYSRPNW-UHFFFAOYSA-N,"InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)",CN1CCCCC1C(=O)Nc2c(C)cccc2C,C15H22N2O,C07528,D08181,4062,46507857,6759,CHEMBL1087,,3922,50417964,246.348,3.19161987,"Amides; Anesthetics; Anesthetics, Local; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Local Anesthesia; Local Anesthetics (Amide); Nervous System; Peripheral Nervous System Agents; Piperidines; Sensory System Agents"
DB00962,Zaleplon,151319-34-5,approved; illicit; investigational,HUNXMJYCHXQEGX-UHFFFAOYSA-N,"InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3",CCN(C(=O)C)c1cccc(c1)-c2ccnc(n23)c(cn3)C#N,C17H15N5O,C07484,D00530,5719,46508267,10102,CHEMBL1521,,5517,86521,305.3339,1.534879686,"Acetates; Acids, Acyclic; Amides; Anticonvulsants; Benzodiazepine hypnotics and sedatives; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Central Nervous System Depression; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fatty Acids; Fatty Acids, Volatile; GABA Agents; GABA Agonists; GABA Modulators; GABA-A Receptor Agonists; gamma-Aminobutyric Acid A Receptor Agonist; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics (Nonbenzodiazepine); Hypnotics and Sedatives; Lipids; Miscellaneous Anxiolytics Sedatives and Hypnotics; Nervous System; Neurotransmitter Agents; Psycholeptics"
DB00963,Bromfenac,91714-94-2,approved,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,"InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)",OC(=O)Cc1c(N)c(ccc1)C(=O)c2ccc(Br)cc2,C15H12BrNO3,,D07541,60726,46508121,240107,CHEMBL1077,27R,54730,50248104,334.165,3.660173814,"Agents causing hyperkalemia; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antirheumatic Agents; Benzene Derivatives; Central Nervous System Agents; Cyclooxygenase Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Brominated; Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Ketones; Nephrotoxic agents; Ophthalmologicals; Peripheral Nervous System Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory Organs; Sensory System Agents"
DB00964,Apraclonidine,66711-21-5,approved,IEJXVRYNEISIKR-UHFFFAOYSA-N,"InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)",Nc1cc(Cl)c(c(Cl)c1)NC2=NCCN2,C9H10Cl2N4,C07668,,2216,46505614,2788,CHEMBL647,,2130,50021812,245.109,1.65616275,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Antiglaucoma Preparations and Miotics; Azoles; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; EENT Drugs, Miscellaneous; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Imidazoles; Imidazolines; Neurotransmitter Agents; Ophthalmics; Ophthalmologicals; Sensory Organs; Sympathomimetics in Glaucoma Therapy"
DB00965,Ethiodized oil,8008-53-5,approved; investigational,,, ,,,D04082,,46505147,,CHEMBL1201458,,,,NA,NA,"Biological Products; Complex Mixtures; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Iodinated Contrast Agents; Iodized Oil; Lipids; Oils; Plant Oils; Plant Preparations; Radiographic Contrast Agent; Roentgenography; X-Ray Contrast Activity"
DB00966,Telmisartan,144701-48-4,approved; investigational,RMMXLENWKUUMAY-UHFFFAOYSA-N,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",c1cccc(c12)nc(n2C)-c(c3)cc(C)c(c34)nc(CCC)n4Cc5ccc(cc5)-c6ccccc6C(=O)O,C33H30N4O2,C07710,D00627,65999,46505370,9434,CHEMBL1017,TLS,59391,50043280,514.6169,6.040852204,"Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin 2 Receptor Blocker; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Angiotensin II receptor blockers (ARBs) and diuretics; Angiotensin II receptor blockers (ARBs), plain; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; BCRP/ABCG2 Inhibitors; Benzene Derivatives; Benzimidazoles; Biphenyl Compounds; BSEP/ABCB11 Substrates; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; P-glycoprotein inhibitors; UGT1A3 substrates"
DB00967,Desloratadine,100643-71-8,approved; investigational,JAUOIFJMECXRGI-UHFFFAOYSA-N,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",C1CNCCC1=C(c(c23)nccc2)c4c(CC3)cc(Cl)cc4,C19H19ClN2,,D03693,124087,46507996,291342,CHEMBL1172,,110575,50073179,310.821,3.968537941,"Anticholinergic Agents; Antihistamines for Systemic Use; Benzocycloheptenes; Central Nervous System Depressants; Cholinergic Agents; Dibenzocycloheptenes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Loratadine and prodrug; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; P-glycoprotein inhibitors; Piperidines; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; QTc Prolonging Agents; Respiratory System"
DB00968,Methyldopa,555-30-6,approved,CJCSPKMFHVPWAR-JTQLQIEISA-N,"InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1",OC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1,C10H13NO4,C07194,D08205,38853,46508535,61058,CHEMBL459,,35562,48449,211.2145,-1.359480317,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents Causing Muscle Toxicity; Amines; Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Aromatic L-amino Acid Decarboxylase Inhibitors; Autonomic Agents; Benzene Derivatives; Bradycardia-Causing Agents; Cardiovascular Agents; Catecholamines; Catechols; Central alpha-2 Adrenergic Agonist; Central Alpha-agonists; COMT Substrates; Dihydroxyphenylalanine; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenols; Phenylalanine; Sympatholytics"
DB00969,Alosetron,122852-42-0,approved; withdrawn,JSWZEAMFRNKZNL-UHFFFAOYSA-N,"InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)",c1cccc(c12)c3c(n2C)CCN(C3=O)Cc4c(C)[nH]cn4,C17H18N4O,,D07129,2099,46506274,253342,CHEMBL1110,,2015,50014558,294.351,1.211900772,"Alimentary Tract and Metabolism; Antidepressive Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (moderate); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Functional Gastrointestinal Disorders; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Neurotransmitter Agents; Pyridines; Serotonin 3 Receptor Antagonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB00970,Dactinomycin,50-76-0,approved; investigational,RJURFGZVJUQBHK-IIXSONLDSA-N,"InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1",C1CC[C@H](N12)C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@H](C)[C@@H](C(=O)N[C@@H](C2=O)C(C)C)NC(=O)c(ccc3C)c(c34)nc5c(o4)c(C)c(=O)c(N)c5C(=O)N[C@H](C(=O)N[C@@H](C6=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](N67)CCC7,C62H86N12O16,C06770,D00214,457193,46509192,27666,CHEMBL1554,,10482167,43866,1255.417,-0.096882453,"Actinomycin; Actinomycines; Amino Acids, Peptides, and Proteins; Anti-Infective Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Cytotoxic Antibiotics and Related Substances; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Macrocyclic Compounds; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nucleic Acid Synthesis Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Peptides; Peptides, Cyclic; Polycyclic Compounds; Protein Synthesis Inhibitors"
DB00971,Selenium Sulfide,7488-56-4,approved,JNMWHTHYDQTDQZ-UHFFFAOYSA-N,InChI=1S/S2Se/c1-3-2,S=[Se]=S,S2Se,,,24087,46507535,135934,CHEMBL1200680,,22519,,143.09,0.9129,Antifungals for Dermatological Use; Antifungals for Topical Use; Dermatologicals; Selenium Compounds
DB00972,Azelastine,58581-89-8,approved,MBUVEWMHONZEQD-UHFFFAOYSA-N,"InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3",CN1CCCC(CC1)n(c2=O)nc(c(c23)cccc3)Cc4ccc(Cl)cc4,C22H24ClN3O,C07768,D07483,2267,46507582,2950,CHEMBL639,,2180,50341448,381.898,4.041263461,"Anti-Allergic Agents; Antiallergic Agents, Excl. Corticosteroids; Antihistamines for Systemic Use; Autonomic Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decongestants and Antiallergics; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Nasal Preparations; Neurotransmitter Agents; Ophthalmologicals; P-glycoprotein inhibitors; Pyridazines; Respiratory System; Respiratory System Agents; Sensory Organs"
DB00973,Ezetimibe,163222-33-1,approved,OLNTVTPDXPETLC-XPWALMASSA-N,"InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1",Oc1ccc(cc1)[C@H]2N(c3ccc(F)cc3)C(=O)[C@@H]2CC[C@H](O)c4ccc(F)cc4,C24H21F2NO3,,D01966,150311,46507625,49040,CHEMBL1138,,132493,50371521,409.4252,4.559127928,"Anticholesteremic Agents; Azetines; BCRP/ABCG2 Substrates; BSEP/ABCB11 Substrates; Cardiovascular System; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Decreased Cholesterol Absorption; Dietary Cholesterol Absorption Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; OATP1B1/SLCO1B1 Substrates; P-glycoprotein substrates; UGT1A1 Substrates; UGT1A3 substrates; UGT2B7 substrates"
DB00974,Edetic acid,60-00-4,approved; vet_approved,KCXVZYZYPLLWCC-UHFFFAOYSA-N,"InChI=1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)",OC(=O)CN(CC(=O)O)CCN(CC(=O)O)CC(=O)O,C10H16N2O8,C00284,D00052,6049,46508301,42191,CHEMBL858,EDT,5826,50330325,292.2426,-4.92467029,"Acetates; Acids, Acyclic; Amines; Anticoagulants; Calcium Chelating Activity; Calcium Chelating Agents; Carboxylic Acids; Chelating Agents; Compounds used in a research, industrial, or household setting; Decreased Coagulation Factor Activity; Diamines; Diet, Food, and Nutrition; Ethylenediamines; Fatty Acids; Fatty Acids, Volatile; Food; Food Additives; Food and Beverages; Food Ingredients; Heavy Metal Antagonists; Hematologic Agents; Lead Chelating Activity; Lead Chelator; Physiological Phenomena; Polyamines; Sequestering Agents"
DB00975,Dipyridamole,58-32-2,approved,IZEKFCXSFNUWAM-UHFFFAOYSA-N,"InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2",C1CCCCN1c2nc(N(CCO)CCO)nc(c23)c(nc(n3)N(CCO)CCO)N4CCCCC4,C24H40N8O4,,D00302,3108,46506292,4653,CHEMBL932,,2997,23620,504.6256,1.806389258,"Anticoagulants; Antiplatelet agents; Blood and Blood Forming Organs; BSEP/ABCB11 Substrates; Cardiovascular Agents; Decreased Platelet Aggregation; Enzyme Inhibitors; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Miscellaneous Vasodilatating Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors Excl. Heparin; Pyrimidines; Vasodilating Agents"
DB00976,Telithromycin,191114-48-4,approved,LJVAJPDWBABPEJ-PNUFFHFMSA-N,"InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1",O[C@@H]1[C@@H](N(C)C)C[C@@H](C)O[C@H]1O[C@H]([C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]2CC)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]([C@@]23C)N(C(O3)=O)CCCCn4cnc(c4)-c5cccnc5,C43H65N5O10,C12009,D01078,3002190,46504510,29688,CHEMBL1136,TEL,2273373,50378137,812.018,5.134463869,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Erythromycin and similars; Ketolide Antibacterial; Ketolides; Lactones; Macrocyclic Compounds; Macrolides; Macrolides, Lincosamides and Streptogramins; Moderate Risk QTc-Prolonging Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Polycyclic Compounds; Polyketides; Protein Synthesis Inhibitors; QTc Prolonging Agents; RNA, Ribosomal, 23S"
DB00977,Ethinylestradiol,57-63-6,approved,BFPYWIDHMRZLRN-SLHNCBLASA-N,"InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1",C#C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(O)cc4,C20H24O2,C07534,D00554,5991,46508618,4903,CHEMBL691,3WF,5770,50187243,296.4034,3.897353088,"Adrenal Cortex Hormones; Antineoplastic and Immunomodulating Agents; BSEP/ABCB11 inducers; BSEP/ABCB11 Inhibitors; COMT Substrates; Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Postcoital; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Endocrine Therapy; Estradiol Congeners; Estrogen Contraceptives; Estrogenic Steroids, Alkylated; Estrogens; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Natural and Semisynthetic Estrogens, Plain; Norpregnanes; Norpregnatrienes; Norsteroids; P-glycoprotein substrates; Polycyclic Compounds; Progestogens and Estrogens, Sequential Preparations; Sex Hormones and Modulators of the Genital System; Steroids; Thyroxine-binding globulin inducers; UGT1A1 Inducers; UGT1A1 Substrates; UGT1A4 substrates; UGT1A9 Substrates; UGT2B7 substrates"
DB00978,Lomefloxacin,98079-51-7,approved; investigational,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,"InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)",CCn1cc(C(=O)O)c(=O)c(c12)cc(F)c(c2F)N3CCNC(C)C3,C17H19F2N3O3,C07078,D02318,3948,46508499,116278,CHEMBL561,,3811,50417952,351.3479,-0.389775894,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; Ophthalmologicals; Photosensitizing Agents; QTc Prolonging Agents; Quinolines; Quinolones; Sensory Organs; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00979,Cyclopentolate,512-15-2,approved,SKYSRIRYMSLOIN-UHFFFAOYSA-N,"InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3",CN(C)CCOC(=O)C(C1(O)CCCC1)c2ccccc2,C17H25NO3,C06932,,2905,46504517,4024,CHEMBL1201338,,2802,82375,291.3853,2.316218386,"Acids, Carbocyclic; Anticholinergic Agents; Autonomic Agents; Carboxylic Acids; Cholinergic Agents; Cholinesterase substrates; Muscarinic Antagonists; Mydriatics; Mydriatics and Cycloplegics; Neurotransmitter Agents; Ophthalmologicals; Parasympatholytics; Peripheral Nervous System Agents; Phenylacetates; Sensory Organs"
DB00980,Ramelteon,196597-26-9,approved; investigational,YLXDSYKOBKBWJQ-LBPRGKRZSA-N,"InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1",CCC(=O)NCC[C@@H]1CCc(c12)ccc3c2CCO3,C16H21NO2,,,208902,46505923,109549,CHEMBL1218,JEV,181000,50118470,259.3434,2.570558396,"Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypnotics and Sedatives; Melatonin Receptor Agonists; Nervous System; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Psycholeptics"
DB00981,Physostigmine,57-47-6,approved; investigational,PIJVFDBKTWXHHD-HIFRSBDPSA-N,"InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1",C1CN(C)[C@@H]([C@@]12C)N(C)c3c2cc(cc3)OC(=O)NC,C15H21N3O2,C06535,D00196,5983,46506998,27953,CHEMBL94,,5763,50222010,275.3461,2.232533073,"Acids, Acyclic; Alkaloids; Antidotes; Antiglaucoma Preparations and Miotics; Autonomic Agents; Carbamates; Carboxylic Acids; Cholinergic Agents; Cholinesterase Inhibitors; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indole Alkaloids; Indoles; Miotics; Neurotransmitter Agents; Ophthalmologicals; Parasympathomimetics; Peripheral Nervous System Agents; Phenylcarbamates; Sensory Organs"
DB00982,Isotretinoin,4759-48-2,approved,SHGAZHPCJJPHSC-XFYACQKRSA-N,"InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-",OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C(C1(C)C)=C(C)CCC1,C20H28O2,,D00348,5282379,46508729,6067,CHEMBL547,,4445539,50031459,300.4351,5.014367711,"Agents Causing Muscle Toxicity; Alkenes; Anti-Acne Preparations; Anti-Acne Preparations for Systemic Use; Anti-Acne Preparations for Topical Use; Biological Factors; Carotenoids; Cyclohexanes; Cyclohexenes; Cycloparaffins; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Misc. Skin and Mucous Membrane Agents; Noxae; Photosensitizing Agents; Pigments, Biological; Polyenes; Retinoids; Retinoids for Topical Use in Acne; Retinoids for Treatment of Acne; Teratogens; Terpenes; Toxic Actions"
DB00983,Formoterol,73573-87-2,approved; investigational,BPZSYCZIITTYBL-UHFFFAOYSA-N,"InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)",COc1ccc(cc1)CC(C)NCC(O)c2cc(NC=O)c(O)cc2,C19H24N2O4,C07805,D07990,3410,46507099,63082,CHEMBL1256786,,3292,86453,344.4049,1.056672736,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Ethanolamines; Long-acting beta-adrenoceptor agonists; OCT1 inhibitors; OCT1 substrates; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists; UGT1A9 Substrates; UGT2B7 substrates"
DB00984,Nandrolone phenpropionate,62-90-8,approved; illicit; investigational,UBWXUGDQUBIEIZ-QNTYDACNSA-N,"InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1",C1CC(=O)C=C(CC2)[C@H]1[C@@H](CC3)[C@@H]2[C@@H]([C@]34C)CC[C@@H]4OC(=O)CCc5ccccc5,C27H34O3,C08155,D00956,229455,46506276,7468,CHEMBL1200412,,199761,,406.5571,5.785410073,"Anabolic Agents; Androgens; Estranes; Estrenes; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Nandrolone and esters; Polycyclic Compounds; Steroids; Testosterone Congeners; Thyroxine-binding globulin inhibitors"
DB00985,Dimenhydrinate,523-87-5,approved,NFLLKCVHYJRNRH-UHFFFAOYSA-N,"InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10)",c1ccccc1C(OCCN(C)C)c2ccccc2,C24H28ClN5O3,,D00520,441281,46504881,94848,CHEMBL1200406,,10210,,469.97,3.651907262,"Alkaloids; Amines; Antiemetics; Autonomic Agents; Benzene Derivatives; Benzhydryl Compounds; Central Nervous System Agents; Central Nervous System Depressants; Drug Combinations; Ethanolamine Derivatives; Ethylamines; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Pharmaceutical Preparations; Purines; Purinones; QTc Prolonging Agents"
DB00986,Glycopyrronium,740028-90-4,approved; investigational; vet_approved,ANGKOCUUWGHLCE-UHFFFAOYSA-N,"InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1",C[N+]1(C)CCC(C1)OC(=O)C(O)(C2CCCC2)c3ccccc3,C19H28NO3,,D00540,9933193,46509133,94449,CHEMBL1201335,,3374,50417445,318.4305,-1.408087993,"Adjuvants, Anesthesia; Adrenergics, Inhalants; Agents producing tachycardia; Alimentary Tract and Metabolism; Amines; Ammonium Compounds; Anticholinergic Agents; Antihidrotics; Antimuscarinics Antispasmodics; Central Nervous System Agents; Cholinergic Agents; Dermatologicals; Drugs for Functional Gastrointestinal Disorders; Drugs for Obstructive Airway Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Pyrrolidines; Quaternary Ammonium Compounds; Respiratory System; Synthetic Anticholinergics, Quaternary Ammonium Compounds"
DB00987,Cytarabine,147-94-4,approved; investigational,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,"InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1",Nc1nc(=O)n(cc1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O,C9H13N3O5,C02961,D00168,6253,46505879,28680,CHEMBL803,AR3,6017,50087289,243.2166,-2.797517284,"Agents Causing Muscle Toxicity; Anti-Infective Agents; Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Arabinonucleosides; Carbohydrates; Cardiotoxic antineoplastic agents; Cytidine Deaminase Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunologic Factors; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Metabolic Inhibitor; Nucleosides; OCT1 substrates; Pyrimidine Analogues; Pyrimidine Nucleosides; Pyrimidines; Ribonucleosides; Toxic Actions"
DB00988,Dopamine,51-61-6,approved,VYFYYTLLBUKUHU-UHFFFAOYSA-N,"InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2",NCCc1cc(O)c(O)cc1,C8H11NO2,C03758,D07870,681,46506043,18243,CHEMBL59,LDP,661,55121,153.1784,0.029550239,"Adrenergic and Dopaminergic Agents; Agents producing tachycardia; Agents that produce hypertension; Amines; Autonomic Agents; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Catecholamines; Catechols; Compounds used in a research, industrial, or household setting; COMT Substrates; Dopamine Agents; Dopamine, metabolism; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Monoamine Oxidase A Substrates; Neurotransmitter Agents; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; Peripheral Nervous System Agents; Phenols; Protective Agents; Selective Beta 1-adrenergic Agonists; Sympathomimetics"
DB00989,Rivastigmine,123441-03-2,approved; investigational,XSVMFMHYUFZWBK-NSHDSACASA-N,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,C14H22N2O2,C11766,D03822,77991,46507452,8874,CHEMBL636,,70377,10620,250.3367,2.409093134,"Acids, Acyclic; Anti-Dementia Drugs; Bradycardia-Causing Agents; Carbamates; Carboxylic Acids; Central Nervous System Agents; Cholinergic Agents; Cholinesterase Inhibitors; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Nervous System; Neuroprotective Agents; Neurotransmitter Agents; Parasympathomemetic (Cholinergic) Agents; Phenylcarbamates; Protective Agents; Psychoanaleptics"
DB00990,Exemestane,107868-30-4,approved; investigational,BFYIZQONLCFLEV-DAELLWKTSA-N,"InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1",O=C1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(C(C3)=C)=CC(=O)C=C4,C20H24O2,C08162,D00963,60198,46508243,4953,CHEMBL1200374,EXM,54278,50398447,296.4034,3.866147778,"Androstanes; Androstenes; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Aromatase Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Endocrine Therapy; Enzyme Inhibitors; Estrogen Antagonists; Fused-Ring Compounds; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroid Synthesis Inhibitors; Steroids"
DB00991,Oxaprozin,21256-18-8,approved,OFPXSFXSNFPTHF-UHFFFAOYSA-N,"InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)",OC(=O)CCc1nc(-c2ccccc2)c(o1)-c3ccccc3,C18H15NO3,C07356,D00463,4614,46506429,7822,CHEMBL1071,,4453,50002861,293.3166,3.463366852,"Acids, Acyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Arylpropionic acid NSAIDS; Azoles; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lipids; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Other Nonsteroidal Anti-inflammatory Agents; Oxazoles; Peripheral Nervous System Agents; Photosensitizing Agents; Propionates; Sensory System Agents"
DB00992,Methyl aminolevulinate,33320-16-0,approved; investigational,YUUAYBAIHCDHHD-UHFFFAOYSA-N,"InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3",COC(=O)CCC(=O)CN,C6H11NO3,,D08204,157922,46507004,724125,CHEMBL1096562,,138950,,145.1564,-0.847093231,"Amino Acids; Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Dermatologicals; Keto Acids; Levulinic Acids; Misc. Skin and Mucous Membrane Agents; Photochemotherapy; Photosensitizing Agents; Photosensitizing agents used for phototherapy; Porphyrin Precursor; Radiation-Sensitizing Agents; Sensitizers Used in Photodynamic/radiation Therapy"
DB00993,Azathioprine,446-86-6,approved,LMEKQMALGUDUQG-UHFFFAOYSA-N,"InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)",Cn1cnc([N+]([O-])=O)c1Sc2ncnc(c23)nc[nH]3,C9H7N7O2S,C06837,D00238,2265,46508252,2948,CHEMBL1542,,2178,50373919,277.263,1.173143958,"Antimetabolites; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Carbohydrates; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunologic Factors; Immunosuppressive Agents; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; P-glycoprotein substrates; Purine Antimetabolite; Purines; Sulfhydryl Compounds; Sulfur Compounds; Thionucleosides; Thiopurine Analogs; Toxic Actions"
DB00994,Neomycin,1404-04-2,approved; vet_approved,,, ,,C00384,D08260,,46505525,7507,,CNY,,,NA,NA,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Topical Use; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antiinfectives and Antiseptics for Local Oral Treatment; Antiinfectives for Systemic Use; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Carbohydrates; Dermatologicals; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inhibitors; Glycosides; Intestinal Antiinfectives; Irrigating Solutions; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Neurotoxic agents; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; Ototoxic agents; Protein Synthesis Inhibitors; Respiratory System; Sensory Organs; Stomatological Preparations; Throat Preparations"
DB00995,Auranofin,34031-32-8,approved; investigational,AUJRCFUBUPVWSZ-XTZHGVARSA-M,"InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13-,14+;;/m1../s1",CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@H]1OC(=O)C,C20H34AuO9PS,,D00237,70788951,46507010,2922,CHEMBL1366,,5293650,50153291,678.484,-1.0203,Antiinflammatory and Antirheumatic Products; Antirheumatic Agents; Drugs that are Mainly Renally Excreted; Gold Compounds; Gold Preparations; Musculo-Skeletal System; Organogold Compounds; Organometallic Compounds; Specific Antirheumatic Agents
DB00996,Gabapentin,60142-96-3,approved; investigational,UGJMXCAKCUNAIE-UHFFFAOYSA-N,"InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)",OC(=O)CC1(CN)CCCCC1,C9H17NO2,,D00332,3446,46506529,42797,CHEMBL940,GBN,3328,50080153,171.2368,-1.273033071,"Acids, Acyclic; Acids, Carbocyclic; Amines; Amino Acids; Amino Acids, Peptides, and Proteins; Aminobutyrates; Analgesics; Anti-epileptic Agent; Anticonvulsants; Butyrates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cyclohexanecarboxylic Acids; Cyclohexanes; Cycloparaffins; Decreased Central Nervous System Disorganized Electrical Activity; Drugs causing inadvertant photosensitivity; Gabapentin and Prodrugs; Miscellaneous Anticonvulsants; Nervous System; Neurotransmitter Agents; Peripheral Nervous System Agents; Photosensitizing Agents; Psychotropic Drugs; Sensory System Agents; Tranquilizing Agents"
DB00997,Doxorubicin,23214-92-8,approved; investigational,AOJJSUZBOXZQNB-TZSSRYMLSA-N,"InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1",COc1cccc(c12)C(=O)c3c(C2=O)c(O)c4c(c3O)C[C@@](O)(C(=O)CO)C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@@H](O5)C,C27H29NO11,C01661,D03899,31703,46507641,28748,CHEMBL53463,DM2,29400,32022,543.5193,0.916421642,"ABVD chemotherapy regimen; Anthracycline Topoisomerase Inhibitor; Anthracyclines; Anthracyclines and Related Substances; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; BEACOPP chemotherapy regimen; BSEP/ABCB11 Substrates; BSEP/ABCB11 Substrates with Narrow Therapeutic Index; Carbohydrates; Cardiotoxic antineoplastic agents; CHOP chemotherapy regimen; CHOP-R chemotherapy regimen; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Cytotoxic Antibiotics and Related Substances; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Glycosides; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Myelosuppressive Agents; Naphthacenes; Narrow Therapeutic Index Drugs; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB00998,Frovatriptan,158747-02-5,approved; investigational,XPSQPHWEGNHMSK-SECBINFHSA-N,"InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1",CN[C@@H](C1)CCc(c12)[nH]c3c2cc(cc3)C(=O)N,C14H17N3O,,D07997,77992,46506288,134991,CHEMBL1279,,70378,50073689,243.3043,1.077976043,"Agents that produce hypertension; Amines; Analgesics; Antidepressive Agents; Antimigraine Preparations; Biogenic Amines; Biogenic Monoamines; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Migraine Disorders; Nervous System; Neurotransmitter Agents; Selective Serotonin 5-HT1 Receptor Agonists; Selective Serotonin Agonists; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 1b Receptor Agonists; Serotonin 1d Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Serotonin-1b and Serotonin-1d Receptor Agonist; Triptans"
DB00999,Hydrochlorothiazide,58-93-5,approved; vet_approved,JZUFKLXOESDKRF-UHFFFAOYSA-N,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",NS(=O)(=O)c(c1)c(Cl)cc(c12)NCNS2(=O)=O,C7H8ClN3O4S2,C07041,D00340,3639,46504440,5778,CHEMBL435,HCZ,3513,13076,297.739,-0.575617776,"Amides; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Benzothiadiazines; Cardiovascular Agents; Cardiovascular System; Diuretics; Drugs causing inadvertant photosensitivity; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Hypotensive Agents; Increased Diuresis; Low-Ceiling Diuretics and Potassium-Sparing Agents; Medications that reduce magnesium levels; Membrane Transport Modulators; Natriuretic Agents; Nephrotoxic agents; Non Potassium Sparing Diuretics; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Substrates; Photosensitizing Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazides"
DB01000,Cyclacillin,3485-14-1,approved,HGBLNBBNRORJKI-WCABBAIRSA-N,"InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)C3(N)CCCCC3,C15H23N3O4S,C12766,D01334,19003,46508073,31444,CHEMBL1200356,,17941,50350474,341.426,-1.914571718,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillins; Sulfur Compounds"
DB01001,Salbutamol,18559-94-9,approved; vet_approved,NDAUXUAQIAJITI-UHFFFAOYSA-N,"InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3",CC(C)(C)NCC(O)c1cc(CO)c(O)cc1,C13H21NO3,,D02147,2083,46505312,2549,CHEMBL714,,1999,25769,239.3107,0.344416151,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Ethanolamines; Medications that reduce magnesium levels; Peripheral Nervous System Agents; Phenethylamines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Reproductive Control Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists; Sympathomimetic (Adrenergic) Agents; Tocolytic Agents"
DB01002,Levobupivacaine,27262-47-1,approved; investigational,LEBVLXFERQHONN-INIZCTEOSA-N,"InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1",CCCCN1CCCC[C@H]1C(=O)Nc2c(C)cccc2C,C18H28N2O,C07887,D08116,92253,46505295,6149,CHEMBL1201193,,83289,50417951,288.4277,4.515518884,"Amides; Amines; Anesthetics; Anesthetics, Local; Anilides; Aniline Compounds; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hypotensive Agents; Nervous System; Neuraxial Anesthetics; Peripheral Nervous System Agents; Sensory System Agents"
DB01003,Cromoglicic acid,16110-51-3,approved,IMZMKUWMOSJXDT-UHFFFAOYSA-N,"InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)",O=c1cc(C(=O)O)oc(c12)cccc2OCC(O)COc3cccc(c34)oc(cc4=O)C(=O)O,C23H16O11,C06928,D07753,2882,46504509,59773,CHEMBL428880,,2779,50440033,468.3665,1.4770117,"Adrenergics, Inhalants; Agents for Dermatitis, Excluding Corticosteroids; Alimentary Tract and Metabolism; Anti-Allergic Agents; Anti-Asthmatic Agents; Antiallergic Agents, Excl. Corticosteroids; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Benzopyrans; Chromones; Cromolyn Sodium; Decongestants and Antiallergics; Decreased Histamine Release; Dermatologicals; Drugs causing inadvertant photosensitivity; Drugs for Obstructive Airway Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Intestinal Antiinflammatory Agents; Mast Cell Stabilizers; Mast-cell Stabilizers; Nasal Preparations; Ophthalmologicals; Photosensitizing Agents; Pyrans; Respiratory System; Respiratory System Agents; Sensory Organs"
DB01004,Ganciclovir,82410-32-0,approved; investigational,IRSCQMHQWWYFCW-UHFFFAOYSA-N,"InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)",O=c1[nH]c(N)nc(c12)n(cn2)COC(CO)CO,C9H13N5O4,,D00333,3454,46507294,465284,CHEMBL182,GA2,3336,85707,255.2306,-2.179902509,"Agents Causing Muscle Toxicity; Agents that reduce seizure threshold; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Ganciclovir; Ganciclovir and prodrug; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; MATE 1 Substrates; MATE 2 Substrates; MATE substrates; Nucleic Acid Synthesis Inhibitors; Nucleoside Analog Antiviral; Nucleosides and Nucleotides; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OCT1 inhibitors; OCT1 substrates; Ophthalmologicals; Purines; Purinones; Sensory Organs"
DB01005,Hydroxyurea,127-07-1,approved,VSNHCAURESNICA-UHFFFAOYSA-N,"InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)",NC(=O)NO,CH4N2O2,C07044,D00341,3657,46506927,44423,CHEMBL467,NHY,3530,50017811,76.0547,-1.367015589,Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Antisickling Agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Hematologic Agents; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nucleic Acid Synthesis Inhibitors
DB01006,Letrozole,112809-51-5,approved; investigational,HPJKCIUCZWXJDR-UHFFFAOYSA-N,"InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H",N#Cc1ccc(cc1)C(n2cncn2)c3ccc(C#N)cc3,C17H11N5,C08163,D00964,3902,46504610,6413,CHEMBL1444,,3765,13061,285.3027,2.935491913,"Agents Causing Muscle Toxicity; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Aromatase Inhibitors; Azoles; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strong); Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Endocrine Therapy; Enzyme Inhibitors; Estrogen Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Nitriles; P-glycoprotein substrates; Steroid Synthesis Inhibitors; Triazoles; UGT2B7 substrates"
DB01007,Tioconazole,65899-73-2,approved,QXHHHPZILQDDPS-UHFFFAOYSA-N,"InChI=1S/C16H13Cl3N2OS/c17-12-1-2-13(14(18)7-12)15(8-21-5-4-20-10-21)22-9-11-3-6-23-16(11)19/h1-7,10,15H,8-9H2",c1nccn1CC(c(c(Cl)c2)ccc2Cl)OCc3c(Cl)scc3,C16H13Cl3N2OS,C08082,D00890,5482,46508604,77898,CHEMBL1200438,,5282,50370218,387.711,5.298761609,"14-alpha Demethylase Inhibitors; Anti-Infective Agents; Antifungal Agents; Antifungal Agents (Vaginal); Antifungals for Dermatological Use; Antifungals for Topical Use; Azole Antifungals; Azoles; Chemically-Induced Disorders; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Imidazole and Triazole Derivatives; Imidazole Derivatives; Metabolic Side Effects of Drugs and Substances; Steroid Synthesis Inhibitors"
DB01008,Busulfan,55-98-1,approved; investigational,COVZYZSDYWQREU-UHFFFAOYSA-N,"InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3",CS(=O)(=O)OCCCCOS(=O)(=O)C,C6H14O6S2,C06862,D00248,2478,46506234,28901,CHEMBL820,,2384,50237623,246.302,-0.759028226,"Acids; Acids, Noncarboxylic; Alcohols; Alkanes; Alkanesulfonates; Alkanesulfonic Acids; Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Butylene Glycols; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Glycols; Hydrocarbons; Hydrocarbons, Acyclic; Immunologic Factors; Immunosuppressive Agents; Mesylates; Myeloablative Agonists; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Sulfonic Acids; Sulfur Acids; Sulfur Compounds; Toxic Actions"
DB01009,Ketoprofen,22071-15-4,approved; vet_approved,DKYWVDODHFEZIM-UHFFFAOYSA-N,"InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)",OC(=O)C(C)c1cc(ccc1)C(=O)c2ccccc2,C16H14O3,C01716,D00132,3825,46505715,6128,CHEMBL571,,3693,50022271,254.2806,3.613333421,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Amino Acids; Amino Acids, Basic; Amino Acids, Diamino; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Arylpropionic acid NSAIDS; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Ketoprofen and isomer; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Other Nonsteroidal Anti-inflammatory Agents; Peripheral Nervous System Agents; Phenylpropionates; Photosensitizing Agents; Propionates; Sensory System Agents; Topical Products for Joint and Muscular Pain; UGT1A1 Substrates"
DB01010,Edrophonium,312-48-1,approved,VWLHWLSRQJQWRG-UHFFFAOYSA-O,"InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1",CC[N+](C)(C)c1cc(O)ccc1,C10H16NO,C06976,,3202,46507530,251408,CHEMBL1104,EDR,3090,120262,166.2401,-1.913807328,"Amines; Ammonium Compounds; Antidotes; Cholinergic Agents; Cholinesterase Inhibitors; Compounds used in a research, industrial, or household setting; Diagnostic Agents; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Phenylammonium Compounds; Protective Agents; Quaternary Ammonium Compounds"
DB01011,Metyrapone,54-36-4,approved; investigational,FJLBFSROUSIWMA-UHFFFAOYSA-N,"InChI=1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3",c1ccncc1C(C)(C)C(=O)c2cnccc2,C14H14N2O,C07205,D00410,4174,46504862,44241,CHEMBL934,MYT,4030,50028166,226.2738,2.028888881,"Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Diagnostic Agents; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Noxae; Pyridines; Steroid Synthesis Inhibitors; Tests for Pituitary Function; Toxic Actions"
DB01012,Cinacalcet,226256-56-0,approved,VDHAWDNDOKGFTD-MRXNPFEDSA-N,"InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1",c1cccc(c12)cccc2[C@@H](C)NCCCc3cc(C(F)(F)F)ccc3,C22H22F3N,,D03504,156419,46506315,48390,CHEMBL1201284,,137743,50416875,357.412,6.273197896,"Anti-Parathyroid Agents; Calcimimetic Agents; Calcium Homeostasis; Calcium-Regulating Hormones and Agents; Calcium-sensing Receptor Agonist; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Increased Calcium-sensing Receptor Sensitivity; Naphthalenes; Other Miscellaneous Therapeutic Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB01013,Clobetasol propionate,25122-46-7,approved,CBGUOGMQLZIXBE-XGQKBEPLSA-N,"InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1",CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)C=C4,C25H32ClFO5,,D01272,32798,46505670,31414,CHEMBL1159650,,30399,39347,466.97,4.177822793,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated; Thyroxine-binding globulin inhibitors"
DB01014,Balsalazide,80573-04-2,approved; investigational,IPOKCKJONYRRHP-FMQUCBEESA-N,"InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+",OC(=O)CCNC(=O)c1ccc(cc1)/N=N/c2ccc(O)c(c2)C(=O)O,C17H15N3O6,,D07488,6335412,46505592,267413,CHEMBL1201346,,10662422,,357.3175,3.17246948,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Alimentary Tract and Metabolism; Aminobenzoates; Aminosalicylate; Aminosalicylic Acids; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Colitis, Ulcerative; Gastrointestinal Agents; Hydrazines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Inflammatory Bowel Diseases; Intestinal Antiinflammatory Agents; meta-Aminobenzoates; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Phenols; Prodrugs; Salicylates; Sensory System Agents"
DB01015,Sulfamethoxazole,723-46-6,approved,JLKIGFTWXXRPMT-UHFFFAOYSA-N,"InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)",Cc1cc(no1)NS(=O)(=O)c2ccc(N)cc2,C10H11N3O3S,C07315,D00447,5329,46508111,9332,CHEMBL443,08D,5138,50029770,253.278,0.790549399,Agents causing hyperkalemia; Agents Causing Muscle Toxicity; Amines; Aniline Compounds; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Pneumocystis Pneumonia; Antiinfectives for Systemic Use; Antimycobacterials; Blood Glucose Lowering Agents; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs for Treatment of Tuberculosis; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Hypoglycemia-Associated Agents; Intermediate-Acting Sulfonamides; Medications that reduce magnesium levels; Methemoglobinemia Associated Agents; Photosensitizing Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sulfanilamides; Sulfonamide Antibacterial; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds
DB01016,Glyburide,10238-21-8,approved,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,"InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)",Clc1ccc(OC)c(c1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,C23H28ClN3O5S,C07022,D00336,3488,46509154,5441,CHEMBL472,GBM,3368,50012957,494.004,3.791110048,Alimentary Tract and Metabolism; BCRP/ABCG2 Substrates; Blood Glucose Lowering Agents; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs Used in Diabetes; Hypoglycemia-Associated Agents; OAT1/SLC22A6 inhibitors; P-glycoprotein inhibitors; Photosensitizing Agents; Sulfones; Sulfonylureas; Sulfur Compounds
DB01017,Minocycline,10118-90-8,approved; investigational,DYKFCLLONBREIL-KVUCHLLUSA-N,"InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O,C23H27N3O7,C07225,D05045,54675783,46504772,50694,CHEMBL1434,MIY,16735907,50103599,457.4764,-3.334191589,"Agents Causing Muscle Toxicity; Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives and Antiseptics for Local Oral Treatment; Antiinfectives for Systemic Use; Drugs causing inadvertant photosensitivity; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; Naphthacenes; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Stomatological Preparations; Tetracyclines"
DB01018,Guanfacine,29110-47-2,approved; investigational,INJOMKTZOLKMBF-UHFFFAOYSA-N,"InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)",NC(=N)NC(=O)Cc1c(Cl)cccc1Cl,C9H9Cl2N3O,C07037,D08031,3519,46506169,5558,CHEMBL862,,3399,81984,246.093,1.737031796,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Amidines; Antiadrenergic Agents, Centrally Acting; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Bradycardia-Causing Agents; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Central alpha-2 Adrenergic Agonist; Central Alpha-agonists; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Guanidines; Hypotensive Agents; Imidazoline Receptor Agonists; MATE 1 Inhibitors; MATE inhibitors; Neurotransmitter Agents; OCT1 inhibitors; OCT1 substrates; OCT2 Substrates"
DB01019,Bethanechol,674-38-4,approved,NZUPCNDJBJXXRF-UHFFFAOYSA-O,"InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1",NC(=O)OC(C)C[N+](C)(C)C,C7H17N2O2,C06850,,2370,46507707,3084,CHEMBL1482,,2280,39342,161.2221,-4.138114261,"Acids, Acyclic; Amines; Ammonium Compounds; Autonomic Agents; Bethanechol Compounds; Carbamates; Carboxylic Acids; Choline Esters; Cholinergic Agents; Cholinergic Agonists; Muscarinic Agonists; Nervous System; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Parasympathomemetic (Cholinergic) Agents; Parasympathomimetics; Peripheral Nervous System Agents; Quaternary Ammonium Compounds; Trimethyl Ammonium Compounds"
DB01020,Isosorbide mononitrate,16051-77-7,approved,YWXYYJSYQOXTPL-SLPGGIOYSA-N,"InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1",O1C[C@H](O)[C@H]([C@H]12)OC[C@H]2O[N+]([O-])=O,C6H9NO6,C07714,D00630,27661,46506594,6062,CHEMBL1311,,25736,,191.1388,-0.481660149,Alcohols; Antianginal Agents; Carbohydrates; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Delayed-Action Preparations; Drugs that are Mainly Renally Excreted; Hypotensive Agents; Methemoglobinemia Associated Agents; Nitrate Vasodilator; Nitrates and Nitrites; Nitric Oxide Donors; Organic Nitrates; Sugar Alcohols; Vasodilating Agents; Vasodilation; Vasodilators Used in Cardiac Diseases
DB01021,Trichlormethiazide,133-67-5,approved; vet_approved,LMJSLTNSBFUCMU-UHFFFAOYSA-N,"InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)",NS(=O)(=O)c(c1)c(Cl)cc(c12)NC(C(Cl)Cl)NS2(=O)=O,C8H8Cl3N3O4S2,C07767,D00658,5560,46508880,9683,CHEMBL1054,,5359,26998,380.656,0.973349459,"Amides; Antihypertensive Agents; Benzothiadiazines; Cardiovascular Agents; Cardiovascular System; Diuretics; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Low-Ceiling Diuretics and Potassium-Sparing Agents; Membrane Transport Modulators; Natriuretic Agents; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazides"
DB01022,Phylloquinone,84-80-0,approved; investigational,MBWXNTAXLNYFJB-NKFFZRIASA-N,"InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1",CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC/C(C)=C/CC(C1=O)=C(C)C(=O)c(c12)cccc2,C31H46O2,C02059,D00148,5284607,46504528,18067,CHEMBL1550,PQN,4447652,24782,450.6957,9.696445808,"Blood and Blood Forming Organs; Coagulants; Diet, Food, and Nutrition; Diterpenes; Drugs that are Mainly Renally Excreted; Fibrin Modulating Agents; Food; Food and Beverages; Growth Substances; Hematologic Agents; Hemostatics; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Increased Prothrombin Activity; Micronutrients; Naphthalenes; Naphthoquinones; Physiological Phenomena; Phytol; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quinones; Reversed Anticoagulation Activity; Terpenes; Vitamin K; Vitamins; Vitamins (Fat Soluble); Warfarin Reversal Agent"
DB01023,Felodipine,72509-76-3,approved; investigational,RZTAMFZIAATZDJ-UHFFFAOYSA-N,"InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3",CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2c(Cl)c(Cl)ccc2,C18H19Cl2NO4,,D00319,3333,46506968,585948,CHEMBL1480,,3216,189379,384.254,3.4404074,"ACE Inhibitors and Calcium Channel Blockers; Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Beta blocking agents and calcium channel blockers; Bradycardia-Causing Agents; BSEP/ABCB11 Substrates; Calcium Channel Blockers; Calcium Channel Blockers (Dihydropyridine); Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Dihydropyridines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB01024,Mycophenolic acid,24280-93-1,approved,HPNSFSBZBAHARI-RUDMXATFSA-N,"InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+",C1OC(=O)c(c12)c(O)c(c(c2C)OC)C/C=C(\C)CCC(=O)O,C17H20O6,,,446541,46504559,168396,CHEMBL866,MOA,393865,19264,320.3371,3.527597448,"Acids, Acyclic; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antineoplastic; Antibiotics, Antitubercular; Antimetabolite Immunosuppressant; Antineoplastic and Immunomodulating Agents; Antituberculosis Agents; Caproates; Carboxylic Acids; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Fatty Acids; Fatty Acids, Volatile; Immunosuppressive Agents; Lipids; Mycophenolic Acid and Prodrugs; Narrow Therapeutic Index Drugs; Selective Immunosuppressants; UGT1A1 Substrates; UGT1A1 substrates with narrow therapeutic index; UGT1A6 substrate; UGT1A6 substrate with narrow therapeutic index; UGT1A9 Substrates; UGT1A9 substrates with narrow therapeutic index; UGT2B7 substrates; UGT2B7 substrates with narrow therapeutic index"
DB01025,Amlexanox,68302-57-8,approved; investigational; withdrawn,SGRYPYWGNKJSDL-UHFFFAOYSA-N,"InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)",CC(C)c(cc1)cc(c12)c(=O)c3c(o2)nc(N)c(c3)C(=O)O,C16H14N2O4,,D01828,2161,46504508,31205,CHEMBL1096,ANW,2076,357857,298.2934,3.654548958,"Alimentary Tract and Metabolism; Amines; Anti-Allergic Agents; Decreased Histamine Release; Drugs for Obstructive Airway Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Ophthalmic Solutions; Pyridines; Respiratory System; Stomatological Preparations"
DB01026,Ketoconazole,65277-42-1,approved; investigational,XMAYWYJOQHXEEK-UHFFFAOYSA-N,"InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3",CC(=O)N1CCN(CC1)c2ccc(cc2)OCC(CO3)OC3(Cn4ccnc4)c5ccc(Cl)cc5Cl,C26H28Cl2N4O4,,D00351,3823,46506746,48339,CHEMBL157101,KTN,3691,151585,531.431,4.191597861,14-alpha Demethylase Inhibitors; Agents causing hyperkalemia; Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; Azole Antifungals; Azoles; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (moderate); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strong); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Gynecological Antiinfectives and Antiseptics; Hepatotoxic Agents; Heterocyclic Compounds; Imidazole and Triazole Derivatives; Imidazole Derivatives; Metabolic Side Effects of Drugs and Substances; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Piperazines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Steroid Synthesis Inhibitors; UGT1A1 Inhibitors; UGT2B7 Inhibitors
DB01028,Methoxyflurane,76-38-0,approved; investigational; vet_approved,RFKMCNOHBTXSMU-UHFFFAOYSA-N,"InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3",COC(F)(F)C(Cl)Cl,C3H4Cl2F2O,C07517,D00544,4116,46508879,6843,CHEMBL1341,,3973,,164.966,2.305878239,"Agents that produce hypertension; Analgesics; Anesthetics; Anesthetics, General; Anesthetics, Inhalation; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Ethers; Ethyl Ethers; Methyl Ethers; Miscellaneous Analgesics and Antipyretics; Nervous System"
DB01029,Irbesartan,138402-11-6,approved; investigational,YOSHYTLCDANDAN-UHFFFAOYSA-N,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",C1CCCC12N=C(CCCC)N(C2=O)Cc3ccc(cc3)-c4ccccc4-c5n[nH]nn5,C25H28N6O,C07469,D00523,3749,46506575,5959,CHEMBL1513,,3618,50042235,428.5294,5.495261917,"Agents Acting on the Renin-Angiotensin System; Agents causing hyperkalemia; Angiotensin 2 Receptor Blocker; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Angiotensin II receptor blockers (ARBs) and diuretics; Angiotensin II receptor blockers (ARBs), plain; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Azoles; Benzene Derivatives; Biphenyl Compounds; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Polycyclic Compounds; Spiro Compounds; Tetrazoles; UGT1A3 substrates"
DB01030,Topotecan,123948-87-8,approved; investigational,UCFGDBYHRUNTLO-QHCPKHFHSA-N,"InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1",CC[C@@]1(O)C(=O)OCc(c12)c(=O)n3c(c2)c4c(C3)cc5c(n4)ccc(O)c5CN(C)C,C23H23N3O5,C11158,D08618,60700,46505204,63632,CHEMBL84,TTC,54705,50034026,421.4458,-0.357095077,Alkaloids; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Immunosuppressive Agents; MATE 1 Inhibitors; MATE 1 Substrates; MATE 1 Substrates with a Narrow Therapeutic Index; MATE 2 Substrates; MATE 2 Substrates with a Narrow Therapeutic Index; MATE inhibitors; MATE substrates; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Topoisomerase I Inhibitors; Topoisomerase Inhibitors
DB01031,Ethinamate,126-52-3,approved; illicit; withdrawn,GXRZIMHKGDIBEW-UHFFFAOYSA-N,"InChI=1S/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11)",NC(=O)OC1(C#C)CCCCC1,C9H13NO2,C07832,D00703,3284,46507468,4884,CHEMBL1576,,3169,,167.205,1.540125099,"Acids, Acyclic; Carboxylic Acids"
DB01032,Probenecid,57-66-9,approved; investigational,DBABZHXKTCFAPX-UHFFFAOYSA-N,"InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)",CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(=O)O,C13H19NO4S,C07372,D00475,4911,46506554,8426,CHEMBL897,,4742,50206509,285.359,2.442872324,"Adjuvants, Pharmaceutic; Amides; Antigout Preparations; Antirheumatic Agents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Musculo-Skeletal System; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OCT1 inhibitors; OCT2 Inhibitors; Pharmaceutic Aids; Pharmaceutical Preparations; Preparations Increasing Uric Acid Excretion; Renal Agents; Sulfonamides; Sulfones; Sulfur Compounds; UGT1A1 Inhibitors; Uricosuric Agents"
DB01033,Mercaptopurine,50-44-2,approved,GLVAUDGFNGKCSF-UHFFFAOYSA-N,"InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)",[nH]1cnc(c12)[nH]cnc2=S,C5H4N4S,C02380,D04931,667490,46506988,94796,CHEMBL1425,PM6,580869,50423778,152.177,-0.121789191,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Drugs for Obstructive Airway Diseases; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunologic Factors; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleoside Metabolic Inhibitor; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Purine Analogues; Purines; Respiratory System; Sulfhydryl Compounds; Sulfur Compounds; Thiopurine Analogs; Toxic Actions; Xanthine derivatives"
DB01035,Procainamide,51-06-9,approved,REQCZEXYDRLIBE-UHFFFAOYSA-N,"InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)",CCN(CC)CCNC(=O)c1ccc(N)cc1,C13H21N3O,C07401,,4913,46507313,8428,CHEMBL640,,4744,39344,235.3253,0.950896654,"Acids, Carbocyclic; Agents Causing Muscle Toxicity; Agents that produce neuromuscular block (indirect); Amides; Aminobenzoates; Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ia; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cholinesterase Inhibitors; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Highest Risk QTc-Prolonging Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; MATE 1 Substrates; MATE 1 Substrates with a Narrow Therapeutic Index; MATE 2 Substrates; MATE 2 Substrates with a Narrow Therapeutic Index; MATE substrates; Membrane Transport Modulators; Narrow Therapeutic Index Drugs; OCT1 inhibitors; OCT2 Inhibitors; OCT2 substrates with narrow therapeutic index; para-Aminobenzoates; QTc Prolonging Agents; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB01036,Tolterodine,124937-51-5,approved; investigational,OOGJQPCLVADCPB-HXUWFJFHSA-N,"InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1",CC(C)N(C(C)C)CC[C@@H](c(cc1C)c(O)cc1)c2ccccc2,C22H31NO,C07750,D00646,443879,46508059,9622,CHEMBL1382,,391967,50165008,325.4876,5.116408884,"Agents producing tachycardia; Alcohols; Amines; Amino Alcohols; Anticholinergic Agents; Benzene Derivatives; Benzhydryl Compounds; Cholinergic Agents; Cresols; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Urinary Frequency and Incontinence; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Genitourinary Smooth Muscle Relaxants; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Muscarinic Antagonists; Neurotransmitter Agents; Phenols; Potential QTc-Prolonging Agents; Propanolamines; Propanols; QTc Prolonging Agents; Urological Agents; Urologicals"
DB01037,Selegiline,14611-51-9,approved; investigational; vet_approved,MEZLKOACVSPNER-GFCCVEGCSA-N,"InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1",C#CCN(C)[C@H](C)Cc1ccccc1,C13H17N,C07245,D03731,26757,46507655,9086,CHEMBL972,,24930,15579,187.286,2.847961859,"Agents that produce hypertension; Agents that reduce seizure threshold; Amines; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Central Nervous System Agents; Central Nervous System Depressants; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Enzyme Inhibitors; Ethylamines; Hypotensive Agents; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Monoamine Oxidase B Inhibitors; Monoamine Oxidase Inhibitors; Nervous System; Neuroprotective Agents; P-glycoprotein inhibitors; Phenethylamines; Protective Agents; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB01039,Fenofibrate,49562-28-9,approved,YMTINGFKWWXKFG-UHFFFAOYSA-N,"InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3",CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2,C20H21ClO4,C07586,D00565,3339,46507371,5001,CHEMBL672,,3222,50085042,360.831,5.277762736,"Acids, Acyclic; Agents Causing Muscle Toxicity; Benzene Derivatives; Benzophenones; BSEP/ABCB11 Substrates; Butyrates; Carboxylic Acids; Cardiovascular System; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (weak); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Ethers; Fatty Acids; Fatty Acids, Volatile; Fibric Acids; Fribic Acid Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Isobutyrates; Ketones; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Lipids; Noxae; P-glycoprotein inhibitors; Peroxisome Proliferator Receptor alpha Agonist; Peroxisome Proliferator-activated Receptor alpha Agonists; Phenols; Phenyl Ethers; Toxic Actions; UGT1A9 Substrates"
DB01041,Thalidomide,50-35-1,approved; investigational; withdrawn,UEJJHQNACJXSKW-UHFFFAOYSA-N,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",c1cccc(c12)C(=O)N(C2=O)C3CCC(=O)NC3=O,C13H10N2O4,C07910,D00754,5426,46505665,74947,CHEMBL468,,5233,50070114,258.2295,0.015707356,"Acids, Carbocyclic; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Cardiotoxic antineoplastic agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Immunologically Active Molecule Activity; Drugs causing inadvertant photosensitivity; Growth Inhibitors; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Imides; Immunologic Factors; Immunomodulatory Agents; Immunosuppressive Agents; Isoindoles; Leprostatic Agents; Myelosuppressive Agents; Noxae; Photosensitizing Agents; Phthalic Acids; Phthalimides; Piperidines; Piperidones; Teratogens; Toxic Actions"
DB01042,Melphalan,148-82-3,approved,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,"InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1",OC(=O)[C@@H](N)Cc1ccc(cc1)N(CCCl)CCCl,C13H18Cl2N2O2,C07122,D00369,460612,46509130,28876,CHEMBL852,,405297,50025837,305.2,0.252196225,"Alkylating Activity; Alkylating Drugs; Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Hydrocarbons; Hydrocarbons, Halogenated; Immunologic Factors; Immunosuppressive Agents; Mustard Compounds; Myeloablative Agonists; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nitrogen Mustard Analogues; Nitrogen Mustard Compounds; Noxae; Phenylalanine; Toxic Actions"
DB01043,Memantine,19982-08-2,approved; investigational,BUGYDGFZZOZRHP-UHFFFAOYSA-N,"InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3",CC12CC3CC(C)(C1)CC(N)(C3)C2,C12H21N,C13736,D08174,4054,46506702,64312,CHEMBL807,,3914,50062599,179.3018,2.066041788,"Anti-Dementia Drugs; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Bridged Compounds; Central Nervous System Agents; Cholinesterase Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (weak); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strong); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Dopamine Agents; Drugs that are Mainly Renally Excreted; Excitatory Amino Acid Antagonists; Hydrocarbons; Hydrocarbons, Cyclic; Macrocyclic Compounds; Miscellaneous Central Nervous System Agents; N-methyl-D-aspartate Receptor Antagonist; Nervous System; Neurotransmitter Agents; NMDA Receptor Antagonists; OCT2 Substrates; Psychoanaleptics"
DB01044,Gatifloxacin,112811-59-3,approved; investigational,XUBOMFCQGDBHNK-UHFFFAOYSA-N,"InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)",CC1CN(CCN1)c(c(F)c2)c(OC)c(c23)n(C4CC4)cc(c3=O)C(=O)O,C19H22FN3O4,C07661,D08011,5379,46506159,5280,CHEMBL31,,5186,50117914,375.3941,-0.580319618,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypoglycemia-Associated Agents; Ophthalmic Solutions; Ophthalmologicals; Pharmaceutical Preparations; Pharmaceutical Solutions; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines; Quinolone Antimicrobial; Quinolones; Sensory Organs; Solutions; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB01045,Rifampicin,13292-46-1,approved,JQXXHWHPUNPDRT-WLSIYKJHSA-N,"InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1",C[C@@]12O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(=O)C)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)C(=O)Nc3c(/C=N/N4CCN(C)CC4)c(O)c5c(C1=O)c(O2)c(C)c(O)c5c3O,C43H58N4O12,C06688,D00211,5381226,46506170,71365,CHEMBL374478,RFP,10468813,50370232,822.9402,2.769896781,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; BSEP/ABCB11 Inhibitors; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (moderate); Cytochrome P-450 CYP1A2 Inducers (strong); Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (moderate); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (moderate); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (moderate); Cytochrome P-450 CYP2C19 Inducers (strong); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strong); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (moderate); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strong); Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP3A7 Inducers (strong); Cytochrome P-450 CYP3A7 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Drugs for Treatment of Tuberculosis; Enzyme Inhibitors; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Lactams, Macrocyclic; Leprostatic Agents; Macrocyclic Compounds; Metabolic Side Effects of Drugs and Substances; Nucleic Acid Synthesis Inhibitors; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; OATP1B3 substrates; P-glycoprotein inducers; Polycyclic Compounds; Rifamycin Antibacterial; Rifamycins; UGT1A1 Inducers; UGT1A9 Inducers; UGT1A9 Inhibitors"
DB01046,Lubiprostone,136790-76-6,approved; investigational,WGFOBBZOWHGYQH-MXHNKVEKSA-N,"InChI=1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15-,17-,20-/m1/s1",CCCCC(F)(F)[C@@](O)(CC1)O[C@@H]([C@H]12)CC(=O)[C@@H]2CCCCCCC(=O)O,C20H32F2O5,C13707,D04790,157920,46505874,,CHEMBL1201134,,138948,,390.468,4.563896638,"Alimentary Tract and Metabolism; Autacoids; Biological Factors; Chloride Channel Agonists; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Eicosanoids; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Inflammation Mediators; Laxatives; Lipids; Membrane Transport Modulators; Miscellaneous GI Drugs; Prostaglandins E"
DB01047,Fluocinonide,356-12-7,approved; investigational,WJOHZNCJWYWUJD-IUGZLZTKSA-N,"InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1",CC(=O)OCC(=O)[C@]12[C@H](OC(O1)(C)C)C[C@@H]3[C@]2(C)C[C@H](O)[C@@]4(F)[C@H]3C[C@H](F)C=5[C@]4(C)C=CC(=O)C5,C26H32F2O7,,D00325,9642,46504523,5109,CHEMBL1501,,9265,,494.5249,2.045523979,"Adrenal Cortex Hormones; Anti-Allergic Agents; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienes; Pregnanes; Steroids; Steroids, Fluorinated; Thyroxine-binding globulin inhibitors"
DB01048,Abacavir,136470-78-5,approved; investigational,MCGSCOLBFJQGHM-SCZZXKLOSA-N,"InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1",C1CC1Nc2nc(N)nc(c23)n(cn3)[C@@H]4C[C@H](CO)C=C4,C14H18N6O,C07624,D07057,441300,46505718,421707,CHEMBL1380,1KX,390063,50366816,286.3323,0.386773901,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Carbohydrates; Deoxyribonucleosides; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Glycosides; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides; Reverse Transcriptase Inhibitors; UGT1A1 Substrates"
DB01049,Ergoloid mesylate,8067-24-1,approved,,, ,,C14055,D02268,,46505963,34706,,,60600935,,NA,NA,"Adrenergic Agents; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Alkaloids; Antidepressive Agents; Cardiovascular Agents; Cardiovascular System; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dihydroergotoxine; Dopamine Agents; Dopamine Agonists; Ergot Alkaloids and Derivatives; Ergot-derivative Dopamine Receptor Agonists; Ergotamines; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; Nootropic Agents; Peripheral Vasodilators; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Sympatholytic (Adrenergic Blocking) Agents; Vasodilating Agents"
DB01050,Ibuprofen,15687-27-1,approved,HEFNNWSXXWATRW-UHFFFAOYSA-N,"InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)",CC(C)Cc1ccc(cc1)C(C)C(=O)O,C13H18O2,C01588,D00126,3672,46507255,5855,CHEMBL521,,3544,50009859,206.2808,3.843558199,"Acids, Carbocyclic; Agents causing angioedema; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antiinflammatory Products for Vaginal Administration; Antirheumatic Agents; Arylpropionic acid NSAIDS; Carboxylic Acids; Central Nervous System Agents; COX-1 Inhibitors; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Experimental Unapproved Treatments for COVID-19; Ibuprofen and isomer; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Other Nonsteroidal Anti-inflammatory Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Phenylpropionates; Propionates; Sensory System Agents; Throat Preparations; Topical Products for Joint and Muscular Pain; UGT1A1 Substrates; UGT1A3 substrates; UGT1A9 Substrates; UGT2B7 substrates"
DB01051,Novobiocin,303-81-1,approved; investigational; vet_approved,YJQPYGGHQPGBLI-KGSXXDOSSA-N,"InChI=1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1",CO[C@@H](C1(C)C)[C@@H](OC(=O)N)[C@@H](O)[C@@H](O1)Oc(cc2)c(C)c(c23)oc(=O)c(c3O)NC(=O)c4ccc(O)c(c4)CC=C(C)C,C31H36N2O11,C05080,,54675769,46507250,28368,CHEMBL36506,NOV,10226117,50226181,612.6243,3.263811166,"Aminocoumarins; Anti-Bacterial Agents; Anti-Infective Agents; BCRP/ABCG2 Inhibitors; Benzopyrans; Carbohydrates; Coumarins; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acid Synthesis Inhibitors; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Pyrans"
DB01053,Benzylpenicillin,61-33-6,approved; vet_approved,JGSARLDLIJGVTE-MBNYWOFBSA-N,"InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)Cc3ccccc3,C16H18N2O4S,C05551,D02336,5904,46506778,18208,CHEMBL29,PNN,5693,50022787,334.39,1.080677953,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; Beta-Lactamase Sensitive Penicillins; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Natural Penicillins; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Substrates; Ophthalmologicals; Penicillin G; Penicillins; Sensory Organs; Sulfur Compounds"
DB01054,Nitrendipine,39562-70-4,approved; investigational,PVHUJELLJLJGLN-UHFFFAOYSA-N,"InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3",CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2cc([N+]([O-])=O)ccc2,C18H20N2O6,C07713,D00629,4507,46508817,7582,CHEMBL475534,,4351,50237611,360.3612,2.172302236,"ACE Inhibitors and Calcium Channel Blockers; Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Bradycardia-Causing Agents; BSEP/ABCB11 Substrates; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Dihydropyridines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB01056,Tocainide,41708-72-9,approved,BUJAGSGYPOAWEI-UHFFFAOYSA-N,"InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14)",CC(N)C(=O)Nc1c(C)cccc1C,C11H16N2O,C07142,D06172,38945,46505385,9611,CHEMBL1762,,35632,50092595,192.2575,1.882433362,"Amides; Amines; Anilides; Aniline Compounds; Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ib; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Membrane Transport Modulators; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB01057,Echothiophate,04-03-6736,approved,BJOLKYGKSZKIGU-UHFFFAOYSA-N,"InChI=1S/C9H23NO3PS/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5/h6-9H2,1-5H3/q+1",CCOP(=O)(OCC)SCC[N+](C)(C)C,C9H23NO3PS,C06975,D02193,10548,46505944,4753,CHEMBL1201341,,10108,,256.323,-3.050055223,Antiglaucoma Preparations and Miotics; Autonomic Agents; Cholinergic Agents; Cholinesterase Inhibitors; Enzyme Inhibitors; Miotics; Neurotransmitter Agents; Ophthalmologicals; Organophosphates; Organophosphorus Compounds; Organothiophosphates; Organothiophosphorus Compounds; Parasympathomimetics; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sensory Organs; Sulfur Compounds
DB01058,Praziquantel,55268-74-1,approved; investigational; vet_approved,FSVJFNAIGNNGKK-UHFFFAOYSA-N,"InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2",C1CCCCC1C(=O)N(CC2=O)CC(N23)c4c(CC3)cccc4,C19H24N2O2,C07367,D00471,4891,46507082,91583,CHEMBL976,,4722,74574,312.4061,2.301562597,"Anthelmintics; Anti-Infective Agents; Antihelminthic; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antitrematodals; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Quinoline Derivatives and Related Substances"
DB01059,Norfloxacin,70458-96-7,approved,OGJPXUAPXNRGGI-UHFFFAOYSA-N,"InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)",CCn1cc(C(=O)O)c(=O)c(c12)cc(F)c(c2)N3CCNCC3,C16H18FN3O3,C06687,D00210,4539,46508634,100246,CHEMBL9,,4380,50045000,319.3308,-0.920489565,"Agents Causing Muscle Toxicity; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Metabolic Side Effects of Drugs and Substances; OAT1/SLC22A6 inhibitors; Ophthalmologicals; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines; Quinolone Antimicrobial; Quinolones; Sensory Organs; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB01060,Amoxicillin,26787-78-0,approved; vet_approved,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,"InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccc(O)cc3,C16H19N3O5S,C06827,D07452,33613,46507578,2676,CHEMBL1082,,31006,50350464,365.404,-2.310176133,"Alimentary Tract and Metabolism; Amides; Aminopenicillins; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Medications that reduce magnesium levels; OAT1/SLC22A6 inhibitors; Penicillin G; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB01061,Azlocillin,37091-66-0,approved,JTWOMNBEOCYFNV-NFFDBFGFSA-N,"InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1",O=C1NCCN1C(=O)N[C@H](c2ccccc2)C(=O)N[C@@H]3C(=O)N([C@@H]34)[C@H](C(S4)(C)C)C(=O)O,C20H23N5O6S,C06839,D02339,6479523,46506654,2956,CHEMBL1537,,4980416,,461.492,-0.325171275,"Agents that reduce seizure threshold; Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillin G; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB01062,Oxybutynin,5633-20-5,approved; investigational,XIQVNETUBQGFHX-UHFFFAOYSA-N,"InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3",CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2,C22H31NO3,C07360,D00465,4634,46508005,7856,CHEMBL1231,,4473,50165019,357.4864,4.438075327,"Acids, Carbocyclic; Agents producing tachycardia; Anticholinergic Agents; Autonomic Agents; Carboxylic Acids; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Urinary Frequency and Incontinence; Genito Urinary System and Sex Hormones; Hydroxy Acids; Muscarinic Antagonists; Neurotransmitter Agents; Parasympatholytics; Peripheral Nervous System Agents; Urological Agents; Urologicals"
DB01063,Acetophenazine,2751-68-0,approved,WNTYBHLDCKXEOT-UHFFFAOYSA-N,"InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3",O=C(C)c(c1)ccc(S2)c1N(c(c23)cccc3)CCCN4CCN(CC4)CCO,C23H29N3O2S,C06807,,17676,46507036,2401,CHEMBL1085,,16708,82475,411.56,2.645620652,"Antipsychotic Agents; Central Nervous System Depressants; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Phenothiazines; Phenothiazines With Piperazine Structure; Psycholeptics; Sulfur Compounds"
DB01064,Isoprenaline,7683-59-2,approved; investigational,JWZZKOKVBUJMES-UHFFFAOYSA-N,"InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3",CC(C)NCC(O)c1cc(O)c(O)cc1,C11H17NO3,C07056,,3779,46507323,64317,CHEMBL434,,3647,25392,211.2576,0.240205682,"Adrenergic Agents; Adrenergic Agonists; Adrenergic and Dopaminergic Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Benzene Derivatives; Bronchodilator Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Catecholamines; Catechols; Compounds used in a research, industrial, or household setting; Drugs for Obstructive Airway Diseases; Ethanolamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; Non-selective Beta-adrenergic Agonists; Peripheral Nervous System Agents; Phenols; Protective Agents; Respiratory System; Respiratory System Agents; Sympathomimetics"
DB01065,Melatonin,73-31-4,approved; nutraceutical; vet_approved,DRLFMBDRBRZALE-UHFFFAOYSA-N,"InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)",COc(cc1)cc(c12)c(c[nH]2)CCNC(=O)C,C13H16N2O2,C01598,D08170,896,46509101,16796,CHEMBL45,ML1,872,9019,232.2783,1.147612787,"Amines; Antioxidants; Biogenic Amines; Biogenic Monoamines; Central Nervous System Agents; Central Nervous System Depressants; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypnotics and Sedatives; Indoles; Melatonin Receptor Agonists; Melatonin, agonists; Melatonin, antagonists & inhibitors; Nervous System; OAT3/SLC22A8 Inhibitors; Protective Agents; Psycholeptics; Tryptamines"
DB01066,Cefditoren,104145-95-1,approved; investigational,KMIPKYQIOVAHOP-YLGJWRNMSA-N,"InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1",Cc1ncsc1/C=C\C(=C2C(=O)O)CS[C@@H](N23)[C@@H](C3=O)NC(=O)/C(=N\OC)c4csc(n4)N,C19H18N6O5S3,,D01628,9870843,46505471,59343,CHEMBL1743,,8046534,,506.578,-0.151377329,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB01067,Glipizide,29094-61-9,approved; investigational,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,"InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)",Cc1ncc(nc1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,C21H27N5O4S,,D00335,3478,46505865,5384,CHEMBL1073,,3359,50012956,445.535,1.426612278,Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Hypoglycemia-Associated Agents; Sulfones; Sulfonylureas; Sulfur Compounds; UGT1A1 Substrates
DB01068,Clonazepam,1622-61-3,approved; illicit,DGBIGWXXNGSACT-UHFFFAOYSA-N,"InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)",[O-][N+](=O)c(cc1)cc(c12)C(=NCC(=O)N2)c3ccccc3Cl,C15H10ClN3O3,,D00280,2802,46507677,3756,CHEMBL452,,2700,50019213,315.711,3.152004688,"Anticonvulsants; Benzazepines; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System"
DB01069,Promethazine,60-87-7,approved; investigational,PWWVAXIEGOYWEE-UHFFFAOYSA-N,"InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3",CN(C)C(C)CN1c(cccc2)c2Sc(c13)cccc3,C17H20N2S,C07404,D00494,4927,46507798,8461,CHEMBL643,,4758,50017696,284.419,4.287570852,"Acid Reducers; Agents producing tachycardia; Agents that reduce seizure threshold; Amines; Anti-Allergic Agents; Anticholinergic Agents; Antidepressive Agents; Antidotes; Antihistamines for Systemic Use; Antihistamines for Topical Use; Antipruritics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Antipsychotic Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H2 Antagonists; Miscellaneous Anxiolytics Sedatives and Hypnotics; Muscarinic Antagonists; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; Phenothiazine Derivatives; Phenothiazines; Photosensitizing Agents; Potential QTc-Prolonging Agents; Propylamines; QTc Prolonging Agents; Respiratory System; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Sulfur Compounds"
DB01070,Dihydrotachysterol,67-96-9,approved,ILYCWAKSDCYMBB-OPCMSESCSA-N,"InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1",CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]([C@@]12C)/C(CCC2)=C/C=C3\C[C@@H](O)CC[C@@H]3C,C28H46O,C06957,D00299,5311071,46507699,4591,CHEMBL2356023,,4470607,,398.6642,7.398204005,"Alimentary Tract and Metabolism; Bone Density Conservation Agents; Cholestanes; Cholestenes; Diet, Food, and Nutrition; Food; Food and Beverages; Fused-Ring Compounds; Growth Substances; Lipids; Membrane Lipids; Micronutrients; Physiological Phenomena; Polycyclic Compounds; Secosteroids; Steroids; Sterols; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)"
DB01072,Atazanavir,198904-31-3,approved; investigational,AXRYRYVKAWYZBR-GASGPIRDSA-N,"InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1",COC(=O)N[C@@H](C(C)(C)C)C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(NC(=O)[C@H](C(C)(C)C)NC(=O)OC)Cc2ccc(cc2)-c3ccccn3,C38H52N6O7,,D07471,148192,46508504,37924,CHEMBL1163,DR7,130642,13934,704.8555,4.539848172,"Amino Acids, Peptides, and Proteins; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV Protease Inhibitors; Hyperglycemia-Associated Agents; Nephrotoxic agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Oligopeptides; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Peptides; Potential QTc-Prolonging Agents; Protease Inhibitors; Pyridines; QTc Prolonging Agents; UDP Glucuronosyltransferases Inhibitors; UGT1A1 Inhibitors"
DB01073,Fludarabine,21679-14-1,approved,HBUBKKRHXORPQB-FJFJXFQQSA-N,"InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1",Nc1nc(F)nc(c12)n(cn2)[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O,C10H12FN5O4,,D01907,657237,46507525,94701,CHEMBL1568,,571392,68391,285.235,-1.470002774,"Adenine Nucleotides; Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Arabinonucleosides; Arabinonucleotides; Carbohydrates; Cardiotoxic antineoplastic agents; DNA (Cytosine-5-)-Methyltransferases, antagonists & inhibitors; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunologic Factors; Immunosuppressive Agents; Myeloablative Agonists; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Metabolic Inhibitor; Nucleosides; Nucleotides; Purine Analogues; Purine Nucleosides; Purine Nucleotides; Purines; Ribonucleosides; Ribonucleotides; Toxic Actions"
DB01074,Perhexiline,6621-47-2,approved; investigational,CYXKNKQEMFBLER-UHFFFAOYSA-N,"InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2",C1CCCNC1CC(C2CCCCC2)C3CCCCC3,C19H35N,,,4746,46504471,35553,CHEMBL75880,,4584,61402,277.4879,5.531308548,"Agents causing hyperkalemia; Antiarrhythmic agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Non-Selective Calcium Channel Blockers; Piperidines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Vasodilating Agents"
DB01075,Diphenhydramine,58-73-1,approved; investigational,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,"InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3",c1ccccc1C(OCCN(C)C)c2ccccc2,C17H21NO,C06960,D00300,3100,46505484,4636,CHEMBL657,2PM,2989,50017674,255.3547,3.651907262,"Agents producing tachycardia; Amines; Aminoalkyl Ethers; Anesthetics; Anesthetics, Local; Anti-Allergic Agents; Anticholinergic Agents; Antiemetics; Antihistamines for Systemic Use; Antihistamines for Topical Use; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Benzene Derivatives; Benzhydryl Compounds; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Drugs causing inadvertant photosensitivity; Ethanolamine Derivatives; Ethylamines; First Generation Antihistamines; Gastrointestinal Agents; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Hypnotics and Sedatives; Muscarinic Antagonists; OCT2 Inhibitors; Photosensitizing Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sleep Aids, Pharmaceutical"
DB01076,Atorvastatin,134523-00-5,approved,XUKUURHRXDUEBC-KAYWLYCHSA-N,"InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1",c1ccccc1NC(=O)c2c(C(C)C)n(c(-c3ccc(F)cc3)c2-c4ccccc4)CC[C@@H](O)C[C@@H](O)CC(=O)O,C33H35FN2O5,C06834,D07474,60823,46506188,39548,CHEMBL1487,117,54810,22164,558.6398,5.387146767,"Agents Causing Muscle Toxicity; Anticholesteremic Agents; Azoles; BSEP/ABCB11 Substrates; Cardiovascular System; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Fatty Acids; Heptanoic Acids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Lipids; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; Pyrroles; Toxic Actions; UGT1A1 Substrates; UGT1A3 substrates"
DB01077,Etidronic acid,2809-21-4,approved,DBVJJBKOTRCVKF-UHFFFAOYSA-N,"InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)",OP(=O)(O)C(C)(O)P(=O)(O)O,C2H8O7P2,C07736,D02373,3305,46507694,4907,CHEMBL871,911,3189,50115102,206.0282,-2.277497331,Bisphosphonates; Bone Density Conservation Agents; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Musculo-Skeletal System; Organophosphonates; Organophosphorus Compounds
DB01078,Deslanoside,17598-65-1,approved,OBATZBGFDSVCJD-LALPQLPRSA-N,"InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1",O=C1OCC(=C1)[C@@H](CC2)[C@](C)([C@]23O)[C@H](O)C[C@H]4[C@H]3CC[C@H]5[C@]4(C)CC[C@@H](C5)O[C@@H]6O[C@H](C)[C@H]([C@H](C6)O)O[C@H]7C[C@H](O)[C@@H]([C@H](O7)C)O[C@H]8C[C@H](O)[C@@H]([C@H](O8)C)O[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O,C47H74O19,,D01240,28620,46507176,31468,CHEMBL1614,,26618,,943.0791,0.595845026,"Antiarrhythmic agents; Carbohydrates; Cardanolides; Cardenolides; Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Digitalis Glycosides; Enzyme Inhibitors; Fused-Ring Compounds; Glycosides; Lanatosides; Polycyclic Compounds; Protective Agents; Steroids"
DB01079,Tegaserod,145158-71-0,approved; investigational; withdrawn,IKBKZGMPCYNSLU-RGVLZGJSSA-N,"InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+",CCCCCNC(=N)N/N=C/c1c[nH]c(c12)ccc(c2)OC,C16H23N5O,,D06056,5362436,46506519,51043,CHEMBL76370,,10609889,79022,301.394,2.954410758,"Alimentary Tract and Metabolism; Antidepressive Agents; BCRP/ABCG2 Substrates; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Constipation; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Laxatives; P-glycoprotein substrates; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB01080,Vigabatrin,68506-86-5,approved,PJDFLNIOAUIZSL-UHFFFAOYSA-N,"InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)",C=CC(N)CCC(=O)O,C6H11NO2,C07500,D00535,5665,46507052,63638,CHEMBL89598,,5463,50118886,129.157,-2.094914785,"Acids, Acyclic; Aminobutyrates; Anti-epileptic Agent; Anticonvulsants; Butyrates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Enzyme Inhibitors; Fatty Acid Derivatives; Fatty Acids; GABA Agents; Lipids; Miscellaneous Anticonvulsants; Nervous System; Neurotransmitter Agents"
DB01081,Diphenoxylate,915-30-0,approved; illicit,HYPPXZBJBPSRLK-UHFFFAOYSA-N,"InChI=1S/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3",c1ccccc1C2(C(=O)OCC)CCN(CC2)CCC(C#N)(c3ccccc3)c4ccccc4,C30H32N2O2,C07872,D00301,13505,46507130,4639,CHEMBL1201294,,12919,50401672,452.5873,5.884015038,"Acids, Heterocyclic; Alimentary Tract and Metabolism; Analgesics; Antidiarrheals; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antipropulsives; Central Nervous System Agents; Central Nervous System Depressants; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isonipecotic Acids; Opioids; Peripheral Nervous System Agents; Piperidines; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB01082,Streptomycin,57-92-1,approved; vet_approved,UCSJYZPVAKXKNQ-HZYVHMACSA-N,"InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1",CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]([C@@]2(O)C=O)[C@@H](O[C@H]2C)O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]3NC(N)=N,C21H39N7O12,C00413,,19649,46506845,17076,CHEMBL372795,SRY,18508,50103513,581.5741,-7.581639359,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antiinfectives for Systemic Use; Antimycobacterials; Carbohydrates; Drugs for Treatment of Tuberculosis; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inhibitors; Glycosides; Intestinal Antiinfectives; Narrow Therapeutic Index Drugs; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; Protein Synthesis Inhibitors; Streptomycins"
DB01083,Orlistat,96829-58-2,approved; investigational,AHLBNYSZXLDEJQ-FWEHEUNISA-N,"InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1",CCCCCCCCCCC[C@H](OC(=O)[C@@H](NC=O)CC(C)C)C[C@@H]1OC(=O)[C@H]1CCCCCC,C29H53NO5,,,3034010,46508309,94686,CHEMBL175247,,2298564,24567,495.7348,8.106577767,"Alimentary Tract and Metabolism; Anti-Obesity Agents; Antiobesity Preparations, Excl. Diet Products; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Enzyme Inhibitors; Intestinal Lipase Inhibitor; Lactones; Lipase Inhibitors; Lipid Regulating Agents; Miscellaneous GI Drugs; Peripherally Acting Antiobesity Products"
DB01084,Emedastine,87233-61-2,approved,KBUZBQVCBVDWKX-UHFFFAOYSA-N,"InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3",CCOCCn1c(nc(c12)cccc2)N3CCCN(C)CC3,C17H26N4O,C07785,D07890,3219,46505109,4779,CHEMBL594,,3106,50019624,302.4145,2.492385693,"Anti-Allergic Agents; Decongestants and Antiallergics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Inhibitors; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Ophthalmologicals; QTc Prolonging Agents; Sensory Organs"
DB01085,Pilocarpine,92-13-7,approved; investigational,QCHFTSOMWOSFHM-WPRPVWTQSA-N,"InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1",O=C1OC[C@@H]([C@@H]1CC)Cc2cncn2C,C11H16N2O2,C07474,D00525,5910,46507475,8207,CHEMBL550,9PL,5699,50008072,208.2569,0.949751419,Alkaloids; Antiglaucoma Preparations and Miotics; Autonomic Agents; Cholinergic Agents; Cholinergic Agonists; Cholinergic Receptor Agonist; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Heterocyclic Compounds; Miotics; Muscarinic Agonists; Nervous System; Neurotransmitter Agents; Ophthalmologicals; Parasympathomemetic (Cholinergic) Agents; Parasympathomimetics; Peripheral Nervous System Agents; Sensory Organs
DB01086,Benzocaine,94-09-7,approved; investigational,BLFLLBZGZJTVJG-UHFFFAOYSA-N,"InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3",CCOC(=O)c1ccc(N)cc1,C9H11NO2,C07527,D00552,2337,46508891,116735,CHEMBL278172,,13854242,197282,165.1891,1.504604781,"Acids, Carbocyclic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Aminobenzoates; Anesthetics; Anesthetics for Topical Use; Anesthetics, Local; Antipruritics and Local Anesthetics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Benzene Derivatives; Benzoates; Carboxylic Acids; Cardiovascular System; Cell-mediated Immunity; Central Nervous System Agents; Central Nervous System Depressants; Dermatologicals; Esters of Aminobenzoic Acid; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Increased Histamine Release; Local Anesthetics (Ester); Methemoglobinemia Associated Agents; Nervous System; P-glycoprotein inhibitors; para-Aminobenzoates; Peripheral Nervous System Agents; Respiratory System; Sensory System Agents; Standardized Chemical Allergen; Throat Preparations; Vasoprotectives"
DB01087,Primaquine,90-34-6,approved,INDBQLZJXZLFIT-UHFFFAOYSA-N,"InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3",c1ccnc(c12)c(cc(c2)OC)NC(C)CCCN,C15H21N3O,C07627,,4908,46508222,8405,CHEMBL506,,4739,71542,259.3467,1.642920959,"Aminoquinolines; Anti-Infective Agents; Antibiotics for Pneumocystis Pneumonia; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Methemoglobinemia Associated Agents; Moderate Risk QTc-Prolonging Agents; P-glycoprotein inhibitors; QTc Prolonging Agents; Quinolines"
DB01088,Iloprost,78919-13-8,approved; investigational,HIFJCPQKFCZDDL-ACWOEMLNSA-N,"InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1",OC(=O)CCC/C=C(C1)\C[C@H]([C@H]12)C[C@@H](O)[C@@H]2/C=C/[C@@H](O)C(C)CC#CC,C22H32O4,,,5311181,46507818,63916,CHEMBL494,,4470703,23954,360.494,3.564378512,"Agents Causing Muscle Toxicity; Anticoagulants; Antiplatelet agents; Autacoids; Biological Factors; Blood and Blood Forming Organs; Cardiovascular Agents; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Fibrinolytic Agents; Hematologic Agents; Hypotensive Agents; Inflammation Mediators; Lipids; Platelet Aggregation Inhibitors Excl. Heparin; Prostacyclin Analogues; Prostaglandins; Prostaglandins, Synthetic; Vasodilating Agents"
DB01089,Deserpidine,131-01-1,approved,CVBMAZKKCSYWQR-WCGOZPBSSA-N,"InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1",COc1c(OC)cc(cc1OC)C(=O)O[C@@H]([C@H](OC)[C@H]2C(=O)OC)C[C@@H]([C@@H]23)CN4[C@H](C3)c5c(CC4)c6c([nH]5)cccc6,C32H38N2O8,C06541,D08194,8550,46505311,27478,CHEMBL1200515,,8232,,578.6527,3.689167208,"Alkaloids; Antiadrenergic Agents, Centrally Acting; Antihypertensive Agents; Cardiovascular System; Catecholamine-depleting Sympatholytic; Decreased Sympathetic Activity; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indole Alkaloids; Indoles; Secologanin Tryptamine Alkaloids"
DB01090,Pentolinium,144-44-5,approved,XSBSKEQEUFOSDD-UHFFFAOYSA-N,"InChI=1S/C15H32N2/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17/h3-15H2,1-2H3/q+2",C1CCC[N+]1(C)CCCCC[N+]2(C)CCCC2,C15H32N2,,,5850,46507977,347401,CHEMBL1271,,5641,50084945,240.428,-6.282373237,"Anticholinergic Agents; Antihypertensive Agents; Autonomic Agents; Cardiovascular Agents; Cholinergic Agents; Ganglion Blockers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Neurotransmitter Agents; Nicotinic Antagonists; Peripheral Nervous System Agents; Pyrrolidines"
DB01091,Butenafine,101828-21-1,approved,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,"InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3",c1cccc(c12)cccc2CN(C)Cc3ccc(cc3)C(C)(C)C,C23H27N,C08067,D07596,2484,46506191,3238,CHEMBL990,,2390,50436713,317.4672,6.173648728,"Amines; Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Benzene Derivatives; Benzyl Compounds; Benzylamine Antifungal; Benzylamines; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic"
DB01092,Ouabain,630-60-4,approved,LPMXVESGRSUGHW-HBYQJFLCSA-N,"InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1",O=C1OCC(=C1)[C@H]2CC[C@@](O)([C@@]23C)[C@H]4[C@H]([C@@H](C3)O)[C@]5(CO)[C@](O)(CC4)C[C@H](C[C@H]5O)O[C@@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O,C29H44O12,C01443,D00112,439501,46505479,472805,CHEMBL222863,OBN,388599,50286739,584.6525,-2.78180589,"Carbohydrates; Cardanolides; Cardenolides; Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Enzyme Inhibitors; Fused-Ring Compounds; Glycosides; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Polycyclic Compounds; Protective Agents; Steroids; Strophanthins; Strophanthus Glycosides"
DB01093,Dimethyl sulfoxide,67-68-5,approved; vet_approved,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,InChI=1S/C2H6OS/c1-4(2)3/h1-2H3,CS(=O)C,C2H6OS,C11143,D01043,679,46505009,28262,CHEMBL504,DMS,659,50026472,78.133,-1.407865647,"Antioxidants; Compounds used in a research, industrial, or household setting; Cryoprotective Agents; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Free Radical Scavengers; Genito Urinary System and Sex Hormones; Miscellaneous Therapeutic Agents; Musculo-Skeletal System; Protective Agents; Solvents; Sulfoxides; Sulfur Compounds; Topical Products for Joint and Muscular Pain; Urologicals"
DB01095,Fluvastatin,93957-54-1,approved,FJLGEFLZQAZZCD-JUFISIKESA-N,"InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m0/s1",Fc1ccc(cc1)-c(c(c23)cccc3)c(n2C(C)C)/C=C/[C@H](O)C[C@H](O)CC(=O)O,C24H26FNO4,C07014,D07983,1548972,46505668,5136,CHEMBL350239,115,1265982,50248235,411.4659,3.825949094,"Agents Causing Muscle Toxicity; Cardiovascular System; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Fatty Acids; Heptanoic Acids; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Indoles; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Lipids; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; UGT1A1 Substrates; UGT1A3 substrates; UGT2B7 substrates"
DB01096,Oxamniquine,21738-42-1,approved,XCGYUJZMCCFSRP-UHFFFAOYSA-N,"InChI=1S/C14H21N3O3/c1-9(2)15-7-12-4-3-10-5-11(8-18)14(17(19)20)6-13(10)16-12/h5-6,9,12,15-16,18H,3-4,7-8H2,1-2H3",CC(C)NCC(N1)CCc(c12)cc(c(c2)[N+]([O-])=O)CO,C14H21N3O3,C07341,D00460,4612,46508789,78416,CHEMBL847,,4451,,279.3348,1.571862171,"Anthelmintics; Anti-Infective Agents; Antihelminthic; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiplatyhelmintic Agents; Antitrematodals; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxyquinolines; Nitro Compounds; Nitroquinolines; Quinoline Derivatives and Related Substances; Quinolines; Schistosomicides"
DB01097,Leflunomide,75706-12-6,approved; investigational,VHOGYURTWQBHIL-UHFFFAOYSA-N,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",Cc1oncc1C(=O)Nc2ccc(C(F)(F)F)cc2,C12H9F3N2O2,C07905,D00749,3899,46506013,6402,CHEMBL960,,3762,50054601,270.2073,2.507085826,"Adjuvants; Agents Causing Muscle Toxicity; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Azoles; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Disease-modifying Antirheumatic Agents; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Leflunomide and metabolite; Selective Immunosuppressants"
DB01098,Rosuvastatin,287714-41-4,approved,BPRHUIZQVSMCRT-VEUZHWNKSA-N,"InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1",CC(C)c1nc(N(C)S(=O)(=O)C)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,C22H28FN3O6S,,D08492,446157,46509022,38545,CHEMBL1496,FBI,393589,18372,481.538,1.922960462,"Agents Causing Muscle Toxicity; Alimentary Tract and Metabolism; Amides; Anticholesteremic Agents; BCRP/ABCG2 Substrates; Benzene Derivatives; BSEP/ABCB11 Substrates; Cardiovascular System; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Enzyme Inhibitors; Fluorobenzenes; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Noxae; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; Pyrimidines; Sulfonamides; Sulfones; Sulfur Compounds; Toxic Actions"
DB01099,Flucytosine,2022-85-7,approved; investigational,XRECTZIEBJDKEO-UHFFFAOYSA-N,"InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)",Nc1c(F)cnc(=O)[nH]1,C4H4FN3O,,D00323,3366,46504735,5100,CHEMBL1463,1LD,3249,50248003,129.0925,-1.038123233,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Antiinfectives for Systemic Use; Antimetabolites; Antimycotics for Systemic Use; Cytosine; Dermatologicals; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Fluorouracil and prodrugs; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Noxae; Nucleoside Analog Antifungal; Photosensitizing Agents; Pyrimidines; Pyrimidinones; Toxic Actions"
DB01100,Pimozide,2062-78-4,approved,YVUQSNJEYSNKRX-UHFFFAOYSA-N,"InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)",c1cc(F)ccc1C(c(cc2)ccc2F)CCCN3CCC(CC3)n4c(=O)[nH]c(c45)cccc5,C28H29F2N3O,C07566,D00560,16362,46507096,8212,CHEMBL1423,,15520,50334150,461.5462,5.825713468,"Agents that reduce seizure threshold; Anti-Dyskinesia Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Benzimidazoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diphenylbutylpiperidine Derivatives; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Miscellaneous Antipsychotics; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Tranquilizing Agents"
DB01101,Capecitabine,154361-50-9,approved; investigational,GAGWJHPBXLXJQN-UORFTKCHSA-N,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1",CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O,C15H22FN3O6,C12650,D01223,60953,46508686,31348,CHEMBL1773,,54916,,359.3501,0.768036047,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carbohydrates; Cardiotoxic antineoplastic agents; Cytidine Deaminase Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Deoxycytidine; Deoxyribonucleosides; Drugs that are Mainly Renally Excreted; Fluoropyrimidines; Fluorouracil and prodrugs; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Metabolic Inhibitor; Nucleosides; Pyrimidine Analogues; Pyrimidine Nucleosides; Pyrimidines; Pyrimidinones; Ribonucleosides; Toxic Actions"
DB01102,Arbutamine,128470-16-6,approved,IIRWWTKISYTTBL-SFHVURJKSA-N,"InChI=1S/C18H23NO4/c20-15-7-4-13(5-8-15)3-1-2-10-19-12-18(23)14-6-9-16(21)17(22)11-14/h4-9,11,18-23H,1-3,10,12H2/t18-/m0/s1",Oc1ccc(cc1O)[C@@H](O)CNCCCCc2ccc(O)cc2,C18H23NO4,,D02976,60789,46509010,50580,CHEMBL1201251,,54785,,317.3795,1.995303225,"Adrenergic Agents; Adrenergic Agonists; Adrenergic and Dopaminergic Agents; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Amines; Benzene Derivatives; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Catechols; Compounds used in a research, industrial, or household setting; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; Phenols; Protective Agents"
DB01104,Sertraline,79617-96-2,approved,VGKDLMBJGBXTGI-SJCJKPOMSA-N,"InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1",c1cccc(c12)[C@@H](CC[C@@H]2NC)c3cc(Cl)c(Cl)cc3,C17H17Cl2N,C07246,D02360,68617,46505341,9123,CHEMBL809,SRE,61881,79021,306.23,5.149299974,"Agents that reduce seizure threshold; Amines; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (moderate); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypoglycemia-Associated Agents; Medications that increase serum magnesium; Membrane Transport Modulators; Monoamine Oxidase A Substrates; Naphthalenes; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; P-glycoprotein inhibitors; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB01105,Sibutramine,106650-56-0,approved; illicit; investigational; withdrawn,UNAANXDKBXWMLN-UHFFFAOYSA-N,"InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3",CC(C)CC(N(C)C)C1(CCC1)c2ccc(Cl)cc2,C17H26ClN,C07247,D08513,5210,46507740,9137,CHEMBL1419,,5021,84742,279.848,5.201850084,"Agents producing tachycardia; Alimentary Tract and Metabolism; Anti-Obesity Agents; Antidepressive Agents; Antiobesity Preparations, Excl. Diet Products; Appetite Depressants; Appetite Suppression; Central Nervous System Agents; Central Nervous System Depressants; Centrally Acting Antiobesity Products; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cycloparaffins; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dopamine Uptake Inhibitors; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Norepinephrine Uptake Inhibitors; Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic; Polycyclic Compounds; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Serotonin Modulators; Stimulants"
DB01106,Levocabastine,79516-68-0,approved; investigational,ZCGOMHNNNFPNMX-KYTRFIICSA-N,"InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23-,25-,26-/m1/s1",c1ccccc1[C@]2(C(=O)O)[C@H](C)CN(CC2)[C@@H](CC3)CC[C@@]3(C#N)c4ccc(F)cc4,C26H29FN2O2,,D01717,54385,46505909,135679,CHEMBL1615438,,16736421,50019405,420.528,2.499427577,"Anti-Allergic Agents; Antiallergic Agents, Excl. Corticosteroids; Central Nervous System Depressants; Decongestants and Antiallergics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Nasal Preparations; Neurotransmitter Agents; Ophthalmologicals; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System; Sensory Organs"
DB01107,Methyprylon,125-64-4,approved; illicit; withdrawn,SIDLZWOQUZRBRU-UHFFFAOYSA-N,"InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13)",CCC1(CC)C(=O)NCC(C)C1=O,C10H17NO2,,D01150,4162,46506891,31837,CHEMBL1200790,,4018,,183.2475,1.884707654,"Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Piperidinedione Derivatives; Piperidines; Psycholeptics"
DB01108,Trilostane,13647-35-3,approved; investigational; vet_approved; withdrawn,KVJXBPDAXMEYOA-CXANFOAXSA-N,"InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1",C1C[C@H](O)[C@@](C)(CC2)[C@@H]1[C@H](CC3)[C@H]2[C@@]([C@@]345)(C)CC(C#N)=C([C@H]4O5)O,C20H27NO3,C12580,D01180,656583,46507062,32260,CHEMBL1200907,,570949,,329.4333,2.300783867,"3-Hydroxysteroid Dehydrogenases, antagonists & inhibitors; Abortifacient Agents; Abortifacient Agents, Steroidal; Adrenal Cortex Hormones; Androstanes; Androstanols; Antiadrenal Preparations; Anticorticosteroids; Antineoplastic Agents; Corticosteroids; Corticosteroids for Systemic Use; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Narrow Therapeutic Index Drugs; Oxidative Phosphorylation Coupling Factors; Polycyclic Compounds; Reproductive Control Agents; Steroids; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Testosterone Congeners"
DB01109,Heparin,9005-49-6,approved; investigational,,, ,,C00374,,,46507594,28304,CHEMBL1909300,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Antivaricose Therapy; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Cardiovascular System; Fibrin Modulating Agents; Glycosaminoglycans; Hematologic Agents; Heparin and similars; Heparin Group; Heparins or Heparinoids for Topical Use; Miscellaneous Therapeutic Agents; Narrow Therapeutic Index Drugs; Ophthalmologicals; Polysaccharides; Sensory Organs; Thyroxine-binding globulin substrates; Vasoprotectives
DB01110,Miconazole,22916-47-8,approved; investigational; vet_approved,BYBLEWFAAKGYCD-UHFFFAOYSA-N,"InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2",Clc1cc(Cl)c(cc1)COC(Cn2ccnc2)c3c(Cl)cc(Cl)cc3,C18H14Cl4N2O,C08070,D00882,4189,46506017,82892,CHEMBL91,,4044,31772,416.129,5.95636836,"14-alpha Demethylase Inhibitors; Anti-Infective Agents; Antifungal Agents; Antifungal Agents (Vaginal); Antifungals for Dermatological Use; Antifungals for Topical Use; Antiinfectives and Antiseptics for Local Oral Treatment; Azole Antifungals; Azoles; Chemically-Induced Disorders; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strong); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Imidazole and Triazole Derivatives; Imidazole Derivatives; Imidazoles; Intestinal Antiinfectives; Metabolic Side Effects of Drugs and Substances; Otologicals; P-glycoprotein inhibitors; Sensory Organs; Steroid Synthesis Inhibitors; Stomatological Preparations; Vaginal Creams, Foams, and Jellies"
DB01111,Colistimethate,12705-41-8,approved; vet_approved,BSSIRFLGSWHWDE-UHFFFAOYSA-I,"InChI=1S/C58H110N16O28S5/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102)/p-5",CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC1=O)CCNCS([O-])(=O)=O,C58H105N16O28S5,,,70789202,46508586,59662,,,26329515,,1634.87,-16.56502555,"Agents that produce neuromuscular block (indirect); Amino Acids, Peptides, and Proteins; Antimicrobial Cationic Peptides; Lipids; Lipopeptides; Macrocyclic Compounds; Membrane Proteins; Nephrotoxic agents; Peptides; Peptides, Cyclic; Polycyclic Compounds; Polymyxin-class Antibacterial; Polymyxins; Pore Forming Cytotoxic Proteins; Proteins"
DB01112,Cefuroxime,55268-75-2,approved,JFPVXVDWJQMJEE-IZRZKJBUSA-N,"InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1",NC(=O)OCC(=C1C(=O)O)CS[C@@H](N12)[C@@H](C2=O)NC(=O)/C(=N\OC)c3ccco3,C16H16N4O8S,C06894,D00262,5479529,46506681,3515,CHEMBL1436,KOV,4586393,50422689,424.385,-0.902973473,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Ophthalmologicals; Second-Generation Cephalosporins; Sensory Organs; Sulfur Compounds; Thiazines"
DB01113,Papaverine,58-74-2,approved; investigational,XQYZDYMELSJDRZ-UHFFFAOYSA-N,"InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3",COc1c(OC)cc(cc1)Cc2nccc(c23)cc(OC)c(c3)OC,C20H21NO4,C06533,D07425,4680,46508003,28241,CHEMBL19224,EV1,4518,14754,339.385,3.080075072,"Alimentary Tract and Metabolism; Alkaloids; Benzylisoquinolines; Cardiovascular Agents; Drugs for Functional Gastrointestinal Disorders; Drugs Used in Erectile Dysfunction; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Isoquinolines; Miscellaneous Vasodilatating Agents; Moderate Risk QTc-Prolonging Agents; Opiate Alkaloids; Papaverine and Derivatives; Phosphodiesterase Inhibitors; QTc Prolonging Agents; Urological Agents; Urologicals; Vasodilating Agents"
DB01114,Chlorpheniramine,132-22-9,approved,SOYKEARSMXGVTM-UHFFFAOYSA-N,"InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3",c1cccnc1C(CCN(C)C)c2ccc(Cl)cc2,C16H19ClN2,C06905,D07398,2725,46508253,52010,CHEMBL505,,2624,35938,274.788,3.584950915,"Anti-Allergic Agents; Antidepressive Agents; Antihistamines for Systemic Use; Antipruritics; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; OCT1 inhibitors; OCT2 Inhibitors; Propylamine Derivatives; Pyridines; QTc Prolonging Agents; Respiratory System; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Substituted Alkylamines"
DB01115,Nifedipine,21829-25-4,approved,HYIMSNHJOBLJNT-UHFFFAOYSA-N,"InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3",COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2ccccc2[N+]([O-])=O,C17H18N2O6,C07266,D00437,4485,46505103,7565,CHEMBL193,C5U,4330,50101817,346.3346,1.815494282,"Adrenal Cortex Hormones; Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Beta blocking agents and calcium channel blockers; Bradycardia-Causing Agents; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Calcium Channel Blockers; Calcium Channel Blockers (Dihydropyridine); Calcium Channel Blockers and Diuretics; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Dihydropyridines; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Pyridines; QTc Prolonging Agents; Reproductive Control Agents; Selective Calcium Channel Blockers With Mainly Vascular Effects; Tocolytic Agents; Vasodilating Agents"
DB01116,Trimethaphan,7187-66-8,approved; investigational,CHQOEHPMXSHGCL-UHFFFAOYSA-N,"InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1",c1ccccc1CN2C(=O)N(C(C23)C[S+]4C3CCC4)Cc5ccccc5,C22H25N2OS,C07174,,23576,46508994,9728,CHEMBL1201329,,22044,82545,365.512,2.324136726,"Adjuvants, Anesthesia; Antiadrenergic Agents, Ganglion-Blocking; Anticholinergic Agents; Antihypertensive Agents; Autonomic Agents; Azoles; Cardiovascular Agents; Cardiovascular System; Central Nervous System Agents; Cholinergic Agents; Cholinesterase substrates; Ganglion Blockers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Neurotransmitter Agents; Nicotinic Antagonists; Peripheral Nervous System Agents; Sulfonium Derivatives; Vasodilating Agents"
DB01117,Atovaquone,95233-18-4,approved,KUCQYCKVKVOKAY-CTYIDZIISA-N,"InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-",c1cccc(c12)C(=O)C(=C(C2=O)O)[C@H]3CC[C@@H](CC3)c4ccc(Cl)cc4,C22H19ClO3,C06835,D00236,74989,46507298,575568,CHEMBL1450,AOQ,10482034,16301,366.837,4.997646358,"Anti-Infective Agents; Antibiotics for Pneumocystis Pneumonia; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Miscellaneous Antiprotozoals; Naphthalenes; Naphthoquinones; P-glycoprotein inhibitors; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quinones"
DB01118,Amiodarone,1951-25-3,approved; investigational,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,"InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3",c1cccc(c12)c(c(o2)CCCC)C(=O)c3cc(I)c(c(I)c3)OCCN(CC)CC,C25H29I2NO3,C06823,D02910,2157,46507387,2663,CHEMBL633,BBI,2072,18957,645.3116,7.635421425,"Agents causing hyperkalemia; Agents Causing Muscle Toxicity; alpha-Galactosidase, antagonists & inhibitors; Antiarrhythmic agents; Antiarrhythmics, Class III; Benzofurans; Bradycardia-Causing Agents; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; BSEP/ABCB11 Substrates with Narrow Therapeutic Index; Calcium Channel Blockers; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (moderate); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Hypotensive Agents; Medications that reduce magnesium levels; Membrane Transport Modulators; Metabolic Side Effects of Drugs and Substances; Narrow Therapeutic Index Drugs; OCT2 Inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; Photosensitizing Agents; Potassium Channel Blockers; QTc Prolonging Agents; Sodium Channel Blockers; Vasodilating Agents"
DB01119,Diazoxide,364-98-7,approved,GDLBFKVLRPITMI-UHFFFAOYSA-N,"InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)",CC(N1)=NS(=O)(=O)c(c12)cc(Cl)cc2,C8H7ClN2O2S,C06949,D00294,3019,46508027,4495,CHEMBL181,20J,2911,86248,230.671,1.000486454,"Amides; Antihypertensive Agents; Arteriolar Smooth Muscle, Agents Acting On; Benzothiadiazines; Cardiovascular Agents; Cardiovascular System; Direct Vasodilators; Diuretics; Drugs for Treatment of Hypoglycemia; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Hypotensive Agents; Sulfonamides; Sulfones; Sulfur Compounds; Thiazide Derivatives; Vasodilating Agents"
DB01120,Gliclazide,21187-98-4,approved,BOVGTQGAOIONJV-UHFFFAOYSA-N,"InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)",Cc1ccc(cc1)S(=O)(=O)NC(=O)NN(C2)CC(C23)CCC3,C15H21N3O3S,,D01599,3475,46505475,31654,CHEMBL427216,,3356,50103512,323.41,1.733641086,Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Hypoglycemia-Associated Agents; Sulfones; Sulfonylureas; Sulfur Compounds
DB01121,Phenacemide,63-98-9,approved,XPFRXWCVYUEORT-UHFFFAOYSA-N,"InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)",NC(=O)NC(=O)Cc1ccccc1,C9H10N2O2,C07428,D00504,4753,46508400,8049,CHEMBL918,,4589,50240044,178.1879,0.459114264,"Acetamides; Acetates; Acids, Acyclic; Amides; Anticonvulsants; Benzene Derivatives; Carboxylic Acids; Central Nervous System Depressants; Fatty Acids; Fatty Acids, Volatile; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lipids; Nervous System"
DB01122,Ambenonium,7648-98-8,approved,OMHBPUNFVFNHJK-UHFFFAOYSA-P,"InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2",Clc1ccccc1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc2ccccc2Cl,C28H42Cl2N4O2,C07773,,2131,46508143,2627,CHEMBL1652,,2046,50262988,537.565,-3.633401448,Amines; Ammonium Compounds; Autonomic Agents; Benzylammonium Compounds; Cholinergic Agents; Cholinesterase Inhibitors; Enzyme Inhibitors; Nervous System; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Parasympathomimetics; Peripheral Nervous System Agents; Quaternary Ammonium Compounds
DB01123,Proflavine,92-62-6,approved,WDVSHHCDHLJJJR-UHFFFAOYSA-N,"InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2",c1cc(N)cc(c12)nc3c(c2)ccc(c3)N,C13H11N3,C11181,,7099,46505401,8452,CHEMBL55400,PRL,6832,12590,209.2465,1.848375646,"Acridines; Aminoacridines; Anti-Infective Agents; Anti-Infective Agents, Local; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring"
DB01124,Tolbutamide,64-77-7,approved; investigational,JLRGJRBPOGGCBT-UHFFFAOYSA-N,"InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)",CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,C12H18N2O3S,C07148,D00380,5505,46508421,27999,CHEMBL782,,5304,50027886,270.348,2.295335827,Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diagnostic Agents; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Hypoglycemia-Associated Agents; OAT1/SLC22A6 inhibitors; Sulfones; Sulfonylureas; Sulfur Compounds; Tests for Diabetes
DB01125,Anisindione,117-37-3,approved,XRCFXMGQEVUZFC-UHFFFAOYSA-N,"InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3",COc1ccc(cc1)C(C2=O)C(=O)c(c23)cccc3,C16H12O3,,D07457,2197,46504660,133809,CHEMBL712,,2112,50280155,252.2647,2.723233999,"Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indans; Indenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic"
DB01126,Dutasteride,164656-23-9,approved; investigational,JWJOTENAMICLJG-QWBYCMEYSA-N,"InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1",FC(F)(F)c1ccc(C(F)(F)F)cc1NC(=O)[C@H]2CC[C@H]([C@@]23C)[C@H]4[C@H](CC3)[C@]5(C)[C@@H](CC4)NC(=O)C=C5,C27H30F6N2O2,,D03820,6918296,46504830,521033,CHEMBL1200969,,5293502,50340481,528.5297,5.792817784,"5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Azasteroids; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs Used in Benign Prostatic Hypertrophy; Enzyme Inhibitors; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroid Synthesis Inhibitors; Steroids; Steroids, Heterocyclic; Urologicals"
DB01127,Econazole,27220-47-9,approved,LEZWWPYKPKIXLL-UHFFFAOYSA-N,"InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2",Clc1ccc(cc1)COC(Cn2ccnc2)c3c(Cl)cc(Cl)cc3,C18H15Cl3N2O,C08068,D03936,3198,46508881,82873,CHEMBL808,,3086,31773,381.684,5.352323684,"14-alpha Demethylase Inhibitors; Anti-Infective Agents; Antifungal Agents; Antifungal Agents (Vaginal); Antifungals for Dermatological Use; Antifungals for Topical Use; Azole Antifungals; Azoles; Chemically-Induced Disorders; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Imidazole and Triazole Derivatives; Imidazole Derivatives; Imidazoles; Metabolic Side Effects of Drugs and Substances; P-glycoprotein inhibitors; Steroid Synthesis Inhibitors"
DB01128,Bicalutamide,90357-06-5,approved,LKJPYSCBVHEWIU-UHFFFAOYSA-N,"InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)",N#Cc1ccc(cc1C(F)(F)F)NC(=O)C(C)(O)CS(=O)(=O)c2ccc(F)cc2,C18H14F4N2O4S,C08160,D00961,2375,46505386,144093,CHEMBL409,,2284,18525,430.373,2.70929555,"Amides; Amines; Androgen Receptor Antagonists; Androgen Receptor Inhibitor; Aniline Compounds; Antiandrogens; Antiandrogens, non-steroidal; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Benzene Derivatives; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Endocrine Therapy; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; Sulfones; Sulfur Compounds"
DB01129,Rabeprazole,117976-89-3,approved; investigational,YREYEVIYCVEVJK-UHFFFAOYSA-N,"InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)",COCCCOc1c(C)c(ncc1)CS(=O)c([nH]2)nc(c23)cccc3,C18H21N3O3S,C07864,D08463,5029,46506366,8768,CHEMBL1219,,4853,50070209,359.443,2.09074323,"2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Acid Reducers; Acids, Acyclic; Alimentary Tract and Metabolism; Anti-Ulcer Agents; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Azoles; BCRP/ABCG2 Inhibitors; Benzimidazoles; Butylpyrazolidines; Carboxylic Acids; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Fatty Acids; Fatty Acids, Volatile; Gastric Acid Lowering Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxy Acids; Lipids; Musculo-Skeletal System; Proton Pump Inhibitors; Proton-pump Inhibitors; Pyrazoles; Pyrazolones; Pyridines; Sulfoxides; Sulfur Compounds; Topical Products for Joint and Muscular Pain"
DB01130,Prednicarbate,73771-04-7,approved; investigational,FNPXMHRZILFCKX-KAJVQRHHSA-N,"InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(OC(=O)OCC)C(=O)COC(=O)CC,C27H36O8,,,6714002,46506799,135791,CHEMBL1200386,,5145991,,488.577,3.831875683,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids"
DB01131,Proguanil,500-92-5,approved,SSOLNOMRVKKSON-UHFFFAOYSA-N,"InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)",CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,C11H16ClN5,C07631,,4923,46506228,8455,CHEMBL1377,,4754,50227829,253.731,2.38110017,"Amidines; Anti-Infective Agents; Antimalarials; Antimetabolites; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Biguanides; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Folic Acid Antagonists; Guanidines; Noxae; Toxic Actions"
DB01132,Pioglitazone,111025-46-8,approved; investigational,HYAFETHFCAUJAY-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)",CCc1cnc(cc1)CCOc2ccc(cc2)CC3SC(=O)NC3=O,C19H20N2O3S,C07675,D08378,4829,46507136,8228,CHEMBL595,,4663,50103521,356.439,3.3282487,"Alimentary Tract and Metabolism; Azoles; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypoglycemia-Associated Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Peroxisome Proliferator Receptor gamma Agonist; Peroxisome Proliferator-activated Receptor Activity; Sulfur Compounds; Thiazoles; Thiazolidinediones"
DB01133,Tiludronic acid,89987-06-4,approved; investigational; vet_approved,DKJJVAGXPKPDRL-UHFFFAOYSA-N,"InChI=1S/C7H9ClO6P2S/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14/h1-4,7H,(H2,9,10,11)(H2,12,13,14)",OP(=O)(O)C(P(=O)(O)O)Sc1ccc(Cl)cc1,C7H9ClO6P2S,C08141,,60937,46505302,9598,CHEMBL1350,,54905,50442524,318.608,1.322081915,"Bisphosphonates; Bone Density Conservation Agents; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Drugs that are Mainly Renally Excreted; Musculo-Skeletal System; Organophosphonates; Organophosphorus Compounds; Phospholipases A, antagonists & inhibitors"
DB01135,Doxacurium,106791-39-3,approved,GBLRQXKSCRCLBZ-UHFFFAOYSA-N,"InChI=1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2",COc(c1)c(OC)c(OC)cc1CC(c(c23)c(OC)c(OC)c(c2)OC)[N+](C)(CC3)CCCOC(=O)CCC(=O)OCCC[N+](C)(CCc(c45)cc(OC)c(OC)c5OC)C4Cc6cc(OC)c(OC)c(c6)OC,C56H78N2O16,C07549,D00760,5284551,46506733,59819,CHEMBL1237123,,54249,,1035.2223,-2.491688722,"Anticholinergic Agents; Central Nervous System Depressants; Cholinesterase substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Muscarinic Antagonists; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular-Blocking Agents (Nondepolarizing); Nicotinic Antagonists; Peripheral Nervous System Agents"
DB01136,Carvedilol,72956-09-3,approved; investigational,OGHNVEJMJSYVRP-UHFFFAOYSA-N,"InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3",COc1ccccc1OCCNCC(O)COc2cccc(c23)[nH]c4c3cccc4,C24H26N2O4,C06875,D00255,2585,46505146,3441,CHEMBL723,,2487,25759,406.4742,3.424854408,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adrenergic beta2-Antagonists; Agents causing hyperkalemia; Alcohols; Alpha and Beta Blocking Agents; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Antioxidants; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Carbazoles; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Indoles; Membrane Transport Modulators; Neurotransmitter Agents; P-glycoprotein inhibitors; Propanolamines; Propanols; Protective Agents; UGT1A1 Substrates; UGT2B7 substrates; Vasodilating Agents"
DB01137,Levofloxacin,100986-85-4,approved; investigational,GSDSWSVVBLHKDQ-JTQLQIEISA-N,"InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1",C1CN(C)CCN1c(c(c2n34)OC[C@@H]3C)c(F)cc2c(=O)c(c4)C(=O)O,C18H20FN3O4,C07660,D08120,149096,46505134,63598,CHEMBL33,LFX,131410,50366826,361.3675,0.654279753,"Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; MATE 1 Inhibitors; MATE 1 Substrates; MATE 2 Inhibitors; MATE inhibitors; MATE substrates; Medications that reduce magnesium levels; Metabolic Side Effects of Drugs and Substances; Moderate Risk QTc-Prolonging Agents; OAT1/SLC22A6 Substrates; OCT1 inhibitors; OCT2 Inhibitors; Ophthalmologicals; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; QTc Prolonging Agents; Quinolines; Quinolone Antimicrobial; Quinolones; Renal Agents; Sensory Organs; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB01138,Sulfinpyrazone,57-96-5,approved,MBGGBVCUIVRRBF-UHFFFAOYSA-N,"InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2",c1ccccc1N2N(c3ccccc3)C(=O)C(C2=O)CCS(=O)c4ccccc4,C23H20N2O3S,C07317,D00449,5342,46504918,9342,CHEMBL832,,5149,50237626,404.482,3.18740856,"Antigout Preparations; Antiplatelet agents; Azoles; BSEP/ABCB11 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Preparations Increasing Uric Acid Excretion; Pyrazoles; Pyrazolones; Renal Agents; Uricosuric Agents"
DB01139,Cefapirin,21593-23-7,approved; vet_approved,UQLLWWBDSUHNEB-CZUORRHYSA-N,"InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1",CC(=O)OCC(=C1C(=O)O)CS[C@@H](N12)[C@@H](C2=O)NC(=O)CSc3ccncc3,C17H17N3O6S2,C06896,,30699,46505227,554446,CHEMBL1599,,28486,50370592,423.463,-2.053037929,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephacetrile; Cephalosporins; First-Generation Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Sulfur Compounds; Thiazines"
DB01140,Cefadroxil,50370-12-2,approved; vet_approved; withdrawn,BOEGTKLJZSQCCD-UEKVPHQBSA-N,"InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1",O=C(O)C1=C(C)CS[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccc(O)cc3,C16H17N3O5S,C06878,D00257,47965,46509128,3479,CHEMBL1644,,43630,50350467,363.388,-2.448523523,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Drugs that are Mainly Renally Excreted; First-Generation Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Sulfur Compounds; Thiazines"
DB01141,Micafungin,235114-32-6,approved; investigational,PIEUQSKUWLMALL-YABMTYFHSA-N,"InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1",CCCCCOc1ccc(cc1)-c2cc(no2)-c3ccc(cc3)C(=O)N[C@H](C(=O)N[C@H](C4=O)[C@@H](C)O)C[C@@H](O)[C@@H](O)NC(=O)[C@H]([C@@H](O)[C@H](C5)C)N5C(=O)[C@H]([C@H](O)CC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](N46)C[C@H](C6)O)[C@H](O)[C@@H](O)c7cc(OS(=O)(=O)O)c(O)cc7,C56H71N9O23S,C15819,D02465,477468,46508208,600520,CHEMBL457547,,419105,,1270.274,-6.338448323,"Amino Acids, Peptides, and Proteins; Anti-Infective Agents; Antifungal Agents; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; COMT Substrates; Echinocandin Antifungal; Echinocandins; Lipids; Lipopeptides; Macrocyclic Compounds; Peptides; Peptides, Cyclic; Polycyclic Compounds"
DB01142,Doxepin,1668-19-5,approved; investigational,ODQWQRRAPPTVAG-UHFFFAOYSA-N,"InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3",CN(C)CC/C=C\1c(cccc2)c2COc(c13)cccc3,C19H21NO,C06971,D07875,667468,46505232,4710,CHEMBL1628227,,3046,50225488,279.3761,3.839974075,"Acid Reducers; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tricyclic; Antipruritics and Local Anesthetics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Dibenzoxepins; Dopamine Antagonists; Drugs that are Mainly Renally Excreted; Ethers, Cyclic; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H2 Antagonists; Hypnotics and Sedatives; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Non-Selective Monoamine Reuptake Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Sleep Aids, Pharmaceutical; Tertiary amine tricyclic antidepressants; Tricyclics and Other Norepinephrine-reuptake Inhibitors"
DB01143,Amifostine,20537-88-6,approved; investigational,JKOQGQFVAUAYPM-UHFFFAOYSA-N,"InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)",NCCCNCCSP(=O)(O)O,C5H15N2O3PS,C06819,,2141,46505305,2636,CHEMBL1006,,2056,,214.223,-3.745495048,"Compounds used in a research, industrial, or household setting; Cytoprotective Agent; Detoxifying Agents for Antineoplastic Treatment; Free Radical Scavenging Activity; Hypotensive Agents; Organophosphates; Organophosphorus Compounds; Organothiophosphates; Organothiophosphorus Compounds; Protective Agents; Radiation-Protective Agents; Sulfur Compounds"
DB01144,Diclofenamide,120-97-8,approved; investigational,GJQPMPFPNINLKP-UHFFFAOYSA-N,"InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)",NS(=O)(=O)c1cc(S(=O)(=O)N)c(Cl)c(Cl)c1,C6H6Cl2N2O4S2,C07459,D00518,3038,46505039,101085,CHEMBL17,I7A,2930,10883,305.159,0.393396708,Amides; Antiglaucoma Preparations and Miotics; Carbonic Anhydrase Inhibitors; Diuretics; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Hypotensive Agents; Ophthalmics; Ophthalmologicals; Sensory Organs; Sulfonamides; Sulfones; Sulfur Compounds
DB01145,Sulfoxone,144-76-3,approved,NEDPPCHNEOMTJV-UHFFFAOYSA-N,"InChI=1S/C14H16N2O6S3/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20)",OS(=O)CNc1ccc(cc1)S(=O)(=O)c2ccc(cc2)NCS(=O)O,C14H16N2O6S3,,,5351,46507392,135651,CHEMBL1570,,5158,,404.482,-1.032958323,Antiinfectives for Systemic Use; Antimycobacterials; Drugs for Treatment of Lepra; Sulfones; Sulfur Compounds
DB01146,Diphenylpyraline,147-20-6,approved; investigational,OWQUZNMMYNAXSL-UHFFFAOYSA-N,"InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3",CN1CCC(CC1)OC(c2ccccc2)c3ccccc3,C19H23NO,,D07862,3103,46504936,59788,CHEMBL1492,,2992,50241333,281.392,3.660068867,"Aminoalkyl Ethers; Antihistamines for Systemic Use; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H1 Antagonists; Respiratory System"
DB01147,Cloxacillin,61-72-3,approved; investigational; vet_approved,LQOLIRLGBULYKD-JKIFEVAISA-N,"InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)c3c(C)onc3-c4ccccc4Cl,C19H18ClN3O5S,C06923,,6098,46507109,49566,CHEMBL891,CXN,5873,50022788,435.881,2.301739658,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; Beta-Lactamase Resistant Penicillins; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; OAT1/SLC22A6 inhibitors; Penicillinase-resistant Penicillins; Penicillins; Sulfur Compounds"
DB01148,Flavoxate,15301-69-6,approved,SPIUTQOUKAMGCX-UHFFFAOYSA-N,"InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3",c1ccccc1-c(c(C)c2=O)oc(c23)c(ccc3)C(=O)OCCN4CCCCC4,C24H25NO4,C07809,,3354,46505138,5088,CHEMBL1493,,3237,,391.4596,4.235423206,"Agents producing tachycardia; Anticholinergic Agents; Autonomic Agents; Benzopyrans; Chromones; Drugs for Urinary Frequency and Incontinence; Drugs that are Mainly Renally Excreted; Flavones; Flavonoids; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Muscarinic Antagonists; Parasympatholytics; Peripheral Nervous System Agents; Pyrans; Urological Agents; Urologicals"
DB01149,Nefazodone,83366-66-9,approved; withdrawn,VRBKIVRKKCLPHA-UHFFFAOYSA-N,"InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3",c1ccccc1OCCn2c(=O)n(nc2CC)CCCN3CCN(CC3)c4cc(Cl)ccc4,C25H32ClN5O2,C07256,D08257,4449,46508323,7494,CHEMBL623,,4294,50069447,470.007,4.652967894,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Analgesics; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Second-Generation; Antidepressive Agents, Triazolopyridine; Azoles; BSEP/ABCB11 Substrates; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; OATP1B3 inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; Psychoanaleptics; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Serotonin Modulators; Serotonin Receptor Antagonists"
DB01150,Cefprozil,92665-29-7,approved,WDLWHQDACQUCJR-ZAMMOSSLSA-N,"InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1",C/C=C/C(=C1C(=O)O)CS[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccc(O)cc3,C18H19N3O5S,C06888,,5281006,46504903,3506,CHEMBL276568,,4444481,,389.426,-1.921689336,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Second-Generation Cephalosporins; Sulfur Compounds; Thiazines"
DB01151,Desipramine,50-47-5,approved; investigational,HCYAFALTSJYZDH-UHFFFAOYSA-N,"InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3",CNCCCN1c(cccc2)c2CCc(c13)cccc3,C18H22N2,C06943,D07791,2995,46504624,47781,CHEMBL72,DSM,2888,35229,266.3807,3.895520857,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tricyclic; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dibenzazepines; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Membrane Transport Modulators; Muscarinic Antagonists; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Tricyclics and Other Norepinephrine-reuptake Inhibitors"
DB01152,Candicidin,1403-17-4,approved; withdrawn,OPGSFDUODIJJGF-JBUZINEHSA-N,"InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-56(74)54(61)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)/b6-5+,9-7+,10-8+,13-11+,14-12+,18-15+,21-16+/t35?,36?,37?,38-,43?,44?,45?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59?/m1/s1",Nc1ccc(cc1)C(=O)CC(O)C(C)CC(C)C2OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC(=O)CC(O)C(C(=O)O)C(O)CC(OC3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C2C,C59H84N2O18,C06690,D03347,,46504812,3349,CHEMBL1200647,,8255412,,1109.317,-0.028119118,Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Lactones; Macrocyclic Compounds; Macrolides; Polycyclic Compounds; Polyketides
DB01153,Sertaconazole,99592-32-2,approved; investigational,JLGKQTAYUIMGRK-UHFFFAOYSA-N,"InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2",Clc1cc(Cl)ccc1C(Cn2cncc2)OCc3csc(c34)c(Cl)ccc4,C20H15Cl3N2OS,,,65863,46507290,83682,CHEMBL1201196,,59273,50051842,437.77,6.22834848,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Azole Antifungals; Azoles; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole and Triazole Derivatives; Imidazole Derivatives; Sulfur Compounds"
DB01154,Thiamylal,77-27-0,approved; vet_approved,XLOMZPUITCYLMJ-UHFFFAOYSA-N,"InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)",CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O,C12H18N2O2S,C07846,D06106,3032285,46506261,9536,CHEMBL440,,2297298,,254.349,2.92370151,"Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Anticonvulsants; Barbiturates; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Psycholeptics; Pyrimidines; Pyrimidinones; Thiobarbiturates"
DB01155,Gemifloxacin,175463-14-6,approved; investigational,ZRCVYEYHRGVLOC-HYARGMPZSA-N,"InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+",CO/N=C1\CN(CC1CN)c(c(F)c2)nc(c23)n(C4CC4)cc(c3=O)C(=O)O,C18H20FN5O4,,D08012,9571107,46507905,101853,CHEMBL430,,7845573,50178917,389.3809,-0.918424387,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; Naphthyridines; QTc Prolonging Agents; Quinolines; Quinolone Antimicrobial; Quinolones; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB01156,Bupropion,34911-55-2,approved,SNPPWIUOZRMYNY-UHFFFAOYSA-N,"InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3",CC(C)(C)NC(C)C(=O)c1cc(Cl)ccc1,C13H18ClNO,C06860,D07591,444,46506896,3219,CHEMBL894,,431,50048392,239.741,3.266112452,"Agents that reduce seizure threshold; Aminoketone; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antiobesity Preparations, Excl. Diet Products; Central Nervous System Agents; Central Nervous System Depressants; Centrally Acting Antiobesity Products; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Uptake Inhibitors; Drug-Related Side Effects and Adverse Reactions; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Increased Dopamine Activity; Increased Norepinephrine Activity; Ketones; Metabolic Side Effects of Drugs and Substances; Miscellaneous Antidepressants; Nervous System; Neurotransmitter Uptake Inhibitors; Norepinephrine Uptake Inhibitors; OCT2 Inhibitors; Photosensitizing Agents; Psychoanaleptics; Psychotropic Drugs; Smoking Cessation Agents"
DB01157,Trimetrexate,52128-35-5,approved; investigational,NOYPYLRCIDNJJB-UHFFFAOYSA-N,"InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)",COc1c(OC)cc(cc1OC)NCc(cc2)c(C)c(c23)c(N)nc(n3)N,C19H23N5O3,C11154,D06238,5583,46505247,9737,CHEMBL119,TMQ,5381,18268,369.4176,2.278113019,"Acids, Acyclic; Acids, Aldehydic; Anti-Infective Agents; Antimetabolites; Antineoplastic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Carbohydrates; Carboxylic Acids; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Folic Acid Antagonists; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxy Acids; Narrow Therapeutic Index Drugs; Noxae; Pharmaceutical Preparations; Quinazolines; Sugar Acids; Toxic Actions; Uronic Acids"
DB01158,Bretylium,59-41-6,approved,AAQOQKQBGPPFNS-UHFFFAOYSA-N,"InChI=1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1",CC[N+](C)(C)Cc1ccccc1Br,C11H17BrN,C06855,D00645,2431,46505320,3172,CHEMBL1199080,,2337,50239966,243.163,-1.122133453,"Adrenergic Agents; Adrenergic Antagonists; Amines; Ammonium Compounds; Antiarrhythmic agents; Antiarrhythmics, Class III; Antihypertensive Agents; Benzylammonium Compounds; Bradycardia-Causing Agents; Bretylium Compounds; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Hypotensive Agents; Medications that reduce magnesium levels; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quaternary Ammonium Compounds"
DB01159,Halothane,151-67-7,approved; vet_approved,BCQZXOMGPXTTIC-UHFFFAOYSA-N,"InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H",ClC(Br)C(F)(F)F,C2HBrClF3,C07515,D00542,3562,46506589,5615,CHEMBL931,HLT,3441,50112212,197.382,2.11935513,"Agents that produce hypertension; Anesthetics; Anesthetics, General; Anesthetics, Inhalation; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Halogenated; Hypotensive Agents; Nervous System; NMDA Receptor Antagonists"
DB01160,Dinoprost tromethamine,38562-01-5,approved; vet_approved,IYGXEHDCSOYNKY-RZHHZEQLSA-N,"InChI=1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1",CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O,C24H45NO8,C12786,D01352,5282415,46509164,31502,CHEMBL1200896,,4445570,,475.616,2.611054417,"Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Angiography; Autacoids; Biological Factors; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Inflammation Mediators; Lipids; Prostaglandins; Prostaglandins F; Reproductive Control Agents; Uterotonic agents"
DB01161,Chloroprocaine,133-16-4,approved,VDANGULDQQJODZ-UHFFFAOYSA-N,"InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3",CCN(CC)CCOC(=O)c1c(Cl)cc(N)cc1,C13H19ClN2O2,C07877,D07678,8612,46508245,3636,CHEMBL1179047,,8293,50239963,270.755,2.484101934,"Acids, Carbocyclic; Aminobenzoates; Anesthetics; Anesthetics, Local; Anticholinergic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase substrates; Esters of Aminobenzoic Acid; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Local Anesthesia; Local Anesthetics (Ester); Nervous System; Nicotinic Antagonists; NMDA Receptor Antagonists; para-Aminobenzoates; Peripheral Nervous System Agents; Sensory System Agents"
DB01162,Terazosin,63590-64-7,approved,VCKUSRYTPJJLNI-UHFFFAOYSA-N,"InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)",COc(c1)c(OC)cc(c12)c(N)nc(n2)N3CCN(CC3)C(=O)C4CCCO4,C19H25N5O4,C07127,D08569,5401,46509129,9445,CHEMBL611,,5208,50033111,387.4329,1.179727592,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Drugs Used in Benign Prostatic Hypertrophy; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Neurotransmitter Agents; P-glycoprotein inhibitors; Peripheral alpha-1 blockers; Quinazolines; Urological Agents; Urologicals"
DB01164,Calcium chloride,10043-52-4,approved,UXVMQQNJUSDDNG-UHFFFAOYSA-L,InChI=1S/Ca.2ClH/h;2*1H/q+2;;/p-2,[Cl-],CaCl2,C08130,,5284359,46507257,3312,CHEMBL1200668,,23237,,110.984,-0.57,"Acidifiers; Acids; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Anions; Blood and Blood Forming Organs; Blood Coagulation Factors; Blood Substitutes and Perfusion Solutions; Calcium Compounds; Calcium Salts; Chlorides; Chlorine Compounds; Electrolyte Solutions; Electrolytes; Genito Urinary System and Sex Hormones; Hemodialysis Solution; I.V. Solution Additives; Ions; Mineral Supplements; Phosphate Binder; Replacement Preparations; Supplements; Urologicals"
DB01165,Ofloxacin,82419-36-1,approved,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,"InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)",C1CN(C)CCN1c(c(c2n34)OCC3C)c(F)cc2c(=O)c(c4)C(=O)O,C18H20FN3O4,C07321,D00453,4583,46507574,7731,CHEMBL4,,4422,50045004,361.3675,0.654279753,"Agents Causing Muscle Toxicity; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; BSEP/ABCB11 Substrates; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Metabolic Side Effects of Drugs and Substances; Moderate Risk QTc-Prolonging Agents; OAT1/SLC22A6 inhibitors; Ophthalmologicals; Otologicals; QTc Prolonging Agents; Quinolines; Quinolone Antimicrobial; Quinolones; Renal Agents; Sensory Organs; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB01166,Cilostazol,73963-72-1,approved; investigational,RRGUKTPIGVIEKM-UHFFFAOYSA-N,"InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)",O=C(N1)CCc(c12)cc(cc2)OCCCCc3nnnn3C4CCCCC4,C20H27N5O2,,D01896,2754,46506317,31401,CHEMBL799,,2652,50225508,369.4607,3.305566183,"Agents producing tachycardia; Anti-Asthmatic Agents; Antiplatelet agents; Autonomic Agents; Azoles; Blood and Blood Forming Organs; Bronchodilator Agents; Cardiovascular Agents; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Fibrin Modulating Agents; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Neuroprotective Agents; Peripheral Nervous System Agents; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors Excl. Heparin; Potential QTc-Prolonging Agents; Protective Agents; QTc Prolonging Agents; Quinolines; Respiratory System Agents; Tetrazoles; Vasodilating Agents"
DB01167,Itraconazole,84625-61-6,approved; investigational,VHVPQPYKVGDNFY-ZPGVKDDISA-N,"InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1",CCC(C)n1ncn(c1=O)-c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OC[C@@H](CO5)O[C@@]5(Cn6cncn6)c7ccc(Cl)cc7Cl,C35H38Cl2N8O4,,D00350,55283,46505954,6076,CHEMBL22587,,49927,50127138,705.633,7.31137112,"14-alpha Demethylase Inhibitors; Agents causing hyperkalemia; Anti-Infective Agents; Antifungal Agents; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; Azole Antifungals; Azoles; Breast Cancer Resistance Protein Inhibitors; Chemically-Induced Disorders; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strong); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strong); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Metabolic Side Effects of Drugs and Substances; P-glycoprotein inhibitors; Photosensitizing Agents; Piperazines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Steroid Synthesis Inhibitors; Triazole Derivatives; Triazoles"
DB01168,Procarbazine,671-16-9,approved; investigational,CPTBDICYNRMXFX-UHFFFAOYSA-N,"InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)",CNNCc1ccc(cc1)C(=O)NC(C)C,C12H19N3O,C07402,D08423,4915,46507706,71417,CHEMBL1321,,4746,,221.2988,0.985734243,"Acids, Carbocyclic; Agents Causing Muscle Toxicity; Alkylating Activity; Alkylating Drugs; Amides; Antidepressive Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BEACOPP chemotherapy regimen; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Depressants; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Methylhydrazines; Monoamine Oxidase Inhibitors; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB01169,Arsenic trioxide,1327-53-3,approved; investigational,IKWTVSLWAPBBKU-UHFFFAOYSA-N,InChI=1S/As2O3/c3-1-5-2-4,O=[As]O[As]=O,As2O3,,D02106,261004,46506448,,CHEMBL1200978,,229103,,197.84,1.0684,Anions; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Arsenicals; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Electrolytes; Highest Risk QTc-Prolonging Agents; Hyperglycemia-Associated Agents; Hypotensive Agents; Immunosuppressive Agents; Ions; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Organometallic Compounds; Oxides; Oxygen Compounds; P-glycoprotein substrates; QTc Prolonging Agents
DB01170,Guanethidine,55-65-2,approved,ACGDKVXYNVEAGU-UHFFFAOYSA-N,"InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)",NC(N)=NCCN1CCCCCCC1,C10H22N4,C07036,D02237,3518,46507567,5557,CHEMBL765,,3398,50239969,198.3085,0.744985035,"Adrenergic Agents; Adrenergic Antagonists; Amidines; Antiadrenergic Agents, Peripherally Acting; Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Autonomic Agents; Cardiovascular Agents; Cardiovascular System; Catecholamine-depleting Sympatholytic; Drugs that are Mainly Renally Excreted; Gastrointestinal Acidifying Agents; Guanidine Derivatives; Guanidine Derivatives and Diuretics; Guanidines; Neurotransmitter Agents; Ophthalmologicals; Peripheral Nervous System Agents; Sensory Organs; Sympatholytics"
DB01171,Moclobemide,71320-77-9,approved; investigational,YHXISWVBGDMDLQ-UHFFFAOYSA-N,"InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)",Clc1ccc(cc1)C(=O)NCCN2CCOCC2,C13H17ClN2O2,,D02561,4235,46504667,83531,CHEMBL86304,,4087,15613,268.739,1.451750923,"Acids, Carbocyclic; Agents that produce hypertension; Agents that reduce seizure threshold; Amides; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Chlorobenzoates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Monoamine Oxidase A Inhibitors; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Monoamine Oxidase Inhibitors; Nervous System; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB01172,Kanamycin,59-01-8,approved; investigational; vet_approved,SBUJHOSQTJFQJX-NOAMYHISSA-N,"InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1",NC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)O[C@@H]2[C@@H](N)C[C@@H](N)[C@@H]([C@H]2O)O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O,C18H36N4O11,C01822,,6032,46508178,17630,CHEMBL1384,KAN,5810,50031282,484.4986,-7.060913449,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antiinfectives for Systemic Use; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Enzyme Inhibitors; Glycosides; Intestinal Antiinfectives; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Ophthalmologicals; Protein Synthesis Inhibitors; Sensory Organs"
DB01173,Orphenadrine,83-98-7,approved,QVYRGXJJSLMXQH-UHFFFAOYSA-N,"InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3",c1ccccc1C(OCCN(C)C)c2ccccc2C,C18H23NO,C07935,D08305,4601,46506085,7789,CHEMBL900,,4440,50062614,269.3813,4.165328651,"Agents producing tachycardia; Amines; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Anticholinergic Agents; Autonomic Agents; Benzene Derivatives; Benzhydryl Compounds; Central Nervous System Agents; Central Nervous System Depressants; Centrally-mediated Muscle Relaxation; Chemically-Induced Disorders; Cholinergic Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strong); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Ethers, Chemically Close to Antihistamines; Ethylamines; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Metabolic Side Effects of Drugs and Substances; Miscellaneous Skeletal Muscle Relaxants; Muscarinic Antagonists; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System; Nervous System; Neurotransmitter Agents; NMDA Receptor Antagonists; Parasympatholytics; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB01174,Phenobarbital,50-06-6,approved; investigational,DDBREPKUVSBGFI-UHFFFAOYSA-N,"InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)",c1ccccc1C2(CC)C(=O)NC(=O)NC2=O,C12H12N2O3,C07434,D00506,4763,46505776,8069,CHEMBL40,,4599,50021437,232.2353,1.406330128,"Anticholinergic Agents; Anticonvulsants; Barbiturates; Barbiturates and Derivatives; BSEP/ABCB11 inducers; Central Nervous System Agents; Central Nervous System Depressants; Chemically-Induced Disorders; Cytochrome P-450 2C18 Inducers; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strong); Cytochrome P-450 CYP2C18 Inducers (strength unknown); Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers (strong); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Inducers (weak); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strong); Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP3A7 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Enzyme Inducing Antiepileptic Drugs; Excitatory Amino Acid Agents; Excitatory Amino Acid Antagonists; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Medications that reduce magnesium levels; Metabolic Side Effects of Drugs and Substances; Methemoglobinemia Associated Agents; Narrow Therapeutic Index Drugs; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; P-glycoprotein inducers; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Phenobarbital and similars; Psycholeptics; Pyrimidines; Pyrimidinones; UGT1A1 Inducers; UGT2B7 inducers"
DB01175,Escitalopram,128196-01-0,approved,WSEQXVZVJXJVFP-FQEVSTJZSA-N,"InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1",Fc1ccc(cc1)[C@]2(CCCN(C)C)OCc(c23)cc(C#N)cc3,C20H21FN2O,,,146570,46507040,36791,CHEMBL1508,68P,129277,50302225,324.3919,3.764304206,"Amines; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Second-Generation; Benzofurans; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Nitriles; P-glycoprotein substrates; Photosensitizing Agents; Propylamines; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB01176,Cyclizine,82-92-8,approved,UVKZSORBKUEBAZ-UHFFFAOYSA-N,"InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3",c1ccccc1C(N2CCN(C)CC2)c3ccccc3,C18H22N2,C06930,D03621,6726,46506232,3994,CHEMBL648,,6470,,266.3807,3.546002349,"Antiemetics; Antihistamines for Systemic Use; Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Neurotransmitter Agents; Peripheral Nervous System Agents; Piperazine Derivatives; Piperazines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB01177,Idarubicin,58957-92-9,approved,XDXDZDZNSLXDNA-TZNDIEGXSA-N,"InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1",O[C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]2C[C@](O)(C(=O)C)Cc(c23)c(O)c4c(c3O)C(=O)c5c(C4=O)cccc5,C26H27NO9,,,42890,46506973,42068,CHEMBL1117,DM5,39117,58490,497.4939,1.897998287,"Anthracycline Topoisomerase Inhibitor; Anthracyclines; Anthracyclines and Related Substances; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carbohydrates; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Cytotoxic Antibiotics and Related Substances; Enzyme Inhibitors; Glycosides; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Myelosuppressive Agents; Naphthacenes; Narrow Therapeutic Index Drugs; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB01178,Chlormezanone,80-77-3,approved; investigational; withdrawn,WEQAYVWKMWHEJO-UHFFFAOYSA-N,"InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3",O=S1(=O)CCC(=O)N(C)C1c2ccc(Cl)cc2,C11H12ClNO3S,,D00268,2717,46505352,3619,CHEMBL1200714,,2616,,273.736,0.91716743,"Anti-Anxiety Agents; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Oxazol, Thiazine, and Triazine Derivatives; Peripheral Nervous System Agents; Psychotropic Drugs; Sulfur Compounds; Thiazines; Tranquilizing Agents"
DB01179,Podofilox,518-28-5,approved,YJGVMLPVUAXIQN-XVVDYKMHSA-N,"InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1",COc1c(OC)cc(cc1OC)[C@@H]2c(cc3c(c4)OCO3)c4[C@H](O)[C@H]([C@@H]25)COC5=O,C22H22O8,C10874,,10607,46505716,50305,CHEMBL61,POD,10162,50035218,414.4053,1.622798269,"Antimitotic Agents; Antineoplastic Agents, Phytogenic; Antiviral Agents; Benzene Derivatives; Benzyl Compounds; Decreased Mitosis; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Keratolytic Agents; Lignans; Misc. Skin and Mucous Membrane Agents; Mitosis Modulators; Naphthalenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Tetrahydronaphthalenes; Tubulin Modulators"
DB01180,Rescinnamine,24815-24-5,approved,SZLZWPPUNLXJEA-QEGASFHISA-N,"InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1",COc1c(OC)cc(cc1OC)/C=C/C(=O)O[C@@H]([C@H](OC)[C@H]2C(=O)OC)C[C@@H]([C@@H]23)CN4[C@H](C3)c5c(CC4)c6c([nH]5)cc(cc6)OC,C35H42N2O9,C06540,D00198,32681,46507786,28572,CHEMBL1668,,4444446,,634.716,4.070086812,"Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Agents that produce hypertension; Alkaloids; Angiotensin-Converting Enzyme Inhibitors; Antiadrenergic Agents, Centrally Acting; Antihypertensive Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indole Alkaloids; Indoles; Secologanin Tryptamine Alkaloids"
DB01181,Ifosfamide,3778-73-2,approved,HOMGKSMUEGBAAB-UHFFFAOYSA-N,"InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)",ClCCNP1(=O)OCCCN1CCCl,C7H15Cl2N2O2P,C07047,D00343,3690,46508335,5864,CHEMBL1024,,3562,189358,261.086,0.096547687,"Acids; Acids, Noncarboxylic; Alkylating Activity; Alkylating Drugs; Anions; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Electrolytes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Halogenated; Immunosuppressive Agents; Ions; Methemoglobinemia Associated Agents; Mustard Compounds; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nitrogen Mustard Analogues; Nitrogen Mustard Compounds; Noxae; Organophosphorus Compounds; Oxazines; Phosphoramide Mustards; Phosphoramides; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Toxic Actions"
DB01182,Propafenone,54063-53-5,approved,JWHAUXFOSRPERK-UHFFFAOYSA-N,"InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3",CCCNCC(O)COc1c(cccc1)C(=O)CCc2ccccc2,C21H27NO3,C07381,D08435,4932,46504529,63619,CHEMBL631,,4763,50067133,341.444,3.536722546,"Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Agents that produce hypertension; Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ic; Bradycardia-Causing Agents; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ketones; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; P-glycoprotein inhibitors; Propiophenones; QTc Prolonging Agents; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB01183,Naloxone,465-65-6,approved; vet_approved,UZHSEJADLWPNLE-GRGSLBFTSA-N,"InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1",[C@]123[C@H]4Oc5c1c(ccc5O)C[C@@H](N(CC2)CC=C)[C@]3(O)CCC4=O,C19H21NO4,C07252,D08249,5284596,46508816,7459,CHEMBL80,,4447644,54795,327.3743,1.62022116,"Alimentary Tract and Metabolism; Alkaloids; Analgesics; Antidotes; Central Nervous System Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Narcotics; Natural Opium Alkaloids; Nervous System; Opiate Alkaloids; Opiate Antagonists; Opioid Antagonists; P-glycoprotein substrates; Peripheral Nervous System Agents; Peripheral Opioid Receptor Antagonists; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; UGT1A1 Substrates"
DB01184,Domperidone,57808-66-9,approved; investigational; vet_approved,FGXWKSZFVQUSTL-UHFFFAOYSA-N,"InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)",c1cc(Cl)cc(c12)[nH]c(=O)n2C3CCN(CC3)CCCn4c(=O)[nH]c(c45)cccc5,C22H24ClN5O2,,D01745,3151,46508314,31515,CHEMBL219916,,3039,50241107,425.911,2.900103093,"Alimentary Tract and Metabolism; Antiemetics; Autonomic Agents; Benzimidazoles; Central Nervous System Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs for Functional Gastrointestinal Disorders; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Neurotransmitter Agents; P-glycoprotein substrates; Peripheral Nervous System Agents; Piperidines; Prokinetic Agents; Propulsives; QTc Prolonging Agents"
DB01185,Fluoxymesterone,76-43-7,approved; illicit,YLRFCQOZQXIBAB-RBZZARIASA-N,"InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1",C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)CC4,C20H29FO3,,D00327,6446,46508867,5120,CHEMBL1445,,6205,18189,336.4409,2.380842098,"3-Oxoandrosten (4) Derivatives; Anabolic Agents; Androgens; Androstanes; Androstenediols; Androstenes; Androstenols; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Sex Hormones and Modulators of the Genital System; Steroids; Steroids, Fluorinated"
DB01186,Pergolide,66104-22-1,approved; investigational; vet_approved; withdrawn,YEHCICAEULNIGD-MZMPZRCHSA-N,"InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1",CSC[C@H](C1)CN(CCC)[C@@H]([C@H]12)Cc3c4c2cccc4[nH]c3,C19H26N2S,C07425,,47811,46507604,63617,CHEMBL531,,43503,50028421,314.488,4.225289858,"Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alkaloids; Anti-Parkinson Drugs; Antidepressive Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dopamine Agents; Dopamine Agonists; Ergolines; Ergot Alkaloids and Derivatives; Ergot-derivative Dopamine Receptor Agonists; Ergot-derived Dopamine Receptor Agonist; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotransmitter Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Agonists; Serotonin Agents; Serotonin Receptor Agonists"
DB01187,Iophendylate,99-79-6,approved,IWRUDYQZPTVTPA-UHFFFAOYSA-N,"InChI=1S/C19H29IO2/c1-3-22-19(21)15-9-7-5-4-6-8-12-16(2)17-13-10-11-14-18(17)20/h10-11,13-14,16H,3-9,12,15H2,1-2H3",CCOC(=O)CCCCCCCCC(C)c1ccccc1I,C19H29IO2,,,3037234,46508391,,CHEMBL951,,2301035,,416.3368,6.886209011,"Benzene Derivatives; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Hydrocarbons, Iodinated; Iodobenzenes; Non-Watersoluble X-Ray Contrast Media; X-Ray Contrast Media, Iodinated"
DB01188,Ciclopirox,29342-05-0,approved; investigational,SCKYRAXSEDYPSA-UHFFFAOYSA-N,"InChI=1S/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3",Cc1cc(=O)n(O)c(c1)C2CCCCC2,C12H17NO2,,D03488,2749,46506333,453011,CHEMBL1413,B4O,2647,66087,207.2689,2.216589469,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Cyclohexanes; Cycloparaffins; Decreased DNA Replication; Decreased Protein Synthesis; Decreased RNA Replication; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydroxypyridones; Macrocyclic Compounds; Polycyclic Compounds; Protein Synthesis Inhibitors; Pyridines; Pyridones; Vaginal Creams, Foams, and Jellies"
DB01189,Desflurane,57041-67-5,approved,DPYMFVXJLLWWEU-UHFFFAOYSA-N,"InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H",FC(F)OC(F)C(F)(F)F,C3H2F6O,C07519,D00546,42113,46505270,4445,CHEMBL1200733,,38403,,168.0378,2.402510823,"Agents that produce hypertension; Anesthetics; Anesthetics, General; Anesthetics, Inhalation; Central Nervous System Agents; Central Nervous System Depressants; Ethers; Ethyl Ethers; Hydrocarbons; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Hypotensive Agents; Methyl Ethers; Nervous System; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB01190,Clindamycin,18323-44-9,approved; vet_approved,KDLRVYVGXIQJDK-NOWPCOIGSA-N,"InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1",CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(Cl)C)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,C18H33ClN2O5S,C06914,D00277,446598,46506073,3745,CHEMBL376185,CLY,27005,,424.98,1.03773764,"Agents that produce neuromuscular block (indirect); Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Pneumocystis Pneumonia; Antiinfectives for Systemic Use; Antiinfectives for Treatment of Acne; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Sebaceous Gland Activity; Dermatologicals; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Glycosides; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lincomycins; Lincosamide Antibacterial; Lincosamides; Macrolides; Macrolides, Lincosamides and Streptogramins; Neurotoxic agents; P-glycoprotein substrates; Protein Synthesis Inhibitors; Pyrrolidines"
DB01191,Dexfenfluramine,3239-44-9,approved; illicit; investigational; withdrawn,DBGIVFWFUFKIQN-VIFPVBQESA-N,"InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3/t9-/m0/s1",CCN[C@@H](C)Cc1cccc(c1)C(F)(F)F,C12H16F3N,,D07805,66265,46508388,439329,CHEMBL248702,,59646,85596,231.2573,3.471487312,"Alimentary Tract and Metabolism; Amines; Antidepressive Agents; Antiobesity Preparations, Excl. Diet Products; Central Nervous System Depressants; Centrally Acting Antiobesity Products; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ethylamines; Neurotransmitter Agents; Phenethylamines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents"
DB01192,Oxymorphone,76-41-5,approved; investigational; vet_approved,UQCNKQCJZOAFTQ-ISWURRPUSA-N,"InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1",[C@]123[C@H]4Oc5c1c(ccc5O)C[C@@H](N(C)CC2)[C@]3(O)CCC4=O,C17H19NO4,C08019,D08323,5284604,46505296,7865,CHEMBL963,,4447650,50001707,301.3371,0.784873473,"Adjuvants; Adjuvants, Anesthesia; Alkaloids; Analgesics; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; High-risk opioids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Morphine Derivatives; Narcotics; Opiate Agonists; Opiate Alkaloids; Opioid Agonist; Opioids; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB01193,Acebutolol,37517-30-9,approved; investigational,GOEMGAFJFRBGGG-UHFFFAOYSA-N,"InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)",CCCC(=O)Nc1ccc(c(c1)C(=O)C)OCC(O)CNC(C)C,C18H28N2O4,C06803,D02338,1978,46509113,2379,CHEMBL642,,1901,25755,336.4259,1.534681571,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Autonomic Agents; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Selective; Beta Blocking Agents, Selective, and Thiazides; Beta-Blockers (Beta1 Selective); Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hypotensive Agents; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; P-glycoprotein substrates; Peripheral Nervous System Agents; Phenoxypropanolamines; Propanolamines; Propanols; QTc Prolonging Agents; Sympathomimetics"
DB01194,Brinzolamide,138890-62-7,approved,HCRKCZRJWPKOAR-JTQLQIEISA-N,"InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1",NS(=O)(=O)c(c1)sc(c12)S(=O)(=O)N(C[C@@H]2NCC)CCCOC,C12H21N3O5S3,C07760,D00652,68844,46507071,3176,CHEMBL220491,BZ1,62077,10885,383.507,-0.674520267,"Amides; Antiglaucoma Preparations and Miotics; Carbonic Anhydrase Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diuretics; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Ophthalmics; Ophthalmologicals; Sensory Organs; Sulfonamides; Sulfones; Sulfur Compounds"
DB01195,Flecainide,54143-55-4,approved; withdrawn,DJBNUMBKLMJRSA-UHFFFAOYSA-N,"InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)",FC(F)(F)COc1cc(c(cc1)OCC(F)(F)F)C(=O)NCC2CCCCN2,C17H20F6N2O3,C07001,D07962,3356,46508078,75984,CHEMBL652,,3239,50131434,414.3427,3.188141905,"Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ic; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Inhibitors; MATE 1 Substrates; MATE inhibitors; MATE substrates; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; Piperidines; QTc Prolonging Agents; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB01196,Estramustine,2998-57-4,approved; investigational,FRPJXPJMRWBBIH-RBRWEJTLSA-N,"InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1",O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(cc4)OC(=O)N(CCCl)CCCl,C23H31Cl2NO3,C11228,D04066,259331,46508765,4868,CHEMBL1575,,227635,50333646,440.403,5.09911391,"Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Estradiol Congeners; Estranes; Estrenes; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Halogenated; Immunosuppressive Agents; Mustard Compounds; Nitrogen Mustard Compounds; Noxae; P-glycoprotein inhibitors; Polycyclic Compounds; Steroids; Toxic Actions"
DB01197,Captopril,62571-86-2,approved,FAKRSMQSSFJEIM-RQJHMYQMSA-N,"InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1",SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,C9H15NO3S,,D00251,44093,46506879,3380,CHEMBL1560,X8Z,40130,21642,217.285,0.726921231,"ACE Inhibitors and Diuretics; Acids, Acyclic; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Agents Causing Muscle Toxicity; Amino Acids; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Hypotensive Agents; Imines; Imino Acids; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; P-glycoprotein inhibitors; Photosensitizing Agents; Protease Inhibitors"
DB01198,Zopiclone,43200-80-2,approved,GBBSUAFBMRNDJC-UHFFFAOYSA-N,"InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3",CN1CCN(CC1)C(=O)OC2N(C(=O)c(c23)nccn3)c4ncc(Cl)cc4,C17H17ClN6O3,,D01372,5735,46505233,32315,CHEMBL135400,,5533,50054136,388.808,0.806543033,"Aza Compounds; Benzodiazepine hypnotics and sedatives; Bicyclo Compounds, Heterocyclic; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Bridged-Ring; Hypnotics (Nonbenzodiazepine); Hypnotics and Sedatives; Methemoglobinemia Associated Agents; Miscellaneous Anxiolytics Sedatives and Hypnotics; Nervous System; Photosensitizing Agents; Psycholeptics; Sleep Initiation and Maintenance Disorders; Zopiclone and prodrugs"
DB01199,Tubocurarine,57-95-4,approved,JFJZZMVDLULRGK-URLMMPGGSA-O,"InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1",C1CN(C)[C@H](c2c13)Cc4ccc(cc4)Oc5c6c(cc(c5O)OC)CC[N+](C)(C)[C@@H]6Cc7cc(c(O)cc7)Oc(c2)c(c3)OC,C37H41N2O6,C07547,,6000,46505279,9774,CHEMBL339427,,5778,50366799,609.7312,3.144135108,"Alkaloids; Amines; Ammonium Compounds; Anticholinergic Agents; Benzylisoquinolines; Central Nervous System Depressants; Cholinergic Agents; Cholinesterase Inhibitors; Cholinesterase substrates; Curare Alkaloids; Ganglion Blockers; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular-Blocking Agents (Nondepolarizing); Neurotoxic agents; Neurotransmitter Agents; Nicotinic Antagonists; Nitrogen Compounds; OCT1 substrates; Onium Compounds; Peripheral Nervous System Agents; Quaternary Ammonium Compounds; Tetrahydroisoquinolines"
DB01200,Bromocriptine,25614-03-3,approved; investigational,OZVBMTJYIDMWIL-AYFBDAFISA-N,"InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1",C1CCN([C@@H]1[C@@]23O)C(=O)[C@H](CC(C)C)N2C(=O)[C@](O3)(C(C)C)NC(=O)[C@H](C=4)CN(C)[C@@H](C45)Cc6c7c5cccc7[nH]c6Br,C32H40BrN5O5,C06856,D03165,31101,46505504,3181,CHEMBL493,08Y,28858,81993,654.595,3.887167808,"Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Alkaloids; Anti-Dyskinesia Agents; Anti-Parkinson Agents (Dopamine Agonist); Anti-Parkinson Drugs; Antidepressive Agents; Blood Glucose Lowering Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Ergolines; Ergot Alkaloids and Derivatives; Ergot-derivative Dopamine Receptor Agonists; Ergotamines; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypotensive Agents; Nervous System; Neurotransmitter Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Prolactine Inhibitors; Serotonin 5-HT2 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists"
DB01201,Rifapentine,61379-65-5,approved; investigational,WDZCUPBHRAEYDL-GZAUEHORSA-N,"InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1",C[C@@]12O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(=O)C)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)C(=O)Nc3c(O)c4c(c(C1=O)c(O2)c(C)c4O)c(O)c3/C=N/N5CCN(CC5)C6CCCC6,C47H64N4O12,C08059,D00879,6323497,46507322,45304,CHEMBL1660,RPT,10482075,,877.0307,3.556884556,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strong); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs for Treatment of Tuberculosis; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Lactams, Macrocyclic; Leprostatic Agents; Macrocyclic Compounds; Polycyclic Compounds; Rifamycin Antimycobacterial; Rifamycins"
DB01202,Levetiracetam,102767-28-2,approved,HPHUVLMMVZITSG-LURJTMIESA-N,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",CC[C@@H](C(=O)N)N1CCCC1=O,C8H14N2O2,C07841,D00709,5284583,46508406,6437,CHEMBL1286,,4447633,50422542,170.212,-0.593605901,"Acetamides; Amides; Anticonvulsants; Central Nervous System Agents; Central Nervous System Depressants; Decreased Central Nervous System Disorganized Electrical Activity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Miscellaneous Anticonvulsants; Nervous System; P-glycoprotein substrates; Pyrrolidines; Pyrrolidinones"
DB01203,Nadolol,42200-33-9,approved,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,"InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1",CC(C)(C)NCC(O)COc1cccc(c12)C[C@@H](O)[C@H](C2)O,C17H27NO4,,D00432,39147,46505509,7444,CHEMBL649,,35815,25766,309.4006,0.865427913,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Autonomic Agents; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Non-Selective; Beta Blocking Agents, Non-Selective, and Thiazides; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Hypotensive Agents; MATE 1 Substrates; MATE 2 Substrates; MATE substrates; Neurotransmitter Agents; P-glycoprotein substrates; Peripheral Nervous System Agents; Phenoxypropanolamines; Photosensitizing Agents; Propanolamines; Propanols; Sympatholytics"
DB01204,Mitoxantrone,65271-80-9,approved; investigational,KKZJGLLVHKMTCM-UHFFFAOYSA-N,"InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2",Oc1ccc(O)c(c12)C(=O)c3c(C2=O)c(NCCNCCO)ccc3NCCNCCO,C22H28N4O6,C11195,D08224,4212,46504608,50729,CHEMBL58,MIX,4067,67690,444.4809,0.651458476,"Analgesics; Anthracenes; Anthracyclines and Related Substances; Anthraquinones; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Cardiotoxic antineoplastic agents; Central Nervous System Agents; Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Cytotoxic Antibiotics and Related Substances; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Peripheral Nervous System Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quinones; Sensory System Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB01205,Flumazenil,78755-81-4,approved,OFBIFZUFASYYRE-UHFFFAOYSA-N,"InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3",CCOC(=O)c(nc1)c(n12)CN(C)C(=O)c3c2ccc(F)c3,C15H14FN3O3,C07825,D00697,3373,46507438,5103,CHEMBL407,FYP,3256,26263,303.2884,0.3279,"Antidotes; Benzazepines; Benzodiazepine Antagonist; Benzodiazepinones; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Miscellaneous Central Nervous System Agents; Neurotransmitter Agents; Protective Agents"
DB01206,Lomustine,13010-47-4,approved; investigational,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,"InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)",ClCCN(N=O)C(=O)NC1CCCCC1,C9H16ClN3O2,C07079,D00363,3950,46506562,6520,CHEMBL514,,3813,50247919,233.695,2.15743697,"Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nitroso Compounds; Nitrosourea Compounds; Nitrosoureas; Noxae; Toxic Actions"
DB01208,Sparfloxacin,110871-86-8,approved; investigational; withdrawn,DZZWHBIBMUVIIW-DTORHVGOSA-N,"InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+",C[C@H]1CN(C[C@@H](C)N1)c(c2F)c(F)c(N)c(c23)c(=O)c(C(=O)O)cn3C4CC4,C19H22F2N4O3,C07662,D00590,60464,46506453,9212,CHEMBL850,,54517,50366822,392.3998,-0.043228147,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antituberculosis Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; P-glycoprotein substrates; QTc Prolonging Agents; Quinolines; Quinolones; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB01209,Dezocine,53648-55-8,approved; investigational,VTMVHDZWSFQSQP-VBNZEHGJSA-N,"InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1",C1CCCC[C@H]([C@@H]2N)Cc(c3[C@@]12C)ccc(O)c3,C16H23NO,C08010,D00838,3033053,46508770,4474,CHEMBL1685,,2297867,50276568,245.3599,3.23009643,"Analgesics; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthalenes; Narcotics; Nervous System; Opioid Antagonists; Opioids; Peripheral Nervous System Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB01210,Levobunolol,47141-42-4,approved,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,"InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1",CC(C)(C)NC[C@H](O)COc1cccc(c12)C(=O)CCC2,C17H25NO3,C07914,,39468,46507518,6438,CHEMBL1201237,,36089,,291.3853,2.182674693,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiglaucoma Preparations and Miotics; Autonomic Agents; Beta-adrenergic Agents; Bradycardia-Causing Agents; Bunolol; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Naphthalenes; Neurotransmitter Agents; Ophthalmologicals; Peripheral Nervous System Agents; Phenoxypropanolamines; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Propanolamines; Propanols; Sensory Organs; Sympatholytics; Tetrahydronaphthalenes"
DB01211,Clarithromycin,81103-11-9,approved,AGOYDEPGAOXOCK-KCBOHYOISA-N,"InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1",C[C@]1(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@@H]([C@@H](C)[C@@H]([C@@H](C)C(=O)O[C@@H]1CC)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C,C38H69NO13,C06912,D00276,84029,46506489,3732,CHEMBL1741,CTY,10342604,50404044,747.9534,3.239515351,"Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; BSEP/ABCB11 Substrates; Chemically-Induced Disorders; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strong); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Enzyme Inhibitors; Erythromycin and similars; Lactones; Macrocyclic Compounds; Macrolide Antimicrobial; Macrolides; Macrolides, Lincosamides and Streptogramins; Metabolic Side Effects of Drugs and Substances; Moderate Risk QTc-Prolonging Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Other Macrolides; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Polyketides; Protein Synthesis Inhibitors; QTc Prolonging Agents"
DB01212,Ceftriaxone,73384-59-5,approved,VAAUVRVFOQPIGI-SPQHTLEESA-N,"InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1",Nc1nc(cs1)/C(=N/OC)C(=O)N[C@H](C2=O)[C@H](N23)SCC(=C3C(=O)O)CSc4nc(=O)c(=O)[nH]n4C,C18H18N8O7S3,C06683,D07659,5479530,46506458,29007,CHEMBL161,,4586394,50103601,554.58,-1.872345184,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephacetrile; Cephalosporins; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; P-glycoprotein inhibitors; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB01213,Fomepizole,7554-65-6,approved; vet_approved,RIKMMFOAQPJVMX-UHFFFAOYSA-N,"InChI=1S/C4H6N2/c1-4-2-5-6-3-4/h2-3H,1H3,(H,5,6)",Cc1c[nH]nc1,C4H6N2,C07837,D00707,3406,46508566,5141,CHEMBL1308,4PZ,3289,50226186,82.1038,0.790851197,"Antidotes; Azoles; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Protective Agents; Pyrazoles"
DB01214,Metipranolol,22664-55-7,approved,BQIPXWYNLPYNHW-UHFFFAOYSA-N,"InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3",CC(C)NCC(O)COc1c(C)c(C)c(c(C)c1)OC(=O)C,C17H27NO4,C07915,D02374,31477,46505935,6897,CHEMBL1291,,29193,,309.4006,2.741744315,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Autonomic Agents; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Non-Selective, and Thiazides; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Hypotensive Agents; Neurotransmitter Agents; Ophthalmologicals; Peripheral Nervous System Agents; Phenoxypropanolamines; Propanolamines; Propanols; Sensory Organs; Sympatholytics"
DB01215,Estazolam,29975-16-4,approved; illicit,CDCHDCWJMGXXRH-UHFFFAOYSA-N,"InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2",c1ccccc1C(c(c23)cc(Cl)cc2)=NCc4n3cnn4,C16H11ClN4,C06981,D00311,3261,46507430,4858,CHEMBL285674,,3146,50240450,294.738,2.0913,"Anti-Anxiety Agents; Anticonvulsants; Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Photosensitizing Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents; Triazolobenzodiazepines"
DB01216,Finasteride,98319-26-7,approved,DBEPLOCGEIEOCV-WSBQPABSSA-N,"InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1",CC(C)(C)NC(=O)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)[C@@H](CC3)NC(=O)C=C4,C23H36N2O2,,D00321,57363,46507645,5062,CHEMBL710,FIT,51714,50334788,372.5441,3.073512023,"5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Androstanes; Androstenes; Azasteroids; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Drugs Used in Benign Prostatic Hypertrophy; Enzyme Inhibitors; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Misc. Skin and Mucous Membrane Agents; Polycyclic Compounds; Steroid Synthesis Inhibitors; Steroids; Steroids, Heterocyclic; Urological Agents; Urologicals"
DB01217,Anastrozole,120511-73-1,approved; investigational,YBBLVLTVTVSKRW-UHFFFAOYSA-N,"InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3",N#CC(C)(C)c1cc(C(C)(C)C#N)cc(c1)Cn2cncn2,C17H19N5,C08159,D00960,2187,46504987,2704,CHEMBL1399,,2102,10015,293.3663,3.028454822,"Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Aromatase Inhibitors; Azoles; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Endocrine Therapy; Enzyme Inhibitors; Estrogen Antagonists; Heterocyclic Compounds; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Medications that reduce magnesium levels; Nitriles; P-glycoprotein substrates; Steroid Synthesis Inhibitors; Triazoles; UGT1A3 substrates; UGT1A4 substrates; UGT2B7 substrates"
DB01218,Halofantrine,69756-53-2,approved,FOHHNHSLJDZUGQ-UHFFFAOYSA-N,"InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3",CCCCN(CCCC)CCC(O)c(c1)c(ccc(c2)C(F)(F)F)c2c(c13)cc(Cl)cc3Cl,C26H30Cl2F3NO,C07634,,37393,46506753,94392,CHEMBL1107,,34303,79214,500.424,8.056956757,"Agents that reduce seizure threshold; Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Highest Risk QTc-Prolonging Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; QTc Prolonging Agents"
DB01219,Dantrolene,7261-97-4,approved; investigational,OZOMQRBLCMDCEG-VIZOYTHASA-N,"InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+",[O-][N+](=O)c1ccc(cc1)-c2ccc(o2)/C=N/N3CC(=O)NC3=O,C14H10N4O5,C06939,D02347,6914273,46504976,4317,CHEMBL1201288,,5290202,50198767,314.257,1.256485485,"Agents causing hyperkalemia; Agents that produce neuromuscular block (indirect); Azoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; Dantrolene and Derivatives; Decreased Striated Muscle Contraction; Decreased Striated Muscle Tone; Direct-acting Skeletal Muscle Relaxants; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydantoins; Imidazoles; Imidazolidines; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Peripheral Nervous System Agents; Thyroxine-binding globulin substrates"
DB01220,Rifaximin,80621-81-4,approved; investigational,NZCRJKRKKOLAOJ-XRCRFVBUSA-N,"InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1",C[C@]12O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(=O)C)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)C(=O)Nc3c4c(nc5n4ccc(c5)C)c6c(c3O)c(O)c(C)c(O1)c6C2=O,C43H51N3O11,,D02554,6436173,46508705,75246,CHEMBL1617,RXM,10482302,50347620,785.8785,4.372090721,"Alimentary Tract and Metabolism; Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics for Topical Use; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strong); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Intestinal Antiinfectives; Lactams; Lactams, Macrocyclic; Macrocyclic Compounds; Polycyclic Compounds; Rifamycin Antibacterial; Rifamycins"
DB01221,Ketamine,6740-88-1,approved; vet_approved,YQEZLKZALYSWHR-UHFFFAOYSA-N,"InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3",C1CCCC(=O)C1(NC)c2ccccc2Cl,C13H16ClNO,C07525,D08098,3821,46508295,6121,CHEMBL742,,3689,50044140,237.725,3.347302666,"Agents producing tachycardia; Amino Acids; Amino Acids, Acidic; Amino Acids, Dicarboxylic; Amino Acids, Peptides, and Proteins; Analgesics; Anesthetics; Anesthetics, Dissociative; Anesthetics, General; Anesthetics, Intravenous; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase Inhibitors; Cyclohexanes; Cycloparaffins; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Excitatory Amino Acid Agents; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Excitatory Amino Acids; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Miscellaneous General Anesthetics; N-Methylaspartate, agonists; N-Methylaspartate, antagonists & inhibitors; Nervous System; Neurotransmitter Agents; NMDA Receptor Antagonists; Peripheral Nervous System Agents; Polycyclic Compounds; Sensory System Agents; Vasodilating Agents"
DB01222,Budesonide,51333-22-3,approved,VOVIALXJUBGFJZ-KWVAZRHASA-N,"InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1",CCCC(O1)O[C@@H]([C@@]12C(=O)CO)C[C@@H]3[C@]2(C)C[C@H](O)[C@H]4[C@H]3CCC=5[C@]4(C)C=CC(=O)C5,C25H34O6,,D00246,5281004,46504869,3207,CHEMBL1370,,4444479,50354850,430.5339,2.73389,"Adrenal Cortex Hormones; Adrenals; Agents to Treat Airway Disease; Alimentary Tract and Metabolism; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Autonomic Agents; Bronchodilator Agents; BSEP/ABCB11 Substrates; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids Acting Locally; Corticosteroids for inhalation use; Corticosteroids for Systemic Use; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (moderate); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Intestinal Antiinflammatory Agents; Nasal Preparations; OAT3/SLC22A8 Substrates; P-glycoprotein substrates; Peripheral Nervous System Agents; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Respiratory System; Respiratory System Agents; Steroids"
DB01223,Aminophylline,317-34-0,approved,FQPFAHBPWDRTLU-UHFFFAOYSA-N,"InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2",[nH]1cnc(c12)n(C)c(=O)n(C)c2=O,C16H24N10O4,,D00227,9433,46508784,2659,CHEMBL1370561,,9062,,420.4264,-0.769321657,"Agents that reduce seizure threshold; Alkaloids; Amines; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cardiotonic Agents; Cardiovascular Agents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Diamines; Drug Combinations; Drugs for Obstructive Airway Diseases; Enzyme Inhibitors; Ethylenediamines; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Neurotransmitter Agents; Peripheral Nervous System Agents; Pharmaceutical Preparations; Phosphodiesterase Inhibitors; Polyamines; Protective Agents; Purinergic Agents; Purinergic Antagonists; Purinergic P1 Receptor Antagonists; Purines; Purinones; Respiratory Smooth Muscle Relaxants; Respiratory System; Respiratory System Agents; Xanthine derivatives; Xanthines and Adrenergics"
DB01224,Quetiapine,111974-69-7,approved,URKOMYMAXPYINW-UHFFFAOYSA-N,"InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2",OCCOCCN1CCN(CC1)C2=Nc(cccc3)c3Sc(c24)cccc4,C21H25N3O2S,C07397,D08456,5002,46504800,8707,CHEMBL716,,4827,50095890,383.507,2.807942516,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Azepines; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Diazepines, Oxazepines, Thiazepines and Oxepines; Dibenzothiazepines; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Hyperglycemia-Associated Agents; Hypotensive Agents; Moderate Risk QTc-Prolonging Agents; Muscarinic Antagonists; Nervous System; P-glycoprotein substrates; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Thiazepines; Thiepins; Tranquilizing Agents"
DB01225,Enoxaparin,9005-49-6,approved,,, ,,,D07510,,46507450,,CHEMBL1201685,,751,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Fibrin Modulating Agents; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Heparin Group; Polysaccharides
DB01226,Mivacurium,133814-19-4,approved,ILVYCEVXHALBSC-OTBYEXOQSA-N,"InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1",COc(c1)c(OC)c(OC)cc1C[C@H](c(c23)cc(OC)c(c2)OC)[N+](C)(CC3)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+](C)(CCc(c45)cc(OC)c(c5)OC)[C@@H]4Cc6cc(OC)c(OC)c(c6)OC,C58H80N2O14,C07550,,5281042,46505071,6958,CHEMBL1182833,,4444509,,1029.2608,-0.759993187,"Agents producing tachycardia; Anticholinergic Agents; Central Nervous System Depressants; Cholinergic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Muscarinic Antagonists; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular-Blocking Agents (Nondepolarizing); Nicotinic Antagonists; Peripheral Nervous System Agents"
DB01227,Levacetylmethadol,1477-40-3,approved; investigational,XBMIVRRWGCYBTQ-AVRDEDQJSA-N,"InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1",c1ccccc1C([C@H](CC)OC(=O)C)(C[C@H](C)N(C)C)c2ccccc2,C23H31NO2,C08012,D04716,15130,46507749,6441,CHEMBL1514,,14401,,353.4977,4.88476934,Analgesics; Anticholinergic Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Drugs Used in Addictive Disorders; Drugs Used in Opioid Dependence; Ketones; Moderate Risk QTc-Prolonging Agents; Narcotics; Nervous System; Nicotinic Antagonists; Opioids; Peripheral Nervous System Agents; QTc Prolonging Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
DB01228,Encainide,66778-36-7,approved; investigational; withdrawn,PJWPNDMDCLXCOM-UHFFFAOYSA-N,"InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)",COc1ccc(cc1)C(=O)Nc2ccccc2CCC3CCCCN3C,C22H28N2O2,C06978,D07894,48041,46504470,4788,CHEMBL315838,,43697,,352.4699,4.492219195,"Amides; Amines; Anilides; Aniline Compounds; Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ic; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Membrane Transport Modulators; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB01229,Paclitaxel,33069-62-4,approved; vet_approved,RCINICONZNJXQF-MZXODVADSA-N,"InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1",c1ccccc1C(=O)O[C@H]([C@@]23O)[C@H]4[C@@](C)([C@@H](O)C[C@@H]5[C@]4(CO5)OC(=O)C)C(=O)[C@H](OC(=O)C)C(C2(C)C)=C(C)[C@H](C3)OC(=O)[C@H](O)[C@H](c6ccccc6)NC(=O)c7ccccc7,C47H51NO14,C07394,D00491,36314,46506910,45863,CHEMBL428647,TA1,10368587,50001839,853.9061,3.53884002,"Agents Causing Muscle Toxicity; Antimitotic Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic and Immunomodulating Agents; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; BSEP/ABCB11 Substrates with Narrow Therapeutic Index; Cardiotoxic antineoplastic agents; Cyclodecanes; Cycloparaffins; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Diterpenes; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hypotensive Agents; Immunosuppressive Agents; Macrocyclic Compounds; Microtubule Inhibition; Microtubule Inhibitors; Mitosis Modulators; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Neurotoxic agents; OATP1B3 substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Taxane Derivatives; Taxoids; Terpenes; Tubulin Modulators"
DB01230,Pemoline,2152-34-3,approved; illicit; investigational; withdrawn,NRNCYVBFPDDJNE-UHFFFAOYSA-N,"InChI=1S/C9H8N2O2/c10-9-11-8(12)7(13-9)6-4-2-1-3-5-6/h1-5,7H,(H2,10,11,12)",NC1=NC(=O)C(O1)c2ccccc2,C9H8N2O2,C07899,D00744,4723,46509085,7953,CHEMBL1177,,4561,,176.172,0.800027732,"Azoles; Central Nervous System Agents; Central Nervous System Stimulants; Centrally Acting Sympathomimetics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Oxazoles; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics"
DB01231,Diphenidol,972-02-1,approved; investigational; withdrawn,OGAKLTJNUQRZJU-UHFFFAOYSA-N,"InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2",c1ccccc1C(O)(c2ccccc2)CCCN3CCCCC3,C21H27NO,C06961,D03858,3055,46506486,4638,CHEMBL936,,2947,50225701,309.4452,4.221518408,"Agents producing tachycardia; Anticholinergic Agents; Antiemetics; Autonomic Agents; Central Nervous System Agents; Emesis Suppression; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists; Peripheral Nervous System Agents"
DB01232,Saquinavir,127779-20-8,approved; investigational,QWAXKHKRTORLEM-UGJKXSETSA-N,"InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1",C1CCC[C@H]([C@H]12)C[C@@H](C(=O)NC(C)(C)C)N(C2)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)N)NC(=O)c(cc4)nc(c45)cccc5,C38H50N6O5,,D00429,441243,46508726,63621,CHEMBL114,ROC,390016,519,670.8408,3.155406786,"Agents Causing Muscle Toxicity; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BCRP/ABCG2 Inhibitors; BSEP/ABCB11 Substrates; Chemically-Induced Disorders; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors (strong); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors (strong); Cytochrome P-450 CYP3A7 Inhibitors (weak); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; HIV Protease Inhibitors; Hyperglycemia-Associated Agents; Isoquinolines; Metabolic Side Effects of Drugs and Substances; Moderate Risk QTc-Prolonging Agents; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Protease Inhibitors; QTc Prolonging Agents; Quinolines"
DB01233,Metoclopramide,364-62-5,approved; investigational,TTWJBBZEZQICBI-UHFFFAOYSA-N,"InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)",CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,C14H22ClN3O2,C07868,D00726,4168,46505631,107736,CHEMBL86,,4024,48320,299.796,1.397270064,"Acids, Carbocyclic; Agents Causing Muscle Toxicity; Agents that modify thyroid function; Alimentary Tract and Metabolism; Amides; Aminobenzoates; Antiemetics; Autonomic Agents; Benzamides and benzamide derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Chlorobenzoates; Cholinesterase Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs for Functional Gastrointestinal Disorders; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxybenzoates; Methemoglobinemia Associated Agents; Neurotransmitter Agents; P-glycoprotein substrates; para-Aminobenzoates; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; Prokinetic Agents; Propulsives; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB01234,Dexamethasone,50-02-2,approved; investigational; vet_approved,UREBDLICKHMUKA-CXSFZGCWSA-N,"InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",OCC(=O)[C@@]1(O)[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)C=C4,C22H29FO5,C15643,D00292,5743,46508930,41879,CHEMBL384467,DEX,5541,18207,392.4611,1.68156968,"Adrenal Cortex Hormones; Adrenals; Agents Causing Muscle Toxicity; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Alimentary Tract and Metabolism; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Autonomic Agents; BCRP/ABCG2 Inhibitors; BSEP/ABCB11 inducers; Cardiovascular System; Central Nervous System Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids for Local Oral Treatment; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Corticosteroids, Dermatological Preparations; Corticosteroids, Moderately Potent (Group II); Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (moderate); Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (moderate); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP3A7 Inducers (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Experimental Unapproved Treatments for COVID-19; Fused-Ring Compounds; Gastrointestinal Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Inducers of Drug Clearance; Medications that reduce magnesium levels; Nasal Preparations; OAT3/SLC22A8 Substrates; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Respiratory System; Sensory Organs; Steroids; Steroids, Fluorinated; Stomatological Preparations; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Vasoprotectives"
DB01235,Levodopa,59-92-7,approved,WTDRDQBEARUVNC-LURJTMIESA-N,"InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1",OC(=O)[C@@H](N)Cc1cc(O)c(O)cc1,C9H11NO4,C00355,D00059,6047,46508120,15765,CHEMBL1009,DAH,5824,60928,197.1879,-1.792181451,"Amines; Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Anti-Dyskinesia Agents; Anti-Parkinson Agents (Dopamine Agonist); Anti-Parkinson Drugs; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Catecholamines; Catechols; Central Nervous System Agents; Central Nervous System Depressants; Dihydroxyphenylalanine; Dopa and Dopa Derivatives; Dopamine Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Levodopa, antagonists & inhibitors; Nervous System; Neurotransmitter Agents; Phenols; Phenylalanine; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB01236,Sevoflurane,28523-86-6,approved; vet_approved,DFEYYRMXOJXZRJ-UHFFFAOYSA-N,"InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2",FCOC(C(F)(F)F)C(F)(F)F,C4H3F7O,C07520,D00547,5206,46508591,9130,CHEMBL1200694,,5017,,200.0548,2.274838758,"Agents that produce hypertension; Anesthetics; Anesthetics, General; Anesthetics, Inhalation; Antiplatelet agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Ethers; Hematologic Agents; Hydrocarbons; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Hypotensive Agents; Methyl Ethers; Nervous System; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB01237,Bromodiphenhydramine,118-23-0,approved,NUNIWXHYABYXKF-UHFFFAOYSA-N,"InChI=1S/C17H20BrNO/c1-19(2)12-13-20-17(14-6-4-3-5-7-14)15-8-10-16(18)11-9-15/h3-11,17H,12-13H2,1-2H3",Brc1ccc(cc1)C(OCCN(C)C)c2ccccc2,C17H20BrNO,,,2444,46506082,59177,CHEMBL1201245,,2350,81465,334.251,4.420659887,"Amines; Aminoalkyl Ethers; Antihistamines for Systemic Use; Benzene Derivatives; Benzhydryl Compounds; Ethylamines; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Respiratory System"
DB01238,Aripiprazole,129722-12-9,approved; investigational,CEUORZQYGODEFX-UHFFFAOYSA-N,"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",Clc1cccc(c1Cl)N2CCN(CC2)CCCCOc(cc3)cc(c34)NC(=O)CC4,C23H27Cl2N3O2,C12564,D01164,60795,46505745,31236,CHEMBL1112,9SC,54790,50130293,448.385,4.901243659,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Aripiprazole and prodrugs; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Hyperglycemia-Associated Agents; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Piperazines; Potential QTc-Prolonging Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; QTc shortening agents; Quinolines; Quinolones; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1D Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB01239,Chlorprothixene,113-59-7,approved; experimental; investigational; withdrawn,WSPOMRSOLSGNFJ-AUWJEWJLSA-N,"InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-",CN(C)CC/C=C\1c(cccc2)c2Sc(c13)ccc(Cl)c3,C18H18ClNS,C07953,D00790,667466,46508957,50931,CHEMBL908,,580849,50240514,315.86,5.065966363,"Agents producing tachycardia; Anticholinergic Agents; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Thioxanthene Derivatives; Thioxanthenes; Tranquilizing Agents; Xanthenes"
DB01240,Epoprostenol,35121-78-9,approved,KAQKFAOMNZTLHT-OZUDYXHBSA-N,"InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1",OC(=O)CCC/C=C(C1)\O[C@H]([C@H]12)C[C@@H](O)[C@@H]2/C=C/[C@@H](O)CCCCC,C20H32O5,C01312,D00106,5280427,46507362,15552,CHEMBL1139,,4445566,,352.4651,2.415704516,"Anticoagulants; Antihypertensive Agents; Antiplatelet agents; Autacoids; Biological Factors; Blood and Blood Forming Organs; Cardiovascular Agents; Drugs that are Mainly Renally Excreted; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Hematologic Agents; Hypotensive Agents; Inflammation Mediators; Lipids; Platelet Aggregation Inhibitors Excl. Heparin; Prostacyclin Analogues; Prostacycline Vasodilator; Prostaglandins; Prostaglandins I; Vasodilating Agents; Vasodilation"
DB01241,Gemfibrozil,25812-30-0,approved,HEMJJKBWTPKOJG-UHFFFAOYSA-N,"InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)",Cc1cc(c(C)cc1)OCCCC(C)(C)C(=O)O,C15H22O3,C07020,D00334,3463,46508264,5296,CHEMBL457,4TX,3345,50110590,250.3334,4.389643824,"Acids, Acyclic; Agents Causing Muscle Toxicity; Benzene Derivatives; Butyrates; Carboxylic Acids; Cardiovascular System; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Ethers; Fatty Acids; Fatty Acids, Volatile; Fibric Acids; Fribic Acid Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Isobutyrates; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Lipids; Metabolic Side Effects of Drugs and Substances; Noxae; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Pentanoic Acids; Peroxisome Proliferator Receptor alpha Agonist; Peroxisome Proliferator-activated Receptor alpha Agonists; Phenols; Phenyl Ethers; Photosensitizing Agents; Toxic Actions; UGT1A1 Inhibitors; UGT1A1 Substrates; UGT1A3 Inhibitors; UGT1A3 substrates; UGT1A9 Substrates; UGT2B7 substrates; Valerates"
DB01242,Clomipramine,303-49-1,approved; investigational; vet_approved,GDLIGKIOYRNHDA-UHFFFAOYSA-N,"InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3",CN(C)CCCN1c(cccc2)c2CCc(c13)ccc(Cl)c3,C19H23ClN2,C06918,D00811,2801,46505157,47780,CHEMBL415,CXX,2699,77970,314.852,4.882613471,"Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antidepressive Agents, Tricyclic; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dibenzazepines; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; P-glycoprotein inhibitors; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Tertiary amine tricyclic antidepressants; Tricyclics and Other Norepinephrine-reuptake Inhibitors"
DB01243,Chloroxine,773-76-2,approved,WDFKMLRRRCGAKS-UHFFFAOYSA-N,"InChI=1S/C9H5Cl2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",Oc1c(Cl)cc(Cl)c(c12)cccn2,C9H5Cl2NO,,D03472,2722,46508620,59477,CHEMBL1200596,,2621,32147,214.048,3.035424502,"Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxyquinolines; Quinolines"
DB01244,Bepridil,64706-54-3,approved; withdrawn,UIEATEWHFDRYRU-UHFFFAOYSA-N,"InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3",CC(C)COCC(N1CCCC1)CN(c2ccccc2)Cc3ccccc3,C24H34N2O,C06847,D07520,2351,46506353,3061,CHEMBL1008,BEP,2261,78577,366.5396,5.487299519,"Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Hypotensive Agents; Membrane Transport Modulators; Non-Selective Calcium Channel Blockers; P-glycoprotein inhibitors; Phenylalkylamine Derivatives; Pyrrolidines; QTc Prolonging Agents; Vasodilating Agents"
DB01245,Decamethonium,156-74-1,approved,MTCUAOILFDZKCO-UHFFFAOYSA-N,"InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2",C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,C16H38N2,C11733,,2968,46507737,41934,CHEMBL1190,DME,2862,50060582,258.4863,-4.871124845,Amines; Ammonium Compounds; Bis-Trimethylammonium Compounds; Central Nervous System Depressants; Cholinesterase Inhibitors; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular Depolarizing Agents; Neurotoxic agents; Nitrogen Compounds; Onium Compounds; Peripheral Nervous System Agents; Quaternary Ammonium Compounds
DB01246,Alimemazine,84-96-8,approved; vet_approved,ZZHLYYDVIOPZBE-UHFFFAOYSA-N,"InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3",CN(C)CC(C)CN1c(cccc2)c2Sc(c13)cccc3,C18H22N2S,C07172,D07125,5574,46508449,9725,CHEMBL829,,5373,50062261,298.446,4.410279125,"Antihistamines for Systemic Use; Antipruritics; Antipsychotic Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 Enzyme Inducers; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Neurotoxic agents; Neurotransmitter Agents; Phenothiazine Derivatives; Phenothiazines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System; Sulfur Compounds"
DB01247,Isocarboxazid,59-63-2,approved,XKFPYPQQHFEXRZ-UHFFFAOYSA-N,"InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)",Cc1cc(no1)C(=O)NNCc2ccccc2,C12H13N3O2,,D02580,3759,46505330,93635,CHEMBL1201168,,3628,163692,231.2505,1.425516649,"Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Azoles; Central Nervous System Agents; Central Nervous System Depressants; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Isoxazoles; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Monoamine Oxidase Inhibitors; Monoamine Oxidase Inhibitors, Non-Selective; Nervous System; Photosensitizing Agents; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB01248,Docetaxel,114977-28-5,approved; investigational,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",c1ccccc1[C@H](NC(=O)OC(C)(C)C)[C@@H](O)C(=O)O[C@@H](C[C@]23O)C(C)=C(C2(C)C)[C@@H](O)C(=O)[C@@]4(C)[C@@H]([C@@]5(OC(=O)C)[C@H](OC5)C[C@@H]4O)[C@@H]3OC(=O)c6ccccc6,C43H53NO14,C11231,D02165,148124,46506766,4672,CHEMBL92,TXL,130581,36351,807.8792,2.916790955,"Agents Causing Muscle Toxicity; Antimitotic Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Cardiotoxic antineoplastic agents; Cyclodecanes; Cycloparaffins; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diterpenes; Hepatotoxic Agents; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Macrocyclic Compounds; Microtubule Inhibition; Microtubule Inhibitors; Mitosis Modulators; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B3 substrates; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Taxane Derivatives; Taxoids; Terpenes; Tubulin Modulators"
DB01249,Iodixanol,92339-11-2,approved,NBQNWMBBSKPBAY-UHFFFAOYSA-N,"InChI=1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62)",OCC(O)CNC(=O)c1c(I)c(c(I)c(c1I)C(=O)NCC(O)CO)N(C(=O)C)CC(O)CN(C(=O)C)c2c(I)c(C(=O)NCC(O)CO)c(I)c(c2I)C(=O)NCC(O)CO,C35H44I6N6O15,,D01474,3724,46504687,31705,CHEMBL1200507,,3593,,1550.1819,-2.062630887,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodinated Contrast Agents; Iodobenzoates; Radiographic Contrast Agent; Roentgenography; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB01250,Olsalazine,15722-48-2,approved,QQBDLJCYGRGAKP-FOCLMDBBSA-N,"InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+",OC(=O)c1cc(ccc1O)/N=N/c2ccc(O)c(c2)C(=O)O,C14H10N2O6,C07323,D00727,6003770,46506356,,CHEMBL425,,10642377,,302.239,4.387174662,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Alimentary Tract and Metabolism; Aminosalicylate; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Gastrointestinal Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Intestinal Antiinflammatory Agents; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Phenols; Salicylates; Sensory System Agents"
DB01251,Gliquidone,33342-05-1,approved; investigational,LLJFMFZYVVLQKT-UHFFFAOYSA-N,"InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)",COc(cc1)cc(c12)C(=O)N(C(=O)C2(C)C)CCc3ccc(cc3)S(=O)(=O)NC(=O)NC4CCCCC4,C27H33N3O6S,,D02430,91610,46508425,93416,CHEMBL383634,,82719,50248247,527.632,4.135768261,Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Sulfones; Sulfonylureas; Sulfur Compounds
DB01253,Ergometrine,60-79-7,approved,WVVSZNPYNCNODU-XTQGRXLLSA-N,"InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1",OC[C@H](C)NC(=O)[C@H](C=1)CN(C)[C@@H](C12)Cc3c4c2cccc4[nH]c3,C19H23N3O2,C07543,D07905,443884,46506922,4822,CHEMBL119443,,391970,50390991,325.4048,1.070695986,"Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alkaloids; Antidepressive Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ergolines; Ergot Alkaloids and Derivatives; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; P-glycoprotein inhibitors; Reproductive Control Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Uterotonic agents"
DB01254,Dasatinib,302962-49-8,approved; investigational,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl,C22H26ClN7O2S,,D03658,3062316,46505143,49375,CHEMBL1421,1N1,2323020,13216,488.006,3.820938309,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Photosensitizing Agents; Potential QTc-Prolonging Agents; Protein Kinase Inhibitors; Pyrimidines; QTc Prolonging Agents; Sulfur Compounds; Thiazoles; Tyrosine Kinase Inhibitors"
DB01255,Lisdexamfetamine,608137-32-2,approved; investigational,VOBHXZCDAVEXEY-JSGCOSHPSA-N,"InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1",c1ccccc1C[C@H](C)NC(=O)[C@@H](N)CCCCN,C15H25N3O,,,11597698,46505358,135925,CHEMBL1201222,,9772458,,263.3785,1.135830796,"Agents producing tachycardia; Agents that produce hypertension; Amines; Amphetamines; Central Nervous System Agents; Central Nervous System Stimulants; Central Nervous System Stimulation; Centrally Acting Sympathomimetics; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Uptake Inhibitors; Ethylamines; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Phenethylamines; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetics"
DB01256,Retapamulin,224452-66-8,approved,STZYTFJPGGDRJD-NHUWBDDWSA-N,"InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22-,24-,26+,27+,28-,29+,30+/m1/s1",C1CC(=O)[C@H]([C@]123)[C@@](C)([C@H](C)CC2)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H](C[C@H]45)C[C@@H](CC4)N5C,C30H47NO4S,,,6918462,46509062,,CHEMBL1658,G34,25064484,,517.763,4.373434361,"Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics for Topical Use; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Hydrocarbons; Pleuromutilin Antibacterial; Pleuromutilins; Terpenes"
DB01259,Lapatinib,231277-92-2,approved; investigational,BCFGMOOMADDAQU-UHFFFAOYSA-N,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",CS(=O)(=O)CCNCc1ccc(o1)-c(cc2)cc(c23)c(ncn3)Nc4cc(Cl)c(cc4)OCc5cc(F)ccc5,C29H26ClFN4O4S,,D04024,208908,46507141,49603,CHEMBL554,FMM,181006,5445,581.058,4.638508798,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Protein Kinase Inhibitors; QTc Prolonging Agents; Quinazolines; Tyrosine Kinase Inhibitors"
DB01260,Desonide,638-94-8,approved; investigational,WBGKWQHBNHJJPZ-LECWWXJVSA-N,"InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1",OCC(=O)[C@]12[C@H](OC(O1)(C)C)C[C@@H]3[C@]2(C)C[C@H](O)[C@H]4[C@H]3CCC=5[C@]4(C)C=CC(=O)C5,C24H32O6,,D03696,5311066,46506186,204734,CHEMBL1201109,,4470603,,416.5073,1.900510933,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Moderately Potent (Group II); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Immunosuppressive Agents; Ophthalmologicals; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Sensory Organs; Steroids"
DB01261,Sitagliptin,486460-32-6,approved; investigational,MFFMDFFZMYYVKS-SECBINFHSA-N,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",Fc1cc(F)c(F)cc1C[C@@H](N)CC(=O)N(C2)CCn(c23)c(nn3)C(F)(F)F,C16H15F6N5O,,D08516,4369359,46505822,40237,CHEMBL1422,715,3571948,11162,407.3136,1.257216276,"Agents causing angioedema; Alimentary Tract and Metabolism; Azoles; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; DPP-IV Inhibitors; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypoglycemia-Associated Agents; Incretins; OAT3/SLC22A8 Substrates; P-glycoprotein substrates; Protease Inhibitors; Triazoles"
DB01262,Decitabine,2353-33-5,approved; investigational,XAUDJQYHKZQPEU-KVQBGUIXSA-N,"InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1",Nc1nc(=O)n(cn1)[C@H]2C[C@H](O)[C@H](O2)CO,C8H12N4O4,,D03665,451668,46505657,50131,CHEMBL1201129,,397844,96274,228.2053,-2.164694889,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Aza Compounds; Carbohydrates; Cytidine Deaminase Substrates; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Metabolic Inhibitor; Nucleosides; Pyrimidine Analogues; Pyrimidine Nucleosides; Pyrimidines; Ribonucleosides; Toxic Actions"
DB01263,Posaconazole,171228-49-2,approved; investigational; vet_approved,RAGOYPUPXAKGKH-XAKZXMRKSA-N,"InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1",C[C@H](O)[C@H](CC)n1ncn(c1=O)-c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OC[C@H](CO5)C[C@]5(Cn6cncn6)c7c(F)cc(F)cc7,C37H42F2N8O4,,D02555,468595,46508639,64355,CHEMBL1397,X2N,411709,50181473,700.7774,5.406185238,"14-alpha Demethylase Inhibitors; Anti-Infective Agents; Antifungal Agents; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; Antiparasitic Agents; Antiprotozoals; Azole Antifungals; Azoles; Chemically-Induced Disorders; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Metabolic Side Effects of Drugs and Substances; P-glycoprotein inhibitors; P-glycoprotein substrates; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Steroid Synthesis Inhibitors; Triazole Derivatives; Trypanocidal Agents"
DB01264,Darunavir,206361-99-1,approved,CJBJHOAVZSMMDJ-HEXNFIEUSA-N,"InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1",O1CC[C@H]([C@H]12)[C@H](CO2)OC(=O)N[C@@H](Cc3ccccc3)[C@H](O)CN(CC(C)C)S(=O)(=O)c4ccc(N)cc4,C27H37N3O7S,,D03656,213039,46506908,367163,CHEMBL1323,17,184733,8125,547.664,2.816817606,"Amides; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Carbamates; Carboxylic Acids; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Experimental Unapproved Treatments for COVID-19; Furans; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV Protease Inhibitors; Hyperglycemia-Associated Agents; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; Protease Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds"
DB01265,Telbivudine,3424-98-4,approved; investigational,IQFYYKKMVGJFEH-CSMHCCOUSA-N,"InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1",O=c1[nH]c(=O)n(cc1C)[C@@H]2C[C@@H](O)[C@@H](O2)CO,C10H14N2O5,,D06675,159269,46508706,63624,CHEMBL374731,LLT,140081,50088372,242.2286,-1.119053589,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Carbohydrates; Deoxyribonucleosides; Direct Acting Antivirals; Enzyme Inhibitors; Glycosides; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Nucleoside Reverse Transcriptase Inhibitors; Nucleosides; Nucleosides and Nucleotides; Pyrimidine Nucleosides; Pyrimidines"
DB01266,Sinecatechins,188265-33-0,approved; investigational; nutraceutical,,, ,,,,,46506183,,,,,,NA,NA,Antiviral Agents; Dermatologicals
DB01267,Paliperidone,144598-75-4,approved,PMXMIIMHBWHSKN-UHFFFAOYSA-N,"InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3",OC1CCCn(c12)c(=O)c(c(n2)C)CCN3CCC(CC3)c4noc(c45)cc(F)cc5,C23H27FN4O3,,D05339,115237,46506296,83804,CHEMBL1621,,103109,50252513,426.4839,1.756555164,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Azoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Hyperglycemia-Associated Agents; Isoxazoles; Nervous System; Neurotoxic agents; Neurotransmitter Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Psycholeptics; Psychotropic Drugs; Pyrimidines; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT1D Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB01268,Sunitinib,557795-19-4,approved; investigational,WINHZLLDWRZWRT-ATVHPVEESA-N,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",CCN(CC)CCNC(=O)c1c(C)[nH]c(c1C)/C=C2\C(=O)Nc(c23)ccc(F)c3,C22H27FN4O2,,D06402,5329102,46507140,38940,CHEMBL535,B49,4486264,4814,398.4738,2.927376814,"Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inhibitors; Blood Glucose Lowering Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Growth Inhibitors; Growth Substances; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypoglycemia-Associated Agents; Immunosuppressive Agents; Indoles; Kinase Inhibitor; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; Potential QTc-Prolonging Agents; Protein Kinase Inhibitors; Pyrroles; QTc Prolonging Agents; Tyrosine Kinase Inhibitors"
DB01273,Varenicline,249296-44-4,approved; investigational,JQSHBVHOMNKWFT-UHFFFAOYSA-N,"InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2",C1NCC(C2)c(c3C12)cc4c(c3)nccn4,C13H13N3,,,5310966,46505502,84500,CHEMBL1396,QMR,148958,50166908,211.268,1.007627996,"Benzazepines; Cholinergic Agents; Cholinergic Agonists; Drugs that are Mainly Renally Excreted; Drugs Used in Addictive Disorders; Drugs Used in Nicotine Dependence; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Miscellaneous Autonomic Drugs; Nervous System; Neurotransmitter Agents; Nicotinic Agonists; OCT2 Inhibitors; OCT2 Substrates; Partial Cholinergic Nicotinic Agonist; Partial Cholinergic Nicotinic Agonists; Quinoxalines; Smoking Cessation Agents"
DB01274,Arformoterol,67346-49-0,approved; investigational,BPZSYCZIITTYBL-YJYMSZOUSA-N,"InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1",COc1ccc(cc1)C[C@@H](C)NC[C@H](O)c2cc(NC=O)c(O)cc2,C19H24N2O4,,D07463,3083544,46506392,408174,CHEMBL1363,H98,2340731,50151720,344.4049,1.056672736,Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Ethanolamines; Long-acting beta-adrenoceptor agonists; Neurotransmitter Agents; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System Agents
DB01275,Hydralazine,86-54-4,approved,RPTUSVTUFVMDQK-UHFFFAOYSA-N,"InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)",c1cccc(c12)cnnc2NN,C8H8N4,C07040,D08044,3637,46507533,5775,CHEMBL276832,HLZ,3511,81461,160.1759,0.751380334,"Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Arteriolar Smooth Muscle, Agents Acting On; Arteriolar Vasodilation; Arteriolar Vasodilator; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Direct Vasodilators; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrazinophthalazine Derivatives; Hydrazinophthalazine Derivatives and Diuretics; Hypotensive Agents; Medications that reduce magnesium levels; Phthalazines; Pyridazines; Vasodilating Agents"
DB01278,Pramlintide,151126-32-8,approved; investigational,TZIRZGBAFTZREM-MKAGXXMWSA-N,"InChI=1S/C171H267N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114-73-276-277-74-115(210-140(245)95(173)38-28-29-49-172)158(263)204-108(65-124(179)237)153(258)217-131(85(16)226)164(269)191-84(15)139(244)216-133(87(18)228)168(273)211-114/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231H,21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,233)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,260)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,251)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,182,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,134-,135-/m0/s1",NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@H]1CC(=O)N)CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc4ccccc4)C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)N)Cc8ccc(O)cc8,C171H267N51O53S2,,D05595,,46509048,135922,CHEMBL2103758,,44241191,,3949.44,-28.27664215,"Alimentary Tract and Metabolism; Amino Acids, Peptides, and Proteins; Amylin Agonists; Amylin Analog; Amyloid; Amyloidogenic Proteins; Blood Glucose Lowering Agents; Drugs Used in Diabetes; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypoglycemia-Associated Agents; Macromolecular Substances; Multiprotein Complexes; Pancreatic Hormones; Peptide Hormones; Peptides; Proteins"
DB01280,Nelarabine,121032-29-9,approved; investigational,IXOXBSCIXZEQEQ-UHTZMRCNSA-N,"InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1",COc1nc(N)nc(c12)n(cn2)[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O,C11H15N5O5,,D05134,3011155,46506325,63612,CHEMBL1201112,,2280207,,297.2673,-1.569849115,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carbohydrates; Glycosides; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleoside Metabolic Inhibitor; Nucleosides; Purine Analogues"
DB01282,Carbetocin,37025-55-1,approved; investigational,NSTRIRCPWQHTIA-DTRKZRJBSA-N,"InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1",COc1ccc(cc1)C[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CSCCCC(=O)N2)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N,C45H69N11O12S,,D07229,16681432,46509009,59204,CHEMBL3301668,,16736854,50044677,988.161,-3.58377149,"Amino Acids, Peptides, and Proteins; Delayed-Action Preparations; Drug Delivery Systems; Drug Therapy; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypotensive Agents; Investigative Techniques; Oxytocin and Analogues; Peptide Hormones; Peptides; Pharmaceutical Preparations; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormones; Pituitary Hormones, Posterior; Posterior Pituitary Lobe Hormones; Reproductive Control Agents; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Technology; Technology, Pharmaceutical; Therapeutics; Uterotonic agents"
DB01283,Lumiracoxib,220991-20-8,approved; investigational,KHPKQFYUPIUARC-UHFFFAOYSA-N,"InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)",Cc1ccc(c(c1)CC(=O)O)Nc2c(Cl)cccc2F,C15H13ClFNO2,,D03714,151166,46506378,73044,CHEMBL404108,LUR,133236,50207446,293.721,4.311087883,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Carboxylic Acids; Central Nervous System Agents; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Musculo-Skeletal System; Nephrotoxic agents; Peripheral Nervous System Agents; Phenylacetates; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents; UGT1A9 Substrates"
DB01284,Tetracosactide,16960-16-0,approved,ZOEFCCMDUURGSE-SQKVDDBVSA-N,"InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,109-,110-,111-/m0/s1",Oc1ccc(cc1)C[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc4c[nH]c(c45)cccc5)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N7CCC[C@H]7C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc8ccc(O)cc8)C(=O)N9CCC[C@H]9C(=O)O,C136H210N40O31S,C06926,D00284,16133751,46506301,3901,CHEMBL2103784,,10481947,50017180,2933.49,-14.06553368,"Adrenals; Adrenocortical Insufficiency; Adrenocorticotropic Hormone; Amino Acids, Peptides, and Proteins; Anterior Pituitary Lobe Hormones and Analogues; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Melanocortins; Nerve Tissue Proteins; Neuropeptides; Peptide Hormones; Peptides; Pituitary; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormones; Pituitary Hormones, Anterior; Pro-Opiomelanocortin; Protein Precursors; Proteins; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB01288,Fenoterol,13392-18-2,approved; investigational,LSLYOANBFKQKPT-UHFFFAOYSA-N,"InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3",Oc1ccc(cc1)CC(C)NCC(O)c2cc(O)cc(O)c2,C17H21NO4,,D04157,3343,46509099,149226,CHEMBL32800,,3226,50131281,303.3529,1.473313852,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Anticholinergic Agents; Autonomic Agents; Benzene Derivatives; Bronchodilator Agents; Catechols; Drugs for Obstructive Airway Diseases; Ethanolamines; Genito Urinary System and Sex Hormones; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Metaproterenol; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenols; Reproductive Control Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists; Sympathomimetics; Sympathomimetics, Labour Repressants; Tocolytic Agents"
DB01291,Pirbuterol,38677-81-5,approved,VQDBNKDJNJQRDG-UHFFFAOYSA-N,"InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3",CC(C)(C)NCC(O)c1nc(CO)c(O)cc1,C12H20N2O3,C07807,,4845,46506379,8245,CHEMBL1094966,,4679,,240.2988,-0.658308346,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cardiotonic Agents; Cardiovascular Agents; Compounds used in a research, industrial, or household setting; Drugs for Obstructive Airway Diseases; Neurotransmitter Agents; Peripheral Nervous System Agents; Protective Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists"
DB01294,Bismuth subsalicylate,14882-18-9,approved; vet_approved,ZREIPSZUJIFJNP-UHFFFAOYSA-K,"InChI=1S/C7H6O3.Bi.H2O/c8-6-4-2-1-3-5(6)7(9)10;;/h1-4,8H,(H,9,10);;1H2/q;+3;/p-3",O[Bi](O1)OC(=O)c(c12)cccc2,C7H5BiO4,C07870,D00728,16682734,46507128,261649,CHEMBL1120,,17215772,,362.0926,1.1143,"Acids, Carbocyclic; Antacids and Adsorbents; Antidiarrheals; Benzene Derivatives; Benzoates; Bismuth containing drugs; Carboxylic Acids; Elements; Elements, Radioactive; Gastrointestinal Agents; Helicobacter Infections; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Isotopes; Metals; Metals, Heavy; Neurotoxic agents; Phenols; Radioisotopes; Salicylates"
DB01296,Glucosamine,3416-24-8,approved; investigational,MSWZFWKMSRAUBD-IVMDWMLBSA-N,"InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6?/m1/s1",N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,C6H13NO5,C00329,D04334,439213,46506420,47977,CHEMBL493287,,388352,,179.1711,-3.039421015,"Amino Sugars; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Carbohydrates; Hexosamines; Musculo-Skeletal System"
DB01297,Practolol,6673-35-4,approved,DURULFYMVIFBIR-UHFFFAOYSA-N,"InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)",CC(C)NCC(O)COc1ccc(cc1)NC(=O)C,C14H22N2O3,C11696,D05587,4883,46507496,258351,CHEMBL6995,,4715,25749,266.3361,0.83192954,"Acetanilides; Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amides; Amines; Amino Alcohols; Anilides; Aniline Compounds; Antiarrhythmic agents; Antihypertensive Agents; Beta Blocking Agents, Selective; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Neurotransmitter Agents; Phenoxypropanolamines; Propanolamines; Propanols"
DB01298,Sulfacytine,17784-12-2,approved,SIBQAECNSSQUOD-UHFFFAOYSA-N,"InChI=1S/C12H14N4O3S/c1-2-16-8-7-11(14-12(16)17)15-20(18,19)10-5-3-9(13)4-6-10/h3-8H,2,13H2,1H3,(H,14,15,17)",CCn1ccc(nc1=O)NS(=O)(=O)c2ccc(N)cc2,C12H14N4O3S,,,5322,46505483,135230,CHEMBL1201056,,5131,,294.33,0.054998476,Amides; Amines; Aniline Compounds; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Sulfonamides; Sulfones; Sulfur Compounds
DB01299,Sulfadoxine,2447-57-6,approved; investigational,PJSFRIWCGOHTNF-UHFFFAOYSA-N,"InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)",COc1ncnc(c1OC)NS(=O)(=O)c2ccc(N)cc2,C12H14N4O4S,C07630,D00580,17134,46507915,9329,CHEMBL1539,,16218,50238671,310.329,0.582047315,"Amides; Amines; Aniline Compounds; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antimalarials; Antiparasitic Agents; Antiprotozoals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Long-Acting Sulfonamides; Renal Agents; Sulfanilamides; Sulfonamides; Sulfones; Sulfur Compounds"
DB01301,Rolitetracycline,751-97-3,approved,HMEYVGGHISAPJR-IAHYZSEUSA-N,"InChI=1S/C27H33N3O8/c1-26(37)13-7-6-8-16(31)17(13)21(32)18-14(26)11-15-20(29(2)3)22(33)19(24(35)27(15,38)23(18)34)25(36)28-12-30-9-4-5-10-30/h6-8,14-15,20,31,33-34,37-38H,4-5,9-12H2,1-3H3,(H,28,36)/t14-,15-,20-,26+,27-/m0/s1",C1CCCN1CNC(=O)C(C2=O)=C(O)[C@@H](N(C)C)[C@@H]([C@@]23O)C[C@H]4C(=C3O)C(=O)c5c([C@@]4(C)O)cccc5O,C27H33N3O8,,D02282,54682938,46507805,63334,CHEMBL1237046,,21111754,,527.5662,-3.038132155,"Agents that produce neuromuscular block (indirect); Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Tetracyclines"
DB01303,Oxtriphylline,4499-40-5,approved,RLANKEDHRWMNRO-UHFFFAOYSA-M,"InChI=1S/C7H8N4O2.C5H14NO/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;1-6(2,3)4-5-7/h3H,1-2H3,(H,8,9,12);7H,4-5H2,1-3H3/q;+1/p-1",[n-]1cnc(c12)n(C)c(=O)n(C)c2=O,C12H21N5O3,,D02017,656652,46507376,,CHEMBL1200434,,25044543,,283.3268,-0.769321657,"Alcohols; Alkaloids; Amines; Amino Alcohols; Ammonium Compounds; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Ethanolamines; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nitrogen Compounds; Onium Compounds; Peripheral Nervous System Agents; Purines; Purinones; Quaternary Ammonium Compounds; Respiratory Smooth Muscle Relaxants; Respiratory System; Respiratory System Agents; Trimethyl Ammonium Compounds; Xanthine derivatives; Xanthines and Adrenergics"
DB01319,Fosamprenavir,226700-79-4,approved,MLBVMOWEQCZNCC-OEMFJLHTSA-N,"InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1",Nc1ccc(cc1)S(=O)(=O)N(CC(C)C)C[C@@H](OP(=O)(O)O)[C@H](Cc2ccccc2)NC(=O)O[C@H]3CCOC3,C25H36N3O9PS,,D02497,131536,46504901,82941,CHEMBL1664,,116245,,585.607,1.918751501,"Acids, Acyclic; Amides; Amprenavir and Prodrugs; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Carboxylic Acids; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; HIV Protease Inhibitors; Hyperglycemia-Associated Agents; Organophosphorus Compounds; Protease Inhibitors; Sulfones; Sulfur Compounds"
DB01320,Fosphenytoin,93390-81-9,approved; investigational,XWLUWCNOOVRFPX-UHFFFAOYSA-N,"InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)",OP(=O)(O)OCN(C(=O)N1)C(=O)C1(c2ccccc2)c3ccccc3,C16H15N2O6P,C07840,D07993,56339,46505168,5165,CHEMBL1201336,,50839,,362.2739,1.668029345,"Anti-epileptic Agent; Anticonvulsants; Azoles; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strong); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Enzyme Inducing Antiepileptic Drugs; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydantoins; Imidazoles; Imidazolidines; Membrane Transport Modulators; Narrow Therapeutic Index Drugs; Nervous System; Phenytoin and Prodrugs; Prodrugs; Sodium Channel Blockers; Thyroxine-binding globulin substrates; UGT1A6 Inhibitors; UGT1A9 Inhibitors"
DB01322,Kava,9000-38-8,approved; investigational; nutraceutical,OMNGEVNATYFZGG-BQYQJAHWSA-N,"InChI=1S/C14H16O3/c1-16-13-9-12(17-14(15)10-13)8-7-11-5-3-2-4-6-11/h3,5-8,10,12H,2,4,9H2,1H3/b8-7+",COC1=CC(=O)OC(C1)/C=C/C2=CCCC=C2,C14H16O3,C07611,,5281052,46505711,,,,4444512,,232.275,2.050274422,NA
DB01323,St. John's Wort,84082-80-4,approved; investigational; nutraceutical,,, ,,,,,46507869,,,,,,NA,NA,Antidepressive Agents; Antidepressive Agents Indicated for Depression; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Herbs and Natural Products; Hyperglycemia-Associated Agents; Nervous System; P-glycoprotein inducers; Psychoanaleptics; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
DB01324,Polythiazide,346-18-9,approved,CYLWJCABXYDINA-UHFFFAOYSA-N,"InChI=1S/C11H13ClF3N3O4S3/c1-18-10(4-23-5-11(13,14)15)17-7-2-6(12)8(24(16,19)20)3-9(7)25(18,21)22/h2-3,10,17H,4-5H2,1H3,(H2,16,19,20)",O=S(=O)(N)c(c1)c(Cl)cc(c12)NC(N(S2(=O)=O)C)CSCC(F)(F)F,C11H13ClF3N3O4S3,C07766,D00657,4870,46508633,8327,CHEMBL1587,,4704,,439.882,1.104555814,"Amides; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Benzothiadiazines; Cardiovascular Agents; Cardiovascular System; Diuretics; Drugs causing inadvertant photosensitivity; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Increased Diuresis; Membrane Transport Modulators; Natriuretic Agents; OAT3/SLC22A8 Substrates; Photosensitizing Agents; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazides"
DB01325,Quinethazone,73-49-4,approved,AGMMTXLNIQSRCG-UHFFFAOYSA-N,"InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)",CCC(N1)NC(=O)c(c12)cc(c(Cl)c2)S(=O)(=O)N,C10H12ClN3O3S,C07342,D00461,6307,46507280,8717,CHEMBL1532,,6068,25898,289.739,1.18539776,"Amides; Cardiovascular Agents; Cardiovascular System; Diuretics; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Low-Ceiling Diuretics, Excl. Thiazides; Membrane Transport Modulators; Natriuretic Agents; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds"
DB01326,Cefamandole,34444-01-4,approved; experimental,OLVCFLKTBJRLHI-AXAPSJFSSA-N,"InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1",Cn1nnnc1SCC(=C2C(=O)O)CS[C@@H](N23)[C@@H](C3=O)NC(=O)[C@H](O)c4ccccc4,C18H18N6O5S2,C06879,D02344,456255,46508882,3480,CHEMBL1146,SMX,401748,50350468,462.503,0.027085616,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Second-Generation Cephalosporins; Sulfur Compounds; Thiazines"
DB01327,Cefazolin,25953-19-9,approved,MLYYVTUWGNIJIB-BXKDBHETSA-N,"InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1",Cc1sc(nn1)SCC(=C2C(=O)O)CS[C@@H](N23)[C@@H](C3=O)NC(=O)Cn4cnnn4,C14H14N8O4S3,C06880,D02299,33255,46506123,474053,CHEMBL1435,,30723,50370587,454.507,-1.519410091,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; First-Generation Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Sulfur Compounds; Thiazines"
DB01328,Cefonicid,61270-58-4,approved; investigational,DYAIAHUQIPBDIP-AXAPSJFSSA-N,"InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1",c1ccccc1[C@@H](O)C(=O)N[C@H](C2=O)[C@H](N23)SCC(=C3C(=O)O)CSc4nnnn4CS(=O)(=O)O,C18H18N6O8S3,C06882,D07644,43594,46505699,3491,CHEMBL1601,,39734,,542.566,-2.515331526,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Second-Generation Cephalosporins; Sulfur Compounds; Thiazines"
DB01329,Cefoperazone,62893-19-0,approved; investigational,GCFBRXLSHGKWDP-XCGNWRKASA-N,"InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1",Cn1nnnc1SCC(=C2C(=O)O)CS[C@@H](N23)[C@@H](C3=O)NC(=O)[C@@H](c4ccc(O)cc4)NC(=O)N5CCN(CC)C(=O)C5=O,C25H27N9O8S2,C06883,,44185,46504543,3493,CHEMBL507674,,40206,50390999,645.67,-0.900489388,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB01330,Cefotetan,69712-56-7,approved,SRZNHPXWXCNNDU-IXOPCIAXSA-N,"InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/b12-6-/t13?,15-,17+/m1/s1",NC(=O)C(C(=O)O)=C1SC(S1)C(=O)N[C@@](C2=O)(OC)[C@H](N23)SCC(=C3C(=O)O)CSc4nnnn4C,C17H17N7O8S4,C06886,D00260,53025,46506572,3499,CHEMBL474579,,47904,80643,575.619,-0.376001456,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Azoles; beta-Lactams; Cephalosporins; Cephamycins; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Second-Generation Cephalosporins; Sulfur Compounds; Tetrazoles; Thiazines"
DB01331,Cefoxitin,35607-66-0,approved,WZOZEZRFJCJXNZ-ZBFHGGJFSA-N,"InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1",NC(=O)OCC(=C1C(=O)O)CS[C@@H](N12)[C@](C2=O)(OC)NC(=O)Cc3cccs3,C16H17N3O7S2,C06887,D02345,441199,46505845,209807,CHEMBL996,CFX,389981,50335563,427.452,0.288359053,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Cephamycins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Second-Generation Cephalosporins; Sulfur Compounds; Thiazines"
DB01332,Ceftizoxime,68401-81-0,approved; withdrawn,NNULBSISHYWZJU-LLKWHZGFSA-N,"InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1",O=C(O)C1=CCS[C@@H](N12)[C@@H](C2=O)NC(=O)/C(=N\OC)c3csc(n3)N,C13H13N5O5S2,C06890,,6533629,46505647,553473,CHEMBL528,,5018818,237182,383.403,-0.846184728,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephacetrile; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB01333,Cefradine,38821-53-3,approved,RDLPVSKMFDYCOR-UEKVPHQBSA-N,"InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1",O=C(O)C1=C(C)CS[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)C3=CCC=CC3,C16H19N3O4S,C06897,D00264,38103,46505082,3547,CHEMBL1604,,34933,50370585,349.405,-2.446831367,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Drugs that are Mainly Renally Excreted; First-Generation Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; MATE 1 Substrates; MATE substrates; Nephrotoxic agents; OAT1/SLC22A6 inhibitors; Sulfur Compounds; Thiazines"
DB01336,Metocurine,5152-30-7,approved,JFXBEKISTKFVAB-AJQTZOPKSA-N,"InChI=1S/C40H48N2O6/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36/h9-14,21-24,31-32H,15-20H2,1-8H3/q+2/t31-,32+/m0/s1",C1C[N+](C)(C)[C@H](c2c13)Cc4ccc(cc4)Oc5c6c(cc(OC)c5OC)CC[N+](C)(C)[C@@H]6Cc7cc(c(cc7)OC)Oc(c2)c(c3)OC,C40H48N2O6,C07919,,21233,46508044,6900,CHEMBL1259,CU9,19961,50237609,652.8189,-1.846410598,"Agents producing tachycardia; Alkaloids; Amines; Ammonium Compounds; Anticholinergic Agents; Benzylisoquinolines; Central Nervous System Depressants; Curare Alkaloids; Drugs, Chinese Herbal; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Muscarinic Antagonists; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular-Blocking Agents (Nondepolarizing); Nicotinic Antagonists; Nitrogen Compounds; Onium Compounds; Peripheral Nervous System Agents; Quaternary Ammonium Compounds; Tetrahydroisoquinolines"
DB01337,Pancuronium,16974-53-1,approved,GVEAYVLWDAFXET-XGHATYIMSA-N,"InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1",C1CCCC[N+]1(C)[C@H]([C@@H]2OC(=O)C)C[C@H]([C@@]23C)[C@H]4[C@H](CC3)[C@]5(C)[C@@H](CC4)C[C@H](OC(=O)C)[C@H](C5)[N+]6(C)CCCCC6,C35H60N2O4,C07551,,441289,46506118,7907,CHEMBL185073,,390052,,572.8619,-3.270247463,"Agents producing tachycardia; Androstanes; Androstanols; Anticholinergic Agents; Central Nervous System Depressants; Cholinergic Agents; Cholinesterase Inhibitors; Fused-Ring Compounds; Muscarinic Antagonists; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular Nondepolarizing Blockade; Neuromuscular-Blocking Agents (Nondepolarizing); Neurotransmitter Agents; Nicotinic Antagonists; OCT1 inhibitors; OCT1 substrates; Peripheral Nervous System Agents; Polycyclic Compounds; Steroids"
DB01338,Pipecuronium,68399-58-6,approved,OWWLUIWOFHMHOQ-XGHATYIMSA-N,"InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1",C[N+]1(C)CCN(CC1)[C@H]([C@@H]2OC(=O)C)C[C@H]([C@@]23C)[C@H]4[C@H](CC3)[C@]5(C)[C@@H](CC4)C[C@H](OC(=O)C)[C@H](C5)N(CC6)CC[N+]6(C)C,C35H62N4O4,C07554,,50192,46508493,8230,CHEMBL1201206,,45517,,602.8912,-5.276740569,"Agents producing tachycardia; Anticholinergic Agents; Central Nervous System Depressants; Cholinergic Agents; Cholinesterase Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular-Blocking Agents (Nondepolarizing); Neurotransmitter Agents; Nicotinic Antagonists; Peripheral Nervous System Agents; Piperazines"
DB01339,Vecuronium,86029-43-8,approved; investigational,BGSZAXLLHYERSY-XQIGCQGXSA-N,"InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1",C1CCCC[N+]1(C)[C@H]([C@@H]2OC(=O)C)C[C@H]([C@@]23C)[C@H]4[C@H](CC3)[C@]5(C)[C@@H](CC4)C[C@H](OC(=O)C)[C@H](C5)N6CCCCC6,C34H57N2O4,C07553,,39765,46507656,9939,CHEMBL1201219,,36358,50424713,557.8274,0.892089153,"Androstanes; Androstanols; Anticholinergic Agents; Central Nervous System Depressants; Cholinergic Agents; Fused-Ring Compounds; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular Nondepolarizing Blockade; Neuromuscular-Blocking Agents (Nondepolarizing); Neurotransmitter Agents; Nicotinic Antagonists; P-glycoprotein substrates; Peripheral Nervous System Agents; Polycyclic Compounds; Steroids"
DB01340,Cilazapril,88768-40-5,approved,HHHKFGXWKKUNCY-FHWLQOOXSA-N,"InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1",O=C(O)[C@@H]1CCCN(N12)CCC[C@@H](C2=O)N[C@H](C(=O)OCC)CCc3ccccc3,C22H31N3O5,,D07699,56330,46505231,3698,CHEMBL515606,,50831,,417.4986,-0.007882288,"ACE Inhibitors and Diuretics; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; P-glycoprotein inhibitors; Protease Inhibitors; Pyridazines"
DB01344,Tolevamer,28210-41-5,approved; investigational,,, ,,,,,46507832,53278,,,,,NA,NA,"Acids; Acids, Noncarboxylic; Benzene Derivatives; Benzylidene Compounds; Cation Exchange Resins; Chelating Agents; Compounds used in a research, industrial, or household setting; Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Ion Exchange Resins; Laboratory Chemicals; Macromolecular Substances; Manufactured Materials; Plastics; Polymers; Polystyrene Sulfonates; Potassium Binder; Potassium Ion Exchange Activity; Potassium-removing Agents; Sequestering Agents; Styrene; Styrenes; Sulfur Acids; Sulfur Compounds"
DB01345,Potassium cation,24203-36-9,approved; investigational,NPYPAHLBTDXSSS-UHFFFAOYSA-N,InChI=1S/K/q+1,[K+],K,C00238,D08403,5462222,46506517,29103,,K,791,,39.0983,0.2,Agents causing hyperkalemia; Diuretics; Drugs that are Mainly Renally Excreted; Increased Large Intestinal Motility; Inhibition Large Intestine Fluid/Electrolyte Absorption; Minerals; Osmotic Activity; Potassium Salt; Replacement Preparations
DB01346,Quinidine barbiturate,,approved,YHRUERMOPBDCFD-UHFFFAOYSA-N,"InChI=1S/C20H24N2O2.C12H12N2O3/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;3-7H,2H2,1H3,(H2,13,14,15,16,17)",COc(cc1)cc(c12)c(ccn2)C(O)C(CC34)N(CC3)CC4C=C,C32H36N4O5,,,53461739,46504552,,,,26329517,,556.652,2.513463951,NA
DB01348,Spirapril,83647-97-6,approved,HRWCVUIFMSZDJS-SZMVWBNQSA-N,"InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1",c1ccccc1CC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(C2)[C@H](C(=O)O)CC23SCCS3,C22H30N2O5S2,,D08529,5311447,46506126,135756,CHEMBL431,,4470933,50017124,466.614,1.603634592,"Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Amino Acids, Peptides, and Proteins; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular System; Dipeptides; Enzyme Inhibitors; Oligopeptides; Peptides; Protease Inhibitors"
DB01351,Amobarbital,57-43-2,approved; illicit,VIROVYVQCGLCII-UHFFFAOYSA-N,"InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)",CC(C)CCC1(CC)C(=O)NC(=O)NC1=O,C11H18N2O3,C07536,D00555,2164,46508165,2673,CHEMBL267894,,2079,,226.2722,1.893251247,"Anticholinergic Agents; Anticonvulsants; Barbiturates; Barbiturates, Plain; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; Psycholeptics; Pyrimidines; Pyrimidinones"
DB01353,Butobarbital,77-28-1,approved; illicit,STDBAQMTJLUMFW-UHFFFAOYSA-N,"InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15)",CCCCC1(CC)C(=O)NC(=O)NC1=O,C10H16N2O3,,D02618,6473,46508397,134884,CHEMBL404422,,6229,,212.2456,1.60623215,"Anticholinergic Agents; Barbiturates, Plain; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Nicotinic Antagonists; Psycholeptics; Pyrimidines; Pyrimidinones"
DB01357,Mestranol,72-33-3,approved,IMSSROKUHAOUJS-MJCUULBUSA-N,"InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1",C#C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(OC)cc4,C21H26O2,C07618,D00575,6291,46507679,6784,CHEMBL1201151,,6054,,310.4299,4.043247144,"Adrenal Cortex Hormones; Contraceptive Agents, Female; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Estradiol Congeners; Estrogen Contraceptives; Estrogenic Steroids, Alkylated; Estrogens; Ethinyl Estradiol; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Norpregnanes; Norpregnatrienes; Norsteroids; Polycyclic Compounds; Steroids; Thyroxine-binding globulin inducers"
DB01359,Penbutolol,38363-40-5,approved; investigational,KQXKVJAGOJTNJS-HNNXBMFYSA-N,"InChI=1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1",CC(C)(C)NC[C@H](O)COc1ccccc1C2CCCC2,C18H29NO2,C07416,D08074,37464,46504929,7954,CHEMBL1290,,34369,,291.4284,3.545216419,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antidepressive Agents; Antihypertensive Agents; Beta Blocking Agents, Non-Selective; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hypotensive Agents; Neurotransmitter Agents; Phenoxypropanolamines; Propanolamines; Propanols; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB01362,Iohexol,66108-95-0,approved,NTHXOOBQLCIOLC-UHFFFAOYSA-N,"InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)",OCC(O)CN(C(=O)C)c1c(I)c(C(=O)NCC(O)CO)c(I)c(c1I)C(=O)NCC(O)CO,C19H26I3N3O9,,D01817,3730,46506178,31709,CHEMBL1200455,,3599,,821.1379,-1.950822455,"Acids, Carbocyclic; Agents that reduce seizure threshold; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodinated Contrast Agents; Iodobenzoates; Radiographic Contrast Agent; Roentgenography; Triiodobenzoic Acids; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB01364,Ephedrine,299-42-3,approved,KWGRBVOPPLSCSI-WPRPVWTQSA-N,"InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1",CN[C@@H](C)[C@H](O)c1ccccc1,C10H15NO,C01575,D00124,9294,46507538,15407,CHEMBL211456,,8935,,165.2322,1.317834728,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Alimentary Tract and Metabolism; Alpha-and Beta-adrenergic Agonists; Amines; Amino Alcohols; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antiobesity Preparations, Excl. Diet Products; Autonomic Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Central Nervous System Agents; Central Nervous System Depressants; Central Nervous System Stimulants; Centrally Acting Antiobesity Products; Cholinesterase substrates; Drugs for Obstructive Airway Diseases; Epinephrine and similars; Ethylamines; Herbs and Natural Products; Increased Norepinephrine Activity; Mydriatics and Cycloplegics; Nasal Preparations; Neurotransmitter Agents; Norepinephrine Releasing Agent; Ophthalmologicals; Peripheral Nervous System Agents; Phenethylamines; Propanolamines; Propanols; Respiratory System; Sensory Organs; Sympathomimetic (Adrenergic) Agents; Sympathomimetics; Sympathomimetics Excl. Antiglaucoma Preparations; Sympathomimetics, Plain; Vasoconstrictor Agents"
DB01365,Mephentermine,100-92-5,approved,RXQCGGRTAILOIN-UHFFFAOYSA-N,"InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3",CNC(C)(C)Cc1ccccc1,C11H17N,C07889,D08180,3677,46505918,6755,CHEMBL1201234,,3549,81455,163.2594,2.517407544,Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Agents producing tachycardia; Agents that produce hypertension; Amines; Amphetamines; Autonomic Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Ethylamines; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenethylamines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetics; Vasoconstrictor Agents
DB01366,Procaterol,72332-33-3,approved; investigational,FKNXQNWAXFXVNW-BLLLJJGKSA-N,"InChI=1S/C16H22N2O3/c1-4-12(17-9(2)3)16(21)11-5-7-13(19)15-10(11)6-8-14(20)18-15/h5-9,12,16-17,19,21H,4H2,1-3H3,(H,18,20)/t12-,16+/m0/s1",CC(C)N[C@@H](CC)[C@H](O)c(ccc1O)c(c12)ccc(=O)[nH]2,C16H22N2O3,,,688561,46507907,,CHEMBL1478530,,599984,50167071,290.3575,0.884129478,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Drugs for Obstructive Airway Diseases; Ethanolamines; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxyquinolines; Neurotransmitter Agents; Peripheral Nervous System Agents; Quinolines; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists; Sympathomimetics"
DB01367,Rasagiline,136236-51-6,approved,RUOKEQAAGRXIBM-GFCCVEGCSA-N,"InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1",C#CCN[C@@H]1CCc(c12)cccc2,C12H13N,,D08469,3052776,46506045,63620,CHEMBL887,RAU,2314553,10989,171.2383,2.303901933,"Agents that produce hypertension; Agents that reduce seizure threshold; Anti-Parkinson Drugs; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Indenes; Monoamine Oxidase B Inhibitors; Monoamine Oxidase Inhibitors; Nervous System; Neuroprotective Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Protective Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB01369,Quinupristin,120138-50-3,approved,WTHRRGMBUAHGNI-LCYNINFDSA-N,"InChI=1S/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35+,37-,38+,39+,40+,43-,44+,45+/m1/s1",Oc1cccnc1C(=O)N[C@H](C(=O)N[C@@H](C2=O)CC)[C@@H](C)OC(=O)[C@H](c3ccccc3)NC(=O)[C@H](CC(=O)[C@@H](C4)CS[C@H](CN56)C(CC5)CC6)N4C(=O)[C@@H](N(C)C(=O)[C@@H](N27)CCC7)Cc8ccc(cc8)N(C)C,C53H67N9O10S,C08032,D00852,5388937,46505148,,CHEMBL1200649,,4470884,,1022.23,2.17814458,"Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Macrocyclic Compounds; Peptides; Peptides, Cyclic; Polycyclic Compounds; Streptogramin Antibacterial; Streptogramins"
DB01370,Aluminium,7429-90-5,approved; investigational,XAGFODPZIPBFFR-UHFFFAOYSA-N,InChI=1S/Al,[Al],Al,C06264,,5359268,46504765,28984,,,4514248,,26.9815,1.45,"Aluminium Compounds; Aluminum and magnesium containing antacids; Antacids; Elements; Gastric Acid Lowering Agents; Metal cations; Metal divalent cations; Metals; Metals, Light"
DB01377,Magnesium oxide,1309-48-4,approved,AXZKOIWUVFPNLO-UHFFFAOYSA-N,InChI=1S/Mg.O/q+2;-2,[O-2],MgO,C12567,D01167,14792,46504815,31794,CHEMBL1200572,,5254017,,40.304,-0.57,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Aluminum and magnesium containing antacids; Anions; Antacids; Calculi Dissolution Agent; Drugs for Acid Related Disorders; Drugs for Constipation; Electrolytes; Gastric Acid Lowering Agents; Gastrointestinal Agents; Ions; Laxatives; Laxatives, magnesium containing; Magnesium Compounds; Magnesium Salts; Metal cations; Metal divalent cations; Mineral Supplements; Minerals; Osmotic Laxatives; Oxides; Oxygen Compounds"
DB01378,Magnesium cation,22537-22-0,approved; nutraceutical,JLVVSXFLKOJNIY-UHFFFAOYSA-N,InChI=1S/Mg/q+2,[Mg+2],Mg,C00305,,888,46508750,18420,,MG,865,15,24.305,-0.57,"Agents that produce neuromuscular block (indirect); Calculi Dissolution Agent; Increased Large Intestinal Motility; Inhibition Large Intestine Fluid/Electrolyte Absorption; Inhibition Small Intestine Fluid/Electrolyte Absorption; Laxatives; Magnesium Ion Exchange Activity; Minerals; Osmotic Activity; Osmotic Laxatives; Polyvalent cation containing laxatives, antacids, oral supplements; Stimulation Large Intestine Fluid/Electrolyte Secretion"
DB01380,Cortisone acetate,50-04-4,approved; investigational,ITRJWOMZKQRYTA-RFZYENFJSA-N,"InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2C(=O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COC(=O)C,C23H30O6,C08173,D00973,5745,46508852,3897,CHEMBL1650,,5543,50455157,402.4807,2.101806099,"17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Adrenals; Anti-Inflammatory Agents; Corticosteroids; Corticosteroids for Systemic Use; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydroxycorticosteroids; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Polycyclic Compounds; Pregnanes; Pregnenes; Steroids"
DB01382,Glymidine,339-44-6,approved; investigational,QFWPJPIVLCBXFJ-UHFFFAOYSA-N,"InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16)",COCCOc1cnc(nc1)NS(=O)(=O)c2ccccc2,C13H15N3O4S,,,9565,46507076,146188,CHEMBL1697838,,9190,,309.341,1.011539988,Alimentary Tract and Metabolism; Amides; Blood Glucose Lowering Agents; Drugs Used in Diabetes; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Sulfonamides; Sulfones; Sulfur Compounds
DB01390,Sodium bicarbonate,144-55-8,approved,UIIMBOGNXHQVGW-UHFFFAOYSA-M,"InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1",OC([O-])=O,CHNaO3,C12603,D01203,516892,46507049,32139,CHEMBL1353,,8609,,84.0066,0.250051366,"Acids; Acids, Noncarboxylic; Alkalies; Anions; Antacids; Antacids and Adsorbents; Bicarbonates; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Carbon Compounds, Inorganic; Carbonates; Carbonic Acid; Electrolyte Solutions; Electrolytes; Gastric Acid Lowering Agents; Hemodialysis Solution; I.V. Solution Additives; Ions; Irrigating Solutions; Radiographic Contrast Agent; Salt Solutions; Sodium Compounds; Urinary Alkalinisers"
DB01392,Yohimbine,146-48-5,approved; investigational; vet_approved,BLGXFZZNTVWLAY-SCYLSFHTSA-N,"InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1",COC(=O)[C@H]1[C@@H](O)CC[C@H]([C@@H]12)CN3[C@@H](C2)c4c(CC3)c5c([nH]4)cccc5,C21H26N2O3,C09256,,8969,46504602,10093,CHEMBL15245,,8622,50203564,354.4427,2.09865826,"Adrenergic Agents; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Alkaloids; Antidepressive Agents; Autonomic Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs Used in Erectile Dysfunction; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indole Alkaloids; Indoles; Mydriatics; Neurotransmitter Agents; Other Miscellaneous Therapeutic Agents; P-glycoprotein inhibitors; Peripheral Nervous System Agents; Secologanin Tryptamine Alkaloids; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1D Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Urological Agents; Urologicals"
DB01393,Bezafibrate,41859-67-0,approved; investigational,IIBYAHWJQTYFKB-UHFFFAOYSA-N,"InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)",OC(=O)C(C)(C)Oc1ccc(cc1)CCNC(=O)c2ccc(Cl)cc2,C19H20ClNO4,,D01366,39042,46509188,47612,CHEMBL264374,PEM,35728,28701,361.819,3.986583346,"Acids, Acyclic; Acids, Carbocyclic; Agents Causing Muscle Toxicity; Amides; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Butyrates; Carboxylic Acids; Cardiovascular System; Chlorobenzoates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ethers; Fatty Acids; Fatty Acids, Volatile; Fibric Acids; Fribic Acid Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Isobutyrates; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Lipids; Noxae; OATP1B1/SLCO1B1 Inhibitors; Phenols; Phenyl Ethers; Toxic Actions"
DB01394,Colchicine,64-86-8,approved,IAKHMKGGTNLKSZ-UHFFFAOYSA-N,"InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)",COc1c(OC)c(OC)cc(c12)CCC(NC(=O)C)c3c2ccc(c(=O)c3)OC,C22H25NO6,C07592,D00570,2833,46505639,23359,CHEMBL87,LOC,2731,,399.437,1.46198857,Agents Causing Muscle Toxicity; Alkaloids; Antigout Preparations; Antimitotic Agents; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Experimental Unapproved Treatments for COVID-19; Heterocyclic Compounds; Immunosuppressive Agents; Mitosis Modulators; Musculo-Skeletal System; P-glycoprotein inducers; P-glycoprotein substrates; Preparations With No Effect on Uric Acid Metabolism; Tubulin Modulators
DB01395,Drospirenone,67392-87-4,approved,METQSPRSQINEEU-HXCATZOESA-N,"InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1",O=C(O1)CC[C@]12[C@]3(C)[C@@H]([C@H]4[C@@H]2C4)[C@H]5[C@H](CC3)[C@]6(C)C([C@H]7[C@@H]5C7)=CC(=O)CC6,C24H30O3,,D03917,68873,46507653,50838,CHEMBL1509,,62105,150275,366.4932,3.366761366,"Adrenal Cortex Hormones; Agents causing hyperkalemia; Androstanes; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Diuretics; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Mineralocorticoid Receptor Antagonists; Natriuretic Agents; Polycyclic Compounds; Progesterone Congeners; Progestin Contraceptives; Progestins; Sex Hormones and Modulators of the Genital System; Steroids"
DB01396,Digitoxin,71-63-6,approved; investigational,WDJUZGPOPHTGOT-XUDUSOBPSA-N,"InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1",O=C1OCC(=C1)[C@H]2CC[C@@](O)([C@@]23C)[C@H]4[C@H](CC3)[C@]5(C)[C@H](CC4)C[C@H](CC5)O[C@H]6C[C@H](O)[C@@H]([C@H](O6)C)O[C@H]7C[C@H](O)[C@@H]([C@H](O7)C)O[C@H]8C[C@H](O)[C@H](O)[C@H](O8)C,C41H64O13,C06955,D00297,441207,46506035,28544,CHEMBL254219,,389987,46356,764.9391,3.597491739,"Antiarrhythmic agents; Carbohydrates; Cardanolides; Cardenolides; Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Digitalis Glycosides; Enzyme Inhibitors; Fused-Ring Compounds; Glycosides; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Potential QTc-Prolonging Agents; Protective Agents; QTc Prolonging Agents; Steroids"
DB01399,Salsalate,552-94-3,approved,WVYADZUPLLSGPU-UHFFFAOYSA-N,"InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)",OC(=O)c1ccccc1OC(=O)c2ccccc2O,C14H10O5,,D00428,5161,46506882,9014,CHEMBL154111,,4977,85244,258.2262,3.638698815,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antirheumatic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Phenols; Salicylic Acid and Derivatives; Sensory System Agents"
DB01400,Neostigmine,59-99-4,approved; vet_approved,ALWKGYPQUAPLQC-UHFFFAOYSA-N,"InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1",CN(C)C(=O)Oc1cc([N+](C)(C)C)ccc1,C12H19N2O2,C07258,D08261,4456,46509161,7514,CHEMBL278020,,4301,50022775,223.2915,-2.245982389,Amines; Ammonium Compounds; Antiglaucoma Preparations and Miotics; Autonomic Agents; Cholinergic Agents; Cholinesterase Inhibitors; Enzyme Inhibitors; Nervous System; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Ophthalmologicals; Parasympathomemetic (Cholinergic) Agents; Parasympathomimetics; Peripheral Nervous System Agents; Phenylammonium Compounds; Quaternary Ammonium Compounds; Sensory Organs
DB01401,Choline magnesium trisalicylate,64425-90-7,approved,FQCQGOZEWWPOKI-UHFFFAOYSA-K,"InChI=1S/3C7H6O3.C5H14NO.Mg/c3*8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7;/h3*1-4,8H,(H,9,10);7H,4-5H2,1-3H3;/q;;;+1;+2/p-3",Oc1ccccc1C([O-])=O,C26H29MgNO10,,,54682045,46505243,,,,10642393,,539.814,1.977263402,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Ammonium Compounds; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antirheumatic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Ethanolamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Nephrotoxic agents; Nitrogen Compounds; Non COX-2 selective NSAIDS; Onium Compounds; Peripheral Nervous System Agents; Phenols; Quaternary Ammonium Compounds; Sensory System Agents; Trimethyl Ammonium Compounds"
DB01403,Methotrimeprazine,60-99-1,approved; investigational,VRQVVMDWGGWHTJ-CQSZACIVSA-N,"InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1",COc(cc1)cc(c12)N(C[C@H](C)CN(C)C)c3c(S2)cccc3,C19H24N2OS,C07192,D00403,72287,46507223,6838,CHEMBL1764,,65239,50418049,328.472,4.25260786,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anticholinergic Agents; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Hyperglycemia-Associated Agents; Muscarinic Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenothiazines; Phenothiazines With Aliphatic Side-Chain; Photosensitizing Agents; Potential QTc-Prolonging Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Tranquilizing Agents"
DB01404,Ginseng,50647-08-0,approved; investigational; nutraceutical,,, ,,,,,46508934,,,,,,NA,NA,Herbs and Natural Products
DB01406,Danazol,17230-88-5,approved,POZRVZJJTULAOH-LHZXLZLDSA-N,"InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1",C#C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=Cc5c(C4)cno5,C22H27NO2,,D00289,28417,46506475,4315,CHEMBL1479,,26436,50423541,337.4553,3.462082192,"Androgens; Antigonadotropins and Similar Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Estrogen Antagonists; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Polycyclic Compounds; Pregnadienes; Pregnanes; Sex Hormones and Modulators of the Genital System; Steroids; Thyroxine-binding globulin inhibitors"
DB01407,Clenbuterol,37148-27-9,approved; investigational; vet_approved,STJMRWALKKWQGH-UHFFFAOYSA-N,"InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,C12H18Cl2N2O,,,2783,46508373,174690,CHEMBL49080,,2681,27958,277.19,2.33438275,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Drugs for Obstructive Airway Diseases; Ethanolamines; Long-acting beta-adrenoceptor agonists; Neurotransmitter Agents; Peripheral Nervous System Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists; Sympathomimetics"
DB01409,Tiotropium,186691-13-4,approved,LERNTVKEWCAPOY-DZZGSBJMSA-N,"InChI=1S/C19H22NO4S2/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15/h3-8,11-13,16-17,22H,9-10H2,1-2H3/q+1/t11-,12-,13+,16-,17+",[C@@H]12[C@@H](O1)[C@@H]3C[C@@H](C[C@H]2[N+]3(C)C)OC(=O)C(O)(c4cccs4)c5cccs5,C19H22NO4S2,,,5487427,46504448,90960,CHEMBL1900528,0HK,19618474,50239981,392.512,-1.757283714,"Adrenergics, Inhalants; Agents producing tachycardia; Agents to Treat Airway Disease; Alkaloids; Anti-Asthmatic Agents; Anticholinergic Agents; Antimuscarinics Antispasmodics; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Bicyclo Compounds; Bicyclo Compounds, Heterocyclic; Bridged Compounds; Bronchodilator Agents; Cholinergic Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Muscarinic Antagonists; Neurotransmitter Agents; Parasympatholytics; Peripheral Nervous System Agents; Polycyclic Compounds; Respiratory System; Respiratory System Agents; Scopolamine Derivatives; Tropanes"
DB01410,Ciclesonide,126544-47-6,approved; investigational,LUKZNWIVRBCLON-GXOBDPJESA-N,"InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1",C1CCCCC1[C@@H](O2)O[C@@H]([C@@]23C(=O)COC(=O)C(C)C)C[C@@H]4[C@]3(C)C[C@H](O)[C@H]5[C@H]4CCC=6[C@]5(C)C=CC(=O)C6,C32H44O7,,D01703,6918155,46508553,31397,CHEMBL2040682,,5293368,,540.697,5.323272523,"Adrenal Cortex Hormones; Adrenals; Agents to Treat Airway Disease; Anti-Allergic Agents; Corticosteroids; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Nasal Preparations; Polycyclic Compounds; Pregnanes; Pregnenes; Respiratory System; Steroids; Thyroxine-binding globulin inhibitors"
DB01413,Cefepime,88040-23-7,approved; investigational,HVFLCNVBZFFHBT-ZKDACBOMSA-N,"InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1",Nc1nc(cs1)/C(=N/OC)C(=O)N[C@@H]2C(=O)N([C@@H]23)C(C([O-])=O)=C(CS3)C[N+]4(C)CCCC4,C19H24N6O5S2,C08111,D02376,5479537,46507919,478164,CHEMBL186,,4586395,50350470,480.561,-4.28758776,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Fourth-Generation Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Sulfur Compounds; Thiazines"
DB01415,Ceftibuten,97519-39-6,approved; investigational,UNJFKXSSGBWRBZ-BJCIPQKHSA-N,"InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1",O=C(O)C1=CCS[C@@H](N12)[C@@H](C2=O)NC(=O)/C(=C\CC(=O)O)c3csc(n3)N,C15H14N4O6S2,C08117,D00922,5282242,46507324,3510,CHEMBL1605,,4445419,50370586,410.425,-1.410396594,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB01416,Cefpodoxime,80210-62-4,approved; vet_approved,WYUSVOMTXWRGEK-HBWVYFAYSA-N,"InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1",COCC(=C1C(=O)O)CS[C@@H](N12)[C@@H](C2=O)NC(=O)/C(=N\OC)c3csc(n3)N,C15H17N5O6S2,C08114,D07650,6335986,46504897,3504,CHEMBL1672,,4891496,50292251,427.455,-1.189891138,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephacetrile; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Prodrugs; Sulfur Compounds; Thiazines; Third-Generation Cephalosporins"
DB01418,Acenocoumarol,152-72-7,approved; investigational,VABCILAOYCMVPS-UHFFFAOYSA-N,"InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3",[O-][N+](=O)c1ccc(cc1)C(CC(=O)C)c(c(=O)o2)c(O)c(c23)cccc3,C19H15NO6,,D07064,54676537,46507631,53766,CHEMBL397420,,10443441,,353.3255,2.684691552,"4-Hydroxycoumarins; Anticoagulants; Benzopyrans; Blood and Blood Forming Organs; Coumarins; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; Pyrans; Vitamin K Antagonists; Warfarin and isomers"
DB01419,Antrafenine,55300-29-3,approved,NWGGKKGAFZIVBJ-UHFFFAOYSA-N,"InChI=1S/C30H26F6N4O2/c31-29(32,33)20-4-3-5-22(18-20)40-14-12-39(13-15-40)16-17-42-28(41)24-6-1-2-7-25(24)38-26-10-11-37-27-19-21(30(34,35)36)8-9-23(26)27/h1-11,18-19H,12-17H2,(H,37,38)",FC(F)(F)c1cc(ccc1)N2CCN(CC2)CCOC(=O)c3ccccc3Nc(ccn4)c(c45)ccc(c5)C(F)(F)F,C30H26F6N4O2,,,68723,46507354,135841,CHEMBL345524,,61973,,588.5435,8.386884484,"Agents causing hyperkalemia; Agents that produce hypertension; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nephrotoxic agents; Non COX-2 selective NSAIDS"
DB01420,Testosterone propionate,57-85-2,approved; investigational; vet_approved; withdrawn,PDMMFKSKQVNJMI-BLQWBTBKSA-N,"InChI=1S/C22H32O3/c1-4-20(24)25-19-8-7-17-16-6-5-14-13-15(23)9-11-21(14,2)18(16)10-12-22(17,19)3/h13,16-19H,4-12H2,1-3H3/t16-,17-,18-,19-,21-,22-/m0/s1",CCC(=O)O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=CC(=O)CC4,C22H32O3,C08158,D00959,5995,46508693,9466,CHEMBL1170,,5774,50215709,344.4877,4.507084555,"Androgens; Androstanes; Androstenes; Androstenols; COMT Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; P-glycoprotein substrates; Polycyclic Compounds; Steroids; Testosterone and derivatives; Testosterone Congeners; Thyroxine-binding globulin inhibitors; UGT1A1 Inducers"
DB01421,Paromomycin,7542-37-2,approved; investigational,UOZODPSAJZTQNH-LSWIJEOBSA-N,"InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1",NC[C@@H]1O[C@@H]([C@H](N)[C@@H](O)[C@@H]1O)O[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4N,C23H45N5O14,C00832,,165580,46505391,7934,CHEMBL370143,PAR,145115,50240054,615.6285,-8.308295949,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Amebicides; Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antiparasitic Agents; Antiprotozoals; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycosides; Intestinal Antiinfectives; Nephrotoxic agents"
DB01424,Aminophenazone,58-15-1,approved; withdrawn,RMMXTBMQSGEXHJ-UHFFFAOYSA-N,"InChI=1S/C13H17N3O/c1-10-12(14(2)3)13(17)16(15(10)4)11-8-6-5-7-9-11/h5-9H,1-4H3",CN(C)c1c(C)n(C)n(c1=O)-c2ccccc2,C13H17N3O,C07539,D00556,6009,46504975,160246,CHEMBL288470,,5787,74258,231.2936,1.150594916,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; Pyrazoles; Pyrazolones"
DB01426,Ajmaline,07-12-4360,approved; experimental,CJDRUOGAGYHKKD-HEFSZTOGSA-N,"InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16?,17-,18+,19+,20+/m0/s1",CC[C@H]([C@H]1O)[C@H](C2)C([C@H]3O)[C@H](C4)N1[C@@H]2[C@@H]([C@@]345)N(C)c6c5cccc6,C20H26N2O2,C06542,D00199,441080,46506449,28462,CHEMBL2357792,,10145712,,326.4326,1.850807787,"Ajmaline and derivatives; Alkaloids; Antiarrhythmic agents; Antiarrhythmics, Class I; Antiarrhythmics, Class Ia; Antiarrhythmics, Class Ic; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indole Alkaloids; Indoles; Membrane Transport Modulators; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Secologanin Tryptamine Alkaloids; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB01427,Amrinone,60719-84-8,approved,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,"InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)",O=c1[nH]cc(cc1N)-c2ccncc2,C10H9N3O,C13594,D00231,3698,46504647,2686,CHEMBL12856,,3570,34651,187.198,-0.568917207,"Amines; Aminopyridines; Calcium-Regulating Hormones and Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Protective Agents; Pyridines; Vasodilating Agents"
DB01428,Oxybenzone,131-57-7,approved; investigational,DXGLGDHPHMLXJC-UHFFFAOYSA-N,"InChI=1S/C14H12O3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15H,1H3",COc1cc(O)c(cc1)C(=O)c2ccccc2,C14H12O3,C14285,D05309,4632,46508419,34283,CHEMBL1625,,4471,50253134,228.2433,3.621362266,"Benzene Derivatives; Compounds used in a research, industrial, or household setting; Cosmetics; Dermatologicals; Drugs that are Mainly Renally Excreted; Household Products; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Ketones; Protective Agents; Radiation-Protective Agents; Sunscreen Agents"
DB01430,Almitrine,27469-53-0,approved,OBDOVFRMEYHSQB-UHFFFAOYSA-N,"InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)",c1cc(F)ccc1C(c(cc2)ccc2F)N3CCN(CC3)c4nc(NCC=C)nc(n4)NCC=C,C26H29F2N7,,D07126,33887,46505517,53778,CHEMBL1183717,,31235,,477.5522,6.049426599,"Alkaloids; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indole Alkaloids; Indoles; Neuroprotective Agents; Pharmaceutical Preparations; Piperazines; Protective Agents; Respiratory System; Respiratory System Agents; Secologanin Tryptamine Alkaloids; Triazines"
DB01432,Cholestyramine,11041-12-6,approved; investigational,,, ,,,,,46506251,,CHEMBL1201625,,,,NA,NA,"Anion Exchange Resins; Anticholesteremic Agents; Benzene Derivatives; Benzylidene Compounds; Bile Acid Sequestrants; Bile-acid Binding Activity; Cardiovascular System; Compounds used in a research, industrial, or household setting; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Ion Exchange Resins; Laboratory Chemicals; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Macromolecular Substances; Manufactured Materials; Medications that reduce magnesium levels; Noxae; Plastics; Polymers; Polystyrenes; Styrene; Styrenes; Toxic Actions"
DB01435,Antipyrine,60-80-0,approved; investigational,VEQOALNAAJBPNY-UHFFFAOYSA-N,"InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3",Cc1cc(=O)n(n1C)-c2ccccc2,C11H12N2O,C13244,D01776,2206,46505216,31225,CHEMBL277474,,2121,50103600,188.2258,1.218971844,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics and Anesthetics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Azoles; Central Nervous System Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Methemoglobinemia Associated Agents; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; Otologicals; Peripheral Nervous System Agents; Pyrazoles; Pyrazolones; Sensory Organs; Sensory System Agents"
DB01436,Alfacalcidol,41294-56-8,approved; nutraceutical,OFHCOWSQAMBJIW-AVJTYSNKSA-N,"InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1",CC(C)CCC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)/C(CCC2)=C/C=C3/C[C@@H](O)C[C@H](O)C3=C,C27H44O2,,D01518,5282181,46505115,31186,CHEMBL1601669,,4445376,,400.6371,5.821855682,Alimentary Tract and Metabolism; Bone Density Conservation Agents; Cholestanes; Cholestenes; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Fused-Ring Compounds; Lipids; Membrane Lipids; Musculo-Skeletal System; Polycyclic Compounds; Secosteroids; Steroids; Sterols; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)
DB01437,Glutethimide,77-21-4,approved; illicit,JMBQKKAJIKAWKF-UHFFFAOYSA-N,"InChI=1S/C13H15NO2/c1-2-13(10-6-4-3-5-7-10)9-8-11(15)14-12(13)16/h3-7H,2,8-9H2,1H3,(H,14,15,16)",c1ccccc1C2(CC)CCC(=O)NC2=O,C13H15NO2,C07489,D00532,3487,46506283,5439,CHEMBL1102,,3367,,217.2637,2.128470322,"Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Piperidinedione Derivatives; Piperidines; Piperidones; Psycholeptics"
DB01438,Phenazopyridine,94-78-0,approved,QPFYXYFORQJZEC-FOCLMDBBSA-N,"InChI=1S/C11H11N5/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8/h1-7H,(H4,12,13,14)/b16-15+",Nc1nc(N)c(cc1)/N=N/c2ccccc2,C11H11N5,C07429,D08346,4756,46507962,71416,CHEMBL1242,,4592,50420356,213.2385,2.692530214,"Amines; Aminopyridines; Antipruritics and Local Anesthetics; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Methemoglobinemia Associated Agents; Nephrotoxic agents; Pyridines; Urologicals"
DB01440,gamma-Hydroxybutyric acid,591-81-1,approved; illicit; investigational,SJZRECIVHVDYJC-UHFFFAOYSA-N,"InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7)",OCCCC(=O)O,C4H8O3,C00989,,3037032,46507548,30830,CHEMBL1342,,9984,50023575,104.1045,-0.514919819,"Acids, Acyclic; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Butyrates; Carboxylic Acids; Central Nervous System Depressants; Central Nervous System Depression; Decreased Central Nervous System Organized Electrical Activity; Fatty Acids; Fatty Acids, Volatile; Hydroxy Acids; Lipids"
DB01452,Diamorphine,561-27-3,approved; illicit; investigational,GVGLGOZIDCSQPN-PVHGPHFFSA-N,"InChI=1S/C21H23NO5/c1-11(23)25-16-6-4-13-10-15-14-5-7-17(26-12(2)24)20-21(14,8-9-22(15)3)18(13)19(16)27-20/h4-7,14-15,17,20H,8-10H2,1-3H3/t14-,15+,17-,20-,21-/m0/s1",C1CN(C)[C@@H]([C@H]2[C@@]134)Cc5c3c(c(cc5)OC(=O)C)O[C@H]4[C@H](C=C2)OC(=O)C,C21H23NO5,C06534,D07286,5462328,46506839,27808,CHEMBL459324,,4575379,,369.411,1.549008933,"Alkaloids; Analgesics; Central Nervous System Agents; Central Nervous System Depressants; Drugs Used in Addictive Disorders; Drugs Used in Opioid Dependence; Heroin, agonists; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Morphine Derivatives; Narcotics; Nervous System; Opiate Alkaloids; Opioids; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; Thyroxine-binding globulin inducers"
DB01495,Dichloralphenazone,480-30-8,approved; illicit,ATKXDQOHNICLQW-UHFFFAOYSA-N,"InChI=1S/C11H12N2O.2C2H3Cl3O2/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10;2*3-2(4,5)1(6)7/h3-8H,1-2H3;2*1,6-7H",Cc1cc(=O)n(n1C)-c2ccccc2,C15H18Cl6N2O5,,,10188,46507898,,CHEMBL1697834,,9776,,519.032,1.218971844,"Alcohols; Azoles; Central Nervous System Depressants; Ethylene Glycols; Glycols; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Psycholeptics; Pyrazoles; Pyrazolones"
DB01501,Difenoxin,28782-42-5,approved; illicit,UFIVBRCCIRTJTN-UHFFFAOYSA-N,"InChI=1S/C28H28N2O2/c29-22-28(24-12-6-2-7-13-24,25-14-8-3-9-15-25)18-21-30-19-16-27(17-20-30,26(31)32)23-10-4-1-5-11-23/h1-15H,16-21H2,(H,31,32)",c1ccccc1C2(C(=O)O)CCN(CC2)CCC(C#N)(c3ccccc3)c4ccccc4,C28H28N2O2,C07871,D03809,34328,46508854,4534,CHEMBL1201321,,31620,,424.5341,2.649648205,"Acids, Heterocyclic; Alimentary Tract and Metabolism; Antidiarrheals; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antipropulsives; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isonipecotic Acids; Piperidines"
DB01544,Flunitrazepam,1622-62-4,approved; illicit,PPTYJKAXVCCBDU-UHFFFAOYSA-N,"InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3",[O-][N+](=O)c(c1)ccc(c12)N(C)C(=O)CN=C2c3ccccc3F,C16H12FN3O3,,D01230,3380,46504553,31622,CHEMBL13280,,3263,25878,313.2832,2.554728017,"Anti-Anxiety Agents; Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents; UGT1A1 Inhibitors; UGT1A3 Inhibitors; UGT2B7 Inhibitors"
DB01551,Dihydrocodeine,125-28-0,approved; illicit,RBOXVHNMENFORY-DNJOTXNNSA-N,"InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1",[C@]123[C@H]4Oc5c1c(ccc5OC)C[C@@H](N(C)CC2)[C@@H]3CC[C@@H]4O,C18H23NO3,,D01481,5284543,46506478,135276,CHEMBL1595,,4447600,,301.3801,1.54896548,"Alkaloids; Analgesics; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Morphine Derivatives; Narcotics; Natural Opium Alkaloids; Nervous System; Opiate Alkaloids; Opioid Agonist; Opioids; Peripheral Nervous System Agents; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Semi-synthetic Opioids; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB01558,Bromazepam,1812-30-2,approved; illicit; investigational,VMIYHDSEFNYJSL-UHFFFAOYSA-N,"InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)",c1cc(Br)cc(c12)C(=NCC(=O)N2)c3ccccn3,C14H10BrN3O,,D01245,2441,46505694,31302,CHEMBL277062,,2347,,316.153,2.544906346,"Anti-Anxiety Agents; Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB01559,Clotiazepam,33671-46-4,approved; illicit,CHBRHODLKOZEPZ-UHFFFAOYSA-N,"InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3",CCc(s1)cc(c12)C(=NCC(=O)N2C)c3ccccc3Cl,C16H15ClN2OS,,D01328,2811,46508776,31425,CHEMBL1697737,,2709,,318.821,4.112953966,"Anti-Anxiety Agents; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Psycholeptics"
DB01563,Chloral hydrate,302-17-0,approved; illicit; investigational; vet_approved,RNFNDJAIBTYOQL-UHFFFAOYSA-N,"InChI=1S/C2H3Cl3O2/c3-2(4,5)1(6)7/h1,6-7H",OC(O)C(Cl)(Cl)Cl,C2H3Cl3O2,C06899,D00265,2707,46507155,28142,CHEMBL455917,,2606,,165.403,0.692355014,Alcohols; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Ethylene Glycols; Glycols; Hypnotics and Sedatives; Miscellaneous Anxiolytics Sedatives and Hypnotics; Nervous System; Psycholeptics
DB01574,Attapulgite,12174-11-7,approved; vet_approved,IXWIAFSBWGYQOE-UHFFFAOYSA-M,InChI=1S/Al.Mg.5H2O.10O.4Si/h;;5*1H2;;;;;;;;;;;;;;/q+3;+2;;;;;;10*-2;4*+4/p-1,[O],AlH9MgO15Si4,,,73415752,46505928,,,,32701176,,412.684,-0.652,"Alimentary Tract and Metabolism; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antidotes; Compounds used in a research, industrial, or household setting; Intestinal Adsorbents; Protective Agents"
DB01575,Kaolin,1332-58-7,approved,KGOIAFZMMLWXLM-UHFFFAOYSA-N,"InChI=1S/2Al.O7Si2.2H2O/c;;1-8(2,3)7-9(4,5)6;;/h;;;2*1H2/q2*+3;-6;;",[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-],Al2H4O9Si2,,,92024769,46508763,,,,21241417,,258.156,-3.858,"Acids; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Aluminium Compounds; Aluminum Silicates; Anions; Antidiarrheals; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Electrolytes; Gastrointestinal Agents; Intestinal Adsorbents; Ions; Metal cations; Metal divalent cations; Minerals; Oxides; Oxygen Compounds; Silicates; Silicon Compounds"
DB01576,Dextroamphetamine,51-64-9,approved; illicit,KWTSXDURSIMDCE-QMMMGPOBSA-N,"InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1",C[C@H](N)Cc1ccccc1,C9H13N,C07884,D03740,5826,46506252,4469,CHEMBL612,1WE,5621,50022723,135.2062,1.804250482,"Agents producing tachycardia; Agents that produce hypertension; Amines; Amphetamines; Central Nervous System Agents; Central Nervous System Stimulants; Central Nervous System Stimulation; Centrally Acting Sympathomimetics; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Uptake Inhibitors; Ethylamines; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Phenethylamines; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetics"
DB01577,Metamfetamine,537-46-2,approved; illicit,MYWUZJCMWCOHBA-VIFPVBQESA-N,"InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1",CN[C@@H](C)Cc1ccccc1,C10H15N,C07164,,10836,46508541,6809,CHEMBL1201201,B40,10379,50359499,149.2328,2.236830875,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Amines; Amphetamine Anorectic; Amphetamines; Antidepressive Agents; Appetite Suppression; Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Central Nervous System Stimulants; Central Nervous System Stimulation; Centrally Acting Sympathomimetics; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Uptake Inhibitors; Drugs that are Mainly Renally Excreted; Ethylamines; Increased Sympathetic Activity; Membrane Transport Modulators; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Peripheral Nervous System Agents; Phenethylamines; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetics"
DB01579,Phendimetrazine,634-03-7,approved; illicit,MFOCDFTXLCYLKU-CMPLNLGQSA-N,"InChI=1S/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3/t10-,12+/m0/s1",CN1CCO[C@H]([C@@H]1C)c2ccccc2,C12H17NO,C07904,D08347,30487,46506122,8059,CHEMBL1615439,,28295,,191.274,2.172484226,"Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Appetite Suppression; Central Nervous System Agents; Central Nervous System Stimulants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Increased Sympathetic Activity; Oxazines; Sympathomimetic Amine Anorectic"
DB01580,Oxprenolol,6452-71-7,approved,CEMAWMOMDPGJMB-UHFFFAOYSA-N,"InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3",CC(C)NCC(O)COc1ccccc1OCC=C,C15H23NO3,,,4631,46508996,91704,CHEMBL546,,4470,50240370,265.348,2.16779773,"Adrenergic Agents; Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Anti-Anxiety Agents; Antiarrhythmic agents; Antihypertensive Agents; Autonomic Agents; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Non-Selective; Beta Blocking Agents, Non-Selective, and Thiazides; Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hypotensive Agents; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; OCT2 Inhibitors; Peripheral Nervous System Agents; Phenoxypropanolamines; Propanolamines; Propanols; QTc Prolonging Agents; Sympatholytics; Tranquilizing Agents; Vasodilating Agents"
DB01581,Sulfamerazine,127-79-7,approved; vet_approved,QPPBRPIAZZHUNT-UHFFFAOYSA-N,"InChI=1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)",Cc1nc(ncc1)NS(=O)(=O)c2ccc(N)cc2,C11H12N4O2S,,D02435,5325,46505036,102130,CHEMBL438,,5134,50238672,264.304,0.518630977,Amides; Amines; Aniline Compounds; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Long-Acting Sulfonamides; Sulfanilamides; Sulfonamide Antibacterial; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds
DB01582,Sulfamethazine,57-68-1,approved; investigational; vet_approved,ASWVTGNCAZCNNR-UHFFFAOYSA-N,"InChI=1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)",Cc1cc(C)nc(n1)NS(=O)(=O)c2ccc(N)cc2,C12H14N4O2S,C19530,,5327,46507146,102265,CHEMBL446,,5136,50238670,278.33,0.650001146,Amides; Amines; Aniline Compounds; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Short-Acting Sulfonamides; Sulfanilamides; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds
DB01583,Liotrix,8065-29-0,approved,LKYWLLWWYBVUPP-XOCLESOZSA-L,"InChI=1S/C15H11I4NO4.C15H12I3NO4.2Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);1-4,6,12,20H,5,19H2,(H,21,22);;/q;;2*+1/p-2/t2*12-;;/m00../s1",[O-]C(=O)[C@@H](N)Cc1cc(I)c(c(I)c1)Oc2cc(I)c(O)c(I)c2,C30H21I7N2Na2O8,,D00361,71371,46506203,6485,,,64467,,1471.8072,3.727307065,"Agents used to treat hypothyroidism; Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; l-Triiodothyronine; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein inducers; Pharmaceutical Preparations; Thyroid Products; Thyronines; Thyroxine-binding globulin substrates"
DB01586,Ursodeoxycholic acid,128-13-2,approved; investigational,RUDATBOHQWOJDD-UZVSRGJWSA-N,"InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1",OC(=O)CC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)[C@H](C[C@@H]3O)C[C@H](O)CC4,C24H40O4,C07880,D00734,31401,46508795,9907,CHEMBL1551,IU5,29131,53721,392.572,3.713305524,Alimentary Tract and Metabolism; Bile Acid Preparations; Bile acids and derivatives; Bile Acids and Salts; Bile and Liver Therapy; Bile Therapy; BSEP/ABCB11 inducers; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Cholagogues and Choleretics; Cholanes; Cholelitholytic Agents; Cholic Acids; Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Fused-Ring Compounds; Gastrointestinal Agents; Polycyclic Compounds; Steroids
DB01587,Ketazolam,27223-35-4,approved,PWAJCNITSBZRBL-UHFFFAOYSA-N,"InChI=1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3",c1ccccc1C23N(C(=O)C=C(O2)C)CC(=O)N(C)c4c3cc(Cl)cc4,C20H17ClN2O3,,,33746,46507008,135556,CHEMBL2104356,,31110,,368.814,3.012867572,"Anti-Anxiety Agents; Benzazepines; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; P-glycoprotein substrates; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB01588,Prazepam,2955-38-6,approved; illicit,MWQCHHACWWAQLJ-UHFFFAOYSA-N,"InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2",c1ccccc1C(c(c23)cc(Cl)cc2)=NCC(=O)N3CC4CC4,C19H17ClN2O,C07366,D00470,4890,46505417,8362,CHEMBL969,,4721,,324.804,3.856663841,"Anti-Anxiety Agents; Benzazepines; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB01589,Quazepam,36735-22-5,approved; illicit,IKMPWMZBZSAONZ-UHFFFAOYSA-N,"InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2",Fc1ccccc1C2=NCC(=S)N(CC(F)(F)F)c(c23)ccc(Cl)c3,C17H11ClF4N2S,C07336,D00457,4999,46505952,8694,CHEMBL1200472,,4825,,386.794,5.063754325,"Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Nervous System; Psycholeptics"
DB01590,Everolimus,159351-69-6,approved,HKVAMNSJSFKALM-GKUWKFKPSA-N,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",OCCO[C@H]1[C@H](OC)C[C@@H](CC1)C[C@@H](C)[C@@H](OC(=O)[C@H](CCCC2)N2C(=O)C(=O)[C@]34O)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H](O3)CC[C@H]4C,C53H83NO14,,D02714,6442177,46505248,68478,CHEMBL1908360,,21106307,50088378,958.24,7.403864314,Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Immunologic Activity; Hyperglycemia-Associated Agents; Immunologic Factors; Immunosuppressive Agents; Kinase Inhibitor; Lactones; Macrocyclic Compounds; Macrolides; mTOR Inhibitor Immunosuppressant; mTOR Inhibitors; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Polyketides; Protein Kinase Inhibitors; Selective Immunosuppressants
DB01591,Solifenacin,242478-37-1,approved,FBOUYBDGKBSUES-VXKWHMMOSA-N,"InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1",C12CCN(CC1)C[C@@H]2OC(=O)N(CCc(c34)cccc4)[C@H]3c5ccccc5,C23H26N2O2,,D08522,154059,46506006,135530,CHEMBL1734,,135771,50370682,362.473,3.960605753,"Agents producing tachycardia; Agents that produce hypertension; Anticholinergic Agents; Cholinergic Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Urinary Frequency and Incontinence; Drugs Used in Benign Prostatic Hypertrophy; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Muscarinic Antagonists; Neurotransmitter Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinuclidines; Tetrahydroisoquinolines; Urological Agents; Urologicals"
DB01592,Iron,7439-89-6,approved,XEEYBQQBJWHFJM-UHFFFAOYSA-N,InChI=1S/Fe,[Fe],Fe,C00023,,23925,46509190,18248,,,22368,,55.845,-0.77,"Alimentary Tract and Metabolism; Antianemia Drugs; Antianemic Preparations; Blood and Blood Forming Organs; Diet, Food, and Nutrition; Elements; Food; Food and Beverages; Growth Substances; Iron Compounds; Iron Preparations; Metals; Metals, Heavy; Micronutrients; Minerals; Organometallic Compounds; Physiological Phenomena; Supplements; Trace Elements; Transition Elements"
DB01593,Zinc,7440-66-6,approved; investigational,HCHKCACWOHOZIP-UHFFFAOYSA-N,InChI=1S/Zn,[Zn],Zn,C00038,,23994,46506903,30185,CHEMBL1201279,,22430,50259154,65.409,0.156,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Cardiovascular System; Copper Absorption Inhibitor; Diet, Food, and Nutrition; Elements; Food; Food and Beverages; Growth Substances; Laxatives; Metal cations; Metal divalent cations; Metals; Metals, Heavy; Micronutrients; Minerals; Physiological Phenomena; Replacement Preparations; Trace Elements; Transition Elements; Vasoprotectives; Zinc Compounds"
DB01595,Nitrazepam,146-22-5,approved,KJONHKAYOJNZEC-UHFFFAOYSA-N,"InChI=1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)",[O-][N+](=O)c(cc1)cc(c12)C(=NCC(=O)N2)c3ccccc3,C15H11N3O3,C07487,D00531,4506,46505806,7581,CHEMBL13209,,4350,50020856,281.2661,2.547960012,"Anti-Anxiety Agents; Anticonvulsants; Benzazepines; Benzodiazepine hypnotics and sedatives; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; GABA Agents; GABA Modulators; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents"
DB01597,Cilastatin,82009-34-5,approved; investigational,DHSUYTOATWAVLW-WFVMDLQDSA-N,"InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1",CC1(C)C[C@@H]1C(=O)N/C(C(=O)O)=C\CCCCSC[C@H](N)C(=O)O,C16H26N2O5S,C01675,D07698,6435415,46505611,3697,CHEMBL766,CIL,4940183,50367502,358.453,-1.26556452,Cycloparaffins; Cyclopropanes; Dipeptidase Inhibitors; Enzyme Inhibitors; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Protease Inhibitors; Renal Dehydropeptidase Inhibitor
DB01598,Imipenem,64221-86-9,approved,ZSKVGTPCRGIANV-ZXFLCMHBSA-N,"InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1",C[C@@H](O)[C@@H](C1=O)[C@H](N12)CC(=C2C(=O)O)SCC/N=C/N,C12H17N3O4S,C06665,,104838,46505744,471744,CHEMBL148,,94631,50049708,299.346,-3.851222544,"Agents that reduce seizure threshold; Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Carbapenems; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Neurotoxic agents; Penem Antibacterial; Sulfur Compounds; Thienamycins"
DB01599,Probucol,23288-49-5,approved; investigational,FYPMFJGVHOHGLL-UHFFFAOYSA-N,"InChI=1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3",CC(C)(C)c1cc(cc(c1O)C(C)(C)C)SC(C)(C)Sc2cc(C(C)(C)C)c(O)c(c2)C(C)(C)C,C31H48O2S2,C07373,D00476,4912,46508876,8427,CHEMBL608,,4743,50007260,516.842,10.56952417,"Anticholesteremic Agents; Antioxidants; Benzene Derivatives; Cardiovascular System; Compounds used in a research, industrial, or household setting; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypolipidemic Agents; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Moderate Risk QTc-Prolonging Agents; Noxae; Phenols; Protective Agents; QTc Prolonging Agents; Toxic Actions"
DB01600,Tiaprofenic acid,33005-95-7,approved,GUHPRPJDBZHYCJ-UHFFFAOYSA-N,"InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)",OC(=O)C(C)c1ccc(s1)C(=O)c2ccccc2,C14H12O3S,,,5468,46504590,32221,CHEMBL365795,,5269,223313,260.308,3.658654214,"Acids, Acyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Carboxylic Acids; Central Nervous System Agents; Fatty Acids; Fatty Acids, Volatile; Lipids; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Other Nonsteroidal Anti-inflammatory Agents; Peripheral Nervous System Agents; Photosensitizing Agents; Propionates; Prostaglandin Antagonists; Sensory System Agents"
DB01601,Lopinavir,192725-17-0,approved,KJHKTHWMRKYKJE-SUGCFTRWSA-N,"InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1",O=C1NCCCN1[C@@H](C(C)C)C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc3ccccc3)NC(=O)COc4c(C)cccc4C,C37H48N4O5,C12871,D01425,92727,46508588,31781,CHEMBL729,AB1,83706,50180655,628.8008,4.687642083,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BSEP/ABCB11 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors (weak); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Experimental Unapproved Treatments for COVID-19; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV Protease Inhibitors; Hyperglycemia-Associated Agents; Metabolic Side Effects of Drugs and Substances; Nephrotoxic agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Protease Inhibitors; Pyrimidinones; QTc Prolonging Agents"
DB01602,Bacampicillin,50972-17-3,approved; investigational,PFOLLRNADZZWEX-FFGRCDKISA-N,"InChI=1S/C21H27N3O7S/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25)/t11?,13-,14-,15+,18-/m1/s1",CCOC(=O)OC(C)OC(=O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccccc3,C21H27N3O7S,C08122,,441397,46507859,2968,CHEMBL1583,,390135,,465.52,1.471288067,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillin G; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB01603,Meticillin,61-32-5,approved; investigational,RJQXTJLFIWVMTO-TYNCELHUSA-N,"InChI=1S/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)/t11-,12+,15-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)c3c(OC)cccc3OC,C17H20N2O6S,C07177,,6087,46508973,6827,CHEMBL575,MII,5862,50103523,380.415,0.78517004,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; Beta-Lactamase Resistant Penicillins; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillins; Sulfur Compounds"
DB01604,Pivampicillin,33817-20-8,approved,ZEMIJUDPLILVNQ-ZXFNITATSA-N,"InChI=1S/C22H29N3O6S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26)/t13-,14-,15+,18-/m1/s1",CC(C)(C)C(=O)OCOC(=O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccccc3,C22H29N3O6S,C11750,,33478,46505340,8255,CHEMBL3182343,,30899,,463.547,2.06519252,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillin G; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB01605,Pivmecillinam,32886-97-8,approved,NPGNOVNWUSPMDP-HLLBOEOZSA-N,"InChI=1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3/t14-,15+,17-/m1/s1",C1CCCCCN1/C=N/[C@@H]2C(=O)N([C@@H]23)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C,C21H33N3O5S,,D02889,115163,46506880,51210,CHEMBL1616433,,16735658,,439.569,2.908542691,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillins; Penicillins With Extended Spectrum; Renal Agents; Sulfur Compounds"
DB01606,Tazobactam,89786-04-9,approved,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,"InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1",O=C1C[C@H](N12)S(=O)(=O)[C@](C)([C@@H]2C(=O)O)Cn3ccnn3,C10H12N4O5S,C07771,D00660,123630,46508088,9421,CHEMBL404,,110216,50053173,300.291,-1.399508449,"Amides; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Aza Compounds; Azabicyclo Compounds; Beta-Lactam Antibacterials; beta-Lactamase Inhibitors; beta-Lactams; Bicyclo Compounds; Bicyclo Compounds, Heterocyclic; Bridged Compounds; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; Polycyclic Compounds; Sulfones; Sulfur Compounds"
DB01607,Ticarcillin,34787-01-4,approved; investigational; vet_approved,OHKOGUYZJXTSFX-KZFFXBSXSA-N,"InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](C(=O)O)c3cscc3,C15H16N2O6S2,C07139,,36921,46505959,9587,CHEMBL1449,,33876,50103522,384.427,0.595798783,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Pseudomonal Beta-Lactams; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB01608,Periciazine,2622-26-6,approved; investigational,LUALIOATIOESLM-UHFFFAOYSA-N,"InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2",OC1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(c4)C#N,C21H23N3OS,,D01485,4747,46505085,31981,CHEMBL251940,,4585,50346422,365.492,3.105111347,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Depressants; Dopamine Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Phenothiazines; Phenothiazines With Piperidine Structure; Psycholeptics; Sulfur Compounds"
DB01609,Deferasirox,201530-41-8,approved; investigational,BOFQWVMAQOTZIW-UHFFFAOYSA-N,"InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)",OC(=O)c1ccc(cc1)-n2nc(-c3ccccc3O)nc2-c4ccccc4O,C21H15N3O4,,D03669,5493381,46506791,49005,CHEMBL550348,,10770206,50088376,373.3615,4.744616195,"Acids, Carbocyclic; Azoles; Benzene Derivatives; Benzoates; Carboxylic Acids; Chelating Agents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Heavy Metal Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iron Chelating Activity; Iron Chelating Agents; Sequestering Agents; Triazoles; UGT1A1 Inhibitors; UGT1A1 Substrates; UGT1A3 Inhibitors; UGT1A9 Inhibitors"
DB01610,Valganciclovir,175865-60-8,approved; investigational,WPVFJKSGQUFQAP-GKAPJAKFSA-N,"InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1",CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc(c12)c(=O)nc([nH]2)N,C14H22N6O5,,D02495,64147,46505524,63635,CHEMBL1201314,,57721,,354.3617,-1.081859998,"Agents that reduce seizure threshold; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Ganciclovir; Ganciclovir and prodrug; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acid Synthesis Inhibitors; Nucleoside Analog Antiviral; Nucleosides and Nucleotides; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; Purines; Purinones"
DB01611,Hydroxychloroquine,118-42-3,approved,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,"InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)",OCCN(CC)CCCC(C)Nc(ccn1)c(c12)ccc(Cl)c2,C18H26ClN3O,C07043,D08050,3652,46508459,5801,CHEMBL1535,,3526,,335.872,2.886971175,"Aminoquinolines; Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Antirheumatic Agents; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; P-glycoprotein inhibitors; Photosensitizing Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines"
DB01612,Amyl Nitrite,8017-89-8,approved,CSDTZUBPSYWZDX-UHFFFAOYSA-N,"InChI=1S/C5H11NO2/c1-2-3-4-5-8-6-7/h2-5H2,1H3",CCCCCON=O,C5H11NO2,C07457,D00517,10026,46507839,55344,CHEMBL3188202,,9632,,117.1463,2.31256604,"Acids; Acids, Noncarboxylic; Anions; Antianginal Agents; Antidotes; Cardiovascular Agents; Electrolytes; Hypotensive Agents; Ions; Methemoglobinemia Associated Agents; Nitrites; Nitrogen Compounds; Organic Nitrates; Vasodilating Agents"
DB01613,Erythrityl tetranitrate,7297-25-8,approved; experimental; investigational,SNFOERUNNSHUGP-ZXZARUISSA-N,"InChI=1S/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+",[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O,C4H6N4O12,,,5284553,46508990,60072,CHEMBL2107583,,4447608,,302.11,1.230457255,"Acids; Acids, Noncarboxylic; Alcohols; Anions; Antianginal Agents; Carbohydrates; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Electrolytes; Erythritol; Ions; Nitrates; Nitric Acid; Nitrogen Compounds; Organic Nitrates; Sugar Alcohols; Vasodilating Agents; Vasodilators Used in Cardiac Diseases"
DB01616,Alverine,150-59-4,approved; investigational,ZPFXAOWNKLFJDN-UHFFFAOYSA-N,"InChI=1S/C20H27N/c1-2-21(17-9-15-19-11-5-3-6-12-19)18-10-16-20-13-7-4-8-14-20/h3-8,11-14H,2,9-10,15-18H2,1H3",c1ccccc1CCCN(CC)CCCc2ccccc2,C20H27N,,D07440,3678,46506981,518413,CHEMBL253371,,3550,37636,281.4351,5.462383395,Alimentary Tract and Metabolism; Amines; Antidepressive Agents; Autonomic Agents; Central Nervous System Depressants; Drugs for Functional Gastrointestinal Disorders; Parasympatholytics; Peripheral Nervous System Agents; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists
DB01618,Molindone,7416-34-4,approved,KLPWJLBORRMFGK-UHFFFAOYSA-N,"InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3",CCc1c(C)[nH]c(c12)CCC(C2=O)CN3CCOCC3,C16H24N2O2,C07230,D08226,23897,46504744,6965,CHEMBL460,,22342,50130290,276.374,2.035115026,"Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indole Derivatives; Indoles; Nervous System; Neurotoxic agents; Psycholeptics; Psychotropic Drugs; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB01619,Phenindamine,82-88-2,approved,ISFHAYSTHMVOJR-UHFFFAOYSA-N,"InChI=1S/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3",c1ccccc1C2c(cccc3)c3C(=C24)CCN(C4)C,C19H19N,C07790,D08353,11291,46508187,8065,CHEMBL278398,,10817,50089147,261.3609,3.619731141,"Antihistamines for Systemic Use; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Neurotransmitter Agents; Respiratory System"
DB01620,Pheniramine,86-21-5,approved,IJHNSHDBIRRJRN-UHFFFAOYSA-N,"InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3",c1cccnc1C(CCN(C)C)c2ccccc2,C16H20N2,,,4761,46505932,91591,CHEMBL1193,,4597,50017656,240.3434,2.980906239,"Anti-Allergic Agents; Antihistamines for Systemic Use; Antihistamines for Topical Use; Antipruritics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Respiratory System"
DB01621,Pipotiazine,39860-99-6,approved; investigational,JOMHSQGEWSNUKU-UHFFFAOYSA-N,"InChI=1S/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3",CN(C)S(=O)(=O)c(cc1)cc(c12)N(c3c(S2)cccc3)CCCN4CCC(CC4)CCO,C24H33N3O3S2,,D08385,62867,46508263,,CHEMBL398880,,56598,81798,475.667,3.129613743,"Antidepressive Agents; Antipsychotic Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Nervous System; Neurotoxic agents; Phenothiazines; Phenothiazines With Piperidine Structure; Photosensitizing Agents; Psycholeptics; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds"
DB01623,Thiothixene,3313-26-6,approved,GFBKORZTTCHDGY-UWVJOHFNSA-N,"InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-",CN(C)S(=O)(=O)c(cc1)cc(c12)/C(c3c(S2)cccc3)=C\CCN4CCN(C)CC4,C23H29N3O2S2,,D00374,941651,46505564,9571,CHEMBL1201,,819430,78576,443.625,3.362424167,"Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Photosensitizing Agents; Potential QTc-Prolonging Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Thioxanthene Derivatives; Thioxanthenes; Tranquilizing Agents; Xanthenes"
DB01624,Zuclopenthixol,53772-83-1,approved; investigational,WFPIAZLQTJBIFN-DVZOWYKESA-N,"InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-",OCCN1CCN(CC1)CC/C=C\2c(cccc3)c3Sc(c24)ccc(Cl)c4,C22H25ClN2OS,,D03556,5311507,46507341,51364,CHEMBL53904,,4470984,79209,400.965,4.22298393,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (First Generation [Typical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Histamine Antagonists; Histamine H1 Antagonists; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Thioxanthene Derivatives; Thioxanthenes; Tranquilizing Agents; Xanthenes"
DB01625,Isopropamide,7492-32-2,approved; vet_approved,JTPUMZTWMWIVPA-UHFFFAOYSA-O,"InChI=1S/C23H32N2O/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3,(H-,24,26)/p+1",c1ccccc1C(C(=O)N)(CC[N+](C)(C(C)C)C(C)C)c2ccccc2,C23H33N2O,C07055,,3775,46507726,6043,CHEMBL1201232,,3643,82074,353.5209,0.13792197,"Agents producing tachycardia; Alimentary Tract and Metabolism; Amines; Ammonium Compounds; Anticholinergic Agents; Drugs for Functional Gastrointestinal Disorders; Muscarinic Antagonists; Nitrogen Compounds; Onium Compounds; Synthetic Anticholinergics, Quaternary Ammonium Compounds"
DB01626,Pargyline,555-57-7,approved,DPWPWRLQFGFJFI-UHFFFAOYSA-N,"InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3",C#CCN(C)Cc1ccccc1,C11H13N,C07414,D08453,4688,46507368,7930,CHEMBL673,,4526,50172756,159.2276,2.142725629,"Agents that produce hypertension; Agents that reduce seizure threshold; Amines; Antidepressive Agents; Antihypertensive Agents; Benzene Derivatives; Benzyl Compounds; Benzylamines; Cardiovascular Agents; Cardiovascular System; Central Nervous System Depressants; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; MAO Inhibitors and Diuretics; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Monoamine Oxidase Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB01627,Lincomycin,154-21-2,approved; vet_approved,OJMMVQQUTAEWLP-KIDUDLJLSA-N,"InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1",CCC[C@H]1CN(C)[C@@H](C1)C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,C18H34N2O6S,C06812,D00223,3000540,46506668,6472,CHEMBL1447,3QB,2272112,50335522,406.54,-0.316854216,"Agents that produce neuromuscular block (indirect); Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Enzyme Inhibitors; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lincosamides; Macrolides, Lincosamides and Streptogramins; Neurotoxic agents; Protein Synthesis Inhibitors; Pyrrolidines"
DB01628,Etoricoxib,202409-33-4,approved; investigational,MNJVRJDLRVPLFE-UHFFFAOYSA-N,"InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3",Cc1ncc(cc1)-c2c(cc(Cl)cn2)-c3ccc(cc3)S(=O)(=O)C,C18H15ClN2O2S,C11718,D03710,123619,46504505,6339,CHEMBL416146,5CH,110209,50072064,358.842,2.793925399,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Central Nervous System Agents; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Peripheral Nervous System Agents; Pyridines; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents; Sulfones; Sulfur Compounds"
DB01632,5-O-phosphono-alpha-D-ribofuranosyl diphosphate,13270-65-0,approved; experimental; investigational,PQGCEDQWHSBAJP-TXICZTDVSA-N,"InChI=1S/C5H13O14P3/c6-3-2(1-16-20(8,9)10)17-5(4(3)7)18-22(14,15)19-21(11,12)13/h2-7H,1H2,(H,14,15)(H2,8,9,10)(H2,11,12,13)/t2-,3-,4-,5-/m1/s1",OP(=O)(O)OP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@H](O1)COP(=O)(O)O,C5H13O14P3,C00119,,7339,46506467,17111,,PRP,7062,25315,390.0696,-2.971134818,Carbohydrates; Pentosephosphates; Sugar Phosphates
DB01638,Sorbitol,50-70-4,approved,FBPFZTCFMRRESA-JGWLITMVSA-N,"InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1",OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,C6H14O6,C00794,D00096,5780,46507030,17924,CHEMBL1682,SOR,5576,,182.1718,-3.730018849,"Alcohols; Alimentary Tract and Metabolism; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Carbohydrates; Compounds used in a research, industrial, or household setting; Diagnostic Agents; Diet, Food, and Nutrition; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Enemas; Flavoring Agents; Food; Food Additives; Food and Beverages; Food Ingredients; Gastrointestinal Agents; Indicators and Reagents; Irrigating Solutions; Laboratory Chemicals; Laxatives; Osmotic Laxatives; Pharmaceutic Aids; Pharmaceutical Preparations; Physiological Phenomena; Sugar Alcohols; Sweetening Agents; Tests for Bile Duct Patency"
DB01656,Roflumilast,162401-32-3,approved,MNDBXUUTURYVHR-UHFFFAOYSA-N,"InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)",C1CC1COc2c(OC(F)F)ccc(c2)C(=O)Nc3c(Cl)cncc3Cl,C17H14Cl2F2N2O3,,D05744,449193,175426853,47657,CHEMBL193240,ROF,395793,14774,403.207,4.447540533,"Acids, Carbocyclic; Agents to Treat Airway Disease; Amides; Amines; Benzene Derivatives; Benzoates; Carboxylic Acids; Cycloparaffins; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Polycyclic Compounds; Pyridines; Respiratory System"
DB01698,Rutin,153-18-4,approved; experimental; investigational,IKGXIBQEEMLURG-NVPNHPEKSA-N,"InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,23+,26+,27-/m0/s1",O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O[C@H]1C)OC[C@H]2O[C@H]([C@H](O)[C@@H](O)[C@@H]2O)Oc(c3=O)c(-c4cc(O)c(O)cc4)oc(c35)cc(O)cc5O,C27H30O16,C05625,,5280805,46508549,28527,CHEMBL226335,RUT,4444362,,610.5175,-0.868760975,"Benzopyrans; Capillary Stabilizing Agents; Cardiovascular System; Chromones; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Flavonoids; Flavonols; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans; Vasoprotectives"
DB01708,Prasterone,53-43-0,approved; investigational; nutraceutical,FMGSKLZLMKYGDP-USOAJAOKSA-N,"InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1",O=C1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(=CC3)C[C@@H](O)CC4,C19H28O2,C01227,D08409,5881,46508824,28689,CHEMBL90593,AND,5670,50223368,288.4244,3.361705055,"17-Ketosteroids; Adjuvants, Immunologic; Adrenal Cortex Hormones; Alimentary Tract and Metabolism; Anabolic Agents for Systemic Use; Anabolic Steroids; Androgens and Estrogens; Androstan Derivatives; Androstanes; Androstenes; Androstenols; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunologic Factors; Ketosteroids; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Polycyclic Compounds; Sex Hormones and Modulators of the Genital System; Steroids; Testosterone Congeners"
DB01718,Cetrimonium,01-10-6899,approved,RLGQACBPNDBWTB-UHFFFAOYSA-N,"InChI=1S/C19H42N/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(2,3)4/h5-19H2,1-4H3/q+1",CCCCCCCCCCCCCCCC[N+](C)(C)C,C19H42N,C11275,D03454,2681,46507665,39561,CHEMBL1183605,16A,2580,58941,284.5435,2.686555844,"Amines; Ammonium Compounds; Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Cetrimonium Compounds; Compounds used in a research, industrial, or household setting; Dermatologicals; Medicated Shampoos; Miscellaneous Local Anti-infectives; Nitrogen Compounds; Onium Compounds; Quaternary Ammonium Compounds; Respiratory System; Throat Preparations; Trimethyl Ammonium Compounds"
DB01744,Camphor,464-49-3,approved,DSSYKIVIOFKYAU-XCBNKYQSSA-N,"InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3/t7-,10+/m1/s1",C[C@]12C(=O)C[C@H](C1(C)C)CC2,C10H16O,C00808,D06392,159055,46508429,15396,CHEMBL504760,CAM,139902,36263,152.2334,2.55298559,"Anti-Infective Agents; Anti-Infective Agents, Local; Antipruritics and Local Anesthetics; Basic Lotions and Liniments; Biological Products; Bornanes; Cardiac Therapy; Cardiovascular System; Complex Mixtures; Hydrocarbons; Ketones; Monoterpenes; Norbornanes; Pharmaceutical Preparations; Plant Extracts; Plant Preparations; Terpenes"
DB01764,Dalfopristin,112362-50-2,approved,SUYRLXYYZQTJHF-VMBLUXKRSA-N,"InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1",CCN(CC)CCS(=O)(=O)[C@@H]1CCN([C@H]12)C(=O)c3nc(oc3)CC(=O)C[C@H](O)\C=C(C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@H](OC2=O)C(C)C,C34H50N4O9S,C08033,D00853,6323289,46506561,,CHEMBL1200937,DOL,16736919,,690.85,1.581890931,"Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Macrocyclic Compounds; Peptides; Peptides, Cyclic; Polycyclic Compounds; Streptogramin Antibacterial; Streptogramins"
DB01783,Pantothenic acid,79-83-4,approved; nutraceutical; vet_approved,GHOKWGTUZJEAQD-ZETCQYMHSA-N,"InChI=1S/C9H17NO5/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13)/t7-/m0/s1",OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)O,C9H17NO5,C00864,D07413,988,46505022,46905,CHEMBL1594,PAU,6361,50240040,219.235,-1.355375107,"Alanine; Alimentary Tract and Metabolism; Amino Acids; Amino Acids, Peptides, and Proteins; Blood Coagulation Factors; Cicatrizants; Dermatologicals; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Imides; Micronutrients; Physiological Phenomena; Preparations for Treatment of Wounds and Ulcers; Vitamin B Complex; Vitamins"
DB01839,Propylene glycol,57-55-6,approved; investigational,DNIAPMSPPWPWGF-UHFFFAOYSA-N,"InChI=1S/C3H8O2/c1-3(5)2-4/h3-5H,2H2,1H3",CC(O)CO,C3H8O2,C00583,D00078,1030,46505685,16997,CHEMBL286398,,13835224,,76.0944,-0.792104056,"Alcohols; Compounds used in a research, industrial, or household setting; Drug Delivery Systems; Drug Therapy; Glycols; Pegylated agents; Pharmaceutic Aids; Pharmaceutical Preparations; Pharmaceutical Vehicles; Propylene Glycols; Solvents; Therapeutics"
DB01914,D-glucose,50-99-7,approved; investigational; vet_approved,GZCGUPFRVQAUEE-SLPGGIOYSA-N,"InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h1,3-6,8-12H,2H2/t3-,4+,5+,6+/m0/s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O,C6H12O6,,,107526,46507147,42758,,GLO,96749,,180.1559,-3.568360563,"Carbohydrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Flavoring Agents; Food; Food Additives; Food and Beverages; Food Ingredients; Glucose; Hexoses; Monosaccharides; Pharmaceutic Aids; Pharmaceutical Preparations; Physiological Phenomena; Sweetening Agents"
DB01956,Taurine,107-35-7,approved; nutraceutical,XOAAWQZATWQOTB-UHFFFAOYSA-N,"InChI=1S/C2H7NO3S/c3-1-2-7(4,5)6/h1-3H2,(H,4,5,6)",NCCS(=O)(=O)O,C2H7NO3S,C00245,D00047,1123,46506189,507393,CHEMBL239243,TAU,1091,50357220,125.147,-2.614687395,"Acids; Acids, Noncarboxylic; Alkanes; Alkanesulfonic Acids; Hydrocarbons; Hydrocarbons, Acyclic; Sulfonic Acids; Sulfur Acids; Sulfur Compounds"
DB01987,Cocarboxylase,136-08-3,approved; experimental,AYEKOFBPNLCAJY-UHFFFAOYSA-N,"InChI=1S/C12H18N4O7P2S/c1-8-11(3-4-22-25(20,21)23-24(17,18)19)26-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7H,3-4,6H2,1-2H3,(H4-,13,14,15,17,18,19,20,21)",OP([O-])(=O)O[P@](=O)(O)OCCc1c(C)[n+](cs1)Cc2cnc(C)nc2N,C12H18N4O7P2S,C00068,,5431,46504577,45931,CHEMBL1236235,TDP,5238,,424.306,-5.811121942,"Azoles; Coenzymes; Diet, Food, and Nutrition; Enzymes and Coenzymes; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Micronutrients; Physiological Phenomena; Pyrimidines; Sulfur Compounds; Thiazoles; Vitamin B Complex; Vitamins"
DB02266,Flufenamic acid,530-78-9,approved,LPEPZBJOKDYZAD-UHFFFAOYSA-N,"InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)",OC(=O)c1ccccc1Nc2cc(C(F)(F)F)ccc2,C14H10F3NO2,C13038,D01581,3371,46507173,42638,CHEMBL23588,FLF,3254,17636,281.2299,5.248602981,"Acids, Carbocyclic; Amines; Aminobenzoates; Aniline Compounds; Anti-Inflammatory Agents; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Benzene Derivatives; Benzoates; Carboxylic Acids; Fenamates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Musculo-Skeletal System; OAT1/SLC22A6 inhibitors; ortho-Aminobenzoates"
DB02300,Calcipotriol,112965-21-6,approved,LWQQLNNNIPYSNX-UROSTWAQSA-N,"InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1",C1CC1[C@H](O)/C=C/[C@@H](C)[C@H]2CC[C@H]([C@@]23C)/C(CCC3)=C/C=C4/C[C@@H](O)C[C@H](O)C4=C,C27H40O3,,D01125,5288783,46507122,50749,CHEMBL1200666,MC9,4450880,50369964,412.6047,3.843350785,Antipsoriatics; Antipsoriatics for Topical Use; Cholestanes; Cholestenes; Dermatologicals; Fused-Ring Compounds; Lipids; Membrane Lipids; Misc. Skin and Mucous Membrane Agents; Polycyclic Compounds; Secosteroids; Steroids; Sterols; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)
DB02325,Isopropyl alcohol,67-63-0,approved; investigational,KFZMGEQAYNKOFK-UHFFFAOYSA-N,"InChI=1S/C3H8O/c1-3(2)4/h3-4H,1-2H3",CC(C)O,C3H8O,C01845,D00137,3776,46508136,17824,CHEMBL582,IPA,3644,,60.095,0.254805911,"Alcohols; Antiseptics and Disinfectants; Compounds used in a research, industrial, or household setting; Dermatologicals; Miscellaneous Local Anti-infectives; Propanols; Solvents"
DB02362,Aminobenzoic acid,150-13-0,approved; experimental,ALYNCZNDIQEVRV-UHFFFAOYSA-N,"InChI=1S/C7H7NO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,8H2,(H,9,10)",Nc1ccc(cc1)C(=O)O,C7H7NO2,C00568,D02456,978,46504695,30753,CHEMBL542,PAB,953,50145829,137.136,0.80190277,"4-Aminobenzoic Acid; Acids, Carbocyclic; Aminobenzoates; Benzene Derivatives; Benzoates; Carboxylic Acids; Dermatologicals; Emollients and Protectives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; para-Aminobenzoates; Protectives Against UV-Radiation; Protectives Against UV-Radiation for Topical Use; Sunscreen Agents; Vitamin B Complex; Vitamins"
DB02513,Thymol,89-83-8,approved,MGSRCZKZVOBKFT-UHFFFAOYSA-N,"InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)6-10(9)11/h4-7,11H,1-3H3",CC(C)c1ccc(C)cc1O,C10H14O,C09908,D01039,6989,46504674,27607,CHEMBL29411,IPB,21105998,50240432,150.2176,3.428111034,"Anti-Infective Agents; Anti-Infective Agents, Local; Antifungal Agents; Benzene Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Monoterpenes; Terpenes"
DB02530,gamma-Aminobutyric acid,56-12-2,approved; investigational,BTCSSZJGUNDROE-UHFFFAOYSA-N,"InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)",NCCCC(=O)O,C4H9NO2,C00334,D00058,119,46507841,59888,CHEMBL96,ABU,116,24183,103.1198,-2.885677198,"Acids, Acyclic; Amino Acids; Amino Acids, Peptides, and Proteins; Aminobutyrates; Butyrates; Carboxylic Acids; Fatty Acids; Fatty Acids, Volatile; GABA Agents; Lipids; Neurotransmitter Agents"
DB02546,Vorinostat,149647-78-9,approved; investigational,WAEXFXRVDQXREF-UHFFFAOYSA-N,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",ONC(=O)CCCCCCC(=O)Nc1ccccc1,C14H20N2O3,,D06320,5311,46508989,45716,CHEMBL98,SHH,5120,19149,264.3202,2.003969249,Amides; Amines; Anilides; Aniline Compounds; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Hydroxamic Acids; Hydroxy Acids; Hydroxylamines; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Potential QTc-Prolonging Agents; QTc Prolonging Agents
DB02638,Terlipressin,14636-12-5,approved; investigational,BENFXAYNYRLAIU-QSVFAHTRSA-N,"InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1",NCCCC[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H](C(=O)N2)CC(=O)N,C52H74N16O15S2,,,72081,46504626,135905,CHEMBL2135460,,65067,,1227.372,-10.09269715,"Amino Acids, Peptides, and Proteins; Cardiovascular Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Moderate Risk QTc-Prolonging Agents; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormones; Pituitary Hormones, Posterior; Posterior Pituitary Lobe Hormones; Proteins; QTc Prolonging Agents; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Vasoconstrictor Agents; Vasopressin and Analogues; Vasopressins"
DB02659,Cholic Acid,81-25-4,approved,BHQCQFFYRZLCQQ-OELDTZBJSA-N,"InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1",OC(=O)CC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](C[C@@H]2O)[C@]4(C)[C@H](C[C@H]3O)C[C@H](O)CC4,C24H40O5,C00695,D10699,221493,46507063,16359,CHEMBL205596,CHD,192176,21680,408.5714,2.482494457,Alimentary Tract and Metabolism; Bile Acid Preparations; Bile acids and derivatives; Bile Acids and Salts; Bile and Liver Therapy; Bile Therapy; BSEP/ABCB11 inducers; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; Cholanes; Cholic Acids; Fused-Ring Compounds; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inducers; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein inducers; Polycyclic Compounds; Steroids
DB02701,Nicotinamide,98-92-0,approved; investigational,DFPAKSUCGFBDDF-UHFFFAOYSA-N,"InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)",NC(=O)c1cccnc1,C6H6N2O,C00153,D00036,936,46507386,17154,CHEMBL1140,NCA,911,27507,122.1246,-0.393786317,"Acids, Heterocyclic; Alimentary Tract and Metabolism; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Micronutrients; Nicotinic Acids; Physiological Phenomena; Pyridines; Vitamin B Complex; Vitamins"
DB02703,Fusidic acid,03-06-6990,approved; investigational,IECPWNUMDGFDKC-MZJAQBGESA-N,"InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1",CC(C)=CCC/C(C(=O)O)=C(/[C@H](C1)OC(=O)C)[C@@H]([C@]12C)C[C@@H](O)[C@@H]3[C@]2(C)CC[C@@H]4[C@]3(C)CC[C@@H](O)[C@H]4C,C31H48O6,C06694,D04281,3000226,46505364,29013,CHEMBL374975,FUA,2271900,58924,516.7092,4.421913816,Agents Causing Muscle Toxicity; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Topical Use; Antiinfectives for Systemic Use; BCRP/ABCG2 Inhibitors; BSEP/ABCB11 Inhibitors; Cholestadienes; Cholestadienols; Cholestanes; Cholestenes; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Enzyme Inhibitors; Fused-Ring Compounds; Lipids; Medicated Dressings; Medicated Dressings With Antiinfectives; Membrane Lipids; OATP1B1/SLCO1B1 Inhibitors; Ophthalmologicals; Other Miscellaneous Antibacterial Agents; Polycyclic Compounds; Protein Synthesis Inhibitors; Sensory Organs; Steroid Antibacterials; Steroids; Sterols; UGT1A1 Substrates
DB02772,Sucrose,57-50-1,approved; experimental; investigational,CZMRCDWAGMRECN-UGDNZRGBSA-N,"InChI=1S/C12H22O11/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12/h4-11,13-20H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1",OC[C@@H](O1)[C@@H](O)[C@H](O)[C@]1(CO)O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O,C12H22O11,C00089,D00025,5988,46506134,17992,CHEMBL253582,SUC,5768,50108105,342.2965,-4.528834964,"Carbohydrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Disaccharides; Flavoring Agents; Food; Food Additives; Food and Beverages; Food Ingredients; Oligosaccharides; Pharmaceutic Aids; Pharmaceutical Preparations; Physiological Phenomena; Polysaccharides; Sweetening Agents"
DB02789,Pregnenolone,145-13-1,approved; experimental,ORNBQBCIOKFOEO-QGVNFLHTSA-N,"InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1",CC(=O)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(=CC3)C[C@@H](O)CC4,C21H32O2,C01953,D00143,8955,46506718,16581,CHEMBL253363,PLO,8611,50375319,316.4776,3.581358453,"Adrenal Cortex Hormones; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydroxycorticosteroids; Polycyclic Compounds; Pregnanes; Pregnenes; Progesterone Congeners; Steroids"
DB02893,D-Methionine,348-67-4,approved; experimental; investigational,FFEARJCKVFRZRR-SCSAIBSYSA-N,"InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1",CSCC[C@@H](N)C(=O)O,C5H11NO2S,C00855,,84815,46505884,57932,CHEMBL1234268,MED,76512,,149.211,-2.189326617,NA
DB02925,Piretanide,55837-27-9,approved,UJEWTUDSLQGTOA-UHFFFAOYSA-N,"InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)",NS(=O)(=O)c1cc(C(=O)O)cc(N2CCCC2)c1Oc3ccccc3,C17H18N2O5S,,D01634,4849,46507197,32015,CHEMBL349803,,4683,50240046,362.4,2.250988002,Amides; Cardiovascular Agents; Cardiovascular System; Diuretics; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; High-Ceiling Diuretics; Membrane Transport Modulators; Natriuretic Agents; Sodium Potassium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds
DB02959,Oxitriptan,08-09-4350,approved; investigational; nutraceutical,LDCYZAJDBXYCGN-VIFPVBQESA-N,"InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)/t9-/m0/s1",OC(=O)[C@@H](N)Cc1c[nH]c(c12)ccc(c2)O,C11H12N2O3,C00643,D07339,439280,46505826,58266,CHEMBL350221,4PQ,388413,50403163,220.2246,-1.389698462,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Antidepressive Agents; Antidepressive Agents, Second-Generation; Central Nervous System Agents; Central Nervous System Depressants; Nervous System; Psychoanaleptics; Psychotropic Drugs; Tryptophan"
DB03017,Lauric acid,143-07-7,approved; experimental,POULHZVOKOAJMA-UHFFFAOYSA-N,"InChI=1S/C12H24O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h2-11H2,1H3,(H,13,14)",CCCCCCCCCCCC(=O)O,C12H24O2,C02679,,3893,46505943,30805,CHEMBL108766,DAO,3756,50180948,200.3178,4.478308118,Fatty Acids; Lipids
DB03085,Glycolic acid,79-14-1,approved; investigational,AEMRFAOFKBGASW-UHFFFAOYSA-N,"InChI=1S/C2H4O3/c3-1-2(4)5/h3H,1H2,(H,4,5)",OCC(=O)O,C2H4O3,C03547,,757,46508186,17497,CHEMBL252557,GOA,737,,76.0514,-1.04059376,"Acetates; Acids, Acyclic; Carboxylic Acids; Dermatologicals; Fatty Acids; Fatty Acids, Volatile; Hydroxy Acids; Keratolytic Agents; Lipids"
DB03088,Pidolic acid,98-79-3,approved; investigational,ODHCTXKNWHHXJC-VKHMYHEASA-N,"InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1",OC(=O)[C@@H]1CCC(=O)N1,C5H7NO3,C01879,,7405,46506886,18183,CHEMBL397976,PCA,7127,,129.114,-0.889669702,"Acids, Acyclic; Alimentary Tract and Metabolism; Amino Acids; Amino Acids, Acidic; Amino Acids, Cyclic; Amino Acids, Dicarboxylic; Amino Acids, Peptides, and Proteins; Carboxylic Acids; Glutamates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imines; Imino Acids; Mineral Supplements; Pyrrolidines; Pyrrolidinones"
DB03128,Acetylcholine,51-84-3,approved; investigational,OIPILFWXSMYKGL-UHFFFAOYSA-N,"InChI=1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1",CC(=O)OCC[N+](C)(C)C,C7H16NO2,C01996,,187,46504484,15355,CHEMBL667,ACH,182,10759,146.2074,-4.221143752,Amines; Antiglaucoma Preparations and Miotics; Biogenic Amines; Cardiovascular Agents; Cholinergic Agents; Cholinergic Agonists; Cholinergic Receptor Agonist; Miotics; Neurotransmitter Agents; OCT1 substrates; Ophthalmologicals; Parasympathomimetics; Sensory Organs; Vasodilating Agents
DB03147,Flavin adenine dinucleotide,146-14-5,approved,VWWQXMAJTJZDQX-UYBVJOGSSA-N,"InChI=1S/C27H33N9O15P2/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H,34,42,43)/t14-,15+,16+,19-,20+,21+,26+/m0/s1",O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6,C27H33N9O15P2,C00016,D00005,643975,46508543,16238,CHEMBL1232653,FAD,559059,,785.5497,-5.297286062,"Adenine Nucleotides; Biological Factors; Carbohydrates; Coenzymes; Enzymes and Coenzymes; Flavins; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Pigments, Biological; Pteridines; Purine Nucleotides; Purines; Ribonucleotides; Vitamin B Complex; Vitamins"
DB03166,Acetic acid,64-19-7,approved,QTBSBXVTEAMEQO-UHFFFAOYSA-N,"InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)",CC(=O)O,C2H4O2,C00033,D00010,176,46506148,15366,CHEMBL539,ACY,171,50074329,60.052,-0.223345714,"Acetates; Acids, Acyclic; Anti-Bacterial Agents; Anti-Infective Agents; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Fatty Acids; Fatty Acids, Volatile; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Indicators and Reagents; Laboratory Chemicals; Lipids; Organic Acids; Otologicals; Sensory Organs"
DB03175,Propyl alcohol,71-23-8,approved; experimental,BDERNNFJNOPAEC-UHFFFAOYSA-N,"InChI=1S/C3H8O/c1-2-3-4/h4H,2-3H2,1H3",CCCO,C3H8O,C05979,,1031,46507424,28831,CHEMBL14687,POL,1004,,60.095,0.360753281,Alcohols; Antiseptics and Disinfectants; Dermatologicals; Propanols
DB03193,Stearic acid,57-11-4,approved; experimental,QIQXTHQIDYTFRH-UHFFFAOYSA-N,"InChI=1S/C18H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-17H2,1H3,(H,19,20)",CCCCCCCCCCCCCCCCCC(=O)O,C18H36O2,C01530,D00119,5281,46508522,28842,CHEMBL46403,STE,5091,50240485,284.4772,7.145720108,Fatty Acids; Lipids
DB03209,Oteracil,937-13-3,approved,RYYCJUAHISIHTL-UHFFFAOYSA-N,"InChI=1S/C4H3N3O4/c8-2(9)1-5-3(10)7-4(11)6-1/h(H,8,9)(H2,5,6,7,10,11)",OC(=O)c1nc(=O)[nH]c(=O)[nH]1,C4H3N3O4,,D06399,4604,46508346,30863,CHEMBL181932,OXC,4443,,157.0843,-1.181113815,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Triazines"
DB03247,Flavin mononucleotide,146-17-8,approved; investigational,FVTCRASFADXXNN-SCRDCRAPSA-N,"InChI=1S/C17H21N4O9P/c1-7-3-9-10(4-8(7)2)21(15-13(18-9)16(25)20-17(26)19-15)5-11(22)14(24)12(23)6-30-31(27,28)29/h3-4,11-12,14,22-24H,5-6H2,1-2H3,(H,20,25,26)(H2,27,28,29)/t11-,12+,14-/m0/s1",O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O,C17H21N4O9P,C00061,,643976,46507603,17621,CHEMBL1201794,FMN,559060,50421345,456.3438,-1.040106291,"Biological Factors; Carbohydrates; Coenzymes; Diet, Food, and Nutrition; Enzymes and Coenzymes; Flavins; Food; Food and Beverages; Glycosides; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Micronutrients; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Physiological Phenomena; Pigments, Biological; Pteridines; Ribonucleotides; Vitamin B Complex; Vitamins"
DB03255,Phenol,108-95-2,approved; experimental,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,"InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H",Oc1ccccc1,C6H6O,C15584,D00033,996,46508193,15882,CHEMBL14060,IPH,971,26187,94.1112,1.669680494,"Anesthetics; Anesthetics, Local; Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Antivaricose Therapy; Benzene Derivatives; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Dermatologicals; Disinfectants; Histamine Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Miscellaneous Therapeutic Agents; Nervous System; Pharmaceutical Preparations; Pharmaceutical Solutions; Phenol and Derivatives; Phenols; Respiratory System; Sclerosing Agents for Local Injection; Sclerosing Solutions; Solutions; Throat Preparations; Vasoprotectives"
DB03310,Glutathione disulfide,27025-41-8,approved; experimental; investigational,YPZRWBKMTBYPTK-BJDJZHNGSA-N,"InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1",OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O,C20H32N6O12S2,C00127,D00031,65359,46508372,17858,CHEMBL1372,GDS,58835,225231,612.631,-10.10905413,"Amino Acids, Peptides, and Proteins; Oligopeptides; Peptides"
DB03312,Brivudine,69304-47-8,approved; investigational,ODZBBRURCPAEIQ-PIXDULNESA-N,"InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1",OC[C@H]1O[C@H](C[C@@H]1O)n2cc(/C=C/Br)c(=O)[nH]c2=O,C11H13BrN2O5,,,446727,46505721,,CHEMBL31634,BVD,394011,,333.135,-0.496567435,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Carbohydrates; Deoxyribonucleosides; Deoxyuridine; Direct Acting Antivirals; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; Pyrimidine Nucleosides; Pyrimidines; Ribonucleosides"
DB03585,Oxyphenbutazone,129-20-4,approved; withdrawn,HFHZKZSRXITVMK-UHFFFAOYSA-N,"InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3",CCCCC1C(=O)N(c2ccccc2)N(C1=O)c3ccc(O)cc3,C19H20N2O3,C19494,,4641,46507285,76258,CHEMBL1228,OPB,4480,200298,324.3737,3.832232444,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Azoles; Butylpyrazolidines; Central Nervous System Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; Ophthalmologicals; Other Nonsteroidal Anti-inflammatory Agents; Peripheral Nervous System Agents; Pyrazoles; Pyrazolones; Sensory Organs; Sensory System Agents; Topical Products for Joint and Muscular Pain"
DB03614,Mecobalamin,13422-55-4,approved; investigational,JEWJRMKHSMTXPP-WZHZPDAFSA-L,"InChI=1S/C62H90N13O14P.CH3.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);1H3;/q;;+2/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1",Cc(c1)c(C)cc(c1[n+]2[Co-3]3456C)n(c2)[C@@H]7[C@H](O)[C@@H]([C@H](O7)CO)OP([O-])(=O)O[C@H](C)CNC(=O)CC[C@@]8(C)C=9N3[C@H]([C@@H]8CC(=O)N)[C@]1(C)[N+]4=C([C@H]([C@]1(C)CC(=O)N)CCC(=O)N)C(C)=C1[N+]6=C([C@H]([C@]1(C)CC(=O)N)CCC(=O)N)C=C1[N+]5=C(C9C)[C@H](C1(C)C)CCC(=O)N,C63H91CoN13O14P,C06453,D03246,71306319,46506610,28115,CHEMBL2448537,COB,28534328,,1344.3823,-13.88479677,"Antianemic Preparations; Azoles; Blood and Blood Forming Organs; Corrinoids; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Macrocyclic Compounds; Polycyclic Compounds; Pyrroles; Tetrapyrroles; Vitamin B Complex; VITAMIN B12 AND FOLIC ACID; Vitamins"
DB03615,Ribostamycin,25546-65-0,approved; experimental,NSKGQURZWSPSBC-VVPCINPTSA-N,"InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17+/m1/s1",O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N,C17H34N4O10,C01759,D08478,33042,46505351,45257,CHEMBL221572,RIO,30581,,454.4727,-6.430578507,Agents that produce neuromuscular block (indirect); Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycosides; Narrow Therapeutic Index Drugs; Nephrotoxic agents
DB03619,Deoxycholic acid,83-44-3,approved,KXGVEGMKQFWNSR-LLQZFEROSA-N,"InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1",C1C[C@@H](O)C[C@H]([C@]12C)CC[C@@H]3[C@@H]2C[C@H](O)[C@@]4(C)[C@H]3CC[C@@H]4[C@H](C)CCC(=O)O,C24H40O4,C04483,,222528,46506360,28834,CHEMBL406393,DXC,193196,50375599,392.572,3.791259254,Bile Acids and Salts; BSEP/ABCB11 inducers; Cholagogues and Choleretics; Cholanes; Cholic Acids; Cytolytic Agent; Decreased Cell Membrane Integrity; Dermatologicals; Fused-Ring Compounds; Gastrointestinal Agents; Other Miscellaneous Therapeutic Agents; Polycyclic Compounds; Steroids
DB03754,Tromethamine,77-86-1,approved,LENZDBCJOHFCAS-UHFFFAOYSA-N,"InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2",OCC(N)(CO)CO,C4H11NO3,C07182,D00396,6503,46506027,9754,CHEMBL1200391,TRS,6257,,121.135,-2.712229118,"Alcohols; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Buffers; Compounds used in a research, industrial, or household setting; Drug Delivery Systems; Drug Therapy; Excipients; Glycols; I.V. Solution Additives; i.v. Solutions; Laboratory Chemicals; Pharmaceutic Aids; Pharmaceutical Preparations; Pharmaceutical Vehicles; Propylene Glycols; Solutions Affecting the Electrolyte Balance; Therapeutics"
DB03756,Doconexent,6217-54-5,approved; investigational,MBMBGCFOFBJSGT-KUBAVDMBSA-N,"InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-",CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O,C22H32O2,C06429,,445580,46506213,28125,CHEMBL367149,HXA,393183,50210259,328.4883,6.752464828,"Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diet, Food, and Nutrition; Dietary Fats; Dietary Fats, Unsaturated; Fats; Fatty Acids; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fish Oils; Food; Food and Beverages; Lipids; Oils; Physiological Phenomena"
DB03766,Propanoic acid,79-09-4,approved; vet_approved,XBDQKXXYIPTUBI-UHFFFAOYSA-N,"InChI=1S/C3H6O2/c1-2-3(4)5/h2H2,1H3,(H,4,5)",CCC(=O)O,C3H6O2,C00163,D02310,1032,46508742,30768,CHEMBL14021,PPI,1005,50082199,74.0785,0.477190133,"Acids, Acyclic; Anti-Infective Agents; Carboxylic Acids; Fatty Acids; Fatty Acids, Volatile; Lipids; Ophthalmologicals; Sensory Organs"
DB03793,Benzoic acid,65-85-0,approved; investigational,WPYMKLBDIGXBTP-UHFFFAOYSA-N,"InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)",OC(=O)c1ccccc1,C7H6O2,C00539,D00038,243,46504911,30746,CHEMBL541,BEZ,238,197302,122.123,1.630828724,"Acids, Carbocyclic; Alimentary Tract and Metabolism; Ammonium Ion Binding Activity; Anti-Infective Agents; Antifungal Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Diagnostic Agents; Diet, Food, and Nutrition; Food; Food Additives; Food and Beverages; Food Ingredients; Food Preservatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Nitrogen Binding Agent; OAT3/SLC22A8 Inhibitors; Physiological Phenomena; Tests for Gastric Secretion; Urea Cycle Disorder Agents; Various Alimentary Tract and Metabolism Products"
DB03796,Palmitic Acid,57-10-3,approved,IPCSVZSSVZVIGE-UHFFFAOYSA-N,"InChI=1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)",CCCCCCCCCCCCCCCC(=O)O,C16H32O2,C00249,D05341,985,46506400,15756,CHEMBL82293,PLM,960,50152850,256.4241,6.256582778,Enzyme Inhibitors; Fatty Acids; Lipids; Palmitic Acids
DB03843,Formaldehyde,50-00-0,approved; vet_approved,WSFSSNUMVMOOMR-UHFFFAOYSA-N,InChI=1S/CH2O/c1-2/h1H2,C=O,CH2O,C00067,D00017,712,46505094,16842,CHEMBL1255,FOR,692,,30.026,-0.466975409,"Aldehydes; Anti-Infective Agents; Anti-Infective Agents, Local; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Disinfectants; Fixatives; Increased Histamine Release; Macromolecular Substances; Manufactured Materials; Standardized Chemical Allergen"
DB03904,Urea,57-13-6,approved; investigational,XSQUKJJJFZCRTK-UHFFFAOYSA-N,"InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4)",NC(=O)N,CH4N2O,C00086,D00023,1176,46508687,16199,CHEMBL985,URE,1143,24961,60.0553,-1.363833862,"Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Carbamide products; Dermatologicals; Diuretics, Osmotic; Emollients and Protectives; i.v. Solutions; Keratolytic Agents; Solutions Producing Osmotic Diuresis"
DB03929,D-Serine,312-84-5,approved; experimental,MTCFGRXMJLQNBG-UWTATZPHSA-N,"InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1",OC(=O)[C@H](N)CO,C3H7NO3,C00740,,71077,46508200,16523,CHEMBL285123,DSN,64231,23167,105.0926,-3.887735233,NA
DB04038,Ergosterol,57-87-4,approved; experimental,DNVPQKQSNYMLRS-APGDWVJJSA-N,"InChI=1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-10,18-20,22,24-26,29H,11-17H2,1-6H3/b8-7+/t19-,20+,22-,24+,25-,26-,27-,28+/m0/s1",CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]([C@@]12C)C=3[C@H](CC2)[C@]4(C)C(=CC3)C[C@@H](O)CC4,C28H44O,C01694,,444679,46505947,16933,CHEMBL1232562,ERG,392539,50378884,396.659,6.632406989,"Cholestanes; Cholestenes; Diet, Food, and Nutrition; Food; Food and Beverages; Fused-Ring Compounds; Growth Substances; Micronutrients; Physiological Phenomena; Polycyclic Compounds; Provitamins; Steroids; Vitamins"
DB04115,Berberine,2086-83-1,approved; investigational,YBHILYKTIRIUTE-UHFFFAOYSA-N,"InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1",COc1c(OC)ccc(c12)cc3[n+](c2)CCc4c3cc5c(c4)OCO5,C20H18NO4,C00757,D00092,2353,46506051,16118,CHEMBL295124,BER,2263,50203126,336.3612,-1.283312286,"Alkaloids; Benzylisoquinolines; Berberine Alkaloids; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines"
DB04160,Pyrophosphoric acid,03-09-2466,approved; experimental,XPPKVPWEQAFLFU-UHFFFAOYSA-N,"InChI=1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)",OP(=O)(O)OP(=O)(O)O,H4O7P2,C00013,,1023,46507760,29888,CHEMBL1160571,PPV,996,50147591,177.9751,-1.441902302,"Acids; Acids, Noncarboxylic; Anions; Electrolytes; Ions; Phosphate salts; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Polyphosphates"
DB04173,Fructose,,approved; experimental,RFSUNEUAIZKAJO-AZGQCCRYSA-N,"InChI=1S/C6H12O6/c7-1-3-4(9)5(10)6(11,2-8)12-3/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m0/s1",OC[C@@]1(O)[C@H](O)[C@@H](O)[C@@H](O1)CO,C6H12O6,,,439553,46504785,43703,,LFR,388644,,180.1559,-2.757999318,"Carbohydrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Flavoring Agents; Food; Food Additives; Food and Beverages; Food Ingredients; Fructose; General Nutrients; Hexoses; Ketoses; Monosaccharides; Pharmaceutic Aids; Pharmaceutical Preparations; Physiological Phenomena; Sweetening Agents"
DB04209,Dequalinium,6707-58-0,approved; investigational,PCSWXVJAIHCTMO-UHFFFAOYSA-P,"InChI=1S/C30H38N4/c1-23-21-27(31)25-15-9-11-17-29(25)33(23)19-13-7-5-3-4-6-8-14-20-34-24(2)22-28(32)26-16-10-12-18-30(26)34/h9-12,15-18,21-22,31-32H,3-8,13-14,19-20H2,1-2H3/p+2",c1cccc(c12)c(N)cc(C)[n+]2CCCCCCCCCC[n+]3c(C)cc(N)c(c34)cccc4,C30H40N4,,,2993,46507206,41872,CHEMBL333826,DEQ,2886,50048403,456.6654,-3.591434698,"Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Miscellaneous Anti-infectives; Quinoline Derivatives; Quinolines; Quinolinium Compounds; Respiratory System; Throat Preparations"
DB04221,Didecyldimethylammonium,20256-56-8,approved; experimental,JGFDZZLUDWMUQH-UHFFFAOYSA-N,"InChI=1S/C22H48N/c1-5-7-9-11-13-15-17-19-21-23(3,4)22-20-18-16-14-12-10-8-6-2/h5-22H2,1-4H3/q+1",CCCCCCCCCC[N+](C)(C)CCCCCCCCCC,C22H48N,,,16958,46504890,,CHEMBL1182247,10A,16067,,326.6232,4.010454859,Amines; Ammonium Compounds; Antiseptics and Disinfectants; Dermatologicals; Nitrogen Compounds; Onium Compounds; Quaternary Ammonium Compounds
DB04224,Oleic Acid,112-80-1,approved; investigational; vet_approved,ZQPPMHVWECSIRJ-MDZDMXLPSA-N,"InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H,19,20)/b10-9+",CCCCCCCC/C=C/CCCCCCCC(=O)O,C18H34O2,C01712,D02315,637517,46506835,27997,CHEMBL460657,ELA,553123,50250904,282.4614,6.783798451,"Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Lipids; Oleic Acids"
DB04272,Citric acid,77-92-9,approved; nutraceutical; vet_approved,KRKNYBCHXYNGOX-UHFFFAOYSA-N,"InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",OC(=O)CC(O)(C(=O)O)CC(=O)O,C6H8O7,C00158,D00037,311,46508995,30769,CHEMBL1261,CIT,305,14672,192.1235,-1.322687452,"Acid Preparations; Acidifying Activity; Acids, Acyclic; Alimentary Tract and Metabolism; Calcium Chelating Activity; Calcium Chelating Agents; Calculi Dissolution Agent; Carboxylic Acids; Chelating Agents; Citrates; Compounds used in a research, industrial, or household setting; Decreased Coagulation Factor Activity; Digestives, Incl. Enzymes; Hematologic Agents; Sequestering Agents; Tricarboxylic Acids; Urinary Acidifying Agents; Urinary Alkalinisers"
DB04339,Carbocisteine,638-23-3,approved; investigational,GBFLZEXEOZUWRN-VKHMYHEASA-N,"InChI=1S/C5H9NO4S/c6-3(5(9)10)1-11-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1",OC(=O)[C@@H](N)CSCC(=O)O,C5H9NO4S,C03727,D00175,193653,46507988,16163,CHEMBL396416,CCS,168055,50213735,179.194,-3.297409033,Cough and Cold Preparations; Expectorants; Respiratory System
DB04348,Taurocholic acid,81-24-3,approved; experimental,WBWWGRHZICKQGZ-HZAMXZRMSA-N,"InChI=1S/C26H45NO7S/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34)/t15-,16+,17-,18-,19+,20+,21-,22+,24+,25+,26-/m1/s1",OS(=O)(=O)CCNC(=O)CC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](C[C@@H]2O)[C@]4(C)[C@H](C[C@H]3O)C[C@H](O)CC4,C26H45NO7S,C05122,,6675,46508273,28865,CHEMBL224867,TCH,6423,50375594,515.703,-0.533411043,"Acids; Acids, Noncarboxylic; Alkanes; Alkanesulfonic Acids; BCRP/ABCG2 Inhibitors; Bile Acids and Salts; BSEP/ABCB11 inducers; BSEP/ABCB11 Substrates; Cholagogues and Choleretics; Cholanes; Cholic Acids; Compounds used in a research, industrial, or household setting; Detergents; Fused-Ring Compounds; Gastrointestinal Agents; Household Products; Hydrocarbons; Hydrocarbons, Acyclic; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inducers; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Steroids; Sulfonic Acids; Sulfur Acids; Sulfur Compounds; Surface-Active Agents"
DB04398,Lactic acid,50-21-5,approved; vet_approved,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,"InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)",CC(O)C(=O)O,C3H6O3,C01432,D00111,612,46505582,78320,CHEMBL1200559,,592,23233,90.0779,-0.471829518,Basic Ointments and Protectants; Carboxylic Acids; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Hydroxy Acids; Lactates; Miscellaneous Local Anti-infectives; Organic Acids
DB04465,Lactose,63-42-3,approved; experimental; investigational,GUBGYTABKSRVRQ-QKKXKWKRSA-N,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11?,12+/m1/s1",OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@H]1O)O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO,C12H22O11,C00243,D00046,440995,46505218,17716,,LAT,389820,,342.2965,-4.703374864,"Carbohydrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Disaccharides; Flavoring Agents; Food; Food Additives; Food and Beverages; Food Ingredients; Oligosaccharides; Pharmaceutic Aids; Pharmaceutical Preparations; Physiological Phenomena; Polysaccharides; Sweetening Agents"
DB04540,Cholesterol,57-88-5,approved; investigational,HVYWMOMLDIMFJA-DPAQBDIFSA-N,"InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1",CC(C)CCC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(=CC3)C[C@@H](O)CC4,C27H46O,C00187,D00040,5997,46508234,16113,CHEMBL112570,CLR,5775,20192,386.6535,7.112889031,BCRP/ABCG2 Inducers; Cholestanes; Cholestenes; Fused-Ring Compounds; Lipids; Membrane Lipids; P-glycoprotein inhibitors; Polycyclic Compounds; Steroids; Sterols
DB04564,Gluconolactone,90-80-2,approved; experimental,PHOQVHQSTUBQQK-SQOUGZDYSA-N,"InChI=1S/C6H10O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-5,7-10H,1H2/t2-,3-,4+,5-/m1/s1",OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O,C6H10O6,C00198,D04332,7027,46506698,16217,CHEMBL1200829,LGC,6760,50366565,178.14,-2.745273186,"Acids, Acyclic; Calculi Dissolution Agent; Carbohydrates; Carboxylic Acids; Hydroxy Acids; Irrigation; Sugar Acids"
DB04570,Latamoxef,64952-97-2,approved; investigational,JWCSIUVGFCSJCK-CAVRMKNVSA-N,"InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1",Cn1nnnc1SCC(=C2C(=O)O)CO[C@@H](N23)[C@](C3=O)(OC)NC(=O)C(C(=O)O)c4ccc(O)cc4,C20H20N6O9S,C07231,D08109,47499,46505546,599928,CHEMBL74632,,43215,50370589,520.473,0.171776065,"Acids; Acids, Noncarboxylic; Amides; Anions; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Electrolytes; Gases; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrogen Sulfide; Ions; Lactams; Nephrotoxic agents; Sulfides; Sulfur Compounds; Third-Generation Cephalosporins"
DB04571,Trioxsalen,3902-71-4,approved,FMHHVULEAZTJMA-UHFFFAOYSA-N,"InChI=1S/C14H12O3/c1-7-4-12(15)17-14-9(3)13-10(6-11(7)14)5-8(2)16-13/h4-6H,1-3H3",Cc(o1)cc(c12)cc3c(c2C)oc(=O)cc3C,C14H12O3,C09314,D01034,5585,46508755,28329,CHEMBL1475,,5383,50240033,228.2433,2.954860333,"Antipsoriatics; Antipsoriatics for Systemic Use; Antipsoriatics for Topical Use; Benzopyrans; Coumarins; Dermatologicals; Furocoumarins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Photosensitizing Agents; Photosensitizing agents used for phototherapy; Psoralens for Systemic Use; Psoralens for Topical Use; Pyrans; Radiation-Sensitizing Agents"
DB04572,Thiotepa,52-24-4,approved; investigational,FOCVUCIESVLUNU-UHFFFAOYSA-N,"InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2",C1CN1P(=S)(N2CC2)N3CC3,C6H12N3PS,C07641,D00583,5453,46505958,9570,CHEMBL671,,5254,50418086,189.218,-1.027380515,"Acids; Acids, Noncarboxylic; Alkylating Activity; Alkylating Drugs; Anions; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Aziridines; Azirines; Cholinesterase Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (moderate); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Electrolytes; Ethylene Imines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunologic Factors; Immunosuppressive Agents; Ions; Myeloablative Agonists; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Organophosphorus Compounds; Phosphoramides; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Toxic Actions; Triethylenephosphoramide"
DB04573,Estriol,50-27-1,approved; investigational; vet_approved,PROQIPRRNZUXQM-ZXXIGWHRSA-N,"InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1",O[C@H]1[C@H](O)C[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(O)cc4,C18H24O3,C05141,D00185,5756,46505881,27974,CHEMBL193482,ESL,5553,50410506,288.3814,2.670597721,"Estradiol Congeners; Estranes; Estrenes; Estrogens; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Natural and Semisynthetic Estrogens, Plain; P-glycoprotein inducers; P-glycoprotein substrates; Polycyclic Compounds; Sex Hormones and Modulators of the Genital System; Steroids; Thyroxine-binding globulin inducers"
DB04574,Estrone sulfate,481-97-0,approved,JKKFKPJIXZFSSB-CBZIJGRNSA-N,"InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1",O=C1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(cc4)OS(=O)(=O)O,C18H22O5S,C02538,,3001028,46508976,17474,CHEMBL494753,,2272513,50366524,350.429,3.833715688,"17-Ketosteroids; Adrenal Cortex Hormones; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estradiol Congeners; Estranes; Estrenes; Estrogens; Estrogens, Conjugated (USP); Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Ketosteroids; MATE 1 Substrates; MATE 2 Substrates; MATE substrates; Polycyclic Compounds; Reproductive Control Agents; Steroids; Thyroxine-binding globulin inducers"
DB04575,Quinestrol,152-43-2,approved,PWZUUYSISTUNDW-VAFBSOEGSA-N,"InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1",C#C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(cc4)OC5CCCC5,C25H32O2,C07619,D00576,9046,46508939,8716,CHEMBL1201165,,8694,,364.5204,5.397949011,"Estradiol Congeners; Estrogenic Steroids, Alkylated; Estrogens; Ethinyl Estradiol; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Norpregnanes; Norpregnatrienes; Norsteroids; Polycyclic Compounds; Steroids; Thyroxine-binding globulin inducers"
DB04657,Carboxin,5234-68-4,approved; experimental,GYSSRZJIHXQEHQ-UHFFFAOYSA-N,"InChI=1S/C12H13NO2S/c1-9-11(16-8-7-15-9)12(14)13-10-5-3-2-4-6-10/h2-6H,7-8H2,1H3,(H,13,14)",S1CCOC(C)=C1C(=O)Nc2ccccc2,C12H13NO2S,C11255,,21307,46507275,3405,CHEMBL1231667,CBE,20027,,235.302,1.512658999,"Agrochemicals; Amides; Amines; Anilides; Aniline Compounds; Compounds used in a research, industrial, or household setting; Fungicides, Industrial; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Oxathiins; Pesticides; Toxic Actions"
DB04703,Hesperidin,520-26-3,approved; investigational,QUQPHWDTPGMPEX-QJBIFVCTSA-N,"InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1",COc1ccc(cc1O)[C@@H](O2)CC(=O)c(c23)c(O)cc(c3)O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O,C28H34O15,C09755,D01038,10621,46506898,28775,CHEMBL449317,H1N,10176,61776,610.5606,-0.314556988,"Benzopyrans; Chromones; Flavanones; Flavonoids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans"
DB04711,Iodipamide,606-17-7,approved,FFINMCNLQNTKLU-UHFFFAOYSA-N,"InChI=1S/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34)",OC(=O)c1c(I)c(c(I)cc1I)NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(c2I)C(=O)O,C20H14I6N2O6,,D01774,3739,46507320,31176,CHEMBL1165268,IDB,3608,,1139.7618,8.248090844,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodinated Contrast Agents; Iodobenzoates; Radiographic Contrast Agent; Roentgenography; Triiodobenzoic Acids; Watersoluble, Hepatotropic X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB04743,Nimesulide,51803-78-2,approved; investigational; withdrawn,HYWYRSMBCFDLJT-UHFFFAOYSA-N,"InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3",CS(=O)(=O)Nc1c(cc([N+]([O-])=O)cc1)Oc2ccccc2,C13H12N2O5S,,D01049,4495,46507721,44445,CHEMBL56367,NIM,4339,50056999,308.31,1.786656371,"Agents causing hyperkalemia; Agents that produce hypertension; Amides; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiarrhythmic agents; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antiplatelet agents; Antirheumatic Agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Central Nervous System Agents; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Musculo-Skeletal System; Nephrotoxic agents; Peripheral Nervous System Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents; Sulfones; Sulfur Compounds; Topical Products for Joint and Muscular Pain"
DB04794,Bifonazole,60628-96-8,approved; investigational,OCAPBUJLXMYKEJ-UHFFFAOYSA-N,"InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H",c1ccccc1C(n2ccnc2)c3ccc(cc3)-c4ccccc4,C22H18N2,,,2378,46507284,78692,CHEMBL277535,TMI,2287,50128548,310.3917,5.234390525,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Azole Antifungals; Azoles; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole and Triazole Derivatives"
DB04812,Benoxaprofen,51234-28-7,approved; withdrawn,MITFXPHMIHQXPI-UHFFFAOYSA-N,"InChI=1S/C16H12ClNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20)",OC(=O)C(C)c(cc1)cc(c12)nc(o2)-c3ccc(Cl)cc3,C16H12ClNO3,,D03080,39941,46508496,76114,CHEMBL340978,,36518,50088388,301.724,4.1294149,"Acids, Acyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Carboxylic Acids; Central Nervous System Agents; Dermatologicals; Enzyme Inhibitors; Fatty Acids; Fatty Acids, Volatile; Lipids; Lipoxygenase Inhibitors; Musculo-Skeletal System; Nephrotoxic agents; Peripheral Nervous System Agents; Propionates; Sensory System Agents"
DB04813,Bithionol,97-18-7,approved; withdrawn,JFIOVJDNOJYLKP-UHFFFAOYSA-N,"InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H",Clc1cc(Cl)cc(c1O)Sc2c(O)c(Cl)cc(Cl)c2,C12H6Cl4O2S,C07967,D00802,2406,46508019,3131,CHEMBL290106,B1T,2313,36880,356.052,5.971043342,"Anthelmintics; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Infective Agents; Anti-Infective Agents, Local; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiplatyhelmintic Agents; Antitrematodals; Benzene Derivatives; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols; Preparations Containing Sulfur"
DB04815,Clioquinol,130-26-7,approved; vet_approved; withdrawn,QCDFBFJGMNKBDO-UHFFFAOYSA-N,"InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",Oc1c(I)cc(Cl)c(c12)cccn2,C9H5ClINO,,,2788,46509081,74460,CHEMBL497,CQL,2686,32188,305.5,3.360324304,"Anti-Infective Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Antiseptics and Disinfectants; Cell-mediated Immunity; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxyquinoline Derivatives; Hydroxyquinolines; Increased Histamine Release; Medicated Dressings; Medicated Dressings With Antiinfectives; Miscellaneous Antifungals; Otologicals; Quinoline Derivatives; Quinolines; Sensory Organs; Standardized Chemical Allergen"
DB04816,Dantron,117-10-2,approved; investigational; withdrawn,QBPFLULOKWLNNW-UHFFFAOYSA-N,"InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H",Oc1cccc(c12)C(=O)c3c(C2=O)c(O)ccc3,C14H8O4,C10312,D07107,2950,46509077,3682,CHEMBL53418,CHZ,2845,11316,240.2109,3.611575431,"Alimentary Tract and Metabolism; Anthracenes; Contact Laxatives; Drugs for Constipation; Enemas; Gastrointestinal Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Laxatives; Mutagens; Noxae; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quinones; Toxic Actions"
DB04817,Metamizole,50567-35-6,approved; investigational; withdrawn,LVWZTYCIRDMTEY-UHFFFAOYSA-N,"InChI=1S/C13H17N3O4S/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11/h4-8H,9H2,1-3H3,(H,18,19,20)",OS(=O)(=O)CN(C)c1c(C)n(C)n(c1=O)-c2ccccc2,C13H17N3O4S,,D08188,522325,46509035,62088,CHEMBL461522,,3000,235671,311.36,-0.818957336,"Agents causing hyperkalemia; Agents that produce hypertension; Aminopyrine; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Azoles; Central Nervous System Agents; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Pyrazoles; Pyrazolones; Sensory System Agents"
DB04820,Nialamide,51-12-7,approved; withdrawn,NOIIUHRQUVNIDD-UHFFFAOYSA-N,"InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22)",c1ccccc1CNC(=O)CCNNC(=O)c2ccncc2,C16H18N4O2,,,4472,46506047,94510,CHEMBL1256841,,4317,163693,298.3397,0.38961667,"Acids, Heterocyclic; Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isonicotinic Acids; Monoamine Oxidase Inhibitors; Monoamine Oxidase Inhibitors, Non-Selective; Nervous System; Psychoanaleptics; Psychotropic Drugs; Pyridines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB04821,Nomifensine,24526-64-5,approved; withdrawn,XXPANQJNYNUNES-UHFFFAOYSA-N,"InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3",Nc1cccc(c12)C(CN(C2)C)c3ccccc3,C16H18N2,,,4528,46505804,116225,CHEMBL273575,,4371,50005548,238.3275,2.624381934,"Antidepressive Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Uptake Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Psychoanaleptics"
DB04822,Oxeladin,468-61-1,approved; withdrawn,IQADUMSPOQKAAO-UHFFFAOYSA-N,"InChI=1S/C20H33NO3/c1-5-20(6-2,18-12-10-9-11-13-18)19(22)24-17-16-23-15-14-21(7-3)8-4/h9-13H,5-8,14-17H2,1-4H3",CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1,C20H33NO3,,,4619,46508573,135424,CHEMBL1500276,,4458,,335.4809,4.430310995,"Acids, Carbocyclic; Antitussive Agents; Carboxylic Acids; Central Nervous System Agents; Cough and Cold Preparations; Respiratory System; Respiratory System Agents"
DB04824,Phenolphthalein,77-09-8,approved; withdrawn,KJFMBFZCATUALV-UHFFFAOYSA-N,"InChI=1S/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22H",c1cc(O)ccc1C2(c(cc3)ccc3O)OC(=O)c(c24)cccc4,C20H14O4,C14286,D05456,4764,46506108,34914,CHEMBL63857,FGT,4600,50077844,318.3228,4.353301456,"Alimentary Tract and Metabolism; Benzene Derivatives; Compounds used in a research, industrial, or household setting; Contact Laxatives; Drugs for Constipation; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indicators and Reagents; Laboratory Chemicals; Laxatives; Phenolphthaleins; Phenols"
DB04825,Prenylamine,390-64-7,approved; withdrawn,IFFPICMESYHZPQ-UHFFFAOYSA-N,"InChI=1S/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3",c1ccccc1CC(C)NCCC(c2ccccc2)c3ccccc3,C24H27N,,D02383,9801,46508663,8397,CHEMBL24072,,9418,50017723,329.4779,6.115356932,"Adrenergic Agents; Agents causing hyperkalemia; Amines; Antiarrhythmic agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Calmodulin, antagonists & inhibitors; Carboxylic Acids; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Ethylamines; Hydroxy Acids; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Phenethylamines; QTc Prolonging Agents; Vasodilating Agents; Vasodilators Used in Cardiac Diseases"
DB04826,Thenalidine,86-12-4,approved; withdrawn,KLOHYVOVXOUKQI-UHFFFAOYSA-N,"InChI=1S/C17H22N2S/c1-18-11-9-16(10-12-18)19(14-17-8-5-13-20-17)15-6-3-2-4-7-15/h2-8,13,16H,9-12,14H2,1H3",c1ccccc1N(Cc2cccs2)C3CCN(C)CC3,C17H22N2S,,,27901,46504731,135187,CHEMBL2105458,,25957,,286.435,3.745450292,"Antihistamines for Systemic Use; Antihistamines for Topical Use; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Respiratory System"
DB04827,Urethane,51-79-6,approved; withdrawn,JOYRKODLDBILNP-UHFFFAOYSA-N,"InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)",CCOC(=O)N,C3H7NO2,C01537,,5641,46505215,17967,CHEMBL462547,,5439,50239974,89.0932,-0.054189237,"Acids, Acyclic; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Antineoplastic Agents; Carbamates; Carboxylic Acids; Carcinogens; Central Nervous System Agents; Central Nervous System Depressants; Noxae; Toxic Actions"
DB04832,Zimelidine,56775-88-3,approved; withdrawn,OYPPVKRFBIWMSX-SXGWCWSVSA-N,"InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9-",c1ccncc1/C(=C\CN(C)C)c2ccc(Br)cc2,C16H17BrN2,,,41987,46504589,135357,CHEMBL37744,,4517305,50020706,317.23,3.508837032,"Antidepressive Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; P-glycoprotein inhibitors; Psychoanaleptics; Pyridines; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB04834,Rapacuronium,465499-11-0,approved; withdrawn,HTIKWNNIPGXLGM-YLINKJIISA-N,"InChI=1S/C37H61N2O4/c1-6-20-39(21-12-9-13-22-39)32-24-30-28-15-14-27-23-33(42-26(3)40)31(38-18-10-8-11-19-38)25-37(27,5)29(28)16-17-36(30,4)35(32)43-34(41)7-2/h6,27-33,35H,1,7-25H2,2-5H3/q+1/t27-,28+,29-,30-,31-,32-,33-,35-,36-,37-/m0/s1",C1CCCC[N+]1(CC=C)[C@H]([C@@H]2OC(=O)CC)C[C@H]([C@@]23C)[C@H]4[C@H](CC3)[C@]5(C)[C@@H](CC4)C[C@H](OC(=O)C)[C@H](C5)N6CCCCC6,C37H61N2O4,,,5311399,46506932,135845,CHEMBL1201352,,4470890,,597.904,2.323874824,Agents producing tachycardia; Androstanes; Androstanols; Anticholinergic Agents; Central Nervous System Depressants; Fused-Ring Compounds; Muscarinic Antagonists; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular-Blocking Agents (Nondepolarizing); Peripheral Nervous System Agents; Polycyclic Compounds; Steroids
DB04835,Maraviroc,376348-65-1,approved; investigational,GSNHKUDZZFZSJB-QYOOZWMWSA-N,"InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25-,26-/m0/s1",CC(C)c1nnc(C)n1[C@@H](C[C@H]23)C[C@@H](CC2)N3CC[C@H](NC(=O)C(CC4)CCC4(F)F)c5ccccc5,C29H41F2N5O,,,3002977,46508040,63608,CHEMBL1201187,MRV,20078004,50334986,513.6655,3.626210654,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Azoles; CCR5 Co-receptor Antagonist; CCR5 Receptor Antagonists; Cyclohexanes; Cycloparaffins; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV Fusion Inhibitors; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Triazoles; Viral Fusion Protein Inhibitors"
DB04837,Clofedanol,791-35-5,approved; withdrawn,WRCHFMBCVFFYEQ-UHFFFAOYSA-N,"InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3",c1ccccc1C(O)(CCN(C)C)c2ccccc2Cl,C17H20ClNO,,,2795,46505324,135207,CHEMBL1201313,,2693,,289.8,3.457834282,Alcohols; Amines; Amino Alcohols; Antitussive Agents; Cough and Cold Preparations; Histamine Antagonists; Histamine H1 Antagonists; Propanols; Respiratory System
DB04838,Cyclandelate,456-59-7,approved,WZHCOOQXZCIUNC-UHFFFAOYSA-N,"InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3",CC1(C)CC(C)CC(C1)OC(=O)C(O)c2ccccc2,C17H24O3,,,2893,46505740,3988,CHEMBL1480987,,2790,50239973,276.3707,3.715085545,"Acids, Carbocyclic; Agents causing hyperkalemia; Antiarrhythmic agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Hydroxy Acids; Mandelic Acids; Peripheral Vasodilators; Vasodilating Agents"
DB04839,Cyproterone acetate,427-51-0,approved; investigational,UWFYSQMTEOIJJG-FDTZYFLXSA-N,"InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1",C[C@]12[C@@H]3[C@@H](C3)C(=O)C=C1C(Cl)=C[C@H]4[C@H]5[C@](C)(CC[C@H]24)[C@](CC5)(C(=O)C)OC(=O)C,C24H29ClO4,,D01368,9880,46506931,50743,CHEMBL139835,CA4,9496,50094569,416.938,3.638856937,"Adrenal Cortex Hormones; Antiandrogens; Antiandrogens and Estrogens; Antineoplastic Agents; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptive Agents, Male; Contraceptives, Oral; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Other Miscellaneous Therapeutic Agents; Polycyclic Compounds; Pregnadienes; Pregnanes; Progestin Contraceptives; Progestins; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids; Steroids, Chlorinated"
DB04840,Debrisoquine,1131-64-2,approved; investigational,JWPGJSVJDAJRLW-UHFFFAOYSA-N,"InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)",NC(=N)N(C1)CCc(c12)cccc2,C10H13N3,C13650,,2966,46507664,34665,CHEMBL169901,,2860,50122613,175.2303,1.067108073,"Adrenergic Agents; Antiadrenergic Agents, Peripherally Acting; Antihypertensive Agents; Autonomic Agents; Cardiovascular Agents; Cardiovascular System; Catecholamines; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Guanidine Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Neurotransmitter Agents; P-glycoprotein substrates; Peripheral Nervous System Agents; Sympatholytics"
DB04841,Flunarizine,52468-60-7,approved,SMANXXCATUTDDT-QPJJXVBHSA-N,"InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+",c1cc(F)ccc1C(c(cc2)ccc2F)N3CCN(CC3)C/C=C/c4ccccc4,C26H26F2N2,,D01303,941361,46507129,135652,CHEMBL30008,,819216,50017702,404.4948,6.165795013,"Agents causing hyperkalemia; Antiarrhythmic agents; Anticonvulsants; Antimigraine Agents, Miscellaneous; Antivertigo Preparations; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Piperazine Derivatives; Piperazines; Vasodilating Agents"
DB04842,Fluspirilene,1841-19-6,approved; investigational,QOYHHIBFXOOADH-UHFFFAOYSA-N,"InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)",c1cc(F)ccc1C(c(cc2)ccc2F)CCCN(CC3)CCC34N(CNC4=O)c5ccccc5,C29H31F2N3O,,D02629,3396,46508202,93369,CHEMBL46516,,3279,26948,475.5727,5.778034304,"Agents causing hyperkalemia; Antiarrhythmic agents; Antidepressive Agents; Antipsychotic Agents; Azoles; Bradycardia-Causing Agents; Calcium Channel Blockers; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diphenylbutylpiperidine Derivatives; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Imidazoles; Moderate Risk QTc-Prolonging Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Piperidines; Polycyclic Compounds; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Spiro Compounds; Tranquilizing Agents"
DB04843,Mepenzolate,25990-43-6,approved,GKNPSSNBBWDAGH-UHFFFAOYSA-N,"InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1",C[N+]1(C)CCCC(C1)OC(=O)C(O)(c2ccccc2)c3ccccc3,C21H26NO3,C07818,,4057,46508905,94411,CHEMBL524004,,3917,50377964,340.436,-0.974686413,"Acids, Carbocyclic; Agents producing tachycardia; Alimentary Tract and Metabolism; Anticholinergic Agents; Carboxylic Acids; Diphenylacetic Acids; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydroxy Acids; Muscarinic Antagonists; Phenylacetates; Synthetic Anticholinergics, Quaternary Ammonium Compounds"
DB04844,Tetrabenazine,58-46-8,approved; investigational,MKJIEFSOBYUXJB-UHFFFAOYSA-N,"InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3",COc(c1)c(OC)cc(c12)C3N(CC2)CC(C(=O)C3)CC(C)C,C19H27NO3,C11168,D08575,6018,46506426,64028,CHEMBL117785,,5796,50017701,317.4226,3.401061659,"Adrenergic Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Membrane Transport Modulators; Miscellaneous Central Nervous System Agents; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; QTc Prolonging Agents; Quinolizines; Tetrabenazine and isomer; Vesicular Monoamine Transporter 2 Inhibitor; Vesicular Monoamine Transporter 2 Inhibitors"
DB04845,Ixabepilone,219989-84-1,approved; investigational,FABUFPQFXZVHFB-PVYNADRNSA-N,"InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1",Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3,C27H42N2O5S,,D04645,6445540,99443224,63605,CHEMBL1201752,,20145579,,506.7,3.393573154,Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Cytotoxic Antibiotics and Related Substances; Immunosuppressive Agents; Lactones; Macrocyclic Compounds; Macrolides; Microtubule Inhibition; Microtubule Inhibitors; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Polyketides; Tubulin Modulators
DB04846,Celiprolol,56980-93-9,approved; investigational,JOATXPAWOHTVSZ-UHFFFAOYSA-N,"InChI=1S/C20H33N3O4/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26)",CCN(CC)C(=O)Nc1ccc(c(c1)C(=O)C)OCC(O)CNC(C)(C)C,C20H33N3O4,,D07660,2663,310264853,94461,CHEMBL27810,,2563,,379.501,1.497576234,"Adrenergic Agents; Adrenergic Agonists; Adrenergic Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Autonomic Agents; Benzene Derivatives; Beta Blocking Agents, Selective; Beta-Blockers (Beta1 Selective); Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenoxypropanolamines; Phenylurea Compounds; Potential QTc-Prolonging Agents; Propanolamines; Propanols; QTc Prolonging Agents; Sympathomimetics; Vasodilating Agents"
DB04854,Febuxostat,144060-53-7,approved,BQSJTQLCZDPROO-UHFFFAOYSA-N,"InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)",CC(C)COc1c(C#N)cc(cc1)-c2nc(C)c(s2)C(=O)O,C16H16N2O3S,,D01206,134018,310264854,31596,CHEMBL1164729,TEI,118173,50320491,316.375,3.520929441,"Antigout Preparations; Antirheumatic Agents; Azoles; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Photosensitizing Agents; Preparations Inhibiting Uric Acid Production; Sulfur Compounds; Thiazoles; Xanthine Oxidase Inhibitors"
DB04855,Dronedarone,141626-36-0,approved,ZQTNQVWKHCQYLQ-UHFFFAOYSA-N,"InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3",CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c2c(CCCC)oc(c23)ccc(c3)NS(=O)(=O)C,C31H44N2O5S,,D02537,208898,175426865,50659,CHEMBL184412,,180996,50151864,556.756,5.277915882,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antiarrhythmic agents; Antiarrhythmics, Class III; Benzofurans; Bradycardia-Causing Agents; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Narrow Therapeutic Index Drugs; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein inhibitors; Photosensitizing Agents; QTc Prolonging Agents"
DB04861,Nebivolol,118457-14-0,approved; investigational,KOHIRBRYDXPAMZ-UHFFFAOYSA-N,"InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2",c1cc(F)cc(c12)CCC(O2)C(O)CNCC(O)C(O3)CCc(c34)cc(F)cc4,C22H25F2NO4,,D05127,71301,99443225,64019,CHEMBL434394,,64421,84735,405.435,3.208403214,"Adrenergic Agents; Adrenergic Agonists; Adrenergic Antagonists; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Benzopyrans; Beta blocking agents and calcium channel blockers; Beta Blocking Agents and Thiazides; Beta Blocking Agents, Selective; Beta Blocking Agents, Selective, and Thiazides; Beta-Blockers (Beta1 Selective); Bradycardia-Causing Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Ethanolamines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Neurotransmitter Agents; Pyrans; Vasodilating Agents"
DB04864,Huperzine A,102518-79-6,approved; experimental,ZRJBHWIHUMBLCN-YQEJDHNASA-N,"InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)/b11-3+/t10-,15+/m0/s1",C1C(C)=C[C@H](/C2=C\C)Cc(c3[C@@]12N)[nH]c(=O)cc3,C15H18N2O,C09992,,854026,175426873,78330,CHEMBL395280,HUP,16736021,50199522,242.3162,0.617715789,"Central Nervous System Agents; Cholinergic Agents; Cholinesterase Inhibitors; Compounds used in a research, industrial, or household setting; Enzyme Inhibitors; Heterocyclic Compounds; Hydrocarbons; Neuroprotective Agents; Neurotransmitter Agents; Protective Agents; Terpenes"
DB04865,Omacetaxine mepesuccinate,26833-87-4,approved; investigational,HYFHYPWGAURHIV-JFIAXGOJSA-N,"InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1",CC(C)(O)CCC[C@@](O)(CC(=O)OC)C(=O)O[C@H](C(=C1)OC)[C@H]([C@]123)c4c(cc5c(c4)OCO5)CCN2CCC3,C29H39NO9,,D08956,285033,175426874,71019,CHEMBL46286,HMT,251215,,545.6213,1.884670679,"Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic and Immunomodulating Agents; Benzazepines; Enzyme Inhibitors; Harringtonines; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Protein Synthesis Inhibitors"
DB04868,Nilotinib,641571-10-0,approved; investigational,HHZIURLSWUIHRB-UHFFFAOYSA-N,"InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)",Cc1cn(cn1)-c2cc(cc(c2)C(F)(F)F)NC(=O)c3ccc(C)c(c3)Nc4nccc(n4)-c5cnccc5,C28H22F3N7O,,D08953,644241,99443226,52172,CHEMBL255863,NIL,559260,50237710,529.5158,5.361539851,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Photosensitizing Agents; Protein Kinase Inhibitors; QTc Prolonging Agents; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors"
DB04871,Lorcaserin,616202-92-7,approved,XTTZERNUQAFMOF-QMMMGPOBSA-N,"InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1",c1c(Cl)ccc(c12)CCNC[C@@H]2C,C11H14ClN,,D06613,11658860,310264855,65353,CHEMBL360328,,9833595,50161646,195.69,2.82916186,"Alimentary Tract and Metabolism; Antidepressive Agents; Antiobesity Preparations, Excl. Diet Products; Central Nervous System Depressants; Centrally Acting Antiobesity Products; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 2c Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2C Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists"
DB04876,Vildagliptin,274901-16-5,approved; investigational,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,"InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1",OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N,C17H25N3O2,,,6918537,99443227,135285,CHEMBL142703,,5293734,11695,303.3993,-0.217394534,"Agents causing angioedema; Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Bridged Compounds; Cycloparaffins; DPP-IV Inhibitors; Drugs Used in Diabetes; Enzyme Inhibitors; Glucagon-Like Peptide 1; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Nitriles; Polycyclic Compounds; Protease Inhibitors; Pyrrolidines"
DB04880,Enoximone,77671-31-9,approved; investigational,ZJKNESGOIKRXQY-UHFFFAOYSA-N,"InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)",CSc1ccc(cc1)C(=O)c2c(C)[nH]c(=O)[nH]2,C12H12N2O2S,,D04004,53708,46505575,135010,CHEMBL249856,,48492,50241379,248.301,1.844280216,"Azoles; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Photosensitizing Agents; Protective Agents; Vasodilating Agents"
DB04890,Bepotastine,125602-71-3,approved,YWGDOWXRIALTES-UHFFFAOYSA-N,"InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)",OC(=O)CCCN1CCC(CC1)OC(c2ccccn2)c3ccc(Cl)cc3,C21H25ClN2O3,,D01654,2350,46504940,71204,CHEMBL1201758,,2260,,388.888,0.552555534,"Anti-Allergic Agents; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H1 Antagonists; Mast Cell Stabilizers"
DB04896,Milnacipran,92623-85-3,approved; investigational,GJJFMKBJSRMPLA-UHFFFAOYSA-N,"InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3",CCN(CC)C(=O)C1(CC1CN)c2ccccc2,C15H22N2O,,D08222,65833,46506141,135005,CHEMBL259209,,9797657,86420,246.354,1.421706623,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Analgesics; Analgesics, Non-Narcotic; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hypoglycemia-Associated Agents; Membrane Transport Modulators; Milnacipran and enantiomer; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Norepinephrine Uptake Inhibitors; Peripheral Nervous System Agents; Polycyclic Compounds; Psychoanaleptics; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Serotonin Modulators"
DB04898,Ximelagatran,192939-46-1,approved; investigational; withdrawn,ZXIBCJHYVWYIKI-PZJWPPBQSA-N,"InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1",CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N2CC[C@H]2C(=O)NCc3ccc(cc3)/C(N)=N/O,C24H35N5O5,,,9574101,46509040,65172,CHEMBL522038,,7848559,,473.5652,0.869306937,"Amines; Anticoagulants; Antithrombins; Azetines; Benzene Derivatives; Benzyl Compounds; Blood and Blood Forming Organs; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Protease Inhibitors; Serine Protease Inhibitors"
DB04908,Flibanserin,167933-07-5,approved; investigational,PPRRDFIXUUSXRA-UHFFFAOYSA-N,"InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)",FC(F)(F)c1cc(ccc1)N2CCN(CC2)CCn3c(=O)[nH]c(c34)cccc4,C20H21F3N4O,,D02577,6918248,175426897,90865,CHEMBL231068,,5293454,,390.4021,3.825141539,"Agents that produce hypertension; Antidepressive Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Miscellaneous Central Nervous System Agents; P-glycoprotein inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Serotonin Receptor Antagonists"
DB04911,Oritavancin,171099-57-3,approved; investigational,VHFGEBVPHAGQPI-LXKZPTCJSA-N,"InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1",C[C@@]1(N)[C@@H](O)[C@H](C)O[C@H](C1)O[C@H]2[C@H](NC3=O)C(=O)N[C@H](C(=O)O)c(cc(O)cc4O)c4c(c5)c(O)ccc5[C@H]3NC(=O)[C@@H](c6cc7Oc(c(Cl)cc28)cc8)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c9ccc(c(Cl)c9)Oc(c6)c7O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H](C1)O[C@@H](C)[C@H](O)[C@@]1(C)NCc1ccc(cc1)-c1ccc(Cl)cc1,C86H97Cl3N10O26,C12034,,16136912,175426900,82699,CHEMBL1688530,,17286443,,1793.101,0.20494861,"Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Glycoconjugates; Glycopeptide Antibacterials; Glycopeptides; Lipids; Lipoglycopeptide Antibacterial; Lipopeptides; Peptides"
DB04918,Ceftobiprole,209467-52-7,approved; investigational,VOAZJEPQLGBXGO-SDAWRPRTSA-N,"InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1",Nc1nc(ns1)/C(=N/O)C(=O)N[C@@H]2C(=O)N([C@@H]23)C(C(=O)O)=C(CS3)/C=C4\CCN(C4=O)[C@@H]5CCNC5,C20H22N8O6S2,,D08885,12993649,175426903,140407,CHEMBL520642,,23350302,,534.57,-4.712068222,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Sulfur Compounds; Thiazines"
DB04920,Clevidipine,167221-71-8,approved; investigational,KPBZROQVTHLCDU-UHFFFAOYSA-N,"InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3",CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2cccc(Cl)c2Cl,C21H23Cl2NO6,,D08892,153994,175426904,135738,CHEMBL1237132,,135722,50088387,456.316,4.089828298,"Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium Channel Blockers (Dihydropyridine); Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cholinesterase substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Dihydropyridines; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB04930,Permethrin,52645-53-1,approved; investigational,RLLPVAHGXHCWKJ-UHFFFAOYSA-N,"InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3",ClC(Cl)=CC(C1(C)C)C1C(=O)OCc2cc(ccc2)Oc3ccccc3,C21H20Cl2O3,C14388,D05443,40326,46505374,34911,CHEMBL1525,,36845,,391.288,5.696099242,"Agrochemicals; Antiparasitic Products, Insecticides and Repellents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Ectoparasiticides, Incl. Scabicides; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents; Enzyme Inhibitors; Hydrocarbons; Insecticides; Monoterpenes; Pesticides; Pyrethrines, Incl. Synthetic Compounds; Pyrethrins; Scabicides and Pediculicides; Terpenes; Toxic Actions"
DB04931,Afamelanotide,75921-69-6,approved; investigational,UAHFGYDRQSXQEB-LEBBXHLNSA-N,"InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1",Oc1ccc(cc1)C[C@H](NC(=O)[C@H](CO)NC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](Cc3ccccc3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc4c[nH]c(c45)cccc5)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](C(C)C)C(=O)N,C78H111N21O19,,,16197727,175426907,,CHEMBL441738,,17310725,82411,1646.8452,-8.175742804,"Amino Acids, Peptides, and Proteins; Compounds used in a research, industrial, or household setting; Dermatologicals; Hormones, Hormone Substitutes, and Hormone Antagonists; Indicators and Reagents; Laboratory Chemicals; Melanocyte-Stimulating Hormones; Peptide Hormones; Peptides; Protective Agents; Protectives Against UV-Radiation; Protectives Against UV-Radiation for Systemic Use; Proteins"
DB04938,Ospemifene,128607-22-7,approved; investigational,LUMKNAVTFCDUIE-VHXPQNKSSA-N,"InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-",OCCOc1ccc(cc1)/C(c2ccccc2)=C(/CCCl)c3ccccc3,C24H23ClO2,,D08958,3036505,175426911,73275,CHEMBL2105395,,2300501,,378.891,5.560388661,"Benzene Derivatives; Benzylidene Compounds; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Estrogen Agonist/Antagonist; Genito Urinary System and Sex Hormones; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Selective Estrogen Receptor Modulators; Sex Hormones and Modulators of the Genital System; Stilbenes"
DB04941,Crofelemer,148465-45-6,approved,,, ,,,D03605,,347909853,,CHEMBL2108184,,,,NA,NA,"Alimentary Tract and Metabolism; Antidiarrheals; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Benzopyrans; Biopolymers; Chromans; Chromones; Compounds used in a research, industrial, or household setting; Flavonoids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Macromolecular Substances; Manufactured Materials; Polymers; Pyrans; Tannins"
DB04946,Iloperidone,133454-47-4,approved,XMXHEBAFVSFQEX-UHFFFAOYSA-N,"InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3",CC(=O)c1cc(OC)c(cc1)OCCCN2CCC(CC2)c3noc(c34)cc(F)cc4,C24H27FN2O4,,D02666,71360,175426913,65173,CHEMBL14376,,64459,50034043,426.4806,3.221352625,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Azoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Histamine Antagonists; Histamine H1 Antagonists; Hyperglycemia-Associated Agents; Nervous System; Neurotoxic agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Schizophrenia; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB04948,Lofexidine,31036-80-3,approved; investigational,KSMAGQUYOIHWFS-UHFFFAOYSA-N,"InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)",N1CCN=C1C(C)Oc2c(Cl)cccc2Cl,C11H12Cl2N2O,,,30668,46508453,51368,CHEMBL17860,,28460,50019646,259.132,2.663057541,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Antidepressive Agents; Antihypertensive Agents; Azoles; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs Used in Addictive Disorders; Drugs Used in Opioid Dependence; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Imidazoles; Imidazolines; MATE 1 Inhibitors; MATE inhibitors; Moderate Risk QTc-Prolonging Agents; Nervous System; Neurotransmitter Agents; Peripheral Nervous System Agents; QTc Prolonging Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Agonists; Serotonin Agents; Serotonin Receptor Agonists"
DB04951,Pirfenidone,53179-13-8,approved; investigational,ISWRGOKTTBVCFA-UHFFFAOYSA-N,"InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3",Cc1cn(c(=O)cc1)-c2ccccc2,C12H11NO,,,40632,175426915,32016,CHEMBL1256391,,37115,50005201,185.2218,2.141857687,"Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antifibrotic Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Central Nervous System Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Peripheral Nervous System Agents; Pyridines; Pyridones; Sensory System Agents"
DB04953,Ezogabine,150812-12-7,approved; investigational,PCOBBVZJEWWZFR-UHFFFAOYSA-N,"InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)",CCOC(=O)Nc1c(N)cc(cc1)NCc2ccc(F)cc2,C16H18FN3O2,C13826,D09569,121892,175426917,68584,CHEMBL41355,,108740,50143558,303.3314,2.698082501,"Acids, Acyclic; Amines; Aniline Compounds; Anticonvulsants; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Diamines; Drugs that are Mainly Renally Excreted; Membrane Transport Modulators; Nervous System; Polyamines; Potassium Channel Opener; Potassium Channel Openers; Potential QTc-Prolonging Agents; QTc Prolonging Agents; UGT1A1 Substrates; UGT1A3 substrates; UGT1A4 substrates; UGT1A9 Substrates"
DB05013,Ingenol mebutate,75567-37-2,approved,VDJHFHXMUKFKET-UXMMOKKRSA-N,"InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16-,17-,18+,19-,21+,24+,25+/m1/s1",C[C@@H]1C[C@@H](C2(C)C)[C@@H]2[C@H](C3=O)C=C(CO)[C@@H](O)[C@]([C@@]134)(O)[C@H](C(=C4)C)OC(=O)/C(C)=C\C,C25H34O6,,D09393,6918670,175426930,66913,CHEMBL1863513,,28533061,,430.541,2.505605261,Cell Death Inducer; Dermatologicals; Hydrocarbons; Increased Cellular Death; Misc. Skin and Mucous Membrane Agents; Terpenes
DB05015,Belinostat,866323-14-0,approved; investigational,NCNRHFGMJRPRSK-MDZDMXLPSA-N,"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+",ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc2ccccc2,C15H14N2O4S,,,6918638,347827703,61076,CHEMBL408513,5OG,5293831,25150,318.35,1.813627203,Amides; Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (weak); Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Hydroxy Acids; Hydroxylamines; Immunosuppressive Agents; Myelosuppressive Agents; P-glycoprotein substrates; Sulfones; Sulfur Compounds; UGT1A1 Substrates; UGT1A1 substrates with narrow therapeutic index
DB05016,Ataluren,775304-57-9,approved; investigational,OOUGLTULBSNHNF-UHFFFAOYSA-N,"InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20)",OC(=O)c1cccc(c1)-c2noc(n2)-c3ccccc3F,C15H9FN2O3,,D09323,11219835,175426931,94805,CHEMBL256997,,9394889,,284.242,3.919392377,"Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B3 inhibitors; Oxazoles; UGT1A9 Substrates"
DB05018,Migalastat,108147-54-2,approved; investigational,LXBIFEVIBLOUGU-DPYQTVNSSA-N,"InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1",OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O,C6H13NO4,,,176077,347827704,135923,CHEMBL110458,DGJ,153388,50163440,163.1717,-2.885743183,"Alimentary Tract and Metabolism; Alkaloids; Carbohydrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imines; Imino Pyranoses; Imino Sugars; Other Miscellaneous Therapeutic Agents; Piperidines; UGT1A1 Substrates; Various Alimentary Tract and Metabolism Products"
DB05039,Indacaterol,312753-06-3,approved,QZZUEBNBZAPZLX-QFIPXVFZSA-N,"InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1",CCc(c1)c(CC)cc(c12)CC(C2)NC[C@H](O)c(ccc3O)c(c34)ccc(=O)[nH]4,C24H28N2O3,,D09318,6918554,175426936,68575,CHEMBL1095777,,5293751,50318159,392.4907,3.263325974,"Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indenes; Long-acting beta-adrenoceptor agonists; P-glycoprotein substrates; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines; Respiratory System; Selective Beta 2-adrenergic Agonists; UGT1A1 Substrates"
DB05057,Erdosteine,84611-23-4,approved; investigational,QGFORSXNKQLDNO-UHFFFAOYSA-N,"InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)",OC(=O)CSCC(=O)NC1CCSC1=O,C8H11NO4S2,,,65632,175426937,135014,CHEMBL1697744,,59073,,249.307,-0.651268225,"Acetates; Acids, Acyclic; Carboxylic Acids; Cough and Cold Preparations; Expectorants; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lipids; Respiratory System; Respiratory System Agents; Sulfhydryl Compounds; Sulfur Compounds"
DB05109,Trabectedin,114899-77-3,approved; investigational,PKVRCIRHQMSYJX-AIFWHQITSA-N,"InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1",O=C(C)Oc1c(C)c(OCO2)c2c3c1[C@@H](SC4)[C@@H]([C@H]5c6c(C[C@H](N5C)[C@@H]7O)cc(C)c(OC)c6O)N7[C@H]3COC(=O)[C@]48c9c(CCN8)cc(O)c(c9)OC,C39H43N3O11S,,,108150,99443229,84050,CHEMBL450449,ECT,97236,,761.837,3.987310563,"Agents Causing Muscle Toxicity; Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Dioxoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Isoquinolines; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Noxae; Tetrahydroisoquinolines; Toxic Actions"
DB05154,Pretomanid,187235-37-6,approved,ZLHZLMOSPGACSZ-NSHDSACASA-N,"InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1",[O-][N+](=O)c(n1)cn(c12)C[C@@H](CO2)OCc3ccc(OC(F)(F)F)cc3,C14H12F3N3O5,,,456199,175426953,,CHEMBL227875,,401693,50363237,359.2574,4.136323639,"Antituberculosis Agents; Azoles; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Nitro Compounds; OAT3/SLC22A8 Inhibitors"
DB05219,Crisaborole,906673-24-3,approved; investigational,USZAGAREISWJDP-UHFFFAOYSA-N,"InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2",OB1OCc(c12)cc(cc2)Oc3ccc(C#N)cc3,C14H10BNO3,,D10873,44591583,175426957,134677,CHEMBL484785,,24701949,50277665,251.05,3.3417,"Agents for Dermatitis, Excluding Corticosteroids; Anti-Inflammatory Agents; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors"
DB05239,Cobimetinib,934660-93-2,approved; investigational,BSMCAPRUBJMWDF-KRWDZBQOSA-N,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",C1CCCN[C@@H]1C2(O)CN(C2)C(=O)c3c(c(F)c(F)cc3)Nc4c(F)cc(I)cc4,C21H21F3IN3O2,,D10405,16222096,310264856,90851,CHEMBL2146883,EUI,17349374,50391802,531.318,5.035852919,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azetines; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; MAP Kinase Kinase 1, antagonists & inhibitors; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; OATP1B3 substrates; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Photosensitizing Agents; Protein Kinase Inhibitors"
DB05245,Silver sulfadiazine,22199-08-2,approved; vet_approved,UEJSSZHHYBHCEL-UHFFFAOYSA-N,"InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1",Nc1ccc(cc1)S(=O)(=O)[N-]c2ncccn2,C10H9AgN4O2S,,D00433,441244,46507881,9142,CHEMBL1382627,,390017,,357.137,0.387260808,"Amides; Amines; Aniline Compounds; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Miscellaneous Local Anti-infectives; Sulfanilamides; Sulfonamide Antibacterial; Sulfonamides; Sulfones; Sulfur Compounds"
DB05246,Methsuximide,77-41-8,approved,AJXPJJZHWIXJCJ-UHFFFAOYSA-N,"InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3",O=C(C1)N(C)C(=O)C1(C)c2ccccc2,C12H13NO2,,D00404,6476,46505339,6846,CHEMBL697,,6231,,203.2371,1.463009058,"Agents causing hyperkalemia; Anti-epileptic Agent; Antiarrhythmic agents; Anticonvulsants; Bradycardia-Causing Agents; Calcium Channel Blockers; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imides; Nervous System; Potential QTc-Prolonging Agents; Pyrrolidines; Pyrrolidinones; QTc Prolonging Agents; Succinimide Derivatives"
DB05260,Gallium nitrate,13494-90-1,approved; investigational,CHPZKNULDCNCBW-UHFFFAOYSA-N,InChI=1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1,[O-][N+]([O-])=O,GaN3O9,,,61635,46508923,,CHEMBL1200983,,55543,,255.738,0.028413764,"Antineoplastic Agents; Bone Resorption Inhibition; Calcium Resorption Inhibitor; Calcium-Regulating Hormones and Agents; Elements; Immunosuppressive Agents; Medications that reduce magnesium levels; Metals; Metals, Heavy"
DB05271,Rotigotine,99755-59-6,approved,KFQYTPMOWPVWEJ-INIZCTEOSA-N,"InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1",c1ccsc1CCN(CCC)[C@H](C2)CCc(c23)c(O)ccc3,C19H25NOS,,D05768,59227,99443232,135351,CHEMBL1303,,53406,50123626,315.48,4.33912796,"Agents that produce hypertension; Anti-Parkinson Agents (Dopamine Agonist); Anti-Parkinson Drugs; Antidepressive Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Naphthalenes; Nervous System; Neurotransmitter Agents; Nonergot-derivative Dopamine Receptor Agonists; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents; Serotonin Receptor Agonists; Sulfur Compounds"
DB05273,Samarium (153Sm) lexidronam,122575-21-7,approved; investigational,JSTADIGKFYFAIY-GJNDDOAHSA-K,"InChI=1S/C6H20N2O12P4.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);/q;+3/p-3/i;1+3",OP(=O)(O)CN(CP([O-])(=O)O)CCN(CP([O-])(=O)O)CP([O-])(=O)O,C6H17N2O12P4Sm,,,76962714,347827722,,,,143933,,586.021,-4.230980741,"Analgesics; Analgesics, Non-Narcotic; Central Nervous System Agents; Pain Palliation (Bone Seeking Agents); Peripheral Nervous System Agents; Radioactive Therapeutic Agent; Radioisotopes; Radiopharmaceutical Activity; Sensory System Agents; Therapeutic Radiopharmaceuticals; Various Pain Palliation Radiopharmaceuticals"
DB05294,Vandetanib,443913-73-3,approved,UHTHHESEBZOYNR-UHFFFAOYSA-N,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",CN1CCC(CC1)COc(c(c2)OC)cc(c23)ncnc3Nc4c(F)cc(Br)cc4,C22H24BrFN4O2,,D06407,3081361,175426969,49960,CHEMBL24828,ZD6,2338979,21,475.354,4.54296475,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Kinase Inhibitor; Narrow Therapeutic Index Drugs; OCT2 Inhibitors; P-glycoprotein inhibitors; Photosensitizing Agents; Protein Kinase Inhibitors; QTc Prolonging Agents; Tyrosine Kinase Inhibitors"
DB05316,Pimavanserin,706779-91-1,approved; investigational,RKEWSXXUOLRFBX-UHFFFAOYSA-N,"InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)",CC(C)COc1ccc(cc1)CNC(=O)N(C2CCN(C)CC2)Cc3ccc(F)cc3,C25H34FN3O2,,,10071196,175426976,133017,CHEMBL2111101,,8246736,139370,427.564,4.012280544,"Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB05351,Dexlansoprazole,138530-94-6,approved; investigational,MJIHNNLFOKEZEW-RUZDIDTESA-N,"InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1",FC(F)(F)COc1c(C)c(ncc1)C[S@@](=O)c([nH]2)nc(c23)cccc3,C16H14F3N3O2S,,,9578005,347827723,135931,CHEMBL1201863,,7852369,,369.36,3.032855237,"2-Pyridinylmethylsulfinylbenzimidazoles; Acid Reducers; Alimentary Tract and Metabolism; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Enzyme Inhibitors; Gastric Acid Lowering Agents; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Proton Pump Inhibitors; Proton-pump Inhibitors; Pyridines; Sulfoxides; Sulfur Compounds"
DB05381,Histamine,51-45-6,approved; investigational,NTYJJOPFIAHURM-UHFFFAOYSA-N,"InChI=1S/C5H9N3/c6-2-1-5-3-7-4-8-5/h3-4H,1-2,6H2,(H,7,8)",NCCc1c[nH]cn1,C5H9N3,C00388,D08040,774,175426988,18295,CHEMBL90,HSM,753,50121205,111.1451,-0.700971144,"Adjuvants, Immunologic; Amines; Antineoplastic and Immunomodulating Agents; Autacoids; Azoles; Biogenic Amines; Biogenic Monoamines; Biological Factors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diagnostic Agents; Ethylamines; Gastric Function; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Agonists; Imidazoles; Inflammation Mediators; Neurotransmitter Agents; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; Other Diagnostics; Tests for Gastric Secretion"
DB05382,Iodine,7553-56-2,approved; investigational,PNDPGZBMCMUPRI-UHFFFAOYSA-N,InChI=1S/I2/c1-2,II,I2,C01382,D00108,807,175426989,17606,CHEMBL1201225,I2I,785,,253.8089,1.358210709,"Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Dermatologicals; Diet, Food, and Nutrition; Elements; Food; Food and Beverages; Growth Substances; Halogens; Herbs and Natural Products; Iodine Products; Micronutrients; Minerals; Miscellaneous Local Anti-infectives; Trace Elements"
DB05389,Tetrachlorodecaoxide,92047-76-2,approved; investigational,VOWOEBADKMXUBU-UHFFFAOYSA-J,"InChI=1S/4ClHO2.O2.H2O/c4*2-1-3;1-2;/h4*(H,2,3);;1H2/p-4",[O-][Cl]=O,Cl4H2O11,,,3000391,175426992,,CHEMBL3707387,,2272021,,319.821,0.179578033,"Anions; Compounds used in a research, industrial, or household setting; Electrolytes; Elements; Gases; Halogens; Ions; Oxygen Compounds; Protective Agents; Radiation-Protective Agents"
DB05521,Telaprevir,402957-28-2,approved; withdrawn,BBAWEDCPNXPBQM-GDEBMMAJSA-N,"InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1",C1CC1NC(=O)C(=O)[C@H](CCC)NC(=O)[C@H]2N(C[C@@H]([C@@H]23)CCC3)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)c5nccnc5,C36H53N7O6,,D09012,3010818,175427024,68595,CHEMBL231813,,2279948,50326056,679.8493,2.5802923,"Amino Acids, Peptides, and Proteins; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; HCV NS3/4A Protease Inhibitors; NS3/4A Protease Inhibitors; OATP1B1/SLCO1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 2B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Peptides; Protease Inhibitors"
DB05528,Mipomersen,1000120-98-8,approved; investigational,XLTMQWVJFPYGMC-QVKFEXRMSA-N,"InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-111(122(381-141)70-362-422(325,441)404-116-50-146(283-66-108(12)196(302)275-228(283)320)387-128(116)76-368-427(330,446)410-120-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)390-130(120)78-370-428(331,447)408-118-52-148(292-91-250-151-186(240)246-89-248-188(151)292)388-131(118)79-371-430(333,449)412-159-134(394-204(169(159)354-37-27-344-17)286-59-101(5)181(235)260-221(286)313)83-375-435(338,454)417-164-138(398-209(174(164)359-42-32-349-22)291-68-110(14)198(304)277-230(291)322)87-377-434(337,453)415-162-136(396-207(172(162)357-40-30-347-20)289-62-104(8)184(238)263-224(289)316)85-376-433(336,452)414-161-133(393-206(171(161)356-39-29-346-19)288-61-103(7)183(237)262-223(288)315)82-374-432(335,451)411-158-121(69-298)391-211(168(158)353-36-26-343-16)296-95-254-155-192(296)267-215(244)271-201(155)307)401-420(323,439)365-74-127-117(51-147(386-127)284-67-109(13)197(303)276-229(284)321)406-425(328,444)369-77-129-119(53-149(389-129)293-92-252-153-190(293)265-213(242)269-199(153)305)409-426(329,445)367-71-123-112(46-142(382-123)279-56-98(2)178(232)257-218(279)310)402-421(324,440)364-73-125-115(49-145(384-125)282-65-107(11)195(301)274-227(282)319)405-424(327,443)366-75-126-114(48-144(385-126)281-64-106(10)194(300)273-226(281)318)403-423(326,442)363-72-124-113(47-143(383-124)280-57-99(3)179(233)258-219(280)311)407-429(332,448)373-81-139-166(176(361-44-34-351-24)212(400-139)297-96-255-156-193(297)268-216(245)272-202(156)308)419-438(341,457)379-86-137-163(173(358-41-31-348-21)208(397-137)290-63-105(9)185(239)264-225(290)317)416-436(339,455)380-88-140-165(175(360-43-33-350-23)210(399-140)295-94-251-152-187(241)247-90-249-189(152)295)418-437(340,456)378-84-135-160(170(355-38-28-345-18)205(395-135)287-60-102(6)182(236)261-222(287)314)413-431(334,450)372-80-132-157(299)167(352-35-25-342-15)203(392-132)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,203+,204+,205+,206+,207+,208+,209+,210+,211+,212+,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?/m0/s1",O=c1nc(N)c(C)cn1[C@@H]2O[C@@H]([C@@H](O)[C@H]2OCCOC)COP(=O)(S)O[C@@H]3[C@H](O[C@H]([C@@H]3OCCOC)n4cc(C)c(N)nc4=O)COP(=O)(S)O[C@@H]5[C@H](O[C@H]([C@@H]5OCCOC)n6cnc(c67)c(N)ncn7)COP(=O)(S)O[C@@H]8[C@H](O[C@H]([C@@H]8OCCOC)n9cc(C)c(N)nc9=O)COP(=O)(S)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cnc(c12)c(=O)[nH]c(n2)N)COP(=O)(S)O[C@H]1C[C@H](n2cc(C)c(N)nc2=O)O[C@@H]1COP(=O)(S)O[C@H]1C[C@H](n2cc(C)c(=O)[nH]c2=O)O[C@@H]1COP(=O)(S)O[C@H]1C[C@H](n2cc(C)c(=O)[nH]c2=O)O[C@@H]1COP(=O)(S)O[C@H]1C[C@H](n2cc(C)c(N)nc2=O)O[C@@H]1COP(=O)(S)O[C@H]1C[C@H](n2cnc(c23)c(=O)[nH]c(n3)N)O[C@@H]1COP(=O)(S)O[C@H]1C[C@H](n2cc(C)c(=O)[nH]c2=O)O[C@@H]1COP(=O)(S)O[C@H]1C[C@H](n2cc(C)c(N)nc2=O)O[C@@H]1COP(=O)(S)O[C@H]1C[C@H](n2cc(C)c(=O)[nH]c2=O)O[C@@H]1COP(=O)(S)O[C@H]1C[C@H](n2cnc(c23)c(=O)[nH]c(n3)N)O[C@@H]1COP(=O)(S)O[C@H]1C[C@H](n2cnc(c23)c(N)ncn3)O[C@@H]1COP(=O)(S)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cc(C)c(N)nc1=O)COP(=O)(S)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cc(C)c(=O)[nH]c1=O)COP(=O)(S)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cc(C)c(N)nc1=O)COP(=O)(S)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cc(C)c(N)nc1=O)COP(=O)(S)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]1OCCOC)n1cnc(c12)c(=O)[nH]c(n2)N,C230H324N67O122P19S19,,D08946,131704297,347827735,,CHEMBL502097,,34983392,,7177.11,-2.902566547,"Anticholesteremic Agents; Antisense Elements (Genetics); Apolipoprotein B-100 Synthesis Inhibitor; Carbohydrates; Cardiovascular System; Compounds used in a research, industrial, or household setting; Decreased Protein Synthesis; Diagnostic Uses of Chemicals; DNA; DNA, Antisense; Glycosides; Hepatotoxic Agents; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Laboratory Chemicals; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Molecular Probes; Noxae; Nucleic Acid Probes; Nucleic Acids; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Oligodeoxyribonucleotides, Antisense; Oligonucleotides; Oligonucleotides, Antisense; Polynucleotides; Toxic Actions"
DB05541,Brivaracetam,357336-20-0,approved; investigational,MSYKRHVOOPPJKU-BDAKNGLRSA-N,"InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1",CCC[C@H]1CN(C(=O)C1)[C@@H](CC)C(=O)N,C11H20N2O2,,D08879,9837243,347827736,133013,CHEMBL607400,,8012964,50422531,212.2887,0.660504256,"Anticonvulsants; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Epoxide Hydrolase Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Miscellaneous Anticonvulsants; Nervous System; Pyrrolidines"
DB05630,Sodium stibogluconate,16037-91-5,approved; investigational,YQDGWZZYGYKDLR-UZVLBLASSA-K,"InChI=1S/2C6H9O7.3Na.10H2O.2O.2Sb/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;;;;;;;;;;;;;;/h2*2-5,7-8H,1H2,(H,12,13);;;;10*1H2;;;;/q2*-3;3*+1;;;;;;;;;;;;-1;+3;+4/p-3/t2*2-,3-,4+,5-;;;;;;;;;;;;;;;;;/m11................./s1",OC[C@@H](O)[C@@H](O1)[C@H](O2)[C@H](C([O-])=O)O[Sb]12(O)O[Sb]34([O-])O[C@@H](C([O-])=O)[C@@H](O3)[C@H](O4)[C@H](O)CO,C12H35Na3O26Sb2,,D00582,56927674,99443233,28148,CHEMBL2079699,,27471272,,907.88,-3.4262,"Acids, Acyclic; Agents Against Leishmaniasis and Trypanosomiasis; Anti-Infective Agents; Antimony Compounds; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiplatyhelmintic Agents; Antiprotozoals; Carbohydrates; Carboxylic Acids; Gluconates; Hydroxy Acids; Organometallic Compounds; Schistosomicides; Sugar Acids"
DB05676,Apremilast,608141-41-9,approved; investigational,IMOZEMNVLZVGJZ-QGZVFWFLSA-N,"InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1",CCOc1cc(ccc1OC)[C@@H](CS(=O)(=O)C)N(C2=O)C(=O)c(c23)cccc3NC(=O)C,C22H24N2O7S,,D08860,11561674,310264858,78540,CHEMBL514800,,9736448,50248919,460.5,1.310207613,"Agents reducing cytokine levels; Anti-Inflammatory Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Disease-modifying Antirheumatic Agents; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Isoindoles; P-glycoprotein substrates; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Phthalimides; Selective Immunosuppressants"
DB05812,Abiraterone,154229-19-3,approved,GZOSMCIZMLWJML-VJLLXTKPSA-N,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",C1C[C@H](O)CC([C@]12C)=CC[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CC=C4c5cccnc5,C24H31NO,,D09701,132971,175427038,68642,CHEMBL254328,AER,117349,25458,349.509,3.965292911,"Androstanes; Androstenes; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strong); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Cytochrome P450 17A1 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Endocrine Therapy; Enzyme Inhibitors; Fused-Ring Compounds; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Metabolic Side Effects of Drugs and Substances; Polycyclic Compounds; Steroid Synthesis Inhibitors; Steroids"
DB05990,Obeticholic acid,459789-99-2,approved,ZXERDUOLZKYMJM-ZWECCWDJSA-N,"InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1",OC(=O)CC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)[C@H]([C@H]([C@H]3O)CC)C[C@H](O)CC4,C26H44O4,C15636,D09360,447715,347827752,43602,CHEMBL566315,CHC,394730,21675,420.6252,4.522847015,Alimentary Tract and Metabolism; Bile Acid Preparations; Bile acids and derivatives; Bile Acids and Salts; Bile and Liver Therapy; Bile Therapy; BSEP/ABCB11 inducers; BSEP/ABCB11 Inhibitors; Cholanes; Cholic Acids; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Farnesoid X Receptor Agonist; Farnesoid X Receptor Agonists; Fused-Ring Compounds; Miscellaneous GI Drugs; Polycyclic Compounds
DB06016,Cariprazine,839712-12-8,approved; investigational,KPWSJANDNDDRMB-QAQDUYKDSA-N,"InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17-",CN(C)C(=O)N[C@H]1CC[C@@H](CC1)CCN2CCN(CC2)c3c(Cl)c(Cl)ccc3,C21H32Cl2N4O,,D09997,11154555,310264859,90933,CHEMBL2028019,,25999972,50443101,427.41,4.056449687,"Agents that produce hypertension; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H1 Antagonists; Nervous System; Neurotoxic agents; Psycholeptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB06077,Lumateperone,313368-91-1,approved; investigational,HOIIHACBCFLJET-SFTDATJTSA-N,"InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1",C1CN(C)c(c2N13)cccc2[C@H]4[C@@H]3CCN(C4)CCCC(=O)c5ccc(F)cc5,C24H28FN3O,,,21302490,310264860,,CHEMBL3306803,,19328801,,393.506,3.585094668,Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Agonists; Neurotoxic agents; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; UGT1A1 Substrates; UGT1A4 substrates
DB06119,Cenobamate,913088-80-9,approved; investigational,GFHAXPJGXSQLPT-VIFPVBQESA-N,"InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1",Clc1ccccc1[C@@H](OC(=O)N)Cn2ncnn2,C10H10ClN5O2,,,,,,CHEMBL3989949,,10136642,,267.67,1.662127134,Anticonvulsants; Central Nervous System Depressants; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; GABA Modulators; UGT2B7 substrates; Voltage-Gated Sodium Channel Blockers
DB06144,Sertindole,106516-24-9,approved; investigational; withdrawn,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,"InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)",Fc1ccc(cc1)-n2cc(c(c23)cc(Cl)cc3)C4CCN(CC4)CCN5CCNC5=O,C24H26ClFN4O,C07567,D00561,60149,46504717,9122,CHEMBL12713,,54229,50001786,440.941,3.7738,"Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Azoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indole Derivatives; Nervous System; Neurotoxic agents; Psycholeptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB06145,Spiramycin,24916-50-5,approved,ACTOXUHEUCPTEW-KWBWCIJSSA-N,"InChI=1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26+,27-,28+,29+,30+,31-,32+,34+,35+,36-,37-,38-,39+,40+,41+,42+,43-/m1/s1",CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O[C@H]2CC[C@@H]([C@@H](O2)C)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]3O[C@H](C)[C@H]([C@@H]([C@H]3O)N(C)C)O[C@@H](C[C@@]4(C)O)O[C@@H](C)[C@@H]4O,C43H74N2O14,,,6440717,347827756,85260,CHEMBL1908369,,4944970,,843.065,2.496113379,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antiparasitic Agents; Antiprotozoals; Carbohydrates; Coccidiostats; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Glycosides; Lactones; Leucomycins; Macrocyclic Compounds; Macrolides; Macrolides, Lincosamides and Streptogramins; Polycyclic Compounds; Polyketides"
DB06147,Sulfathiazole,72-14-0,approved; vet_approved,JNMRHUJNCSQMMB-UHFFFAOYSA-N,"InChI=1S/C9H9N3O2S2/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9/h1-6H,10H2,(H,11,12)",Nc1ccc(cc1)S(=O)(=O)Nc2nccs2,C9H9N3O2S2,C11169,D01047,5340,175427054,9337,CHEMBL437,YTZ,5148,50027796,255.317,0.975027931,"Amides; Amines; Aniline Compounds; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Azoles; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Short-Acting Sulfonamides; Sulfanilamides; Sulfathiazoles; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds; Thiazoles"
DB06148,Mianserin,24219-97-4,approved; investigational,UEQUQVLFIPOEMF-UHFFFAOYSA-N,"InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3",CN(C1)CCN(C12)c3c(cccc3)Cc4c2cccc4,C18H20N2,,,4184,46508096,51137,CHEMBL6437,,4040,50222218,264.3648,3.831197652,"Adrenergic Agents; Agents that produce hypertension; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tetracyclic; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dibenzazepines; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Nervous System; Neurotransmitter Agents; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists"
DB06149,Teicoplanin,61036-62-2,approved; investigational,,, ,,C15820,D02142,,46507509,29687,,,,,NA,NA,"Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Glycoconjugates; Glycopeptide Antibacterials; Glycopeptides; Lipids; Lipoglycopeptides; Lipopeptides; Peptides"
DB06150,Sulfadimethoxine,122-11-2,approved; vet_approved,ZZORFUFYDOWNEF-UHFFFAOYSA-N,"InChI=1S/C12H14N4O4S/c1-19-11-7-10(14-12(15-11)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)",COc1nc(OC)nc(c1)NS(=O)(=O)c2ccc(N)cc2,C12H14N4O4S,,D01142,5323,99443234,32161,CHEMBL62193,,5132,50238669,310.329,1.260833337,Amides; Amines; Aniline Compounds; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Long-Acting Sulfonamides; Sulfanilamides; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds
DB06151,Acetylcysteine,616-91-1,approved; investigational,PWKSKIMOESPYIA-BYPYZUCNSA-N,"InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1",CC(=O)N[C@@H](CS)C(=O)O,C5H9NO3S,C06809,D00221,12035,99443235,28939,CHEMBL600,SC2,11540,50420190,163.195,-0.711312742,"Amino Acids; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Anti-Infective Agents; Antidote for Acetaminophen Overdose; Antidotes; Antioxidants; Compounds used in a research, industrial, or household setting; Cough and Cold Preparations; Cysteine; Decreased Respiratory Secretion Viscosity; Expectorants; Free Radical Scavengers; Increased Glutathione Concentration; OATP1B1/SLCO1B1 Inhibitors; Ophthalmologicals; Protective Agents; Reduction Activity; Respiratory System; Respiratory System Agents; Sensory Organs; Sulfhydryl Compounds; Sulfur Compounds"
DB06152,Nylidrin,447-41-6,approved,PTGXAUBQBSGPKF-UHFFFAOYSA-N,"InChI=1S/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3",c1ccccc1CCC(C)NC(C)C(O)c2ccc(O)cc2,C19H25NO2,,,4567,347827757,91656,CHEMBL114655,,4407,50240096,299.414,3.053808593,"2-Amino-1-Phenylethanol Derivatives; Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-Agonists; Agents causing hyperkalemia; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Antiarrhythmic agents; Autonomic Agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Ethylamines; Genito Urinary System and Sex Hormones; Miscellaneous Vasodilatating Agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Peripheral Vasodilators; Phenethylamines; Propanolamines; Propanols; Reproductive Control Agents; Sympathomimetics; Sympathomimetics, Labour Repressants; Tocolytic Agents; Vasodilating Agents"
DB06153,Pizotifen,15574-96-6,approved,FIADGNVRKBPQEU-UHFFFAOYSA-N,"InChI=1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3",CN1CCC(CC1)=C2c(ccs3)c3CCc(c24)cccc4,C19H21NS,,,27400,347827758,50212,CHEMBL294951,,25497,82088,295.44,4.492244677,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anticholinergic Agents; Antidepressive Agents; Antimigraine Agents, Miscellaneous; Antimigraine Preparations; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H1 Antagonists; Muscarinic Antagonists; Nervous System; Neurotransmitter Agents; Peripheral Nervous System Agents; Psychotropic Drugs; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT1D Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Thiophenes"
DB06154,Pentaerythritol tetranitrate,78-11-5,approved,TZRXHJWUDPFEEY-UHFFFAOYSA-N,"InChI=1S/C5H8N4O12/c10-6(11)18-1-5(2-19-7(12)13,3-20-8(14)15)4-21-9(16)17/h1-4H2",[O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O,C5H8N4O12,,D01721,6518,347827759,25879,CHEMBL466659,,6271,,316.1366,0.055472053,Alcohols; Antianginal Agents; Carbohydrates; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Drugs that are Mainly Renally Excreted; Fibrin Modulating Agents; Glycols; Hematologic Agents; Organic Nitrates; Polysaccharides; Propylene Glycols; Vasodilating Agents; Vasodilators Used in Cardiac Diseases
DB06155,Rimonabant,168273-06-1,approved; investigational,JZCPYUJPEARBJL-UHFFFAOYSA-N,"InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)",C1CCCCN1NC(=O)c(c(C)c2-c(cc3)ccc3Cl)nn2-c4c(Cl)cc(Cl)cc4,C22H21Cl3N4O,C14319,D05731,104850,99443236,34967,CHEMBL111,AY6,94641,21278,463.787,5.907997435,"Agents producing tachycardia; Alimentary Tract and Metabolism; Anti-Obesity Agents; Antiobesity Preparations, Excl. Diet Products; Azoles; Cannabinoid Receptor Antagonists; Cannabinoids and similars; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neurotransmitter Agents; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1, antagonists & inhibitors"
DB06174,Noscapine,128-62-1,approved; investigational,AKNNEGZIBPJZJG-MSOLQXFVSA-N,"InChI=1S/C22H23NO7/c1-23-8-7-11-9-14-20(29-10-28-14)21(27-4)15(11)17(23)18-12-5-6-13(25-2)19(26-3)16(12)22(24)30-18/h5-6,9,17-18H,7-8,10H2,1-4H3/t17-,18+/m1/s1",COc(cc1)c(OC)c(c12)C(=O)O[C@@H]2[C@@H]3N(C)CCc(c34)cc5c(OCO5)c4OC,C22H23NO7,C09592,,,,73237,CHEMBL364713,,242139,50424716,413.4205,2.580710038,"Alkaloids; Antitussive Agents; Central Nervous System Agents; Cough and Cold Preparations; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Opiate Alkaloids; Opium Alkaloids and Derivatives; Respiratory System; Respiratory System Agents"
DB06176,Romidepsin,128517-07-7,approved; investigational,OHRURASPPZQGQM-GCCNXGTGSA-N,"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1",O=C([C@H]12)N/C(=C\C)C(=O)N[C@@H](C(C)C)C(=O)O[C@@H](CC(=O)N[C@H](C(C)C)C(=O)N1)/C=C/CCSSC2,C24H36N4O6S2,,D06637,57515973,310264861,61080,CHEMBL343448,,10122002,19151,540.69,1.077951401,"Amino Acids, Peptides, and Proteins; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Highest Risk QTc-Prolonging Agents; Histone Deacetylase Inhibitors; Macrocyclic Compounds; Narrow Therapeutic Index Drugs; OATP1B3 substrates; P-glycoprotein substrates; Peptides; Peptides, Cyclic; Polycyclic Compounds; QTc Prolonging Agents"
DB06193,Pixantrone,144510-96-3,approved; investigational,PEZPMAYDXJQYRV-UHFFFAOYSA-N,"InChI=1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2",NCCNc1ccc(NCCN)c(c12)C(=O)c3c(C2=O)ccnc3,C17H19N5O2,,,134019,347827761,135945,CHEMBL167731,,118174,,325.372,0.352622285,"Anthracyclines and Related Substances; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytotoxic Antibiotics and Related Substances; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB06196,Icatibant,130308-48-4,approved; investigational,QURWXBZNHXJZBE-SKXRKSCCSA-N,"InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1",NC(=N)NCCC[C@@H](C(=O)O)NC(=O)[C@H](C[C@@H]([C@@H]12)CCCC2)N1C(=O)[C@@H](Cc(c34)cccc4)N(C3)C(=O)[C@H](CO)NC(=O)[C@H](Cc5cccs5)NC(=O)CNC(=O)[C@@H]6C[C@@H](O)CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N,C59H89N19O13S,,D04492,71364,99443237,68556,CHEMBL2028850,,5293384,50406750,1304.54,-7.664003138,"Agents causing angioedema; Amino Acids, Peptides, and Proteins; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Autacoids; Biological Factors; Blood and Blood Forming Organs; Bradykinin B2 Receptor Antagonists; Bradykinin Receptor Antagonists; Central Nervous System Agents; Complement Inactivating Agents; Drugs that are Mainly Renally Excreted; Drugs Used in Hereditary Angioedema; Immunologic Factors; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Kinins; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptides; Peripheral Nervous System Agents; Proteins; Sensory System Agents"
DB06201,Rufinamide,106308-44-5,approved,POGQSBRIGCQNEG-UHFFFAOYSA-N,"InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)",NC(=O)c1cn(nn1)Cc2c(F)cccc2F,C10H8F2N4O,,D05775,129228,175427055,134966,CHEMBL1201754,,114471,,238.1935,1.266597642,"Anticonvulsants; Azoles; Carboxamide Derivatives; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Miscellaneous Anticonvulsants; Nervous System; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB06202,Lasofoxifene,180916-16-9,approved; investigational,GXESHMAMLJKROZ-IAPPQJPRSA-N,"InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1",c1cc(O)cc(c12)CC[C@H](c3ccccc3)[C@@H]2c4ccc(cc4)OCCN5CCCC5,C28H31NO2,,D04672,216416,347827762,,CHEMBL328190,C3D,187585,20606,413.5512,5.972224038,"Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthalenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Selective Estrogen Receptor Modulators; Sex Hormones and Modulators of the Genital System"
DB06203,Alogliptin,850649-61-5,approved,ZSBOMTDTBDDKMP-OAHLLOKOSA-N,"InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1",N[C@H]1CN(CCC1)c2cc(=O)n(C)c(=O)n2Cc3c(C#N)cccc3,C18H21N5O2,,D06553,11450633,175427056,72323,CHEMBL376359,T22,9625485,16285,339.3916,1.155640152,"Agents causing angioedema; Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; DPP-IV Inhibitors; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Incretins; Protease Inhibitors; Pyrimidines; Pyrimidinones"
DB06204,Tapentadol,175591-23-8,approved,KWTWDQCKEHXFFR-SMDDNHRTSA-N,"InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1",CN(C)C[C@H](C)[C@@H](CC)c1cc(O)ccc1,C14H23NO,,D06007,9838022,175427057,135935,CHEMBL1201776,,8013742,50386381,221.3385,2.958533627,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Analgesics; Antidepressive Agents; Benzene Derivatives; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Membrane Transport Modulators; Narcotics; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Opiate Agonists; Opioid Agonist; Opioids; Peripheral Nervous System Agents; Phenols; Phenylpropylamine opioids; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; UGT1A9 Substrates; UGT2B7 substrates"
DB06206,Sugammadex,343306-71-8,approved,WHRODDIHRRDWEW-VTHZAVIASA-N,"InChI=1S/C72H112O48S8/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88)/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-/m1/s1",OC(=O)CCSC[C@@H](O[C@@H]12)[C@H]([C@H](O)[C@H]1O)O[C@H]3O[C@H](CSCCC(=O)O)[C@H]([C@H](O)[C@H]3O)O[C@H]4O[C@H](CSCCC(=O)O)[C@H]([C@H](O)[C@H]4O)O[C@H]5O[C@H](CSCCC(=O)O)[C@H]([C@H](O)[C@H]5O)O[C@H]6O[C@H](CSCCC(=O)O)[C@H]([C@H](O)[C@H]6O)O[C@H]7O[C@H](CSCCC(=O)O)[C@H]([C@H](O)[C@H]7O)O[C@H]8O[C@H](CSCCC(=O)O)[C@H]([C@H](O)[C@H]8O)O[C@H]9O[C@@H]([C@@H](O2)[C@H](O)[C@H]9O)CSCCC(=O)O,C72H112O48S8,,D05940,6918585,347827763,90953,CHEMBL2111107,,32689915,,2002.12,-5.417171355,"Antidotes; Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Cyclodextrins; Dextrins; Diet, Food, and Nutrition; Dietary Carbohydrates; Food; Food and Beverages; gamma-Cyclodextrins; Glucans; Macrocyclic Compounds; Macromolecular Substances; Manufactured Materials; Physiological Phenomena; Polycyclic Compounds; Polymers; Polysaccharides; Starch"
DB06207,Silodosin,160970-54-7,approved,PNCPYILNMDWPEY-QGZVFWFLSA-N,"InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1",OCCCN1CCc(c12)cc(cc2C(=O)N)C[C@@H](C)NCCOc3ccccc3OCC(F)(F)F,C25H32F3N3O4,,D01965,5312125,175427058,135929,CHEMBL24778,,4471557,50160154,495.5345,3.04673584,"Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs Used in Benign Prostatic Hypertrophy; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; P-glycoprotein substrates; Peripheral alpha-1 blockers; Selective Alfa-1-adrenergic Blocking Agents; UGT2B7 substrates; Urological Agents; Urologicals"
DB06209,Prasugrel,150322-43-3,approved,DTGLZDAWLRGWQN-UHFFFAOYSA-N,"InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3",CC(=O)Oc(s1)cc(c12)CN(CC2)C(C(=O)C3CC3)c4ccccc4F,C20H20FNO3S,,D05597,6918456,99443238,87723,CHEMBL1201772,,5293653,,373.441,4.307205803,"Anticoagulants; Antiplatelet agents; Blood and Blood Forming Organs; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Decreased Platelet Aggregation; Drugs that are Mainly Renally Excreted; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; P2Y12 Platelet Inhibitor; Piperazines; Platelet Aggregation Inhibitors Excl. Heparin; Purinergic P2Y Receptor Antagonists; Sulfur Compounds; Thiophenes"
DB06210,Eltrombopag,496775-61-2,approved,XDXWLKQMMKQXPV-QYQHSDTDSA-N,"InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22-",Cc1ccc(cc1C)N2N=C(C)/C(C2=O)=N/Nc3cccc(c3O)-c4cccc(c4)C(=O)O,C25H22N4O4,,D03978,9846180,175427059,85010,CHEMBL461101,,19879943,,442.4666,6.026236313,"Acids, Carbocyclic; Azoles; BCRP/ABCG2 Inhibitors; Benzene Derivatives; Blood and Blood Forming Organs; Breast Cancer Resistance Protein Inhibitors; Carboxylic Acids; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hematinics; Hemostatics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Increased Megakaryocyte Maturation; Increased Platelet Production; OATP1B1/SLCO1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Thrombopoietin Receptor Agonist; Thrombopoietin Receptor Agonists; UGT1A1 Inhibitors; UGT1A1 Substrates; UGT1A3 Inhibitors; UGT1A3 substrates; UGT1A4 Inhibitors; UGT1A6 Inhibitors; UGT1A9 Inhibitors; UGT2B15 Inhibitors; UGT2B7 Inhibitors"
DB06211,Doripenem,148016-81-3,approved; investigational,AVAACINZEOAHHE-VFZPANTDSA-N,"InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1",C[C@@H](O)[C@@H](C1=O)[C@H](N12)[C@@H](C)C(=C2C(=O)O)S[C@@H]3CN[C@@H](C3)CNS(=O)(=O)N,C15H24N4O6S2,,D03895,73303,310264862,135928,CHEMBL491571,O6P,66040,50088382,420.504,-5.563490933,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Carbapenems; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; OAT3/SLC22A8 Substrates; Penem Antibacterial; Sulfur Compounds"
DB06212,Tolvaptan,150683-30-0,approved,GYHCTFXIZSNGJT-XMMPIXPASA-N,"InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)/t24-/m1/s1",Cc1ccccc1C(=O)Nc2cc(C)c(cc2)C(=O)N3CCC[C@@H](O)c(c34)cc(Cl)cc4,C26H25ClN2O3,,D01213,443894,175427060,,CHEMBL344159,,391976,,448.941,5.35018372,"Agents causing hyperkalemia; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diuretics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Natriuretic Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Vasopressin V2 Receptor Antagonist; Vasopressin V2 Receptor Antagonists"
DB06213,Regadenoson,313348-27-5,approved; investigational,LZPZPHGJDAGEJZ-AKAIJSEGSA-N,"InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1",CNC(=O)c1cn(nc1)-c(nc2N)nc(c23)n(cn3)[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O,C15H18N8O5,,D05711,219024,175427061,135613,CHEMBL317052,,189859,50119132,390.354,-2.252042983,"Adenosine A2 Receptor Agonists; Azoles; Cardiac Therapy; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; Purinergic Agents; Purinergic Agonists; Purinergic P1 Receptor Agonists"
DB06215,Ferumoxytol,722492-56-0,approved; investigational,WTFXARWRTYJXII-UHFFFAOYSA-N,InChI=1S/3Fe.4O/q+2;2*+3;4*-2,[O-2],Fe3O4,,D04177,16211978,347827764,50821,,,4937312,,231.531,-0.77,"Compounds used in a research, industrial, or household setting; Ferric Compounds; Ferrous Compounds; Hematinics; Hematologic Agents; Iron Compounds; Magnetic Resonance Contrast Activity; Minerals; Organometallic Compounds; Paramagnetic Contrast Agent; Parenteral Iron Replacement; Parenteral Nutrition Solutions; Pharmaceutical Preparations; Pharmaceutical Solutions; Solutions"
DB06216,Asenapine,65576-45-6,approved,GMDCDXMAFMEDAG-BTJKTKAUSA-N,"InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-",CN(C1)CC(C12)c3c(cccc3)Oc4c2cc(Cl)cc4,C21H20ClNO5,,D02995,11954293,175427062,71253,CHEMBL3544974,,10128588,,401.84,3.724606574,"Acid Reducers; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diazepines, Oxazepines, Thiazepines and Oxepines; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H2 Antagonists; Hyperglycemia-Associated Agents; Nervous System; Neurotoxic agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Serotonin Receptor Antagonists; Tranquilizing Agents; UGT1A4 substrates"
DB06217,Vernakalant,794466-70-9,approved; investigational,VBHQKCBVWWUUKN-KZNAEPCWSA-N,"InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1",COc1c(OC)cc(cc1)CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3,C20H31NO4,,D06665,9930049,347827765,135956,CHEMBL2111112,,8105680,,349.471,2.513554539,"Antiarrhythmic agents; Antiarrhythmics, Class III; Benzene Derivatives; Cardiac Therapy; Cardiovascular System; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Ethers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Methyl Ethers; Phenols; Phenyl Ethers; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB06218,Lacosamide,175481-36-4,approved,VPPJLAIAVCUEMN-GFCCVEGCSA-N,"InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1",COC[C@@H](NC(=O)C)C(=O)NCc1ccccc1,C13H18N2O3,,D07299,219078,175427063,135939,CHEMBL58323,,189902,50300204,250.2936,-0.022441605,"Acetamides; Acetates; Acids, Acyclic; Alkanes; Amides; Anti-epileptic Agent; Anticonvulsants; Bradycardia-Causing Agents; Carboxylic Acids; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Decreased Central Nervous System Disorganized Electrical Activity; Fatty Acids; Fatty Acids, Volatile; Hydrocarbons; Hydrocarbons, Acyclic; Lipids; Membrane Transport Modulators; Miscellaneous Anticonvulsants; Nervous System; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers"
DB06219,Dalbavancin,171500-79-1,approved; investigational,,, ,,,D03640,23724878,310264863,82721,CHEMBL3301669,,30791917,,NA,NA,"Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Glycoconjugates; Glycopeptide Antibacterials; Glycopeptides; Lipids; Lipoglycopeptide Antibacterial; Lipoglycopeptides; Lipopeptides; Peptides"
DB06228,Rivaroxaban,366789-02-8,approved,KGFYHTZWPPHNLQ-AWEZNQCLSA-N,"InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1",Clc1ccc(s1)C(=O)NC[C@H]2CN(C(=O)O2)c3ccc(cc3)N4CCOCC4=O,C19H18ClN3O5S,,D07086,9875401,175427064,68579,CHEMBL198362,RIV,8051086,7840,435.881,1.897644719,"Anticoagulants; Antithrombins; BCRP/ABCG2 Substrates; Blood and Blood Forming Organs; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Factor Xa Inhibitors; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Morpholines; Oxazines; P-glycoprotein substrates; Protease Inhibitors; Serine Protease Inhibitors; Sulfur Compounds; Thiophenes"
DB06230,Nalmefene,55096-26-9,approved; investigational; withdrawn,WJBLNOPPDWQMCH-MBPVOVBZSA-N,"InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1",[C@]123[C@H]4Oc5c1c(ccc5O)C[C@@H](N(CC2)CC6CC6)[C@]3(O)CCC4=C,C21H25NO3,C08027,D05111,,,7457,CHEMBL982,,4447642,50045776,339.435,1.947647967,"Alkaloids; Antipruritics; Appetite Depressants; Central Nervous System Agents; Drugs that are Mainly Renally Excreted; Drugs Used in Addictive Disorders; Drugs Used in Alcohol Dependence; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Nervous System; Neuroprotective Agents; Opiate Alkaloids; Opioid Antagonists; Peripheral Nervous System Agents; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents; UGT1A3 substrates; UGT2B7 substrates"
DB06237,Avanafil,330784-47-9,approved,WEAJZXNPAWBCOA-INIZCTEOSA-N,"InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1",COc1c(Cl)cc(cc1)CNc2c(C(=O)NCc3ncccn3)cnc(n2)N4CCC[C@H]4CO,C23H26ClN7O3,,D03217,9869929,175427065,66876,CHEMBL1963681,,8045620,235766,483.951,2.77881291,"Cyclic Nucleotide Phosphodiesterases, Type 5; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs Used in Erectile Dysfunction; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Phosphodiesterase 5 Inhibitors; Urologicals; Vasodilating Agents"
DB06243,Eflornithine,70052-12-9,approved; withdrawn,VLCYCQAOQCDTCN-UHFFFAOYSA-N,"InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)",NCCCC(N)(C(F)F)C(=O)O,C6H12F2N2O2,C07997,D07883,3009,310264864,41948,CHEMBL830,,2902,50028197,182.171,-2.908437201,"Agents Against Leishmaniasis and Trypanosomiasis; Amino Acids; Amino Acids, Basic; Amino Acids, Diamino; Amino Acids, Peptides, and Proteins; Anti-Infective Agents; Antineoplastic Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Decarboxylase Inhibitor; Decarboxylase Inhibitors; Dermatologicals; Enzyme Inhibitors; Misc. Skin and Mucous Membrane Agents; Ornithine Decarboxylase Inhibitors; Trypanocidal Agents"
DB06249,Arzoxifene,182133-25-1,approved; investigational,MCGDSOGUHLTADD-UHFFFAOYSA-N,"InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3",COc1ccc(cc1)-c(s2)c(c(c23)ccc(c3)O)Oc4ccc(cc4)OCCN5CCCCC5,C28H29NO4S,,,,,,CHEMBL226267,,156104,19442,475.6,5.892588143,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Sulfur Compounds"
DB06261,Hexaminolevulinate,140898-97-1,approved,RYQOILLJDKPETL-UHFFFAOYSA-N,"InChI=1S/C11H21NO3/c1-2-3-4-5-8-15-11(14)7-6-10(13)9-12/h2-9,12H2,1H3",NCC(=O)CCC(=O)OCCCCCC,C11H21NO3,,D04436,6433083,310264865,134892,CHEMBL1201784,,4938272,,215.293,1.365943113,"Amino Acids; Amino Acids, Peptides, and Proteins; Carbon Radioisotopes; Carboxylic Acids; Diagnostic Agents; Keto Acids; Levulinic Acids; Other Diagnostics; Photosensitizing Agents"
DB06262,Droxidopa,23651-95-8,approved; investigational,QXWYKJLNLSIPIN-JGVFFNPUSA-N,"InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1",OC(=O)[C@@H](N)[C@H](O)c1cc(O)c(O)cc1,C9H11NO5,,D01277,92974,99443239,31524,CHEMBL2103827,,83927,50103611,213.189,-2.711013612,"Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Acids; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Amino Alcohols; Anti-Dyskinesia Agents; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular System; Catecholamines; Catechols; Central Nervous System Agents; Drugs that are Mainly Renally Excreted; Epinephrine and similars; Ethanolamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Increased Blood Pressure; Phenols"
DB06267,Udenafil,268203-93-6,approved; investigational,IYFNEFQTYQPVOC-UHFFFAOYSA-N,"InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)",CCCc1nn(C)c(c12)c(=O)nc([nH]2)-c3c(OCCC)ccc(c3)S(=O)(=O)NCCC4CCCN4C,C25H36N6O4S,,D10027,6918523,99443240,135926,CHEMBL2103849,,5293720,,516.656,1.662940769,"Amides; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs Used in Erectile Dysfunction; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Sulfones; Sulfur Compounds; Urologicals; Vasodilating Agents"
DB06268,Sitaxentan,184036-34-8,approved; investigational; withdrawn,PHWXUGHIIBDVKD-UHFFFAOYSA-N,"InChI=1S/C18H15ClN2O6S2/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18/h3-5,7,21H,6,8H2,1-2H3",Cc1noc(c1Cl)NS(=O)(=O)c2c(scc2)C(=O)Cc(c(C)c3)cc(c34)OCO4,C18H15ClN2O6S2,,D07171,216235,99443241,135736,CHEMBL282724,,187436,50058126,454.905,3.091685922,"Antihypertensive Agents; Antihypertensives for Pulmonary Arterial Hypertension; Azoles; Cardiovascular System; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Endothelin Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Sulfur Compounds"
DB06274,Alvimopan,156053-89-3,approved; investigational,UPNUIXSCZBYVBB-JVFUWBCBSA-N,"InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1",Oc1cccc(c1)[C@@]2(C)[C@@H](C)CN(CC2)C[C@@H](C(=O)NCC(=O)O)Cc3ccccc3,C25H32N2O4,,D02878,5488548,99443242,135686,CHEMBL270190,,4589864,50088381,424.5326,0.822153591,"Alimentary Tract and Metabolism; Drugs for Constipation; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Opioid Antagonists; Peripheral Opioid Receptor Antagonists; Receptors, Opioid, mu, antagonists & inhibitors"
DB06282,Levocetirizine,130018-77-8,approved,ZKLPARSLTMPFCP-OAQYLSRUSA-N,"InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1",OC(=O)COCCN1CCN(CC1)[C@H](c2ccccc2)c3ccc(Cl)cc3,C21H25ClN2O3,,D07402,1549000,310264866,94559,CHEMBL1201191,LCR,1266001,85030,388.89,0.873692831,"Antihistamines for Systemic Use; Central Nervous System Depressants; Cetirizine and isomer; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Neurotransmitter Agents; Piperazine Derivatives; Piperazines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB06283,Ziconotide,107452-89-1,approved,,, ,,,D06363,,347910345,,CHEMBL2103752,,,,NA,NA,"Analgesics; Analgesics, Non-Narcotic; Antiarrhythmic agents; Calcium Channel Blockers; Calcium Channels, N-Type; Calcium-Regulating Hormones and Agents; Central Nervous System Agents; Central Nervous System Depressants; Complex Mixtures; Compounds used in a research, industrial, or household setting; Conotoxins; Fluids and Secretions; Marine Toxins; Membrane Transport Modulators; Mollusk Venoms; N-Calcium Channel Receptor Antagonists; Narrow Therapeutic Index Drugs; Nervous System; Neuroprotective Agents; Peripheral Nervous System Agents; Protective Agents; Sensory System Agents; Toxins, Biological; Vasodilating Agents; Venoms"
DB06287,Temsirolimus,162635-04-3,approved,CBPNZQVSJQDFBE-FUXHJELOSA-N,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",OCC(C)(CO)C(=O)O[C@@H]1CC[C@H](C[C@H]1OC)C[C@@H](C)[C@@H](OC(=O)[C@H](CCCC2)N2C(=O)C(=O)[C@]34O)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H](O3)CC[C@H]4C,C56H87NO16,C15182,D06068,23724530,99443243,79699,CHEMBL1201182,,21468899,50343413,1030.2871,7.129959347,Agents causing angioedema; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Kinase Inhibitor; Lactones; Macrocyclic Compounds; Macrolides; mTOR Inhibitors; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Polyketides; Protein Kinase Inhibitors; Sirolimus and Prodrugs
DB06288,Amisulpride,71675-85-9,approved; investigational,NTJOBXMMWNYJFB-UHFFFAOYSA-N,"InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)",CCN1CCCC1CNC(=O)c2cc(S(=O)(=O)CC)c(N)cc2OC,C17H27N3O4S,,D07310,2159,99443244,64045,CHEMBL243712,,2074,81790,369.479,0.251287685,"Acids, Carbocyclic; Amides; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Potential QTc-Prolonging Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB06290,Simeprevir,923604-59-5,approved,JTZZSQYMACOLNN-VDWJNHBNSA-N,"InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1",C1CC1S(=O)(=O)NC(=O)[C@]23[C@H](C2)/C=C\CCCCN(C)C(=O)[C@H]4[C@H](C(=O)N3)C[C@H](C4)Oc5cc(-c6nc(cs6)C(C)C)nc(c57)c(C)c(cc7)OC,C38H47N5O7S2,,D10081,24873435,175427067,134743,CHEMBL501849,30B,23331536,50336504,749.939,4.556754259,"Amides; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; BSEP/ABCB11 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; HCV NS3/4A Protease Inhibitors; HCV Protease Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; NS3/4A Protease Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; OATP1B3 substrates; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Protease Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds"
DB06292,Dapagliflozin,461432-26-8,approved,JVHXJTBJCFBINQ-ADAARDCZSA-N,"InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1",CCOc1ccc(cc1)Cc2c(Cl)ccc(c2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O,C21H25ClO6,,D08897,9887712,175427068,85078,CHEMBL429910,,8063384,20880,408.873,2.110900303,"Alimentary Tract and Metabolism; Benzene Derivatives; Blood Glucose Lowering Agents; Carbohydrates; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diuretics; Drugs Used in Diabetes; Glycosides; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; P-glycoprotein substrates; Sodium-glucose co-transporter 2 (SGLT2) inhibitors; Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; Sodium-Glucose Transport Proteins, antagonists & inhibitors; Sodium-Glucose Transporter 2 Inhibitors; UGT1A9 Substrates; UGT2B7 substrates"
DB06335,Saxagliptin,361442-04-8,approved,QGJUIPDUBHWZPV-SGTAVMJGSA-N,"InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1",[C@H]12[C@@H](C2)C[C@@H](C#N)N1C(=O)[C@@H](N)C34CC5CC(C3)CC(O)(C5)C4,C18H25N3O2,,D08996,11243969,99443245,71272,CHEMBL385517,,9419005,50225074,315.41,-0.079534432,"Agents causing angioedema; Alimentary Tract and Metabolism; Amino Acids, Peptides, and Proteins; Blood Glucose Lowering Agents; Bridged Compounds; Cycloparaffins; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; DPP-IV Inhibitors; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Enzyme Inhibitors; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hypoglycemia-Associated Agents; Incretins; Macrocyclic Compounds; OAT3/SLC22A8 Substrates; Oligopeptides; Peptides; Polycyclic Compounds; Protease Inhibitors"
DB06401,Bazedoxifene,198481-32-2,approved; investigational,UCJGJABZCDBEDK-UHFFFAOYSA-N,"InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3",c1cc(O)ccc1-c(c2C)n(c(c23)ccc(O)c3)Cc4ccc(cc4)OCCN5CCCCCC5,C30H34N2O3,,D03062,154257,310264867,135947,CHEMBL46740,29S,135921,50099585,470.613,6.005592582,"Bone Density Conservation Agents; Estrogen Agonist/Antagonist; Estrogen Receptor Modulators; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Selective Estrogen Receptor Modulators; Sex Hormones and Modulators of the Genital System; UGT1A1 Substrates"
DB06402,Telavancin,372151-71-8,approved,ONUMZHGUFYIKPM-MXNFEBESSA-N,"InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1",CCCCCCCCCCNCCN[C@@]1(C)C[C@@H](O[C@@H](C)[C@H]1O)O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc(c34)c5cc(c3)[C@@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c6ccc(O4)c(Cl)c6)C(=O)N[C@@H]7c8cc(c(O)cc8)c9c(cc(O)c(c9O)CNCP(=O)(O)O)[C@@H](C(=O)O)NC(=O)[C@@H](NC7=O)[C@H](O)c1cc(Cl)c(O5)cc1,C80H106Cl2N11O27P,,,3081362,175427069,71229,CHEMBL507870,,2338980,,1755.65,-6.162542771,"Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Drugs that are Mainly Renally Excreted; Glycoconjugates; Glycopeptide Antibacterials; Glycopeptides; Glycosides; Lipids; Lipoglycopeptide Antibacterial; Lipopeptides; Moderate Risk QTc-Prolonging Agents; Peptides; QTc Prolonging Agents"
DB06403,Ambrisentan,177036-94-1,approved; investigational,OUJTZYPIHDYQMC-LJQANCHMSA-N,"InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1",c1ccccc1C(OC)(c2ccccc2)[C@@H](C(=O)O)Oc3nc(C)cc(n3)C,C22H22N2O4,,,6918493,310264868,135949,CHEMBL1111,,5293690,50146710,378.428,3.499580327,"Acids, Carbocyclic; Antihypertensive Agents; Antihypertensives for Pulmonary Arterial Hypertension; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Endothelin Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypertension, Pulmonary; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; UGT1A3 substrates; UGT1A9 Substrates; UGT2B7 substrates; Vasodilating Agents"
DB06410,Doxercalciferol,54573-75-0,approved,HKXBNHCUPKIYDM-CGMHZMFXSA-N,"InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1",CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]([C@@]12C)/C(CCC2)=C/C=C3/C[C@@H](O)C[C@H](O)C3=C,C28H44O2,C08211,D01009,46705423,347827769,4712,CHEMBL1200810,V2H,4444554,,412.6478,5.746953121,"Anti-Parathyroid Agents; Bone Density Conservation Agents; Calcium Homeostasis; Cholestanes; Cholestenes; Diet, Food, and Nutrition; Food; Food and Beverages; Fused-Ring Compounds; Growth Substances; Lipids; Medications that increase serum magnesium; Membrane Lipids; Micronutrients; Physiological Phenomena; Polycyclic Compounds; Secosteroids; Steroids; Sterols; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)"
DB06412,Oxymetholone,434-07-1,approved; illicit,ICMWWNHDUZJFDW-DHODBPELSA-N,"InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1",C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)[C@@H](CC3)CC(=O)/C(C4)=C\O,C21H32O3,C07393,D00490,5281034,310264869,7864,CHEMBL1200585,,4444502,,332.484,3.552729479,"Alimentary Tract and Metabolism; Anabolic Agents; Anabolic Agents for Systemic Use; Anabolic Steroids; Androgens; Androstan Derivatives; Androstanes; Androstanols; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroids; Thyroxine-binding globulin inhibitors"
DB06413,Armodafinil,112111-43-0,approved; investigational,YFGHCGITMMYXAQ-LJQANCHMSA-N,"InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1",c1ccccc1C([S@](=O)CC(=O)N)c2ccccc2,C15H15NO2S,,D03215,9690109,310264870,77590,CHEMBL1201192,,7962943,50336892,273.35,1.53283444,"Benzene Derivatives; Benzhydryl Compounds; Central Nervous System Agents; Central Nervous System Stimulants; Centrally Acting Sympathomimetics; Chemically-Induced Disorders; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Metabolic Side Effects of Drugs and Substances; Modafinil and isomer; Nervous System; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Wakefulness-Promoting Agents"
DB06414,Etravirine,269055-15-4,approved,PYGWGZALEOIKDF-UHFFFAOYSA-N,"InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)",Cc1cc(C#N)cc(C)c1Oc2c(Br)c(N)nc(n2)Nc3ccc(C#N)cc3,C20H15BrN6O,,D04112,193962,175427070,63589,CHEMBL308954,65B,168313,50103642,435.277,5.536511323,"Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Non-Nucleoside Reverse Transcriptase Inhibitors; Nonnucleoside Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; P-glycoprotein inducers; Reverse Transcriptase Inhibitors"
DB06415,Calfactant,183325-78-2,approved,,, ,,,D03317,,347910351,,CHEMBL1201447,,,,NA,NA,Alveolar Surface Tension Reduction; Bradycardia-Causing Agents; Complex Mixtures; Pulmonary Surfactants; Respiratory System Agents; Surface-Active Agents; Surfactant Activity
DB06439,Tyloxapol,25301-02-4,approved; investigational,,, ,,,D03261,,175427071,,CHEMBL1201548,,26330335,,NA,NA,"Alcohols; Compounds used in a research, industrial, or household setting; Cough and Cold Preparations; Detergents; Ethylene Glycols; Expectorants; Glycols; Household Products; Macromolecular Substances; Manufactured Materials; Polymers; Respiratory System; Surface-Active Agents"
DB06441,Cangrelor,163706-06-7,approved,PAEBIVWUMLRPSK-IDTAVKCVSA-N,"InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1",FC(F)(F)CCSc(n1)nc(NCCSC)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O,C17H25Cl2F3N5O12P3S2,,D03359,9854012,310264872,90841,CHEMBL334966,,8029718,50118225,776.35,-0.124448006,"Adenine Nucleotides; Anticoagulants; Antiplatelet agents; Blood and Blood Forming Organs; Carbohydrates; Decreased Platelet Aggregation; Glycosides; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; P2Y12 Platelet Inhibitor; Platelet Aggregation Inhibitors Excl. Heparin; Purine Nucleotides; Purinergic Agents; Purinergic Antagonists; Purinergic P2 Receptor Antagonists; Purinergic P2Y Receptor Antagonists; Purines; Ribonucleotides"
DB06480,Prucalopride,179474-81-8,approved,ZPMNHBXQOOVQJL-UHFFFAOYSA-N,"InChI=1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23)",COCCCN1CCC(CC1)NC(=O)c(cc(Cl)c2N)c(c23)OCC3,C18H26ClN3O3,,,3052762,310264873,135552,CHEMBL117287,,2314539,50122872,367.87,0.744688497,"Alimentary Tract and Metabolism; Antidepressive Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Laxatives; Miscellaneous GI Drugs; Neurotransmitter Agents; P-glycoprotein substrates; Serotonin Agents"
DB06589,Pazopanib,444731-52-6,approved,CUIHSIWYWATEQL-UHFFFAOYSA-N,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",Cc1n(C)nc(c12)cc(cc2)N(C)c3ccnc(n3)Nc4ccc(C)c(c4)S(=O)(=O)N,C21H23N7O2S,,D05380,10113978,175427074,71219,CHEMBL477772,,8289501,26474,437.518,3.548707246,"Amides; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Kinase Inhibitor; Moderate Risk QTc-Prolonging Agents; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; QTc Prolonging Agents; Receptors, Vascular Endothelial Growth Factor, antagonists & inhibitors; Sulfones; Sulfur Compounds; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors"
DB06590,Ceftaroline fosamil,229016-73-3,approved; investigational,ZCCUWMICIWSJIX-NQJJCJBVSA-N,"InChI=1S/C22H21N8O8PS4/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10/h4-8,14,19H,3,9H2,1-2H3,(H4-,24,25,27,28,31,33,34,35,36,37)/b26-13-/t14-,19-/m1/s1",OP(=O)(O)Nc1nc(ns1)/C(=N/OCC)C(=O)N[C@H](C2=O)[C@H](N23)SCC(=C3C([O-])=O)Sc4nc(cs4)-c5cc[n+](C)cc5,C22H21N8O8PS4,,D08884,9852981,175427075,70718,CHEMBL501122,,8028692,,684.67,-3.716400504,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Sulfur Compounds; Thiazines"
DB06594,Agomelatine,138112-76-2,approved; investigational,YJYPHIXNFHFHND-UHFFFAOYSA-N,"InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)",COc(cc1)cc(c12)c(ccc2)CCNC(=O)C,C15H17NO2,,D02578,82148,175427076,134990,CHEMBL10878,AWY,74141,50035179,243.301,2.038327551,"Acetates; Acids, Acyclic; Amides; Antidepressive Agents; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Fatty Acids; Fatty Acids, Volatile; Lipids; Melatonin, agonists; Nervous System; Psychoanaleptics; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB06595,Midostaurin,120685-11-2,approved; investigational,BMGQWWVMWDBQGC-IIFHNQTCSA-N,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1",c1ccccc1C(=O)N(C)[C@@H]([C@H]2OC)C[C@@H](O3)n(c4c5n6[C@]23C)c7c(cccc7)c4c8c(CNC8=O)c5c9c6cccc9,C35H30N4O4,,D05029,9829523,347827778,63452,CHEMBL608533,2K2,8005258,50326053,570.649,5.433789878,"Alkaloids; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carbazoles; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strong); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strong); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP3A7 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indole Alkaloids; Indoles; Kinase Inhibitor; Narrow Therapeutic Index Drugs; Protein Kinase C, antagonists & inhibitors; Protein Kinase Inhibitors; Receptor Tyrosine Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB06603,Panobinostat,404950-80-7,approved; investigational,FPOHNWQLNRZRFC-ZHACJKMWSA-N,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",c1cccc(c12)c(c([nH]2)C)CCNCc3ccc(cc3)/C=C/C(=O)NO,C21H23N3O2,,D10019,6918837,310264874,85990,CHEMBL483254,LBH,5294028,29589,349.434,2.477624283,"Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Histone Deacetylase Inhibitors; Hydroxamic Acids; Hydroxy Acids; Hydroxylamines; Immunosuppressive Agents; Indoles; Moderate Risk QTc-Prolonging Agents; P-glycoprotein substrates; QTc Prolonging Agents"
DB06605,Apixaban,503612-47-3,approved,QNZCBYKSOIHPEH-UHFFFAOYSA-N,"InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)",COc1ccc(cc1)-n2nc(C(=O)N)c(c23)CCN(C3=O)c4ccc(cc4)N5CCCCC5=O,C25H25N5O4,,D03213,10182969,175427077,72296,CHEMBL231779,GG2,8358471,19023,459.4971,1.827072246,"Anticoagulants; Antithrombins; Azoles; BCRP/ABCG2 Substrates; Blood and Blood Forming Organs; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Factor Xa Inhibitors; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; P-glycoprotein substrates; Protease Inhibitors; Pyridines; Serine Protease Inhibitors"
DB06608,Tafenoquine,106635-80-7,approved; investigational,LBHLFPGPEGDCJG-UHFFFAOYSA-N,"InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3",FC(F)(F)c(c1)cccc1Oc(c(c23)c(C)cc(n2)OC)c(OC)cc3NC(C)CCCN,C24H28F3N3O3,,,,,141487,CHEMBL298470,,103196,,463.501,4.971264277,"Aminoquinolines; Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiprotozoals; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; OCT2 Inhibitors; Quinolines"
DB06614,Peramivir,330600-85-6,approved; investigational,XRQDFNLINLXZLB-CKIKVBCHSA-N,"InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1",CC(=O)N[C@@H](C(CC)CC)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(N)=N,C15H28N4O4,,,154234,175427078,85202,CHEMBL139367,BCZ,135903,5024,328.4072,-2.121477642,"Amidines; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cycloparaffins; Direct Acting Antivirals; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Neuraminidase Inhibitors; Neuraminidase, antagonists & inhibitors; Polycyclic Compounds"
DB06616,Bosutinib,380843-75-4,approved,UBPYILGKFZZVDX-UHFFFAOYSA-N,"InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)",COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4,C26H29Cl2N5O3,,D03252,5328940,175427079,39112,CHEMBL288441,DB8,4486102,4552,530.446,4.087721831,"Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB06626,Axitinib,319460-85-0,approved; investigational,RITAVMQDGBJQJZ-FMIVXFBMSA-N,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",CNC(=O)c1c(cccc1)Sc(c2)ccc(c23)c(n[nH]3)/C=C/c4ccccn4,C22H18N4OS,,D03218,6450551,347827779,66910,CHEMBL1289926,AXI,4953153,25117,386.47,4.148864336,"Acids, Carbocyclic; Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indazoles; Kinase Inhibitor; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Pyrazoles; Receptor Tyrosine Kinase Inhibitors; Tyrosine Kinase Inhibitors; UGT1A1 Substrates"
DB06636,Isavuconazonium,742049-41-8,approved; investigational,RSWOJTICKMKTER-QXLBVTBOSA-N,"InChI=1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1",CNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]2cn(nc2)C[C@](O)(c3c(F)ccc(F)c3)[C@@H](C)c4nc(cs4)-c5ccc(C#N)cc5,C35H35F2N8O5S,,D10643,6918606,310264875,85978,CHEMBL1183349,,5293801,,717.77,0.524089279,"Anti-Infective Agents; Antifungal Agents; Azole Antifungals; Azoles; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isavuconazole and Prodrugs; P-glycoprotein inhibitors"
DB06637,Dalfampridine,504-24-5,approved,NUKYPUAOHBNCPY-UHFFFAOYSA-N,"InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)",Nc1ccncc1,C5H6N2,C13728,D04127,1727,175427081,34385,CHEMBL284348,,1664,10458,94.1145,0.286413164,"Amines; Aminopyridines; Cardiovascular Agents; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Narrow Therapeutic Index Drugs; Nervous System; OCT2 Substrates; OCT2 substrates with narrow therapeutic index; Other Miscellaneous Therapeutic Agents; Potassium Channel Antagonists; Potassium Channel Blockers; Pyridines"
DB06654,Safinamide,133865-89-1,approved; investigational,NEMGRZFTLSKBAP-LBPRGKRZSA-N,"InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1",NC(=O)[C@H](C)NCc1ccc(cc1)OCc2cc(F)ccc2,C17H19FN2O2,,,131682,347827780,134718,CHEMBL396778,,116349,50078694,302.349,2.480903371,"Agents that produce hypertension; Agents that reduce seizure threshold; Amines; Amino Acids; Amino Acids, Peptides, and Proteins; Anti-Parkinson Drugs; Antidepressive Agents; BCRP/ABCG2 Inhibitors; Benzene Derivatives; Benzyl Compounds; Breast Cancer Resistance Protein Inhibitors; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dopamine Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Monoamine Oxidase B Inhibitors; Monoamine Oxidase Inhibitors; Nervous System; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB06663,Pasireotide,396091-73-9,approved,VMZMNAABQBOLAK-DBILLSOUSA-N,"InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1",NCCNC(=O)O[C@@H](C1)C[C@H](N12)C(=O)N[C@@H](c3ccccc3)C(=O)N[C@H](Cc4c[nH]c(c45)cccc5)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C2=O)Cc6ccccc6)Cc7ccc(cc7)OCc8ccccc8,C58H66N10O9,,D10147,9941444,175427082,72312,CHEMBL3349607,,8117062,,1047.2062,2.676563247,"Amino Acids, Peptides, and Proteins; Bradycardia-Causing Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Hypoglycemia-Associated Agents; Hypothalamic Hormones; Nerve Tissue Proteins; Neuropeptides; Pancreatic Hormones; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormone Release Inhibiting Hormones; Potential QTc-Prolonging Agents; Proteins; QTc Prolonging Agents; Somatostatin Agonists; Somatostatin and Analogues; Somatostatin Receptor Agonists; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB06684,Vilazodone,163521-12-8,approved,SGEGOXDYSFKCPT-UHFFFAOYSA-N,"InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)",NC(=O)c(o1)cc(c12)cc(cc2)N3CCN(CC3)CCCCc4c[nH]c(c45)ccc(c5)C#N,C26H27N5O2,,D09698,6918314,175427083,70707,CHEMBL439849,,5293518,50151982,441.5249,3.715303906,"Agents that produce hypertension; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Benzofurans; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Piperazines; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists"
DB06689,Ethanolamine oleate,09-11-2272,approved,KGWDUNBJIMUFAP-KVVVOXFISA-N,"InChI=1S/C18H34O2.C2H7NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;3-1-2-4/h9-10H,2-8,11-17H2,1H3,(H,19,20);4H,1-3H2/b10-9-;",CCCCCCCC/C=C\CCCCCCCC(=O)O,C20H41NO3,,D02276,5282489,99443246,,CHEMBL3989529,,4445632,,343.5444,6.783798451,"Antivaricose Therapy; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Lipids; Pharmaceutical Preparations; Pharmaceutical Solutions; Sclerosing Agents for Local Injection; Sclerosing Solutions; Solutions; Vasoprotectives"
DB06690,Nitrous oxide,10024-97-2,approved; vet_approved,GQPLMRYTRLFLPF-UHFFFAOYSA-N,InChI=1S/N2O/c1-2-3,[N-]=[N+]=O,N2O,C00887,D00102,948,310264877,17045,CHEMBL1234579,N2O,923,,44.0128,-0.446774191,"Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anesthetics; Anesthetics, General; Anesthetics, Inhalation; Anions; Central Nervous System Agents; Central Nervous System Depressants; Electrolytes; Gases; Ions; Methemoglobinemia Associated Agents; Nervous System; Nitrogen Compounds; Nitrogen Oxides; Oxides; Oxygen Compounds; Peripheral Nervous System Agents; Sensory System Agents"
DB06691,Mepyramine,91-84-9,approved; vet_approved,YECBIJXISLIIDS-UHFFFAOYSA-N,"InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3",COc1ccc(cc1)CN(CCN(C)C)c2ncccc2,C17H23N3O,C11798,D08183,4992,175427084,6762,CHEMBL511,,4818,22567,285.384,3.043521152,"Amines; Aminopyridines; Anti-Allergic Agents; Antihistamines for Systemic Use; Antihistamines for Topical Use; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Hypnotics and Sedatives; Neurotransmitter Agents; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Respiratory System; Sleep Aids, Pharmaceutical; Substituted Ethylene Diamines"
DB06694,Xylometazoline,526-36-3,approved; investigational,HUCJFAOMUPXHDK-UHFFFAOYSA-N,"InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)",Cc1cc(C(C)(C)C)cc(C)c1CC2=NCCN2,C16H24N2,C07913,D08684,5709,99443248,10082,CHEMBL312448,,5507,30703,244.3752,3.775539242,"Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Antiarrhythmic agents; Antihistamine Drugs; Azoles; Calcium Channel Blockers; Cardiovascular Agents; Decongestants and Antiallergics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nasal Decongestants; Nasal Preparations; Ophthalmologicals; Respiratory System; Respiratory System Agents; Sensory Organs; Sympathomimetics Used as Decongestants; Sympathomimetics, Plain; Vasoconstrictor Agents; Vasodilating Agents"
DB06695,Dabigatran etexilate,211915-06-9,approved,KSGXQBZTULBEEQ-UHFFFAOYSA-N,"InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)",CCCCCCOC(=O)/N=C(/N)c1ccc(cc1)NCc(n2C)nc(c23)cc(cc3)C(=O)N(CCC(=O)OCC)c4ncccc4,C34H41N7O5,,D07144,6445226,99443249,70746,CHEMBL539697,,4948999,50432209,627.7332,4.593332732,"Anticoagulants; Antithrombins; Benzimidazoles; Blood and Blood Forming Organs; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; P-glycoprotein substrates; Protease Inhibitors; Pyridines; Serine Protease Inhibitors; UGT1A9 Substrates; UGT2B7 substrates"
DB06697,Artemether,71963-77-4,approved,SXYIRMFQILZOAM-HVNFFKDJSA-N,"InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1",[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3O[C@H](OC)[C@@H]4C,C16H26O5,,D02483,68911,99443251,195280,CHEMBL566534,D8Z,62138,50022886,298.3746,3.48139202,"Anions; Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Artemisinin and Derivatives, Plain; Artemisinins; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (weak); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Electrolytes; Free Radicals; Highest Risk QTc-Prolonging Agents; Hydrocarbons; Ions; Oxides; Oxygen Compounds; Peroxides; QTc Prolonging Agents; Reactive Oxygen Species; Sesquiterpenes; Terpenes"
DB06698,Betahistine,5638-76-6,approved; investigational,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,"InChI=1S/C8H12N2/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H3",CNCCc1ccccn1,C8H12N2,,D07522,2366,99443252,35677,CHEMBL24441,,2276,96589,136.1943,0.632406845,"Antivertigo Preparations; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Agonists; Histamine Antagonists; Miscellaneous Central Nervous System Agents; Miscellaneous Therapeutic Agents; Nervous System; Neurotransmitter Agents; Pyridines; Vasodilating Agents"
DB06699,Degarelix,214766-78-6,approved,MEUCPCLKGZSHTA-XYAYPHGZSA-N,"InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1",NC(=O)[C@@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccc(cc2)NC(=O)N)NC(=O)[C@H](Cc3ccc(cc3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc5cccnc5)NC(=O)[C@@H](Cc6ccc(Cl)cc6)NC(=O)[C@H](NC(=O)C)Cc(c7)ccc(c78)cccc8,C82H103ClN18O16,,D08901,16136245,99443253,135961,CHEMBL415606,,17292756,50102450,1632.29,0.177050207,"Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Gonadotropin-releasing Hormone Antagonists; Gonadotropin-Releasing Hormone, antagonists & inhibitors; Hormone Antagonists and Related Agents; Peptides; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB06700,Desvenlafaxine,93413-62-8,approved; investigational,KYYIDSXMWOZKMP-UHFFFAOYSA-N,"InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3",C1CCCCC1(O)C(CN(C)C)c2ccc(O)cc2,C16H25NO2,,D07793,125017,99443254,83527,CHEMBL1118,,111300,86748,263.3752,2.293426606,"Agents producing tachycardia; Agents that reduce seizure threshold; Alcohols; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Benzene Derivatives; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cyclohexanes; Cyclohexanols; Cycloparaffins; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fatty Alcohols; Hexanols; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypoglycemia-Associated Agents; Lipids; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Norepinephrine Uptake Inhibitors; Phenols; Psychoanaleptics; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Serotonin Modulators"
DB06701,Dexmethylphenidate,40431-64-9,approved; investigational,DUGOZIWVEXMGBE-CHWSQXEVSA-N,"InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1",C1CCCN[C@H]1[C@H](C(=O)OC)c2ccccc2,C14H19NO2,,,154101,99443255,51860,CHEMBL827,,135807,50062915,233.3062,2.254935082,"Agents that produce hypertension; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Central Nervous System Stimulants; Central Nervous System Stimulation; Centrally Acting Sympathomimetics; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Dopamine Agents; Dopamine Uptake Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Methylphenidate and isomer; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Phenylacetates; Piperidines; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB06702,Fesoterodine,286930-02-7,approved,DCCSDBARQIPTGU-HSZRJFAPSA-N,"InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1",c1ccccc1[C@@H](CCN(C(C)C)C(C)C)c2c(OC(=O)C(C)C)ccc(c2)CO,C26H37NO3,,D07226,6918558,99443256,135920,CHEMBL1201764,,5293755,,411.5769,5.698894813,"Agents producing tachycardia; Anticholinergic Agents; Benzene Derivatives; Cholinergic Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Urinary Frequency and Incontinence; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Muscarinic Antagonists; Neurotransmitter Agents; P-glycoprotein substrates; Urological Agents; Urologicals"
DB06703,Gadobutrol,770691-21-9,approved,ZPDFIIGFYAHNSK-YYLIZZNMSA-K,"InChI=1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/m0./s1",OC[C@H](O)[C@H](CO)[N+]1([Gd-]234)CC[N+]2(CC([O-])=O)CC[N+]3(CC([O-])=O)CC[N+]4(CC([O-])=O)CC1,C18H31GdN4O9,,D07420,70678987,99443257,68841,CHEMBL2218860,,28533281,,604.72,-4.570196766,"Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Gadolinium-based Contrast Agent; Magnetic Resonance Contrast Activity; Magnetic Resonance Imaging Contrast Media; Other Diagnostics; Paramagnetic Contrast Media"
DB06704,Iobenguane,80663-95-2,approved; investigational,PDWUPXJEEYOOTR-UHFFFAOYSA-N,"InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)",NC(N)=NCc1cc(I)ccc1,C8H10IN3,,D04559,60860,175427085,92769,CHEMBL818,,54847,,275.0896,1.640254646,"Amidines; Benzene Derivatives; Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Enzyme Inhibitors; Guanidines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Hydrocarbons, Iodinated; Indicators and Reagents; Iodine (131I) Compounds; Iodobenzenes; Laboratory Chemicals; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Therapeutic Radiopharmaceuticals; Tumour Detection"
DB06705,Gadofosveset trisodium,193901-90-5,approved,XGOSYNSWSRUASG-UHFFFAOYSA-H,"InChI=1S/C33H44N3O14P.Gd.3Na/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;;;;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);;;;/q;+3;3*+1/p-6",[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC(N(CC([O-])=O)CC([O-])=O)COP([O-])(=O)OC(CC1)CCC1(c2ccccc2)c3ccccc3,C33H38GdN3Na3O14P,,D04286,73049652,175427086,,CHEMBL1908362,,58829621,,957.87,-1.177820681,"Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Elements; Gadolinium-based Contrast Agent; Lanthanoid Series Elements; Magnetic Resonance Angiography; Magnetic Resonance Contrast Activity; Magnetic Resonance Imaging Contrast Media; Metals; Metals, Rare Earth; Paramagnetic Contrast Agent; Paramagnetic Contrast Media"
DB06706,Isometheptene,503-01-5,approved,XVQUOJBERHHONY-UHFFFAOYSA-N,"InChI=1S/C9H19N/c1-8(2)6-5-7-9(3)10-4/h6,9-10H,5,7H2,1-4H3",CNC(C)CCC=C(C)C,C9H19N,,,22297,99443258,134765,CHEMBL1697841,,21106328,,141.2539,2.318172513,Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alimentary Tract and Metabolism; Amines; Drugs for Functional Gastrointestinal Disorders; Methemoglobinemia Associated Agents
DB06707,Levonordefrin,829-74-3,approved,GEFQWZLICWMTKF-CDUCUWFYSA-N,"InChI=1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3/t5-,9-/m0/s1",C[C@H](N)[C@H](O)c1cc(O)c(O)cc1,C9H13NO3,C11768,D02388,164739,99443259,10304,CHEMBL677,,144416,50223426,183.2044,-0.392674043,"Adrenergic Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Cardiovascular Agents; Catecholamines; Catechols; Epinephrine and similars; Ethanolamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols; Vasoconstrictor Agents"
DB06708,Lumefantrine,82186-77-4,approved,DYLGFOYVTXJFJP-MYYYXRDXSA-N,"InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-",CCCCN(CCCC)CC(O)c(cc(Cl)c1)c(c12)c3c(cc(Cl)cc3)C\2=C\c4ccc(Cl)cc4,C30H32Cl3NO,,D03821,6437380,99443260,156095,CHEMBL38827,,4941944,50238630,528.94,9.191258858,"Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Fluorenes; Highest Risk QTc-Prolonging Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; QTc Prolonging Agents"
DB06709,Methacholine,55-92-5,approved; investigational,NZWOPGCLSHLLPA-UHFFFAOYSA-N,"InChI=1S/C8H18NO2/c1-7(11-8(2)10)6-9(3,4)5/h7H,6H2,1-5H3/q+1",CC(=O)OC(C)C[N+](C)(C)C,C8H18NO2,C07471,,1993,99443261,6804,CHEMBL978,,1916,48918,160.234,-3.804568728,Amines; Ammonium Compounds; Autonomic Agents; Bronchoconstrictor Agents; Cholinergic Agents; Cholinergic Agonists; Cholinergic Receptor Agonist; Diagnostic Agents; Methacholine Compounds; Miotics; Muscarinic Agonists; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Other Diagnostics; Parasympathomimetics; Peripheral Nervous System Agents; Quaternary Ammonium Compounds; Respiratory System Agents; Trimethyl Ammonium Compounds
DB06710,Methyltestosterone,58-18-4,approved,GCKMFJBGXUYNAG-HLXURNFRSA-N,"InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1",C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=CC(=O)CC4,C20H30O2,C07198,D00408,6010,99443262,27436,CHEMBL1395,,5788,50410531,302.451,3.645999966,"3-Oxoandrosten (4) Derivatives; Anabolic Agents; Androgens; Androgens and Estrogens; Androstanes; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OAT3/SLC22A8 Inducers; Polycyclic Compounds; Sex Hormones and Modulators of the Genital System; Steroids; Testosterone Congeners; Thyroxine-binding globulin inhibitors"
DB06711,Naphazoline,835-31-4,approved; investigational,CNIIGCLFLJGOGP-UHFFFAOYSA-N,"InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)",N1CCN=C1Cc2cccc(c23)cccc3,C14H14N2,,D08253,4436,99443263,93363,CHEMBL761,,4283,50001922,210.2744,2.19311695,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Azoles; Cardiovascular Agents; Decongestants and Antiallergics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Nasal Decongestants; Nasal Preparations; Neurotransmitter Agents; Ophthalmologicals; Respiratory System; Respiratory System Agents; Sensory Organs; Sympathomimetics Used as Decongestants; Sympathomimetics, Plain; Vasoconstrictor Agents"
DB06712,Nilvadipine,75530-68-6,approved; investigational,FAIIFDPAEUKBEP-UHFFFAOYSA-N,"InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3",COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1c2cc([N+]([O-])=O)ccc2,C19H19N3O6,,D01908,4494,99443264,31911,CHEMBL517427,,4338,50103634,385.3707,2.239046583,"Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Dihydropyridines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; Moderate Risk QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB06713,Norelgestromin,53016-31-2,approved; investigational,ISHXLNHNDMZNMC-XUDSTZEESA-N,"InChI=1S/C21H29NO2/c1-3-20-11-9-17-16-8-6-15(22-24)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23-24H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1",C#C[C@]1(O)CC[C@H]([C@@]12CC)[C@H]3[C@H](CC2)[C@@H]4C(CC3)=C/C(CC4)=N/O,C21H29NO2,,D05205,62930,99443265,135398,CHEMBL1200807,,56648,,327.468,3.671276388,"Adrenal Cortex Hormones; Amines; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drug Combinations; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hydroxylamines; Norpregnanes; Norpregnenes; Norsteroids; Pharmaceutical Preparations; Polycyclic Compounds; Progestins; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB06714,Propylhexedrine,101-40-6,approved,JCRIVQIOJSSCQD-UHFFFAOYSA-N,"InChI=1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3",CNC(C)CC1CCCCC1,C10H21N,,D05637,7558,99443266,134783,CHEMBL2105275,,7277,,155.2804,2.704594756,Amines
DB06715,Potassium Iodide,7681-11-0,approved,NLKNQRATVPKPDG-UHFFFAOYSA-M,InChI=1S/HI.K/h1H;/q;+1/p-1,[K+],IK,C08219,D01016,4875,99443267,8346,CHEMBL1141,,4709,,166.0028,0.2,Anions; Antidotes; Antithyroid agents; Cough and Cold Preparations; Electrolytes; Expectorants; Iodides; Iodine Compounds; Ions; Minerals; Ophthalmologicals; Potassium Compounds; Potassium Salt; Respiratory System; Sensory Organs; Thyroid Products
DB06716,Fospropofol,258516-89-1,approved; illicit; investigational,QVNNONOFASOXQV-UHFFFAOYSA-N,"InChI=1S/C13H21O5P/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16)",CC(C)c1cccc(C(C)C)c1OCOP(=O)(O)O,C13H21O5P,,D04257,3038498,99443268,135193,CHEMBL1201766,,2302062,,288.2766,3.602025751,"Agents that reduce seizure threshold; Anesthetics; Anesthetics, General; Benzene Derivatives; Central Nervous System Agents; Central Nervous System Depressants; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypnotics and Sedatives; Phenols"
DB06717,Fosaprepitant,172673-20-0,approved,BARDROPHSZEBKC-OITMNORJSA-N,"InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1",FC(F)(F)c1cc(cc(c1)C(F)(F)F)[C@@H](C)O[C@H]2OCCN(Cc3nc(=O)n([nH]3)P(=O)(O)O)[C@H]2c4ccc(F)cc4,C23H22F7N4O6P,,D06597,219090,99443269,64321,CHEMBL1199324,,189912,,614.4066,2.400678929,"Antiemetics; Aprepitant and Prodrugs; Autonomic Agents; Central Nervous System Agents; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Miscellaneous Antiemetics; Morpholines; Neurokinin 1 Antagonists; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; Oxazines; Peripheral Nervous System Agents; Substance P/Neurokinin-1 Receptor Antagonist"
DB06718,Stanozolol,10418-03-8,approved; vet_approved,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,"InChI=1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1",C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)[C@@H](CC3)Cc5c(C4)c[nH]n5,C21H32N2O,C07311,D00444,25249,99443270,9249,CHEMBL2079587,,23582,,328.4916,3.807240012,"Alimentary Tract and Metabolism; Anabolic Agents; Anabolic Agents for Systemic Use; Anabolic Steroids; Androgens; Androstan Derivatives; Androstanes; Androstanols; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroids; Thyroxine-binding globulin inhibitors"
DB06723,Aluminum hydroxide,21645-51-2,approved; investigational,WNROFYMDJYEPJX-UHFFFAOYSA-K,InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3,[OH-],AlH3O3,C13391,,10176082,175427087,33130,CHEMBL1200706,,8351587,,78.0036,1.45,"Acids; Acids, Noncarboxylic; Adjuvants, Immunologic; Alimentary Tract and Metabolism; Alkalies; Aluminium Compounds; Aluminum and magnesium containing antacids; Anions; Antacids; Antacids and Adsorbents; Carbon Compounds, Inorganic; Carbonic Acid; Drugs for Acid Related Disorders; Electrolytes; Gastric Acid Lowering Agents; Gastrointestinal Agents; Hydroxides; Immunologic Factors; Ions; Metal cations; Metal divalent cations; Miscellaneous Local Anti-infectives"
DB06724,Calcium carbonate,471-34-1,approved; investigational,VTYYLEPIZMXCLO-UHFFFAOYSA-L,"InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2",[O-]C([O-])=O,CCaO3,C08129,D00932,10112,310264878,3311,CHEMBL1200539,,9708,,100.087,0.250051366,"Acids; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Alkalies; Anions; Antacids; Antacids and Adsorbents; Blood Coagulation Factors; Calcium Compounds; Calcium Salts; Carbon Compounds, Inorganic; Carbonates; Carbonic Acid; Drugs for Acid Related Disorders; Electrolytes; Gastric Acid Lowering Agents; Gastrointestinal Agents; Ions; Mineral Supplements; Minerals; Phosphate Binder; Polyvalent cation containing laxatives, antacids, oral supplements; Replacement Preparations"
DB06725,Lornoxicam,70374-39-9,approved; investigational,WLHQHAUOOXYABV-UHFFFAOYSA-N,"InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)",Clc(c1)sc(c12)C(O)=C(N(S2(=O)=O)C)C(=O)Nc3ccccn3,C13H10ClN3O4S2,,D01866,54690031,99443271,31783,CHEMBL1569487,,10442760,92331,371.81,0.638027856,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Central Nervous System Agents; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Oxicams; Peripheral Nervous System Agents; Sensory System Agents; Sulfur Compounds; Thiazines"
DB06729,Sulfaphenazole,526-08-9,approved,QWCJHSGMANYXCW-UHFFFAOYSA-N,"InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2",Nc1ccc(cc1)S(=O)(=O)Nc2ccnn2-c3ccccc3,C15H14N4O2S,,D01954,5335,99443275,77780,CHEMBL1109,,5144,50090677,314.362,1.807094661,"Amides; Amines; Aniline Compounds; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Azoles; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Intermediate-Acting Sulfonamides; Long-Acting Sulfonamides; Ophthalmologicals; Pyrazoles; Sensory Organs; Sulfanilamides; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds"
DB06736,Aceclofenac,89796-99-6,approved; investigational,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,"InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)",OC(=O)COC(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl,C16H13Cl2NO4,,D01545,71771,347827785,31159,CHEMBL93645,,64809,50109016,354.18,3.882886598,"Acetic Acid Derivatives and Related Substances; Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Carboxylic Acids; Central Nervous System Agents; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Musculo-Skeletal System; Nephrotoxic agents; Peripheral Nervous System Agents; Phenylacetates; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents; Topical Products for Joint and Muscular Pain"
DB06742,Ambroxol,18683-91-5,approved; investigational,JBDGDEWWOUBZPM-XYPYZODXSA-N,"InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2/t10-,11-",Nc1c(Br)cc(Br)cc1CN[C@H]2CC[C@H](O)CC2,C13H18Br2N2O,,,2132,347827790,135590,CHEMBL153479,,10276826,50395322,378.108,2.652725947,"Adrenergics for Systemic Use; Amines; Aniline Compounds; Cough and Cold Preparations; Cyclohexanes; Cyclohexylamines; Cycloparaffins; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Expectorants; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists"
DB06751,Drotaverine,14009-24-6,approved; investigational,OMFNSKIUKYOYRG-MOSHPQCFSA-N,"InChI=1S/C24H31NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-10,13-16,25H,5-8,11-12H2,1-4H3/b20-13-",CCOc1c(OCC)cc(cc1)/C=C2\NCCc(c23)cc(OCC)c(c3)OCC,C24H31NO4,,,1712095,99443287,135630,CHEMBL551978,,1361582,50237620,397.5072,4.191374697,"Alimentary Tract and Metabolism; Alkaloids; Analgesics; Autonomic Agents; Benzylisoquinolines; Cardiovascular Agents; Central Nervous System Agents; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Opiate Alkaloids; Papaverine and Derivatives; Parasympatholytics; Peripheral Nervous System Agents; Sensory System Agents; Vasodilating Agents"
DB06753,Triclofos,306-52-5,approved; withdrawn,YYQRGCZGSFRBAM-UHFFFAOYSA-N,"InChI=1S/C2H4Cl3O4P/c3-2(4,5)1-9-10(6,7)8/h1H2,(H2,6,7,8)",OP(=O)(O)OCC(Cl)(Cl)Cl,C2H4Cl3O4P,C07165,D08634,,,9695,CHEMBL1201317,,5362,,229.37,0.933012924,Central Nervous System Depressants; Hypnotics and Sedatives; Nervous System; Organophosphorus Compounds; Psycholeptics
DB06754,Danaparoid,308068-55-5,approved; withdrawn,,, ,,,,,347910366,,,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Chondroitin; Fibrin Modulating Agents; Fibrinolytic Agents; Glycosaminoglycans; Hematologic Agents; Heparin and similars; Heparinoids; Polysaccharides
DB06755,Beta carotene,7235-40-7,approved; nutraceutical,OENHQHLEOONYIE-JLTXGRSLSA-N,"InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+",CC1(C)CCCC(C)=C1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C(C2(C)C)=C(C)CCC2,C40H56,C02094,D03101,5280489,347827791,17579,CHEMBL1293,BCR,4444129,54988,536.888,11.1240811,"Alimentary Tract and Metabolism; Alkenes; Biological Factors; Carotenoids; Cyclohexanes; Cyclohexenes; Cycloparaffins; Dermatologicals; Diet, Food, and Nutrition; Emollients and Protectives; Food; Food and Beverages; Growth Substances; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Micronutrients; Physiological Phenomena; Pigments, Biological; Polycyclic Compounds; Polyenes; Protectives Against UV-Radiation; Protectives Against UV-Radiation for Systemic Use; Provitamins; Terpenes; Vitamin A; Vitamins; Vitamins (Fat Soluble)"
DB06756,Glycine betaine,107-43-7,approved; nutraceutical,KWIUHFFTVRNATP-UHFFFAOYSA-N,"InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3",C[N+](C)(C)CC([O-])=O,C5H11NO2,C00719,D07523,247,310264879,17750,CHEMBL1182,,242,50103520,117.1463,-4.494183842,"Acid Preparations; Alimentary Tract and Metabolism; Amines; Amino Acids and Derivatives; Ammonium Compounds; Cholinesterase Inhibitors; Digestives, Incl. Enzymes; Gastrointestinal Agents; Hypolipidemic Agents; Lipid Regulating Agents; Lipotropic Agents; Methylating Activity; Methylating Agent; Nitrogen Compounds; Noxae; Onium Compounds; Other Miscellaneous Therapeutic Agents; Quaternary Ammonium Compounds; Toxic Actions; Trimethyl Ammonium Compounds"
DB06757,Manganese,7439-96-5,approved; nutraceutical,WAEMQWOKJMHJLA-UHFFFAOYSA-N,InChI=1S/Mn/q+2,[Mn+2],Mn,C19610,D04854,27854,310264880,29035,CHEMBL2103742,MN,25916,,54.938,-0.156,"Acids; Acids, Noncarboxylic; Anions; Chlorine Compounds; Diet, Food, and Nutrition; Electrolytes; Elements; Food; Food and Beverages; Growth Substances; Ions; Magnetic Resonance Contrast Activity; Metals; Metals, Heavy; Micronutrients; Minerals; Paramagnetic Contrast Agent; Physiological Phenomena; Replacement Preparations; Sulfur Acids; Sulfur Compounds; Sulfuric Acids; Trace Elements; Transition Elements"
DB06762,Pinacidil,60560-33-0,approved,IVVNZDGDKPTYHK-UHFFFAOYSA-N,"InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)",CC(C)(C)C(C)N/C(NC#N)=N/c1ccncc1,C13H19N5,,,,,91706,CHEMBL1159,,4660,50240750,245.33,1.935866624,"Amidines; Antihypertensive Agents; Arteriolar Smooth Muscle, Agents Acting On; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Guanidine Derivatives; Guanidines; Membrane Transport Modulators; Vasodilating Agents"
DB06764,Tetryzoline,84-22-0,approved,BYJAVTDNIXVSPW-UHFFFAOYSA-N,"InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)",N1CCN=C1C2CCCc(c23)cccc3,C13H16N2,C07912,D08578,5419,310264881,28674,CHEMBL1266,,5226,96559,200.285,2.240890623,"Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Autonomic Agents; Azoles; Cardiovascular Agents; Compounds used in a research, industrial, or household setting; Decongestants and Antiallergics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nasal Decongestants; Nasal Preparations; Ophthalmic Solutions; Ophthalmologicals; Peripheral Nervous System Agents; Pharmaceutical Preparations; Pharmaceutical Solutions; Respiratory System; Respiratory System Agents; Sensory Organs; Solutions; Sympathomimetics; Sympathomimetics Used as Decongestants; Sympathomimetics, Plain; Vasoconstrictor Agents"
DB06766,Alcaftadine,147084-10-4,approved,MWTBKTRZPHJQLH-UHFFFAOYSA-N,"InChI=1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-5-3-2-4-14(17)8-11-22-16(13-23)12-20-19(18)22/h2-5,12-13H,6-11H2,1H3",CN1CCC(CC1)=C2c(ncc3C=O)n3CCc(c24)cccc4,C19H21N3O,,D06552,19371515,99443288,71023,CHEMBL1201747,,14201635,,307.3895,2.171389332,"Azoles; Decongestants and Antiallergics; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Neurotransmitter Agents; Ophthalmologicals; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Sensory Organs"
DB06767,Ammonium chloride,12125-02-9,approved; investigational; vet_approved,NLXLAEXVIDQMFP-UHFFFAOYSA-N,InChI=1S/ClH.H3N/h1H;1H3,[NH4+],ClH4N,C12538,,25517,347827792,31206,CHEMBL1200939,,23807,,53.491,0.612338722,"Acidifiers; Acidifying Agents; Acids; Acids, Noncarboxylic; Agents causing hyperkalemia; Ammonium Compounds; Anions; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Chlorides; Chlorine Compounds; Drugs that are Mainly Renally Excreted; Electrolyte Solutions; Electrolytes; Genito Urinary System and Sex Hormones; I.V. Solution Additives; Ions; Nitrogen Compounds; Urinary Acidifying Agents; Urologicals"
DB06768,Ammonium lactate,515-98-0,approved,RZOBLYBZQXQGFY-UHFFFAOYSA-N,"InChI=1S/C3H6O3.H3N/c1-2(4)3(5)6;/h2,4H,1H3,(H,5,6);1H3",CC(O)C([O-])=O,C3H9NO3,,D02920,62358,175427089,,CHEMBL1200747,,56149,,107.1085,-0.471829518,alpha-Hydroxy Acid
DB06769,Bendamustine,16506-27-7,approved; investigational,YTKUWDBFDASYHO-UHFFFAOYSA-N,"InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)",OC(=O)CCCc(n1C)nc(c12)cc(cc2)N(CCCl)CCCl,C16H21Cl2N3O2,,D07085,65628,310264882,135515,CHEMBL487253,,59069,173621,358.263,1.664994863,"Acids, Acyclic; Alkylating Activity; Alkylating Drugs; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic and Immunomodulating Agents; Benzimidazoles; Butyrates; Carboxylic Acids; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Halogenated; Immunosuppressive Agents; Lipids; Mustard Compounds; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nitrogen Mustard Analogues; Nitrogen Mustard Compounds; Noxae; P-glycoprotein substrates with narrow therapeutic index; Toxic Actions"
DB06770,Benzyl alcohol,100-51-6,approved,WVDDGKGOMKODPV-UHFFFAOYSA-N,"InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2",OCc1ccccc1,C7H8O,C03485,D00077,244,175427090,17987,CHEMBL720,10,13860335,,108.1378,1.205896049,"Alcohols; Anesthetics; Anesthetics, Local; Antiparasitic Products, Insecticides and Repellents; Benzene Derivatives; Benzyl Alcohols; Benzyl Compounds; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 Substrates; Ectoparasiticides, Incl. Scabicides; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Pediculicides; Peripheral Nervous System Agents; Sensory System Agents"
DB06771,Besifloxacin,141388-76-3,approved,QFFGVLORLPOAEC-SNVBAGLBSA-N,"InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1",N[C@@H]1CCCCN(C1)c(c2Cl)c(F)cc(c23)c(=O)c(C(=O)O)cn3C4CC4,C19H21ClFN3O3,,D08872,10178705,175427091,135622,CHEMBL1201760,,8354210,,393.84,0.541157576,"Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; Ophthalmologicals; QTc Prolonging Agents; Quinolines; Quinolone Antimicrobial; Quinolones; Sensory Organs; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB06772,Cabazitaxel,183133-96-2,approved,BMQGVNUXMIRLCK-OAGWZNDDSA-N,"InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1",c1ccccc1C(=O)O[C@H]([C@@]23O)[C@H]4[C@@](C)([C@@H](OC)C[C@@H]5[C@]4(CO5)OC(=O)C)C(=O)[C@H](OC)C(C2(C)C)=C(C)[C@H](C3)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6,C45H57NO14,,D09755,9854073,99443289,63584,CHEMBL1201748,,8029779,,835.9324,4.203043962,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Cardiotoxic antineoplastic agents; Cyclodecanes; Cycloparaffins; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Diterpenes; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Macrocyclic Compounds; Microtubule Inhibition; Microtubule Inhibitors; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Taxane Derivatives; Taxoids; Terpenes"
DB06774,Capsaicin,404-86-4,approved,YKPUWZUDDOIDPM-SOFGYWHQSA-N,"InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+",COc1c(O)ccc(c1)CNC(=O)CCCC/C=C/C(C)C,C18H27NO3,C06866,D00250,1548943,347827793,3374,CHEMBL294199,4DY,1265957,20461,305.4119,3.749669544,"Alkaloids; Alkenes; Alkynes; Amides; Anesthetics; Anesthetics, Local; Antipruritics; Basic Lotions and Liniments; Benzene Derivatives; Capsaicin and Similar Agents; Capsaicin, antagonists & inhibitors; Catechols; Cholinesterase Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Heterocyclic Compounds; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lipids; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Musculo-Skeletal System; Nervous System; Peripheral Nervous System Agents; Phenols; Polyunsaturated Alkamides; Sensory System Agents; Solanaceous Alkaloids; Topical Products for Joint and Muscular Pain"
DB06775,Carglumic acid,1188-38-1,approved,LCQLHJZYVOQKHU-VKHMYHEASA-N,"InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1",NC(=O)N[C@H](C(=O)O)CCC(=O)O,C6H10N2O5,C05829,D07130,121396,99443290,71028,CHEMBL1201780,,108351,,190.154,-1.44656095,"Alimentary Tract and Metabolism; Amino Acids; Amino Acids and Derivatives; Amino Acids, Acidic; Amino Acids, Dicarboxylic; Amino Acids, Peptides, and Proteins; Ammonia Detoxicants; Carbamoyl Phosphate Synthetase 1 Activator; Carbamoyl Phosphate Synthetase 1 Activators"
DB06776,Sodium cellulose phosphate,9038-41-9,approved,,, ,,,,,,,CHEMBL1201457,,,,NA,NA,"Biopolymers; Calcium Binder; Calcium Chelating Activity; Carbohydrates; Cation Exchange Resins; Compounds used in a research, industrial, or household setting; Drugs for Treatment of Hypercalcemia; Glucans; Macromolecular Substances; Manufactured Materials; Polymers; Polysaccharides"
DB06777,Chenodeoxycholic acid,474-25-9,approved,RUDATBOHQWOJDD-BSWAIDMHSA-N,"InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1",OC(=O)CC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)[C@H](C[C@H]3O)C[C@H](O)CC4,C24H40O4,C02528,D00163,10133,99443291,16755,CHEMBL240597,JN3,9728,21674,392.572,3.713305524,Alimentary Tract and Metabolism; Bile Acid Preparations; Bile acids and derivatives; Bile Acids and Salts; Bile and Liver Therapy; Bile Therapy; Cholanes; Cholic Acids; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Gastrointestinal Agents; Polycyclic Compounds; Steroids; UGT2B7 Inhibitors
DB06778,Cupric sulfate,7758-98-7,approved,ARUVKPQLZAKDPS-UHFFFAOYSA-L,"InChI=1S/Cu.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",[O-]S([O-])(=O)=O,CuO4S,C18713,,24462,347827794,23414,CHEMBL604,,22870,,159.609,-0.841552023,"Acids; Acids, Noncarboxylic; Anions; Antidotes; Autonomic Agents; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Copper-containing Intrauterine Device; Electrolytes; Emetics; Gastrointestinal Agents; Ions; Peripheral Nervous System Agents; Protective Agents; Sulfates; Sulfur Acids; Sulfur Compounds; Sulfuric Acids"
DB06779,Dalteparin,9005-49-6,approved,,, ,,,D03353,,347910371,,,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Fibrin Modulating Agents; Fibrinolytic Agents; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Polysaccharides
DB06780,Desoxycorticosterone acetate,56-47-3,approved,VPGRYOFKCNULNK-ACXQXYJUSA-N,"InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CC[C@@H]4C(=O)COC(=O)C,C23H32O4,C14554,D03698,,,34671,CHEMBL1200542,,5737,,372.505,3.772481765,"Adrenal Cortex Hormones; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Desoxycorticosterone; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydroxycorticosteroids; Mineralocorticoids; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids"
DB06781,Difluprednate,23674-86-4,approved,WYQPLTPSGFELIB-JTQPXKBDSA-N,"InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1",C1=CC(=O)C=C([C@]12C)[C@@H](F)C[C@@H]3[C@]2(F)[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(OC(=O)CCC)C(=O)COC(=O)C,C27H34F2O7,C12695,D01266,443936,99443292,31485,CHEMBL1201749,,391990,,508.5515,3.004232893,"Adrenal Cortex Hormones; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated"
DB06782,Dimercaprol,59-52-9,approved,WQABCVAJNWAXTE-UHFFFAOYSA-N,"InChI=1S/C3H8OS2/c4-1-3(6)2-5/h3-6H,1-2H2",OCC(S)CS,C3H8OS2,C02924,D00167,3080,99443293,64198,CHEMBL1597,,2971,50103608,124.225,0.211734882,"Antidotes; Chelating Agents; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Heavy Metal Antagonists; Metal Chelating Activity; Metal Chelator; Sequestering Agents; Sulfhydryl Compounds; Sulfur Compounds"
DB06783,Prussian blue,14038-43-8,approved,DNMNDNSFJMUUFM-UHFFFAOYSA-N,InChI=1S/18CN.7Fe/c18*1-2;;;;;;;/q;;;;;;;;;;;;;;;;;;3*-4;4*+3,N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N,C18Fe7N18,,,2724251,310264883,30069,,,20074656,,859.239,-0.2594,"Acids; Acids, Noncarboxylic; Anions; Antidotes; Chelating Activity; Coloring Agents; Compounds used in a research, industrial, or household setting; Cyanides; Decorporation Agent; Electrolytes; Ferrous Compounds; Hydrogen Cyanide; Ion Exchange Activity; Ions; Iron Compounds; Nitrogen Compounds; Organometallic Compounds; Protective Agents"
DB06784,Gallium citrate Ga-67,41183-64-6,approved,YEEGWNXDUZONAA-RYDPDVNUSA-K,"InChI=1S/C6H8O7.Ga/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3/i;1-3",[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O,C6H5GaO7,,,65430,347827795,31645,CHEMBL1200994,,58893,,256.0279,-1.322687452,Gallium; Gallium Radioisotopes; Radioactive Diagnostic Agent; Radiopharmaceutical Activity
DB06785,Ganirelix,124904-93-4,approved,GJNXBNATEDXMAK-PFLSVRRQSA-N,"InChI=1S/C80H113ClN18O13/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89)/t50-,60-,61+,62+,63-,64+,65-,66-,67+,68+/m1/s1",NC(=O)[C@@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc3cccnc3)NC(=O)[C@@H](Cc4ccc(Cl)cc4)NC(=O)[C@H](NC(=O)C)Cc(cc5)cc(c56)cccc6,C80H113ClN18O13,,D08010,16130957,310264884,135910,CHEMBL1251,,17287671,50102454,1570.35,1.618023815,"Amino Acids, Peptides, and Proteins; Anti-Gonadotropin-Releasing Hormones; Decreased GnRH Secretion; Gonadotropin Releasing Hormone Receptor Antagonists; Gonadotropin-releasing Hormone Antagonists; Gonadotropin-Releasing Hormone, antagonists & inhibitors; Hormone Antagonists; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormone-Releasing Hormones; Proteins; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB06786,Halcinonide,3093-35-4,approved; investigational; withdrawn,MUQNGPZZQDCDFT-JNQJZLCISA-N,"InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1",ClCC(=O)[C@]12[C@H](OC(O1)(C)C)C[C@@H]3[C@]2(C)C[C@H](O)[C@@]4(F)[C@H]3CCC=5[C@]4(C)CCC(=O)C5,C24H32ClFO5,,D01308,443943,347827796,31663,CHEMBL1200845,,391997,50240097,454.96,3.300886228,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Very Potent (Group IV); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Immunosuppressive Agents; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids"
DB06787,Hexocyclium,6004-98-4,approved,ZRYHPQCHHOKSMD-UHFFFAOYSA-N,"InChI=1S/C20H33N2O/c1-22(2)15-13-21(14-16-22)17-20(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3,5-6,9-10,19,23H,4,7-8,11-17H2,1-2H3/q+1",C[N+]1(C)CCN(CC1)CC(O)(C2CCCCC2)c3ccccc3,C20H33N2O,C07811,,24199,310264885,5707,CHEMBL1201325,,22621,81959,317.496,-0.992857414,"Agents producing tachycardia; Alimentary Tract and Metabolism; Anticholinergic Agents; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists; Synthetic Anticholinergics, Quaternary Ammonium Compounds"
DB06788,Histrelin,76712-82-8,approved,BKEMVGVBBDMHKL-VYFXDUNUSA-N,"InChI=1S/C66H86N18O12.2C2H4O2/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47;2*1-2(3)4/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71);2*1H3,(H,3,4)/t47-,48-,49-,50-,51-,52-,53+,54-,55-;;/m0../s1",CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2cn(cn2)Cc3ccccc3)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CO)NC(=O)[C@H](Cc5c[nH]c(c56)cccc6)NC(=O)[C@H](Cc7c[nH]cn7)NC(=O)[C@@H]8CCC(=O)N8,C70H94N18O16,,D02369,56927879,347827797,63530,CHEMBL1201255,,26606349,,1443.632,-2.138446575,"Adrenal Cortex Hormones; Amino Acids, Peptides, and Proteins; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Gonadotropin Releasing Hormone Receptor Agonist; Gonadotropin Releasing Hormone Receptor Agonists; Gonadotropin-releasing hormone agonist; Hormones; Hormones and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Hypothalamic Hormones; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary Hormone-Releasing Hormones; Potential QTc-Prolonging Agents; Proteins; QTc Prolonging Agents"
DB06789,Hydroxyprogesterone caproate,630-56-8,approved; investigational,DOMWKUIIPQCAJU-LJHIYBGHSA-N,"InChI=1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h17,21-23H,5-16H2,1-4H3/t21-,22+,23+,25+,26+,27+/m1/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CC[C@@]4(C(=O)C)OC(=O)CCCCC,C27H40O4,C08148,D00949,169870,310264886,5812,CHEMBL1200848,,148552,70293,428.6041,5.87654653,"Adrenal Cortex Hormones; Antineoplastic Agents; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Corpus Luteum Hormones; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Estrogen Antagonists; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormone Antagonists; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydroxyprogesterones; Hyperglycemia-Associated Agents; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Progesterone and Derivatives; Progesterone Congeners; Progestin Contraceptives; Progestins; Steroids"
DB06791,Lanreotide,108736-35-2,approved,PUDHBTGHUJUUFI-UHFFFAOYSA-N,"InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)",c1cccc(c12)[nH]cc2CC(C(=O)NC3CCCCN)NC(=O)C(Cc4ccc(O)cc4)NC(=O)C(CSSCC(NC(=O)C(NC3=O)C(C)C)C(=O)NC(C(C)O)C(=O)N)NC(=O)C(N)Cc(cc5)cc(c56)cccc6,C54H69N11O10S2,,D04666,71349,310264887,,CHEMBL1201185,,64450,,1096.33,-0.332761691,"Acromegaly; Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Bradycardia-Causing Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Hypoglycemia-Associated Agents; Hypothalamic Hormones; Macrocyclic Compounds; Nerve Tissue Proteins; Neuropeptides; Other Miscellaneous Therapeutic Agents; Pancreatic Hormones; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormone Release Inhibiting Hormones; Polycyclic Compounds; Proteins; Somatostatin and Analogues; Somatostatin Receptor Agonists; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB06792,Lanthanum carbonate,587-26-8,approved,NZPIUJUFIFZSPW-UHFFFAOYSA-H,"InChI=1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6",[O-]C([O-])=O,C3La2O9,,,168924,310264888,,CHEMBL2096647,,147758,,457.835,0.250051366,"Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Elements; Kidney Failure, Chronic; Lanthanoid Series Elements; Metal cations; Metals; Metals, Rare Earth; Phosphate Binder; Phosphate-removing Agents"
DB06794,Lodoxamide,53882-12-5,approved,RVGLGHVJXCETIO-UHFFFAOYSA-N,"InChI=1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21)",OC(=O)C(=O)Nc1cc(C#N)cc(c1Cl)NC(=O)C(=O)O,C11H6ClN3O6,,D04762,44564,310264890,135333,CHEMBL1201266,,40543,50259889,311.63,0.827995705,"Acids, Aldehydic; Alcohols; Amino Acids; Amino Acids, Peptides, and Proteins; Anti-Allergic Agents; Antioxidants; Carboxylic Acids; Decongestants and Antiallergics; Decreased Histamine Release; Glycols; Glyoxylates; Histamine Agents; Mast Cell Stabilizers; Neurotransmitter Agents; Ophthalmologicals; Propylene Glycols; Sensory Organs"
DB06795,Mafenide,138-39-6,approved; vet_approved,TYMRLRRVMHJFTF-UHFFFAOYSA-N,"InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)",NCc1ccc(cc1)S(=O)(=O)N,C7H10N2O2S,C07106,D02351,3998,310264891,6633,CHEMBL419,6LH,3858,10860,186.232,-0.543209137,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Dermatologicals; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Methemoglobinemia Associated Agents; Sulfonamide Antibacterial; Sulfonamides; Sulfones; Sulfur Compounds"
DB06796,Mangafodipir,155319-91-8,approved; investigational; withdrawn,CXFKOLCMCRBYPL-UHFFFAOYSA-L,"InChI=1S/C22H32N4O14P2.Mn/c1-13-21(31)15(5-17(23-13)11-39-41(33,34)35)7-25(9-19(27)28)3-4-26(10-20(29)30)8-16-6-18(12-40-42(36,37)38)24-14(2)22(16)32;/h5-6,31-32H,3-4,7-12H2,1-2H3,(H,27,28)(H,29,30)(H2,33,34,35)(H2,36,37,38);/q;+2/p-2",OP(=O)(O)OCc1nc(C)c(O)c(c1)CN(CC([O-])=O)CCN(CC([O-])=O)Cc2cc(COP(=O)(O)O)nc(C)c2O,C22H30MnN4O14P2,,,131704299,310264892,,,,32700460,,691.382,-1.784896137,"Acetates; Acids, Acyclic; Amines; Carboxylic Acids; Coenzymes; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Diamines; Drugs that are Mainly Renally Excreted; Enzymes and Coenzymes; Ethylenediamines; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lipids; Magnetic Resonance Contrast Activity; Magnetic Resonance Imaging Contrast Media; Paramagnetic Contrast Agent; Paramagnetic Contrast Media; Picolines; Polyamines; Pyridines"
DB06797,Mebutamate,64-55-1,approved,LEROTMJVBFSIMP-UHFFFAOYSA-N,"InChI=1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14)",NC(=O)OCC(C)(C(C)CC)COC(=O)N,C10H20N2O4,,D01807,,,31804,CHEMBL1200922,,5919,,232.2768,1.21427198,Anti-Anxiety Agents; Carbamates; Central Nervous System Depressants; Nervous System; Psycholeptics
DB06799,Methenamine,100-97-0,approved; vet_approved,VKYKSIONXSXAKP-UHFFFAOYSA-N,InChI=1S/C6H12N4/c1-7-2-9-4-8(1)5-10(3-7)6-9/h1-6H2,N12CN3CN(C1)CN(C3)C2,C6H12N4,,D00393,4101,310264893,6824,CHEMBL1201270,,3959,,140.1863,0.392133857,"Acids, Carbocyclic; Amides; Amines; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Benzene Derivatives; Benzoates; Bridged Compounds; Carboxylic Acids; Cycloparaffins; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Keto Acids; Macrocyclic Compounds; Polyamines; Polycyclic Compounds; Renal Agents; Urinary Acidifying Agents"
DB06800,Methylnaltrexone,916055-93-1,approved,JVLBPIPGETUEET-WIXLDOGYSA-O,"InChI=1S/C21H25NO4/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13/h4-5,12,16,19,25H,2-3,6-11H2,1H3/p+1/t16-,19+,20+,21-,22-/m1/s1",C1CC1C[N@@+](C)(CC2)[C@@H]([C@]3([C@@]245)O)Cc6c4c(c(O)cc6)O[C@H]5C(=O)CC3,C21H26NO4,,D06618,16089915,175427092,,CHEMBL1186579,,17248532,,356.441,-2.492788006,"Alimentary Tract and Metabolism; Alkaloids; Amines; Ammonium Compounds; Central Nervous System Agents; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Miscellaneous GI Drugs; Morphinans; Narcotics; Nitrogen Compounds; Onium Compounds; Opiate Alkaloids; Opioid Antagonists; Opioids; Peripheral Nervous System Agents; Peripheral Opioid Receptor Antagonists; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents"
DB06802,Nepafenac,78281-72-8,approved; investigational,QEFAQIPZVLVERP-UHFFFAOYSA-N,"InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)",NC(=O)Cc1cccc(c1N)C(=O)c2ccccc2,C15H14N2O2,,D05143,151075,99443294,75922,CHEMBL1021,,133160,50228731,254.2839,2.084478575,"Acetamides; Acetates; Acids, Acyclic; Acids, Carbocyclic; Agents causing hyperkalemia; Amides; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antirheumatic Agents; Benzene Derivatives; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Fatty Acids; Fatty Acids, Volatile; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lipids; Nephrotoxic agents; Ophthalmologicals; Peripheral Nervous System Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory Organs; Sensory System Agents"
DB06803,Niclosamide,50-65-7,approved; investigational; vet_approved,RJMUSRYZPJIFPJ-UHFFFAOYSA-N,"InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)",Clc1ccc(O)c(c1)C(=O)Nc2c(Cl)cc([N+]([O-])=O)cc2,C13H8Cl2N2O4,,D00436,4477,99443295,7553,CHEMBL1448,,4322,11242,327.12,3.909638842,"Agrochemicals; Amides; Amines; Anilides; Aniline Compounds; Anthelmintics; Anti-Infective Agents; Anticestodal Agents; Anticestodals; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiplatyhelmintic Agents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Molluscacides; Pesticides; Salicylamides; Salicylanilides; Salicylic Acid Derivatives; Toxic Actions"
DB06804,Nonoxynol-9,26027-38-3,approved; withdrawn,FBWNMEQMRUMQSO-UHFFFAOYSA-N,"InChI=1S/C33H60O10/c1-2-3-4-5-6-7-8-9-32-10-12-33(13-11-32)43-31-30-42-29-28-41-27-26-40-25-24-39-23-22-38-21-20-37-19-18-36-17-16-35-15-14-34/h10-13,34H,2-9,14-31H2,1H3",CCCCCCCCCc1ccc(cc1)OCCOCCOCCOCCOCCOCCOCCOCCOCCO,C33H60O10,,D06490,72385,99443296,53775,CHEMBL1410,,65319,50442874,616.8235,4.819639181,"Adrenal Cortex Hormones; Alcohols; Antispermatogenic Agents; Compounds used in a research, industrial, or household setting; Contraceptive Agents, Female; Contraceptive Agents, Male; Ethylene Glycols; Glycols; Hormonal Contraceptives for Systemic Use; Macromolecular Substances; Manufactured Materials; Noxae; Polyethylene Glycols; Polymers; Reproductive Control Agents; Spermatocidal Agents; Surface-Active Agents; Toxic Actions"
DB06807,Phenyl aminosalicylate,133-11-9,approved,DNVVZWSVACQWJE-UHFFFAOYSA-N,"InChI=1S/C13H11NO3/c14-9-6-7-11(12(15)8-9)13(16)17-10-4-2-1-3-5-10/h1-8,15H,14H2",Nc1cc(O)c(cc1)C(=O)Oc2ccccc2,C13H11NO3,,,,,114203,CHEMBL1200868,,8290,,229.235,3.152189953,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Phenols; Salicylates"
DB06809,Plerixafor,110078-46-1,approved,YIQPUIGJQJDJOS-UHFFFAOYSA-N,"InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2",C1CCNCCNCCCNCCN1Cc2ccc(cc2)CN3CCCNCCNCCCNCC3,C28H54N8,,D08971,65015,99443297,125354,CHEMBL18442,,58531,50035696,502.782,-0.433592071,"Adjuvants, Immunologic; Anti-HIV Agents; Anti-Infective Agents; Antineoplastic and Immunomodulating Agents; Drugs that are Mainly Renally Excreted; Hematinics; Hematopoietic Stem Cell Mobilizer; Increased Hematopoietic Stem Cell Mobilization"
DB06810,Plicamycin,18378-89-7,approved; investigational; withdrawn,CFCUWKMKBJTWLW-BKHRDMLASA-N,"InChI=1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1",C[C@@]1(O)[C@H](O)[C@@H](C)O[C@H](C1)O[C@H]2[C@@H](O)[C@@H](C)O[C@H](C2)O[C@H]3[C@H](O)[C@@H](C)O[C@H](C3)O[C@H](C4=O)[C@H]([C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)Cc(c45)cc6c(c5O)c(O)c(C)c(c6)O[C@H]7C[C@H]([C@H](O)[C@H](O7)C)O[C@H]8C[C@@H](O)[C@H](O)[C@H](O8)C,C52H76O24,C12389,D00468,163659,99443298,31856,CHEMBL1237054,,143544,,1085.1454,2.072890883,"Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Calcium-Regulating Hormones and Agents; Carbohydrates; Coloring Agents; Compounds used in a research, industrial, or household setting; Cytotoxic Antibiotics and Related Substances; Enzyme Inhibitors; Fluorescent Dyes; Glycosides; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indicators and Reagents; Laboratory Chemicals; Luminescent Agents; Naphthacenes; Nucleic Acid Synthesis Inhibitors; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Protein Synthesis Inhibitors"
DB06811,Polidocanol,9002-92-0,approved,ONJQDTZCDSESIW-UHFFFAOYSA-N,"InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3",CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C30H62O10,C13493,D01993,656641,175427093,46859,CHEMBL1231723,CE9,570993,,582.8073,3.939091691,"Alcohols; Antivaricose Therapy; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Detergents; Ethylene Glycols; Glycols; Household Products; Macromolecular Substances; Manufactured Materials; Pegylated agents; Pharmaceutical Preparations; Pharmaceutical Solutions; Polyethylene Glycols; Polymers; Sclerosing Activity; Sclerosing Agents for Local Injection; Sclerosing Solutions; Solutions; Surface-Active Agents; Vascular Sclerosing Activity; Vasoprotectives"
DB06812,Povidone-iodine,25655-41-8,approved,,, ,,C08043,D00863,,347910372,8347,CHEMBL1201724,,,,NA,NA,"Alkenes; Anti-Infective Agents; Anti-Infective Agents, Local; Antifungal Agents (Vaginal); Antiseptics and Disinfectants; Compounds used in a research, industrial, or household setting; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Acyclic; Iodine Compounds; Iodine Products; Iodophors; Irrigating Solutions; Macromolecular Substances; Manufactured Materials; Medicated Dressings; Medicated Dressings With Antiinfectives; Medicated Shampoos; Miscellaneous Local Anti-infectives; Ophthalmologicals; Plastics; Polyenes; Polymers; Polyvinyls; Pyrrolidines; Pyrrolidinones; Respiratory System; Sensory Organs; Throat Preparations; Vinyl Compounds"
DB06813,Pralatrexate,146464-95-1,approved; investigational,OGSBUKJUDHAQEA-WMCAAGNKSA-N,"InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1",Nc1nc(N)nc(c12)ncc(n2)CC(CC#C)c3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O,C23H23N7O5,,D05589,148121,175427094,71223,CHEMBL1201746,,130578,,477.4726,0.325347193,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Biological Factors; Drugs that are Mainly Renally Excreted; Folic Acid Analogues; Folic Acid Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Narrow Therapeutic Index Drugs; Pigments, Biological; Pteridines; Pterins"
DB06814,Protokylol,136-70-9,approved; vet_approved,LUMAEVHDZXIGEP-UHFFFAOYSA-N,"InChI=1S/C18H21NO5/c1-11(6-12-2-5-17-18(7-12)24-10-23-17)19-9-16(22)13-3-4-14(20)15(21)8-13/h2-5,7-8,11,16,19-22H,6,9-10H2,1H3",O1COc(c12)ccc(c2)CC(C)NCC(O)c3ccc(O)c(O)c3,C18H21NO5,,,,,135413,CHEMBL1201273,,4798,,331.368,1.481601322,"Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Catecholamines; Catechols; Dioxoles; Epinephrine and similars; Ethanolamines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Long-acting beta-adrenoceptor agonists; Phenols"
DB06815,Pyrithione,1121-31-9,approved,FGVVTMRZYROCTH-UHFFFAOYSA-N,"InChI=1S/C5H5NOS/c7-6-4-2-1-3-5(6)8/h1-4,8H",[O-][n+]1c(S)cccc1,C5H5NOS,,,26041,347827800,36584,CHEMBL1356238,,10446934,50366038,127.16,0.195501614,"Anti-Infective Agents; Antifungal Agents; Dermatologicals; Drugs that are Mainly Renally Excreted; Gallium Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Keratolytic Agents; Miscellaneous Local Anti-infectives; Radiopharmaceuticals; Sulfur Compounds"
DB06816,Pyrvinium,7187-62-4,approved,QMHSXPLYMTVAMK-UHFFFAOYSA-N,"InChI=1S/C26H28N3/c1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5/h6-18H,1-5H3/q+1",CN(C)c(cc1)cc(c12)ccc([n+]2C)/C=C/c3c(C)n(c(C)c3)-c4ccccc4,C26H28N3,C07412,,5281035,310264894,8687,CHEMBL1201303,,21125,,382.53,1.407420983,"Anthelmintics; Anti-Infective Agents; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Quinolines; Quinolinium Compounds"
DB06817,Raltegravir,518048-05-0,approved,CZFFBEXEKNGXKS-UHFFFAOYSA-N,"InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)",Fc1ccc(cc1)CNC(=O)c2c(O)c(=O)n(C)c(n2)C(C)(C)NC(=O)c3nnc(o3)C,C20H21FN6O5,,D06676,54671008,175427095,,CHEMBL254316,RLT,16445111,25351,444.4163,-0.388226561,"Agents Causing Muscle Toxicity; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Direct Acting Antivirals; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV Integrase Inhibitors; Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor; Integrase Inhibitors; Pyrrolidines; Pyrrolidinones; UGT1A1 Substrates"
DB06819,Phenylbutyric acid,1821-12-1,approved; investigational,OBKXEAXTFZPCHS-UHFFFAOYSA-N,"InChI=1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)",OC(=O)CCCc1ccccc1,C10H12O2,,D05868,4775,310264895,41500,CHEMBL1469,CLT,4611,,164.2011,2.500131435,"Acids, Carbocyclic; Alimentary Tract and Metabolism; Ammonium Ion Binding Activity; Antineoplastic Agents; Carboxylic Acids; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Nitrogen Binding Agent; Urea Cycle Disorder Agents; Various Alimentary Tract and Metabolism Products"
DB06820,Sulconazole,61318-90-9,approved,AFNXATANNDIXLG-UHFFFAOYSA-N,"InChI=1S/C18H15Cl3N2S/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2",Clc1ccc(cc1)CSC(Cn2ccnc2)c3c(Cl)cc(Cl)cc3,C18H15Cl3N2S,C08076,D08535,5318,310264896,77776,CHEMBL1221,,5127,31770,397.74,6.062066128,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Azole Antifungals; Azoles; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole and Triazole Derivatives"
DB06821,Sulfameter,651-06-9,approved,GPTONYMQFTZPKC-UHFFFAOYSA-N,"InChI=1S/C11H12N4O3S/c1-18-9-6-13-11(14-7-9)15-19(16,17)10-4-2-8(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)",COc1cnc(nc1)NS(=O)(=O)c2ccc(N)cc2,C11H12N4O3S,,D02517,,,53727,CHEMBL1200359,,5135,,280.3,0.229589542,"Amides; Amines; Aniline Compounds; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Leprostatic Agents; Long-Acting Sulfonamides; Renal Agents; Sulfanilamides; Sulfonamide Antibacterial; Sulfonamides; SULFONAMIDES AND TRIMETHOPRIM; Sulfones; Sulfur Compounds"
DB06822,Tinzaparin,01-08-9041,approved,,, ,,,D06398,,347910373,,,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Fibrin Modulating Agents; Fibrinolytic Agents; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Polysaccharides
DB06823,Tiopronin,02-02-1953,approved; investigational,YTGJWQPHMWSCST-UHFFFAOYSA-N,"InChI=1S/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8)",CC(S)C(=O)NCC(=O)O,C5H9NO3S,C12876,D01430,5483,347827801,32229,CHEMBL1314,,5283,50020805,163.19,-0.53329929,"Amino Acids; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Cystine Disulfide Reduction; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; N-substituted Glycines; Peptides; Peptoids; Reducing and Complexing Thiol; Sulfur Compounds; Urologicals"
DB06824,Triethylenetetramine,112-24-3,approved; investigational,VILCJCGEZXAXTO-UHFFFAOYSA-N,"InChI=1S/C6H18N4/c7-1-3-9-5-6-10-4-2-8/h9-10H,1-8H2",NCCNCCNCCN,C6H18N4,C07166,,5565,310264897,39501,CHEMBL609,104,21106175,50323751,146.2339,-2.151249504,"Alimentary Tract and Metabolism; Amines; Chelating Agents; Compounds used in a research, industrial, or household setting; Diamines; Drugs that are Mainly Renally Excreted; Ethylenediamines; Metal Chelating Activity; Metal Chelator; Polyamines; Sequestering Agents; Various Alimentary Tract and Metabolism Products"
DB06825,Triptorelin,57773-63-4,approved; vet_approved,VXKHXGOKWPXYNA-PGBVPBMZSA-N,"InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1",NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2c[nH]c(c23)cccc3)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CO)NC(=O)[C@H](Cc5c[nH]c(c56)cccc6)NC(=O)[C@H](Cc7c[nH]cn7)NC(=O)[C@@H]8CCC(=O)N8,C64H82N18O13,,D06247,25074470,310264898,63633,CHEMBL1201334,,17290424,,1311.473,-3.586037537,"Adrenal Cortex Hormones; Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Gonadotropin Releasing Hormone Receptor Agonist; Gonadotropin Releasing Hormone Receptor Agonists; Gonadotropin-releasing hormone agonist; Hormones; Hormones and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Hypothalamic Hormones; Luteolytic Agents; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary Hormone-Releasing Hormones; Potential QTc-Prolonging Agents; Proteins; QTc Prolonging Agents; Reproductive Control Agents"
DB06826,Unoprostone,120373-36-6,approved; investigational,TVHAZVBUYQMHBC-SNHXEXRGSA-N,"InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1",CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O,C22H38O5,,,5311236,347827802,39455,CHEMBL1201407,,4470755,,382.541,3.913706746,"Antiglaucoma Preparations and Miotics; Antihypertensive Agents; Autacoids; Biological Factors; Cardiovascular Agents; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Inflammation Mediators; Lipids; Ophthalmologicals; Prostaglandins; Prostaglandins F; Prostaglandins, Synthetic; Sensory Organs"
DB06827,Viomycin,32988-50-4,approved,GXFAIFRPOKBQRV-GHXCTMGLSA-N,"InChI=1S/C25H43N13O10/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48)/b13-7-/t10-,11+,12-,14-,15-,17-,18-/m0/s1",N=C1N[C@H](C[C@@H](N1)O)[C@@H]2NC(=O)/C(=C/NC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC2=O)NC(=O)C[C@@H](N)CCCN,C25H43N13O10,C01540,,3037981,175427096,15782,CHEMBL3085436,,2301596,,685.69,-11.04974455,"Agents that produce neuromuscular block (indirect); Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antituberculosis Agents; Enzyme Inhibitors; Macrocyclic Compounds; Medications that reduce magnesium levels; Neurotoxic agents; Peptides; Peptides, Cyclic; Polycyclic Compounds; Protein Synthesis Inhibitors"
DB07565,Chloramphenicol succinate,3544-94-3,approved,LIRCDOVJWUGTMW-ZWNOBZJWSA-N,"InChI=1S/C15H16Cl2N2O8/c16-14(17)15(24)18-10(7-27-12(22)6-5-11(20)21)13(23)8-1-3-9(4-2-8)19(25)26/h1-4,10,13-14,23H,5-7H2,(H,18,24)(H,20,21)/t10-,13-/m1/s1",[O-][N+](=O)c1ccc(cc1)[C@@H](O)[C@H](NC(=O)C(Cl)Cl)COC(=O)CCC(=O)O,C15H16Cl2N2O8,C11727,,656580,99444036,3606,CHEMBL1201281,CL8,570947,,423.202,1.144691645,"Alcohols; Anti-Bacterial Agents; Anti-Infective Agents; Benzene Derivatives; Glycols; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Narrow Therapeutic Index Drugs; Nitro Compounds; Nitrobenzenes; P-glycoprotein substrates; Propylene Glycols"
DB07776,Flavone,525-82-6,approved; experimental,VHBFFQKBGNRLFZ-UHFFFAOYSA-N,InChI=1S/C15H10O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-10H,c1cccc(c12)oc(cc2=O)-c3ccccc3,C15H10O2,C15608,,10680,99444247,42491,CHEMBL275638,FLN,10230,50028962,222.2387,2.967385099,"Benzopyrans; Chromones; Flavones; Flavonoids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans"
DB08439,Parecoxib,198470-84-7,approved,TZRHLKRLEZJVIJ-UHFFFAOYSA-N,"InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)",CCC(=O)NS(=O)(=O)c1ccc(cc1)-c2c(C)onc2-c3ccccc3,C19H18N2O4S,,D02709,119828,99444910,73038,CHEMBL1206690,PXB,106990,,370.422,3.512828511,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Azoles; Central Nervous System Agents; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Nephrotoxic agents; Peripheral Nervous System Agents; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sensory System Agents"
DB08604,Triclosan,3380-34-5,approved; investigational,XEFQLINVKFYRCS-UHFFFAOYSA-N,"InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H",Oc1cc(Cl)ccc1Oc2c(Cl)cc(Cl)cc2,C12H7Cl3O2,C12059,D06226,5564,99445075,164200,CHEMBL849,TCL,5363,8726,289.542,4.982101706,"Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Benzene Derivatives; Dermatologicals; Ethers; Fatty Acid Synthesis Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypolipidemic Agents; Lipid Regulating Agents; Medicated Dressings; Medicated Dressings With Antiinfectives; Miscellaneous Local Anti-infectives; Noxae; Phenol and Derivatives; Phenols; Phenyl Ethers; Toxic Actions"
DB08797,Salicylamide,65-45-2,approved,SKZKKFZAGNVIMN-UHFFFAOYSA-N,"InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)",NC(=O)c1ccccc1O,C7H7NO2,,D01811,5147,99445267,32114,CHEMBL27577,OHB,4963,50056900,137.136,1.170320789,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Amides; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Ligands; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Salicylic Acid and Derivatives; Sensory System Agents"
DB08799,Antazoline,91-75-8,approved,REYFJDPCWQRWAA-UHFFFAOYSA-N,"InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)",c1ccccc1N(CC2=NCCN2)Cc3ccccc3,C17H19N3,,D07458,2200,99445269,84115,CHEMBL1305,,2115,76862,265.3529,2.876392188,"Anti-Allergic Agents; Antiallergic Agents, Excl. Corticosteroids; Antihistamines for Systemic Use; Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Imidazoles; Moderate Risk QTc-Prolonging Agents; Nasal Preparations; Neurotransmitter Agents; QTc Prolonging Agents; Respiratory System"
DB08801,Dimetindene,5636-83-9,approved; investigational,MVMQESMQSYOVGV-UHFFFAOYSA-N,"InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3",c1cccnc1C(C)C2=C(CCN(C)C)Cc(c23)cccc3,C20H24N2,,D07853,21855,99445271,135222,CHEMBL22108,,20541,81452,292.418,3.73870461,"Agents producing tachycardia; Anti-Allergic Agents; Anticholinergic Agents; Antihistamines for Systemic Use; Antihistamines for Topical Use; Antipruritics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indenes; Muscarinic Antagonists; Neurotransmitter Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Pyridines; Respiratory System; Substituted Alkylamines"
DB08804,Nandrolone decanoate,360-70-3,approved; illicit,JKWKMORAXJQQSR-MOPIKTETSA-N,"InChI=1S/C28H44O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h19,22-26H,3-18H2,1-2H3/t22-,23+,24+,25-,26-,28-/m0/s1",C1CC(=O)C=C(CC2)[C@H]1[C@@H](CC3)[C@@H]2[C@@H]([C@]34C)CC[C@@H]4OC(=O)CCCCCCCCC,C28H44O3,C08154,D00955,9677,99445274,7467,CHEMBL1200946,,9296,,428.6472,7.31901809,"Anabolic Agents; Androgens; Bone Density Conservation Agents; Estranes; Estrenes; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Nandrolone and esters; Polycyclic Compounds; Steroids; Testosterone Congeners; Thyroxine-binding globulin inhibitors"
DB08809,Dichloroacetic acid,79-43-6,approved; investigational,JXTHNDFMNIQAHM-UHFFFAOYSA-N,"InChI=1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)",OC(=O)C(Cl)Cl,C2H2Cl2O2,C11149,,6597,175427097,36386,CHEMBL13960,TF4,10771217,227588,128.942,1.058182613,"Acetates; Acids, Acyclic; Carboxylic Acids; Chloroacetates; Fatty Acids; Fatty Acids, Volatile; Hydrocarbons; Hydrocarbons, Chlorinated; Hydrocarbons, Halogenated; Lipids"
DB08813,Nadroparin,,approved; investigational,,, ,,,,,347910374,,,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Fibrin Modulating Agents; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Polysaccharides
DB08814,Triflusal,322-79-2,approved; investigational,RMWVZGDJPAKBDE-UHFFFAOYSA-N,"InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)",CC(=O)Oc1c(C(=O)O)ccc(c1)C(F)(F)F,C10H7F3O4,,,9458,347827803,94721,CHEMBL1332032,,9086,,248.157,2.11593818,"Acids, Carbocyclic; Anticoagulants; Antiplatelet agents; Benzene Derivatives; Benzoates; Blood and Blood Forming Organs; Carboxylic Acids; Hematologic Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Phenols; Platelet Aggregation Inhibitors Excl. Heparin"
DB08815,Lurasidone,367514-87-2,approved; investigational,PQXKDMSYBGKCJA-CVTJIBDQSA-N,"InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1",[C@@H]12[C@H]3CC[C@H](C3)[C@@H]1C(=O)N(C2=O)C[C@@H]4CCCC[C@H]4CN5CCN(CC5)c6nsc(c67)cccc7,C28H36N4O2S,,D04820,213046,175427100,70735,CHEMBL1237021,,184739,85222,492.676,4.556549749,"Adrenergic Agents; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Azoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Indole Derivatives; Isoindoles; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Potential QTc-Prolonging Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Thiazoles; Tranquilizing Agents"
DB08816,Ticagrelor,274693-27-5,approved,OEKWJQXRCDYSHL-FNOIDJSQSA-N,"InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1",Fc1ccc(cc1F)[C@@H]2C[C@H]2Nc3nc(SCCC)nc(c34)n(nn4)[C@@H]5C[C@@H]([C@@H](O)[C@H]5O)OCCO,C23H28F2N6O4S,,D09017,9871419,175427101,68558,CHEMBL398435,TIQ,8047109,50397205,522.568,2.278667876,"Anticoagulants; Antiplatelet agents; Blood and Blood Forming Organs; Carbohydrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Decreased Platelet Aggregation; Glycosides; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; P-glycoprotein inhibitors; P-glycoprotein substrates; P2Y12 Platelet Inhibitor; Phenylalanine Hydroxylase Activators; Platelet Aggregation Inhibitors Excl. Heparin; Purine Nucleosides; Purinergic Agents; Purinergic Antagonists; Purinergic P2 Receptor Antagonists; Purinergic P2Y Receptor Antagonists; Purines; Ribonucleosides"
DB08818,Hyaluronic acid,9004-61-9,approved; vet_approved,KIUKXJAPPMFGSW-MNSSHETKSA-N,"InChI=1S/C28H44N2O23/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45)/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18?,19?,20+,21+,22+,25-,26+,27-,28-/m1/s1",CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]2O[C@H](C(=O)O)[C@H]([C@H](O)[C@H]2O)O[C@@H]3O[C@H](CO)[C@@H](O)C([C@H]3NC(=O)C)O[C@@H]4O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]4O,C28H44N2O23,C00518,D08043,24759,310264899,,,,23145,,776.6486,-8.180567466,"Adjuvants, Immunologic; Carbohydrates; Cicatrizants; Compounds used in a research, industrial, or household setting; Dermatologicals; Glycosaminoglycans; Immunologic Factors; Lubricants; Musculo-Skeletal System; Nasal Preparations; Ophthalmologicals; Polysaccharides; Preparations for Treatment of Wounds and Ulcers; Protective Agents; Respiratory System; Sensory Organs; Surgical Aids; Viscoelastic Substances; Viscosupplements"
DB08819,Tafluprost,209860-87-7,approved,WSNODXPBBALQOF-VEJSHDCNSA-N,"InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1",CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc2ccccc2,C25H34F2O5,,D06274,9868491,175427102,66899,CHEMBL1963683,,8044182,,452.5313,4.292322371,"Antiglaucoma Preparations and Miotics; Autacoids; Biological Factors; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Increased Prostaglandin Activity; Inflammation Mediators; Lipids; Ophthalmics; Ophthalmologicals; Prostaglandin analogs reducing intraocular pressure (IOP); Prostaglandin Receptor Agonists; Prostaglandins; Prostaglandins, Synthetic; Sensory Organs"
DB08820,Ivacaftor,873054-44-5,approved,PURKAOJPTOLRMP-UHFFFAOYSA-N,"InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)",CC(C)(C)c1cc(C(C)(C)C)c(O)cc1NC(=O)c(c2=O)c[nH]c(c23)cccc3,C24H28N2O3,,D09916,16220172,175427103,66901,CHEMBL2010601,VX7,17347474,50032693,392.4907,5.758022158,"Amines; Aniline Compounds; Benzene Derivatives; Chloride Channel Activation Potentiators; Chloride Channel Agonists; Cystic Fibrosis Transmembrane Conductance Regulator Potentiators; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Membrane Transport Modulators; P-glycoprotein inhibitors; Phenols; Quinolines; Respiratory System"
DB08822,Azilsartan medoxomil,863031-21-4,approved; investigational,QJFSABGVXDWMIW-UHFFFAOYSA-N,"InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)",O=c1oc(c(o1)C)COC(=O)c2cccc(c23)nc(OCC)n3Cc4ccc(cc4)-c5ccccc5-c6noc(=O)[nH]6,C30H24N4O8,,D08865,11238823,175427104,68845,CHEMBL2028661,,9413866,,568.5336,6.034498228,"Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Angiotensin 2 Receptor Blocker; Angiotensin II receptor blockers (ARBs) and diuretics; Angiotensin II receptor blockers (ARBs), plain; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Azoles; Cardiovascular System; Decreased Blood Pressure; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypotensive Agents; Oxazoles"
DB08823,Spinosad,168316-95-8,approved; investigational; vet_approved,JFLRKDZMHNBDQS-SGSTVUCESA-N,"InChI=1S/C42H67NO10.C41H65NO10/c1-11-26-13-12-14-35(53-37-16-15-34(43(6)7)24(4)49-37)23(3)38(45)33-20-31-29(32(33)21-36(44)51-26)17-22(2)28-18-27(19-30(28)31)52-42-41(48-10)40(47-9)39(46-8)25(5)50-42;1-10-26-12-11-13-34(52-36-17-16-33(42(5)6)23(3)48-36)22(2)37(44)32-20-30-28(31(32)21-35(43)50-26)15-14-25-18-27(19-29(25)30)51-41-40(47-9)39(46-8)38(45-7)24(4)49-41/h17,20,23-32,34-35,37,39-42H,11-16,18-19,21H2,1-10H3;14-15,20,22-31,33-34,36,38-41H,10-13,16-19,21H2,1-9H3/t23-,24-,25+,26+,27-,28+,29-,30-,31-,32+,34+,35+,37+,39+,40-,41-,42+;22-,23-,24+,25-,26+,27-,28-,29-,30-,31+,33+,34+,36+,38+,39-,40-,41+/m11/s1",CO[C@@H]1[C@H](OC)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H](C2)C[C@H]([C@@H]23)C(C)=C[C@@H]4[C@H]3C=C5[C@H]4CC(=O)O[C@@H](CC)CCC[C@@H]([C@H](C5=O)C)O[C@H]6CC[C@H](N(C)C)[C@H](O6)C,C83H132N2O20,,D09384,17754356,175427105,39211,CHEMBL2040681,,16736513,,1477.963,5.843439882,"Agrochemicals; Compounds used in a research, industrial, or household setting; Insecticides; Lactones; Macrocyclic Compounds; Pediculicides; Pesticides; Pharmaceutical Preparations; Polycyclic Compounds; Polyketides; Toxic Actions"
DB08824,Ioflupane I-123,155798-07-5,approved,HXWLAJVUJSVENX-HFIFKADTSA-N,"InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4",FCCCN([C@H]12)[C@@H](CC1)C[C@@H]([C@@H]2C(=O)OC)c3ccc([123I])cc3,C18H23FINO2,,D10014,3086674,175427106,68855,CHEMBL3989517,,2343241,,427.291,3.701130282,"Alkaloids; Aza Compounds; Azabicyclo Compounds; Bicyclo Compounds, Heterocyclic; Carbon Radioisotopes; Central Nervous System; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Fluorine Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Iodine (123I) Compounds; Iodine Radioisotopes; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Tropanes"
DB08826,Deferiprone,30652-11-0,approved,TZXKOCQBRNJULO-UHFFFAOYSA-N,"InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3",Cn1ccc(=O)c(O)c1C,C7H9NO2,,D07416,2972,175427107,68554,CHEMBL70927,,2866,,139.1519,0.61204795,"Chelating Agents; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Heavy Metal Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Iron Chelating Activity; Iron Chelating Agents; Pyridines; Pyridones; Sequestering Agents; UGT1A6 substrate"
DB08827,Lomitapide,182431-12-5,approved; investigational,MBBCVAKAJPKAKM-UHFFFAOYSA-N,"InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)",c1cccc2c1C(C(=O)NCC(F)(F)F)(c(c23)cccc3)CCCCN4CCC(CC4)NC(=O)c5c(cccc5)-c6ccc(C(F)(F)F)cc6,C39H37F6N3O2,,D09637,9853053,175427108,72297,CHEMBL354541,,8028764,50098320,693.7204,7.704397379,"Cardiovascular System; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Microsomal Triglyceride Transfer Protein Inhibitor; Microsomal Triglyceride Transfer Protein Inhibitors; Miscellaneous Antilipemic Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors"
DB08828,Vismodegib,879085-55-9,approved; investigational,BPQMGSKTAYIVFO-UHFFFAOYSA-N,"InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)",CS(=O)(=O)c1cc(Cl)c(cc1)C(=O)Nc2ccc(Cl)c(c2)-c3ccccn3,C19H14Cl2N2O3S,,D09992,24776445,175427109,66903,CHEMBL473417,VIS,23337846,50249522,421.297,3.928931777,"Amides; Amines; Aniline Compounds; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hedgehog Pathway Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; P-glycoprotein substrates; Smoothened Receptor Antagonists"
DB08842,Acetylcarnitine,3040-38-8,approved; investigational,RDHQFKQIGNGIED-MRVPVSSYSA-N,"InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1",CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C,C9H17NO4,C02571,,7045767,175427117,57589,CHEMBL1697733,,5406074,,203.238,-4.446380638,"Amines; Ammonium Compounds; Central Nervous System Agents; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Micronutrients; Nervous System; Nitrogen Compounds; Nootropic Agents; Onium Compounds; Physiological Phenomena; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Quaternary Ammonium Compounds; Trimethyl Ammonium Compounds"
DB08860,Pitavastatin,147511-69-1,approved,VGYFMXBACGZSIL-MCBHFWOFSA-N,"InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1",OC(=O)C[C@H](O)C[C@H](O)/C=C/c(c(C1CC1)nc(c23)cccc3)c2-c4ccc(F)cc4,C25H24FNO4,C13334,D01862,5282452,175427122,32020,CHEMBL1201753,,4445604,86707,421.4608,2.924036168,"Agents Causing Muscle Toxicity; Anticholesteremic Agents; BCRP/ABCG2 Substrates; BSEP/ABCB11 Substrates; Cardiovascular System; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; Toxic Actions; UGT1A3 substrates; UGT2B7 substrates"
DB08862,Cholecystokinin,9011-97-6,approved; investigational,,, ,,,,,347910375,,,,,,NA,NA,"Amino Acids, Peptides, and Proteins; Cholagogues and Choleretics; Cholecystokinin, agonists; Cholecystokinin, antagonists & inhibitors; Diagnostic Agents; Gastrointestinal Agents; Gastrointestinal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Peptides; Tests for Pancreatic Function"
DB08864,Rilpivirine,500287-72-9,approved,YIBOMRUWOWDFLG-ONEGZZNKSA-N,"InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+",N#C/C=C/c1cc(C)c(c(c1)C)Nc2ccnc(n2)Nc3ccc(C#N)cc3,C22H18N6,,D09720,6451164,175427123,68606,CHEMBL175691,T27,4953643,222178,366.4185,5.473225503,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strong); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Nitriles; Non-Nucleoside Reverse Transcriptase Inhibitors; Nonnucleoside Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Pyrimidines; QTc Prolonging Agents; Reverse Transcriptase Inhibitors"
DB08865,Crizotinib,877399-52-5,approved,KTEIFNKAUNYNJU-GFCCVEGCSA-N,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",Clc1c(F)ccc(Cl)c1[C@@H](C)Oc2cc(cnc2N)-c3cn(nc3)C4CCNCC4,C21H22Cl2FN5O,,D09731,11626560,310264901,64310,CHEMBL601719,VGH,9801307,50306682,450.337,3.57411674,"Amines; Aminopyridines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Bradycardia-Causing Agents; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; Moderate Risk QTc-Prolonging Agents; Narrow Therapeutic Index Drugs; OCT2 Inhibitors; Organic Cation Transporter 1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Piperidines; Protein Kinase Inhibitors; Pyridines; QTc Prolonging Agents; Receptor Tyrosine Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB08867,Ulipristal,159811-51-5,approved,HKDLNTKNLJPAIY-WKWWZUSTSA-N,"InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1",CN(C)c1ccc(cc1)[C@@H](C2)C(=C3C(CC4)=CC(=O)CC3)[C@@H]4[C@@H]([C@]25C)CC[C@]5(O)C(=O)C,C28H35NO3,,D09567,13559281,310264902,71025,CHEMBL2103846,,19349271,,433.592,4.180761779,"Adrenal Cortex Hormones; Contraceptive Agents, Female; Contraceptives, Postcoital; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Norpregnanes; Norsteroids; Polycyclic Compounds; Progesterone Agonist/Antagonist; Progesterone Receptor Modulators; Reproductive Control Agents; Selective Progesterone Receptor Modulators; Sex Hormones and Modulators of the Genital System; Steroids"
DB08868,Fingolimod,162359-55-9,approved; investigational,KKGQTZUTZRNORY-UHFFFAOYSA-N,"InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3",CCCCCCCCc1ccc(cc1)CCC(N)(CO)CO,C19H33NO2,,D10001,107970,175427125,63115,CHEMBL314854,,97087,50158336,307.4708,4.060977926,Alcohols; Amines; Amino Alcohols; Antineoplastic and Immunomodulating Agents; Bradycardia-Causing Agents; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 Substrates; Experimental Unapproved Treatments for COVID-19; Glycols; Immunologic Factors; Immunomodulatory Agents; Immunosuppressive Agents; P-glycoprotein inducers; P-glycoprotein inhibitors; Propylene Glycols; QTc Prolonging Agents; Selective Immunosuppressants; Sphingosine 1-phosphate Receptor Modulator
DB08869,Tesamorelin,218949-48-5,approved; investigational,LAJJBLZKAIOLRM-YHAVXTEWSA-N,"InChI=1S/C216H360N72O63S/c1-25-28-30-53-161(304)256-142(90-118-54-58-120(294)59-55-118)193(334)251-114(21)175(316)271-147(94-165(308)309)194(335)252-115(22)176(317)286-168(109(16)26-2)209(350)279-144(89-117-43-31-29-32-44-117)201(342)288-170(116(23)293)210(351)280-146(93-160(226)303)200(341)284-152(102-292)205(346)275-143(91-119-56-60-121(295)61-57-119)198(339)263-128(51-41-81-244-215(236)237)182(323)262-124(46-34-36-76-218)192(333)285-167(108(14)15)207(348)278-138(85-104(6)7)179(320)248-98-164(307)254-131(63-69-154(220)297)186(327)273-141(88-107(12)13)197(338)283-149(99-289)203(344)253-113(20)174(315)258-126(49-39-79-242-213(232)233)181(322)261-123(45-33-35-75-217)185(326)272-140(87-106(10)11)196(337)274-139(86-105(8)9)195(336)267-135(67-73-158(224)301)190(331)277-148(95-166(310)311)202(343)287-169(110(17)27-3)208(349)269-136(74-83-352-24)191(332)282-150(100-290)204(345)264-129(52-42-82-245-216(238)239)183(324)266-133(65-71-156(222)299)189(330)265-130(62-68-153(219)296)178(319)247-97-163(306)255-132(64-70-155(221)298)187(328)281-151(101-291)206(347)276-145(92-159(225)302)199(340)268-134(66-72-157(223)300)188(329)260-122(47-37-77-240-211(228)229)177(318)246-96-162(305)249-111(18)172(313)257-125(48-38-78-241-212(230)231)180(321)250-112(19)173(314)259-127(50-40-80-243-214(234)235)184(325)270-137(171(227)312)84-103(4)5/h28-32,43-44,54-61,103-116,122-152,167-170,289-295H,25-27,33-42,45-53,62-102,217-218H2,1-24H3,(H2,219,296)(H2,220,297)(H2,221,298)(H2,222,299)(H2,223,300)(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,312)(H,246,318)(H,247,319)(H,248,320)(H,249,305)(H,250,321)(H,251,334)(H,252,335)(H,253,344)(H,254,307)(H,255,306)(H,256,304)(H,257,313)(H,258,315)(H,259,314)(H,260,329)(H,261,322)(H,262,323)(H,263,339)(H,264,345)(H,265,330)(H,266,324)(H,267,336)(H,268,340)(H,269,349)(H,270,325)(H,271,316)(H,272,326)(H,273,327)(H,274,337)(H,275,346)(H,276,347)(H,277,331)(H,278,348)(H,279,350)(H,280,351)(H,281,328)(H,282,332)(H,283,338)(H,284,341)(H,285,333)(H,286,317)(H,287,343)(H,288,342)(H,308,309)(H,310,311)(H4,228,229,240)(H4,230,231,241)(H4,232,233,242)(H4,234,235,243)(H4,236,237,244)(H4,238,239,245)/b30-28+/t109?,110?,111-,112-,113-,114-,115-,116?,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,167-,168-,169-,170-/m0/s1",CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N)CC(C)C,C216H360N72O63S,,D09015,56928011,347827804,63626,CHEMBL1237026,,34999256,,5005.76,-34.82914468,"Amino Acids, Peptides, and Proteins; Anterior Pituitary Lobe Hormones and Analogues; Growth Hormone Releasing Factor Analog; Growth Hormone-Releasing Hormone; Growth Substances; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Increased GHRH Activity; Lipodystrophy; Nerve Tissue Proteins; Neuropeptides; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormone-Releasing Hormones; Proteins; Somatotropin Agonists; Somatropin and Somatropin Agonists; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB08871,Eribulin,253128-41-5,approved; investigational,UFNVPOGXISZXJD-JBQZKEIOSA-N,"InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1",[C@]123CC[C@@H]4O[C@H](C(C4)=C)CC[C@@H]5O[C@@H](C(=C)[C@@H](C5)C)C[C@H]6[C@@H]([C@@H](OC)[C@H](O6)C[C@H](O)CN)CC(=O)C[C@@H]7O[C@H]8[C@H](CC7)O[C@@H]9[C@H]([C@H]8O1)O[C@H]([C@@H]9O2)C3,C40H59NO11,,D08914,73425383,175427126,63587,CHEMBL1683590,6K9,24721813,,729.908,2.307778076,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Microtubule Inhibition; Microtubule Inhibitors; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB08872,Gabapentin enacarbil,478296-72-9,approved; investigational,TZDUHAJSIBHXDL-UHFFFAOYSA-N,"InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19)",CC(C)C(=O)OC(C)OC(=O)NCC1(CC(=O)O)CCCCC1,C16H27NO6,,D09539,9883933,347827805,68840,CHEMBL1628502,,8059607,,329.393,2.763469242,"Acids, Acyclic; Amino Acids; Amino Acids, Peptides, and Proteins; Aminobutyrates; Anti-epileptic Agent; Butyrates; Carboxylic Acids; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Fatty Acids; Fatty Acids, Volatile; Gabapentin and Prodrugs; Lipids"
DB08873,Boceprevir,394730-60-0,approved; withdrawn,LHHCSNFAOIFYRV-DOVBMPENSA-N,"InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1",CC(C)(C)NC(=O)N[C@@H](C(C)(C)C)C(=O)N(C[C@@H]([C@@H]12)C2(C)C)[C@@H]1C(=O)NC(C(=O)C(=O)N)CC3CCC3,C27H45N5O5,,D08876,10324367,175427127,68621,CHEMBL218394,HU5,8499830,12311,519.6767,1.775296396,"Acids, Acyclic; Amino Acids; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; Carboxylic Acids; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strong); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; HCV NS3/4A Protease Inhibitors; Imines; Imino Acids; NS3/4A Protease Inhibitors; P-glycoprotein inhibitors; Protease Inhibitors"
DB08874,Fidaxomicin,873857-62-6,approved,ZVGNESXIJDCBKN-UUEYKCAUSA-N,"InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1",CC(C)C(=O)O[C@H](C1(C)C)[C@H](O)[C@H](O)[C@@H](O1)O[C@@H]2[C@@H](CC)/C=C(\C)[C@@H](O)C/C=C/C=C(/C(=O)O[C@H]([C@@H](C)O)C/C=C(\C)/C=C/2C)CO[C@@H]3O[C@H](C)[C@H]([C@H](O)[C@@H]3OC)OC(=O)c4c(CC)c(Cl)c(O)c(Cl)c4O,C52H74Cl2O18,,D09394,70678896,175427128,68590,CHEMBL1255800,FI8,8209640,,1058.05,8.556184697,"Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Carbohydrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Intestinal Antiinfectives; Lactones; Macrocyclic Compounds; Macrolide Antibacterial; Macrolides; Other Macrolides; P-glycoprotein substrates; Polycyclic Compounds; Polyketides"
DB08875,Cabozantinib,849217-68-1,approved; investigational,ONIQOQHATWINJY-UHFFFAOYSA-N,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",COc(c1)c(OC)cc(c12)nccc2Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5,C28H24FN3O5,,D10062,25102847,347827806,72317,CHEMBL2105717,,25948202,50021574,501.514,4.658062448,"Amides; Amines; Aniline Compounds; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; Narrow Therapeutic Index Drugs; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases, antagonists & inhibitors; Tyrosine Kinase Inhibitors"
DB08877,Ruxolitinib,941678-49-5,approved,HFNKQEVNSGCOJV-OAHLLOKOSA-N,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",C1CCCC1[C@@H](CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4,C17H18N6,,D09959,25126798,175427129,66919,CHEMBL1789941,RXT,25027389,50355501,306.365,2.479321834,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Janus Kinases, antagonists & inhibitors; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB08880,Teriflunomide,163451-81-8,approved,UTNUDOFZCWSZMS-YFHOEESVSA-N,"InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-",C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,C12H9F3N2O2,,D10172,54684141,347827807,68540,CHEMBL973,A26,16737143,50018011,270.2073,2.138883199,"Acids, Acyclic; Amines; Analgesics; Analgesics, Non-Narcotic; Aniline Compounds; Anti-Inflammatory Agents; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Benzene Derivatives; Butyrates; Carboxylic Acids; Central Nervous System Agents; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Inducers (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Dihydroorotate Dehydrogenase Inhibitors; Fatty Acids; Fatty Acids, Volatile; Hepatotoxic Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Immunologic Factors; Immunomodulatory Agents; Immunosuppressive Agents; Leflunomide and metabolite; Lipids; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; Peripheral Nervous System Agents; Pyrimidine Synthesis Inhibitor; Selective Immunosuppressants; Sensory System Agents"
DB08881,Vemurafenib,918504-65-1,approved,GPXBXXGIAQBQNI-UHFFFAOYSA-N,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",CCCS(=O)(=O)Nc1c(F)c(c(F)cc1)C(=O)c2c[nH]c(c23)ncc(c3)-c4ccc(Cl)cc4,C23H18ClF2N3O3S,,D09996,42611257,175427131,63637,CHEMBL1229517,32,24747352,50396483,489.922,4.622483135,"Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Indoles; Kinase Inhibitor; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Photosensitizing Agents; Protein Kinase Inhibitors; QTc Prolonging Agents; Sulfonamides; Sulfones; Sulfur Compounds; Tyrosine Kinase Inhibitors"
DB08882,Linagliptin,668270-12-0,approved,LTXREWYXXSTFRX-QGZVFWFLSA-N,"InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1",CC#CCn1c(N(C[C@@H]2N)CCC2)nc(c13)n(C)c(=O)n(c3=O)Cc(nc4C)nc(c45)cccc5,C25H28N8O2,,D09566,10096344,175427132,68610,CHEMBL237500,356,8271879,50228403,472.5422,2.802632814,"Agents causing angioedema; Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; DPP-IV Inhibitors; Drugs Used in Diabetes; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Incretins; OCT1 inhibitors; OCT2 Inhibitors; OCT2 Substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; Protease Inhibitors; Purines; Quinazolines"
DB08883,Perampanel,380917-97-5,approved,PRMWGUBFXWROHD-UHFFFAOYSA-N,"InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H",c1ccccc1-n2c(=O)c(-c3ccccc3C#N)cc(c2)-c4ncccc4,C23H15N3O,,D08964,9924495,347827808,71013,CHEMBL1214124,6ZP,8100130,50184410,349.393,4.106756876,"AMPA Receptor Antagonists; Anticonvulsants; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (weak); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Miscellaneous Anticonvulsants; Nervous System; Noncompetitive AMPA Glutamate Receptor Antagonist; Pyridines; Receptors, AMPA, antagonists & inhibitors"
DB08884,Gadoxetic acid,135326-11-3,approved,PCZHWPSNPWAQNF-LMOVPXPDSA-K,"InChI=1S/C23H33N3O11.Gd/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);/q;+3/p-3/t17-;/m0./s1",CCOc1ccc(cc1)C[C@H](N(CC(=O)O)CC(=O)O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O,C23H30GdN3O11,,D04288,131704314,175427133,,CHEMBL1201768,,189907,,681.75,-4.260546431,"Acetates; Acids, Acyclic; Amines; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Fatty Acids; Fatty Acids, Volatile; Gadolinium-based Contrast Agent; Lipids; Magnetic Resonance Contrast Activity; Magnetic Resonance Imaging Contrast Media; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Organometallic Compounds; Other Diagnostics; Paramagnetic Contrast Agent; Paramagnetic Contrast Media; Polyamines"
DB08887,Icosapent ethyl,86227-47-6,approved; investigational; nutraceutical,SSQPWTVBQMWLSZ-AAQCHOMXSA-N,"InChI=1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-",CCOC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC,C22H34O2,C16184,D01892,9831415,175427134,84883,CHEMBL2095209,,8007147,,330.5042,6.727951165,"Antiplatelet agents; Autacoids; Biological Factors; Diet, Food, and Nutrition; Dietary Fats; Dietary Fats, Unsaturated; Eicosanoids; Fats; Fatty Acids; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fish Oils; Food; Food and Beverages; Hematologic Agents; Hypolipidemic Agents; Inflammation Mediators; Lipids; Miscellaneous Antilipemic Agents; Oils; Physiological Phenomena"
DB08889,Carfilzomib,868540-17-4,approved; investigational,BLMPQMFVWMYDKT-NZTKNTHTSA-N,"InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1",c1ccccc1C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)[C@@]2(C)CO2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCc3ccccc3)NC(=O)CN4CCOCC4,C40H57N5O7,,D08880,11556711,175427135,65347,CHEMBL451887,,9731489,50277889,719.9099,4.197719257,"Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Peptides; Proteasome Inhibitors"
DB08890,Linaclotide,851199-59-2,approved,KXGCNMMJRFDFNR-WDRJZQOASA-N,"InChI=1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1",Oc1ccc(cc1)C[C@@H](C(=O)O)NC(=O)[C@H](CSSC[C@H]23)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N2)Cc5ccc(O)cc5)NC(=O)[C@@H](N)CSSC[C@H](NC3=O)C(=O)N[C@@H](CC(=O)N)C(=O)N6[C@@H](CCC6)C(=O)N[C@@H](C)C(=O)N4,C59H79N15O21S6,,D09355,16158208,175427136,68551,CHEMBL3301675,,17314504,,1526.736,-10.77539908,"Alimentary Tract and Metabolism; Amino Acids, Peptides, and Proteins; Drugs for Constipation; Enzyme Activators; Gastrointestinal Agents; Guanylate Cyclase Activators; Guanylate Cyclase-C Agonist; Guanylyl Cyclase C Agonists; Laxatives; Miscellaneous GI Drugs"
DB08893,Mirabegron,223673-61-8,approved,PBAPPPCECJKMCM-IBGZPJMESA-N,"InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1",Nc1nc(cs1)CC(=O)Nc2ccc(cc2)CCNC[C@H](O)c3ccccc3,C21H24N4O2S,,D09535,9865528,175427137,65349,CHEMBL2095212,,8041219,,396.506,2.88641137,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Amides; Amines; Anilides; Aniline Compounds; Azoles; Cholinesterase substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Urinary Frequency and Incontinence; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Neurotransmitter Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Selective Beta 3-adrenergic Agonists; Sulfur Compounds; Urological Agents; Urologicals"
DB08895,Tofacitinib,477600-75-2,approved; investigational,UJLAWZDWDVHWOW-YPMHNXCESA-N,"InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1",C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3,C16H20N6O,,D09970,9926791,347827811,71200,CHEMBL221959,MI1,8102425,50193995,312.3696,1.244714428,"Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Azoles; Biologics for Rheumatoid Arthritis Treatment; Bradycardia-Causing Agents; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Disease-modifying Antirheumatic Agents; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Janus Kinase 3, antagonists & inhibitors; Janus Kinase Inhibitor; Janus Kinase Inhibitors; Myelosuppressive Agents; Protein Kinase Inhibitors; Selective Immunosuppressants"
DB08896,Regorafenib,755037-03-7,approved,FNHKPVJBJVTLMP-UHFFFAOYSA-N,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F,C21H15ClF4N4O3,,D10138,11167602,175427139,68647,CHEMBL1946170,,9342697,50363397,482.815,4.486031697,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Benzene Derivatives; Bradycardia-Causing Agents; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Kinase Inhibitor; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors; UGT1A9 Inhibitors; UGT1A9 Substrates"
DB08897,Aclidinium,727649-81-2,approved,ASMXXROZKSBQIH-VITNCHFBSA-N,"InChI=1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1/t20?,22-,27?/m0/s1",c1ccsc1C(O)(c2cccs2)C(=O)O[C@@H](C3)C(CC4)CC[N+]34CCCOc5ccccc5,C26H30NO4S2,,D08837,11434515,175427140,65346,CHEMBL1194325,,9609381,50296331,484.651,0.446525622,"Adrenergics, Inhalants; Agents producing tachycardia; Agents to Treat Airway Disease; Alkaloids; Anticholinergic Agents; Antimuscarinics Antispasmodics; Aza Compounds; Azabicyclo Compounds; Bicyclo Compounds, Heterocyclic; Cholinesterase substrates; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Muscarinic Antagonists; Respiratory System"
DB08899,Enzalutamide,915087-33-1,approved,WXCXUHSOUPDCQV-UHFFFAOYSA-N,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",CNC(=O)c1c(F)cc(cc1)N(C2(C)C)C(=S)N(C2=O)c3ccc(C#N)c(c3)C(F)(F)F,C21H16F4N4O2S,,D10218,15951529,175427141,68534,CHEMBL1082407,,13093347,50425732,464.436,4.15541124,"Androgen Receptor Antagonists; Androgen Receptor Inhibitor; Antiandrogens; Antiandrogens, non-steroidal; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (moderate); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (moderate); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strong); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Endocrine Therapy; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists and Related Agents; Hydantoins; Imidazoles; Imidazolidines; P-glycoprotein inhibitors; Thyroxine-binding globulin substrates"
DB08901,Ponatinib,943319-70-8,approved; investigational,PHXJVRSECIGDHY-UHFFFAOYSA-N,"InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)",CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5,C29H27F3N6O,,D09950,24826799,175427142,78543,CHEMBL1171837,0LI,24747381,50322535,532.5595,4.965714124,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB08903,Bedaquiline,843663-66-1,approved,QUIJNHUBAXPXFS-XLJNKUFUSA-N,"InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1",Brc(c1)ccc(c12)nc(OC)c(c2)[C@@H](c3ccccc3)[C@@](O)(CCN(C)C)c4cccc(c45)cccc5,C32H31BrN2O2,C14122,D09872,5388906,175427143,72292,CHEMBL376488,BQ1,4534966,50063995,555.505,7.132617517,"Anti-Bacterial Agents; Anti-Infective Agents; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diarylquinoline Antimycobacterial; Drugs for Treatment of Tuberculosis; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Moderate Risk QTc-Prolonging Agents; Mycobacterium tuberculosis; QTc Prolonging Agents; Quinolines"
DB08905,Formestane,566-48-3,approved; investigational; withdrawn,OSVMTWJCGUFAOD-KZQROQTASA-N,"InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1",O=C1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=C(O)C(=O)CC4,C19H26O3,,D07260,11273,175427144,75172,CHEMBL132530,,10799,225704,302.4079,3.410293322,"17-Ketosteroids; Adrenal Cortex Hormones; Androstanes; Androstenes; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Aromatase Inhibitors; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Drugs that are Mainly Renally Excreted; Endocrine Therapy; Enzyme Inhibitors; Estrogen Antagonists; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Ketosteroids; Polycyclic Compounds; Steroid Synthesis Inhibitors; Steroids; Testosterone Congeners"
DB08906,Fluticasone furoate,397864-44-7,approved,XTULMSXFIHGYFS-VLSRWLAYSA-N,"InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1",C1=CC(=O)C=C([C@]12C)[C@@H](F)C[C@@H]3[C@]2(F)[C@@H](O)C[C@@]4(C)[C@H]3C[C@@H](C)[C@@]4(C(=O)SCF)OC(=O)c5ccco5,C27H29F3O6S,,D06315,9854489,175427145,74899,CHEMBL1676,GW6,8030195,50354851,538.576,4.131889851,Adrenal Cortex Hormones; Agents to Treat Airway Disease; Androstanes; Androstenes; Corticosteroids; Corticosteroids for inhalation use; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Fused-Ring Compounds; Glucocorticoids; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Nasal Preparations; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Respiratory System; Steroids; Thyroxine-binding globulin inhibitors
DB08907,Canagliflozin,842133-18-0,approved,XTNGUQKDFGDXSJ-ZXGKGEBGSA-N,"InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1",O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1c2ccc(C)c(c2)Cc3ccc(s3)-c4ccc(F)cc4,C24H25FO5S,,D09592,24812758,175427146,73274,CHEMBL2048484,,26333259,50386885,444.516,3.520655085,"Agents causing hyperkalemia; Alimentary Tract and Metabolism; Blood Glucose Lowering Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diuretics; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Glucosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Sodium-glucose co-transporter 2 (SGLT2) inhibitors; Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; Sulfur Compounds; Thiophenes; UGT1A9 Substrates"
DB08908,Dimethyl fumarate,624-49-7,approved; investigational,LDCRTTXIJACKKU-ONEGZZNKSA-N,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+",COC(=O)/C=C/C(=O)OC,C6H8O4,,D03846,637568,347827812,76004,CHEMBL2107333,,553171,,144.1253,0.717540447,"Acids, Acyclic; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Dermatologicals; Dicarboxylic Acids; Fumarates; Immunologic Factors; Immunosuppressive Agents; Miscellaneous Central Nervous System Agents; Radiation-Sensitizing Agents"
DB08909,Glycerol phenylbutyrate,611168-24-2,approved,ZSDBFLMJVAGKOU-UHFFFAOYSA-N,"InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2",c1ccccc1CCCC(=O)OCC(OC(=O)CCCc2ccccc2)COC(=O)CCCc3ccccc3,C33H38O6,,D10127,10482134,175427147,134745,CHEMBL2105745,,8657541,,530.6512,7.654793657,"Acids, Carbocyclic; Alcohols; Alimentary Tract and Metabolism; Carbohydrates; Carboxylic Acids; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Nitrogen Binding Agent; Sugar Alcohols; Triose Sugar Alcohols; Urea Cycle Disorder Agents; Various Alimentary Tract and Metabolism Products"
DB08910,Pomalidomide,19171-19-8,approved,UVSMNLNDYGZFPF-UHFFFAOYSA-N,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",Nc1cccc(c12)C(=O)N(C2=O)C3CCC(=O)NC3=O,C13H11N3O4,,D08976,134780,175427148,72690,CHEMBL43452,,118785,65456,273.2441,-0.163218598,"Acids, Carbocyclic; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Growth Inhibitors; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Imides; Immunologic Factors; Immunosuppressive Agents; Isoindoles; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; Phthalic Acids; Phthalimides; Piperidines; Piperidones; Thalidomide Analog"
DB08911,Trametinib,871700-17-3,approved,LIRYPHYGHXZJBZ-UHFFFAOYSA-N,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",Fc1cc(I)ccc1Nc2n(C)c(=O)c(C)c(c23)n(c(=O)n(c3=O)C4CC4)-c5cc(NC(=O)C)ccc5,C26H23FIN5O4,,D10175,11707110,175427149,75998,CHEMBL2103875,,9881833,,615.3948,3.182718303,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; MAP Kinase Kinase 1, antagonists & inhibitors; MAP Kinase Kinase 2, antagonists & inhibitors; Narrow Therapeutic Index Drugs; Protein Kinase Inhibitors; Pyridines; Pyrimidines"
DB08912,Dabrafenib,1195765-45-7,approved; investigational,BFSMGDJOXZAERB-UHFFFAOYSA-N,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F,C23H20F3N5O2S2,,D10064,44462760,175427150,75045,CHEMBL2028663,P06,25948204,50428286,519.562,5.459618017,"Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strong); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (moderate); Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydroxylamines; Hyperglycemia-Associated Agents; Kinase Inhibitor; Narrow Therapeutic Index Drugs; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Organic Anion Transporter 1 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Photosensitizing Agents; Potential QTc-Prolonging Agents; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf, antagonists & inhibitors; QTc Prolonging Agents"
DB08913,Radium Ra 223 dichloride,444811-40-9,approved; investigational,RWRDJVNMSZYMDV-SIUYXFDKSA-L,InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2/i;;1-3,[Cl-],Cl2Ra,,D10398,,175427151,74895,CHEMBL2107816,,28528370,,293.924,0,"Antineoplastic Agents; Elements; Elements, Radioactive; Isotopes; Metals; Metals, Alkaline Earth; Metals, Heavy; Radioactive alpha-Particle Emitting Therapeutic Agent; Radioisotopes"
DB08916,Afatinib,850140-72-6,approved,ULXXDDBFHOBEHA-CWDCEQMOSA-N,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",CN(C)C/C=C/C(=O)Nc(c1)c(O[C@H]2CCOC2)cc(c13)ncnc3Nc4cc(Cl)c(F)cc4,C24H25ClFN5O3,,D09724,10184653,175427153,61390,CHEMBL1173655,0WM,8360155,50322823,485.938,3.758361295,"Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Quinazolines; Tyrosine Kinase Inhibitors"
DB08917,Ferric carboxymaltose,9007-72-1,approved,,, ,,,D08920,,347910386,,CHEMBL2108597,,,,NA,NA,"Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Disaccharides; Glucans; Iron Compounds; Macromolecular Substances; Manufactured Materials; Oligosaccharides; Organometallic Compounds; Parenteral Iron Replacement; Phosphate Binder; Polymers; Polysaccharides"
DB08918,Levomilnacipran,96847-54-0,approved; investigational,GJJFMKBJSRMPLA-DZGCQCFKSA-N,"InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1",CCN(CC)C(=O)[C@]1(C[C@H]1CN)c2ccccc2,C15H22N2O,,D10072,6917779,175427154,136040,CHEMBL99946,,5293005,50032379,246.348,1.421706623,"Adrenergic Uptake Inhibitors; Agents producing tachycardia; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cycloparaffins; Cyclopropanes; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hypoglycemia-Associated Agents; Macrocyclic Compounds; Membrane Transport Modulators; Milnacipran and enantiomer; Miscellaneous Antidepressants; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Norepinephrine Uptake Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Serotonin Modulators"
DB08930,Dolutegravir,1051375-16-6,approved,RHWKPHLQXYSBKR-BMIGLBTASA-N,"InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1",C[C@@H]1CCO[C@H](N12)Cn3c(C2=O)c(O)c(=O)c(c3)C(=O)NCc4ccc(F)cc4F,C20H19F2N3O5,,D10066,54726191,175427161,76010,CHEMBL1229211,DLU,25051637,50062551,419.3788,1.104252226,"Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BCRP/ABCG2 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; HIV Integrase Inhibitors; Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor; Integrase Inhibitors; Miscellaneous Antiretrovirals*; Multidrug and Toxin Extrusion Transporter 1 Inhibitors; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; UGT1A1 Substrates; UGT1A3 substrates; UGT1A9 Substrates"
DB08931,Riociguat,625115-55-1,approved,WXXSNCNJFUAIDG-UHFFFAOYSA-N,"InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)",COC(=O)N(C)c1c(N)nc(nc1N)-c2nn(c(c23)nccc3)Cc4c(F)cccc4,C20H19FN8O2,,D09572,11304743,310264904,76018,CHEMBL2107834,,9479719,,422.4157,2.685566484,"Antihypertensive Agents; Antihypertensives for Pulmonary Arterial Hypertension; Azoles; BCRP/ABCG2 Substrates; Cardiovascular System; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Enzyme Activators; Guanylate Cyclase; Guanylate Cyclase Stimulators; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Soluble Guanylate Cyclase Stimulator; Vasodilating Agents"
DB08932,Macitentan,441798-33-0,approved,JGCMEBMXRHSZKX-UHFFFAOYSA-N,"InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)",CCCNS(=O)(=O)Nc1c(-c2ccc(Br)cc2)c(ncn1)OCCOc3ncc(Br)cn3,C19H20Br2N6O4S,,D10135,16004692,175427162,76607,CHEMBL2103873,,13134960,50395626,588.273,3.685126328,"Amides; Antihypertensive Agents; Antihypertensives for Pulmonary Arterial Hypertension; Cardiovascular System; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Sulfones; Sulfur Compounds; Vasodilating Agents"
DB08933,Luliconazole,187164-19-8,approved,YTAOBBFIOAEMLL-REQDGWNSSA-N,"InChI=1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1",Clc1cc(Cl)c(cc1)[C@@H]2CS/C(S2)=C(/C#N)n3ccnc3,C14H9Cl2N3S2,C13478,D01980,3003141,175427163,34825,CHEMBL2105689,,2273807,,354.27,4.069960694,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Azole Antifungals; Azoles; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 Enzyme Inhibitors; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole and Triazole Derivatives"
DB08934,Sofosbuvir,1190307-88-0,approved,TTZHDVOVKQGIBA-IQWMDFIBSA-N,"InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1",c1ccccc1O[P@](=O)(N[C@@H](C)C(=O)OC(C)C)OC[C@H]([C@@H](O)[C@]2(F)C)O[C@H]2n3ccc(=O)[nH]c3=O,C22H29FN3O9P,,D10366,45375808,175427164,85083,CHEMBL1259059,,26286922,50239940,529.458,1.283604145,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; BCRP/ABCG2 Substrates; Carbohydrates; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Glycosides; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Nucleotides; P-glycoprotein substrates; Pyrimidine Nucleosides; Pyrimidine Nucleotides; Pyrimidines; Ribonucleosides; Ribonucleotides; RNA Replicase Inhibitors; Uracil Nucleotides"
DB08936,Chlorcyclizine,82-93-9,approved,WFNAKBGANONZEQ-UHFFFAOYSA-N,"InChI=1S/C18H21ClN2/c1-20-11-13-21(14-12-20)18(15-5-3-2-4-6-15)16-7-9-17(19)10-8-16/h2-10,18H,11-14H2,1H3",c1ccccc1C(c(cc2)ccc2Cl)N3CCN(C)CC3,C18H21ClN2,,,2710,175427165,94402,CHEMBL22150,,2609,50329371,300.826,4.150047026,"Antihistamines for Systemic Use; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H1 Antagonists; Piperazine Derivatives; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB08938,Magaldrate,74978-16-8,approved; withdrawn,SPPNVMTVMQOKSC-UHFFFAOYSA-A,"InChI=1S/5Al.10Mg.2H2O4S.32H2O/c;;;;;;;;;;;;;;;2*1-5(2,3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h;;;;;;;;;;;;;;;2*(H2,1,2,3,4);32*1H2/q5*+3;10*+2;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/p-35",[O-]S([O-])(=O)=O,Al5H33Mg10O40S2,,D04832,3086011,310264905,,CHEMBL3833350,,,,1115.3,-0.841552023,Alimentary Tract and Metabolism; Alkalies; Aluminium Compounds; Aluminum and magnesium containing antacids; Anions; Antacids; Antacids With Antiflatulents; Drugs for Acid Related Disorders; Electrolytes; Gastric Acid Lowering Agents; Gastrointestinal Agents; Hydroxides; Ions; Magnesium Compounds; Metal cations; Metal divalent cations
DB08941,Isoxsuprine,395-28-8,approved; withdrawn,BMUKKTUHUDJSNZ-HBUWYVDXSA-N,"InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3/t13-,14-,18-/m1/s1",c1ccccc1OC[C@@H](C)N[C@H](C)[C@@H](O)c2ccc(O)cc2,C18H23NO3,,,11779629,310264908,,,,9954311,,301.386,2.564600513,2-Amino-1-Phenylethanol Derivatives; Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Autonomic Agents; Cardiovascular Agents; Cardiovascular System; Ethylamines; Hypotensive Agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Peripheral Vasodilators; Phenethylamines; Propanolamines; Propanols; Reproductive Control Agents; Sympathomimetics; Tocolytic Agents; Vasodilating Agents
DB08942,Isoxicam,34552-84-6,approved; withdrawn,YYUAYBYLJSNDCX-UHFFFAOYSA-N,"InChI=1S/C14H13N3O5S/c1-8-7-11(16-22-8)15-14(19)12-13(18)9-5-3-4-6-10(9)23(20,21)17(12)2/h3-7,18H,1-2H3,(H,15,16,19)",c1cccc(c12)C(O)=C(N(S2(=O)=O)C)C(=O)Nc3noc(C)c3,C14H13N3O5S,,D04639,54677972,310264909,76163,CHEMBL53292,ICD,10442695,,335.335,0.770242019,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Central Nervous System Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Sensory System Agents; Sulfur Compounds; Thiazines"
DB08943,Isoconazole,27523-40-6,approved,MPIPASJGOJYODL-UHFFFAOYSA-N,"InChI=1S/C18H14Cl4N2O/c19-12-4-5-13(17(22)8-12)18(9-24-7-6-23-11-24)25-10-14-15(20)2-1-3-16(14)21/h1-8,11,18H,9-10H2",Clc1cc(Cl)ccc1C(Cn2cncc2)OCc3c(Cl)cccc3Cl,C18H14Cl4N2O,,D04624,3760,310264910,83667,CHEMBL1571863,,3629,31771,416.129,5.95636836,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Azole Antifungals; Azoles; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole and Triazole Derivatives; Imidazole Derivatives; Imidazoles; Ointments"
DB08944,Isoaminile,77-51-0,approved; withdrawn,WFLSCFISQHLEED-GOEBONIOSA-N,"InChI=1S/C16H24N2/c1-13(2)16(12-17,11-14(3)18(4)5)15-9-7-6-8-10-15/h6-10,13-14H,11H2,1-5H3/t14-,16+/m0/s1",CN(C)[C@@H](C)C[C@@](C#N)(C(C)C)c1ccccc1,C16H24N2,,D08088,12162152,310264911,,,,64873333,,244.382,3.632742921,Antitussive Agents; Central Nervous System Agents; Cough and Cold Preparations; Nitriles; Respiratory System; Respiratory System Agents
DB08946,Iopanoic acid,96-83-3,approved; withdrawn,OIRFJRBSRORBCM-UHFFFAOYSA-N,"InChI=1S/C11H12I3NO2/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14/h4-5H,2-3,15H2,1H3,(H,16,17)",CCC(C(=O)O)Cc1c(I)c(N)c(I)cc1I,C11H12I3NO2,C08217,,3735,310264912,5951,CHEMBL867,,3604,,570.9319,4.578601729,"Benzene Derivatives; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Hydrocarbons, Iodinated; Iodobenzenes; Watersoluble, Hepatotropic X-Ray Contrast Media; X-Ray Contrast Media, Iodinated"
DB08947,Iopamidol,60166-93-0,approved,XQZXYNRDCRIARQ-LURJTMIESA-N,"InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1",C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(c1I)C(=O)NC(CO)CO,C17H22I3N3O8,,D01797,65492,310264913,31711,CHEMBL1200932,,58940,,777.0853,-0.742935373,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodinated Contrast Agents; Iodobenzoates; Radiographic Contrast Agent; Roentgenography; Triiodobenzoic Acids; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB08949,Inositol nicotinate,02-11-6556,approved; withdrawn,MFZCIDXOLLEMOO-GYSGTQPESA-N,"InChI=1S/C42H30N6O12/c49-37(25-7-1-13-43-19-25)55-31-32(56-38(50)26-8-2-14-44-20-26)34(58-40(52)28-10-4-16-46-22-28)36(60-42(54)30-12-6-18-48-24-30)35(59-41(53)29-11-5-17-47-23-29)33(31)57-39(51)27-9-3-15-45-21-27/h1-24,31-36H/t31-,32-,33-,34+,35-,36-",c1ccncc1C(=O)O[C@H]2[C@H](OC(=O)c3cccnc3)[C@@H](OC(=O)c4cccnc4)[C@H](OC(=O)c5cccnc5)[C@H](OC(=O)c6cccnc6)[C@@H]2OC(=O)c7cccnc7,C42H30N6O12,,D01813,3720,347827813,31699,CHEMBL1094982,,16736141,,810.732,3.883754878,"Acids, Heterocyclic; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nicotinic Acid and Derivatives; Other Nutritional Agents; Peripheral Vasodilators; Pyridines; Vasodilating Agents; Vitamin B Complex; Vitamins"
DB08950,Indoramin,26844-12-2,approved; withdrawn,JXZZEXZZKAWDSP-UHFFFAOYSA-N,"InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)",c1ccccc1C(=O)NC2CCN(CC2)CCc3c[nH]c(c34)cccc4,C22H25N3O,,D04531,33625,310264915,135470,CHEMBL279516,,31014,50033113,347.4534,3.186264618,"Acids, Carbocyclic; Adrenergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Amides; Antiadrenergic Agents, Peripherally Acting; Antihypertensive Agents; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Indoles; Neurotransmitter Agents; Peripheral alpha-1 blockers; Piperidines"
DB08954,Ifenprodil,23210-56-2,approved; investigational; withdrawn,UYNVMODNBIQBMV-UHFFFAOYSA-N,"InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3",Oc1ccc(cc1)C(O)C(C)N2CCC(CC2)Cc3ccccc3,C21H27NO2,,D08064,3689,310264919,93829,CHEMBL305187,,3561,50083351,325.4446,3.571001446,"Adrenergic Agents; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Anti-Parkinson Drugs; Anticonvulsants; Cardiovascular Agents; Cardiovascular System; Central Nervous System Depressants; Excitatory Amino Acid Agents; Excitatory Amino Acid Antagonists; Experimental Unapproved Treatments for COVID-19; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Neurotransmitter Agents; NMDA Receptor Antagonists; Peripheral Vasodilators; Receptors, N-Methyl-D-Aspartate; Vasodilating Agents"
DB08958,Hexetidine,141-94-6,approved; investigational,DTOUUUZOYKYHEP-UHFFFAOYSA-N,"InChI=1S/C21H45N3/c1-6-10-12-19(8-3)14-23-16-21(5,22)17-24(18-23)15-20(9-4)13-11-7-2/h19-20H,6-18,22H2,1-5H3",CCCCC(CC)CN(CC1(C)N)CN(C1)CC(CC)CCCC,C21H45N3,,D07068,3607,310264923,94339,CHEMBL144673,,3481,,339.6021,5.735905589,"Alimentary Tract and Metabolism; Anti-Infective Agents; Anti-Infective Agents, Local; Antifungal Agents; Antiinfectives and Antiseptics for Local Oral Treatment; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Pyrimidines; Stomatological Preparations"
DB08964,Gemeprost,64318-79-2,approved; withdrawn,KYBOHGVERHWSSV-VNIVIJDLSA-N,"InChI=1S/C23H38O5/c1-5-6-15-23(2,3)21(26)14-13-18-17(19(24)16-20(18)25)11-9-7-8-10-12-22(27)28-4/h10,12-14,17-18,20-21,25-26H,5-9,11,15-16H2,1-4H3/b12-10+,14-13+/t17-,18-,20-,21-/m1/s1",CCCCC(C)(C)[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC/C=C/C(=O)OC,C23H38O5,,D02073,5282237,310264927,135626,CHEMBL1908315,,4445416,,394.552,4.707216349,"Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Autacoids; Biological Factors; Drugs that are Mainly Renally Excreted; Eicosanoids; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Genito Urinary System and Sex Hormones; Inflammation Mediators; Lipids; Prostaglandins; Prostaglandins E; Prostaglandins E, Synthetic; Reproductive Control Agents; Uterotonic agents"
DB08965,Fusafungine,1393-87-9,approved; withdrawn,MIZMDSVSLSIMSC-OGLSAIDSSA-N,"InChI=1S/C33H57N3O9/c1-16(2)22-31(40)43-26(20(9)10)29(38)35(14)24(18(5)6)33(42)45-27(21(11)12)30(39)36(15)23(17(3)4)32(41)44-25(19(7)8)28(37)34(22)13/h16-27H,1-15H3/t22-,23-,24-,25?,26?,27?/m0/s1",CC(C)C1OC(=O)[C@H](C(C)C)N(C)C(=O)C(C(C)C)OC(=O)[C@H](C(C)C)N(C)C(=O)C(C(C)C)OC(=O)[C@H](C(C)C)N(C)C1=O,C33H57N3O9,,,3084092,310264928,,,,2341206,,639.8204,4.964367353,"Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Macrocyclic Compounds; Peptides; Peptides, Cyclic; Polycyclic Compounds; Respiratory System; Throat Preparations"
DB08966,Fursultiamine,804-30-8,approved,JTLXCMOFVBXEKD-FOWTUZBSSA-N,"InChI=1S/C17H26N4O3S2/c1-12(16(5-6-22)26-25-10-15-4-3-7-24-15)21(11-23)9-14-8-19-13(2)20-17(14)18/h8,11,15,22H,3-7,9-10H2,1-2H3,(H2,18,19,20)/b16-12+",Cc1ncc(c(n1)N)CN(C=O)/C(C)=C(\CCO)SSCC2CCCO2,C17H26N4O3S2,,,3002119,310264929,135636,CHEMBL1740659,,2273321,,398.543,-0.466706055,"Azoles; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Micronutrients; Physiological Phenomena; Pyrimidines; Sulfur Compounds; Thiazoles; Vitamin B Complex; Vitamins"
DB08967,Dimetotiazine,7456-24-8,approved,VWNWVCJGUMZDIU-UHFFFAOYSA-N,"InChI=1S/C19H25N3O2S2/c1-14(20(2)3)13-22-16-8-6-7-9-18(16)25-19-11-10-15(12-17(19)22)26(23,24)21(4)5/h6-12,14H,13H2,1-5H3",CN(C)S(=O)(=O)c(c1)ccc(c12)Sc3c(cccc3)N2CC(C)N(C)C,C19H25N3O2S2,,,3089,310264930,135616,CHEMBL346977,,2979,,391.55,3.340953753,"Analgesics; Antimigraine Preparations; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Nervous System; Neurotransmitter Agents; Sulfur Compounds"
DB08971,Fluocortolone,152-97-6,approved; withdrawn,GAKMQHDJQHZUTJ-ULHLPKEOSA-N,"InChI=1S/C22H29FO4/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-21(15,2)20(13)17(26)9-22(14,3)19(11)18(27)10-24/h4-5,7,11,13-14,16-17,19-20,24,26H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20-,21+,22+/m1/s1",OCC(=O)[C@H]1[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4,C22H29FO4,,,9053,310264934,135581,CHEMBL251634,,8701,,376.4617,1.967714851,"Adrenal Cortex Hormones; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Anti-Inflammatory Agents; Cardiovascular System; Corticosteroids; Corticosteroids for Systemic Use, Plain; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Ophthalmologicals; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnanes; Sensory Organs; Steroids; Steroids, Fluorinated; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Vasoprotectives"
DB08973,Fluclorolone acetonide,3693-39-8,approved; withdrawn,NJNWEGFJCGYWQT-VSXGLTOVSA-N,"InChI=1S/C24H29Cl2FO5/c1-20(2)31-19-9-13-14-8-16(27)15-7-12(29)5-6-21(15,3)23(14,26)17(25)10-22(13,4)24(19,32-20)18(30)11-28/h5-7,13-14,16-17,19,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1",OCC(=O)[C@]12[C@H](OC(O1)(C)C)C[C@@H]3[C@]2(C)C[C@H](Cl)[C@@]4(Cl)[C@H]3C[C@H](F)C=5[C@]4(C)C=CC(=O)C5,C24H29Cl2FO5,,,20054914,310264936,135787,CHEMBL461332,,16735814,,487.39,3.422490507,Fused-Ring Compounds; Polycyclic Compounds; Pregnadienes; Pregnanes; Steroids
DB08976,Floctafenine,23779-99-9,approved; withdrawn,APQPGQGAWABJLN-UHFFFAOYSA-N,"InChI=1S/C20H17F3N2O4/c21-20(22,23)15-6-3-5-13-17(8-9-24-18(13)15)25-16-7-2-1-4-14(16)19(28)29-11-12(27)10-26/h1-9,12,26-27H,10-11H2,(H,24,25)",OCC(O)COC(=O)c1ccccc1Nc2ccnc(c23)c(C(F)(F)F)ccc3,C20H17F3N2O4,,,76958517,310264938,31612,CHEMBL2105075,,3243,,406.3552,4.431714738,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Aminobenzoates; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Miscellaneous Analgesics and Antipyretics; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Sensory System Agents"
DB08981,Fenbufen,36330-85-5,approved,ZPAKPRAICRBAOD-UHFFFAOYSA-N,"InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)",OC(=O)CCC(=O)c1ccc(cc1)-c2ccccc2,C16H14O3,,D01344,3335,310264942,31599,CHEMBL277522,,3218,50240374,254.2806,3.002981444,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Carboxylic Acids; Central Nervous System Agents; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Propionates; Sensory System Agents"
DB08987,Etidocaine,36637-18-0,approved,VTUSIVBDOCDNHS-UHFFFAOYSA-N,"InChI=1S/C17H28N2O/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5/h9-11,15H,6-8,12H2,1-5H3,(H,18,20)",CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C,C17H28N2O,C07530,D04095,37497,310264948,4904,CHEMBL492,,34400,50225497,276.417,4.456722392,"Acetanilides; Amides; Amines; Anesthetics; Anesthetics, Local; Anilides; Aniline Compounds; Central Nervous System Agents; Central Nervous System Depressants; Local Anesthetics (Amide); Nervous System; Peripheral Nervous System Agents; Sensory System Agents"
DB08988,Ethoheptazine,77-15-6,approved; withdrawn,WGJHHMKQBWSQIY-UHFFFAOYSA-N,"InChI=1S/C16H23NO2/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16/h4-6,8-9H,3,7,10-13H2,1-2H3",c1ccccc1C2(C(=O)OCC)CCCN(C)CC2,C16H23NO2,,D01435,6469,310264949,135074,CHEMBL170797,,6225,,261.3593,2.900369061,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring"
DB08995,Diosmin,520-27-4,approved; investigational,GZSOSUNBTXMUFQ-YFAPSIMESA-N,"InChI=1S/C28H32O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-8,10,19,21-30,32-37H,9H2,1-2H3/t10-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1",COc1c(O)cc(cc1)-c(o2)cc(=O)c(c23)c(O)cc(c3)O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O,C28H32O15,C10039,D07858,5281613,310264956,4631,CHEMBL231884,,4444932,153267,608.5447,-0.442975904,"Benzopyrans; Capillary Stabilizing Agents; Cardiovascular System; Chromones; Flavones; Flavonoids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans; Vasoprotectives"
DB09009,Articaine,23964-58-1,approved,QTGIAADRBBLJGA-UHFFFAOYSA-N,"InChI=1S/C13H20N2O3S/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4/h7,9,14H,5-6H2,1-4H3,(H,15,16)",CCCNC(C)C(=O)Nc1c(C(=O)OC)scc1C,C13H20N2O3S,,D07468,32170,310264968,91834,CHEMBL1093,,29837,50225496,284.374,3.247281053,"Amides; Anesthetics; Anesthetics, Local; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hyperglycemia-Associated Agents; Local Anesthesia; Local Anesthetics (Amide); Nervous System; Peripheral Nervous System Agents; Sensory System Agents; Sulfur Compounds; Thiophenes"
DB09015,Canrenoic acid,4138-96-9,approved; withdrawn,PBKZPPIHUVSDNM-WNHSNXHDSA-N,"InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1",OC(=O)CC[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(C=C3)=CC(=O)CC4,C22H30O4,,,656615,310264973,50156,CHEMBL1616951,,570976,,358.478,2.930927604,"Agents causing hyperkalemia; Cardiovascular Agents; Cardiovascular System; Diuretics; Fused-Ring Compounds; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Mineralocorticoid Receptor Antagonists; Natriuretic Agents; Polycyclic Compounds; Potassium-Sparing Diuretics; Pregnadienes; Pregnanes; Steroids"
DB09016,Butriptyline,35941-65-2,approved,,, ,,,D07601,21772,347910390,,CHEMBL2110816,,,,NA,5.441353889,"Agents that produce hypertension; Agents that reduce seizure threshold; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzocycloheptenes; Central Nervous System Agents; Central Nervous System Depressants; Histamine Antagonists; Histamine H1 Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Moderate Risk QTc-Prolonging Agents; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Non-Selective Monoamine Reuptake Inhibitors; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tertiary amine tricyclic antidepressants; Tranquilizing Agents"
DB09019,Bromhexine,3572-43-8,approved,OJGDCBLYJGHCIH-UHFFFAOYSA-N,"InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3",C1CCCCC1N(C)Cc2cc(Br)cc(Br)c2N,C14H20Br2N2,,D07542,2442,310264976,77032,CHEMBL253376,,2348,50239965,376.13,4.422492411,"Amines; Aniline Compounds; Cough and Cold Preparations; Cyclohexanes; Cyclohexylamines; Cycloparaffins; Expectorants; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Respiratory System; Respiratory System Agents"
DB09020,Bisacodyl,603-50-9,approved,KHOITXIGCFIULA-UHFFFAOYSA-N,"InChI=1S/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3",CC(=O)Oc1ccc(cc1)C(c2ccccn2)c3ccc(cc3)OC(=O)C,C22H19NO4,,D00245,2391,310264977,3125,CHEMBL942,,2299,61400,361.3906,3.612595577,"Alimentary Tract and Metabolism; Benzene Derivatives; Contact Laxatives; Cresols; Drugs for Constipation; Enemas; Gastrointestinal Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Increased Large Intestinal Motility; Laxatives; Phenols; Stimulation Large Intestine Fluid/Electrolyte Secretion"
DB09026,Aliskiren,173334-57-1,approved; investigational,UXOWGYHJODZGMF-QORCZRPOSA-N,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",COCCCOc1c(OC)ccc(c1)C[C@H](C(C)C)C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N,C30H53N3O6,,D03208,5493444,310264980,601027,CHEMBL1639,C41,4591452,17950,551.7583,3.124512225,"Acids, Acyclic; Agents Acting on the Renin-Angiotensin System; Agents causing hyperkalemia; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Benzene Derivatives; Carboxylic Acids; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dicarboxylic Acids; Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Methyl Ethers; P-glycoprotein substrates; Renin-Inhibitors"
DB09027,Ledipasvir,1256388-51-8,approved,VRTWBAAJJOHBQU-KMWAZVGDSA-N,"InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1",COC(=O)N[C@@H](C(C)C)C(=O)N(CC12CC1)[C@@H](C2)c3nc(c[nH]3)-c(c4)ccc(c45)c6c(C5(F)F)cc(cc6)-c(c7)ccc(c78)[nH]c(n8)[C@H]([C@@H]19)N([C@@H](C9)CC1)C(=O)[C@H](C(C)C)NC(=O)OC,C49H54F2N8O6,,D10442,67505836,310264981,85089,CHEMBL2374220,,29271894,,888.9999,7.177163442,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; Breast Cancer Resistance Protein Inhibitors; Direct Acting Antivirals; Drugs that are Mainly Renally Excreted; Hepatitis C Virus NS5A Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic"
DB09030,Vorapaxar,618385-01-6,approved,ZBGXUVOIWDMMJE-QHNZEKIYSA-N,"InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1",CCOC(=O)N[C@@H](C1)CC[C@H]([C@@H]12)[C@@H]([C@H]3[C@@H](C2)C(=O)O[C@@H]3C)/C=C/c4ccc(cn4)-c5cc(F)ccc5,C29H33FN2O4,,D09765,10077130,310264983,82702,CHEMBL493982,VPX,8252668,50261110,492.5817,5.036946574,"Anticoagulants; Antiplatelet agents; Blood and Blood Forming Organs; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; P-glycoprotein inhibitors; Platelet Aggregation Inhibitors Excl. Heparin; Protease-activated Receptor-1 Antagonist; Protease-activated Receptor-1 Antagonists; Receptor, PAR-1, antagonists & inhibitors; Receptors, Thrombin, antagonists & inhibitors"
DB09031,Miltefosine,58066-85-6,approved; investigational,PQLXHQMOHUQAKB-UHFFFAOYSA-N,"InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3",CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C,C21H46NO4P,,D02494,3599,310264984,75283,CHEMBL125,,3473,50034220,407.576,2.250848523,Alcohols; Amines; Amino Alcohols; Ammonium Compounds; Anti-Infective Agents; Antifungal Agents; Antileishmanial; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Antiparasitic Agents; Antiprotozoals; Ethanolamines; Narrow Therapeutic Index Drugs; Nitrogen Compounds; Onium Compounds; Quaternary Ammonium Compounds; Trimethyl Ammonium Compounds
DB09034,Suvorexant,1030377-33-3,approved; investigational,JYTNQNCOQXFQPK-MRXNPFEDSA-N,"InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1",c1cc(Cl)cc(c12)nc(o2)N3CC[C@@H](C)N(CC3)C(=O)c4c(ccc(C)c4)-n5nccn5,C23H23ClN6O2,,D10082,24965990,310264985,82698,CHEMBL1083659,SUV,24662178,50318701,450.93,4.0394,"Azoles; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Miscellaneous Anxiolytics Sedatives and Hypnotics; Nervous System; Neurotransmitter Agents; Orexin Receptor Antagonists; P-glycoprotein inhibitors; Psycholeptics; Sleep Aids, Pharmaceutical"
DB09038,Empagliflozin,864070-44-0,approved,OBWASQILIWPZMG-QZMOQZSNSA-N,"InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1",OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c2ccc(Cl)c(c2)Cc3ccc(cc3)O[C@H]4CCOC4,C23H27ClO7,,D10459,11949646,310264986,82720,CHEMBL2107830,,10123957,150162,450.91,1.655318706,"Alimentary Tract and Metabolism; BCRP/ABCG2 Substrates; Benzene Derivatives; Blood Glucose Lowering Agents; Diuretics; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Glycosides; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; Sodium-glucose co-transporter 2 (SGLT2) inhibitors; Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; UGT1A3 substrates; UGT1A9 Substrates; UGT2B7 substrates"
DB09039,Eliglustat,491833-29-5,approved,FJZZPCZKBUKGGU-AUSIDOKSSA-N,"InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1",CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c(c2)ccc(c23)OCCO3,C23H36N2O4,,D09893,23652731,310264987,82752,CHEMBL2110588,,28475348,,404.551,3.208246669,"Alimentary Tract and Metabolism; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Gaucher Disease; Glucosylceramide Synthase Inhibitor; Glucosylceramide Synthase Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Other Miscellaneous Therapeutic Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; QTc Prolonging Agents; Various Alimentary Tract and Metabolism Products"
DB09040,Efinaconazole,164650-44-6,approved,NFEZZTICAUWDHU-RDTXWAMCSA-N,"InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1",C=C1CCN(CC1)[C@H](C)[C@](O)(Cn2cncn2)c3c(F)cc(F)cc3,C18H22F2N4O,,D10021,489181,310264988,82718,CHEMBL2103877,,428538,,348.398,2.242855958,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Azole Antifungals; Azoles; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazole and Triazole Derivatives"
DB09041,Tavaborole,174671-46-6,approved; investigational,LFQDNHWZDQTITF-UHFFFAOYSA-N,"InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2",OB1OCc(c12)cc(F)cc2,C7H6BFO2,,D10169,11499245,310264989,77942,CHEMBL443052,,9674047,50370987,151.93,2.2372,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Oxaborole Antifungal; Protein Synthesis Inhibitors"
DB09042,Tedizolid phosphate,856867-55-5,approved,QCGUSIANLFXSGE-GFCCVEGCSA-N,"InChI=1S/C17H16FN6O6P/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(30-17(24)25)9-29-31(26,27)28/h2-7,12H,8-9H2,1H3,(H2,26,27,28)/t12-/m1/s1",Cn1nnc(n1)-c2ccc(cn2)-c3ccc(cc3F)N4C[C@@H](OC4=O)COP(=O)(O)O,C17H16FN6O6P,,D09686,11476460,310264990,83326,CHEMBL2105669,,9651289,50017198,450.323,1.968414354,"Anti-Bacterial Agents; Anti-Infective Agents; Antidepressive Agents; Azoles; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Myelosuppressive Agents; Organophosphorus Compounds; Oxazolidinone Antibacterial; Oxazolidinones; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators"
DB09047,Finafloxacin,209342-40-5,approved; investigational,FYMHQCNFKNMJAV-HOTGVXAUSA-N,"InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1",O1CCN[C@H]([C@@H]12)CN(C2)c(c3C#N)c(F)cc(c34)c(=O)c(C(=O)O)cn4C5CC5,C20H19FN4O4,,D10575,11567473,310264991,85176,CHEMBL1908370,,9742243,,398.394,-1.0753612,"Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antineoplastic Agents; Enzyme Inhibitors; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Quinolines; Quinolone Antimicrobial; Quinolones; Renal Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB09048,Netupitant,290297-26-6,approved; investigational,WAXQNWCZJDTGBU-UHFFFAOYSA-N,"InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3",FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(C)(C)C(=O)N(C)c2cnc(N3CCN(C)CC3)cc2-c4ccccc4C,C30H32F6N4O,,D10572,6451149,310264992,85155,CHEMBL206253,GAW,4953629,50178574,578.603,7.256654907,"Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Netupitant and prodrug; Neurokinin 1 Antagonists; P-glycoprotein inhibitors; Substance P/Neurokinin-1 Receptor Antagonist"
DB09049,Naloxegol,854601-70-0,approved,XNKCCCKFOQNXKV-ZRSCBOBOSA-N,"InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1",COCCOCCOCCOCCOCCOCCOCCO[C@H]([C@H]1[C@]234)CC[C@@]3(O)[C@H](N(CC4)CC=C)Cc5c2c(O1)c(O)cc5,C34H53NO11,,D10479,56959087,310264993,82975,CHEMBL2219418,,28651656,,651.794,1.356417584,"Alcohols; Alimentary Tract and Metabolism; Alkaloids; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Constipation; Ethylene Glycols; Glycols; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Macromolecular Substances; Manufactured Materials; Miscellaneous GI Drugs; Narcotics; Opiate Alkaloids; Opioid Antagonists; Opioids; Peripheral Nervous System Agents; Peripheral Opioid Receptor Antagonists; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Polymers; Sensory System Agents"
DB09050,Ceftolozane,689293-68-3,approved; investigational,JHFNIHVVXRKLEF-DCZLAGFPSA-N,"InChI=1S/C23H30N12O8S2/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42)/b31-11-/t12-,18-/m1/s1",NCCNC(=O)Nc1c(N)n(C)[n+](c1)CC(CS2)=C(C([O-])=O)N([C@H]23)C(=O)[C@H]3NC(=O)/C(=N\OC(C)(C)C(=O)O)c4nsc(n4)N,C23H30N12O8S2,,D10097,53234134,310264994,134719,CHEMBL2103872,,25999973,,666.69,-8.68119589,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azabicyclo Compounds; beta-Lactams; Bicyclo Compounds; Bicyclo Compounds, Heterocyclic; Bridged Compounds; Cephalosporins; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Polycyclic Compounds; Sulfur Compounds; Thiazines"
DB09053,Ibrutinib,936563-96-1,approved,XYFPWWZEPKGCCK-GOSISDBHSA-N,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",C=CC(=O)N1C[C@@H](CCC1)n(c(c23)ncnc3N)nc2-c4ccc(cc4)Oc5ccccc5,C25H24N6O2,,D10223,24821094,310264995,76612,CHEMBL1873475,1.00E+08,26637187,50357312,440.507,3.630226299,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB09054,Idelalisib,870281-82-6,approved,IFSDAJWBUCMOAH-HNNXBMFYSA-N,"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1",n1c[nH]c(c12)ncnc2N[C@@H](CC)c(nc(c34)cccc4F)n(c3=O)-c5ccccc5,C22H18FN7O,,D10560,11625818,310264996,82701,CHEMBL2216870,40L,9800565,150175,415.432,3.361083963,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Kinase Inhibitor; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Quinazolines; UGT1A4 Inhibitors; UGT1A4 substrates"
DB09055,Acipimox,51037-30-0,approved; investigational,DJQOOSBJCLSSEY-UHFFFAOYSA-N,"InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10)",Cc1[n+]([O-])cc(nc1)C(=O)O,C6H6N2O3,,D07190,5310993,347827819,94688,CHEMBL345714,,4470534,50208130,154.125,-2.521175933,"Agents Causing Muscle Toxicity; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypolipidemic Agents; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Nicotinic Acid and Derivatives; Noxae; Toxic Actions"
DB09056,Amorolfine,78613-35-1,approved; investigational,MQHLMHIZUIDKOO-AYHJJNSGSA-N,"InChI=1S/C21H35NO/c1-7-21(5,6)20-10-8-19(9-11-20)12-16(2)13-22-14-17(3)23-18(4)15-22/h8-11,16-18H,7,12-15H2,1-6H3/t16?,17-,18+",C[C@@H]1CN(C[C@@H](O1)C)CC(C)Cc2ccc(cc2)C(C)(C)CC,C21H35NO,,,,,599440,CHEMBL489411,,49010,,317.517,5.617119813,"Anti-Infective Agents; Antifungal Agents; Antifungals for Dermatological Use; Antifungals for Topical Use; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Oxazines"
DB09059,Atosiban,90779-69-4,approved; investigational,VWXRQYYUEIYXCZ-OBIMUBPZSA-N,"InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1",CCOc1ccc(cc1)C[C@@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CSSCCC(=O)N2)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N,C43H67N11O12S2,,D03008,,,135899,CHEMBL382301,,4470550,50177595,994.19,-4.606656256,"Amino Acids, Peptides, and Proteins; Genito Urinary System and Sex Hormones; Hormone Antagonists; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptide Hormones; Peptides; Pituitary Hormones; Pituitary Hormones, Posterior; Reproductive Control Agents; Tocolytic Agents"
DB09060,Avibactam,1192500-31-4,approved,NDCUAPJVLWFHHB-UHNVWZDZSA-N,"InChI=1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1",[C@@H]12CC[C@@H](C(=O)N)N(C1)C(=O)N2OS(=O)(=O)O,C7H11N3O6S,,,9835049,310264997,85984,CHEMBL1689063,,8010770,50339145,265.24,-3.606539515,"Anti-Infective Agents; Aza Compounds; beta-Lactamase Inhibitors; Bicyclo Compounds, Heterocyclic; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; OAT3/SLC22A8 Substrates"
DB09061,Cannabidiol,13956-29-1,approved; investigational,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,"InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1",CCCCCc1cc(O)c(c(O)c1)[C@@H]2C=C(C)CC[C@H]2C(C)=C,C21H30O2,C07578,,644019,347827820,69478,CHEMBL190461,P0T,559095,50121429,314.469,6.325201127,Agents producing tachycardia; Agents that produce hypertension; Anticonvulsants; Antidepressive Agents; BCRP/ABCG2 Inhibitors; Cannabinoids and similars; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hydrocarbons; Nervous System; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Serotonin Agents; Serotonin Receptor Agonists; Terpenes
DB09063,Ceritinib,1032900-25-6,approved,VERWOWGGCGHDQE-UHFFFAOYSA-N,"InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)",C1CNCCC1c2cc(OC(C)C)c(cc2C)Nc3ncc(Cl)/c([nH]3)=N\c4ccccc4S(=O)(=O)C(C)C,C28H36ClN5O3S,,D10551,57379345,310264998,78432,CHEMBL2403108,4MK,29315053,50436850,558.135,5.805270894,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Bradycardia-Causing Agents; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hyperglycemia-Associated Agents; Kinase Inhibitor; Moderate Risk QTc-Prolonging Agents; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Protein Kinase Inhibitors; QTc Prolonging Agents; Receptor Protein-Tyrosine Kinases, antagonists & inhibitors; Sulfur Compounds; Tyrosine Kinase Inhibitors"
DB09064,Ciprofibrate,52214-84-3,approved; investigational,KPSRODZRAIWAKH-UHFFFAOYSA-N,"InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)",OC(=O)C(C)(C)Oc1ccc(cc1)C(C2)C2(Cl)Cl,C13H14Cl2O3,,D03521,,,50867,CHEMBL557555,,2661,50371235,289.15,3.622386258,"Acids, Acyclic; Agents Causing Muscle Toxicity; Benzene Derivatives; Butyrates; Carboxylic Acids; Carcinogens; Cardiovascular System; Ethers; Fatty Acids; Fatty Acids, Volatile; Fibric Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypolipidemic Agents; Isobutyrates; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Lipids; Noxae; Peroxisome Proliferators; Phenols; Phenyl Ethers; Toxic Actions"
DB09065,Cobicistat,1004316-88-4,approved,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,"InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1",CC(C)c1nc(cs1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@@H](Cc3ccccc3)CC[C@H](Cc4ccccc4)NC(=O)OCc5cncs5,C40H53N7O5S2,,D09881,25151504,310264999,72291,CHEMBL2095208,,25084912,50447471,776.03,4.98528028,"Acids, Acyclic; Anti-HIV Agents; Anti-Infective Agents; Antiinfectives for Systemic Use; Azoles; BCRP/ABCG2 Inhibitors; Breast Cancer Resistance Protein Inhibitors; Carbamates; Carboxylic Acids; Chemically-Induced Disorders; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strong); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strong); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Metabolic Side Effects of Drugs and Substances; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; Other Miscellaneous Therapeutic Agents; P-glycoprotein inhibitors; Sulfur Compounds; Thiazoles"
DB09067,Corticorelin ovine triflutate,121249-14-7,approved,QEEJLLNYQOBRRM-KSHGRFHLSA-N,"InChI=1S/C205H339N59O63S/c1-30-104(21)159(198(322)225-106(23)163(214)287)259-193(317)142(87-157(285)286)253-184(308)132(77-99(11)12)246-182(306)130(75-97(7)8)244-172(296)117(46-36-38-67-207)231-170(294)118(47-39-68-221-204(215)216)233-189(313)139(84-151(213)274)251-194(318)143(91-266)256-188(312)137(82-113-88-219-93-223-113)241-165(289)108(25)227-169(293)120(51-58-147(209)270)234-173(297)121(52-59-148(210)271)229-164(288)107(24)228-179(303)128(73-95(3)4)243-176(300)123(54-61-150(212)273)236-190(314)140(85-155(281)282)242-166(290)109(26)226-168(292)116(45-35-37-66-206)239-200(324)161(110(27)268)261-178(302)126(65-72-328-29)238-174(298)124(55-62-152(275)276)237-181(305)134(79-101(15)16)254-197(321)158(103(19)20)258-177(301)125(56-63-153(277)278)235-171(295)119(48-40-69-222-205(217)218)232-180(304)129(74-96(5)6)245-183(307)131(76-98(9)10)247-187(311)138(83-114-89-220-94-224-114)250-186(310)136(81-112-43-33-32-34-44-112)255-201(325)162(111(28)269)262-192(316)135(80-102(17)18)248-191(315)141(86-156(283)284)252-185(309)133(78-100(13)14)249-195(319)144(92-267)257-199(323)160(105(22)31-2)260-196(320)145-49-41-70-263(145)203(327)146-50-42-71-264(146)202(326)127(57-64-154(279)280)240-175(299)122(53-60-149(211)272)230-167(291)115(208)90-265/h32-34,43-44,88-89,93-111,115-146,158-162,265-269H,30-31,35-42,45-87,90-92,206-208H2,1-29H3,(H2,209,270)(H2,210,271)(H2,211,272)(H2,212,273)(H2,213,274)(H2,214,287)(H,219,223)(H,220,224)(H,225,322)(H,226,292)(H,227,293)(H,228,303)(H,229,288)(H,230,291)(H,231,294)(H,232,304)(H,233,313)(H,234,297)(H,235,295)(H,236,314)(H,237,305)(H,238,298)(H,239,324)(H,240,299)(H,241,289)(H,242,290)(H,243,300)(H,244,296)(H,245,307)(H,246,306)(H,247,311)(H,248,315)(H,249,319)(H,250,310)(H,251,318)(H,252,309)(H,253,308)(H,254,321)(H,255,325)(H,256,312)(H,257,323)(H,258,301)(H,259,317)(H,260,320)(H,261,302)(H,262,316)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H4,215,216,221)(H4,217,218,222)/t104-,105-,106-,107-,108-,109-,110+,111+,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,158-,159-,160-,161-,162-/m0/s1",NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H](N)CO,C205H339N59O63S,,D03592,16132344,310265000,65307,CHEMBL1201591,,17289003,,4670.38,-27.32351102,"Amino Acids, Peptides, and Proteins; Diagnostic Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Nerve Tissue Proteins; Neuropeptides; Peptide Hormones; Peptides; Pituitary Hormone-Releasing Hormones; Proteins; Tests for Pituitary Function"
DB09068,Vortioxetine,508233-74-7,approved; investigational,YQNWZWMKLDQSAC-UHFFFAOYSA-N,"InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3",Cc1ccc(c(C)c1)Sc2ccccc2N3CCNCC3,C18H22N2S,,D10184,71768094,310265001,76016,CHEMBL2104993,,8141643,50400902,298.45,4.760953559,"Agents that produce hypertension; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Piperazines; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Agonists; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB09069,Trimetazidine,5011-34-7,approved; investigational,UHWVSEOVJBQKBE-UHFFFAOYSA-N,"InChI=1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3",COc1c(OC)c(OC)c(cc1)CN2CCNCC2,C14H22N2O3,,D01606,21109,310265002,94789,CHEMBL203266,,19853,80613,266.341,0.905700428,"Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Piperazines; Vasodilating Agents"
DB09070,Tibolone,5630-53-5,approved; investigational,WZDGZWOAQTVYBX-XOINTXKNSA-N,"InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1",C#C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)C4=C(C[C@H]3C)CC(=O)CC4,C21H28O2,,D01639,444008,347827821,32223,CHEMBL2103774,,392038,,312.453,3.100844063,"Anabolic Agents; Antineoplastic Agents, Hormonal; Cardiovascular Agents; Estrogen Receptor Modulators; Estrogens; Estrogens,antiestrogens,estrogen Agonist-antagonists; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormone Antagonists; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Norpregnanes; Norsteroids; Polycyclic Compounds; Sex Hormones and Modulators of the Genital System; Steroids"
DB09071,Tasimelteon,609799-22-6,approved; investigational,PTOIAAWZLUQTIO-GXFFZTMASA-N,"InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1",CCC(=O)NC[C@@H]1C[C@H]1c2cccc(c23)OCC3,C15H19NO2,,D09388,10220503,310265003,79042,CHEMBL2103822,,8395995,,245.322,1.977541168,"Central Nervous System Depressants; Cycloparaffins; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hypnotics and Sedatives; Macrocyclic Compounds; Melatonin Receptor Agonists; Nervous System; Polycyclic Compounds; Psycholeptics; Receptors, Melatonin, agonists"
DB09072,Sodium oxybate,502-85-2,approved,XYGBKMMCQDZQOZ-UHFFFAOYSA-M,"InChI=1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1",OCCCC([O-])=O,C4H7NaO3,,,23663870,347827822,,CHEMBL1200682,,9983,,126.087,-0.514919819,"Acids, Acyclic; Adjuvants, Anesthesia; Anesthetics; Anesthetics, General; Anesthetics, Intravenous; Butyrates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Fatty Acids; Fatty Acids, Volatile; Hydroxy Acids; Hydroxybutyrates; Lipids; Miscellaneous Central Nervous System Agents; Nervous System"
DB09073,Palbociclib,571190-30-2,approved; investigational,AHJRHEGDXFFMBM-UHFFFAOYSA-N,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",C1CCCC1n2c(=O)c(C(=O)C)c(C)c(c23)cnc(n3)Nc4ncc(cc4)N5CCNCC5,C24H29N7O2,,D10372,5330286,310265004,85993,CHEMBL189963,LQQ,4487437,6309,447.5328,2.770733064,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cyclin-Dependent Kinases, antagonists & inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OCT1 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors"
DB09074,Olaparib,763113-22-0,approved,FDLYAMZZIXQODN-UHFFFAOYSA-N,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",c1cccc(c12)c(=O)[nH]nc2Cc3ccc(F)c(c3)C(=O)N4CCN(CC4)C(=O)C5CC5,C24H23FN4O3,,D09730,,,83766,CHEMBL521686,09L,23343272,27566,434.4628,1.963878423,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; Poly(ADP-ribose) Polymerase Inhibitors; Pyridazines"
DB09075,Edoxaban,480449-70-5,approved,HGVDHZBSSITLCT-JLJPHGGASA-N,"InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1",CN(C1)CCc(c12)nc(s2)C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc4ncc(Cl)cc4,C24H30ClN7O4S,,D09546,10280735,310265005,85973,CHEMBL1269025,,8456212,50328731,548.06,0.901659543,"Anticoagulants; Antithrombins; Azoles; Blood and Blood Forming Organs; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Factor Xa Inhibitors; Fibrinolytic Agents; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; P-glycoprotein substrates; Protease Inhibitors; Serine Protease Inhibitors; Sulfur Compounds"
DB09076,Umeclidinium,869185-19-3,approved,FVTWTVQXNAJTQP-UHFFFAOYSA-N,"InChI=1S/C29H34NO2/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25/h1-15,31H,16-24H2/q+1",c1ccccc1C(O)(c2ccccc2)C34CC[N+](CC3)(CC4)CCOCc5ccccc5,C29H34NO2,,D10180,11519070,347827824,79041,CHEMBL1187833,,9693858,50267614,428.595,0.68222118,"Adrenergics, Inhalants; Agents producing tachycardia; Agents to Treat Airway Disease; Anticholinergic Agents; Antimuscarinics Antispasmodics; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Muscarinic Antagonists; P-glycoprotein substrates; Pulmonary Disease, Chronic Obstructive, drug therapy; Respiratory System"
DB09078,Lenvatinib,417716-92-8,approved; investigational,WOSKHXYHFSIKNG-UHFFFAOYSA-N,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4,C21H19ClN4O4,,D09919,9823820,310265006,85994,CHEMBL1289601,LEV,7999567,50331094,426.86,2.521606795,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Benzene Derivatives; BSEP/ABCB11 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Kinase Inhibitor; Moderate Risk QTc-Prolonging Agents; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; QTc Prolonging Agents; Receptor Tyrosine Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB09079,Nintedanib,656247-17-5,approved,XZXHXSATPCNXJR-ZIADKAODSA-N,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5,C31H33N5O4,,D10481,9809715,310265007,85164,CHEMBL502835,XIN,7985471,50026612,539.6248,2.789856603,"Antifibrotic Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; OCT1 inhibitors; OCT1 substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; UGT1A1 Substrates"
DB09080,Olodaterol,868049-49-4,approved,COUYJEVMBVSIHV-SFHVURJKSA-N,"InChI=1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1",COc1ccc(cc1)CC(C)(C)NC[C@H](O)c(cc(O)c2)c(c23)OCC(=O)N3,C21H26N2O5,,D10145,11504295,310265008,82700,CHEMBL605846,,9679097,,386.448,1.193140701,"Adrenergic Agonists; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Long-acting beta-adrenoceptor agonists; Oxazines; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists"
DB09081,Idebenone,58186-27-9,approved; investigational,VMHWZDULLBLUMS-UHFFFAOYSA-N,"InChI=1S/C21H34O5/c1-16-17(19(24)21(26-3)20(25-2)18(16)23)14-12-10-8-6-4-5-7-9-11-13-15-22/h22H,4-15H2,1-3H3",COC1=C(OC)C(=O)C(=C(C)C1=O)CCCCCCCCCCCCO,C21H34O5,,D01750,12881464,310265009,31687,CHEMBL252556,,14944546,,366.498,4.457130904,"Antioxidants; Benzoquinones; Coenzymes; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Enzymes and Coenzymes; Nervous System; Protective Agents; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Quinones"
DB09082,Vilanterol,503068-34-6,approved,DAFYYTQWSAWIGS-DEOSSOPVSA-N,"InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1",OCc1c(O)ccc(c1)[C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl,C24H33Cl2NO5,,D09696,10184665,347827825,75037,CHEMBL1198857,,8360167,50416060,486.43,3.598011516,"Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Benzene Derivatives; Benzyl Compounds; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Chlorinated; Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Immunosuppressive Agents; Long-acting beta-adrenoceptor agonists; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB09083,Ivabradine,155974-00-8,approved,ACRHBAYQBXXRTO-OAQYLSRUSA-N,"InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1",COc(c1)c(OC)cc(c12)[C@H](C2)CN(C)CCCN(C(=O)C3)CCc(c34)cc(OC)c(c4)OC,C27H36N2O5,,D07165,132999,310265010,85966,CHEMBL471737,,117373,50326992,468.594,2.722445298,"Benzazepines; Bradycardia-Causing Agents; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists; Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker; Miscellaneous Cardiac Drugs; QTc Prolonging Agents"
DB09084,Benzydamine,642-72-8,approved,CNBGNNVCVSKAQZ-UHFFFAOYSA-N,"InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3",CN(C)CCCOc1nn(c(c12)cccc2)Cc3ccccc3,C19H23N3O,,,12555,310265011,94563,CHEMBL12610,,12036,50103598,309.413,3.659847397,"Agents causing hyperkalemia; Agents that produce hypertension; Alimentary Tract and Metabolism; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antiinflammatory Products for Vaginal Administration; Azoles; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indazoles; Mouthwashes and Gargles; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Pyrazoles; Respiratory System; Stomatological Preparations; Throat Preparations; Topical Products for Joint and Muscular Pain"
DB09085,Tetracaine,94-24-6,approved; vet_approved,GKCBAIGFKIBETG-UHFFFAOYSA-N,"InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3",CCCCNc1ccc(cc1)C(=O)OCCN(C)C,C15H24N2O2,C07526,D00551,5411,310265012,9468,CHEMBL698,TE4,5218,50017659,264.369,2.792044444,"Acids, Carbocyclic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Aminobenzoates; Anesthetics; Anesthetics for Topical Use; Anesthetics, General; Anesthetics, Local; Antipruritics and Local Anesthetics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Benzene Derivatives; Benzoates; Carboxylic Acids; Cardiovascular System; Central Nervous System Agents; Central Nervous System Depressants; Dental Agents; Dermatologicals; Esters of Aminobenzoic Acid; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Local Anesthesia; Local Anesthetics (Ester); Nervous System; Ophthalmologicals; para-Aminobenzoates; Peripheral Nervous System Agents; Sensory Organs; Sensory System Agents; Vasoprotectives"
DB09086,Eugenol,97-53-0,approved,RRAFCDWBNXTKKO-UHFFFAOYSA-N,"InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3",COc1c(O)ccc(c1)CC=C,C10H12O2,C10453,,3314,310265013,4917,CHEMBL42710,EOL,13876103,50164168,164.2011,2.610579962,"Acids, Carbocyclic; Anti-Infective Agents; Caffeic Acids; Carboxylic Acids; Cell-mediated Immunity; Cinnamates; Compounds used in a research, industrial, or household setting; Increased Histamine Release; Solvents; Standardized Chemical Allergen"
DB09087,Potassium alum,10043-67-1,approved,GRLPQNLYRHEGIJ-UHFFFAOYSA-J,"InChI=1S/Al.K.2H2O4S/c;;2*1-5(2,3)4/h;;2*(H2,1,2,3,4)/q+3;+1;;/p-4",[O-]S([O-])(=O)=O,AlKO8S2,,,24856,310265014,86463,,,23239,,258.205,-0.841552023,"Acids; Acids, Noncarboxylic; Adjuvants, Immunologic; Aluminium Compounds; Anions; Electrolytes; Immunologic Factors; Ions; Metal cations; Metal divalent cations; Potassium Salt; Sulfates; Sulfur Acids; Sulfur Compounds; Sulfuric Acids"
DB09088,Amylocaine,644-26-8,approved; withdrawn,FDMBBCOBEAVDAO-UHFFFAOYSA-N,"InChI=1S/C14H21NO2/c1-5-14(2,11-15(3)4)17-13(16)12-9-7-6-8-10-12/h6-10H,5,11H2,1-4H3",CN(C)CC(C)(CC)OC(=O)c1ccccc1,C14H21NO2,C14169,D07454,10767,310265015,34981,CHEMBL1740065,,10312,,235.327,3.21504139,"Acids, Carbocyclic; Benzene Derivatives; Carboxylic Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic"
DB09089,Trimebutine,39133-31-8,approved,LORDFXWUHHSAQU-UHFFFAOYSA-N,"InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3",c1ccccc1C(CC)(N(C)C)COC(=O)c2cc(OC)c(OC)c(c2)OC,C22H29NO5,,,5573,310265016,94458,CHEMBL190044,,5372,83417,387.476,4.109692756,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents producing tachycardia; Alimentary Tract and Metabolism; Antiarrhythmic agents; Anticholinergic Agents; Antimuscarinics Antispasmodics; Autonomic Agents; Benzene Derivatives; Benzoates; Bradycardia-Causing Agents; Calcium Channel Blockers; Carboxylic Acids; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Functional Gastrointestinal Disorders; Drugs that are Mainly Renally Excreted; Ethers; Gastrointestinal Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoate Ethers; Hydroxybenzoates; Muscarinic Antagonists; Parasympatholytics; Peripheral Nervous System Agents; Phenols; Phenyl Ethers; Potential QTc-Prolonging Agents; Prokinetic Agents; QTc Prolonging Agents; Synthetic Anticholinergics, Esters With Tertiary Amino Group"
DB09090,Pinaverium,59995-65-2,approved,DDHUTBKXLWCZCO-UHFFFAOYSA-N,"InChI=1S/C26H41BrNO4/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27/h15,17,19,21-22H,5-14,16,18H2,1-4H3/q+1",COc1c(OC)cc(c(Br)c1)C[N+]2(CCOCC2)CCOCCC(CCC34)C(C3)C4(C)C,C26H41BrNO4,,,40704,310265017,135811,CHEMBL1909324,,37182,50101975,511.52,0.673948145,"Agents causing hyperkalemia; Alimentary Tract and Metabolism; Antiarrhythmic agents; Autonomic Agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Miscellaneous GI Drugs; Oxazines; Parasympatholytics; Peripheral Nervous System Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Vasodilating Agents"
DB09091,Tixocortol,61951-99-3,approved; withdrawn,YWDBSCORAARPPF-VWUMJDOOSA-N,"InChI=1S/C21H30O4S/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-26)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25-26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",SCC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)CC4,C21H30O4S,,,162955,310265018,63560,,,143053,,378.53,2.318979902,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Alimentary Tract and Metabolism; Anti-Allergic Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Cell-mediated Immunity; Corticosteroids; Corticosteroids Acting Locally; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydroxycorticosteroids; Immunosuppressive Agents; Increased Histamine Release; Intestinal Antiinflammatory Agents; Nasal Preparations; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Respiratory System; Standardized Chemical Allergen; Steroids"
DB09092,Xanthinol,2530-97-4,approved; withdrawn,DSFGXPJYDCSWTA-UHFFFAOYSA-N,"InChI=1S/C13H21N5O4/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2/h8-9,19-20H,4-7H2,1-3H3",OCCN(C)CC(O)Cn1cnc(c12)n(C)c(=O)n(c2=O)C,C13H21N5O4,,,9913,310265019,94314,CHEMBL1624126,,9526,,311.342,-1.847438023,"Acids, Heterocyclic; Alkaloids; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nicotinic Acids; Peripheral Vasodilators; Purine Derivatives; Purines; Purinones; Pyridines; Vasodilating Agents"
DB09093,Chlortetracycline,57-62-5,approved; investigational; vet_approved,CYDMQBQPVICBEU-XRNKAMNCSA-N,"InChI=1S/C22H23ClN2O8/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21/h4-5,7-8,15,26,28-29,32-33H,6H2,1-3H3,(H2,24,31)/t7-,8-,15-,21-,22-/m0/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c([C@@]3(C)O)c(Cl)ccc4O,C22H23ClN2O8,C06571,D07689,54708735,310265020,27644,CHEMBL404520,CTC,10469370,,478.88,-2.898117049,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antibiotics for Topical Use; Antiinfectives and Antiseptics for Local Oral Treatment; Antiinfectives for Systemic Use; Antiparasitic Agents; Antiprotozoals; Dermatologicals; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; Ophthalmologicals; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Protein Synthesis Inhibitors; Sensory Organs; Stomatological Preparations; Tetracyclines"
DB09094,Podophyllin,9000-55-9,approved,KOUZYZCESNTXJO-UHFFFAOYSA-N,"InChI=1S/2C22H24O9.2C22H22O8/c2*1-27-16-4-10(5-17(28-2)21(16)29-3)18-11-6-14-15(31-9-30-14)7-12(11)20(24)13(8-23)19(18)22(25)26;2*1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h2*4-7,13,18-20,23-24H,8-9H2,1-3H3,(H,25,26);2*4-7,13,18-20,23H,8-9H2,1-3H3",COc1c(OC)cc(cc1OC)C2C(C(=O)O)C(CO)C(O)c(c23)cc4c(c3)OCO4,C88H92O34,,,11979494,310265021,,,,10152781,,1693.67,0.958327145,"Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Products; Caustics; Complex Mixtures; Compounds used in a research, industrial, or household setting; Dermatologicals; Keratolytic Agents; Misc. Skin and Mucous Membrane Agents; Noxae; Pharmaceutical Preparations; Plant Extracts; Plant Preparations; Toxic Actions"
DB09095,Difluocortolone,09-06-2607,approved; investigational; withdrawn,OGPWIDANBSLJPC-RFPWEZLHSA-N,"InChI=1S/C22H28F2O4/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-21(15,3)22(14,24)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1",OCC(=O)[C@H]1[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4,C22H28F2O4,,,11954369,310265022,135624,CHEMBL509924,,10128664,,394.459,2.01132178,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnanes; Steroids; Steroids, Fluorinated"
DB09096,Benzoyl peroxide,94-36-0,approved,OMPJBNCRMGITSC-UHFFFAOYSA-N,InChI=1S/C14H10O4/c15-13(11-7-3-1-4-8-11)17-18-14(16)12-9-5-2-6-10-12/h1-10H,c1ccccc1C(=O)OOC(=O)c2ccccc2,C14H10O4,C19346,D03093,7187,310265023,82405,CHEMBL1200370,,6919,,242.2268,3.946932388,"Acids, Carbocyclic; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Benzene Derivatives; Benzoates; Carboxylic Acids; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Keratolytic Agents; Nitrogen Binding Agent; Peroxides"
DB09097,Quinagolide,87056-78-8,approved; investigational,GDFGTRDCCWFXTG-ZIFCJYIRSA-N,"InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1",Oc1cccc(c12)C[C@@H]3[C@@H](C2)C[C@@H](CN3CCC)NS(=O)(=O)N(CC)CC,C20H33N3O3S,,,3086401,310265024,135627,CHEMBL290962,,2343034,50225362,395.56,2.496315316,"Dopamine Agents; Dopamine Agonists; Dopamine D2 Receptor Agonists; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Miscellaneous Therapeutic Agents; Neurotransmitter Agents; Prolactine Inhibitors; Quinolines"
DB09099,Somatostatin,38916-34-6,approved; investigational,NHXLMOGPVYXJNR-ATOGVRKGSA-N,"InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t41-,42+,43+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-,63-/m0/s1",c1ccccc1C[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)CSSC[C@H](NC(=O)CNC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)[C@@H](C)O)CCCCN)Cc5c[nH]c(c56)cccc6,C76H104N18O19S2,,D07431,16129681,310265025,64628,CHEMBL1823872,,17286507,81767,1637.9,-8.234491845,"Amino Acids, Peptides, and Proteins; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Nerve Tissue Proteins; Neuropeptides; P-glycoprotein substrates; Pancreatic Hormones; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormone Release Inhibiting Hormones; Proteins; Somatostatin and Analogues; Somatostatin, agonists; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB09101,Elvitegravir,697761-98-1,approved,JUZYLCPPVHEVSV-LJQANCHMSA-N,"InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1",OC[C@H](C(C)C)n1cc(C(=O)O)c(=O)c(c12)cc(c(c2)OC)Cc3c(F)c(Cl)ccc3,C23H23ClFNO5,,,5277135,310265026,72289,CHEMBL204656,ELV,4441060,50183273,447.884,4.667943047,"Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; HIV Integrase; HIV Integrase Inhibitors; Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor; Quinolines; UGT1A1 Substrates"
DB09102,Daclatasvir,1009119-64-5,approved; investigational,FKRSSPOQAMALKA-CUPIEXAXSA-N,"InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1",COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2ncc([nH]2)-c3ccc(cc3)-c4ccc(cc4)-c5cnc([nH]5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC,C40H50N8O6,,D10105,25154714,310265027,82977,CHEMBL2023898,,24609522,50387084,738.89,4.176941445,"Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; Azoles; BCRP/ABCG2 Inhibitors; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; HCV Replication Complex Inhibitors; Hepatitis C Virus NS5A Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates"
DB09104,Magnesium hydroxide,1309-42-8,approved; investigational,VTHJTEIRLNZDEV-UHFFFAOYSA-L,InChI=1S/Mg.2H2O/h;2*1H2/q+2;;/p-2,[OH-],H2MgO2,C07876,,73981,310265028,6637,CHEMBL1200718,,14107,,58.32,-0.57,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Alkalies; Aluminum and magnesium containing antacids; Anions; Antacids; Antacids and Adsorbents; Basic Ointments and Protectants; Calculi Dissolution Agent; Drugs for Acid Related Disorders; Drugs that are Mainly Renally Excreted; Electrolytes; Emollients Demulcents and Protectants; Gastric Acid Lowering Agents; Gastrointestinal Agents; Genito Urinary System and Sex Hormones; Hydroxides; Ions; Laxatives; Laxatives, magnesium containing; Magnesium Compounds; Magnesium Salts; Metal cations; Metal divalent cations; Osmotic Laxatives; Urologicals"
DB09106,Hydroxyethyl Starch,9005-27-0,approved,,, ,,,D03335,,347910407,,CHEMBL2108448,,,,NA,NA,"Biomimetic Materials; Biopolymers; Blood and Blood Forming Organs; Blood and Related Products; Blood Substitutes; Blood Substitutes and Perfusion Solutions; Blood Substitutes and Plasma Protein Fractions; Carbohydrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Dietary Carbohydrates; Drugs that are Mainly Renally Excreted; Food; Food and Beverages; Glucans; Hematologic Agents; Increased Intravascular Volume; Macromolecular Substances; Manufactured Materials; Osmotic Activity; Physiological Phenomena; Plasma Substitutes; Polymers; Polysaccharides; Replacement Preparations; Starch"
DB09110,Coenzyme M,3375-50-6,approved; investigational,ZNEWHQLOPFWXOF-UHFFFAOYSA-N,"InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)",OS(=O)(=O)CCS,C2H6O3S2,C03576,,598,310265029,17905,CHEMBL1098319,COM,578,,142.197,-0.402824427,"Acids; Acids, Noncarboxylic; Alkanes; Alkanesulfonates; Alkanesulfonic Acids; Compounds used in a research, industrial, or household setting; Cough and Cold Preparations; Cytoprotective Agent; Detoxifying Agents for Antineoplastic Treatment; Expectorants; Hydrocarbons; Hydrocarbons, Acyclic; Mesna; Protective Agents; Respiratory System; Sulfhydryl Compounds; Sulfonic Acids; Sulfur Acids; Sulfur Compounds"
DB09111,Pentastarch,9005-27-0,approved; investigational,,, ,,,,,347910411,,,,,,NA,NA,"Biomimetic Materials; Biopolymers; Blood Substitutes; Carbohydrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Dietary Carbohydrates; Drugs that are Mainly Renally Excreted; Food; Food and Beverages; Glucans; Hematologic Agents; Increased Intravascular Volume; Macromolecular Substances; Manufactured Materials; Osmotic Activity; Physiological Phenomena; Plasma Substitutes; Polymers; Polysaccharides; Starch"
DB09112,Nitrous acid,7782-77-6,approved; investigational,IOVCWXUNBOPUCH-UHFFFAOYSA-N,"InChI=1S/HNO2/c2-1-3/h(H,2,3)",ON=O,HNO2,C00088,,23668193,310265030,25567,CHEMBL1161681,,22936,50147619,47.0134,0.166137638,"Acids; Acids, Noncarboxylic; Anions; Antidotes; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Electrolytes; Food; Food Additives; Food and Beverages; Food Ingredients; Food Preservatives; Hypotensive Agents; Indicators and Reagents; Ions; Laboratory Chemicals; Nitrites; Nitrogen Compounds; Physiological Phenomena; Sodium Compounds"
DB09114,Colfosceril palmitate,63-89-8,approved; investigational; withdrawn,KILNVBDSWZSGLL-KXQOOQHDSA-N,"InChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/t38-/m1/s1",CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,C40H80NO8P,,,452110,310265031,72999,CHEMBL1200737,PCF,398235,,734.0389,8.113796379,Alcohols; Carbohydrates; Glycerophosphates; Glycerophospholipids; Lipids; Lung Surfactants; Membrane Lipids; Phosphatidic Acids; Phosphatidylcholines; Phospholipids; Pulmonary Surfactants; Respiratory System; Sugar Alcohols; Sugar Phosphates; Triose Sugar Alcohols
DB09115,Diiodohydroxyquinoline,83-73-8,approved,UXZFQZANDVDGMM-UHFFFAOYSA-N,"InChI=1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",Ic1cc(I)c(O)c(c12)nccc2,C9H5I2NO,C07636,D00581,3728,310265032,5950,CHEMBL86754,,3597,66035,396.954,3.685224106,"Amebicides; Anti-Infective Agents; Antiparasitic Agents; Antiprotozoals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxyquinolines; Quinoline Derivatives; Quinolines"
DB09116,Calcium carbimide,156-62-7,approved; withdrawn,MYFXBBAEXORJNB-UHFFFAOYSA-N,InChI=1S/CN2.Ca/c2-1-3;/q-2;+2,[N-]=C=[N-],CCaN2,C19113,D03288,56955933,310265033,64301,CHEMBL3301667,,21106503,,80.103,-0.253634083,Drugs Used in Addictive Disorders; Drugs Used in Alcohol Dependence; Nervous System
DB09117,Paraldehyde,123-63-7,approved; investigational,SQYNKIJPMDEDEG-UHFFFAOYSA-N,"InChI=1S/C6H12O3/c1-4-7-5(2)9-6(3)8-4/h4-6H,1-3H3",CC1OC(C)OC(O1)C,C6H12O3,C07834,,31264,310265034,27909,CHEMBL1410743,,21106173,,132.1577,0.877974953,Acetaldehyde; Anticonvulsants; Central Nervous System Agents; Central Nervous System Depressants; Hypnotics and Sedatives; Nervous System; Psycholeptics
DB09118,Stiripentol,49763-96-4,approved,IBLNKMRFIPWSOY-FNORWQNLSA-N,"InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+",CC(C)(C)C(O)/C=C/c(cc1)cc(c12)OCO2,C14H18O3,,,5311454,310265035,,CHEMBL1983350,,4470940,,234.295,3.121116286,"Anticonvulsants; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (strong); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dioxoles; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Miscellaneous Anticonvulsants; Nervous System; Photosensitizing Agents"
DB09119,Eslicarbazepine acetate,236395-14-5,approved,QIALRBLEEWJACW-INIZCTEOSA-N,"InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1",CC(=O)O[C@H]1Cc(cccc2)c2N(C(=O)N)c(c13)cccc3,C17H16N2O3,,D09612,179344,310265036,87016,CHEMBL87992,,156110,50240669,296.326,2.172866386,"Anticonvulsants; Carboxamide Derivatives; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (moderate); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Eslicarbazepine and prodrugs; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Membrane Transport Modulators; Nervous System; Sodium Channel Blockers; UGT1A1 Substrates; Voltage-Gated Sodium Channel Blockers"
DB09120,Zucapsaicin,25775-90-0,approved; investigational,YKPUWZUDDOIDPM-VURMDHGXSA-N,"InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6-",COc1c(O)ccc(c1)CNC(=O)CCCC/C=C\C(C)C,C18H27NO3,,,1548942,310265037,135952,CHEMBL313971,,1265956,,305.4119,3.749669544,"Alkaloids; Alkenes; Alkynes; Amides; Benzene Derivatives; Capsaicin and Similar Agents; Catechols; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Heterocyclic Compounds; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lipids; Musculo-Skeletal System; Other Nonsteroidal Anti-inflammatory Agents; Phenols; Polyunsaturated Alkamides; Solanaceous Alkaloids; Topical Products for Joint and Muscular Pain"
DB09121,Aurothioglucose,12192-57-3,approved; withdrawn,XHVAWZZCDCWGBK-WYRLRVFGSA-M,"InChI=1S/C6H12O5S.Au/c7-1-2-3(8)4(9)5(10)6(12)11-2;/h2-10,12H,1H2;/q;+1/p-1/t2-,3-,4+,5-,6-;/m1./s1",OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O,C6H11AuO5S,C08193,D00991,6104,310265038,2930,,,5879,,392.18,-2.2418,Antiinflammatory and Antirheumatic Products; Antirheumatic Agents; Drugs that are Mainly Renally Excreted; Gold Preparations; Musculo-Skeletal System; Organogold Compounds; Organometallic Compounds; Specific Antirheumatic Agents
DB09123,Dienogest,65928-58-7,approved,AZFLJNIPTRTECV-FUMNGEBKSA-N,"InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1",N#CC[C@]1(O)CC[C@H]([C@@]12C)[C@H]3C(CC2)=C4C(CC3)=CC(=O)CC4,C20H25NO2,,,68861,310265039,70708,CHEMBL1201864,,62093,,311.425,2.312852497,"Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptive Agents, Male; Contraceptives, Oral; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estranes; Estrenes; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormone Antagonists; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Polycyclic Compounds; Pregnadien Derivatives; Progestin Contraceptives; Progestins; Progestogens and Estrogens, Sequential Preparations; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids; Testosterone Congeners"
DB09124,Medrogestone,977-79-7,approved; withdrawn,HCFSGRMEEXUOSS-JXEXPEPMSA-N,"InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1",CC(=O)[C@@]1(C)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(C(=C3)C)=CC(=O)CC4,C23H32O2,,,9949848,310265040,135446,CHEMBL2106825,,8125459,,340.507,4.586058318,"Adrenal Cortex Hormones; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Polycyclic Compounds; Pregnadien Derivatives; Pregnadienes; Pregnanes; Progestins; Progestogens and Estrogens, Sequential Preparations; Sex Hormones and Modulators of the Genital System; Steroids"
DB09125,Potassium citrate,866-84-2,approved; investigational; vet_approved,QEEAPRPFLLJWCF-UHFFFAOYSA-K,"InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3",[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O,C6H5K3O7,,,13344,310265041,64733,CHEMBL1200458,,12775,,306.394,-1.322687452,"Acids, Acyclic; Agents causing hyperkalemia; Alimentary Tract and Metabolism; Alkalinizing Activity; Anticoagulants; Calculi Dissolution Agent; Carboxylic Acids; Cardiovascular Agents; Citrates; Citric Acid Derivatives; Diuretics; Expectorants; Metabolic Alkalinizer; Mineral Supplements; Natriuretic Agents; Potassium Salt; Replacement Preparations; Respiratory System Agents; Tricarboxylic Acids; Urinary Alkalinisers"
DB09128,Brexpiprazole,913611-97-9,approved; investigational,ZKIAIYBUSXZPLP-UHFFFAOYSA-N,"InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)",c1cc(=O)[nH]c(c12)cc(cc2)OCCCCN3CCN(CC3)c(ccc4)c(c45)ccs5,C25H27N3O2S,,D10309,11978813,310265043,134716,CHEMBL2105760,,10152155,194780,433.57,4.649702593,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antidepressive Agents; Antidepressive Agents Indicated for Depression; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Dopamine D2 Receptor Agonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Psycholeptics; Quinolines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Serotonin Receptor Antagonists; Sulfur Compounds"
DB09129,Chromic chloride,10025-73-7,approved,QSWDMMVNRMROPK-UHFFFAOYSA-K,InChI=1S/3ClH.Cr/h3*1H;/q;;;+3/p-3,[Cl-],Cl3Cr,,,6452300,310265044,53351,,,23193,,158.355,0.612338722,"Acids; Acids, Noncarboxylic; Anions; Antioxidants; Chlorine Compounds; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Electrolytes; Ions; Minerals; Protective Agents; Replacement Preparations"
DB09130,Copper,7440-50-8,approved; investigational,RYGMFSIKBFXOCR-UHFFFAOYSA-N,InChI=1S/Cu,[Cu],Cu,C00070,,23978,310265045,28694,,,22414,,63.546,0.156,"Copper-containing Intrauterine Device; Decreased Embryonic Implantation; Decreased Sperm Motility; Diet, Food, and Nutrition; Elements; Food; Food and Beverages; Growth Substances; Inhibit Ovum Fertilization; Metals; Metals, Heavy; Micronutrients; Minerals; Physiological Phenomena; Replacement Preparations; Trace Elements; Transition Elements"
DB09131,Cupric Chloride,7447-39-4,approved; investigational,ORTQZVOHEJQUHG-UHFFFAOYSA-L,InChI=1S/2ClH.Cu/h2*1H;/q;;+2/p-2,Cl[Cu]Cl,Cl2Cu,,,24014,310265046,49553,CHEMBL1200553,CUL,22447,,134.452,0.519,"Elements; Metals; Metals, Heavy; Transition Elements"
DB09132,Gadoteric acid,72573-82-1,approved,GFSTXYOTEVLASN-UHFFFAOYSA-K,"InChI=1S/C16H28N4O8.Gd/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26;/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3",OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,C16H25GdN4O8,,D08007,158536,310265047,73732,CHEMBL3833326,,139460,,558.65,-7.670609858,"Alcohols; Amino Sugars; Carbohydrates; Chelating Agents; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Gadolinium-based Contrast Agent; Hexosamines; Magnetic Resonance Imaging Contrast Media; Paramagnetic Contrast Media; Roentgenography; Sequestering Agents; Sugar Alcohols"
DB09133,Iothalamic acid,2276-90-6,approved,UXIGWFXRQKWHHA-UHFFFAOYSA-N,"InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)",CNC(=O)c1c(I)c(C(=O)O)c(I)c(c1I)NC(=O)C,C11H9I3N2O4,,D01258,3737,310265048,31713,CHEMBL1201300,,3606,,613.916,2.729688886,"Acids, Carbocyclic; Alcohols; Amino Sugars; Benzene Derivatives; Benzoates; Carbohydrates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Hexosamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodobenzoates; Radiographic Contrast Agent; Roentgenography; Sugar Alcohols; Triiodobenzoic Acids; Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB09134,Ioversol,87771-40-2,approved,AMDBBAQNWSUWGN-UHFFFAOYSA-N,"InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)",OCCN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(c1I)C(=O)NCC(O)CO,C18H24I3N3O9,,D01555,3741,310265049,31717,CHEMBL1200614,,3610,,807.115,-2.137735559,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodinated Contrast Agents; Iodobenzoates; Radiographic Contrast Agent; Roentgenography; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB09135,Ioxilan,107793-72-6,approved,UUMLTINZBQPNGF-UHFFFAOYSA-N,"InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)",OCC(O)CN(C(=O)C)c1c(I)c(C(=O)NCC(O)CO)c(I)c(c1I)C(=O)NCCO,C18H24I3N3O8,,D02161,3743,310265050,135884,CHEMBL1201075,,3612,,791.116,-1.320487513,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodinated Contrast Agents; Iodobenzoates; Radiographic Contrast Agent; Triiodobenzoic Acids; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB09136,Isosulfan blue,748080-29-7,approved,YFKDCGWIINMRQY-UHFFFAOYSA-O,"InChI=1S/C27H32N2O6S2/c1-5-28(6-2)22-13-9-20(10-14-22)27(21-11-15-23(16-12-21)29(7-3)8-4)25-19-24(36(30,31)32)17-18-26(25)37(33,34)35/h9-19H,5-8H2,1-4H3,(H-,30,31,32,33,34,35)/p+1",CCN(CC)c1ccc(cc1)C(=C2C=CC(C=C2)=[N+](CC)CC)c3cc(S(=O)(=O)O)ccc3S(=O)(=O)O,C27H33N2O6S2,,,50108,310265051,,CHEMBL1615783,,4533,,545.69,2.048418756,"Amines; Aniline Compounds; Coloring Agents; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted"
DB09137,Technetium Tc-99m mebrofenin,1415247-71-0,approved,JLJSYHOPCNWUNE-NLQOEHMXSA-N,"InChI=1S/C15H19BrN2O5.Tc/c1-8-4-9(2)15(10(3)14(8)16)17-11(19)5-18(6-12(20)21)7-13(22)23;/h4H,5-7H2,1-3H3,(H,17,19)(H,20,21)(H,22,23);/i;1+2",OC(=O)CN(CC(=O)O)CC(=O)Nc1c(C)c(Br)c(C)cc1C,C15H19BrN2O5Tc,,D06037,11431716,310265052,,CHEMBL2110555,,,,484.23,NA,"Acids, Acyclic; Amino Acids; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Hepatic and Reticulo Endothelial System; Imines; Indicators and Reagents; Laboratory Chemicals; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Organometallic Compounds; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Technetium (99Mtc) Compounds"
DB09138,Technetium Tc-99m medronate,121524-79-6,approved,IUPNVOAUFBLQME-SGNQUONSSA-J,"InChI=1S/CH6O6P2.2H2O.Tc/c2-8(3,4)1-9(5,6)7;;;/h1H2,(H2,2,3,4)(H2,5,6,7);2*1H2;/q;;;+4/p-4/i;;;1+1",[O-]P([O-])(=O)CP([O-])([O-])=O,CH6O8P2Tc,,D02029,131704315,310265053,32186,CHEMBL2110576,,34995234,,305.906,-2.35491473,"Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Indicators and Reagents; Laboratory Chemicals; Organometallic Compounds; Organophosphonates; Organophosphorus Compounds; Organotechnetium Compounds; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Skeleton; Technetium (99Mtc) Compounds"
DB09139,Technetium Tc-99m oxidronate,72945-61-0,approved,SIJNDWFHVBDXDY-NLQOEHMXSA-N,"InChI=1S/CH6O7P2.Tc/c2-1(9(3,4)5)10(6,7)8;/h1-2H,(H2,3,4,5)(H2,6,7,8);/i;1+2",OP(=O)(O)C(O)P(=O)(O)O,CH6O7P2Tc,,D06041,123801,347827826,,,,,,290.906,-1.979410279,Diagnostic Radiopharmaceuticals; Drugs that are Mainly Renally Excreted; Organometallic Compounds; Organophosphonates; Organophosphorus Compounds; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Skeleton; Technetium (99Mtc) Compounds
DB09140,Oxygen,7782-44-7,approved; vet_approved,MYMOFIZGZYHOMD-UHFFFAOYSA-N,InChI=1S/O2/c1-2,O=O,O2,C00007,D00003,977,310265054,27140,CHEMBL1234886,OXY,952,,31.9988,-0.27723173,Chalcogens; Elements; Gases; Medical Gases; Miscellaneous Therapeutic Agents; Other Miscellaneous Therapeutic Agents
DB09142,Sincalide,25126-32-3,approved,IZTQOLKUZKXIRV-YRVFCXMDSA-N,"InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1",OS(=O)(=O)Oc1ccc(cc1)C[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](Cc2c[nH]c(c23)cccc3)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N)Cc4ccccc4,C49H62N10O16S3,,D05845,9833444,310265055,135946,CHEMBL1121,,8009168,21147,1143.27,-2.414597934,"Amino Acids, Peptides, and Proteins; Cholecystokinin Analog; Diagnostic Agents; Gallbladder Function; Gastrointestinal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OATP1B3 substrates; Peptides; Tests for Bile Duct Patency"
DB09143,Sonidegib,956697-53-3,approved; investigational,VZZJRYRQSPEMTK-CALCHBBNSA-N,"InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+",C[C@H]1CN(C[C@H](O1)C)c2ccc(cn2)NC(=O)c3cccc(c3C)-c4ccc(OC(F)(F)F)cc4,C26H26F3N3O3,,D10119,24775005,310265056,90863,CHEMBL2105737,,25027390,50394562,485.507,6.756367519,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Benzene Derivatives; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Hedgehog Pathway Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Narrow Therapeutic Index Drugs; Smoothened Receptor Antagonists"
DB09144,Uridine triacetate,4105-38-8,approved; investigational,AUFUWRKPQLGTGF-FMKGYKFTSA-N,"InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1",CC(=O)OC[C@H]1O[C@H]([C@H](OC(=O)C)[C@@H]1OC(=O)C)n2ccc(=O)[nH]c2=O,C15H18N2O9,,D09985,20058,310265057,90914,CHEMBL2107381,,18897,,370.314,-1.091865911,"Acids, Acyclic; Alimentary Tract and Metabolism; Carbohydrates; Carboxylic Acids; Fatty Acids; Fatty Acids, Volatile; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lipids; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Pyrimidine Analog; Pyrimidine Nucleosides; Pyrimidines; Ribonucleosides; Various Alimentary Tract and Metabolism Products"
DB09145,Water,7732-18-5,approved,XLYOFNOQVPJJNP-UHFFFAOYSA-N,InChI=1S/H2O/h1H2,[O],H2O,C00001,D00001,962,310265058,15377,CHEMBL1098659,HOH,937,,18.0153,-0.652,"Diluents; EENT Drugs, Miscellaneous; Irrigating Solutions; Other Miscellaneous Therapeutic Agents; Oxygen Compounds"
DB09146,Iron sucrose,8047-67-4,approved,FWZTTZUKDVJDCM-CEJAUHOTSA-M,"InChI=1S/C12H22O11.5Fe.2Na.4H2O.8O/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;;;;;;;;;;;;;;;;;;;/h4-11,13-20H,1-3H2;;;;;;;;4*1H2;;;;;;;;/q;5*+3;2*+1;;;;;8*-2/p-1/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;/m1.................../s1",OC[C@@H](O1)[C@@H](O)[C@H](O)[C@]1(CO)O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O,C12H29Fe5Na2O23,,,91663255,310265059,,CHEMBL1200823,,32699616,,866.546,-4.528834964,"Acids, Acyclic; Carbohydrates; Carboxylic Acids; Disaccharides; Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Ferric Compounds; Hydroxy Acids; Iron Compounds; Iron Preparations; Iron Trivalent, Oral Preparations; Oligosaccharides; Organometallic Compounds; Pharmaceutical Preparations; Phosphate Binder; Phosphate-removing Agents; Polysaccharides; Sugar Acids"
DB09148,Florbetaben (18F),902143-01-5,approved,NCWZOASIUQVOFA-FWZJPQCDSA-N,"InChI=1S/C21H26FNO3/c1-23-20-8-4-18(5-9-20)2-3-19-6-10-21(11-7-19)26-17-16-25-15-14-24-13-12-22/h2-11,23H,12-17H2,1H3/b3-2+/i22-1",CNc1ccc(cc1)/C=C/c2ccc(cc2)OCCOCCOCC[18F],C21H26FNO3,,D10002,11501341,310265061,79033,CHEMBL566752,,9676143,,358.444,3.735232458,"Amines; Benzene Derivatives; Benzylidene Compounds; Central Nervous System; Diagnostic Radiopharmaceuticals; Drugs that are Mainly Renally Excreted; Fluorine Radioisotopes; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Positron Emitting Activity; Radioactive Diagnostic Agent"
DB09149,Florbetapir (18F),956103-76-7,approved; investigational,YNDIAUKFXKEXSV-CRYLGTRXSA-N,"InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1",CNc1ccc(cc1)/C=C/c2cnc(cc2)OCCOCCOCC[18F],C20H25FN2O3,,D09617,24822371,310265062,66880,CHEMBL1774461,,26348452,,359.432,3.112017561,Alcohols; Amines; Central Nervous System; Diagnostic Radiopharmaceuticals; Drugs that are Mainly Renally Excreted; Fluorine Radioisotopes; Glycols; Positron Emitting Activity; Radioactive Diagnostic Agent
DB09151,Flutemetamol (18F),765922-62-1,approved; investigational,VVECGOCJFKTUAX-HUYCHCPVSA-N,"InChI=1S/C14H11FN2OS/c1-16-11-4-2-8(6-10(11)15)14-17-12-5-3-9(18)7-13(12)19-14/h2-7,16,18H,1H3/i15-1",CNc1c([18F])cc(cc1)-c(s2)nc(c23)ccc(c3)O,C14H11FN2OS,,D10231,15950376,310265064,76611,CHEMBL2042122,,13092196,,273.32,3.450156757,"Amines; Azoles; Central Nervous System; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indicators and Reagents; Laboratory Chemicals; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Sulfur Compounds; Thiazoles"
DB09152,Nitrogen,7727-37-9,approved; vet_approved,IJGRMHOSHXDMSA-UHFFFAOYSA-N,InChI=1S/N2/c1-2,N#N,N2,C00697,D00083,947,310265065,17997,CHEMBL142438,HDZ,922,,28.0134,0.311530256,Elements; Gases; Medical Gases; Miscellaneous Therapeutic Agents; Other Miscellaneous Therapeutic Agents
DB09153,Sodium chloride,7647-14-5,approved; vet_approved,FAPWRFPIFSIZLT-UHFFFAOYSA-M,InChI=1S/ClH.Na/h1H;/q;+1/p-1,[Na+],ClNa,C13563,D02056,5234,310265066,26710,CHEMBL1200574,,5044,50098543,58.443,-0.77,"Acids; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Anions; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Chlorides; Chlorine Compounds; Diluents; EENT Drugs, Miscellaneous; Electrolyte Solutions; Electrolytes; I.V. Solution Additives; Ions; Irrigating Solutions; Mineral Supplements; Miscellaneous Therapeutic Agents; Other Miscellaneous Therapeutic Agents; Replacement Preparations; Respiratory Agents, Miscellaneous; Salt Solutions; Sodium; Sodium Compounds"
DB09154,Sodium citrate,68-04-2,approved; investigational,HRXKRNGNAMMEHJ-UHFFFAOYSA-K,"InChI=1S/C6H8O7.3Na/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3",[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O,C6H5Na3O7,,D05855,6224,310265067,53258,CHEMBL1355,,5989,,258.068,-1.322687452,"Acids, Acyclic; Antacids and Adsorbents; Anticoagulants; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Buffers; Calculi Dissolution Agent; Carboxylic Acids; Citrates; Citric Acid Derivatives; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Food; Food Additives; Food and Beverages; Food Ingredients; Food Preservatives; Hematologic Agents; Irrigating Solutions; Laboratory Chemicals; Miscellaneous Anticoagulants; Miscellaneous GI Drugs; Neurotoxic agents; Physiological Phenomena; Salt Solutions; Tricarboxylic Acids; Urinary Alkalinisers"
DB09155,Helium,7440-59-7,approved; investigational; vet_approved,SWQJXJOGLNCZEY-UHFFFAOYSA-N,InChI=1S/He,[He],He,,D04420,23987,310265068,33681,CHEMBL1796997,,22423,,4.0026,0,Elements; Gases; Medical Gases; Miscellaneous Therapeutic Agents; Noble Gases; Other Miscellaneous Therapeutic Agents
DB09156,Iopromide,73334-07-3,approved,DGAIEPBNLOQYER-UHFFFAOYSA-N,"InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)",COCC(=O)Nc1c(I)c(C(=O)N(C)CC(O)CO)c(I)c(c1I)C(=O)NCC(O)CO,C18H24I3N3O8,,D01893,3736,310265069,63578,CHEMBL1725,,3605,,791.1119,-0.444897046,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodinated Contrast Agents; Iodobenzoates; Radiographic Contrast Agent; Roentgenography; Triiodobenzoic Acids; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB09157,Carbon dioxide,124-38-9,approved; investigational; vet_approved,CURLTUGMZLYLDI-UHFFFAOYSA-N,InChI=1S/CO2/c2-1-3,O=C=O,CO2,C00011,D00004,280,310265070,16526,CHEMBL1231871,CO2,274,,44.0095,-0.278957109,"Anions; Carbon Compounds, Inorganic; Electrolytes; Gases; Ions; Medical Gases; Miscellaneous Therapeutic Agents; Other Diagnostics; Other Miscellaneous Therapeutic Agents; Oxides; Oxygen Compounds; Radiographic Contrast Agent; X-Ray Contrast Activity"
DB09158,Trypan blue free acid,2538-83-2,approved,ZBNARPCCDMHDDV-HVMBLDELSA-N,"InChI=1S/C34H28N6O14S4/c1-15-7-17(3-5-25(15)37-39-31-27(57(49,50)51)11-19-9-21(55(43,44)45)13-23(35)29(19)33(31)41)18-4-6-26(16(2)8-18)38-40-32-28(58(52,53)54)12-20-10-22(56(46,47)48)14-24(36)30(20)34(32)42/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)/b39-37+,40-38+",Nc1cc(S(=O)(=O)O)cc(c12)cc(S(=O)(=O)O)c(c2O)/N=N/c3ccc(cc3C)-c4cc(C)c(cc4)/N=N/c(c(c5)S(=O)(=O)O)c(O)c(c56)c(N)cc(c6)S(=O)(=O)O,C34H28N6O14S4,C19307,,9562061,310265071,78900,CHEMBL1089641,,14833963,,872.87,1.134738843,"Acids; Acids, Noncarboxylic; Arylsulfonates; Arylsulfonic Acids; Azo Compounds; Coloring Agents; Compounds used in a research, industrial, or household setting; Diagnostic Dye; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthalenes; Naphthalenesulfonates; Ocular Disorders; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sulfonic Acids; Sulfur Acids; Sulfur Compounds"
DB09160,Technetium Tc-99m tetrofosmin,127455-27-0,approved,HBJYDUADMKVTGP-RCUQKECRSA-N,"InChI=1S/2C18H40O4P2.2H2O.Tc/c2*1-5-19-9-13-23(14-10-20-6-2)17-18-24(15-11-21-7-3)16-12-22-8-4;;;/h2*5-18H2,1-4H3;2*1H2;/i;;;;1+1",CCOCCP(CCOCC)CCP(CCOCC)CCOCC,C36H84O10P4Tc,,D06050,131704316,310265073,,,,,,898.86,1.14,"Cardiovascular System; Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Indicators and Reagents; Laboratory Chemicals; Organometallic Compounds; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Technetium (99Mtc) Compounds"
DB09161,Technetium Tc-99m sestamibi,109581-73-9,approved; investigational,ZBTQTVSNLRPJHI-UHFFFAOYSA-N,"InChI=1S/6C6H11NO.Tc/c6*1-6(2,8-4)5-7-3;/h6*5H2,1-2,4H3;/q;;;;;;+1",COC(C)(C)C[N+]#[C-],C36H66N6O6Tc,,D01060,22617237,310265074,9423,CHEMBL2074398,,58829659,,775.96,-1.308232819,"Cardiovascular System; Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Indicators and Reagents; Laboratory Chemicals; Nitriles; Organometallic Compounds; Organotechnetium Compounds; P-glycoprotein substrates; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Technetium (99Mtc) Compounds"
DB09163,Technetium Tc-99m exametazime,99944-78-2,approved,,, ,,,D02284,,347910416,,CHEMBL2111018,,,,NA,NA,"Amines; Central Nervous System; Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Hydroxylamines; Indicators and Reagents; Laboratory Chemicals; Organometallic Compounds; Organotechnetium Compounds; Oximes; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Technetium (99Mtc) Compounds"
DB09164,Technetium Tc-99m disofenin,,approved,JNJYQGLIZTUSCW-NLQOEHMXSA-N,"InChI=1S/C18H26N2O5.Tc/c1-11(2)13-6-5-7-14(12(3)4)18(13)19-15(21)8-20(9-16(22)23)10-17(24)25;/h5-7,11-12H,8-10H2,1-4H3,(H,19,21)(H,22,23)(H,24,25);/i;1+2",CC(C)c1cccc(C(C)C)c1NC(=O)CN(CC(=O)O)CC(=O)O,C18H26N2O5Tc,,,11430828,347827828,,,,,,449.321,1.006154069,"Amino Acids; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Hepatic and Reticulo Endothelial System; Imines; Imino Acids; Indicators and Reagents; Laboratory Chemicals; Organometallic Compounds; Organotechnetium Compounds; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Technetium (99Mtc) Compounds"
DB09165,Technetium Tc-99m pyrophosphate,52997-54-3,approved,OOGKGVXDDGJCPO-NLQOEHMXSA-J,"InChI=1S/H4O7P2.Tc/c1-8(2,3)7-9(4,5)6;/h(H2,1,2,3)(H2,4,5,6);/q;+4/p-4/i;1+2",[O-]P([O-])(=O)OP([O-])([O-])=O,O7P2Tc,,,6452753,347827829,,,,,,272.847,-1.441902302,"Acids; Acids, Noncarboxylic; Anions; Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Diphosphates; Drugs that are Mainly Renally Excreted; Electrolytes; Indicators and Reagents; Ions; Laboratory Chemicals; Phosphate salts; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Polyphosphates; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Skeleton; Technetium (99Mtc) Compounds; Technetium Compounds"
DB09167,Dosulepin,113-53-1,approved,PHTUQLWOUWZIMZ-GZTJUZNOSA-N,"InChI=1S/C19H21NS/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+",CN(C)CC/C=C/1c(cccc2)c2CSc(c13)cccc3,C19H21NS,,D07872,5284550,310265076,36803,CHEMBL1492500,,4447605,,295.44,4.522084514,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Agents that reduce seizure threshold; Anticholinergic Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dibenzothiepins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Membrane Transport Modulators; Muscarinic Antagonists; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Non-Selective Monoamine Reuptake Inhibitors; Potential QTc-Prolonging Agents; Psychoanaleptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT1A Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists; Sulfur Compounds; Tertiary amine tricyclic antidepressants; Thiepins"
DB09183,Dasabuvir,1132935-63-7,approved,NBRBXGKOEOGLOI-UHFFFAOYSA-N,"InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)",O=c1[nH]c(=O)ccn1-c2cc(C(C)(C)C)c(OC)c(c2)-c(cc3)cc(c34)ccc(c4)NS(=O)(=O)C,C26H27N3O5S,,D10582,56640146,310265091,85182,CHEMBL3137312,,29776744,,493.58,3.42356982,"Amides; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; BCRP/ABCG2 Inhibitors; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; P-glycoprotein substrates; Pyrimidines; Pyrimidinones; RNA Replicase Inhibitors; Sulfones; Sulfur Compounds; UGT1A1 Inhibitors"
DB09185,Viloxazine,46817-91-8,approved; investigational; withdrawn,YWPHCCPCQOJSGZ-UHFFFAOYSA-N,"InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3",CCOc1ccccc1OCC2CNCCO2,C13H19NO3,,D08673,5666,310265093,94405,CHEMBL306700,,5464,50025691,237.299,1.491574443,"Adrenergic Agents; Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Second-Generation; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Morpholines; Nervous System; Neurotransmitter Agents; Neurotransmitter Uptake Inhibitors; Oxazines; Psychoanaleptics; Psychotropic Drugs"
DB09195,Lorpiprazole,108785-69-9,approved,BNRMWKUVWLKDQJ-YJBOKZPZSA-N,"InChI=1S/C21H26F3N5/c22-21(23,24)16-4-2-5-17(13-16)28-11-9-27(10-12-28)8-7-19-25-26-20-18-6-1-3-15(18)14-29(19)20/h2,4-5,13,15,18H,1,3,6-12,14H2/t15-,18-/m0/s1",C1CC[C@H]([C@H]12)Cn3c2nnc3CCN4CCN(CC4)c5cccc(c5)C(F)(F)F,C21H26F3N5,,,20055414,310265103,,,,16736802,,405.469,3.224533985,Antidepressive Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin 5-HT2C Receptor Antagonists; Serotonin Agents; Serotonin Modulators; Serotonin Receptor Antagonists
DB09205,Moxisylyte,54-32-0,approved; investigational,VRYMTAVOXVTQEF-UHFFFAOYSA-N,"InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3",CN(C)CCOc1c(C(C)C)cc(c(c1)C)OC(=O)C,C16H25NO3,,D08239,4260,310265113,94754,CHEMBL159226,,4110,50452139,279.38,3.199910587,Adrenergic Agents; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Amines; Autonomic Agents; Cardiovascular Agents; Cardiovascular System; Cholinesterase substrates; Dimethylamines; Drugs that are Mainly Renally Excreted; Drugs Used in Erectile Dysfunction; Genito Urinary System and Sex Hormones; Methylamines; Miotics; Neurotransmitter Agents; Peripheral Nervous System Agents; Peripheral Vasodilators; Sympatholytics; Urologicals; Vasodilating Agents
DB09209,Pholcodine,509-67-1,approved; illicit,GPFAJKDEDBRFOS-FKQDBXSBSA-N,"InChI=1S/C23H30N2O4/c1-24-7-6-23-16-3-4-18(26)22(23)29-21-19(5-2-15(20(21)23)14-17(16)24)28-13-10-25-8-11-27-12-9-25/h2-5,16-18,22,26H,6-14H2,1H3/t16-,17+,18-,22-,23-/m0/s1",C1CN(C)[C@@H]([C@H]2[C@@]134)Cc5c3c(O[C@H]4[C@@H](O)C=C2)c(cc5)OCCN6CCOCC6,C23H30N2O4,,D07385,5311356,310265116,53579,CHEMBL2105224,,4470854,,398.4953,1.143095354,"Alkaloids; Analgesics; Antitussive Agents; Central Nervous System Agents; Cough and Cold Preparations; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Morphine Derivatives; Opiate Alkaloids; Opium Alkaloids and Derivatives; Oxazines; Peripheral Nervous System Agents; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Respiratory System; Respiratory System Agents; Sensory System Agents"
DB09210,Piracetam,7491-74-9,approved; investigational,GMZVRMREEHBGGF-UHFFFAOYSA-N,"InChI=1S/C6H10N2O2/c7-5(9)4-8-3-1-2-6(8)10/h1-4H2,(H2,7,9)",NC(=O)CN1CCCC1=O,C6H10N2O2,,,,,32010,CHEMBL36715,PZI,4677,62877,142.1558,-1.684892538,"Acetamides; Acetates; Acids, Acyclic; Amides; Carboxylic Acids; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lipids; Nervous System; Neuroprotective Agents; Nootropic Agents; Protective Agents; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Pyrrolidines; Pyrrolidinones"
DB09212,Loxoprofen,68767-14-6,approved,YMBXTVYHTMGZDW-UHFFFAOYSA-N,"InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)",OC(=O)C(C)c1ccc(cc1)CC2CCCC2=O,C15H18O3,,D08149,3965,310265119,76172,CHEMBL19299,,3828,50140320,246.3016,3.345719083,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Carboxylic Acids; Central Nervous System Agents; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Sensory System Agents; UGT2B7 substrates"
DB09213,Dexibuprofen,51146-56-6,approved; investigational,HEFNNWSXXWATRW-JTQLQIEISA-N,"InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1",CC(C)Cc1ccc(cc1)[C@H](C)C(=O)O,C13H18O2,,D03715,39912,310265120,43415,CHEMBL175,IBP,36498,50169047,206.2808,3.843558199,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Carboxylic Acids; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Ibuprofen and isomer; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Phenylpropionates; Propionates; UGT1A1 Substrates; UGT1A3 substrates; UGT1A9 Substrates; UGT2B7 substrates"
DB09214,Dexketoprofen,22161-81-5,approved; investigational,DKYWVDODHFEZIM-NSHDSACASA-N,"InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/t11-/m0/s1",OC(=O)[C@@H](C)c1cc(ccc1)C(=O)c2ccccc2,C16H14O3,,D07269,667550,310265121,76128,CHEMBL75435,9KL,580922,50088570,254.2806,3.613333421,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Alcohols; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Carboxylic Acids; Central Nervous System Agents; Drugs that are Mainly Renally Excreted; Glycols; Ketoprofen and isomer; Musculo-Skeletal System; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Phenylpropionates; Propionates; Propylene Glycols; Sensory System Agents; Topical Products for Joint and Muscular Pain"
DB09216,Tolfenamic acid,13710-19-5,approved; investigational,YEZNLOUZAIOMLT-UHFFFAOYSA-N,"InChI=1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)",Cc1c(Cl)cccc1Nc2ccccc2C(=O)O,C14H12ClNO2,,D01183,610479,310265123,32243,CHEMBL121626,TLF,530683,35905,261.704,5.488220565,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Aminobenzoates; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiarrhythmic agents; Antidepressive Agents; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Benzene Derivatives; Benzoates; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Carboxylic Acids; Cardiovascular Agents; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fenamates; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Membrane Transport Modulators; Migraine Disorders, drug therapy; Musculo-Skeletal System; Nephrotoxic agents; Neurotransmitter Agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Prostaglandin Antagonists; Sensory System Agents; Serotonin Agents; Serotonin Receptor Antagonists"
DB09219,Bisoxatin,17692-24-9,approved,BPKUDUSVDVLOPY-UHFFFAOYSA-N,"InChI=1S/C20H15NO4/c22-15-9-5-13(6-10-15)20(14-7-11-16(23)12-8-14)19(24)21-17-3-1-2-4-18(17)25-20/h1-12,22-23H,(H,21,24)",c1cccc(c12)OC(C(=O)N2)(c(cc3)ccc3O)c4ccc(O)cc4,C20H15NO4,,,28689,310265126,135955,,,26684,,333.343,3.745624145,Alimentary Tract and Metabolism; Contact Laxatives; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Laxatives
DB09220,Nicorandil,65141-46-0,approved; investigational,LBHIOVVIQHSOQN-UHFFFAOYSA-N,"InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)",[O-][N+](=O)OCCNC(=O)c1cccnc1,C8H9N3O4,C13280,D01810,47528,310265127,31905,CHEMBL284906,,43240,,211.177,-0.161697622,"Acids; Acids, Heterocyclic; Acids, Noncarboxylic; Agents causing hyperkalemia; Anions; Antiarrhythmic agents; Antihypertensive Agents; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Diet, Food, and Nutrition; Drugs that are Mainly Renally Excreted; Electrolytes; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Ions; Micronutrients; Nicotinic Acids; Nitrates; Nitric Acid; Nitrogen Compounds; Physiological Phenomena; Pyridines; Vasodilating Agents; Vasodilators Used in Cardiac Diseases"
DB09225,Zotepine,26615-21-4,approved; investigational; withdrawn,HDOZVRUNCMBHFH-UHFFFAOYSA-N,"InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3",CN(C)CCOC1=Cc(cccc2)c2Sc(c13)ccc(Cl)c3,C18H18ClNOS,,D01321,5736,310265131,32316,CHEMBL285802,ZOT,5534,35255,331.86,4.510560188,"Antidepressive Agents; Antipsychotic Agents; Antipsychotic Agents (Second Generation [Atypical]); Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Psycholeptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Sulfur Compounds; Thiepins; Tranquilizing Agents"
DB09236,Lacidipine,103890-78-4,approved; investigational,GKQPCPXONLDCMU-CCEZHUSRSA-N,"InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+",CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c2ccccc2/C=C/C(=O)OC(C)(C)C,C26H33NO6,,D04657,5311217,310265140,135737,CHEMBL460291,,4470736,,455.551,4.185153483,"Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Membrane Transport Modulators; Mutagens; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB09237,Levamlodipine,103129-82-4,approved; investigational,HTIQEAQVCYTUBX-KRWDZBQOSA-N,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1",CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c2ccccc2Cl,C20H25ClN2O5,,,9822750,310265141,53796,CHEMBL2111097,6UB,7998499,,408.88,1.635595452,"Acids, Heterocyclic; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nicotinic Acids; P-glycoprotein substrates; Pyridines"
DB09238,Manidipine,89226-50-6,approved; investigational,ANEBWFXPVPTEET-UHFFFAOYSA-N,"InChI=1S/C35H38N4O6/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-16,23,32-33,36H,17-22H2,1-3H3",COC(=O)C1=C(C)NC(C)=C(C1c2cc(N(=O)=O)ccc2)C(=O)OCCN3CCN(CC3)C(c4ccccc4)c5ccccc5,C35H38N4O6,,,4008,347827830,135849,CHEMBL1085699,,3868,,610.711,5.189971688,"ACE Inhibitors and Calcium Channel Blockers; Agents causing hyperkalemia; Antiarrhythmic agents; Antihypertensive Agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (weak); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dihydropyridine Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Pyridines; Selective Calcium Channel Blockers With Mainly Vascular Effects; Vasodilating Agents"
DB09241,Methylene blue,61-73-4,approved; investigational,CXKWCBBOMKCUKX-UHFFFAOYSA-M,"InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1",CN(C)c(cc1)cc(c12)[s+]c3c(n2)ccc(c3)N(C)C,C16H18ClN3S,C00220,,6099,310265144,6872,CHEMBL405110,,5874,,319.85,2.613303665,"Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antidotes; Antipsychotic Agents; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Diagnostic Agents; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Gastric Function; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; Miscellaneous Therapeutic Agents; Monoamine Oxidase Inhibitors; Neurotoxic agents; OCT2 Inhibitors; Oxidation-Reduction Agent; P-glycoprotein inhibitors; P-glycoprotein substrates; Phenothiazines; Photosensitizing Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sulfur Compounds; Tests for Gastric Secretion; UGT1A4 Inhibitors; UGT1A9 Inhibitors"
DB09242,Moxonidine,75438-57-2,approved; investigational,WPNJAUFVNXKLIM-UHFFFAOYSA-N,"InChI=1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)",COc1nc(C)nc(Cl)c1NC2=NCCN2,C9H12ClN5O,C07451,D05087,4810,310265145,7009,CHEMBL19236,,4645,50050093,241.677,1.538777066,"Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Antiadrenergic Agents, Centrally Acting; Antihypertensive Agents; Azoles; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Imidazoline Receptor Agonists; Sympatholytics"
DB09255,Dextran,9004-54-0,approved; investigational; vet_approved,,, ,,C00372,D00060,,347910421,,,,,,NA,NA,"Anticoagulants; Biomimetic Materials; Biopolymers; Blood and Blood Forming Organs; Blood and Related Products; Blood Substitutes; Blood Substitutes and Perfusion Solutions; Blood Substitutes and Plasma Protein Fractions; Carbohydrates; Compounds used in a research, industrial, or household setting; Dextrans; Drugs that are Mainly Renally Excreted; Glucans; Hematologic Agents; Increased Intravascular Volume; Macromolecular Substances; Manufactured Materials; Osmotic Activity; Plasma Substitutes; Polymers; Polysaccharides"
DB09256,Tegafur,17902-23-7,approved; investigational,WFWLQNSHRPWKFK-UHFFFAOYSA-N,"InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)",O=c1[nH]c(=O)n(cc1F)C2CCCO2,C8H9FN2O3,C12673,D01244,5386,310265158,32188,CHEMBL20883,,5193,,200.169,0.023826538,"Antimetabolites; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fluoropyrimidines; Fluorouracil and prodrugs; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Narrow Therapeutic Index Drugs; Noxae; Pyrimidine Analogues; Pyrimidines; Pyrimidinones; Thyroxine-binding globulin inducers; Toxic Actions"
DB09257,Gimeracil,103766-25-2,approved,ZPLQIPFOCGIIHV-UHFFFAOYSA-N,"InChI=1S/C5H4ClNO2/c6-3-2-7-5(9)1-4(3)8/h1-2H,(H2,7,8,9)",Oc1cc(=O)[nH]cc1Cl,C5H4ClNO2,,D01846,54679224,310265159,31652,CHEMBL1730601,,3353,,145.54,0.126444768,"Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring"
DB09258,Bemiparin,91449-79-5,approved; investigational,,, ,,,,,347910422,,,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Blood and Blood Forming Organs; Carbohydrates; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Polysaccharides
DB09259,Reviparin,01-08-9041,approved; investigational,,, ,,,D03337,,347910423,,,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Fibrin Modulating Agents; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Polysaccharides
DB09260,Parnaparin,9005-49-6,approved; investigational,,, ,,,,,347910424,,,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Fibrin Modulating Agents; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Polysaccharides
DB09261,Certoparin,,approved; investigational,,, ,,,,,347910425,,,,,,NA,NA,Agents causing hyperkalemia; Anticoagulants; Carbohydrates; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Polysaccharides
DB09263,Patiromer,1260643-52-4,approved; investigational,,, ,,,D10148,,347910426,,CHEMBL2107875,,,,NA,NA,"Compounds used in a research, industrial, or household setting; Macromolecular Substances; Manufactured Materials; Potassium Binder; Potassium Ion Binding Activity; Potassium-removing Agents"
DB09265,Lixisenatide,320367-13-3,approved,XVVOERDUTLJJHN-IAEQDCLQSA-N,"InChI=1S/C215H347N61O65S/c1-16-115(10)173(210(337)256-141(68-74-170(299)300)194(321)261-148(94-122-98-232-126-50-24-23-49-124(122)126)199(326)258-143(89-111(2)3)196(323)247-134(58-32-40-83-223)189(316)262-149(96-160(226)285)180(307)235-100-161(286)233-104-165(290)274-85-42-60-156(274)207(334)267-154(108-280)206(333)265-151(105-277)181(308)237-101-162(287)239-117(12)213(340)276-87-44-62-158(276)214(341)275-86-43-61-157(275)208(335)268-153(107-279)204(331)249-132(56-30-38-81-221)187(314)246-131(55-29-37-80-220)186(313)245-130(54-28-36-79-219)185(312)244-129(53-27-35-78-218)184(311)243-128(52-26-34-77-217)183(310)242-127(176(227)303)51-25-33-76-216)272-201(328)146(92-120-45-19-17-20-46-120)260-197(324)144(90-112(4)5)257-190(317)135(59-41-84-231-215(228)229)255-209(336)172(114(8)9)271-177(304)116(11)240-182(309)138(65-71-167(293)294)251-192(319)139(66-72-168(295)296)252-193(320)140(67-73-169(297)298)253-195(322)142(75-88-342-15)254-191(318)137(63-69-159(225)284)250-188(315)133(57-31-39-82-222)248-203(330)152(106-278)266-198(325)145(91-113(6)7)259-200(327)150(97-171(301)302)263-205(332)155(109-281)269-212(339)175(119(14)283)273-202(329)147(93-121-47-21-18-22-48-121)264-211(338)174(118(13)282)270-164(289)103-236-179(306)136(64-70-166(291)292)241-163(288)102-234-178(305)125(224)95-123-99-230-110-238-123/h17-24,45-50,98-99,110-119,125,127-158,172-175,232,277-283H,16,25-44,51-97,100-109,216-224H2,1-15H3,(H2,225,284)(H2,226,285)(H2,227,303)(H,230,238)(H,233,286)(H,234,305)(H,235,307)(H,236,306)(H,237,308)(H,239,287)(H,240,309)(H,241,288)(H,242,310)(H,243,311)(H,244,312)(H,245,313)(H,246,314)(H,247,323)(H,248,330)(H,249,331)(H,250,315)(H,251,319)(H,252,320)(H,253,322)(H,254,318)(H,255,336)(H,256,337)(H,257,317)(H,258,326)(H,259,327)(H,260,324)(H,261,321)(H,262,316)(H,263,332)(H,264,338)(H,265,333)(H,266,325)(H,267,334)(H,268,335)(H,269,339)(H,270,289)(H,271,304)(H,272,328)(H,273,329)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H4,228,229,231)/t115-,116-,117-,118+,119+,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,172-,173-,174-,175-/m0/s1",c1[nH]cnc1C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4c[nH]c(c45)cccc5)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N7CCC[C@H]7C(=O)N8CCC[C@H]8C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N)CCCCN,C215H347N61O65S,,D09729,131704317,310265161,85662,CHEMBL2108336,,17295846,,4858.56,-33.10335577,"Alimentary Tract and Metabolism; Amino Acids, Peptides, and Proteins; Blood Glucose Lowering Agents; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; GLP-1 Agonists; Glucagon-like Peptide-1 (GLP-1) Agonists; Glucagon-like peptide-1 (GLP-1) analogues; Incretin Mimetics"
DB09266,Technetium Tc-99m tilmanocept,1262984-82-6,approved; investigational,,, ,,,,,347910428,,,,,,NA,NA,Diagnostic Radiopharmaceuticals; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Technetium (99Mtc) Compounds; Tumour Detection
DB09267,Strontium ranelate,135459-87-9,approved; withdrawn,XXUZFRDUEGQHOV-UHFFFAOYSA-J,"InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4",[O-]C(=O)CN(CC([O-])=O)c1c(C#N)c(CC([O-])=O)c(s1)C([O-])=O,C12H6N2O8SSr2,,,6918182,310265162,,CHEMBL3707306,,5293393,50248156,513.49,0.267561022,"Bone Density Conservation Agents; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Musculo-Skeletal System; Strontium; Sulfur Compounds"
DB09268,Picosulfuric acid,10040-34-3,approved,UJIDKYTZIQTXPM-UHFFFAOYSA-N,"InChI=1S/C18H15NO8S2/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25/h1-12,18H,(H,20,21,22)(H,23,24,25)",OS(=O)(=O)Oc1ccc(cc1)C(c2ccccn2)c3ccc(cc3)OS(=O)(=O)O,C18H15NO8S2,,,5243,310265163,,CHEMBL1741134,,5053,,437.44,-1.515115243,"Acids, Acyclic; Alimentary Tract and Metabolism; Carboxylic Acids; Contact Laxatives; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Laxatives; Pyridines; Tricarboxylic Acids"
DB09269,Phenylacetic acid,103-82-2,approved,WLJVXDMOQOGPHL-UHFFFAOYSA-N,"InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)",OC(=O)Cc1ccccc1,C8H8O2,C07086,,999,310265164,30745,CHEMBL1044,PAC,10181341,16419,136.1479,1.610994105,"Acids, Carbocyclic; Ammonium Ion Binding Activity; Carboxylic Acids; Nitrogen Binding Agent; Noxae; Toxic Actions; Urea Cycle Disorder Agents"
DB09270,Ubidecarenone,303-98-0,approved; investigational; nutraceutical,ACTIUHUUMQJHFO-UPTCCGCDSA-N,"InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+",COC1=C(OC)C(=O)C(=C(C)C1=O)C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C,C59H90O4,C11378,D01065,5281915,310265165,46245,CHEMBL454801,U10,4445197,,863.3435,17.15612829,"Agents Causing Muscle Toxicity; Benzoquinones; Cardiac Therapy; Cardiovascular System; Coenzymes; Diet, Food, and Nutrition; Electron Transport Chain Complex Proteins; Enzymes and Coenzymes; Food; Food and Beverages; Growth Substances; Hypoglycemia-Associated Agents; Micronutrients; Other Nutritional Agents; P-glycoprotein substrates; Physiological Phenomena; Quinones; Vitamins"
DB09272,Eluxadoline,864821-90-9,approved; investigational,QFNHIDANIVGXPE-FNZWTVRRSA-N,"InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1",Cc1cc(C(=O)N)cc(C)c1C[C@H](N)C(=O)N(Cc2cc(C(=O)O)c(cc2)OC)[C@@H](C)c3nc(c[nH]3)-c4ccccc4,C32H35N5O5,,D10403,11250029,310265167,85980,CHEMBL2159122,,9425062,50393720,569.662,1.798414933,"Alimentary Tract and Metabolism; Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antipropulsives; Azoles; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Miscellaneous GI Drugs; Mixed Agonist / Antagonist Opioids; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; Opioid Antagonists; Opioids; Receptors, Opioid, delta, antagonists & inhibitors; Receptors, Opioid, mu, agonists; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB09274,Artesunate,88495-63-0,approved; investigational,FIHJKUPKCHIPAT-AHIGJZGOSA-N,"InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1",[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3O[C@H]([C@@H]4C)OC(=O)CCC(=O)O,C19H28O8,,D02482,6917864,310265169,63918,CHEMBL361497,D95,5293084,,384.425,3.104253674,"Acids, Acyclic; Anions; Anthelmintics; Anti-Infective Agents; Antimalarials; Antineoplastic Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiplatyhelmintic Agents; Antiprotozoals; Antiviral Agents; Artemisinin and Derivatives, Plain; Artemisinins; BCRP/ABCG2 Substrates; Carboxylic Acids; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 Substrates; Dicarboxylic Acids; Electrolytes; Free Radicals; Hydrocarbons; Ions; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; Oxides; Oxygen Compounds; P-glycoprotein substrates; Peroxides; Reactive Oxygen Species; Schistosomicides; Terpenes; UGT1A9 Substrates; UGT2B7 substrates"
DB09275,Bismuth subcitrate potassium,880149-29-1,approved; investigational,YDDTTXDPCSCLKY-UHFFFAOYSA-H,"InChI=1S/2C6H7O7.Bi.5K/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;/h2*1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;;/q2*-1;+3;5*+1/p-6",[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O,C12H8BiK5O14,,,118987133,347827831,,,,34989447,,780.654,-1.322687452,Bismuth containing drugs; Neurotoxic agents
DB09276,Sodium aurothiomalate,12244-57-4,approved; investigational,VXIHRIQNJCRFQX-UHFFFAOYSA-K,"InChI=1S/C4H6O4S.Au.2Na/c5-3(6)1-2(9)4(7)8;;;/h2,9H,1H2,(H,5,6)(H,7,8);;;/q;3*+1/p-3",[O-]C(=O)CC(S[Au])C([O-])=O,C4H3AuNa2O4S,,,16760302,310265170,35864,,,20946,,390.07,-0.1051,"Acids, Acyclic; Antiinflammatory and Antirheumatic Products; Antirheumatic Agents; Carboxylic Acids; Dicarboxylic Acids; Drugs that are Mainly Renally Excreted; Gold Compounds; Gold Preparations; Hydroxy Acids; Malates; Musculo-Skeletal System; Organogold Compounds; Organometallic Compounds; Specific Antirheumatic Agents; Sulfhydryl Compounds; Sulfur Compounds; Thiomalates; UGT1A1 Inhibitors"
DB09277,Choline C 11,87591-54-6,approved; investigational,SGMZJAMFUVOLNK-ULWFUOSBSA-M,"InChI=1S/C5H14NO.ClH/c1-6(2,3)4-5-7;/h7H,4-5H2,1-3H3;1H/q+1;/p-1/i1-1;",C[N+](C)([11CH3])CCO,C5H14ClNO,,,14989482,310265171,72321,CHEMBL2095207,,28514887,,138.62,-4.662269163,Drugs that are Mainly Renally Excreted
DB09278,Activated charcoal,64365-11-3,approved,OKTJSMMVPCPJKN-UHFFFAOYSA-N,InChI=1S/C,[C],C,,D03251,297,347827832,27594,CHEMBL2106049,,4575370,,12.011,0,"Adsorption; Alimentary Tract and Metabolism; Anions; Antacids and Adsorbents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antidotes; Antifoaming Agents; Carbon; Charcoal Preparations; Compounds used in a research, industrial, or household setting; Electrolytes; Elements; Intestinal Adsorbents; Ions; Microspheres; Oxygen Compounds; Protective Agents"
DB09280,Lumacaftor,936727-05-8,approved,UFSKUSARDNFIRC-UHFFFAOYSA-N,"InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)",O=C(O)c1cccc(c1)-c2nc(ccc2C)NC(=O)C3(CC3)c(c4)ccc(c45)OC(O5)(F)F,C24H18F2N2O5,,D10134,16678941,310265173,90951,CHEMBL2103870,,17611836,,452.414,5.768111058,"Amines; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Dioxoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; P-glycoprotein inducers; P-glycoprotein inhibitors; Pyridines; Respiratory System"
DB09281,Magnesium trisilicate,14987-04-3,approved,GXGAKHNRMVGRPK-UHFFFAOYSA-N,"InChI=1S/2Mg.O8Si3/c;;1-9(2)7-11(5,6)8-10(3)4/q2*+2;-4",[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O,Mg2O8Si3,,D03271,5311266,310265174,,CHEMBL2096633,,4470779,,260.857,-2.6712,"Acids; Acids, Noncarboxylic; Agents that produce neuromuscular block (indirect); Aluminum and magnesium containing antacids; Anions; Antacids; Calculi Dissolution Agent; Drugs that are Mainly Renally Excreted; Electrolytes; Gastric Acid Lowering Agents; Gastrointestinal Agents; Ions; Laxatives; Magnesium Compounds; Metal cations; Metal divalent cations; Minerals; Osmotic Laxatives; Oxides; Oxygen Compounds; Silicates; Silicon Compounds"
DB09282,Molsidomine,25717-80-0,approved; investigational,XLFWDASMENKTKL-UHFFFAOYSA-N,"InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3",CCOC(=O)[N-]c1c[n+](no1)N2CCOCC2,C9H14N4O4,,D01320,5353788,310265175,92623,CHEMBL1329455,,4090,39912,242.235,-1.01689134,"Azoles; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Morpholines; Nitric Oxide Donors; Oxadiazoles; Oxazines; Oxazoles; Sydnones; Vasodilating Agents; Vasodilators Used in Cardiac Diseases"
DB09287,Polyethylene glycol,25322-68-3,approved; vet_approved,,, ,,,D03370,,347910429,,CHEMBL1201478,,,,NA,NA,"Alcohols; Alimentary Tract and Metabolism; Compounds used in a research, industrial, or household setting; Drug Delivery Systems; Drug Therapy; Drugs for Constipation; Electrolytes; Ethylene Glycols; Excipients; Gastrointestinal Agents; Glycols; Laxatives; Macromolecular Substances; Manufactured Materials; Osmotic Activity; Osmotic Laxatives; P-glycoprotein inhibitors; Pegylated agents; Pharmaceutic Aids; Pharmaceutical Preparations; Pharmaceutical Vehicles; Polyethylene Glycols; Polymers; Solvents; Stimulation Large Intestine Fluid/Electrolyte Secretion; Surface-Active Agents; Therapeutics"
DB09291,Rolapitant,552292-08-7,approved; investigational,FIVSJYGQAIEMOC-ZGNKEGEESA-N,"InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1",FC(F)(F)c1cc(cc(c1)C(F)(F)F)[C@@H](C)OC[C@](CC2)(c3ccccc3)NC[C@@]24CCC(=O)N4,C25H26F6N2O2,,D10742,10311306,310265183,90908,CHEMBL3707331,,8486772,,500.485,5.003099035,"Alimentary Tract and Metabolism; Antiemetics and Antinauseants; BCRP/ABCG2 Inhibitors; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Cyclic; Neurokinin 1 Antagonists; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; P-glycoprotein inhibitors; Polycyclic Compounds; Substance P/Neurokinin-1 Receptor Antagonist"
DB09292,Sacubitril,149709-62-6,approved,PYNXFZCZUAOOQC-UTKZUKDTSA-N,"InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m1/s1",CCOC(=O)[C@H](C)C[C@H](NC(=O)CCC(=O)O)Cc1ccc(cc1)-c2ccccc2,C24H29NO5,,D10225,9811834,310265184,134714,CHEMBL3137301,,7987587,,411.498,3.787722778,"Acids, Acyclic; Agents causing angioedema; Amino Acids; Amino Acids, Peptides, and Proteins; Azoles; Butyrates; Carboxylic Acids; Cardiovascular System; Drugs that are Mainly Renally Excreted; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypotensive Agents; Lipids; Neprilysin Inhibitor; Neprilysin, antagonists & inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors"
DB09293,Iodide I-131,14914-30-8,approved; investigational,XMBWDFGMSWQBCA-RNFDNDRNSA-M,InChI=1S/HI/h1H/p-1/i1+4,[131I-],I,,D02259,167195,310265185,,CHEMBL1201084,,146281,,130.9067,1.02055578,Diagnostic Radiopharmaceuticals; Iodine (131I) Compounds; Radioactive Therapeutic Agent; Radiopharmaceutical Activity; Therapeutic Radiopharmaceuticals; Thyroid Diagnostic Radiopharmaceuticals
DB09296,Ombitasvir,1258226-87-7,approved; investigational,PIDFDZJZLOTZTM-KHVQSSSXSA-N,"InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1",COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC,C50H67N7O8,,D10745,54767916,310265188,85183,CHEMBL3127326,,31136214,,894.127,7.488872402,"Acids, Acyclic; Amides; Amines; Aniline Compounds; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; BCRP/ABCG2 Substrates; Carboxylic Acids; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; Hepatitis C Virus NS5A Inhibitor; P-glycoprotein substrates; UGT1A1 Inhibitors"
DB09297,Paritaprevir,1216941-48-8,approved; investigational,UAUIUKWPKRJZJV-QPLHLKROSA-N,"InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1",C1CC1S(=O)(=O)NC(=O)[C@]23[C@@H](C2)/C=C\CCCCC[C@H](NC(=O)c4cnc(C)cn4)C(=O)N5[C@H](C(=O)N3)C[C@H](C5)Oc6nc(cccc7)c7c(c68)cccc8,C40H43N7O7S,,D10580,68498031,310265189,85188,CHEMBL3391662,,32700634,,765.89,2.489347323,Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; BCRP/ABCG2 Inhibitors; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; HCV NS3/4A Protease Inhibitors; NS3/4A Protease Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; OATP1B3 substrates; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; UGT1A1 Inhibitors
DB09299,Tenofovir alafenamide,379270-37-8,approved,LDEKQSIMHVQZJK-CAQYMETFSA-N,"InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1",c1ccccc1O[P@](=O)(N[C@@H](C)C(=O)OC(C)C)CO[C@H](C)Cn2cnc(c23)c(N)ncn3,C21H29N6O5P,,D10428,9574768,310265191,90926,CHEMBL2107825,,7849225,,476.474,1.875368177,"Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Direct Acting Antivirals; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Nephrotoxic agents; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; Purines; Tenofovir and prodrugs"
DB09300,Butylscopolamine,7182-53-8,approved; investigational; vet_approved,YBCNXCRZPWQOBR-WVHCHWADSA-N,"InChI=1S/C21H30NO4/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14/h5-9,15-20,23H,3-4,10-13H2,1-2H3/q+1/t15-,16-,17-,18+,19-,20+,22?/m1/s1",CCCC[N+]1(C)[C@H]([C@H](O2)[C@H]2[C@H]13)C[C@@H](C3)OC(=O)[C@H](CO)c4ccccc4,C21H30NO4,,D01451,6852391,310265192,145701,CHEMBL1618102,,21782131,,360.473,-1.943485307,"Agents producing tachycardia; Alimentary Tract and Metabolism; Alkaloids; Amines; Ammonium Compounds; Anticholinergic Agents; Antimuscarinics Antispasmodics; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Belladonna Alkaloids, Semisynthetic, Quaternary Ammonium Compounds; Belladonna and Derivatives, Plain; Bicyclo Compounds, Heterocyclic; Cholinergic Agents; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Muscarinic Antagonists; Neurotransmitter Agents; Nitrogen Compounds; Onium Compounds; Parasympatholytics; Peripheral Nervous System Agents; Quaternary Ammonium Compounds; Scopolamine Derivatives; Tropanes"
DB09301,Chondroitin sulfate,24967-93-9,approved; investigational; nutraceutical,,, ,,C00607,D00080,,347910430,,,,,,NA,NA,"Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Carbohydrates; Chondroitin; Drugs that are Mainly Renally Excreted; Glycosaminoglycans; Musculo-Skeletal System; Polysaccharides"
DB09313,Ioxaglic acid,59017-64-0,approved; investigational,TYYBFXNZMFNZJT-UHFFFAOYSA-N,"InChI=1S/C24H21I6N5O8/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43)",CNC(=O)c1c(I)c(c(I)c(c1I)N(C)C(=O)C)C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(c2I)C(=O)NCCO,C24H21I6N5O8,,D01761,3742,310265198,31718,CHEMBL1201291,,3611,,1268.886,3.751404304,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodobenzoates; Radiographic Contrast Agent; Triiodobenzoic Acids; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB09314,Technetium Tc-99m pertechnetate,23288-61-1,approved; investigational,ZTFPRNKAHXDALS-RCUQKECRSA-N,InChI=1S/4H2O.Tc/h4*1H2;/q;;;;-1/i;;;;1+1,[O],H8O4Tc,,D08761,131709156,310265199,,CHEMBL2109884,,,,169.968,-0.652,"Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Indicators and Reagents; Laboratory Chemicals; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Technetium Compounds; Thyroid Diagnostic Radiopharmaceuticals"
DB09315,Xenon-133,14932-42-4,approved,FHNFHKCVQCLJFQ-NJFSPNSNSA-N,InChI=1S/Xe/i1+2,[133Xe],Xe,,,66376,310265200,,CHEMBL1200685,,59751,,132.9059,0,Diagnostic Radiopharmaceuticals; Elements; Gases; Inhalation Diagnostic Agent; Isotopes; Noble Gases; Radioisotopes; Radiopharmaceutical Activity; Respiratory System; Xenon; Xenon Isotopes
DB09316,Thallous Chloride,7791-12-0,approved,GBECUEIQVRDUKB-UHFFFAOYSA-M,InChI=1S/ClH.Tl/h1H;/q;+1/p-1,[Cl-],ClTl,C15226,,24642,310265201,37117,CHEMBL2110567,,23044,,239.836,0.5345,"Elements; Metals; Metals, Heavy; Radioactive Diagnostic Agent"
DB09317,"Synthetic Conjugated Estrogens, A",,approved,,, ,,,,,347910437,,CHEMBL1201649,,,,NA,NA,"Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estrogens; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Thyroxine-binding globulin inducers"
DB09318,"Synthetic Conjugated Estrogens, B",746658-13-9,approved,,, ,,,D05987,,347910438,,CHEMBL1201467,,,,NA,NA,"Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estrogens; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Thyroxine-binding globulin inducers"
DB09319,Carindacillin,35531-88-5,approved; investigational,JIRBAUWICKGBFE-MNRDOXJOSA-N,"InChI=1S/C26H26N2O6S/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32)/t18?,19-,20+,23-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)C(c3ccccc3)C(=O)Oc(cc4)cc(c45)CCC5,C26H26N2O6S,,,,,52015,CHEMBL1596,,84127,,494.56,3.626894876,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillin G; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB09320,Procaine benzylpenicillin,54-35-3,approved; vet_approved,WHRVRSCEWKLAHX-LQDWTQKMSA-N,"InChI=1S/C16H18N2O4S.C13H20N2O2/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);5-8H,3-4,9-10,14H2,1-2H3/t11-,12+,14-;/m1./s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)Cc3ccccc3,C29H38N4O6S,,,5903,310265202,52154,CHEMBL1628385,,5692,,570.71,1.080677953,"Acids, Carbocyclic; Amides; Aminobenzoates; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Benzene Derivatives; Benzoates; Beta-Lactam Antibacterials; Beta-Lactamase Sensitive Penicillins; beta-Lactams; Carboxylic Acids; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lactams; para-Aminobenzoates; Penicillin G; Penicillins; Sulfur Compounds"
DB09321,Zinc oxide,1314-13-2,approved,XLOMVQKBTHCTTD-UHFFFAOYSA-N,InChI=1S/O.Zn,O=[Zn],OZn,,D01170,14806,310265203,36560,CHEMBL1201128,,14122,,81.408,-0.1954,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Anions; Basic Ointments and Protectants; Basic Powders and Demulcents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Copper Absorption Inhibitor; Cosmetics; Dermatologicals; Electrolytes; Household Products; Ions; Metal cations; Metal divalent cations; Oxides; Oxygen Compounds; Protective Agents; Radiation-Protective Agents; Sunscreen Agents; Vasoprotectives; Zinc Compounds"
DB09322,Zinc sulfate,7733-02-0,approved; investigational,NWONKYPBYAMBJT-UHFFFAOYSA-L,"InChI=1S/H2O4S.Zn/c1-5(2,3)4;/h(H2,1,2,3,4);/q;+2/p-2",[O-]S([O-])(=O)=O,O4SZn,,,24424,310265204,35176,CHEMBL1200929,,22833,,161.472,-0.841552023,"Acids; Acids, Noncarboxylic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Alimentary Tract and Metabolism; Anions; Astringents; Cardiovascular System; Copper Absorption Inhibitor; Dermatologicals; Electrolytes; Ions; Metal cations; Metal divalent cations; Mineral Supplements; Minerals; Misc. Skin and Mucous Membrane Agents; Sulfates; Sulfur Acids; Sulfur Compounds; Sulfuric Acids; Vasoprotectives; Zinc Compounds"
DB09324,Sulbactam,68373-14-8,approved,FKENQMMABCRJMK-RITPCOANSA-N,"InChI=1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1",O=C1C[C@H](N12)S(=O)(=O)C(C)(C)[C@@H]2C(=O)O,C8H11NO5S,C07770,D02223,130313,310265206,9321,CHEMBL403,0RN,115306,50021954,233.242,-0.891405583,"Amides; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactamase Inhibitors; beta-Lactams; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Sulfur Compounds"
DB09325,Sodium fluoride,7681-49-4,approved,PUZPDOWCWNUUKD-UHFFFAOYSA-M,InChI=1S/FH.Na/h1H;/q;+1/p-1,[F-],FNa,C08142,,5235,310265207,28741,CHEMBL1528,,5045,50209223,41.9882,0.14883864,"Alimentary Tract and Metabolism; Anions; Caries Prophylactic Agents; Cariostatic Agents; Compounds used in a research, industrial, or household setting; Dental Agents; Drugs that are Mainly Renally Excreted; Fluorides; Fluorine Compounds; Ions; Manufactured Materials; Mineral Supplements; Miscellaneous Therapeutic Agents; Mouthwashes and Gargles; Protective Agents; Sodium Compounds; Stomatological Preparations"
DB09326,Ammonia N-13,34819-78-8,approved,QGZKDVFQNNGYKY-BJUDXGSMSA-N,InChI=1S/H3N/h1H3/i1-1,[13NH3],H3N,,,119432,310265208,135980,CHEMBL1201189,,106665,,16.03,-0.978,Radioactive Diagnostic Agent; Radiopharmaceutical Activity
DB09327,Tegafur-uracil,74578-38-4,approved; investigational,DHMYGZIEILLVNR-UHFFFAOYSA-N,"InChI=1S/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8)",O=c1[nH]c(=O)n(cc1F)C2CCCO2,C12H13FN4O5,,,104747,310265209,,,,94558,,312.257,0.023826538,Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 Substrates
DB09330,Osimertinib,1421373-65-0,approved,DUYJMQONPNNFPI-UHFFFAOYSA-N,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",CN(C)CCN(C)c1cc(OC)c(cc1NC(=O)C=C)Nc2nccc(n2)-c3cn(C)c(c34)cccc4,C28H33N7O2,,,71496458,310265210,90943,CHEMBL3353410,YY3,31042598,50029668,499.619,4.486981489,"Acids, Acyclic; Acrylates; Amides; Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Breast Cancer Resistance Protein Inhibitors; Carboxylic Acids; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB09332,Kappadione,131-13-5,approved,GZBACHSOZNEZOG-UHFFFAOYSA-J,"InChI=1S/C11H12O8P2.4Na/c1-7-6-10(18-20(12,13)14)8-4-2-3-5-9(8)11(7)19-21(15,16)17;;;;/h2-6H,1H3,(H2,12,13,14)(H2,15,16,17);;;;/q;4*+1/p-4",c1cccc(c12)c(OP([O-])([O-])=O)c(C)cc2OP([O-])([O-])=O,C11H8Na4O8P2,,,8555,310265211,,,,8237,,422.084,1.561283027,NA
DB09333,Iopodic acid,5587-89-3,approved; investigational; withdrawn,YQNFBOJPTAXAKV-UHFFFAOYSA-N,"InChI=1S/C12H13I3N2O2/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19/h5-6H,3-4H2,1-2H3,(H,18,19)",CN(C)/C=N/c1c(I)cc(I)c(c1I)CCC(=O)O,C12H13I3N2O2,,,5241,310265212,,CHEMBL3306201,,20473670,,597.961,3.402889446,"Benzene Derivatives; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Hydrocarbons, Iodinated; Iodobenzenes; Watersoluble, Hepatotropic X-Ray Contrast Media; X-Ray Contrast Media, Iodinated"
DB09335,Alatrofloxacin,146961-76-4,approved; withdrawn,UUZPPAMZDFLUHD-VUJLHGSVSA-N,"InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1",C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H]1[C@@H]([C@@H]12)CN(C2)c(c(F)c3)nc(c34)n(cc(c4=O)C(=O)O)-c5ccc(F)cc5F,C26H25F3N6O5,,,3086677,310265213,135829,CHEMBL1201197,,21243647,,558.518,-0.833638065,"Anti-Infective Agents; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Quinolines; Quinolones; Topoisomerase II Inhibitors; Topoisomerase Inhibitors"
DB09336,Technetium Tc-99m nofetumomab merpentan,165942-79-0,approved; withdrawn,,, ,,,,,347910442,,,,,,NA,NA,NA
DB09337,Medical air,132259-10-0,approved; vet_approved,,, ,,,,,347910443,,,,,,NA,NA,Medical Gases; Other Miscellaneous Therapeutic Agents
DB09340,Tyropanoic acid,27293-82-9,approved,YMOXVLQZFAUUKI-UHFFFAOYSA-N,"InChI=1S/C15H18I3NO3/c1-3-5-12(20)19-14-11(17)7-10(16)9(13(14)18)6-8(4-2)15(21)22/h7-8H,3-6H2,1-2H3,(H,19,20)(H,21,22)",CCCC(=O)Nc1c(I)cc(I)c(c1I)CC(CC)C(=O)O,C15H18I3NO3,,,5611,310265215,135862,CHEMBL1201261,,5409,,641.026,6.212766028,"Compounds used in a research, industrial, or household setting; Contrast Media; Watersoluble, Hepatotropic X-Ray Contrast Media; X-Ray Contrast Media, Iodinated"
DB09341,"Dextrose, unspecified form",,approved; vet_approved,,, ,,,,,310265216,,,,,,NA,NA,"Caloric Agents; Cardiac Function; Compounds used in a research, industrial, or household setting; Diabetes Mellitus; Hemodialysis Solution; Miscellaneous Therapeutic Agents"
DB09342,Propoxycaine,86-43-1,approved,CAJIGINSTLKQMM-UHFFFAOYSA-N,"InChI=1S/C16H26N2O3/c1-4-10-20-15-12-13(17)7-8-14(15)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3",CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,C16H26N2O3,C07895,,6843,310265217,8496,CHEMBL1195,,6582,50225492,294.395,2.601716342,"Acids, Carbocyclic; Aminobenzoates; Anesthetics; Anesthetics, Local; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoate Ethers; Hydroxybenzoates; para-Aminobenzoates; Peripheral Nervous System Agents; Phenols; Phenyl Ethers; Sensory System Agents"
DB09343,Tipiracil,183204-74-2,approved; investigational,QQHMKNYGKVVGCZ-UHFFFAOYSA-N,"InChI=1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)",O=c1[nH]c(=O)[nH]c(c1Cl)CN2CCCC2=N,C9H11ClN4O2,,,6323266,310265218,90879,CHEMBL235668,,13243748,20079,242.662,-1.981075347,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Substrates; MATE substrates; OCT2 Substrates; OCT2 substrates with narrow therapeutic index; Pyrimidines; Pyrimidinones; Thymidine Phosphorylase Inhibitor"
DB09345,Pramocaine,140-65-8,approved,DQKXQSGTHWVTAD-UHFFFAOYSA-N,"InChI=1S/C17H27NO3/c1-2-3-12-20-16-5-7-17(8-6-16)21-13-4-9-18-10-14-19-15-11-18/h5-8H,2-4,9-15H2,1H3",CCCCOc1ccc(cc1)OCCCN2CCOCC2,C17H27NO3,C07892,,4886,310265219,8357,CHEMBL1198,PX9,4717,50225493,293.407,2.841906109,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Anesthetics; Anesthetics for Topical Use; Anesthetics, Local; Antipruritics and Local Anesthetics; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Cardiovascular System; Central Nervous System Agents; Central Nervous System Depressants; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Oxazines; Peripheral Nervous System Agents; Sensory System Agents; Vasoprotectives"
DB09346,Metrizoic acid,1949-45-7,approved,GGGDNPWHMNJRFN-UHFFFAOYSA-N,"InChI=1S/C12H11I3N2O4/c1-4(18)16-10-7(13)6(12(20)21)8(14)11(9(10)15)17(3)5(2)19/h1-3H3,(H,16,18)(H,20,21)",CC(=O)N(C)c1c(I)c(C(=O)O)c(I)c(c1I)NC(=O)C,C12H11I3N2O4,C14165,,2528,310265220,34847,CHEMBL1736,,2433,,627.943,2.757148962,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodobenzoates; Radiographic Contrast Agent; Triiodobenzoic Acids; Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media; X-Ray Contrast Activity; X-Ray Contrast Media, Iodinated"
DB09348,Propiolactone,57-57-8,approved; withdrawn,VEZXCJBBBCKRPI-UHFFFAOYSA-N,InChI=1S/C3H4O2/c4-3-1-2-5-3/h1-2H2,O=C1CCO1,C3H4O2,C19297,D05630,2365,310265222,49073,CHEMBL1200627,,2275,,72.063,-0.139109899,"Anti-Infective Agents; Compounds used in a research, industrial, or household setting; Disinfectants; Lactones"
DB09350,Piperonyl butoxide,51-03-6,approved; vet_approved,FIPWRIJSWJWJAI-UHFFFAOYSA-N,"InChI=1S/C19H30O5/c1-3-5-7-20-8-9-21-10-11-22-14-17-13-19-18(23-15-24-19)12-16(17)6-4-2/h12-13H,3-11,14-15H2,1-2H3",CCCCOCCOCCOCc(cc(c12)OCO2)c(c1)CCC,C19H30O5,C18880,D08383,5794,310265223,32687,CHEMBL1201131,,5590,181115,338.4385,4.104762737,"Agrochemicals; Benzodioxoles; Compounds used in a research, industrial, or household setting; Dioxoles; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pesticide Synergists; Pesticides; Toxic Actions"
DB09351,Levobetaxolol,93221-48-8,approved; investigational,NWIUTZDMDHAVTP-KRWDZBQOSA-N,"InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1",CC(C)NC[C@H](O)COc1ccc(cc1)CCOCC2CC2,C18H29NO3,,,60657,310265224,59254,CHEMBL1201274,,54669,25752,307.434,2.539234387,Adrenergic Antagonists; Adrenergic beta-Antagonists; Agents causing hyperkalemia; Bradycardia-Causing Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates
DB09352,Hydroxyamphetamine,103-86-6,approved,GIKNHHRFLCDOEU-UHFFFAOYSA-N,"InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3",CC(N)Cc1ccc(O)cc1,C9H13NO,,,3651,347827833,103855,CHEMBL1546,,3525,81459,151.2056,0.999905754,Adrenergic Agonists; Amines; Amphetamines; Autonomic Agents; Ethylamines; Mydriatics; Peripheral Nervous System Agents; Phenethylamines; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetics
DB09353,Octasulfur,10544-50-0,approved,JLQNHALFVCURHW-UHFFFAOYSA-N,InChI=1S/S8/c1-2-4-6-8-7-5-3-1,S1SSSSSSS1,S8,,,66348,347827834,29385,,PS9,59726,,256.52,4.755188349,Chalcogens; Elements; Keratolytic Agents
DB09355,Sulfabenzamide,127-71-9,approved,PBCZLFBEBARBBI-UHFFFAOYSA-N,"InChI=1S/C13H12N2O3S/c14-11-6-8-12(9-7-11)19(17,18)15-13(16)10-4-2-1-3-5-10/h1-9H,14H2,(H,15,16)",Nc1ccc(cc1)S(=O)(=O)NC(=O)c2ccccc2,C13H12N2O3S,,,,,94677,CHEMBL1243,BS4,5128,,276.311,1.593133376,Amides; Sulfones; Sulfur Compounds
DB09357,Dexpanthenol,81-13-0,approved,SNPLKNRPJHDVJA-ZETCQYMHSA-N,"InChI=1S/C9H19NO4/c1-9(2,6-12)7(13)8(14)10-4-3-5-11/h7,11-13H,3-6H2,1-2H3,(H,10,14)/t7-/m0/s1",OCC(C)(C)[C@@H](O)C(=O)NCCCO,C9H19NO4,C05944,D00193,131204,347827835,,CHEMBL1200979,,115991,,205.2515,-1.700513424,"Alanine; Alimentary Tract and Metabolism; Amino Acids; Amino Acids, Peptides, and Proteins; Cicatrizants; Dermatologicals; Drugs that are Mainly Renally Excreted; Imides; Ophthalmologicals; Preparations for Treatment of Wounds and Ulcers; Sensory Organs; Vitamin B Complex; Vitamins; Wound Healing"
DB09364,Procaine merethoxylline,60064-28-0,approved,XRCLWOYOVQUZLE-UHFFFAOYSA-M,"InChI=1S/C15H20NO6.C13H20N2O2.Hg.H2O/c1-11(21-8-7-20-2)9-16-15(19)12-5-3-4-6-13(12)22-10-14(17)18;1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11;;/h3-6,11H,1,7-10H2,2H3,(H,16,19)(H,17,18);5-8H,3-4,9-10,14H2,1-2H3;;1H2/q;;+1;/p-1",COCCOC(C)C/N=C(\O)c1ccccc1OCC([O-])=O,C28H41HgN3O9,,,,,,,,21243345,,764.24,0.83365999,NA
DB09366,Propyliodone,587-61-1,approved,ROSXARVHJNYYDO-UHFFFAOYSA-N,"InChI=1S/C10H11I2NO3/c1-2-3-16-9(14)6-13-4-7(11)10(15)8(12)5-13/h4-5H,2-3,6H2,1H3",CCCOC(=O)Cn1cc(I)c(=O)c(I)c1,C10H11I2NO3,,D01755,,,32064,CHEMBL1200821,,4780,,447.011,3.131378206,"Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Iodopyridones; Non-Watersoluble X-Ray Contrast Media; Pyridines; Pyridones; X-Ray Contrast Media, Iodinated"
DB09369,Polyestradiol phosphate,28014-46-2,approved,,, ,,,D07434,,,,CHEMBL1201477,,,,NA,NA,"Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Estradiol Congeners; Estranes; Estrenes; Estrogens; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroids"
DB09370,Sodium phosphate P 32,7635-46-3,approved,BNIILDVGGAEEIG-JCIGTKTHSA-L,"InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2/i;;5+1",O[32P]([O-])([O-])=O,HNa2O4P,,,,,,CHEMBL2107525,,64319,,142.957,-1.020103823,Antineoplastic Agents; Diagnostic Agents; Narrow Therapeutic Index Drugs; Radioactive Diagnostic Agent; Therapeutic Radiopharmaceuticals; Various Therapeutic Radiopharmaceuticals
DB09371,Norethynodrel,68-23-5,approved,ICTXHFFSOAJUMG-SLHNCBLASA-N,"InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,16-18,22H,4-12H2,2H3/t16-,17-,18+,19+,20+/m1/s1",C#C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)C4=C(CC3)CC(=O)CC4,C20H26O2,C14249,D05207,,,34895,CHEMBL1387,,5995,50410507,298.426,2.813824966,"Adrenal Cortex Hormones; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Norpregnanes; Norpregnenes; Norsteroids; Polycyclic Compounds; Progestin Contraceptives; Progestins; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB09372,Tannic acid,1401-55-4,approved,LRBQNJMCXXYXIU-YIILYMKVSA-N,"InChI=1S/C76H52O46/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26/h1-20,52,63-65,76-101H,21H2/t52-,63-,64+,65-,76?/m1/s1",Oc1c(O)cc(cc1O)C(=O)Oc2c(O)c(O)cc(c2)C(=O)OC[C@H]3OC(OC(=O)c4cc(c(O)c(O)c4)OC(=O)c5cc(O)c(O)c(O)c5)[C@H](OC(=O)c6cc(c(O)c(O)c6)OC(=O)c7cc(O)c(O)c(O)c7)[C@@H](OC(=O)c8cc(c(O)c(O)c8)OC(=O)c9cc(O)c(O)c(O)c9)[C@@H]3OC(=O)c1cc(c(O)c(O)c1)OC(=O)c1cc(O)c(O)c(O)c1,C76H52O46,,,,347910448,75211,,,17288010,,1701.206,13.51200405,"Compounds used in a research, industrial, or household setting"
DB09373,Trolamine polypeptide oleate condensate,,approved; vet_approved,,, ,,,,,,,,,,,NA,NA,NA
DB09374,Indocyanine green acid form,28782-33-4,approved; investigational,BDBMLMBYCXNVMC-UHFFFAOYSA-O,"InChI=1S/C43H48N2O6S2/c1-42(2)38(44(28-14-16-30-52(46,47)48)36-26-24-32-18-10-12-20-34(32)40(36)42)22-8-6-5-7-9-23-39-43(3,4)41-35-21-13-11-19-33(35)25-27-37(41)45(39)29-15-17-31-53(49,50)51/h5-13,18-27H,14-17,28-31H2,1-4H3,(H-,46,47,48,49,50,51)/p+1",c1cccc(c12)c3c(cc2)N(CCCCS(=O)(=O)O)C(\C3(C)C)=C/C=C/C=C/C=C/C(C4(C)C)=[N+](CCCCS(=O)(=O)O)c(c45)ccc6c5cccc6,C43H49N2O6S2,,D01342,11967809,347827836,31696,CHEMBL1615807,,18109,,753.99,6.053551064,"BSEP/ABCB11 Substrates; Cardiac Function; Coloring Agents; Compounds used in a research, industrial, or household setting; Diagnostic Dye; Liver Function; Roentgenography"
DB09375,Chymotrypsin,03-07-9004,approved; vet_approved,,, ,,,D03484,,347910449,,CHEMBL1201465,,,,NA,NA,"Blood and Blood Forming Organs; Chymotrypsin, antagonists & inhibitors; Endopeptidases; Enzymes; Enzymes and Coenzymes; Hydrolases; Ophthalmologicals; Peptide Hydrolases; Sensory Organs; Serine Endopeptidases; Serine Proteases; Surgical Aids"
DB09376,Lapyrium,109260-82-4,approved,UGJWZYARKOFRDB-UHFFFAOYSA-O,"InChI=1S/C21H34N2O3/c1-2-3-4-5-6-7-8-9-11-14-21(25)26-18-15-22-20(24)19-23-16-12-10-13-17-23/h10,12-13,16-17H,2-9,11,14-15,18-19H2,1H3/p+1",CCCCCCCCCCCC(=O)OCCNC(=O)C[n+]1ccccc1,C21H35N2O3,,,22660,347827837,135534,CHEMBL1201786,,21241,,363.521,0.15959902,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Pyridines"
DB09377,Undecoylium chloride iodine complex,1338-54-1,approved,OSCJJMKLQGAGML-UHFFFAOYSA-N,"InChI=1S/C12H16N2O3.ClH/c1-2-12(16)17-9-6-13-11(15)10-14-7-4-3-5-8-14;/h3-5,7-8H,2,6,9-10H2,1H3;1H",CCC(=O)OCCNC(=O)C[n+]1ccccc1,C12H17ClN2O3,,,,,,,,14224,,272.73,-3.841518965,NA
DB09378,Fluprednisolone,53-34-9,approved,MYYIMZRZXIQBGI-HVIRSNARSA-N,"InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1",OCC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4,C21H27FO5,C14618,D04227,,,34474,CHEMBL1200774,,5665,,378.44,0.933270631,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Corticosteroids for Systemic Use; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated"
DB09380,Sodium chromate Cr-51,10039-53-9,approved,PXLIDIMHPNPGMH-PJWPDVOUSA-N,InChI=1S/Cr.2Na.4O/q;2*+1;;;2*-1/i1-1;;;;;;,[O-][51Cr]([O-])(=O)=O,CrNa2O4,,,,,,,,2338409,,160.92,-2.5252,Radioactive Diagnostic Agent
DB09381,Esterified estrogens,,approved,,, ,,,,,347910451,,,,,,NA,NA,Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Estrogens; Thyroxine-binding globulin inducers
DB09382,Iodohippurate sodium I-131,881-17-4,approved,XYITYKDGJLHYPW-UDYUCQKZSA-M,"InChI=1S/C9H8INO3.Na/c10-7-4-2-1-3-6(7)9(14)11-5-8(12)13;/h1-4H,5H2,(H,11,14)(H,12,13);/q;+1/p-1/i10+4;",[O-]C(=O)CNC(=O)c1c([131I])cccc1,C9H7INNaO3,,,,,134740,CHEMBL1200763,,64825,,331.055,1.454489963,Diagnostic Radiopharmaceuticals; Renal System
DB09383,Meprednisone,1247-42-3,approved; investigational,PIDANAQULIKBQS-RNUIGHNZSA-N,"InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1",OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]([C@@]12C)[C@H]3[C@H](C(=O)C2)[C@]4(C)C(CC3)=CC(=O)C=C4,C22H28O5,,,,,135573,CHEMBL1201148,,4447637,,372.461,2.023477004,"Adrenal Cortex Hormones; Corticosteroids; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Glucocorticoids; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnanes; Steroids; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroxine-binding globulin inhibitors"
DB09385,Cyanocobalamin Co-57,13115-03-2,approved,FSCKVFYFBCQWRU-LFHMENBZSA-L,"InChI=1S/C62H91N13O14P.CN.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-2;/h20-21,23,28,31,34-37,41,52-53,56-57,70,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;/q;-1;+3/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56?,57+,59-,60+,61+,62+;;/m1../s1/i;;1-2",Cc(c1)c(C)cc(c12)[nH+]cn2[C@@H]3[C@H](O)[C@@H]([C@H](O3)CO)OP([O-])(=O)O[C@H](C)CNC(=O)CC[C@](C)([C@@H](CC(=O)N)C4[C@]56C)/C([N-]4)=C(\C)C7=N/C(C(C)(C)[C@@H]7CCC(=O)N)=C\C8=N/C([C@@](C)(CC(=O)N)[C@@H]8CCC(=O)N)=C(/C)C(=N5)[C@H]([C@]6(C)CC(=O)N)CCC(=O)N,C63H89CoN14O14P,,,,,,,,,,1354.399,-2.055057174,Radioactive Diagnostic Agent; Radiopharmaceutical Activity
DB09389,Norgestrel,6533-00-2,approved,WWYNJERNGUHSAO-UHFFFAOYSA-N,"InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3",C#CC1(O)CCC(C12CC)C3C(CC2)C4C(CC3)=CC(=O)CC4,C21H28O2,,D00954,4542,347827838,7630,CHEMBL2107797,,4383,,312.453,3.661796602,"Adrenal Cortex Hormones; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Norpregnanes; Norpregnenes; Norsteroids; Polycyclic Compounds; Progestin Contraceptives; Progestins; Progestogens and Estrogens, Sequential Preparations; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB09394,Phosphoric acid,7664-38-2,approved,NBIIXXVUZAFLBC-UHFFFAOYSA-N,"InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)",OP(=O)(O)O,H3O4P,C00009,,1004,347827839,26078,CHEMBL1187,,979,14671,97.9952,-1.020103823,"Acid Etching, Dental; Acids; Acids, Noncarboxylic; Compounds used in a research, industrial, or household setting; Dental Materials; Drugs that are Mainly Renally Excreted; Manufactured Materials; Phosphorus Acids; Phosphorus Compounds"
DB09395,Sodium acetate,127-09-3,approved; investigational,VMHLLURERBWHNL-UHFFFAOYSA-M,"InChI=1S/C2H4O2.Na/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1",CC([O-])=O,C2H3NaO2,,,517045,347827840,32954,CHEMBL1354,,29105,,82.0338,-0.223345714,"Acetates; Acids, Acyclic; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Carboxylic Acids; Drugs that are Mainly Renally Excreted; Electrolyte Solutions; Fatty Acids; Fatty Acids, Volatile; I.V. Solution Additives; Lipids; Replacement Preparations"
DB09397,Technetium Tc-99m sulfur colloid,,approved; investigational,FJTPHHNWVXNMEK-NLQOEHMXSA-N,InChI=1S/S8.Tc/c1-2-4-6-8-7-5-3-1;/i;1+2,S1SSSSSSS1,S8Tc,,D06048,76957057,347827842,,CHEMBL1201529,,,,355.39,4.755188349,"Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Hepatic and Reticulo Endothelial System; Indicators and Reagents; Laboratory Chemicals; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Sulfur Compounds; Technetium (99Mtc), Particles and Colloids; Technetium Compounds"
DB09398,Fluoride ion F-18,67862-54-8,approved,KRHYYFGTRYWZRS-BJUDXGSMSA-M,InChI=1S/FH/h1H/p-1/i1-1,[18F-],F,,,23690531,347827843,,CHEMBL1248,,8373100,,18.0015,0.14883864,Diagnostic Radiopharmaceuticals; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Tumour Detection
DB09400,Selenomethionine Se-75,1187-56-0,approved,RJFAYQIBOAGBLC-ZEMBQCNESA-N,"InChI=1S/C5H11NO2Se/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1/i9-4",C[75Se]CC[C@H](N)C(=O)O,C5H11NO2Se,,,,,,CHEMBL1201054,,59637,,192.071,-3.301994959,Selenium Compounds
DB09401,Isosorbide,652-67-5,approved; investigational,KLDXJTOLSGUMSJ-JGWLITMVSA-N,"InChI=1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/s1",O[C@H]1CO[C@@H]([C@@H]12)[C@@H](CO2)O,C6H10O4,,,,,6060,CHEMBL1200660,,12077,,146.1412,-1.406611704,"Adrenal Cortex Hormones; Alcohols; Antianginal Agents; Carbohydrates; Cardiovascular Agents; Contraceptive Agents, Male; Diuretics; Diuretics, Osmotic; Hormonal Contraceptives for Systemic Use; Hydrocarbons; Natriuretic Agents; Noxae; Organic Nitrates; Reproductive Control Agents; Sesquiterpenes; Sugar Alcohols; Terpenes; Toxic Actions; Vasodilating Agents"
DB09403,Iocetamic acid,16034-77-8,approved,GSVQIUGOUKJHRC-UHFFFAOYSA-N,"InChI=1S/C12H13I3N2O3/c1-5(12(19)20)4-17(6(2)18)11-8(14)3-7(13)10(16)9(11)15/h3,5H,4,16H2,1-2H3,(H,19,20)",OC(=O)C(C)CN(C(=O)C)c1c(I)cc(I)c(N)c1I,C12H13I3N2O3,,,,,91662,CHEMBL1200770,,25724,,613.96,2.992252849,"Benzene Derivatives; Contrast Media; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; Hydrocarbons, Iodinated; Watersoluble, Hepatotropic X-Ray Contrast Media; X-Ray Contrast Media, Iodinated"
DB09407,Magnesium chloride,7786-30-3,approved,TWRXJAOTZQYOKJ-UHFFFAOYSA-L,InChI=1S/2ClH.Mg/h2*1H;/q;;+2/p-2,[Mg+2],Cl2Mg,C07755,,5360315,347827844,6636,CHEMBL2219642,,22987,,95.211,-0.57,"Acids; Acids, Noncarboxylic; Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Anions; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Calculi Dissolution Agent; Chlorides; Chlorine Compounds; Drugs that are Mainly Renally Excreted; Electrolyte Solutions; Electrolytes; Hemodialysis Solution; I.V. Solution Additives; Ions; Magnesium Compounds; Metal cations; Metal divalent cations; Mineral Supplements; Minerals"
DB09409,Magnesium acetate tetrahydrate,16674-78-5,approved,XKPKPGCRSHFTKM-UHFFFAOYSA-L,"InChI=1S/2C2H4O2.Mg.4H2O/c2*1-2(3)4;;;;;/h2*1H3,(H,3,4);;4*1H2/q;;+2;;;;/p-2",CC([O-])=O,C4H14MgO8,,,134717,347827845,,CHEMBL3989858,,118734,,214.453,-0.223345714,Agents that produce neuromuscular block (indirect); Calculi Dissolution Agent; Laxatives; Osmotic Laxatives
DB09413,Monopotassium phosphate,7778-77-0,approved; investigational; vet_approved,GNSKLFRGEWLPPA-UHFFFAOYSA-M,"InChI=1S/K.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1",OP([O-])(=O)O,H2KO4P,,,516951,347827846,63036,CHEMBL1200925,,22914,50004328,136.0855,-1.020103823,"Acids; Acids, Noncarboxylic; Anions; Buffers; Cariostatic Agents; Compounds used in a research, industrial, or household setting; Dental Materials; Electrolytes; Ions; Laboratory Chemicals; Laxatives; Manufactured Materials; Osmotic Laxatives; Phosphate salts; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Potassium Salt; Protective Agents; Replacement Preparations"
DB09414,Dipotassium phosphate,04-11-7758,approved,ZPWVASYFFYYZEW-UHFFFAOYSA-L,"InChI=1S/2K.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2",OP([O-])([O-])=O,HK2O4P,C13197,,24450,347827847,131527,CHEMBL1200459,,22858,,174.1759,-1.020103823,"Acids; Acids, Noncarboxylic; Anions; Buffers; Cariostatic Agents; Compounds used in a research, industrial, or household setting; Dental Materials; Electrolytes; Ions; Laboratory Chemicals; Laxatives; Manufactured Materials; Osmotic Laxatives; Phosphate salts; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Potassium Salt; Protective Agents"
DB09418,Potassium perchlorate,7778-74-7,approved; investigational,YLMGFJXSLBMXHK-UHFFFAOYSA-M,"InChI=1S/ClHO4.K/c2-1(3,4)5;/h(H,2,3,4,5);/q;+1/p-1",[O-][Cl](=O)(=O)=O,ClKO4,,,516900,347827848,,CHEMBL1200696,,22913,,138.549,-0.097653697,"Acids; Acids, Noncarboxylic; Antithyroid agents; Chlorine Compounds; Drugs that are Mainly Renally Excreted; Perchlorates; Potassium Salt; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Thyroid Products"
DB09419,Xylose,58-86-6,approved,PYMYPHUHKUWMLA-VPENINKCSA-N,"InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h1,3-5,7-10H,2H2/t3-,4+,5+/m0/s1",OC[C@@H](O)[C@H](O)[C@@H](O)C=O,C5H10O5,,,644160,347827849,15936,,XLS,559198,,150.1299,-2.938025621,Carbohydrates; Monosaccharides; Pentoses
DB09420,Iodide I-123,69239-56-1,approved,XMBWDFGMSWQBCA-AHCXROLUSA-M,InChI=1S/HI/h1H/p-1/i1-4,[123I-],I,,,135300,347827850,,CHEMBL1249,,119193,,122.9061,1.02055578,Diagnostic Radiopharmaceuticals; Elements; Halogens; Iodine Isotopes; Isotopes; Radioactive Diagnostic Agent; Radioisotopes; Radiopharmaceutical Activity; Thyroid Diagnostic Radiopharmaceuticals
DB09421,Protirelin,24305-27-9,approved; investigational,XNSAINXGIQZQOO-SRVKXCTJSA-N,"InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1",O=C1N[C@@H](CC1)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N3CCC[C@H]3C(=O)N,C16H22N6O4,C03958,D00176,638678,347827851,35940,CHEMBL1472,,554166,50072394,362.3837,-3.267828731,"Amino Acids, Peptides, and Proteins; Diagnostic Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary Hormone-Releasing Hormones; Proteins; Tests for Thyreoidea Function; Thyroid Products; Thyrotropin-Releasing Hormone"
DB09423,Technetium Tc-99m polyphosphate,,approved,,, ,,,,,,,,,,,NA,NA,"Acids; Acids, Noncarboxylic; Anions; Electrolytes; Ions; Phosphate salts; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds"
DB09425,Indium In-111 pentetate,135998-32-2,approved,BLALCKLYSDDAOC-JWFOFJTQSA-K,"InChI=1S/C14H23N3O10.In/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3/i;1-4",OC(=O)CN(CC(=O)O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O,C14H20InN3O10,,D04527,131704319,347827852,,,,25048228,,501.23,-6.273562252,Central Nervous System; Diagnostic Radiopharmaceuticals; Lead Chelator; Radioactive Diagnostic Agent; Radiopharmaceutical Activity
DB09443,Krypton Kr 81m,15678-91-8,approved,DNNSSWSSYDEUBZ-OIOBTWANSA-N,InChI=1S/Kr/i1-3,[81Kr],Kr,,,,,136002,CHEMBL1201096,,59755,,80.9166,0,Diagnostic Radiopharmaceuticals; Respiratory System
DB09449,"Sodium phosphate, monobasic",7558-80-7,approved,AJPJDKMHJJGVTQ-UHFFFAOYSA-M,"InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1",OP([O-])(=O)O,H2NaO4P,,,23672064,347827853,37585,CHEMBL1368,,22626,,119.977,-1.020103823,"Acids; Acids, Noncarboxylic; Agents that reduce seizure threshold; Anions; Electrolytes; Ions; Laxatives; Osmotic Laxatives; Phosphate salts; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Potassium Salt; Urinary Acidifying Agents"
DB09460,Sodium carbonate,497-19-8,approved,CDBYLPFSWZWCQE-UHFFFAOYSA-L,"InChI=1S/CH2O3.2Na/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2",[O-]C([O-])=O,CNa2O3,,,10340,347827855,29377,CHEMBL186314,,9916,,105.9884,0.250051366,"Acids; Acids, Noncarboxylic; Alkalies; Anions; Carbon Compounds, Inorganic; Carbonic Acid; Electrolytes; Ions"
DB09461,Xenon Xe-127,13994-19-9,approved,FHNFHKCVQCLJFQ-AHCXROLUSA-N,InChI=1S/Xe/i1-4,[127Xe],Xe,,,,,,CHEMBL1200673,,146100,,126.9052,0,Elements; Gases; Inhalation Diagnostic Agent; Isotopes; Noble Gases; Radioactive Diagnostic Agent; Radioisotopes; Radiopharmaceutical Activity; Xenon; Xenon Isotopes
DB09462,Glycerin,56-81-5,approved; investigational,PEDCQBHIVMGVHV-UHFFFAOYSA-N,"InChI=1S/C3H8O3/c4-1-3(6)2-5/h3-6H,1-2H2",OCC(O)CO,C3H8O3,C00116,D00028,753,347827856,17754,CHEMBL692,GOL,733,,92.0938,-1.839014023,"Alcohols; Alimentary Tract and Metabolism; Basic Ointments and Protectants; Carbohydrates; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Cryoprotective Agents; Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Drugs for Constipation; Enemas; Increased Histamine Release; Increased IgG Production; Irrigating Solutions; Laxatives; Non-Standardized Chemical Allergen; Osmotic Laxatives; Other Cold and Cough Preparations; Other Diagnostics; Protective Agents; Solvents; Sugar Alcohols; Triose Sugar Alcohols"
DB09472,Sodium sulfate,7757-82-6,approved; vet_approved,PMZURENOXWZQFD-UHFFFAOYSA-L,"InChI=1S/2Na.H2O4S/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2",[O-]S([O-])(=O)=O,Na2O4S,C13199,D01732,24436,347827857,32149,CHEMBL233406,,22844,50101993,142.042,-0.841552023,"Acids; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Anions; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Electrolytes; Gastrointestinal Agents; Ions; Laxatives; Mineral Supplements; Osmotic Laxatives; Sodium; Sulfur Acids; Sulfur Compounds; Sulfuric Acids"
DB09473,Indium In-111 oxyquinoline,65389-08-4,approved,AEGSYIKLTCZUEZ-FZTWWWDYSA-K,"InChI=1S/3C9H7NO.In/c3*11-8-5-1-3-7-4-2-6-10-9(7)8;/h3*1-6,11H;/q;;;+3/p-3/i;;;1-4",[O-]c1cccc(c12)cccn2,C27H18InN3O3,,D04526,119117,347827858,,,,106429,,543.364,1.82733515,Radioactive Diagnostic Agent; Radiopharmaceutical Activity
DB09477,Enalaprilat,76420-72-9,approved,LZFZMUMEGBBDTC-QEJZJMRPSA-N,"InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1",OC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N[C@H](C(=O)O)CCc2ccccc2,C18H24N2O5,C11720,D03769,5462501,347827859,4786,CHEMBL577,EAL,4575429,50367254,348.3936,-1.050258626,"Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Amino Acids, Peptides, and Proteins; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Decreased Blood Pressure; Dipeptides; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hypotensive Agents; Oligopeptides; Peptides; Photosensitizing Agents; Protease Inhibitors"
DB09479,Rubidium Rb-82,,approved; investigational,NCCSSGKUIKYAJD-OIOBTWANSA-N,InChI=1S/Rb/q+1/i1-3,[82Rb+],Rb,,,71357,347827860,,CHEMBL1200727,,8351588,,81.9177,0,Radioactive Diagnostic Agent; Radiopharmaceutical Activity
DB09480,Iofetamine I-123,75917-92-9,approved,ISEHJSHTIVKELA-DCWJVSPSSA-N,"InChI=1S/C12H18IN/c1-9(2)14-10(3)8-11-4-6-12(13)7-5-11/h4-7,9-10,14H,8H2,1-3H3/i13-4",CC(C)NC(C)Cc1ccc([123I])cc1,C12H18IN,,,,,31708,,,137706,,299.189,3.939158333,"Agents producing tachycardia; Agents that produce hypertension; Amines; Amphetamines; Central Nervous System; Compounds used in a research, industrial, or household setting; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Ethylamines; Indicators and Reagents; Iodine (123I) Compounds; Laboratory Chemicals; Phenethylamines; Radiopharmaceuticals; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetics"
DB09481,Magnesium carbonate,546-93-0,approved; investigational,ZLNQQNXFFQJAID-UHFFFAOYSA-L,"InChI=1S/CH2O3.Mg/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2",[O-]C([O-])=O,CMgO3,C12893,,11029,347827861,31793,CHEMBL1200736,,10563,,84.314,0.250051366,"Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Aluminum and magnesium containing antacids; Antacids; Bleaching Agents; Calculi Dissolution Agent; Compounds used in a research, industrial, or household setting; Drugs for Acid Related Disorders; Drugs for Constipation; Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Drugs that are Mainly Renally Excreted; Elements; Gastric Acid Lowering Agents; Hygroscopic Agents; Laxatives; Laxatives, magnesium containing; Magnesium Compounds; Metal cations; Metal divalent cations; Metals; Metals, Alkaline Earth; Metals, Light; Noxae; Osmotic Laxatives; Oxidants; Toxic Actions"
DB09483,Potassium lactate,996-31-6,approved,PHZLMBHDXVLRIX-UHFFFAOYSA-M,"InChI=1S/C3H6O3.K/c1-2(4)3(5)6;/h2,4H,1H3,(H,5,6);/q;+1/p-1",CC(O)C([O-])=O,C3H5KO3,,,,,,CHEMBL1200664,,55189,,128.1683,-0.471829518,Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Electrolyte Solutions; I.V. Solution Additives; Laxatives; Potassium Salt
DB09484,Sodium fluorophosphate,10163-15-2,approved,BFDWBSRJQZPEEB-UHFFFAOYSA-L,"InChI=1S/FH2O3P.2Na/c1-5(2,3)4;;/h(H2,2,3,4);;/q;2*+1/p-2",[O-]P([O-])(F)=O,FNa2O3P,,D05864,,347910454,86431,CHEMBL1908359,,22686,,143.949,-0.542296759,"Acids; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Anions; Caries Prophylactic Agents; Cariostatic Agents; Compounds used in a research, industrial, or household setting; Dental Agents; Electrolytes; Fluorides; Fluorine Compounds; Hydrofluoric Acid; Ions; Laxatives; Manufactured Materials; Mineral Supplements; Osmotic Laxatives; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Protective Agents; Stomatological Preparations; Toothpastes"
DB09487,Iotrolan,79770-24-4,approved,XUHXFSYUBXNTHU-UHFFFAOYSA-N,"InChI=1S/C37H48I6N6O18/c1-48(32-28(40)22(34(64)44-12(4-50)16(58)8-54)26(38)23(29(32)41)35(65)45-13(5-51)17(59)9-55)20(62)3-21(63)49(2)33-30(42)24(36(66)46-14(6-52)18(60)10-56)27(39)25(31(33)43)37(67)47-15(7-53)19(61)11-57/h12-19,50-61H,3-11H2,1-2H3,(H,44,64)(H,45,65)(H,46,66)(H,47,67)",OCC(O)C(CO)NC(=O)c1c(I)c(c(I)c(c1I)C(=O)NC(CO)C(O)CO)N(C)C(=O)CC(=O)N(C)c2c(I)c(C(=O)NC(CO)C(O)CO)c(I)c(c2I)C(=O)NC(CO)C(O)CO,C37H48I6N6O18,,D01714,,,31715,CHEMBL1200555,,3607,,1626.242,-3.66653661,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodobenzoates; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Media, Iodinated"
DB09488,Acrivastine,87848-99-5,approved,PWACSDKDOHSSQD-IUTFFREVSA-N,"InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+",C1CCCN1C/C=C(\c2ccc(C)cc2)c3cccc(n3)/C=C/C(=O)O,C22H24N2O2,,D02760,5284514,310265225,83168,CHEMBL1224,,4447574,,348.4382,1.710666395,"Antihistamines for Systemic Use; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Neurotransmitter Agents; Potential QTc-Prolonging Agents; Pyridines; QTc Prolonging Agents; Respiratory System"
DB09490,Indium In-111 chloride,50800-85-6,approved,PSCMQHVBLHHWTO-FZTWWWDYSA-K,InChI=1S/3ClH.In/h3*1H;/q;;;+3/p-3/i;;;1-4,Cl[111In](Cl)Cl,Cl3In,,,49800058,347827862,,,,4954694,,217.26,1.9035,Radioactive Diagnostic Agent; Radiopharmaceutical Activity
DB09494,Cetyl alcohol,36653-82-4,approved,BXWNKGSJHAJOGX-UHFFFAOYSA-N,"InChI=1S/C16H34O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h17H,2-16H2,1H3",CCCCCCCCCCCCCCCCO,C16H34O,,,2682,347827863,16125,CHEMBL706,PL3,2581,,242.4406,6.140145926,Alcohols; Drugs that are Mainly Renally Excreted; Lipids
DB09495,Avobenzone,70356-09-1,approved; investigational,XNEFYCZVKIDDMS-UHFFFAOYSA-N,"InChI=1S/C20H22O3/c1-20(2,3)16-9-5-14(6-10-16)18(21)13-19(22)15-7-11-17(23-4)12-8-15/h5-12H,13H2,1-4H3",COc1ccc(cc1)C(=O)CC(=O)c2ccc(cc2)C(C)(C)C,C20H22O3,,,51040,310265226,134751,CHEMBL1200522,,46261,,310.393,4.564745835,"Compounds used in a research, industrial, or household setting; Cosmetics; Dermatologicals; Household Products; Ketones; Protective Agents; Radiation-Protective Agents; Sunscreen Agents"
DB09496,Octinoxate,5466-77-3,approved; investigational,YBGZDTIWKVFICR-JLHYYAGUSA-N,"InChI=1S/C18H26O3/c1-4-6-7-15(5-2)14-21-18(19)13-10-16-8-11-17(20-3)12-9-16/h8-13,15H,4-7,14H2,1-3H3/b13-10+",COc1ccc(cc1)/C=C/C(=O)OCC(CC)CCCC,C18H26O3,,D05225,5355130,347827864,88667,CHEMBL1200608,,4511170,,290.3972,5.38022022,"Acids, Carbocyclic; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Cosmetics; Dermatologicals; Drugs that are Mainly Renally Excreted; Emollients and Protectives; Household Products; Protective Agents; Protectives Against UV-Radiation; Protectives Against UV-Radiation for Topical Use; Radiation-Protective Agents; Sunscreen Agents"
DB09498,Strontium chloride Sr-89,38270-90-5,approved; investigational,AHBGXTDRMVNFER-FCHARDOESA-L,InChI=1S/2ClH.Sr/h2*1H;/q;;+2/p-2/i;;1+1,[Cl-],Cl2Sr,,,5362485,347827865,36383,CHEMBL1200625,,64523,,159.81,0.612338722,"Elements; Metals; Metals, Alkaline Earth; Metals, Heavy; Pain Palliation (Bone Seeking Agents); Radioactive Therapeutic Agent; Strontium Radioisotopes; Therapeutic Radiopharmaceuticals; Various Pain Palliation Radiopharmaceuticals"
DB09499,Thiosulfuric acid,13686-28-7,approved; investigational,DHCDFWKWKRSZHF-UHFFFAOYSA-N,"InChI=1S/H2O3S2/c1-5(2,3)4/h(H2,1,2,3,4)",OS(=O)(=S)O,H2O3S2,C05529,,24478,347827866,29279,CHEMBL1208642,,22886,,114.144,0.048317561,"Acids; Acids, Noncarboxylic; Anions; Anti-Infective Agents; Antidotes; Antioxidants; Antituberculosis Agents; Chelating Agents; Compounds used in a research, industrial, or household setting; Electrolytes; Ions; Minerals; Protective Agents; Sequestering Agents; Sulfates; Sulfur Acids; Sulfur Compounds; Sulfuric Acids"
DB09501,Ferric ammonium citrate,1185-57-5,approved; experimental,FRHBOQMZUOWXQL-UHFFFAOYSA-N,"InChI=1S/C6H8O7.Fe.H3N/c7-3(8)1-6(13,5(11)12)2-4(9)10;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;1H3/q;+3;",OC(=O)CC(O)(C(=O)O)CC(=O)O,C6H11FeNO7,,,,,,,,2006378,,264.997,-1.322687452,Amines; Ammonium Compounds; Contrast Media; Iron Compounds; Magnetic Resonance Imaging Contrast Media; Nitrogen Compounds; Onium Compounds; Organometallic Compounds; Paramagnetic Contrast Media
DB09502,Fludeoxyglucose (18F),63503-12-8,approved; investigational,AOYNUTHNTBLRMT-MXWOLSILSA-N,"InChI=1S/C6H11FO5/c7-3(1-8)5(11)6(12)4(10)2-9/h1,3-6,9-12H,2H2/t3-,4+,5+,6+/m0/s1/i7-1",O=C[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO,C6H11FO5,,,68614,347827867,49136,CHEMBL1808698,,61878,,181.15,-2.677268789,"Carbohydrates; Compounds used in a research, industrial, or household setting; Deoxy Sugars; Deoxyglucose; Diagnostic Radiopharmaceuticals; Diagnostic Uses of Chemicals; Drugs that are Mainly Renally Excreted; Indicators and Reagents; Laboratory Chemicals; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Radiopharmaceuticals; Tumour Detection"
DB09507,Ferumoxsil,171544-35-7,approved; experimental,,, ,,,,,,,,,,,NA,NA,"Colloids; Complex Mixtures; Compounds used in a research, industrial, or household setting; Contrast Media; Ferric Compounds; Ferrosoferric Oxide; Ferrous Compounds; Investigative Techniques; Iron Compounds; Macromolecular Substances; Magnetic Resonance Imaging Contrast Media; Magnets; Manufactured Materials; Metal Nanoparticles; Minerals; Nanoparticles; Nanostructures; Organometallic Compounds; Organosilicon Compounds; Pharmaceutical Preparations; Polymers; Silicon Compounds; Superparamagnetic Contrast Media; Technology; Technology, Pharmaceutical"
DB09508,Ferumoxides,,approved,,, ,,,,,,,,,,,NA,NA,"Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Ferric Compounds; Ferrosoferric Oxide; Ferrous Compounds; Glucans; Iron Compounds; Macromolecular Substances; Magnets; Manufactured Materials; Metal Nanoparticles; Minerals; Nanoparticles; Nanostructures; Organometallic Compounds; Polymers; Polysaccharides; Suspensions"
DB09510,Urea C-13,58069-82-2,approved,XSQUKJJJFZCRTK-OUBTZVSYSA-N,"InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4)/i1+1",N[13C](=O)N,CH4N2O,,D01749,636363,347827869,32285,CHEMBL2096648,,552162,,61.048,-1.363833862,Diagnostic Agents; Helicobacter pylori Diagnostic
DB09511,Talc,,approved,,, ,,,,,347910456,,,,,,NA,NA,"Acids; Acids, Noncarboxylic; Anions; Antiperspirants; Compounds used in a research, industrial, or household setting; Cosmetics; Electrolytes; Household Products; Ions; Magnesium Compounds; Metal cations; Metal divalent cations; Minerals; Oxides; Oxygen Compounds; Silicates; Silicon Compounds"
DB09512,Simethicone,8050-81-5,approved,AMTWCFIAVKBGOD-UHFFFAOYSA-N,"InChI=1S/C6H18O2Si2.O2Si/c1-7-10(5,6)8-9(2,3)4;1-3-2/h1-6H3;",CO[Si](C)(C)O[Si](C)(C)C,C6H18O4Si3,,,,347910457,,CHEMBL1200838,,4938661,,238.461,1.7616,"Antifoaming Agents; Compounds used in a research, industrial, or household setting; Dermatologicals; Dimethylpolysiloxanes; Emollients; Macromolecular Substances; Manufactured Materials; Organosilicon Compounds; Polymers; Silicon Compounds; Silicones; Siloxanes; Surface-Active Agents"
DB09513,Urea C-14,594-05-8,approved,XSQUKJJJFZCRTK-NJFSPNSNSA-N,"InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4)/i1+2",N[14C](=O)N,CH4N2O,,,11457650,347827870,134711,CHEMBL2096635,,9632491,,62.048,-1.363833862,NA
DB09516,Mequinol,150-76-5,approved,NWVVVBRKAWDGAB-UHFFFAOYSA-N,"InChI=1S/C7H8O2/c1-9-7-4-2-6(8)3-5-7/h2-5,8H,1H3",COc1ccc(O)cc1,C7H8O2,,,9015,347827871,69441,CHEMBL544,4KS,8665,,124.1372,1.512009229,"Antioxidants; Benzene Derivatives; Compounds used in a research, industrial, or household setting; Depigmenting Activity; Dermatologicals; Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lentigo; Melanin Synthesis Inhibitors; Methyl Ethers; Phenols; Phenyl Ethers; Protective Agents; Skin Lightening Agent"
DB09517,Sodium ferric gluconate complex,34089-81-1,approved,MQBDAEHWGRMADS-XNHLMZCASA-M,"InChI=1S/5C12H22O11.C6H12O7.2Fe.Na.3O/c5*13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;7-1-2(8)3(9)4(10)5(11)6(12)13;;;;;;/h5*4-11,13-20H,1-3H2;2-5,7-11H,1H2,(H,12,13);;;;;;/q;;;;;;2*+3;+1;3*-2/p-1/t5*4-,5-,6-,7-,8+,9-,10+,11-,12+;2-,3-,4+,5-;;;;;;/m111111....../s1",OC[C@@H](O1)[C@@H](O)[C@H](O)[C@]1(CO)O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O,C66H121Fe2NaO65,,,76968835,347827872,,,,34989638,,2089.309,-4.528834964,Iron Preparations; Parenteral Iron Replacement; Phosphate Binder
DB09526,Hydroquinone,123-31-9,approved; investigational,QIGBRXMKCJKVMJ-UHFFFAOYSA-N,"InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H",Oc1ccc(O)cc1,C6H6O2,C00530,D00073,785,310265227,17594,CHEMBL537,HQE,764,26190,110.1106,1.366115173,"Antioxidants; Benzene Derivatives; Compounds used in a research, industrial, or household setting; Depigmenting Activity; Depigmenting Agents; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Melanin Synthesis Inhibitor; Melanin Synthesis Inhibitors; Mutagens; Noxae; Phenols; Protective Agents; Radiation-Protective Agents; Toxic Actions"
DB09531,Perflexane,355-42-0,approved,ZJIJAJXFLBMLCK-UHFFFAOYSA-N,"InChI=1S/C6F14/c7-1(8,3(11,12)5(15,16)17)2(9,10)4(13,14)6(18,19)20",FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,C6F14,,,,,39427,CHEMBL1200607,,9262,,338.044,4.884288275,"Diagnostic Agents; Hydrocarbons; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Ultrasound Contrast Activity; Ultrasound Contrast Media"
DB09534,Ecamsule,92761-26-7,approved,HEAHZSUCFKFERC-UHFFFAOYSA-N,"InChI=1S/C28H34O8S2/c1-25(2)21-9-11-27(25,15-37(31,32)33)23(29)19(21)13-17-5-7-18(8-6-17)14-20-22-10-12-28(24(20)30,26(22,3)4)16-38(34,35)36/h5-8,13-14,21-22H,9-12,15-16H2,1-4H3,(H,31,32,33)(H,34,35,36)",OS(=O)(=O)CC12C(C)(C)C(CC1)/C(C2=O)=C/c3ccc(cc3)/C=C(C(C4(C)C)CC5)/C(=O)C45CS(=O)(=O)O,C28H34O8S2,,,9915879,347827874,135830,CHEMBL3989850,,28534218,,562.69,4.100861719,"Acids; Acids, Noncarboxylic; Compounds used in a research, industrial, or household setting; Cosmetics; Dermatologicals; Household Products; Hydrocarbons; Monoterpenes; Norbornanes; Protective Agents; Radiation-Protective Agents; Sulfur Acids; Sulfur Compounds; Sunscreen Agents; Terpenes"
DB09535,Octocrylene,6197-30-4,approved; investigational,,, ,,,,,347910458,,,,,,NA,NA,"Acids, Acyclic; Carboxylic Acids; Sunscreen Agents"
DB09536,Titanium dioxide,13463-67-7,approved,GWEVSGVZZGPLCZ-UHFFFAOYSA-N,InChI=1S/2O.Ti,O=[Ti]=O,O2Ti,C13409,,26042,347827875,32234,,,24256,,79.865,-0.7028,"Astringents and Deodorants; Biocompatible Materials; Coloring Agents; Compounds used in a research, industrial, or household setting; Cosmetics; Dermatologicals; Elements; Household Products; Manufactured Materials; Metals; Metals, Light; Photosensitizing Agents; Protective Agents; Radiation-Protective Agents; Radiation-Sensitizing Agents; Sunscreen Agents; Transition Elements; Water Pollutants, Chemical"
DB09537,Iodine povacrylex,845736-10-9,approved,,, ,,,,,347910459,,,,,,NA,NA,NA
DB09539,Omega-3-acid ethyl esters,308081-97-2,approved; investigational,,, ,,,,,347910460,,,,,,NA,NA,"Autacoids; Biological Factors; Diet, Food, and Nutrition; Dietary Fats; Dietary Fats, Unsaturated; Eicosanoids; Fats; Fatty Acids; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fish Oils; Food; Food and Beverages; Inflammation Mediators; Lipids; Nootropic Agents; Oils; Pharmaceutical Preparations; Physiological Phenomena"
DB09543,Methyl salicylate,119-36-8,approved; vet_approved,OSWPMRLSEDHDFF-UHFFFAOYSA-N,"InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3",COC(=O)c1ccccc1O,C8H8O3,C12305,D01087,4133,347827876,31832,CHEMBL108545,,13848808,,152.1473,2.323157458,"Acids, Carbocyclic; Antirheumatic Agents; Benzene Derivatives; Benzoates; Betula; Biological Products; Carboxylic Acids; Complex Mixtures; Compounds used in a research, industrial, or household setting; Fixatives; Gaultheria; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Lipids; Oils; Pharmaceutical Preparations; Phenols; Plant Preparations; Salicylates"
DB09546,Iobenguane sulfate I-123,80663-95-2,approved; investigational,XNACDNPGABUBFR-FKNPGSCZSA-N,"InChI=1S/2C8H10IN3.H2O4S/c2*9-7-3-1-2-6(4-7)5-12-8(10)11;1-5(2,3)4/h2*1-4H,5H2,(H4,10,11,12);(H2,1,2,3,4)/i2*9-4;",NC(=N)NCc1cc([123I])ccc1,C16H22I2N6O4S,,,56840904,347827877,,CHEMBL3989523,,32701571,,640.26,1.69418798,Drugs that are Mainly Renally Excreted; Radioactive Diagnostic Agent; Radiopharmaceutical Activity
DB09552,Thonzonium,25466-36-8,approved,IOYZYMQFUSNATM-UHFFFAOYSA-N,"InChI=1S/C32H55N4O/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27-36(2,3)28-26-35(32-33-24-19-25-34-32)29-30-20-22-31(37-4)23-21-30/h19-25H,5-18,26-29H2,1-4H3/q+1",CCCCCCCCCCCCCCCC[N+](C)(C)CCN(c1ncccn1)Cc2ccc(OC)cc2,C32H55N4O,,,5456,347827878,94514,CHEMBL1201322,,5257,59083,511.818,4.918398089,"Amines; Ammonium Compounds; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nitrogen Compounds; Onium Compounds"
DB09555,Dexchlorpheniramine maleate,2438-32-6,approved,DBAKFASWICGISY-DASCVMRKSA-N,"InChI=1S/C16H19ClN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1",c1cccnc1[C@@H](CCN(C)C)c2ccc(Cl)cc2,C20H23ClN2O4,C07783,,5281070,347827879,4465,CHEMBL1200927,,4444527,,390.86,3.584950915,"Agents that reduce seizure threshold; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors; Pyridines; QTc Prolonging Agents; Stereoisomerism"
DB09561,Sodium glycerophosphate,1334-74-3,approved,GEKBIENFFVFKRG-UHFFFAOYSA-L,"InChI=1S/C3H9O6P.2Na/c4-1-3(5)2-9-10(6,7)8;;/h3-5H,1-2H2,(H2,6,7,8);;/q;2*+1/p-2",OCC(O)COP([O-])([O-])=O,C3H7Na2O6P,,,22251426,347827880,,CHEMBL3040581,,14071,,216.036,-1.962580054,Alcohols; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Carbohydrates; Electrolyte Solutions; I.V. Solution Additives; Lipids; Membrane Lipids; Phosphate salts; Phospholipids; Sugar Alcohols; Sugar Phosphates; Triose Sugar Alcohols
DB09563,Choline C-11,94793-58-5,approved,OEYIOHPDSNJKLS-BJUDXGSMSA-N,"InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1/i1-1",C[N+](C)([11CH3])CCO,C5H14NO,,,449688,347827881,72322,,,396147,,103.173,-4.662269163,Radioactive Diagnostic Agent; Radiopharmaceutical Activity
DB09567,Olive oil,8001-25-0,approved,,, ,,,,,347910464,,,,,,NA,NA,"Biological Products; Complex Mixtures; Diet, Food, and Nutrition; Dietary Fats; Dietary Fats, Unsaturated; Fats; Fats, Unsaturated; Food; Food and Beverages; Lipid Emulsion; Lipids; Oils; Physiological Phenomena; Plant Oils; Plant Preparations"
DB09568,Omega-3-carboxylic acids,,approved; investigational,,, ,,,,,347910465,,,,,,NA,NA,"Fatty Acids, Omega-3"
DB09570,Ixazomib,1072833-77-2,approved; investigational,MXAYKZJJDUDWDS-LBPRGKRZSA-N,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)c1cc(Cl)ccc1Cl,C14H19BCl2N2O4,,D10130,25183872,310265228,90942,CHEMBL2141296,6V8,25027391,50398609,361.03,2.5677,"Amino Acids; Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Narrow Therapeutic Index Drugs; Protease Inhibitors; Proteasome Inhibitors"
DB09571,Levmetamfetamine,33817-09-3,approved,MYWUZJCMWCOHBA-SECBINFHSA-N,"InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m1/s1",CN[C@H](C)Cc1ccccc1,C10H15N,,,36604,347827882,136013,CHEMBL1927030,,33634,50359500,149.237,2.236830875,NA
DB11056,Stannous chloride,7772-99-8,approved,AXZWODMDQAVCJE-UHFFFAOYSA-L,InChI=1S/2ClH.Sn/h2*1H;/q;;+2/p-2,[Cl-],Cl2Sn,,,,,78067,,,22887,,189.62,0.612338722,NA
DB11057,Mineral oil,8042-47-5,approved; vet_approved,,, ,,,,,347911096,,,,,,NA,NA,"Alimentary Tract and Metabolism; Basic Ointments and Protectants; Dermatologicals; Drugs for Constipation; Emollients; Hydrocarbons; Laxatives; Softener and Emollient Laxatives; Softeners, Emollients"
DB11058,Petrolatum,08-03-8009,approved; investigational,,, ,,,D05304,,347911097,,,,,,NA,NA,"Basic Ointments and Protectants; Compounds used in a research, industrial, or household setting; Dermatologicals; Emollients; Hydrocarbons; Ointment Bases; Pharmaceutic Aids; Pharmaceutical Preparations"
DB11059,Carboxymethylcellulose,07-11-9000,approved; investigational,,, ,,,,,347911098,,CHEMBL1909054,,,,NA,NA,"Anorexigenic Agents & Respiratory and CNS Stimulants; Artificial Tears; Biopolymers; Bulk-Forming Laxatives; Carbohydrates; Carboxymethylcellulose Sodium; Cellulose; Compounds used in a research, industrial, or household setting; EENT Drugs, Miscellaneous; Gastrointestinal Agents; Glucans; Laxatives; Macromolecular Substances; Manufactured Materials; Polymers; Polysaccharides"
DB11060,Polyvinyl alcohol,9002-89-5,approved,,, ,,,,,347911099,,,,,,NA,NA,"Alcohols; Alkenes; Artificial Tears; Compounds used in a research, industrial, or household setting; EENT Drugs, Miscellaneous; Hydrocarbons; Hydrocarbons, Acyclic; Macromolecular Substances; Manufactured Materials; Plastics; Polyenes; Polymers; Polyvinyls; Vinyl Compounds"
DB11061,Povidone,9003-39-8,approved,,, ,,C19509,D02295,,347911100,,,,,,NA,NA,"Alkenes; Artificial Tears; Biomimetic Materials; Blood Substitutes; Compounds used in a research, industrial, or household setting; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Acyclic; Macromolecular Substances; Manufactured Materials; Pharmaceutic Aids; Pharmaceutical Preparations; Plasma Substitutes; Plastics; Polyenes; Polymers; Polyvinyls; Pyrrolidines; Pyrrolidinones; Vinyl Compounds"
DB11062,Octisalate,118-60-5,approved; investigational,FMRHJJZUHUTGKE-UHFFFAOYSA-N,"InChI=1S/C15H22O3/c1-3-5-8-12(4-2)11-18-15(17)13-9-6-7-10-14(13)16/h6-7,9-10,12,16H,3-5,8,11H2,1-2H3",CCCCC(CC)COC(=O)c1c(O)cccc1,C15H22O3,,,,347911101,88639,CHEMBL1329203,,8061,,250.3334,5.345735294,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Cosmetics; Dermatologicals; Household Products; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Phenols; Protective Agents; Radiation-Protective Agents; Sunscreen Agents"
DB11063,Polysorbate 80,9005-65-6,approved,,, ,,,,,347911102,,,,,,NA,NA,"Alcohols; Artificial Tears; Compounds used in a research, industrial, or household setting; Drug Delivery Systems; Drug Therapy; Ethylene Glycols; Excipients; Glycols; Macromolecular Substances; Manufactured Materials; Pharmaceutic Aids; Pharmaceutical Preparations; Pharmaceutical Vehicles; Polyethylene Glycols; Polymers; Surface-Active Agents; Therapeutics"
DB11064,Homosalate,118-56-9,approved; investigational,WSSJONWNBBTCMG-UHFFFAOYSA-N,"InChI=1S/C16H22O3/c1-11-8-12(10-16(2,3)9-11)19-15(18)13-6-4-5-7-14(13)17/h4-7,11-12,17H,8-10H2,1-3H3",CC1(C)CC(C)CC(C1)OC(=O)c2c(O)cccc2,C16H22O3,,,,347911103,91642,CHEMBL1377575,,8059,,262.349,4.996513303,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Cosmetics; Dermatologicals; Household Products; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Phenols; Protective Agents; Radiation-Protective Agents; Sunscreen Agents"
DB11068,Selenic acid,06-08-7783,approved,QYHFIVBSNOWOCQ-UHFFFAOYSA-N,"InChI=1S/H2O4Se/c1-5(2,3)4/h(H2,1,2,3,4)",O[Se](=O)(=O)O,H2O4Se,C05697,,1089,347827883,18170,CHEMBL2097002,SE4,1058,50147596,144.97,-1.6279,"Alimentary Tract and Metabolism; Antioxidants; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Micronutrients; Mineral Supplements; Physiological Phenomena; Protective Agents; Selenium Compounds; Trace Elements"
DB11071,Phenyl salicylate,118-55-8,approved,ZQBAKBUEJOMQEX-UHFFFAOYSA-N,"InChI=1S/C13H10O3/c14-12-9-5-4-8-11(12)13(15)16-10-6-2-1-3-7-10/h1-9,14H",Oc1ccccc1C(=O)Oc2ccccc2,C13H10O3,C14163,,8361,347827884,34918,CHEMBL1339216,,8058,,214.2167,3.981115907,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Genito Urinary System and Sex Hormones; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Phenols; Urologicals"
DB11072,Hydrogen fluoride,7664-39-3,approved; investigational,KRHYYFGTRYWZRS-UHFFFAOYSA-N,InChI=1S/FH/h1H,[F],FH,C16487,,14917,347827885,29228,CHEMBL1232767,,14214,,20.0063,0.14883864,"Acids; Acids, Noncarboxylic; Dental Agents; Fluorine Compounds"
DB11073,Cetylpyridinium,7773-52-6,approved,NEUSVAOJNUQRTM-UHFFFAOYSA-N,"InChI=1S/C21H38N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22/h15,17-18,20-21H,2-14,16,19H2,1H3/q+1",CCCCCCCCCCCCCCCC[n+]1ccccc1,C21H38N,,,2683,347827886,32914,CHEMBL305906,,2582,80992,304.541,3.470928024,"Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Compounds used in a research, industrial, or household setting; Dermatologicals; Detergents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Household Products; Irrigating Solutions; Medicated Dressings; Medicated Dressings With Antiinfectives; Miscellaneous Anti-infectives; Mouthwashes and Gargles; Pyridines; Pyridinium Compounds; Quaternary Ammonium Compounds; Respiratory System; Surface-Active Agents; Throat Preparations"
DB11074,Dimethicone,63148-62-9,approved,,, ,,,,,347911104,,,,,,NA,NA,"Antifoaming Agents; Basic Ointments and Protectants; Compounds used in a research, industrial, or household setting; Macromolecular Substances; Manufactured Materials; Misc. Skin and Mucous Membrane Agents; Organosilicon Compounds; Polymers; Scabicides and Pediculicides; Silicon Compounds; Silicones; Siloxanes; Skin Barrier Activity"
DB11075,Hypromellose,9004-65-3,approved,,, ,,,,,347911105,,,,,,NA,NA,"Artificial Tears; Biopolymers; Carbohydrates; Cellulose; Compounds used in a research, industrial, or household setting; EENT Drugs, Miscellaneous; Glucans; Macromolecular Substances; Manufactured Materials; Ophthalmologicals; Other Diagnostics; Polymers; Polysaccharides; Sensory Organs; Surgical Aids; Viscoelastic Substances"
DB11077,Polyethylene glycol 400,25322-68-3,approved,,, ,,,,,347911107,,,,,,NA,NA,"Alcohols; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; EENT Drugs, Miscellaneous; Ethylene Glycols; Glycols; Macromolecular Substances; Manufactured Materials; P-glycoprotein inhibitors; Pegylated agents; Polymers"
DB11079,Trolamine salicylate,2174-16-5,approved,UEVAMYPIMMOEFW-UHFFFAOYSA-N,"InChI=1S/C7H6O3.C6H15NO3/c8-6-4-2-1-3-5(6)7(9)10;8-4-1-7(2-5-9)3-6-10/h1-4,8H,(H,9,10);8-10H,1-6H2",OCCN(CCO)CCO,C13H21NO6,,,25213,347827887,,CHEMBL2107288,,23549,,287.312,1.977263402,"Acids, Carbocyclic; Agents causing hyperkalemia; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Benzene Derivatives; Benzoates; Carboxylic Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Nephrotoxic agents; Non COX-2 selective NSAIDS; Phenols; Salicylates; Sunscreen Agents"
DB11080,Silver nitrate,7761-88-8,approved; investigational,SQGYOTSLMSWVJD-UHFFFAOYSA-N,InChI=1S/Ag.NO3/c;2-1(3)4/q+1;-1,[O-]N(=O)=O,AgNO3,,D01730,516904,347827888,32130,CHEMBL177367,,22878,,169.8731,0.028413764,"Acids; Acids, Noncarboxylic; Anions; Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Dermatologicals; Electrolytes; Ions; Nitrates; Nitric Acid; Nitrogen Compounds; Silver Compounds"
DB11081,Aluminum chloride,7446-70-0,approved; investigational,VSCWAEJMTAWNJL-UHFFFAOYSA-K,InChI=1S/Al.3ClH/h;3*1H/q+3;;;/p-3,Cl[Al](Cl)Cl,AlCl3,,,24012,347827889,30114,CHEMBL3833401,,22445,,133.341,1.6535,"Acids; Acids, Noncarboxylic; Aluminium Compounds; Anions; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Antiperspirants; Astringents and Deodorants; Chlorides; Chlorine Compounds; Compounds used in a research, industrial, or household setting; Cosmetics; Dental Agents; Dermatologicals; Electrolytes; Household Products; Ions; Metal cations; Metal divalent cations"
DB11082,Coal tar,8007-45-2,approved,,, ,,,,,347911108,,,,,,NA,NA,Complex Mixtures; Dermatologicals; Keratolytic Agents; Keratoplastic Agents; Tars
DB11085,Resorcinol,108-46-3,approved,GHMLBKRAJCXXBS-UHFFFAOYSA-N,"InChI=1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H",Oc1cc(O)ccc1,C6H6O2,C01751,D00133,5054,347827890,27810,CHEMBL24147,RCO,4878,26189,110.1106,1.366115173,"Agents that modify thyroid function; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Infective Agents; Benzene Derivatives; Dermatologicals; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Ophthalmologicals; Phenols; Root Canal Filling Materials; Sensory Organs"
DB11089,Docusate,10041-19-7,approved,HNSDLXPSAYFUHK-UHFFFAOYSA-N,"InChI=1S/C20H38O7S/c1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2/h16-18H,5-15H2,1-4H3,(H,23,24,25)",CCCCC(CC)COC(=O)CC(S(=O)(=O)O)C(=O)OCC(CC)CCCC,C20H38O7S,C07874,D00305,,347911112,534,CHEMBL1477036,,10862,,422.577,5.238073509,"Alimentary Tract and Metabolism; Drugs for Constipation; Enemas; Laxatives; Softener and Emollient Laxatives; Softeners, Emollients; Succinates; Surface-Active Agents"
DB11090,Potassium nitrate,7757-79-1,approved,FGIUAXJPYTZDNR-UHFFFAOYSA-N,InChI=1S/K.NO3/c;2-1(3)4/q+1;-1,[O-][N+]([O-])=O,KNO3,,,24434,347827891,63043,CHEMBL1644029,,22843,,101.1032,0.028413764,"Acids; Acids, Noncarboxylic; Anions; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Electrolytes; Explosive Agents; Ions; Nitric Acid; Nitrogen Compounds; Potassium Salt"
DB11091,Hydrogen peroxide,7722-84-1,approved; vet_approved,MHAJPDPJQMAIIY-UHFFFAOYSA-N,InChI=1S/H2O2/c1-2/h1-2H,OO,H2O2,C00027,,784,347827892,16240,CHEMBL71595,PEO,763,,34.0147,-0.447202414,"Alimentary Tract and Metabolism; Anions; Anti-Infective Agents; Anti-Infective Agents, Local; Antifibrinolytic Agents; Antiinfectives and Antiseptics for Local Oral Treatment; Antiseptics and Disinfectants; Compounds used in a research, industrial, or household setting; Dermatologicals; Electrolytes; Free Radicals; Ions; Noxae; Otologicals; Oxidants; Oxides; Oxygen Compounds; Peroxides; Reactive Oxygen Species; Sensory Organs; Stomatological Preparations; Toxic Actions"
DB11092,Stannous fluoride,7783-47-3,approved,ANOBYBYXJXCGBS-UHFFFAOYSA-L,InChI=1S/2FH.Sn/h2*1H;/q;;+2/p-2,F[Sn]F,F2Sn,,D05919,24550,347827893,135933,CHEMBL1909079,,22956,,156.71,0.185,"Alimentary Tract and Metabolism; Caries Prophylactic Agents; Compounds used in a research, industrial, or household setting; Stomatological Preparations"
DB11093,Calcium citrate,813-94-5,approved; investigational,FNAQSUUGMSOBHW-UHFFFAOYSA-H,"InChI=1S/2C6H8O7.3Ca/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6",[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O,C12H10Ca3O14,,,13136,347827894,,CHEMBL2106123,,12584,,498.432,-1.322687452,"Acids, Acyclic; Alimentary Tract and Metabolism; Blood Coagulation Factors; Calcium Compounds; Calcium Salts; Carboxylic Acids; Citrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Food; Food Additives; Food and Beverages; Food Ingredients; Mineral Supplements; Phosphate Binder; Physiological Phenomena; Polyvalent cation containing laxatives, antacids, oral supplements; Tricarboxylic Acids"
DB11094,Vitamin D,1406-16-2,approved; nutraceutical; vet_approved,,, ,,,,,347911113,,,,,,NA,NA,"Bone Density Conservation Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Diet, Food, and Nutrition; Food; Food and Beverages; Fused-Ring Compounds; Growth Substances; Micronutrients; Physiological Phenomena; Polycyclic Compounds; Secosteroids; Steroids; Vitamin D and Analogues; Vitamins; Vitamins (Fat Soluble)"
DB11096,Meradimate,134-09-8,approved,SOXAGEOHPCXXIO-UHFFFAOYSA-N,"InChI=1S/C17H25NO2/c1-11(2)13-9-8-12(3)10-16(13)20-17(19)14-6-4-5-7-15(14)18/h4-7,11-13,16H,8-10,18H2,1-3H3",CC(C)C1CCC(C)CC1OC(=O)c2ccccc2N,C17H25NO2,,,,,135974,CHEMBL1597075,,8312,,275.392,4.980647042,"Acids, Carbocyclic; Aminobenzoates; Benzene Derivatives; Benzoates; Carboxylic Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Sunscreen Agents"
DB11098,Potassium bicarbonate,298-14-6,approved,TYJJADVDDVDEDZ-UHFFFAOYSA-M,"InChI=1S/CH2O3.K/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1",OC([O-])=O,CHKO3,C18606,,516893,347827895,81862,CHEMBL2106975,,55053,,100.1151,0.250051366,"Acids; Acids, Noncarboxylic; Agents causing hyperkalemia; Alimentary Tract and Metabolism; Alkalies; Anions; Carbon Compounds, Inorganic; Carbonates; Carbonic Acid; Drugs that are Mainly Renally Excreted; Electrolytes; Ions; Mineral Supplements; Potassium Salt"
DB11100,Allantoin,97-59-6,approved,POJWUDADGALRAB-UHFFFAOYSA-N,"InChI=1S/C4H6N4O3/c5-3(10)6-1-2(9)8-4(11)7-1/h1H,(H3,5,6,10)(H2,7,8,9,11)",NC(=O)NC1NC(=O)NC1=O,C4H6N4O3,C01551,D00121,,347911116,15676,CHEMBL593429,,199,,158.1154,-2.360540882,"Azoles; Basic Ointments and Protectants; Dermatologicals; Herbs and Natural Products; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydantoins; Imidazoles; Imidazolidines; Thyroxine-binding globulin substrates"
DB11102,N-acetyltyrosine,537-55-3,approved,CAHKINHBCWCHCF-JTQLQIEISA-N,"InChI=1S/C11H13NO4/c1-7(13)12-10(11(15)16)6-8-2-4-9(14)5-3-8/h2-5,10,14H,6H2,1H3,(H,12,13)(H,15,16)/t10-/m0/s1",CC(=O)N[C@H](C(=O)O)Cc1ccc(O)cc1,C11H13NO4,,,68310,347827896,21563,CHEMBL65543,3NF,61606,50043802,223.2252,0.592896334,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Drugs that are Mainly Renally Excreted"
DB11104,Sulfur hexafluoride,2551-62-4,approved,SFZCNBIFKDRMGX-UHFFFAOYSA-N,"InChI=1S/F6S/c1-7(2,3,4,5)6",FS(F)(F)(F)(F)F,F6S,,D05962,17358,347827897,30496,CHEMBL1796998,,16425,,146.05,2.276488861,"Acids; Acids, Noncarboxylic; Anions; Electrolytes; Fluorides; Fluorine Compounds; Gases; Hydrofluoric Acid; Ions; Other Diagnostics; Sulfur Compounds; Ultrasound Contrast Activity; Ultrasound Contrast Media"
DB11105,Benzalkonium,,approved; investigational,,, ,,,,,347911117,,,,,,NA,NA,"Amines; Ammonium Compounds; Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Benzalkonium Compounds; Benzylammonium Compounds; Compounds used in a research, industrial, or household setting; Dermatologicals; Detergents; Household Products; Medicated Dressings; Medicated Dressings With Antiinfectives; Miscellaneous Local Anti-infectives; Nitrogen Compounds; Onium Compounds; Pharmaceutic Aids; Pharmaceutical Preparations; Preservatives, Pharmaceutical; Quaternary Ammonium Compounds; Respiratory System; Surface-Active Agents; Throat Preparations"
DB11108,Aluminum sesquichlorohydrate,,approved,,, ,,,,,347911118,,,,,,NA,NA,"Acids; Acids, Noncarboxylic; Alkalies; Aluminium Compounds; Anions; Chlorine Compounds; Electrolytes; Hydroxides; Ions; Metal cations; Metal divalent cations"
DB11110,Magnesium citrate,3344-18-1,approved,PLSARIKBYIPYPF-UHFFFAOYSA-H,"InChI=1S/2C6H8O7.3Mg/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6",[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O,C12H10Mg3O14,,,6099959,347827901,131391,CHEMBL3989480,,2925651,,451.113,-1.322687452,"Acids, Acyclic; Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Calculi Dissolution Agent; Carboxylic Acids; Citrates; Drugs for Constipation; Gastrointestinal Agents; Irrigating Solutions; Laxatives; Laxatives, magnesium containing; Magnesium Compounds; Metal cations; Metal divalent cations; Mineral Supplements; Osmotic Laxatives; Salt Solutions; Tricarboxylic Acids"
DB11112,Lanolin,8006-54-0,approved,,, ,,,,,347911120,,,,,,NA,NA,"Basic Ointments and Protectants; Compounds used in a research, industrial, or household setting; Cosmetics; Household Products; Lipids; Waxes"
DB11114,Eucalyptus oil,8000-48-4,approved,,, ,,,,,347911122,,,,,,NA,NA,Biological Products; Complex Mixtures; Drugs that are Mainly Renally Excreted; Lipids; Oils; Other Cold and Cough Preparations; Plant Oils; Plant Preparations
DB11115,Ensulizole,27503-81-7,approved,UVCJGUGAGLDPAA-UHFFFAOYSA-N,"InChI=1S/C13H10N2O3S/c16-19(17,18)10-6-7-11-12(8-10)15-13(14-11)9-4-2-1-3-5-9/h1-8H,(H,14,15)(H,16,17,18)",OS(=O)(=O)c(cc1)cc(c12)[nH]c(n2)-c3ccccc3,C13H10N2O3S,,,33919,347827902,135132,CHEMBL1987518,,31267,181124,274.29,-0.137752718,"Acids; Acids, Noncarboxylic; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Sulfur Acids; Sulfur Compounds; Sunscreen Agents"
DB11116,Aluminum zirconium trichlorohydrex gly,134375-99-8,approved; experimental,,, ,,,,,347911123,,,,,,NA,NA,NA
DB11117,Undecylenic acid,112-38-9,approved; investigational,FRPZMMHWLSIFAZ-UHFFFAOYSA-N,"InChI=1S/C11H20O2/c1-2-3-4-5-6-7-8-9-10-11(12)13/h2H,1,3-10H2,(H,12,13)",OC(=O)CCCCCCCCC=C,C11H20O2,,,,347911124,35045,CHEMBL1276010,,10771160,50248304,184.2753,3.729751466,"Antifungals for Dermatological Use; Antifungals for Topical Use; Dermatologicals; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Lipids"
DB11118,Ammonia,7664-41-7,approved,,, ,,,,,347911125,,,,,,NA,NA,Gases; Nitrogen Compounds
DB11119,Sodium iodide,7681-82-5,approved,FVAUCKIRQBBSSJ-UHFFFAOYSA-M,InChI=1S/HI.Na/h1H;/q;+1/p-1,[Na+],INa,C14042,,5238,347827903,33167,CHEMBL1644695,,5048,50098561,149.8942,1.02055578,Anions; Electrolytes; Iodides; Iodine Compounds; Ions; Replacement Preparations; Sodium Compounds; Thyroid Diagnostic Radiopharmaceuticals
DB11120,Turpentine,9005-90-7,approved; experimental,,, ,,,,,347911126,,,,,,NA,NA,"Biological Products; Biopolymers; Complex Mixtures; Compounds used in a research, industrial, or household setting; Irritants; Lipids; Macromolecular Substances; Manufactured Materials; Noxae; Oils; Oils, Volatile; Plant Exudates; Polymers; Resins, Plant; Solvents; Toxic Actions"
DB11121,Chloroxylenol,88-04-0,approved,OSDLLIBGSJNGJE-UHFFFAOYSA-N,"InChI=1S/C8H9ClO/c1-5-3-7(10)4-6(2)8(5)9/h3-4,10H,1-2H3",Cc1cc(O)cc(C)c1Cl,C8H9ClO,C14715,D03473,2723,347827904,34393,CHEMBL398440,,21106017,50238619,156.61,3.300567949,"Anti-Infective Agents; Anti-Infective Agents, Local; Antiparasitic Agents; Antiplatyhelmintic Agents; Antiseptics and Disinfectants; Benzene Derivatives; Compounds used in a research, industrial, or household setting; Dermatologicals; Disinfectants; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Miscellaneous Local Anti-infectives; Phenol and Derivatives; Schistosomicides"
DB11123,Hypochlorite,14380-61-1,approved,WQYVRQLZKVEZGA-UHFFFAOYSA-N,InChI=1S/ClO/c1-2/q-1,[O-]Cl,ClO,,,61739,347827905,29222,,,55632,,51.452,0.318193898,"Acids; Acids, Noncarboxylic; Anions; Anti-Infective Agents; Antiseptics and Disinfectants; Chlorine Compounds; Compounds used in a research, industrial, or household setting; Dermatologicals; Disinfectants; Electrolytes; Free Radicals; Ions; Miscellaneous Local Anti-infectives; Noxae; Oxidants; Oxides; Oxygen Compounds; Reactive Oxygen Species; Sodium Compounds; Toxic Actions"
DB11124,Racepinephrine,329-65-7,approved,,, ,,,,,347911128,,,,,,NA,NA,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Alpha-and Beta-adrenergic Agonists; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Bronchodilator Agents; Cardiovascular Agents; Catecholamines; Catechols; Epinephrine and similars; Ethanolamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Mydriatics; Neurotransmitter Agents; Peripheral Nervous System Agents; Phenols; Respiratory System Agents; Sympathomimetics; Vasoconstrictor Agents"
DB11125,Benzethonium,10172-60-8,approved,SIYLLGKDQZGJHK-UHFFFAOYSA-N,"InChI=1S/C27H42NO2/c1-26(2,3)22-27(4,5)24-13-15-25(16-14-24)30-20-19-29-18-17-28(6,7)21-23-11-9-8-10-12-23/h8-16H,17-22H2,1-7H3/q+1",CC(C)(C)CC(C)(C)c1ccc(cc1)OCCOCC[N+](C)(C)Cc2ccccc2,C27H42NO2,,,2335,347827906,94725,CHEMBL1182210,,2245,50203812,412.637,2.370639882,"Amines; Ammonium Compounds; Anti-Infective Agents; Anti-Infective Agents, Local; Antiseptics and Disinfectants; Benzylammonium Compounds; Dermatologicals; Miscellaneous Local Anti-infectives; Nitrogen Compounds; Onium Compounds; Quaternary Ammonium Compounds; Respiratory System; Throat Preparations"
DB11126,Calcium gluconate,299-28-5,approved; vet_approved,NEEHYRZPVYRGPP-IYEMJOQQSA-L,"InChI=1S/2C6H12O7.Ca/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,C12H22CaO14,C08133,,9290,347827907,3309,CHEMBL2106119,,8932,,430.372,-3.409744311,"Acids, Acyclic; Alimentary Tract and Metabolism; Blood Coagulation Factors; Calcium Salts; Carbohydrates; Carboxylic Acids; Dermatologicals; Gluconates; Hydroxy Acids; Mineral Supplements; Minerals; Phosphate Binder; Replacement Preparations; Sugar Acids"
DB11127,Selenious acid,7783-00-8,approved; investigational,MCAHWIHFGHIESP-UHFFFAOYSA-N,"InChI=1S/H2O3Se/c1-4(2)3/h(H2,1,2,3)",O[Se](=O)O,H2O3Se,,,1091,347827908,26642,CHEMBL2009089,,1060,,128.97,-1.2765,"Alimentary Tract and Metabolism; Diet, Food, and Nutrition; Drugs that are Mainly Renally Excreted; Food; Food and Beverages; Growth Substances; Micronutrients; Mineral Supplements; Minerals; Physiological Phenomena; Replacement Preparations; Selenium Compounds; Sodium Compounds; Trace Elements"
DB11129,Carbamide peroxide,124-43-6,approved,AQLJVWUFPCUVLO-UHFFFAOYSA-N,"InChI=1S/CH4N2O.H2O2/c2-1(3)4;1-2/h(H4,2,3,4);1-2H",NC(=O)N,CH6N2O3,,,31294,347827910,75178,CHEMBL3184026,,29034,,94.07,-1.363833862,"Anions; Anti-Infective Agents; Anti-Infective Agents, Local; Bleaching Agents; Compounds used in a research, industrial, or household setting; Electrolytes; Free Radicals; Ions; Noxae; Oxidants; Oxides; Oxygen Compounds; Peroxides; Reactive Oxygen Species; Tooth Bleaching Agents; Toxic Actions"
DB11130,Opium,8008-60-4,approved; illicit,,, ,,,,,347911129,,,,,,NA,NA,"Alimentary Tract and Metabolism; Analgesics; Antidiarrheals; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antipropulsives; Antitussive Agents; Biological Products; Central Nervous System Agents; Central Nervous System Depressants; Complex Mixtures; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Narcotics; Natural Opium Alkaloids; Nervous System; Opiate Agonists; Opioids; Peripheral Nervous System Agents; Pharmaceutical Preparations; Plant Extracts; Plant Preparations; Respiratory System Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB11132,Silicon dioxide,7631-86-9,approved,VYPSYNLAJGMNEJ-UHFFFAOYSA-N,InChI=1S/O2Si/c1-3-2,O=[Si]=O,O2Si,,,22644374,347827911,30563,CHEMBL3188292,,22683,,60.0843,-0.6578,"Acids; Acids, Noncarboxylic; Anions; Colloids; Complex Mixtures; Compounds used in a research, industrial, or household setting; Dental Casting Investment; Electrolytes; Gels; Hygroscopic Agents; Investigative Techniques; Ions; Minerals; Oxides; Oxygen Compounds; Pharmaceutical Preparations; Silicon Compounds; Technology; Technology, Pharmaceutical"
DB11133,Omega-3 fatty acids,329042-31-1,approved; nutraceutical,,, ,,,,,347911131,,,,,,NA,NA,"Diet, Food, and Nutrition; Dietary Fats; Dietary Fats, Unsaturated; Fats; Fatty Acids; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fish Oils; Food; Food and Beverages; Lipids; Membrane Lipids; Oils; Phospholipids; Physiological Phenomena"
DB11134,Cupric oxide,1317-38-0,approved,KKCXRELNMOYFLS-UHFFFAOYSA-N,InChI=1S/Cu.O/q+2;-2,[O-2],CuO,,,164827,347827912,75955,CHEMBL1909057,,144499,,79.545,-0.652,"Copper-containing Intrauterine Device; Diet, Food, and Nutrition; Elements; Food; Food and Beverages; Growth Substances; Metals; Metals, Heavy; Micronutrients; Physiological Phenomena; Trace Elements; Transition Elements"
DB11135,Selenium,7782-49-2,approved; investigational; vet_approved,BUGBHKTXTAQXES-UHFFFAOYSA-N,InChI=1S/Se,[Se],Se,C01529,,6326970,347827913,27568,,,4885617,,78.96,0.1473,"Alimentary Tract and Metabolism; Antioxidants; Chalcogens; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Drugs that are Mainly Renally Excreted; Elements; Food; Food and Beverages; Growth Substances; Micronutrients; Mineral Supplements; Minerals; Physiological Phenomena; Polyvalent cation containing laxatives, antacids, oral supplements; Protective Agents; Selenium Compounds; Trace Elements"
DB11136,Chromium,7440-47-3,approved,VYZAMTAEIAYCRO-UHFFFAOYSA-N,InChI=1S/Cr,[Cr],Cr,C06268,,23976,347827914,28073,,,22412,,51.9961,-0.156,"Cell-mediated Immunity; Chromium; Diet, Food, and Nutrition; Drugs that are Mainly Renally Excreted; Elements; Food; Food and Beverages; Growth Substances; Increased Histamine Release; Metals; Metals, Heavy; Micronutrients; Minerals; Physiological Phenomena; Standardized Chemical Allergen; Trace Elements; Transition Elements"
DB11137,Molybdenum,7439-98-7,approved,ZOKXTWBITQBERF-UHFFFAOYSA-N,InChI=1S/Mo,[Mo],Mo,C00150,,23932,347827915,28685,,MO,22374,,95.94,0,"Diet, Food, and Nutrition; Elements; Food; Food and Beverages; Growth Substances; Metals; Metals, Heavy; Micronutrients; Physiological Phenomena; Trace Elements; Transition Elements"
DB11140,Chromium Cr-51,14392-02-0,approved,VYZAMTAEIAYCRO-BJUDXGSMSA-N,InChI=1S/Cr/i1-1,[51Cr],Cr,,,104786,347827916,50076,,,94591,,50.9448,-0.156,"Chromium; Chromium Isotopes; Elements; Isotopes; Metals; Metals, Heavy; Radioisotopes; Transition Elements"
DB11141,Manganese gluconate,6485-39-8,approved,OXHQNTSSPHKCPB-IYEMJOQQSA-L,"InChI=1S/2C6H12O7.Mn/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,C12H22MnO14,,,,347911132,,,,21514,,445.232,-3.409744311,"Acids, Acyclic; Carbohydrates; Carboxylic Acids; Hydroxy Acids; Paramagnetic Contrast Agent; Sugar Acids"
DB11142,Selenomethionine,3211-76-5,approved; investigational,RJFAYQIBOAGBLC-BYPYZUCNSA-N,"InChI=1S/C5H11NO2Se/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1",C[Se]CC[C@H](N)C(=O)O,C5H11NO2Se,C05335,,105024,347827917,62621,CHEMBL113178,MSE,94765,,196.11,-3.301994959,"Amino Acids; Amino Acids, Essential; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Organoselenium Compounds; Selenium Compounds; Sulfur Compounds"
DB11143,Cresol,1319-77-3,approved,,, ,,,,,347911133,,,,,,NA,NA,"Benzene Derivatives; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols; Standardized Chemical Allergen"
DB11145,Oxyquinoline,148-24-3,approved; vet_approved,MCJGNVYPOGVAJF-UHFFFAOYSA-N,"InChI=1S/C9H7NO/c11-8-5-1-3-7-4-2-6-10-9(7)8/h1-6,11H",Oc1cccc(c12)cccn2,C9H7NO,C19434,,1923,347827918,48981,CHEMBL310555,HQY,1847,32203,145.158,1.82733515,"Alimentary Tract and Metabolism; Anti-Infective Agents, Local; Antiinfectives and Antiseptics for Local Oral Treatment; Antiseptics and Disinfectants; Dermatologicals; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxyquinolines; Quinoline Derivatives; Quinolines; Respiratory System; Stomatological Preparations; Throat Preparations"
DB11147,Aluminum zirconium pentachlorohydrate,173762-83-9,approved,,, ,,,,,347911134,,,,,,NA,NA,NA
DB11148,Butamben,94-25-7,approved; withdrawn,IUWVALYLNVXWKX-UHFFFAOYSA-N,"InChI=1S/C11H15NO2/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7H,2-3,8,12H2,1H3",CCCCOC(=O)c1ccc(N)cc1,C11H15NO2,C07875,,2482,347827919,3231,CHEMBL127516,,2388,50240094,193.246,2.471695841,"Acids, Carbocyclic; Aminobenzoates; Anesthetics; Anesthetics, Local; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Cholinesterase substrates; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; para-Aminobenzoates; Peripheral Nervous System Agents; Sensory System Agents"
DB11149,Aluminum zirconium tetrachlorohydrex gly,90604-80-1,approved,,, ,,,,,347911135,,,,,,NA,NA,NA
DB11150,Barium sulfate,7727-43-7,approved,TZCXTZWJZNENPQ-UHFFFAOYSA-L,"InChI=1S/Ba.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",[O-]S([O-])(=O)=O,BaO4S,,,24414,347827920,133326,CHEMBL2105897,,22823,,233.39,-0.841552023,"Acids; Acids, Noncarboxylic; Anions; Barium Compounds; Barium Sulfate Containing X-Ray Contrast Media; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Electrolytes; Ions; Radiographic Contrast Agent; Sulfates; Sulfur Acids; Sulfur Compounds; Sulfuric Acids; X-Ray Contrast Activity; X-Ray Contrast Media, Non-Iodinated"
DB11151,Sodium hydroxide,1310-73-2,approved,HEMHJVSKTPXQMS-UHFFFAOYSA-M,InChI=1S/Na.H2O/h;1H2/q+1;/p-1,[OH-],HNaO,C12569,,14798,347827921,32145,CHEMBL2105794,,14114,,39.9971,-0.77,"Alkalies; Anions; Caustics; Compounds used in a research, industrial, or household setting; Electrolytes; Hydroxides; Ions; Noxae; Sodium Compounds; Toxic Actions"
DB11152,Trichloroacetate,76-03-9,approved,,, ,,,,,347911136,,,,,,NA,NA,"Acetates; Acids, Acyclic; Carboxylic Acids; Caustics; Chloroacetates; Compounds used in a research, industrial, or household setting; Fatty Acids; Fatty Acids, Volatile; Hydrocarbons; Hydrocarbons, Chlorinated; Hydrocarbons, Halogenated; Lipids; Noxae; Toxic Actions; Trichloroacetic Acid"
DB11153,Potassium hydroxide,1310-58-3,approved,KWYUFKZDYYNOTN-UHFFFAOYSA-M,InChI=1S/K.H2O/h;1H2/q+1;/p-1,[OH-],HKO,C12568,D01168,14797,347827922,32035,CHEMBL2103983,,14113,,56.1056,0.2,"Alkalies; Anions; Compounds used in a research, industrial, or household setting; Electrolytes; Indicators and Reagents; Ions; Laboratory Chemicals; Potassium Salt"
DB11155,Triclocarban,101-20-2,approved,ICUTUKXCWQYESQ-UHFFFAOYSA-N,"InChI=1S/C13H9Cl3N2O/c14-8-1-3-9(4-2-8)17-13(19)18-10-5-6-11(15)12(16)7-10/h1-7H,(H2,17,18,19)",Clc1ccc(cc1)NC(=O)Nc2cc(Cl)c(Cl)cc2,C13H9Cl3N2O,,D06223,7547,347827924,48347,CHEMBL1076347,9EG,7266,25730,315.58,4.93078919,"Amides; Amines; Anilides; Aniline Compounds; Anti-Infective Agents; Anti-Infective Agents, Local; Benzene Derivatives; Environmental Pollutants; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Miscellaneous Local Anti-infectives; Phenylurea Compounds; Toxic Actions; Water Pollutants; Water Pollutants, Chemical"
DB11156,Pyrantel,15686-83-6,approved; vet_approved,YSAUAVHXTIETRK-AATRIKPKSA-N,"InChI=1S/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3/b6-5+",c1ccsc1/C=C/C2=NCCCN2C,C11H14N2S,C07409,D08451,708857,347827925,8654,CHEMBL1626223,,618121,,206.31,1.963549525,"Anthelmintics; Anti-Infective Agents; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular Depolarizing Agents; Peripheral Nervous System Agents; Pyrimidines; Sulfur Compounds; Tetrahydropyrimidine Derivatives; Thiophenes"
DB11157,Anthralin,1143-38-0,approved,NUZWLKWWNNJHPT-UHFFFAOYSA-N,"InChI=1S/C14H10O3/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-6,15-16H,7H2",Oc1cccc(c12)Cc3c(C2=O)c(O)ccc3,C14H10O3,C06831,,2202,347827926,37510,CHEMBL46469,,2117,50041802,226.231,4.244016421,"Anthracenes; Antipsoriatics; Antipsoriatics for Topical Use; Antracen Derivatives; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic"
DB11158,Pectin,9000-69-5,approved; investigational; vet_approved,,, ,,,,,347911137,,,,,,NA,NA,"Alimentary Tract and Metabolism; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Biological Products; Biopolymers; Carbohydrates; Complex Mixtures; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Food; Food Additives; Food and Beverages; Food Ingredients; Intestinal Adsorbents; Macromolecular Substances; Manufactured Materials; Pharmaceutical Preparations; Physiological Phenomena; Plant Extracts; Plant Preparations; Polymers; Polysaccharides"
DB11159,Sodium sulfide,1313-82-2,approved,GRVFOGOEDUUMBP-UHFFFAOYSA-N,InChI=1S/2Na.S/q2*+1;-2,[Na+],Na2S,,,14804,347827927,76208,CHEMBL2107611,,14120,,78.04,-0.77,"Acids; Acids, Noncarboxylic; Anions; Electrolytes; Gases; Hydrogen Sulfide; Ions; Sulfur Compounds"
DB11160,Phenyltoloxamine,92-12-6,approved,IZRPKIZLIFYYKR-UHFFFAOYSA-N,"InChI=1S/C17H21NO/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3",CN(C)CCOc1ccccc1Cc2ccccc2,C17H21NO,,,7077,347827928,135047,CHEMBL186720,,6810,50151046,255.361,3.9260131,"Benzene Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic"
DB11161,Polyethylene glycol 300,25322-68-3,approved,,, ,,,,,347911138,,,,,,NA,NA,"Alcohols; Compounds used in a research, industrial, or household setting; Ethylene Glycols; Glycols; Macromolecular Substances; Manufactured Materials; Polymers"
DB11164,Bicisate,121251-02-3,approved; investigational,RZQNBTMGBODDSK-UWVGGRQHSA-N,"InChI=1S/C12H24N2O4S2/c1-3-17-11(15)9(7-19)13-5-6-14-10(8-20)12(16)18-4-2/h9-10,13-14,19-20H,3-8H2,1-2H3/t9-,10-/m0/s1",CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC,C12H24N2O4S2,,,72048,347827929,,,,65035,,324.45,0.638721175,Diagnostic Agents; Drugs that are Mainly Renally Excreted
DB11168,Calcium threonate,70753-61-6,approved,ZJXGOFZGZFVRHK-BALCVSAKSA-L,"InChI=1S/2C4H8O5.Ca/c2*5-1-2(6)3(7)4(8)9;/h2*2-3,5-7H,1H2,(H,8,9);/q;;+2/p-2/t2*2-,3+;/m00./s1",OC[C@H](O)[C@@H](O)C([O-])=O,C8H14CaO10,,,13388558,347827930,,,,9337769,,310.268,-2.149074427,"Acids, Acyclic; Blood Coagulation Factors; Carboxylic Acids; Fatty Acids; Fatty Acids, Volatile; Lipids"
DB11169,Ferrous asparto glycinate,,approved,,, ,,,,,347911142,,,,,,NA,NA,NA
DB11171,Ferric sulfate,10028-22-5,approved,YHGPYBQVSJBGHH-UHFFFAOYSA-H,"InChI=1S/2Fe.3H2O4S.5H2O/c;;3*1-5(2,3)4;;;;;/h;;3*(H2,1,2,3,4);5*1H2/q2*+3;;;;;;;;/p-6",[O-]S([O-])(=O)=O,Fe2H10O17S3,,,23443659,347827931,,,,11640309,,489.93,-0.841552023,Hematinics; Iron Compounds; Organometallic Compounds; Parenteral Iron Replacement; Phosphate Binder
DB11176,Zeaxanthin,144-68-3,approved; investigational,JKQXZKUSFCKOGQ-QAYBQHTQSA-N,"InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-24,35-36,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36-/m1/s1",CC1(C)C[C@H](O)CC(C)=C1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C(C2(C)C)=C(C)C[C@@H](O)C2,C40H56O2,C06098,,5280899,347827933,27547,CHEMBL2359248,,4444421,,568.886,8.350644046,"Alkenes; Biological Factors; Carotenoids; Cyclohexanes; Cyclohexenes; Cycloparaffins; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Pigments, Biological; Polycyclic Compounds; Polyenes; Terpenes; Xanthophylls"
DB11178,Polysorbate 20,9005-64-5,approved,,, ,,,,,347911144,,,,,,NA,NA,"Alcohols; Compounds used in a research, industrial, or household setting; Drug Delivery Systems; Drug Therapy; Ethylene Glycols; Excipients; Glycols; Macromolecular Substances; Manufactured Materials; Pharmaceutic Aids; Pharmaceutical Preparations; Pharmaceutical Vehicles; Polyethylene Glycols; Polymers; Surface-Active Agents; Therapeutics"
DB11179,Exametazime,105613-48-7,approved,,, ,,,,,347911145,,,,,,NA,NA,Ketones
DB11180,Tetrofosmin,127502-06-1,approved,QCWJONLQSHEGEJ-UHFFFAOYSA-N,"InChI=1S/C18H40O4P2/c1-5-19-9-13-23(14-10-20-6-2)17-18-24(15-11-21-7-3)16-12-22-8-4/h5-18H2,1-4H3",CCOCCP(CCOCC)CCP(CCOCC)CCOCC,C18H40O4P2,,,4274,347827934,135598,CHEMBL1615784,,4124,,382.462,1.14,NA
DB11181,Homatropine,87-00-3,approved,ZTVIKZXZYLEVOL-MCOXGKPRSA-N,"InChI=1S/C16H21NO3/c1-17-12-7-8-13(17)10-14(9-12)20-16(19)15(18)11-5-3-2-4-6-11/h2-6,12-15,18H,7-10H2,1H3/t12-,13+,14+,15?",[C@@H]12CC[C@@H](N1C)C[C@@H](C2)OC(=O)C(O)c3ccccc3,C16H21NO3,C07814,,,347911146,5747,CHEMBL1618018,,16498795,50240066,275.348,1.593867434,"Alkaloids; Anticholinergic Agents; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Bicyclo Compounds, Heterocyclic; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Muscarinic Agonists; Muscarinic Antagonists; Mydriatics and Cycloplegics; Ophthalmologicals; Parasympatholytics; Peripheral Nervous System Agents; Sensory Organs"
DB11182,Rose bengal,,approved; investigational,VDNLFJGJEQUWRB-UHFFFAOYSA-N,"InChI=1S/C20H4Cl4I4O5/c21-10-8(9(20(31)32)11(22)13(24)12(10)23)7-3-1-5(25)16(29)14(27)18(3)33-19-4(7)2-6(26)17(30)15(19)28/h1-2,29H,(H,31,32)",OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c2c(cc(I)c(=O)c3I)c3oc(c24)c(I)c(O)c(I)c4,C20H4Cl4I4O5,,,,347911147,87202,CHEMBL1208422,,23774,,973.673,8.77987963,"Coloring Agents; Colouring Agents; Compounds used in a research, industrial, or household setting; Diagnostic Agents; Fluoresceins; Fluorescent Dyes; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Indicators and Reagents; Laboratory Chemicals; Luminescent Agents; Ophthalmologicals; Other Diagnostics; Polycyclic Compounds; Sensory Organs; Spiro Compounds; Xanthenes"
DB11183,Light green SF yellowish,5141-20-8,approved; experimental,DGOBMKYRQHEFGQ-UHFFFAOYSA-L,"InChI=1S/C37H36N2O9S3.2Na/c1-3-38(25-27-7-5-9-35(23-27)50(43,44)45)32-17-11-29(12-18-32)37(31-15-21-34(22-16-31)49(40,41)42)30-13-19-33(20-14-30)39(4-2)26-28-8-6-10-36(24-28)51(46,47)48;;/h5-24H,3-4,25-26H2,1-2H3,(H2-,40,41,42,43,44,45,46,47,48);;/q;2*+1/p-2",[O-]S(=O)(=O)c1cccc(c1)CN(CC)c2ccc(cc2)C(c3ccc(S([O-])(=O)=O)cc3)=C4C=CC(C=C4)=[N+](CC)Cc5cc(S([O-])(=O)=O)ccc5,C37H34N2Na2O9S3,,,21223,347827935,87065,,,19952,,792.848,2.67663036,"Acids; Acids, Noncarboxylic; Amines; Ammonium Compounds; Arylsulfonates; Arylsulfonic Acids; Nitrogen Compounds; Onium Compounds; Quaternary Ammonium Compounds; Sulfonic Acids; Sulfur Acids; Sulfur Compounds"
DB11184,Oftasceine,1461-15-0,approved,DEGAKNSWVGKMLS-UHFFFAOYSA-N,"InChI=1S/C30H26N2O13/c33-21-7-23-19(5-15(21)9-31(11-25(35)36)12-26(37)38)30(18-4-2-1-3-17(18)29(43)45-30)20-6-16(22(34)8-24(20)44-23)10-32(13-27(39)40)14-28(41)42/h1-8,33-34H,9-14H2,(H,35,36)(H,37,38)(H,39,40)(H,41,42)",OC(=O)CN(CC(=O)O)Cc(c1)c(O)cc(c1C23c4c(C(O2)=O)cccc4)Oc5c3cc(c(c5)O)CN(CC(=O)O)CC(=O)O,C30H26N2O13,,,65079,347827936,51903,CHEMBL1973733,,58589,,622.539,-4.020893537,NA
DB11186,Pentoxyverine,77-23-6,approved; investigational,CFJMRBQWBDQYMK-UHFFFAOYSA-N,"InChI=1S/C20H31NO3/c1-3-21(4-2)14-15-23-16-17-24-19(22)20(12-8-9-13-20)18-10-6-5-7-11-18/h5-7,10-11H,3-4,8-9,12-17H2,1-2H3",CCN(CC)CCOCCOC(=O)C1(CCCC1)c2ccccc2,C20H31NO3,,,2562,347827938,94484,CHEMBL73234,,2464,94507,333.472,3.966585092,"Antitussive Agents; Central Nervous System Agents; Cough and Cold Preparations; Cycloparaffins; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Respiratory System; Respiratory System Agents"
DB11189,Magnesium glycinate,14783-68-7,approved,AACACXATQSKRQG-UHFFFAOYSA-L,"InChI=1S/2C2H5NO2.Mg/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2",NCC([O-])=O,C4H8MgN2O4,,,84645,347827939,,,,76358,,172.423,-3.409459573,Agents that produce neuromuscular block (indirect); Calculi Dissolution Agent; Laxatives; Osmotic Laxatives
DB11190,Pantethine,16816-67-4,approved; investigational,DJWYOLJPSHDSAL-ROUUACIJSA-N,"InChI=1S/C22H42N4O8S2/c1-21(2,13-27)17(31)19(33)25-7-5-15(29)23-9-11-35-36-12-10-24-16(30)6-8-26-20(34)18(32)22(3,4)14-28/h17-18,27-28,31-32H,5-14H2,1-4H3,(H,23,29)(H,24,30)(H,25,33)(H,26,34)/t17-,18-/m0/s1",OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO,C22H42N4O8S2,C12661,D01234,452306,347827940,31959,CHEMBL2104786,,398402,,554.721,-3.379128931,Alimentary Tract and Metabolism; Sulfhydryl Compounds; Sulfur Compounds; Vitamin B Complex; Vitamins
DB11191,Cobamamide,13870-90-1,approved,ZIHHMGTYZOSFRC-OUCXYWSSSA-L,"InChI=1S/C62H90N13O14P.C10H12N5O3.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-4-6(16)7(17)10(18-4)15-3-14-5-8(11)12-2-13-9(5)15;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);2-4,6-7,10,16-17H,1H2,(H2,11,12,13);/q;;+2/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;4-,6-,7-,10-;/m11./s1",Nc1ncnc(c12)n(cn2)[C@H]3[C@H](O)[C@H](O)[C@H](O3)C[Co-3]4567[N+]8=C9C(C)=C1N4[C@@H]([C@]2(C)[N+]5=C([C@H]([C@]2(C)CC(=O)N)CCC(=O)N)C(C)=C2[N+]6=C([C@@H](CCC(=O)N)[C@]2(C)CC(=O)N)C=C8C(C)(C)[C@@H]9CCC(=O)N)[C@H](CC(=O)N)[C@@]1(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1c2c([n+]7c1)cc(C)c(C)c2,C72H100CoN18O17P,,D00042,,347911148,18408,CHEMBL3833359,B1Z,21864853,,1579.5818,-14.54490682,"Antianemic Preparations; Azoles; Blood and Blood Forming Organs; Coenzymes; Corrinoids; Enzymes and Coenzymes; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Macrocyclic Compounds; Polycyclic Compounds; Pyrroles; Tetrapyrroles; Vitamin B Complex; VITAMIN B12 AND FOLIC ACID; Vitamins"
DB11193,Papain,9001-73-4,approved,,, ,,,,,347911149,,,,,,NA,NA,"Cysteine Endopeptidases; Cysteine Proteases; Endopeptidases; Enzymes; Enzymes and Coenzymes; Gastrointestinal Agents; Hydrolases; Papain, antagonists & inhibitors; Peptide Hydrolases"
DB11197,Ferrous cysteine glycinate,,approved,NIBOCUPOPAKNJE-NVKWYWNSSA-L,"InChI=1S/2C3H7NO2S.C2H5NO2.Fe/c2*4-2(1-7)3(5)6;3-1-2(4)5;/h2*2,7H,1,4H2,(H,5,6);1,3H2,(H,4,5);/q;;;+2/p-2/t2*2-;;/m00../s1",OC(=O)[C@@H](N)CS,C8H17FeN3O6S2,,,,,,,,34987810,,371.2,-2.792133298,NA
DB11200,Aluminum zirconium octachlorohydrex gly,174514-58-0,approved,WYANSMZYIOPJFV-UHFFFAOYSA-L,"InChI=1S/C2H5NO2.Al.ClH.2H2O.Zr/c3-1-2(4)5;;;;;/h1,3H2,(H,4,5);;1H;2*1H2;/q;+3;;;;+4/p-2",NCC([O-])=O,C2H8AlClNO4Zr,,,,347911153,,,,32698594,,263.74,-3.409459573,NA
DB11201,Menthyl salicylate,89-46-3,approved,SJOXEWUZWQYCGL-DVOMOZLQSA-N,"InChI=1S/C17H24O3/c1-11(2)13-9-8-12(3)10-16(13)20-17(19)14-6-4-5-7-15(14)18/h4-7,11-13,16,18H,8-10H2,1-3H3/t12-,13+,16-/m1/s1",CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)c2ccccc2O,C17H24O3,,,,,135976,,,16736426,,276.376,5.506007674,NA
DB11202,N-alkyl ethylbenzyl dimethyl ammonium (C12-C14),,approved,,, ,,,,,347911154,,,,,,NA,NA,NA
DB11204,Panthenol,16485-10-2,approved,,, ,,,D03726,,,27373,CHEMBL1371937,,,,NA,NA,"Alanine; Amino Acids; Amino Acids, Peptides, and Proteins; Imides; Vitamin B Complex; Vitamins; Wound Healing"
DB11205,Alcloxa,1317-25-5,approved,IMZDRXBSGZPLDE-UHFFFAOYSA-H,"InChI=1S/C4H6N4O3.2Al.ClH.4H2O/c5-3(10)6-1-2(9)8-4(11)7-1;;;;;;;/h1H,(H5,5,6,7,8,9,10,11);;;1H;4*1H2/q;2*+3;;;;;/p-6",NC(=O)NC1NC(=O)[N-]C1=O,C4H9Al2ClN4O7,,,,,,,,32698939,,314.55,-2.360540882,NA
DB11206,Bemotrizinol,187393-00-6,approved,XVAMCHGMPYWHNL-UHFFFAOYSA-N,"InChI=1S/C38H49N3O5/c1-6-10-12-26(8-3)24-45-30-18-20-32(34(42)22-30)37-39-36(28-14-16-29(44-5)17-15-28)40-38(41-37)33-21-19-31(23-35(33)43)46-25-27(9-4)13-11-7-2/h14-23,26-27,42-43H,6-13,24-25H2,1-5H3",CCCCC(CC)COc1cc(O)c(cc1)-c2nc(nc(n2)-c3ccc(OC)cc3)-c4c(O)cc(cc4)OCC(CC)CCCC,C38H49N3O5,,,,,135857,CHEMBL2104956,,10645286,,627.826,11.62152937,"Benzene Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Sunscreen Agents"
DB11207,Amiloxate,71617-10-2,approved,UBNYRXMKIIGMKK-RMKNXTFCSA-N,"InChI=1S/C15H20O3/c1-12(2)10-11-18-15(16)9-6-13-4-7-14(17-3)8-5-13/h4-9,12H,10-11H2,1-3H3/b9-6+",COc1ccc(cc1)/C=C/C(=O)OCCC(C)C,C15H20O3,,,,,,CHEMBL1476782,,1266578,,248.322,3.968560495,"Acids, Carbocyclic; Carboxylic Acids; Sunscreen Agents"
DB11208,Aluminum chlorohydrex propylene glycol,53026-85-0,approved,,, ,,,,,347911155,,,,,,NA,NA,NA
DB11209,Iron protein succinylate,250705-13-6,approved; investigational,,, ,,,,,,,,,,,NA,NA,"Acids, Acyclic; Amino Acids, Peptides, and Proteins; Anemia, Hypochromic, drug therapy; Carboxylic Acids; Dicarboxylic Acids; Ferric Compounds; Hematinics; Hematologic Agents; Proteins"
DB11210,Ferrous bisglycinate,20150-34-9,approved,GIPOFCXYHMWROH-UHFFFAOYSA-L,"InChI=1S/2C2H5NO2.Fe/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2",NCC([O-])=O,C4H8FeN2O4,,,9837124,347827942,,,,8012845,,203.963,-3.409459573,"Amino Acids; Amino Acids, Peptides, and Proteins; Iron Compounds; Organometallic Compounds"
DB11217,Arbutin,497-76-7,approved,BJRNKVDFDLYUGJ-RMPHRYRLSA-N,"InChI=1S/C12H16O7/c13-5-8-9(15)10(16)11(17)12(19-8)18-7-3-1-6(14)2-4-7/h1-4,8-17H,5H2/t8-,9-,10+,11-,12-/m1/s1",OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)Oc2ccc(O)cc2,C12H16O7,C06186,,440936,347827943,18305,CHEMBL232202,,389765,50219502,272.2512,-0.901952921,Carbohydrates; Glucosides; Glycosides
DB11219,Enzacamene,36861-47-9,approved,HEOCBCNFKCOKBX-SDNWHVSQSA-N,"InChI=1S/C18H22O/c1-12-5-7-13(8-6-12)11-14-15-9-10-18(4,16(14)19)17(15,2)3/h5-8,11,15H,9-10H2,1-4H3/b14-11+",Cc1ccc(cc1)/C=C(/C(=O)C23C)C(C2(C)C)CC3,C18H22O,,,7019255,347827944,135937,CHEMBL2104261,,4939160,50103609,254.373,5.120853596,Bornanes; Hydrocarbons; Ketones; Monoterpenes; Norbornanes; Sunscreen Agents; Terpenes
DB11221,Dioxybenzone,131-53-3,approved,MEZZCSHVIGVWFI-UHFFFAOYSA-N,"InChI=1S/C14H12O4/c1-18-9-6-7-11(13(16)8-9)14(17)10-4-2-3-5-12(10)15/h2-8,15-16H,1H3",COc1cc(O)c(cc1)C(=O)c2ccccc2O,C14H12O4,C14283,D03853,,,34208,CHEMBL1326877,,8251,,244.246,3.967796944,"Benzene Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Ketones; Sunscreen Agents"
DB11225,Peg-100 stearate,9004-99-3,approved,,, ,,,,,,,,,,,NA,NA,Pegylated agents
DB11226,Ethylhexyl methoxycrylene,947753-66-4,approved; experimental,WAJCJDLRJVDSSD-UHFFFAOYSA-N,"InChI=1S/C25H29NO3/c1-4-6-10-19(5-2)18-29-25(27)23(17-26)24(20-11-8-7-9-12-20)21-13-15-22(28-3)16-14-21/h7-9,11-16,19H,4-6,10,18H2,1-3H3",CCCCC(CC)COC(=O)/C(C#N)=C(\c1ccccc1)c2ccc(OC)cc2,C25H29NO3,,,,,,,,52085894,,391.511,6.625277419,NA
DB11228,Methylcellulose,9004-67-5,approved,,, ,,,D04996,,347911158,53448,,,23107149,,NA,NA,"Alimentary Tract and Metabolism; Biopolymers; Bulk-Forming Laxatives; Carbohydrates; Cellulose; Compounds used in a research, industrial, or household setting; Drugs for Constipation; EENT Drugs, Miscellaneous; Glucans; Laxatives; Macromolecular Substances; Manufactured Materials; Polymers; Polysaccharides"
DB11230,Magnesium Aluminum Silicate,1327-43-1,approved,,, ,,,,,,,,,,,NA,NA,"Acids; Acids, Noncarboxylic; Agents that produce neuromuscular block (indirect); Anions; Electrolytes; Ions; Minerals; Oxides; Oxygen Compounds; Pharmaceutic Aids; Silicon Compounds"
DB11231,Lycopene,502-65-8,approved; investigational,OAIJSZIZWZSQBC-GYZMGTAESA-N,"InChI=1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+",CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C=C(\C)CCC=C(C)C,C40H56,C05432,,446925,347827946,15948,CHEMBL501174,LYC,394156,,536.888,11.93183182,"Alkenes; Anti-Inflammatory Agents; Anticarcinogenic Agents; Antioxidants; Biological Factors; Carotenoids; Compounds used in a research, industrial, or household setting; Cyclohexanes; Cyclohexenes; Cycloparaffins; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Pigments, Biological; Polycyclic Compounds; Polyenes; Protective Agents; Radiation-Protective Agents; Terpenes"
DB11232,Saccharide isomerate,100843-69-4,approved,,, ,,,,,,,,,,,NA,NA,NA
DB11235,Thonzylamine,91-85-0,approved,GULNIHOSWFYMRN-UHFFFAOYSA-N,"InChI=1S/C16H22N4O/c1-19(2)11-12-20(16-17-9-4-10-18-16)13-14-5-7-15(21-3)8-6-14/h4-10H,11-13H2,1-3H3",COc1ccc(cc1)CN(CCN(C)C)c2ncccn2,C16H22N4O,,,5457,347827947,104017,CHEMBL1623738,,5258,,286.379,2.422011711,"Agents producing tachycardia; Antiallergic Agents, Excl. Corticosteroids; Anticholinergic Agents; Antihistamines for Systemic Use; Antihistamines for Topical Use; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Muscarinic Antagonists; Nasal Preparations; Neurotransmitter Agents; Respiratory System; Substituted Ethylene Diamines"
DB11237,Trypsin,07-07-9002,approved; vet_approved,,, ,,,,,347911160,,,,,,NA,NA,Blood and Blood Forming Organs; Dermatologicals; Endopeptidases; Enzymes; Enzymes and Coenzymes; Hydrolases; Musculo-Skeletal System; Peptide Hydrolases; Preparations for Treatment of Wounds and Ulcers; Serine Endopeptidases; Serine Proteases
DB11238,Borage oil,,approved; investigational,,, ,,,,,347911161,,,,,,NA,NA,"Agents that reduce seizure threshold; Antirheumatic Agents; Biological Products; Complex Mixtures; Dietary Fats, Unsaturated; Fatty Acids; Fatty Acids, Essential; Fatty Acids, Omega-6; Fatty Acids, Unsaturated; Linolenic Acids; Lipids; Oils; Plant Preparations"
DB11239,Aluminum sulfate,10043-01-3,approved,DIZPMCHEQGEION-UHFFFAOYSA-H,"InChI=1S/2Al.3H2O4S/c;;3*1-5(2,3)4/h;;3*(H2,1,2,3,4)/q2*+3;;;/p-6",[O-]S([O-])(=O)=O,Al2O12S3,,,24850,347827948,74768,CHEMBL3833402,,23233,,342.151,-0.841552023,"Acids; Acids, Noncarboxylic; Adjuvants, Immunologic; Aluminium Compounds; Anions; Electrolytes; Immunologic Factors; Ions; Metal cations; Metal divalent cations; Sulfates; Sulfur Acids; Sulfur Compounds; Sulfuric Acids"
DB11242,Gelatin,9000-70-8,approved; vet_approved,,, ,,,,,347911163,,,,,,NA,NA,"Amino Acids, Peptides, and Proteins; Proteins; Scleroproteins"
DB11243,Ethyl macadamiate,,approved,,, ,,,,,347911164,,,,,,NA,NA,NA
DB11246,Copper gluconate,527-09-3,approved; investigational,OCUCCJIRFHNWBP-IYEMJOQQSA-L,"InChI=1S/2C6H12O7.Cu/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,C12H22CuO14,C12278,,10692,347827950,31431,,,10242,,453.841,-3.409744311,Copper-containing Intrauterine Device
DB11248,Zinc gluconate,04-02-4468,approved; vet_approved,WHMDKBIGKVEYHS-IYEMJOQQSA-L,"InChI=1S/2C6H12O7.Zn/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,C12H22O14Zn,,,443445,347827951,29708,CHEMBL3833377,,391659,,455.67,-3.409744311,"Acids, Acyclic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Alimentary Tract and Metabolism; Carbohydrates; Carboxylic Acids; Cardiovascular System; Copper Absorption Inhibitor; Hydroxy Acids; Metal cations; Metal divalent cations; Mineral Supplements; Sugar Acids; Vasoprotectives; Zinc Compounds"
DB11251,Tocopherol,1406-66-2,approved; investigational,,, ,,,,,347911165,,,,,,NA,NA,"Alimentary Tract and Metabolism; Antioxidants; Benzopyrans; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diet, Food, and Nutrition; Drugs that are Mainly Renally Excreted; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Micronutrients; Physiological Phenomena; Protective Agents; Pyrans; Vitamin E; Vitamins; Vitamins (Fat Soluble)"
DB11253,Xanthan gum,11138-66-2,approved,,, ,,,,,347911167,,,,,,NA,NA,"Antigens; Antigens, Bacterial; Biological Factors; Carbohydrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Drug Carriers; Food; Food Additives; Food and Beverages; Food Ingredients; Physiological Phenomena; Polysaccharides"
DB11254,Hexylresorcinol,136-77-6,approved,WFJIVOKAWHGMBH-UHFFFAOYSA-N,"InChI=1S/C12H18O2/c1-2-3-4-5-6-10-7-8-11(13)9-12(10)14/h7-9,13-14H,2-6H2,1H3",CCCCCCc1c(O)cc(O)cc1,C12H18O2,,,3610,347827952,93749,CHEMBL443605,,21106121,50292636,194.2701,4.102379887,"Anthelmintics; Anti-Infective Agents; Anti-Infective Agents, Local; Antiparasitic Agents; Benzene Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Miscellaneous Anti-infectives; Phenols; Resorcinols; Respiratory System; Throat Preparations"
DB11255,Chromium picolinate,14639-25-9,approved,CBDQOLKNTOMMTL-UHFFFAOYSA-K,"InChI=1S/3C6H5NO2.Cr/c3*8-6(9)5-3-1-2-4-7-5;/h3*1-4H,(H,8,9);/q;;;+3/p-3",[O-]C(=O)c1ncccc1,C18H12CrN3O6,,,625469,347827953,50369,,,133913,,418.3005,-0.65133148,"Acids, Heterocyclic; Compounds used in a research, industrial, or household setting; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Iron Chelating Agents; Pyridines; Sequestering Agents; Standardized Chemical Allergen"
DB11256,Levomefolic acid,31690-09-2,approved; investigational,ZNOVTXRBGFNYRX-STQMWFEESA-N,"InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1",O=c1nc(N)[nH]c(c12)NC[C@@H](N2C)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O,C20H25N7O6,C00440,,444412,347827954,15641,CHEMBL1231574,THH,392351,50391007,459.4558,-3.816718781,"Amino Acids; Amino Acids, Acidic; Amino Acids, Dicarboxylic; Amino Acids, Peptides, and Proteins; Biological Factors; Coenzymes; Enzymes and Coenzymes; Folic Acid and Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pigments, Biological; Pteridines; Pterins; Vitamin B Complex; Vitamins"
DB11257,Fluoride ion,16984-48-8,approved,KRHYYFGTRYWZRS-UHFFFAOYSA-M,InChI=1S/FH/h1H/p-1,[F-],F,C00742,,28179,347827955,17051,CHEMBL1362,F,26214,26978,18.9984,0.14883864,NA
DB11260,Diacetyl benzoyl lathyrol,218916-52-0,approved,JPYYWXPAHJBKJX-VWSFRBHVSA-N,"InChI=1S/C31H38O7/c1-17-13-14-23-24(30(23,6)7)15-18(2)28(34)31(38-21(5)33)16-19(3)27(25(31)26(17)36-20(4)32)37-29(35)22-11-9-8-10-12-22/h8-12,15,19,23-27H,1,13-14,16H2,2-7H3/b18-15+/t19-,23-,24+,25-,26-,27-,31+/m0/s1",c1ccccc1C(=O)O[C@@H]([C@@H](C)C2)[C@@H]([C@]23OC(=O)C)[C@@H](OC(=O)C)C(=C)CC[C@H]4[C@H](C4(C)C)/C=C(\C)C3=O,C31H38O7,,,10577938,347827957,136008,CHEMBL552128,,8753322,,522.638,5.709693759,NA
DB11261,Atractylodes japonica root,,approved,,, ,,,,,347911169,,,,,,NA,NA,NA
DB11262,Bisoctrizole,103597-45-1,approved,FQUNFJULCYSSOP-UHFFFAOYSA-N,"InChI=1S/C41H50N6O2/c1-38(2,3)24-40(7,8)28-20-26(36(48)34(22-28)46-42-30-15-11-12-16-31(30)43-46)19-27-21-29(41(9,10)25-39(4,5)6)23-35(37(27)49)47-44-32-17-13-14-18-33(32)45-47/h11-18,20-23,48-49H,19,24-25H2,1-10H3",c1cccc(c12)nn(n2)-c3cc(C(C)(C)CC(C)(C)C)cc(c3O)Cc4c(O)c(cc(c4)C(C)(C)CC(C)(C)C)-n(n5)nc(c56)cccc6,C41H50N6O2,,,,,135865,CHEMBL2104957,,2808671,,658.891,11.8391,Sunscreen Agents
DB11263,Polydatin,27208-80-6,approved,HSTZMXCBWJGKHG-CUYWLFDKSA-N,"InChI=1S/C20H22O8/c21-10-16-17(24)18(25)19(26)20(28-16)27-15-8-12(7-14(23)9-15)2-1-11-3-5-13(22)6-4-11/h1-9,16-26H,10H2/b2-1+/t16-,17-,18+,19-,20-/m1/s1",OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)Oc2cc(cc(O)c2)/C=C/c3ccc(O)cc3,C20H22O8,C10275,,5281718,347827958,8198,CHEMBL142652,,4445034,60919,390.388,1.134322793,"Benzene Derivatives; Benzylidene Compounds; Carbohydrates; Drugs, Chinese Herbal; Glycosides; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic"
DB11264,Calcium glycerophosphate,27214-00-2,approved,UHHRFSOMMCWGSO-UHFFFAOYSA-L,"InChI=1S/C3H9O6P.Ca/c4-1-3(2-5)9-10(6,7)8;/h3-5H,1-2H2,(H2,6,7,8);/q;+2/p-2",OCC(CO)OP([O-])([O-])=O,C3H7CaO6P,C12935,D01488,,347911170,31336,CHEMBL3707206,,56554,,210.135,-1.962580054,NA
DB11266,Sea salt,,approved,,, ,,,,,347911171,,,,,,NA,NA,NA
DB11269,Diethylamino hydroxybenzoyl hexyl benzoate,302776-68-7,approved,FDATWRLUYRHCJE-UHFFFAOYSA-N,"InChI=1S/C24H31NO4/c1-4-7-8-11-16-29-24(28)20-13-10-9-12-19(20)23(27)21-15-14-18(17-22(21)26)25(5-2)6-3/h9-10,12-15,17,26H,4-8,11,16H2,1-3H3",CCCCCCOC(=O)c1ccccc1C(=O)c2ccc(cc2O)N(CC)CC,C24H31NO4,,,,,136006,,,8286957,,397.515,6.817206608,"Amines; Aniline Compounds; Benzene Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Ketones; Phenols; Sunscreen Agents"
DB11270,Atractylodes japonica root oil,,approved,,, ,,,,,347911172,,,,,,NA,NA,NA
DB11271,Polysilicone-15,207574-74-1,approved,,, ,,,,,,,,,,,NA,NA,Sunscreen Agents
DB11273,Dihydroergocornine,25447-65-8,approved,SEALOBQTUQIVGU-QNIJNHAOSA-N,"InChI=1S/C31H41N5O5/c1-16(2)26-28(38)35-11-7-10-24(35)31(40)36(26)29(39)30(41-31,17(3)4)33-27(37)19-12-21-20-8-6-9-22-25(20)18(14-32-22)13-23(21)34(5)15-19/h6,8-9,14,16-17,19,21,23-24,26,32,40H,7,10-13,15H2,1-5H3,(H,33,37)/t19-,21-,23-,24+,26+,30-,31+/m1/s1",C1CCN([C@@H]1[C@@]23O)C(=O)[C@H](C(C)C)N2C(=O)[C@](O3)(C(C)C)NC(=O)[C@H](C4)CN(C)[C@@H]([C@H]45)Cc6c7c5cccc7[nH]c6,C31H41N5O5,,,,,59909,CHEMBL2365712,,147720,,563.699,3.059032918,"Agents that produce hypertension; Alkaloids; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Dopamine Agents; Dopamine Agonists; Ergot Alkaloids and Derivatives; Ergot-derivative Dopamine Receptor Agonists; Ergotamines; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents"
DB11274,Dihydro-alpha-ergocryptine,25447-66-9,approved,PBUNVLRHZGSROC-VTIMJTGVSA-N,"InChI=1S/C32H43N5O5/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38)/t20-,22-,24-,25+,26+,31-,32+/m1/s1",C1CCN([C@@H]1[C@@]23O)C(=O)[C@H](CC(C)C)N2C(=O)[C@](O3)(C(C)C)NC(=O)[C@H](C4)CN(C)[C@@H]([C@H]45)Cc6c7c5cccc7[nH]c6,C32H43N5O5,,,,,59919,CHEMBL1743263,,102887,81453,577.726,3.425730177,Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates
DB11275,Epicriptine,88660-47-3,approved,SBFXHXZNBNFPHV-PXXBSISHSA-N,"InChI=1S/C32H43N5O5/c1-6-18(4)27-29(39)36-12-8-11-25(36)32(41)37(27)30(40)31(42-32,17(2)3)34-28(38)20-13-22-21-9-7-10-23-26(21)19(15-33-23)14-24(22)35(5)16-20/h7,9-10,15,17-18,20,22,24-25,27,33,41H,6,8,11-14,16H2,1-5H3,(H,34,38)/t18-,20-,22-,24-,25+,27+,31-,32+/m1/s1",C1CCN([C@@H]1[C@@]23O)C(=O)[C@H]([C@H](C)CC)N2C(=O)[C@](O3)(C(C)C)NC(=O)[C@H](C4)CN(C)[C@@H]([C@H]45)Cc6c7c5cccc7[nH]c6,C32H43N5O5,,,,,135927,CHEMBL2106411,,59102,,577.726,3.503650993,Alkaloids; Heterocyclic Compounds
DB11277,Aluminum zirconium pentachlorohydrex gly,,approved,,, ,,,,,347911174,,,,,,NA,NA,NA
DB11278,DL-Methylephedrine,1201-56-5,approved,FMCGSUUBYTWNDP-ONGXEEELSA-N,"InChI=1S/C11H17NO/c1-9(12(2)3)11(13)10-7-5-4-6-8-10/h4-9,11,13H,1-3H3/t9-,11-/m0/s1",CN(C)[C@@H](C)[C@H](O)c1ccccc1,C11H17NO,,,,,113556,CHEMBL445001,,58315,,179.263,1.700882666,Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Drugs that are Mainly Renally Excreted
DB11279,Brilliant green cation,18198-35-1,approved; vet_approved,HXCILVUBKWANLN-UHFFFAOYSA-N,"InChI=1S/C27H33N2/c1-5-28(6-2)25-18-14-23(15-19-25)27(22-12-10-9-11-13-22)24-16-20-26(21-17-24)29(7-3)8-4/h9-21H,5-8H2,1-4H3/q+1",CCN(CC)c1ccc(cc1)C(c2ccccc2)=C3C=CC(C=C3)=[N+](CC)CC,C27H33N2,,,12449,347827961,88176,CHEMBL1589793,,11942,81263,385.574,2.714699089,"Amines; Ammonium Compounds; Anti-Infective Agents; Anti-Infective Agents, Local; Coloring Agents; Compounds used in a research, industrial, or household setting; Nitrogen Compounds; Onium Compounds"
DB11282,Diethyltoluamide,134-62-3,approved,MMOXZBCLCQITDF-UHFFFAOYSA-N,"InChI=1S/C12H17NO/c1-4-13(5-2)12(14)11-8-6-7-10(3)9-11/h6-9H,4-5H2,1-3H3",CCN(CC)C(=O)c1cc(C)ccc1,C12H17NO,C10935,D02379,,,7071,CHEMBL1453317,DE3,4133,,191.2695,2.49827554,"Acids, Carbocyclic; Agrochemicals; Amides; Antiparasitic Products, Insecticides and Repellents; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Insect Repellents; Insecticides and Repellents; Pesticides; Protective Agents; Toxic Actions"
DB11283,DL-dimyristoylphosphatidylcholine,18656-38-7,approved,CITHEXJVPOWHKC-UHFFFAOYSA-N,"InChI=1S/C36H72NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-35(38)42-32-34(33-44-46(40,41)43-31-30-37(3,4)5)45-36(39)29-27-25-23-21-19-17-15-13-11-9-7-2/h34H,6-33H2,1-5H3",CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC,C36H72NO8P,,,,,241349,CHEMBL316257,,24408,,677.945,6.335521719,"Alcohols; Carbohydrates; Compounds used in a research, industrial, or household setting; Glycerophosphates; Glycerophospholipids; Indicators and Reagents; Laboratory Chemicals; Lipids; Membrane Lipids; Phosphatidic Acids; Phosphatidylcholines; Phospholipids; Sugar Alcohols; Sugar Phosphates; Triose Sugar Alcohols"
DB11284,DL-dimyristoylphosphatidylglycerol,61361-72-6,approved,BPHQZTVXXXJVHI-UHFFFAOYSA-N,"InChI=1S/C34H67O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-33(37)41-29-32(30-43-45(39,40)42-28-31(36)27-35)44-34(38)26-24-22-20-18-16-14-12-10-8-6-4-2/h31-32,35-36H,3-30H2,1-2H3,(H,39,40)",CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC,C34H67O10P,,,,,,,,96926,,666.874,9.158776859,Alcohols; Carbohydrates; Glycerophosphates; Glycerophospholipids; Lipids; Membrane Lipids; Phosphatidic Acids; Phospholipids; Sugar Alcohols; Sugar Phosphates; Triose Sugar Alcohols
DB11285,Ethyl ferulate,4046-02-0,approved; experimental,ATJVZXXHKSYELS-FNORWQNLSA-N,"InChI=1S/C12H14O4/c1-3-16-12(14)7-5-9-4-6-10(13)11(8-9)15-2/h4-8,13H,3H2,1-2H3/b7-5+",CCOC(=O)/C=C/c1cc(OC)c(O)cc1,C12H14O4,,,,,,CHEMBL286796,ZYC,643791,50297424,222.2372,2.410885017,"Acids, Carbocyclic; Carboxylic Acids; Cinnamates"
DB11293,Rice bran oil,,approved,,, ,,,,,347911177,,,,,,NA,NA,Biological Products; Complex Mixtures; Lipids; Oils; Plant Oils; Plant Preparations
DB11295,Trichophyton verrucosum,,approved,,, ,,,,,347911179,,,,,,NA,NA,NA
DB11298,Thioredoxin,52500-60-4,approved,,, ,,,,,347911180,,,,,,NA,NA,"Amino Acids, Peptides, and Proteins; Proteins; Thioredoxins; Thioredoxins, antagonists & inhibitors"
DB11299,Vanillyl butyl ether,82654-98-6,approved,VLDFMKOUUQYFGF-UHFFFAOYSA-N,"InChI=1S/C12H18O3/c1-3-4-7-15-9-10-5-6-11(13)12(8-10)14-2/h5-6,8,13H,3-4,7,9H2,1-2H3",CCCCOCc1cc(OC)c(O)cc1,C12H18O3,,,5084146,347827963,,,,4260417,,210.2695,2.71168498,NA
DB11301,Curcuma aromatica root oil,94349-73-2,approved,,, ,,,,,347911182,,,,,,NA,NA,NA
DB11304,Phenoxyethanol,122-99-6,approved,QCDWFXQBSFUVSP-UHFFFAOYSA-N,"InChI=1S/C8H10O2/c9-6-7-10-8-4-2-1-3-5-8/h1-5,9H,6-7H2", ,C8H10O2,,,31236,347827964,64275,CHEMBL1229846,268,13848467,,138.166,1.125472538,"Alcohols; Anesthetics; Anti-Infective Agents; Anti-Infective Agents, Local; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Glycols"
DB11306,Bentonite,,approved,,, ,,,,,,,,,,,NA,NA,"Acids; Acids, Noncarboxylic; Aluminium Compounds; Aluminum Silicates; Anions; Antidotes; Compounds used in a research, industrial, or household setting; Electrolytes; Ions; Metal cations; Metal divalent cations; Minerals; Oxides; Oxygen Compounds; Protective Agents; Silicates; Silicon Compounds"
DB11315,Methscopolamine,13265-10-6,approved,LZCOQTDXKCNBEE-IKIFYQGPSA-N,"InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12-,13-,14-,15+,16-,17+/m1/s1",[C@H]12[C@H]3[C@H](O3)[C@H]([N+]1(C)C)C[C@H](C2)OC(=O)[C@H](CO)c4ccccc4,C18H24NO4,,,71183,347827965,135361,CHEMBL376897,3C0,21106347,50241132,318.392,-3.267384321,"Agents producing tachycardia; Alimentary Tract and Metabolism; Alkaloids; Anticholinergic Agents; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Belladonna Alkaloids, Semisynthetic, Quaternary Ammonium Compounds; Belladonna and Derivatives, Plain; Bicyclo Compounds, Heterocyclic; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Muscarinic Antagonists; Mydriatics and Cycloplegics; Ophthalmologicals; Parasympatholytics; Peripheral Nervous System Agents; Scopolamine Derivatives; Sensory Organs; Synthetic Anticholinergics, Quaternary Ammonium Compounds; Tropanes"
DB11323,Glycol salicylate,87-28-5,approved,LVYLCBNXHHHPSB-UHFFFAOYSA-N,"InChI=1S/C9H10O4/c10-5-6-13-9(12)7-3-1-2-4-8(7)11/h1-4,10-11H,5-6H2",OCCOC(=O)c1ccccc1O,C9H10O4,,,6880,347827966,86541,CHEMBL173562,,6616,,182.175,1.633055446,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Gels; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Phenols"
DB11326,Boric acid,10043-35-3,approved,KGBXLFKZBHKPEV-UHFFFAOYSA-N,InChI=1S/BH3O3/c2-1(3)4/h2-4H,OB(O)O,BH3O3,C12486,,7628,347827967,33118,CHEMBL42403,BO3,7346,39817,61.833,-0.5086,"Acids; Acids, Noncarboxylic; Agrochemicals; Anti-Infective Agents; Boron Compounds; Compounds used in a research, industrial, or household setting; Insecticides; Otologicals; Pesticides; Sensory Organs; Toxic Actions"
DB11327,Dipyrithione,3696-28-4,approved,ZHDBTKPXEJDTTQ-UHFFFAOYSA-N,InChI=1S/C10H8N2O2S2/c13-11-7-3-1-5-9(11)15-16-10-6-2-4-8-12(10)14/h1-8H,[O-][n+]1ccccc1SSc2cccc[n+]2[O-],C10H8N2O2S2,,,,,136010,CHEMBL549473,,2998,,252.31,0.831842187,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring"
DB11328,Tetradecyl hydrogen sulfate (ester),300-52-7,approved,GROJOWHVXQYQGN-UHFFFAOYSA-N,"InChI=1S/C14H30O4S/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17/h12-14H,5-11H2,1-4H3,(H,15,16,17)",CCCCC(CC)CCC(CC(C)C)OS(=O)(=O)O,C14H30O4S,,,,,75275,CHEMBL1201345,,8441,,294.45,5.040855316,Drugs that are Mainly Renally Excreted
DB11329,C11-12 isoparaffin,246538-76-1,approved,,, ,,,,,347911187,,,,,,NA,NA,NA
DB11331,1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)),185435-28-3,approved; experimental,PAZGBAOHGQRCBP-DDDNOICHSA-N,"InChI=1S/C40H77O10P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-40(44)50-38(36-49-51(45,46)48-34-37(42)33-41)35-47-39(43)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,37-38,41-42H,3-16,19-36H2,1-2H3,(H,45,46)/b18-17-/t37?,38-/m1/s1",CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC(O)CO)OC(=O)CCCCCCC/C=C\CCCCCCCC,C40H77O10P,,,,,34080,,,4446626,,749.02,11.46426719,NA
DB11332,Sinapultide,138531-07-4,approved,QSIRXSYRKZHJHX-TWXHAJHVSA-N,"InChI=1S/C126H238N26O22/c1-69(2)53-90(137-106(153)85(132)43-33-38-48-127)114(161)145-98(61-77(17)18)122(169)149-99(62-78(19)20)118(165)141-91(54-70(3)4)110(157)133-86(44-34-39-49-128)107(154)138-95(58-74(11)12)115(162)146-103(66-82(27)28)123(170)150-100(63-79(21)22)119(166)142-92(55-71(5)6)111(158)134-87(45-35-40-50-129)108(155)139-96(59-75(13)14)116(163)147-104(67-83(29)30)124(171)151-101(64-80(23)24)120(167)143-93(56-72(7)8)112(159)135-88(46-36-41-51-130)109(156)140-97(60-76(15)16)117(164)148-105(68-84(31)32)125(172)152-102(65-81(25)26)121(168)144-94(57-73(9)10)113(160)136-89(126(173)174)47-37-42-52-131/h69-105H,33-68,127-132H2,1-32H3,(H,133,157)(H,134,158)(H,135,159)(H,136,160)(H,137,153)(H,138,154)(H,139,155)(H,140,156)(H,141,165)(H,142,166)(H,143,167)(H,144,168)(H,145,161)(H,146,162)(H,147,163)(H,148,164)(H,149,169)(H,150,170)(H,151,171)(H,152,172)(H,173,174)/t85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-/m0/s1",NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)O)CCCCN,C126H238N26O22,,,,,,CHEMBL2103901,,16742247,,2469.45,5.443623068,"Amino Acids, Peptides, and Proteins; Pulmonary Surfactants"
DB11333,Poloxamer 188,691397-13-4,approved; investigational,,, ,,,,,347911189,,CHEMBL2108134,,,,NA,NA,"Alcohols; Compounds used in a research, industrial, or household setting; Drug Delivery Systems; Drug Therapy; Ethylene Glycols; Excipients; Glycols; Macromolecular Substances; Manufactured Materials; Pharmaceutic Aids; Pharmaceutical Preparations; Pharmaceutical Vehicles; Polyethylene Glycols; Polymers; Surface-Active Agents; Therapeutics"
DB11336,Kinetin,525-79-1,approved,QANMHLXAZMSUEX-UHFFFAOYSA-N,"InChI=1S/C10H9N5O/c1-2-7(16-3-1)4-11-9-8-10(13-5-12-8)15-6-14-9/h1-3,5-6H,4H2,(H2,11,12,13,14,15)",c1ccoc1CNc2ncnc(c23)nc[nH]3,C10H9N5O,C08272,,3830,347827968,27407,CHEMBL228792,H35,3698,181147,215.2114,0.512953612,"Cytokinins; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Plant Growth Regulators; Purines"
DB11340,Ubiquinol,992-78-9,approved; investigational,QNTNKSLOFHEFPK-UPTCCGCDSA-N,"InChI=1S/C59H92O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42,60-61H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+",COc1c(OC)c(O)c(c(C)c1O)C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C,C59H92O4,,,9962735,347827969,64183,,,8138335,,865.3594,18.23018951,Benzoquinones; Coenzymes; Enzymes and Coenzymes; Quinones
DB11341,Ichthammol,8029-68-3,approved,,, ,,,,,347911191,,,,,,NA,NA,Amines; Ammonium Compounds; Dermatologicals; Nitrogen Compounds; Onium Compounds
DB11342,Aluminum oxide,1344-28-1,approved,PNEYBMLMFCGWSK-UHFFFAOYSA-N,InChI=1S/2Al.3O/q2*+3;3*-2,[O-2],Al2O3,,,9989226,347827970,,CHEMBL3707210,,8164808,,101.96,-0.652,Aluminium Compounds; Aluminum Oxides; Anions; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Dermatologicals; Electrolytes; Ions; Metal cations; Metal divalent cations; Oxides; Oxygen Compounds
DB11343,Silanol,70131-67-8,approved,SCPYDCQAZCOKTP-UHFFFAOYSA-N,"InChI=1S/H4OSi/c1-2/h1H,2H3",O[SiH3],H4OSi,,,6327522,347827971,37173,,,125395,,48.116,-1.4692,Organosilicon Compounds; Silicon Compounds
DB11346,Rubidium,7440-17-7,approved; investigational,IGLNJRXAVVLDKE-UHFFFAOYSA-N,InChI=1S/Rb,[Rb],Rb,,,,,33322,,,4512975,,85.4678,0,"Elements; Metals; Metals, Alkali; Metals, Heavy"
DB11348,Calcium Phosphate,10103-46-5,approved,QORWJWZARLRLPR-UHFFFAOYSA-H,"InChI=1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6",[O-]P([O-])([O-])=O,Ca3O8P2,C08136,,24456,347827972,9679,CHEMBL2106566,,22864,,310.177,-1.020103823,"Acids; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Anions; Biocompatible Materials; Blood Coagulation Factors; Calcium Compounds; Calcium Salts; Ceramics; Compounds used in a research, industrial, or household setting; Electrolytes; Ions; Manufactured Materials; Mineral Supplements; Phosphate salts; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds"
DB11352,Ascorbyl phosphate,,approved,,, ,,,,,347911194,,,,,,NA,NA,Vitamin C and analogues; Vitamins
DB11355,Propolis wax,,approved,,, ,,,,,347911195,,,,,,NA,NA,NA
DB11356,Polyquaternium-10 (400 cps at 2%),81859-24-7,approved,,, ,,,,,347911196,,,,,,NA,NA,NA
DB11357,Linseed oil,66071-03-2,approved; investigational,,, ,,,,,347911197,,,,,,NA,NA,"Biological Products; Complex Mixtures; Fats; Fats, Unsaturated; Lipids; Oils; Plant Oils; Plant Preparations"
DB11359,Guaiacol,90-05-1,approved,LHGVFZTZFXWLCP-UHFFFAOYSA-N,"InChI=1S/C7H8O2/c1-9-7-5-3-2-4-6(7)8/h2-5,8H,1H3",COc1c(O)cccc1,C7H8O2,C01502,D00117,460,347827973,28591,CHEMBL13766,JZ3,447,50240369,124.139,1.512009229,"Benzene Derivatives; Catechols; Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Methyl Ethers; Phenols; Phenyl Ethers"
DB11360,Lactobacillus plantarum,,approved; investigational,,, ,,,,,347911199,,,,,,NA,NA,NA
DB11362,Selexipag,475086-01-2,approved,QXWZQTURMXZVHJ-UHFFFAOYSA-N,"InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)",c1ccccc1-c2ncc(nc2-c3ccccc3)N(C(C)C)CCCCOCC(=O)NS(=O)(=O)C,C26H32N4O4S,,D09994,9913767,310265229,90844,CHEMBL238804,,8089417,50235383,496.63,3.764971419,"Acetates; Acids, Acyclic; Amides; Antihypertensive Agents; Blood and Blood Forming Organs; Carboxylic Acids; Cardiovascular Agents; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lipids; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates; Platelet Aggregation Inhibitors Excl. Heparin; Prodrugs; Prostacyclin Receptor Agonist; Prostacyclin Receptor Agonists; Receptors, Prostaglandin, agonists; Vasodilating Agents"
DB11363,Alectinib,1256580-46-7,approved; investigational,KDGFLJKFZUIJMX-UHFFFAOYSA-N,"InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3",C1COCCN1C2CCN(CC2)c(c3)c(CC)cc(c34)C(=O)c5c(C4(C)C)[nH]c6c5ccc(c6)C#N,C30H34N4O2,,D10542,49806720,310265230,90936,CHEMBL1738797,EMH,26326738,50362781,482.6166,4.887412174,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Kinase Inhibitor; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB11386,Chlorobutanol,57-15-8,approved; investigational; vet_approved,OSASVXMJTNOKOY-UHFFFAOYSA-N,"InChI=1S/C4H7Cl3O/c1-3(2,8)4(5,6)7/h8H,1-2H3",CC(C)(O)C(Cl)(Cl)Cl,C4H7Cl3O,,D01942,5977,347827977,134813,CHEMBL1439973,,13842993,50417941,177.45,1.753730648,"Alcohols; Alimentary Tract and Metabolism; Antiemetics and Antinauseants; Butanols; Chlorohydrins; Compounds used in a research, industrial, or household setting; Fatty Alcohols; Lipids; Pharmaceutic Aids; Pharmaceutical Preparations; Preservatives, Pharmaceutical"
DB11387,Chloroform,67-66-3,approved; vet_approved,HEDRZPFGACZZDS-UHFFFAOYSA-N,InChI=1S/CHCl3/c2-1(3)4/h1H,ClC(Cl)Cl,CHCl3,C13827,,,,35255,CHEMBL44618,MCH,5977,,119.378,1.825300514,"Anesthetics; Anesthetics, General; Compounds used in a research, industrial, or household setting; Hydrocarbons; Hydrocarbons, Chlorinated; Hydrocarbons, Halogenated; Nervous System; Solvents; Trihalomethanes"
DB11431,Moxidectin,113507-06-5,approved; investigational; vet_approved,YZBLFMPOMVTDJY-LSGXYNIPSA-N,"InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1",C1O[C@@H]2[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C3)C4)[C@]2(O)C\1=C\C=C\[C@H](C)C/C(C)=C/C[C@H]3O[C@@]45C/C(=N\OC)[C@H](C)[C@H](O5)/C(C)=C/C(C)C,C37H53NO8,,D05084,,,,CHEMBL2104415,,22901017,,639.83,5.669639849,"Agrochemicals; Anthelmintics; Anti-Infective Agents; Antinematodal Agents; Antiparasitic Agents; Compounds used in a research, industrial, or household setting; Insecticides; Lactones; Macrocyclic Compounds; Pesticides; Polycyclic Compounds; Polyketides; Toxic Actions"
DB11496,2-mercaptobenzothiazole,149-30-4,approved; experimental; vet_approved,YXIWHUQXZSMYRE-UHFFFAOYSA-N,"InChI=1S/C7H5NS2/c9-7-8-5-3-1-2-4-6(5)10-7/h1-4H,(H,8,9)",S=c(s1)[nH]c(c12)cccc2,C7H5NS2,C14437,,,,34292,CHEMBL111654,,608157,50444459,167.251,2.879384047,"Anti-Infective Agents; Azoles; Cell-mediated Immunity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Increased Histamine Release; Standardized Chemical Allergen; Sulfur Compounds; Thiazoles"
DB11512,Dihydrostreptomycin,128-46-1,approved; investigational; vet_approved; withdrawn,ASXBYYWOLISCLQ-HZYVHMACSA-N,"InChI=1S/C21H41N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h5-18,26,29-36H,3-4H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1",CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]([C@@]2(O)CO)[C@@H](O[C@H]2C)O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]3NC(N)=N,C21H41N7O12,C01023,D07840,,,38291,CHEMBL1950576,71R,388489,,583.596,-7.349804055,Agents that produce neuromuscular block (indirect); Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycosides; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Ophthalmologicals; Sensory Organs
DB11560,Lesinurad,878672-00-5,approved; investigational,FGQFOYHRJSUHMR-UHFFFAOYSA-N,"InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)",OC(=O)CSc1nnc(Br)n1-c2ccc(C3CC3)c(c24)cccc4,C17H14BrN3O2S,,D09921,53465279,347827983,90929,CHEMBL2105720,,28527877,37953,404.28,4.089902325,"Acetates; Acids, Acyclic; Antigout Preparations; Antirheumatic Agents; Azoles; Carboxylic Acids; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Lipids; Musculo-Skeletal System; Preparations Increasing Uric Acid Excretion; Renal Agents; Sulfhydryl Compounds; Sulfur Compounds; Urate Transporter 1 Inhibitor; Urate Transporter 1 Inhibitors; Uricosuric Agents"
DB11570,Padimate O,21245-02-3,approved,WYWZRNAHINYAEF-UHFFFAOYSA-N,"InChI=1S/C17H27NO2/c1-5-7-8-14(6-2)13-20-17(19)15-9-11-16(12-10-15)18(3)4/h9-12,14H,5-8,13H2,1-4H3",CCCCC(CC)COC(=O)c1ccc(cc1)N(C)C,C17H27NO2,,D05335,30541,347827986,135932,CHEMBL1323699,,28343,,277.408,5.107344475,"Acids, Carbocyclic; Aminobenzoates; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Cosmetics; Dermatologicals; Household Products; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Protective Agents; Radiation-Protective Agents; Sunscreen Agents"
DB11573,Aluminum chlorohydrate,12359-72-7,approved,ZLVPDILYQLCEJO-UHFFFAOYSA-H,InChI=1S/2Al.ClH.6H2O/h;;1H;6*1H2/q2*+3;;;;;;;/p-6,[OH-],Al2ClH7O6,,,71586946,347827987,,,,32699791,,192.46,-0.652,Alkalies; Aluminium Compounds; Anions; Astringents and Deodorants; Dermatologicals; Drugs Affecting Bone Structure and Mineralization; Drugs for Treatment of Bone Diseases; Electrolytes; Hydroxides; Ions; Medicated Dressings; Medicated Dressings With Antiinfectives; Metal cations; Metal divalent cations; Musculo-Skeletal System
DB11574,Elbasvir,1370468-36-2,approved,BVAZQCUMNICBAQ-PZHYSIFUSA-N,"InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1",COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2ncc([nH]2)-c(cc3)cc(c34)cc5n4[C@H](c6ccccc6)Oc7c5ccc(c7)-c8cnc([nH]8)[C@@H]9CCCN9C(=O)[C@H](C(C)C)NC(=O)OC,C49H55N9O7,,D10625,71661251,347827988,132967,CHEMBL3039514,,30843797,,882.035,6.140535606,"Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; Azoles; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Experimental Unapproved Treatments for COVID-19; Hepatitis C Virus NS5A Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; P-glycoprotein inhibitors; P-glycoprotein substrates"
DB11575,Grazoprevir,1350514-68-9,approved,OBMNJSNZOWALQB-NCQNOWPTSA-N,"InChI=1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1",COc(cc1)cc(c12)nc3c(n2)CCCCC[C@H]4[C@@H](C4)OC(=O)N[C@@H](C(C)(C)C)C(=O)N5C[C@H](O3)C[C@H]5C(=O)N[C@@]6(C[C@H]6C=C)C(=O)NS(=O)(=O)C7CC7,C38H50N6O9S,,D10639,44603531,347827989,132975,CHEMBL2063090,SUE,28506694,,766.903,3.35294537,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; HCV NS3/4A Protease Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; NS3/4A Protease Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates"
DB11577,Indigotindisulfonic acid,483-20-5,approved,CFZXDJWFRVEWSR-BUHFOSPRSA-N,"InChI=1S/C16H10N2O8S2/c19-15-9-5-7(27(21,22)23)1-3-11(9)17-13(15)14-16(20)10-6-8(28(24,25)26)2-4-12(10)18-14/h1-6,17-18H,(H,21,22,23)(H,24,25,26)/b14-13+",OS(=O)(=O)c(cc1)cc(c12)C(=O)C(\N2)=C(C3=O)/Nc(c34)ccc(c4)S(=O)(=O)O,C16H10N2O8S2,,,5282430,347827990,90117,CHEMBL1091250,,4445584,,422.389,1.014174001,"Coloring Agents; Compounds used in a research, industrial, or household setting; Diagnostic Agents; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Kidney Function; Tests for Renal Function and Ureteral Injuries"
DB11578,Hard fat,,approved,,, ,,,,,,,,,,,NA,NA,Pharmaceutical Vehicles; Suppositories
DB11579,Light Mineral Oil,92062-35-6,approved,,, ,,,,,347911206,,,,,,NA,NA,Basic Ointments and Protectants
DB11581,Venetoclax,1257044-40-8,approved; investigational,LQBVNQSMGBZMKD-UHFFFAOYSA-N,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",Clc1ccc(cc1)C(CC2(C)C)=C(CC2)CN3CCN(CC3)c4ccc(c(c4)Oc(c5)cnc(c56)[nH]cc6)C(=O)NS(=O)(=O)c7ccc(c(c7)[N+]([O-])=O)NCC8CCOCC8,C45H50ClN7O7S,,D10679,49846579,347827991,133021,CHEMBL3137309,LBM,29315017,60828,868.45,6.762158638,"Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCL-2 Inhibitor; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Bicyclo Compounds; Bridged Compounds; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Increased Cellular Death; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Polycyclic Compounds; Sulfones; Sulfur Compounds"
DB11583,Cetalkonium,10328-34-4,approved,QDYLMAYUEZBUFO-UHFFFAOYSA-N,"InChI=1S/C25H46N/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-20-23-26(2,3)24-25-21-18-17-19-22-25/h17-19,21-22H,4-16,20,23-24H2,1-3H3/q+1",CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,C25H46N,,,31203,347827993,135523,CHEMBL1624075,,28944,,360.649,4.411028961,"Alcohols; Amines; Ammonium Compounds; Anti-Infective Agents; Anti-Infective Agents, Local; Compounds used in a research, industrial, or household setting; Lipids; Nitrogen Compounds; Onium Compounds; Surface-Active Agents"
DB11584,Pipradrol,467-60-7,approved,XSWHNYGMWWVAIE-UHFFFAOYSA-N,"InChI=1S/C18H21NO/c20-18(15-9-3-1-4-10-15,16-11-5-2-6-12-16)17-13-7-8-14-19-17/h1-6,9-12,17,19-20H,7-8,13-14H2",N1CCCCC1C(O)(c2ccccc2)c3ccccc3,C18H21NO,,,,,135101,CHEMBL2110938,,9681,,267.372,3.320915131,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics"
DB11585,Drometrizole trisiloxane,155633-54-8,approved,HUVYTMDMDZRHBN-UHFFFAOYSA-N,"InChI=1S/C24H39N3O3Si3/c1-18-14-20(15-19(2)17-33(9,29-31(3,4)5)30-32(6,7)8)24(28)23(16-18)27-25-21-12-10-11-13-22(21)26-27/h10-14,16,19,28H,15,17H2,1-9H3",C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)Cc1c(O)c(cc(C)c1)-n(n2)nc(c23)cccc3,C24H39N3O3Si3,,,,,,,,8024601,,501.849,7.251,"Azoles; Compounds used in a research, industrial, or household setting; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Macromolecular Substances; Manufactured Materials; Organosilicon Compounds; Polymers; Silicon Compounds"
DB11586,Asunaprevir,630420-16-5,approved; investigational; withdrawn,XRWSZZJLZRKHHD-WVWIJVSJSA-N,"InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1",c1cc(Cl)cc(c12)c(ncc2OC)O[C@@H]3C[C@H](N(C3)C(=O)[C@H](C(C)(C)C)NC(=O)OC(C)(C)C)C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C5CC5,C35H46ClN5O9S,,,16076883,347827994,134723,CHEMBL2105735,2R9,17235944,,748.286,3.366020222,"Amides; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (weak); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; HCV Protease Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; HIV Protease Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Protease Inhibitors; Sulfones; Sulfur Compounds"
DB11587,Etafedrine,48141-64-6,approved,IRVLBORJKFZWMI-JQWIXIFHSA-N,"InChI=1S/C12H19NO/c1-4-13(3)10(2)12(14)11-8-6-5-7-9-11/h5-10,12,14H,4H2,1-3H3/t10-,12-/m0/s1",CCN(C)[C@@H](C)[C@H](O)c1ccccc1,C12H19NO,,,,,,,,85308,,193.29,2.05769062,Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Drugs that are Mainly Renally Excreted; Ethylamines; Phenethylamines; Propanolamines; Propanols
DB11588,Carbon monoxide,630-08-0,approved; investigational,UGFAIRIUMAVXCW-UHFFFAOYSA-N,InChI=1S/CO/c1-2, ,CO,C00237,D09706,281,347827995,17245,CHEMBL1231840,CMO,275,,28.01,NA,"Anions; Carbon Compounds, Inorganic; Electrolytes; Gases; Gasotransmitters; Ions; Neurotransmitter Agents; Noxae; Oxides; Oxygen Compounds; Toxic Actions"
DB11589,Neon,09-01-7440,approved; investigational,GKAOGPIIYCISHV-UHFFFAOYSA-N,InChI=1S/Ne,[Ne],Ne,,,23935,347827996,33310,,,22377,,20.1797,0,Elements; Gases; Noble Gases
DB11590,Thimerosal,54-64-8,approved,RTKIYNMVFMVABJ-UHFFFAOYSA-L,"InChI=1S/C7H6O2S.C2H5.Hg.Na/c8-7(9)5-3-1-2-4-6(5)10;1-2;;/h1-4,10H,(H,8,9);1H2,2H3;;/q;;2*+1/p-2",CC[Hg]Sc1ccccc1C([O-])=O,C9H9HgNaO2S,,D00864,16684434,347827997,9546,CHEMBL508338,,5697,,404.81,2.3534,"Alkylmercury Compounds; Antiseptics and Disinfectants; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Dermatologicals; Ethylmercury Compounds; Increased Histamine Release; Mercurial Products; Organomercury Compounds; Organometallic Compounds; Pharmaceutic Aids; Pharmaceutical Preparations; Preservatives, Pharmaceutical; Standardized Chemical Allergen"
DB11591,Bilastine,202189-78-4,approved; investigational,ACCMWZWAEFYUGZ-UHFFFAOYSA-N,"InChI=1S/C28H37N3O3/c1-4-34-20-19-31-25-8-6-5-7-24(25)29-26(31)22-14-17-30(18-15-22)16-13-21-9-11-23(12-10-21)28(2,3)27(32)33/h5-12,22H,4,13-20H2,1-3H3,(H,32,33)",CCOCCn1c(nc(c12)cccc2)C3CCN(CC3)CCc4ccc(cc4)C(C)(C)C(=O)O,C28H37N3O3,,,185460,347827998,135954,CHEMBL1742423,,161234,,463.622,2.409230746,"Antihistamines for Systemic Use; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB11594,Domiphen,13900-14-6,approved; experimental,YXUPZGKORWTXID-UHFFFAOYSA-N,"InChI=1S/C22H40NO/c1-4-5-6-7-8-9-10-11-12-16-19-23(2,3)20-21-24-22-17-14-13-15-18-22/h13-15,17-18H,4-12,16,19-21H2,1-3H3/q+1",CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,C22H40NO,,,3149,347828001,135978,CHEMBL1187011,,3037,,334.567,2.552330791,Alimentary Tract and Metabolism; Amines; Ammonium Compounds; Antiinfectives and Antiseptics for Local Oral Treatment; Miscellaneous Anti-infectives; Miscellaneous Local Anti-infectives; Nitrogen Compounds; Onium Compounds; Stomatological Preparations
DB11596,Levoleucovorin,68538-85-2,approved; investigational,VVIAGPKUTFNRDU-STQMWFEESA-N,"InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12-,13-/m0/s1",Nc([nH]1)nc(=O)c(c12)N(C=O)[C@H](CN2)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O,C20H23N7O7,,D04715,149436,347828002,63606,CHEMBL1908841,FFO,131714,286,473.4393,-2.84629402,"Antidotes; Biological Factors; Coenzymes; Compounds used in a research, industrial, or household setting; Detoxifying Agents for Antineoplastic Treatment; Enzymes and Coenzymes; Folate Analog; Folic Acid Analogues; Folic Acid and Derivatives; Formyltetrahydrofolates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Leucovorin Calcium-Levoleucovorin; Pigments, Biological; Protective Agents; Pteridines; Pterins; Tetrahydrofolates; Vitamin B Complex; Vitamins"
DB11599,"Starch, corn",9005-25-8,approved; nutraceutical,,, ,,,,,347911210,,,,,,NA,NA,"Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Dietary Carbohydrates; Food; Food and Beverages; Glucans; Macromolecular Substances; Manufactured Materials; Physiological Phenomena; Polymers; Polysaccharides; Starch"
DB11602,Hydroxyethyl cellulose,9004-62-0,approved,DFJVHKAPIXJTSC-UHFFFAOYSA-N,"InChI=1S/C36H70O19/c1-19(37)9-45-17-27-29(47-11-21(3)39)31(48-12-22(4)40)34(51-15-25(7)43)36(54-27)55-30-28(18-46-10-20(2)38)53-35(52-16-26(8)44)33(50-14-24(6)42)32(30)49-13-23(5)41/h19-44H,9-18H2,1-8H3",CC(O)COCC1OC(C(OCC(C)O)C(OCC(C)O)C1OCC(C)O)OC2C(COCC(C)O)OC(OCC(C)O)C(OCC(C)O)C2OCC(C)O,C36H70O19,,D04474,4327536,347828003,85249,CHEMBL2109076,,3532118,,806.937,-1.746578733,"Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Glucans; Macromolecular Substances; Manufactured Materials; Ophthalmic Solutions; Polymers; Polysaccharides; Saliva, Artificial"
DB11605,Myrrh,9000-45-7,approved,,, ,,,,,347911215,,,,,,NA,NA,NA
DB11609,Normethadone,467-85-6,approved; illicit,WCJFBSYALHQBSK-UHFFFAOYSA-N,"InChI=1S/C20H25NO/c1-4-19(22)20(15-16-21(2)3,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14H,4,15-16H2,1-3H3",c1ccccc1C(C(=O)CC)(CCN(C)C)c2ccccc2,C20H25NO,,D07384,10090,347828004,135242,CHEMBL346331,,9687,,295.426,4.590596611,Analgesics; Antitussive Agents; Central Nervous System Agents; Central Nervous System Depressants; Cough and Cold Preparations; Ketones; Narcotics; Opioids; Opium Alkaloids and Derivatives; Peripheral Nervous System Agents; Respiratory System; Respiratory System Agents; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
DB11610,Oxilofrine,365-26-4,approved,OXFGTKPPFSCSMA-XVKPBYJWSA-N,"InChI=1S/C10H15NO2/c1-7(11-2)10(13)8-3-5-9(12)6-4-8/h3-7,10-13H,1-2H3/t7-,10-/m0/s1",CN[C@@H](C)[C@H](O)c1ccc(O)cc1,C10H15NO2,,D08314,688009,347828005,134822,CHEMBL1160695,,599505,,181.235,0.283556692,Alcohols; Amines; Amino Alcohols; Ethylamines; Phenethylamines; Propanolamines; Propanols
DB11611,Lifitegrast,1025967-78-5,approved,JFOZKMSJYSPYLN-QHCPKHFHSA-N,"InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1",CS(=O)(=O)c1cc(ccc1)C[C@@H](C(=O)O)NC(=O)c(c(Cl)c2)c(Cl)c(c23)CCN(C3)C(=O)c(c4)ccc(c45)cco5,C29H24Cl2N2O7S,,D10374,11965427,347828006,133023,CHEMBL2048028,,10139520,50386331,615.48,4.020511439,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Anti-Inflammatory Agents; Anti-inflammatory Agents, Miscellaneous; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Lymphocyte Function-Associated Antigen-1; Lymphocyte Function-Associated Antigen-1 Antagonist; Lymphocyte Function-Associated Antigen-1 Antagonists; Ophthalmic Solutions; Ophthalmologicals; Pharmaceutical Preparations; Pharmaceutical Solutions; Sensory Organs; Solutions; Sulfur Compounds"
DB11613,Velpatasvir,1377049-84-7,approved; investigational,FHCUMDQMBHQXKK-CDIODLITSA-N,"InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1",c1ccccc1[C@@H](NC(=O)OC)C(=O)N2C[C@@H](COC)C[C@H]2c3ncc([nH]3)-c(c4)ccc(c45)c6c(OC5)cc7c(c6)ccc8c7[nH]c(n8)[C@@H]9CC[C@H](C)N9C(=O)[C@H](C(C)C)NC(=O)OC,C49H54N8O8,,D10806,67683363,347828007,133009,CHEMBL3545062,,34501056,,883.019,5.107198364,"Acids, Acyclic; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Breast Cancer Resistance Protein Inhibitors; Carboxylic Acids; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; Hepatitis C Virus NS5A Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; Organic Anion Transporting Polypeptide 2B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates"
DB11614,Rupatadine,158876-82-5,approved,WUZYKBABMWJHDL-UHFFFAOYSA-N,"InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3",Cc1cc(cnc1)CN2CCC(CC2)=C3c(ccc(Cl)c4)c4CCc(c35)cccn5,C26H26ClN3,,,133017,347828008,135673,CHEMBL91397,,117388,50036935,415.97,5.371807958,"Antihistamines for Systemic Use; Benzocycloheptenes; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dibenzocycloheptenes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Piperidines; Platelet Activating Factor, antagonists & inhibitors; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB11619,Gestrinone,16320-04-0,approved,BJJXHLWLUDYTGC-ANULTFPQSA-N,"InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1",C#C[C@]1(O)CC[C@H]([C@@]12CC)[C@H]3C(C=C2)=C4C(CC3)=CC(=O)CC4,C21H24O2,,D04317,27812,347828012,89642,CHEMBL1868702,,25877,50423515,308.4141,2.85063764,"Adrenal Cortex Hormones; Antigonadotropins and Similar Agents; Contraceptive Agents, Female; Contraceptives, Oral; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Norpregnanes; Norpregnatrienes; Norsteroids; Polycyclic Compounds; Progestin Contraceptives; Progestins; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB11622,Dehydrocholic acid,81-23-2,approved; investigational,OHXPGWPVLFPUSM-KLRNGDHRSA-N,"InChI=1S/C24H34O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29)/t13-,14+,16-,17+,18+,22+,23+,24-/m1/s1",OC(=O)CC[C@@H](C)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2=O)[C@]4(C)[C@H](CC3=O)CC(=O)CC4,C24H34O5,C13154,D01693,6674,347828014,31459,CHEMBL514446,,6422,,402.531,3.639037218,Bile Acids and Salts; Cholagogues and Choleretics; Cholanes; Cholic Acids; Fused-Ring Compounds; Gastrointestinal Agents; Laxatives; Polycyclic Compounds; Steroids
DB11629,Laropiprant,571170-77-9,approved; investigational; withdrawn,NXFFJDQHYLNEJK-CYBMUJFWSA-N,"InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1",c1cc(Cl)ccc1Cn(c(c23)c(S(=O)(=O)C)cc(F)c2)c4c3CC[C@@H]4CC(=O)O,C21H19ClFNO4S,,,,,135942,CHEMBL426559,,8043333,50205275,435.89,3.868291078,"Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring"
DB11630,Temoporfin,122341-38-2,approved; investigational,LYPFDBRUNKHDGX-LWQDQPMZSA-N,"InChI=1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-17,19,21-24,46-47,49-52H,18,20H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-",Oc1cccc(c1)-c(c23)c4ccc([nH]4)c(-c5cc(O)ccc5)c6nc(cc6)c(-c7cc(O)ccc7)c8[nH]c(cc8)c(c(n2)CC3)-c9cc(O)ccc9,C44H32N4O4,C11730,D06066,,,9437,CHEMBL500576,,54754,,680.764,9.21423938,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; Biological Factors; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Macrocyclic Compounds; Narrow Therapeutic Index Drugs; Photosensitizing Agents; Pigments, Biological; Polycyclic Compounds; Porphyrins; Pyrroles; Radiation-Sensitizing Agents; Sensitizers Used in Photodynamic/radiation Therapy; Tetrapyrroles"
DB11632,Opicapone,923287-50-7,approved; investigational,ASOADIZOVZTJSR-UHFFFAOYSA-N,"InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3",Clc1c(C)[n+]([O-])c(Cl)c(c1C)-c2noc(n2)-c3cc([N+]([O-])=O)c(O)c(O)c3,C15H10Cl2N4O6,,,,,134699,CHEMBL1089318,,24667564,50019329,413.17,3.051714506,"Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Azoles; Central Nervous System Agents; COMT Inhibitors; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Dopamine Agents; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Oxazoles"
DB11633,Isavuconazole,241479-67-4,approved; investigational,DDFOUSQFMYRUQK-RCDICMHDSA-N,"InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1",c1ncnn1C[C@](O)(c2c(F)ccc(F)c2)[C@@H](C)c3nc(cs3)-c4ccc(C#N)cc4,C22H17F2N5OS,,,,,85979,CHEMBL409153,,5293682,,437.47,4.143500234,"Anti-Infective Agents; Antifungal Agents; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; Azole Antifungals; Azoles; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (weak); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (moderate); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isavuconazole and Prodrugs; OCT2 Inhibitors; P-glycoprotein inhibitors; Triazole Derivatives; UGT1A9 Inhibitors"
DB11634,Colestilan chloride,95522-45-5,approved; investigational; withdrawn,,, ,(C7H11N2O)n.Cl,,,,,,,,,,NA,NA,Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Fused-Ring Compounds; Polycyclic Compounds; Steroids
DB11635,Tocofersolan,9002-96-4,approved,,, ,C33H54O5(C2H4O)n,,,,347911221,,,,,,NA,NA,"Alimentary Tract and Metabolism; Benzopyrans; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drug Carriers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans; Vitamin E; Vitamins; Vitamins (Fat Soluble)"
DB11636,Nomegestrol,58691-88-6,approved,KZUIYQJTUIACIG-YBZCJVABSA-N,"InChI=1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1",CC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@@H]4C(C(=C3)C)=CC(=O)CC4,C21H28O3,,D07222,,,135993,CHEMBL2105722,,62024,,328.452,2.982571773,"Adrenal Cortex Hormones; Antineoplastic Agents, Hormonal; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Polycyclic Compounds; Pregnadien Derivatives; Pregnadienes; Pregnanes; Progesterone Congeners; Progestins; Progestogens and Estrogens, Sequential Preparations; Sex Hormones and Modulators of the Genital System; Steroids"
DB11637,Delamanid,681492-22-8,approved; investigational,XDAOLTSRNUSPPH-XMMPIXPASA-N,"InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1",[O-][N+](=O)c(n1)cn(c12)C[C@](O2)(C)COc3ccc(cc3)N4CCC(CC4)Oc5ccc(OC(F)(F)F)cc5,C25H25F3N4O6,,,,,134742,CHEMBL218650,,4981055,,534.492,6.143707376,"Antiinfectives for Systemic Use; Antimycobacterials; Azoles; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs for Treatment of Tuberculosis; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Moderate Risk QTc-Prolonging Agents; Nitro Compounds; QTc Prolonging Agents"
DB11640,Amifampridine,54-96-6,approved; investigational,OYTKINVCDFNREN-UHFFFAOYSA-N,"InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)",Nc1ccncc1N,C5H7N3,,,,,135948,CHEMBL354077,L89,5705,50416493,109.132,-0.902278519,"Amines; Aminopyridines; Cardiovascular Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Iodine Radioisotopes; Membrane Transport Modulators; Miscellaneous Central Nervous System Agents; Moderate Risk QTc-Prolonging Agents; Nervous System; Peripheral Nervous System Agents; Potassium Channel Antagonists; Potassium Channel Blockers; Pyridines; QTc Prolonging Agents"
DB11641,Vinflunine,162652-95-1,approved; investigational,NMDYYWFGPIMTKO-KLCPSUAYSA-N,"InChI=1S/C45H54F2N4O8/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3/t26-,27+,36-,37+,38+,42+,43+,44-,45-/m0/s1",C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(CN(C6)C[C@@H](C7)C(F)(F)C)c9c([nH]8)cccc9,C45H54F2N4O8,,,,,90241,CHEMBL2110725,,8804619,,816.944,4.645811736,"Alkaloids; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indole Alkaloids; Indoles; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Secologanin Tryptamine Alkaloids; Vinca Alkaloids"
DB11642,Pitolisant,362665-56-3,approved; investigational,NNACHAUCXXVJSP-UHFFFAOYSA-N,"InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2",Clc1ccc(cc1)CCCOCCCN2CCCCC2,C17H26ClNO,,,,,134709,CHEMBL462605,,8123714,50247053,295.85,4.115267492,"Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Antagonists; Moderate Risk QTc-Prolonging Agents; Nervous System; OCT1 inhibitors; Photosensitizing Agents; QTc Prolonging Agents; Receptors, Histamine H3"
DB11644,Tafamidis,594839-88-0,approved; investigational,TXEIIPDJKFWEEC-UHFFFAOYSA-N,"InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)",OC(=O)c(c1)ccc(c12)nc(o2)-c3cc(Cl)cc(Cl)c3,C14H7Cl2NO3,,D09673,11001318,347828016,78538,CHEMBL2103837,3MI,9176510,50197883,308.116,4.210307917,"Anti-Inflammatory Agents; BCRP/ABCG2 Inhibitors; Fused-Ring Compounds; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunologic Factors; Miscellaneous Cardiac Drugs; Nervous System; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Polycyclic Compounds"
DB11652,Tucatinib,937263-43-9,approved; investigational,SDEAXTCZPQIFQM-UHFFFAOYSA-N,"InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)",CC1(C)N=C(OC1)Nc(c2)ccc(c23)ncnc3Nc4cc(C)c(cc4)Oc(cc5)cc(n56)ncn6,C26H24N8O2,,,51039094,347828023,,CHEMBL3989868,,34995558,,480.532,5.25061488,Antineoplastic Agents; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Substrates; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Tyrosine Kinase Inhibitors
DB11653,Bremelanotide,189691-06-3,approved; investigational,FFHBJDQSGDNCIV-MFVUMRCOSA-N,"InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1",CCCC[C@H](NC(=O)C)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc2c[nH]c(c23)cccc3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@@H](NC1=O)Cc5cnc[nH]5,C50H68N14O10,,,9941379,347828024,,CHEMBL2070241,,8116997,50389769,1025.182,-3.216479519,"Amino Acids, Peptides, and Proteins; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Macrocyclic Compounds; Melanocortins; Melanocyte-Stimulating Hormones; Nerve Tissue Proteins; Neuropeptides; Peptide Hormones; Peptides; Pituitary Hormones; Pituitary Hormones, Anterior; Polycyclic Compounds; Pro-Opiomelanocortin; Protein Precursors; Proteins; Receptor, Melanocortin, Type 3, agonists; Receptor, Melanocortin, Type 4, agonists"
DB11660,Latanoprostene bunod,860005-21-6,approved; investigational,LOVMMUBRQUFEAH-UIEAZXIASA-N,"InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1",c1ccccc1CC[C@H](O)CC[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)OCCCCO[N+]([O-])=O,C27H41NO8,,,11156438,347828030,,CHEMBL2364612,,9331546,,507.624,3.793364352,"Antiglaucoma Preparations and Miotics; Autacoids; Biological Factors; Drugs that are Mainly Renally Excreted; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Inflammation Mediators; Lipids; Ophthalmologicals; Prostaglandin analogs reducing intraocular pressure (IOP); Prostaglandins; Prostaglandins, Synthetic; Sensory Organs"
DB11672,Curcumin,458-37-7,approved; experimental; investigational,VFLDPWHFBUODDF-FCXRPNKRSA-N,"InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+",COc1cc(ccc1O)/C=C/C(=O)CC(=O)/C=C/c2cc(OC)c(O)cc2,C21H20O6,,,969516,347828040,3962,CHEMBL140,CC9,839564,50140172,368.3799,4.124524551,"Alkanes; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antineoplastic Agents; Antirheumatic Agents; Benzene Derivatives; Catechols; Central Nervous System Agents; Coloring Agents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Diarylheptanoids; Enzyme Inhibitors; Heptanes; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Phenols; Sensory System Agents"
DB11677,Triheptanoin,620-67-7,approved; investigational,PJHKBYALYHRYSK-UHFFFAOYSA-N,"InChI=1S/C24H44O6/c1-4-7-10-13-16-22(25)28-19-21(30-24(27)18-15-12-9-6-3)20-29-23(26)17-14-11-8-5-2/h21H,4-20H2,1-3H3",CCCCCCC(=O)OCC(OC(=O)CCCCCC)COC(=O)CCCCCC,C24H44O6,,,69286,347828045,,CHEMBL4297585,,62497,,428.61,6.920793729,Glycerides; Lipids; Triglycerides
DB11689,Selumetinib,606143-52-6,approved; investigational,CYOHGALHFOKKQC-UHFFFAOYSA-N,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",OCCONC(=O)c(c1)c(c(F)c(c12)ncn2C)Nc3c(Cl)cc(Br)cc3,C17H15BrClFN4O3,,D09666,10127622,347828055,90227,CHEMBL1614701,3EW,8303141,50355497,457.68,4.273922356,"BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; P-glycoprotein substrates; Tyrosine Kinase Inhibitors; UGT1A1 Substrates"
DB11691,Naldemedine,916072-89-4,approved; investigational,AXQACEQYCPKDMV-RZAWKFBISA-N,"InChI=1S/C32H34N4O6/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39)/t22-,26+,31+,32-/m1/s1",[C@]123[C@H]4Oc5c1c(ccc5O)C[C@@H](N(CC2)CC6CC6)[C@]3(O)CC(=C4O)C(=O)NC(C)(C)c7nc(no7)-c8ccccc8,C32H34N4O6,,,54732242,347828056,,CHEMBL2105755,,28530803,,570.646,2.425656088,"Alimentary Tract and Metabolism; Alkaloids; Drugs for Constipation; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Opiate Alkaloids; Opioid Antagonists; Peripheral Opioid Receptor Antagonists; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; UGT1A3 substrates"
DB11699,Tropisetron,89565-68-4,approved; investigational,ZNRGQMMCGHDTEI-ITGUQSILSA-N,"InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13+",[C@@H]12CC[C@@H](N1C)C[C@@H](C2)OC(=O)c3c[nH]c(c34)cccc4,C17H20N2O2,C13666,,656665,347828064,32269,CHEMBL56564,TKT,16736476,50108392,284.3529,2.627622507,"Alimentary Tract and Metabolism; Antiarrhythmic agents; Antidepressive Agents; Antiemetics; Antiemetics and Antinauseants; Autonomic Agents; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Neurotransmitter Agents; Peripheral Nervous System Agents; Serotonin 5-HT3 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists"
DB11703,Acalabrutinib,1420477-60-6,approved; investigational,WDENQIQQYWYTPO-IBGZPJMESA-N,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",CC#CC(=O)N1CCC[C@H]1c2nc(c(n23)c(N)ncc3)-c4ccc(cc4)C(=O)Nc5ccccn5,C26H23N7O2,,,71226662,347828068,,CHEMBL3707348,,36764951,50175583,465.517,2.561967258,"Acids, Carbocyclic; Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Kinase Inhibitor; Narrow Therapeutic Index Drugs; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB11705,Iomeprol,78649-41-9,approved; investigational,NJKDOADNQSYQEV-UHFFFAOYSA-N,"InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)",OCC(=O)N(C)c1c(I)c(C(=O)NCC(O)CO)c(I)c(c1I)C(=O)NCC(O)CO,C17H22I3N3O8,,D01719,3731,347828070,31710,CHEMBL2107214,,3600,,777.089,-1.447633547,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodobenzoates; Triiodobenzoic Acids; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Media, Iodinated"
DB11712,Tezacaftor,1152311-62-0,approved; investigational,MJUVRTYWUMPBTR-MRXNPFEDSA-N,"InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1",OC[C@H](O)Cn1c(C(C)(C)CO)cc(c12)cc(c(F)c2)NC(=O)C3(CC3)c(c4)ccc(c45)OC(O5)(F)F,C26H27F3N2O6,,D11041,46199646,347828077,,CHEMBL3544914,,28637762,281054,520.505,4.025537837,"BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Dioxoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; P-glycoprotein inhibitors; P-glycoprotein substrates; Respiratory System"
DB11718,Encorafenib,1269440-17-6,approved; investigational,CMJCXYNUCSMDBY-ZDUSSCGKSA-N,"InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1",COC(=O)N[C@@H](C)CNc1nccc(n1)-c2cn(C(C)C)nc2-c3cc(Cl)cc(c3F)NS(=O)(=O)C,C22H27ClFN7O4S,,,50922675,347828081,,CHEMBL3301612,,28536139,221688,540.01,2.646308768,"Acids, Acyclic; Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Carboxylic Acids; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Moderate Risk QTc-Prolonging Agents; Protein Kinase Inhibitors; QTc Prolonging Agents; Sulfones; Sulfur Compounds"
DB11730,Ribociclib,1211441-98-3,approved; investigational,RHXHGRAEPCAFML-UHFFFAOYSA-N,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",C1CCCC1n2c(C(=O)N(C)C)cc(c23)cnc(n3)Nc4ccc(cn4)N5CCNCC5,C23H30N8O,,D10883,44631912,347828089,,CHEMBL3545110,6ZZ,30798107,148264,434.548,2.379943386,"Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Kinase Inhibitor; Narrow Therapeutic Index Drugs; Protein Kinase Inhibitors; Pyridines; QTc Prolonging Agents"
DB11732,Lasmiditan,439239-90-4,approved; investigational,XEDHVZKDSYZQBF-UHFFFAOYSA-N,"InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)",CN1CCC(CC1)C(=O)c2cccc(n2)NC(=O)c3c(F)cc(F)cc3F,C19H18F3N3O2,,,11610526,347828091,,CHEMBL3039520,,9785281,,377.367,3.300145203,Amides; BCRP/ABCG2 Inhibitors; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Heterocyclic Compounds; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; OCT1 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
DB11735,Galactose,59-23-4,approved; investigational,GZCGUPFRVQAUEE-KCDKBNATSA-N,"InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h1,3-6,8-12H,2H2/t3-,4+,5+,6-/m0/s1",O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO,C6H12O6,,,3037556,347828093,17118,,,2301265,,180.1559,-3.568360563,Carbohydrates; Contrast Media; Diagnostic Agents; Hexoses; Monosaccharides; Tests for Liver Functional Capacity; Ultrasound Contrast Media
DB11738,Rilmenidine,54187-04-1,approved; investigational,CQXADFVORZEARL-UHFFFAOYSA-N,"InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)",C1CC1C(C2CC2)NC3=NCCO3,C10H16N2O,C11120,,68712,347828096,8862,CHEMBL289480,,61963,50070328,180.251,1.576446459,"Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Agents producing tachycardia; Agents that produce hypertension; Antiadrenergic Agents, Centrally Acting; Antihypertensive Agents; Autonomic Agents; Azoles; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoline Receptor Agonists; Neurotransmitter Agents; Oxazoles; Peripheral Nervous System Agents; Sympatholytics"
DB11742,Ebastine,90729-43-4,approved; investigational,MJJALKDDGIKVBE-UHFFFAOYSA-N,"InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3",CC(C)(C)c1ccc(cc1)C(=O)CCCN2CCC(CC2)OC(c3ccccc3)c4ccccc4,C32H39NO2,,,3191,347828100,31528,CHEMBL305660,,3079,22873,469.6576,6.963021436,"Antihistamines for Systemic Use; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Ketones; Neurotransmitter Agents; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Respiratory System"
DB11748,Benfotiamine,22457-89-2,approved; experimental,BTNNPSLJPBRMLZ-LGMDPLHJSA-N,"InChI=1S/C19H23N4O6PS/c1-13(23(12-24)11-16-10-21-14(2)22-18(16)20)17(8-9-29-30(26,27)28)31-19(25)15-6-4-3-5-7-15/h3-7,10,12H,8-9,11H2,1-2H3,(H2,20,21,22)(H2,26,27,28)/b17-13-",c1ccccc1C(=O)S/C(CCOP(=O)(O)O)=C(/C)N(C=O)Cc2cnc(C)nc2N,C19H23N4O6PS,,,3032771,347828105,41039,CHEMBL3183549,,2297665,,466.45,-2.237317757,"Adjuvants, Immunologic; Alimentary Tract and Metabolism; Azoles; Compounds used in a research, industrial, or household setting; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunologic Factors; Pyrimidines; Sequestering Agents; Sulfur Compounds; Thiazoles; Vitamin B Complex; Vitamins"
DB11750,Clobetasol,25122-41-2,approved; experimental; investigational,FCSHDIVRCWTZOX-DVTGEIKXSA-N,"InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1",ClCC(=O)[C@@]1(O)[C@@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)C=C4,C22H28ClFO4,,,5311051,347828107,205919,CHEMBL1201362,,4470588,,410.907,3.036161536,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Very Potent (Group IV); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated; Thyroxine-binding globulin inhibitors"
DB11753,Rifamycin,6998-60-3,approved; investigational,HJYYPODYNSCCOU-ODRIEIDWSA-N,"InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1",C[C@@]12O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(=O)C)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)C(=O)Nc3c(O)c4c(c(c3)O)c(C1=O)c(O2)c(C)c4O,C37H47NO12,C12044,D02549,,347911235,29673,CHEMBL437765,,16735998,50391000,697.778,4.174343762,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antiinfectives for Systemic Use; Antimycobacterials; Antirheumatic Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strong); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Drugs for Treatment of Tuberculosis; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Lactams, Macrocyclic; Macrocyclic Compounds; MATE 1 Inhibitors; MATE inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Ophthalmologicals; Otologicals; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Rifamycins; Sensory Organs"
DB11757,Istradefylline,155270-99-8,approved; investigational,IQVRBWUUXZMOPW-PKNBQFBNSA-N,"InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+",COc1ccc(cc1OC)/C=C/c(n2C)nc(c23)n(CC)c(=O)n(c3=O)CC,C20H24N4O4,,,5311037,347828111,134726,CHEMBL431770,,4470574,50176050,384.436,2.417824491,"Adenosine A2 Receptor Antagonists; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; Neurotransmitter Agents; OAT1/SLC22A6 inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inhibitors; Purinergic Agents; Purinergic Antagonists; Purinergic P1 Receptor Antagonists"
DB11760,Talazoparib,1207456-01-6,approved; investigational,HWGQMRYQVZSGDQ-HZPDHXFCSA-N,"InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1",Cn1ncnc1[C@@H]2[C@@H](c(cc3)ccc3F)Nc(c4c25)cc(F)cc4c(=O)[nH]n5,C19H14F2N6O,,,44819241,347828114,,CHEMBL3137320,2YQ,28637772,50084621,380.359,2.111473602,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Poly(ADP-ribose) Polymerase Inhibitors; Pyridazines"
DB11761,Tenapanor,1234423-95-0,approved; investigational,DNHPDWGIXIMXSA-CXNSMIOJSA-N,"InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1",Clc1cc(Cl)cc(c12)[C@@H](CN(C2)C)c3cc(ccc3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c4cc(ccc4)[C@@H]5CN(C)Cc(c56)c(Cl)cc(Cl)c6,C50H66Cl4N8O10S2,,,71587953,347828115,,CHEMBL3304485,,32056950,,1145.04,5.024090239,"Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Sulfur Compounds"
DB11768,Zytron,299-85-4,approved; investigational,PJFGPJQBWSEWKX-UHFFFAOYSA-N,"InChI=1S/C10H14Cl2NO2PS/c1-7(2)13-16(17,14-3)15-10-5-4-8(11)6-9(10)12/h4-7H,1-3H3,(H,13,17)",CC(C)NP(=S)(OC)Oc1ccc(Cl)cc1Cl,C10H14Cl2NO2PS,,,9299,347828121,,,,8940,,314.16,3.913918106,Amines; Organophosphorus Compounds; Sulfur Compounds
DB11791,Capmatinib,1029712-80-8,approved; investigational,LIOLIMKSCNQPLV-UHFFFAOYSA-N,"InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)",CNC(=O)c1c(F)cc(cc1)-c(cn2)nn(c23)c(cn3)Cc(cc4)cc(c45)cccn5,C23H17FN6O,,,25145656,347828140,,CHEMBL3188267,,25069712,50146167,412.428,2.964354428,"Acids, Carbocyclic; Amides; Antineoplastic Agents; Azoles; BCRP/ABCG2 Inhibitors; Benzene Derivatives; Benzoates; Carboxylic Acids; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, Bridged-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; P-glycoprotein substrates; Tyrosine Kinase Inhibitors"
DB11793,Niraparib,1038915-60-4,approved; investigational,PCHKPVIQAHNQLW-CQSZACIVSA-N,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",O=C(N)c1cccc(c12)cn(n2)-c3ccc(cc3)[C@@H]4CCCNC4,C19H20N4O,,,24958200,347828142,,CHEMBL1094636,3JD,24531930,50316226,320.396,2.468050342,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazoles"
DB11799,Bictegravir,1611493-60-7,approved; investigational,SOLUWJRYJLAZCX-LYOVBCGYSA-N,"InChI=1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1",Fc1cc(F)cc(F)c1CNC(=O)c(c2)c(=O)c(O)c(n23)C(=O)N4[C@@H](C3)O[C@@H]5CC[C@H]4C5,C21H18F3N3O5,,,90311989,347828148,,CHEMBL3989866,KLQ,44208822,330048,449.386,1.355710744,"Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; MATE 1 Inhibitors; MATE inhibitors; UGT1A1 Substrates"
DB11815,Tilarginine,17035-90-4,approved; investigational,NTNWOCRCBQPEKQ-YFKPBYRVSA-N,"InChI=1S/C7H16N4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11)/t5-/m0/s1",CNC(=N)NCCC[C@H](N)C(=O)O,C7H16N4O2,C03884,,132862,347828162,60257,CHEMBL256147,NMM,117259,92900,188.2275,-2.871708094,"Amino Acids; Amino Acids, Basic; Amino Acids, Diamino; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Arginine; Enzyme Inhibitors; Nitric Oxide Synthase, antagonists & inhibitors"
DB11817,Baricitinib,1187594-09-7,approved; investigational,XUZMWHLSFXCVMG-UHFFFAOYSA-N,"InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)",CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4,C16H17N7O2S,,D10308,44205240,347828164,95341,CHEMBL2105759,3JW,26373084,50021656,371.42,-0.188574155,"Amides; Antineoplastic and Immunomodulating Agents; Azetines; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Janus Kinase Inhibitor; Janus Kinase Inhibitors; MATE 2 Inhibitors; MATE 2 Substrates; MATE 2 Substrates with a Narrow Therapeutic Index; MATE inhibitors; MATE substrates; Narrow Therapeutic Index Drugs; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OAT3/SLC22A8 Substrates; OATP1B3 inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Selective Immunosuppressants; Sulfones; Sulfur Compounds"
DB11823,Esketamine,33643-46-8,approved; investigational,YQEZLKZALYSWHR-ZDUSSCGKSA-N,"InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3/t13-/m0/s1",C1CCCC(=O)[C@@]1(NC)c2ccccc2Cl,C13H16ClNO,,D07283,182137,347828170,60799,CHEMBL395091,,158414,,237.73,3.347302666,"Agents producing tachycardia; Anesthetics; Anesthetics, General; Antidepressive Agents; Central Nervous System Agents; Central Nervous System Depressants; Cyclohexanes; Cycloparaffins; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (weak); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Nervous System; Polycyclic Compounds; Psychoanaleptics; Psychotropic Drugs"
DB11827,Ertugliflozin,1210344-57-2,approved; investigational,MCIACXAZCBVDEE-CUUWFGFTSA-N,"InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1",CCOc1ccc(cc1)Cc2cc(ccc2Cl)[C@]34OC[C@@](O3)(CO)[C@@H](O)[C@H](O)[C@H]4O,C22H25ClO7,,,44814423,347828173,,CHEMBL1770248,,26340533,50342885,436.89,2.316586536,"Alimentary Tract and Metabolism; BCRP/ABCG2 Substrates; Blood Glucose Lowering Agents; Diuretics; Drugs Used in Diabetes; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; P-glycoprotein substrates; Sodium-glucose co-transporter 2 (SGLT2) inhibitors; Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; UGT1A1 Inhibitors; UGT1A4 Inhibitors; UGT1A9 Substrates; UGT2B7 substrates"
DB11828,Neratinib,698387-09-6,approved; investigational,JWNPDZNEKVCWMY-VQHVLOKHSA-N,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",CN(C)C/C=C/C(=O)Nc(c(c1)OCC)cc(c12)c(c(cn2)C#N)Nc3ccc(c(Cl)c3)OCc4ccccn4,C30H29ClN6O3,,,9915743,347828174,61397,CHEMBL180022,,8091392,50161957,557.05,4.469318862,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB11835,Indium In-111 pentetreotide,139096-04-1,approved; investigational,ZKZPXKKVDJOAIS-JWFOFJTQSA-J,"InChI=1S/C62H84N12O19S2.In/c1-35(76)47(32-75)69-59(88)49-34-95-94-33-48(70-55(84)44(25-37-13-5-3-6-14-37)65-50(78)29-74(31-52(81)82)24-23-73(30-51(79)80)22-20-41(61(90)91)62(92)93)58(87)67-45(26-38-15-7-4-8-16-38)56(85)68-46(27-39-28-64-42-18-10-9-17-40(39)42)57(86)66-43(19-11-12-21-63)54(83)72-53(36(2)77)60(89)71-49;/h3-10,13-18,28,35-36,41,43-49,53,64,75-77H,11-12,19-27,29-34,63H2,1-2H3,(H,65,78)(H,66,86)(H,67,87)(H,68,85)(H,69,88)(H,70,84)(H,71,89)(H,72,83)(H,79,80)(H,81,82)(H,90,91)(H,92,93);/q;+3/p-4/i;1-4",NCCCCC1/C([O-])=N/C(C(C)O)/C(O)=N/C(/C(O)=N/C(C(C)O)CO)CSSCC(C(\O)=N\C(Cc2ccccc2)C(\O)=N\C(C(=N\1)\O)Cc3c[nH]c(c34)cccc4)/N=C(\O)C(Cc5ccccc5)/N=C(\[O-])CN(CC([O-])=O)CCN(CC([O-])=O)CCC(C(=O)O)C(=O)O,C62H80InN12O19S2,,,131704321,347828180,,,,,,1472.41,3.785215532,"Amino Acids, Peptides, and Proteins; Diagnostic Radiopharmaceuticals; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Indium (111In) Compounds; Indium Radioisotopes; Nerve Tissue Proteins; Neuropeptides; Pancreatic Hormones; Peptide Hormones; Peptides; Pituitary Hormone Release Inhibiting Hormones; Proteins; Radioactive Diagnostic Agent; Radiopharmaceutical Activity; Tumour Detection"
DB11837,Osilodrostat,928134-65-0,approved; investigational,USUZGMWDZDXMDG-CYBMUJFWSA-N,"InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1",c1ncc(n12)CC[C@@H]2c3c(F)cc(C#N)cc3,C13H10FN3,,,44139752,347828182,,CHEMBL3099695,,29340911,50444549,227.242,2.110041006,"Azoles; Cytochrome P-450 CYP11B2, antagonists & inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Inhibitors; MATE inhibitors; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT2 Inhibitors; UGT1A4 substrates; UGT2B7 substrates"
DB11842,Angiotensin II,4474-91-3,approved; investigational,CZGUSIXMZVURDU-JZXHSEFVSA-N,"InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1",NC(N)=NCCC[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)O)Cc4ccccc4,C50H71N13O12,C02135,,172198,347828186,58506,CHEMBL408403,,150504,50236697,1046.1786,-5.273500998,"Amino Acids, Peptides, and Proteins; Angiotensin II, antagonists & inhibitors; Angiotensins; Autacoids; Biological Factors; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Inflammation Mediators; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Proteins; Vasoconstriction; Vasoconstrictor Agents"
DB11855,Revefenacin,864750-70-9,approved; investigational,FYDWDCIFZSGNBU-UHFFFAOYSA-N,"InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)",O=C(N)C1CCN(CC1)Cc2ccc(cc2)C(=O)N(C)CCN3CCC(CC3)OC(=O)Nc4ccccc4-c5ccccc5,C35H43N5O4,,,11753673,347828196,,CHEMBL3833319,,9928376,,597.76,3.811556905,"Amides; Anticholinergic Agents; BCRP/ABCG2 Substrates; Benzene Derivatives; Bronchodilator Agents; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Muscarinic Antagonists; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; P-glycoprotein substrates"
DB11859,Brexanolone,516-54-1,approved; investigational,AURFZBICLPNKBZ-SYBPFIFISA-N,"InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1",O=C(C)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)[C@@H](CC3)C[C@H](O)CC4,C21H34O2,C13712,,92786,347828198,50169,CHEMBL207538,,83760,50191342,318.4935,3.986937934,"Anesthetics; Anticonvulsants; Biopolymers; Carbohydrates; Central Nervous System Agents; Central Nervous System Depressants; Compounds used in a research, industrial, or household setting; Corpus Luteum Hormones; Cyclodextrins; Dextrins; Diet, Food, and Nutrition; Dietary Carbohydrates; Food; Food and Beverages; Fused-Ring Compounds; GABA Modulators; Glucans; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Macrocyclic Compounds; Macromolecular Substances; Manufactured Materials; Pharmaceutical Preparations; Physiological Phenomena; Polycyclic Compounds; Polymers; Polysaccharides; Pregnanes; Pregnenediones; Pregnenes; Progesterone Congeners; Starch; Steroids"
DB11901,Apalutamide,956104-40-8,approved; investigational,HJBWBFZLDZWPHF-UHFFFAOYSA-N,"InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)",CNC(=O)c1ccc(cc1F)N(C23CCC2)C(=S)N(C3=O)c4cc(C(F)(F)F)c(C#N)nc4,C21H15F4N5O2S,,,24872560,347828234,,CHEMBL3183409,,28424131,50094975,477.44,3.460339361,"Antiandrogens; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strong); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inducers (strong); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Endocrine Therapy; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists and Related Agents; Imidazoles; Imidazolidines; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inducers; OCT2 Inhibitors; P-glycoprotein inducers; Prostatic Neoplasms, drug therapy"
DB11915,Valbenazine,1025504-45-3,approved; investigational,GEJDGVNQKABXKG-CFKGEZKQSA-N,"InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1",COc(c1)c(OC)cc(c12)[C@@H]3N(CC2)C[C@@H](CC(C)C)[C@@H](C3)OC(=O)[C@@H](N)C(C)C,C24H38N2O4,,,24795069,347828246,,CHEMBL2364639,,28536134,,418.578,3.645750238,"Amino Acids; Amino Acids, Branched-Chain; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Quinolizines; Vesicular Monoamine Transporter 2 Inhibitor; Vesicular Monoamine Transporter 2 Inhibitors"
DB11921,Deflazacort,14484-47-0,approved; investigational,FBHSPRKOSMHSIF-GRMWVWQJSA-N,"InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1",CC(=O)OCC(=O)[C@]12[C@H](OC(=N1)C)C[C@@H]3[C@]2(C)C[C@H](O)[C@H]4[C@H]3CCC=5[C@]4(C)C=CC(=O)C5,C25H31NO6,,D03671,189821,347828252,135720,CHEMBL1201891,,164861,,441.524,1.802185119,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids for Systemic Use; Corticosteroids for Systemic Use, Plain; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Glucocorticoids; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Polycyclic Compounds; Steroids; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB11936,Bempedoic acid,738606-46-7,approved; investigational,HYHMLYSLQUKXKP-UHFFFAOYSA-N,"InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)",OC(=O)C(C)(C)CCCCCC(O)CCCCCC(C)(C)C(=O)O,C19H36O5,,,10472693,347828263,,CHEMBL3545313,,8648104,,344.492,5.303054981,"Acids, Acyclic; Carboxylic Acids; Cardiovascular System; Enzyme Inhibitors; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; OATP1B3 substrates; UGT2B7 substrates"
DB11942,Selinexor,1393477-72-9,approved; investigational,DEVSOMFAQLZNKR-RJRFIUFISA-N,"InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-",FC(F)(F)c1cc(C(F)(F)F)cc(c1)-c2nn(cn2)/C=C\C(=O)NNc3nccnc3,C17H11F6N7O,,,71481097,347828269,,CHEMBL3545185,,32701989,,443.313,3.074814472,Azoles; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; OATP1B3 inhibitors
DB11943,Delafloxacin,189279-58-1,approved; investigational,DYDCPNMLZGFQTM-UHFFFAOYSA-N,"InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)",Fc1cc(F)c(nc1N)-n2cc(C(=O)O)c(=O)c(c23)cc(F)c(c3Cl)N4CC(O)C4,C18H12ClF3N4O4,,,487101,347828270,,CHEMBL2105637,,427049,,440.76,2.558647892,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (weak); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Drugs that are Mainly Renally Excreted; Fluoroquinolone Antibacterial; Fluoroquinolones; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Quinolines; Quinolones; UGT1A1 Substrates; UGT1A3 substrates"
DB11951,Lemborexant,1369764-02-2,approved; investigational,MUGXRYIUWFITCP-PGRDOPGGSA-N,"InChI=1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)/t18-,22+/m0/s1",Cc1ncc(c(n1)C)OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc4ncc(F)cc4,C22H20F2N4O2,,,56944144,347828277,,CHEMBL3545367,NRK,34500836,50093793,410.425,3.34352123,"Central Nervous System Depressants; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Orexin Receptor Antagonists; P-glycoprotein substrates; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders"
DB11952,Duvelisib,1201438-56-3,approved; investigational,SJVQHLPISAIATJ-ZDUSSCGKSA-N,"InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1",Clc1cccc(c12)cc(n(c2=O)-c3ccccc3)[C@H](C)Nc(ncn4)c(c45)nc[nH]5,C22H17ClN6O,,D10555,50905713,347828278,131169,CHEMBL3039502,,28637766,50193013,416.87,3.670915106,"BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; P-glycoprotein substrates; Phosphatidylinositol 3-Kinases, antagonists & inhibitors"
DB11963,Dacomitinib,1110813-31-4,approved; investigational,LVXJQMNHJWSHET-AATRIKPKSA-N,"InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+",C1CCCCN1C/C=C/C(=O)Nc(c(c2)OC)cc(c23)c(ncn3)Nc4cc(Cl)c(F)cc4,C24H25ClFN5O2,,D09883,11511120,347828287,132268,CHEMBL2110732,1C9,9685914,112499,469.939,4.707501069,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strong); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; OCT1 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Protein Kinase Inhibitors; Quinazolines; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors"
DB11967,Binimetinib,606143-89-9,approved; investigational,ACWZRVQXLIRSDF-UHFFFAOYSA-N,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",OCCONC(=O)c(c1)c(c(F)c(c12)ncn2C)Nc3ccc(Br)cc3F,C17H15BrF2N4O3,,,10288191,347828291,145371,CHEMBL3187723,,8463660,,441.233,3.812579616,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; MAP Kinase Kinase 1, antagonists & inhibitors; MAP Kinase Kinase 2, antagonists & inhibitors; P-glycoprotein substrates with narrow therapeutic index; Protein Kinase Inhibitors; UGT1A1 Substrates; UGT1A1 substrates with narrow therapeutic index"
DB11978,Glasdegib,1095173-27-5,approved; investigational,SFNSLLSYNZWZQG-VQIMIIECSA-N,"InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1",N#Cc1ccc(cc1)NC(=O)N[C@@H]2CCN(C)[C@H](C2)c([nH]3)nc(c34)cccc4,C21H22N6O,,,25166913,347828300,145428,CHEMBL2043437,,28518072,50385635,374.448,2.279843071,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Benzene Derivatives; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Hedgehog Pathway Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; QTc Prolonging Agents; Smoothened Receptor Antagonists; UGT1A9 Substrates"
DB11979,Elagolix,834153-87-6,approved; investigational,HEAUOKZIVMZVQL-VWLOTQADSA-N,"InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1",COc1cccc(c1F)-c2c(C)n(Cc3c(C(F)(F)F)cccc3F)c(=O)n(c2=O)C[C@H](NCCCC(=O)O)c4ccccc4,C32H30F5N3O5,,,11250647,347828301,,CHEMBL1208155,,9425680,,631.6,3.142224604,"Anti-Gonadotropin-Releasing Hormones; Antigonadotropins and Similar Agents; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 Substrates; Gonadotropin-releasing Hormone Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Halogenated; Hypothalamic Hormones; OATP1B1/SLCO1B1 Substrates; P-glycoprotein inhibitors; P-glycoprotein substrates; Pituitary and Hypothalamic Hormones and Analogues; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; UGT1A1 Substrates"
DB11986,Entrectinib,1108743-60-7,approved; investigational,HAYYBYPASCDWEQ-UHFFFAOYSA-N,"InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)",CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6,C31H34F2N6O2,,,25141092,347828307,,CHEMBL1983268,YMX,24808589,158154,560.65,5.398975585,"Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; Benzene Derivatives; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Protein Kinase Inhibitors; Pyrazoles; QTc Prolonging Agents; Tyrosine Kinase Inhibitors"
DB11989,Benznidazole,22994-85-0,approved; investigational,CULUWZNBISUWAS-UHFFFAOYSA-N,"InChI=1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)",[O-][N+](=O)c1nccn1CC(=O)NCc2ccccc2,C12H12N4O3,,D02489,31593,347828309,133833,CHEMBL110,,29299,50089916,260.253,1.321875931,"Agents Against Leishmaniasis and Trypanosomiasis; Anti-Infective Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Azoles; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Immunologic Factors; Mutagens; Nitro Compounds; Nitroimidazole Derivatives; Noxae; Toxic Actions; Trypanocidal Agents"
DB11994,Diacerein,13739-02-1,approved; investigational,TYNLGDBUJLVSMA-UHFFFAOYSA-N,"InChI=1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)",CC(=O)Oc1cccc(c12)C(=O)c3c(C2=O)c(OC(=O)C)cc(c3)C(=O)O,C19H12O8,,,26248,347828314,94708,CHEMBL41286,,24456,32018,368.297,1.790810931,"Anthracenes; Anti-Inflammatory Agents; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Musculo-Skeletal System; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quinones"
DB11995,Avatrombopag,570406-98-3,approved; investigational,OFZJKCQENFPZBH-UHFFFAOYSA-N,"InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)",OC(=O)C1CCN(CC1)c2c(Cl)cc(cn2)C(=O)Nc3nc(-c4cc(Cl)cs4)c(s3)N5CCN(CC5)C6CCCCC6,C29H34Cl2N6O3S2,,,9852519,347828315,,CHEMBL2103883,,8028230,,649.65,4.173269004,"Azoles; BCRP/ABCG2 Inhibitors; Blood and Blood Forming Organs; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (weak); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Hemostatics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; OAT3/SLC22A8 Inhibitors; P-glycoprotein substrates; Receptors, Thrombopoietin, agonists; Sulfur Compounds"
DB12001,Abemaciclib,1231929-97-7,approved; investigational,UZWDCWONPYILKI-UHFFFAOYSA-N,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(F)c(n3)-c(c4)cc(F)c(c45)nc(C)n5C(C)C,C27H32F2N8,,,46220502,347828320,,CHEMBL3301610,6ZV,29340700,50110183,506.606,4.415418176,"Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; MATE 1 Inhibitors; MATE 1 Substrates; MATE 1 Substrates with a Narrow Therapeutic Index; MATE 2 Inhibitors; MATE inhibitors; MATE substrates; Narrow Therapeutic Index Drugs; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Pyridines"
DB12010,Fostamatinib,901119-35-5,approved; investigational,GKDRMWXFWHEQQT-UHFFFAOYSA-N,"InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)",COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O,C23H26FN6O9P,,,11671467,347828328,,CHEMBL2103830,2RC,9846198,50431381,580.4595,1.458436975,"BCRP/ABCG2 Inhibitors; Blood and Blood Forming Organs; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hemostatics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Phosphodiesterase 5 Inhibitors; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors; UGT1A9 Substrates; Vasodilating Agents"
DB12015,Alpelisib,1217486-61-7,approved; investigational,STUWGJZDJHPWGZ-LBPRGKRZSA-N,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",FC(F)(F)C(C)(C)c1nccc(c1)-c2c(C)nc(s2)NC(=O)N3CCC[C@H]3C(=O)N,C19H22F3N5O2S,,,56649450,347828332,93752,CHEMBL2396661,1LT,28424123,50436459,441.47,2.809562895,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Substrates; Breast Cancer Resistance Protein Inhibitors; Breast Neoplasms; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (moderate); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (moderate); Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; Phosphatidylinositol 3-Kinases, antagonists & inhibitors; Sulfur Compounds"
DB12020,Tecovirimat,869572-92-9,approved; investigational,CSKDFZIMJXRJGH-VWLPUNTISA-N,"InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+",FC(F)(F)c1ccc(cc1)C(=O)NN(C2=O)C(=O)[C@@H]([C@@H]23)[C@H]4[C@H]5[C@H](C5)[C@@H]3C=C4,C19H15F3N2O3,,,16124688,347828336,,CHEMBL1257073,,17281586,,376.335,2.074620233,"Acids, Carbocyclic; Amides; Antiviral Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; UGT1A1 Substrates; UGT1A4 substrates"
DB12026,Voxilaprevir,1535212-07-7,approved; investigational,MZBLZLWXUBZHSL-FZNJKFJKSA-N,"InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1",C1CC1(C)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@H]([C@@H]([C@H]34)CC)N(C3)C(=O)[C@H](C(C)(C)C)NC(=O)O[C@H]5[C@@H](C5)CCCCC(F)(F)c6c(O4)nc7c(n6)ccc(c7)OC,C40H52F4N6O9S,,,89921642,347828341,,CHEMBL3707372,L9P,44209500,,868.94,4.90459061,Amides; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; HCV NS3/4A Protease Inhibitors; NS3/4A Protease Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; OATP1B3 substrates; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Sulfones; Sulfur Compounds
DB12035,Sarecycline,1035654-66-0,approved; investigational,PQJQFLNBMSCUSH-SBAJWEJLSA-N,"InChI=1S/C24H29N3O8/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33/h5-6,11,13,18,28,30-31,34H,7-9H2,1-4H3,(H2,25,33)/t11-,13-,18-,24-/m0/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(CN(C)OC)ccc4O,C24H29N3O8,,,54681908,347828347,,CHEMBL2364632,,28540486,,487.509,-3.065152057,"Anti-Acne Preparations; Anti-Acne Preparations for Systemic Use; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; P-glycoprotein inhibitors; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Tetracyclines"
DB12070,Letermovir,917389-32-3,approved; investigational,FWYSMLBETOMXAG-QHCPKHFHSA-N,"InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1",COc1cccc(c1)N2CCN(CC2)C(=Nc(c34)c(F)ccc4)N([C@H]3CC(=O)O)c5cc(C(F)(F)F)ccc5OC,C29H28F4N4O4,,,,,,CHEMBL1241951,,26352849,,572.561,4.642071611,"Acids, Acyclic; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; BCRP/ABCG2 Inhibitors; BSEP/ABCB11 Inhibitors; Carboxylic Acids; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (moderate); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Cytomegalovirus DNA Terminase Complex Inhibitor; Direct Acting Antivirals; DNA Terminase Complex Inhibitors; Fatty Acids; Fatty Acids, Volatile; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lipids; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; UGT1A1 Substrates; UGT1A3 substrates"
DB12091,Gadolinium,7440-54-2,approved; investigational,UIWYJDYFSGRHKR-UHFFFAOYSA-N,InChI=1S/Gd,[Gd],Gd,,,23982,347828395,33375,,GD,22418,,157.25,0,"Anti-Inflammatory Agents; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Elements; Lanthanoid Series Elements; Metals; Metals, Rare Earth"
DB12095,Telotristat ethyl,1033805-22-9,approved; investigational,MDSQOJYHHZBZKA-GBXCKJPGSA-N,"InChI=1S/C27H26ClF3N6O3/c1-3-39-25(38)20(32)12-16-4-6-17(7-5-16)21-14-23(35-26(33)34-21)40-24(27(29,30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37/h4-11,13-14,20,24H,3,12,32H2,1-2H3,(H2,33,34,35)/t20-,24+/m0/s1",CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c2nc(N)nc(c2)O[C@@H](C(F)(F)F)c3ccc(Cl)cc3-n4ccc(n4)C,C27H26ClF3N6O3,,,25025298,347828399,,CHEMBL2105695,,28189674,,574.99,5.5370985,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Antidiarrheals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Tryptophan Hydroxylase Inhibitor"
DB12097,Mannitol busulfan,1187-00-4,approved; investigational,ODOISJJCWUVNDJ-WCTZXXKLSA-N,"InChI=1S/C8H18O10S2/c1-19(13,14)17-3-5(9)7(11)8(12)6(10)4-18-20(2,15)16/h5-12H,3-4H2,1-2H3/t5-,6-,7-,8-/m1/s1",CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(=O)(=O)C,C8H18O10S2,,,142775,347828401,,,,125962,,338.34,-3.857690404,Agents causing hyperkalemia
DB12107,Vaborbactam,1360457-46-0,approved; investigational,IOOWNWLVCOUUEX-WPRPVWTQSA-N,"InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1",OB1O[C@H](CC(=O)O)CC[C@@H]1NC(=O)Cc2cccs2,C12H16BNO5S,,,56649692,347828408,,CHEMBL3317857,4D6,35035409,50089084,297.13,1.8551,"Acids; Acids, Noncarboxylic; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactamase Inhibitors; Boron Compounds; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds"
DB12127,Sultamicillin,76497-13-7,approved; investigational,OPYGFNJSCUDTBT-PMLPCWDUSA-N,"InChI=1S/C25H30N4O9S2/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31)/t14-,15-,16-,17+,18+,21-/m1/s1",c1ccccc1[C@@H](N)C(=O)N[C@H](C2=O)[C@H](N23)SC(C)(C)[C@@H]3C(=O)OCOC(=O)[C@@H](C(C)(C)S4(=O)=O)N([C@H]45)C(=O)C5,C25H30N4O9S2,,,444022,347828426,51770,CHEMBL506110,,392048,,594.65,-0.402403776,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillin G; Penicillins; Sulfur Compounds"
DB12130,Lorlatinib,1454846-35-5,approved; investigational,IIXWYSCJSQVBQM-LLVKDONJSA-N,"InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1",Fc(c1)ccc(c12)C(=O)N(C)Cc3c(c(C#N)n(n3)C)c4cc(O[C@@H]2C)c(N)nc4,C21H19FN6O2,,,71731823,347828429,143117,CHEMBL3286830,5P8,32813339,50018830,406.421,1.629058127,"Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; Lactams; Macrocyclic Compounds; Polycyclic Compounds; Protein Kinase Inhibitors; UGT1A3 substrates"
DB12141,Gilteritinib,1254053-43-4,approved; investigational,GYQYAJJFPNQOOW-UHFFFAOYSA-N,"InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)",C1COCCC1Nc2c(CC)nc(C(=O)N)c(n2)Nc3ccc(c(c3)OC)N4CCC(CC4)N5CCN(C)CC5,C29H44N8O3,,,49803313,347828438,145372,CHEMBL3301622,C6F,32055842,144315,552.724,2.793400956,"Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Inhibitors; MATE inhibitors; Moderate Risk QTc-Prolonging Agents; OCT1 inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; QTc Prolonging Agents; Tyrosine Kinase Inhibitors"
DB12147,Erdafitinib,1346242-81-6,approved; investigational,OLAHOMJCDNXHFI-UHFFFAOYSA-N,"InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3",COc1cc(cc(c1)OC)N(CCNC(C)C)c(c2)ccc(c23)ncc(n3)-c4cn(C)nc4,C25H30N6O2,,,67462786,347828443,,CHEMBL3545376,5SF,35308353,,446.555,3.517252989,"Antineoplastic Agents; Azoles; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Receptors, Fibroblast Growth Factor, antagonists & inhibitors; Tumor Suppressor Proteins; Tyrosine Kinase Inhibitors"
DB12153,Citicoline,987-78-0,approved; experimental,RZZPDXZPRHQOCG-OJAKKHQRSA-N,"InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1",C[N+](C)(C)CCOP([O-])(=O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2ccc(N)nc2=O,C14H26N4O11P2,C00307,D00057,,347911290,16436,CHEMBL1231700,CDC,13207,,488.324,-7.108613166,"Alcohols; Amines; Amino Alcohols; Ammonium Compounds; Carbohydrates; Central Nervous System Agents; Cytidine Diphosphate; Cytosine Nucleotides; Ethanolamines; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Nitrogen Compounds; Nootropic Agents; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Onium Compounds; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics; Pyrimidine Nucleotides; Pyrimidines; Quaternary Ammonium Compounds; Ribonucleotides; Trimethyl Ammonium Compounds"
DB12161,Deutetrabenazine,1392826-25-3,approved; investigational,MKJIEFSOBYUXJB-WEZHFFAMSA-N,"InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m0/s1/i3D3,4D3",[2H]C([2H])([2H])Oc(c1)c(OC([2H])([2H])[2H])cc(c12)CCN3[C@H]2CC(=O)[C@H](C3)CC(C)C,C19H27NO3,,,73442840,347828453,,,,32700662,,323.466,3.401061659,"Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; QTc Prolonging Agents; Quinolizines; Tetrabenazine and isomer"
DB12208,Iron isomaltoside 1000,1370654-58-2,approved; investigational,,, ,,,,,347911299,,,,,,NA,NA,Carbohydrates; Hematinics; Hematologic Agents; Iron Compounds; Oligosaccharides; Organometallic Compounds; Polysaccharides
DB12243,Edaravone,89-25-8,approved; investigational,QELUYTUMUWHWMC-UHFFFAOYSA-N,"InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3",CC1=NN(C(=O)C1)c2ccccc2,C10H10N2O,C13008,D01552,4021,347828521,31530,CHEMBL290916,,3881,50200541,174.203,1.526700628,"Antioxidants; Azoles; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Free Radical Scavengers; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Miscellaneous Central Nervous System Agents; Nervous System; Neuroprotective Agents; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; Protective Agents; Pyrazoles; Pyrazolones"
DB12245,Triclabendazole,68786-66-3,approved; investigational,NQPDXQQQCQDHHW-UHFFFAOYSA-N,"InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)",CSc([nH]1)nc(c12)cc(c(Cl)c2)Oc3cccc(Cl)c3Cl,C14H9Cl3N2OS,,D07364,50248,347828523,94759,CHEMBL1086440,,45565,58491,359.65,5.884392354,"Anthelmintics; Anti-Infective Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiplatyhelmintic Agents; Antitrematodals; Benzimidazoles; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2A6 Inhibitors; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Potential QTc-Prolonging Agents; QTc Prolonging Agents"
DB12267,Brigatinib,1197953-54-0,approved; investigational,AILRADAXUVEEIR-UHFFFAOYSA-N,"InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)",CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C,C29H39ClN7O2P,,,68165256,347828538,,CHEMBL3545311,6GY,34982928,50185140,584.1,3.659,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; Narrow Therapeutic Index Drugs; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB12277,Polihexanide,28757-47-3,approved; investigational,,, ,,,,,347911310,,,,,,NA,NA,"Amidines; Anti-Infective Agents; Antiseptics and Disinfectants; Biguanides and Amidines; Compounds used in a research, industrial, or household setting; Dermatologicals; Disinfectants; Guanidines"
DB12278,Propiverine,60569-19-9,approved; investigational,QPCVHQBVMYCJOM-UHFFFAOYSA-N,"InChI=1S/C23H29NO3/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21/h4-13,21H,3,14-18H2,1-2H3",c1ccccc1C(OCCC)(c2ccccc2)C(=O)OC3CCN(C)CC3,C23H29NO3,C07852,D08441,4942,347828547,8493,CHEMBL1078261,,4773,,367.4813,4.252704124,"Acids, Carbocyclic; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents producing tachycardia; Agents that produce hypertension; Anticholinergic Agents; Autonomic Agents; Carboxylic Acids; Cholinergic Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diphenylacetic Acids; Drugs for Urinary Frequency and Incontinence; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Hydroxy Acids; Muscarinic Antagonists; Neurotransmitter Agents; Parasympatholytics; Peripheral Nervous System Agents; Phenylacetates; Urological Agents; Urologicals"
DB12293,Nefopam,13669-70-0,approved; investigational,RGPDEAGGEXEMMM-UHFFFAOYSA-N,"InChI=1S/C17H19NO/c1-18-11-12-19-17(14-7-3-2-4-8-14)16-10-6-5-9-15(16)13-18/h2-10,17H,11-13H2,1H3",c1cccc(c12)C(OCCN(C2)C)c3ccccc3,C17H19NO,,,4450,347828561,88318,CHEMBL465026,,4295,50237616,253.345,3.403134563,"Analgesics; Analgesics, Non-Narcotic; Azocines; Central Nervous System Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Oxazocines; Peripheral Nervous System Agents; Sensory System Agents"
DB12300,P-nitrobiphenyl,92-93-3,approved; experimental; investigational,BAJQRLZAPXASRD-UHFFFAOYSA-N,InChI=1S/C12H9NO2/c14-13(15)12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9H,O=N(=O)c1ccc(cc1)-c2ccccc2,C12H9NO2,C19473,,7114,347828566,82504,CHEMBL352531,,21109008,,199.209,3.560455367,NA
DB12301,Doravirine,1338225-97-0,approved; investigational,ZIAOVIPSKUPPQW-UHFFFAOYSA-N,"InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)",Cn1c(=O)[nH]nc1Cn2ccc(C(F)(F)F)c(c2=O)Oc3cc(C#N)cc(Cl)c3,C17H11ClF3N5O3,,,58460047,347828567,,CHEMBL2364608,2KW,28424197,,425.749,2.230642024,"Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Azoles; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Non-Nucleoside Reverse Transcriptase Inhibitors; Nonnucleoside Reverse Transcriptase Inhibitors; Pyridines"
DB12313,Dopexamine,86197-47-9,approved; investigational,RYBJORHCUPVNMB-UHFFFAOYSA-N,"InChI=1S/C22H32N2O2/c25-21-11-10-20(18-22(21)26)13-17-24-15-7-2-1-6-14-23-16-12-19-8-4-3-5-9-19/h3-5,8-11,18,23-26H,1-2,6-7,12-17H2",Oc1c(O)cc(cc1)CCNCCCCCCNCCc2ccccc2,C22H32N2O2,,,55483,347828578,135507,CHEMBL77622,,50102,50239997,356.5017,2.977305047,"Adrenergic Agents; Adrenergic Agonists; Adrenergic and Dopaminergic Agents; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Amines; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Catecholamines; Catechols; Dopamine Agents; Dopamine Agonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Neurotransmitter Agents; Nonergot-derivative Dopamine Receptor Agonists; Phenols; Vasodilating Agents"
DB12328,Cantharidin,56-25-7,approved; investigational,DHZBEENLJMYSHQ-XCVPVQRUSA-N,"InChI=1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3/t5-,6+,9+,10-",O=C1OC(=O)[C@@]2(C)[C@H](CC3)O[C@H]3[C@@]12C,C10H12O4,C16778,,5944,347828590,64213,CHEMBL48449,,5731,50090505,196.202,1.059183069,"Benzofurans; Compounds used in a research, industrial, or household setting; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Irritants; Noxae; Toxic Actions"
DB12329,Eravacycline,1207283-85-9,approved; investigational,HLFSMUUOKPBTSM-ISIOAQNYSA-N,"InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34,36-37,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(F)cc(c4O)NC(=O)CN5CCCC5,C27H31FN4O8,,,54726192,347828591,,CHEMBL1951095,,28495485,,558.563,-3.492646298,"Anti-Bacterial Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Monoamine Oxidase A Substrates; Naphthacenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Tetracyclines"
DB12332,Rucaparib,283173-50-2,approved; investigational,HMABYWSNWIZPAG-UHFFFAOYSA-N,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",CNCc1ccc(cc1)-c([nH]2)c3CCNC(=O)c(c3c24)cc(F)c4,C19H18FN3O,,D10079,9931954,347828593,134689,CHEMBL1173055,RPB,8107584,50446130,323.371,2.454489927,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (moderate); Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; OCT1 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Poly(ADP-ribose) Polymerase Inhibitors; UGT1A1 Inhibitors"
DB12343,Temocillin,66148-78-5,approved; investigational,BVCKFLJARNKCSS-DWPRYXJFSA-N,"InChI=1S/C16H18N2O7S2/c1-15(2)9(12(22)23)18-13(24)16(25-3,14(18)27-15)17-10(19)8(11(20)21)7-4-5-26-6-7/h4-6,8-9,14H,1-3H3,(H,17,19)(H,20,21)(H,22,23)/t8?,9-,14+,16-/m0/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@](C2=O)(OC)NC(=O)C(C(=O)O)c3cscc3,C16H18N2O7S2,,,171758,347828601,51817,CHEMBL1276310,,150149,,414.45,1.201430463,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; beta-Lactams; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Penicillins; Penicillins With Extended Spectrum; Sulfur Compounds"
DB12362,Diaminopropanol tetraacetic acid,3148-72-9,approved; investigational,WYMDDFRYORANCC-UHFFFAOYSA-N,"InChI=1S/C11H18N2O9/c14-7(1-12(3-8(15)16)4-9(17)18)2-13(5-10(19)20)6-11(21)22/h7,14H,1-6H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22)",OC(=O)CN(CC(=O)O)CC(O)CN(CC(=O)O)CC(=O)O,C11H18N2O9,,,18465,347828615,,,,17441,,322.27,-6.831160107,NA
DB12364,Betrixaban,330942-05-7,approved; investigational,XHOLNRLADUSQLD-UHFFFAOYSA-N,"InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)",Clc1cnc(cc1)NC(=O)c2cc(OC)ccc2NC(=O)c3ccc(cc3)C(=N)N(C)C,C23H22ClN5O3,,,10275777,347828616,140421,CHEMBL512351,,18981107,50249298,451.91,3.028056961,"Acids, Carbocyclic; Amides; Anticoagulants; Antithrombins; Benzene Derivatives; Benzoates; Blood and Blood Forming Organs; Carboxylic Acids; Enzyme Inhibitors; Factor Xa Inhibitors; Fibrinolytic Agents; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; P-glycoprotein substrates; Protease Inhibitors; Serine Protease Inhibitors"
DB12371,Siponimod,1230487-00-9,approved; investigational,KIHYPELVXPAIDH-HNSNBQBZSA-N,"InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+",OC(=O)C1CN(C1)Cc2ccc(cc2CC)/C(C)=N/OCc3ccc(c(c3)C(F)(F)F)C4CCCCC4,C29H35F3N2O3,,,44599207,347828622,,CHEMBL2336071,,29315058,50428142,516.605,4.307383411,"Agents that produce hypertension; Antineoplastic and Immunomodulating Agents; Azetines; Benzene Derivatives; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Heterocyclic Compounds; Immunomodulatory Agents; Immunosuppressive Agents; Narrow Therapeutic Index Drugs; Receptors, Lysosphingolipid, antagonists & inhibitors; Selective Immunosuppressants"
DB12377,Relebactam,1174018-99-5,approved; investigational,SMOBCLHAZXOKDQ-ZJUUUORDSA-N,"InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1",OS(=O)(=O)ON([C@@H]12)C(=O)N(C1)[C@@H](CC2)C(=O)NC3CCNCC3,C12H20N4O6S,,,44129647,347828625,,CHEMBL3112741,,31137585,1858,348.37,-3.113184377,"Aza Compounds; beta-Lactamase Inhibitors; Bicyclo Compounds; Bicyclo Compounds, Heterocyclic; Bridged Compounds; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Bridged-Ring; Hydrocarbons; Hydrocarbons, Cyclic; MATE 1 Substrates; MATE 2 Substrates; MATE substrates; OAT3/SLC22A8 Substrates; Polycyclic Compounds"
DB12401,Bromperidol,10457-90-6,approved; investigational,RKLNONIVDFXQRX-UHFFFAOYSA-N,"InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2",Brc1ccc(cc1)C2(O)CCN(CC2)CCCC(=O)c3ccc(F)cc3,C21H23BrFNO2,,,2448,347828647,31305,CHEMBL28218,,2354,81484,420.322,3.82582175,Antipsychotic Agents; Butyrophenone Derivatives; Butyrophenones; Central Nervous System Agents; Central Nervous System Depressants; Ketones; Nervous System; Neurotoxic agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents
DB12407,Iobitridol,136949-58-1,approved; investigational,YLPBXIKWXNRACS-UHFFFAOYSA-N,"InChI=1S/C20H28I3N3O9/c1-25(3-10(31)7-29)19(34)12-14(21)13(20(35)26(2)4-11(32)8-30)16(23)17(15(12)22)24-18(33)9(5-27)6-28/h9-11,27-32H,3-8H2,1-2H3,(H,24,33)",OCC(O)CN(C)C(=O)c1c(I)c(C(=O)N(C)CC(O)CO)c(I)c(c1I)NC(=O)C(CO)CO,C20H28I3N3O9,,D01181,65985,347828653,31701,CHEMBL2107212,,59379,,835.169,-1.365119626,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodobenzoates; Triiodobenzoic Acids; Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media; X-Ray Contrast Media, Iodinated"
DB12434,Steviolbioside,41093-60-1,approved; investigational,OMHUCGDTACNQEX-OSHKXICASA-N,"InChI=1S/C32H50O13/c1-15-11-31-9-5-18-29(2,7-4-8-30(18,3)28(40)41)19(31)6-10-32(15,14-31)45-27-25(23(38)21(36)17(13-34)43-27)44-26-24(39)22(37)20(35)16(12-33)42-26/h16-27,33-39H,1,4-14H2,2-3H3,(H,40,41)/t16-,17-,18+,19+,20-,21-,22+,23+,24-,25-,26+,27+,29-,30-,31-,32+/m1/s1",C1CC[C@@](C)(C(=O)O)[C@@H](CC2)[C@]1(C)[C@@H]([C@@]234)CC[C@](C3)(C(C4)=C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O,C32H50O13,,,16401639,347828676,145030,,,10209449,,642.739,0.106859708,"Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Diterpenes; Flavoring Agents; Food; Food Additives; Food and Beverages; Food Ingredients; Hydrocarbons; Pharmaceutic Aids; Pharmaceutical Preparations; Physiological Phenomena; Stevia; Sweetening Agents; Terpenes"
DB12455,Omadacycline,389139-89-3,approved; investigational,JEECQCWWSTZDCK-IQZGDKDPSA-N,"InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34,36-37,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1",O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)cc(c4O)CNCC(C)(C)C,C29H40N4O7,,,54697325,347828696,,CHEMBL1689772,,20131003,,556.66,-2.179127677,"Anti-Bacterial Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthacenes; P-glycoprotein substrates; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Tetracyclines"
DB12457,Rimegepant,1289023-67-1,approved; investigational,KRNAOFGYEFKHPB-ANJVHQHFSA-N,"InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1",c1ccc(F)c(F)c1[C@@H]([C@@H]2N)CC[C@H](c(c23)nccc3)OC(=O)N4CCC(CC4)n5c(=O)[nH]c(c56)nccc6,C28H28F2N6O3,,,51049968,347828697,,CHEMBL2178422,,27289072,50400098,534.568,2.946938789,"Antimigraine Preparations; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Inhibitors; MATE inhibitors; Migraine Disorders; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; OCT2 Inhibitors; P-glycoprotein substrates"
DB12466,Favipiravir,259793-96-9,approved; investigational,ZCGNOVWYSGBHAU-UHFFFAOYSA-N,"InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)",NC(=O)c1nc(F)cnc1O,C5H4FN3O2,,,492405,347828705,134722,CHEMBL221722,,431002,,157.104,0.251916396,"Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Experimental Unapproved Treatments for COVID-19; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; P-glycoprotein inhibitors"
DB12473,Taurolidine,19388-87-5,approved; investigational,AJKIRUJIDFJUKJ-UHFFFAOYSA-N,"InChI=1S/C7H16N4O4S2/c12-16(13)3-1-10(5-8-16)7-11-2-4-17(14,15)9-6-11/h8-9H,1-7H2",O=S1(=O)CCN(CN1)CN(CC2)CNS2(=O)=O,C7H16N4O4S2,,,29566,347828711,135173,CHEMBL2105420,,27486,,284.35,-2.465751424,"Acids; Acids, Noncarboxylic; Alkanes; Alkanesulfonic Acids; Anti-Infective Agents; Anti-Infective Agents, Local; Antineoplastic Agents; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Acyclic; Irrigating Solutions; Sulfonic Acids; Sulfur Acids; Sulfur Compounds; Thiazines"
DB12474,Lynestrenol,52-76-6,approved; investigational,YNVGQYHLRCDXFQ-XGXHKTLJSA-N,"InChI=1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1",C#C[C@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@@H]4C(CC3)=CCCC4,C20H28O,C13037,,5857,347828712,31790,CHEMBL2107431,,5648,,284.443,4.036700516,"Adrenal Cortex Hormones; Combination Contraceptives (with Estrogen and derivatives); Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Estren Derivatives; Fused-Ring Compounds; Genito Urinary System and Sex Hormones; Hormonal Contraceptives for Systemic Use; Norpregnanes; Norpregnenes; Norsteroids; Polycyclic Compounds; Progestin Contraceptives; Progestins; Progestogens and Estrogens, Sequential Preparations; Reproductive Control Agents; Sex Hormones and Modulators of the Genital System; Steroids"
DB12483,Copanlisib,1032568-63-0,approved; investigational,PZBCKZWLPGJMAO-UHFFFAOYSA-N,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",Nc1ncc(cn1)C(=O)NC2=Nc(c3C(N24)=NCC4)c(OC)c(cc3)OCCCN5CCOCC5,C23H28N8O4,,,24989044,347828721,,CHEMBL3218576,6.00E+02,25069683,50204093,480.529,0.319244066,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; MATE 2 Inhibitors; MATE inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index"
DB12492,Piritramide,302-41-0,approved; investigational,IHEHEFLXQFOQJO-UHFFFAOYSA-N,"InChI=1S/C27H34N4O/c28-22-26(23-10-4-1-5-11-23,24-12-6-2-7-13-24)14-19-30-20-15-27(16-21-30,25(29)32)31-17-8-3-9-18-31/h1-2,4-7,10-13H,3,8-9,14-21H2,(H2,29,32)",C1CCCCN1C2(C(=O)N)CCN(CC2)CCC(C#N)(c3ccccc3)c4ccccc4,C27H34N4O,,,9331,347828727,135699,CHEMBL559288,,8967,,430.5851,3.39474421,"Acids, Heterocyclic; Analgesics; Central Nervous System Agents; Central Nervous System Depressants; Diphenylpropylamine Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isonipecotic Acids; Narcotics; Nervous System; Opioids; Peripheral Nervous System Agents; Piperidines; Sensory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB12500,Fedratinib,936091-26-8,approved; investigational,JOOXLOJCABQBSG-UHFFFAOYSA-N,"InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)",CC(C)(C)NS(=O)(=O)c1cc(ccc1)Nc2nc(ncc2C)Nc3ccc(cc3)OCCN4CCCC4,C27H36N6O3S,,,16722836,347828733,91408,CHEMBL1287853,2TA,17626393,50332294,524.678,4.635707146,"Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Sulfones; Sulfur Compounds; Tyrosine Kinase Inhibitors"
DB12523,Mizolastine,108612-45-9,approved; investigational,PVLJETXTTWAYEW-UHFFFAOYSA-N,"InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)",O=c1[nH]c(ncc1)N(C)C2CCN(CC2)c(nc(c34)cccc4)n3Cc5ccc(F)cc5,C24H25FN6O,,,65906,347828752,31857,CHEMBL94454,,59315,22877,432.503,3.733408288,"Antihistamines for Systemic Use; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; QTc Prolonging Agents; Respiratory System"
DB12529,Nitrite,14797-65-0,approved; investigational,IOVCWXUNBOPUCH-UHFFFAOYSA-M,"InChI=1S/HNO2/c2-1-3/h(H,2,3)/p-1",[O-]N=O,NO2,,,946,347828757,16301,,NO2,921,26989,46.0055,0.166137638,NA
DB12532,Oxetacaine,126-27-2,approved; investigational,FTLDJPRFCGDUFH-UHFFFAOYSA-N,"InChI=1S/C28H41N3O3/c1-27(2,19-23-13-9-7-10-14-23)29(5)25(33)21-31(17-18-32)22-26(34)30(6)28(3,4)20-24-15-11-8-12-16-24/h7-16,32H,17-22H2,1-6H3",c1ccccc1CC(C)(C)N(C)C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc2ccccc2,C28H41N3O3,C12552,,4621,347828759,31947,CHEMBL127592,,4460,50017672,467.654,3.157425136,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Anesthetics; Anesthetics, Local; Cardiovascular System; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Vasoprotectives"
DB12537,Benzodiazepine,12794-10-4,approved; investigational,SVUOLADPCWQTTE-UHFFFAOYSA-N,"InChI=1S/C9H8N2/c1-2-6-9-8(4-1)5-3-7-10-11-9/h1-7,11H",N1N=CC=Cc(c12)cccc2,C9H8N2,,,134664,347828763,,CHEMBL4297264,,118687,,144.177,2.119088783,"Benzazepines; Benzodiazepines and benzodiazepine derivatives; Benzodiazepines, antagonists & inhibitors; Central Nervous System Depressants; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring"
DB12554,Mebeverine,07-06-3625,approved; investigational,VYVKHNNGDFVQGA-UHFFFAOYSA-N,"InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3",COc1ccc(cc1)CC(C)N(CC)CCCCOC(=O)c2cc(OC)c(OC)cc2,C25H35NO5,,,4031,347828778,91514,CHEMBL282121,,3891,,429.557,4.886193217,"Agents Causing Muscle Toxicity; Agents producing tachycardia; Alimentary Tract and Metabolism; Amines; Anticholinergic Agents; Autonomic Agents; Central Nervous System Agents; Drugs for Functional Gastrointestinal Disorders; Ethylamines; Muscarinic Antagonists; Parasympatholytics; Peripheral Nervous System Agents; Synthetic Anticholinergics, Esters With Tertiary Amino Group"
DB12602,Pentetreotide,138661-02-6,approved; investigational,CNLWNYCFDMAZCB-HUVROIHYSA-N,"InChI=1S/C63H87N13O19S2/c1-37(78)48(34-77)70-62(94)50-36-97-96-35-49(71-58(90)45(25-39-13-5-3-6-14-39)66-51(80)29-75(31-53(83)84)23-21-74(30-52(81)82)22-24-76(32-54(85)86)33-55(87)88)61(93)68-46(26-40-15-7-4-8-16-40)59(91)69-47(27-41-28-65-43-18-10-9-17-42(41)43)60(92)67-44(19-11-12-20-64)57(89)73-56(38(2)79)63(95)72-50/h3-10,13-18,28,37-38,44-50,56,65,77-79H,11-12,19-27,29-36,64H2,1-2H3,(H,66,80)(H,67,92)(H,68,93)(H,69,91)(H,70,94)(H,71,90)(H,72,95)(H,73,89)(H,81,82)(H,83,84)(H,85,86)(H,87,88)/t37-,38-,44+,45-,46+,47-,48-,49+,50+,56+/m1/s1",NCCCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)CO)CSSC[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](C(=O)N1)Cc3c[nH]c(c34)cccc4)NC(=O)[C@@H](Cc5ccccc5)NC(=O)CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC(=O)O,C63H87N13O19S2,,,72128,347828819,,,,65105,,1394.58,-8.972936327,"Acetates; Acids, Acyclic; Amines; Amino Acids, Peptides, and Proteins; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Diagnostic Uses of Chemicals; Fatty Acids; Fatty Acids, Volatile; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Indicators and Reagents; Indium Radioisotopes; Laboratory Chemicals; Lipids; Macrocyclic Compounds; Nerve Tissue Proteins; Neuropeptides; Pancreatic Hormones; Peptide Hormones; Peptides; Peptides, Cyclic; Pituitary Hormone Release Inhibiting Hormones; Polyamines; Polycyclic Compounds; Proteins; Radiopharmaceuticals; Terbium"
DB12612,Ozanimod,1306760-87-1,approved; investigational,XRVDGNKRPOAQTN-FQEVSTJZSA-N,"InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1",CC(C)Oc1c(C#N)cc(cc1)-c2nc(no2)-c(ccc3)c(c34)CC[C@@H]4NCCO,C23H24N4O3,,,52938427,347828826,,CHEMBL3707247,,34979946,,404.47,3.963043418,"Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Indenes; Oxazoles; P-glycoprotein substrates; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Selective Immunosuppressants"
DB12615,Plazomicin,1154757-24-0,approved; investigational,IYDYFVUFSPQPPV-PEXOCOHZSA-N,"InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1",CN[C@@H]([C@@]1(C)O)[C@@H](O)[C@H](OC1)O[C@H]2[C@H](NC(=O)[C@@H](O)CCN)C[C@H](N)[C@H]([C@@H]2O)O[C@H]3OC(=CC[C@H]3N)CNCCO,C25H48N6O10,,,42613186,347828829,,CHEMBL1650559,EDS,26390008,,592.691,-6.099558394,Agents that produce neuromuscular block (indirect); Aminoglycoside Antibacterials; Anti-Bacterial Agents; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Gentamicins; Glycosides; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; Narrow Therapeutic Index Drugs; Nephrotoxic agents
DB12667,Protionamide,14222-60-7,approved; investigational,VRDIULHPQTYCLN-UHFFFAOYSA-N,"InChI=1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12)",CCCc1cc(ccn1)C(=S)N,C9H12N2S,,D01195,666418,347828871,32066,CHEMBL1378024,,579891,,180.27,1.772557949,"Acids, Heterocyclic; Anti-Bacterial Agents; Anti-Infective Agents; Antiinfectives for Systemic Use; Antimycobacterials; Antituberculosis Agents; Drugs for Treatment of Tuberculosis; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isonicotinic Acids; Pyridines; Thiocarbamide Derivatives"
DB12674,Lurbinectedin,497871-47-3,approved; investigational,YDDMIZRDDREKEP-HWTBNCOESA-N,"InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1",O=C(C)Oc1c(C)c(OCO2)c2c3c1[C@@H](SC4)[C@@H]([C@H]5c6c(C[C@H](N5C)[C@@H]7O)cc(C)c(OC)c6O)N7[C@H]3COC(=O)[C@]48c9c(CCN8)c1c([nH]9)ccc(c1)OC,C41H44N4O10S,,,57327016,347828878,,CHEMBL4297516,,32701856,,784.88,4.516239304,"Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; OCT1 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Pyridines"
DB12710,Perazine,84-97-9,approved; investigational,WEYVCQFUGFRXOM-UHFFFAOYSA-N,"InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3",CN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)cccc4,C20H25N3S,C16903,,4744,347828908,59118,CHEMBL1697766,,4582,260166,339.5,3.778075145,"Antipsychotic Agents; Central Nervous System Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Antagonists; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Phenothiazines; Phenothiazines With Piperazine Structure; Psycholeptics; Psychotropic Drugs; Sulfur Compounds; Tranquilizing Agents"
DB12728,Fenpropidin,67306-00-7,approved; experimental,MGNFYQILYYYUBS-UHFFFAOYSA-N,"InChI=1S/C19H31N/c1-16(15-20-12-6-5-7-13-20)14-17-8-10-18(11-9-17)19(2,3)4/h8-11,16H,5-7,12-15H2,1-4H3",CC(C)(C)c1ccc(cc1)CC(C)CN2CCCCC2,C19H31N,C18726,,91694,347828922,83291,CHEMBL1889041,,82797,,273.464,5.408267682,"Agrochemicals; Compounds used in a research, industrial, or household setting; Fungicides, Industrial; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Pesticides; Toxic Actions"
DB12754,Iodide,20461-54-5,approved; experimental,XMBWDFGMSWQBCA-UHFFFAOYSA-M,InChI=1S/HI/h1H/p-1,[I-],I,C00708,,30165,347828942,16382,CHEMBL185537,IOD,28015,26981,126.9045,1.02055578,NA
DB12767,Gaxilose,14087-31-1,approved; investigational,BYZQBCIYLALLPA-NOPGXMAYSA-N,"InChI=1S/C11H20O10/c12-1-4(15)7(16)5(2-13)20-11-10(19)9(18)8(17)6(3-14)21-11/h1,4-11,13-19H,2-3H2/t4-,5+,6+,7+,8-,9-,10+,11+/m0/s1",O=C[C@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,C11H20O10,,,3082054,347828953,,,,2339540,,312.271,-4.708861267,Carbohydrates; Oligosaccharides; Polysaccharides
DB12783,Benserazide,322-35-0,approved; investigational,BNQDCRGUHNALGH-UHFFFAOYSA-N,"InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)",OCC(N)C(=O)NNCc1c(O)c(O)c(O)cc1,C10H15N3O5,,D03082,2327,347828964,64187,CHEMBL1096979,,2237,49122,257.246,-1.902004133,Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Aromatic L-amino Acid Decarboxylase Inhibitors; Central Nervous System Agents; Dopamine Agents; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydrazines; Neurotransmitter Agents
DB12789,Dinoprost,551-11-1,approved; investigational,PXGPLTODNUVGFL-YNNPMVKQSA-N,"InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1",OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCCCC,C20H34O5,C00639,,5280363,347828968,15553,CHEMBL815,,4444062,50035622,354.487,2.611054417,"Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Autacoids; Biological Factors; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Genito Urinary System and Sex Hormones; Inflammation Mediators; Lipids; Prostaglandins; Prostaglandins F; Reproductive Control Agents; Uterotonic agents"
DB12792,Boscalid,188425-85-6,approved; experimental,WYEMLYFITZORAB-UHFFFAOYSA-N,"InChI=1S/C18H12Cl2N2O/c19-13-9-7-12(8-10-13)14-4-1-2-6-16(14)22-18(23)15-5-3-11-21-17(15)20/h1-11H,(H,22,23)",Clc1ccc(cc1)-c2c(cccc2)NC(=O)c3c(Cl)nccc3,C18H12Cl2N2O,C18547,,213013,347828970,81822,CHEMBL1076544,,184713,,343.207,4.922950086,"Acids, Heterocyclic; Benzene Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Nicotinic Acids; Pyridines"
DB12808,Trifarotene,895542-09-3,approved; investigational,MFBCDACCJCDGBA-UHFFFAOYSA-N,"InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)",C1CCCN1c2ccc(cc2C(C)(C)C)-c3cc(-c4ccc(cc4)C(=O)O)ccc3OCCO,C29H33NO4,,,11518241,347828982,,CHEMBL3707313,,9693029,,459.586,5.151702798,Alkenes; Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Misc. Skin and Mucous Membrane Agents; Polycyclic Compounds; Polyenes; Retinoids for Topical Use in Acne
DB12821,Perflubutane,355-25-9,approved; investigational,KAVGMUDTWQVPDF-UHFFFAOYSA-N,"InChI=1S/C4F10/c5-1(6,3(9,10)11)2(7,8)4(12,13)14",FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F,C4F10,,,9638,347828991,134964,CHEMBL2104979,,13862701,,238.028,3.483002846,"Anions; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Electrolytes; Elements; Hydrocarbons; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Ions; Iron Compounds; Metals; Metals, Heavy; Organometallic Compounds; Oxygen Compounds; Transition Elements"
DB12825,Lefamulin,1061337-51-6,approved; investigational,KPVIXBKIJXZQJX-CSOZIWFHSA-N,"InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16?,17-,18+,20+,21+,22+,24-,25-,26+,27-,28-/m0/s1",C1CC(=O)[C@H]([C@]123)[C@@](C)(C(C)CC2)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O,C28H45NO5S,,,25185057,347828993,,CHEMBL3291398,62B,,50019649,507.73,2.901315492,Acetates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Hydrocarbons; P-glycoprotein substrates; Pleuromutilins; QTc Prolonging Agents; Sulfur Compounds
DB12834,Secnidazole,3366-95-8,approved,KPQZUUQMTUIKBP-UHFFFAOYSA-N,"InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3",CC(O)Cn1c(C)ncc1N(=O)=O,C7H11N3O3,,,71815,347829000,94433,CHEMBL498847,,64839,50349330,185.183,-0.0427352,"Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Imidazoles; Nitro Compounds; Nitroimidazole Antimicrobial; Nitroimidazole Derivatives; Nitroimidazoles"
DB12839,Pegvaliase,1585984-95-7,approved; investigational,NPOCDVAOUKODSQ-ZDUSSCGKSA-N,"InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1",COCCOCCCCCC(=O)NCCCC[C@H](N)C(=O)O,C15H30N2O5,,,86278362,347829004,,,,58172730,,318.414,-1.960435867,"Amino Acids, Peptides, and Proteins; Ammonia-Lyases; Carbon-Nitrogen Lyases; Enzymes; Enzymes and Coenzymes; Lyases; Pegylated agents; Proteins"
DB12865,Etelcalcetide,1262780-97-1,approved; investigational,ANIAZGVDEUQPRI-ZJQCGQFWSA-N,"InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1",NC(=N)NCCC[C@H](C(=O)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@H](NC(=O)C)CSSC[C@H](N)C(=O)O,C38H73N21O10S2,,D10676,71511839,347829023,134700,CHEMBL3545184,,32697932,,1048.26,-11.43623323,"Amino Acids, Peptides, and Proteins; Anti-Parathyroid Agents; Calcium Homeostasis; Calcium-sensing Receptor Agonist; Increased Calcium-sensing Receptor Sensitivity; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
DB12867,Benperidol,2062-84-2,approved; investigational,FEBOTPHFXYHVPL-UHFFFAOYSA-N,"InChI=1S/C22H24FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)",c1cccc(c12)nc(O)n2C3CCN(CC3)CCCC(=O)c4ccc(F)cc4,C22H24FN3O2,,,16363,347829025,93403,CHEMBL297302,,15521,81492,381.451,3.79126911,Antipsychotic Agents; Butyrophenone Derivatives; Butyrophenones; Central Nervous System Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Antagonists; Ketones; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; Tranquilizing Agents
DB12877,Oxatomide,60607-34-3,approved; investigational,BAINIUMDFURPJM-UHFFFAOYSA-N,"InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)",c1cccc(c12)[nH]c(=O)n2CCCN3CCN(CC3)C(c4ccccc4)c5ccccc5,C27H30N4O,,D01773,4615,347829033,31943,CHEMBL13828,,4454,76863,426.564,4.624845892,"Anti-Allergic Agents; Anti-Asthmatic Agents; Antihistamines for Systemic Use; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Piperazine Derivatives; QTc Prolonging Agents; Respiratory System; Respiratory System Agents"
DB12887,Tazemetostat,1403254-99-8,approved; investigational,NSQSAUGJQHDYNO-UHFFFAOYSA-N,"InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)",O=c1[nH]c(C)cc(C)c1CNC(=O)c2c(C)c(N(CC)C3CCOCC3)cc(c2)-c4ccc(cc4)CN5CCOCC5,C34H44N4O4,,,66558664,347829042,,CHEMBL3414621,,30208713,172038,572.75,3.452795437,"Amides; BCRP/ABCG2 Substrates; Benzene Derivatives; Benzoates; Carboxylic Acids; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; P-glycoprotein substrates; Pyridines"
DB12911,Nicoboxil,13912-80-6,approved; investigational,IZJRISIINLJVBU-UHFFFAOYSA-N,"InChI=1S/C12H17NO3/c1-2-3-7-15-8-9-16-12(14)11-5-4-6-13-10-11/h4-6,10H,2-3,7-9H2,1H3",CCCCOCCOC(=O)c1cnccc1,C12H17NO3,C13138,D01677,14866,347829061,32322,CHEMBL2105161,,14176,,223.272,2.035973859,"Acids, Heterocyclic; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Pyridines"
DB12924,Ozenoxacin,245765-41-7,approved; investigational,XPIJWUTXQAGSLK-UHFFFAOYSA-N,"InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)",CNc1ncc(cc1C)-c(c2C)ccc(c23)c(=O)c(C(=O)O)cn3C4CC4,C21H21N3O3,,,9863827,347829069,136050,CHEMBL3990047,,8039521,,363.417,2.536957386,"Amines; Anti-Bacterial Agents; Antibiotics for Topical Use; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyridines; Quinolines; Quinolone Antimicrobial"
DB12938,Isoxaflutole,141112-29-0,approved; experimental; investigational,OYIKARCXOQLFHF-UHFFFAOYSA-N,"InChI=1S/C15H12F3NO4S/c1-24(21,22)12-6-9(15(16,17)18)4-5-10(12)13(20)11-7-19-23-14(11)8-2-3-8/h4-8H,2-3H2,1H3",C1CC1c2oncc2C(=O)c3c(S(=O)(=O)C)cc(C(F)(F)F)cc3,C15H12F3NO4S,,,84098,347829082,141213,CHEMBL1887147,,75869,,359.32,2.138631919,"Amino Acids, Peptides, and Proteins; Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Proteins; Neoplasm Proteins; Proteins; Tumor Suppressor Proteins"
DB12941,Darolutamide,1297538-32-9,approved; investigational,BLIJXOOIHRSQRB-PXYINDEMSA-N,"InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1",CC(O)c1cc(n[nH]1)C(=O)N[C@@H](C)Cn2ccc(n2)-c3ccc(C#N)c(Cl)c3,C19H19ClN6O2,,,67171867,347829085,,CHEMBL4297185,,38772320,309979,398.85,2.446195382,"Antiandrogens; Antiandrogens, non-steroidal; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Endocrine Therapy; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hormone Antagonists and Related Agents; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein substrates; UGT1A1 Substrates; UGT1A9 Substrates"
DB12942,Lactitol,585-86-4,approved; investigational,VQHSOMBJVWLPSR-JVCRWLNRSA-N,"InChI=1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5+,6+,7+,8-,9-,10+,11+,12-/m0/s1",OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,C12H24O11,,D08266,157355,347829086,75323,CHEMBL1661,,138481,50240023,344.3124,-5.500854494,"Alcohols; Alimentary Tract and Metabolism; Carbohydrates; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Drugs for Constipation; Flavoring Agents; Food; Food Additives; Food and Beverages; Food Ingredients; Gastrointestinal Agents; Laxatives; Osmotic Laxatives; Pharmaceutic Aids; Pharmaceutical Preparations; Sweetening Agents"
DB12945,Dihydralazine,484-23-1,approved; experimental,VQKLRVZQQYVIJW-UHFFFAOYSA-N,"InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)",c1cccc(c12)c(NN)nnc2NN,C8H10N6,,,10230,347829088,134841,CHEMBL35505,,9813,50088433,190.21,0.737480473,"Antihypertensive Agents; Arteriolar Smooth Muscle, Agents Acting On; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrazinophthalazine Derivatives; Hydrazinophthalazine Derivatives and Diuretics; Phthalazines; Pyridazines"
DB12952,Methylprednisone,91523-05-6,approved; investigational,SVYCRJXQZUCUND-PQXSVQADSA-N,"InChI=1S/C22H28O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,19,23,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,19+,20-,21-,22-/m0/s1",C1=CC(=O)C=C([C@]12C)[C@@H](C)C[C@@H]3[C@@H]2C(=O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)CO,C22H28O5,,,124653,347829094,,,,110996,,372.461,1.945523274,Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates
DB12954,Terizidone,25683-71-0,approved; investigational,ODKYYBOHSVLGNU-IAGONARPSA-N,"InChI=1S/C14H14N4O4/c19-13-11(7-21-17-13)15-5-9-1-2-10(4-3-9)6-16-12-8-22-18-14(12)20/h1-6,11-12H,7-8H2,(H,17,19)(H,18,20)/b15-5+,16-6+",O=C1NOCC1/N=C/c2ccc(cc2)/C=N/C3CONC3=O,C14H14N4O4,,,65720,347829095,135278,CHEMBL2107553,,59144,,302.29,-0.341826407,"Antiinfectives for Systemic Use; Antimycobacterials; Azoles; Drugs for Treatment of Tuberculosis; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Oxazoles"
DB12965,Silver,7440-22-4,approved; investigational,BQCADISMDOOEFD-UHFFFAOYSA-N,InChI=1S/Ag,[Ag],Ag,C06710,,23954,347829105,9141,,,22394,,107.8682,-0.73,"Antiseptics and Disinfectants; Dermatologicals; Elements; Metals; Metals, Heavy; Silver Compounds; Transition Elements"
DB12978,Pexidartinib,1029044-16-3,approved; investigational,JGWRKYUXBBNENE-UHFFFAOYSA-N,"InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)",FC(F)(F)c1ccc(cn1)CNc2ncc(cc2)Cc3c[nH]c(c34)ncc(Cl)c4,C20H15ClF3N5,,,25151352,347829117,145373,CHEMBL3813873,P31,35308322,50177716,417.82,4.537698868,"Amines; Antineoplastic Agents; Azoles; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Pyridines; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors; UGT1A4 substrates"
DB12982,Silicon,7440-21-3,approved; investigational,XUIMIQQOPSSXEZ-UHFFFAOYSA-N,InChI=1S/Si,[Si],Si,,,5461123,347829121,27573,,,4574465,,28.085,0.045,"Diet, Food, and Nutrition; Elements; Food; Food and Beverages; Growth Substances; Metalloids; Micronutrients; Minerals; Physiological Phenomena; Trace Elements"
DB13063,Parthenolide,20554-84-1,approved; investigational,KTEXNACQROZXEV-SLXBATTESA-N,"InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13-,15+/m0/s1",C1C/C=C(\C)CC[C@@H](C(C(O2)=O)=C)[C@H]2[C@H](O3)[C@@]13C,C15H20O3,C07609,,6473881,347829191,,CHEMBL540445,,20126246,50433441,248.3175,3.071292598,"Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Asteraceae; Cell-mediated Immunity; Central Nervous System Agents; Hydrocarbons; Increased Histamine Release; Magnoliaceae; NF-kappa B, antagonists & inhibitors; Peripheral Nervous System Agents; Sensory System Agents; Standardized Chemical Allergen; Terpenes"
DB13074,Macimorelin,381231-18-1,approved; investigational,UJVDJAPJQWZRFR-DHIUTWEWSA-N,"InChI=1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1",c1cccc(c12)[nH]cc2C[C@@H](NC(=O)C(C)(C)N)C(=O)N[C@@H](NC=O)Cc3c[nH]c(c34)cccc4,C26H30N6O3,,D10563,,,,CHEMBL278623,,7980698,50125886,474.565,1.671594393,"Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diagnostic Agents; Growth Hormone Secretagogue Receptor Agonist; Growth Hormone Secretagogue Receptor Agonists; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Highest Risk QTc-Prolonging Agents; QTc Prolonging Agents; Tests for Pituitary Function"
DB13076,Yttrium Y-90,10098-91-6,approved; investigational,VWQVUPCCIRVNHF-OUBTZVSYSA-N,InChI=1S/Y/i1+1,[90Y],Y,,,104760,347829203,,,,94570,,89.9072,0,"Acids, Acyclic; Anti-Inflammatory Agents; Carboxylic Acids; Elements; Isotopes; Metals; Metals, Rare Earth; Radioisotopes; Therapeutic Radiopharmaceuticals; Transition Elements; Tricarboxylic Acids; Yttrium; Yttrium (90Y) Compounds; Yttrium Isotopes; Yttrium Radioisotopes"
DB13085,Riamet,141204-94-6,approved; investigational,,, ,,,,,347911423,,,,,,NA,NA,NA
DB13100,Biguanide,56-03-1,approved; investigational,XNCOSPRUTUOJCJ-UHFFFAOYSA-N,"InChI=1S/C2H7N5/c3-1(4)7-2(5)6/h(H7,3,4,5,6,7)",NC(=N)NC(N)=N,C2H7N5,C07672,,5939,347829224,3095,,,5726,,101.113,-1.45801473,NA
DB13114,Amitriptylinoxide,4317-14-0,approved; investigational,ZPMKQFOGINQDAM-UHFFFAOYSA-N,"InChI=1S/C20H23NO/c1-21(2,22)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3",CN(=O)(C)CCC=C1c(cccc2)c2CCc(c13)cccc3,C20H23NO,,,20313,347829237,135224,CHEMBL627,,19137,112778,293.41,3.685159732,"Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzocycloheptenes; Central Nervous System Depressants; Dibenzocycloheptenes; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Narrow Therapeutic Index Drugs; Neurotoxic agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB13116,Norflurane,811-97-2,approved; experimental,LVGUZGTVOIAKKC-UHFFFAOYSA-N,"InChI=1S/C2H2F4/c3-1-2(4,5)6/h1H2",FCC(F)(F)F,C2H2F4,,D05208,13129,347829239,,CHEMBL2104432,,12577,,102.032,1.327610942,"Aerosol Propellants; Aerosols; Anesthetics; Central Nervous System Agents; Central Nervous System Depressants; Colloids; Complex Mixtures; Hydrocarbons; Hydrocarbons, Halogenated; Investigative Techniques; Pharmaceutical Preparations; Technology; Technology, Pharmaceutical"
DB13117,Pentafluoropropane,460-73-1,approved; investigational,MSSNHSVIGIHOJA-UHFFFAOYSA-N,"InChI=1S/C3H3F5/c4-2(5)1-3(6,7)8/h2H,1H2",FC(F)CC(F)(F)F,C3H3F5,,,68030,347829240,,,,61345,,134.049,1.488403719,"Hydrocarbons; Hydrocarbons, Halogenated"
DB13125,Lusutrombopag,1110766-97-6,approved; investigational,NOZIJMHMKORZBA-KJCUYJGMSA-N,"InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1",CCCCCCO[C@@H](C)c1c(OC)c(ccc1)-c2csc(n2)NC(=O)c3cc(Cl)c(c(Cl)c3)/C=C(\C)C(=O)O,C29H32Cl2N2O5S,,,49843517,347829248,136051,CHEMBL2107831,,28529616,,591.54,8.555446221,"Acids, Carbocyclic; Azoles; BCRP/ABCG2 Substrates; Blood and Blood Forming Organs; Carboxylic Acids; Hemostatics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; P-glycoprotein substrates; Sulfur Compounds"
DB13136,Fluindione,957-56-2,approved; investigational,NASXCEITKQITLD-UHFFFAOYSA-N,"InChI=1S/C15H9FO2/c16-10-7-5-9(6-8-10)13-14(17)11-3-1-2-4-12(11)15(13)18/h1-8,13H",Fc1ccc(cc1)C(C2=O)C(=O)c(c23)cccc3,C15H9FO2,,,68942,347829254,134975,CHEMBL24924,,62167,50280156,240.233,3.023607201,"Anticoagulants; Blood and Blood Forming Organs; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Hematologic Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indans; Indenes; Narrow Therapeutic Index Drugs; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Vitamin K Antagonists"
DB13139,Levosalbutamol,34391-04-3,approved; investigational,NDAUXUAQIAJITI-LBPRGKRZSA-N,"InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m0/s1",CC(C)(C)NC[C@H](O)c1cc(CO)c(O)cc1,C13H21NO3,C11770,D08124,123600,347829257,8746,CHEMBL1002,68H,110192,50361247,239.3107,0.344416151,Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Ethanolamines; Ethylamines; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Phenethylamines
DB13142,Calcium glubionate anhydrous,97635-31-9,approved,YPCRNBPOUVJVMU-LCGAVOCYSA-L,"InChI=1S/C12H22O12.C6H12O7.Ca/c13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12;7-1-2(8)3(9)4(10)5(11)6(12)13;/h3-10,12-20H,1-2H2,(H,21,22);2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t3-,4-,5+,6+,7-,8-,9-,10-,12+;2-,3-,4+,5-;/m11./s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,C18H32CaO19,,,131704325,347829259,,CHEMBL2219740,,58310,,592.513,-9.5725,Alimentary Tract and Metabolism; Calcium Salts; Carbohydrates; Infant Food; Mineral Supplements; Oligosaccharides; Polysaccharides
DB13145,Nedaplatin,95734-82-0,approved; investigational,GYAVMUDJCHAASE-UHFFFAOYSA-M,"InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1",[NH3+][Pt]1([NH3+])OCC(=O)O1,C2H8N2O3Pt,C12862,D01416,9548889,347829261,31898,,,7972206,,303.181,NA,Antineoplastic Agents; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Organometallic Compounds; Platinum Compounds
DB13146,Fluciclovine (18F),222727-39-1,approved,NTEDWGYJNHZKQW-DGMDOPGDSA-N,"InChI=1S/C5H8FNO2/c6-3-1-5(7,2-3)4(8)9/h3H,1-2,7H2,(H,8,9)/t3-,5-/i6-1",OC(=O)[C@]1(N)C[C@H]([18F])C1,C5H8FNO2,,,450601,347829262,134703,CHEMBL254468,,23313216,,132.125,-2.912872962,"Cycloparaffins; Diagnostic Radiopharmaceuticals; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Positron Emitting Activity; Radioactive Diagnostic Agent; Tumour Detection"
DB13153,Levomenol,23089-26-1,approved; experimental,RGZSQWQPBWRIAQ-CABCVRRESA-N,"InChI=1S/C15H26O/c1-12(2)6-5-11-15(4,16)14-9-7-13(3)8-10-14/h6-7,14,16H,5,8-11H2,1-4H3/t14-,15+/m1/s1",CC1=CC[C@H](CC1)[C@@](C)(O)CCC=C(C)C,C15H26O,C09621,,442343,347829263,125,CHEMBL1096927,,390796,50382730,222.372,3.911965513,Biological Products; Complex Mixtures; Hydrocarbons; Lipids; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Oils; Pharmaceutical Preparations; Plant Preparations; Terpenes
DB13154,Parachlorophenol,106-48-9,approved,WXNZTHHGJRFXKQ-UHFFFAOYSA-N,"InChI=1S/C6H5ClO/c7-5-1-3-6(8)4-2-5/h1-4,8H",Oc1ccc(Cl)cc1,C6H5ClO,C02124,D00149,4684,347829264,28078,CHEMBL57053,4CH,13875219,,128.556,2.273725171,"Anti-Infective Agents; Anti-Infective Agents, Local; Benzene Derivatives; Chlorobenzenes; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Chlorinated; Hydrocarbons, Cyclic; Hydrocarbons, Halogenated; OATP1B3 substrates; Phenols"
DB13155,Esculin,531-75-9,approved,XHCADAYNFIFUHF-TVKJYDDYSA-N,"InChI=1S/C15H16O9/c16-5-10-12(19)13(20)14(21)15(24-10)23-9-3-6-1-2-11(18)22-8(6)4-7(9)17/h1-4,10,12-17,19-21H,5H2/t10-,12-,13+,14-,15-/m1/s1",OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)Oc(c2)c(O)cc(c23)oc(=O)cc3,C15H16O9,C09264,,5281417,347829265,4853,CHEMBL482581,,4444765,,340.284,-1.091839121,"Benzopyrans; Carbohydrates; Coumarins; Glucosides; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans"
DB13156,Inosine pranobex,36703-88-5,approved,YLDCUKJMEKGGFI-KSIULYHRSA-N,"InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;3*5-/m1...111/s1",OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(=O)[nH]cn3,C52H78N10O17,,D01995,131704326,347829266,,,,58829622,,1115.249,-2.478538037,"Acetanilides; Adjuvants, Immunologic; Amides; Amines; Anilides; Aniline Compounds; Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Carbohydrates; Drugs that are Mainly Renally Excreted; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunologic Factors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Purine Nucleosides; Purines; Ribonucleosides"
DB13157,Sodium lauryl sulfoacetate,1847-58-1,approved; experimental,UAJTZZNRJCKXJN-UHFFFAOYSA-M,"InChI=1S/C14H28O5S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-19-14(15)13-20(16,17)18;/h2-13H2,1H3,(H,16,17,18);/q;+1/p-1",CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O,C14H27NaO5S,,,23668827,347829267,,,,15024,,330.41,4.000519783,Alimentary Tract and Metabolism; Drugs for Constipation; Enemas
DB13158,Clobetasone,54063-32-0,approved,XXIFVOHLGBURIG-OZCCCYNHSA-N,"InChI=1S/C22H26ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-16,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19-,20-,21-,22-/m0/s1",ClCC(=O)[C@@](O)([C@@H](C)C1)[C@@](C)(CC2=O)[C@@H]1[C@@H]([C@]23F)CCC=4[C@]3(C)C=CC(=O)C4,C22H26ClFO4,,D07717,71387,347829268,,,,64482,,408.89,3.599689241,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Moderately Potent (Group II); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Dermatologicals; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunosuppressive Agents; Ointments; Ophthalmologicals; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Sensory Organs; Steroids; Steroids, Fluorinated"
DB13163,Terpin hydrate,06-01-2451,approved; experimental,JGKJMBOJWVAMIJ-OFAZAQPOSA-N,"InChI=1S/C10H20O2.H2O/c1-9(2,11)8-4-6-10(3,12)7-5-8;/h8,11-12H,4-7H2,1-3H3;1H2/t8-,10+;",CC(C)(O)[C@@H](CC1)CC[C@]1(C)O,C10H22O3,,,17141,347829270,,,,16736914,,190.283,1.186716034,"Alcohols; Cyclohexanes; Cyclohexanols; Cycloparaffins; Expectorants; Fatty Alcohols; Hexanols; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Lipids; Macrocyclic Compounds; Monoterpenes; Polycyclic Compounds; Respiratory System Agents; Terpenes"
DB13166,Zofenopril,81872-10-8,approved,IAIDUHCBNLFXEF-MNEFBYGVSA-N,"InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18+,19+/m1/s1",c1ccccc1C(=O)SC[C@@H](C)C(=O)N2C[C@H](C[C@H]2C(=O)O)Sc3ccccc3,C22H23NO4S2,,D08688,92400,347829273,78539,CHEMBL331378,,83422,50084629,429.55,4.308535977,"ACE Inhibitors and Diuretics; Acids, Acyclic; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Amino Acids; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Enzyme Inhibitors; Imines; Imino Acids; Protease Inhibitors"
DB13167,Alclofenac,22131-79-9,approved; withdrawn,ARHWPKZXBHOEEE-UHFFFAOYSA-N,"InChI=1S/C11H11ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h2-4,6H,1,5,7H2,(H,13,14)",OC(=O)Cc1cc(Cl)c(cc1)OCC=C,C11H11ClO3,,D01252,30951,347829274,31183,CHEMBL94081,,28714,,226.66,2.788617339,"Acetic Acid Derivatives and Related Substances; Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Carboxylic Acids; Central Nervous System Agents; Drugs that are Mainly Renally Excreted; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Sensory System Agents"
DB13170,Plecanatide,467426-54-6,approved; investigational,NSPHQWLKCGGCQR-DLJDZFDSSA-N,"InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1",[C@@H]12NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)O)CC(C)C)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CSSC2)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CC(=O)N,C65H104N18O26S4,,,70693500,347829276,,CHEMBL2103867,,28530494,,1681.89,3.714340025,"Alimentary Tract and Metabolism; Amino Acids, Peptides, and Proteins; Drugs for Constipation; Enzyme Activators; Gastrointestinal Agents; Guanylate Cyclase Activators; Guanylate Cyclase-C Agonist; Guanylyl Cyclase C Agonists; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Laxatives; Peptide Hormones; Peptides; Receptors, Guanylate Cyclase-Coupled, agonists"
DB13178,Inositol,87-89-8,approved; investigational; withdrawn,CDAISMWEOUEBRE-GPIVLXJGSA-N,"InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3-,4+,5-,6-",O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,C6H12O6,C00137,D08079,,347829280,17268,CHEMBL1222251,INS,10239179,,180.1559,-3.782009652,"Alcohols; Alimentary Tract and Metabolism; Carbohydrates; Diet, Food, and Nutrition; Drugs that are Mainly Renally Excreted; Food; Food and Beverages; Growth Substances; Micronutrients; Other Nutritional Agents; Physiological Phenomena; Sugar Alcohols; Vitamin B Complex; Vitamins"
DB13179,Troleandomycin,09-09-2751,approved,LQCLVBQBTUVCEQ-QTFUVMRISA-N,"InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1",O1C[C@]12C(=O)[C@H](C)[C@@H](OC(=O)C)[C@@H](C)[C@@H](C)OC(=O)[C@H](C)[C@@H](O[C@H]3C[C@H](OC)[C@H]([C@@H](O3)C)OC(=O)C)[C@H](C)[C@H]([C@@H](C)C2)O[C@@H]4O[C@H](C)C[C@H](N(C)C)[C@H]4OC(=O)C,C41H67NO15,C12753,D01322,202225,347829281,45735,CHEMBL564085,TAO,16707,50370258,813.9684,4.298514645,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strong); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strong); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Lactones; Macrocyclic Compounds; Macrolides; Macrolides, Lincosamides and Streptogramins; P-glycoprotein inhibitors; Polycyclic Compounds; Polyketides"
DB13180,Gluconic Acid,526-95-4,approved; investigational,RGHNJXZEOKUKBD-SQOUGZDYSA-N,"InChI=1S/C6H12O7/c7-1-2(8)3(9)4(10)5(11)6(12)13/h2-5,7-11H,1H2,(H,12,13)/t2-,3-,4+,5-/m1/s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O,C6H12O7,C00257,,10690,347829282,33198,CHEMBL464345,GCO,10240,,196.1553,-3.409744311,"Acids, Acyclic; Carbohydrates; Carboxylic Acids; Chelating Agents; Hydroxy Acids; Laxatives; Osmotic Laxatives; Sugar Acids"
DB13209,Bismuth subnitrate,1304-85-4,approved,QGWDKKHSDXWPET-UHFFFAOYSA-E,InChI=1S/5Bi.4NO3.9H2O.O/c;;;;;4*2-1(3)4;;;;;;;;;;/h;;;;;;;;;9*1H2;/q5*+3;4*-1;;;;;;;;;;-2/p-9,[O-][N+]([O-])=O,Bi5H9N4O22,C13102,D01642,,,31293,,,32699716,,1461.98,0.83680039,"Alimentary Tract and Metabolism; Antacids; Bismuth containing drugs; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Elements; Elements, Radioactive; Gastric Acid Lowering Agents; Gastrointestinal Agents; Isotopes; Metals; Metals, Heavy; Neurotoxic agents; Radioisotopes"
DB13211,Guanoxan,2165-19-7,approved,HIUVKVDQFXDZHU-UHFFFAOYSA-N,"InChI=1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13)",NC(=N)NCC(O1)COc(c12)cccc2,C10H13N3O2,,,,,134871,CHEMBL76725,,15704,,207.233,0.415390852,"Amidines; Antiadrenergic Agents, Peripherally Acting; Antihypertensive Agents; Cardiovascular System; Guanidine Derivatives"
DB13213,Butaperazine,653-03-2,approved,DVLBYTMYSMAKHP-UHFFFAOYSA-N,"InChI=1S/C24H31N3OS/c1-3-7-22(28)19-10-11-24-21(18-19)27(20-8-4-5-9-23(20)29-24)13-6-12-26-16-14-25(2)15-17-26/h4-5,8-11,18H,3,6-7,12-17H2,1-2H3",CCCC(=O)c(cc1)cc(c12)N(c3c(S2)cccc3)CCCN4CCN(C)CC4,C24H31N3OS,,,,,135663,CHEMBL1697826,,12078,,409.59,4.480827176,"Antipsychotic Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Phenothiazines; Phenothiazines With Piperazine Structure; Psycholeptics; Sulfur Compounds"
DB13216,Oxolamine,959-14-8,approved,IDCHQQSVJAAUQQ-UHFFFAOYSA-N,"InChI=1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3",CCN(CC)CCc1nc(no1)-c2ccccc2,C14H19N3O,,,,,94607,CHEMBL1620875,,13143,,245.326,3.137691262,"Antitussive Agents; Azoles; Central Nervous System Agents; Cough and Cold Preparations; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Oxazoles; Respiratory System; Respiratory System Agents"
DB13218,Mandelic acid,90-64-2,approved,IWYDHOAUDWTVEP-UHFFFAOYSA-N,"InChI=1S/C8H8O3/c9-7(8(10)11)6-4-2-1-3-5-6/h1-5,7,9H,(H,10,11)",OC(=O)C(O)c1ccccc1,C8H8O3,,,,,35825,CHEMBL1609,,1253,92715,152.149,0.895835645,"Acids, Carbocyclic; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Carboxylic Acids; Hydroxy Acids; Irrigating Solutions"
DB13219,Medifoxamine,32359-34-5,approved,QNMGHBMGNRQPNL-UHFFFAOYSA-N,"InChI=1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3",c1ccccc1OC(CN(C)C)Oc2ccccc2,C16H19NO2,,,,,135061,CHEMBL85231,,33212,,257.333,3.80414675,Amines; Antidepressive Agents; Central Nervous System Depressants; Nervous System; Psychoanaleptics
DB13221,Apronalide,528-92-7,approved,KSUUMAWCGDNLFK-UHFFFAOYSA-N,"InChI=1S/C9H16N2O2/c1-4-5-7(6(2)3)8(12)11-9(10)13/h4,6-7H,1,5H2,2-3H3,(H3,10,11,12,13)",C=CCC(C(C)C)C(=O)NC(=O)N,C9H16N2O2,,,,,134827,CHEMBL509282,,10264,,184.239,1.185033674,Central Nervous System Depressants; Hypnotics and Sedatives; Nervous System; Psycholeptics
DB13222,Tilbroquinol,09-09-7175,approved,JMOVFFLYGIQXMM-UHFFFAOYSA-N,"InChI=1S/C10H8BrNO/c1-6-5-8(11)10(13)9-7(6)3-2-4-12-9/h2-5,13H,1H3",Oc1c(Br)cc(C)c(c12)cccn2,C10H8BrNO,,,,,134965,CHEMBL1788385,,59034,,238.084,3.109509164,"Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxyquinoline Derivatives; Hydroxyquinolines; Quinolines"
DB13225,Dibenzepin,4498-32-2,approved,QPGGEKPRGVJKQB-UHFFFAOYSA-N,"InChI=1S/C18H21N3O/c1-19(2)12-13-21-17-11-7-6-10-16(17)20(3)15-9-5-4-8-14(15)18(21)22/h4-11H,12-13H2,1-3H3",CN(C)CCN(C1=O)c(cccc2)c2N(C)c(c13)cccc3,C18H21N3O,,,,,93394,CHEMBL1442422,,9048,50101814,295.386,2.638197238,"Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antidepressive Agents, Tricyclic; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Non-Selective Monoamine Reuptake Inhibitors; Psychoanaleptics; Psychotropic Drugs; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB13228,Flosequinan,76568-02-0,approved,UYGONJYYUKVHDD-UHFFFAOYSA-N,"InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3",Cn1cc(S(=O)C)c(=O)c(c12)ccc(F)c2,C11H10FNO2S,,,,,134972,CHEMBL1908307,,3672315,,239.26,0.718719899,"Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Quinolone Vasodilators; Vasodilating Agents; Vasodilators Used in Cardiac Diseases"
DB13231,Calcium lactate,814-80-2,approved; investigational; vet_approved,MKJXYGKVIBWPFZ-UHFFFAOYSA-L,"InChI=1S/2C3H6O3.Ca/c2*1-2(4)3(5)6;/h2*2,4H,1H3,(H,5,6);/q;;+2/p-2",CC(O)C([O-])=O,C6H10CaO6,,,13144,347829287,,CHEMBL2106111,,12592,,218.218,-0.471829518,Alimentary Tract and Metabolism; Calcium Salts; Carboxylic Acids; Hydroxy Acids; Mineral Supplements
DB13235,Perboric acid,14034-78-7,approved,PEYVWSJAZONVQK-UHFFFAOYSA-N,InChI=1S/BHO3/c2-1-4-3/h3H,OOB=O,BHO3,,,,,30175,CHEMBL3707334,,102872,,59.82,0.4836,"Acids; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Anions; Antiinfectives and Antiseptics for Local Oral Treatment; Boric Acids; Boron Compounds; Electrolytes; Ions; Stomatological Preparations; Tooth Bleaching"
DB13245,Thiram,137-26-8,approved; experimental,KUAZQDVKQLNFPE-UHFFFAOYSA-N,InChI=1S/C6H12N2S4/c1-7(2)5(9)11-12-6(10)8(3)4/h1-4H3,CN(C)C(=S)SSC(=S)N(C)C,C6H12N2S4,C11160,D06114,,,9495,CHEMBL120563,,5256,43362,240.433,2.732527103,"Acids, Acyclic; Agrochemicals; Antiparasitic Products, Insecticides and Repellents; Carbamates; Carboxylic Acids; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Dimethyldithiocarbamate; Ectoparasiticides, Incl. Scabicides; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents; Fungicides, Industrial; Increased Histamine Release; Mutagens; Noxae; Pesticides; Standardized Chemical Allergen; Sulfur Compounds; Sulfur Containing Products; Thiocarbamates; Toxic Actions"
DB13246,Quinupramine,31721-17-2,approved,JCBQCKFFSPGEDY-UHFFFAOYSA-N,"InChI=1S/C21H24N2/c1-3-7-19-16(5-1)9-10-17-6-2-4-8-20(17)23(19)21-15-22-13-11-18(21)12-14-22/h1-8,18,21H,9-15H2",N12CCC(CC1)C(C2)N3c(cccc4)c4CCc(c35)cccc5,C21H24N2,,,,,135292,CHEMBL107360,,84098,,304.437,4.575613535,"Agents that produce hypertension; Agents that reduce seizure threshold; Antidepressive Agents; Antidepressive Agents, Tricyclic; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Narrow Therapeutic Index Drugs; Nervous System; Neurotoxic agents; Non-Selective Monoamine Reuptake Inhibitors; Psychoanaleptics; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB13247,Pramiracetam,68497-62-1,approved,ZULJGOSFKWFVRX-UHFFFAOYSA-N,"InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18)",CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O,C14H27N3O2,,,,,135110,CHEMBL159776,,46801,,269.389,0.104194009,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nervous System; Psychoanaleptics; Psychostimulants, Agents Used for Adhd and Nootropics"
DB13248,Phthalylsulfathiazole,85-73-4,approved,PBMSWVPMRUJMPE-UHFFFAOYSA-N,"InChI=1S/C17H13N3O5S2/c21-15(13-3-1-2-4-14(13)16(22)23)19-11-5-7-12(8-6-11)27(24,25)20-17-18-9-10-26-17/h1-10H,(H,18,20)(H,19,21)(H,22,23)",OC(=O)c1ccccc1C(=O)Nc2ccc(cc2)S(=O)(=O)Nc3nccs3,C17H13N3O5S2,C07659,,,,9336,CHEMBL1524273,,4641,,403.43,2.553421599,"Alimentary Tract and Metabolism; Amides; Amines; Aniline Compounds; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Azoles; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Intestinal Antiinfectives; Sulfanilamides; Sulfonamides; Sulfones; Sulfur Compounds; Thiazoles"
DB13249,Magnesium silicate,1343-88-0,approved,ZADYMNAVLSWLEQ-UHFFFAOYSA-N,InChI=1S/Mg.3O.Si/q+2;3*-2;+4,[O-2],MgO3Si,,,,,,,,32698785,,100.387,-0.652,"Acids; Acids, Noncarboxylic; Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Aluminum and magnesium containing antacids; Anions; Antacids; Drugs for Acid Related Disorders; Electrolytes; Gastric Acid Lowering Agents; Ions; Magnesium Compounds; Metal cations; Metal divalent cations; Minerals; Oxides; Oxygen Compounds; Silicates; Silicon Compounds"
DB13253,Proxibarbal,2537-29-3,approved,VNLMRPAWAMPLNZ-UHFFFAOYSA-N,"InChI=1S/C10H14N2O4/c1-3-4-10(5-6(2)13)7(14)11-9(16)12-8(10)15/h3,6,13H,1,4-5H2,2H3,(H2,11,12,14,15,16)",CC(O)CC1(CC=C)C(=O)NC(=O)NC1=O,C10H14N2O4,,,,,134928,CHEMBL2105233,,16406,,226.232,-0.162428093,"Barbiturates, Plain; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hypnotics and Sedatives; Nervous System; Psycholeptics; Pyrimidines; Pyrimidinones"
DB13256,Clothiapine,2058-52-8,approved,KAAZGXDPUNNEFN-UHFFFAOYSA-N,"InChI=1S/C18H18ClN3S/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3",CN1CCN(CC1)C2=Nc(cccc3)c3Sc(c24)ccc(Cl)c4,C18H18ClN3S,,,,,31424,CHEMBL304902,,15510,50040237,343.87,4.149064713,"Antipsychotic Agents; Azepines; Central Nervous System Agents; Central Nervous System Depressants; Diazepines, Oxazepines, Thiazepines and Oxepines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotoxic agents; Psycholeptics; Psychotropic Drugs; Sulfur Compounds; Thiazepines; Thiepins; Tranquilizing Agents"
DB13257,Ferrous sulfate anhydrous,7720-78-7,approved,BAUYGSIQEAFULO-UHFFFAOYSA-L,"InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",[O-]S([O-])(=O)=O,FeO4S,,,62662,347829289,75832,CHEMBL1200830,,22804,,151.908,-0.841552023,"Anemia, Iron-Deficiency; Delayed-Action Preparations; Hematinics; Iron Compounds; Iron Preparations; Minerals; Organometallic Compounds; Pharmaceutical Preparations; Polyvalent cation containing laxatives, antacids, oral supplements"
DB13258,Etofamide,25287-60-9,approved,QTRALMGDQMIVFF-UHFFFAOYSA-N,"InChI=1S/C19H20Cl2N2O5/c1-2-27-12-11-22(19(24)18(20)21)13-14-3-7-16(8-4-14)28-17-9-5-15(6-10-17)23(25)26/h3-10,18H,2,11-13H2,1H3",CCOCCN(C(=O)C(Cl)Cl)Cc1ccc(cc1)Oc2ccc([N+]([O-])=O)cc2,C19H20Cl2N2O5,,,,,135692,CHEMBL1788393,,59142,,427.28,4.173169067,"Acetates; Acids, Acyclic; Amebicides; Amides; Anti-Infective Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Carboxylic Acids; Dichloroacetamide Derivatives; Fatty Acids; Fatty Acids, Volatile; Lipids"
DB13259,Ethyl chloride,75-00-3,approved; experimental; investigational,HRYZWHHZPQKTII-UHFFFAOYSA-N,"InChI=1S/C2H5Cl/c1-2-3/h2H2,1H3",CCCl,C2H5Cl,C18248,,6337,347829290,47554,CHEMBL46058,,6097,,64.514,1.192822742,"Anesthetics; Anesthetics, Local; Central Nervous System Agents; Central Nervous System Depressants; Hydrocarbons; Hydrocarbons, Chlorinated; Hydrocarbons, Halogenated; Nervous System; Peripheral Nervous System Agents; Sensory System Agents"
DB13262,Aceclidine,827-61-2,approved,WRJPSSPFHGNBMG-UHFFFAOYSA-N,"InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3",CC(=O)OC(CN12)C(CC1)CC2,C9H15NO2,,,,,93847,CHEMBL20835,,1902,50034625,169.224,0.298197344,"Antiglaucoma Preparations and Miotics; Autonomic Agents; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Miotics; Ophthalmologicals; Parasympathomimetics; Peripheral Nervous System Agents; Sensory Organs"
DB13265,Hexobendine,54-03-5,approved,KRQAMFQCSAJCRH-UHFFFAOYSA-N,"InChI=1S/C30H44N2O10/c1-31(11-9-15-41-29(33)21-17-23(35-3)27(39-7)24(18-21)36-4)13-14-32(2)12-10-16-42-30(34)22-19-25(37-5)28(40-8)26(20-22)38-6/h17-20H,9-16H2,1-8H3",COc1c(OC)cc(cc1OC)C(=O)OCCCN(C)CCN(C)CCCOC(=O)c2cc(OC)c(OC)c(c2)OC,C30H44N2O10,,,,,135843,CHEMBL127300,,5573,50225480,592.686,2.993101545,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoate Ethers; Hydroxybenzoates; Phenols; Phenyl Ethers; Vasodilating Agents; Vasodilators Used in Cardiac Diseases"
DB13267,Ritiometan,34914-39-1,approved,ZBNBQISDCFIEQC-UHFFFAOYSA-N,"InChI=1S/C7H10O6S3/c8-4(9)1-14-7(15-2-5(10)11)16-3-6(12)13/h7H,1-3H2,(H,8,9)(H,10,11)(H,12,13)",OC(=O)CSC(SCC(=O)O)SCC(=O)O,C7H10O6S3,,,,,136023,CHEMBL2105322,,59206,,286.33,1.151138315,Nasal Preparations; Respiratory System
DB13268,Acetarsol,97-44-9,approved; withdrawn,ODFJOVXVLFUVNQ-UHFFFAOYSA-N,"InChI=1S/C8H10AsNO5/c1-5(11)10-7-4-6(9(13,14)15)2-3-8(7)12/h2-4,12H,1H3,(H,10,11)(H2,13,14,15)",CC(=O)Nc1cc([As](=O)(O)O)ccc1O,C8H10AsNO5,,,,,135135,CHEMBL1330792,,1908,50240028,275.0903,-0.0305,"Agents Against Leishmaniasis and Trypanosomiasis; Alimentary Tract and Metabolism; Anti-Infective Agents; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Arsenicals; Drugs that are Mainly Renally Excreted; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Intestinal Antiinfectives; Organometallic Compounds"
DB13269,Dichlorobenzyl alcohol,1777-82-8,approved,DBHODFSFBXJZNY-UHFFFAOYSA-N,"InChI=1S/C7H6Cl2O/c8-6-2-1-5(4-10)7(9)3-6/h1-3,10H,4H2",OCc1c(Cl)cc(Cl)cc1,C7H6Cl2O,,,,,48220,CHEMBL3184437,,14918,,177.02,2.413985401,"Alcohols; Anti-Infective Agents, Local; Benzene Derivatives; Benzyl Compounds; Drugs that are Mainly Renally Excreted; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Respiratory System; Throat Preparations"
DB13270,Dibekacin,34493-98-6,approved,JJCQSGDBDPYCEO-XVZSLQNASA-N,"InChI=1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1",NC[C@@H]1CC[C@@H](N)[C@H](O1)O[C@@H]2[C@@H](N)C[C@@H](N)[C@@H]([C@H]2O)O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O,C18H37N5O8,,D07811,,,37945,CHEMBL560976,84D,413666,,451.521,-5.329802952,Agents that produce neuromuscular block (indirect); Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycosides; Narrow Therapeutic Index Drugs; Nephrotoxic agents
DB13273,Sultopride,53583-79-2,approved,UNRHXEPDKXPRTM-UHFFFAOYSA-N,"InChI=1S/C17H26N2O4S/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20)",CCN1CCCC1CNC(=O)c2cc(S(=O)(=O)CC)ccc2OC,C17H26N2O4S,C11708,,,,9356,CHEMBL277945,,5164,86720,354.47,1.080213639,"Acids, Carbocyclic; Amides; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Moderate Risk QTc-Prolonging Agents; Nervous System; Neurotoxic agents; Neurotransmitter Agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Tranquilizing Agents"
DB13274,Micronomicin,52093-21-7,approved,DNYGXMICFMACRA-XHEDQWPISA-N,"InChI=1S/C20H41N5O7/c1-20(28)8-29-19(14(27)17(20)25-3)32-16-12(23)6-11(22)15(13(16)26)31-18-10(21)5-4-9(30-18)7-24-2/h9-19,24-28H,4-8,21-23H2,1-3H3/t9-,10+,11-,12+,13-,14+,15+,16-,17+,18+,19+,20-/m0/s1",CNC[C@@H]1CC[C@@H](N)[C@H](O1)O[C@@H]2[C@@H](N)C[C@@H](N)[C@@H]([C@H]2O)O[C@@H](OC[C@]3(C)O)[C@H](O)[C@H]3NC,C20H41N5O7,C17706,,,,81283,CHEMBL373081,,2301017,,463.576,-3.553730554,Agents that produce neuromuscular block (indirect); Aminoglycoside Antibacterials; Anti-Bacterial Agents; Anti-Infective Agents; Benzalkonium Compounds; Carbohydrates; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Glycosides; Irritants; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Ophthalmic Solutions; Ophthalmologicals; Sensory Organs
DB13277,Benziodarone,68-90-6,approved; withdrawn,CZCHIEJNWPNBDE-UHFFFAOYSA-N,"InChI=1S/C17H12I2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3",c1cccc(c12)c(c(o2)CC)C(=O)c3cc(I)c(O)c(I)c3,C17H12I2O3,,,,,135814,CHEMBL232201,,6001,50209206,518.089,5.868129607,"Antigout Preparations; Antirheumatic Agents; Cardiac Therapy; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Renal Agents; Uricosuric Agents; Vasodilators Used in Cardiac Diseases"
DB13278,Bucetin,1083-57-4,approved; withdrawn,LIAWQASKBFCRNR-UHFFFAOYSA-N,"InChI=1S/C12H17NO3/c1-3-16-11-6-4-10(5-7-11)13-12(15)8-9(2)14/h4-7,9,14H,3,8H2,1-2H3,(H,13,15)",CCOc1ccc(cc1)NC(=O)CC(C)O,C12H17NO3,,,,,31311,CHEMBL1697856,,13507,,223.272,1.246432587,"Amines; Aminophenols; Analgesics; Anilides; Aniline Compounds; Benzene Derivatives; Ethers; Ethyl Ethers; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Nervous System; Phenols; Phenyl Ethers"
DB13279,Carbocromen,804-10-4,approved; withdrawn,KLOIYEQEVSIOOO-UHFFFAOYSA-N,"InChI=1S/C20H27NO5/c1-5-21(6-2)11-10-17-14(4)16-9-8-15(12-18(16)26-20(17)23)25-13-19(22)24-7-3/h8-9,12H,5-7,10-11,13H2,1-4H3",CCOC(=O)COc(cc1)cc(c12)oc(=O)c(c2C)CCN(CC)CC,C20H27NO5,,,,,135525,CHEMBL163672,,12084,,361.438,2.731571255,"Benzopyrans; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Coumarins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans; Vasodilating Agents; Vasodilators Used in Cardiac Diseases"
DB13282,Benzododecinium,10328-35-5,approved,CYDRXTMLKJDRQH-UHFFFAOYSA-N,"InChI=1S/C21H38N/c1-4-5-6-7-8-9-10-11-12-16-19-22(2,3)20-21-17-14-13-15-18-21/h13-15,17-18H,4-12,16,19-20H2,1-3H3/q+1",CCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,C21H38N,,,,,135611,CHEMBL1907001,,8424,,304.541,2.632754301,"Amines; Ammonium Compounds; Anti-Infective Agents; Anti-Infective Agents, Local; Benzylammonium Compounds; Compounds used in a research, industrial, or household setting; Dermatologicals; Disinfectants; Medicated Dressings; Medicated Dressings With Antiinfectives; Nitrogen Compounds; Onium Compounds; Quaternary Ammonium Compounds"
DB13284,Meticrane,1084-65-7,approved,FNQQBFNIYODEMB-UHFFFAOYSA-N,"InChI=1S/C10H13NO4S2/c1-7-5-8-3-2-4-16(12,13)10(8)6-9(7)17(11,14)15/h5-6H,2-4H2,1H3,(H2,11,14,15)",O=S(=O)(N)c(c1)c(C)cc(c12)CCCS2(=O)=O,C10H13NO4S2,,,,,31839,CHEMBL1318341,,4021,,275.34,0.569652906,"Cardiovascular System; Diuretics; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Low-Ceiling Diuretics, Excl. Thiazides; Sulfonamides"
DB13286,Bumadizone,3583-64-0,approved,FLWFHHFTIRLFPV-UHFFFAOYSA-N,"InChI=1S/C19H22N2O3/c1-2-3-14-17(19(23)24)18(22)21(16-12-8-5-9-13-16)20-15-10-6-4-7-11-15/h4-13,17,20H,2-3,14H2,1H3,(H,23,24)",CCCCC(C(=O)O)C(=O)N(c1ccccc1)Nc2ccccc2,C19H22N2O3,,,,,76119,CHEMBL2105456,,18080,,326.396,4.722469984,"Acetic Acid Derivatives and Related Substances; Acids, Acyclic; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Carboxylic Acids; Central Nervous System Agents; Dicarboxylic Acids; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Sensory System Agents"
DB13288,Tromantadine,53783-83-8,approved,UXQDWARBDDDTKG-UHFFFAOYSA-N,"InChI=1S/C16H28N2O2/c1-18(2)3-4-20-11-15(19)17-16-8-12-5-13(9-16)7-14(6-12)10-16/h12-14H,3-11H2,1-2H3,(H,17,19)",CN(C)CCOCC(=O)NC12CC3CC(C1)CC(C3)C2,C16H28N2O2,,,,,135163,CHEMBL3989506,,57947,,280.412,1.129317131,"Anti-Infective Agents; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Bridged Compounds; Cyclic Amines; Cycloparaffins; Dermatologicals; Direct Acting Antivirals; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Macrocyclic Compounds; Polycyclic Compounds"
DB13292,Pimethixene,314-03-4,approved,NZLVRVYNQYGMAB-UHFFFAOYSA-N,"InChI=1S/C19H19NS/c1-20-12-10-14(11-13-20)19-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)19/h2-9H,10-13H2,1H3",CN1CCC(CC1)=C2c(cccc3)c3Sc(c24)cccc4,C19H19NS,,,,,94787,CHEMBL152408,,4656,50097224,293.43,4.231750075,"Antihistamines for Systemic Use; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Respiratory System; Sulfur Compounds; Xanthenes"
DB13293,Ipecac,8012-96-2,approved; withdrawn,,, ,,,,,347911447,,CHEMBL2108372,,,,NA,NA,Agents Causing Muscle Toxicity; Antidotes; Autonomic Agents; Biological Products; Central Nervous System Agents; Complex Mixtures; Cough and Cold Preparations; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Emetics; Expectorants; Gastrointestinal Agents; Peripheral Nervous System Agents; Pharmaceutical Preparations; Plant Extracts; Plant Preparations; Respiratory System
DB13295,Atracurium,64228-79-1,approved; experimental; investigational,,, ,,,,,,,,,,,NA,NA,"Alkaloids; Anticholinergic Agents; Benzylisoquinolines; Central Nervous System Depressants; Cholinergic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Isoquinolines; Muscle Relaxants; Muscle Relaxants, Peripherally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Neuromuscular Blocking Agents; Neuromuscular Nondepolarizing Blockade; Neuromuscular-Blocking Agents (Nondepolarizing); Neurotransmitter Agents; Nicotinic Antagonists; Peripheral Nervous System Agents"
DB13306,Chlorquinaldol,72-80-0,approved,GPTXWRGISTZRIO-UHFFFAOYSA-N,"InChI=1S/C10H7Cl2NO/c1-5-2-3-6-7(11)4-8(12)10(14)9(6)13-5/h2-4,14H,1H3",c1cc(C)nc(c12)c(O)c(Cl)cc2Cl,C10H7Cl2NO,,D07208,,,74500,CHEMBL224325,,6062,76302,228.07,3.166794671,"Anti-Infective Agents; Anti-Infective Agents, Local; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Antiseptics and Disinfectants; Cell-mediated Immunity; Chloroquinolinols; Dermatologicals; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydroxyquinoline Derivatives; Hydroxyquinolines; Increased Histamine Release; Quinoline Derivatives; Quinolines; Respiratory System; Standardized Chemical Allergen; Throat Preparations"
DB13322,Hydrotalcite,12304-65-3,approved; experimental; investigational,BEBILBPAQKONJS-UHFFFAOYSA-L,"InChI=1S/CH2O3.2Al.6Mg.12H2O.9O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;;;12*1H2;;;;;;;;;/q;2*+3;6*+2;;;;;;;;;;;;;9*-2/p-2",[O-]C([O-])=O,CH24Al2Mg6O24,,,,,,,,32698917,,619.973,0.250051366,Alimentary Tract and Metabolism; Alkalies; Aluminium Compounds; Aluminum and magnesium containing antacids; Anions; Antacids; Drugs for Acid Related Disorders; Electrolytes; Gastric Acid Lowering Agents; Gastrointestinal Agents; Hydroxides; Ions; Magnesium Compounds; Metal cations; Metal divalent cations
DB13323,Trichloroethylene,79-01-6,approved,XSTXAVWGXDQKEL-UHFFFAOYSA-N,InChI=1S/C2HCl3/c3-1-2(4)5/h1H,ClC=C(Cl)Cl,C2HCl3,C06790,,,,16602,CHEMBL279816,TCV,13837280,,131.388,2.17833483,"Agents that produce hypertension; Anesthetics; Anesthetics, General; Anesthetics, Inhalation; Central Nervous System Agents; Central Nervous System Depressants; Compounds used in a research, industrial, or household setting; Hydrocarbons; Hydrocarbons, Chlorinated; Hydrocarbons, Halogenated; Nervous System; Solvents"
DB13337,Pheneticillin,147-55-7,approved,NONJJLVGHLVQQM-JHXYUMNGSA-N,"InChI=1S/C17H20N2O5S/c1-9(24-10-7-5-4-6-8-10)13(20)18-11-14(21)19-12(16(22)23)17(2,3)25-15(11)19/h4-9,11-12,15H,1-3H3,(H,18,20)(H,22,23)/t9?,11-,12+,15-/m1/s1",O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)C(C)Oc3ccccc3,C17H20N2O5S,,,,,52427,CHEMBL1614637,,240055,50240064,364.42,1.332005949,Anti-Bacterial Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials; Beta-Lactamase Sensitive Penicillins; beta-Lactams; Penicillins
DB13345,Dihydroergocristine,17479-19-5,approved; experimental,DEQITUUQPICUMR-HJPBWRTMSA-N,"InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1",c1ccccc1C[C@@H](C(=O)N([C@@H]2[C@@]34O)CCC2)N3C(=O)[C@](O4)(C(C)C)NC(=O)[C@H](C5)CN(C)[C@@H]([C@H]56)Cc7c8c6cccc8[nH]c7,C35H41N5O5,,D07834,,,59912,CHEMBL601773,,96884,50390992,611.743,3.827820329,"Adrenergic Agents; Adrenergic Antagonists; Agents that produce hypertension; Alkaloids; BSEP/ABCB11 Substrates; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Ergot Alkaloids and Derivatives; Ergotamines; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; Peripheral Vasodilators; Vasodilating Agents"
DB13346,Bufexamac,2438-72-4,approved; withdrawn,MXJWRABVEGLYDG-UHFFFAOYSA-N,"InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)",CCCCOc1ccc(cc1)CC(=O)NO,C12H17NO3,,D01271,2466,347829293,31317,CHEMBL94394,A4Z,2372,50015144,223.272,1.967097513,"Acetamides; Acetates; Acetic Acid Derivatives and Related Substances; Acids, Acyclic; Agents causing hyperkalemia; Amides; Amines; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antineoplastic Agents; Antirheumatic Agents; Benzene Derivatives; Benzeneacetamides; Carboxylic Acids; Central Nervous System Agents; Fatty Acids; Fatty Acids, Volatile; Histone Deacetylase Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxamic Acids; Hydroxy Acids; Hydroxylamines; Lipids; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Sensory System Agents; Topical Products for Joint and Muscular Pain"
DB13372,Calcium alginate,9005-35-0,approved; experimental,,, ,,,,,,,,,,,NA,NA,"Blood and Blood Forming Organs; Compounds used in a research, industrial, or household setting; Hemostatics; Local Hemostatics"
DB13381,Sodium feredetate,15708-41-5,approved,MKWYFZFMAMBPQK-UHFFFAOYSA-J,"InChI=1S/C10H16N2O8.Fe.Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;/q;+3;+1/p-4",[O-]C(=O)C[N+]1(CC(O2)=O)CC[N+]([Fe-2]1234)(CC(=O)O3)CC(O4)=O,C10H12FeN2NaO8,,D07145,,,78292,CHEMBL1705709,,25555,,367.047,-1.475148383,"Acetates; Acids, Acyclic; Amines; Antianemic Preparations; Blood and Blood Forming Organs; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Diamines; Ethylenediamines; Fatty Acids; Fatty Acids, Volatile; Iron Chelating Agents; Iron Compounds; Iron Preparations; Iron Trivalent, Oral Preparations; Organometallic Compounds; Parenteral Iron Replacement; Polyamines; Sequestering Agents"
DB13421,Edoxudine,15176-29-1,approved; investigational; withdrawn,XACKNLSZYYIACO-DJLDLDEBSA-N,"InChI=1S/C11H16N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h4,7-9,14-15H,2-3,5H2,1H3,(H,12,16,17)/t7-,8+,9+/m0/s1",CCc1cn(c(=O)[nH]c1=O)[C@H]2C[C@H](O)[C@H](O2)CO,C11H16N2O5,,,66377,347829299,135051,CHEMBL318153,,59752,50132292,256.258,-0.674484924,"Anti-Infective Agents; Antiviral Agents; Carbohydrates; Deoxyribonucleosides; Dermatologicals; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Pyrimidine Nucleosides; Pyrimidines; Ribonucleosides"
DB13444,Ioxitalamic acid,28179-44-4,approved,OLAOYPRJVHUHCF-UHFFFAOYSA-N,"InChI=1S/C12H11I3N2O5/c1-4(19)17-10-8(14)5(11(20)16-2-3-18)7(13)6(9(10)15)12(21)22/h18H,2-3H2,1H3,(H,16,20)(H,17,19)(H,21,22)",CC(=O)Nc1c(I)c(C(=O)O)c(I)c(c1I)C(=O)NCCO,C12H11I3N2O5,,D07418,,,83517,CHEMBL2107239,,31782,,643.942,2.039586874,"Acids, Carbocyclic; Alcohols; Amino Sugars; Benzene Derivatives; Benzoates; Carbohydrates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Hexosamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Iodobenzoates; Sugar Alcohols; Triiodobenzoic Acids; Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media; X-Ray Contrast Media, Iodinated"
DB13501,Bendazac,20187-55-7,approved; withdrawn,BYFMCKSPFYVMOU-UHFFFAOYSA-N,"InChI=1S/C16H14N2O3/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12/h1-9H,10-11H2,(H,19,20)",O=C(O)COc1nn(c(c12)cccc2)Cc3ccccc3,C16H14N2O3,,,,,31257,CHEMBL1089221,,2223,,282.299,3.059226444,"Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antirheumatic Agents; Azoles; Central Nervous System Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Ophthalmologicals; Peripheral Nervous System Agents; Pyrazoles; Sensory Organs; Sensory System Agents; Topical Products for Joint and Muscular Pain"
DB13503,Tyrothricin,1404-88-2,approved,,, ,,,,,,,CHEMBL577736,,398608,,NA,NA,"Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Antibiotics for Topical Use; Cholinesterase Inhibitors; Dermatologicals; Macrocyclic Compounds; Ophthalmologicals; Peptides; Peptides, Cyclic; Polycyclic Compounds; Respiratory System; Sensory Organs; Throat Preparations"
DB13518,Alginic acid,9005-32-7,approved; investigational,,, ,,C01768,D02324,131704328,347829302,17548,,,,,NA,NA,"Acids, Acyclic; Acids, Aldehydic; Alginates; Alimentary Tract and Metabolism; Carbohydrates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Glucuronates; Hexuronic Acids; Hydroxy Acids; Polysaccharides; Sugar Acids; Uronic Acids"
DB13520,Metergoline,17692-51-2,approved,WZHJKEUHNJHDLS-QTGUNEKASA-N,"InChI=1S/C25H29N3O2/c1-27-14-18(13-26-25(29)30-16-17-7-4-3-5-8-17)11-21-20-9-6-10-22-24(20)19(12-23(21)27)15-28(22)2/h3-10,15,18,21,23H,11-14,16H2,1-2H3,(H,26,29)/t18-,21+,23+/m0/s1",Cn1cc(c2c13)C[C@@H]4[C@@H](c2ccc3)C[C@H](CN4C)CNC(=O)OCc5ccccc5,C25H29N3O2,,D07218,28693,347829303,64216,CHEMBL19215,,26687,30704,403.526,3.986986028,"Agents that produce hypertension; Alkaloids; Antidepressive Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Agonists; Ergolines; Ergot Alkaloids and Derivatives; Ergot-derivative Dopamine Receptor Agonists; Genito Urinary System and Sex Hormones; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Neurotransmitter Agents; Prolactine Inhibitors; Serotonin Agents; Serotonin Receptor Agonists; Serotonin Receptor Antagonists"
DB13532,Cyclopenthiazide,742-20-1,approved,BKYKPTRYDKTTJY-UHFFFAOYSA-N,"InChI=1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)",NS(=O)(=O)c(c(Cl)c1)cc(c12)S(=O)(=O)NC(N2)CC3CCCC3,C13H18ClN3O4S2,,,2904,347829304,91686,CHEMBL1373254,,2801,,379.87,1.447787424,"Amides; Antihypertensive Agents; Benzothiadiazines; Cardiovascular Agents; Cardiovascular System; Diuretics; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hyperglycemia-Associated Agents; Low-Ceiling Diuretics and Potassium-Sparing Agents; Membrane Transport Modulators; Natriuretic Agents; Sodium Chloride Symporter Inhibitors; Sulfonamides; Sulfones; Sulfur Compounds; Thiazides"
DB13583,Mephenesin,59-47-2,approved,JWDYCNIAQWPBHD-UHFFFAOYSA-N,"InChI=1S/C10H14O3/c1-8-4-2-3-5-10(8)13-7-9(12)6-11/h2-5,9,11-12H,6-7H2,1H3",Cc1ccccc1OCC(O)CO,C10H14O3,,,,,94398,CHEMBL229128,,3919,50238673,182.219,1.008558986,"Alcohols; Central Nervous System Agents; Central Nervous System Depressants; Glycols; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Musculo-Skeletal System; Neuromuscular Agents; Peripheral Nervous System Agents; Propylene Glycols"
DB13595,Almasilate,71205-22-6,approved; experimental,XFKLULFTFNRQOX-UHFFFAOYSA-N,"InChI=1S/2Al.Mg.2O4Si.H2O/c;;;2*1-5(2,3)4;/h;;;;;1H2/q2*+3;+2;2*-4;",[O-][Si]([O-])([O-])[O-],Al2H2MgO9Si2,,D07419,131704329,347829306,,,,32700646,,280.445,-2.6008,"Acids; Acids, Noncarboxylic; Alimentary Tract and Metabolism; Aluminum and magnesium containing antacids; Anions; Antacids; Drugs for Acid Related Disorders; Drugs that are Mainly Renally Excreted; Electrolytes; Gastric Acid Lowering Agents; Ions; Minerals; Oxides; Oxygen Compounds; Pharmaceutic Aids; Silicon Compounds"
DB13615,Mifamurtide,838853-48-8,approved; experimental,NGIYLSFJGRLEMI-MHTUOZSYSA-M,"InChI=1S/C59H109N6O19P.Na.H2O/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68;;/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79);;1H2/q;+1;/p-1/t43-,44-,45+,47+,48+,49-,50+,54+,55+;;/m0../s1",CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(=O)N)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](C=O)NC(=O)C,C59H110N6NaO20P,,,,,,,,32700228,,1277.515,5.566524969,"Acids, Acyclic; Adjuvants, Immunologic; Alcohols; Amino Acids, Peptides, and Proteins; Amino Sugars; Antineoplastic and Immunomodulating Agents; Carbohydrates; Carboxylic Acids; Glycerophosphates; Glycerophospholipids; Glycoconjugates; Glycopeptides; Hydroxy Acids; Immunologic Factors; Lipids; Membrane Lipids; Muramic Acids; Peptides; Phosphatidic Acids; Phospholipids; Sugar Acids; Sugar Alcohols; Sugar Phosphates; Triose Sugar Alcohols"
DB13620,Potassium gluconate,299-27-4,approved,HLCFGWHYROZGBI-JJKGCWMISA-M,"InChI=1S/C6H12O7.K/c7-1-2(8)3(9)4(10)5(11)6(12)13;/h2-5,7-11H,1H2,(H,12,13);/q;+1/p-1/t2-,3-,4+,5-;/m1./s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,C6H11KO7,,D01298,16760467,347829307,32032,CHEMBL2106978,,8931,,234.245,-3.409744311,Alimentary Tract and Metabolism; Mineral Supplements; Potassium Salt
DB13624,Methoxyphenamine,93-30-1,approved,OEHAYUOVELTAPG-UHFFFAOYSA-N,"InChI=1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3",CNC(C)Cc1ccccc1OC,C11H17NO,,,,,134817,CHEMBL2010507,,3974,,179.2588,2.07915961,Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Agents producing tachycardia; Agents that produce hypertension; Amines; Amphetamines; Drugs for Obstructive Airway Diseases; Ethylamines; Neurotransmitter Agents; Non-selective Beta-adrenergic Agonists; Phenethylamines; Respiratory System; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetics
DB13628,Ethyl hydroxybenzoate,120-47-8,approved; experimental,NUVBSKCKDOMJSU-UHFFFAOYSA-N,"InChI=1S/C9H10O3/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6,10H,2H2,1H3",CCOC(=O)c1ccc(O)cc1,C9H10O3,,D01647,,,31575,CHEMBL15841,E4B,13846749,50428380,166.1739,2.029965413,"Acids, Carbocyclic; Antifungals for Dermatological Use; Antifungals for Topical Use; Benzene Derivatives; Benzoates; Carboxylic Acids; Cell-mediated Immunity; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Increased Histamine Release; Phenols; Standardized Chemical Allergen"
DB13657,Benorilate,5003-48-5,approved,FEJKLNWAOXSSNR-UHFFFAOYSA-N,"InChI=1S/C17H15NO5/c1-11(19)18-13-7-9-14(10-8-13)23-17(21)15-5-3-4-6-16(15)22-12(2)20/h3-10H,1-2H3,(H,18,19)",CC(=O)Nc1ccc(cc1)OC(=O)c2ccccc2OC(=O)C,C17H15NO5,,,,,135340,CHEMBL162036,,19846,,313.309,2.47965257,"Acids, Carbocyclic; Agents causing hyperkalemia; Agents that produce hypertension; Amides; Amines; Analgesics; Analgesics, Non-Narcotic; Anilides; Aniline Compounds; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Benzene Derivatives; Benzoates; Carboxylic Acids; Central Nervous System Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Phenols; Salicylic Acid and Derivatives; Sensory System Agents"
DB13680,Naftazone,15687-37-3,approved,TZGBBMBARSFJBG-UKTHLTGXSA-N,"InChI=1S/C11H9N3O2/c12-11(16)14-13-9-6-5-7-3-1-2-4-8(7)10(9)15/h1-6H,(H3,12,14,16)/b13-9+",NC(=O)N/N=C(C1=O)\C=Cc(c12)cccc2,C11H9N3O2,,,,,134890,CHEMBL2106794,,4698034,,215.212,1.295965772,"Capillary Stabilizing Agents; Cardiovascular System; Coagulants; Hematologic Agents; Hemostatics; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthalenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quinones; Vasoprotectives"
DB13682,Cefpirome,84957-29-9,approved,DKOQGJHPHLTOJR-WHRDSVKCSA-N,"InChI=1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1",Nc1nc(cs1)/C(=N/OC)C(=O)N[C@H](C2=O)[C@H](N23)SCC(=C3C([O-])=O)C[n+](ccc4)c(c45)CCC5,C22H22N6O5S2,C11199,D07649,,,3503,CHEMBL65794,,4586396,,514.577,-4.020851634,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; beta-Lactams; Cephalosporins; Fourth-Generation Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Nephrotoxic agents; Sulfur Compounds; Thiazines"
DB13707,Sodium tartrate,868-18-8,approved,HELHAJAZNSDZJO-OLXYHTOASA-L,"InChI=1S/C4H6O6.2Na/c5-1(3(7)8)2(6)4(9)10;;/h1-2,5-6H,(H,7,8)(H,9,10);;/q;2*+1/p-2/t1-,2-;;/m1../s1",[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O,C4H4Na2O6,,,162637,347829311,63017,CHEMBL2107781,,142788,,194.05,-1.828799889,"Acids, Acyclic; Alimentary Tract and Metabolism; Carbohydrates; Carboxylic Acids; Dicarboxylic Acids; Drugs for Constipation; Hydroxy Acids; Laxatives; Osmotic Laxatives; Sugar Acids"
DB13711,Tritoqualine,14504-73-5,approved,IRGJVQIJENCTQF-UHFFFAOYSA-N,"InChI=1S/C26H32N2O8/c1-6-31-23-17-16(18(27)24(32-7-2)25(23)33-8-3)26(29)36-21(17)19-15-13(9-10-28(19)4)11-14-20(22(15)30-5)35-12-34-14/h11,19,21H,6-10,12,27H2,1-5H3",CCOc1c(OCC)c(OCC)c(N)c(c12)C(=O)OC2C3N(C)CCc(c34)cc5c(OCO5)c4OC,C26H32N2O8,,,,,135802,CHEMBL2104445,,65119,,500.548,3.314536682,"Antihistamines for Systemic Use; Cholagogues and Choleretics; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Agents; Histamine Antagonists; Neurotransmitter Agents; Respiratory System"
DB13720,Diphemanil,15394-62-4,approved; vet_approved; withdrawn,LCTZPQRFOZKZNK-UHFFFAOYSA-N,"InChI=1S/C20H24N/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12H,13-16H2,1-2H3/q+1",c1ccccc1C(=C(CC2)CC[N+]2(C)C)c3ccccc3,C20H24N,,,,,93636,CHEMBL1201340,,5897,74260,278.418,-0.146090189,"Agents producing tachycardia; Alimentary Tract and Metabolism; Anti-Asthmatic Agents; Anticholinergic Agents; Autonomic Agents; Bronchodilator Agents; Drugs for Functional Gastrointestinal Disorders; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Muscarinic Antagonists; Parasympatholytics; Peripheral Nervous System Agents; Respiratory System Agents; Synthetic Anticholinergics, Quaternary Ammonium Compounds"
DB13743,Sodium aurotiosulfate,33614-49-2,approved; experimental,KZNBHWLDPGWJMM-UHFFFAOYSA-J,"InChI=1S/Au.3Na.2H2O3S2.2H2O/c;;;;2*1-5(2,3)4;;/h;;;;2*(H2,1,2,3,4);2*1H2/q4*+1;;;;/p-4",[O-]S([S-])(=O)=O,AuH4Na3O8S4,,,,,,CHEMBL3833379,,142087,,526.2,-0.095971004,"Acids; Acids, Noncarboxylic; Anions; Antiinflammatory and Antirheumatic Products; Antirheumatic Agents; Electrolytes; Gold Compounds; Gold Preparations; Ions; Laxatives; Musculo-Skeletal System; Osmotic Laxatives; Sodium Compounds; Specific Antirheumatic Agents; Sulfates; Sulfur Acids; Sulfur Compounds; Sulfuric Acids; Thiosulfates"
DB13746,Bioallethrin,584-79-2,approved; experimental,,, ,,,,15558638,347829312,39118,CHEMBL1788403,,18923353,,NA,NA,"Agents causing hyperkalemia; Agrochemicals; Antiarrhythmic agents; Antiparasitic Products, Insecticides and Repellents; Bradycardia-Causing Agents; Calcium Channel Blockers; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Ectoparasiticides, Incl. Scabicides; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents; Hydrocarbons; Insecticides; Monoterpenes; Pesticides; Pyrethrines, Incl. Synthetic Compounds; Pyrethrins; Stereoisomerism; Terpenes; Toxic Actions"
DB13747,Trolamine,102-71-6,approved,GSEJCLTVZPLZKY-UHFFFAOYSA-N,"InChI=1S/C6H15NO3/c8-4-1-7(2-5-9)3-6-10/h8-10H,1-6H2",OCCN(CCO)CCO,C6H15NO3,C06771,D00215,7618,347829313,28621,CHEMBL446061,211,13835630,,149.1882,-1.88013657,Alcohols; Amines; Amino Alcohols; Cicatrizants; Dermatologicals; Drugs that are Mainly Renally Excreted; Preparations for Treatment of Wounds and Ulcers
DB13749,Magnesium gluconate,59625-89-7,approved; investigational,HJWFTNWQKDPLAS-SYAJEJNSSA-L,"InChI=1S/2C6H12O7.Mg.2H2O/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;/h2*2-5,7-11H,1H2,(H,12,13);;2*1H2/q;;+2;;/p-2/t2*2-,3-,4+,5-;;;/m11.../s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,C12H26MgO16,,,71587201,347829314,,CHEMBL3989640,,28295928,,450.629,-3.409744311,"Acids, Acyclic; Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Carbohydrates; Carboxylic Acids; Hydroxy Acids; Magnesium Compounds; Metal cations; Metal divalent cations; Mineral Supplements; Sugar Acids"
DB13751,Glycyrrhizic acid,1405-86-3,approved; experimental,LPLVUJXQOOQHMX-QWBHMCJMSA-N,"InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1",C1C[C@](C)(C(=O)O)C[C@H]([C@]12C)C=3[C@@](C)(CC2)[C@@]4(C)[C@H](C(=O)C3)[C@]5(C)[C@@H](CC4)C(C)(C)[C@H](CC5)O[C@H]6O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]7O,C42H62O16,C02284,D00157,,,15939,CHEMBL441687,,14263,50185127,822.942,3.130205821,"Alimentary Tract and Metabolism; Anti-Inflammatory Agents; Bile and Liver Therapy; BSEP/ABCB11 Substrates; Hydrocarbons; Liver Therapy; Liver Therapy, Lipotropics; Pentacyclic Triterpenes; Terpenes; Triterpenes"
DB13766,Lidoflazine,3416-26-0,approved; experimental,ZBIAKUMOEKILTF-UHFFFAOYSA-N,"InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)",Cc1cccc(C)c1NC(=O)CN2CCN(CC2)CCCC(c3ccc(F)cc3)c4ccc(F)cc4,C30H35F2N3O,,,,,93095,CHEMBL92870,,3789,23619,491.627,6.584915623,"Agents causing hyperkalemia; Antiarrhythmic agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Non-Selective Calcium Channel Blockers; Piperazines; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Vasodilating Agents"
DB13781,Xamoterol,81801-12-9,approved,DXPOSRCHIDYWHW-UHFFFAOYSA-N,"InChI=1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)",Oc1ccc(cc1)OCC(O)CNCCNC(=O)N2CCOCC2,C16H25N3O5,C11775,D06328,155774,347829315,10055,CHEMBL75753,,137213,,339.392,-0.820827465,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Amines; Amino Alcohols; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular System; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Morpholines; Neurotransmitter Agents; Oxazines; Phenoxypropanolamines; Propanolamines; Propanols"
DB13783,Acemetacin,53164-05-9,approved; investigational,FSQKKOOTNAMONP-UHFFFAOYSA-N,"InChI=1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)",Clc1ccc(cc1)C(=O)n2c(C)c(c(c23)cc(cc3)OC)CC(=O)OCC(=O)O,C21H18ClNO6,,D01582,1981,347829316,31162,CHEMBL189171,,1904,50336272,415.83,3.153551744,"Acetic Acid Derivatives and Related Substances; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigout Preparations; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Central Nervous System Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; Peripheral Nervous System Agents; Sensory System Agents; UGT2B7 substrates"
DB13800,Calcium levulinate,591-64-0,approved; experimental,APKDPOQXVKRLEP-UHFFFAOYSA-L,"InChI=1S/2C5H8O3.Ca/c2*1-4(6)2-3-5(7)8;/h2*2-3H2,1H3,(H,7,8);/q;;+2/p-2",CC(=O)CCC([O-])=O,C10H14CaO6,C18380,,,,81717,,,11090,,270.294,-0.068857445,Alimentary Tract and Metabolism; Calcium Salts; Carboxylic Acids; Enzyme Inhibitors; Keto Acids; Mineral Supplements
DB13801,Muzolimine,55294-15-0,approved; withdrawn,RLWRMIYXDPXIEX-UHFFFAOYSA-N,"InChI=1S/C11H11Cl2N3O/c1-6(16-11(17)5-10(14)15-16)7-2-3-8(12)9(13)4-7/h2-4,6H,5H2,1H3,(H2,14,15)",Clc1ccc(cc1Cl)C(C)N2N=C(N)CC2=O,C11H11Cl2N3O,,,,,135124,CHEMBL1697760,,37766,,272.13,2.138478204,"Antihypertensive Agents; Azoles; Cardiovascular Agents; Cardiovascular System; Diuretics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; High-Ceiling Diuretics; Natriuretic Agents; Pyrazoles; Pyrazolone Derivatives"
DB13813,Iodoform,75-47-8,approved; experimental; vet_approved,OKJPEAGHQZHRQV-UHFFFAOYSA-N,InChI=1S/CHI3/c2-1(3)4/h1H,IC(I)I,CHI3,C13383,D01910,6374,347829319,37758,CHEMBL1451116,,6134,,393.732,4.64714878,"Dermatologicals; Hydrocarbons; Hydrocarbons, Halogenated; Medicated Dressings; Medicated Dressings With Antiinfectives; Miscellaneous Local Anti-infectives"
DB13838,Noxytiolin,15599-39-0,approved,JLMHZVYLAQPMOZ-UHFFFAOYSA-N,"InChI=1S/C3H8N2OS/c1-4-3(7)5-2-6/h6H,2H2,1H3,(H2,4,5,7)",CNC(=S)NCO,C3H8N2OS,,,,,134756,CHEMBL2106441,,4418329,,120.17,-0.606613216,"Anti-Infective Agents; Anti-Infective Agents, Local; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Irrigating Solutions; Sulfur Compounds; Thiourea"
DB13848,Fluorodopa (18F),92812-82-3,approved; experimental,PAXWQORCRCBOCU-RPDRGXCHSA-N,"InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1",OC(=O)[C@@H](N)Cc1cc(O)c(O)cc1[18F],C9H10FNO4,,,,,49166,CHEMBL3400972,,50970,,214.183,-1.649556441,"Amines; Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Benzene Derivatives; Catecholamines; Catechols; Diagnostic Radiopharmaceuticals; Fluorine Radioisotopes; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols; Phenylalanine"
DB13851,Artemotil,75887-54-6,approved,NLYNIRQVMRLPIQ-XQLAAWPRSA-N,"InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1",[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3O[C@@H]([C@@H]4C)OCC,C17H28O5,,,,,135335,CHEMBL301267,,2272064,50426305,312.406,3.838199975,"Amebicides; Anions; Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiplatyhelmintic Agents; Antiprotozoals; Artemisinin and Derivatives, Plain; Electrolytes; Free Radicals; Hydrocarbons; Ions; Oxides; Oxygen Compounds; Peroxides; Reactive Oxygen Species; Schistosomicides; Sesquiterpenes; Terpenes"
DB13853,Anethole trithione,532-11-6,approved; experimental,KYLIZBIRMBGUOP-UHFFFAOYSA-N,"InChI=1S/C10H8OS3/c1-11-8-4-2-7(3-5-8)9-6-10(12)14-13-9/h2-6H,1H3",COc1ccc(cc1)-c2cc(=S)ss2,C10H8OS3,,D01584,2194,347829320,31221,CHEMBL178862,,2109,,240.35,3.286603848,"Alimentary Tract and Metabolism; Anisoles; Benzene Derivatives; EENT Drugs, Miscellaneous; Ethers; Gastrointestinal Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Methyl Ethers; Phenols; Phenyl Ethers; Sulfur Compounds; Thiones; Various Alimentary Tract and Metabolism Products"
DB13854,Gamolenic acid,506-26-3,approved; investigational,VZCCETWTMQHEPK-QNEBEIHSSA-N,"InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-",CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O,C18H30O2,C06426,D07213,,,28661,CHEMBL464982,,4444436,50269532,278.4296,6.059955138,"Agents that reduce seizure threshold; Dermatologicals; Fatty Acids; Fatty Acids, Essential; Fatty Acids, Omega-6; Fatty Acids, Unsaturated; Linolenic Acids; Lipids"
DB13858,Dimazole,95-27-2,approved; withdrawn,WGMYEOIMVYADRJ-UHFFFAOYSA-N,"InChI=1S/C15H23N3OS/c1-5-18(6-2)9-10-19-12-7-8-13-14(11-12)20-15(16-13)17(3)4/h7-8,11H,5-6,9-10H2,1-4H3",CCN(CC)CCOc(cc1)cc(c12)sc(n2)N(C)C,C15H23N3OS,,,,,103934,CHEMBL1184360,,8384,,293.43,3.480354795,"Antifungals for Dermatological Use; Antifungals for Topical Use; Azoles; Dermatologicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Sulfur Compounds"
DB13867,Fluticasone,90566-53-3,approved; experimental,MGNNYOODZCAHBA-GQKYHHCASA-N,"InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1",FCSC(=O)[C@@]1(O)[C@H](C)C[C@H]([C@@]12C)[C@H]3[C@](F)([C@H](C2)O)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4,C22H27F3O4S,C07815,D07981,,,5134,CHEMBL1201396,,4470631,,444.51,2.576343358,"Adrenal Cortex Hormones; Androstadienes; Androstanes; Androstenes; Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Autonomic Agents; Bronchodilator Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Corticosteroids for inhalation use; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Drugs for Obstructive Airway Diseases; Fused-Ring Compounds; Glucocorticoids; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Medications that reduce magnesium levels; Nasal Preparations; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Polycyclic Compounds; Respiratory System; Respiratory System Agents; Steroids; Thyroxine-binding globulin inhibitors"
DB13872,Lormetazepam,848-75-9,approved,FJIKWRGCXUCUIG-UHFFFAOYSA-N,"InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3",c1c(Cl)ccc(c12)N(C)C(=O)C(O)N=C2c3ccccc3Cl,C16H12Cl2N2O2,,,13314,347829324,52993,CHEMBL22097,,12750,,335.185,3.391391557,"Benzazepines; Benzodiazepines and benzodiazepine derivatives; Benzodiazepinones; Central Nervous System Agents; Central Nervous System Depressants; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hypnotics and Sedatives; Nervous System; Psycholeptics"
DB13873,Fenofibric acid,42017-89-0,approved,MQOBSOSZFYZQOK-UHFFFAOYSA-N,"InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)",OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2,C17H15ClO4,,,64929,347829325,83469,CHEMBL981,,58457,28700,318.75,4.358485701,"Acids, Acyclic; Agents Causing Muscle Toxicity; Anticholesteremic Agents; Benzene Derivatives; Benzophenones; Butyrates; Carboxylic Acids; Cardiovascular System; Drugs that are Mainly Renally Excreted; Ethers; Fatty Acids; Fatty Acids, Volatile; Fibric Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypolipidemic Agents; Hypolipidemic Agents Indicated for Hyperlipidemia; Isobutyrates; Ketones; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Lipids; Noxae; Peroxisome Proliferator Receptor alpha Agonist; Phenols; Phenyl Ethers; Toxic Actions"
DB13874,Enasidenib,1446502-11-9,approved; investigational,DYLUUSLLRIQKOE-UHFFFAOYSA-N,"InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)",CC(C)(O)CNc1nc(-c2nc(C(F)(F)F)ccc2)nc(n1)Nc3cc(C(F)(F)F)ncc3,C19H17F6N7O,,,89683805,347829326,145374,CHEMBL3989908,69Q,38772329,,473.383,4.586206418,"Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Isocitrate Dehydrogenase 2 Inhibitor; Isocitrate Dehydrogenase 2 Inhibitors; Narrow Therapeutic Index Drugs; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; Pyridines; UGT1A1 Inhibitors; UGT1A1 Substrates; UGT1A1 substrates with narrow therapeutic index; UGT1A3 substrates; UGT1A3 substrates with narrow therapeutic index; UGT1A4 substrates; UGT1A9 Substrates; UGT1A9 substrates with narrow therapeutic index; UGT2B7 substrates; UGT2B7 substrates with narrow therapeutic index"
DB13878,Pibrentasvir,1353900-92-1,approved; investigational,VJYSBPDEJWLKKJ-NLIMODCCSA-N,"InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1",COC(=O)N[C@@H]([C@@H](C)OC)C(=O)N1CCC[C@H]1c([nH]2)nc(c23)cc(c(F)c3)[C@H]4CC[C@@H](N4c5cc(F)c(c(F)c5)N6CCC(CC6)c7ccc(F)cc7)c(c(F)c8)cc(c89)nc([nH]9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC,C57H65F5N10O8,,,58031952,347829329,,CHEMBL3545123,,35013016,,1113.201,7.630376646,"Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Direct Acting Antivirals; Hepatitis C Virus NS5A Inhibitor; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; UGT1A1 Inhibitors"
DB13879,Glecaprevir,1365970-03-1,approved; investigational,MLSQGNCUYAMAHD-ITNVBOSISA-N,"InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1",C1CC1(C)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H](N34)C[C@H](C3)Oc5c(nc6c(n5)cccc6)C(F)(F)\C=C\CO[C@H]7[C@@H](CCC7)OC(=O)N[C@H](C4=O)C(C)(C)C,C38H46F4N6O9S,,D10814,66828839,347829330,,CHEMBL3545363,O31,35013015,,838.87,3.954976136,"Amides; Antiinfectives for Systemic Use; Antiviral Agents; Antivirals for Systemic Use; Antivirals for treatment of HCV infections; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Breast Cancer Resistance Protein Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Direct Acting Antivirals; HCV NS3/4A Protease Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; NS3/4A Protease Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; OATP1B3 substrates; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Sulfones; Sulfur Compounds; UGT1A1 Inhibitors"
DB13882,Methyl nicotinate,93-60-7,approved,YNBADRVTZLEFNH-UHFFFAOYSA-N,"InChI=1S/C7H7NO2/c1-10-7(9)6-3-2-4-8-5-6/h2-5H,1H3",COC(=O)c1cnccc1,C7H7NO2,,,7151,347829331,134761,CHEMBL379845,,21111785,,137.136,0.759050353,"Acids, Heterocyclic; Anti-Inflammatory Agents; Erythema; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Inflammation; Nicotinic Acids; Pyridines"
DB13885,Ferric subsulfate,1310-45-8,approved; experimental,,, ,,,,,347911454,,,,,,NA,NA,"Acids; Acids, Noncarboxylic; Anions; Coagulants; Electrolytes; Hematologic Agents; Hemostatics; Ions; Iron Compounds; Organometallic Compounds; Parenteral Iron Replacement; Phosphate Binder; Sulfur Acids; Sulfur Compounds; Sulfuric Acids"
DB13908,Amylmetacresol,1300-94-3,approved,CKGWFZQGEQJZIL-UHFFFAOYSA-N,"InChI=1S/C12H18O/c1-3-4-5-6-11-8-7-10(2)9-12(11)13/h7-9,13H,3-6H2,1-2H3",CCCCCc1ccc(C)cc1O,C12H18O,,,,,48213,CHEMBL1512677,,14076,,178.275,4.474797933,"Benzene Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Miscellaneous Anti-infectives; Phenols"
DB13909,Bismuth subgallate,99-26-3,approved,JAONZGLTYYUPCT-UHFFFAOYSA-K,"InChI=1S/C7H6O5.Bi.H2O/c8-4-1-3(7(11)12)2-5(9)6(4)10;;/h1-2,8-10H,(H,11,12);;1H2/q;+3;/p-3",O[Bi](O1)Oc(c12)cc(C(=O)O)cc2O,C7H5BiO6,,D01398,,,31292,CHEMBL1592101,,10607905,,394.091,0.5455,"Acids, Carbocyclic; Antacids and Adsorbents; Anti-Infective Agents; Antidiarrheals; Benzene Derivatives; Benzoates; Bismuth containing drugs; Carboxylic Acids; Coagulants; Drugs that are Mainly Renally Excreted; Hematologic Agents; Hemostatics; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Neurotoxic agents; Phenols"
DB13910,Valproate bismuth,60364-28-5,approved,YZDVVHSLIPLZLO-UHFFFAOYSA-K,"InChI=1S/3C8H16O2.Bi/c3*1-3-5-7(6-4-2)8(9)10;/h3*7H,3-6H2,1-2H3,(H,9,10);/q;;;+3/p-3",CCCC(C([O-])=O)CCC,C24H45BiO6,,,,,,,,20137751,,638.598,2.798451071,"Bismuth containing drugs; EENT Drugs, Miscellaneous; Neurotoxic agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
DB13911,Phloxine B,18472-87-2,approved,GVKCHTBDSMQENH-UHFFFAOYSA-L,"InChI=1S/C20H4Br4Cl4O5.2Na/c21-5-1-3-7(8-9(20(31)32)13(26)15(28)14(27)12(8)25)4-2-6(22)17(30)11(24)19(4)33-18(3)10(23)16(5)29;;/h1-2,29H,(H,31,32);;/q;2*+1/p-2",[O-]C(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c2c(cc(Br)c(=O)c3Br)c3oc(c24)c(Br)c([O-])c(Br)c4,C20H2Br4Cl4Na2O5,,,,,87192,CHEMBL61441,,2006228,,829.63,8.161131123,"Coloring Agents; Compounds used in a research, industrial, or household setting; Dental Agents; Fluoresceins; Fluorescent Dyes; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Indicators and Reagents; Laboratory Chemicals; Luminescent Agents; Polycyclic Compounds; Spiro Compounds; Xanthenes"
DB13925,Dotatate gallium Ga-68,1027785-90-5,approved; investigational,XBJPSVQFCQFGDC-WSCOIBMGSA-K,"InChI=1S/C65H90N14O19S2.Ga/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1-2",NCCCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)CSSC[C@@H](C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(=O)N1)Cc3c[nH]c(c34)cccc4)NC(=O)[C@@H](Cc5ccccc5)NC(=O)CN6CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC6,C65H87GaN14O19S2,,,,,,,,58828606,,1500.54,-8.351902509,"Amino Acids, Peptides, and Proteins; Gallium Radioisotopes; Macrocyclic Compounds; Peptides; Peptides, Cyclic; Polycyclic Compounds; Positron Emitting Activity; Radioactive Diagnostic Agent"
DB13928,Semaglutide,910463-68-2,approved; investigational,DLSWIYLPEUIQAV-CCUURXOWSA-N,"InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1",OC(=O)CCCCCCCCCCCCCCCCC(=O)N[C@@H](C(=O)O)CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc2c[nH]c(c23)cccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)O)CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc6c[nH]cn6,C187H291N45O59,,,,,,CHEMBL3616752,,34985066,50121400,4113.641,-17.29217018,"Alimentary Tract and Metabolism; Amino Acids, Peptides, and Proteins; Blood Glucose Lowering Agents; Drugs Used in Diabetes; Gastrointestinal Hormones; GLP-1 Agonists; Glucagon-like Peptide-1 (GLP-1) Agonists; Glucagon-like peptide-1 (GLP-1) analogues; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Incretin Mimetics; Pancreatic Hormones; Peptide Hormones; Peptides; Proteins"
DB13931,Netarsudil,1254032-66-0,approved,OURRXQUGYQRVML-AREMUKBSSA-N,"InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1",Cc1cc(C)c(cc1)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc(c3)ccc(c34)cncc4,C28H27N3O3,,,,,,,,34980598,,453.542,4.727226518,"Acids, Carbocyclic; Alanine; Amino Acids; Amino Acids, Peptides, and Proteins; Antiglaucoma Preparations and Miotics; Benzene Derivatives; Carboxylic Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Ophthalmologicals; Rho Kinase Inhibitor; Rho Kinase Inhibitors; Sensory Organs"
DB13943,Testosterone cypionate,58-20-8,approved,HPFVBGJFAYZEBE-ZLQWOROUSA-N,"InChI=1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CC[C@@H]4OC(=O)CCC5CCCC5,C27H40O3,C08156,D00957,,,9463,CHEMBL1201101,,390140,,412.614,6.108652409,"Anabolic Agents; Androgens; Androstanes; Androstenes; Androstenols; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Delayed-Action Preparations; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OAT3/SLC22A8 Inducers; P-glycoprotein inhibitors; Polycyclic Compounds; Steroids; Testosterone and derivatives; Testosterone Congeners; Thyroxine-binding globulin inhibitors"
DB13944,Testosterone enanthate,315-37-7,approved,VOCBWIIFXDYGNZ-IXKNJLPQSA-N,"InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CC[C@@H]4OC(=O)CCCCCC,C26H40O3,C08157,,,,9464,CHEMBL1200335,,9045,,400.594,6.285359215,"Adrenal Cortex Hormones; Androgens; Androstanes; Androstenes; Androstenols; BCRP/ABCG2 Substrates; Contraceptive Agents, Male; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OAT3/SLC22A8 Inducers; P-glycoprotein inhibitors; Polycyclic Compounds; Steroids; Testosterone and derivatives; Testosterone Congeners; Thyroxine-binding globulin inhibitors"
DB13946,Testosterone undecanoate,5949-44-0,approved; investigational,UDSFVOAUHKGBEK-CNQKSJKFSA-N,"InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1",CCCCCCCCCCC(=O)O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=CC(=O)CC4,C30H48O3,,,,,135741,CHEMBL2107067,,58664,,456.711,8.063633875,"Androgens; Androstanes; Androstenes; Androstenols; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OAT3/SLC22A8 Inducers; P-glycoprotein inhibitors; Polycyclic Compounds; Steroids; Testosterone and derivatives; Testosterone Congeners; Thyroxine-binding globulin inhibitors"
DB13947,Testosterone enantate benzilic acid hydrazone,18625-33-7,approved; experimental,PTVXYACXDYZNID-JKXGKYMWSA-N,"InChI=1S/C40H52N2O4/c1-4-5-6-13-18-36(43)46-35-22-21-33-32-20-19-30-27-31(23-25-38(30,2)34(32)24-26-39(33,35)3)41-42-37(44)40(45,28-14-9-7-10-15-28)29-16-11-8-12-17-29/h7-12,14-17,27,32-35,45H,4-6,13,18-26H2,1-3H3,(H,42,44)/t32-,33-,34-,35-,38-,39-/m0/s1",c1ccccc1C(O)(c2ccccc2)C(=O)N/N=C(/CC3)C=C([C@]34C)CC[C@H]5[C@H]6[C@](C)(CC[C@H]45)[C@H](CC6)OC(=O)CCCCCC,C40H52N2O4,,,,,,,,34995240,,624.866,8.489464162,"Androstanes; Androstenes; Androstenols; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroids; Testosterone and derivatives; Testosterone Congeners"
DB13949,Ferric cation,20074-52-6,approved,VTLYFUHAOXGGBS-UHFFFAOYSA-N,InChI=1S/Fe/q+3,[Fe+3],Fe,C14819,,,,29034,,FE,27815,,55.845,-0.77,"Iron Compounds; Parenteral Iron Replacement; Phosphate Binder; Phosphate Chelating Activity; Polyvalent cation containing laxatives, antacids, oral supplements"
DB13952,Estradiol acetate,4245-41-4,approved; investigational; vet_approved,FHXBMXJMKMWVRG-SLHNCBLASA-N,"InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1",O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(cc4)OC(=O)C,C20H26O3,,D04061,9818306,,135981,CHEMBL1200430,,7994056,,314.4186,3.656327624,BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estrogens; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Thyroxine-binding globulin inducers; UGT1A1 Substrates
DB13953,Estradiol benzoate,50-50-0,approved; investigational; vet_approved,UYIFTLBWAOGQBI-BZDYCCQFSA-N,"InChI=1S/C25H28O3/c1-25-14-13-20-19-10-8-18(28-24(27)16-5-3-2-4-6-16)15-17(19)7-9-21(20)22(25)11-12-23(25)26/h2-6,8,10,15,20-23,26H,7,9,11-14H2,1H3/t20-,21-,22+,23+,25+/m1/s1",O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(cc4)OC(=O)c5ccccc5,C25H28O3,C13444,,222757,,77006,CHEMBL282575,,193412,56905,376.488,5.710502063,"Adrenal Cortex Hormones; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Estradiol Congeners; Estranes; Estrenes; Estrogens; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Reproductive Control Agents; Steroids; UGT1A1 Substrates"
DB13954,Estradiol cypionate,313-06-4,approved; investigational; vet_approved,UOACKFBJUYNSLK-XRKIENNPSA-N,"InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1",C1CCCC1CCC(=O)O[C@H]2CC[C@H]([C@@]23C)[C@H]4[C@H](CC3)c5c(CC4)cc(O)cc5,C26H36O3,C14640,D04063,9403,,34745,CHEMBL1200973,,9033,,396.5622,6.488730439,"Adrenal Cortex Hormones; BCRP/ABCG2 Inhibitors; Contraceptive Agents, Female; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estradiol Congeners; Estranes; Estrenes; Estrogen Contraceptives; Estrogens; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Reproductive Control Agents; Steroids; Thyroxine-binding globulin inducers; UGT1A1 Substrates"
DB13955,Estradiol dienanthate,7732-97-0,approved; investigational; vet_approved,OVAHZPTYWMWNKO-CAHAWPIUSA-N,"InChI=1S/C32H48O4/c1-4-6-8-10-12-30(33)35-24-15-17-25-23(22-24)14-16-27-26(25)20-21-32(3)28(27)18-19-29(32)36-31(34)13-11-9-7-5-2/h15,17,22,26-29H,4-14,16,18-21H2,1-3H3/t26-,27-,28+,29+,32+/m1/s1",CCCCCCC(=O)O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(cc4)OC(=O)CCCCCC,C32H48O4,,,,,,,,145199,,496.732,9.055074049,"BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estradiol Congeners; Estranes; Estrenes; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Steroids; UGT1A1 Substrates"
DB13956,Estradiol valerate,979-32-8,approved; investigational; vet_approved,RSEPBGGWRJCQGY-RBRWEJTLSA-N,"InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1",c1cc(O)cc(CC2)c1[C@@H](CC3)[C@@H]2[C@@H]([C@]34C)CC[C@@H]4OC(=O)CCCC,C23H32O3,C12859,,13791,,31561,CHEMBL1511,,13194,,356.4984,5.776299916,"Adrenal Cortex Hormones; BCRP/ABCG2 Inhibitors; Contraceptive Agents, Female; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Estradiol Congeners; Estradiol, agonists; Estranes; Estrenes; Estrogen Contraceptives; Estrogens; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormonal Contraceptives for Systemic Use; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OATP1B1/SLCO1B1 Inhibitors; OCT1 inhibitors; OCT2 Inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Steroids; Thyroxine-binding globulin inducers; UGT1A1 Substrates"
DB13959,Medium-chain triglycerides,438544-49-1,approved,,, ,,,,,,,,,,,NA,NA,NA
DB13960,Bronopol,52-51-7,approved,LVDKZNITIUWNER-UHFFFAOYSA-N,"InChI=1S/C3H6BrNO4/c4-3(1-6,2-7)5(8)9/h6-7H,1-2H2",OCC(Br)([N+]([O-])=O)CO,C3H6BrNO4,C13034,D01577,,,31306,CHEMBL1408862,,2356,50248122,199.988,-0.185740764,"Alcohols; Anti-Infective Agents; Anti-Infective Agents, Local; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Glycols; Increased Histamine Release; Indicators and Reagents; Laboratory Chemicals; Preservatives, Pharmaceutical; Standardized Chemical Allergen"
DB13962,Calcium saccharate,5793-88-4,approved; experimental,UGZVNIRNPPEDHM-SBBOJQDXSA-L,"InChI=1S/C6H10O8.Ca/c7-1(3(9)5(11)12)2(8)4(10)6(13)14;/h1-4,7-10H,(H,11,12)(H,13,14);/q;+2/p-2/t1-,2-,3-,4+;/m0./s1",[O-]C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O,C6H8CaO8,,,,,,CHEMBL2104217,,136477,,248.2,-3.089469773,Replacement Preparations
DB13966,Isopropyl myristate,110-27-0,approved; experimental,AXISYYRBXTVTFY-UHFFFAOYSA-N,"InChI=1S/C17H34O2/c1-4-5-6-7-8-9-10-11-12-13-14-15-17(18)19-16(2)3/h16H,4-15H2,1-3H3",CCCCCCCCCCCCCC(=O)OC(C)C,C17H34O2,,,,,90027,CHEMBL207602,,7751,,270.4507,6.286722483,Fatty Acids; Lipids; Myristic Acids; Scabicides and Pediculicides
DB13967,Patent Blue,25305-77-5,approved,DHAHKSQXIXFZJB-UHFFFAOYSA-O,"InChI=1S/C27H32N2O7S2/c1-5-28(6-2)21-13-9-19(10-14-21)27(20-11-15-22(16-12-20)29(7-3)8-4)23-17-24(30)26(38(34,35)36)18-25(23)37(31,32)33/h9-18H,5-8H2,1-4H3,(H2-,30,31,32,33,34,35,36)/p+1",CCN(CC)c1ccc(cc1)C(c2c(S(=O)(=O)O)cc(c(O)c2)S(=O)(=O)O)=C3C=CC(C=C3)=[N+](CC)CC,C27H33N2O7S2,,,,,59601,,,69520,,561.69,2.396697285,"Amines; Aniline Compounds; Coloring Agents; Compounds used in a research, industrial, or household setting; Diagnostic Agents; Drugs that are Mainly Renally Excreted; Other Diagnostics"
DB13970,Dioctyldimonium,20256-55-7,approved; experimental,MELGLHXCBHKVJG-UHFFFAOYSA-N,"InChI=1S/C18H40N/c1-5-7-9-11-13-15-17-19(3,4)18-16-14-12-10-8-6-2/h5-18H2,1-4H3/q+1",CCCCCCCC[N+](C)(C)CCCCCCCC,C18H40N,,,,,,CHEMBL2366023,,56344,,270.524,2.232180199,Amines; Ammonium Compounds; Nitrogen Compounds; Onium Compounds
DB13971,Vanadium,7440-62-2,approved; experimental,LEONUFNNVUYDNQ-UHFFFAOYSA-N,InChI=1S/V,[V],V,,,,,27698,,,22426,,50.9415,0,"Diet, Food, and Nutrition; Elements; Food; Food and Beverages; Growth Substances; Metals; Metals, Heavy; Micronutrients; Physiological Phenomena; Trace Elements; Transition Elements"
DB13972,Racemethionine,59-51-8,approved; experimental,FFEARJCKVFRZRR-UHFFFAOYSA-N,"InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)",CSCCC(N)C(=O)O,C5H11NO2S,C01733,D04983,,,16811,CHEMBL274119,,853,86195,149.211,-2.189326617,"Amino Acids; Amino Acids, Essential; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Sulfur Compounds"
DB13977,Potassium carbonate,584-08-7,approved,BWHMMNNQKKPAPP-UHFFFAOYSA-L,"InChI=1S/CH2O3.2K/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2",[O-]C([O-])=O,CK2O3,,D02038,,,131526,CHEMBL2105894,,10949,,138.2055,0.250051366,"Acids; Acids, Noncarboxylic; Alkalies; Anions; Carbon Compounds, Inorganic; Carbonic Acid; Electrolytes; Elements; Ions; Metals; Metals, Alkali; Metals, Light; Potassium Salt"
DB13980,Copper Cu-64,13981-25-4,approved,,, ,,,,,,,,,,,NA,NA,NA
DB13982,Lutetium Lu-177,14265-75-9,approved,OHSVLFRHMCKCQY-NJFSPNSNSA-N,InChI=1S/Lu/i1+2,[177Lu],Lu,,,,,,,,141480,,176.9438,0,"Elements; Isotopes; Lanthanoid Series Elements; Metals; Metals, Rare Earth; Transition Elements"
DB13985,Lutetium Lu 177 dotatate,437608-50-9,approved; investigational,MXDPZUIOZWKRAA-PRDSJKGBSA-K,"InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2",NCCCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)CSSC[C@@H](C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(=O)N1)Cc3c[nH]c(c34)cccc4)NC(=O)[C@@H](Cc5ccccc5)NC(=O)CN6CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC6,C65H87LuN14O19S2,,,,,,,,32699095,,1609.55,-8.351902509,"Amino Acids, Peptides, and Proteins; Lutetium; Macrocyclic Compounds; Organometallic Compounds; Peptides; Peptides, Cyclic; Polycyclic Compounds"
DB13987,Strontium chloride,10476-85-4,approved,AHBGXTDRMVNFER-UHFFFAOYSA-L,InChI=1S/2ClH.Sr/h2*1H;/q;;+2/p-2,[Cl-],Cl2Sr,,,,,,CHEMBL2219640,,55440,,158.52,-0.3,"Drugs that are Mainly Renally Excreted; Elements; Metals; Metals, Alkaline Earth; Metals, Heavy; Strontium Radioisotopes"
DB13995,Ferric pyrophosphate citrate,1802359-96-1,approved; investigational,SXAWSYZURCZSDX-UHFFFAOYSA-B,"InChI=1S/3C6H8O7.4Fe.3H4O7P2/c3*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;3*1-8(2,3)7-9(4,5)6/h3*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;3*(H2,1,2,3)(H2,4,5,6)/q;;;4*+3;;;/p-12",[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O,C18H24Fe4O42P6,,,,,,CHEMBL3833317,,34994433,,1321.571,-1.322687452,Enzymes; Enzymes and Coenzymes; Hydrolases; Parenteral Iron Replacement; Peptide Hydrolases; Phosphate Binder; Phosphate salts
DB13996,Magnesium acetate,142-72-3,approved,UEGPKNKPLBYCNK-UHFFFAOYSA-L,"InChI=1S/2C2H4O2.Mg/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2",CC([O-])=O,C4H6MgO4,,,,,62964,CHEMBL1200691,,8556,,142.393,-0.223345714,Agents that produce neuromuscular block (indirect); Calculi Dissolution Agent; Laxatives; Osmotic Laxatives
DB13997,Baloxavir marboxil,1985606-14-1,approved; investigational,RZVPBGBYGMDSBG-GGAORHGYSA-N,"InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1",COC(=O)OCOc(c(=O)cc1)c(n12)C(=O)N3[C@@H](COCC3)N2[C@H]4c(ccc(F)c5F)c5CSc(c46)cccc6,C27H23F2N3O7S,,D11021,,,,CHEMBL4297503,,59718643,,571.55,3.38447094,"Anti-Infective Agents; Antiviral Agents; Antivirals for Systemic Use; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Direct Acting Antivirals; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Sulfur Compounds; UGT1A3 substrates"
DB14001,alpha-Tocopherol succinate,03-03-4345,approved; nutraceutical; vet_approved,IELOKBJPULMYRW-NJQVLOCASA-N,"InChI=1S/C33H54O5/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-20-33(8)21-19-28-27(7)31(25(5)26(6)32(28)38-33)37-30(36)18-17-29(34)35/h22-24H,9-21H2,1-8H3,(H,34,35)/t23-,24-,33-/m1/s1",CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)CCC(=O)O,C33H54O5,,,,,135821,CHEMBL81421,,19171,,530.79,10.2434063,"Antioxidants; Benzopyrans; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Micronutrients; Physiological Phenomena; Protective Agents; Pyrans; Tocopherols; Vitamin E; Vitamins; Vitamins (Fat Soluble)"
DB14002,D-alpha-Tocopherol acetate,58-95-7,approved; nutraceutical; vet_approved,ZAKOWWREFLAJOT-CEFNRUSXSA-N,"InChI=1S/C31H52O3/c1-21(2)13-10-14-22(3)15-11-16-23(4)17-12-19-31(9)20-18-28-26(7)29(33-27(8)32)24(5)25(6)30(28)34-31/h21-23H,10-20H2,1-9H3/t22-,23-,31-/m1/s1",CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)C,C31H52O3,C13202,D01735,,,32321,CHEMBL1047,,77987,,472.7428,10.41854356,"Compounds used in a research, industrial, or household setting; Tocopherols; Vitamin E; Vitamins; Vitamins (Fat Soluble)"
DB14003,alpha-Tocopherol acetate,7695-91-2,approved,,, ,,,,,,,,,,,NA,NA,"Antioxidants; Benzopyrans; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Micronutrients; P-glycoprotein substrates; Physiological Phenomena; Protective Agents; Pyrans; Tocopherols; Vitamin E; Vitamins; Vitamins (Fat Soluble)"
DB14005,Dimethicone 410,9006-65-9,approved,,, ,,,,,,,,,,,NA,NA,NA
DB14006,Choline salicylate,2016-36-6,approved; nutraceutical,UDKCHVLMFQVBAA-UHFFFAOYSA-M,"InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1",Oc1ccccc1C([O-])=O,C12H19NO4,,D00810,,,3668,CHEMBL2104095,,15385,,241.287,1.977263402,"Acids, Carbocyclic; Alcohols; Amines; Amino Alcohols; Ammonium Compounds; Analgesics; Benzene Derivatives; Benzoates; Carboxylic Acids; Drugs that are Mainly Renally Excreted; Ethanolamines; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Nervous System; Nitrogen Compounds; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; Onium Compounds; Pharmaceutical Preparations; Phenols; Quaternary Ammonium Compounds; Salicylates; Salicylic Acid and Derivatives; Trimethyl Ammonium Compounds"
DB14007,Pentetic acid,67-43-6,approved,QPCDCPDFJACHGM-UHFFFAOYSA-N,"InChI=1S/C14H23N3O10/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27)",OC(=O)CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC(=O)O,C14H23N3O10,,,,,35739,CHEMBL780,,2945,,393.349,-6.273562252,"Acetates; Acids, Acyclic; Amines; Antidotes; Carboxylic Acids; Chelating Agents; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Fatty Acids; Fatty Acids, Volatile; Iron Chelating Agents; Lead Chelating Activity; Lead Chelator; Lipids; Polyamines; Protective Agents; Sequestering Agents"
DB14015,Sodium bisulfite,7631-90-5,approved,DWAQJAXMDSEUJJ-UHFFFAOYSA-M,"InChI=1S/Na.H2O3S/c;1-4(2)3/h;(H2,1,2,3)/q+1;/p-1",OS([O-])=O,HNaO3S,,,,,26709,CHEMBL1689285,,571016,,104.061,-1.154687263,"Anions; Anti-Infective Agents; Anti-Infective Agents, Local; Antioxidants; Compounds used in a research, industrial, or household setting; Electrolytes; Ions; Mutagens; Noxae; Protective Agents; Sulfur Compounds; Toxic Actions"
DB14018,Bromotheophylline,10381-75-6,approved,SKTFQHRVFFOHTQ-UHFFFAOYSA-N,"InChI=1S/C7H7BrN4O2/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h1-2H3,(H,9,10)",[nH]1c(Br)nc(c12)n(C)c(=O)n(C)c2=O,C7H7BrN4O2,,,,,,CHEMBL316160,,11315,50045345,259.063,0.294745457,"Alcohols; Alkaloids; Amines; Amino Alcohols; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Diuretics; Drugs for Obstructive Airway Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pharmaceutical Preparations; Propanols; Purines; Purinones; Respiratory System; Xanthine derivatives"
DB14019,Fosnetupitant,1703748-89-3,approved,HZIYEEMJNBKMJH-UHFFFAOYSA-N,"InChI=1S/C31H35F6N4O5P/c1-20-8-6-7-9-24(20)25-17-27(40-10-12-41(5,13-11-40)19-46-47(43,44)45)38-18-26(25)39(4)28(42)29(2,3)21-14-22(30(32,33)34)16-23(15-21)31(35,36)37/h6-9,14-18H,10-13,19H2,1-5H3,(H-,43,44,45)",FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(C)(C)C(=O)N(C)c2cnc(N(CC3)CC[N+]3(C)COP([O-])(=O)O)cc2-c4ccccc4C,C31H35F6N4O5P,,,,,,CHEMBL3989917,,44208829,,688.608,0.797957259,Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Netupitant and prodrug; Substance P/Neurokinin-1 Receptor Antagonist
DB14020,Benzoin,119-53-9,approved; experimental,ISAOCJYIOMOJEB-UHFFFAOYSA-N,"InChI=1S/C14H12O2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13,15H",c1ccccc1C(O)C(=O)c2ccccc2,C14H12O2,C01408,,,,17682,CHEMBL190677,,8093,22728,212.2439,2.650074694,Acetophenones; Ketones
DB14033,Acetyl sulfisoxazole,80-74-0,approved; vet_approved,JFNWFXVFBDDWCX-UHFFFAOYSA-N,"InChI=1S/C13H15N3O4S/c1-8-9(2)15-20-13(8)16(10(3)17)21(18,19)12-6-4-11(14)5-7-12/h4-7H,14H2,1-3H3",Cc1noc(c1C)N(C(=O)C)S(=O)(=O)c2ccc(N)cc2,C13H15N3O4S,,,6662,,135975,CHEMBL1200910,,6410,,309.34,0.719221418,Amides; Amines; Aniline Compounds; Anti-Bacterial Agents; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 Enzyme Inhibitors; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Sulfanilamides; Sulfonamide Antibacterial; Sulfonamides; Sulfones; Sulfur Compounds
DB14046,Dichlorobenzene,25321-22-6,approved; experimental,,, ,,,,,,,,,,,NA,NA,Benzene Derivatives; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 Substrates
DB14048,Sodium zirconium cyclosilicate,17141-74-1,approved; investigational,ARVUQMBOTBOHPL-UHFFFAOYSA-N,"InChI=1S/2Na.O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/q2*+1;-6;",[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1,Na2O9Si3Zr,,D10727,,,,,,,,365.452,-3.7716,"Acids; Acids, Noncarboxylic; Anions; Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Electrolytes; Gastric Acid Lowering Agents; Ions; Minerals; Oxides; Oxygen Compounds; Potassium Binder; Potassium-removing Agents; Silicon Compounds"
DB14075,Imidurea,39236-46-9,approved; experimental,ZCTXEAQXZGPWFG-UHFFFAOYSA-N,"InChI=1S/C11H16N8O8/c20-2-18-4(6(22)16-10(18)26)14-8(24)12-1-13-9(25)15-5-7(23)17-11(27)19(5)3-21/h4-5,20-21H,1-3H2,(H2,12,14,24)(H2,13,15,25)(H,16,22,26)(H,17,23,27)",O=C1NC(=O)C(N1CO)NC(=O)NCNC(=O)NC2N(CO)C(=O)NC2=O,C11H16N8O8,,,,,51805,CHEMBL65433,,35067,66981,388.297,-5.047803642,"Cell-mediated Immunity; Increased Histamine Release; Pharmaceutic Aids; Preservatives, Pharmaceutical; Standardized Chemical Allergen"
DB14078,Medronic acid,1984-15-2,approved; investigational,MBKDYNNUVRNNRF-UHFFFAOYSA-N,"InChI=1S/CH6O6P2/c2-8(3,4)1-9(5,6)7/h1H2,(H2,2,3,4)(H2,5,6,7)",OP(=O)(O)CP(=O)(O)O,CH6O6P2,,D04887,,,43945,CHEMBL180570,MDN,15308,50162816,176.0023,-2.35491473,NA
DB14082,Betiatide,103725-47-9,approved; experimental,VDPYMEBVIDZKMD-UHFFFAOYSA-N,"InChI=1S/C15H17N3O6S/c19-11(16-6-12(20)18-8-14(22)23)7-17-13(21)9-25-15(24)10-4-2-1-3-5-10/h1-5H,6-9H2,(H,16,19)(H,17,21)(H,18,20)(H,22,23)",OC(=O)CNC(=O)CNC(=O)CNC(=O)CSC(=O)c1ccccc1,C15H17N3O6S,,,,,136015,CHEMBL3183117,,161231,,367.38,-1.417848017,NA
DB14083,Bisphenol A diglycidyl ether,1675-54-3,approved; experimental,LCFVJGUPQDGYKZ-UHFFFAOYSA-N,"InChI=1S/C21H24O4/c1-21(2,15-3-7-17(8-4-15)22-11-19-13-24-19)16-5-9-18(10-6-16)23-12-20-14-25-20/h3-10,19-20H,11-14H2,1-2H3",C1OC1COc2ccc(cc2)C(C)(C)c3ccc(cc3)OCC4CO4,C21H24O4,C14348,,,,34578,CHEMBL258558,,2199,50241439,340.4129,4.019296765,"Benzene Derivatives; Carcinogens; Cell-mediated Immunity; Ethers; Ethers, Cyclic; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Increased Histamine Release; Macrocyclic Compounds; Noxae; Polycyclic Compounds; Standardized Chemical Allergen; Toxic Actions"
DB14084,Butylparaben,94-26-8,approved; experimental,QFOHBWFCKVYLES-UHFFFAOYSA-N,"InChI=1S/C11H14O3/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7,12H,2-3,8H2,1H3",CCCCOC(=O)c1ccc(O)cc1,C11H14O3,,D01420,,,88542,CHEMBL459008,27K,6916,23448,194.2271,2.997056473,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Cell-mediated Immunity; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Increased Histamine Release; Phenols; Standardized Chemical Allergen"
DB14086,Cianidanol,154-23-4,approved; withdrawn,PFTAWBLQPZVEMU-DZGCQCFKSA-N,"InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15+/m0/s1",Oc1ccc(cc1O)[C@@H](O2)[C@@H](O)Cc(c23)c(O)cc(c3)O,C15H14O6,C06562,,,,15600,CHEMBL311498,KXN,8711,60836,290.2681,1.795107015,"Benzopyrans; Catechin; Chromans; Chromones; Flavonoids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans"
DB14089,Dimercaptosuccinic acid,2418-14-6,approved; experimental,ACTRVOBWPAIOHC-UHFFFAOYSA-N,"InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)",OC(=O)C(S)C(S)C(=O)O,C4H6O4S2,,,,,,CHEMBL28721,,8988,60868,182.218,0.258827046,"Chelating Agents; Compounds used in a research, industrial, or household setting; Metal Chelator"
DB14096,"1,2-icosapentoyl-sn-glycero-3-phosphoserine",,approved; experimental,WQVNGJIIARFEJV-XSLFZJRCSA-N,"InChI=1S/C47H72NO10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39-46(50)58-43(41-56-59(53,54)57-42-44(48)47(51)52)40-55-45(49)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h5-8,11-14,17-20,23-26,29-32,43-44H,3-4,9-10,15-16,21-22,27-28,33-42,48H2,1-2H3,(H,51,52)(H,53,54)/b7-5-,8-6-,13-11-,14-12-,19-17-,20-18-,25-23-,26-24-,31-29-,32-30-/t43-,44+/m1/s1",CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC(COP(=O)(O)OCC(N)C(=O)O)COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC,C47H72NO10P,,,,,,,,32699258,,842.064,9.875408184,NA
DB14099,"1,2-Distearoyllecithin",4539-70-2,approved; experimental,NRJAVPSFFCBXDT-UHFFFAOYSA-N,"InChI=1S/C44H88NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h42H,6-41H2,1-5H3",CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,C44H88NO8P,,,,,,CHEMBL113644,,58655,,790.161,9.892071039,Alcohols; Carbohydrates; Glycerophosphates; Glycerophospholipids; Lipids; Membrane Lipids; Phosphatidic Acids; Phospholipids; Sugar Alcohols; Sugar Phosphates; Triose Sugar Alcohols
DB14101,Soy isoflavones,,approved; experimental,,, ,,,,,,,,,,,NA,NA,NA
DB14104,Linoleic acid,60-33-3,approved; experimental,OYHQOLUKZRVURQ-HZJYTTRNSA-N,"InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-",CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,C18H32O2,C01595,,,,17351,CHEMBL267476,EIC,4444105,22231,280.4455,6.421876794,"Fatty Acids; Fatty Acids, Essential; Fatty Acids, Omega-6; Fatty Acids, Unsaturated; Linoleic Acids; Lipids"
DB14105,"Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)",200880-41-7,approved; experimental,LDWIWSHBGAIIMV-ODZMYOIVSA-M,"InChI=1S/C38H75O10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-37(41)45-33-36(34-47-49(43,44)46-32-35(40)31-39)48-38(42)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h35-36,39-40H,3-34H2,1-2H3,(H,43,44);/q;+1/p-1/t35?,36-;/m1./s1",CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC(O)CO)COC(=O)CCCCCCCCCCCCCCC,C38H74NaO10P,,,,,,,,29763754,,744.964,10.93705152,NA
DB14106,Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate,103694-84-4,approved,WJRFSUVOHUMYAO-UHFFFAOYSA-N,"InChI=1S/4C6H11NO.BF4.Cu/c4*1-6(2,8-4)5-7-3;2-1(3,4)5;/h4*5H2,1-2,4H3;;/q;;;;-1;+1",COC(C)(C)C[N+]#[C-],C24H44BCuF4N4O4,,,,,,,,58827688,,602.99,-1.308232819,NA
DB14109,alpha-Arbutin,84380-01-8,approved; experimental,BJRNKVDFDLYUGJ-ZIQFBCGOSA-N,"InChI=1S/C12H16O7/c13-5-8-9(15)10(16)11(17)12(19-8)18-7-3-1-6(14)2-4-7/h1-4,8-17H,5H2/t8-,9-,10+,11-,12+/m1/s1",OC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)Oc2ccc(O)cc2,C12H16O7,C12079,,,,29710,CHEMBL226495,,139552,,272.253,-0.901952921,NA
DB14110,Butylene glycol,107-88-0,approved; experimental,PUPZLCDOIYMWBV-UHFFFAOYSA-N,"InChI=1S/C4H10O2/c1-4(6)2-3-5/h4-6H,2-3H2,1H3",CC(O)CCO,C4H10O2,,,,,52683,CHEMBL3186475,,13837670,,90.121,-0.732144317,Alcohols; Glycols
DB14116,Silodrate,12408-47-8,approved; experimental,JAUGGEIKQIHSMF-UHFFFAOYSA-N,InChI=1S/2Al.2Mg.3O3Si.H2O.2O/c;;;;3*1-4(2)3;;;/h;;;;;;;1H2;;/q2*+3;2*+2;3*-2;;2*-2,[O-][Si]([O-])=O,Al2H2Mg2O12Si3,,,,,,,,32699010,,380.832,-1.3788,NA
DB14120,Phenylethyl resorcinol,85-27-8,approved; experimental,PQSXNIMHIHYFEE-UHFFFAOYSA-N,"InChI=1S/C14H14O2/c1-10(11-5-3-2-4-6-11)13-8-7-12(15)9-14(13)16/h2-10,15-16H,1H3",c1ccccc1C(C)c2ccc(O)cc2O,C14H14O2,,,,,,CHEMBL3961037,,9346995,240731,214.264,3.744928296,"Benzene Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols"
DB14123,Racementhol,89-78-1,approved; experimental,,, ,,,,,,,,,,,NA,NA,NA
DB14139,Hydroxyethyl ethylcellulose,9004-58-4,approved; experimental,,, ,,,,,,,,,,,NA,NA,"Biopolymers; Carbohydrates; Compounds used in a research, industrial, or household setting; Glucans; Macromolecular Substances; Manufactured Materials; Polymers; Polysaccharides"
DB14141,p-Phenylenediamine,106-50-3,approved; experimental,CBCKQZAAMUWICA-UHFFFAOYSA-N,"InChI=1S/C6H8N2/c7-5-1-2-6(8)4-3-5/h1-4H,7-8H2",Nc1ccc(N)cc1,C6H8N2,C19499,,,,51403,CHEMBL403741,,13835179,,108.144,0.315393908,"Amines; Aniline Compounds; Antigens; Antigens, Bacterial; Azo Compounds; Biological Factors; Cell-mediated Immunity; Coloring Agents; Compounds used in a research, industrial, or household setting; Diamines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Increased Histamine Release; Indicators and Reagents; Laboratory Chemicals; Polyamines; Standardized Chemical Allergen; Tuberculin"
DB14143,Distearyldimonium,14357-21-2,approved; experimental,OGQYPPBGSLZBEG-UHFFFAOYSA-N,"InChI=1S/C38H80N/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h5-38H2,1-4H3/q+1",CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC,C38H80N,,,,,,,,7592,,551.064,11.1235535,"Adjuvants, Immunologic; Amines; Ammonium Compounds; Anti-Infective Agents; Compounds used in a research, industrial, or household setting; Immunologic Factors; Nitrogen Compounds; Onium Compounds; Surface-Active Agents"
DB14150,Chloric acid,7790-93-4,approved; experimental,XTEGARKTQYYJKE-UHFFFAOYSA-N,"InChI=1S/ClHO3/c2-1(3)4/h(H,2,3,4)",O[Cl](=O)=O,ClHO3,C01485,,,,17322,CHEMBL1161633,LCO,18513,,84.459,0.040962168,"Agrochemicals; Anions; Chlorine Compounds; Compounds used in a research, industrial, or household setting; Electrolytes; Herbicides; Ions; Pesticides; Toxic Actions"
DB14151,Phosphorus,7723-14-0,approved; experimental,OAICVXFJPJFONN-UHFFFAOYSA-N,InChI=1S/P,[P],P,,,,,30207,,,4575369,,30.9738,0.3,Elements; Phosphorus
DB14156,Synthetic camphor,76-22-2,approved; experimental,DSSYKIVIOFKYAU-UHFFFAOYSA-N,"InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3",CC12C(C)(C)C(CC1)CC2=O,C10H16O,C18369,,,,36773,CHEMBL15768,,2441,,152.2334,2.55298559,NA
DB14158,Microcrystalline cellulose,9004-34-6,approved; experimental; investigational,,, ,,,,,,,,,,,NA,NA,"Biopolymers; Carbohydrates; Cellulose; Compounds used in a research, industrial, or household setting; Drug Delivery Systems; Drug Therapy; Excipients; Glucans; Macromolecular Substances; Manufactured Materials; Pharmaceutic Aids; Pharmaceutical Preparations; Pharmaceutical Vehicles; Polymers; Polysaccharides; Therapeutics"
DB14159,Oxidronic acid,15468-10-7,approved,HJZKOAYDRQLPME-UHFFFAOYSA-N,"InChI=1S/CH6O7P2/c2-1(9(3,4)5)10(6,7)8/h1-2H,(H2,3,4,5)(H2,6,7,8)",OP(=O)(O)C(O)P(=O)(O)O,CH6O7P2,,,,,134844,CHEMBL1615775,,25412,,192,-1.979410279,Organophosphonates; Organophosphorus Compounds
DB14173,Diazolidinylurea,78491-02-8,approved; experimental,SOROIESOUPGGFO-UHFFFAOYSA-N,"InChI=1S/C8H14N4O7/c13-1-9-7(18)10(2-14)5-6(17)12(4-16)8(19)11(5)3-15/h5,13-16H,1-4H2,(H,9,18)",OCNC(=O)N(CO)C1N(CO)C(=O)N(C1=O)CO,C8H14N4O7,,,,,136014,CHEMBL3187032,,56078,,278.2194,-3.785840898,Cell-mediated Immunity; Increased Histamine Release; Standardized Chemical Allergen
DB14174,Dipentamethylenethiuram disulfide,94-37-1,approved; experimental,KNBRWWCHBRQLNY-UHFFFAOYSA-N,InChI=1S/C12H20N2S4/c15-11(13-7-3-1-4-8-13)17-18-12(16)14-9-5-2-6-10-14/h1-10H2,C1CCCCN1C(=S)SSC(=S)N2CCCCC2,C12H20N2S4,,,,,,CHEMBL121516,,6920,50414948,320.55,4.433259367,"Cell-mediated Immunity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Increased Histamine Release; Standardized Chemical Allergen"
DB14175,alpha-Amyl cinnamaldehyde,122-40-7,approved; experimental,HMKKIXGYKWDQSV-KAMYIIQDSA-N,"InChI=1S/C14H18O/c1-2-3-5-10-14(12-15)11-13-8-6-4-7-9-13/h4,6-9,11-12H,2-3,5,10H2,1H3/b14-11-",CCCCC/C(C=O)=C/c1ccccc1,C14H18O,C12288,,,,32318,CHEMBL1611291,,1361549,,202.2921,4.151295157,Cell-mediated Immunity; Increased Histamine Release; Perfume; Standardized Chemical Allergen
DB14176,Benzylparaben,94-18-8,approved; experimental,MOZDKDIOPSPTBH-UHFFFAOYSA-N,"InChI=1S/C14H12O3/c15-13-8-6-12(7-9-13)14(16)17-10-11-4-2-1-3-5-11/h1-9,15H,10H2",Oc1ccc(cc1)C(=O)OCc2ccccc2,C14H12O3,C14393,D07518,,,34571,CHEMBL447861,,6912,,228.247,3.397630576,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Cell-mediated Immunity; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Increased Histamine Release; Phenols; Standardized Chemical Allergen"
DB14177,Propylparaben,94-13-3,approved; experimental,QELSKZZBTMNZEB-UHFFFAOYSA-N,"InChI=1S/C10H12O3/c1-2-7-13-10(12)8-3-5-9(11)6-4-8/h3-6,11H,2,7H2,1H3",CCCOC(=O)c1ccc(O)cc1,C10H12O3,,D01422,,,32063,CHEMBL194014,36M,6907,70190,180.2005,2.552487808,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Increased Histamine Release; Pharmaceutic Aids; Pharmaceutical Preparations; Phenols; Preservatives, Pharmaceutical; Standardized Chemical Allergen"
DB14178,Tetramethylthiuram monosulfide,97-74-5,approved; experimental,REQPQFUJGGOFQL-UHFFFAOYSA-N,InChI=1S/C6H12N2S3/c1-7(2)5(9)11-6(10)8(3)4/h1-4H3,CN(C)C(=S)SC(=S)N(C)C,C6H12N2S3,,,,,,CHEMBL571700,,7070,50414949,208.36,2.13812856,"Acids, Acyclic; Carbamates; Carboxylic Acids; Cell-mediated Immunity; Dimethyldithiocarbamate; Increased Histamine Release; Standardized Chemical Allergen; Sulfur Compounds; Thiocarbamates"
DB14180,Nickel sulfate,7786-81-4,approved; experimental,LGQLOGILCSXPEA-UHFFFAOYSA-L,"InChI=1S/Ni.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",[O-]S([O-])(=O)=O,NiO4S,,,,,53001,CHEMBL3990696,,22989,,154.756,-0.841552023,"Compounds used in a research, industrial, or household setting; Elements; Irritants; Metals; Metals, Heavy; Noxae; Toxic Actions; Transition Elements"
DB14181,Lanolin alcohols,8027-33-6,approved; experimental,,, ,,,,,,,,,,,NA,NA,Cell-mediated Immunity; Increased Histamine Release; Standardized Chemical Allergen
DB14182,Dichromate,13907-47-6,approved; investigational,SOCTUWSJJQCPFX-UHFFFAOYSA-N,InChI=1S/2Cr.7O/q;;;;;;;2*-1,[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O,Cr2O7,,,,,33141,,,22911,,215.986,-3.7068,"Anions; Caustics; Chromates; Chromium Compounds; Coloring Agents; Compounds used in a research, industrial, or household setting; Electrolytes; Ions; Noxae; Toxic Actions"
DB14183,Geraniol,106-24-1,approved; experimental,GLZPCOQZEFWAFX-JXMROGBWSA-N,"InChI=1S/C10H18O/c1-9(2)5-4-6-10(3)7-8-11/h5,7,11H,4,6,8H2,1-3H3/b10-7+",CC(C)=CCC/C(C)=C/CO,C10H18O,C01500,,,,17447,CHEMBL25719,64Z,13849989,50037023,154.253,2.502383296,Cell-mediated Immunity; Hydrocarbons; Increased Histamine Release; Standardized Chemical Allergen
DB14184,Cinnamaldehyde,14371-10-9,approved; experimental,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,InChI=1S/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4+,O=C/C=C/c1ccccc1,C9H8O,C00903,,,,16731,CHEMBL293492,9Y6,553117,50203065,132.1592,1.977470008,"Aldehydes; Antimutagenic Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Drugs that are Mainly Renally Excreted; Flavoring Agents; Food; Food Additives; Food and Beverages; Food Ingredients; Increased Histamine Release; Pharmaceutic Aids; Pharmaceutical Preparations; Physiological Phenomena; Protective Agents; Standardized Chemical Allergen"
DB14185,Aripiprazole lauroxil,1259305-29-7,approved; investigational,DDINXHAORAAYAD-UHFFFAOYSA-N,"InChI=1S/C36H51Cl2N3O4/c1-2-3-4-5-6-7-8-9-10-16-35(43)45-28-41-33-27-30(19-17-29(33)18-20-34(41)42)44-26-12-11-21-39-22-24-40(25-23-39)32-15-13-14-31(37)36(32)38/h13-15,17,19,27H,2-12,16,18,20-26,28H2,1H3",CCCCCCCCCCCC(=O)OCN1C(=O)CCc(c12)ccc(c2)OCCCCN3CCN(CC3)c4c(Cl)c(Cl)ccc4,C36H51Cl2N3O4,,D10364,,,90930,CHEMBL2219425,,28651973,,660.72,9.328087901,"Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents that produce hypertension; Antidepressive Agents; Antipsychotic Agents; Aripiprazole and prodrugs; Central Nervous System Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Histamine Antagonists; Histamine H1 Antagonists; Neurotoxic agents; Piperazines; Potential QTc-Prolonging Agents; Psychotropic Drugs; QTc Prolonging Agents; Quinolines; Quinolones; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT2A Receptor Antagonists; Serotonin Agents; Serotonin Receptor Antagonists; Tranquilizing Agents"
DB14186,Cinnamyl alcohol,4407-36-7,approved; experimental,OOCCDEMITAIZTP-QPJJXVBHSA-N,"InChI=1S/C9H10O/c10-8-4-7-9-5-2-1-3-6-9/h1-7,10H,8H2/b7-4+",OC/C=C/c1ccccc1,C9H10O,C02394,,,,33227,CHEMBL324794,,21105870,50310446,134.1751,1.815811722,Alcohols; Cell-mediated Immunity; Drugs that are Mainly Renally Excreted; Increased Histamine Release; Standardized Chemical Allergen
DB14187,Hydroxycitronellal,107-75-5,approved; experimental,WPFVBOQKRVRMJB-UHFFFAOYSA-N,"InChI=1S/C10H20O2/c1-9(6-8-11)5-4-7-10(2,3)12/h8-9,12H,4-7H2,1-3H3",O=CCC(C)CCCC(C)(C)O,C10H20O2,,,,,53459,CHEMBL3186027,,7600,,172.2646,1.644340713,Cell-mediated Immunity; Hydrocarbons; Increased Histamine Release; Perfume; Standardized Chemical Allergen
DB14188,Isoeugenol,97-54-1,approved; experimental,BJIOGJUNALELMI-UHFFFAOYSA-N,"InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3-7,11H,1-2H3",COc1cc(/C=C/C)ccc1O,C10H12O2,C10469,,,,18224,CHEMBL2135887,,7061,,164.204,2.635346291,"Acids, Carbocyclic; Caffeic Acids; Carboxylic Acids; Cell-mediated Immunity; Cinnamates; Increased Histamine Release; Standardized Chemical Allergen"
DB14189,Ethylenediamine,107-15-3,approved; experimental,PIICEJLVQHRZGT-UHFFFAOYSA-N,InChI=1S/C2H8N2/c3-1-2-4/h1-4H2,NCCN,C2H8N2,,D01114,,,30347,CHEMBL816,EDN,13835550,7972,60.0983,-1.422442674,"Allergens; Amines; Cell-mediated Immunity; Dermatitis, Contact; Diamines; Increased Histamine Release; Polyamines; Standardized Chemical Allergen"
DB14190,P-Tert-Butylphenol-Formaldehyde Resin (Low Molecular Weight),,approved; experimental,,, ,,,,,,,,,,,NA,NA,Cell-mediated Immunity; Increased Histamine Release; Standardized Chemical Allergen
DB14191,Diphenylguanidine,102-06-7,approved; experimental,OWRCNXZUPFZXOS-UHFFFAOYSA-N,"InChI=1S/C13H13N3/c14-13(15-11-7-3-1-4-8-11)16-12-9-5-2-6-10-12/h1-10H,(H3,14,15,16)",c1ccccc1NC(=N)Nc2ccccc2,C13H13N3,,,,,144319,CHEMBL77675,,7313,50010769,211.268,3.131316674,Amidines; Cell-mediated Immunity; Increased Histamine Release; Standardized Chemical Allergen
DB14192,"N,N'-diphenyl-1,4-phenylenediamine",74-31-7,approved; experimental,,, ,,,,,,,,,,,NA,NA,"Amines; Aniline Compounds; Antioxidants; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Diamines; Increased Histamine Release; Polyamines; Protective Agents; Standardized Chemical Allergen"
DB14193,Ditiocarb zinc,14324-55-1,approved,RKQOSDAEEGPRER-UHFFFAOYSA-L,"InChI=1S/2C5H11NS2.Zn/c2*1-3-6(4-2)5(7)8;/h2*3-4H2,1-2H3,(H,7,8);/q;;+2/p-2",CCN(C([S-])=S)CC,C10H20N2S4Zn,,,,,144351,CHEMBL3182813,,24810,,361.948,2.00746073,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Allergens; Cardiovascular System; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Increased Histamine Release; Metal cations; Metal divalent cations; Standardized Chemical Allergen; Vasoprotectives; Zinc Compounds"
DB14194,Zinc dibutyldithiocarbamate,136-23-2,approved; experimental,BOXSVZNGTQTENJ-UHFFFAOYSA-L,"InChI=1S/2C9H19NS2.Zn/c2*1-3-5-7-10(9(11)12)8-6-4-2;/h2*3-8H2,1-2H3,(H,11,12);/q;;+2/p-2",CCCCN(C([S-])=S)CCCC,C18H36N2S4Zn,,,,,144323,CHEMBL2373108,,8360,,474.12,3.94164285,"Acids, Acyclic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Carbamates; Carboxylic Acids; Cardiovascular System; Cell-mediated Immunity; Increased Histamine Release; Metal cations; Metal divalent cations; Standardized Chemical Allergen; Sulfur Compounds; Vasoprotectives; Zinc Compounds"
DB14195,4-(Isopropylamino)diphenylamine,101-72-4,approved; experimental,OUBMGJOQLXMSNT-UHFFFAOYSA-N,"InChI=1S/C15H18N2/c1-12(2)16-14-8-10-15(11-9-14)17-13-6-4-3-5-7-13/h3-12,16-17H,1-2H3",CC(C)Nc1ccc(cc1)Nc2ccccc2,C15H18N2,,,,,63569,CHEMBL1449018,,7292,,226.323,3.659332698,"Amines; Aniline Compounds; Antioxidants; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Diamines; Increased Histamine Release; Polyamines; Protective Agents; Standardized Chemical Allergen"
DB14196,"N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine",101-87-1,approved,ZRMMVODKVLXCBB-UHFFFAOYSA-N,"InChI=1S/C18H22N2/c1-3-7-15(8-4-1)19-17-11-13-18(14-12-17)20-16-9-5-2-6-10-16/h1,3-4,7-8,11-14,16,19-20H,2,5-6,9-10H2",C1CCCCC1Nc2ccc(cc2)Nc3ccccc3,C18H22N2,,,,,,,,83143,,266.388,4.68522025,Amines; Aniline Compounds; Cell-mediated Immunity; Diamines; Increased Histamine Release; Polyamines; Standardized Chemical Allergen
DB14197,Methylchloroisothiazolinone,26172-55-4,approved; experimental,DHNRXBZYEKSXIM-UHFFFAOYSA-N,"InChI=1S/C4H4ClNOS/c1-6-4(7)2-3(5)8-6/h2H,1H3",Cn1sc(Cl)cc1=O,C4H4ClNOS,,,,,53621,CHEMBL1738962,,30800,,149.59,1.351312403,"Anti-Infective Agents; Azoles; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Disinfectants; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Increased Histamine Release; Preservatives, Pharmaceutical; Standardized Chemical Allergen; Sulfur Compounds"
DB14198,Quaternium-15,4080-31-3,approved; experimental,UKHVLWKBNNSRRR-UHFFFAOYSA-M,"InChI=1S/C9H16ClN4.ClH/c10-2-1-3-14-7-11-4-12(8-14)6-13(5-11)9-14;/h1-2H,3-9H2;1H/q+1;/p-1",Cl/C=C/C[N+]12CN3CN(C1)CN(C3)C2,C9H16Cl2N4,,,,,59607,,,23621565,,251.156,-2.721755409,"Amines; Bridged Compounds; Cell-mediated Immunity; Cycloparaffins; Hydrocarbons; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Increased Histamine Release; Macrocyclic Compounds; Polyamines; Polycyclic Compounds; Preservatives, Pharmaceutical; Standardized Chemical Allergen"
DB14199,Bromothalonil,35691-65-7,approved; experimental,DHVLDKHFGIVEIP-UHFFFAOYSA-N,"InChI=1S/C6H6Br2N2/c7-4-6(8,5-10)2-1-3-9/h1-2,4H2",BrCC(Br)(C#N)CCC#N,C6H6Br2N2,,,,,62823,CHEMBL3188084,,55806,,265.936,1.756947667,"Allergens; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Increased Histamine Release; Pharmaceutic Aids; Pharmaceutical Preparations; Preservatives, Pharmaceutical; Standardized Chemical Allergen"
DB14200,Thiohexam,95-33-0,approved; experimental,DEQZTKGFXNUBJL-UHFFFAOYSA-N,"InChI=1S/C13H16N2S2/c1-2-6-10(7-3-1)15-17-13-14-11-8-4-5-9-12(11)16-13/h4-5,8-10,15H,1-3,6-7H2",C1CCCCC1NSc(s2)nc(c23)cccc3,C13H16N2S2,,,,,,CHEMBL1591074,,6962,,264.41,4.617399854,"Azoles; Cell-mediated Immunity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Increased Histamine Release; Standardized Chemical Allergen; Sulfur Compounds; Thiazoles"
DB14201,"2,2'-Dibenzothiazyl disulfide",120-78-5,approved; experimental,AFZSMODLJJCVPP-UHFFFAOYSA-N,InChI=1S/C14H8N2S4/c1-3-7-11-9(5-1)15-13(17-11)19-20-14-16-10-6-2-4-8-12(10)18-14/h1-8H,c1cccc(c12)nc(s2)SSc(s3)nc(c34)cccc4,C14H8N2S4,,,,,53239,CHEMBL508112,,8139,50444458,332.47,6.222696859,"Azoles; Cell-mediated Immunity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Increased Histamine Release; Latex Hypersensitivity; Standardized Chemical Allergen; Sulfur Compounds; Thiazoles"
DB14202,Morpholinylmercaptobenzothiazole,102-77-2,approved; experimental,MHKLKWCYGIBEQF-UHFFFAOYSA-N,"InChI=1S/C11H12N2OS2/c1-2-4-10-9(3-1)12-11(15-10)16-13-5-7-14-8-6-13/h1-4H,5-8H2",C1COCCN1Sc(s2)nc(c23)cccc3,C11H12N2OS2,,,,,,CHEMBL1530581,,7337,,252.35,2.541722955,"Azoles; Cell-mediated Immunity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Increased Histamine Release; Oxazines; Standardized Chemical Allergen; Sulfur Compounds; Thiazoles"
DB14203,Disperse Blue 106,68516-81-4,approved; experimental,UIHYHADQHHUIOF-WUKNDPDISA-N,"InChI=1S/C14H17N5O3S/c1-3-18(6-7-20)11-4-5-12(10(2)8-11)16-17-14-15-9-13(23-14)19(21)22/h4-5,8-9,20H,3,6-7H2,1-2H3/b17-16+",OCCN(CC)c1ccc(c(C)c1)/N=N/c2ncc(s2)N(=O)=O,C14H17N5O3S,,,,,,,,97163,,335.38,4.116333626,Allergens; Cell-mediated Immunity; Increased Histamine Release; Standardized Chemical Allergen
DB14206,Cobalt chloride,7646-79-9,approved; experimental,GVPFVAHMJGGAJG-UHFFFAOYSA-L,InChI=1S/2ClH.Co/h2*1H;/q;;+2/p-2,[Cl-],Cl2Co,,,,,35696,,,22708,,129.839,0.612338722,"Antimutagenic Agents; Compounds used in a research, industrial, or household setting; Elements; Metals; Metals, Heavy; Protective Agents; Transition Elements"
DB14212,Methylparaben,99-76-3,approved,LXCFILQKKLGQFO-UHFFFAOYSA-N,"InChI=1S/C8H8O3/c1-11-8(10)6-2-4-7(9)5-3-6/h2-5,9H,1H3",COC(=O)c1ccc(O)cc1,C8H8O3,,D01400,,,31835,CHEMBL325372,MPB,7176,50209100,152.1473,1.673157458,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Cell-mediated Immunity; Compounds used in a research, industrial, or household setting; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Increased Histamine Release; Pharmaceutic Aids; Pharmaceutical Preparations; Phenols; Preservatives, Pharmaceutical; Standardized Chemical Allergen"
DB14476,DL-alpha-Tocopherol,10191-41-0,approved; experimental; investigational,GVJHHUAWPYXKBD-UHFFFAOYSA-N,"InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3",CC(C)CCCC(C)CCCC(C)CCCC(O1)(C)CCc(c12)c(C)c(O)c(C)c2C,C29H50O2,,,,,93909,CHEMBL49563,,2032,50436220,430.717,10.50771726,Vitamin E; Vitamins; Vitamins (Fat Soluble)
DB14477,DL-alpha tocopheryl acetate,52225-20-4,approved; experimental,,, ,,,,,,,,,,,NA,NA,NA
DB14478,Povidone K30,9003-39-8,approved; experimental,,, ,,,,,,,,,,,NA,NA,NA
DB14481,Calcium phosphate dihydrate,7789-77-7,approved,XAAHAAMILDNBPS-UHFFFAOYSA-L,"InChI=1S/Ca.H3O4P.2H2O/c;1-5(2,3)4;;/h;(H3,1,2,3,4);2*1H2/q+2;;;/p-2",OP([O-])([O-])=O,CaH5O6P,,,,,4496,,,94606,,172.086,-1.020103823,"Acids; Acids, Noncarboxylic; Anions; Calcium Compounds; Electrolytes; Ions; Phosphate salts; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds"
DB14482,Sodium ascorbate,134-03-2,approved; nutraceutical,PPASLZSBLFJQEF-RXSVEWSESA-M,"InChI=1S/C6H8O6.Na/c7-1-2(8)5-3(9)4(10)6(11)12-5;/h2,5,7-10H,1H2;/q;+1/p-1/t2-,5+;/m0./s1",OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-],C6H7NaO6,,D05853,,,113451,CHEMBL591665,,16736174,,198.106,-1.913558876,"Compounds used in a research, industrial, or household setting; Laxatives; Osmotic Laxatives; Urinary Acidifying Agents; Vitamin C and analogues; Vitamins"
DB14483,Calcium ascorbate,5743-27-1,approved; nutraceutical,BLORRZQTHNGFTI-ZZMNMWMASA-L,"InChI=1S/2C6H8O6.Ca/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1",OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-],C12H14CaO12,,,,,,CHEMBL2146095,,22900989,,390.31,-1.913558876,"Acids, Acyclic; Antioxidants; Carbohydrates; Carboxylic Acids; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Hydroxy Acids; Micronutrients; Physiological Phenomena; Protective Agents; Sugar Acids; Urinary Acidifying Agents; Vitamin C and analogues; Vitamins"
DB14484,Magnesium ascorbate,15431-40-0,approved; nutraceutical,AIOKQVJVNPDJKA-ZZMNMWMASA-L,"InChI=1S/2C6H8O6.Mg/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1",OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-],C12H14MgO12,,,,,,,,17339241,,374.537,-1.913558876,"Compounds used in a research, industrial, or household setting; Urinary Acidifying Agents"
DB14485,Zinc ascorbate,331242-75-2,approved; nutraceutical,WWRJFSIRMWUMAE-ZZMNMWMASA-L,"InChI=1S/2C6H8O6.Zn/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1",OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-],C12H14O12Zn,,,,,,,,34988958,,415.61,-1.913558876,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Cardiovascular System; Metal cations; Metal divalent cations; Polyvalent cation containing laxatives, antacids, oral supplements; Urinary Acidifying Agents; Vasoprotectives; Vitamin C and analogues; Vitamins; Zinc Compounds"
DB14486,Niacinamide ascorbate,1987-71-9,approved; nutraceutical,JMORAWFVNMGOKQ-MGMRMFRLSA-N,"InChI=1S/C6H6N2O.C6H8O6/c7-6(9)5-2-1-3-8-4-5;7-1-2(8)5-3(9)4(10)6(11)12-5/h1-4H,(H2,7,9);2,5,7-10H,1H2/t;2-,5+/m.0/s1",OCC(O)[C@H]1OC(=O)C(O)=C1O,C12H14N2O7,,,,,,,,18895044,,298.251,-1.913558876,Urinary Acidifying Agents; Vitamin C and analogues; Vitamins
DB14487,Zinc acetate,557-34-6,approved; investigational,DJWUNCQRNNEAKC-UHFFFAOYSA-L,"InChI=1S/2C2H4O2.Zn/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2",CC([O-])=O,C4H6O4Zn,,,,,62984,CHEMBL1200928,,10719,,183.497,-0.223345714,"Acetates; Acids, Acyclic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Alimentary Tract and Metabolism; Carboxylic Acids; Cardiovascular System; Copper Absorption Inhibitor; Fatty Acids; Fatty Acids, Volatile; Lipids; Metal cations; Metal divalent cations; Various Alimentary Tract and Metabolism Products; Vasoprotectives; Zinc Compounds"
DB14488,Ferrous gluconate,299-29-6,approved,VRIVJOXICYMTAG-IYEMJOQQSA-L,"InChI=1S/2C6H12O7.Fe/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,C12H22FeO14,,,9291,,,,,19953133,,446.139,-3.409744311,"Anemia, Iron-Deficiency; Antianemia Drugs; Antianemic Preparations; Blood and Blood Forming Organs; Hematinics; Hematologic Agents; Iron Bivalent, Oral Preparations; Iron Compounds; Iron Preparations; Minerals; Organometallic Compounds; Polyvalent cation containing laxatives, antacids, oral supplements"
DB14489,Ferrous succinate,10030-90-7,approved,MDXRFOWKIZPNTA-UHFFFAOYSA-L,"InChI=1S/C4H6O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H2,(H,5,6)(H,7,8);/q;+2/p-2",[O-]C(=O)CCC([O-])=O,C4H4FeO4,,,159252,,,,,8640173,,171.917,-0.398482967,"Antianemic Preparations; Blood and Blood Forming Organs; Hematinics; Hematologic Agents; Iron Bivalent, Oral Preparations; Iron Compounds; Iron Preparations; Organometallic Compounds"
DB14490,Ferrous ascorbate,24808-52-4,approved,RFBYLSCVRUTUSB-ZZMNMWMASA-L,"InChI=1S/2C6H8O6.Fe/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1",OC[C@H](O)[C@H]1OC(=O)C(O)=C1O,C12H14FeO12,,,54710214,,,,,21169558,,406.077,-1.913558876,"Antianemic Preparations; Blood and Blood Forming Organs; Compounds used in a research, industrial, or household setting; Iron Bivalent, Oral Preparations; Iron Preparations; Polyvalent cation containing laxatives, antacids, oral supplements; Urinary Acidifying Agents"
DB14491,Ferrous fumarate,141-01-5,approved,PMVSDNDAUGGCCE-TYYBGVCCSA-L,"InChI=1S/C4H4O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H,(H,5,6)(H,7,8);/q;+2/p-2/b2-1+;",[O-]C(=O)/C=C/C([O-])=O,C4H2FeO4,,,6433164,,31607,CHEMBL1200640,,10607713,,169.901,-0.040914331,"Antianemic Preparations; Blood and Blood Forming Organs; Diet, Food, and Nutrition; Food; Food and Beverages; Growth Substances; Iron Bivalent, Oral Preparations; Iron Compounds; Iron Preparations; Micronutrients; Minerals; Organometallic Compounds; Physiological Phenomena; Trace Elements"
DB14496,Sodium molybdate,7631-95-0,approved; experimental,TVXXNOYZHKPKGW-UHFFFAOYSA-N,InChI=1S/Mo.2Na.4O/q;2*+1;;;2*-1,[O-][Mo]([O-])(=O)=O,MoNa2O4,C15455,,,,75215,,,55350,,205.93,-1.7752,"Elements; Metals; Metals, Heavy; Transition Elements"
DB14498,Potassium acetate,127-08-2,approved; investigational,SCVFZCLFOSHCOH-UHFFFAOYSA-M,"InChI=1S/C2H4O2.K/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1",CC([O-])=O,C2H3KO2,C12554,,,,32029,CHEMBL1201058,,29104,,98.1423,-0.223345714,"Acetates; Acids, Acyclic; Agents causing hyperkalemia; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Carboxylic Acids; Drugs that are Mainly Renally Excreted; Electrolyte Solutions; Fatty Acids; Fatty Acids, Volatile; I.V. Solution Additives; Lipids; Potassium Compounds; Potassium Salt; Replacement Preparations"
DB14499,Potassium sulfate,7778-80-5,approved; investigational,OTYBMLCTZGSZBG-UHFFFAOYSA-L,"InChI=1S/2K.H2O4S/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2",[O-]S([O-])(=O)=O,K2O4S,C13192,,,,32036,CHEMBL2021424,,22915,,174.259,-0.841552023,"Acids; Acids, Noncarboxylic; Anions; Drugs that are Mainly Renally Excreted; Electrolytes; Ions; Laxatives; Osmotic Laxatives; Potassium Salt; Sulfur Acids; Sulfur Compounds; Sulfuric Acids"
DB14500,Potassium,07-09-7440,approved; experimental,NTTOTNSKUYCDAV-UHFFFAOYSA-N,InChI=1S/K.H,[KH],K,,,,,32589,,,16787786,,39.0983,-0.126,"Agents causing hyperkalemia; Cardiovascular System; Diuretics; Elements; High-Ceiling Diuretics; Low-Ceiling Diuretics, Excl. Thiazides; Metals; Metals, Alkali; Metals, Light; Minerals; Potassium Salt; Replacement Preparations"
DB14501,Ferrous glycine sulfate,14729-84-1,approved,YJYOLOWXCPIBSY-UHFFFAOYSA-L,"InChI=1S/2C2H5NO2.Fe.H2O4S/c2*3-1-2(4)5;;1-5(2,3)4/h2*1,3H2,(H,4,5);;(H2,1,2,3,4)/q;;+2;/p-2",NCC([O-])=O,C4H10FeN2O8S,,,167159,,,CHEMBL3707208,,146251,,302.041,-3.409459573,"Antianemic Preparations; Blood and Blood Forming Organs; Iron Bivalent, Oral Preparations; Iron Preparations"
DB14502,"Sodium phosphate, dibasic",7558-79-4,approved,BNIILDVGGAEEIG-UHFFFAOYSA-L,"InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2",OP([O-])([O-])=O,HNa2O4P,C13558,,,,34683,CHEMBL1060,,22625,,141.9588,-1.020103823,"Acids; Acids, Noncarboxylic; Anions; Electrolytes; Ions; Laxatives; Osmotic Laxatives; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds; Urinary Acidifying Agents"
DB14503,"Sodium phosphate, monobasic, unspecified form",,approved,,, ,,,,,,,,,,,NA,NA,Laxatives; Osmotic Laxatives
DB14504,"Sodium phosphate, dibasic, unspecified form",10140-65-5,approved; experimental,,, ,,,,,,,,,,,NA,NA,Laxatives; Osmotic Laxatives
DB14505,Sodium borate,1330-43-4,approved; experimental,UQGFMSUEHSUPRD-UHFFFAOYSA-N,InChI=1S/B4O7.2Na/c5-1-7-3-9-2(6)10-4(8-1)11-3;;/q-2;2*+1,b12ob([O-])ob(o1)ob(o2)[O-],B4Na2O7,,,,,,,,8395345,,201.219,4.6836,"Acids; Acids, Noncarboxylic; Anions; Anti-Infective Agents; Boric Acids; Boron Compounds; Electrolytes; Ions; Ophthalmologicals; Sensory Organs"
DB14506,Lithium hydroxide,1310-65-2,approved; withdrawn,WMFOQBRAJBCJND-UHFFFAOYSA-M,InChI=1S/Li.H2O/h;1H2/q+1;/p-1,[OH-],HLiO,,,,,33979,,,3802,,23.95,0,Drugs that are Mainly Renally Excreted; Lithium Compounds
DB14507,Lithium citrate,919-16-4,approved,WJSIUCDMWSDDCE-UHFFFAOYSA-K,"InChI=1S/C6H8O7.3Li/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3",[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O,C6H5Li3O7,,,,,64735,CHEMBL1201170,,12932,,209.92,-1.322687452,"Acids, Acyclic; Antidepressive Agents; Antimanic Agents; Carboxylic Acids; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Lithium Compounds; Mood Stabilizer; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Neurotoxic agents; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Tricarboxylic Acids"
DB14509,Lithium carbonate,554-13-2,approved,XGZVUEUWXADBQD-UHFFFAOYSA-L,"InChI=1S/CH2O3.2Li/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2",[O-]C([O-])=O,CLi2O3,C07964,,,,6504,CHEMBL1200826,,10654,,73.89,0.250051366,"Acids; Acids, Noncarboxylic; Alkalies; Anions; Antidepressive Agents; Antimanic Agents; Carbon Compounds, Inorganic; Carbonates; Carbonic Acid; Central Nervous System Agents; Central Nervous System Depressants; Drugs that are Mainly Renally Excreted; Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index; Electrolytes; Enzyme Inhibitors; Ions; Lithium Compounds; Medications that increase serum magnesium; Mood Stabilizer; Narrow Therapeutic Index Drugs; Nephrotoxic agents; Nervous System; Neurotoxic agents; Psycholeptics; Psychotropic Drugs; QTc Prolonging Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Tranquilizing Agents"
DB14512,Mometasone furoate,83919-23-7,approved; investigational; vet_approved,WOFMFGQZHJDGCX-ZULDAHANSA-N,"InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@]2(Cl)[C@@H](O)C[C@@]4(C)[C@H]3C[C@@H](C)[C@@]4(C(=O)CCl)OC(=O)c5ccco5,C27H30Cl2O6,C07817,D00690,,,47564,CHEMBL1161,MOF,390091,50148733,521.429,5.05520811,"Adrenal Cortex Hormones; Adrenals; Adrenergics, Inhalants; Anti-Allergic Agents; Anti-Inflammatory Agents; Corticosteroids; Corticosteroids for inhalation use; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dermatologicals; Drugs for Obstructive Airway Diseases; Fused-Ring Compounds; Glucocorticoids; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Nasal Preparations; Polycyclic Compounds; Pregnadienes; Respiratory System; Steroids; Thyroxine-binding globulin inhibitors"
DB14513,Magnesium,7439-95-4,approved; experimental; investigational,RSHAOIXHUHAZPM-UHFFFAOYSA-N,InChI=1S/Mg.2H,[MgH2],H2Mg,,,,,,CHEMBL2146125,,16787263,,26.321,-1.402,"Calculi Dissolution Agent; Elements; Laxatives; Magnesium Compounds; Metal cations; Metal divalent cations; Metals; Metals, Alkaline Earth; Metals, Light; Minerals; Osmotic Laxatives"
DB14517,Aluminium phosphate,7784-30-7,approved; investigational,ILRRQNADMUWWFW-UHFFFAOYSA-K,"InChI=1S/Al.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+3;/p-3",[O-]P([O-])([O-])=O,AlO4P,,,,,,CHEMBL3833315,,58204,,121.9529,-1.020103823,"Acids; Acids, Noncarboxylic; Adjuvants, Immunologic; Alimentary Tract and Metabolism; Aluminium Compounds; Aluminum and magnesium containing antacids; Anions; Antacids; Drugs for Acid Related Disorders; Electrolytes; Gastric Acid Lowering Agents; Gastrointestinal Agents; Immunologic Factors; Ions; Metal cations; Metal divalent cations; Phosphoric Acids; Phosphorus Acids; Phosphorus Compounds"
DB14518,Aluminum acetate,139-12-8,approved; investigational,WCOATMADISNSBV-UHFFFAOYSA-K,"InChI=1S/3C2H4O2.Al/c3*1-2(3)4;/h3*1H3,(H,3,4);/q;;;+3/p-3",CC([O-])=O,C6H9AlO6,,,,,,CHEMBL1201015,,8427,,204.1136,-0.223345714,"Acids, Acyclic; Carboxylic Acids; Fatty Acids; Fatty Acids, Volatile; Lipids"
DB14520,Tetraferric tricitrate decahydrate,,approved,UISKQNNAQKPSDO-UHFFFAOYSA-E,"InChI=1S/3C6H7O7.4Fe.10H2O/c3*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;;;;;;;;/h3*1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;10*1H2/q3*-1;4*+3;;;;;;;;;;/p-9",[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O,C18H32Fe4O31,,,,,,CHEMBL3301597,,34993203,,967.803,-1.322687452,"Anemia, Iron-Deficiency; Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Iron Compounds; Organometallic Compounds; Phosphate Binder"
DB14527,Chromic nitrate,13548-38-4,approved,PHFQLYPOURZARY-UHFFFAOYSA-N,InChI=1S/Cr.3NO3/c;3*2-1(3)4/q+3;3*-1,[O-][N+]([O-])=O,CrN3O9,,,,,86204,,,23000,,238.0108,-2.574421943,"Acids; Acids, Noncarboxylic; Anions; Drugs that are Mainly Renally Excreted; Electrolytes; Ions; Nitric Acid; Nitrogen Compounds"
DB14528,Chromium gluconate,33661-40-4,approved,ANPGUZATXCGJJH-OPDGVEILSA-K,"InChI=1S/3C6H12O7.Cr/c3*7-1-2(8)3(9)4(10)5(11)6(12)13;/h3*2-5,7-11H,1H2,(H,12,13);/q;;;+3/p-3/t3*2-,3-,4+,5-;/m111./s1",OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,C18H33CrO21,,,,,,,,32701256,,637.437,-3.409744311,Drugs that are Mainly Renally Excreted
DB14529,Chromium nicotinate,64452-96-6,approved; experimental,MSPQQAUTCRWLGR-UHFFFAOYSA-K,"InChI=1S/3C6H5NO2.Cr/c3*8-6(9)5-2-1-3-7-4-5;/h3*1-4H,(H,8,9);/q;;;+3/p-3",[O-]C(=O)c1cnccc1,C18H12CrN3O6,,,,,50368,,,8085563,,418.305,-0.166445648,Drugs that are Mainly Renally Excreted; Nicotinic Acids
DB14530,Chromous sulfate,13825-86-0,approved,RYPRIXSYXLDSOA-UHFFFAOYSA-L,"InChI=1S/Cr.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",[O-]S([O-])(=O)=O,CrO4S,,,,,,,,55589,,148.05,-0.841552023,Drugs that are Mainly Renally Excreted
DB14533,Zinc chloride,7646-85-7,approved; investigational,JIAARYAFYJHUJI-UHFFFAOYSA-L,InChI=1S/2ClH.Zn/h2*1H;/q;;+2/p-2,[Cl-],Cl2Zn,,,,,49976,CHEMBL1200679,,5525,,136.315,0.612338722,"Acids; Acids, Noncarboxylic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Anions; Basic Ointments and Protectants; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Cardiovascular System; Chlorine Compounds; Compounds used in a research, industrial, or household setting; Copper Absorption Inhibitor; Cosmetics; Dental Agents; EENT Drugs, Miscellaneous; Electrolyte Solutions; Electrolytes; Household Products; I.V. Solution Additives; Ions; Manufactured Materials; Metal cations; Metal divalent cations; Mouthwashes; Skin Ulcer, drug therapy; Vasoprotectives; Zinc Compounds"
DB14539,Hydrocortisone acetate,50-03-3,approved; vet_approved,ALEXXDVDDISNDU-JZYPGELDSA-N,"InChI=1S/C23H32O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-18,20,26,28H,4-9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COC(=O)C,C23H32O6,C02821,D00165,5744,,17609,CHEMBL1091,,5542,,404.4966,1.716291845,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Administration, Topical; Adrenal Cortex Hormones; Aerosols; Anti-Inflammatory Agents; Corticosteroids; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocortisone and derivatives; Hydroxycorticosteroids; Immunosuppressive Agents; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids"
DB14540,Hydrocortisone butyrate,13609-67-1,approved; vet_approved,BMCQMVFGOVHVNG-TUFAYURCSA-N,,C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@@]4(C(=O)CO)OC(=O)CCC,C25H36O6,,D01619,,,31674,CHEMBL1683,,24344,323672,432.557,2.861396357,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Administration, Topical; Adrenal Cortex Hormones; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Moderately Potent (Group II); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocortisone and derivatives; Hydroxycorticosteroids; Immunosuppressive Agents; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids"
DB14541,Hydrocortisone cypionate,508-99-6,approved; investigational; vet_approved,DLVOSEUFIRPIRM-KAQKJVHQSA-N,"InChI=1S/C29H42O6/c1-27-13-11-20(30)15-19(27)8-9-21-22-12-14-29(34,28(22,2)16-23(31)26(21)27)24(32)17-35-25(33)10-7-18-5-3-4-6-18/h15,18,21-23,26,31,34H,3-14,16-17H2,1-2H3/t21-,22-,23-,26+,27-,28-,29-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COC(=O)CCC5CCCC5,C29H42O6,C08176,D00976,,,5783,CHEMBL1549,,193884,50371265,486.649,4.018395546,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Corticosteroids; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocortisone and derivatives; Hydroxycorticosteroids; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids"
DB14542,Hydrocortisone phosphate,3863-59-0,approved; vet_approved,BGSOJVFOEQLVMH-VWUMJDOOSA-N,"InChI=1S/C21H31O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25H,3-8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COP(=O)(O)O,C21H31O8P,,,,,68634,CHEMBL1641,,390143,,442.445,1.151600403,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocortisone and derivatives; Hydroxycorticosteroids; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids"
DB14543,Hydrocortisone probutate,72590-77-3,approved; vet_approved,FOGXJPFPZOHSQS-AYVLZSQQSA-N,"InChI=1S/C28H40O7/c1-5-7-24(33)35-28(22(31)16-34-23(32)6-2)13-11-20-19-9-8-17-14-18(29)10-12-26(17,3)25(19)21(30)15-27(20,28)4/h14,19-21,25,30H,5-13,15-16H2,1-4H3/t19-,20-,21-,25+,26-,27-,28-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(OC(=O)CCC)C(=O)COC(=O)CC,C28H40O7,C13358,D01886,636398,,31675,CHEMBL1200953,,552186,,488.613,4.003057614,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Moderately Potent (Group II); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Dermatologicals; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocortisone and derivatives; Hydroxycorticosteroids; Immunosuppressive Agents; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids"
DB14544,Hydrocortisone valerate,57524-89-7,approved; vet_approved,FZCHYNWYXKICIO-FZNHGJLXSA-N,"InChI=1S/C26H38O6/c1-4-5-6-22(31)32-26(21(30)15-27)12-10-19-18-8-7-16-13-17(28)9-11-24(16,2)23(18)20(29)14-25(19,26)3/h13,18-20,23,27,29H,4-12,14-15H2,1-3H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@@]4(C(=O)CO)OC(=O)CCCC,C26H38O6,,,5282494,,50865,CHEMBL1200562,,4445635,,446.5763,3.305965022,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocortisone and derivatives; Hydroxycorticosteroids; Immunosuppressive Agents; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids"
DB14545,Hydrocortisone succinate,2203-97-6,approved,VWQWXZAWFPZJDA-CGVGKPPMSA-N,"InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1",C1CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COC(=O)CCC(=O)O,C25H34O8,,D01442,,,31677,CHEMBL977,,15760,50016931,462.539,1.541154592,"11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocortisone and derivatives; Hydroxycorticosteroids; Immunosuppressive Agents; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids"
DB14548,"Zinc sulfate, unspecified form",,approved; experimental,,, ,,,,,,,,,,,NA,NA,Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Cardiovascular System; Copper Absorption Inhibitor; Metal cations; Metal divalent cations; Vasoprotectives; Zinc Compounds
DB14550,Gallium chloride Ga-67,,approved,UPWPDUACHOATKO-MPZFSRPWSA-K,InChI=1S/3ClH.Ga/h3*1H;/q;;;+3/p-3/i;;;1-3,[Cl-],Cl3Ga,,,,,,,,32699043,,173.28,0,NA
DB14554,Dotatate,177943-88-3,approved; experimental,QVFLVLMYXXNJDT-CSBVGUNJSA-N,"InChI=1S/C65H90N14O19S2/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98)/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+/m1/s1",NCCCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)CSSC[C@@H](C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(=O)N1)Cc3c[nH]c(c34)cccc4)NC(=O)[C@@H](Cc5ccccc5)NC(=O)CN6CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC6)CC(=O)O,C65H90N14O19S2,,,,,,CHEMBL441920,,9345959,50165166,1435.63,-8.351902509,Radioactive Diagnostic Agent
DB14567,Brown iron oxide,52357-70-7,approved; experimental,,, ,,,,,,,,,,,NA,NA,NA
DB14568,Ivosidenib,1448347-49-6,approved; investigational,WIJZXSAJMHAVGX-DHLKQENFSA-N,"InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1",FC1(F)CC(C1)NC(=O)[C@H](c2c(Cl)cccc2)N(c3cc(F)cnc3)C(=O)[C@@H]4CCC(=O)N4c5nccc(c5)C#N,C28H22ClF3N6O3,,,,,145430,CHEMBL3989958,,38772333,,582.97,3.012925504,"Amino Acids; Amino Acids, Peptides, and Proteins; Antineoplastic Agents; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Moderate Risk QTc-Prolonging Agents; OAT3/SLC22A8 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with narrow therapeutic index; QTc Prolonging Agents"
DB14569,Tedizolid,856866-72-3,approved; investigational,XFALPSLJIHVRKE-GFCCVEGCSA-N,"InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1",Cn1nnc(n1)-c2ncc(cc2)-c3c(F)cc(cc3)N4C[C@H](CO)OC4=O,C17H15FN6O3,,D09685,,,82717,CHEMBL1257051,U7V,9409096,,370.344,2.118811395,"Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Azoles; Breast Cancer Resistance Protein Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Oxazoles; Oxazolidinone Antibacterial"
DB14574,Cobalt,7440-48-4,approved; experimental,GUTLYIVDDKVIGB-UHFFFAOYSA-N,InChI=1S/Co,[Co],Co,C19171,,,,27638,,3CO,94547,,58.9332,0.23,"Cell-mediated Immunity; Cobalt; Diet, Food, and Nutrition; Elements; Food; Food and Beverages; Growth Substances; Increased Histamine Release; Metals; Metals, Heavy; Micronutrients; Physiological Phenomena; Standardized Chemical Allergen; Trace Elements; Transition Elements"
DB14575,Eslicarbazepine,104746-04-5,approved,BMPDWHIDQYTSHX-AWEZNQCLSA-N,"InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1",c1cccc(c12)[C@@H](O)Cc3c(N2C(=O)N)cccc3,C15H14N2O2,,,,,,CHEMBL315985,,8057180,,254.2839,1.731740976,"Anticonvulsants; Carboxamide Derivatives; Cardiovascular Agents; Central Nervous System Depressants; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Eslicarbazepine and prodrugs; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Membrane Transport Modulators; Nervous System; Sodium Channel Blockers; UGT1A1 Substrates; Voltage-Gated Sodium Channel Blockers"
DB14583,Segesterone acetate,7759-35-5,approved; experimental; investigational,CKFBRGLGTWAVLG-GOMYTPFNSA-N,"InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1",CC(=O)O[C@]1(C(=O)C)C(=C)C[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@@H]4C(CC3)=CC(=O)CC4,C23H30O4,,,,,135563,CHEMBL3707377,,97161,,370.489,3.637538313,"Adrenal Cortex Hormones; Contraceptive Agents, Female; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Drug Implants; Fused-Ring Compounds; Hormonal Contraceptives for Systemic Use; Intravaginal Contraceptives; Norpregnanes; Norpregnenes; Norsteroids; Polycyclic Compounds; Reproductive Control Agents; Steroids"
DB14586,Citrus bioflavonoids,12002-36-7,approved; experimental,,, ,,,,,,,,,,,NA,NA,"Benzopyrans; Chromones; Flavonoids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pyrans"
DB00873,Loteprednol,129260-79-3,approved; experimental,YPZVAYHNBBHPTO-MXRBDKCISA-N,"InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1",ClCOC(=O)[C@@]1(O)CC[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)[C@]4(C)C(CC3)=CC(=O)C=C4,C21H27ClO5,,,,,50848,,,8041134,,394.889,2.520263464,Adrenal Cortex Hormones; Androstadienes; Androstanes; Androstenes; Anti-Allergic Agents; Anti-Inflammatory Agents; Corticosteroid Hormone Receptor Agonists; Corticosteroids; Fused-Ring Compounds; Ophthalmologicals; Polycyclic Compounds; Sensory Organs; Steroids
DB14598,Edetate calcium disodium anhydrous,62-33-9,approved,SHWNNYZBHZIQQV-UHFFFAOYSA-J,"InChI=1S/C10H16N2O8.Ca.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;/q;+2;2*+1/p-4",[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O,C10H12CaN2Na2O8,,,6109,,4757,CHEMBL1200375,,5883,,374.268,-4.92467029,"Anticoagulants; Calcium Chelating Activity; Calcium Chelating Agents; Chelating Activity; Chelating Agents; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Iron Chelating Activity; Iron Chelating Agents; Lead Chelating Activity; Lead Chelator; Metal Chelating Activity; Metal Chelator"
DB14600,Edetate disodium anhydrous,139-33-3,approved; vet_approved,ZGTMUACCHSMWAC-UHFFFAOYSA-L,"InChI=1S/C10H16N2O8.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;/q;2*+1/p-2",OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)O,C10H14N2Na2O8,,D03945,8759,,64734,CHEMBL1749,,8429,,336.2063,-4.92467029,Anticoagulants; Calcium Chelating Activity; Calcium Chelating Agents; Chelating Activity; Chelating Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Iron Chelating Agents; Lead Chelator; Metal Chelator
DB14627,Oxyphenisatin acetate,115-33-3,approved; investigational; withdrawn,PHPUXYRXPHEJDF-UHFFFAOYSA-N,"InChI=1S/C24H19NO5/c1-15(26)29-19-11-7-17(8-12-19)24(18-9-13-20(14-10-18)30-16(2)27)21-5-3-4-6-22(21)25-23(24)28/h3-14H,1-2H3,(H,25,28)",CC(=O)Oc1ccc(cc1)C2(C(=O)Nc(c23)cccc3)c4ccc(cc4)OC(=O)C,C24H19NO5,,,,,135638,CHEMBL1402684,,7971,,401.418,3.653180661,"Gastrointestinal Agents; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Laxatives"
DB14631,Prednisolone phosphate,302-25-0,approved; vet_approved,JDOZJEUDSLGTLU-VWUMJDOOSA-N,"InChI=1S/C21H29O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h5,7,9,14-16,18,23,25H,3-4,6,8,10-11H2,1-2H3,(H2,26,27,28)/t14-,15-,16-,18+,19-,20-,21-/m0/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COP(=O)(O)O,C21H29O8P,,,,,145705,CHEMBL1201231,,65064,,440.429,1.149423893,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OAT3/SLC22A8 Substrates; P-glycoprotein inducers; P-glycoprotein substrates; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids"
DB14632,Prednisolone tebutate,7681-14-3,approved; vet_approved,HUMXXHTVHHLNRO-KAJVQRHHSA-N,"InChI=1S/C27H38O6/c1-24(2,3)14-22(31)33-15-21(30)27(32)11-9-19-18-7-6-16-12-17(28)8-10-25(16,4)23(18)20(29)13-26(19,27)5/h8,10,12,18-20,23,29,32H,6-7,9,11,13-15H2,1-5H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COC(=O)CC(C)(C)C,C27H38O6,C08182,D00982,93055,,8381,CHEMBL1200909,,84007,,458.587,3.446286063,Fused-Ring Compounds; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids
DB14638,Diloxanide furoate,3736-81-0,approved,BDYYDXJSHYEDGB-UHFFFAOYSA-N,"InChI=1S/C14H11Cl2NO4/c1-17(13(18)12(15)16)9-4-6-10(7-5-9)21-14(19)11-3-2-8-20-11/h2-8,12H,1H3",ClC(Cl)C(=O)N(C)c1ccc(cc1)OC(=O)c2ccco2,C14H11Cl2NO4,C07637,D02480,,,4601,CHEMBL1334860,,18400,70295,328.147,3.078232636,"Amebicides; Anti-Infective Agents; Antiparasitic Agents; Antiprotozoals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring"
DB14642,Lypressin,50-57-7,approved,BJFIDCADFRDPIO-DZCXQCEKSA-N,"InChI=1S/C46H65N13O12S2/c47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1",NC(=O)C[C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC[C@H](NC1=O)C(=O)N4CCC[C@H]4C(=O)NC(CCCCN)C(=O)NCC(=O)N,C46H65N13O12S2,,,,,94802,CHEMBL1200690,,559125,,1056.23,2.27501405,"Amino Acids, Peptides, and Proteins; Antidiuretic Agents; Cardiovascular Agents; Coagulants; Hematologic Agents; Hemostatics; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Natriuretic Agents; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary and Hypothalamic Hormones and Analogues; Pituitary Hormones; Pituitary Hormones, Posterior; Posterior Pituitary Lobe Hormones; Proteins; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Vasoconstrictor Agents; Vasopressin and Analogues; Vasopressins"
DB14643,Methylprednisolone aceponate,86401-95-8,approved; vet_approved,DALKLAYLIPSCQL-YPYQNWSCSA-N,"InChI=1S/C27H36O7/c1-6-23(32)34-27(22(31)14-33-16(3)28)10-8-19-18-11-15(2)20-12-17(29)7-9-25(20,4)24(18)21(30)13-26(19,27)5/h7,9,12,15,18-19,21,24,30H,6,8,10-11,13-14H2,1-5H3/t15-,18-,19-,21-,24+,25-,26-,27-/m0/s1",C1=CC(=O)C=C([C@]12C)[C@@H](C)C[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(OC(=O)CC)C(=O)COC(=O)C,C27H36O7,,,,,135762,CHEMBL1697782,,56717,,472.578,3.142795688,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Corticosteroids, Dermatological Preparations; Corticosteroids, Potent (Group III); Dermatologicals; Fused-Ring Compounds; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids"
DB14644,Methylprednisolone hemisuccinate,2921-57-5,approved,IMBXEJJVJRTNOW-XYMSELFBSA-N,"InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1",C1=CC(=O)C=C([C@]12C)[C@@H](C)C[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COC(=O)CCC(=O)O,C26H34O8,,,,,135765,CHEMBL1201265,,16034,,474.55,1.825997178,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Corticosteroids; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuroprotective Agents; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Protective Agents; Steroids"
DB14646,Prednisone acetate,125-10-0,approved; experimental; investigational,MOVRKLZUVNCBIP-RFZYENFJSA-N,"InChI=1S/C23H28O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-17,20,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2C(=O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COC(=O)C,C23H28O6,C14668,D08416,,,34655,CHEMBL1507567,,82567,,400.471,2.099629588,"Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Corticosteroids; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnanes; Steroids; Thyroxine-binding globulin inhibitors"
DB14649,Dexamethasone acetate,1177-87-3,approved; investigational; vet_approved,AKUJBENLRBOFTD-RPRRAYFGSA-N,"InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17+,18+,19+,21+,22+,23+,24+/m1/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@]2(F)[C@@H](O)C[C@@]4(C)[C@H]3C[C@@H](C)[C@]4(O)C(=O)COC(=O)C,C24H31FO6,C08174,D07796,236702,,4463,CHEMBL1530428,,206624,50103620,434.4977,2.12269509,"Anti-Inflammatory Agents; BCRP/ABCG2 Inhibitors; BSEP/ABCB11 inducers; Cytochrome P-450 CYP2A6 Inducers; Cytochrome P-450 CYP2A6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2E1 Inducers; Cytochrome P-450 CYP2E1 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (moderate); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (moderate); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP3A7 Inducers (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Fused-Ring Compounds; OAT3/SLC22A8 Substrates; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated"
DB14650,Menadiol diphosphate,84-98-0,approved; nutraceutical,JTNHOVZOOVVGHI-UHFFFAOYSA-N,"InChI=1S/C11H12O8P2/c1-7-6-10(18-20(12,13)14)8-4-2-3-5-9(8)11(7)19-21(15,16)17/h2-6H,1H3,(H2,12,13,14)(H2,15,16,17)",c1cccc(c12)c(OP(=O)(O)O)c(C)cc2OP(=O)(O)O,C11H12O8P2,,,8556,,134713,CHEMBL1201348,,8238,,334.1557,1.561283027,"Diterpenes; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Naphthalenes; Naphthoquinones; Phytol; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quinones; Terpenes"
DB14655,Drostanolone propionate,521-12-0,approved; illicit,NOTIQUSPUUHHEH-UXOVVSIBSA-N,"InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1",CCC(=O)O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)[C@@H](CC3)CC(=O)[C@H](C)C4,C23H36O3,,D01534,,,31523,CHEMBL1201048,,194604,,360.538,5.095905168,Androstanes; Fused-Ring Compounds; Polycyclic Compounds; Steroids; Testosterone and derivatives
DB14656,Chlorphenesin carbamate,886-74-8,approved; vet_approved; withdrawn,SKPLBLUECSEIFO-UHFFFAOYSA-N,"InChI=1S/C10H12ClNO4/c11-7-1-3-9(4-2-7)15-5-8(13)6-16-10(12)14/h1-4,8,13H,5-6H2,(H2,12,14)",NC(=O)OCC(O)COc1ccc(Cl)cc1,C10H12ClNO4,C07930,D00770,,,3643,CHEMBL607710,,2623,,245.66,1.206762149,Alcohols; Glycols; Propylene Glycols
DB14657,Paramethasone acetate,1597-82-6,approved,HYRKAAMZBDSJFJ-LFDBJOOHSA-N,"InChI=1S/C24H31FO6/c1-12-7-16-15-9-18(25)17-8-14(27)5-6-22(17,3)21(15)19(28)10-23(16,4)24(12,30)20(29)11-31-13(2)26/h5-6,8,12,15-16,18-19,21,28,30H,7,9-11H2,1-4H3/t12-,15+,16+,18+,19+,21-,22+,23+,24+/m1/s1",C1=CC(=O)C=C([C@]12C)[C@@H](F)C[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3C[C@@H](C)[C@]4(O)C(=O)COC(=O)C,C24H31FO6,C12656,D01229,,,31963,CHEMBL1200342,,391984,,434.504,1.739368868,"Fused-Ring Compounds; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated"
DB14658,Chloramphenicol palmitate,530-43-8,approved; vet_approved,PXKHGMGELZGJQE-ILBGXUMGSA-N,"InChI=1S/C27H42Cl2N2O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-24(32)37-20-23(30-27(34)26(28)29)25(33)21-16-18-22(19-17-21)31(35)36/h16-19,23,25-26,33H,2-15,20H2,1H3,(H,30,34)/t23-,25-/m1/s1",CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+]([O-])=O)cc1,C27H42Cl2N2O6,C11726,D01072,,,3605,CHEMBL1506,,391613,,561.54,7.79975739,"Alcohols; Benzene Derivatives; Glycols; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Nitro Compounds; Nitrobenzenes; Propylene Glycols"
DB14669,Betamethasone phosphate,360-63-4,approved; vet_approved,VQODGRNSFPNSQE-DVTGEIKXSA-N,"InChI=1S/C22H30FO8P/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30)/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@]2(F)[C@@H](O)C[C@@]4(C)[C@H]3C[C@H](C)[C@]4(O)C(=O)COP(=O)(O)O,C22H30FO8P,,,,,68603,CHEMBL1201207,,96937,,472.446,1.558003648,"Adrenal Cortex Hormones; Corticosteroids; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OAT3/SLC22A8 Substrates; P-glycoprotein inducers; P-glycoprotein substrates; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated"
DB14674,Estramustine phosphate,4891-15-0,approved; investigational,ADFOJJHRTBFFOF-RBRWEJTLSA-N,"InChI=1S/C23H32Cl2NO6P/c1-23-9-8-18-17-5-3-16(31-22(27)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)32-33(28,29)30/h3,5,14,18-21H,2,4,6-13H2,1H3,(H2,28,29,30)/t18-,19-,20+,21+,23+/m1/s1",OP(=O)(O)O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(cc4)OC(=O)N(CCCl)CCCl,C23H32Cl2NO6P,,,,,68643,CHEMBL1756,,227633,50333645,520.38,4.975547879,NA
DB14677,Gestonorone caproate,1253-28-7,approved,XURCMZMFZXXQDJ-UKNJCJGYSA-N,"InChI=1S/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1",C1CC(=O)C=C(CC2)[C@H]1[C@@H](CC3)[C@@H]2[C@@H]([C@]34C)CC[C@@]4(C(=O)C)OC(=O)CCCCC,C26H38O4,,,,,31650,CHEMBL2107389,,391969,,414.586,5.57649941,Fused-Ring Compounds; Norpregnanes; Norpregnenes; Norsteroids; Polycyclic Compounds; Pregnanes; Pregnenediones; Pregnenes; Steroids
DB14684,Calcium polycarbophil,126040-58-2,approved,,, ,,,,,,,,,,,NA,NA,"Alimentary Tract and Metabolism; Antidiarrheals; Bulk-Forming Laxatives; Calcium Salts; Compounds used in a research, industrial, or household setting; Dental Materials; Drug Carriers; Drugs for Constipation; Gastrointestinal Agents; Gels; Laxatives; Macromolecular Substances; Manufactured Materials; Phosphate Binder; Plastics; Polymers; Resins, Synthetic"
DB14702,Sodium metavanadate,13718-26-8,approved; experimental,CMZUMMUJMWNLFH-UHFFFAOYSA-N,InChI=1S/Na.3O.V/q+1;;;-1;,[O-][V](=O)=O,NaO3V,,,,,75221,CHEMBL294467,,24427,,121.9295,-1.239,Vanadates
DB14703,Dexamethasone metasulfobenzoate,16978-57-7,approved; experimental,TWQWRHIQRAZHPR-XNXCGYEVSA-N,"InChI=1S/C29H33FO9S/c1-16-11-22-21-8-7-18-13-19(31)9-10-26(18,2)28(21,30)23(32)14-27(22,3)29(16,35)24(33)15-39-25(34)17-5-4-6-20(12-17)40(36,37)38/h4-6,9-10,12-13,16,21-23,32,35H,7-8,11,14-15H2,1-3H3,(H,36,37,38)/t16-,21+,22+,23+,26+,27+,28+,29+/m1/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@]2(F)[C@@H](O)C[C@@]4(C)[C@H]3C[C@@H](C)[C@]4(O)C(=O)COC(=O)c5cccc(c5)S(=O)(=O)O,C29H33FO9S,,,,,,CHEMBL3305965,,56740,,576.63,1.215380523,"Fused-Ring Compounds; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Steroids; Steroids, Fluorinated"
DB14723,Larotrectinib,1223403-58-4,approved; investigational,NYNZQNWKBKUAII-KBXCAEBGSA-N,"InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1",O[C@H]1CCN(C1)C(=O)Nc(cn2)c(n23)nc(cc3)N4CCC[C@@H]4c5c(F)ccc(F)c5,C21H22F2N6O2,,,,,,CHEMBL3889654,,44210503,136597,428.444,2.440532355,"Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; P-glycoprotein substrates; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors"
DB14725,Cefamandole nafate,57268-80-1,approved,RRJHESVQVSRQEX-SUYBPPKGSA-N,"InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30)/t12-,14-,17-/m1/s1",Cn1nnnc1SCC(=C2C(=O)O)CS[C@@H](N23)[C@@H](C3=O)NC(=O)[C@H](OC=O)c4ccccc4,C19H18N6O6S2,,,,,53654,CHEMBL1201218,,4447585,,490.51,0.419512318,"Amides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Cephalosporins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Sulfur Compounds; Thiazines"
DB00781,Polymyxin B,1404-26-8,approved; vet_approved,WQVJHHACXVLGBL-BPJDFBQWSA-N,"InChI=1S/C56H98N16O13/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80)/t32?,33-,34-,36+,37+,38-,39+,40+,41+,42+,43-,45+,46+/m1/s1",C[C@@H](O)[C@@H]1NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC,C56H98N16O13,,,,,,CHEMBL1201283,,25045120,50410807,1203.499,-7.249170608,"Alimentary Tract and Metabolism; Amino Acids, Peptides, and Proteins; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Antiinfectives for Systemic Use; Antimicrobial Cationic Peptides; Intestinal Antiinfectives; Lipopeptides; Macrocyclic Compounds; Neurotoxic agents; Ophthalmological and Otological Preparations; Ophthalmologicals; Otologicals; Peptides; Peptides, Cyclic; Polycyclic Compounds; Polymyxin-class Antibacterial; Polymyxins; Pore Forming Cytotoxic Proteins; Proteins; Sensory Organs"
DB14752,Racephedrine,90-81-3,approved; experimental,,, ,,,,,,,,,,,NA,NA,Adrenergic Agonists; Alpha-and Beta-adrenergic Agonists; Herbs and Natural Products; Sympathomimetic (Adrenergic) Agents
DB14753,Hydroxystilbamidine,495-99-8,approved,TUESWZZJYCLFNL-DAFODLJHSA-N,"InChI=1S/C16H16N4O/c17-15(18)12-5-2-10(3-6-12)1-4-11-7-8-13(16(19)20)9-14(11)21/h1-9,21H,(H3,17,18)(H3,19,20)/b4-1+",NC(=N)c1ccc(cc1)/C=C/c2c(O)cc(cc2)C(N)=N,C16H16N4O,,,,,,CHEMBL1301,,10612853,,280.331,1.243840056,"Amidines; Benzene Derivatives; Benzylidene Compounds; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Stilbenes"
DB14754,Solriamfetol,178429-62-4,approved,UCTRAOBQFUDCSR-SECBINFHSA-N,"InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1",NC(=O)OC[C@H](N)Cc1ccccc1,C10H14N2O2,,,,,,CHEMBL4297620,,8305853,,194.234,0.864920392,"Acids, Acyclic; Adrenergic Agents; Adrenergic Uptake Inhibitors; Agents producing tachycardia; Agents that produce hypertension; Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Antidepressive Agents; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Depressants; Dopamine Agents; Dopamine Uptake Inhibitors; Drugs that are Mainly Renally Excreted; MATE 1 Substrates; MATE substrates; Norepinephrine Reuptake Inhibitor; OCT2 Substrates"
DB14763,Cycloguanil,516-21-2,approved,QMNFFXRFOJIOKZ-UHFFFAOYSA-N,"InChI=1S/C11H14ClN5/c1-11(2)16-9(13)15-10(14)17(11)8-5-3-7(12)4-6-8/h3-6H,1-2H3,(H4,13,14,15,16)",CC1(C)N=C(N)N=C(N)N1c2ccc(Cl)cc2,C11H14ClN5,,,,,135029,CHEMBL747,1CY,8697,18792,251.715,1.701151545,"Amidines; Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Biguanides; Enzyme Inhibitors; Folic Acid Antagonists; Guanidines; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring"
DB14783,Diroximel fumarate,1577222-14-0,approved; investigational,YIMYDTCOUQIDMT-SNAWJCMRSA-N,"InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+",COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O,C11H13NO6,,,,,,CHEMBL3989944,,57423290,,255.226,-0.223779991,Fumarates; Hepatotoxic Agents
DB14840,Ripretinib,1442472-39-0,approved,CEFJVGZHQAGLHS-UHFFFAOYSA-N,"InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)",CNc(c1)ncc(c12)cc(c(=O)n2CC)-c3c(Br)cc(F)c(c3)NC(=O)Nc4ccccc4,C24H21BrFN5O2,,,,,,CHEMBL4216467,,67886378,,510.367,4.392531297,BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; MATE 1 Inhibitors; MATE inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors
DB14879,Cefiderocol,1225208-94-5,approved; investigational,DBPPRLRVDVJOCL-FQRUVTKNSA-N,"InChI=1S/C30H34ClN7O10S2/c1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31/h5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47)/t20-,26-/m1/s1",OC(=O)C(C)(C)O/N=C(/c1csc(n1)N)C(=O)N[C@H](C2=O)[C@H](N23)SCC(=C3C([O-])=O)C[N+]4(CCCC4)CCNC(=O)c5c(Cl)c(O)c(O)cc5,C30H34ClN7O10S2,,,,,,CHEMBL3989974,,52084902,,752.21,-2.929949314,"Amides; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Drugs that are Mainly Renally Excreted; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Lactams; Sulfur Compounds"
DB14914,Flortaucipir F-18,1522051-90-6,approved; investigational,GETAAWDSFUCLBS-SJPDSGJFSA-N,"InChI=1S/C16H10FN3/c17-16-4-2-11(8-19-16)10-1-3-12-13-9-18-6-5-14(13)20-15(12)7-10/h1-9,20H/i17-1",[18F]c1ccc(cn1)-c(c2)ccc(c23)c4c([nH]3)ccnc4,C16H10FN3,,,,,,CHEMBL3545253,,32701063,,262.278,2.839398803,"Compounds used in a research, industrial, or household setting; Contrast Media; Diagnostic Uses of Chemicals; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Pyridines"
DB14975,Voxelotor,1446321-46-5,approved; investigational,FWCVZAQENIZVMY-UHFFFAOYSA-N,"InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3",CC(C)n1nccc1-c2c(cccn2)COc3cccc(O)c3C=O,C19H19N3O3,,,,,,CHEMBL4101807,,37999268,50235297,337.379,3.535632112,"Aldehydes; Azoles; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring"
DB15035,Zanubrutinib,1691249-45-2,approved; investigational,RNOAOAWBMHREKO-QFIPXVFZSA-N,"InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1",C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5,C27H29N5O3,,,,,,CHEMBL3936761,,64835237,250082,471.561,3.415974261,"Antineoplastic Agents; Azoles; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; Protein Kinase Inhibitors; Teratogens"
DB15091,Upadacitinib,1310726-60-3,approved; investigational,WYQFJHHDOKWSHR-MNOVXSKESA-N,"InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1",FC(F)(F)CNC(=O)N1C[C@@H](CC)[C@H](C1)c2cnc(n23)cnc4c3cc[nH]4,C17H19F3N6O,,,,,,CHEMBL3622821,,44210449,,380.375,0.846313073,"Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Disease-modifying Antirheumatic Agents; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Janus Kinase Inhibitors; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Protein Kinase Inhibitors; Selective Immunosuppressants"
DB15102,Pemigatinib,1513857-77-6,approved; investigational,HCDMJFOHIXMBOV-UHFFFAOYSA-N,"InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)",COc1c(F)c(c(F)c(c1)OC)N(C(=O)N2CC)Cc(c23)cnc4c3cc([nH]4)CN5CCOCC5,C24H27F2N5O4,,,,,,CHEMBL4297522,,68007304,301310,487.508,1.816332956,"Antineoplastic Agents; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fibroblast Growth Factor 2, antagonists & inhibitors; Kinase Inhibitor; MATE 1 Inhibitors; MATE inhibitors; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors; Receptors, Fibroblast Growth Factor, antagonists & inhibitors"
DB15233,Avapritinib,1703793-34-3,approved; investigational,DWYRIWUZIJHQKQ-SANMLTNESA-N,"InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1",Cn1cc(cn1)-c(c2)cn(c23)ncnc3N4CCN(CC4)c5ncc(cn5)[C@@](C)(N)c6ccc(F)cc6,C26H27FN10,,,,,,CHEMBL4204794,,58828673,,498.57,3.263014941,Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Protein Kinase Inhibitors
DB15328,Ubrogepant,1374248-77-7,approved; investigational,DDOOFTLHJSMHLN-ZQHRPCGSSA-N,"InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1",c1ccccc1[C@H]2[C@@H](C)N(CC(F)(F)F)C(=O)[C@H](C2)NC(=O)c(c3)cnc(C4)c3C[C@@]45c6c(NC5=O)nccc6,C29H26F3N5O3,,,,,,CHEMBL2364638,,28536135,,549.554,3.068489865,"Antimigraine Preparations; Azoles; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; OATP1B3 substrates; OCT2 Inhibitors; P-glycoprotein substrates; UGT1A1 Inhibitors"
DB15444,Elexacaftor,2216712-66-0,approved; investigational,MVRHVFSOIWFBTE-INIZCTEOSA-N,"InChI=1S/C26H34F3N7O4S/c1-16-12-25(5,6)35(13-16)22-18(23(37)33-41(38,39)19-14-34(7)31-17(19)2)8-9-20(30-22)36-11-10-21(32-36)40-15-24(3,4)26(27,28)29/h8-11,14,16H,12-13,15H2,1-7H3,(H,33,37)/t16-/m0/s1",FC(F)(F)C(C)(C)COc1nn(cc1)-c2nc(N(C3(C)C)C[C@@H](C)C3)c(cc2)C(=O)NS(=O)(=O)c4cn(C)nc4C,C26H34F3N7O4S,,,,,,CHEMBL4298128,,75531299,,597.66,5.037833923,Azoles; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Membrane Transport Modulators; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates
DB15465,Benzhydrocodone,1259440-61-3,approved,VPMRSLWWUXNYRY-NDOYXKHWSA-N,"InChI=1S/C25H25NO4/c1-26-13-12-25-17-9-11-20(29-24(27)15-6-4-3-5-7-15)23(25)30-22-19(28-2)10-8-16(21(22)25)14-18(17)26/h3-8,10-11,17-18,23H,9,12-14H2,1-2H3/t17-,18-,23+,25+/m1/s1",[C@@]123c4c5ccc(OC)c4O[C@H]1C(=CC[C@H]3[C@@H](C5)N(C)CC2)OC(=O)c6ccccc6,C25H25NO4,,,,,,CHEMBL3137321,,34222482,,403.478,3.712008725,Opioids
DB15467,Cinoxate,104-28-9,approved,CMDKPGRTAQVGFQ-RMKNXTFCSA-N,"InChI=1S/C14H18O4/c1-3-17-10-11-18-14(15)9-6-12-4-7-13(16-2)8-5-12/h4-9H,3,10-11H2,1-2H3/b9-6+",CCOCCOC(=O)/C=C/c1ccc(OC)cc1,C14H18O4,,,,,,CHEMBL2104045,,4523729,,250.294,2.66747483,"Acids, Carbocyclic; Carboxylic Acids; Sunscreen Agents"
DB15477,Alloin,8015-61-0,approved; experimental,AFHJQYHRLPMKHU-CGISPIQUSA-N,"InChI=1S/C21H22O9/c22-6-8-4-10-14(21-20(29)19(28)17(26)13(7-23)30-21)9-2-1-3-11(24)15(9)18(27)16(10)12(25)5-8/h1-5,13-14,17,19-26,28-29H,6-7H2/t13-,14?,17-,19+,20-,21+/m1/s1",OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2c(cccc3O)c3C(=O)c(c24)c(O)cc(c4)CO,C21H22O9,,,,,73222,CHEMBL497001,,8042387,50269016,418.398,0.414989726,"Anthracenes; Anthraquinones; Biological Products; Cascara; Complex Mixtures; Gastrointestinal Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Laxatives; Pharmaceutical Preparations; Plant Extracts; Plant Preparations; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Quinones"
DB15479,Zirconium chloride hydroxide,10119-31-0,approved; experimental,BLKLTTCUAPDQEG-UHFFFAOYSA-L,InChI=1S/ClH.H2O.Zr/h1H;1H2;/q;;+2/p-2,O[ZrH2]Cl,ClHOZr,,,,,,,,13432518,,143.68,0.0983,NA
DB15480,Resorcinol monoacetate,102-29-4,approved; experimental,ZZPKZRHERLGEKA-UHFFFAOYSA-N,"InChI=1S/C8H8O3/c1-6(9)11-8-4-2-3-7(10)5-8/h2-5,10H,1H3",CC(=O)Oc1cc(O)ccc1,C8H8O3,C12064,,,,29672,CHEMBL1593874,,4879,,152.149,1.276941469,"Benzene Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols"
DB15494,Edotreotide gallium Ga-68,,approved,PZBPHYLKIMOZPR-FIYGWYQWSA-K,"InChI=1S/C65H92N14O18S2.Ga/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53;/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90);/q;+3/p-3/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+;/m1./s1/i;1-2",NCCCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)CO)CSSC[C@@H](C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(=O)N1)Cc3c[nH]c(c34)cccc4)NC(=O)[C@@H](Cc5ccccc5)NC(=O)CN6CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC6,C65H89GaN14O18S2,,,,,,,,52083916,,1486.55,-9.627594645,Diagnostic Radiopharmaceuticals; Gallium Radioisotopes; Radiopharmaceuticals; Tumour Detection
DB15534,Colchiceine,477-27-0,approved; experimental,PRGILOMAMBLWNG-UHFFFAOYSA-N,"InChI=1S/C21H23NO6/c1-11(23)22-15-7-5-12-9-18(26-2)20(27-3)21(28-4)19(12)13-6-8-16(24)17(25)10-14(13)15/h6,8-10,15H,5,7H2,1-4H3,(H,22,23)(H,24,25)",COc(c1)c(OC)c(OC)c(c12)c3c(C(CC2)NC(=O)C)cc(=O)c(O)cc3,C21H23NO6,,,,,,CHEMBL323668,,9750,66784,385.416,1.349161181,Alkaloids; Colchicine Derivatives; Heterocyclic Compounds; Tubulin Inhibiting Agent
DB15566,Prednisolone acetate,52-21-1,approved; vet_approved,LRJOMUJRLNCICJ-JZYPGELDSA-N,"InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1",C1=CC(=O)C=C([C@]12C)CC[C@@H]3[C@@H]2[C@@H](O)C[C@@]4(C)[C@H]3CC[C@]4(O)C(=O)COC(=O)C,C23H30O6,C08180,,5834,,8380,CHEMBL1152,,5629,,402.4807,1.714115335,Adrenal Cortex Hormones; Anti-Inflammatory Agents; Corticosteroids; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Fused-Ring Compounds; P-glycoprotein substrates; Polycyclic Compounds; Pregnadienes; Pregnadienetriols; Pregnanes; Prodrugs; Steroids
DB15576,Ethyl salicylate,118-61-6,approved; experimental,GYCKQBWUSACYIF-UHFFFAOYSA-N,"InChI=1S/C9H10O3/c1-2-12-9(11)7-5-3-4-6-8(7)10/h3-6,10H,2H2,1H3",CCOC(=O)c1ccccc1O,C9H10O3,,,,,88839,CHEMBL2251610,,21105897,,166.1739,2.679965413,"Acids, Carbocyclic; Benzene Derivatives; Benzoates; Carboxylic Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Phenols"
DB15594,Brilliant blue G,6104-58-1,approved,RWVGQQGBQSJDQV-UHFFFAOYSA-M,"InChI=1S/C47H49N3O7S2.Na/c1-6-49(31-35-11-9-13-43(29-35)58(51,52)53)40-21-25-45(33(4)27-40)47(37-15-17-38(18-16-37)48-39-19-23-42(24-20-39)57-8-3)46-26-22-41(28-34(46)5)50(7-2)32-36-12-10-14-44(30-36)59(54,55)56;/h9-30H,6-8,31-32H2,1-5H3,(H2,51,52,53,54,55,56);/q;+1/p-1",CCOc1ccc(cc1)Nc2ccc(cc2)/C(=C3/C=C/C(C=C3C)=[N+](/CC)Cc4cc(S([O-])(=O)=O)ccc4)c5c(C)cc(cc5)N(CC)Cc6cc(S([O-])(=O)=O)ccc6,C47H48N3NaO7S2,,,,,,CHEMBL4173394,,4884338,,854.02,5.644339296,"Amines; Aniline Compounds; Compounds used in a research, industrial, or household setting; Indicators and Reagents; Laboratory Chemicals"
DB15598,Ferric maltol,33725-54-1,approved,AHPWLYJHTFAWKI-UHFFFAOYSA-K,"InChI=1S/3C6H6O3.Fe/c3*1-4-6(8)5(7)2-3-9-4;/h3*2-3,8H,1H3;/q;;;+3/p-3",Cc1c([O-])c(=O)cco1,C18H15FeO9,,,,,,,,148265,,431.154,0.546427919,"Antianemic Preparations; Blood and Blood Forming Organs; Hematinics; Hematologic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Iron Compounds; Iron Preparations; Iron Trivalent, Oral Preparations; Organometallic Compounds; Pyrans; UGT1A6 substrate"
DB15617,Ferric derisomaltose,1345510-43-1,approved,JTQTXQSGPZRXJF-DOJSGGEQSA-N,"InChI=1S/C18H34O16.Fe/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18;/h5-30H,1-4H2;/q;+3/t5-,6+,7+,8+,9+,10+,11+,12+,13-,14-,15+,16+,17-,18-;/m0./s1",OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O,C18H34FeO16,,,,,,,,,,562.297,-7.27169014,"Anemia, Iron-Deficiency; Antianemia Drugs; Antianemic Preparations; Iron Compounds; Parenteral Iron Replacement"
DB15678,Calcium undecylenate,1322-14-1,approved; experimental,CLOKKBBIKHZGNX-UHFFFAOYSA-L,"InChI=1S/2C11H20O2.Ca/c2*1-2-3-4-5-6-7-8-9-10-11(12)13;/h2*2H,1,3-10H2,(H,12,13);/q;;+2/p-2",[O-]C(=O)CCCCCCCCC=C,C22H38CaO4,,,,,,CHEMBL2104130,,14175,,406.62,3.729751466,NA
DB15679,Aluminum subacetate,142-03-0,approved; experimental,HQQUTGFAWJNQIP-UHFFFAOYSA-K,"InChI=1S/2C2H4O2.Al.H2O/c2*1-2(3)4;;/h2*1H3,(H,3,4);;1H2/q;;+3;/p-3",CC(=O)O[Al](O)OC(=O)C,C4H7AlO5,,,,,,CHEMBL1532734,,8373332,,162.0769,-0.3996,Astringents
DB15685,Selpercatinib,2152628-33-4,approved; investigational,XIIOFHFUYBLOLW-UHFFFAOYSA-N,"InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3",COc1ncc(cc1)CN(C23)C(C2)CN(C3)c4ccc(cn4)-c5cc(OCC(C)(C)O)cn(c56)ncc6C#N,C29H31N7O3,,,,,,,,72379991,,525.613,3.13938739,Agents that produce hypertension; Antineoplastic Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hepatotoxic Agents; MATE 1 Inhibitors; MATE inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; QTc Prolonging Agents; Tyrosine Kinase Inhibitors
DB15690,Fluoroestradiol F-18,94153-53-4,approved,KDLLNMRYZGUVMA-ZYMZXAKXSA-N,"InChI=1S/C18H23FO2/c1-18-7-6-13-12-5-3-11(20)8-10(12)2-4-14(13)15(18)9-16(19)17(18)21/h3,5,8,13-17,20-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1/i19-1",O[C@H]1[C@H]([18F])C[C@H]([C@@]12C)[C@H]3[C@H](CC2)c4c(CC3)cc(O)cc4,C18H23FO2,,,,,,,,9045262,,289.381,3.561689495,"Estradiol Congeners; Estranes; Estrogens; Estrogens, agonists; Fluorine Radioisotopes; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroids"
